<!DOCTYPE html>
<!-- Created by pdf2htmlEX (https://github.com/coolwanglu/pdf2htmlex) -->
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta name="generator" content="pdf2htmlEX"/>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
<style type="text/css">
/*! 
 * Base CSS for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/coolwanglu/pdf2htmlEX/blob/master/share/LICENSE
 */#sidebar{position:absolute;top:0;left:0;bottom:0;width:250px;padding:0;margin:0;overflow:auto}#page-container{position:absolute;top:0;left:0;margin:0;padding:0;border:0}@media screen{#sidebar.opened+#page-container{left:250px}#page-container{bottom:0;right:0;overflow:auto}.loading-indicator{display:none}.loading-indicator.active{display:block;position:absolute;width:64px;height:64px;top:50%;left:50%;margin-top:-32px;margin-left:-32px}.loading-indicator img{position:absolute;top:0;left:0;bottom:0;right:0}}@media print{@page{margin:0}html{margin:0}body{margin:0;-webkit-print-color-adjust:exact}#sidebar{display:none}#page-container{width:auto;height:auto;overflow:visible;background-color:transparent}.d{display:none}}.pf{position:relative;background-color:white;overflow:hidden;margin:0;border:0}.pc{position:absolute;border:0;padding:0;margin:0;top:0;left:0;width:100%;height:100%;overflow:hidden;display:block;transform-origin:0 0;-ms-transform-origin:0 0;-webkit-transform-origin:0 0}.pc.opened{display:block}.bf{position:absolute;border:0;margin:0;top:0;bottom:0;width:100%;height:100%;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}.bi{position:absolute;border:0;margin:0;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}@media print{.pf{margin:0;box-shadow:none;page-break-after:always;page-break-inside:avoid}@-moz-document url-prefix(){.pf{overflow:visible;border:1px solid #fff}.pc{overflow:visible}}}.c{position:absolute;border:0;padding:0;margin:0;overflow:hidden;display:block}.t{position:absolute;white-space:pre;font-size:1px;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%;unicode-bidi:bidi-override;-moz-font-feature-settings:"liga" 0}.t:after{content:''}.t:before{content:'';display:inline-block}.t span{position:relative;unicode-bidi:bidi-override}._{display:inline-block;color:transparent;z-index:-1}::selection{background:rgba(127,255,255,0.4)}::-moz-selection{background:rgba(127,255,255,0.4)}.pi{display:none}.d{position:absolute;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%}.it{border:0;background-color:rgba(255,255,255,0.0)}.ir:hover{cursor:pointer}</style>
<style type="text/css">
/*! 
 * Fancy styles for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/coolwanglu/pdf2htmlEX/blob/master/share/LICENSE
 */@keyframes fadein{from{opacity:0}to{opacity:1}}@-webkit-keyframes fadein{from{opacity:0}to{opacity:1}}@keyframes swing{0{transform:rotate(0)}10%{transform:rotate(0)}90%{transform:rotate(720deg)}100%{transform:rotate(720deg)}}@-webkit-keyframes swing{0{-webkit-transform:rotate(0)}10%{-webkit-transform:rotate(0)}90%{-webkit-transform:rotate(720deg)}100%{-webkit-transform:rotate(720deg)}}@media screen{#sidebar{background-color:#2f3236;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI0IiBoZWlnaHQ9IjQiPgo8cmVjdCB3aWR0aD0iNCIgaGVpZ2h0PSI0IiBmaWxsPSIjNDAzYzNmIj48L3JlY3Q+CjxwYXRoIGQ9Ik0wIDBMNCA0Wk00IDBMMCA0WiIgc3Ryb2tlLXdpZHRoPSIxIiBzdHJva2U9IiMxZTI5MmQiPjwvcGF0aD4KPC9zdmc+")}#outline{font-family:Georgia,Times,"Times New Roman",serif;font-size:13px;margin:2em 1em}#outline ul{padding:0}#outline li{list-style-type:none;margin:1em 0}#outline li>ul{margin-left:1em}#outline a,#outline a:visited,#outline a:hover,#outline a:active{line-height:1.2;color:#e8e8e8;text-overflow:ellipsis;white-space:nowrap;text-decoration:none;display:block;overflow:hidden;outline:0}#outline a:hover{color:#0cf}#page-container{background-color:#9e9e9e;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI1IiBoZWlnaHQ9IjUiPgo8cmVjdCB3aWR0aD0iNSIgaGVpZ2h0PSI1IiBmaWxsPSIjOWU5ZTllIj48L3JlY3Q+CjxwYXRoIGQ9Ik0wIDVMNSAwWk02IDRMNCA2Wk0tMSAxTDEgLTFaIiBzdHJva2U9IiM4ODgiIHN0cm9rZS13aWR0aD0iMSI+PC9wYXRoPgo8L3N2Zz4=");-webkit-transition:left 500ms;transition:left 500ms}.pf{margin:13px auto;box-shadow:1px 1px 3px 1px #333;border-collapse:separate}.pc.opened{-webkit-animation:fadein 100ms;animation:fadein 100ms}.loading-indicator.active{-webkit-animation:swing 1.5s ease-in-out .01s infinite alternate none;animation:swing 1.5s ease-in-out .01s infinite alternate none}.checked{background:no-repeat url(data:image/png;base64,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)}}</style>
<style type="text/css">
.ff0{font-family:sans-serif;visibility:hidden;}
@font-face{font-family:ff1;src:url('data:application/font-woff;base64,d09GRgABAAAAAA7wAA4AAAAAFhwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABRAAAABoAAAAcg5ZPTkdERUYAAAFgAAAAHQAAACAAQAAET1MvMgAAAYAAAABBAAAAVlXDYsVjbWFwAAABxAAAAHQAAAFiI+Mx82N2dCAAAAI4AAAABAAAAAQAIQJ5Z2FzcAAAAjwAAAAIAAAACP//AANnbHlmAAACRAAACbwAAA3gewp3xGhlYWQAAAwAAAAAMQAAADYQk/CSaGhlYQAADDQAAAAgAAAAJAahA9pobXR4AAAMVAAAAEwAAABMLqYBvGxvY2EAAAygAAAAKAAAACgbdh8cbWF4cAAADMgAAAAfAAAAIABXALduYW1lAAAM6AAAAc0AAAQRba5gD3Bvc3QAAA64AAAAOAAAAEgA4wGmeJxjYGBgZACCq08X1YPoazfC0mE0AFbpB7MAAHicY2BkYGDgA2IJBhBgYmAEQiEgZgHzGAAFEABFAAAAeJxjYGTaxxTBwMrAwNTFtIeBgaEHQjM+YDBkZAKKMrAzM8AAIwMSCEhzTWFQAMJQpnf/PwJVvmPgh6kBAOQACzcAAAB4nGNgYGBmgGAZBkYGEIgB8hjBfBYGByDNw8DBwARkKzA4Mngy+DOE/v8PFAXxXBh8GIL+////+P/h/wf/7/+/F2oCHDCyMcCFGJmABBMDmgKI1XgBCwMDKxs7BycXAwM3Dy8fAwO/gKAQIU2DBwAAJE4RIAAhAnkAAAAB//8AAnicdVZbbBzVGZ5zzsyZs7P32bl4b7O7M+vZzV68m1nvrGOvb5tkY3KDBBOD5biGQASlCjSitIUW3ColbSSkioeqhLZAqlZVkKISVZWIUBWeQKVSW9GHClWi9KEgWhBIrUQRsfvPrB0nQfFFnj1zZvxd/v/7D4e5AsehCj7LEU7kRl5GXKN7UeS5D52XqfC37kWC4ZJ7mXjLgrd8UaTo8+5F5K234oV4qRW3Cijw/uuv47NXjhfwnRyH1z9ev4I/wP/kDnAL8HaLilRVtAnkZJFilWzLjCDLnESjsNKZQh2345bs9mhnCrccXZN1A+mbm80R2Ek3N8O24ZZN4AUixejS+2MUq9GKxCqVSn57kqfUsFPssJbpU55Kek8RKGV3BxK3SEPlPJOEbK/pLBCJpdSIEFz775/EA5QP8PhLKPFinoWliJCUEEY4nGD1yB8nb/utAW9kmJqKnF1715z+c2JEVEMIk5DC4krrdwpCclhY+5TDXGr9Conh17kKt4vjEu3Rkl1FHmZHazluy9F0TVVABMu8nrubUBUDqYrubeu47VG75PEFtegpik2XycfLyXuTJ38y83Cjdewd+ZlUacbiKRvP8uIT8N/je7oPDc/VrfJjU82YjNHq/jP1jJimhAy7S+fmH+88SBAOJGmygXbP8StfSxupdLt59PTE18vVliSZFTCHq4BXPwPsD8AHD6cHxrOk4+aQFkUe6BtcmMSjgHPAsKVrnZZT9GnqBta9J+BmyW4g4r+mDVscz39d8W7Z3jfiESnnR2rlppmbEmhMIE0hjtITd549WjuMmWSaMZ4kNJvSkfr2jIZkLWAgcFxTMaGywNO7otXCj/GykovGWEpEmDJNIGIgarlouXuO7QwyXsimbxWJRMQfRRFChA2xaOajey5nlKiYEjHYjCh/YC/PCMNiYDmQRPzaOwI1LJVhFluq9SiAZFm1QChoZIBGJ/HvuWXQKL6hDtBSPVrA2BzQsraK3Fdsy2nYHgd326MbojkG8kWbBkqbog2UwQtKJilB1SkUUyRqIuKDiZx9IJxwGcPm7mp5xoSyLMsRRHDZYQxZ+x2EGnYwHKEoIWMsJHgW76QqDfzi2mWBFOMmvE1eqXUZ5llasSj9nxISk8wrdagVFu4i3E+dRxkhSxGGLxIUDu0TKGZYyk0WpQDwH13/hOTxW9DP3DCQVBW/lr2m9YTw6nsawV/1qsdQxJGNwoYOB8r2tcyn4BdUgiX8Vz72necOPd9c6ronLvROZCJSSBRDEj8kEsPp3Xt813B9cc9dC9ujgZhSYZTYs8XhCQNLzDTeO8VUItHe+Ph9L/VPN+4pqMFwTIq8EQbnAne0+wcr35h5dXFXipVrt6SUgM4wAsZJBnwy0K/jUPPfAz8LJkDZChyAHkUbtgE9D3r7evTTaAM8dDRctAqOt2urI7ym39oDjQ9X2g2lcbWZvPiDK7x/7VKER4WiJKH57RP1miSNZjCODMGFYM1W3XpdkorJKBJCaG+ICSgYHQHvjzZHqtVQqKgGMZa1MmRcoWt3jlLG3GAIgw5L4ertZ0xRlwhGoEBDO2+uxp+hdiqgQtbBmirp+f7xcoQy41QnNQR7iL+qZYXn5a8orxlpHZ6G0IM74Wh85buZEOgHeYeWQb9J0E/9ArlrEw7K/hplrjcfpAEMCbXCJGLt3FabK2LGyhWeJ1hWR8HsbfuqlZk8z5htY/TMQeFjqkW2KjebQVz/YkmOiV4E+PzSwnucl2k29OsZwNeDeoVMiyDRLviw7E1j5estux4YVX1n9dZgPOFHZUzK4sG1C+XpPIG+9DDiYKICHZmf3tbcayFJctUwxvzYann4UIz+BbqH/4UB6UsooAJjrbFnTTUKEDeQRrWVlcqRD6qC8GiV+phDUJOXAfMqfGjHSlYEw5Dz+qxkYy9RaVzRvyCzvamzfGOPuYNZOoU7stei15ATBwV586jC/8Y82bWHZw/jYFCi5JSgLTFBELfVmITTLdPuGhhUGClLNCDnalCH2dlGZhzHxdiFGF9uB04Q3pq900aU1WQJmg6lXcqIvatU3WWBm1ORMCbIGUMaT8+ek+R1jtdkHnUjY28zee3z19z5DZMJTdI9dW7dfCmXBsNhIV5ZW6yxpW+qCEswiqFQE4r2j771CnH9MoUlnUVUA/SMrP8HvPLnGoxZOFRc0+H0GrYD4exN4bzEGgwzmIZ6y5vlN9TJ1d6GqRaH95VGsP+DSuclrKVSUBXzWvQIoXByUHmxXshTMDIqynuUITGBowH2ZlT/OY9FXjDkPAiTdYyiYUg0k+WjITlGrIl0+lBDYL/GeOqxS8+VLK8rCcxxu/7E5Sfrk4iCFp6sAbaupt+8/4zzdEhWNmoLZGj/4am1TzPgRD9v3j0usrcxnMn8DDcgw+NcDSrM8Ua96NkOwOHs5eqmHeH90DbgGDZF2qMjGJ3/wbHv73WffuCRExMLS/dfQHJIV9OZSLUxevBWa8ddzVxg+77b8Vu3PfTKk0d37usVn7/vqZOrNYDGQkqkcnp26YcHStv7i7uNg0/d3gAMDvTl2+DJYe7YwJWbFGHbbcc3Z6W+cYjyAaswanxnWluPif7k9E9OQaQNsPsTiH7GU8VhQZKaGqlOpjCjpo3zJVGMRmarudOhh/vuJTNF99PdkgqTFOv1jNaLZWg3k9JKWUnGGanWLycDteZ8Cqqt6/7UsMWhwEaVFe59FYkOTUP2kOnmzC8NPmSyk8HlQEL0spWE6oEHnWIuh3prf+fTZacUmytXqej3urv+CfoMvOhzXAeOER4l4Oid//yh2vHpwkh1/HC9OlP944Y+OE16ueBxtMy2l1EHNcqb2p5S8/DM/JLr9MeO9LphFqaxGI2JRC+VZt3xTPHIsbrzyMqXZ2QqBMVgCMUQehezrmsNd3f0ZvKm01i5o9McErwHA8/yAhYwm91W6Vldo5jKNdqLy6vNkByK0QuUAY/1T8HPN/BH3JyXWR4akTaQDQf5AQPfXj9CB582iFRR/OYDA5mZ+yuFMSooAuL1BAweKg3VzuXd7plIIxgWRELSSFB4oVrMPZ6JJsaphPK7m/U5mzBxRw6C5YXPItFjASwSMbK4l8rSEKYUxZkUM14QsYgCR1LylX91tvkT0HcynfI8Ca5/gt/1a9M7wd/kvDIIT49LayM7bjpEvDOvSAcBXrKPRRMjkJ72XGW4B0hZRUshQmh2ZLG4Tx8PYj1WZIyYY9l0I4UlWrRETAP7dn91YcdCTkarH/qj2e/vJIO9y996oHlHaSqljT/0mwfnIVeS/k2mB0qhZ3/V/fbOqaHiPTs47v8DVBNUeJxjYGQAg9357+7G89t8ZZBnfgHiX7sRlg6j/3/4/5H5ANM7BkYGDgYmkCgAtasQEwAAAHicY2BkYGB69/8jAwPzk/8f/n9kPsAAFEEBwgDS4Qh/AWwAIQAAAAABTQAAANIAAALo//ADRAAaAq4AKgJ0AB4DQwA0A1oAHAGEABoCngAmA+QADAMoAA4DUgA0AssAMgIoADYC0v/4AukACwAAACoAKgAqACoAogEAAZICEgJ6AxoDagPEBGwE9AU2BboGHgaEBvB4nGNgZGBgEGZoY2BiAAEQycgAEnNg0AMJAAASZAEPAHicrZLBattAEIZ/SU5oCy05lPqQy9BTQiIhyxCi3IzB4JRQsCE5y9baEZG9RisCvuQZ+iQ9tG+UvkV76a/VkhpKCy2R2J1PuzP/zKwWwBt8hof2+eS9d+yh631z7OOF/9pxgL7/4LiDrv/oeA+vggPH++gGH+jpdV5SSGxUwx4i76tjHwfeD8cBFv47xx1E/hfHe3jrf3e8jyg4xBAaG2xRocASt6ghOMIcx7Q9pHxjnD5xssNnO5ySBsipNYMiT6loqKWwohWMsaamZpaNnTO7lyPiXhNZ8hVMnmow9kvRKnrfO9/dDENqGEZpKgvjmoiMo7bquc2cke+4prH47/ow1JttVSxvazmaH0svTePTZk7sfGbnVAa5nimZbk2tVkbG67muNrrKapVHIoOylEmjYGSijKruudoGDDNT6rUURjKpqyxXq6y6E734mx7wETcY4YpFX+KEbe0eRcjWmqYKNqq5ltP9ZnQ1vjwZtMnCqVoVM11y4zfPX1sjK1ZbW/GfNGeW8DRi2guOfyuhjUl4V0L0ORLq9HDONHpdj3S1VJJEsVzIH0rlTtIL+2ES986fr/1re7cMfds71PSGa1WZgr8klmdL9BOXosPpAAAAeJxjYGIAg//NDEYM2IAwEDMyMDEwM6gwqDNoMGgyaDFoM+gw6DMYMBgC9ZgymDGYM1gAAJYnBIk=')format("woff");}.ff1{font-family:ff1;line-height:0.765000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2;src:url('data:application/font-woff;base64,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')format("woff");}.ff2{font-family:ff2;line-height:0.860000;font-style:normal;font-weight:normal;visibility:visible;}
.ff3{font-family:TimesNewRoman,monospace;font-weight:normal;font-style:normal;line-height:1.313477;visibility:visible;}
@font-face{font-family:ff4;src:url('data:application/font-woff;base64,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')format("woff");}.ff4{font-family:ff4;line-height:0.752000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff5;src:url('data:application/font-woff;base64,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')format("woff");}.ff5{font-family:ff5;line-height:0.988000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff6;src:url('data:application/font-woff;base64,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')format("woff");}.ff6{font-family:ff6;line-height:1.123000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff7;src:url('data:application/font-woff;base64,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')format("woff");}.ff7{font-family:ff7;line-height:0.987000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff8;src:url('data:application/font-woff;base64,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')format("woff");}.ff8{font-family:ff8;line-height:1.006000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff9;src:url('data:application/font-woff;base64,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')format("woff");}.ff9{font-family:ff9;line-height:1.123000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffa;src:url('data:application/font-woff;base64,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')format("woff");}.ffa{font-family:ffa;line-height:0.987000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffb;src:url('data:application/font-woff;base64,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')format("woff");}.ffb{font-family:ffb;line-height:0.970000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffc;src:url('data:application/font-woff;base64,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')format("woff");}.ffc{font-family:ffc;line-height:1.019000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffd;src:url('data:application/font-woff;base64,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')format("woff");}.ffd{font-family:ffd;line-height:0.988000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffe;src:url('data:application/font-woff;base64,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')format("woff");}.ffe{font-family:ffe;line-height:0.913000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:fff;src:url('data:application/font-woff;base64,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')format("woff");}.fff{font-family:fff;line-height:0.927246;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff10;src:url('data:application/font-woff;base64,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')format("woff");}.ff10{font-family:ff10;line-height:1.025000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff11;src:url('data:application/font-woff;base64,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')format("woff");}.ff11{font-family:ff11;line-height:0.994000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff12;src:url('data:application/font-woff;base64,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')format("woff");}.ff12{font-family:ff12;line-height:0.985000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff13;src:url('data:application/font-woff;base64,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')format("woff");}.ff13{font-family:ff13;line-height:0.718000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff14;src:url('data:application/font-woff;base64,d09GRgABAAAAABTgAA0AAAAAG/gAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABMAAAABoAAAAczjEDgEdERUYAAAFMAAAAHQAAACAAbQAET1MvMgAAAWwAAABIAAAAVlZG/6pjbWFwAAABtAAAANQAAAGin25S2mdhc3AAAAKIAAAACAAAAAj//wADZ2x5ZgAAApAAAA7NAAATdIpNC+VoZWFkAAARYAAAADAAAAA2EBLv5mhoZWEAABGQAAAAIQAAACQGZAJ+aG10eAAAEbQAAADnAAABAHtyBhdsb2NhAAASnAAAAIIAAACCkGqLjG1heHAAABMgAAAAHAAAACAAhQAubmFtZQAAEzwAAAEnAAACxKRsiW1wb3N0AAAUZAAAAHsAAACiBoAGeXicY2BgYGQAgqtPF9WD6BrVDQ0wGgBMsQZ/AAB4nGNgZGBg4ANiCQYQYGJgBEJ7IGYB8xgABv8AcgAAAHicY2Bk/MH4hYGVgYGpi2kPgyxDD4j+P5fxAYMhIxNQlIGNmQEMGhgYGBmQQECaawpQREFBmJnrvzoDAzMXw00GqBoAiRAMPHicY2BgYGaAYBkGRgYQmAPkMYL5LAwNYFoAKMLDoMCgyWDEYMJgxmDFYM/gyRDKEM6QyVCpIPz/P1CVAoMGgzZY1hIo68jgA5RNZMgGyf5//P/O/9v/b/2/+f/6/8v/L/2/8P/8/2P/jz7QgdqIEzCyMcCVMDIBCSZ0BRCngwALKwMbOwcnFzcPLwMfAz8Dg4AgSFiIQVhEVExcQlJKGugVWTl5BUUlZRVVBjW4GeoamlraOrp6+gwGhkbGJqZm5haWVtY2tnb43UYusCdRPQD+FSsaAAAAAf//AAJ4nG1YC1gb15WeewUaECAk6wUI9Bohjd5o9BiEELIBvRAv8xZgIeIAjg3ENrbBtQN2EufVde3WJk3atFs3bveRbLpZ7GTzxd24rd02myb9+nLX7X4bN93P227ixHm4W6f1aO+dgUAfgDQDmnvuOf/5/3POhQBEa34buCQqIpQEAaSAFJNilVKtId0g4GeD6Btcao7XOC01LpbuylQwS20j8LvWqDv5tfuGO7ebG00np8Zm3t7XSqHl+X/IjwFaJOFtKbEp0toEsJWA32JldQDQGu/R9IisNa71mrSOoLVrELw/Nv0/BxOGmLXJ1fPUYqZ90hSmPkMAgiIMkIYyogTZIimSYinWx/pISKsv2u+1X0Tvs3aQnrx8Gf3gvX+bv5dYIU4QcoJglcLOAb/VEvAHfYx6ZYu7wWiqkxnqKIvHm2hyyn1lNplEonCZPQyBvgDBEG8CE4gSIn4/FphUv1SBaC6HP1Pk3yeeR7ZLsG0xZVq1+rzHYHS7DUZPs8njMRlcLuzH9fw9EMLb2E4xoACEXLAHvApv/3G36CRBQKI2/wEUwwKinNBjlBBIgj0WWyT9FspESgFKgY9hmwAUR4MdOzLZkLd7dnjsgMMeomsohz1gM1Agln7C3Tw+mlh2p8e7fQ6m9qjf5/JYFpG/2PI2KOKxE/lII+tTIEBYsG0ko+B+rpiIdjfIfgJF3EAmA+xOVfMSWlOGnv0AlhIaIXflIBgGaCVGEblkxd6BD+6JDCXdTf/i4GZVrx/tiOQ8R+5LDoBPZ7vcXrpgJLdnJ9PU2jqexDi8m4+AN5EPJoKoJSmrshxGgZgyssAnEpPItgZFHIX8Rj7wppKpLtDPUEUKOfexHLj3vWvRlEsXTAWgUGUZoVE6FdLRUSBVnFR8zQA7wXnu6yGNCChFuviS6mV9ZTUgMLYWhK0CXkL8MyIXMP+w26rVlKFYWBEPsJjHNwgVZzN2Q6g9NXZm78jES5Gn04+4aDah8jrCW+Eck3NFbaPJ3U/M5L53JtCr4mxOt50NeBvG8V753+R9EEDJ6l4oj0g8mO3r9OCTKWzFBiG4Zzz6xZRz5rXa+sbE6Nm5zPYDdfZwt5sOhnUguev73f4OeUxzosu0vX3uSxPD3tBk2uV3xgiBM+8DEbiI8omyo1iPKCjacH/egLnochl5Trrd4CJ/MRrc3Btrd8hWLn8LXIHfJBQC/xBGlIUX6FqWRRsYDq4sThZmxQ9krKZgmspOJnv+26HX2fELBic7IrMnu4OM3uBNxdvu/EDvQH93OBA2/46clsNzBIlZZaSsSL4o7R6Akg3lB2W/zh0CCw8myor16uxLL8Fz3N1feTjmeBHrUETUorW9cAXpWEtYBGR1SA8YXwdQCLA6AIkx/eQOCaW3PR0IWc30eP9/nv6P3F2LzkDOendY57B5Gyfds6xVo4M14TGVpD1AD5rMOrjSlbXWXqgwveOgr2plYaEGBPIfwVH4ClGFa8BGJWrWRNoEfAwcbXbERlpoJtnalLJl98wejvj9pzp3wkfS1gH/N2JtHZ72pgfm+l/Y0pwghPyhtykUUxlRucYVIRYNisaKghAJQUy1NQYWxp87/YXBcWP4sNrQl9yV2OV3OMErw6+F/Q64Umne/KkExXDiZOQs8hfbDSO7fI00kj5UJ42kUQHDVJ6w/kz5MxfQqLi503Al+82xK9vRg6trkCWiWKiraI2IUkAH9R79HeV3Wvajh7ddyHKX0BOAYPO/g4fgBaLmz/CIAiqAZLxeuOChGNvb2cA0tbeGrNZ5Lj51eO+RvtjUQwtwLs6wdd/tbEurzmW5F9ljM7OvR0ZX/Ti+6jvyAHvhE/kU8Pjpudb3Wvee3hN+txGu3OkAm7mLcIV7G6iEHKF1wIXWiYR1wHUK+3ynA0e39vnz6JdCXHeMyCZ43sp98fS+xVwOPfZP/DNSRLRq9EyFYCPIikkRJbLwF4VPoSaDrEJUPbA7XFKsqvnlXZWFgNTO7/3xE5oCUWXFt3ivnu2gfSEuDb6aYg3j3Bjy8GC4PsqAR9cwPslzGNsXWaxrhlHRU8CTp+ZH7QXFFSjIpYlKSVHFFt5ix5dcqYPcM8jS2YFM737QInAnhDj5ONJrOZ+Fv+gXq0kR+PP4vSNdubk92fjQ4vT8kYWBgM1/KOVzNYLXHng/4H5w7vCPG9qOZI/Fgy8PPsYyP/2EmwPI11JCJdQDB4bEx2BqruoMDsy178jW7zt9bn8genjXoG+4zVgHlcspD3cbrpgdU0M3KUbw9ShcRr5WE/ZVX0lEcWQCO221WPFQ8VcdX+5vN1hkda46h8S8yRFKd/j37B6NDx6Znl9aGPLTgUPtXhzF/qubq+VifU1hqpjxl4EH5g7/sDGNAwpc6hICwrXyDzDB55Zaw0ut0QE80SAPLDzPNhQRtHliflBEGvSyJvF9otpC2i2r2jx36qejY4f8bMpd32tW18CK3GIxqGk0fFkpKdpeOl2v5K6gCrLdRf+iRi7Ujvxt1Hu64WXc73it4MKvB0J5trK43aAa6wE8BEgw3c2t/fUdRlvH4jOfWRgJ9w6nBmtdsabGM/sPwwe3+hrserq82n1g14lwJhBnjU55lSYRHj8mcBwNJbAfxUjyGsbqYWG/+bnFfUv/rIQrY3eehX1j+LlE/kOUjxW+p4vwcCf0QSQKMZ8WzMblu2UmS9d8drZ4Yl9OWlA8OkTLS8cRC+l0UtvQmbA4wVUu2loZ3VzdAL4n7D+X50RPCvpBM86qcJB4lVg4Pjl/ET3JvXpMBEoSRZ9+SD4PJHXUqUXSFHgMcT0NWtOPXlBy/wrPcy92fvbhbrCVe/rznonDoFngvDb/HngHilFvxTlEXUOMJlJLYAPzeYTXyhEaUt9RlNiKixTDltBYJNHg3bqwfYtcZ/ZXG0zaamNsE7gWDn3f7VG16P2dPV29T/p6xiUao2WpwUaFaGFPA8KKhNcJNZ9BQWdWFEcQJQ85QOLKj1lbDtCOTRCSqaaWgaWkRLJNVba3XCWTlGgH3I8sNLQ2M9X11mitAgyPnPGzbI0LvHS3x1KfS9fpze5nurL/W9UwNCLgSOU/ApdhEV+HPqmvG9sNihRcbqxlPJTWka4P0725voF0MD7cAX7SVmszPtowHIi1DPcO/Z0rjGOwonrdAK8hJZuEjCPU8ECyakrjjwLR+jZBFjbMyUBpVi1qzCyH/alci67MnNB52VqdNWJIaeAbd95Kp8vUWnfbcx2P+xOyMvYfufNKt3kp2Oez8lr7EPwK5UlLWIXagdymxH/WMtfkLiYZnnPgV67mZZkDir2OVNw0vK93POJPbk/33xt1xmTQIMkaVWCpybG5QKdxe9jW5PhQ++eZWCzVmIiJjCpea2/lreAi/C++m5IWEyIIbmNoxEX5wscEATg0/zTaxNJj7on+ip624KZ+RlZXKo/TkSj8VlJhMaY7uc4jvaEto+AbnbFRRwXPAzS/O6EUkqja2gXuCboRJMwKA94GEq5jKS2TBIqVBfZr492WaH80LgXlkO1bjvh7ds361O6oTW9vNrVqwDWL5//se+QXXJ0Wb7BgS2Hk2e4vu9t2SD3U/YEhrw3zAs0f6AxxHdVRjCruUAGe7/huAx3VEBa1TyfFwK3vN8RnDqhKd8sry0uKqXEPGrDPVpm5L4B+g8TB2rgXoPMuxuLfE6+rtruDmCsYu1p4BfXfcp7v62Mr7qq1djzKoTHPM7N7JzyORjsden39zh/AR2htVf42lCH/CvlTA6kgRaxVLXgHZT9/4tDxH52QVy/MzqvKwHs/4n4rBfRbv/YfvfND6BljcHw2NIMWofX4nIjWiTeSHisOFJVXDJZWlBaKjTaHS5JRS+H18Cy3I7BJC1vK7OYKDzizwyVoSIuCuYHmcMs6Vv41rNbvEGr4LKDBAcIbRenplJiujusSOxPF5uqEKb4zLSuf3CTpHe4v7BtxBsFXVHbub8GAVmH22bnzoJuWmhgn9wIYT/vttkAmM8yu5gncRHtr/mTvjRuqwc3CjpkESbck49Nt8vJJhaRt2hMEZ0wq7nHQpd9EZ5HV7Fav3ekb5vOCa8ItpKkSwerG4wRlEsjWBMCtpx7qG/3qfQPb5js8SWOnO2kEfZ97Izt4+tVs9/DIocjQ4KcQl2/kbeisKUE1zbxe09BJTHCPp5BwSOGLGn/eDNrbdiQtRcbdB2WySUWRcdS1OTav1RtSBm9VKFqrNYGx+NOeHjVZ+1QVbGjz2S1B2j20lTbXua9XBemjfC015+2wDGlIzs8sKAMkkuRf6IZvQbBMLt0/S8sLIkMnGr09B/dtVgbq3LVOALYk6sGbTMudX1T9W7K49e+7n/J0bZdYDX/DDmXXsF9GscnWaucG1MFyXZmajcZmkgqEeEm6XQ24HUUZ7mXQkwnYXcExVENuoTPVt2EJYVjv13+lXQvYg287I412Jtg4tTg91edMDtjqa6iGsX33ZMC1Dsqgsyo1dPfW6cBWxq6vqJaqzf2JCexjXf4DsBOexBzFfXq1MqrWiI5KVRAdikmw0zYeEqsrqzUBP1NPRkKykEy+XysFH3dyN2uUGoWkVeW2mihg6Ewx2t4Wnveu/A1YiHjCz7Di1ULPm2UFQeHmXthdrh3Vg44MGymO74lLaOPWyjgs4B5L0XVmX2+AMTlAu4o756ioC9lBDNv15znUBwvxXI57O6tQq/g5geSu5tp3G8VAXfNZcJsrBL+Tc79hQpANAIkwa3DwJjrv1/Azr9XCUrg/l2MTGhLH6dOoVfgKb/5xorS4EJLFwCWZmjLMFoiAzHZgVwkAlHQGfMwVXHg4qFLACeUVcEvGHanrv3lTvXub4bYwZ72C3n4PIT9bkwrKDdFwTSlQytBsDX7/g/vvL6zVgfJHjt+emHdKC3eBj29wH5aPtBdpnwbKq6oZpuiEYOeDPA0rkb/8DMP/48vKl3d0IOOD9uGgK7lbTKORadW4nBVGFVXq3FtdAGTuzyEvqcyghippK9LJXXbYMgoGZNzrvqh9GFQI9u8Qb4Nba/9PMrLg1iauahOI9vX9P3lEMtsAAAB4nGNgZACD8gcMMvH8Nl8ZuJlfgPjXboRlwOj/K/+rM89k5mJgYuAAYiAAAFUIDGV4nGNgZGBg5vqvDiTd/6/8n8M8kyGFQZQBGTgAAIT6BecAAAB4nB2OTytEARTFzzlvYTGZjZrMk5mp571pikg0ZEFSLwtZsZiV70DZsVA+A/kENjY+gGyVhS2lZhZiwUIsiK6TW/f+buf+5Qf+jRsOfbOHNW7HuZaRsRIvXMUsKxjhUTypgZxnaCrFsBrxpgKF2vHMaesX2NFK3KiHXE3Ma9+sWr8z99DVofPC/oA8WUBVx9ZPseg7uU7MTXMpvhjec4AyKbErYMw3WrxEpg7a/Pb8ZAzU8S8FUg6hzh9zFJ2k5t5xpKq7N4tXtTDBLddu45PrmFENU7zHnK5R8jGuOIh39uP3D8IROtEAAAAAAAAAAAAAAAAmAEwAZACEAJIAqAC4AOoBBAEsAWYBnAHSAfgCKgJIAoYCsgLeAvgDDgM8A1gDaAN6A6oD0AQABCYEaASkBNoE7gUaBUoFhAW+BeYGHgZaBogGygb8BxoHOgdgB54HyAfuCCoIXAh8CK4I3AkICSQJWAl8CawJugAAeJxjYGRgYHBg0GZgZgABJiBmZICIgQEADXEAtHictZC/aoNQFMa/mxihpGTsJMU9KHqzSGYxGGLJlF2aSxCMN/hn7dQn6Fb6Dl36AH2ubv3UO2TqUIhyPb/z5zv3eAAs8AmB8Vng0bCAg5PhCWy8GZ4iEnPDFhzxYniGufgybDP+w0ph3dFzBlXPAhE8wxPc49XwFBe8G7bYPzY8w4P4MGwz/o0tNBSrC35jnv2Vj61Wl0LFaj9Y4Ak7pEj4brBExpIWOSUlOjSDf6Sww5lDpUOupP9M4S5Nks0yU22+L7smU8eiO3tpm5cFs9dCjDnwDo2KPXpbc3EKLiR8BLRrnv/OMqolQsZXPJIdQ64Ria7aRNcn5Uo/cNfuXzMzLUNv5ckgjG62lgOFNRsUwyZcTtn/PQ6qbgpduaEf3OrqXy2ifa0AeJxtzDlOAgEAQNHHUELYCTHBhgiyJWyCxopCBYSwr8ptuBFno9c5AD957RfwdwtddN1rGIoIRMXEJSSlpGVk5eQVPCh6VPKkrOJZVU1dQ1NLWye89rzoG3j15t2HT19Gxia+Tc3MLSytrG1s7ewdHJ38+HV2/QeJuRD4AA==')format("woff");}.ff14{font-family:ff14;line-height:0.995000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff15;src:url('data:application/font-woff;base64,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')format("woff");}.ff15{font-family:ff15;line-height:0.958000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff16;src:url('data:application/font-woff;base64,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')format("woff");}.ff16{font-family:ff16;line-height:1.019000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff17;src:url('data:application/font-woff;base64,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')format("woff");}.ff17{font-family:ff17;line-height:1.123000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff18;src:url('data:application/font-woff;base64,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')format("woff");}.ff18{font-family:ff18;line-height:0.913000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff19;src:url('data:application/font-woff;base64,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')format("woff");}.ff19{font-family:ff19;line-height:1.025000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff1a;src:url('data:application/font-woff;base64,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')format("woff");}.ff1a{font-family:ff1a;line-height:0.987000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff1b;src:url('data:application/font-woff;base64,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')format("woff");}.ff1b{font-family:ff1b;line-height:0.994000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff1c;src:url('data:application/font-woff;base64,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')format("woff");}.ff1c{font-family:ff1c;line-height:0.927246;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff1d;src:url('data:application/font-woff;base64,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')format("woff");}.ff1d{font-family:ff1d;line-height:0.988000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff1e;src:url('data:application/font-woff;base64,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')format("woff");}.ff1e{font-family:ff1e;line-height:1.006000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff1f;src:url('data:application/font-woff;base64,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')format("woff");}.ff1f{font-family:ff1f;line-height:0.995000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff20;src:url('data:application/font-woff;base64,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')format("woff");}.ff20{font-family:ff20;line-height:0.942000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff21;src:url('data:application/font-woff;base64,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')format("woff");}.ff21{font-family:ff21;line-height:0.848000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff22;src:url('data:application/font-woff;base64,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')format("woff");}.ff22{font-family:ff22;line-height:0.958000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff23;src:url('data:application/font-woff;base64,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')format("woff");}.ff23{font-family:ff23;line-height:0.943000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff24;src:url('data:application/font-woff;base64,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')format("woff");}.ff24{font-family:ff24;line-height:0.970000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff25;src:url('data:application/font-woff;base64,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')format("woff");}.ff25{font-family:ff25;line-height:0.941000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff26;src:url('data:application/font-woff;base64,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')format("woff");}.ff26{font-family:ff26;line-height:0.913000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff27;src:url('data:application/font-woff;base64,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')format("woff");}.ff27{font-family:ff27;line-height:0.625000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff28;src:url('data:application/font-woff;base64,d09GRgABAAAAAA7kAA0AAAAAFEgAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABMAAAABoAAAAczjEDgEdERUYAAAFMAAAAHQAAACAAVwAET1MvMgAAAWwAAABFAAAAVlYhYKhjbWFwAAABtAAAAMYAAAGq0CPulmdhc3AAAAJ8AAAACAAAAAj//wADZ2x5ZgAAAoQAAAjEAAALZMf1iy9oZWFkAAALSAAAAC8AAAA2EF3vvmhoZWEAAAt4AAAAIAAAACQGcwLuaG10eAAAC5gAAAB4AAAAqFF4Bmtsb2NhAAAMEAAAAFYAAABWNyQ0LG1heHAAAAxoAAAAHgAAACAAbwA8bmFtZQAADIgAAAH+AAADzOf+3d1wb3N0AAAOiAAAAFsAAAB2BKYE2HicY2BgYGQAgqtPF9WD6BrVDQ0wGgBMsQZ/AAB4nGNgZGBg4ANiCQYQYGJgBEJNIGYB8xgABg0AXAAAAHicY2BkYmf8wsDKwMDUxbSHgYGhB0IzPmAwZGQCijKwMTPAAIIFBAFprikMDgwKDCuZHv5XAap8yHAHKMwIkgMA3LULdgAAAHicY2BgYGaAYBkGRgYQWALkMYL5LAwdQFqOQQAowsegwKDDYMRgymDF4MLgweDPEMIQzpDJUMBQxbDy/3+gOpC8HpJ8MFA+kSGHoQgk///x/xv/r/+/+v/i/xP/j/7f/3/P/13/N/5f/3/d/waovXgAIxsDXBEjE5BgQlcA8QIMsDCwsrFzcDIwcIF43HBxHiDmhTD5gJhfgIFBEC4pJCwiKiYuISnFwCAtIysnz6CgqKSsoqqmrkHIeahAkzTlxAIAiLUqVwAAAAAAAf//AAJ4nG1WC2xT5xW+57+OHcfExLGvnadf148kOE7i62snceIk5OWEhJA5j5uYvCAx1M0GS2GD0qbiFTIxiAajW0upCgmTNq3bmJCGtEdWWvbQWlRtmgqVqEqZkApjG2Xs1eZm596bhE5aovuw/d9zvvN95/vPpYDqX/4itUilqHUUxfEcY9LTGj7E9+80WpzZGXxqmydiM6nBnzZK4VqKktfSFBVmWH5xZyqVoihY/uvyA/CS29L3QLNG8D5u/Ae5vbSO/B0foAjlXn5ANGQRf7dQlCvLnkVhGqefDkbpgJXAd8X34YjOzg3sGeDsutWbGhJcehs2bRucaCsvb5sYXL1BHBOYZwfG0+HVwBpYPqoKw47hBW+pPz8nnSwuNcCjFlqdVeh3Yn6g8vD0Ka73UJSRxaRcwIyFkvWg1jgYRxTqIErzQQ/r1NNHBHcwFioYns6vrixr+5IOpkWbqqdzyGPzZTW1esL5BhW82TAWtKZPjZbGKt25RbXt8R2HS0NmU3G5I9BZ6KwukHPasWZCfkQ5MKcmpGSkWaefeDkrcIGQnE/jNTqYS9aqrq3HMxz8aJ2nucmvTqi7o43dQlMX18HDJBl8w/fsjoLKWMhtKN5SGYkMNbXFG1Wwv0/hVtaEqJBbjaKKUVZmp6QNvCzpQ6huPF0g15EvE6pscKyAoQ0rOLqBPT6f7WuabPrFz0Z3T02Q6788x23f3u4nB5ZunJo5ehzr6cQYM3IM5JxD1h14cAbiHhsTvzY2BheheCkAXeIlcl18D3N6sf472BMaKl/S3ONUZ5kD2Z/Xnbxw7O6xY3fvM1zncy8/18kxqzd3gczPi+I89I1vT26uqNic3L56Q8ncVmDsSYxdhh9YP6BuhDHZQBaVdXr9wHMmMxeIEiyuDDx8EPm30kRI0Dtb8wMhR+8788G+ocCJjhJbYm+3rSrqqRs8/dLzz8ZSlawWPutoycgJeVpNZd6Xagf8TLOnv2qgK8MSdIU5xuk6OnTQWdYUkHDokZNe5ASZN/IOBjvRoCetj8bIvr6+pVmyT1qTRVH0a7hmvewNmjOu/OM9vPed5E+fmiHnU+fJzNM/Ty6Q+NLr5PrSFRKTjwCJKxq7lh+SbJJHFVG81MFyNYzBxAXCjJp1erzSiUdS6wDllNiw8GqNnmZwRWiuW/17g7em1FGoNbl1vJvevCu2Nc1ory35hv8AW5Gj/Yv5AGPzMiN122HyB6rswiqP+Aebqj5jg7u3p9Fg87PWtGxVda+Rzf9dnyGLTjc4LYmYgqsacaVhbdkU9jwntQMXCgdWZWDdiIWRhAidiAskPDqx11IxUjccIFA4d2Ig1BzDVvm0i5ye4kYHw1t+9dYHQ/Fdsr7W5YdwC+vNlfRFm6jlSsKcZCBFTTPc6s1ObWqeK23W9apy/T2hyekXnhsehcTuPd2/bYiw9XWeU3sOXtgt42Qx3iPEaaKs8o7Bs2rJiUpfgCVsABmlxB08ipOyZN1IhWXvxIbWXAMR78SaQwMn5lCXQKw/PDjKTZ12FeZoQC1WJXbFhz7A+EXIgwrxMlKvuzk9aNRrQBmHHNvtkOqAiwJdtiEkSGB3TYmHOjdVbRL/BGzGbE3vQkFfoUvCPH8yPtD8+ivDSq9jj4Ga3JCcC6y82XF8kAtYGCleIXCgFoRYbHZdgVlfkCPAVTEKV9sGnyFdpNDeIGNzYe15lJaqxN5Zq9NtMOnTkATay0lOSQvWAsv8Dyscf1ipHHZDhsEV6AqYSyqLnWlCVrLAZzNnptPEN/I5okAj01Ev2i222hLOYU4z2SNF8QzG5DIXZ2WbVS1r5LVjXQ1Yz33UxKzs4UFZZoPSQ1J/w32hNBLtEQRSP5BXHnBZYFx8BfqqI/GEeAcb55+92lzvRqUPG/F8FmPJe6ARg4SRpbMC/hHd0mOiGxlXuHyyTl51VpBExc+UgocG2WO4Q3KMDIJYokS6MDJABZ88JvCbhjip2ebg7HptvrPWk1sRcgq+VIvg8Zk3lBYQXfuAwW7Kslpz17PtQfFF+EJ1XW9YfANSRVXrXW0B8Q61xkEelfOEA72cbCW/REIgKgUUpGxPaNjYulGJIiV6wgO7/AnRYjyNNGdDwVDAbFI7iclKcCsM+olTD+z0venpe2ymrV6ot2Uqlxc/XFj4cAG4aG1jcXFjrXJZ8XcF+lvqHfRNeK13aAmfxMya0w0nJTvPneiJE0Nu6wbF6CM+8gAdnXhrKUneb88pdClGbxH/QynzBDowtl7RQqnYwmAXXMRiI0JmhqOmHcrFd4muP0knupWZ+hDexWdKV/YFPfrWBlZgTGqlla20MtGebPqw2EvvNxb7vJVC98Y9iUi/L18DvZCRV+3jmn01yf1TPXyXNycNviKku2ry9GZTfahrON9d6ck1Wd2mkmKrdX2uday7z1rE2WQ/Lv8bgJxDr0t+NEWAkSjw8LIxsQqAHt6WactW1fhbW4UeNOT3i5tBRSI8DLSdOiX3WhPW8THRSTEcLO9FWaQAnLSj48wycPBxnBR21DZPCBNF1Xa90EHKSzt7YZ948Rl7qMoGdoyRjoH+jDGkqS9PE874r2+O/np4MTk7Bt+Tul7sW51R13Dd/5s/yWTiW6PjZGJbkqSEbydScEZ8Gp+bgLPSsfQYzii+kWb+PYwhXY2sV8MavZwlzEHgyu5D07uu/PDL+/dPQqb46No1PF+5ojyzXCLXaJbxEY2023h5qYXCCOKzr48dqczJcRo9Tru2ILfAke+4On4cgYsn52prahkjSd+idfeQXCwCKIn4P2IsLUVpAd/YeHDwDnhb/A00iO0QEW/BGXhTnGlrhufb0MbLn+D7wd/w/UCHPqigqLS1vRjfZFe6WNpu0jiFefk3i/wioVbmFUy9+tFHr567fVssu3T44KVLBw/9GH7SpE+2jB/46nj7UxmN2oaypo7ujWX1xpsXzt+4+dqFm3Bg9vLl2ZnLl99p7z86njwYby+p2Bpr2cb/F84MkaR4nGNgZAADOWX7a/H8Nl8ZuJlfgPjXboRlwej/7/+rMC9gegjkcjAwgUQBXDINagB4nGNgZGBgevhfhYGBecP/9//fMy9gAIqgAC0AsncHZXicYxRjAANGXyAWA+NwCP7/nkmHQRWIU4FYCogVQOJMlxgCgdiXmYtBnWk2gyFTMgMf8wYGAaC8ChBbMX5hkAPSykCsAVTPB6KB2JHhHoMzCDM7MjiC+FA1VkB7fYF6FKBqXYBsDqD5fECaG4rlmR7+/wQAWbYbIQAAAAAAAAAAAAAAFgAiADIAWgByAKwA4ADyARQBLAFaAZ4BsAHSAh4CSgJyAqIC0ALwAzwDYgN2A4QDvgPmBA4EPARWBJgEugTcBPAFEgUsBVIFagWyAAB4nGNgZGBg0GKwZGBmAAEmIGZkAIk5gPkMAAx9AKwAAHicnVJNa9tAEH2SHUPpBz71PMeE2IqlEGLnZgLOB3YIBEKvsrVxRGyt2JUN/h+lP6PH/oPSn9FjD/0DPfbtWjWhFAqR2Jm3q5k3b0YL4B0+I8D2+RRENQ7QDn7UOEQrbNW4gU44r3ET7fBLjffwOvxe4xbajbeMDJqvSNTxWQ4HkOBrjUO8CX7VuIEP4Z/4JiT8WOM9vA+/1bjF8584h0aJDQxyzPGICoJ9zHBAH2OAPk7Q2eHTZ3iwwwP0iIbIyDWFIr4joyWXwpJecIWCnJpVSm9T/y1DxG8uc8FXnmmwfqfoFf26jr2kX/hdxcgZWYTexTpUed7M10yJn3im8UA7ZlRBXFFV6fUNceGzCsYfeUWOaVvXYsUuLPcZV+pVOSURcK7Ljcnnj5Xszw4kHvRPOs6eejtwdtCTYaanSu42tlJLK1fFTJtSm7RSWSQyXCzEM1gxyiqz5umlWqxVlc9Sya2kUpk0U8vUPIl+kHFe6GpTKhleSFpkR9pIzly7mto8y1OTK0tdN7hlkxOuaxz+Y0y4uR1PxteHu0pgsPL9rTgtTFSWr+hHHEXBrJEfydyPKmHj7veecf2vzjYq4aXo4pgrYWbMq4KRLqqRNnMlSdSTM/lbD4+SuHvcTXpx/0Xt3PuL4n6a68BdS6ca98rYXBcSR72X0P4GR3q1EAAAeJxty7sKggAAQNGTfkCkBi3NQW0NCc5mT/ARvetrGvtok2YP3PEK/LUfS33mXQOB0NBIJJYYm5iaWXTPSiqTWytsbO3sHRyVKrXGydnF1c3dw9PL2/cH4PULfgA=')format("woff");}.ff28{font-family:ff28;line-height:0.957000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff29;src:url('data:application/font-woff;base64,d09GRgABAAAAAA4MAA0AAAAAFDAAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABMAAAABoAAAAczjEDgEdERUYAAAFMAAAAHQAAACAARAAET1MvMgAAAWwAAABEAAAAVlagX+VjbWFwAAABsAAAAJsAAAGSSFtQ1mdhc3AAAAJMAAAACAAAAAj//wADZ2x5ZgAAAlQAAAinAAALlD5unOxoZWFkAAAK/AAAADEAAAA2Dt7vOmhoZWEAAAswAAAAIQAAACQE5QFcaG10eAAAC1QAAABaAAAAXCHzAKVsb2NhAAALsAAAADAAAAAwGSgcNm1heHAAAAvgAAAAHQAAACAAWwBmbmFtZQAADAAAAAHMAAAEOGTCe5pwb3N0AAANzAAAAD8AAABQAhEC+nicY2BgYGQAgqtPF9WD6BrVDQ0wGgBMsQZ/AAB4nGNgZGBg4ANiCQYQYGJgBEIxIGYB8xgABTwASQAAAHicY2BknM4UwcDKwMDUxbSHwYShB0T/92V8wGDIyAQUZWBnZoABRgYkEJDmmsKgyKDAUMG09t8VoMq1jDowNQAzFQwxeJxjYGBgZoBgGQZGBhDoAfIYwXwWhgIgLcEgABThYFBg0GHQYwhgSGRIY8gEyhQzlDFU/P8PVIGQSQbK5DAUMZSCZP4//n/j//X/2/4v+7/0/+L/C/8v+D///zyoLVgBIxsDXJqRCUgwoSuAOBUGWBhYcRsGBWzoAuwMHJxc3AwMPAwMvHz8AoIMQsIMIqIMYgRNog8AAI6EILIAAAAAAf//AAJ4nF1WXYwbVxmde+/Mnf/xeDx/Ho/H9ozt8dper3dsj73rjXeTzSabVEmVZJM2UQhJ1KwKCm2ShjYJUQGhpi1UVKUIRbwQUinwAuKhEgIkkFCREKoED5EQPPAKQrwShER3uTPeTdJ6bM3M9dy55zvf+c53KUBx29epD6k7VJGihrqCAj9ognpYH07AoF8P+x1yinuR+aE3061wACCEAJTcRTGTlR2z2bSDcZAXGEZGXFTWjAzI6JLpr1PkA6j29iPqp9R1SqQoy69PX2To+LJbrRR9vyZUXbs+Y+VrFAUpYfsTeBf+kOpSe8hUFo9BlAE48Dsg8BXyGwxjMhQPc3ELJDe9KHmb5QHywsDPIZMMDPodGPhA6+R6dQFCIKJgb1gdV2gOIl6rlIXXcrMdjKEEf69vnAx85/13VxY3nP7z571uy3CA+7ODgsEDCKCgC40a+O2aYGCkFQvj6MzXwJe2fqe+enhmyZUSvOb2I/AncJ8KqZjg7UWsAsjX0HvRMC4Bk00x94chAUcin5AnrGGMSAAEZT3w02fBd2MeyUMMZiS1g2kJIflcr9zE184aM89+YyVyVOa/+ZuaXciFrUYb3BdK7+n4DVZaxIhHvHPUyd2EP256qw9u+i63dff9WrepeHtGt2fLU/5rBOMJcI+qUFTNmkLawWKmrIUJEJxgJrAAr7BM9nTXHy2/PCbcqA4na6ViOGNEEn1eQKyz1J87cPcLdU33bG//uePrnsIl60DK3n4EZ+EHVI/al3Jhshiy2HxMBZpSsbN+nCSPkFEnieyAZRCjhJCEj2TGBIB3viNwSP6RyABBiTCRFsJ2e9H1G0Lri/Pl5oHxkfV2YZWRNY+mAaDRTDFfOdrLiLXTdgN+IOLSltkyTTJTRCxrB7bjXqHXLs1XRnfHR8p/yVgQARtv/cD2r36rqWqvV04kMfiEq1uEqyLJ6NNspWgJXSxOmEpjQj5mp4kE7QxGxsVxNNo7XjtWqZ09vC6UzZU2U/NXxeyS1XxJRDjYG/cn7w4mgX20V6fz88VgiaG2N7u65jerSZ62e1t/hiL8CbVMUbleIvsWUBALg92asciyBQKHcDUGE3r46Qwq7H82eUTIeoEu2X5m83v1jqNbeYiy6wfOnOIhg/gNxpLyRd062e4NC7k5FnuypatZUcUq+KbgcOrVE9caW38PCrpbMlQgguOCLUh7vV7TcNoNxyh0iryph3bPGiVcNQlXiwTvfFKruVRBE/B0rieIQB30E3XNgfoymDC9yNDDpzzgHyNNkhc4hEVMc7noQL1Ii7zFu6qkLmEsEP2wObfsh1pVKVVq+VKtDuy78xkF9EU2mSMYs66Ls35xNX90BKX9GPMMzfF6wTbksvPHqm3VKpbZnNaBTvBuEH2WiMel/pESGbEIp8pPcU/Z7j+wZsoYkuP7MvMHy5I7MsOQumRmT4eK/jr4aA9nMZlP/rZUyyBGYBk27BgZIVmjRWrgr0Q/FymKxAuT4HEafaIfQ88Aa0dH1oROLxRIFjU+VSQEwDCeTkxFkOAcxPWnBlprXFGRuQUWY4mGzx1tlcvcrYt5b8DlzWG44OQ9QcpzrCXQnBkjRqEh40SrZVVbahnapbkiX0LSsoyWe0AStItt26wk99IvjUMhq8yLhHkWvVjNHjpMf+zmGq/RYeWQX/J1oVZZs4xFj1XWifXQAleMAk1y715uXD04b5zihAdvy7z44oofneKmvg/+RbhYI3yzu3HsqmE4QbtE7Fxg/UkawFQ+w3iHwPtlJK5I9P5OxugTsXCYy8/uKevaHM7Ulw5WnFLckIQWzzICxtq52MeSbHAty9ws1y6exfIv7mC1TwRDY9GuWoace4W2upOwYjXe2ixXJcRwiLcnHmMG/oJxQ7Av9MZE3w2C/w7Br1DeTufaMQECKIymrTFFRwzhXnd9Y3Fj/pl2c+HS4shtWHppqTbIC+t73zi7sjKJ73T2xZ+bu1zQCsPJmX16gdTP9le3HoKH0KEWqVWK6hGn/Gyzq08FSrod6SpTEZER8iVKwga760g5tAPlrf2yUnQFmgESdPt+NS4gYo0MTdtOkPlVeV+WyAWhg8+VkHya5lCUMdeO3HpeePX4O62S/lFY5A0MAYAImVy1CTWub2KGR+yp8nkRuZAGGFyBR0Y3Tk/Aha2fy185ORqmdUXcC9wjPM2SKKagd4lJ85y4VJLm9LxjVlMl395HYxh1RVbqSogl0IwTsZFrsO7Zlum5Sk5Updyak5N9xKD79wQszGSJTSA2WDXLN+g9X3bbPiediZqNTZzgoEi+RgRHL9nD4F3btEyyI4g7MOwwj21nB4She7Rl/u/kardvqoEstF3AiwYDM7SI4LFVr2tkyxyfyeYxK3ESqN8eP1N2NLvh+J5U0HwOOawp60LvSKGYs3zX9bicSkCD3uN9D/gnwUP8HKTbFhLyZzX+ZGfwWOv+jlukud3tylc84m4yOtAQ+LaccqWej8tD9s4L2aKmF1qaOKtCFooInTymmwtzqvVSvgTiM1j6+JodZtM8Ooc96T36N56qLXbGn3fVqoaQgJjzjlp+82VTvdHoTnETX4cOwU26eI5UK+k7hj51pQnsRWkeWWW3Cw764WM7T2MK0zpJ2vyvowGCZHeYKzUUbb4yP7GgwGFQ4hxeZQJrUFuRlVLBzO8LX1lplPJOcBArI7BRV9SMVQ8qcUfNZCEUBNhVOoV205zrto+faWhWRvMa9uaVlY2SFY0Wnj2KFTXFzRO+HxLch0j+w2DaglKyI4M4/HC6zSHkDlLHKYHek6aejMbk76TFxsN+kh+Sl397dKEQNbRGhkWsSucK7uUGlvUZGqsQGcHA0W3OplfMeqBqDo1lTredCy1OE1osp7Bo+VCrfTmsLhXq2VUNQ5pbefPr5mHyKsBxtX6tULpwNl/X1fllFtGIOXD7226sYJoc10k4/wfqlrP9AHicY2BkAIM3F5NuxPPbfGXgZn4B4l+7EZYFo/8b/7vCdItpLQMzAwcDE0gUAKStDwYAAAB4nGNgZGBgWvvvCpD88N/4vyzTLYYUBg0GZCAOALEXB0IAAAB4nGM4wQAGjL5AAsT+w8ABxDpMCQxcjJcZxBjtGFQZHzBIMBYxKDFq/DdmVGHQYmRiEGH6wKDNJMSgwziLQYPxwf96xjIGFUYLoDnfgHqlgGouMnACAN/aEKsAAAAAAAAAAAAAAAAALgBEAJwA7gEiAYQBwgIaAnICpAMqA4oDugQeBGIEqgUGBWIFynicY2BkYGAQZ0hmYGIAARDJyAAScwDzGQAOfwDCAAAAeJy1Urtu2zAUPZKcIH2g6NTNwB06JEhkSMoSazOEBDAQdLCB7LLFOEJk0yCFoN6750869Df6JV3yA1l6RLFB0CFDgIgg79G999wXCeATfiJA//0I3nscYBj89jjEQfDocYRx+N3jAYbhg8d7+BB99Xgfw6ihZzB4x0AHjtXhAHlw73GIz8EfjyOYcODxAHn4y+M9fIk+eryPPEpQQGOLHQxqrHCDFoJDLHFEmWLMleDkCWdEE1TkLKCI52RachTWlIIpNuRqRtu6s3S2CiPaOmbDJZg95bLuT1Eqet953+cZCsawZGlGFvI6RsnduuiVy1wS31Kncf3q+lDo7c7Uq5tWDpdHko7HyUl3ZjKp9ELJfGdbtbYy3Sy12WpTtqoaiUyaRmYdy8pMWWXuqO0JRWkbvZHaSimtKSu1Ls2t6OuX4gHfcMkiC65zHLOV5+3HbKdrpGZzmrqKni3tDTVLUi+nRXF+POkTx3O1rhe6qaZt2dQ0/8/FPwfgwoVvnTS8mW5yGWeSUObcry+q52d8PTFOuTPGTHHGlHrTXmizUpKNEsnlxeJpz9L4NM6S9OwtR3TlXqGlb//aUjcDXClja15lOkreMPtf3YzRjHicbcPbCUBQAADQ4xpAvuzBCvIo5RWRcWxrCe4ATh2B94lvpT9FnAhSmVyl1mh1eoPRZLZYbXaH0/UBZpgJCgA=')format("woff");}.ff29{font-family:ff29;line-height:0.985000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2a;src:url('data:application/font-woff;base64,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')format("woff");}.ff2a{font-family:ff2a;line-height:0.924000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2b;src:url('data:application/font-woff;base64,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')format("woff");}.ff2b{font-family:ff2b;line-height:0.921000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2c;src:url('data:application/font-woff;base64,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')format("woff");}.ff2c{font-family:ff2c;line-height:0.921000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2d;src:url('data:application/font-woff;base64,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')format("woff");}.ff2d{font-family:ff2d;line-height:0.921000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2e;src:url('data:application/font-woff;base64,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')format("woff");}.ff2e{font-family:ff2e;line-height:0.718000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2f;src:url('data:application/font-woff;base64,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')format("woff");}.ff2f{font-family:ff2f;line-height:0.912000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff30;src:url('data:application/font-woff;base64,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')format("woff");}.ff30{font-family:ff30;line-height:0.929000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff31;src:url('data:application/font-woff;base64,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')format("woff");}.ff31{font-family:ff31;line-height:0.938477;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff32;src:url('data:application/font-woff;base64,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')format("woff");}.ff32{font-family:ff32;line-height:0.980000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff33;src:url('data:application/font-woff;base64,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')format("woff");}.ff33{font-family:ff33;line-height:0.945000;font-style:normal;font-weight:normal;visibility:visible;}
.ff34{font-family:TimesNewRoman,monospace;font-weight:normal;font-style:normal;line-height:1.313477;visibility:visible;}
@font-face{font-family:ff35;src:url('data:application/font-woff;base64,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')format("woff");}.ff35{font-family:ff35;line-height:0.765000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff36;src:url('data:application/font-woff;base64,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')format("woff");}.ff36{font-family:ff36;line-height:0.860000;font-style:normal;font-weight:normal;visibility:visible;}
.m11{transform:matrix(0.000000,-0.224998,0.250000,0.000000,0,0);-ms-transform:matrix(0.000000,-0.224998,0.250000,0.000000,0,0);-webkit-transform:matrix(0.000000,-0.224998,0.250000,0.000000,0,0);}
.m10{transform:matrix(0.000000,-0.237501,0.250000,0.000000,0,0);-ms-transform:matrix(0.000000,-0.237501,0.250000,0.000000,0,0);-webkit-transform:matrix(0.000000,-0.237501,0.250000,0.000000,0,0);}
.me{transform:matrix(0.000000,-0.239999,0.250000,0.000000,0,0);-ms-transform:matrix(0.000000,-0.239999,0.250000,0.000000,0,0);-webkit-transform:matrix(0.000000,-0.239999,0.250000,0.000000,0,0);}
.m1{transform:matrix(0.000000,-0.250000,0.250000,0.000000,0,0);-ms-transform:matrix(0.000000,-0.250000,0.250000,0.000000,0,0);-webkit-transform:matrix(0.000000,-0.250000,0.250000,0.000000,0,0);}
.mf{transform:matrix(0.000000,-0.350001,0.250000,0.000000,0,0);-ms-transform:matrix(0.000000,-0.350001,0.250000,0.000000,0,0);-webkit-transform:matrix(0.000000,-0.350001,0.250000,0.000000,0,0);}
.m4{transform:matrix(0.225000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.225000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.225000,0.000000,0.000000,0.250000,0,0);}
.m7{transform:matrix(0.227500,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.227500,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.227500,0.000000,0.000000,0.250000,0,0);}
.m5{transform:matrix(0.230000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.230000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.230000,0.000000,0.000000,0.250000,0,0);}
.ma{transform:matrix(0.232481,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.232481,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.232481,0.000000,0.000000,0.250000,0,0);}
.m6{transform:matrix(0.232500,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.232500,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.232500,0.000000,0.000000,0.250000,0,0);}
.m3{transform:matrix(0.235000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.235000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.235000,0.000000,0.000000,0.250000,0,0);}
.md{transform:matrix(0.235000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.235000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.235000,0.000000,0.000000,0.250000,0,0);}
.m9{transform:matrix(0.237500,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.237500,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.237500,0.000000,0.000000,0.250000,0,0);}
.mc{transform:matrix(0.240000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.240000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.240000,0.000000,0.000000,0.250000,0,0);}
.mb{transform:matrix(0.244537,0.000000,-0.051979,0.244537,0,0);-ms-transform:matrix(0.244537,0.000000,-0.051979,0.244537,0,0);-webkit-transform:matrix(0.244537,0.000000,-0.051979,0.244537,0,0);}
.m8{transform:matrix(0.245000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.245000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.245000,0.000000,0.000000,0.250000,0,0);}
.m2{transform:matrix(0.247500,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.247500,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.247500,0.000000,0.000000,0.250000,0,0);}
.m12{transform:matrix(0.249880,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.249880,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.249880,0.000000,0.000000,0.250000,0,0);}
.m0{transform:matrix(0.250000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.250000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.250000,0.000000,0.000000,0.250000,0,0);}
.m13{transform:matrix(0.263207,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.263207,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.263207,0.000000,0.000000,0.250000,0,0);}
.v0{vertical-align:0.000000px;}
.ls376{letter-spacing:-7.680000px;}
.ls248{letter-spacing:-6.120000px;}
.ls257{letter-spacing:-5.688000px;}
.ls35{letter-spacing:-5.420000px;}
.ls254{letter-spacing:-5.292000px;}
.ls246{letter-spacing:-5.228000px;}
.ls38{letter-spacing:-4.960000px;}
.ls41{letter-spacing:-4.592000px;}
.ls14b{letter-spacing:-2.473800px;}
.ls288{letter-spacing:-1.780000px;}
.ls2a7{letter-spacing:-1.708000px;}
.ls371{letter-spacing:-1.700400px;}
.ls35d{letter-spacing:-1.695200px;}
.ls2a4{letter-spacing:-1.684000px;}
.ls305{letter-spacing:-1.648000px;}
.lscf{letter-spacing:-1.624000px;}
.ls269{letter-spacing:-1.580000px;}
.ls116{letter-spacing:-1.544000px;}
.ls2a6{letter-spacing:-1.524000px;}
.ls215{letter-spacing:-1.508600px;}
.ls2f2{letter-spacing:-1.496000px;}
.lsf8{letter-spacing:-1.476000px;}
.ls214{letter-spacing:-1.474400px;}
.ls275{letter-spacing:-1.448000px;}
.lsea{letter-spacing:-1.444000px;}
.ls1cd{letter-spacing:-1.440000px;}
.ls358{letter-spacing:-1.424800px;}
.ls2f1{letter-spacing:-1.408000px;}
.ls1f5{letter-spacing:-1.375600px;}
.ls33e{letter-spacing:-1.368000px;}
.ls343{letter-spacing:-1.360000px;}
.ls375{letter-spacing:-1.352000px;}
.ls367{letter-spacing:-1.349600px;}
.ls304{letter-spacing:-1.348000px;}
.ls260{letter-spacing:-1.344000px;}
.ls307{letter-spacing:-1.336000px;}
.lsb5{letter-spacing:-1.324000px;}
.ls30c{letter-spacing:-1.312000px;}
.ls1cc{letter-spacing:-1.308000px;}
.ls34f{letter-spacing:-1.296000px;}
.ls2b1{letter-spacing:-1.292000px;}
.ls366{letter-spacing:-1.288000px;}
.ls30d{letter-spacing:-1.284000px;}
.ls1c1{letter-spacing:-1.280000px;}
.ls2e6{letter-spacing:-1.272000px;}
.ls36d{letter-spacing:-1.268000px;}
.ls36e{letter-spacing:-1.260000px;}
.ls225{letter-spacing:-1.256000px;}
.ls2d8{letter-spacing:-1.252000px;}
.ls28a{letter-spacing:-1.248000px;}
.ls226{letter-spacing:-1.244000px;}
.ls2ee{letter-spacing:-1.236000px;}
.ls2c3{letter-spacing:-1.228000px;}
.lsff{letter-spacing:-1.224000px;}
.ls361{letter-spacing:-1.220000px;}
.ls228{letter-spacing:-1.216000px;}
.ls227{letter-spacing:-1.208000px;}
.ls12b{letter-spacing:-1.200800px;}
.ls31c{letter-spacing:-1.200000px;}
.ls1c0{letter-spacing:-1.196000px;}
.ls2ea{letter-spacing:-1.188000px;}
.ls353{letter-spacing:-1.184000px;}
.ls289{letter-spacing:-1.180000px;}
.ls36b{letter-spacing:-1.172000px;}
.ls261{letter-spacing:-1.170400px;}
.lsdb{letter-spacing:-1.168000px;}
.ls1c8{letter-spacing:-1.164000px;}
.ls267{letter-spacing:-1.159000px;}
.ls216{letter-spacing:-1.155200px;}
.ls35b{letter-spacing:-1.148000px;}
.ls330{letter-spacing:-1.144000px;}
.ls176{letter-spacing:-1.136200px;}
.ls1ff{letter-spacing:-1.136000px;}
.ls21c{letter-spacing:-1.132000px;}
.ls1a1{letter-spacing:-1.128600px;}
.ls29f{letter-spacing:-1.128000px;}
.ls26a{letter-spacing:-1.124000px;}
.ls68{letter-spacing:-1.120000px;}
.ls117{letter-spacing:-1.116000px;}
.ls188{letter-spacing:-1.112000px;}
.ls2e5{letter-spacing:-1.108000px;}
.ls2c7{letter-spacing:-1.104000px;}
.ls162{letter-spacing:-1.096000px;}
.lse9{letter-spacing:-1.092000px;}
.ls6f{letter-spacing:-1.088000px;}
.ls2b3{letter-spacing:-1.080000px;}
.ls2cd{letter-spacing:-1.076000px;}
.ls284{letter-spacing:-1.072000px;}
.ls306{letter-spacing:-1.068000px;}
.ls2b4{letter-spacing:-1.064000px;}
.ls29d{letter-spacing:-1.060000px;}
.ls66{letter-spacing:-1.056000px;}
.ls1fb{letter-spacing:-1.052000px;}
.ls60{letter-spacing:-1.048000px;}
.ls286{letter-spacing:-1.044000px;}
.ls63{letter-spacing:-1.040000px;}
.ls2b9{letter-spacing:-1.036000px;}
.ls205{letter-spacing:-1.032000px;}
.ls58{letter-spacing:-1.028000px;}
.ls383{letter-spacing:-1.026000px;}
.ls2ef{letter-spacing:-1.024000px;}
.ls22b{letter-spacing:-1.020000px;}
.ls36a{letter-spacing:-1.016000px;}
.ls1ec{letter-spacing:-1.014600px;}
.lsc0{letter-spacing:-1.012000px;}
.lsbd{letter-spacing:-1.008000px;}
.lsdf{letter-spacing:-1.004000px;}
.ls202{letter-spacing:-1.000000px;}
.ls1d2{letter-spacing:-0.996000px;}
.ls24e{letter-spacing:-0.992000px;}
.ls153{letter-spacing:-0.988000px;}
.lse0{letter-spacing:-0.984000px;}
.ls287{letter-spacing:-0.980000px;}
.ls12c{letter-spacing:-0.976600px;}
.ls2d3{letter-spacing:-0.976000px;}
.ls74{letter-spacing:-0.972000px;}
.ls108{letter-spacing:-0.965200px;}
.ls18a{letter-spacing:-0.964000px;}
.ls33f{letter-spacing:-0.960000px;}
.ls98{letter-spacing:-0.956000px;}
.ls1f6{letter-spacing:-0.953800px;}
.ls1f{letter-spacing:-0.952000px;}
.ls7e{letter-spacing:-0.948000px;}
.lsaf{letter-spacing:-0.944000px;}
.ls111{letter-spacing:-0.940000px;}
.ls20{letter-spacing:-0.936000px;}
.ls8d{letter-spacing:-0.932000px;}
.ls15a{letter-spacing:-0.928000px;}
.lse{letter-spacing:-0.924800px;}
.ls237{letter-spacing:-0.924000px;}
.ls250{letter-spacing:-0.923400px;}
.lsc9{letter-spacing:-0.920000px;}
.ls219{letter-spacing:-0.916000px;}
.ls5a{letter-spacing:-0.912000px;}
.ls25b{letter-spacing:-0.908000px;}
.ls2a9{letter-spacing:-0.904000px;}
.ls23d{letter-spacing:-0.900600px;}
.ls2c5{letter-spacing:-0.900000px;}
.ls141{letter-spacing:-0.896000px;}
.ls206{letter-spacing:-0.892000px;}
.ls197{letter-spacing:-0.888000px;}
.ls17d{letter-spacing:-0.884000px;}
.lsb4{letter-spacing:-0.880000px;}
.ls7b{letter-spacing:-0.876000px;}
.ls10a{letter-spacing:-0.874000px;}
.ls26e{letter-spacing:-0.872000px;}
.ls14f{letter-spacing:-0.868000px;}
.ls125{letter-spacing:-0.864000px;}
.ls87{letter-spacing:-0.860000px;}
.ls1ac{letter-spacing:-0.856000px;}
.ls1d5{letter-spacing:-0.852000px;}
.ls1bc{letter-spacing:-0.851200px;}
.lsde{letter-spacing:-0.848000px;}
.ls1f7{letter-spacing:-0.847400px;}
.lsab{letter-spacing:-0.844000px;}
.lsd9{letter-spacing:-0.843600px;}
.ls232{letter-spacing:-0.840000px;}
.ls203{letter-spacing:-0.836000px;}
.ls15f{letter-spacing:-0.832000px;}
.ls37e{letter-spacing:-0.828400px;}
.ls165{letter-spacing:-0.828000px;}
.lsc7{letter-spacing:-0.824000px;}
.ls356{letter-spacing:-0.820800px;}
.ls102{letter-spacing:-0.820000px;}
.ls37f{letter-spacing:-0.817000px;}
.ls65{letter-spacing:-0.816000px;}
.ls2ac{letter-spacing:-0.812000px;}
.ls2bf{letter-spacing:-0.808000px;}
.ls23c{letter-spacing:-0.805600px;}
.ls2f0{letter-spacing:-0.804000px;}
.ls11b{letter-spacing:-0.801800px;}
.ls4b{letter-spacing:-0.800000px;}
.lsfe{letter-spacing:-0.796000px;}
.ls1f1{letter-spacing:-0.792000px;}
.ls8{letter-spacing:-0.790400px;}
.ls61{letter-spacing:-0.788000px;}
.ls7{letter-spacing:-0.787200px;}
.lsf7{letter-spacing:-0.784000px;}
.ls1c2{letter-spacing:-0.782800px;}
.ls17f{letter-spacing:-0.780000px;}
.ls22c{letter-spacing:-0.776000px;}
.ls2f4{letter-spacing:-0.775663px;}
.ls2a0{letter-spacing:-0.772000px;}
.ls24a{letter-spacing:-0.768000px;}
.ls273{letter-spacing:-0.764000px;}
.lsf6{letter-spacing:-0.760760px;}
.lsb1{letter-spacing:-0.760000px;}
.ls1b9{letter-spacing:-0.756000px;}
.ls139{letter-spacing:-0.752400px;}
.ls21d{letter-spacing:-0.752000px;}
.ls19f{letter-spacing:-0.748600px;}
.lsa0{letter-spacing:-0.748000px;}
.ls128{letter-spacing:-0.744000px;}
.ls10{letter-spacing:-0.742400px;}
.lsd4{letter-spacing:-0.741000px;}
.ls83{letter-spacing:-0.740000px;}
.ls2ae{letter-spacing:-0.736000px;}
.ls223{letter-spacing:-0.733400px;}
.ls56{letter-spacing:-0.732000px;}
.ls2e7{letter-spacing:-0.728000px;}
.lsd1{letter-spacing:-0.724000px;}
.lsbc{letter-spacing:-0.720000px;}
.ls107{letter-spacing:-0.718200px;}
.lsa9{letter-spacing:-0.716000px;}
.ls25c{letter-spacing:-0.712000px;}
.ls47{letter-spacing:-0.708000px;}
.ls43{letter-spacing:-0.704000px;}
.ls1b4{letter-spacing:-0.703000px;}
.ls145{letter-spacing:-0.700000px;}
.ls79{letter-spacing:-0.696000px;}
.ls294{letter-spacing:-0.692000px;}
.ls121{letter-spacing:-0.691600px;}
.ls14d{letter-spacing:-0.690000px;}
.lsbe{letter-spacing:-0.688000px;}
.ls16b{letter-spacing:-0.684000px;}
.ls2d4{letter-spacing:-0.683200px;}
.ls2e4{letter-spacing:-0.681200px;}
.ls5f{letter-spacing:-0.680000px;}
.ls109{letter-spacing:-0.676400px;}
.lsfa{letter-spacing:-0.676000px;}
.lsec{letter-spacing:-0.672000px;}
.ls1ba{letter-spacing:-0.668000px;}
.ls1e5{letter-spacing:-0.665000px;}
.lsbb{letter-spacing:-0.664000px;}
.ls190{letter-spacing:-0.660000px;}
.ls1e3{letter-spacing:-0.657400px;}
.ls161{letter-spacing:-0.656000px;}
.lsd3{letter-spacing:-0.653600px;}
.lsf9{letter-spacing:-0.652000px;}
.lsed{letter-spacing:-0.648000px;}
.ls318{letter-spacing:-0.646000px;}
.ls1db{letter-spacing:-0.644000px;}
.lsc6{letter-spacing:-0.640000px;}
.ls1fc{letter-spacing:-0.636000px;}
.ls174{letter-spacing:-0.634600px;}
.ls17b{letter-spacing:-0.632000px;}
.ls354{letter-spacing:-0.628000px;}
.lse7{letter-spacing:-0.624000px;}
.ls382{letter-spacing:-0.623200px;}
.ls25{letter-spacing:-0.620000px;}
.ls10b{letter-spacing:-0.619400px;}
.lsb9{letter-spacing:-0.616000px;}
.ls15c{letter-spacing:-0.612000px;}
.ls70{letter-spacing:-0.608000px;}
.ls163{letter-spacing:-0.604000px;}
.ls1e6{letter-spacing:-0.600400px;}
.lseb{letter-spacing:-0.600000px;}
.ls302{letter-spacing:-0.596664px;}
.ls6d{letter-spacing:-0.596000px;}
.ls1de{letter-spacing:-0.592800px;}
.ls28c{letter-spacing:-0.592000px;}
.ls16d{letter-spacing:-0.588000px;}
.ls27b{letter-spacing:-0.587600px;}
.ls26b{letter-spacing:-0.584000px;}
.ls264{letter-spacing:-0.581400px;}
.ls1d1{letter-spacing:-0.580000px;}
.lsf{letter-spacing:-0.576000px;}
.ls270{letter-spacing:-0.572000px;}
.ls22a{letter-spacing:-0.568000px;}
.ls9f{letter-spacing:-0.564000px;}
.ls349{letter-spacing:-0.562400px;}
.ls1d4{letter-spacing:-0.560000px;}
.ls1cf{letter-spacing:-0.558000px;}
.ls218{letter-spacing:-0.556000px;}
.ls179{letter-spacing:-0.554800px;}
.ls5{letter-spacing:-0.553600px;}
.ls18f{letter-spacing:-0.552000px;}
.ls132{letter-spacing:-0.551000px;}
.ls78{letter-spacing:-0.548000px;}
.lsa2{letter-spacing:-0.544000px;}
.ls1e{letter-spacing:-0.540000px;}
.ls185{letter-spacing:-0.536000px;}
.lsd{letter-spacing:-0.534400px;}
.ls5b{letter-spacing:-0.532000px;}
.ls249{letter-spacing:-0.528000px;}
.ls1df{letter-spacing:-0.524400px;}
.lsb8{letter-spacing:-0.524000px;}
.ls11{letter-spacing:-0.521600px;}
.ls1c4{letter-spacing:-0.520600px;}
.ls21f{letter-spacing:-0.520000px;}
.ls236{letter-spacing:-0.516000px;}
.ls25f{letter-spacing:-0.515200px;}
.ls23e{letter-spacing:-0.513000px;}
.ls150{letter-spacing:-0.512000px;}
.lsae{letter-spacing:-0.508000px;}
.lsbf{letter-spacing:-0.504000px;}
.ls276{letter-spacing:-0.501000px;}
.lsa7{letter-spacing:-0.500000px;}
.ls8f{letter-spacing:-0.496000px;}
.ls2db{letter-spacing:-0.495600px;}
.ls1ca{letter-spacing:-0.494000px;}
.ls48{letter-spacing:-0.492000px;}
.ls170{letter-spacing:-0.490200px;}
.lsfc{letter-spacing:-0.488000px;}
.ls1a4{letter-spacing:-0.484000px;}
.ls106{letter-spacing:-0.482600px;}
.ls62{letter-spacing:-0.480000px;}
.lsfd{letter-spacing:-0.476000px;}
.ls1c5{letter-spacing:-0.475000px;}
.ls33{letter-spacing:-0.472000px;}
.ls272{letter-spacing:-0.470400px;}
.ls34{letter-spacing:-0.468000px;}
.ls120{letter-spacing:-0.467400px;}
.ls32{letter-spacing:-0.464000px;}
.ls42{letter-spacing:-0.460000px;}
.ls320{letter-spacing:-0.456400px;}
.ls1fa{letter-spacing:-0.456000px;}
.ls381{letter-spacing:-0.452200px;}
.ls239{letter-spacing:-0.452000px;}
.ls345{letter-spacing:-0.448000px;}
.ls138{letter-spacing:-0.444600px;}
.ls91{letter-spacing:-0.444000px;}
.ls2e1{letter-spacing:-0.440800px;}
.ls229{letter-spacing:-0.440000px;}
.ls2e3{letter-spacing:-0.437000px;}
.ls22{letter-spacing:-0.436000px;}
.ls2df{letter-spacing:-0.433200px;}
.ls1ae{letter-spacing:-0.432000px;}
.ls104{letter-spacing:-0.429400px;}
.ls290{letter-spacing:-0.428000px;}
.ls2e2{letter-spacing:-0.425600px;}
.ls126{letter-spacing:-0.424000px;}
.lsd6{letter-spacing:-0.421800px;}
.ls222{letter-spacing:-0.420000px;}
.ls130{letter-spacing:-0.418000px;}
.ls2a2{letter-spacing:-0.416000px;}
.ls32d{letter-spacing:-0.414400px;}
.ls105{letter-spacing:-0.414200px;}
.lsa{letter-spacing:-0.412800px;}
.ls3e{letter-spacing:-0.412000px;}
.ls137{letter-spacing:-0.410400px;}
.ls29b{letter-spacing:-0.408000px;}
.ls1dc{letter-spacing:-0.406600px;}
.ls100{letter-spacing:-0.406000px;}
.ls28{letter-spacing:-0.404000px;}
.ls31a{letter-spacing:-0.402800px;}
.ls5d{letter-spacing:-0.400000px;}
.ls19{letter-spacing:-0.399600px;}
.lscc{letter-spacing:-0.399000px;}
.ls2f6{letter-spacing:-0.397776px;}
.ls2a8{letter-spacing:-0.396000px;}
.ls357{letter-spacing:-0.395200px;}
.ls18{letter-spacing:-0.392400px;}
.ls245{letter-spacing:-0.392000px;}
.ls20a{letter-spacing:-0.389200px;}
.ls73{letter-spacing:-0.388000px;}
.ls380{letter-spacing:-0.387600px;}
.ls274{letter-spacing:-0.384000px;}
.ls11c{letter-spacing:-0.383800px;}
.ls2d7{letter-spacing:-0.380800px;}
.lsd5{letter-spacing:-0.380000px;}
.ls67{letter-spacing:-0.376000px;}
.ls2f5{letter-spacing:-0.373908px;}
.ls1e9{letter-spacing:-0.372400px;}
.lse2{letter-spacing:-0.372000px;}
.ls45{letter-spacing:-0.368000px;}
.ls76{letter-spacing:-0.364000px;}
.ls334{letter-spacing:-0.361200px;}
.ls46{letter-spacing:-0.360000px;}
.ls2cc{letter-spacing:-0.356000px;}
.lsf5{letter-spacing:-0.353400px;}
.ls7a{letter-spacing:-0.352000px;}
.lsc{letter-spacing:-0.348800px;}
.ls21b{letter-spacing:-0.348000px;}
.ls204{letter-spacing:-0.344000px;}
.ls6a{letter-spacing:-0.340000px;}
.ls151{letter-spacing:-0.336000px;}
.ls23f{letter-spacing:-0.334400px;}
.lse3{letter-spacing:-0.332000px;}
.ls147{letter-spacing:-0.330600px;}
.ls1b2{letter-spacing:-0.328000px;}
.ls1e8{letter-spacing:-0.326800px;}
.ls3a{letter-spacing:-0.324000px;}
.ls213{letter-spacing:-0.323000px;}
.ls201{letter-spacing:-0.320000px;}
.ls3b{letter-spacing:-0.316000px;}
.lsc5{letter-spacing:-0.312000px;}
.ls1a0{letter-spacing:-0.311600px;}
.ls32f{letter-spacing:-0.310800px;}
.ls2c0{letter-spacing:-0.308000px;}
.ls32e{letter-spacing:-0.305200px;}
.ls122{letter-spacing:-0.304000px;}
.ls18b{letter-spacing:-0.300000px;}
.ls303{letter-spacing:-0.297000px;}
.ls1b6{letter-spacing:-0.296400px;}
.ls2da{letter-spacing:-0.296000px;}
.lsc8{letter-spacing:-0.292000px;}
.ls24f{letter-spacing:-0.288800px;}
.ls247{letter-spacing:-0.288000px;}
.ls1a6{letter-spacing:-0.284000px;}
.ls2dd{letter-spacing:-0.282800px;}
.ls1e1{letter-spacing:-0.280000px;}
.ls75{letter-spacing:-0.276000px;}
.ls13b{letter-spacing:-0.272000px;}
.ls31{letter-spacing:-0.268000px;}
.lsc4{letter-spacing:-0.264000px;}
.ls6b{letter-spacing:-0.260000px;}
.ls19b{letter-spacing:-0.258400px;}
.ls283{letter-spacing:-0.258000px;}
.ls1a5{letter-spacing:-0.256000px;}
.ls3d{letter-spacing:-0.252000px;}
.ls11f{letter-spacing:-0.250800px;}
.ls17a{letter-spacing:-0.248000px;}
.ls19e{letter-spacing:-0.247000px;}
.ls282{letter-spacing:-0.246400px;}
.ls244{letter-spacing:-0.244000px;}
.ls1e4{letter-spacing:-0.243200px;}
.lsaa{letter-spacing:-0.240000px;}
.lsce{letter-spacing:-0.237000px;}
.ls140{letter-spacing:-0.236000px;}
.lsf3{letter-spacing:-0.235600px;}
.ls25e{letter-spacing:-0.235200px;}
.ls37{letter-spacing:-0.232000px;}
.ls7f{letter-spacing:-0.228000px;}
.ls1bd{letter-spacing:-0.224200px;}
.ls10e{letter-spacing:-0.224000px;}
.ls317{letter-spacing:-0.220400px;}
.ls64{letter-spacing:-0.220000px;}
.ls1d9{letter-spacing:-0.216000px;}
.ls12f{letter-spacing:-0.212800px;}
.ls30e{letter-spacing:-0.212400px;}
.ls16e{letter-spacing:-0.212000px;}
.ls131{letter-spacing:-0.209000px;}
.ls95{letter-spacing:-0.208000px;}
.ls27{letter-spacing:-0.204000px;}
.ls37c{letter-spacing:-0.201600px;}
.ls22d{letter-spacing:-0.200000px;}
.ls200{letter-spacing:-0.196000px;}
.ls192{letter-spacing:-0.192000px;}
.ls30f{letter-spacing:-0.190800px;}
.ls233{letter-spacing:-0.188000px;}
.ls184{letter-spacing:-0.184000px;}
.ls1e0{letter-spacing:-0.182400px;}
.lsa4{letter-spacing:-0.180000px;}
.ls148{letter-spacing:-0.178600px;}
.ls1d8{letter-spacing:-0.176000px;}
.ls217{letter-spacing:-0.174800px;}
.ls1b3{letter-spacing:-0.172000px;}
.ls1e7{letter-spacing:-0.171000px;}
.ls13c{letter-spacing:-0.168000px;}
.ls30{letter-spacing:-0.164000px;}
.ls166{letter-spacing:-0.160000px;}
.ls1a2{letter-spacing:-0.159600px;}
.ls191{letter-spacing:-0.156000px;}
.ls17{letter-spacing:-0.154800px;}
.ls181{letter-spacing:-0.152000px;}
.lsef{letter-spacing:-0.148000px;}
.ls12e{letter-spacing:-0.144400px;}
.lsba{letter-spacing:-0.144000px;}
.ls85{letter-spacing:-0.140000px;}
.ls90{letter-spacing:-0.136000px;}
.ls325{letter-spacing:-0.132000px;}
.ls6{letter-spacing:-0.131200px;}
.ls1f3{letter-spacing:-0.129200px;}
.ls368{letter-spacing:-0.128800px;}
.ls12a{letter-spacing:-0.128000px;}
.lsf0{letter-spacing:-0.125400px;}
.ls93{letter-spacing:-0.124000px;}
.ls1d0{letter-spacing:-0.123000px;}
.ls189{letter-spacing:-0.120000px;}
.ls1be{letter-spacing:-0.116000px;}
.ls143{letter-spacing:-0.112000px;}
.ls1bb{letter-spacing:-0.110200px;}
.ls8a{letter-spacing:-0.108000px;}
.ls262{letter-spacing:-0.104000px;}
.ls24{letter-spacing:-0.100000px;}
.ls1f4{letter-spacing:-0.098800px;}
.ls146{letter-spacing:-0.096000px;}
.ls31e{letter-spacing:-0.095760px;}
.ls92{letter-spacing:-0.092000px;}
.ls133{letter-spacing:-0.091200px;}
.ls1d{letter-spacing:-0.088000px;}
.ls20f{letter-spacing:-0.087400px;}
.ls9c{letter-spacing:-0.084000px;}
.ls155{letter-spacing:-0.083600px;}
.ls333{letter-spacing:-0.081200px;}
.ls3c{letter-spacing:-0.080000px;}
.ls172{letter-spacing:-0.076000px;}
.ls171{letter-spacing:-0.072200px;}
.ls182{letter-spacing:-0.072000px;}
.ls158{letter-spacing:-0.070000px;}
.ls2ab{letter-spacing:-0.068000px;}
.ls255{letter-spacing:-0.067200px;}
.ls173{letter-spacing:-0.064600px;}
.ls26{letter-spacing:-0.064000px;}
.ls12d{letter-spacing:-0.060800px;}
.ls97{letter-spacing:-0.060000px;}
.ls379{letter-spacing:-0.057600px;}
.ls256{letter-spacing:-0.056000px;}
.ls25a{letter-spacing:-0.052000px;}
.lsa8{letter-spacing:-0.048000px;}
.ls14e{letter-spacing:-0.044000px;}
.lscb{letter-spacing:-0.042000px;}
.ls149{letter-spacing:-0.041800px;}
.ls1a9{letter-spacing:-0.040000px;}
.ls33d{letter-spacing:-0.038400px;}
.ls134{letter-spacing:-0.038000px;}
.ls5e{letter-spacing:-0.036000px;}
.ls31b{letter-spacing:-0.032000px;}
.ls9{letter-spacing:-0.028800px;}
.ls53{letter-spacing:-0.028000px;}
.ls2fd{letter-spacing:-0.027844px;}
.ls11d{letter-spacing:-0.026600px;}
.ls44{letter-spacing:-0.024000px;}
.ls20b{letter-spacing:-0.022800px;}
.ls2{letter-spacing:-0.022400px;}
.ls160{letter-spacing:-0.020000px;}
.ls156{letter-spacing:-0.019000px;}
.ls2fb{letter-spacing:-0.017403px;}
.ls1b{letter-spacing:-0.016800px;}
.ls8e{letter-spacing:-0.016000px;}
.ls13a{letter-spacing:-0.015200px;}
.ls2a5{letter-spacing:-0.014400px;}
.ls2ff{letter-spacing:-0.013922px;}
.ls2f8{letter-spacing:-0.013259px;}
.ls14{letter-spacing:-0.012000px;}
.ls154{letter-spacing:-0.011400px;}
.ls1{letter-spacing:-0.011200px;}
.ls15{letter-spacing:-0.010800px;}
.ls2fe{letter-spacing:-0.010442px;}
.ls69{letter-spacing:-0.009600px;}
.ls20c{letter-spacing:-0.009000px;}
.ls279{letter-spacing:-0.008800px;}
.ls4f{letter-spacing:-0.008400px;}
.ls13{letter-spacing:-0.008000px;}
.ls135{letter-spacing:-0.007980px;}
.lsd8{letter-spacing:-0.007600px;}
.ls2f3{letter-spacing:-0.007200px;}
.ls2fa{letter-spacing:-0.006961px;}
.ls301{letter-spacing:-0.006630px;}
.ls198{letter-spacing:-0.006300px;}
.lsac{letter-spacing:-0.006000px;}
.ls9a{letter-spacing:-0.005600px;}
.ls31f{letter-spacing:-0.005040px;}
.ls80{letter-spacing:-0.004800px;}
.ls27a{letter-spacing:-0.004400px;}
.ls285{letter-spacing:-0.004200px;}
.ls12{letter-spacing:-0.004000px;}
.lsd2{letter-spacing:-0.003800px;}
.ls16{letter-spacing:-0.003600px;}
.ls2fc{letter-spacing:-0.003481px;}
.ls4{letter-spacing:-0.003200px;}
.ls7d{letter-spacing:-0.003000px;}
.ls34b{letter-spacing:-0.002800px;}
.ls33b{letter-spacing:-0.001920px;}
.ls0{letter-spacing:0.000000px;}
.ls33a{letter-spacing:0.001280px;}
.ls34e{letter-spacing:0.002107px;}
.ls26d{letter-spacing:0.003000px;}
.ls300{letter-spacing:0.003315px;}
.ls2f9{letter-spacing:0.003481px;}
.ls11e{letter-spacing:0.003800px;}
.ls50{letter-spacing:0.004000px;}
.ls308{letter-spacing:0.004800px;}
.ls86{letter-spacing:0.005600px;}
.ls118{letter-spacing:0.007600px;}
.ls1c3{letter-spacing:0.008000px;}
.ls323{letter-spacing:0.009600px;}
.ls9e{letter-spacing:0.011200px;}
.ls1e2{letter-spacing:0.012000px;}
.ls35a{letter-spacing:0.014400px;}
.ls1dd{letter-spacing:0.015200px;}
.ls2f{letter-spacing:0.016000px;}
.lsc3{letter-spacing:0.016800px;}
.ls1f2{letter-spacing:0.019000px;}
.ls297{letter-spacing:0.020000px;}
.ls1c{letter-spacing:0.022400px;}
.ls177{letter-spacing:0.022800px;}
.ls2e{letter-spacing:0.024000px;}
.ls1ea{letter-spacing:0.026600px;}
.ls4e{letter-spacing:0.028000px;}
.ls1fe{letter-spacing:0.032000px;}
.lse8{letter-spacing:0.033600px;}
.ls6c{letter-spacing:0.036000px;}
.ls26f{letter-spacing:0.038400px;}
.ls268{letter-spacing:0.039200px;}
.ls152{letter-spacing:0.040000px;}
.ls124{letter-spacing:0.041800px;}
.ls4d{letter-spacing:0.044000px;}
.ls52{letter-spacing:0.044800px;}
.ls4c{letter-spacing:0.048000px;}
.lscd{letter-spacing:0.051000px;}
.ls10c{letter-spacing:0.052000px;}
.ls210{letter-spacing:0.053200px;}
.ls2b0{letter-spacing:0.056000px;}
.ls115{letter-spacing:0.060000px;}
.ls96{letter-spacing:0.064000px;}
.ls169{letter-spacing:0.064600px;}
.lsb{letter-spacing:0.067200px;}
.lsfb{letter-spacing:0.068000px;}
.lsb3{letter-spacing:0.072000px;}
.ls25d{letter-spacing:0.076000px;}
.ls1ce{letter-spacing:0.078400px;}
.ls119{letter-spacing:0.079800px;}
.ls180{letter-spacing:0.080000px;}
.ls18c{letter-spacing:0.084000px;}
.lsa6{letter-spacing:0.088000px;}
.ls11a{letter-spacing:0.091200px;}
.ls114{letter-spacing:0.092000px;}
.ls103{letter-spacing:0.096000px;}
.ls26c{letter-spacing:0.098000px;}
.ls2bb{letter-spacing:0.100000px;}
.ls2bc{letter-spacing:0.104000px;}
.ls123{letter-spacing:0.106400px;}
.ls81{letter-spacing:0.108000px;}
.ls22e{letter-spacing:0.110200px;}
.ls224{letter-spacing:0.112000px;}
.ls1b7{letter-spacing:0.114000px;}
.lsc1{letter-spacing:0.116000px;}
.ls14a{letter-spacing:0.117800px;}
.lsd0{letter-spacing:0.120000px;}
.ls32c{letter-spacing:0.124000px;}
.ls1c9{letter-spacing:0.128000px;}
.lsc2{letter-spacing:0.132000px;}
.ls136{letter-spacing:0.136000px;}
.ls220{letter-spacing:0.140000px;}
.ls352{letter-spacing:0.144000px;}
.ls194{letter-spacing:0.148000px;}
.ls2b2{letter-spacing:0.152000px;}
.ls208{letter-spacing:0.156000px;}
.ls207{letter-spacing:0.160000px;}
.ls19c{letter-spacing:0.163400px;}
.lse4{letter-spacing:0.164000px;}
.ls310{letter-spacing:0.168000px;}
.ls278{letter-spacing:0.172000px;}
.ls335{letter-spacing:0.173600px;}
.ls168{letter-spacing:0.174800px;}
.ls29a{letter-spacing:0.176000px;}
.ls199{letter-spacing:0.178600px;}
.ls1bf{letter-spacing:0.180000px;}
.lse5{letter-spacing:0.184000px;}
.ls19a{letter-spacing:0.186200px;}
.ls112{letter-spacing:0.188000px;}
.ls295{letter-spacing:0.192000px;}
.ls2c2{letter-spacing:0.196000px;}
.ls24b{letter-spacing:0.200000px;}
.ls1d6{letter-spacing:0.204000px;}
.ls84{letter-spacing:0.208000px;}
.ls1ef{letter-spacing:0.209000px;}
.ls1b8{letter-spacing:0.210000px;}
.ls1ab{letter-spacing:0.212000px;}
.lsb2{letter-spacing:0.216000px;}
.ls319{letter-spacing:0.216600px;}
.ls281{letter-spacing:0.220000px;}
.ls1d3{letter-spacing:0.224000px;}
.ls1cb{letter-spacing:0.224200px;}
.ls39{letter-spacing:0.228000px;}
.lse1{letter-spacing:0.231000px;}
.ls71{letter-spacing:0.232000px;}
.ls28f{letter-spacing:0.236000px;}
.ls1eb{letter-spacing:0.239400px;}
.ls280{letter-spacing:0.240000px;}
.ls1a8{letter-spacing:0.244000px;}
.ls1aa{letter-spacing:0.248000px;}
.lsf4{letter-spacing:0.250800px;}
.ls2d1{letter-spacing:0.252000px;}
.ls110{letter-spacing:0.256000px;}
.ls2e0{letter-spacing:0.258000px;}
.ls309{letter-spacing:0.260000px;}
.ls7c{letter-spacing:0.264000px;}
.ls19d{letter-spacing:0.266000px;}
.ls2a{letter-spacing:0.268000px;}
.ls16a{letter-spacing:0.269800px;}
.ls29{letter-spacing:0.272000px;}
.ls266{letter-spacing:0.273600px;}
.ls23b{letter-spacing:0.276000px;}
.ls2b6{letter-spacing:0.280000px;}
.ls313{letter-spacing:0.281200px;}
.ls24d{letter-spacing:0.284000px;}
.ls72{letter-spacing:0.288000px;}
.ls347{letter-spacing:0.292000px;}
.ls2d{letter-spacing:0.296000px;}
.ls2c8{letter-spacing:0.300000px;}
.ls23a{letter-spacing:0.304000px;}
.ls2c{letter-spacing:0.308000px;}
.ls94{letter-spacing:0.312000px;}
.ls20d{letter-spacing:0.315400px;}
.ls2b{letter-spacing:0.316000px;}
.ls211{letter-spacing:0.319200px;}
.ls2b5{letter-spacing:0.320000px;}
.ls242{letter-spacing:0.324000px;}
.ls355{letter-spacing:0.328000px;}
.ls10d{letter-spacing:0.332000px;}
.ls1fd{letter-spacing:0.336000px;}
.lsd7{letter-spacing:0.338200px;}
.ls29c{letter-spacing:0.340000px;}
.ls8c{letter-spacing:0.344000px;}
.ls1ee{letter-spacing:0.345800px;}
.ls337{letter-spacing:0.348000px;}
.ls129{letter-spacing:0.352000px;}
.ls1ed{letter-spacing:0.353400px;}
.ls34d{letter-spacing:0.353949px;}
.ls2de{letter-spacing:0.356000px;}
.ls15e{letter-spacing:0.360000px;}
.ls193{letter-spacing:0.361000px;}
.ls40{letter-spacing:0.364000px;}
.ls1b5{letter-spacing:0.364800px;}
.ls331{letter-spacing:0.368000px;}
.ls316{letter-spacing:0.368600px;}
.ls3f{letter-spacing:0.372000px;}
.lsda{letter-spacing:0.372400px;}
.ls21e{letter-spacing:0.376000px;}
.ls2aa{letter-spacing:0.380000px;}
.ls311{letter-spacing:0.383800px;}
.ls341{letter-spacing:0.384000px;}
.ls238{letter-spacing:0.388000px;}
.ls164{letter-spacing:0.392000px;}
.ls240{letter-spacing:0.397600px;}
.ls2f7{letter-spacing:0.397776px;}
.ls1d7{letter-spacing:0.400000px;}
.ls15b{letter-spacing:0.404000px;}
.ls195{letter-spacing:0.408000px;}
.ls16c{letter-spacing:0.412000px;}
.ls34c{letter-spacing:0.415016px;}
.ls144{letter-spacing:0.416000px;}
.lsa1{letter-spacing:0.420000px;}
.ls315{letter-spacing:0.421800px;}
.ls9b{letter-spacing:0.424000px;}
.lsca{letter-spacing:0.428000px;}
.ls1c7{letter-spacing:0.429400px;}
.ls231{letter-spacing:0.432000px;}
.ls2ce{letter-spacing:0.436000px;}
.lse6{letter-spacing:0.440000px;}
.ls15d{letter-spacing:0.444000px;}
.ls36c{letter-spacing:0.448000px;}
.ls18e{letter-spacing:0.452000px;}
.ls57{letter-spacing:0.456000px;}
.ls234{letter-spacing:0.460000px;}
.ls296{letter-spacing:0.464000px;}
.ls2ed{letter-spacing:0.467200px;}
.ls22f{letter-spacing:0.468000px;}
.ls54{letter-spacing:0.472000px;}
.ls2c6{letter-spacing:0.476000px;}
.ls2ec{letter-spacing:0.476800px;}
.ls235{letter-spacing:0.480000px;}
.ls1ad{letter-spacing:0.484000px;}
.ls241{letter-spacing:0.488000px;}
.ls37b{letter-spacing:0.492000px;}
.ls348{letter-spacing:0.496000px;}
.ls30b{letter-spacing:0.500000px;}
.lsa5{letter-spacing:0.504000px;}
.ls263{letter-spacing:0.508000px;}
.ls2d6{letter-spacing:0.509600px;}
.ls89{letter-spacing:0.512000px;}
.ls88{letter-spacing:0.516000px;}
.ls13d{letter-spacing:0.520000px;}
.ls175{letter-spacing:0.520600px;}
.ls55{letter-spacing:0.524000px;}
.ls212{letter-spacing:0.524400px;}
.ls2af{letter-spacing:0.528000px;}
.ls2ca{letter-spacing:0.532000px;}
.ls178{letter-spacing:0.535800px;}
.ls324{letter-spacing:0.536000px;}
.ls2eb{letter-spacing:0.536400px;}
.ls1a3{letter-spacing:0.540000px;}
.ls142{letter-spacing:0.544000px;}
.ls291{letter-spacing:0.548000px;}
.lsdd{letter-spacing:0.552000px;}
.ls1b0{letter-spacing:0.556000px;}
.ls31d{letter-spacing:0.558000px;}
.ls271{letter-spacing:0.560000px;}
.ls259{letter-spacing:0.564000px;}
.ls2d0{letter-spacing:0.568000px;}
.lsdc{letter-spacing:0.572000px;}
.ls365{letter-spacing:0.576000px;}
.ls8b{letter-spacing:0.580000px;}
.ls77{letter-spacing:0.584000px;}
.ls314{letter-spacing:0.585200px;}
.ls186{letter-spacing:0.588000px;}
.ls196{letter-spacing:0.592000px;}
.ls2cb{letter-spacing:0.596000px;}
.ls27f{letter-spacing:0.599200px;}
.ls17e{letter-spacing:0.600000px;}
.ls159{letter-spacing:0.608000px;}
.ls277{letter-spacing:0.612000px;}
.ls16f{letter-spacing:0.615600px;}
.ls9d{letter-spacing:0.616000px;}
.ls1f0{letter-spacing:0.619400px;}
.ls5c{letter-spacing:0.620000px;}
.ls29e{letter-spacing:0.624000px;}
.lsf1{letter-spacing:0.627000px;}
.ls1a7{letter-spacing:0.628000px;}
.ls59{letter-spacing:0.632000px;}
.ls350{letter-spacing:0.636000px;}
.ls2a3{letter-spacing:0.640000px;}
.ls1f9{letter-spacing:0.644000px;}
.ls4a{letter-spacing:0.648000px;}
.ls346{letter-spacing:0.652000px;}
.ls1af{letter-spacing:0.656000px;}
.ls2d2{letter-spacing:0.660000px;}
.ls37d{letter-spacing:0.664000px;}
.ls377{letter-spacing:0.668000px;}
.ls321{letter-spacing:0.672000px;}
.ls2dc{letter-spacing:0.676000px;}
.ls6e{letter-spacing:0.680000px;}
.ls230{letter-spacing:0.684000px;}
.lsf2{letter-spacing:0.687800px;}
.ls370{letter-spacing:0.688000px;}
.ls113{letter-spacing:0.696000px;}
.ls2a1{letter-spacing:0.700000px;}
.ls183{letter-spacing:0.704000px;}
.ls21a{letter-spacing:0.708000px;}
.lsa3{letter-spacing:0.716000px;}
.ls298{letter-spacing:0.724000px;}
.ls2d5{letter-spacing:0.728000px;}
.ls332{letter-spacing:0.736000px;}
.ls36{letter-spacing:0.740000px;}
.ls344{letter-spacing:0.744000px;}
.ls253{letter-spacing:0.744800px;}
.ls30a{letter-spacing:0.748000px;}
.ls299{letter-spacing:0.752000px;}
.ls49{letter-spacing:0.756000px;}
.ls32b{letter-spacing:0.760000px;}
.ls2ad{letter-spacing:0.764000px;}
.ls369{letter-spacing:0.776000px;}
.ls340{letter-spacing:0.780000px;}
.lsb0{letter-spacing:0.788000px;}
.ls312{letter-spacing:0.801800px;}
.ls360{letter-spacing:0.804000px;}
.ls258{letter-spacing:0.820000px;}
.ls28d{letter-spacing:0.824000px;}
.ls157{letter-spacing:0.832000px;}
.ls13e{letter-spacing:0.836000px;}
.ls187{letter-spacing:0.840000px;}
.ls18d{letter-spacing:0.844000px;}
.ls322{letter-spacing:0.848000px;}
.ls82{letter-spacing:0.856000px;}
.ls2c9{letter-spacing:0.864000px;}
.ls37a{letter-spacing:0.868000px;}
.ls32a{letter-spacing:0.880000px;}
.ls17c{letter-spacing:0.892000px;}
.ls21{letter-spacing:0.900000px;}
.ls342{letter-spacing:0.904000px;}
.ls1c6{letter-spacing:0.904400px;}
.ls28b{letter-spacing:0.916000px;}
.ls13f{letter-spacing:0.920000px;}
.ls2e8{letter-spacing:0.924000px;}
.ls28e{letter-spacing:0.928000px;}
.ls359{letter-spacing:0.932000px;}
.lsb7{letter-spacing:0.936000px;}
.ls2c1{letter-spacing:0.944000px;}
.ls362{letter-spacing:0.948000px;}
.ls2cf{letter-spacing:0.960000px;}
.ls33c{letter-spacing:0.976000px;}
.ls292{letter-spacing:0.988000px;}
.ls1da{letter-spacing:0.992000px;}
.ls363{letter-spacing:1.000000px;}
.ls251{letter-spacing:1.010800px;}
.ls1f8{letter-spacing:1.020000px;}
.ls2b7{letter-spacing:1.032000px;}
.ls378{letter-spacing:1.040000px;}
.ls252{letter-spacing:1.071600px;}
.ls329{letter-spacing:1.076000px;}
.ls221{letter-spacing:1.088000px;}
.ls167{letter-spacing:1.092000px;}
.ls2bd{letter-spacing:1.096000px;}
.ls35e{letter-spacing:1.108000px;}
.ls34a{letter-spacing:1.120000px;}
.ls326{letter-spacing:1.128000px;}
.ls243{letter-spacing:1.144000px;}
.ls336{letter-spacing:1.196000px;}
.ls2b8{letter-spacing:1.200000px;}
.ls127{letter-spacing:1.224000px;}
.ls2c4{letter-spacing:1.236000px;}
.ls35f{letter-spacing:1.252000px;}
.ls1b1{letter-spacing:1.272000px;}
.ls364{letter-spacing:1.280000px;}
.ls328{letter-spacing:1.284000px;}
.ls327{letter-spacing:1.288000px;}
.ls2ba{letter-spacing:1.304000px;}
.ls2e9{letter-spacing:1.324000px;}
.ls35c{letter-spacing:1.340000px;}
.ls27c{letter-spacing:1.383200px;}
.ls27d{letter-spacing:1.391600px;}
.ls27e{letter-spacing:1.397200px;}
.lsb6{letter-spacing:1.408000px;}
.ls2be{letter-spacing:1.412000px;}
.ls265{letter-spacing:1.425000px;}
.ls351{letter-spacing:1.472000px;}
.ls209{letter-spacing:1.554000px;}
.ls36f{letter-spacing:1.556000px;}
.ls14c{letter-spacing:1.556800px;}
.ls20e{letter-spacing:1.630200px;}
.ls2d9{letter-spacing:1.716000px;}
.ls373{letter-spacing:1.940400px;}
.ls372{letter-spacing:1.948800px;}
.ls374{letter-spacing:1.957200px;}
.ls24c{letter-spacing:2.758000px;}
.ls1a{letter-spacing:2.780400px;}
.ls51{letter-spacing:2.786000px;}
.ls101{letter-spacing:2.788800px;}
.lsee{letter-spacing:2.791600px;}
.ls3{letter-spacing:2.794400px;}
.lsad{letter-spacing:2.797200px;}
.ls99{letter-spacing:2.800000px;}
.ls10f{letter-spacing:8.184000px;}
.ls23{letter-spacing:11.608000px;}
.ls293{letter-spacing:96.860000px;}
.ls338{letter-spacing:235.490400px;}
.ls339{letter-spacing:303.344800px;}
.sc_{text-shadow:none;}
.sc2{text-shadow:-0.015em 0 rgb(35,31,32),0 0.015em rgb(35,31,32),0.015em 0 rgb(35,31,32),0 -0.015em  rgb(35,31,32);}
.sc1{text-shadow:-0.015em 0 rgb(255,255,255),0 0.015em rgb(255,255,255),0.015em 0 rgb(255,255,255),0 -0.015em  rgb(255,255,255);}
.sc0{text-shadow:-0.015em 0 transparent,0 0.015em transparent,0.015em 0 transparent,0 -0.015em  transparent;}
@media screen and (-webkit-min-device-pixel-ratio:0){
.sc_{-webkit-text-stroke:0px transparent;}
.sc2{-webkit-text-stroke:0.015em rgb(35,31,32);text-shadow:none;}
.sc1{-webkit-text-stroke:0.015em rgb(255,255,255);text-shadow:none;}
.sc0{-webkit-text-stroke:0.015em transparent;text-shadow:none;}
}
.ws23{word-spacing:-8.564000px;}
.ws530{word-spacing:-2.164000px;}
.ws59a{word-spacing:-2.020000px;}
.ws58a{word-spacing:-1.964000px;}
.ws4a8{word-spacing:-1.912000px;}
.ws4e6{word-spacing:-1.744000px;}
.ws591{word-spacing:-1.640800px;}
.ws4de{word-spacing:-1.500000px;}
.ws134{word-spacing:-1.348000px;}
.ws135{word-spacing:-1.344000px;}
.ws25d{word-spacing:-1.340000px;}
.wsdd{word-spacing:-1.336000px;}
.ws230{word-spacing:-1.332000px;}
.ws93{word-spacing:-1.328000px;}
.ws160{word-spacing:-1.324000px;}
.ws2c2{word-spacing:-1.320000px;}
.ws7f{word-spacing:-1.316000px;}
.ws262{word-spacing:-1.312000px;}
.ws1a6{word-spacing:-1.308000px;}
.ws10a{word-spacing:-1.304000px;}
.ws3c1{word-spacing:-1.300000px;}
.ws1a8{word-spacing:-1.296000px;}
.wsf0{word-spacing:-1.292000px;}
.ws2a{word-spacing:-1.288000px;}
.ws30e{word-spacing:-1.284000px;}
.ws130{word-spacing:-1.280000px;}
.ws362{word-spacing:-1.276800px;}
.ws18a{word-spacing:-1.276000px;}
.ws31{word-spacing:-1.272000px;}
.wsfa{word-spacing:-1.268000px;}
.ws153{word-spacing:-1.265400px;}
.ws1c{word-spacing:-1.264000px;}
.ws302{word-spacing:-1.261600px;}
.wse7{word-spacing:-1.260000px;}
.ws207{word-spacing:-1.256000px;}
.ws3ee{word-spacing:-1.254400px;}
.ws26{word-spacing:-1.252000px;}
.ws38e{word-spacing:-1.248000px;}
.ws2d1{word-spacing:-1.246400px;}
.wsd0{word-spacing:-1.244000px;}
.ws1eb{word-spacing:-1.242600px;}
.ws203{word-spacing:-1.240000px;}
.ws294{word-spacing:-1.236000px;}
.ws36a{word-spacing:-1.235000px;}
.ws381{word-spacing:-1.232000px;}
.wse9{word-spacing:-1.228000px;}
.ws1e1{word-spacing:-1.224000px;}
.ws313{word-spacing:-1.223600px;}
.ws233{word-spacing:-1.220000px;}
.ws24a{word-spacing:-1.219800px;}
.wse2{word-spacing:-1.216000px;}
.ws5aa{word-spacing:-1.215200px;}
.ws1bb{word-spacing:-1.212200px;}
.wsc9{word-spacing:-1.212000px;}
.ws249{word-spacing:-1.208400px;}
.wsb1{word-spacing:-1.208000px;}
.ws3f9{word-spacing:-1.204600px;}
.wsab{word-spacing:-1.204000px;}
.ws264{word-spacing:-1.200000px;}
.ws361{word-spacing:-1.197000px;}
.ws278{word-spacing:-1.196000px;}
.ws91{word-spacing:-1.192000px;}
.ws3e{word-spacing:-1.188000px;}
.ws336{word-spacing:-1.185600px;}
.ws189{word-spacing:-1.184000px;}
.ws28{word-spacing:-1.180000px;}
.ws2a0{word-spacing:-1.178000px;}
.ws173{word-spacing:-1.176000px;}
.ws2cf{word-spacing:-1.174200px;}
.ws104{word-spacing:-1.172000px;}
.ws267{word-spacing:-1.168000px;}
.ws567{word-spacing:-1.164800px;}
.ws17b{word-spacing:-1.164000px;}
.ws192{word-spacing:-1.162800px;}
.ws27a{word-spacing:-1.160000px;}
.ws3f0{word-spacing:-1.159200px;}
.ws29f{word-spacing:-1.159000px;}
.ws25{word-spacing:-1.156000px;}
.ws335{word-spacing:-1.155200px;}
.ws394{word-spacing:-1.152000px;}
.ws30{word-spacing:-1.148000px;}
.wsec{word-spacing:-1.144000px;}
.ws334{word-spacing:-1.143800px;}
.ws245{word-spacing:-1.140000px;}
.ws39e{word-spacing:-1.136200px;}
.ws18c{word-spacing:-1.136000px;}
.wsa4{word-spacing:-1.132000px;}
.ws1c8{word-spacing:-1.128000px;}
.wsc0{word-spacing:-1.124000px;}
.ws48{word-spacing:-1.120000px;}
.ws200{word-spacing:-1.116000px;}
.ws318{word-spacing:-1.113400px;}
.ws110{word-spacing:-1.112000px;}
.ws2bd{word-spacing:-1.109600px;}
.ws19f{word-spacing:-1.108000px;}
.ws20b{word-spacing:-1.105800px;}
.ws53{word-spacing:-1.104000px;}
.ws30a{word-spacing:-1.102000px;}
.wsbd{word-spacing:-1.100000px;}
.ws317{word-spacing:-1.098200px;}
.ws76{word-spacing:-1.096000px;}
.ws3cf{word-spacing:-1.094400px;}
.ws58{word-spacing:-1.092000px;}
.ws1b3{word-spacing:-1.088000px;}
.ws3ce{word-spacing:-1.086800px;}
.ws41{word-spacing:-1.084000px;}
.ws1c3{word-spacing:-1.080000px;}
.ws1f1{word-spacing:-1.079200px;}
.wsb0{word-spacing:-1.076000px;}
.ws2bf{word-spacing:-1.075400px;}
.ws5a7{word-spacing:-1.072800px;}
.ws312{word-spacing:-1.072000px;}
.ws2a7{word-spacing:-1.068000px;}
.ws21{word-spacing:-1.064000px;}
.ws18{word-spacing:-1.062000px;}
.ws2d2{word-spacing:-1.060200px;}
.ws83{word-spacing:-1.060000px;}
.ws345{word-spacing:-1.056000px;}
.ws9{word-spacing:-1.052800px;}
.ws1f0{word-spacing:-1.052600px;}
.ws2fb{word-spacing:-1.052000px;}
.ws197{word-spacing:-1.048800px;}
.ws4b4{word-spacing:-1.048000px;}
.ws1f4{word-spacing:-1.045000px;}
.ws206{word-spacing:-1.044000px;}
.ws1ef{word-spacing:-1.041200px;}
.ws13b{word-spacing:-1.040000px;}
.ws4f{word-spacing:-1.036000px;}
.ws1d5{word-spacing:-1.033600px;}
.ws347{word-spacing:-1.032000px;}
.ws1b2{word-spacing:-1.028000px;}
.ws1a4{word-spacing:-1.024000px;}
.ws1bf{word-spacing:-1.022200px;}
.ws11{word-spacing:-1.020800px;}
.ws172{word-spacing:-1.020000px;}
.ws215{word-spacing:-1.016000px;}
.ws96{word-spacing:-1.012000px;}
.ws350{word-spacing:-1.008000px;}
.ws2d9{word-spacing:-1.004000px;}
.wsb7{word-spacing:-1.000000px;}
.ws3d1{word-spacing:-0.999400px;}
.ws47e{word-spacing:-0.996000px;}
.ws66{word-spacing:-0.992000px;}
.ws1f8{word-spacing:-0.991800px;}
.wsb3{word-spacing:-0.988000px;}
.wsbb{word-spacing:-0.984000px;}
.ws386{word-spacing:-0.980400px;}
.ws138{word-spacing:-0.980000px;}
.ws2f1{word-spacing:-0.978000px;}
.ws1bc{word-spacing:-0.976600px;}
.ws1f9{word-spacing:-0.976000px;}
.ws74{word-spacing:-0.972000px;}
.ws40d{word-spacing:-0.968000px;}
.ws385{word-spacing:-0.965200px;}
.ws50{word-spacing:-0.964000px;}
.ws31b{word-spacing:-0.961400px;}
.ws161{word-spacing:-0.960000px;}
.ws31a{word-spacing:-0.957600px;}
.ws229{word-spacing:-0.956000px;}
.ws209{word-spacing:-0.953800px;}
.ws7e{word-spacing:-0.952000px;}
.ws4{word-spacing:-0.950400px;}
.ws34{word-spacing:-0.948000px;}
.ws55{word-spacing:-0.944000px;}
.ws54{word-spacing:-0.940000px;}
.ws1e8{word-spacing:-0.938600px;}
.ws34c{word-spacing:-0.936000px;}
.ws343{word-spacing:-0.932000px;}
.ws199{word-spacing:-0.931000px;}
.ws1dc{word-spacing:-0.928000px;}
.ws2ff{word-spacing:-0.924000px;}
.ws2bc{word-spacing:-0.920000px;}
.ws5e{word-spacing:-0.916000px;}
.ws31e{word-spacing:-0.912000px;}
.ws155{word-spacing:-0.908200px;}
.wse6{word-spacing:-0.908000px;}
.ws12d{word-spacing:-0.904000px;}
.ws330{word-spacing:-0.900600px;}
.ws2cd{word-spacing:-0.900000px;}
.ws1d1{word-spacing:-0.896800px;}
.ws43c{word-spacing:-0.896000px;}
.wsd{word-spacing:-0.892800px;}
.ws5b{word-spacing:-0.892000px;}
.ws43{word-spacing:-0.888000px;}
.ws2b0{word-spacing:-0.885400px;}
.ws14a{word-spacing:-0.884000px;}
.ws5f{word-spacing:-0.880000px;}
.ws201{word-spacing:-0.876000px;}
.ws89{word-spacing:-0.872000px;}
.ws210{word-spacing:-0.870200px;}
.ws2a5{word-spacing:-0.868000px;}
.ws37e{word-spacing:-0.864000px;}
.ws156{word-spacing:-0.862600px;}
.ws68{word-spacing:-0.860000px;}
.ws12{word-spacing:-0.857600px;}
.wsde{word-spacing:-0.856000px;}
.ws109{word-spacing:-0.852000px;}
.ws12e{word-spacing:-0.848000px;}
.ws118{word-spacing:-0.844000px;}
.ws4fa{word-spacing:-0.843600px;}
.ws168{word-spacing:-0.840000px;}
.ws4fe{word-spacing:-0.839800px;}
.ws2ea{word-spacing:-0.836000px;}
.ws502{word-spacing:-0.832200px;}
.ws15f{word-spacing:-0.832000px;}
.ws4bd{word-spacing:-0.828400px;}
.ws127{word-spacing:-0.828000px;}
.ws28e{word-spacing:-0.824000px;}
.ws78{word-spacing:-0.820000px;}
.ws1d6{word-spacing:-0.817000px;}
.wscc{word-spacing:-0.816000px;}
.ws2e0{word-spacing:-0.813200px;}
.ws1d{word-spacing:-0.812000px;}
.ws102{word-spacing:-0.808000px;}
.wsb5{word-spacing:-0.804000px;}
.wsdc{word-spacing:-0.800000px;}
.ws4e8{word-spacing:-0.798000px;}
.ws216{word-spacing:-0.796000px;}
.ws27d{word-spacing:-0.794200px;}
.ws2f4{word-spacing:-0.792000px;}
.ws20a{word-spacing:-0.790400px;}
.wsfe{word-spacing:-0.788000px;}
.ws38f{word-spacing:-0.784000px;}
.ws175{word-spacing:-0.780000px;}
.ws142{word-spacing:-0.777000px;}
.ws12f{word-spacing:-0.776000px;}
.ws131{word-spacing:-0.772000px;}
.ws3ad{word-spacing:-0.771400px;}
.ws3f1{word-spacing:-0.768000px;}
.ws120{word-spacing:-0.764000px;}
.ws2df{word-spacing:-0.763800px;}
.ws304{word-spacing:-0.760000px;}
.wsa3{word-spacing:-0.756000px;}
.ws8e{word-spacing:-0.752000px;}
.ws36e{word-spacing:-0.748000px;}
.ws36b{word-spacing:-0.744800px;}
.wsa2{word-spacing:-0.744000px;}
.ws26e{word-spacing:-0.740000px;}
.ws1f7{word-spacing:-0.737200px;}
.ws128{word-spacing:-0.736000px;}
.ws1f2{word-spacing:-0.733400px;}
.ws27{word-spacing:-0.732000px;}
.ws1be{word-spacing:-0.729600px;}
.ws178{word-spacing:-0.728000px;}
.ws2fe{word-spacing:-0.724000px;}
.ws258{word-spacing:-0.720000px;}
.ws4d8{word-spacing:-0.717000px;}
.ws214{word-spacing:-0.716000px;}
.ws13c{word-spacing:-0.712000px;}
.ws438{word-spacing:-0.708000px;}
.ws191{word-spacing:-0.704000px;}
.ws516{word-spacing:-0.700000px;}
.ws231{word-spacing:-0.696000px;}
.ws17c{word-spacing:-0.692000px;}
.ws18f{word-spacing:-0.688000px;}
.ws1f5{word-spacing:-0.687800px;}
.ws30b{word-spacing:-0.684000px;}
.ws393{word-spacing:-0.680000px;}
.ws3ea{word-spacing:-0.676000px;}
.ws10{word-spacing:-0.675200px;}
.ws84{word-spacing:-0.672000px;}
.wsa{word-spacing:-0.668800px;}
.ws242{word-spacing:-0.668000px;}
.ws37f{word-spacing:-0.664000px;}
.ws28d{word-spacing:-0.660000px;}
.wsb6{word-spacing:-0.656000px;}
.ws205{word-spacing:-0.652000px;}
.ws24b{word-spacing:-0.649800px;}
.ws60{word-spacing:-0.648000px;}
.ws67{word-spacing:-0.644000px;}
.ws3ec{word-spacing:-0.640000px;}
.wsf1{word-spacing:-0.636000px;}
.ws6b{word-spacing:-0.632000px;}
.ws14e{word-spacing:-0.628000px;}
.ws562{word-spacing:-0.624000px;}
.ws72{word-spacing:-0.620000px;}
.ws315{word-spacing:-0.619400px;}
.ws180{word-spacing:-0.616000px;}
.ws13f{word-spacing:-0.615000px;}
.wsc7{word-spacing:-0.612000px;}
.ws1df{word-spacing:-0.608000px;}
.wsff{word-spacing:-0.604000px;}
.ws2ad{word-spacing:-0.600000px;}
.ws4ba{word-spacing:-0.596000px;}
.ws1d7{word-spacing:-0.592800px;}
.ws11c{word-spacing:-0.592000px;}
.ws40b{word-spacing:-0.588000px;}
.ws450{word-spacing:-0.584000px;}
.ws2c6{word-spacing:-0.581400px;}
.ws41a{word-spacing:-0.580000px;}
.ws1e5{word-spacing:-0.577600px;}
.ws4c1{word-spacing:-0.576800px;}
.ws38c{word-spacing:-0.576000px;}
.ws25f{word-spacing:-0.572000px;}
.ws408{word-spacing:-0.571200px;}
.ws1ad{word-spacing:-0.568000px;}
.ws86{word-spacing:-0.564000px;}
.ws24d{word-spacing:-0.562400px;}
.wsa0{word-spacing:-0.560000px;}
.ws372{word-spacing:-0.556000px;}
.ws6c{word-spacing:-0.552000px;}
.ws256{word-spacing:-0.548000px;}
.ws48e{word-spacing:-0.544000px;}
.ws154{word-spacing:-0.543400px;}
.ws2c1{word-spacing:-0.540000px;}
.ws1ab{word-spacing:-0.536000px;}
.wsb2{word-spacing:-0.532000px;}
.ws3{word-spacing:-0.528000px;}
.ws238{word-spacing:-0.524000px;}
.ws281{word-spacing:-0.520600px;}
.ws19c{word-spacing:-0.520000px;}
.ws342{word-spacing:-0.516000px;}
.ws1e3{word-spacing:-0.513000px;}
.ws90{word-spacing:-0.512000px;}
.ws113{word-spacing:-0.508000px;}
.ws16b{word-spacing:-0.504000px;}
.ws2dc{word-spacing:-0.501600px;}
.ws1a0{word-spacing:-0.500000px;}
.ws1e2{word-spacing:-0.497800px;}
.ws2b7{word-spacing:-0.496000px;}
.ws27e{word-spacing:-0.494000px;}
.wscd{word-spacing:-0.492000px;}
.ws306{word-spacing:-0.490200px;}
.ws1db{word-spacing:-0.488000px;}
.ws590{word-spacing:-0.487200px;}
.ws133{word-spacing:-0.484000px;}
.wsa1{word-spacing:-0.480000px;}
.ws305{word-spacing:-0.478800px;}
.wsb8{word-spacing:-0.476000px;}
.ws122{word-spacing:-0.472000px;}
.ws3da{word-spacing:-0.470400px;}
.ws25c{word-spacing:-0.468000px;}
.ws28c{word-spacing:-0.464000px;}
.ws1a3{word-spacing:-0.460000px;}
.ws1bd{word-spacing:-0.456000px;}
.ws1ca{word-spacing:-0.452000px;}
.ws94{word-spacing:-0.448000px;}
.ws3eb{word-spacing:-0.444000px;}
.ws158{word-spacing:-0.440800px;}
.ws77{word-spacing:-0.440000px;}
.ws2d0{word-spacing:-0.437000px;}
.ws371{word-spacing:-0.436000px;}
.ws13d{word-spacing:-0.432000px;}
.ws2d{word-spacing:-0.428000px;}
.ws368{word-spacing:-0.425600px;}
.ws223{word-spacing:-0.424000px;}
.wsd8{word-spacing:-0.420000px;}
.ws1f{word-spacing:-0.416000px;}
.ws4a1{word-spacing:-0.412000px;}
.ws11a{word-spacing:-0.408000px;}
.wsbc{word-spacing:-0.404000px;}
.ws1e{word-spacing:-0.400000px;}
.wsf2{word-spacing:-0.396000px;}
.ws3fb{word-spacing:-0.392000px;}
.ws369{word-spacing:-0.391400px;}
.ws2b5{word-spacing:-0.388000px;}
.wsac{word-spacing:-0.384000px;}
.ws3a8{word-spacing:-0.383800px;}
.wsae{word-spacing:-0.380000px;}
.ws147{word-spacing:-0.376000px;}
.ws2d5{word-spacing:-0.372000px;}
.ws11f{word-spacing:-0.368000px;}
.ws1c1{word-spacing:-0.364000px;}
.ws2a1{word-spacing:-0.361000px;}
.ws3cd{word-spacing:-0.360000px;}
.wsd7{word-spacing:-0.356000px;}
.ws348{word-spacing:-0.352000px;}
.ws16d{word-spacing:-0.348000px;}
.ws2ed{word-spacing:-0.344000px;}
.ws17d{word-spacing:-0.340000px;}
.ws10e{word-spacing:-0.336000px;}
.ws36c{word-spacing:-0.334400px;}
.ws390{word-spacing:-0.332000px;}
.ws339{word-spacing:-0.330600px;}
.ws418{word-spacing:-0.328000px;}
.ws212{word-spacing:-0.324000px;}
.ws338{word-spacing:-0.323000px;}
.ws8b{word-spacing:-0.320000px;}
.ws8c{word-spacing:-0.316000px;}
.ws8a{word-spacing:-0.312000px;}
.ws3ab{word-spacing:-0.308000px;}
.ws85{word-spacing:-0.304000px;}
.ws286{word-spacing:-0.300000px;}
.ws8{word-spacing:-0.297600px;}
.ws3f{word-spacing:-0.296000px;}
.ws422{word-spacing:-0.292000px;}
.ws2d6{word-spacing:-0.288000px;}
.ws50f{word-spacing:-0.284000px;}
.ws283{word-spacing:-0.280000px;}
.ws470{word-spacing:-0.276000px;}
.ws52c{word-spacing:-0.272000px;}
.ws324{word-spacing:-0.269800px;}
.ws3c5{word-spacing:-0.268000px;}
.ws3a4{word-spacing:-0.264000px;}
.ws358{word-spacing:-0.260000px;}
.ws331{word-spacing:-0.254600px;}
.ws101{word-spacing:-0.252000px;}
.wsf4{word-spacing:-0.244000px;}
.wse{word-spacing:-0.243200px;}
.ws3a{word-spacing:-0.240000px;}
.ws3cb{word-spacing:-0.232000px;}
.ws587{word-spacing:-0.228000px;}
.ws41b{word-spacing:-0.224000px;}
.ws412{word-spacing:-0.220000px;}
.wsdb{word-spacing:-0.212000px;}
.ws31c{word-spacing:-0.209000px;}
.ws44a{word-spacing:-0.208000px;}
.ws3aa{word-spacing:-0.192000px;}
.ws3a1{word-spacing:-0.188000px;}
.ws32d{word-spacing:-0.180000px;}
.ws145{word-spacing:-0.176000px;}
.ws3b4{word-spacing:-0.172000px;}
.wsc{word-spacing:-0.169600px;}
.ws47a{word-spacing:-0.168000px;}
.ws2c{word-spacing:-0.164000px;}
.ws2b{word-spacing:-0.160000px;}
.ws9d{word-spacing:-0.156000px;}
.ws42{word-spacing:-0.152000px;}
.ws4fc{word-spacing:-0.148200px;}
.ws425{word-spacing:-0.148000px;}
.ws568{word-spacing:-0.144000px;}
.wse0{word-spacing:-0.140000px;}
.ws53e{word-spacing:-0.136000px;}
.ws3f8{word-spacing:-0.133000px;}
.ws53f{word-spacing:-0.132000px;}
.ws4f4{word-spacing:-0.128000px;}
.ws140{word-spacing:-0.123000px;}
.ws274{word-spacing:-0.120000px;}
.ws5d{word-spacing:-0.116000px;}
.ws2ba{word-spacing:-0.112000px;}
.ws296{word-spacing:-0.108000px;}
.ws3f7{word-spacing:-0.106400px;}
.ws24{word-spacing:-0.104000px;}
.ws471{word-spacing:-0.100000px;}
.ws3ac{word-spacing:-0.096000px;}
.ws1ae{word-spacing:-0.092000px;}
.ws415{word-spacing:-0.089600px;}
.ws4e9{word-spacing:-0.088000px;}
.ws1ba{word-spacing:-0.087400px;}
.ws528{word-spacing:-0.080000px;}
.ws1dd{word-spacing:-0.076000px;}
.ws8f{word-spacing:-0.068000px;}
.ws36{word-spacing:-0.064000px;}
.ws15d{word-spacing:-0.060000px;}
.ws548{word-spacing:-0.056000px;}
.ws578{word-spacing:-0.050400px;}
.ws404{word-spacing:-0.048000px;}
.ws58b{word-spacing:-0.044800px;}
.ws5a{word-spacing:-0.044000px;}
.ws583{word-spacing:-0.040000px;}
.ws179{word-spacing:-0.039200px;}
.ws544{word-spacing:-0.036000px;}
.ws4ed{word-spacing:-0.032000px;}
.ws144{word-spacing:-0.028000px;}
.ws26b{word-spacing:-0.024000px;}
.ws139{word-spacing:-0.022400px;}
.ws523{word-spacing:-0.020000px;}
.ws56b{word-spacing:-0.019200px;}
.ws566{word-spacing:-0.019000px;}
.wsfd{word-spacing:-0.016800px;}
.ws27c{word-spacing:-0.016000px;}
.ws4bf{word-spacing:-0.015200px;}
.ws510{word-spacing:-0.014400px;}
.ws2dd{word-spacing:-0.012000px;}
.ws1cc{word-spacing:-0.011400px;}
.wsca{word-spacing:-0.011200px;}
.ws4cb{word-spacing:-0.009944px;}
.ws4e0{word-spacing:-0.009600px;}
.ws40{word-spacing:-0.008000px;}
.ws1d2{word-spacing:-0.007600px;}
.ws95{word-spacing:-0.005600px;}
.ws405{word-spacing:-0.005200px;}
.wsc1{word-spacing:-0.004800px;}
.ws81{word-spacing:-0.004000px;}
.ws1d4{word-spacing:-0.003800px;}
.ws17{word-spacing:-0.003600px;}
.ws4cf{word-spacing:-0.003481px;}
.ws4d6{word-spacing:-0.003315px;}
.ws117{word-spacing:-0.002800px;}
.ws552{word-spacing:-0.002075px;}
.ws551{word-spacing:-0.001779px;}
.ws0{word-spacing:0.000000px;}
.ws550{word-spacing:0.001779px;}
.ws533{word-spacing:0.001920px;}
.ws2{word-spacing:0.002800px;}
.ws115{word-spacing:0.003000px;}
.wsf{word-spacing:0.003200px;}
.ws4d2{word-spacing:0.003481px;}
.ws1a{word-spacing:0.003600px;}
.ws19a{word-spacing:0.003800px;}
.ws14{word-spacing:0.004000px;}
.ws542{word-spacing:0.004200px;}
.ws413{word-spacing:0.004400px;}
.ws1b0{word-spacing:0.004800px;}
.ws406{word-spacing:0.005200px;}
.ws17a{word-spacing:0.005600px;}
.ws35e{word-spacing:0.006000px;}
.ws4d7{word-spacing:0.006630px;}
.ws4d0{word-spacing:0.006961px;}
.ws16{word-spacing:0.007200px;}
.ws218{word-spacing:0.007600px;}
.ws15{word-spacing:0.008000px;}
.ws4c0{word-spacing:0.008400px;}
.ws2b2{word-spacing:0.009000px;}
.ws554{word-spacing:0.009600px;}
.ws4d4{word-spacing:0.010442px;}
.ws1{word-spacing:0.011200px;}
.ws1d3{word-spacing:0.011400px;}
.ws370{word-spacing:0.012000px;}
.ws4c8{word-spacing:0.012800px;}
.ws4ce{word-spacing:0.013259px;}
.ws4d5{word-spacing:0.013922px;}
.ws414{word-spacing:0.014000px;}
.ws35b{word-spacing:0.015200px;}
.ws4e5{word-spacing:0.016000px;}
.ws34a{word-spacing:0.016800px;}
.ws4d1{word-spacing:0.017403px;}
.ws219{word-spacing:0.019000px;}
.ws64{word-spacing:0.020000px;}
.ws4be{word-spacing:0.022800px;}
.ws55e{word-spacing:0.024000px;}
.ws4d3{word-spacing:0.027844px;}
.ws4a6{word-spacing:0.032000px;}
.ws535{word-spacing:0.033600px;}
.ws449{word-spacing:0.044000px;}
.ws472{word-spacing:0.048000px;}
.ws18e{word-spacing:0.056000px;}
.ws569{word-spacing:0.060000px;}
.ws565{word-spacing:0.068000px;}
.ws409{word-spacing:0.076000px;}
.ws376{word-spacing:0.080000px;}
.ws5af{word-spacing:0.088000px;}
.ws63{word-spacing:0.092000px;}
.ws5ab{word-spacing:0.096000px;}
.ws1b4{word-spacing:0.100000px;}
.ws5be{word-spacing:0.104000px;}
.ws5bd{word-spacing:0.108000px;}
.ws476{word-spacing:0.112000px;}
.ws4db{word-spacing:0.116000px;}
.ws4c3{word-spacing:0.120000px;}
.ws5c9{word-spacing:0.124000px;}
.ws123{word-spacing:0.128000px;}
.ws4ab{word-spacing:0.132000px;}
.ws10b{word-spacing:0.136000px;}
.ws20c{word-spacing:0.144400px;}
.ws10c{word-spacing:0.148000px;}
.ws2da{word-spacing:0.152000px;}
.ws29c{word-spacing:0.155800px;}
.wsf3{word-spacing:0.156000px;}
.ws4c5{word-spacing:0.160000px;}
.ws44e{word-spacing:0.164000px;}
.ws45{word-spacing:0.172000px;}
.wsc6{word-spacing:0.180000px;}
.ws427{word-spacing:0.184000px;}
.ws349{word-spacing:0.188000px;}
.ws366{word-spacing:0.193800px;}
.ws33b{word-spacing:0.196000px;}
.ws9c{word-spacing:0.204000px;}
.ws4cc{word-spacing:0.205649px;}
.ws531{word-spacing:0.208000px;}
.ws586{word-spacing:0.212000px;}
.ws2c5{word-spacing:0.212800px;}
.ws402{word-spacing:0.213000px;}
.ws49a{word-spacing:0.216000px;}
.ws2a2{word-spacing:0.216600px;}
.ws448{word-spacing:0.220000px;}
.ws3ef{word-spacing:0.224000px;}
.ws152{word-spacing:0.224200px;}
.ws27f{word-spacing:0.228000px;}
.wscb{word-spacing:0.232000px;}
.ws4ee{word-spacing:0.236000px;}
.ws571{word-spacing:0.240000px;}
.ws23d{word-spacing:0.244000px;}
.ws546{word-spacing:0.252000px;}
.ws184{word-spacing:0.256000px;}
.ws108{word-spacing:0.260000px;}
.ws536{word-spacing:0.268000px;}
.ws9b{word-spacing:0.272000px;}
.ws16c{word-spacing:0.276000px;}
.ws4c2{word-spacing:0.280000px;}
.ws279{word-spacing:0.284000px;}
.wse1{word-spacing:0.288000px;}
.ws30c{word-spacing:0.292000px;}
.ws491{word-spacing:0.300000px;}
.ws52e{word-spacing:0.304000px;}
.ws466{word-spacing:0.308000px;}
.ws539{word-spacing:0.312000px;}
.ws526{word-spacing:0.316000px;}
.ws15c{word-spacing:0.320000px;}
.ws4d9{word-spacing:0.324000px;}
.ws1b9{word-spacing:0.326800px;}
.ws1aa{word-spacing:0.328000px;}
.ws44b{word-spacing:0.332000px;}
.ws1b8{word-spacing:0.334400px;}
.ws496{word-spacing:0.344000px;}
.ws3bd{word-spacing:0.348000px;}
.ws33{word-spacing:0.352000px;}
.ws1ea{word-spacing:0.357200px;}
.ws514{word-spacing:0.368000px;}
.ws4b9{word-spacing:0.372000px;}
.ws352{word-spacing:0.376000px;}
.ws159{word-spacing:0.376200px;}
.ws2c3{word-spacing:0.380000px;}
.ws26a{word-spacing:0.384000px;}
.ws1a9{word-spacing:0.388000px;}
.ws2ac{word-spacing:0.392000px;}
.ws54a{word-spacing:0.396000px;}
.ws16e{word-spacing:0.400000px;}
.ws4aa{word-spacing:0.404000px;}
.ws48c{word-spacing:0.408000px;}
.ws40f{word-spacing:0.412000px;}
.ws51e{word-spacing:0.416000px;}
.ws37{word-spacing:0.420000px;}
.ws5c1{word-spacing:0.424000px;}
.ws5c2{word-spacing:0.428000px;}
.ws3d0{word-spacing:0.429400px;}
.ws3d7{word-spacing:0.432000px;}
.ws5a9{word-spacing:0.436000px;}
.ws310{word-spacing:0.440000px;}
.ws453{word-spacing:0.444000px;}
.ws498{word-spacing:0.452000px;}
.wsf5{word-spacing:0.456000px;}
.ws332{word-spacing:0.459800px;}
.ws4c9{word-spacing:0.460000px;}
.ws419{word-spacing:0.468000px;}
.ws19d{word-spacing:0.472000px;}
.ws4bb{word-spacing:0.477000px;}
.ws82{word-spacing:0.480000px;}
.ws4e4{word-spacing:0.484000px;}
.ws579{word-spacing:0.488000px;}
.ws308{word-spacing:0.490200px;}
.ws580{word-spacing:0.496000px;}
.ws417{word-spacing:0.500000px;}
.ws185{word-spacing:0.504000px;}
.ws3d9{word-spacing:0.508000px;}
.ws47{word-spacing:0.512000px;}
.ws273{word-spacing:0.516000px;}
.wsa6{word-spacing:0.520000px;}
.ws146{word-spacing:0.528000px;}
.ws4f1{word-spacing:0.532000px;}
.ws42f{word-spacing:0.536000px;}
.ws29{word-spacing:0.540000px;}
.ws22b{word-spacing:0.544000px;}
.ws53d{word-spacing:0.548000px;}
.ws2bb{word-spacing:0.552000px;}
.ws323{word-spacing:0.558600px;}
.ws18d{word-spacing:0.560000px;}
.ws459{word-spacing:0.568000px;}
.ws367{word-spacing:0.570000px;}
.ws43e{word-spacing:0.572000px;}
.ws54e{word-spacing:0.576000px;}
.ws5ba{word-spacing:0.584000px;}
.ws40a{word-spacing:0.592000px;}
.ws298{word-spacing:0.596000px;}
.ws4eb{word-spacing:0.600000px;}
.wse8{word-spacing:0.608000px;}
.ws29a{word-spacing:0.611800px;}
.wsda{word-spacing:0.612000px;}
.ws420{word-spacing:0.616000px;}
.ws14d{word-spacing:0.624000px;}
.ws543{word-spacing:0.628000px;}
.ws2f5{word-spacing:0.632000px;}
.ws486{word-spacing:0.636000px;}
.ws48b{word-spacing:0.640000px;}
.wsf8{word-spacing:0.644000px;}
.ws295{word-spacing:0.648000px;}
.ws51b{word-spacing:0.652000px;}
.ws1a7{word-spacing:0.656000px;}
.ws59e{word-spacing:0.660000px;}
.wsc4{word-spacing:0.664000px;}
.ws21e{word-spacing:0.668000px;}
.ws59{word-spacing:0.672000px;}
.ws169{word-spacing:0.676000px;}
.ws521{word-spacing:0.680000px;}
.ws325{word-spacing:0.680200px;}
.ws45e{word-spacing:0.684000px;}
.ws513{word-spacing:0.688000px;}
.ws522{word-spacing:0.692000px;}
.ws3e8{word-spacing:0.700000px;}
.ws24f{word-spacing:0.703000px;}
.ws250{word-spacing:0.706800px;}
.ws45c{word-spacing:0.708000px;}
.ws595{word-spacing:0.712000px;}
.ws2f{word-spacing:0.716000px;}
.ws319{word-spacing:0.718200px;}
.ws2a6{word-spacing:0.720000px;}
.ws3e7{word-spacing:0.724000px;}
.ws426{word-spacing:0.728000px;}
.wse3{word-spacing:0.732000px;}
.ws285{word-spacing:0.736000px;}
.ws43d{word-spacing:0.744000px;}
.ws32e{word-spacing:0.744800px;}
.ws346{word-spacing:0.748000px;}
.ws2de{word-spacing:0.760000px;}
.ws534{word-spacing:0.768000px;}
.ws4b0{word-spacing:0.772000px;}
.ws33e{word-spacing:0.780000px;}
.ws441{word-spacing:0.784000px;}
.ws4ac{word-spacing:0.796000px;}
.ws2b1{word-spacing:0.798000px;}
.ws4b3{word-spacing:0.800000px;}
.ws41e{word-spacing:0.804000px;}
.wsaf{word-spacing:0.808000px;}
.ws500{word-spacing:0.809400px;}
.ws3fd{word-spacing:0.812000px;}
.ws143{word-spacing:0.813000px;}
.ws12b{word-spacing:0.820000px;}
.ws112{word-spacing:0.824000px;}
.ws3c8{word-spacing:0.828000px;}
.ws253{word-spacing:0.832000px;}
.ws18b{word-spacing:0.836000px;}
.ws50c{word-spacing:0.840000px;}
.ws4c4{word-spacing:0.848000px;}
.ws28f{word-spacing:0.852000px;}
.ws303{word-spacing:0.855000px;}
.ws2b3{word-spacing:0.856000px;}
.ws5a1{word-spacing:0.860000px;}
.ws97{word-spacing:0.872000px;}
.ws475{word-spacing:0.876000px;}
.ws3bf{word-spacing:0.884000px;}
.ws3c0{word-spacing:0.888000px;}
.ws38a{word-spacing:0.892000px;}
.ws297{word-spacing:0.896000px;}
.ws25a{word-spacing:0.900000px;}
.ws3c6{word-spacing:0.904000px;}
.ws71{word-spacing:0.908000px;}
.ws564{word-spacing:0.916000px;}
.ws87{word-spacing:0.928000px;}
.ws329{word-spacing:0.931000px;}
.ws598{word-spacing:0.932000px;}
.ws237{word-spacing:0.936000px;}
.ws487{word-spacing:0.940000px;}
.ws57b{word-spacing:0.944000px;}
.ws328{word-spacing:0.946200px;}
.ws5c6{word-spacing:0.948000px;}
.ws4e2{word-spacing:0.956000px;}
.ws2a9{word-spacing:0.960000px;}
.ws356{word-spacing:0.964000px;}
.ws446{word-spacing:0.972000px;}
.ws33d{word-spacing:0.976000px;}
.ws2ce{word-spacing:0.984000px;}
.ws59f{word-spacing:0.988000px;}
.ws354{word-spacing:0.992000px;}
.ws42b{word-spacing:0.996000px;}
.ws252{word-spacing:1.000000px;}
.ws532{word-spacing:1.004000px;}
.ws1a5{word-spacing:1.008000px;}
.ws5ae{word-spacing:1.012000px;}
.ws45d{word-spacing:1.016000px;}
.ws3a5{word-spacing:1.020000px;}
.ws511{word-spacing:1.024000px;}
.ws509{word-spacing:1.028000px;}
.ws2e4{word-spacing:1.036000px;}
.wsd2{word-spacing:1.044000px;}
.wsf6{word-spacing:1.048000px;}
.ws13{word-spacing:1.052800px;}
.ws116{word-spacing:1.056000px;}
.ws3e3{word-spacing:1.060000px;}
.ws25b{word-spacing:1.068000px;}
.ws3be{word-spacing:1.076000px;}
.ws1ed{word-spacing:1.080000px;}
.ws22a{word-spacing:1.084000px;}
.ws473{word-spacing:1.088000px;}
.ws538{word-spacing:1.092000px;}
.ws5b7{word-spacing:1.096000px;}
.ws236{word-spacing:1.100000px;}
.ws4ef{word-spacing:1.104000px;}
.ws3e4{word-spacing:1.112000px;}
.ws3b0{word-spacing:1.116000px;}
.ws163{word-spacing:1.120000px;}
.ws92{word-spacing:1.124000px;}
.ws254{word-spacing:1.128000px;}
.ws2a3{word-spacing:1.132000px;}
.ws5c4{word-spacing:1.136000px;}
.ws4df{word-spacing:1.140000px;}
.ws398{word-spacing:1.144000px;}
.ws391{word-spacing:1.148000px;}
.ws3d4{word-spacing:1.151400px;}
.ws32{word-spacing:1.152000px;}
.ws431{word-spacing:1.156000px;}
.ws5b5{word-spacing:1.160000px;}
.ws316{word-spacing:1.162800px;}
.ws44f{word-spacing:1.164000px;}
.ws111{word-spacing:1.168000px;}
.ws593{word-spacing:1.176000px;}
.ws58d{word-spacing:1.180000px;}
.ws5a6{word-spacing:1.184000px;}
.ws151{word-spacing:1.189400px;}
.ws1b7{word-spacing:1.192000px;}
.ws442{word-spacing:1.200000px;}
.ws480{word-spacing:1.204000px;}
.ws3e0{word-spacing:1.208000px;}
.ws2e{word-spacing:1.212000px;}
.ws48f{word-spacing:1.216000px;}
.ws58c{word-spacing:1.224000px;}
.ws106{word-spacing:1.228000px;}
.ws377{word-spacing:1.232000px;}
.ws22f{word-spacing:1.240000px;}
.ws582{word-spacing:1.244000px;}
.ws26d{word-spacing:1.248000px;}
.ws257{word-spacing:1.252000px;}
.ws195{word-spacing:1.254000px;}
.ws4e3{word-spacing:1.256000px;}
.ws49d{word-spacing:1.268000px;}
.ws36f{word-spacing:1.272000px;}
.ws2ab{word-spacing:1.276000px;}
.ws3a2{word-spacing:1.288000px;}
.ws14b{word-spacing:1.292000px;}
.ws211{word-spacing:1.295800px;}
.ws14c{word-spacing:1.296000px;}
.wsed{word-spacing:1.300000px;}
.ws2b4{word-spacing:1.304000px;}
.ws266{word-spacing:1.308000px;}
.ws53a{word-spacing:1.316000px;}
.wsc5{word-spacing:1.320000px;}
.ws50b{word-spacing:1.324000px;}
.ws378{word-spacing:1.328000px;}
.ws2f6{word-spacing:1.332000px;}
.ws23a{word-spacing:1.340000px;}
.ws384{word-spacing:1.344000px;}
.ws3c2{word-spacing:1.360000px;}
.ws171{word-spacing:1.364000px;}
.ws170{word-spacing:1.368000px;}
.ws5b4{word-spacing:1.372000px;}
.ws440{word-spacing:1.380000px;}
.ws43f{word-spacing:1.384000px;}
.ws9a{word-spacing:1.388000px;}
.ws50a{word-spacing:1.392000px;}
.ws2b6{word-spacing:1.396000px;}
.ws255{word-spacing:1.412000px;}
.ws45a{word-spacing:1.416000px;}
.ws58f{word-spacing:1.428000px;}
.ws6e{word-spacing:1.432000px;}
.ws4f2{word-spacing:1.448000px;}
.ws503{word-spacing:1.460000px;}
.ws4f3{word-spacing:1.468000px;}
.wsad{word-spacing:1.472000px;}
.ws4f7{word-spacing:1.476000px;}
.ws494{word-spacing:1.488000px;}
.ws12c{word-spacing:1.492000px;}
.ws246{word-spacing:1.497200px;}
.ws4d{word-spacing:1.500000px;}
.ws307{word-spacing:1.501000px;}
.ws4b{word-spacing:1.504000px;}
.ws4a{word-spacing:1.508000px;}
.ws7a{word-spacing:1.512000px;}
.ws2e8{word-spacing:1.524000px;}
.wsbe{word-spacing:1.528000px;}
.ws291{word-spacing:1.532000px;}
.ws559{word-spacing:1.536000px;}
.ws525{word-spacing:1.544000px;}
.ws5c{word-spacing:1.548000px;}
.ws3e9{word-spacing:1.564000px;}
.ws52f{word-spacing:1.568000px;}
.wsba{word-spacing:1.580000px;}
.wsdf{word-spacing:1.584000px;}
.wsd1{word-spacing:1.588000px;}
.ws4a7{word-spacing:1.592000px;}
.ws17e{word-spacing:1.596000px;}
.ws62{word-spacing:1.600000px;}
.ws359{word-spacing:1.608000px;}
.ws5b3{word-spacing:1.612000px;}
.ws5b2{word-spacing:1.616000px;}
.ws55f{word-spacing:1.624000px;}
.ws208{word-spacing:1.630200px;}
.ws515{word-spacing:1.632000px;}
.ws506{word-spacing:1.640000px;}
.ws46b{word-spacing:1.648000px;}
.ws5bf{word-spacing:1.652000px;}
.ws57c{word-spacing:1.672000px;}
.ws52b{word-spacing:1.676000px;}
.ws4ea{word-spacing:1.688000px;}
.ws181{word-spacing:1.692000px;}
.ws10d{word-spacing:1.700000px;}
.ws2c4{word-spacing:1.704000px;}
.ws80{word-spacing:1.712000px;}
.ws1c6{word-spacing:1.720000px;}
.ws61{word-spacing:1.724000px;}
.ws421{word-spacing:1.728000px;}
.ws4da{word-spacing:1.736000px;}
.ws247{word-spacing:1.736600px;}
.ws1ec{word-spacing:1.748000px;}
.ws37c{word-spacing:1.760000px;}
.ws227{word-spacing:1.764000px;}
.ws188{word-spacing:1.768000px;}
.ws505{word-spacing:1.772000px;}
.ws22e{word-spacing:1.776000px;}
.ws5a3{word-spacing:1.780000px;}
.ws45b{word-spacing:1.784000px;}
.ws33c{word-spacing:1.788000px;}
.ws4b1{word-spacing:1.796000px;}
.ws4b2{word-spacing:1.800000px;}
.ws477{word-spacing:1.804000px;}
.ws2e2{word-spacing:1.808800px;}
.ws284{word-spacing:1.812000px;}
.wsd9{word-spacing:1.816000px;}
.wsa5{word-spacing:1.820000px;}
.ws28a{word-spacing:1.824000px;}
.ws2d7{word-spacing:1.828000px;}
.ws490{word-spacing:1.832000px;}
.ws259{word-spacing:1.840000px;}
.ws2cc{word-spacing:1.844000px;}
.ws512{word-spacing:1.852000px;}
.ws493{word-spacing:1.864000px;}
.ws48a{word-spacing:1.868000px;}
.ws374{word-spacing:1.880000px;}
.ws529{word-spacing:1.884000px;}
.ws52a{word-spacing:1.888000px;}
.wsf7{word-spacing:1.908000px;}
.ws451{word-spacing:1.912000px;}
.ws3c9{word-spacing:1.916000px;}
.ws17f{word-spacing:1.920000px;}
.ws23b{word-spacing:1.924000px;}
.ws40e{word-spacing:1.928000px;}
.ws4b5{word-spacing:1.932000px;}
.ws49{word-spacing:1.936000px;}
.ws469{word-spacing:1.952000px;}
.ws56a{word-spacing:1.956000px;}
.ws375{word-spacing:1.968000px;}
.ws3b3{word-spacing:1.972000px;}
.ws3bb{word-spacing:1.980000px;}
.ws518{word-spacing:1.984000px;}
.ws3f5{word-spacing:1.987400px;}
.ws380{word-spacing:1.988000px;}
.ws3e2{word-spacing:2.012000px;}
.ws3e1{word-spacing:2.016000px;}
.ws344{word-spacing:2.020000px;}
.ws488{word-spacing:2.036000px;}
.ws36d{word-spacing:2.044000px;}
.ws495{word-spacing:2.048000px;}
.ws4ca{word-spacing:2.052000px;}
.ws4e7{word-spacing:2.056000px;}
.ws3db{word-spacing:2.064000px;}
.ws5bc{word-spacing:2.076000px;}
.ws465{word-spacing:2.080000px;}
.ws288{word-spacing:2.084000px;}
.ws239{word-spacing:2.092000px;}
.ws468{word-spacing:2.100000px;}
.ws277{word-spacing:2.116000px;}
.ws3a7{word-spacing:2.124000px;}
.ws467{word-spacing:2.128000px;}
.ws16a{word-spacing:2.136000px;}
.ws3cc{word-spacing:2.140000px;}
.ws19{word-spacing:2.145600px;}
.ws1af{word-spacing:2.148000px;}
.ws1a1{word-spacing:2.156000px;}
.ws597{word-spacing:2.164000px;}
.ws65{word-spacing:2.168000px;}
.ws594{word-spacing:2.176000px;}
.ws51c{word-spacing:2.180000px;}
.ws57e{word-spacing:2.188000px;}
.ws2e5{word-spacing:2.192000px;}
.ws46a{word-spacing:2.208000px;}
.ws558{word-spacing:2.216000px;}
.ws4dc{word-spacing:2.220000px;}
.ws2ae{word-spacing:2.228000px;}
.ws462{word-spacing:2.232000px;}
.ws28b{word-spacing:2.240000px;}
.ws30d{word-spacing:2.256000px;}
.ws4b6{word-spacing:2.260000px;}
.ws1b1{word-spacing:2.264000px;}
.wsbf{word-spacing:2.268000px;}
.ws3ba{word-spacing:2.284000px;}
.ws5c3{word-spacing:2.288000px;}
.ws3b9{word-spacing:2.292000px;}
.ws599{word-spacing:2.300000px;}
.ws1ce{word-spacing:2.302800px;}
.ws6{word-spacing:2.313600px;}
.ws1cd{word-spacing:2.314200px;}
.ws217{word-spacing:2.316000px;}
.ws5{word-spacing:2.316800px;}
.ws57a{word-spacing:2.320000px;}
.ws7b{word-spacing:2.324000px;}
.ws54b{word-spacing:2.328000px;}
.ws340{word-spacing:2.332000px;}
.wsa9{word-spacing:2.336000px;}
.ws445{word-spacing:2.352000px;}
.ws34f{word-spacing:2.364000px;}
.ws41d{word-spacing:2.368000px;}
.ws30f{word-spacing:2.372000px;}
.ws26c{word-spacing:2.376000px;}
.ws35d{word-spacing:2.380000px;}
.ws3a3{word-spacing:2.384000px;}
.ws3a9{word-spacing:2.392000px;}
.ws41c{word-spacing:2.396000px;}
.ws51f{word-spacing:2.408000px;}
.ws489{word-spacing:2.412000px;}
.ws508{word-spacing:2.416000px;}
.ws474{word-spacing:2.420000px;}
.ws39a{word-spacing:2.428000px;}
.ws213{word-spacing:2.436000px;}
.ws592{word-spacing:2.440000px;}
.ws49e{word-spacing:2.452000px;}
.ws4c7{word-spacing:2.456000px;}
.ws7{word-spacing:2.460800px;}
.ws55a{word-spacing:2.464000px;}
.ws20f{word-spacing:2.466200px;}
.ws289{word-spacing:2.468000px;}
.ws31d{word-spacing:2.470000px;}
.ws2ec{word-spacing:2.472000px;}
.wsee{word-spacing:2.480000px;}
.ws5b1{word-spacing:2.492000px;}
.ws23c{word-spacing:2.496000px;}
.ws435{word-spacing:2.500000px;}
.ws452{word-spacing:2.504000px;}
.ws15e{word-spacing:2.508000px;}
.ws4ec{word-spacing:2.524000px;}
.ws333{word-spacing:2.549800px;}
.ws561{word-spacing:2.552000px;}
.ws1f3{word-spacing:2.553600px;}
.ws572{word-spacing:2.556000px;}
.ws290{word-spacing:2.560000px;}
.ws38b{word-spacing:2.564000px;}
.ws504{word-spacing:2.572000px;}
.ws196{word-spacing:2.572600px;}
.ws57d{word-spacing:2.576000px;}
.ws39b{word-spacing:2.580000px;}
.ws3c3{word-spacing:2.584000px;}
.ws275{word-spacing:2.588000px;}
.ws35c{word-spacing:2.589000px;}
.ws47c{word-spacing:2.592000px;}
.ws524{word-spacing:2.616000px;}
.ws3f2{word-spacing:2.628000px;}
.ws4f0{word-spacing:2.632000px;}
.ws7d{word-spacing:2.648000px;}
.ws3ca{word-spacing:2.656000px;}
.ws3dc{word-spacing:2.672000px;}
.ws271{word-spacing:2.676000px;}
.wsfb{word-spacing:2.680000px;}
.ws190{word-spacing:2.684000px;}
.ws57f{word-spacing:2.696000px;}
.ws432{word-spacing:2.704000px;}
.ws540{word-spacing:2.708000px;}
.ws570{word-spacing:2.724000px;}
.wse4{word-spacing:2.732000px;}
.ws322{word-spacing:2.739800px;}
.ws4af{word-spacing:2.740000px;}
.wsd3{word-spacing:2.748000px;}
.ws40c{word-spacing:2.752000px;}
.ws5a8{word-spacing:2.756000px;}
.ws5a4{word-spacing:2.764000px;}
.ws54c{word-spacing:2.768000px;}
.ws456{word-spacing:2.780000px;}
.ws455{word-spacing:2.784000px;}
.ws1c0{word-spacing:2.792000px;}
.ws32f{word-spacing:2.793000px;}
.ws166{word-spacing:2.808000px;}
.ws265{word-spacing:2.820000px;}
.ws34b{word-spacing:2.824000px;}
.ws537{word-spacing:2.828000px;}
.ws379{word-spacing:2.832000px;}
.ws46d{word-spacing:2.836000px;}
.ws3ff{word-spacing:2.840000px;}
.ws2f0{word-spacing:2.847000px;}
.ws1ac{word-spacing:2.848000px;}
.ws5a2{word-spacing:2.852000px;}
.ws457{word-spacing:2.860000px;}
.ws5ad{word-spacing:2.864000px;}
.ws44d{word-spacing:2.868000px;}
.ws51{word-spacing:2.876000px;}
.ws5c7{word-spacing:2.884000px;}
.ws55d{word-spacing:2.888000px;}
.ws4dd{word-spacing:2.892000px;}
.ws55c{word-spacing:2.896000px;}
.ws3a0{word-spacing:2.912000px;}
.ws292{word-spacing:2.916000px;}
.ws41f{word-spacing:2.924000px;}
.ws59b{word-spacing:2.936000px;}
.ws478{word-spacing:2.940000px;}
.ws44c{word-spacing:2.952000px;}
.ws3de{word-spacing:2.956000px;}
.ws4b7{word-spacing:2.960000px;}
.ws5c0{word-spacing:2.964000px;}
.ws399{word-spacing:2.972000px;}
.ws2be{word-spacing:2.975400px;}
.ws4a2{word-spacing:2.980000px;}
.ws263{word-spacing:2.984000px;}
.ws37d{word-spacing:2.988000px;}
.ws392{word-spacing:3.004000px;}
.ws47b{word-spacing:3.008000px;}
.ws5a0{word-spacing:3.012000px;}
.ws483{word-spacing:3.016000px;}
.ws4b8{word-spacing:3.020000px;}
.ws388{word-spacing:3.024000px;}
.ws585{word-spacing:3.028000px;}
.ws1f6{word-spacing:3.028600px;}
.ws497{word-spacing:3.040000px;}
.ws10f{word-spacing:3.044000px;}
.ws22{word-spacing:3.048000px;}
.ws27b{word-spacing:3.052000px;}
.ws581{word-spacing:3.056000px;}
.ws560{word-spacing:3.064000px;}
.ws2e7{word-spacing:3.080000px;}
.ws124{word-spacing:3.084000px;}
.ws234{word-spacing:3.096000px;}
.ws228{word-spacing:3.099000px;}
.ws463{word-spacing:3.100000px;}
.ws5bb{word-spacing:3.104000px;}
.ws5b0{word-spacing:3.108000px;}
.ws4bc{word-spacing:3.111000px;}
.ws311{word-spacing:3.116000px;}
.ws2af{word-spacing:3.119800px;}
.ws454{word-spacing:3.132000px;}
.ws484{word-spacing:3.136000px;}
.ws16f{word-spacing:3.138000px;}
.ws1c9{word-spacing:3.140000px;}
.ws183{word-spacing:3.148000px;}
.ws56f{word-spacing:3.152000px;}
.ws507{word-spacing:3.156000px;}
.ws2c9{word-spacing:3.159000px;}
.ws584{word-spacing:3.160000px;}
.ws50e{word-spacing:3.164000px;}
.ws4c6{word-spacing:3.168000px;}
.ws3ed{word-spacing:3.172000px;}
.ws187{word-spacing:3.176000px;}
.ws485{word-spacing:3.188000px;}
.ws3d5{word-spacing:3.192000px;}
.ws519{word-spacing:3.204000px;}
.ws59d{word-spacing:3.208000px;}
.ws589{word-spacing:3.212000px;}
.ws269{word-spacing:3.220000px;}
.ws5ac{word-spacing:3.228000px;}
.ws129{word-spacing:3.232000px;}
.ws576{word-spacing:3.236000px;}
.ws577{word-spacing:3.240000px;}
.ws287{word-spacing:3.248000px;}
.ws88{word-spacing:3.252000px;}
.ws3d3{word-spacing:3.252800px;}
.ws3bc{word-spacing:3.256000px;}
.ws1de{word-spacing:3.268000px;}
.ws8d{word-spacing:3.276000px;}
.ws2ef{word-spacing:3.279000px;}
.ws46c{word-spacing:3.288000px;}
.ws4ae{word-spacing:3.292000px;}
.ws4f6{word-spacing:3.296000px;}
.ws39d{word-spacing:3.300000px;}
.ws38d{word-spacing:3.304000px;}
.ws54f{word-spacing:3.308000px;}
.ws2db{word-spacing:3.313600px;}
.ws35{word-spacing:3.316000px;}
.ws141{word-spacing:3.318000px;}
.ws337{word-spacing:3.328800px;}
.ws114{word-spacing:3.330000px;}
.ws3fa{word-spacing:3.332000px;}
.ws9f{word-spacing:3.344000px;}
.ws34e{word-spacing:3.356000px;}
.ws35a{word-spacing:3.357000px;}
.ws2e1{word-spacing:3.363000px;}
.ws517{word-spacing:3.364000px;}
.ws261{word-spacing:3.368000px;}
.ws4f5{word-spacing:3.372000px;}
.ws545{word-spacing:3.376000px;}
.ws34d{word-spacing:3.380000px;}
.ws2d8{word-spacing:3.384000px;}
.wscf{word-spacing:3.392000px;}
.ws23e{word-spacing:3.396000px;}
.ws2f3{word-spacing:3.400000px;}
.ws382{word-spacing:3.404000px;}
.ws461{word-spacing:3.408000px;}
.ws51a{word-spacing:3.416000px;}
.ws45f{word-spacing:3.428000px;}
.ws32c{word-spacing:3.448000px;}
.ws5b8{word-spacing:3.452000px;}
.ws482{word-spacing:3.460000px;}
.ws4f9{word-spacing:3.465600px;}
.ws49b{word-spacing:3.468000px;}
.ws4f8{word-spacing:3.469400px;}
.ws33f{word-spacing:3.472000px;}
.ws3e6{word-spacing:3.480000px;}
.ws3e5{word-spacing:3.488000px;}
.ws588{word-spacing:3.492000px;}
.ws2fc{word-spacing:3.500000px;}
.ws42e{word-spacing:3.504000px;}
.ws56c{word-spacing:3.508000px;}
.ws51d{word-spacing:3.516000px;}
.ws2a4{word-spacing:3.520000px;}
.ws3d6{word-spacing:3.522600px;}
.ws479{word-spacing:3.524000px;}
.wsb{word-spacing:3.526400px;}
.ws4a5{word-spacing:3.532000px;}
.ws3fc{word-spacing:3.536000px;}
.ws556{word-spacing:3.544000px;}
.ws492{word-spacing:3.548000px;}
.ws437{word-spacing:3.552000px;}
.ws3d2{word-spacing:3.553000px;}
.ws125{word-spacing:3.556000px;}
.ws19e{word-spacing:3.560000px;}
.ws428{word-spacing:3.564000px;}
.ws3b7{word-spacing:3.568000px;}
.ws1fe{word-spacing:3.572000px;}
.ws423{word-spacing:3.576000px;}
.ws194{word-spacing:3.579600px;}
.ws575{word-spacing:3.580000px;}
.ws3fe{word-spacing:3.584000px;}
.ws351{word-spacing:3.588000px;}
.ws1e7{word-spacing:3.591000px;}
.ws20{word-spacing:3.592000px;}
.ws9e{word-spacing:3.596000px;}
.ws14f{word-spacing:3.600000px;}
.ws50d{word-spacing:3.604000px;}
.ws5a5{word-spacing:3.616000px;}
.ws49c{word-spacing:3.624000px;}
.ws49f{word-spacing:3.628000px;}
.wsc3{word-spacing:3.636000px;}
.ws56d{word-spacing:3.640000px;}
.ws193{word-spacing:3.640400px;}
.ws13a{word-spacing:3.644000px;}
.ws32a{word-spacing:3.644200px;}
.ws32b{word-spacing:3.648000px;}
.ws248{word-spacing:3.651800px;}
.ws1fd{word-spacing:3.652000px;}
.ws52d{word-spacing:3.656000px;}
.ws21f{word-spacing:3.660000px;}
.ws2fa{word-spacing:3.664000px;}
.ws3dd{word-spacing:3.668000px;}
.wsd5{word-spacing:3.672000px;}
.wsa8{word-spacing:3.676000px;}
.ws387{word-spacing:3.680000px;}
.ws4fb{word-spacing:3.682200px;}
.ws573{word-spacing:3.684000px;}
.ws574{word-spacing:3.688000px;}
.ws29e{word-spacing:3.697400px;}
.ws164{word-spacing:3.700000px;}
.ws11b{word-spacing:3.704000px;}
.ws20d{word-spacing:3.705000px;}
.ws42c{word-spacing:3.708000px;}
.ws309{word-spacing:3.708800px;}
.ws53c{word-spacing:3.712000px;}
.ws596{word-spacing:3.716000px;}
.ws430{word-spacing:3.724000px;}
.ws464{word-spacing:3.728000px;}
.ws251{word-spacing:3.731600px;}
.ws69{word-spacing:3.736000px;}
.ws148{word-spacing:3.740000px;}
.ws365{word-spacing:3.743000px;}
.ws37a{word-spacing:3.744000px;}
.ws24c{word-spacing:3.746800px;}
.ws541{word-spacing:3.748000px;}
.ws46{word-spacing:3.752000px;}
.ws39f{word-spacing:3.756000px;}
.ws56e{word-spacing:3.760000px;}
.ws1d8{word-spacing:3.762000px;}
.ws4a9{word-spacing:3.764000px;}
.ws434{word-spacing:3.768000px;}
.ws2d3{word-spacing:3.772000px;}
.ws103{word-spacing:3.776000px;}
.ws341{word-spacing:3.780000px;}
.ws373{word-spacing:3.784000px;}
.ws165{word-spacing:3.788000px;}
.ws3f6{word-spacing:3.788600px;}
.ws447{word-spacing:3.792000px;}
.ws1c5{word-spacing:3.796000px;}
.ws499{word-spacing:3.800000px;}
.ws59c{word-spacing:3.804000px;}
.ws397{word-spacing:3.808000px;}
.ws2cb{word-spacing:3.812000px;}
.ws39c{word-spacing:3.816000px;}
.ws2ca{word-spacing:3.820000px;}
.ws5b6{word-spacing:3.824000px;}
.ws33a{word-spacing:3.826600px;}
.ws3a6{word-spacing:3.828000px;}
.ws1cb{word-spacing:3.832000px;}
.ws126{word-spacing:3.836000px;}
.ws2e3{word-spacing:3.838000px;}
.ws547{word-spacing:3.840000px;}
.ws6a{word-spacing:3.844000px;}
.ws4fd{word-spacing:3.845600px;}
.ws22c{word-spacing:3.848000px;}
.ws443{word-spacing:3.852000px;}
.ws555{word-spacing:3.856000px;}
.ws75{word-spacing:3.860000px;}
.ws2a8{word-spacing:3.864000px;}
.ws79{word-spacing:3.868000px;}
.ws527{word-spacing:3.872000px;}
.wsfc{word-spacing:3.876000px;}
.ws410{word-spacing:3.880000px;}
.ws221{word-spacing:3.884000px;}
.ws25e{word-spacing:3.892000px;}
.ws15a{word-spacing:3.895000px;}
.ws4a3{word-spacing:3.896000px;}
.ws4ff{word-spacing:3.898800px;}
.ws119{word-spacing:3.900000px;}
.ws2c7{word-spacing:3.902600px;}
.ws268{word-spacing:3.904000px;}
.ws280{word-spacing:3.906400px;}
.wsb4{word-spacing:3.908000px;}
.wsd4{word-spacing:3.912000px;}
.ws58e{word-spacing:3.916000px;}
.ws162{word-spacing:3.920000px;}
.ws327{word-spacing:3.921600px;}
.ws3df{word-spacing:3.924000px;}
.ws186{word-spacing:3.928000px;}
.ws157{word-spacing:3.929200px;}
.ws55b{word-spacing:3.932000px;}
.ws2c0{word-spacing:3.936000px;}
.ws167{word-spacing:3.940000px;}
.ws42d{word-spacing:3.944000px;}
.ws202{word-spacing:3.948000px;}
.ws364{word-spacing:3.948200px;}
.ws35f{word-spacing:3.952000px;}
.ws47d{word-spacing:3.956000px;}
.ws4a0{word-spacing:3.960000px;}
.ws3c4{word-spacing:3.964000px;}
.ws70{word-spacing:3.968000px;}
.ws1fc{word-spacing:3.972000px;}
.wsce{word-spacing:3.976000px;}
.ws226{word-spacing:3.980000px;}
.ws429{word-spacing:3.984000px;}
.ws105{word-spacing:3.988000px;}
.ws46f{word-spacing:3.992000px;}
.ws54d{word-spacing:3.996000px;}
.ws241{word-spacing:3.997600px;}
.ws5c5{word-spacing:4.000000px;}
.ws29d{word-spacing:4.001400px;}
.ws3b1{word-spacing:4.004000px;}
.ws2b8{word-spacing:4.008000px;}
.ws276{word-spacing:4.012000px;}
.ws4e1{word-spacing:4.016000px;}
.ws198{word-spacing:4.016600px;}
.ws6f{word-spacing:4.020000px;}
.ws396{word-spacing:4.024000px;}
.ws321{word-spacing:4.028000px;}
.ws150{word-spacing:4.031800px;}
.ws3b6{word-spacing:4.032000px;}
.ws320{word-spacing:4.035600px;}
.ws73{word-spacing:4.036000px;}
.ws2eb{word-spacing:4.039400px;}
.ws272{word-spacing:4.040000px;}
.ws270{word-spacing:4.044000px;}
.ws2f8{word-spacing:4.048000px;}
.ws501{word-spacing:4.050800px;}
.ws177{word-spacing:4.052000px;}
.ws4a4{word-spacing:4.056000px;}
.ws13e{word-spacing:4.060000px;}
.ws44{word-spacing:4.064000px;}
.wsf9{word-spacing:4.068000px;}
.ws326{word-spacing:4.069800px;}
.ws100{word-spacing:4.072000px;}
.ws204{word-spacing:4.076000px;}
.ws244{word-spacing:4.080000px;}
.ws299{word-spacing:4.081200px;}
.ws243{word-spacing:4.084000px;}
.ws224{word-spacing:4.088000px;}
.ws23f{word-spacing:4.088800px;}
.ws2f9{word-spacing:4.092000px;}
.ws235{word-spacing:4.096000px;}
.ws19b{word-spacing:4.100000px;}
.ws1ff{word-spacing:4.104000px;}
.ws520{word-spacing:4.108000px;}
.ws29b{word-spacing:4.111600px;}
.ws460{word-spacing:4.112000px;}
.ws2b9{word-spacing:4.116000px;}
.ws7c{word-spacing:4.120000px;}
.ws1e4{word-spacing:4.123000px;}
.ws389{word-spacing:4.124000px;}
.ws56{word-spacing:4.128000px;}
.wse5{word-spacing:4.132000px;}
.ws47f{word-spacing:4.136000px;}
.ws1e0{word-spacing:4.140000px;}
.wsd6{word-spacing:4.144000px;}
.ws5b9{word-spacing:4.148000px;}
.ws20e{word-spacing:4.149600px;}
.ws43b{word-spacing:4.152000px;}
.ws1e9{word-spacing:4.153400px;}
.ws3b5{word-spacing:4.156000px;}
.ws1d9{word-spacing:4.157200px;}
.ws1c2{word-spacing:4.160000px;}
.ws563{word-spacing:4.164000px;}
.ws395{word-spacing:4.164800px;}
.ws3b2{word-spacing:4.168000px;}
.ws314{word-spacing:4.168600px;}
.ws182{word-spacing:4.172000px;}
.ws400{word-spacing:4.176000px;}
.ws1d0{word-spacing:4.176200px;}
.wsea{word-spacing:4.180000px;}
.ws39{word-spacing:4.184000px;}
.ws1cf{word-spacing:4.187600px;}
.ws2e9{word-spacing:4.188000px;}
.ws3b{word-spacing:4.196000px;}
.ws549{word-spacing:4.200000px;}
.ws240{word-spacing:4.202800px;}
.wsaa{word-spacing:4.204000px;}
.ws1e6{word-spacing:4.206600px;}
.ws1a2{word-spacing:4.208000px;}
.ws481{word-spacing:4.212000px;}
.ws363{word-spacing:4.214200px;}
.ws1c7{word-spacing:4.216000px;}
.ws3f3{word-spacing:4.220000px;}
.ws1da{word-spacing:4.221800px;}
.ws38{word-spacing:4.224000px;}
.wsb9{word-spacing:4.228000px;}
.ws2d4{word-spacing:4.232000px;}
.ws3af{word-spacing:4.233200px;}
.ws424{word-spacing:4.236000px;}
.ws1b6{word-spacing:4.240000px;}
.ws31f{word-spacing:4.240800px;}
.ws15b{word-spacing:4.244000px;}
.ws24e{word-spacing:4.244600px;}
.ws2aa{word-spacing:4.248000px;}
.ws416{word-spacing:4.252000px;}
.ws301{word-spacing:4.252200px;}
.ws42a{word-spacing:4.256000px;}
.ws300{word-spacing:4.259800px;}
.wsa7{word-spacing:4.260000px;}
.ws2c8{word-spacing:4.263600px;}
.ws4e{word-spacing:4.264000px;}
.ws3ae{word-spacing:4.267400px;}
.ws2f2{word-spacing:4.268000px;}
.ws222{word-spacing:4.272000px;}
.ws11d{word-spacing:4.276000px;}
.ws2fd{word-spacing:4.280000px;}
.wsc8{word-spacing:4.284000px;}
.ws2f7{word-spacing:4.288000px;}
.ws3c7{word-spacing:4.292000px;}
.ws98{word-spacing:4.296000px;}
.ws136{word-spacing:4.300000px;}
.ws1c4{word-spacing:4.304000px;}
.ws176{word-spacing:4.308000px;}
.ws403{word-spacing:4.312000px;}
.ws436{word-spacing:4.316000px;}
.ws411{word-spacing:4.320000px;}
.ws225{word-spacing:4.324000px;}
.ws174{word-spacing:4.328000px;}
.ws357{word-spacing:4.332000px;}
.ws458{word-spacing:4.336000px;}
.ws355{word-spacing:4.340000px;}
.ws282{word-spacing:4.344000px;}
.ws401{word-spacing:4.348000px;}
.ws353{word-spacing:4.352000px;}
.ws1ee{word-spacing:4.356000px;}
.ws137{word-spacing:4.360000px;}
.ws293{word-spacing:4.364000px;}
.ws444{word-spacing:4.368000px;}
.ws149{word-spacing:4.372000px;}
.ws132{word-spacing:4.376000px;}
.ws11e{word-spacing:4.380000px;}
.wsc2{word-spacing:4.384000px;}
.ws48d{word-spacing:4.388000px;}
.ws1fb{word-spacing:4.392000px;}
.ws1b5{word-spacing:4.396000px;}
.ws2ee{word-spacing:4.400000px;}
.ws107{word-spacing:4.404000px;}
.ws26f{word-spacing:4.408000px;}
.ws260{word-spacing:4.412000px;}
.ws121{word-spacing:4.416000px;}
.ws12a{word-spacing:4.420000px;}
.ws22d{word-spacing:4.424000px;}
.wsef{word-spacing:4.428000px;}
.ws3b8{word-spacing:4.432000px;}
.ws46e{word-spacing:4.436000px;}
.ws3d8{word-spacing:4.440000px;}
.ws6d{word-spacing:4.444000px;}
.wseb{word-spacing:4.448000px;}
.ws37b{word-spacing:4.452000px;}
.ws99{word-spacing:4.456000px;}
.ws220{word-spacing:4.460000px;}
.ws232{word-spacing:4.464000px;}
.ws3c{word-spacing:4.468000px;}
.ws433{word-spacing:4.472000px;}
.ws3d{word-spacing:4.476000px;}
.ws383{word-spacing:4.480000px;}
.ws439{word-spacing:4.484000px;}
.ws1fa{word-spacing:4.488000px;}
.ws2e6{word-spacing:4.492000px;}
.ws53b{word-spacing:4.496000px;}
.ws43a{word-spacing:4.508000px;}
.ws557{word-spacing:4.528000px;}
.ws3f4{word-spacing:4.826000px;}
.ws52{word-spacing:4.956000px;}
.ws4c{word-spacing:6.460000px;}
.ws4ad{word-spacing:6.476000px;}
.ws360{word-spacing:7.440400px;}
.ws57{word-spacing:9.080000px;}
.ws553{word-spacing:11.558196px;}
.ws4cd{word-spacing:13.122630px;}
.ws5c8{word-spacing:16.784000px;}
.ws21c{word-spacing:141.500600px;}
.ws21b{word-spacing:161.564600px;}
.ws21d{word-spacing:205.800400px;}
.ws21a{word-spacing:221.209400px;}
.ws407{word-spacing:468.696800px;}
.ws1b{word-spacing:739.101600px;}
._7{margin-left:-648.000000px;}
._b6{margin-left:-334.224000px;}
._c9{margin-left:-312.588577px;}
._c7{margin-left:-204.941126px;}
._b7{margin-left:-196.600000px;}
._b5{margin-left:-175.560000px;}
._c5{margin-left:-95.373945px;}
._c8{margin-left:-68.955172px;}
._d1{margin-left:-31.960000px;}
._d2{margin-left:-26.720000px;}
._cf{margin-left:-25.240000px;}
._ce{margin-left:-23.920000px;}
._cd{margin-left:-22.840000px;}
._d3{margin-left:-21.760000px;}
._d0{margin-left:-20.520000px;}
._b4{margin-left:-18.811080px;}
._c3{margin-left:-16.334206px;}
._65{margin-left:-11.503794px;}
._7e{margin-left:-8.560000px;}
._ae{margin-left:-6.468000px;}
._c{margin-left:-4.956000px;}
._4b{margin-left:-3.891600px;}
._b{margin-left:-2.614400px;}
._a{margin-left:-1.571200px;}
._8{width:1.086400px;}
._9{width:2.856000px;}
._66{width:3.949006px;}
._67{width:5.810400px;}
._6{width:7.288708px;}
._5{width:8.526414px;}
._95{width:9.868600px;}
._64{width:10.932000px;}
._7c{width:12.025806px;}
._3{width:13.202194px;}
._68{width:14.608181px;}
._2{width:16.576088px;}
._1{width:17.602925px;}
._0{width:19.069835px;}
._4{width:20.316709px;}
._7a{width:25.356000px;}
._b1{width:26.952000px;}
._44{width:28.846800px;}
._39{width:30.362400px;}
._a6{width:32.140800px;}
._46{width:33.278400px;}
._5a{width:34.790400px;}
._a7{width:36.057600px;}
._54{width:38.350800px;}
._a8{width:40.003200px;}
._50{width:41.480000px;}
._40{width:42.962400px;}
._1d{width:44.013600px;}
._33{width:45.090000px;}
._52{width:46.776000px;}
._15{width:48.218400px;}
._49{width:49.996800px;}
._ac{width:51.594400px;}
._13{width:52.754400px;}
._97{width:54.672000px;}
._3b{width:56.044000px;}
._18{width:58.408000px;}
._1a{width:59.692000px;}
._2d{width:61.680000px;}
._11{width:63.408000px;}
._7d{width:65.184000px;}
._79{width:67.262400px;}
._7b{width:68.798400px;}
._17{width:71.013600px;}
._4c{width:72.863200px;}
._83{width:75.621153px;}
._89{width:77.686865px;}
._88{width:79.396318px;}
._93{width:81.303702px;}
._8e{width:84.354340px;}
._82{width:85.445215px;}
._78{width:87.768800px;}
._87{width:88.769500px;}
._81{width:90.858728px;}
._90{width:92.519455px;}
._86{width:94.680430px;}
._c0{width:96.567745px;}
._85{width:99.157949px;}
._84{width:100.174204px;}
._aa{width:103.220400px;}
._8d{width:104.600051px;}
._a1{width:105.634932px;}
._9f{width:110.322396px;}
._22{width:111.738400px;}
._9e{width:113.495319px;}
._80{width:115.351959px;}
._92{width:118.281332px;}
._91{width:120.688630px;}
._7f{width:123.311009px;}
._31{width:126.137600px;}
._71{width:127.325600px;}
._8f{width:128.696654px;}
._62{width:133.627200px;}
._8b{width:135.623362px;}
._8c{width:136.649362px;}
._c6{width:139.040735px;}
._8a{width:140.411362px;}
._bf{width:141.739574px;}
._9a{width:147.641260px;}
._bd{width:151.635200px;}
._af{width:158.189200px;}
._6e{width:162.060000px;}
._9c{width:165.187285px;}
._6d{width:171.704000px;}
._57{width:175.357600px;}
._a5{width:176.713932px;}
._bc{width:178.627200px;}
._a9{width:181.223600px;}
._96{width:182.880000px;}
._bb{width:184.166400px;}
._ba{width:186.924800px;}
._9d{width:190.219540px;}
._98{width:194.566188px;}
._72{width:195.908000px;}
._77{width:197.020000px;}
._a0{width:200.709140px;}
._76{width:202.380000px;}
._32{width:212.161200px;}
._75{width:219.572000px;}
._74{width:221.024000px;}
._69{width:223.292000px;}
._73{width:228.928000px;}
._70{width:232.001600px;}
._6b{width:238.568000px;}
._6c{width:242.528000px;}
._6a{width:246.688000px;}
._58{width:249.030000px;}
._b8{width:251.692000px;}
._6f{width:254.936000px;}
._56{width:256.978800px;}
._be{width:261.529510px;}
._2e{width:270.514400px;}
._55{width:274.716000px;}
._a2{width:276.631132px;}
._b3{width:277.844000px;}
._ca{width:284.051872px;}
._a3{width:294.563332px;}
._e{width:300.956400px;}
._38{width:311.776000px;}
._4f{width:316.184400px;}
._2c{width:326.185200px;}
._59{width:330.366400px;}
._36{width:359.474400px;}
._ad{width:364.479200px;}
._d{width:366.015600px;}
._94{width:382.674511px;}
._a4{width:390.718532px;}
._5e{width:392.842800px;}
._cc{width:396.562000px;}
._45{width:403.923600px;}
._35{width:404.960400px;}
._4d{width:412.842400px;}
._2b{width:415.340800px;}
._9b{width:427.701277px;}
._99{width:429.067532px;}
._60{width:431.466000px;}
._b9{width:442.530000px;}
._25{width:449.634400px;}
._5d{width:458.092800px;}
._24{width:466.902000px;}
._53{width:469.044000px;}
._26{width:486.616000px;}
._61{width:488.790800px;}
._23{width:494.463600px;}
._c4{width:497.811200px;}
._48{width:499.226400px;}
._b0{width:522.094800px;}
._34{width:525.205600px;}
._37{width:527.576400px;}
._4e{width:534.959600px;}
._b2{width:537.306400px;}
._30{width:539.420400px;}
._28{width:559.404000px;}
._ab{width:561.984400px;}
._5f{width:570.218400px;}
._3e{width:574.064800px;}
._42{width:579.410800px;}
._cb{width:584.756800px;}
._16{width:588.495600px;}
._3f{width:590.412400px;}
._2a{width:607.443200px;}
._47{width:610.766000px;}
._43{width:630.295200px;}
._21{width:677.154400px;}
._51{width:684.528000px;}
._3a{width:696.067200px;}
._c2{width:704.148800px;}
._1c{width:706.564800px;}
._29{width:724.777200px;}
._41{width:729.498400px;}
._27{width:734.695200px;}
._3d{width:736.106400px;}
._1f{width:770.512000px;}
._1b{width:781.146400px;}
._20{width:787.986000px;}
._19{width:799.516000px;}
._5b{width:800.539200px;}
._5c{width:807.634800px;}
._1e{width:827.204400px;}
._2f{width:854.557200px;}
._14{width:872.395200px;}
._4a{width:881.038800px;}
._3c{width:886.795200px;}
._c1{width:900.357200px;}
._12{width:929.152000px;}
._10{width:958.012000px;}
._63{width:1017.446400px;}
._f{width:1076.165600px;}
.fca{color:rgb(187,189,191);}
.fc9{color:rgb(117,196,192);}
.fc8{color:rgb(128,130,132);}
.fc7{color:rgb(197,227,225);}
.fc2{color:rgb(0,0,0);}
.fc3{color:rgb(35,31,32);}
.fc4{color:rgb(0,158,147);}
.fc6{color:rgb(61,53,55);}
.fc5{color:rgb(118,120,122);}
.fc1{color:transparent;}
.fc0{color:rgb(255,255,255);}
.fs1d{font-size:9.600000px;}
.fs24{font-size:12.097600px;}
.fs1c{font-size:12.800000px;}
.fs22{font-size:17.786400px;}
.fs1e{font-size:19.200000px;}
.fs20{font-size:19.209600px;}
.fs21{font-size:20.750800px;}
.fsd{font-size:21.000000px;}
.fs23{font-size:21.071200px;}
.fs2{font-size:24.000000px;}
.fs15{font-size:25.200000px;}
.fse{font-size:26.600000px;}
.fs1{font-size:27.504560px;}
.fs5{font-size:28.000000px;}
.fs1f{font-size:28.800000px;}
.fsa{font-size:30.000000px;}
.fsc{font-size:30.800000px;}
.fs7{font-size:32.000000px;}
.fs1a{font-size:32.617600px;}
.fs16{font-size:33.148000px;}
.fs1b{font-size:34.805600px;}
.fs9{font-size:36.000000px;}
.fs18{font-size:37.390800px;}
.fsb{font-size:38.000000px;}
.fs19{font-size:39.777600px;}
.fs8{font-size:40.000000px;}
.fs13{font-size:40.893652px;}
.fs12{font-size:42.000000px;}
.fs17{font-size:43.092400px;}
.fs11{font-size:44.000000px;}
.fs3{font-size:48.000000px;}
.fs10{font-size:52.000000px;}
.fs6{font-size:56.000000px;}
.fs0{font-size:73.345520px;}
.fsf{font-size:96.000000px;}
.fs4{font-size:112.000000px;}
.fs14{font-size:168.000000px;}
.y6{bottom:0.000000px;}
.ye37{bottom:0.000339px;}
.ye3c{bottom:0.230700px;}
.y9a2{bottom:1.450000px;}
.yb0c{bottom:1.637000px;}
.yac8{bottom:1.750000px;}
.yc8d{bottom:2.338900px;}
.ybe6{bottom:2.510000px;}
.yabd{bottom:3.210000px;}
.y99d{bottom:3.224400px;}
.y9a1{bottom:3.450000px;}
.yb5d{bottom:3.554000px;}
.yc8b{bottom:3.618900px;}
.yb0b{bottom:3.637000px;}
.ya52{bottom:3.716000px;}
.yb27{bottom:3.721000px;}
.yac7{bottom:3.750000px;}
.y95f{bottom:3.980000px;}
.yc74{bottom:4.297000px;}
.yaec{bottom:5.031000px;}
.ya7c{bottom:5.329000px;}
.yf9b{bottom:5.656000px;}
.ya51{bottom:5.716000px;}
.y95e{bottom:5.980000px;}
.y10a7{bottom:6.122200px;}
.yc75{bottom:6.297000px;}
.yc73{bottom:6.297100px;}
.yaeb{bottom:7.031000px;}
.yc7a{bottom:7.047000px;}
.ya7b{bottom:7.329000px;}
.yb44{bottom:7.556000px;}
.yc79{bottom:9.047100px;}
.y9da{bottom:9.401000px;}
.ybd1{bottom:11.617000px;}
.yc31{bottom:11.937100px;}
.ybad{bottom:12.267000px;}
.y9c2{bottom:12.501000px;}
.yb2c{bottom:12.550000px;}
.y9cb{bottom:13.159000px;}
.yb0e{bottom:13.654000px;}
.y10ab{bottom:13.681000px;}
.yaca{bottom:13.767000px;}
.y10a4{bottom:14.279000px;}
.ya1f{bottom:14.329000px;}
.yb2b{bottom:14.550000px;}
.yb28{bottom:14.748000px;}
.yb97{bottom:14.877000px;}
.yb47{bottom:14.970000px;}
.y10a5{bottom:15.079000px;}
.y9ca{bottom:15.159000px;}
.y9c3{bottom:15.501000px;}
.y9c1{bottom:15.501500px;}
.ya54{bottom:15.733000px;}
.yb46{bottom:16.970000px;}
.yaee{bottom:17.047000px;}
.ya7e{bottom:17.346000px;}
.y9e2{bottom:19.457000px;}
.ybb4{bottom:19.572000px;}
.y10aa{bottom:20.745400px;}
.yb5c{bottom:21.054000px;}
.ybac{bottom:21.267000px;}
.ybb3{bottom:21.572000px;}
.yc32{bottom:22.271100px;}
.y9e1{bottom:22.456800px;}
.yb0a{bottom:22.510000px;}
.y216{bottom:22.825650px;}
.yc70{bottom:22.997100px;}
.yb99{bottom:23.651000px;}
.yb09{bottom:24.510000px;}
.y927{bottom:25.157650px;}
.yb00{bottom:25.271000px;}
.yabb{bottom:25.383000px;}
.yb96{bottom:25.575000px;}
.yb98{bottom:25.651000px;}
.yc68{bottom:26.387100px;}
.y9bf{bottom:26.393500px;}
.ya48{bottom:27.349000px;}
.y1ce{bottom:27.637150px;}
.y10a9{bottom:27.809800px;}
.ya{bottom:28.348500px;}
.yae2{bottom:28.665100px;}
.ya70{bottom:28.962000px;}
.ybd5{bottom:29.463000px;}
.ybd7{bottom:29.713000px;}
.yc77{bottom:30.397000px;}
.y596{bottom:30.936200px;}
.ybe9{bottom:31.640100px;}
.y152{bottom:31.862500px;}
.ybd3{bottom:32.394000px;}
.yc76{bottom:32.400000px;}
.yc78{bottom:32.400100px;}
.ybd4{bottom:32.463000px;}
.ybd6{bottom:32.713000px;}
.y215{bottom:32.825400px;}
.y295{bottom:33.358300px;}
.ybe8{bottom:33.640000px;}
.y9a0{bottom:33.832800px;}
.y24b{bottom:34.697150px;}
.y885{bottom:34.697450px;}
.ya16{bottom:34.859000px;}
.y10a6{bottom:34.874200px;}
.y999{bottom:35.128700px;}
.y926{bottom:35.157400px;}
.y151{bottom:35.362600px;}
.y99f{bottom:35.832800px;}
.yef3{bottom:35.903100px;}
.y99c{bottom:36.008400px;}
.ya57{bottom:36.836000px;}
.y294{bottom:36.858300px;}
.y95d{bottom:36.988000px;}
.yd60{bottom:37.079900px;}
.y6ab{bottom:37.312550px;}
.y1cd{bottom:37.636900px;}
.y4eb{bottom:37.640450px;}
.y7c{bottom:37.797800px;}
.yabe{bottom:37.933000px;}
.y925{bottom:38.657500px;}
.y95c{bottom:38.988000px;}
.y8b6{bottom:39.027700px;}
.yc94{bottom:39.034900px;}
.y9c5{bottom:39.058000px;}
.ya78{bottom:39.202000px;}
.y438{bottom:39.648000px;}
.y4a5{bottom:39.856900px;}
.yacd{bottom:39.870000px;}
.y95a{bottom:39.915400px;}
.yc8c{bottom:40.382900px;}
.y595{bottom:40.935950px;}
.y1cc{bottom:41.136900px;}
.ya77{bottom:41.202000px;}
.yaf1{bottom:41.484000px;}
.yab9{bottom:41.881000px;}
.yc9d{bottom:42.138000px;}
.y8b5{bottom:42.527700px;}
.y945{bottom:42.634600px;}
.ye62{bottom:42.731700px;}
.y214{bottom:42.825150px;}
.y858{bottom:43.155100px;}
.yc3e{bottom:44.332000px;}
.y7a9{bottom:44.415300px;}
.y164{bottom:44.696900px;}
.y150{bottom:44.697100px;}
.y884{bottom:44.697200px;}
.y3bd{bottom:44.724250px;}
.ybe5{bottom:45.148000px;}
.yc72{bottom:45.522100px;}
.yec6{bottom:45.540900px;}
.y99e{bottom:45.563400px;}
.y53d{bottom:45.811000px;}
.ya46{bottom:45.916000px;}
.y62d{bottom:46.010200px;}
.yb2e{bottom:46.383000px;}
.y686{bottom:46.598500px;}
.yb0f{bottom:46.707000px;}
.y105d{bottom:46.753700px;}
.yacb{bottom:46.820000px;}
.y864{bottom:46.907900px;}
.yb0d{bottom:46.957000px;}
.yac9{bottom:47.070000px;}
.yd5f{bottom:47.079650px;}
.yc71{bottom:47.081100px;}
.y27{bottom:47.121600px;}
.y956{bottom:47.228600px;}
.y13b1{bottom:47.249850px;}
.y6aa{bottom:47.312300px;}
.yc3d{bottom:47.332100px;}
.y1079{bottom:47.413600px;}
.y15b6{bottom:47.540150px;}
.y4ea{bottom:47.640200px;}
.yf37{bottom:47.661900px;}
.y105e{bottom:47.753700px;}
.y105c{bottom:47.754000px;}
.y118e{bottom:47.876650px;}
.yfc3{bottom:47.901900px;}
.yffd{bottom:47.904900px;}
.y7a8{bottom:47.915400px;}
.y924{bottom:47.992000px;}
.y1469{bottom:48.054700px;}
.y9c4{bottom:48.059000px;}
.y453{bottom:48.062400px;}
.y998{bottom:48.128700px;}
.y163{bottom:48.196900px;}
.y14f{bottom:48.197200px;}
.y883{bottom:48.197400px;}
.y705{bottom:48.280500px;}
.yb2d{bottom:48.383000px;}
.y747{bottom:48.399900px;}
.y9c0{bottom:48.486500px;}
.y156b{bottom:48.740400px;}
.ya55{bottom:48.786000px;}
.yce7{bottom:48.834800px;}
.yef2{bottom:48.903100px;}
.ya53{bottom:49.036000px;}
.ye13{bottom:49.179600px;}
.yd11{bottom:49.227800px;}
.y12f7{bottom:49.276500px;}
.y53c{bottom:49.311000px;}
.y1005{bottom:49.566300px;}
.yc58{bottom:49.566400px;}
.y40a{bottom:49.673550px;}
.y7b{bottom:49.797500px;}
.yf99{bottom:49.996500px;}
.y685{bottom:50.098500px;}
.yaef{bottom:50.101000px;}
.yd2f{bottom:50.251400px;}
.y49a{bottom:50.251900px;}
.ybcf{bottom:50.264600px;}
.yaed{bottom:50.351000px;}
.y901{bottom:50.366100px;}
.ya7f{bottom:50.399000px;}
.ya81{bottom:50.449000px;}
.y1cb{bottom:50.471750px;}
.y842{bottom:50.586700px;}
.ya7d{bottom:50.649000px;}
.yb45{bottom:50.786000px;}
.y6a9{bottom:50.812300px;}
.y46a{bottom:50.897100px;}
.y594{bottom:50.935700px;}
.y4e9{bottom:51.140200px;}
.yd10{bottom:51.227800px;}
.y9db{bottom:51.346000px;}
.yb92{bottom:51.398800px;}
.y923{bottom:51.492100px;}
.y4f9{bottom:51.503200px;}
.y72f{bottom:51.593900px;}
.y1437{bottom:51.913900px;}
.y140c{bottom:52.248200px;}
.y145c{bottom:52.248300px;}
.y1021{bottom:52.408800px;}
.y437{bottom:52.648000px;}
.y213{bottom:52.824900px;}
.y4a4{bottom:52.856900px;}
.y149b{bottom:53.047000px;}
.ybb2{bottom:53.083000px;}
.y65c{bottom:53.271800px;}
.y97d{bottom:53.574200px;}
.y155b{bottom:53.575900px;}
.yf76{bottom:53.581600px;}
.y15e1{bottom:53.589900px;}
.ybd2{bottom:53.867000px;}
.ybae{bottom:53.933000px;}
.yfed{bottom:54.070300px;}
.y7fd{bottom:54.106400px;}
.y129{bottom:54.219900px;}
.y1484{bottom:54.260800px;}
.yb61{bottom:54.380000px;}
.y593{bottom:54.435800px;}
.ybe2{bottom:54.583000px;}
.y3bc{bottom:54.724000px;}
.yc66{bottom:54.779800px;}
.ybb1{bottom:55.083000px;}
.ye46{bottom:55.105700px;}
.y14aa{bottom:55.235600px;}
.y1f2{bottom:55.271700px;}
.y1589{bottom:55.393400px;}
.y9d8{bottom:55.409800px;}
.ya1e{bottom:55.467000px;}
.y944{bottom:55.634600px;}
.ye61{bottom:55.731700px;}
.y1511{bottom:55.919400px;}
.ya14{bottom:55.994100px;}
.y189{bottom:56.100800px;}
.y857{bottom:56.155100px;}
.ya6e{bottom:56.277300px;}
.y11ac{bottom:56.381100px;}
.y293{bottom:56.729900px;}
.yb9b{bottom:56.849000px;}
.y14cc{bottom:56.896200px;}
.y1153{bottom:56.897100px;}
.yb25{bottom:57.023300px;}
.yd5e{bottom:57.079400px;}
.y1320{bottom:57.280800px;}
.yc9a{bottom:57.301000px;}
.y3f6{bottom:57.333800px;}
.ye78{bottom:57.401000px;}
.y62c{bottom:57.509950px;}
.yec5{bottom:57.541300px;}
.yabc{bottom:57.635000px;}
.yab8{bottom:57.715600px;}
.y153f{bottom:57.733400px;}
.y9c9{bottom:57.896900px;}
.y26{bottom:57.921600px;}
.y14ef{bottom:57.924050px;}
.y31d{bottom:58.031400px;}
.yb01{bottom:58.073000px;}
.y1121{bottom:58.106700px;}
.yb95{bottom:58.128000px;}
.yabf{bottom:58.186000px;}
.y3bb{bottom:58.224000px;}
.y9bb{bottom:58.519800px;}
.ycfa{bottom:58.558500px;}
.y9bd{bottom:58.660500px;}
.y1128{bottom:58.708500px;}
.yb9a{bottom:58.849000px;}
.ya45{bottom:58.916000px;}
.yde1{bottom:58.919400px;}
.y141d{bottom:59.054600px;}
.yc69{bottom:59.153100px;}
.y14ba{bottom:59.243500px;}
.y1032{bottom:59.243800px;}
.y115f{bottom:59.244100px;}
.y13b0{bottom:59.250250px;}
.yc99{bottom:59.301000px;}
.y478{bottom:59.473700px;}
.yc8e{bottom:59.532900px;}
.y15b5{bottom:59.540550px;}
.y129e{bottom:59.580800px;}
.yd5d{bottom:59.704400px;}
.y1224{bottom:59.720700px;}
.yc0a{bottom:59.731700px;}
.yfde{bottom:59.740100px;}
.y118d{bottom:59.877050px;}
.y9c8{bottom:59.896900px;}
.y863{bottom:59.907900px;}
.yc9c{bottom:60.110000px;}
.ya49{bottom:60.152000px;}
.y1172{bottom:60.227800px;}
.y955{bottom:60.228600px;}
.y1525{bottom:60.377700px;}
.y1078{bottom:60.413600px;}
.y1ca{bottom:60.471500px;}
.yf36{bottom:60.661900px;}
.y105b{bottom:60.754000px;}
.yfc2{bottom:60.901900px;}
.yffc{bottom:60.904900px;}
.y1468{bottom:61.054700px;}
.y452{bottom:61.062400px;}
.y409{bottom:61.173300px;}
.y704{bottom:61.280500px;}
.y746{bottom:61.399900px;}
.yae3{bottom:61.467100px;}
.y156a{bottom:61.740400px;}
.ya71{bottom:61.765000px;}
.y7a{bottom:61.797200px;}
.yce6{bottom:61.834800px;}
.y159c{bottom:61.888100px;}
.y5b4{bottom:61.889200px;}
.yef1{bottom:61.903100px;}
.ye33{bottom:62.066246px;}
.yc9b{bottom:62.110000px;}
.ye12{bottom:62.179600px;}
.y12f6{bottom:62.276500px;}
.y778{bottom:62.453400px;}
.y1004{bottom:62.566300px;}
.yc57{bottom:62.566400px;}
.y212{bottom:62.824650px;}
.yf98{bottom:62.996500px;}
.y751{bottom:63.116400px;}
.yd2e{bottom:63.251400px;}
.y499{bottom:63.251900px;}
.ybce{bottom:63.264600px;}
.y841{bottom:63.586700px;}
.yee2{bottom:63.612550px;}
.y3d8{bottom:63.711400px;}
.y592{bottom:63.770400px;}
.y469{bottom:63.897100px;}
.y1c9{bottom:63.971600px;}
.yc2f{bottom:64.028600px;}
.yd0f{bottom:64.227800px;}
.y808{bottom:64.235900px;}
.yd86{bottom:64.275650px;}
.yb91{bottom:64.398800px;}
.y4f8{bottom:64.503200px;}
.y72e{bottom:64.593900px;}
.y1436{bottom:64.913900px;}
.y140b{bottom:65.248200px;}
.y145b{bottom:65.248300px;}
.yc9e{bottom:65.373000px;}
.y1020{bottom:65.408800px;}
.yf75{bottom:65.582000px;}
.y15e0{bottom:65.589900px;}
.y13f1{bottom:65.599400px;}
.y436{bottom:65.648000px;}
.ybaf{bottom:65.683000px;}
.y15e8{bottom:65.739900px;}
.y2ac{bottom:65.767500px;}
.y4a3{bottom:65.856900px;}
.y149a{bottom:66.047000px;}
.y65b{bottom:66.271800px;}
.yb06{bottom:66.490900px;}
.y97c{bottom:66.574200px;}
.y155a{bottom:66.575900px;}
.yac4{bottom:66.605000px;}
.yf11{bottom:66.724100px;}
.y997{bottom:66.798000px;}
.yfec{bottom:67.070300px;}
.y7fc{bottom:67.106400px;}
.yb94{bottom:67.128000px;}
.y128{bottom:67.219900px;}
.y1483{bottom:67.260800px;}
.y591{bottom:67.270500px;}
.ye32{bottom:67.331060px;}
.y137d{bottom:67.407300px;}
.y2ab{bottom:67.530100px;}
.ybe1{bottom:67.583000px;}
.yc65{bottom:67.779800px;}
.y14a9{bottom:68.235600px;}
.y1f1{bottom:68.271700px;}
.y11ab{bottom:68.380800px;}
.y1588{bottom:68.393400px;}
.y9d7{bottom:68.409800px;}
.yb05{bottom:68.491000px;}
.yb4c{bottom:68.506000px;}
.ya4e{bottom:68.571000px;}
.yac3{bottom:68.605000px;}
.y943{bottom:68.634600px;}
.ydf4{bottom:68.663500px;}
.ye60{bottom:68.731700px;}
.y13d0{bottom:68.745900px;}
.y1510{bottom:68.919400px;}
.ya13{bottom:68.994100px;}
.y62b{bottom:69.009700px;}
.y188{bottom:69.100800px;}
.y856{bottom:69.155100px;}
.ya6d{bottom:69.277300px;}
.y131f{bottom:69.281200px;}
.yc93{bottom:69.528900px;}
.yec4{bottom:69.541700px;}
.y292{bottom:69.729900px;}
.yae8{bottom:69.885000px;}
.y14cb{bottom:69.896200px;}
.y1152{bottom:69.897100px;}
.y14ee{bottom:69.924450px;}
.ye45{bottom:69.940550px;}
.ydbb{bottom:69.944300px;}
.ydae{bottom:69.946750px;}
.yb24{bottom:70.023300px;}
.ya76{bottom:70.184000px;}
.y7e3{bottom:70.257400px;}
.y3f5{bottom:70.333800px;}
.ye77{bottom:70.401000px;}
.y260{bottom:70.423100px;}
.yc89{bottom:70.483100px;}
.ya4d{bottom:70.571000px;}
.y12da{bottom:70.586700px;}
.y119c{bottom:70.607400px;}
.y8d1{bottom:70.635800px;}
.y153e{bottom:70.733400px;}
.y9de{bottom:70.770100px;}
.y31c{bottom:71.031400px;}
.y1120{bottom:71.106700px;}
.y13af{bottom:71.250650px;}
.y9ba{bottom:71.519800px;}
.ycf9{bottom:71.558500px;}
.y10c{bottom:71.596600px;}
.y1127{bottom:71.708500px;}
.y118c{bottom:71.877450px;}
.yae7{bottom:71.885100px;}
.ya44{bottom:71.916000px;}
.yde0{bottom:71.919400px;}
.y141c{bottom:72.054600px;}
.ya75{bottom:72.184000px;}
.y14b9{bottom:72.243500px;}
.y1031{bottom:72.243800px;}
.y115e{bottom:72.244100px;}
.y477{bottom:72.473700px;}
.y129d{bottom:72.580800px;}
.y67a{bottom:72.671900px;}
.y1312{bottom:72.715050px;}
.y1223{bottom:72.720700px;}
.y8f1{bottom:72.730500px;}
.yc09{bottom:72.731700px;}
.yfdd{bottom:72.740100px;}
.y9dd{bottom:72.770000px;}
.ybec{bottom:72.810000px;}
.y211{bottom:72.824400px;}
.y862{bottom:72.907900px;}
.y1171{bottom:73.227800px;}
.y954{bottom:73.228600px;}
.y1c8{bottom:73.306200px;}
.y1524{bottom:73.377700px;}
.y1077{bottom:73.413600px;}
.yf35{bottom:73.661900px;}
.yfa3{bottom:73.720000px;}
.y105a{bottom:73.754000px;}
.y79{bottom:73.796900px;}
.yfc1{bottom:73.901900px;}
.yffb{bottom:73.904900px;}
.y38d{bottom:74.024700px;}
.y1467{bottom:74.054700px;}
.y451{bottom:74.062400px;}
.y8b4{bottom:74.067100px;}
.y38c{bottom:74.101300px;}
.yd2c{bottom:74.251400px;}
.y703{bottom:74.280500px;}
.y12ae{bottom:74.401800px;}
.yb5a{bottom:74.503100px;}
.yb4b{bottom:74.543000px;}
.yce5{bottom:74.834800px;}
.y159b{bottom:74.888100px;}
.y5b3{bottom:74.889200px;}
.yef0{bottom:74.903100px;}
.y881{bottom:74.925300px;}
.ye11{bottom:75.179600px;}
.y9be{bottom:75.230500px;}
.y12f5{bottom:75.276500px;}
.y777{bottom:75.453400px;}
.y1003{bottom:75.566300px;}
.yc56{bottom:75.566400px;}
.yee1{bottom:75.612950px;}
.yfa2{bottom:75.720100px;}
.ybe4{bottom:75.814000px;}
.y6c5{bottom:75.999200px;}
.ybf{bottom:76.053900px;}
.y750{bottom:76.116400px;}
.yd2d{bottom:76.251400px;}
.yd2b{bottom:76.251600px;}
.y498{bottom:76.251900px;}
.ybcd{bottom:76.264600px;}
.yd85{bottom:76.276050px;}
.yb5e{bottom:76.304000px;}
.y210{bottom:76.324500px;}
.y840{bottom:76.586700px;}
.y408{bottom:76.644300px;}
.y406{bottom:76.644700px;}
.y3d7{bottom:76.711400px;}
.y1c7{bottom:76.806200px;}
.y468{bottom:76.897100px;}
.y14f2{bottom:76.903700px;}
.y14f3{bottom:76.903800px;}
.yb42{bottom:76.968700px;}
.yc2e{bottom:77.028600px;}
.y15b4{bottom:77.209600px;}
.yd0e{bottom:77.227800px;}
.y127a{bottom:77.228400px;}
.y745{bottom:77.234900px;}
.y807{bottom:77.235900px;}
.yb90{bottom:77.398800px;}
.y4f7{bottom:77.503200px;}
.yb4a{bottom:77.543000px;}
.yf74{bottom:77.582400px;}
.y15df{bottom:77.589900px;}
.y72d{bottom:77.593900px;}
.y15ed{bottom:77.739900px;}
.y9e0{bottom:77.759800px;}
.y1435{bottom:77.913900px;}
.y140a{bottom:78.248200px;}
.y145a{bottom:78.248300px;}
.y6c4{bottom:78.249200px;}
.y101f{bottom:78.408800px;}
.y882{bottom:78.425300px;}
.yc92{bottom:78.528900px;}
.y13f0{bottom:78.599400px;}
.y435{bottom:78.648000px;}
.y4a2{bottom:78.856900px;}
.y1499{bottom:79.047000px;}
.yb03{bottom:79.108000px;}
.yac1{bottom:79.221000px;}
.y65a{bottom:79.271800px;}
.y407{bottom:79.494200px;}
.y69f{bottom:79.545800px;}
.y97b{bottom:79.574200px;}
.y1559{bottom:79.575900px;}
.yf10{bottom:79.724100px;}
.y996{bottom:79.798000px;}
.ye44{bottom:79.940300px;}
.yfeb{bottom:80.070300px;}
.yb29{bottom:80.082000px;}
.y4e2{bottom:80.084800px;}
.y7fb{bottom:80.106400px;}
.y127{bottom:80.219900px;}
.y1482{bottom:80.260800px;}
.y11aa{bottom:80.380500px;}
.y137c{bottom:80.407300px;}
.y1569{bottom:80.409400px;}
.y523{bottom:80.571000px;}
.ybe0{bottom:80.583000px;}
.ye3a{bottom:80.662700px;}
.y9df{bottom:80.759800px;}
.yc64{bottom:80.779800px;}
.y922{bottom:80.894500px;}
.ya4b{bottom:81.187000px;}
.y9c6{bottom:81.198000px;}
.y9c7{bottom:81.198100px;}
.y14a8{bottom:81.235600px;}
.y1f0{bottom:81.271700px;}
.y131e{bottom:81.281600px;}
.y1587{bottom:81.393400px;}
.y9d6{bottom:81.409800px;}
.ye39{bottom:81.548500px;}
.y942{bottom:81.634600px;}
.ydf3{bottom:81.663500px;}
.yf97{bottom:81.665500px;}
.y10ee{bottom:81.665900px;}
.y13cf{bottom:81.745900px;}
.y150f{bottom:81.919400px;}
.y14ed{bottom:81.924850px;}
.y62a{bottom:81.926850px;}
.ydba{bottom:81.944700px;}
.ydad{bottom:81.947150px;}
.ya12{bottom:81.994100px;}
.y187{bottom:82.100800px;}
.ycca{bottom:82.106400px;}
.y855{bottom:82.155100px;}
.ya6c{bottom:82.277300px;}
.yae5{bottom:82.501100px;}
.y119b{bottom:82.607800px;}
.y291{bottom:82.729900px;}
.ya73{bottom:82.800000px;}
.y14ca{bottom:82.896200px;}
.y1151{bottom:82.897100px;}
.yb23{bottom:83.023300px;}
.y7e2{bottom:83.257400px;}
.y3f4{bottom:83.333800px;}
.ye76{bottom:83.401000px;}
.y25f{bottom:83.423100px;}
.yc88{bottom:83.483100px;}
.y12d9{bottom:83.586700px;}
.y8d0{bottom:83.635800px;}
.y153d{bottom:83.733400px;}
.y9dc{bottom:83.963000px;}
.y31b{bottom:84.031400px;}
.y111f{bottom:84.106700px;}
.y9b9{bottom:84.519800px;}
.ycb3{bottom:84.558500px;}
.y10b{bottom:84.596600px;}
.ybaa{bottom:84.656100px;}
.y1126{bottom:84.708500px;}
.y1311{bottom:84.715450px;}
.yab7{bottom:84.888800px;}
.yddf{bottom:84.919400px;}
.y141b{bottom:85.054600px;}
.y14b8{bottom:85.243500px;}
.y1030{bottom:85.243800px;}
.y115d{bottom:85.244100px;}
.yc33{bottom:85.271100px;}
.y476{bottom:85.473700px;}
.y129c{bottom:85.580800px;}
.y679{bottom:85.671900px;}
.y1222{bottom:85.720700px;}
.y8f0{bottom:85.730500px;}
.yc08{bottom:85.731700px;}
.yfdc{bottom:85.740100px;}
.yae0{bottom:85.786700px;}
.y78{bottom:85.796600px;}
.y861{bottom:85.907900px;}
.y25{bottom:86.133300px;}
.y1170{bottom:86.227800px;}
.y1523{bottom:86.377700px;}
.y1076{bottom:86.413600px;}
.yf34{bottom:86.661900px;}
.y1059{bottom:86.754000px;}
.yfc0{bottom:86.901900px;}
.yffa{bottom:86.904900px;}
.y1466{bottom:87.054700px;}
.y450{bottom:87.062400px;}
.y8b3{bottom:87.067100px;}
.yec3{bottom:87.210750px;}
.y702{bottom:87.280500px;}
.ye5f{bottom:87.401000px;}
.y12ad{bottom:87.401800px;}
.yb59{bottom:87.503100px;}
.yee0{bottom:87.613350px;}
.ya43{bottom:87.750600px;}
.y14e{bottom:87.776200px;}
.yce4{bottom:87.834800px;}
.y5b2{bottom:87.889200px;}
.yeef{bottom:87.903100px;}
.y880{bottom:87.925300px;}
.ybb0{bottom:88.016000px;}
.y405{bottom:88.144450px;}
.ye10{bottom:88.179600px;}
.yd84{bottom:88.276450px;}
.y776{bottom:88.453400px;}
.y69d{bottom:88.545800px;}
.y1002{bottom:88.566300px;}
.y10c1{bottom:88.676900px;}
.y9d{bottom:88.745100px;}
.y13ae{bottom:88.919700px;}
.ybe{bottom:89.053900px;}
.y953{bottom:89.063300px;}
.y74f{bottom:89.116400px;}
.y15b3{bottom:89.210000px;}
.yd2a{bottom:89.251600px;}
.y497{bottom:89.251900px;}
.ybcc{bottom:89.264600px;}
.y118b{bottom:89.546500px;}
.yf73{bottom:89.582800px;}
.y83f{bottom:89.586700px;}
.y15de{bottom:89.589900px;}
.y3d6{bottom:89.711400px;}
.y467{bottom:89.897100px;}
.yb41{bottom:89.968700px;}
.yc2d{bottom:90.028600px;}
.y38b{bottom:90.115300px;}
.y38a{bottom:90.191800px;}
.yd0d{bottom:90.227800px;}
.y1279{bottom:90.228400px;}
.y744{bottom:90.234900px;}
.y806{bottom:90.235900px;}
.yb8f{bottom:90.398800px;}
.y4f6{bottom:90.503200px;}
.y72c{bottom:90.593900px;}
.y159a{bottom:90.723100px;}
.y1361{bottom:90.767800px;}
.yb10{bottom:90.779000px;}
.y6c3{bottom:90.833900px;}
.yb02{bottom:90.876000px;}
.yacc{bottom:90.892000px;}
.y1434{bottom:90.913900px;}
.yac0{bottom:90.990000px;}
.y3ab{bottom:91.034000px;}
.y1409{bottom:91.248200px;}
.yc55{bottom:91.401000px;}
.y101e{bottom:91.408800px;}
.yc91{bottom:91.549900px;}
.y13ef{bottom:91.599400px;}
.y2bc{bottom:91.796000px;}
.y4a1{bottom:91.856900px;}
.y69e{bottom:92.045900px;}
.y1498{bottom:92.047000px;}
.yb49{bottom:92.059000px;}
.y10a2{bottom:92.212800px;}
.y659{bottom:92.271800px;}
.y11a9{bottom:92.380200px;}
.y11a8{bottom:92.380400px;}
.yc7c{bottom:92.497000px;}
.y97a{bottom:92.574200px;}
.y1558{bottom:92.575900px;}
.ybe7{bottom:92.674000px;}
.yf0f{bottom:92.724100px;}
.y995{bottom:92.798000px;}
.ya1c{bottom:92.839000px;}
.ya56{bottom:92.858000px;}
.ya4a{bottom:92.956000px;}
.yfea{bottom:93.070300px;}
.y6c2{bottom:93.083900px;}
.y4e1{bottom:93.084800px;}
.y7fa{bottom:93.106400px;}
.y126{bottom:93.219900px;}
.y137b{bottom:93.407300px;}
.y1568{bottom:93.409400px;}
.y629{bottom:93.426600px;}
.y522{bottom:93.571000px;}
.ybdf{bottom:93.583000px;}
.y24a{bottom:93.738300px;}
.y921{bottom:93.894500px;}
.y14f1{bottom:93.903800px;}
.ydb9{bottom:93.945100px;}
.y12f4{bottom:93.945800px;}
.ydac{bottom:93.947550px;}
.yb48{bottom:94.059000px;}
.yaf0{bottom:94.172000px;}
.y14a7{bottom:94.235600px;}
.yae4{bottom:94.270100px;}
.y1ef{bottom:94.271700px;}
.y1586{bottom:94.393400px;}
.y9d5{bottom:94.409800px;}
.ya80{bottom:94.471000px;}
.ya72{bottom:94.569000px;}
.y119a{bottom:94.608200px;}
.ydf2{bottom:94.663500px;}
.yf96{bottom:94.665500px;}
.y10ed{bottom:94.665900px;}
.y13ce{bottom:94.745900px;}
.y150e{bottom:94.919400px;}
.ya11{bottom:94.994100px;}
.y186{bottom:95.100800px;}
.ycc9{bottom:95.106400px;}
.y854{bottom:95.155100px;}
.ya6b{bottom:95.277300px;}
.yc7b{bottom:95.497000px;}
.y290{bottom:95.729900px;}
.yb04{bottom:95.885000px;}
.y1150{bottom:95.897100px;}
.yac2{bottom:95.998000px;}
.yb22{bottom:96.023300px;}
.y7e1{bottom:96.257400px;}
.ye75{bottom:96.401000px;}
.y25e{bottom:96.423100px;}
.yc87{bottom:96.483100px;}
.y7a1{bottom:96.535400px;}
.y12d8{bottom:96.586700px;}
.yc63{bottom:96.614300px;}
.y1310{bottom:96.715850px;}
.y1459{bottom:96.917400px;}
.y111e{bottom:97.106700px;}
.yaa0{bottom:97.165600px;}
.y434{bottom:97.317400px;}
.y9b8{bottom:97.519800px;}
.y69c{bottom:97.545800px;}
.ycb2{bottom:97.558500px;}
.y10a{bottom:97.596600px;}
.y1125{bottom:97.708500px;}
.y233{bottom:97.741850px;}
.y52{bottom:97.781400px;}
.y77{bottom:97.796300px;}
.ye86{bottom:97.903400px;}
.ydde{bottom:97.919400px;}
.ya4c{bottom:97.964000px;}
.y141a{bottom:98.054600px;}
.y14b7{bottom:98.243500px;}
.y102f{bottom:98.243800px;}
.y115c{bottom:98.244100px;}
.yc3c{bottom:98.267100px;}
.y590{bottom:98.478100px;}
.y129b{bottom:98.580800px;}
.y678{bottom:98.671900px;}
.y1221{bottom:98.720700px;}
.y8ef{bottom:98.730500px;}
.yc07{bottom:98.731700px;}
.yfdb{bottom:98.740100px;}
.y20f{bottom:98.889200px;}
.y860{bottom:98.907900px;}
.y1481{bottom:98.930100px;}
.y131d{bottom:98.950650px;}
.y24{bottom:99.133300px;}
.yec2{bottom:99.211150px;}
.y116f{bottom:99.227800px;}
.yae6{bottom:99.279100px;}
.y1522{bottom:99.377700px;}
.y8cf{bottom:99.470800px;}
.ya74{bottom:99.577000px;}
.y14ec{bottom:99.593900px;}
.y14f0{bottom:99.613750px;}
.y404{bottom:99.644200px;}
.yf33{bottom:99.661900px;}
.y1058{bottom:99.754000px;}
.y31a{bottom:99.866400px;}
.yfbf{bottom:99.901900px;}
.yff9{bottom:99.904900px;}
.y1465{bottom:100.054700px;}
.y44f{bottom:100.062400px;}
.y8b2{bottom:100.067100px;}
.y548{bottom:100.261800px;}
.yc37{bottom:100.266000px;}
.yd83{bottom:100.276850px;}
.y701{bottom:100.280500px;}
.y941{bottom:100.303600px;}
.y12ac{bottom:100.401800px;}
.yba9{bottom:100.490800px;}
.yb58{bottom:100.503100px;}
.yab6{bottom:100.723400px;}
.y14d{bottom:100.776200px;}
.yce3{bottom:100.834800px;}
.y5b1{bottom:100.889200px;}
.yf89{bottom:100.903100px;}
.y13ad{bottom:100.920100px;}
.y87f{bottom:100.925300px;}
.ye0f{bottom:101.179600px;}
.y775{bottom:101.453400px;}
.y118a{bottom:101.546900px;}
.y14c9{bottom:101.565200px;}
.y1001{bottom:101.566300px;}
.y15dd{bottom:101.589900px;}
.yadf{bottom:101.621400px;}
.y10c0{bottom:101.676900px;}
.y9c{bottom:101.745100px;}
.y3f3{bottom:102.003100px;}
.ybd{bottom:102.053900px;}
.y74e{bottom:102.116400px;}
.yd29{bottom:102.251600px;}
.y496{bottom:102.251900px;}
.ybcb{bottom:102.264600px;}
.yc36{bottom:102.266100px;}
.y153c{bottom:102.402400px;}
.yc98{bottom:102.494000px;}
.y83e{bottom:102.586700px;}
.y3d5{bottom:102.711400px;}
.yb40{bottom:102.968700px;}
.yc2c{bottom:103.028600px;}
.ycf8{bottom:103.227800px;}
.y9fe{bottom:103.228100px;}
.y1278{bottom:103.228400px;}
.y805{bottom:103.235900px;}
.yb8e{bottom:103.398800px;}
.y4f5{bottom:103.503200px;}
.yc34{bottom:103.505100px;}
.yd3b{bottom:103.574200px;}
.y72b{bottom:103.593900px;}
.y1599{bottom:103.723100px;}
.y1360{bottom:103.767800px;}
.yc17{bottom:103.912800px;}
.y1433{bottom:103.913900px;}
.y3aa{bottom:104.034000px;}
.y475{bottom:104.142900px;}
.y101d{bottom:104.408800px;}
.yc97{bottom:104.494000px;}
.yc35{bottom:104.597100px;}
.y4a0{bottom:104.856900px;}
.y10a1{bottom:105.212800px;}
.y658{bottom:105.271800px;}
.yea6{bottom:105.279600px;}
.yedf{bottom:105.282400px;}
.y979{bottom:105.574200px;}
.y1557{bottom:105.575900px;}
.yf0e{bottom:105.724100px;}
.y994{bottom:105.798000px;}
.ydc1{bottom:105.945500px;}
.y743{bottom:106.069900px;}
.yfe9{bottom:106.070300px;}
.y4e0{bottom:106.084800px;}
.y7f9{bottom:106.106400px;}
.y389{bottom:106.205800px;}
.y125{bottom:106.219900px;}
.y388{bottom:106.282400px;}
.y628{bottom:106.343750px;}
.y137a{bottom:106.407300px;}
.y1567{bottom:106.409400px;}
.y521{bottom:106.571000px;}
.y249{bottom:106.738300px;}
.y15b2{bottom:106.879050px;}
.y920{bottom:106.894500px;}
.y11a7{bottom:107.214800px;}
.y14a6{bottom:107.235600px;}
.yf72{bottom:107.251850px;}
.y1ee{bottom:107.271700px;}
.y1585{bottom:107.393400px;}
.y9d4{bottom:107.409800px;}
.ydf1{bottom:107.663500px;}
.yf95{bottom:107.665500px;}
.y10ec{bottom:107.665900px;}
.y13cd{bottom:107.745900px;}
.y150d{bottom:107.919400px;}
.ya10{bottom:107.994100px;}
.y185{bottom:108.100800px;}
.ycc8{bottom:108.106400px;}
.y853{bottom:108.155100px;}
.y466{bottom:108.566300px;}
.y130f{bottom:108.716250px;}
.y28f{bottom:108.729900px;}
.yc8f{bottom:108.810900px;}
.y114f{bottom:108.897100px;}
.y134c{bottom:108.919100px;}
.ya1d{bottom:108.953000px;}
.y2bb{bottom:108.965300px;}
.yb21{bottom:109.023300px;}
.yd5c{bottom:109.093350px;}
.y232{bottom:109.241600px;}
.y7e0{bottom:109.257400px;}
.ye74{bottom:109.401000px;}
.y25d{bottom:109.423100px;}
.yc86{bottom:109.483100px;}
.y7a0{bottom:109.535400px;}
.y12d7{bottom:109.586700px;}
.y51{bottom:109.781100px;}
.y76{bottom:109.796000px;}
.y1408{bottom:109.917400px;}
.y111d{bottom:110.106700px;}
.y13ee{bottom:110.268700px;}
.y9b7{bottom:110.519800px;}
.ycb1{bottom:110.558500px;}
.y109{bottom:110.596600px;}
.y1104{bottom:110.661600px;}
.y1124{bottom:110.708500px;}
.y1497{bottom:110.716000px;}
.ye85{bottom:110.903400px;}
.yddd{bottom:110.919400px;}
.y131c{bottom:110.951050px;}
.y1419{bottom:111.054600px;}
.y1c6{bottom:111.084200px;}
.y14b6{bottom:111.243500px;}
.y102e{bottom:111.243800px;}
.y115b{bottom:111.244100px;}
.yfa5{bottom:111.282000px;}
.y952{bottom:111.401800px;}
.y58f{bottom:111.478100px;}
.y14eb{bottom:111.594300px;}
.ydb8{bottom:111.614150px;}
.ydab{bottom:111.616600px;}
.y677{bottom:111.671900px;}
.ye8{bottom:111.717400px;}
.yc06{bottom:111.731700px;}
.ye5e{bottom:111.739800px;}
.yfda{bottom:111.740100px;}
.y547{bottom:111.761550px;}
.y20e{bottom:111.889200px;}
.y85f{bottom:111.907900px;}
.y23{bottom:112.133300px;}
.ybde{bottom:112.252000px;}
.y1199{bottom:112.277250px;}
.y95b{bottom:112.285800px;}
.y8ce{bottom:112.470800px;}
.y403{bottom:112.521450px;}
.y99b{bottom:112.599400px;}
.yf32{bottom:112.661900px;}
.yc96{bottom:112.707000px;}
.y319{bottom:112.866400px;}
.yfbe{bottom:112.901900px;}
.yff8{bottom:112.904900px;}
.y13ac{bottom:112.920500px;}
.ya9f{bottom:113.000200px;}
.y1464{bottom:113.054700px;}
.y44e{bottom:113.062400px;}
.yfa4{bottom:113.282000px;}
.y940{bottom:113.303600px;}
.y12ab{bottom:113.401800px;}
.yb57{bottom:113.503100px;}
.y1075{bottom:113.587200px;}
.y15dc{bottom:113.589900px;}
.y15e9{bottom:113.739900px;}
.y14c{bottom:113.776200px;}
.y5b0{bottom:113.889200px;}
.yc39{bottom:113.901100px;}
.yf88{bottom:113.903100px;}
.y87e{bottom:113.925300px;}
.yc3b{bottom:113.952000px;}
.ye0e{bottom:114.179600px;}
.y959{bottom:114.285400px;}
.y774{bottom:114.453400px;}
.y6a8{bottom:114.458600px;}
.y6a7{bottom:114.535200px;}
.y14c8{bottom:114.565200px;}
.y8ee{bottom:114.565500px;}
.y1000{bottom:114.566300px;}
.y10bf{bottom:114.676900px;}
.yc95{bottom:114.706900px;}
.ya42{bottom:114.923100px;}
.yeee{bottom:115.076300px;}
.y74d{bottom:115.116400px;}
.yd28{bottom:115.251600px;}
.y495{bottom:115.251900px;}
.y10d5{bottom:115.331000px;}
.y153b{bottom:115.402400px;}
.y83d{bottom:115.586700px;}
.y3d4{bottom:115.711400px;}
.yc38{bottom:115.901100px;}
.yc3a{bottom:115.952100px;}
.yb3f{bottom:115.968700px;}
.yc2b{bottom:116.028600px;}
.yd0c{bottom:116.227800px;}
.y9fd{bottom:116.228100px;}
.y804{bottom:116.235900px;}
.yb8d{bottom:116.398800px;}
.y4f4{bottom:116.503200px;}
.y72a{bottom:116.593900px;}
.yce2{bottom:116.669500px;}
.y1598{bottom:116.723100px;}
.y135f{bottom:116.767800px;}
.yec1{bottom:116.880200px;}
.yc16{bottom:116.912800px;}
.y1432{bottom:116.913900px;}
.y3a9{bottom:117.034000px;}
.y129a{bottom:117.249800px;}
.yede{bottom:117.282800px;}
.y1220{bottom:117.389700px;}
.yb60{bottom:117.396000px;}
.y101c{bottom:117.408800px;}
.y627{bottom:117.843500px;}
.y116e{bottom:117.897100px;}
.yd82{bottom:117.945900px;}
.y1521{bottom:118.046700px;}
.ybca{bottom:118.099200px;}
.y11c9{bottom:118.147800px;}
.y10a0{bottom:118.212800px;}
.y401{bottom:118.271200px;}
.y657{bottom:118.271800px;}
.yea5{bottom:118.279600px;}
.y12f3{bottom:118.284700px;}
.y1057{bottom:118.423000px;}
.y978{bottom:118.574200px;}
.yc54{bottom:118.575200px;}
.y1556{bottom:118.575900px;}
.yc6a{bottom:118.671100px;}
.y8b1{bottom:118.736100px;}
.y144e{bottom:118.772600px;}
.y993{bottom:118.798000px;}
.y15b1{bottom:118.879450px;}
.y700{bottom:118.949500px;}
.y742{bottom:119.069900px;}
.yfe8{bottom:119.070300px;}
.y7f8{bottom:119.106400px;}
.y1189{bottom:119.215950px;}
.y124{bottom:119.219900px;}
.yf71{bottom:119.252250px;}
.y1379{bottom:119.407300px;}
.y1566{bottom:119.409400px;}
.y520{bottom:119.571000px;}
.ya6f{bottom:119.616000px;}
.yc90{bottom:119.635900px;}
.y248{bottom:119.738300px;}
.y91f{bottom:119.894500px;}
.y1ed{bottom:120.271700px;}
.ya1b{bottom:120.365000px;}
.y1584{bottom:120.393400px;}
.y9d3{bottom:120.409800px;}
.ydf0{bottom:120.663500px;}
.yf94{bottom:120.665500px;}
.y10eb{bottom:120.665900px;}
.y130e{bottom:120.716650px;}
.y387{bottom:120.736500px;}
.y231{bottom:120.741350px;}
.y13cc{bottom:120.745900px;}
.y150c{bottom:120.919400px;}
.ya0f{bottom:120.994100px;}
.yd5b{bottom:121.093750px;}
.y184{bottom:121.100800px;}
.ycc7{bottom:121.106400px;}
.y852{bottom:121.155100px;}
.y1458{bottom:121.256000px;}
.y28e{bottom:121.729900px;}
.y50{bottom:121.780800px;}
.y75{bottom:121.795700px;}
.y114e{bottom:121.897100px;}
.y1277{bottom:121.897400px;}
.y134b{bottom:121.919100px;}
.y4df{bottom:121.919800px;}
.yb20{bottom:122.023300px;}
.y7df{bottom:122.257400px;}
.y384{bottom:122.296400px;}
.ye73{bottom:122.401000px;}
.y25c{bottom:122.423100px;}
.yc85{bottom:122.483100px;}
.y79f{bottom:122.535400px;}
.y12d6{bottom:122.586700px;}
.ye38{bottom:122.609709px;}
.y385{bottom:122.636500px;}
.ye30{bottom:122.694021px;}
.y131b{bottom:122.951450px;}
.y900{bottom:123.064900px;}
.y14a5{bottom:123.070300px;}
.y111c{bottom:123.106700px;}
.y9b{bottom:123.249100px;}
.y546{bottom:123.261300px;}
.y1480{bottom:123.268700px;}
.y2ba{bottom:123.300150px;}
.y9b6{bottom:123.519800px;}
.y49f{bottom:123.526200px;}
.ybc{bottom:123.557900px;}
.ycb0{bottom:123.558500px;}
.y14ea{bottom:123.594700px;}
.y108{bottom:123.596600px;}
.ydb7{bottom:123.614550px;}
.ydaa{bottom:123.617000px;}
.y1496{bottom:123.716000px;}
.yc62{bottom:123.787600px;}
.yddc{bottom:123.919400px;}
.y402{bottom:124.021200px;}
.y1418{bottom:124.054600px;}
.y1c3{bottom:124.084100px;}
.y1c5{bottom:124.084200px;}
.y571{bottom:124.134550px;}
.y14b5{bottom:124.243500px;}
.y102d{bottom:124.243800px;}
.y115a{bottom:124.244100px;}
.y1198{bottom:124.277650px;}
.yf0d{bottom:124.393100px;}
.y951{bottom:124.401800px;}
.y58e{bottom:124.478100px;}
.y11ca{bottom:124.642116px;}
.y676{bottom:124.671900px;}
.ye5d{bottom:124.739800px;}
.yfd9{bottom:124.740100px;}
.y20d{bottom:124.889200px;}
.y85e{bottom:124.907900px;}
.y22{bottom:125.133300px;}
.ybdd{bottom:125.252000px;}
.y386{bottom:125.486500px;}
.y15db{bottom:125.589900px;}
.yf31{bottom:125.661900px;}
.y15e6{bottom:125.739900px;}
.ye31{bottom:125.742808px;}
.yfbd{bottom:125.901900px;}
.yff7{bottom:125.904900px;}
.y1463{bottom:126.054700px;}
.y44d{bottom:126.062400px;}
.y12aa{bottom:126.401800px;}
.y433{bottom:126.490600px;}
.y1103{bottom:126.496300px;}
.yb56{bottom:126.503100px;}
.y82b{bottom:126.518200px;}
.ye84{bottom:126.738400px;}
.y14b{bottom:126.776200px;}
.y5af{bottom:126.889200px;}
.yf87{bottom:126.903100px;}
.y87d{bottom:126.925300px;}
.ye0d{bottom:127.179600px;}
.y773{bottom:127.453400px;}
.ya1a{bottom:127.526000px;}
.y14c7{bottom:127.565200px;}
.y8ed{bottom:127.565500px;}
.yc05{bottom:127.566300px;}
.y1c4{bottom:127.584300px;}
.yba8{bottom:127.664100px;}
.y10be{bottom:127.676900px;}
.yc6c{bottom:127.683100px;}
.yc6d{bottom:127.711100px;}
.yab5{bottom:127.896600px;}
.ya41{bottom:127.923100px;}
.y74c{bottom:128.116400px;}
.yd27{bottom:128.251600px;}
.y494{bottom:128.251900px;}
.y8cd{bottom:128.305800px;}
.y10d4{bottom:128.331000px;}
.y83c{bottom:128.586700px;}
.y1074{bottom:128.586800px;}
.yb08{bottom:128.677000px;}
.yac6{bottom:128.789000px;}
.yade{bottom:128.794600px;}
.yec0{bottom:128.880600px;}
.yb3e{bottom:128.968700px;}
.yc2a{bottom:129.028600px;}
.yd0b{bottom:129.227800px;}
.y9fc{bottom:129.228100px;}
.y803{bottom:129.235900px;}
.yedd{bottom:129.283200px;}
.y4f3{bottom:129.503200px;}
.y729{bottom:129.593900px;}
.y1597{bottom:129.723100px;}
.y135e{bottom:129.767800px;}
.yc15{bottom:129.912800px;}
.y1431{bottom:129.913900px;}
.yd81{bottom:129.946300px;}
.y3a8{bottom:130.034000px;}
.yc6e{bottom:130.205100px;}
.y1299{bottom:130.249800px;}
.y6ea{bottom:130.291200px;}
.ye7{bottom:130.386400px;}
.y121f{bottom:130.389700px;}
.y101b{bottom:130.408800px;}
.y474{bottom:130.481500px;}
.y6a6{bottom:130.549200px;}
.y13ab{bottom:130.589550px;}
.yb07{bottom:130.677000px;}
.y626{bottom:130.760650px;}
.yac5{bottom:130.789000px;}
.yc6f{bottom:130.828100px;}
.ya50{bottom:130.922000px;}
.y1520{bottom:131.046700px;}
.y3f2{bottom:131.176300px;}
.y109f{bottom:131.212800px;}
.y1188{bottom:131.216350px;}
.y656{bottom:131.271800px;}
.yea4{bottom:131.279600px;}
.y12f2{bottom:131.284700px;}
.y1056{bottom:131.423000px;}
.y318{bottom:131.535700px;}
.y977{bottom:131.574200px;}
.yc53{bottom:131.575200px;}
.y1555{bottom:131.575900px;}
.y144d{bottom:131.772600px;}
.y992{bottom:131.798000px;}
.y6ff{bottom:131.949500px;}
.y93f{bottom:131.972600px;}
.y741{bottom:132.069900px;}
.yaea{bottom:132.071000px;}
.y7f7{bottom:132.106400px;}
.y123{bottom:132.219900px;}
.yb8c{bottom:132.233400px;}
.y230{bottom:132.241100px;}
.ya7a{bottom:132.368000px;}
.y1378{bottom:132.407300px;}
.y1565{bottom:132.409400px;}
.y51f{bottom:132.571000px;}
.y130d{bottom:132.717050px;}
.ya19{bottom:132.897000px;}
.ya17{bottom:132.898000px;}
.ya4f{bottom:132.922000px;}
.yd5a{bottom:133.094150px;}
.y1ec{bottom:133.271700px;}
.y1583{bottom:133.393400px;}
.y9d2{bottom:133.409800px;}
.ydef{bottom:133.663500px;}
.yf93{bottom:133.665500px;}
.y10ea{bottom:133.665900px;}
.y13cb{bottom:133.745900px;}
.y4f{bottom:133.780500px;}
.y74{bottom:133.795400px;}
.y13b2{bottom:133.885100px;}
.y150b{bottom:133.919400px;}
.yae9{bottom:134.071000px;}
.y153a{bottom:134.071400px;}
.y183{bottom:134.100800px;}
.ycc6{bottom:134.106400px;}
.y1407{bottom:134.256000px;}
.ya79{bottom:134.368000px;}
.y3d3{bottom:134.380400px;}
.ye2f{bottom:134.436700px;}
.y8b0{bottom:134.571100px;}
.y13ed{bottom:134.607200px;}
.y1210{bottom:134.607462px;}
.y28d{bottom:134.729900px;}
.y2b9{bottom:134.799900px;}
.y114d{bottom:134.897100px;}
.y1276{bottom:134.897400px;}
.yfe7{bottom:134.904900px;}
.y134a{bottom:134.919100px;}
.y131a{bottom:134.951850px;}
.y7de{bottom:135.257400px;}
.ye72{bottom:135.401000px;}
.y25b{bottom:135.423100px;}
.yc84{bottom:135.483100px;}
.y79e{bottom:135.535400px;}
.y12d5{bottom:135.586700px;}
.y14e9{bottom:135.595100px;}
.ydb6{bottom:135.614950px;}
.yda9{bottom:135.617400px;}
.y570{bottom:135.634300px;}
.y91e{bottom:135.729500px;}
.y60f{bottom:135.804500px;}
.y8ff{bottom:136.064900px;}
.y111b{bottom:136.106700px;}
.y5e3{bottom:136.175400px;}
.y9a{bottom:136.249100px;}
.y147f{bottom:136.268700px;}
.y15b0{bottom:136.548500px;}
.ybb{bottom:136.557900px;}
.y107{bottom:136.596600px;}
.y1495{bottom:136.716000px;}
.yfa0{bottom:136.717600px;}
.ya0e{bottom:136.828700px;}
.yddb{bottom:136.919400px;}
.yf70{bottom:136.921300px;}
.y1417{bottom:137.054600px;}
.y1c2{bottom:137.084100px;}
.y14b4{bottom:137.243500px;}
.y1159{bottom:137.244100px;}
.ye2d{bottom:137.283000px;}
.yf0c{bottom:137.393100px;}
.y58d{bottom:137.478100px;}
.y15da{bottom:137.589900px;}
.y465{bottom:137.739600px;}
.ye5c{bottom:137.739800px;}
.yfd8{bottom:137.740100px;}
.yf0b{bottom:137.843600px;}
.yb1f{bottom:137.857900px;}
.y20c{bottom:137.889200px;}
.y85d{bottom:137.907900px;}
.y82a{bottom:138.017950px;}
.y21{bottom:138.133300px;}
.ybdc{bottom:138.252000px;}
.y383{bottom:138.386900px;}
.y247{bottom:138.407300px;}
.yf30{bottom:138.661900px;}
.y400{bottom:138.839900px;}
.yfbc{bottom:138.901900px;}
.yff6{bottom:138.904900px;}
.y1462{bottom:139.054700px;}
.y66e{bottom:139.062400px;}
.y9b5{bottom:139.354500px;}
.ycaf{bottom:139.393100px;}
.y545{bottom:139.475700px;}
.y432{bottom:139.490600px;}
.yc61{bottom:139.622200px;}
.ye83{bottom:139.738400px;}
.y14a{bottom:139.776200px;}
.y5ae{bottom:139.889200px;}
.yf86{bottom:139.903100px;}
.y87c{bottom:139.925300px;}
.ya9e{bottom:140.173400px;}
.ye0c{bottom:140.179600px;}
.y950{bottom:140.236500px;}
.y772{bottom:140.453400px;}
.y120d{bottom:140.461681px;}
.y120f{bottom:140.462300px;}
.y1144{bottom:140.510150px;}
.y14c6{bottom:140.565200px;}
.ycf7{bottom:140.566300px;}
.yba7{bottom:140.664100px;}
.yab4{bottom:140.896600px;}
.y74b{bottom:141.116400px;}
.yd26{bottom:141.251600px;}
.y493{bottom:141.251900px;}
.y1191{bottom:141.283600px;}
.y8cc{bottom:141.305800px;}
.y10d3{bottom:141.331000px;}
.y83b{bottom:141.586700px;}
.yd80{bottom:141.946700px;}
.yb3d{bottom:141.968700px;}
.yc29{bottom:142.028600px;}
.y120e{bottom:142.189800px;}
.yd0a{bottom:142.227800px;}
.y9fb{bottom:142.228100px;}
.y802{bottom:142.235900px;}
.y625{bottom:142.260400px;}
.yc6b{bottom:142.364100px;}
.y4f2{bottom:142.503200px;}
.y13aa{bottom:142.589950px;}
.y728{bottom:142.593900px;}
.y135d{bottom:142.767800px;}
.yc14{bottom:142.912800px;}
.y1430{bottom:142.913900px;}
.y3a7{bottom:143.034000px;}
.y109e{bottom:143.212900px;}
.y1298{bottom:143.249800px;}
.y675{bottom:143.340900px;}
.y121e{bottom:143.389700px;}
.y8ec{bottom:143.400500px;}
.y101a{bottom:143.408800px;}
.y6e9{bottom:143.513100px;}
.ya40{bottom:143.758100px;}
.yce1{bottom:143.843000px;}
.y151f{bottom:144.046700px;}
.y3f1{bottom:144.176300px;}
.y109d{bottom:144.212800px;}
.y655{bottom:144.271800px;}
.yea3{bottom:144.279600px;}
.y12f1{bottom:144.284700px;}
.y1055{bottom:144.423000px;}
.y976{bottom:144.574200px;}
.yc52{bottom:144.575200px;}
.y1554{bottom:144.575900px;}
.yadd{bottom:144.629200px;}
.y44c{bottom:144.731700px;}
.y144c{bottom:144.772600px;}
.y991{bottom:144.798000px;}
.y6fe{bottom:144.949500px;}
.y740{bottom:145.069900px;}
.y12a9{bottom:145.070800px;}
.y7f6{bottom:145.106400px;}
.ybc9{bottom:145.272400px;}
.y1377{bottom:145.407300px;}
.y1564{bottom:145.409400px;}
.yb2a{bottom:145.415000px;}
.y1596{bottom:145.558100px;}
.y51e{bottom:145.571000px;}
.y4e{bottom:145.780200px;}
.y73{bottom:145.795100px;}
.y354{bottom:146.219500px;}
.y120c{bottom:146.316519px;}
.y10bd{bottom:146.345900px;}
.y1582{bottom:146.393400px;}
.yebf{bottom:146.549650px;}
.y6a5{bottom:146.639700px;}
.ydee{bottom:146.663500px;}
.yf92{bottom:146.665500px;}
.y10e9{bottom:146.665900px;}
.y13ca{bottom:146.745900px;}
.y150a{bottom:146.919400px;}
.yedc{bottom:146.952250px;}
.y116d{bottom:147.070300px;}
.y1539{bottom:147.071400px;}
.y182{bottom:147.100800px;}
.ycc5{bottom:147.106400px;}
.y56f{bottom:147.134050px;}
.ybeb{bottom:147.142000px;}
.y1406{bottom:147.256000px;}
.y3d2{bottom:147.380400px;}
.y14e8{bottom:147.595500px;}
.y13ec{bottom:147.607200px;}
.ydc0{bottom:147.615350px;}
.y28c{bottom:147.729900px;}
.y114c{bottom:147.897100px;}
.y1275{bottom:147.897400px;}
.y1349{bottom:147.919100px;}
.y2fe{bottom:148.216500px;}
.y7dd{bottom:148.257400px;}
.ybed{bottom:148.310000px;}
.y851{bottom:148.328300px;}
.ye71{bottom:148.401000px;}
.y22f{bottom:148.408250px;}
.y25a{bottom:148.423100px;}
.y79d{bottom:148.535400px;}
.y15af{bottom:148.548900px;}
.y12d4{bottom:148.586700px;}
.y91d{bottom:148.729500px;}
.y1187{bottom:148.885400px;}
.yf6f{bottom:148.921700px;}
.yb5f{bottom:149.054000px;}
.ye6{bottom:149.055400px;}
.y4de{bottom:149.092800px;}
.y2b8{bottom:149.136100px;}
.ybea{bottom:149.142000px;}
.y5e2{bottom:149.175400px;}
.y99{bottom:149.249100px;}
.y147e{bottom:149.268700px;}
.yf9f{bottom:149.384200px;}
.y829{bottom:149.517700px;}
.yba{bottom:149.557900px;}
.y15d9{bottom:149.589900px;}
.y106{bottom:149.596600px;}
.y1494{bottom:149.716000px;}
.y15ec{bottom:149.739900px;}
.ydda{bottom:149.919400px;}
.y1416{bottom:150.054600px;}
.y60e{bottom:150.139750px;}
.y14a4{bottom:150.243500px;}
.y1158{bottom:150.244100px;}
.y130c{bottom:150.386100px;}
.yf09{bottom:150.393400px;}
.y8af{bottom:150.406100px;}
.y58c{bottom:150.478100px;}
.y93e{bottom:150.641600px;}
.y464{bottom:150.739600px;}
.ye5b{bottom:150.739800px;}
.yfd7{bottom:150.740100px;}
.yd59{bottom:150.763200px;}
.yb5b{bottom:150.841000px;}
.yf0a{bottom:150.843200px;}
.y122{bottom:150.888500px;}
.y20b{bottom:150.889200px;}
.y544{bottom:150.975450px;}
.y5cc{bottom:151.123900px;}
.y20{bottom:151.133300px;}
.ybdb{bottom:151.252000px;}
.y246{bottom:151.407300px;}
.yf2f{bottom:151.661900px;}
.ye3b{bottom:151.668700px;}
.y7c0{bottom:151.776850px;}
.y8fe{bottom:151.899900px;}
.yfbb{bottom:151.901900px;}
.yff5{bottom:151.904900px;}
.y1eb{bottom:151.941000px;}
.y1143{bottom:152.009900px;}
.y1461{bottom:152.054700px;}
.y66d{bottom:152.062400px;}
.ya18{bottom:152.143000px;}
.y11e7{bottom:152.168611px;}
.y120b{bottom:152.171357px;}
.y11c6{bottom:152.273477px;}
.y431{bottom:152.490600px;}
.y49e{bottom:152.699400px;}
.y5ad{bottom:152.889200px;}
.yf85{bottom:152.903100px;}
.ya9d{bottom:153.173400px;}
.ye0b{bottom:153.179600px;}
.ydb5{bottom:153.284000px;}
.yda8{bottom:153.286450px;}
.y771{bottom:153.453400px;}
.y14c5{bottom:153.565200px;}
.ycf6{bottom:153.566300px;}
.y12be{bottom:153.566400px;}
.yba6{bottom:153.664100px;}
.y1102{bottom:153.669500px;}
.y624{bottom:153.760150px;}
.yab3{bottom:153.896600px;}
.y102b{bottom:153.912800px;}
.y1197{bottom:153.947100px;}
.yd25{bottom:154.251600px;}
.y492{bottom:154.251900px;}
.y3{bottom:154.276380px;}
.y10d2{bottom:154.331000px;}
.y381{bottom:154.477500px;}
.y83a{bottom:154.586700px;}
.y13a9{bottom:154.590350px;}
.yc04{bottom:154.739600px;}
.y111a{bottom:154.775700px;}
.y49d{bottom:154.949400px;}
.y6e8{bottom:155.012850px;}
.yc28{bottom:155.028600px;}
.y801{bottom:155.235900px;}
.y4f1{bottom:155.503200px;}
.ye82{bottom:155.573400px;}
.y727{bottom:155.593900px;}
.y1c1{bottom:155.753100px;}
.yc13{bottom:155.912800px;}
.y102a{bottom:155.913100px;}
.y142f{bottom:155.913900px;}
.y1297{bottom:156.249800px;}
.y674{bottom:156.340900px;}
.y121d{bottom:156.389700px;}
.y8eb{bottom:156.400500px;}
.yfff{bottom:156.401000px;}
.y1019{bottom:156.408800px;}
.yce0{bottom:156.843000px;}
.y151e{bottom:157.046700px;}
.y8cb{bottom:157.140800px;}
.y3f0{bottom:157.176300px;}
.y109c{bottom:157.212800px;}
.y654{bottom:157.271800px;}
.yea2{bottom:157.279600px;}
.y12f0{bottom:157.284700px;}
.y1054{bottom:157.423000px;}
.y975{bottom:157.574200px;}
.yc51{bottom:157.575200px;}
.yfa1{bottom:157.618300px;}
.y144b{bottom:157.772600px;}
.y4d{bottom:157.779900px;}
.y72{bottom:157.794800px;}
.y990{bottom:157.798000px;}
.yb3c{bottom:157.803300px;}
.y6fd{bottom:157.949500px;}
.y12a8{bottom:158.070800px;}
.ybc8{bottom:158.272400px;}
.y1376{bottom:158.407300px;}
.y149{bottom:158.445200px;}
.yebe{bottom:158.550050px;}
.y1595{bottom:158.558100px;}
.y51d{bottom:158.571000px;}
.y56e{bottom:158.633800px;}
.y102c{bottom:158.912900px;}
.yedb{bottom:158.952650px;}
.y353{bottom:159.219500px;}
.y10bc{bottom:159.345900px;}
.y1581{bottom:159.393400px;}
.yb8b{bottom:159.406200px;}
.ya3f{bottom:159.593100px;}
.y14e7{bottom:159.595900px;}
.yd7f{bottom:159.615750px;}
.yded{bottom:159.663500px;}
.yf91{bottom:159.665500px;}
.y10e8{bottom:159.665900px;}
.y13c9{bottom:159.745900px;}
.y74a{bottom:159.785600px;}
.yc8a{bottom:159.821000px;}
.y22e{bottom:159.908000px;}
.y1509{bottom:159.919400px;}
.y1061{bottom:159.920900px;}
.y116c{bottom:160.070300px;}
.y1538{bottom:160.071400px;}
.y181{bottom:160.100800px;}
.ycc4{bottom:160.106400px;}
.y1405{bottom:160.256000px;}
.y3d1{bottom:160.380400px;}
.y13eb{bottom:160.607200px;}
.y2b7{bottom:160.635850px;}
.y1186{bottom:160.885800px;}
.y9fa{bottom:160.897100px;}
.y73f{bottom:160.904900px;}
.y1348{bottom:160.919100px;}
.y828{bottom:161.017450px;}
.y2fd{bottom:161.216500px;}
.y7dc{bottom:161.257400px;}
.ye70{bottom:161.401000px;}
.y259{bottom:161.423100px;}
.y135c{bottom:161.437100px;}
.y79c{bottom:161.535400px;}
.y12d3{bottom:161.586700px;}
.y15d8{bottom:161.589900px;}
.yf3e{bottom:161.601000px;}
.y3a6{bottom:161.703300px;}
.y91c{bottom:161.729500px;}
.y6a4{bottom:161.941150px;}
.yfe6{bottom:162.078100px;}
.y4dd{bottom:162.092800px;}
.y5e1{bottom:162.175400px;}
.y710{bottom:162.228100px;}
.y98{bottom:162.249100px;}
.y147d{bottom:162.268700px;}
.y130b{bottom:162.386500px;}
.y543{bottom:162.475200px;}
.yb9{bottom:162.557900px;}
.y94f{bottom:162.575400px;}
.y105{bottom:162.596600px;}
.y5cb{bottom:162.623650px;}
.yf9e{bottom:162.685300px;}
.y1493{bottom:162.716000px;}
.yd58{bottom:162.763600px;}
.ydd9{bottom:162.919400px;}
.y14b3{bottom:163.243500px;}
.y1157{bottom:163.244100px;}
.y1553{bottom:163.244900px;}
.y7bf{bottom:163.276600px;}
.y120a{bottom:163.312462px;}
.yf08{bottom:163.393400px;}
.y58b{bottom:163.478100px;}
.y1142{bottom:163.509650px;}
.y463{bottom:163.739600px;}
.ye5a{bottom:163.739800px;}
.y7f5{bottom:163.775700px;}
.y317{bottom:163.872500px;}
.y20a{bottom:163.889200px;}
.ya0d{bottom:164.001600px;}
.y1563{bottom:164.078400px;}
.yf3d{bottom:164.226100px;}
.y245{bottom:164.407300px;}
.y60d{bottom:164.474300px;}
.yf2e{bottom:164.661900px;}
.y8fd{bottom:164.899900px;}
.yfba{bottom:164.901900px;}
.yff4{bottom:164.904900px;}
.yb1e{bottom:165.031100px;}
.y93d{bottom:165.058600px;}
.y66c{bottom:165.062400px;}
.y85c{bottom:165.081500px;}
.y623{bottom:165.259900px;}
.ydb4{bottom:165.284400px;}
.yda7{bottom:165.286850px;}
.y430{bottom:165.490600px;}
.yf84{bottom:165.903100px;}
.y1f{bottom:166.133300px;}
.ya9c{bottom:166.173400px;}
.ye0a{bottom:166.179600px;}
.y15ae{bottom:166.217950px;}
.y28b{bottom:166.399200px;}
.y770{bottom:166.453400px;}
.y6e7{bottom:166.512600px;}
.y9b4{bottom:166.527700px;}
.y14c4{bottom:166.565200px;}
.ycae{bottom:166.566300px;}
.y1274{bottom:166.566400px;}
.yf6e{bottom:166.590750px;}
.y121{bottom:166.723500px;}
.yc60{bottom:166.795200px;}
.yab2{bottom:166.896600px;}
.y87b{bottom:167.098500px;}
.yd24{bottom:167.251600px;}
.y491{bottom:167.251900px;}
.y10d1{bottom:167.331000px;}
.y1017{bottom:167.408900px;}
.y6a2{bottom:167.690900px;}
.ye5{bottom:167.724400px;}
.yc03{bottom:167.739600px;}
.y6a1{bottom:167.767400px;}
.y1119{bottom:167.775700px;}
.yc27{bottom:168.028600px;}
.y4f0{bottom:168.503200px;}
.ye81{bottom:168.573400px;}
.y726{bottom:168.593900px;}
.y1415{bottom:168.723800px;}
.y1c0{bottom:168.753100px;}
.yc12{bottom:168.912800px;}
.y1029{bottom:168.913100px;}
.y8ae{bottom:169.075100px;}
.y1073{bottom:169.101400px;}
.y1207{bottom:169.166446px;}
.y1209{bottom:169.167300px;}
.y1296{bottom:169.249800px;}
.y1016{bottom:169.408800px;}
.yfd6{bottom:169.409100px;}
.y4c{bottom:169.779600px;}
.y71{bottom:169.794500px;}
.ycdf{bottom:169.843000px;}
.y151d{bottom:170.046700px;}
.y8ca{bottom:170.140800px;}
.y3ef{bottom:170.176300px;}
.y109b{bottom:170.212800px;}
.y653{bottom:170.271800px;}
.yea1{bottom:170.279600px;}
.y12ef{bottom:170.284700px;}
.y1052{bottom:170.423000px;}
.y382{bottom:170.568000px;}
.yd3a{bottom:170.574200px;}
.yc50{bottom:170.575200px;}
.yafe{bottom:170.597000px;}
.ye42{bottom:170.639300px;}
.y1460{bottom:170.723800px;}
.y144a{bottom:170.772600px;}
.y98f{bottom:170.798000px;}
.y1208{bottom:170.894900px;}
.y6fc{bottom:170.949500px;}
.yeda{bottom:170.953050px;}
.ycd{bottom:171.061900px;}
.y12a7{bottom:171.070800px;}
.ybc7{bottom:171.272400px;}
.y10bb{bottom:171.345900px;}
.y22d{bottom:171.407750px;}
.y148{bottom:171.445200px;}
.y1594{bottom:171.558100px;}
.y51c{bottom:171.571000px;}
.y14e6{bottom:171.596300px;}
.yd7e{bottom:171.616150px;}
.y56d{bottom:171.759050px;}
.yadc{bottom:171.802400px;}
.y2b6{bottom:172.135600px;}
.y352{bottom:172.219500px;}
.y8ea{bottom:172.235500px;}
.y13a8{bottom:172.259400px;}
.y10ba{bottom:172.345900px;}
.y1580{bottom:172.393400px;}
.yb8a{bottom:172.406200px;}
.y1018{bottom:172.409000px;}
.y827{bottom:172.517200px;}
.ya3e{bottom:172.593100px;}
.ydec{bottom:172.663500px;}
.y10e7{bottom:172.665900px;}
.y4af{bottom:172.717600px;}
.y13c8{bottom:172.745900px;}
.y1185{bottom:172.886200px;}
.y1508{bottom:172.919400px;}
.y1060{bottom:172.920900px;}
.y116b{bottom:173.070300px;}
.y1537{bottom:173.071400px;}
.y180{bottom:173.100800px;}
.ycc3{bottom:173.106400px;}
.y1404{bottom:173.256000px;}
.y3d0{bottom:173.380400px;}
.y974{bottom:173.408800px;}
.y1053{bottom:173.423100px;}
.y6a3{bottom:173.440900px;}
.y15d7{bottom:173.589900px;}
.y13ea{bottom:173.607200px;}
.y9f9{bottom:173.897100px;}
.y44b{bottom:173.904900px;}
.y1347{bottom:173.919100px;}
.y5ca{bottom:174.123400px;}
.y7db{bottom:174.257400px;}
.y130a{bottom:174.386900px;}
.ye6f{bottom:174.401000px;}
.y9d9{bottom:174.417000px;}
.y258{bottom:174.423100px;}
.y79b{bottom:174.535400px;}
.y14a3{bottom:174.582100px;}
.y142e{bottom:174.582900px;}
.y91b{bottom:174.729500px;}
.y1141{bottom:175.009400px;}
.y673{bottom:175.010100px;}
.y1206{bottom:175.021284px;}
.y121c{bottom:175.058900px;}
.yfe5{bottom:175.078100px;}
.y4dc{bottom:175.092800px;}
.y41d{bottom:175.127350px;}
.y5e0{bottom:175.175400px;}
.y70f{bottom:175.228100px;}
.y97{bottom:175.249100px;}
.y147c{bottom:175.268700px;}
.yb8{bottom:175.557900px;}
.y94e{bottom:175.575400px;}
.y104{bottom:175.596600px;}
.y1492{bottom:175.716000px;}
.ydd8{bottom:175.919400px;}
.y60c{bottom:175.974050px;}
.yebd{bottom:176.219100px;}
.y14b2{bottom:176.243500px;}
.y1156{bottom:176.244100px;}
.y1552{bottom:176.244900px;}
.yf07{bottom:176.393400px;}
.y462{bottom:176.739600px;}
.ye59{bottom:176.739800px;}
.y542{bottom:176.839850px;}
.y316{bottom:176.872500px;}
.y209{bottom:176.889200px;}
.ya0c{bottom:177.001600px;}
.y1562{bottom:177.078400px;}
.ydb3{bottom:177.284800px;}
.yda6{bottom:177.287250px;}
.y244{bottom:177.407300px;}
.y56b{bottom:177.508800px;}
.y8fc{bottom:177.899900px;}
.yfb9{bottom:177.901900px;}
.yff3{bottom:177.904900px;}
.ybab{bottom:178.003000px;}
.yb1d{bottom:178.031100px;}
.y66b{bottom:178.062400px;}
.y15ad{bottom:178.218350px;}
.y42f{bottom:178.490600px;}
.yf6d{bottom:178.591150px;}
.yf83{bottom:178.903100px;}
.ye41{bottom:179.046500px;}
.ya9b{bottom:179.173400px;}
.ye09{bottom:179.179600px;}
.y76f{bottom:179.453400px;}
.y93c{bottom:179.475600px;}
.y9b3{bottom:179.527700px;}
.ycad{bottom:179.566300px;}
.y1273{bottom:179.566400px;}
.y120{bottom:179.723500px;}
.y6e6{bottom:179.734500px;}
.yc5f{bottom:179.795200px;}
.yab1{bottom:179.896600px;}
.y5ac{bottom:180.062400px;}
.y85b{bottom:180.081100px;}
.y490{bottom:180.251900px;}
.y12d2{bottom:180.256000px;}
.y10d0{bottom:180.331000px;}
.yd57{bottom:180.432650px;}
.y622{bottom:180.489200px;}
.y11c5{bottom:180.558893px;}
.yc02{bottom:180.739600px;}
.y1118{bottom:180.775700px;}
.y11e6{bottom:180.842585px;}
.y11e3{bottom:180.843104px;}
.y1205{bottom:180.876123px;}
.y483{bottom:180.932400px;}
.yc26{bottom:181.028600px;}
.y7be{bottom:181.052800px;}
.y1072{bottom:181.101100px;}
.y1ea{bottom:181.115700px;}
.y1e{bottom:181.133300px;}
.y958{bottom:181.321400px;}
.ybe3{bottom:181.421000px;}
.y4ef{bottom:181.503200px;}
.ye80{bottom:181.573400px;}
.y725{bottom:181.593900px;}
.y1bf{bottom:181.753100px;}
.y839{bottom:181.759900px;}
.y4b{bottom:181.779300px;}
.y70{bottom:181.794500px;}
.yc11{bottom:181.912800px;}
.y1028{bottom:181.913100px;}
.y8ad{bottom:182.075100px;}
.y58a{bottom:182.147100px;}
.y109a{bottom:182.212800px;}
.y1295{bottom:182.249800px;}
.y14c3{bottom:182.400200px;}
.y1015{bottom:182.408800px;}
.yfd5{bottom:182.409100px;}
.y540{bottom:182.589600px;}
.y1101{bottom:182.842700px;}
.ycde{bottom:182.843000px;}
.y22c{bottom:182.907500px;}
.y1190{bottom:182.953450px;}
.y151c{bottom:183.046700px;}
.y2fc{bottom:183.051500px;}
.ye3e{bottom:183.077300px;}
.y850{bottom:183.172100px;}
.y3ee{bottom:183.176300px;}
.y1099{bottom:183.212800px;}
.y56c{bottom:183.258800px;}
.y652{bottom:183.271800px;}
.yea0{bottom:183.279600px;}
.y12ee{bottom:183.284700px;}
.yf2d{bottom:183.330900px;}
.y1050{bottom:183.423000px;}
.yd39{bottom:183.574200px;}
.yc4f{bottom:183.575200px;}
.ydbf{bottom:183.616550px;}
.y2b5{bottom:183.635350px;}
.yb76{bottom:183.669500px;}
.yf52{bottom:183.713550px;}
.y1449{bottom:183.772600px;}
.y98e{bottom:183.798000px;}
.y6fb{bottom:183.949500px;}
.ycc{bottom:184.061900px;}
.y12a6{bottom:184.070800px;}
.y4ae{bottom:184.217350px;}
.y13a7{bottom:184.259800px;}
.ybc6{bottom:184.272400px;}
.y34e{bottom:184.408900px;}
.y147{bottom:184.445200px;}
.y51b{bottom:184.571000px;}
.yadb{bottom:184.802400px;}
.yb3b{bottom:184.976500px;}
.y8e9{bottom:185.235500px;}
.yd09{bottom:185.235600px;}
.y10b9{bottom:185.345900px;}
.y157f{bottom:185.393400px;}
.y1375{bottom:185.580900px;}
.y15d6{bottom:185.589900px;}
.ydeb{bottom:185.663500px;}
.y13c7{bottom:185.745900px;}
.y1507{bottom:185.919400px;}
.yd23{bottom:185.920600px;}
.y105f{bottom:185.920900px;}
.y8c9{bottom:185.975800px;}
.y116a{bottom:186.070300px;}
.y1536{bottom:186.071400px;}
.y17f{bottom:186.100800px;}
.ycc2{bottom:186.106400px;}
.y1403{bottom:186.256000px;}
.y3cf{bottom:186.380400px;}
.y1309{bottom:186.387300px;}
.ye4{bottom:186.393400px;}
.y11c4{bottom:186.412693px;}
.y11c8{bottom:186.413212px;}
.y1051{bottom:186.423100px;}
.yafd{bottom:186.431600px;}
.y13e9{bottom:186.607200px;}
.y41c{bottom:186.627100px;}
.y11e5{bottom:186.697423px;}
.y11e2{bottom:186.697942px;}
.y1204{bottom:186.730961px;}
.yf90{bottom:186.839100px;}
.y9f8{bottom:186.897100px;}
.y44a{bottom:186.904900px;}
.y1346{bottom:186.919100px;}
.y380{bottom:187.053700px;}
.y1593{bottom:187.393100px;}
.ye6e{bottom:187.401000px;}
.y257{bottom:187.423100px;}
.y79a{bottom:187.535400px;}
.y14a2{bottom:187.582100px;}
.y142d{bottom:187.582900px;}
.yfe4{bottom:188.078100px;}
.y4db{bottom:188.092800px;}
.y5df{bottom:188.175400px;}
.yebc{bottom:188.219500px;}
.y70e{bottom:188.228100px;}
.yb89{bottom:188.241200px;}
.y96{bottom:188.249100px;}
.y147b{bottom:188.268700px;}
.y541{bottom:188.339600px;}
.ya3d{bottom:188.427700px;}
.y5c9{bottom:188.458900px;}
.y10e6{bottom:188.500500px;}
.y94d{bottom:188.575400px;}
.y103{bottom:188.596600px;}
.yed9{bottom:188.622100px;}
.y1491{bottom:188.716000px;}
.y6a0{bottom:188.742100px;}
.y826{bottom:188.746500px;}
.ydd7{bottom:188.919400px;}
.y749{bottom:188.958900px;}
.y14b1{bottom:189.243500px;}
.y1155{bottom:189.244100px;}
.y1551{bottom:189.244900px;}
.y14e5{bottom:189.265350px;}
.yd7d{bottom:189.285200px;}
.yf06{bottom:189.393400px;}
.y461{bottom:189.739600px;}
.ye58{bottom:189.739800px;}
.y315{bottom:189.872500px;}
.y208{bottom:189.889200px;}
.y672{bottom:190.010100px;}
.y1561{bottom:190.078400px;}
.y7f4{bottom:190.114200px;}
.y60b{bottom:190.308600px;}
.y1184{bottom:190.555250px;}
.y91a{bottom:190.564500px;}
.yf6c{bottom:190.591550px;}
.y135b{bottom:190.610300px;}
.y748{bottom:190.721400px;}
.y3a5{bottom:190.876500px;}
.y351{bottom:190.888800px;}
.yfb8{bottom:190.901900px;}
.yff2{bottom:190.904900px;}
.yb1c{bottom:191.031100px;}
.y66a{bottom:191.062400px;}
.y6e5{bottom:191.234250px;}
.y1140{bottom:191.318200px;}
.y42e{bottom:191.490600px;}
.yf82{bottom:191.903100px;}
.y621{bottom:191.988950px;}
.ya9a{bottom:192.173400px;}
.ye08{bottom:192.179600px;}
.y11c3{bottom:192.268050px;}
.y11c7{bottom:192.268569px;}
.y482{bottom:192.432150px;}
.yd56{bottom:192.433050px;}
.y76e{bottom:192.453400px;}
.y9b2{bottom:192.527700px;}
.y11e4{bottom:192.552261px;}
.y7bd{bottom:192.552550px;}
.y11e1{bottom:192.552780px;}
.ycac{bottom:192.566300px;}
.y1272{bottom:192.566400px;}
.y1203{bottom:192.585799px;}
.y132e{bottom:192.746400px;}
.yc5e{bottom:192.795200px;}
.ya0b{bottom:192.836600px;}
.yab0{bottom:192.896600px;}
.y1414{bottom:193.062400px;}
.y1071{bottom:193.100800px;}
.y8fb{bottom:193.734900px;}
.yc01{bottom:193.739600px;}
.y1117{bottom:193.775700px;}
.y4a{bottom:193.779000px;}
.y93b{bottom:193.892600px;}
.y1e9{bottom:194.115700px;}
.y22b{bottom:194.407250px;}
.ye7f{bottom:194.573400px;}
.y724{bottom:194.593900px;}
.y1be{bottom:194.753100px;}
.yc10{bottom:194.912800px;}
.y1027{bottom:194.913100px;}
.ydb2{bottom:194.953850px;}
.yda5{bottom:194.956300px;}
.y145f{bottom:195.062400px;}
.y2b4{bottom:195.135100px;}
.y589{bottom:195.147100px;}
.y1294{bottom:195.249800px;}
.y766{bottom:195.287700px;}
.y14c2{bottom:195.400200px;}
.y1014{bottom:195.408800px;}
.yfd4{bottom:195.409100px;}
.y11f{bottom:195.558500px;}
.y28a{bottom:195.572400px;}
.y1196{bottom:195.616950px;}
.y4ad{bottom:195.717100px;}
.y1100{bottom:195.842700px;}
.ycdd{bottom:195.843000px;}
.y15ac{bottom:195.887400px;}
.y151b{bottom:196.046700px;}
.y2fb{bottom:196.051500px;}
.y243{bottom:196.076300px;}
.y84f{bottom:196.172100px;}
.y3ed{bottom:196.176300px;}
.y1098{bottom:196.212800px;}
.y13a6{bottom:196.260200px;}
.y651{bottom:196.271800px;}
.ye9f{bottom:196.279600px;}
.y12ed{bottom:196.284700px;}
.yf2c{bottom:196.330900px;}
.y104e{bottom:196.423000px;}
.ye43{bottom:196.503900px;}
.yd38{bottom:196.574200px;}
.yb75{bottom:196.669500px;}
.y1448{bottom:196.772600px;}
.yc25{bottom:196.863300px;}
.y6fa{bottom:196.949500px;}
.yb7{bottom:197.061900px;}
.y12a5{bottom:197.070800px;}
.yf9d{bottom:197.203900px;}
.ybc5{bottom:197.272400px;}
.y34d{bottom:197.408900px;}
.y146{bottom:197.445200px;}
.y15d5{bottom:197.589900px;}
.y15e5{bottom:197.739900px;}
.y973{bottom:197.747700px;}
.yada{bottom:197.802400px;}
.yf51{bottom:198.048100px;}
.yd08{bottom:198.235600px;}
.y56a{bottom:198.324900px;}
.y10b8{bottom:198.345900px;}
.y1308{bottom:198.387700px;}
.y157e{bottom:198.393400px;}
.y1202{bottom:198.440637px;}
.ydea{bottom:198.663500px;}
.y13c6{bottom:198.745900px;}
.yd22{bottom:198.920600px;}
.y48f{bottom:198.920900px;}
.y8c8{bottom:198.975800px;}
.y10cf{bottom:199.000000px;}
.y1169{bottom:199.070300px;}
.y1394{bottom:199.074100px;}
.y17e{bottom:199.100800px;}
.ycc1{bottom:199.106400px;}
.y1457{bottom:199.256000px;}
.y3ce{bottom:199.380400px;}
.y121b{bottom:199.397500px;}
.y104f{bottom:199.423100px;}
.y13e8{bottom:199.607200px;}
.y98d{bottom:199.632700px;}
.y9f7{bottom:199.897100px;}
.y449{bottom:199.904900px;}
.y1345{bottom:199.919100px;}
.y7da{bottom:200.013300px;}
.y4ee{bottom:200.172500px;}
.yebb{bottom:200.219900px;}
.y825{bottom:200.246250px;}
.y1592{bottom:200.393100px;}
.ye6d{bottom:200.401000px;}
.y256{bottom:200.423100px;}
.y799{bottom:200.535400px;}
.y1374{bottom:200.580500px;}
.ya2f{bottom:200.582100px;}
.y142c{bottom:200.582900px;}
.yed8{bottom:200.622500px;}
.y8ac{bottom:200.744100px;}
.yb3a{bottom:200.811200px;}
.y41b{bottom:200.963750px;}
.yfe3{bottom:201.078100px;}
.y4da{bottom:201.092800px;}
.y5de{bottom:201.175400px;}
.y70d{bottom:201.228100px;}
.yb88{bottom:201.241200px;}
.y95{bottom:201.249100px;}
.y14e4{bottom:201.265750px;}
.y147a{bottom:201.268700px;}
.yd7c{bottom:201.285600px;}
.y102{bottom:201.596600px;}
.y1490{bottom:201.716000px;}
.y60a{bottom:201.808350px;}
.yf8f{bottom:201.838700px;}
.ydd6{bottom:201.919400px;}
.y87a{bottom:201.941000px;}
.y14b0{bottom:202.243500px;}
.yc4e{bottom:202.244200px;}
.y1550{bottom:202.244900px;}
.yf05{bottom:202.393400px;}
.y8e8{bottom:202.487400px;}
.y1183{bottom:202.555650px;}
.y6e4{bottom:202.734000px;}
.y460{bottom:202.739600px;}
.ye57{bottom:202.739800px;}
.y5c8{bottom:202.793450px;}
.y6f{bottom:202.800200px;}
.y113f{bottom:202.817950px;}
.y207{bottom:202.889200px;}
.y2ce{bottom:203.078100px;}
.y1560{bottom:203.078400px;}
.y519{bottom:203.240300px;}
.y620{bottom:203.488700px;}
.y135a{bottom:203.610300px;}
.y3a4{bottom:203.876500px;}
.yfb7{bottom:203.901900px;}
.yff1{bottom:203.904900px;}
.y481{bottom:203.931900px;}
.yb1b{bottom:204.031100px;}
.y669{bottom:204.062400px;}
.ye36{bottom:204.132900px;}
.y42d{bottom:204.490600px;}
.y1506{bottom:204.588400px;}
.y12d1{bottom:204.594600px;}
.y53f{bottom:204.645900px;}
.y1535{bottom:204.740400px;}
.yf81{bottom:204.903100px;}
.y1402{bottom:204.925300px;}
.ye3{bottom:205.062400px;}
.y1070{bottom:205.100500px;}
.y75a{bottom:205.119200px;}
.ya99{bottom:205.173400px;}
.y69b{bottom:205.227800px;}
.y76d{bottom:205.453400px;}
.y9b1{bottom:205.527700px;}
.ycab{bottom:205.566300px;}
.y12bd{bottom:205.566400px;}
.y49{bottom:205.778700px;}
.yc5d{bottom:205.795200px;}
.ya0a{bottom:205.836600px;}
.yaaf{bottom:205.896600px;}
.y22a{bottom:205.907000px;}
.y1413{bottom:206.062400px;}
.ye3d{bottom:206.502200px;}
.y2b3{bottom:206.634850px;}
.y8fa{bottom:206.734900px;}
.yc00{bottom:206.739600px;}
.y51a{bottom:206.740400px;}
.y1116{bottom:206.775700px;}
.y7bc{bottom:206.887100px;}
.ydb1{bottom:206.954250px;}
.yda4{bottom:206.956700px;}
.y1e8{bottom:207.115700px;}
.y94c{bottom:207.244400px;}
.ye7e{bottom:207.573400px;}
.y723{bottom:207.593900px;}
.y15ab{bottom:207.887800px;}
.yc0f{bottom:207.912800px;}
.y1026{bottom:207.913100px;}
.y145e{bottom:208.062400px;}
.y588{bottom:208.147100px;}
.y1293{bottom:208.249800px;}
.yf6b{bottom:208.260600px;}
.y765{bottom:208.287700px;}
.y93a{bottom:208.309600px;}
.y14c1{bottom:208.400200px;}
.y1013{bottom:208.408800px;}
.yfd3{bottom:208.409100px;}
.y37f{bottom:208.557600px;}
.y11e{bottom:208.558500px;}
.y289{bottom:208.572400px;}
.y10a8{bottom:208.745700px;}
.y1201{bottom:208.805662px;}
.y10ff{bottom:208.842700px;}
.ycdc{bottom:208.843000px;}
.y151a{bottom:209.046700px;}
.y2fa{bottom:209.051500px;}
.y242{bottom:209.076300px;}
.y84e{bottom:209.172100px;}
.y3ec{bottom:209.176300px;}
.y918{bottom:209.233800px;}
.y650{bottom:209.271800px;}
.ye9e{bottom:209.279600px;}
.y12ec{bottom:209.284700px;}
.yf2b{bottom:209.330900px;}
.y6b8{bottom:209.409700px;}
.y104c{bottom:209.423000px;}
.yf50{bottom:209.547850px;}
.yd37{bottom:209.574200px;}
.y15d4{bottom:209.589900px;}
.yb74{bottom:209.669500px;}
.y1447{bottom:209.772600px;}
.yb6{bottom:210.061900px;}
.yd55{bottom:210.102100px;}
.ybc4{bottom:210.272400px;}
.y34c{bottom:210.408900px;}
.y145{bottom:210.445200px;}
.y1bd{bottom:210.588100px;}
.y972{bottom:210.747700px;}
.yad9{bottom:210.802400px;}
.ye07{bottom:210.848900px;}
.yd07{bottom:211.235600px;}
.y273{bottom:211.294450px;}
.y569{bottom:211.324900px;}
.y10b7{bottom:211.345900px;}
.y157d{bottom:211.393400px;}
.yde9{bottom:211.663500px;}
.y314{bottom:211.707500px;}
.y13c5{bottom:211.745900px;}
.y824{bottom:211.746000px;}
.yd21{bottom:211.920600px;}
.y48e{bottom:211.920900px;}
.y132d{bottom:211.959800px;}
.y10ce{bottom:212.000000px;}
.y1097{bottom:212.047400px;}
.y1168{bottom:212.070300px;}
.y1393{bottom:212.074100px;}
.y17d{bottom:212.100800px;}
.ycc0{bottom:212.106400px;}
.y4ab{bottom:212.112550px;}
.y1456{bottom:212.256000px;}
.y3cd{bottom:212.380400px;}
.y104d{bottom:212.423100px;}
.y41a{bottom:212.463500px;}
.y13e7{bottom:212.607200px;}
.yed7{bottom:212.622900px;}
.y919{bottom:212.733900px;}
.y9f6{bottom:212.897100px;}
.y448{bottom:212.904900px;}
.y1344{bottom:212.919100px;}
.y512{bottom:213.123900px;}
.y14e3{bottom:213.266150px;}
.yd7b{bottom:213.286000px;}
.y1591{bottom:213.393100px;}
.ye6c{bottom:213.401000px;}
.y255{bottom:213.423100px;}
.y798{bottom:213.535400px;}
.ya2e{bottom:213.582100px;}
.y142b{bottom:213.582900px;}
.yafc{bottom:213.604800px;}
.y13a5{bottom:213.929250px;}
.y1134{bottom:213.981450px;}
.yfe2{bottom:214.078100px;}
.y4d9{bottom:214.092800px;}
.y70c{bottom:214.228100px;}
.y94{bottom:214.249100px;}
.y1479{bottom:214.268700px;}
.y5c7{bottom:214.293200px;}
.y113e{bottom:214.317700px;}
.y121a{bottom:214.397500px;}
.y1182{bottom:214.556050px;}
.y101{bottom:214.596600px;}
.y11fe{bottom:214.659150px;}
.y1200{bottom:214.660500px;}
.y6e{bottom:214.799900px;}
.y5ab{bottom:214.905200px;}
.ydd5{bottom:214.919400px;}
.y879{bottom:214.941000px;}
.y14af{bottom:215.243500px;}
.yc4d{bottom:215.244200px;}
.y154f{bottom:215.244900px;}
.ya3c{bottom:215.600700px;}
.y6f9{bottom:215.618500px;}
.y10e5{bottom:215.673700px;}
.y45f{bottom:215.739600px;}
.ye56{bottom:215.739800px;}
.y206{bottom:215.889200px;}
.y6e3{bottom:215.955900px;}
.y892{bottom:216.035000px;}
.y2cd{bottom:216.078100px;}
.y155f{bottom:216.078400px;}
.y8c7{bottom:216.227800px;}
.y11ff{bottom:216.388000px;}
.yf9c{bottom:216.522400px;}
.y8ab{bottom:216.579100px;}
.y838{bottom:216.602700px;}
.y1359{bottom:216.610300px;}
.y3a3{bottom:216.876500px;}
.yfb6{bottom:216.901900px;}
.y114b{bottom:216.904900px;}
.yb1a{bottom:217.031100px;}
.y668{bottom:217.062400px;}
.yb87{bottom:217.076200px;}
.y106f{bottom:217.100200px;}
.y350{bottom:217.227800px;}
.y42c{bottom:217.490600px;}
.y1505{bottom:217.588400px;}
.y53e{bottom:217.645900px;}
.y1534{bottom:217.740400px;}
.y48{bottom:217.778700px;}
.yf80{bottom:217.903100px;}
.y2b2{bottom:218.134600px;}
.y2b1{bottom:218.134750px;}
.ya98{bottom:218.173400px;}
.y69a{bottom:218.227800px;}
.y7bb{bottom:218.386850px;}
.y61f{bottom:218.390250px;}
.y76c{bottom:218.453400px;}
.y9b0{bottom:218.527700px;}
.ycaa{bottom:218.566300px;}
.y73e{bottom:218.574200px;}
.yc5c{bottom:218.795200px;}
.yd95{bottom:218.954650px;}
.yda3{bottom:218.957100px;}
.y609{bottom:218.977700px;}
.y1412{bottom:219.062400px;}
.y1d{bottom:219.331600px;}
.y759{bottom:219.454200px;}
.y480{bottom:219.479250px;}
.y12d0{bottom:219.594600px;}
.y8f9{bottom:219.734900px;}
.ybff{bottom:219.739600px;}
.y1115{bottom:219.775700px;}
.y5dd{bottom:219.844400px;}
.y94b{bottom:220.244400px;}
.yf6a{bottom:220.261000px;}
.y148f{bottom:220.385200px;}
.y872{bottom:220.460950px;}
.y11fd{bottom:220.513988px;}
.yeed{bottom:220.588400px;}
.y722{bottom:220.593900px;}
.y229{bottom:220.732750px;}
.yc0e{bottom:220.912800px;}
.y1025{bottom:220.913100px;}
.yf4f{bottom:221.047600px;}
.yf04{bottom:221.062400px;}
.y1292{bottom:221.249800px;}
.y764{bottom:221.287700px;}
.y1012{bottom:221.408800px;}
.yfd2{bottom:221.409100px;}
.y37e{bottom:221.557600px;}
.y288{bottom:221.572400px;}
.y15d3{bottom:221.589900px;}
.ya09{bottom:221.671200px;}
.yaae{bottom:221.731300px;}
.y10fe{bottom:221.842700px;}
.ycdb{bottom:221.843000px;}
.y1519{bottom:222.046700px;}
.y2f9{bottom:222.051500px;}
.yd54{bottom:222.102500px;}
.y84d{bottom:222.172100px;}
.y3eb{bottom:222.176300px;}
.y917{bottom:222.233800px;}
.y64f{bottom:222.271800px;}
.ye9d{bottom:222.279600px;}
.y12eb{bottom:222.284700px;}
.yf2a{bottom:222.330900px;}
.y6b7{bottom:222.409700px;}
.y104b{bottom:222.423000px;}
.yd36{bottom:222.574200px;}
.yb73{bottom:222.669500px;}
.y939{bottom:222.726600px;}
.y1446{bottom:222.772600px;}
.y272{bottom:222.794200px;}
.yb5{bottom:223.061900px;}
.ybc3{bottom:223.272400px;}
.ye7d{bottom:223.408400px;}
.y34b{bottom:223.408900px;}
.y144{bottom:223.445200px;}
.y1bc{bottom:223.588100px;}
.y4a9{bottom:223.612300px;}
.ye2{bottom:223.731400px;}
.y971{bottom:223.747700px;}
.yad8{bottom:223.802400px;}
.y132c{bottom:223.960200px;}
.y419{bottom:223.963250px;}
.y98c{bottom:223.971200px;}
.yc24{bottom:224.036500px;}
.y4ac{bottom:224.222500px;}
.y14c0{bottom:224.235200px;}
.yd06{bottom:224.235600px;}
.y10b6{bottom:224.345900px;}
.y157c{bottom:224.393400px;}
.y1307{bottom:224.560900px;}
.yed6{bottom:224.623300px;}
.yde8{bottom:224.663500px;}
.y13c4{bottom:224.745900px;}
.y1ac{bottom:224.911000px;}
.yd20{bottom:224.920600px;}
.y48d{bottom:224.920900px;}
.y7f3{bottom:224.956700px;}
.y10cd{bottom:225.000000px;}
.y1392{bottom:225.074100px;}
.y14e2{bottom:225.266550px;}
.ydbe{bottom:225.286400px;}
.y3cc{bottom:225.380400px;}
.y8e7{bottom:225.404900px;}
.y1133{bottom:225.481200px;}
.y15aa{bottom:225.556850px;}
.y13e6{bottom:225.607200px;}
.y1e7{bottom:225.784700px;}
.y5c6{bottom:225.792950px;}
.y113d{bottom:225.817450px;}
.y9f5{bottom:225.897100px;}
.y447{bottom:225.904900px;}
.y13a4{bottom:225.929650px;}
.y2d2{bottom:226.001800px;}
.y511{bottom:226.041050px;}
.y11bc{bottom:226.264086px;}
.y11fc{bottom:226.368827px;}
.yeba{bottom:226.393100px;}
.ye6b{bottom:226.401000px;}
.y254{bottom:226.423100px;}
.y4aa{bottom:226.462300px;}
.y11e0{bottom:226.516133px;}
.y11d9{bottom:226.517171px;}
.y797{bottom:226.535400px;}
.ya2d{bottom:226.582100px;}
.y142a{bottom:226.582900px;}
.y6d{bottom:226.799600px;}
.yfe1{bottom:227.078100px;}
.y4d8{bottom:227.092800px;}
.y11d{bottom:227.227800px;}
.y93{bottom:227.249100px;}
.y1478{bottom:227.268700px;}
.y6e2{bottom:227.455650px;}
.y313{bottom:227.542500px;}
.y100{bottom:227.596600px;}
.y2d1{bottom:227.764300px;}
.y5aa{bottom:227.905200px;}
.y878{bottom:227.941000px;}
.yb39{bottom:227.984200px;}
.y823{bottom:227.989400px;}
.yc4c{bottom:228.244200px;}
.y154e{bottom:228.244900px;}
.ya3b{bottom:228.600700px;}
.y6f8{bottom:228.618500px;}
.y10e4{bottom:228.673700px;}
.y45e{bottom:228.739600px;}
.ye55{bottom:228.739800px;}
.y205{bottom:228.889200px;}
.y1c{bottom:228.931600px;}
.y2cc{bottom:229.078100px;}
.y155e{bottom:229.078400px;}
.y106e{bottom:229.099900px;}
.y1401{bottom:229.264300px;}
.yafb{bottom:229.439500px;}
.y518{bottom:229.578900px;}
.y837{bottom:229.602700px;}
.y1358{bottom:229.610300px;}
.y3a2{bottom:229.876500px;}
.y61e{bottom:229.890000px;}
.yfb5{bottom:229.901900px;}
.y114a{bottom:229.904900px;}
.y667{bottom:230.062400px;}
.y684{bottom:230.171500px;}
.y681{bottom:230.171550px;}
.y1319{bottom:230.291950px;}
.y42b{bottom:230.490600px;}
.y1504{bottom:230.588400px;}
.y1167{bottom:230.739600px;}
.y17c{bottom:230.769800px;}
.yf7f{bottom:230.903100px;}
.y1455{bottom:230.925300px;}
.yd7a{bottom:230.955050px;}
.yda2{bottom:230.957500px;}
.y47f{bottom:230.979000px;}
.y14ae{bottom:231.078100px;}
.ya97{bottom:231.173400px;}
.y76b{bottom:231.453400px;}
.yca9{bottom:231.566300px;}
.y1343{bottom:231.588100px;}
.yc5b{bottom:231.795200px;}
.y871{bottom:231.960700px;}
.y11c2{bottom:232.117887px;}
.y11bb{bottom:232.118924px;}
.y11fb{bottom:232.223665px;}
.y1181{bottom:232.225100px;}
.y34f{bottom:232.227400px;}
.y228{bottom:232.232500px;}
.y11df{bottom:232.370971px;}
.y11d8{bottom:232.372009px;}
.y1010{bottom:232.408900px;}
.y8aa{bottom:232.414100px;}
.y7ba{bottom:232.721400px;}
.ybfe{bottom:232.739600px;}
.y1114{bottom:232.775700px;}
.y5dc{bottom:232.844400px;}
.yb19{bottom:232.865800px;}
.y70b{bottom:232.897100px;}
.y891{bottom:233.035100px;}
.y94a{bottom:233.244400px;}
.y7d9{bottom:233.438800px;}
.ydd4{bottom:233.588400px;}
.y15d2{bottom:233.589900px;}
.y15e3{bottom:233.739900px;}
.y758{bottom:233.788750px;}
.yc0d{bottom:233.912800px;}
.y1024{bottom:233.913100px;}
.yf03{bottom:234.062400px;}
.yd53{bottom:234.102900px;}
.y1291{bottom:234.249800px;}
.y763{bottom:234.287700px;}
.y9af{bottom:234.362300px;}
.y100f{bottom:234.408800px;}
.yfd1{bottom:234.409100px;}
.y37d{bottom:234.557600px;}
.y287{bottom:234.572400px;}
.y10fd{bottom:234.842700px;}
.y2f8{bottom:235.051500px;}
.y84c{bottom:235.172100px;}
.y3ea{bottom:235.176300px;}
.y12ea{bottom:235.284700px;}
.y2b0{bottom:235.304100px;}
.y587{bottom:235.320300px;}
.yf29{bottom:235.330900px;}
.yf4e{bottom:235.384700px;}
.y6b6{bottom:235.409700px;}
.y104a{bottom:235.423000px;}
.y1373{bottom:235.423300px;}
.y418{bottom:235.463000px;}
.y8f8{bottom:235.569900px;}
.yd35{bottom:235.574200px;}
.y568{bottom:235.663900px;}
.yb72{bottom:235.669500px;}
.yb86{bottom:235.745200px;}
.y132b{bottom:235.960600px;}
.y241{bottom:236.249500px;}
.ybc2{bottom:236.272400px;}
.ye7c{bottom:236.408400px;}
.y34a{bottom:236.408900px;}
.y1533{bottom:236.409400px;}
.y143{bottom:236.445200px;}
.y1bb{bottom:236.588100px;}
.y118f{bottom:236.623700px;}
.y970{bottom:236.747700px;}
.y98b{bottom:236.971200px;}
.yc23{bottom:237.036500px;}
.y4a8{bottom:237.099850px;}
.ye06{bottom:237.187500px;}
.yd05{bottom:237.235600px;}
.y14e1{bottom:237.266950px;}
.y1195{bottom:237.286800px;}
.y10b5{bottom:237.345900px;}
.y157b{bottom:237.393400px;}
.y1011{bottom:237.409000px;}
.y15a9{bottom:237.557250px;}
.yde7{bottom:237.663500px;}
.y1411{bottom:237.731700px;}
.y13c3{bottom:237.745900px;}
.y1ab{bottom:237.911000px;}
.yd1f{bottom:237.920600px;}
.y48c{bottom:237.920900px;}
.yf69{bottom:237.930050px;}
.y7f2{bottom:237.956700px;}
.y11c1{bottom:237.972725px;}
.y11ba{bottom:237.973763px;}
.y10cc{bottom:238.000000px;}
.y271{bottom:238.005550px;}
.y1391{bottom:238.074100px;}
.y11fa{bottom:238.078503px;}
.y11de{bottom:238.225810px;}
.y11d7{bottom:238.226847px;}
.y3cb{bottom:238.380400px;}
.y8e6{bottom:238.404900px;}
.y1b{bottom:238.531600px;}
.y938{bottom:238.561600px;}
.y13e5{bottom:238.607200px;}
.y47{bottom:238.782900px;}
.y1e6{bottom:238.784700px;}
.y6c{bottom:238.799300px;}
.y9f4{bottom:238.897100px;}
.y446{bottom:238.904900px;}
.y6e1{bottom:238.955400px;}
.y510{bottom:238.958200px;}
.y1096{bottom:239.220700px;}
.y721{bottom:239.263200px;}
.y1590{bottom:239.393100px;}
.ye6a{bottom:239.401000px;}
.y253{bottom:239.423100px;}
.y608{bottom:239.430550px;}
.y822{bottom:239.489150px;}
.y796{bottom:239.535400px;}
.ya2c{bottom:239.582100px;}
.y1429{bottom:239.582900px;}
.yad7{bottom:239.637100px;}
.y699{bottom:239.731500px;}
.y145d{bottom:239.731700px;}
.y502{bottom:239.921650px;}
.y14bf{bottom:240.070200px;}
.yfe0{bottom:240.078100px;}
.y4d7{bottom:240.092800px;}
.y5c5{bottom:240.127500px;}
.ycda{bottom:240.512000px;}
.yff{bottom:240.596600px;}
.y1518{bottom:240.716000px;}
.y1219{bottom:240.736900px;}
.y5a9{bottom:240.905200px;}
.y64e{bottom:240.941000px;}
.ye9c{bottom:240.948900px;}
.yb38{bottom:240.984200px;}
.y106d{bottom:241.099600px;}
.yc4b{bottom:241.244200px;}
.y154d{bottom:241.244900px;}
.y61d{bottom:241.389750px;}
.ya3a{bottom:241.600700px;}
.y6f7{bottom:241.618500px;}
.y2d0{bottom:241.671100px;}
.y10e3{bottom:241.673700px;}
.y45d{bottom:241.739600px;}
.ye54{bottom:241.739800px;}
.y203{bottom:241.889200px;}
.y2cb{bottom:242.078100px;}
.y155d{bottom:242.078400px;}
.yed5{bottom:242.292350px;}
.yf8e{bottom:242.351700px;}
.ye1{bottom:242.400400px;}
.y47e{bottom:242.478750px;}
.y1357{bottom:242.610300px;}
.y4a6{bottom:242.849600px;}
.y3a1{bottom:242.876500px;}
.yfb4{bottom:242.901900px;}
.y1149{bottom:242.904900px;}
.yd79{bottom:242.955450px;}
.y666{bottom:243.062400px;}
.y312{bottom:243.377500px;}
.y2cf{bottom:243.433600px;}
.y42a{bottom:243.490600px;}
.y1503{bottom:243.588400px;}
.y13a3{bottom:243.598700px;}
.y227{bottom:243.732250px;}
.y17b{bottom:243.769800px;}
.y11c0{bottom:243.827563px;}
.y11b9{bottom:243.828601px;}
.yf7e{bottom:243.903100px;}
.y11f9{bottom:243.933341px;}
.y11dd{bottom:244.080648px;}
.y11d6{bottom:244.081685px;}
.y7b9{bottom:244.221150px;}
.y1180{bottom:244.225500px;}
.y1400{bottom:244.263900px;}
.y76a{bottom:244.453400px;}
.y683{bottom:244.506050px;}
.y680{bottom:244.506100px;}
.yb4{bottom:244.565900px;}
.yca8{bottom:244.566300px;}
.y1342{bottom:244.588100px;}
.y148e{bottom:244.724200px;}
.yc5a{bottom:244.795200px;}
.y204{bottom:244.889200px;}
.y14a1{bottom:245.251300px;}
.y100e{bottom:245.408900px;}
.y15d1{bottom:245.589900px;}
.ybfd{bottom:245.739600px;}
.y1113{bottom:245.775700px;}
.y5db{bottom:245.844400px;}
.y70a{bottom:245.897100px;}
.y12cf{bottom:245.933600px;}
.y1477{bottom:245.937900px;}
.yd52{bottom:246.103300px;}
.y949{bottom:246.244400px;}
.y7d8{bottom:246.438800px;}
.ydd3{bottom:246.588400px;}
.y10fc{bottom:246.842700px;}
.yf4d{bottom:246.884450px;}
.yc0c{bottom:246.912800px;}
.yff0{bottom:246.913100px;}
.y417{bottom:246.962750px;}
.ya96{bottom:247.008100px;}
.yf02{bottom:247.062400px;}
.y1290{bottom:247.249800px;}
.y762{bottom:247.287700px;}
.y100d{bottom:247.408800px;}
.y37c{bottom:247.557600px;}
.y286{bottom:247.572400px;}
.ye35{bottom:247.689991px;}
.y73d{bottom:247.747400px;}
.y10fb{bottom:247.842700px;}
.y132a{bottom:247.961000px;}
.y2f7{bottom:248.051500px;}
.y757{bottom:248.123300px;}
.y870{bottom:248.128500px;}
.y1a{bottom:248.131600px;}
.y3e9{bottom:248.176300px;}
.y8a9{bottom:248.249100px;}
.y836{bottom:248.271700px;}
.y12e9{bottom:248.284700px;}
.y2af{bottom:248.303900px;}
.yf28{bottom:248.330900px;}
.y6b5{bottom:248.409700px;}
.y1049{bottom:248.423000px;}
.y1372{bottom:248.423300px;}
.y8f7{bottom:248.569900px;}
.yd34{bottom:248.574200px;}
.y12bc{bottom:248.575100px;}
.y4a7{bottom:248.599600px;}
.ydb0{bottom:248.624100px;}
.yda1{bottom:248.626550px;}
.y567{bottom:248.663900px;}
.yb71{bottom:248.669500px;}
.y119d{bottom:248.733700px;}
.yb85{bottom:248.745200px;}
.y92{bottom:248.753100px;}
.ya08{bottom:248.844200px;}
.yaad{bottom:248.903800px;}
.y8c6{bottom:249.070700px;}
.y14e0{bottom:249.267350px;}
.ybc1{bottom:249.272400px;}
.y916{bottom:249.407000px;}
.y349{bottom:249.408900px;}
.y1532{bottom:249.409400px;}
.y142{bottom:249.445200px;}
.y270{bottom:249.505300px;}
.y1ba{bottom:249.588100px;}
.y11bf{bottom:249.682401px;}
.y11b8{bottom:249.683439px;}
.y96f{bottom:249.747700px;}
.y11f8{bottom:249.788179px;}
.yf68{bottom:249.930450px;}
.y11dc{bottom:249.935486px;}
.y11d5{bottom:249.936524px;}
.y1445{bottom:249.946200px;}
.y98a{bottom:249.971200px;}
.yd04{bottom:250.235600px;}
.y10b4{bottom:250.345900px;}
.y157a{bottom:250.393400px;}
.yde6{bottom:250.663500px;}
.y13c2{bottom:250.745900px;}
.y46{bottom:250.782600px;}
.y6b{bottom:250.799000px;}
.y1aa{bottom:250.911000px;}
.yd1e{bottom:250.920600px;}
.y48b{bottom:250.920900px;}
.y607{bottom:250.930300px;}
.y7f1{bottom:250.956700px;}
.y821{bottom:250.988900px;}
.y10cb{bottom:251.000000px;}
.y3ca{bottom:251.380400px;}
.y501{bottom:251.421400px;}
.y13e4{bottom:251.607200px;}
.y5c4{bottom:251.627250px;}
.y113c{bottom:251.651750px;}
.y1e5{bottom:251.784700px;}
.y50f{bottom:251.875350px;}
.y445{bottom:251.904900px;}
.ye7b{bottom:252.243400px;}
.y795{bottom:252.535400px;}
.ya2b{bottom:252.582100px;}
.y1428{bottom:252.582900px;}
.y698{bottom:252.731500px;}
.yc22{bottom:252.871100px;}
.y937{bottom:252.978600px;}
.y14be{bottom:253.070200px;}
.yfd0{bottom:253.078100px;}
.y4d6{bottom:253.092800px;}
.y106c{bottom:253.099300px;}
.ycd9{bottom:253.512000px;}
.y6e0{bottom:253.550800px;}
.y84b{bottom:253.841100px;}
.y5a8{bottom:253.905200px;}
.y1390{bottom:253.909100px;}
.y877{bottom:253.941000px;}
.y47d{bottom:253.978500px;}
.yb37{bottom:253.984200px;}
.y555{bottom:254.238650px;}
.y8e5{bottom:254.239900px;}
.yc4a{bottom:254.244200px;}
.yed4{bottom:254.292750px;}
.yf8d{bottom:254.351400px;}
.ya39{bottom:254.600700px;}
.y6f6{bottom:254.618500px;}
.y10e2{bottom:254.673700px;}
.y9f3{bottom:254.731700px;}
.y45c{bottom:254.739600px;}
.ye53{bottom:254.739800px;}
.y202{bottom:254.889200px;}
.yd78{bottom:254.955850px;}
.y2ca{bottom:255.078100px;}
.y155c{bottom:255.078400px;}
.ycbf{bottom:255.114200px;}
.y15a8{bottom:255.226300px;}
.y226{bottom:255.232000px;}
.y1454{bottom:255.264300px;}
.y11be{bottom:255.537240px;}
.y11b7{bottom:255.538277px;}
.ye34{bottom:255.570514px;}
.y13a2{bottom:255.599100px;}
.y1356{bottom:255.610300px;}
.y11f7{bottom:255.643018px;}
.y7b8{bottom:255.720900px;}
.y61c{bottom:255.724300px;}
.y1218{bottom:255.736500px;}
.y11db{bottom:255.790324px;}
.y11d4{bottom:255.791362px;}
.y3a0{bottom:255.876500px;}
.yfb3{bottom:255.901900px;}
.y1148{bottom:255.904900px;}
.y117f{bottom:256.225900px;}
.y11c{bottom:256.400600px;}
.y429{bottom:256.490600px;}
.y1502{bottom:256.588400px;}
.yafa{bottom:256.612700px;}
.y161{bottom:256.739500px;}
.y17a{bottom:256.769800px;}
.y769{bottom:257.453400px;}
.yb3{bottom:257.565900px;}
.yca7{bottom:257.566300px;}
.y1341{bottom:257.588100px;}
.y15d0{bottom:257.589900px;}
.y19{bottom:257.731600px;}
.ye69{bottom:258.070300px;}
.y252{bottom:258.092100px;}
.y14ad{bottom:258.251900px;}
.yf4c{bottom:258.384200px;}
.ybfc{bottom:258.739600px;}
.y1112{bottom:258.775700px;}
.y682{bottom:258.840600px;}
.y67f{bottom:258.840650px;}
.y5da{bottom:258.844400px;}
.y709{bottom:258.897100px;}
.y311{bottom:259.212500px;}
.y948{bottom:259.244400px;}
.yfe{bottom:259.265600px;}
.y1306{bottom:259.403400px;}
.y7d7{bottom:259.438800px;}
.ydd2{bottom:259.588400px;}
.y756{bottom:259.623050px;}
.y86f{bottom:259.628250px;}
.y148d{bottom:259.723800px;}
.y1166{bottom:259.912800px;}
.yfef{bottom:259.913100px;}
.y154c{bottom:259.913900px;}
.y1329{bottom:259.961400px;}
.yb18{bottom:260.038600px;}
.yf01{bottom:260.062400px;}
.y162{bottom:260.239600px;}
.y128f{bottom:260.249800px;}
.y761{bottom:260.287700px;}
.y100c{bottom:260.408800px;}
.y285{bottom:260.572400px;}
.ydaf{bottom:260.624500px;}
.yda0{bottom:260.626950px;}
.y73c{bottom:260.747400px;}
.ye2e{bottom:260.766300px;}
.y10fa{bottom:260.842700px;}
.y12ce{bottom:260.933200px;}
.y26f{bottom:261.005050px;}
.y2f6{bottom:261.051500px;}
.ye0{bottom:261.069400px;}
.y3e8{bottom:261.176300px;}
.yeb9{bottom:261.235900px;}
.y8a8{bottom:261.249100px;}
.y835{bottom:261.271700px;}
.y12e8{bottom:261.284700px;}
.y416{bottom:261.297300px;}
.yf27{bottom:261.330900px;}
.y890{bottom:261.373800px;}
.y11bd{bottom:261.392078px;}
.y11b6{bottom:261.393115px;}
.y1048{bottom:261.423000px;}
.y1371{bottom:261.423300px;}
.y11f6{bottom:261.497856px;}
.y9ae{bottom:261.534800px;}
.yd33{bottom:261.574200px;}
.y12bb{bottom:261.575100px;}
.y11da{bottom:261.645162px;}
.y11d3{bottom:261.646200px;}
.y566{bottom:261.663900px;}
.y91{bottom:261.753100px;}
.ya07{bottom:261.844200px;}
.y1410{bottom:262.070700px;}
.ybc0{bottom:262.272400px;}
.y348{bottom:262.408900px;}
.y1531{bottom:262.409400px;}
.yc0b{bottom:262.747400px;}
.y96e{bottom:262.747700px;}
.y45{bottom:262.782600px;}
.y6a{bottom:262.798700px;}
.y989{bottom:262.971200px;}
.y113b{bottom:263.151500px;}
.yd03{bottom:263.235600px;}
.y10b3{bottom:263.345900px;}
.y50e{bottom:263.375100px;}
.y1579{bottom:263.393400px;}
.y49c{bottom:263.418200px;}
.yde5{bottom:263.663500px;}
.y158f{bottom:263.731700px;}
.y13c1{bottom:263.745900px;}
.y1a9{bottom:263.911000px;}
.yd1d{bottom:263.920600px;}
.y48a{bottom:263.920900px;}
.y2ed{bottom:263.953700px;}
.y2eb{bottom:263.953950px;}
.y7f0{bottom:263.956700px;}
.y10ca{bottom:264.000000px;}
.y8c5{bottom:264.070300px;}
.y8f6{bottom:264.404900px;}
.yffe{bottom:264.408800px;}
.yb70{bottom:264.504100px;}
.yb84{bottom:264.579800px;}
.y13e3{bottom:264.607200px;}
.yaac{bottom:264.738800px;}
.y1e4{bottom:264.784700px;}
.y2ad{bottom:264.789400px;}
.y444{bottom:264.904900px;}
.y1444{bottom:264.945800px;}
.y6df{bottom:265.050550px;}
.y106b{bottom:265.099000px;}
.ye7a{bottom:265.243400px;}
.y606{bottom:265.266800px;}
.y1b8{bottom:265.422800px;}
.y794{bottom:265.535400px;}
.ya2a{bottom:265.582100px;}
.y1427{bottom:265.582900px;}
.y697{bottom:265.731500px;}
.y554{bottom:265.738400px;}
.y500{bottom:265.793950px;}
.yfcf{bottom:266.078100px;}
.y4d5{bottom:266.092800px;}
.y37b{bottom:266.226900px;}
.yed3{bottom:266.293150px;}
.yf8c{bottom:266.351100px;}
.y517{bottom:266.421400px;}
.ycd8{bottom:266.512000px;}
.y10e1{bottom:266.673700px;}
.y2ec{bottom:266.803800px;}
.yad6{bottom:266.809900px;}
.y5a7{bottom:266.905200px;}
.y138f{bottom:266.909100px;}
.y14df{bottom:266.936400px;}
.y876{bottom:266.941000px;}
.yd77{bottom:266.956250px;}
.yb36{bottom:266.984200px;}
.y2ae{bottom:267.151900px;}
.y15a7{bottom:267.226700px;}
.y8e4{bottom:267.239900px;}
.yc49{bottom:267.244200px;}
.y11f5{bottom:267.352694px;}
.y936{bottom:267.395600px;}
.y820{bottom:267.553700px;}
.yf67{bottom:267.599500px;}
.ya38{bottom:267.600700px;}
.y10e0{bottom:267.673700px;}
.y45b{bottom:267.739600px;}
.ye52{bottom:267.739800px;}
.y201{bottom:267.889200px;}
.y2c9{bottom:268.078100px;}
.y141{bottom:268.114200px;}
.y516{bottom:268.183900px;}
.y84a{bottom:268.258100px;}
.y720{bottom:268.436400px;}
.ya6a{bottom:268.566300px;}
.y1355{bottom:268.610300px;}
.y225{bottom:268.696650px;}
.y586{bottom:268.749300px;}
.y5c3{bottom:268.796600px;}
.y1147{bottom:268.904900px;}
.y14bd{bottom:268.905200px;}
.y1b9{bottom:268.922800px;}
.yc67{bottom:269.134000px;}
.y11b{bottom:269.400600px;}
.y428{bottom:269.490600px;}
.y1501{bottom:269.588400px;}
.y14a0{bottom:269.589900px;}
.y61b{bottom:269.606050px;}
.yaf9{bottom:269.612700px;}
.y160{bottom:269.739500px;}
.y179{bottom:269.769800px;}
.y7b7{bottom:269.810450px;}
.yf4b{bottom:269.883950px;}
.y1517{bottom:269.889500px;}
.y64d{bottom:270.115100px;}
.ye9b{bottom:270.122100px;}
.y665{bottom:270.235600px;}
.y1453{bottom:270.263900px;}
.y1476{bottom:270.276500px;}
.y768{bottom:270.453400px;}
.yca6{bottom:270.566300px;}
.y1340{bottom:270.588100px;}
.y1217{bottom:270.736100px;}
.yf7d{bottom:271.076300px;}
.y240{bottom:271.092100px;}
.y86e{bottom:271.128000px;}
.y14ac{bottom:271.251900px;}
.ybfb{bottom:271.739600px;}
.yfdf{bottom:271.747400px;}
.y1111{bottom:271.775700px;}
.y1318{bottom:271.961800px;}
.ye05{bottom:272.030000px;}
.y47c{bottom:272.056800px;}
.y947{bottom:272.244400px;}
.yfd{bottom:272.265600px;}
.yd50{bottom:272.276500px;}
.y1305{bottom:272.403400px;}
.y7d6{bottom:272.438800px;}
.y26e{bottom:272.504800px;}
.ydd1{bottom:272.588400px;}
.yd94{bottom:272.624900px;}
.yd9f{bottom:272.627350px;}
.y415{bottom:272.797050px;}
.y1165{bottom:272.912800px;}
.yfee{bottom:272.913100px;}
.y154b{bottom:272.913900px;}
.y18{bottom:273.001200px;}
.yf00{bottom:273.062400px;}
.ye68{bottom:273.070300px;}
.y67e{bottom:273.175200px;}
.y128e{bottom:273.249800px;}
.y13a1{bottom:273.268150px;}
.y6f5{bottom:273.287500px;}
.y760{bottom:273.287700px;}
.y100b{bottom:273.408800px;}
.y73b{bottom:273.747400px;}
.y117e{bottom:273.894950px;}
.y2f5{bottom:274.051500px;}
.y1095{bottom:274.064100px;}
.ya95{bottom:274.181300px;}
.yeb8{bottom:274.235900px;}
.y834{bottom:274.271700px;}
.y12e7{bottom:274.284700px;}
.yf26{bottom:274.330900px;}
.y1047{bottom:274.423000px;}
.y1370{bottom:274.423300px;}
.y223{bottom:274.446400px;}
.y9ad{bottom:274.534800px;}
.yfb2{bottom:274.570900px;}
.yd32{bottom:274.574200px;}
.y113a{bottom:274.651250px;}
.y69{bottom:274.798400px;}
.ya06{bottom:274.844200px;}
.y310{bottom:275.047500px;}
.y1069{bottom:275.298700px;}
.y619{bottom:275.355800px;}
.y9d1{bottom:275.408800px;}
.y347{bottom:275.408900px;}
.y1530{bottom:275.409400px;}
.y2ea{bottom:275.453700px;}
.y7b5{bottom:275.560200px;}
.y6b4{bottom:275.583000px;}
.yb17{bottom:275.873600px;}
.y988{bottom:275.971200px;}
.y10c9{bottom:276.000000px;}
.yd02{bottom:276.235600px;}
.y10b2{bottom:276.345900px;}
.y1578{bottom:276.393400px;}
.y49b{bottom:276.418200px;}
.y6de{bottom:276.550300px;}
.y10f9{bottom:276.677300px;}
.y13c0{bottom:276.745900px;}
.y755{bottom:276.792400px;}
.y1a8{bottom:276.911000px;}
.yd1c{bottom:276.920600px;}
.y489{bottom:276.920900px;}
.y7ef{bottom:276.956700px;}
.y10c8{bottom:277.000000px;}
.y140f{bottom:277.070300px;}
.y8a7{bottom:277.084100px;}
.y106a{bottom:277.098700px;}
.y1068{bottom:277.100500px;}
.y3c9{bottom:277.136300px;}
.y4ff{bottom:277.293700px;}
.yd51{bottom:277.498800px;}
.y5d9{bottom:277.513400px;}
.y708{bottom:277.566300px;}
.y13e2{bottom:277.607200px;}
.y1328{bottom:277.630450px;}
.y50d{bottom:277.711150px;}
.yaab{bottom:277.738800px;}
.y1e3{bottom:277.784700px;}
.y443{bottom:277.904900px;}
.ybbf{bottom:278.107100px;}
.yf78{bottom:278.293550px;}
.y11f4{bottom:278.349062px;}
.yf8b{bottom:278.350800px;}
.y1b7{bottom:278.422800px;}
.y793{bottom:278.535400px;}
.ya29{bottom:278.582100px;}
.y1426{bottom:278.582900px;}
.y14de{bottom:278.936800px;}
.y1194{bottom:278.956650px;}
.y81f{bottom:279.053450px;}
.yb2{bottom:279.069900px;}
.yfce{bottom:279.078100px;}
.y4d4{bottom:279.092800px;}
.y13ff{bottom:279.106400px;}
.y284{bottom:279.241700px;}
.y515{bottom:279.256350px;}
.ycd7{bottom:279.512000px;}
.yf66{bottom:279.599900px;}
.y605{bottom:279.601350px;}
.ydf{bottom:279.738400px;}
.y3e7{bottom:279.845600px;}
.y5a6{bottom:279.905200px;}
.y138e{bottom:279.909100px;}
.y875{bottom:279.941000px;}
.y36c{bottom:279.959950px;}
.yb35{bottom:279.984200px;}
.yc21{bottom:280.044400px;}
.y553{bottom:280.072950px;}
.y224{bottom:280.196400px;}
.y8e3{bottom:280.239900px;}
.y12ba{bottom:280.244100px;}
.yc48{bottom:280.244200px;}
.y565{bottom:280.332900px;}
.yba5{bottom:280.393100px;}
.ya37{bottom:280.600700px;}
.y10df{bottom:280.673700px;}
.y45a{bottom:280.739600px;}
.ye51{bottom:280.739800px;}
.y2c8{bottom:281.078100px;}
.ye79{bottom:281.078400px;}
.y61a{bottom:281.105800px;}
.y140{bottom:281.114200px;}
.y7b6{bottom:281.310200px;}
.yf4a{bottom:281.383700px;}
.y96d{bottom:281.416700px;}
.y71f{bottom:281.436400px;}
.y15cf{bottom:281.589900px;}
.y935{bottom:281.812600px;}
.y9f2{bottom:281.904900px;}
.y14bc{bottom:281.905200px;}
.y585{bottom:282.166300px;}
.y427{bottom:282.490600px;}
.y1500{bottom:282.588400px;}
.y149f{bottom:282.589900px;}
.y17{bottom:282.601200px;}
.yaf8{bottom:282.612700px;}
.y86d{bottom:282.627750px;}
.yad5{bottom:282.644900px;}
.y849{bottom:282.675100px;}
.y15f{bottom:282.739500px;}
.y178{bottom:282.769800px;}
.y1516{bottom:282.889500px;}
.y64c{bottom:283.115100px;}
.ye9a{bottom:283.122100px;}
.y90{bottom:283.257100px;}
.y1475{bottom:283.276500px;}
.y133f{bottom:283.588100px;}
.y44{bottom:283.787100px;}
.yed2{bottom:283.962200px;}
.y23f{bottom:284.092100px;}
.y11f1{bottom:284.200763px;}
.y11f3{bottom:284.203900px;}
.y915{bottom:284.250100px;}
.y14ab{bottom:284.251900px;}
.y414{bottom:284.296800px;}
.y696{bottom:284.400500px;}
.ya69{bottom:284.401000px;}
.yd76{bottom:284.625300px;}
.ybfa{bottom:284.739600px;}
.y1110{bottom:284.775700px;}
.y15a6{bottom:284.895750px;}
.ye04{bottom:285.030000px;}
.yfc{bottom:285.265600px;}
.y13a0{bottom:285.268550px;}
.y3ba{bottom:285.293300px;}
.y3b9{bottom:285.369800px;}
.y1304{bottom:285.403400px;}
.y7d5{bottom:285.438800px;}
.ydd0{bottom:285.588400px;}
.y117d{bottom:285.895350px;}
.y1164{bottom:285.912800px;}
.y1023{bottom:285.913100px;}
.y154a{bottom:285.913900px;}
.y47b{bottom:285.925650px;}
.y11f2{bottom:285.931400px;}
.yeff{bottom:286.062400px;}
.y1094{bottom:286.063800px;}
.y1139{bottom:286.151000px;}
.y6f4{bottom:286.287500px;}
.y75f{bottom:286.287700px;}
.yca5{bottom:286.401000px;}
.y100a{bottom:286.408800px;}
.y67d{bottom:286.484850px;}
.y73a{bottom:286.747400px;}
.y68{bottom:286.798400px;}
.y2f4{bottom:287.051500px;}
.y5c2{bottom:287.063500px;}
.ya94{bottom:287.181300px;}
.yeb7{bottom:287.235900px;}
.y833{bottom:287.271700px;}
.y1354{bottom:287.279600px;}
.y12e6{bottom:287.284700px;}
.yf25{bottom:287.330900px;}
.y1046{bottom:287.423000px;}
.y136f{bottom:287.423300px;}
.yfb1{bottom:287.570900px;}
.y1271{bottom:287.574200px;}
.y6dd{bottom:288.050050px;}
.y11a{bottom:288.069600px;}
.y346{bottom:288.408900px;}
.y152f{bottom:288.409400px;}
.y987{bottom:288.971200px;}
.y1067{bottom:289.100200px;}
.ycf5{bottom:289.235600px;}
.y514{bottom:289.256100px;}
.y10b1{bottom:289.345900px;}
.y26d{bottom:289.444950px;}
.y1327{bottom:289.630850px;}
.y88f{bottom:289.712500px;}
.y13bf{bottom:289.745900px;}
.y2e9{bottom:289.790150px;}
.yd1b{bottom:289.920600px;}
.y488{bottom:289.920900px;}
.y7ee{bottom:289.956700px;}
.y10c7{bottom:290.000000px;}
.y11f0{bottom:290.055602px;}
.y753{bottom:290.154200px;}
.yd93{bottom:290.293950px;}
.yd9e{bottom:290.296400px;}
.yf8a{bottom:290.350500px;}
.y9ac{bottom:290.369800px;}
.y5d8{bottom:290.513400px;}
.y81e{bottom:290.553200px;}
.y1e2{bottom:290.784700px;}
.yde4{bottom:290.836700px;}
.y442{bottom:290.904900px;}
.y957{bottom:290.914000px;}
.y14dd{bottom:290.937200px;}
.y513{bottom:291.018600px;}
.y604{bottom:291.101100px;}
.y1b6{bottom:291.422800px;}
.y36b{bottom:291.459700px;}
.y792{bottom:291.535400px;}
.y552{bottom:291.572700px;}
.ya28{bottom:291.582100px;}
.y479{bottom:291.675400px;}
.yb6f{bottom:291.677300px;}
.yb16{bottom:291.708300px;}
.yb83{bottom:291.753400px;}
.y128d{bottom:291.919100px;}
.y50c{bottom:292.045700px;}
.yb1{bottom:292.069900px;}
.yfcd{bottom:292.078100px;}
.y4d3{bottom:292.092800px;}
.y13fe{bottom:292.106400px;}
.y16{bottom:292.201200px;}
.y67b{bottom:292.234600px;}
.y4fe{bottom:292.390850px;}
.y2aa{bottom:292.506400px;}
.ycd6{bottom:292.512000px;}
.y754{bottom:292.516700px;}
.yf49{bottom:292.883450px;}
.y5a5{bottom:292.905200px;}
.y8a6{bottom:292.919100px;}
.y874{bottom:292.941000px;}
.yb34{bottom:292.984200px;}
.yc20{bottom:293.044400px;}
.y8f5{bottom:293.239900px;}
.yd31{bottom:293.243500px;}
.y12b9{bottom:293.244100px;}
.yc47{bottom:293.244200px;}
.y564{bottom:293.332900px;}
.yc83{bottom:293.393100px;}
.yaaa{bottom:293.573800px;}
.y15ce{bottom:293.589900px;}
.ya36{bottom:293.600700px;}
.y200{bottom:293.645100px;}
.y10de{bottom:293.673700px;}
.y459{bottom:293.739600px;}
.ye50{bottom:293.739800px;}
.y15ef{bottom:293.739900px;}
.y13f{bottom:294.114200px;}
.y86c{bottom:294.127500px;}
.y96c{bottom:294.416700px;}
.y71e{bottom:294.436400px;}
.y148c{bottom:294.566300px;}
.y3e6{bottom:294.845600px;}
.y9f1{bottom:294.904900px;}
.y1577{bottom:295.062400px;}
.y37a{bottom:295.400100px;}
.y11b2{bottom:295.467485px;}
.y426{bottom:295.490600px;}
.y584{bottom:295.583300px;}
.y14ff{bottom:295.588400px;}
.y149e{bottom:295.589900px;}
.y15e{bottom:295.739500px;}
.y138d{bottom:295.744100px;}
.y177{bottom:295.769800px;}
.y12cd{bottom:295.775700px;}
.y43{bottom:295.786800px;}
.y413{bottom:295.796550px;}
.y11ce{bottom:295.882285px;}
.y11d2{bottom:295.898783px;}
.y11ef{bottom:295.910440px;}
.yed1{bottom:295.962600px;}
.y8e2{bottom:296.074900px;}
.ye99{bottom:296.122100px;}
.y934{bottom:296.229600px;}
.y8f{bottom:296.257100px;}
.y13e1{bottom:296.276500px;}
.y133e{bottom:296.588100px;}
.y222{bottom:296.602000px;}
.yd75{bottom:296.625700px;}
.y15a5{bottom:296.896150px;}
.y618{bottom:296.929400px;}
.y23e{bottom:297.092100px;}
.y914{bottom:297.250100px;}
.y1425{bottom:297.251900px;}
.yf65{bottom:297.268950px;}
.y7b4{bottom:297.340900px;}
.y695{bottom:297.400500px;}
.y47a{bottom:297.425400px;}
.y767{bottom:297.626600px;}
.y1138{bottom:297.650750px;}
.ybf9{bottom:297.739600px;}
.y110f{bottom:297.775700px;}
.y67c{bottom:297.984600px;}
.ye03{bottom:298.030000px;}
.y1093{bottom:298.063500px;}
.yfb{bottom:298.265600px;}
.y1303{bottom:298.403400px;}
.yde{bottom:298.407400px;}
.y7d4{bottom:298.438800px;}
.yaf7{bottom:298.447300px;}
.yad4{bottom:298.479600px;}
.y158e{bottom:298.574200px;}
.ydcf{bottom:298.588400px;}
.y8c4{bottom:298.911900px;}
.y1163{bottom:298.912800px;}
.y1549{bottom:298.913900px;}
.yefe{bottom:299.062400px;}
.ya15{bottom:299.183000px;}
.y6f3{bottom:299.287500px;}
.y6f1{bottom:299.287700px;}
.y30f{bottom:299.386000px;}
.y1009{bottom:299.408800px;}
.ye67{bottom:299.409200px;}
.y6dc{bottom:299.549800px;}
.y2c7{bottom:299.747400px;}
.y1443{bottom:299.788300px;}
.ya93{bottom:300.181300px;}
.yeb6{bottom:300.235900px;}
.y832{bottom:300.271700px;}
.y12e5{bottom:300.284700px;}
.y136e{bottom:300.423300px;}
.y1270{bottom:300.574200px;}
.y26c{bottom:300.944700px;}
.y1066{bottom:301.099900px;}
.y30e{bottom:301.148500px;}
.y752{bottom:301.154200px;}
.y11b5{bottom:301.321805px;}
.y11b1{bottom:301.322324px;}
.y10b0{bottom:301.345900px;}
.y3b8{bottom:301.383800px;}
.y5c1{bottom:301.399100px;}
.y345{bottom:301.408900px;}
.y152e{bottom:301.409400px;}
.y3b7{bottom:301.460300px;}
.y1515{bottom:301.558500px;}
.y1326{bottom:301.631250px;}
.y11cd{bottom:301.737124px;}
.y11ee{bottom:301.765278px;}
.y64b{bottom:301.784100px;}
.y15{bottom:301.801200px;}
.y11d1{bottom:301.844022px;}
.y81d{bottom:302.052950px;}
.yd01{bottom:302.235600px;}
.y1353{bottom:302.279600px;}
.y6f2{bottom:302.287500px;}
.yd92{bottom:302.294350px;}
.yd9d{bottom:302.296800px;}
.y10af{bottom:302.345900px;}
.yf9a{bottom:302.350000px;}
.y13be{bottom:302.745900px;}
.yd1a{bottom:302.920600px;}
.y487{bottom:302.920900px;}
.y139f{bottom:302.937600px;}
.y7ed{bottom:302.956700px;}
.yfb0{bottom:303.405900px;}
.y5d7{bottom:303.513400px;}
.y50b{bottom:303.545450px;}
.y117c{bottom:303.564400px;}
.y1e1{bottom:303.784700px;}
.yf79{bottom:303.805600px;}
.y10f8{bottom:303.850600px;}
.y4fd{bottom:303.890600px;}
.y119{bottom:303.904600px;}
.y441{bottom:303.904900px;}
.y1a7{bottom:304.084200px;}
.y2e8{bottom:304.124700px;}
.yf48{bottom:304.383200px;}
.y791{bottom:304.535400px;}
.ya27{bottom:304.582100px;}
.yb6e{bottom:304.677300px;}
.yba4{bottom:304.731700px;}
.yb82{bottom:304.753400px;}
.y986{bottom:304.805900px;}
.yb0{bottom:305.069900px;}
.y664{bottom:305.078100px;}
.y4d2{bottom:305.092800px;}
.y13fd{bottom:305.106400px;}
.ybbe{bottom:305.280400px;}
.y603{bottom:305.435650px;}
.y2a9{bottom:305.506400px;}
.ycd5{bottom:305.512000px;}
.y15cd{bottom:305.589900px;}
.y86b{bottom:305.627250px;}
.y10c6{bottom:305.834600px;}
.y5a4{bottom:305.905200px;}
.y551{bottom:305.908500px;}
.y8a5{bottom:305.919100px;}
.yf7c{bottom:305.919400px;}
.y873{bottom:305.941000px;}
.yf24{bottom:305.999900px;}
.yc1f{bottom:306.044400px;}
.y1045{bottom:306.092300px;}
.y9ab{bottom:306.204800px;}
.y12b8{bottom:306.244100px;}
.y563{bottom:306.332900px;}
.ya35{bottom:306.600700px;}
.y10dd{bottom:306.673700px;}
.y458{bottom:306.739600px;}
.y12a4{bottom:306.739800px;}
.y13e{bottom:307.114200px;}
.yd4f{bottom:307.119000px;}
.y11b4{bottom:307.176643px;}
.y11b0{bottom:307.177162px;}
.y96b{bottom:307.416700px;}
.y71d{bottom:307.436400px;}
.y148b{bottom:307.566300px;}
.y11cc{bottom:307.591962px;}
.y53b{bottom:307.599850px;}
.y11ed{bottom:307.620116px;}
.y42{bottom:307.786500px;}
.y11d0{bottom:307.789261px;}
.y67{bottom:307.802400px;}
.y9f0{bottom:307.904900px;}
.yed0{bottom:307.963000px;}
.y1576{bottom:308.062400px;}
.y379{bottom:308.400100px;}
.y1216{bottom:308.414200px;}
.y283{bottom:308.414900px;}
.y425{bottom:308.490600px;}
.y14fe{bottom:308.588400px;}
.y149d{bottom:308.589900px;}
.y36a{bottom:308.602000px;}
.y14dc{bottom:308.606250px;}
.yd74{bottom:308.626100px;}
.y15d{bottom:308.739500px;}
.y138c{bottom:308.744100px;}
.y176{bottom:308.769800px;}
.y583{bottom:309.000300px;}
.y8e1{bottom:309.074900px;}
.ye98{bottom:309.122100px;}
.y3c8{bottom:309.143900px;}
.y1137{bottom:309.150500px;}
.yf64{bottom:309.269350px;}
.y1474{bottom:309.276500px;}
.yaa9{bottom:309.408400px;}
.y133d{bottom:309.588100px;}
.y1092{bottom:310.063200px;}
.y23d{bottom:310.092100px;}
.y412{bottom:310.131100px;}
.y913{bottom:310.250100px;}
.y1424{bottom:310.251900px;}
.y7b3{bottom:310.340900px;}
.y694{bottom:310.400500px;}
.y6b3{bottom:310.425000px;}
.ybf8{bottom:310.739600px;}
.ye02{bottom:311.030000px;}
.yfa{bottom:311.265600px;}
.y1302{bottom:311.403400px;}
.y7d3{bottom:311.438800px;}
.y158d{bottom:311.574200px;}
.ydce{bottom:311.588400px;}
.y8c3{bottom:311.911900px;}
.y1162{bottom:311.912800px;}
.yc46{bottom:311.913200px;}
.y1548{bottom:311.913900px;}
.y933{bottom:312.064600px;}
.y6f0{bottom:312.287700px;}
.ye4f{bottom:312.408800px;}
.y26b{bottom:312.444450px;}
.y739{bottom:312.747400px;}
.y1442{bottom:312.788300px;}
.y11b3{bottom:313.031481px;}
.y11af{bottom:313.032000px;}
.y1065{bottom:313.099600px;}
.ya92{bottom:313.181300px;}
.y473{bottom:313.234400px;}
.y671{bottom:313.235200px;}
.yeb5{bottom:313.235900px;}
.y831{bottom:313.271700px;}
.y12e4{bottom:313.284700px;}
.y136d{bottom:313.423300px;}
.y11cb{bottom:313.446800px;}
.y11ec{bottom:313.474954px;}
.y81c{bottom:313.552700px;}
.ycb{bottom:313.573900px;}
.ya68{bottom:313.574200px;}
.ycf4{bottom:313.574500px;}
.y110e{bottom:313.610250px;}
.y1317{bottom:313.631650px;}
.y4c5{bottom:313.711200px;}
.y11cf{bottom:313.734500px;}
.y2f3{bottom:314.225200px;}
.ydbd{bottom:314.294750px;}
.yd9c{bottom:314.297200px;}
.ye66{bottom:314.408800px;}
.y344{bottom:314.408900px;}
.y12cc{bottom:314.445000px;}
.yb55{bottom:314.504100px;}
.y1514{bottom:314.558500px;}
.y15a4{bottom:314.565200px;}
.y64a{bottom:314.784100px;}
.y6db{bottom:314.847850px;}
.y139e{bottom:314.938000px;}
.ydc{bottom:315.076500px;}
.yd00{bottom:315.235600px;}
.y10ae{bottom:315.345900px;}
.y117b{bottom:315.564800px;}
.y2e7{bottom:315.624450px;}
.y5c0{bottom:315.733650px;}
.y13bd{bottom:315.745900px;}
.yf47{bottom:315.882950px;}
.yd19{bottom:315.920600px;}
.y486{bottom:315.920900px;}
.y7ec{bottom:315.956700px;}
.y334{bottom:316.190300px;}
.y128c{bottom:316.258200px;}
.y5d6{bottom:316.513400px;}
.y1e0{bottom:316.784700px;}
.y118{bottom:316.904600px;}
.y440{bottom:316.904900px;}
.y602{bottom:316.935400px;}
.y4fc{bottom:317.015750px;}
.y14{bottom:317.070800px;}
.ydd{bottom:317.076400px;}
.ydb{bottom:317.079800px;}
.y86a{bottom:317.127000px;}
.yeec{bottom:317.257400px;}
.yb43{bottom:317.323000px;}
.y3b6{bottom:317.474400px;}
.y790{bottom:317.535400px;}
.y3b5{bottom:317.550900px;}
.ya26{bottom:317.582100px;}
.y15cc{bottom:317.589900px;}
.yb6d{bottom:317.677300px;}
.yc82{bottom:317.731700px;}
.yb81{bottom:317.753400px;}
.y8e{bottom:317.761100px;}
.y50a{bottom:317.880000px;}
.y88e{bottom:318.051200px;}
.yaf{bottom:318.069900px;}
.y663{bottom:318.078100px;}
.y4d1{bottom:318.092800px;}
.y13fc{bottom:318.106400px;}
.ybbd{bottom:318.280400px;}
.y2a8{bottom:318.506400px;}
.ycd4{bottom:318.512000px;}
.y1b5{bottom:318.596000px;}
.yb15{bottom:318.881400px;}
.y5a3{bottom:318.905200px;}
.y8a4{bottom:318.919100px;}
.yf7b{bottom:318.919400px;}
.yf23{bottom:318.999900px;}
.yc1e{bottom:319.044400px;}
.y53a{bottom:319.099600px;}
.y9aa{bottom:319.204800px;}
.yfaf{bottom:319.240900px;}
.y12b7{bottom:319.244100px;}
.y1325{bottom:319.300300px;}
.y11eb{bottom:319.329793px;}
.y562{bottom:319.332900px;}
.ya34{bottom:319.600700px;}
.y10dc{bottom:319.673700px;}
.y457{bottom:319.739600px;}
.y12a3{bottom:319.739800px;}
.y41{bottom:319.786500px;}
.yd91{bottom:319.963400px;}
.y152d{bottom:320.078400px;}
.y13d{bottom:320.114200px;}
.yd4e{bottom:320.119000px;}
.y550{bottom:320.243050px;}
.y1215{bottom:320.413900px;}
.y96a{bottom:320.416700px;}
.y71c{bottom:320.436400px;}
.y148a{bottom:320.566300px;}
.y14db{bottom:320.606650px;}
.y13e0{bottom:320.615100px;}
.y1136{bottom:320.650250px;}
.y9ef{bottom:320.904900px;}
.y221{bottom:320.941000px;}
.y617{bottom:321.267400px;}
.y378{bottom:321.400100px;}
.y282{bottom:321.414900px;}
.y149c{bottom:321.589900px;}
.y411{bottom:321.630850px;}
.y138b{bottom:321.744100px;}
.y175{bottom:321.769800px;}
.y10a3{bottom:322.063000px;}
.ye97{bottom:322.122100px;}
.y3c7{bottom:322.143900px;}
.y1473{bottom:322.276500px;}
.y582{bottom:322.417300px;}
.y133c{bottom:322.588100px;}
.y4fa{bottom:322.765500px;}
.y23c{bottom:323.092100px;}
.y1423{bottom:323.251900px;}
.y693{bottom:323.400500px;}
.y6b2{bottom:323.425000px;}
.ybf7{bottom:323.739600px;}
.y26a{bottom:323.944200px;}
.y3e5{bottom:324.018800px;}
.ye01{bottom:324.030000px;}
.yf9{bottom:324.265600px;}
.y7d2{bottom:324.438800px;}
.y158c{bottom:324.574200px;}
.ydcd{bottom:324.588400px;}
.y8e0{bottom:324.909900px;}
.y8c2{bottom:324.911900px;}
.y1161{bottom:324.912800px;}
.yc45{bottom:324.913200px;}
.y1547{bottom:324.913900px;}
.y932{bottom:325.064600px;}
.y1064{bottom:325.099300px;}
.y369{bottom:325.202550px;}
.y6ef{bottom:325.287700px;}
.ye4e{bottom:325.408800px;}
.yaf6{bottom:325.620600px;}
.yecf{bottom:325.632050px;}
.yad3{bottom:325.652400px;}
.y738{bottom:325.747400px;}
.y1441{bottom:325.788300px;}
.ya91{bottom:326.181300px;}
.y472{bottom:326.234400px;}
.y670{bottom:326.235200px;}
.yefd{bottom:326.235600px;}
.y830{bottom:326.271700px;}
.y12e3{bottom:326.284700px;}
.yd73{bottom:326.295150px;}
.y6da{bottom:326.347600px;}
.y136c{bottom:326.423300px;}
.y15a3{bottom:326.565600px;}
.yca4{bottom:326.574200px;}
.ycf3{bottom:326.574500px;}
.y81b{bottom:326.598850px;}
.y110d{bottom:326.610300px;}
.y4c4{bottom:326.628600px;}
.y13{bottom:326.670800px;}
.y1575{bottom:326.731700px;}
.yf63{bottom:326.938400px;}
.y1ff{bottom:327.070600px;}
.y5bf{bottom:327.233400px;}
.y14fd{bottom:327.257400px;}
.yf46{bottom:327.382700px;}
.y15c{bottom:327.408500px;}
.y343{bottom:327.408900px;}
.y1513{bottom:327.558500px;}
.y117a{bottom:327.565200px;}
.y333{bottom:327.690050px;}
.y649{bottom:327.784100px;}
.ycff{bottom:328.235600px;}
.y601{bottom:328.435150px;}
.y4fb{bottom:328.515500px;}
.y869{bottom:328.626750px;}
.y13bc{bottom:328.745900px;}
.y66{bottom:328.807800px;}
.y912{bottom:328.919100px;}
.yd18{bottom:328.920600px;}
.y2c6{bottom:328.920900px;}
.y7eb{bottom:328.956700px;}
.y985{bottom:329.144500px;}
.y2f2{bottom:329.224800px;}
.y128b{bottom:329.258200px;}
.y509{bottom:329.379750px;}
.ya67{bottom:329.408800px;}
.y5d5{bottom:329.513400px;}
.y15cb{bottom:329.589900px;}
.y1df{bottom:329.784700px;}
.y117{bottom:329.904600px;}
.y43f{bottom:329.904900px;}
.y2e6{bottom:329.959000px;}
.y1301{bottom:330.072700px;}
.yeeb{bottom:330.257400px;}
.y11ae{bottom:330.335978px;}
.ya25{bottom:330.582100px;}
.y539{bottom:330.599350px;}
.yb6c{bottom:330.677300px;}
.yb80{bottom:330.753400px;}
.y8d{bottom:330.761100px;}
.yae{bottom:331.069900px;}
.y662{bottom:331.078100px;}
.y4d0{bottom:331.092800px;}
.y1452{bottom:331.106400px;}
.y10ad{bottom:331.180600px;}
.ybbc{bottom:331.280400px;}
.y1324{bottom:331.300700px;}
.yde3{bottom:331.348800px;}
.y1352{bottom:331.453100px;}
.y2a7{bottom:331.506400px;}
.ycd3{bottom:331.512000px;}
.y54f{bottom:331.742800px;}
.yb14{bottom:331.881400px;}
.yeb4{bottom:331.904900px;}
.y5a2{bottom:331.905200px;}
.y8a3{bottom:331.919100px;}
.yd90{bottom:331.963800px;}
.yd9b{bottom:331.966250px;}
.yf22{bottom:331.999900px;}
.y3b4{bottom:332.005000px;}
.yc1d{bottom:332.044400px;}
.y1135{bottom:332.150000px;}
.y1132{bottom:332.150050px;}
.y9a9{bottom:332.204800px;}
.yfae{bottom:332.240900px;}
.y12b6{bottom:332.244100px;}
.y561{bottom:332.332900px;}
.y819{bottom:332.348600px;}
.y1214{bottom:332.413600px;}
.ya33{bottom:332.600700px;}
.y139d{bottom:332.607050px;}
.y456{bottom:332.739600px;}
.y12a2{bottom:332.739800px;}
.y10f7{bottom:333.024300px;}
.y152c{bottom:333.078400px;}
.y13c{bottom:333.114200px;}
.yd4d{bottom:333.119000px;}
.y969{bottom:333.416700px;}
.y71b{bottom:333.436400px;}
.y3b1{bottom:333.564900px;}
.y1489{bottom:333.566300px;}
.y13df{bottom:333.615100px;}
.y9ee{bottom:333.904900px;}
.y3b2{bottom:333.905000px;}
.y220{bottom:333.941000px;}
.y616{bottom:334.267400px;}
.y377{bottom:334.400100px;}
.y281{bottom:334.414900px;}
.y9d0{bottom:334.589900px;}
.y7b2{bottom:334.679900px;}
.y138a{bottom:334.744100px;}
.y174{bottom:334.769800px;}
.yca{bottom:335.077900px;}
.ye96{bottom:335.122100px;}
.y3c6{bottom:335.143900px;}
.y1044{bottom:335.265800px;}
.y1472{bottom:335.276500px;}
.y10db{bottom:335.508400px;}
.y133b{bottom:335.588100px;}
.y424{bottom:335.663900px;}
.yda{bottom:335.748800px;}
.y581{bottom:335.834300px;}
.y410{bottom:335.965400px;}
.y23b{bottom:336.092100px;}
.y1422{bottom:336.251900px;}
.y11ad{bottom:336.265000px;}
.y12{bottom:336.270800px;}
.y692{bottom:336.400500px;}
.y6b1{bottom:336.425000px;}
.yaa8{bottom:336.581400px;}
.y368{bottom:336.702300px;}
.ybf6{bottom:336.739600px;}
.y3b3{bottom:336.755100px;}
.y13fb{bottom:336.775700px;}
.y3e4{bottom:337.018800px;}
.ye00{bottom:337.030000px;}
.y1063{bottom:337.099000px;}
.yf8{bottom:337.265600px;}
.y7d1{bottom:337.438800px;}
.y158b{bottom:337.574200px;}
.ydcc{bottom:337.588400px;}
.yece{bottom:337.632450px;}
.y6d9{bottom:337.847350px;}
.y8df{bottom:337.909900px;}
.y8c1{bottom:337.911900px;}
.y1160{bottom:337.912800px;}
.yc44{bottom:337.913200px;}
.y1546{bottom:337.913900px;}
.y81a{bottom:338.098600px;}
.y269{bottom:338.226050px;}
.y6ee{bottom:338.287700px;}
.yd72{bottom:338.295550px;}
.ye4d{bottom:338.408800px;}
.y15a2{bottom:338.566000px;}
.yad2{bottom:338.652400px;}
.y10c5{bottom:338.677500px;}
.y5be{bottom:338.733150px;}
.y737{bottom:338.747400px;}
.y12cb{bottom:338.783500px;}
.y1440{bottom:338.788300px;}
.yb54{bottom:338.842700px;}
.y1a6{bottom:338.926700px;}
.yf62{bottom:338.938800px;}
.ya90{bottom:339.181300px;}
.y332{bottom:339.189800px;}
.y82f{bottom:339.271700px;}
.y12e2{bottom:339.284700px;}
.y136b{bottom:339.423300px;}
.y4c3{bottom:339.545900px;}
.y1179{bottom:339.565600px;}
.yba3{bottom:339.574200px;}
.ycf2{bottom:339.574500px;}
.y600{bottom:339.934900px;}
.y1fe{bottom:340.070600px;}
.y868{bottom:340.126500px;}
.y14fc{bottom:340.257400px;}
.y342{bottom:340.408900px;}
.y648{bottom:340.784100px;}
.y40{bottom:340.792000px;}
.y65{bottom:340.807500px;}
.y508{bottom:340.879500px;}
.ycfe{bottom:341.235600px;}
.y1008{bottom:341.243500px;}
.yaf5{bottom:341.455200px;}
.y2e5{bottom:341.458750px;}
.y15ca{bottom:341.589900px;}
.yf45{bottom:341.717250px;}
.y13bb{bottom:341.745900px;}
.y911{bottom:341.919100px;}
.yd17{bottom:341.920600px;}
.y2c5{bottom:341.920900px;}
.y7ea{bottom:341.956700px;}
.y984{bottom:342.144500px;}
.y128a{bottom:342.258200px;}
.y983{bottom:342.294500px;}
.y5d4{bottom:342.513400px;}
.y1de{bottom:342.784700px;}
.y800{bottom:342.904900px;}
.y54e{bottom:343.242550px;}
.y15b{bottom:343.243500px;}
.yeea{bottom:343.257400px;}
.y1323{bottom:343.301100px;}
.yde2{bottom:343.348500px;}
.ya24{bottom:343.582100px;}
.y4ed{bottom:343.582900px;}
.y931{bottom:343.733600px;}
.yb7f{bottom:343.753400px;}
.y8c{bottom:343.761100px;}
.yd8f{bottom:343.964200px;}
.yd9a{bottom:343.966650px;}
.y267{bottom:343.975800px;}
.yad{bottom:344.069900px;}
.y661{bottom:344.078100px;}
.y4cf{bottom:344.092800px;}
.ybbb{bottom:344.280400px;}
.y1213{bottom:344.413300px;}
.y1212{bottom:344.413500px;}
.y1351{bottom:344.453100px;}
.y2a6{bottom:344.506400px;}
.ycd2{bottom:344.512000px;}
.y139c{bottom:344.607450px;}
.y78e{bottom:344.708600px;}
.yb13{bottom:344.881400px;}
.yeb3{bottom:344.904900px;}
.y8a2{bottom:344.919100px;}
.y538{bottom:344.933900px;}
.yc1c{bottom:345.044400px;}
.y12b5{bottom:345.244100px;}
.ya32{bottom:345.600700px;}
.y116{bottom:345.739600px;}
.y12a1{bottom:345.739800px;}
.y11{bottom:345.870800px;}
.y10f6{bottom:346.024300px;}
.y152b{bottom:346.078400px;}
.y13b{bottom:346.114200px;}
.yd4c{bottom:346.119000px;}
.y88d{bottom:346.389900px;}
.y968{bottom:346.416700px;}
.y71a{bottom:346.436400px;}
.y1131{bottom:346.484600px;}
.yb6b{bottom:346.512000px;}
.y1488{bottom:346.566300px;}
.y13de{bottom:346.615100px;}
.y9ed{bottom:346.904900px;}
.y21f{bottom:346.941000px;}
.y615{bottom:347.267400px;}
.y376{bottom:347.400100px;}
.y40f{bottom:347.465150px;}
.y9cf{bottom:347.589900px;}
.y11ea{bottom:347.638034px;}
.y7b1{bottom:347.679900px;}
.y1389{bottom:347.744100px;}
.y173{bottom:347.769800px;}
.yf21{bottom:347.834900px;}
.y9a8{bottom:348.039500px;}
.yfad{bottom:348.075900px;}
.yc9{bottom:348.077900px;}
.y78b{bottom:348.103100px;}
.ye95{bottom:348.122100px;}
.y3c5{bottom:348.143900px;}
.y560{bottom:348.167900px;}
.y78f{bottom:348.208600px;}
.y1043{bottom:348.265800px;}
.y1471{bottom:348.276500px;}
.y43e{bottom:348.574200px;}
.y133a{bottom:348.588100px;}
.y23a{bottom:349.092100px;}
.y1062{bottom:349.098700px;}
.ye65{bottom:349.250900px;}
.y1421{bottom:349.251900px;}
.y6d7{bottom:349.347100px;}
.y691{bottom:349.400500px;}
.ybda{bottom:349.401000px;}
.y6b0{bottom:349.425000px;}
.ye3f{bottom:349.544100px;}
.yaa7{bottom:349.581400px;}
.yecd{bottom:349.632850px;}
.y3b0{bottom:349.655400px;}
.y268{bottom:349.725800px;}
.ybf5{bottom:349.739600px;}
.y1451{bottom:349.775700px;}
.y3e3{bottom:350.018800px;}
.y5bd{bottom:350.232900px;}
.y14da{bottom:350.276100px;}
.yd71{bottom:350.295950px;}
.y7d0{bottom:350.438800px;}
.y471{bottom:350.573400px;}
.y5a1{bottom:350.574200px;}
.ydcb{bottom:350.588400px;}
.y10c4{bottom:350.677200px;}
.y331{bottom:350.689800px;}
.y8c0{bottom:350.911900px;}
.y140e{bottom:350.912800px;}
.yc43{bottom:350.913200px;}
.y1545{bottom:350.913900px;}
.y6ed{bottom:351.287700px;}
.ye4c{bottom:351.408800px;}
.y5ff{bottom:351.434650px;}
.yad1{bottom:351.652400px;}
.y736{bottom:351.747400px;}
.y12ca{bottom:351.783500px;}
.y1a5{bottom:351.926700px;}
.ya8f{bottom:352.181300px;}
.y6d8{bottom:352.197100px;}
.y82e{bottom:352.271700px;}
.y12e1{bottom:352.284700px;}
.y507{bottom:352.379250px;}
.y4c2{bottom:352.463350px;}
.yba2{bottom:352.574200px;}
.ycf1{bottom:352.574500px;}
.y3f{bottom:352.791700px;}
.y64{bottom:352.807200px;}
.y867{bottom:352.817150px;}
.yd16{bottom:352.920700px;}
.y2e4{bottom:352.958500px;}
.y1fd{bottom:353.070600px;}
.y818{bottom:353.085900px;}
.yf44{bottom:353.217000px;}
.y14fb{bottom:353.257400px;}
.y341{bottom:353.408900px;}
.y1b4{bottom:353.438800px;}
.y11e9{bottom:353.566538px;}
.y15c9{bottom:353.589900px;}
.y365{bottom:353.686650px;}
.ye40{bottom:353.687588px;}
.y15eb{bottom:353.739900px;}
.y8de{bottom:353.744900px;}
.y110c{bottom:353.783500px;}
.y647{bottom:353.784100px;}
.ycfd{bottom:354.235600px;}
.y1300{bottom:354.411300px;}
.yd9{bottom:354.417800px;}
.y1512{bottom:354.731700px;}
.y54d{bottom:354.742300px;}
.y910{bottom:354.919100px;}
.yd15{bottom:354.920600px;}
.y2c4{bottom:354.920900px;}
.y7e9{bottom:354.956700px;}
.y1289{bottom:355.258200px;}
.y1316{bottom:355.301500px;}
.y5d3{bottom:355.513400px;}
.y1dd{bottom:355.784700px;}
.y7ff{bottom:355.904900px;}
.y580{bottom:355.921300px;}
.yf7{bottom:355.934600px;}
.ydbc{bottom:355.964600px;}
.yd99{bottom:355.967050px;}
.y15a1{bottom:356.235050px;}
.yee9{bottom:356.257400px;}
.y537{bottom:356.433650px;}
.ya23{bottom:356.582100px;}
.ya66{bottom:356.582200px;}
.y4ec{bottom:356.582900px;}
.yf61{bottom:356.607850px;}
.yb7e{bottom:356.753400px;}
.y660{bottom:357.078100px;}
.y4ce{bottom:357.092800px;}
.y1178{bottom:357.234650px;}
.ybba{bottom:357.280400px;}
.y1350{bottom:357.453100px;}
.y143f{bottom:357.457600px;}
.y2a5{bottom:357.506400px;}
.yb12{bottom:357.881400px;}
.yeb2{bottom:357.904900px;}
.y982{bottom:357.979100px;}
.yc1b{bottom:358.044400px;}
.y136a{bottom:358.092300px;}
.y930{bottom:358.150600px;}
.y865{bottom:358.566900px;}
.ya31{bottom:358.600700px;}
.y115{bottom:358.739600px;}
.y10f5{bottom:359.024300px;}
.y15a{bottom:359.078100px;}
.y152a{bottom:359.078400px;}
.y139{bottom:359.114200px;}
.y1211{bottom:359.247900px;}
.y967{bottom:359.416700px;}
.y719{bottom:359.436400px;}
.y11e8{bottom:359.495041px;}
.y1487{bottom:359.566300px;}
.y78a{bottom:359.603100px;}
.y9ec{bottom:359.904900px;}
.y21e{bottom:359.941000px;}
.yfcc{bottom:360.078200px;}
.y614{bottom:360.267400px;}
.y375{bottom:360.400100px;}
.y13ba{bottom:360.414900px;}
.yee4{bottom:360.445700px;}
.y9ce{bottom:360.589900px;}
.y7b0{bottom:360.679900px;}
.y1388{bottom:360.744100px;}
.y172{bottom:360.769800px;}
.yf20{bottom:360.834900px;}
.yefc{bottom:361.076900px;}
.yc8{bottom:361.077900px;}
.y13fa{bottom:361.114200px;}
.ye94{bottom:361.122100px;}
.y10{bottom:361.140400px;}
.y3c4{bottom:361.143900px;}
.y1042{bottom:361.265800px;}
.y1470{bottom:361.276500px;}
.y280{bottom:361.588100px;}
.yd8e{bottom:361.633250px;}
.yd4b{bottom:361.953700px;}
.y239{bottom:362.092100px;}
.ye64{bottom:362.250900px;}
.y1420{bottom:362.251900px;}
.y14d9{bottom:362.276500px;}
.y6af{bottom:362.425000px;}
.y1130{bottom:362.578400px;}
.yaa6{bottom:362.581400px;}
.y13a{bottom:362.614300px;}
.ybf4{bottom:362.739600px;}
.y5fe{bottom:362.934400px;}
.y3e2{bottom:363.018800px;}
.y6d6{bottom:363.179200px;}
.ycd1{bottom:363.181300px;}
.y7cf{bottom:363.438800px;}
.y470{bottom:363.573400px;}
.y5a0{bottom:363.574200px;}
.y8a1{bottom:363.588100px;}
.ydca{bottom:363.588400px;}
.yfac{bottom:363.910900px;}
.y8bf{bottom:363.911900px;}
.y140d{bottom:363.912800px;}
.y12b4{bottom:363.913100px;}
.yc42{bottom:363.913200px;}
.y1544{bottom:363.913900px;}
.y10ac{bottom:364.023100px;}
.y2f1{bottom:364.067300px;}
.y6ec{bottom:364.287700px;}
.y866{bottom:364.316900px;}
.ye4b{bottom:364.408800px;}
.y2e3{bottom:364.458250px;}
.y5bc{bottom:364.567450px;}
.y40e{bottom:364.634500px;}
.yad0{bottom:364.652400px;}
.yf43{bottom:364.716750px;}
.y735{bottom:364.747400px;}
.y12c9{bottom:364.783500px;}
.y3e{bottom:364.791400px;}
.y63{bottom:364.806900px;}
.y1a4{bottom:364.926700px;}
.ya8e{bottom:365.181300px;}
.y367{bottom:365.186000px;}
.y364{bottom:365.186400px;}
.y690{bottom:365.235500px;}
.y8b{bottom:365.265100px;}
.y13dd{bottom:365.284400px;}
.y12e0{bottom:365.284700px;}
.y108b{bottom:365.477400px;}
.ydf5{bottom:365.563000px;}
.yac{bottom:365.573900px;}
.yc81{bottom:365.574200px;}
.ycf0{bottom:365.574500px;}
.y15c8{bottom:365.589900px;}
.y3af{bottom:365.706900px;}
.yd13{bottom:365.920700px;}
.y266{bottom:365.948700px;}
.y1fc{bottom:366.070600px;}
.y817{bottom:366.085900px;}
.y54c{bottom:366.242050px;}
.y14fa{bottom:366.257400px;}
.y2f0{bottom:366.317300px;}
.y340{bottom:366.408900px;}
.y1b3{bottom:366.438800px;}
.y8dd{bottom:366.744900px;}
.y4c1{bottom:366.797900px;}
.yecc{bottom:367.301900px;}
.y12ff{bottom:367.411300px;}
.yd8{bottom:367.417800px;}
.y330{bottom:367.859100px;}
.y90f{bottom:367.919100px;}
.yd14{bottom:367.920600px;}
.y2c3{bottom:367.920900px;}
.y7e8{bottom:367.956700px;}
.yd70{bottom:367.965000px;}
.y506{bottom:368.131200px;}
.y15a0{bottom:368.235450px;}
.y1288{bottom:368.258200px;}
.y10da{bottom:368.350900px;}
.yba1{bottom:368.408800px;}
.y1007{bottom:368.416700px;}
.y5d2{bottom:368.513400px;}
.yf60{bottom:368.608250px;}
.yaf4{bottom:368.628400px;}
.y1dc{bottom:368.784700px;}
.y1574{bottom:368.904900px;}
.yf6{bottom:368.934600px;}
.y1177{bottom:369.235050px;}
.yee8{bottom:369.257400px;}
.y57f{bottom:369.338300px;}
.ya22{bottom:369.582100px;}
.ya65{bottom:369.582200px;}
.yb7d{bottom:369.753400px;}
.y65f{bottom:370.078100px;}
.y4cd{bottom:370.092800px;}
.ybb9{bottom:370.280400px;}
.y134f{bottom:370.453100px;}
.y2a4{bottom:370.506400px;}
.y3ac{bottom:370.706600px;}
.yf{bottom:370.740400px;}
.y536{bottom:370.768200px;}
.yb11{bottom:370.881400px;}
.yeb1{bottom:370.904900px;}
.yc1a{bottom:371.044400px;}
.y1369{bottom:371.092300px;}
.y126f{bottom:371.243500px;}
.ya30{bottom:371.600700px;}
.y10d9{bottom:371.665600px;}
.y114{bottom:371.739600px;}
.y1529{bottom:372.078400px;}
.y138{bottom:372.114200px;}
.y966{bottom:372.416700px;}
.y718{bottom:372.436400px;}
.y646{bottom:372.453100px;}
.y1486{bottom:372.566300px;}
.y92f{bottom:372.567600px;}
.y1267{bottom:372.817800px;}
.y9eb{bottom:372.904900px;}
.y21d{bottom:372.941000px;}
.y613{bottom:373.267400px;}
.y374{bottom:373.400100px;}
.y13b9{bottom:373.414900px;}
.y9cd{bottom:373.589900px;}
.yd8d{bottom:373.633650px;}
.yd98{bottom:373.636100px;}
.y7af{bottom:373.679900px;}
.yb53{bottom:373.685200px;}
.ybd9{bottom:373.739600px;}
.y1387{bottom:373.744100px;}
.y171{bottom:373.769800px;}
.yf1f{bottom:373.834900px;}
.y789{bottom:373.938100px;}
.yefb{bottom:374.076900px;}
.yc7{bottom:374.077900px;}
.y13f9{bottom:374.114200px;}
.ye93{bottom:374.122100px;}
.y3c3{bottom:374.143900px;}
.y1041{bottom:374.265800px;}
.y139b{bottom:374.276900px;}
.y5fd{bottom:374.434150px;}
.y7fe{bottom:374.574200px;}
.y6d5{bottom:374.678950px;}
.y88c{bottom:374.728600px;}
.y159{bottom:374.912800px;}
.y238{bottom:375.092100px;}
.y9a7{bottom:375.212400px;}
.y1154{bottom:375.251300px;}
.y196{bottom:375.251900px;}
.y55f{bottom:375.340900px;}
.yaa5{bottom:375.581400px;}
.y3ae{bottom:375.706600px;}
.ybf3{bottom:375.739600px;}
.y1339{bottom:375.761700px;}
.y3e1{bottom:376.018800px;}
.y5bb{bottom:376.067200px;}
.ydff{bottom:376.203200px;}
.y7ce{bottom:376.438800px;}
.y46f{bottom:376.573400px;}
.y59f{bottom:376.574200px;}
.y8a0{bottom:376.588100px;}
.ydc9{bottom:376.588400px;}
.y40d{bottom:376.634900px;}
.y3d{bottom:376.791100px;}
.y62{bottom:376.806600px;}
.y2ef{bottom:376.901900px;}
.y8be{bottom:376.911900px;}
.y1146{bottom:376.912800px;}
.y112f{bottom:376.912950px;}
.y12b3{bottom:376.913100px;}
.yc41{bottom:376.913200px;}
.y6eb{bottom:377.287700px;}
.ye4a{bottom:377.408800px;}
.y15c7{bottom:377.589900px;}
.yacf{bottom:377.652400px;}
.y10f4{bottom:377.693300px;}
.y15ee{bottom:377.739900px;}
.y43d{bottom:377.747400px;}
.y12c8{bottom:377.783500px;}
.y1a3{bottom:377.926700px;}
.ye63{bottom:378.085900px;}
.y110b{bottom:378.122100px;}
.ya8d{bottom:378.181300px;}
.y6ae{bottom:378.260000px;}
.y8a{bottom:378.265100px;}
.yab{bottom:378.573900px;}
.yc80{bottom:378.574200px;}
.ycef{bottom:378.574500px;}
.y2e2{bottom:378.792800px;}
.ydfe{bottom:378.828300px;}
.y1088{bottom:378.857600px;}
.y85a{bottom:378.948700px;}
.y1fb{bottom:379.070600px;}
.y2ee{bottom:379.151900px;}
.y14f9{bottom:379.257400px;}
.yecb{bottom:379.302300px;}
.y1268{bottom:379.312100px;}
.y33f{bottom:379.408900px;}
.y1b2{bottom:379.438800px;}
.y82d{bottom:379.445400px;}
.ydfc{bottom:379.447400px;}
.y363{bottom:379.520950px;}
.yfab{bottom:379.745900px;}
.y10d8{bottom:379.790000px;}
.y14d8{bottom:379.945550px;}
.y146f{bottom:379.945800px;}
.yd6f{bottom:379.965400px;}
.y11a6{bottom:380.257400px;}
.ye{bottom:380.340400px;}
.y12fe{bottom:380.411300px;}
.y54b{bottom:380.576600px;}
.yf5f{bottom:380.608650px;}
.y90e{bottom:380.919100px;}
.y2c2{bottom:380.920900px;}
.y7e7{bottom:380.956700px;}
.y505{bottom:381.131000px;}
.y4c0{bottom:381.134750px;}
.y5d1{bottom:381.513400px;}
.yaf3{bottom:381.628400px;}
.y143e{bottom:381.796800px;}
.yf42{bottom:381.886100px;}
.y1573{bottom:381.904900px;}
.yf5{bottom:381.934600px;}
.y32f{bottom:382.194550px;}
.yee7{bottom:382.257400px;}
.y535{bottom:382.267950px;}
.y981{bottom:382.317400px;}
.y8dc{bottom:382.579900px;}
.ya21{bottom:382.582100px;}
.ya64{bottom:382.582200px;}
.y1543{bottom:382.582900px;}
.yb7c{bottom:382.753400px;}
.y57e{bottom:382.755300px;}
.y75e{bottom:382.956700px;}
.y65e{bottom:383.078100px;}
.y4cc{bottom:383.092800px;}
.y1006{bottom:383.416700px;}
.y134e{bottom:383.453100px;}
.y2a3{bottom:383.506400px;}
.yeb0{bottom:383.904900px;}
.y12df{bottom:383.953700px;}
.yc19{bottom:384.044400px;}
.y1368{bottom:384.092300px;}
.y455{bottom:384.739600px;}
.y1528{bottom:385.078400px;}
.y137{bottom:385.114200px;}
.y965{bottom:385.416700px;}
.y717{bottom:385.436400px;}
.y788{bottom:385.438100px;}
.y645{bottom:385.453100px;}
.yd8c{bottom:385.634050px;}
.yd97{bottom:385.636500px;}
.y159f{bottom:385.904500px;}
.yd7{bottom:386.086800px;}
.y6d4{bottom:386.178700px;}
.y139a{bottom:386.277300px;}
.y373{bottom:386.400100px;}
.y423{bottom:386.506400px;}
.y9cc{bottom:386.589900px;}
.y7ae{bottom:386.679900px;}
.yb52{bottom:386.685200px;}
.y170{bottom:386.769800px;}
.yf1e{bottom:386.834900px;}
.y1176{bottom:386.904100px;}
.y1287{bottom:386.927200px;}
.y10c3{bottom:386.947000px;}
.yefa{bottom:387.076900px;}
.yc6{bottom:387.077900px;}
.y13f8{bottom:387.114200px;}
.ye92{bottom:387.122100px;}
.y3c2{bottom:387.143900px;}
.y1040{bottom:387.265800px;}
.y1db{bottom:387.453700px;}
.y5ba{bottom:387.566950px;}
.y158a{bottom:387.574200px;}
.y158{bottom:387.912800px;}
.y10d7{bottom:387.914500px;}
.ycbe{bottom:387.948900px;}
.y237{bottom:388.092100px;}
.y9a6{bottom:388.212400px;}
.y195{bottom:388.251900px;}
.y55e{bottom:388.340900px;}
.y112e{bottom:388.412700px;}
.yd96{bottom:388.486500px;}
.yaa4{bottom:388.581400px;}
.y9ea{bottom:388.739600px;}
.y3c{bottom:388.790800px;}
.y61{bottom:388.806300px;}
.yd4a{bottom:389.126900px;}
.y7cd{bottom:389.438800px;}
.y59e{bottom:389.574200px;}
.y1386{bottom:389.579100px;}
.y89f{bottom:389.588100px;}
.ydc8{bottom:389.588400px;}
.y15c6{bottom:389.589900px;}
.y13dc{bottom:389.623300px;}
.y15e2{bottom:389.739900px;}
.y8bd{bottom:389.911900px;}
.y12b2{bottom:389.913100px;}
.yc40{bottom:389.913200px;}
.yd{bottom:389.940400px;}
.y40c{bottom:389.996700px;}
.ya47{bottom:390.270000px;}
.y265{bottom:390.287700px;}
.y2e1{bottom:390.292550px;}
.y113{bottom:390.408800px;}
.yace{bottom:390.652400px;}
.y10f3{bottom:390.693300px;}
.y43c{bottom:390.747400px;}
.y1338{bottom:390.761300px;}
.y12c7{bottom:390.783500px;}
.y366{bottom:391.020300px;}
.y362{bottom:391.020700px;}
.y110a{bottom:391.122100px;}
.ya8c{bottom:391.181300px;}
.y92e{bottom:391.236600px;}
.y89{bottom:391.265100px;}
.yeca{bottom:391.302700px;}
.ye2c{bottom:391.424400px;}
.yaa{bottom:391.573900px;}
.yc7f{bottom:391.574200px;}
.ycee{bottom:391.574500px;}
.y5fc{bottom:391.603500px;}
.y3ad{bottom:391.757800px;}
.y612{bottom:391.936700px;}
.y14d7{bottom:391.945950px;}
.y859{bottom:391.948700px;}
.y7a7{bottom:392.041200px;}
.ydfb{bottom:392.069800px;}
.y13b8{bottom:392.084200px;}
.y14f8{bottom:392.257400px;}
.ycd0{bottom:392.354500px;}
.y1087{bottom:392.390000px;}
.y68f{bottom:392.408500px;}
.y1b1{bottom:392.438800px;}
.y1145{bottom:392.747400px;}
.y11a5{bottom:393.257400px;}
.y1266{bottom:393.265574px;}
.y12fd{bottom:393.411300px;}
.y816{bottom:393.589900px;}
.y32e{bottom:393.694300px;}
.y30d{bottom:393.694400px;}
.y30b{bottom:393.694650px;}
.y90d{bottom:393.919100px;}
.y2c1{bottom:393.920900px;}
.y7e6{bottom:393.956700px;}
.ycfc{bottom:394.408800px;}
.y82c{bottom:394.445000px;}
.y504{bottom:394.492700px;}
.y5d0{bottom:394.513400px;}
.ybd0{bottom:394.619000px;}
.yaf2{bottom:394.628400px;}
.y3e0{bottom:394.688100px;}
.y10ef{bottom:394.740600px;}
.y143d{bottom:394.796800px;}
.y10c2{bottom:394.829300px;}
.y1572{bottom:394.904900px;}
.yf4{bottom:394.934600px;}
.yb26{bottom:395.220000px;}
.y46e{bottom:395.242400px;}
.yee6{bottom:395.257400px;}
.y980{bottom:395.317400px;}
.y4bf{bottom:395.469300px;}
.y8db{bottom:395.579900px;}
.yfaa{bottom:395.580900px;}
.ya20{bottom:395.582100px;}
.ya63{bottom:395.582200px;}
.y126e{bottom:395.582900px;}
.yb7b{bottom:395.753400px;}
.y10d6{bottom:395.796800px;}
.y75d{bottom:395.956700px;}
.yfcb{bottom:396.078100px;}
.y4cb{bottom:396.092800px;}
.y57d{bottom:396.172300px;}
.y27f{bottom:396.430600px;}
.y134d{bottom:396.453100px;}
.y2a2{bottom:396.506400px;}
.y30c{bottom:396.544500px;}
.y1a1{bottom:396.596300px;}
.y534{bottom:396.602500px;}
.yeaf{bottom:396.904900px;}
.y787{bottom:396.938100px;}
.y12de{bottom:396.953700px;}
.y1315{bottom:396.971350px;}
.yc18{bottom:397.044400px;}
.y1367{bottom:397.092300px;}
.yd6e{bottom:397.634450px;}
.y1fa{bottom:397.739600px;}
.y54a{bottom:397.745900px;}
.y159e{bottom:397.904900px;}
.y33e{bottom:398.078100px;}
.y1527{bottom:398.078400px;}
.yf5e{bottom:398.277700px;}
.y964{bottom:398.416700px;}
.y716{bottom:398.436400px;}
.yf40{bottom:398.446950px;}
.y644{bottom:398.453100px;}
.y1175{bottom:398.904500px;}
.y372{bottom:399.400100px;}
.y6d3{bottom:399.400600px;}
.yc{bottom:399.540400px;}
.y485{bottom:399.589900px;}
.y7ad{bottom:399.679900px;}
.yb6a{bottom:399.685200px;}
.y1485{bottom:399.739600px;}
.y16f{bottom:399.769800px;}
.yf1d{bottom:399.834900px;}
.y1286{bottom:399.927200px;}
.y1265{bottom:399.935400px;}
.y1263{bottom:399.935437px;}
.yc5{bottom:400.077900px;}
.y1a2{bottom:400.096100px;}
.y21c{bottom:400.114200px;}
.ye91{bottom:400.122100px;}
.y3c1{bottom:400.143900px;}
.y103f{bottom:400.265800px;}
.yf41{bottom:400.678000px;}
.y3b{bottom:400.790500px;}
.y60{bottom:400.806300px;}
.y40b{bottom:400.996700px;}
.y236{bottom:401.092100px;}
.y9a5{bottom:401.212400px;}
.y194{bottom:401.251900px;}
.y55d{bottom:401.340900px;}
.y1091{bottom:401.444000px;}
.yaa3{bottom:401.581400px;}
.y15c5{bottom:401.589900px;}
.y1264{bottom:401.662900px;}
.ybf2{bottom:401.739600px;}
.y65d{bottom:401.747400px;}
.y1da{bottom:401.870700px;}
.yd49{bottom:402.126900px;}
.y848{bottom:402.265300px;}
.y7cc{bottom:402.438800px;}
.yb51{bottom:402.519800px;}
.y59d{bottom:402.574200px;}
.y1385{bottom:402.579100px;}
.y89e{bottom:402.588100px;}
.ydc7{bottom:402.588400px;}
.y112d{bottom:402.747250px;}
.y8bc{bottom:402.911900px;}
.y12b1{bottom:402.913100px;}
.yc3f{bottom:402.913200px;}
.y88b{bottom:403.067300px;}
.y264{bottom:403.287700px;}
.yd8b{bottom:403.303100px;}
.ye49{bottom:403.408800px;}
.y1090{bottom:403.444000px;}
.y7a6{bottom:403.540950px;}
.y10f2{bottom:403.693300px;}
.y157{bottom:403.747400px;}
.y136{bottom:403.783500px;}
.y14d6{bottom:403.946350px;}
.y1109{bottom:404.122100px;}
.ya8b{bottom:404.181300px;}
.y88{bottom:404.265100px;}
.y146e{bottom:404.284800px;}
.yc7e{bottom:404.574200px;}
.y13db{bottom:404.622900px;}
.y2e0{bottom:404.627100px;}
.y5b9{bottom:404.736300px;}
.yd6{bottom:404.755800px;}
.y32d{bottom:405.194050px;}
.y30a{bottom:405.194400px;}
.y14f7{bottom:405.257400px;}
.yccf{bottom:405.354500px;}
.y361{bottom:405.355250px;}
.y68e{bottom:405.408500px;}
.y1b0{bottom:405.438800px;}
.y503{bottom:405.492700px;}
.y92d{bottom:405.653600px;}
.yef9{bottom:405.745900px;}
.y11a4{bottom:406.257400px;}
.ye2b{bottom:406.307900px;}
.y12fc{bottom:406.411300px;}
.y815{bottom:406.589900px;}
.y1262{bottom:406.605262px;}
.y2c0{bottom:406.920900px;}
.y7e5{bottom:406.956700px;}
.y4be{bottom:406.969050px;}
.y143c{bottom:407.796800px;}
.y1571{bottom:407.904900px;}
.ydfd{bottom:407.926300px;}
.yf3{bottom:407.934600px;}
.y533{bottom:408.102250px;}
.y39f{bottom:408.243500px;}
.yee5{bottom:408.257400px;}
.y97f{bottom:408.317400px;}
.y8f4{bottom:408.579900px;}
.yfa9{bottom:408.580900px;}
.yba0{bottom:408.582100px;}
.ya62{bottom:408.582200px;}
.y126d{bottom:408.582900px;}
.yb7a{bottom:408.753400px;}
.y75c{bottom:408.956700px;}
.y1314{bottom:408.971750px;}
.yfca{bottom:409.078100px;}
.y4ca{bottom:409.092800px;}
.y27e{bottom:409.430600px;}
.y2a1{bottom:409.506400px;}
.y57c{bottom:409.589300px;}
.y1a0{bottom:409.596300px;}
.yd6d{bottom:409.634850px;}
.yeae{bottom:409.904900px;}
.yf3f{bottom:409.946700px;}
.y1366{bottom:410.092300px;}
.yced{bottom:410.243500px;}
.yf5d{bottom:410.278100px;}
.y1f8{bottom:410.739600px;}
.y6d2{bottom:410.900350px;}
.y1174{bottom:410.904900px;}
.ye29{bottom:411.058300px;}
.y46d{bottom:411.077400px;}
.y847{bottom:411.107800px;}
.y786{bottom:411.272700px;}
.y8da{bottom:411.414900px;}
.y963{bottom:411.416700px;}
.y715{bottom:411.436400px;}
.y643{bottom:411.453100px;}
.ydfa{bottom:411.631400px;}
.y371{bottom:412.400100px;}
.y90c{bottom:412.588100px;}
.y484{bottom:412.589900px;}
.yb69{bottom:412.685200px;}
.y549{bottom:412.748600px;}
.y3a{bottom:412.790500px;}
.yf1c{bottom:412.834900px;}
.y1285{bottom:412.927200px;}
.ya9{bottom:413.077900px;}
.y13f7{bottom:413.114200px;}
.ye90{bottom:413.122100px;}
.y1234{bottom:413.143166px;}
.y3c0{bottom:413.143900px;}
.y5cf{bottom:413.182700px;}
.y103e{bottom:413.265800px;}
.y1261{bottom:413.275088px;}
.y1248{bottom:413.276103px;}
.y5fb{bottom:413.298150px;}
.y15c4{bottom:413.589900px;}
.y235{bottom:414.092100px;}
.y9a4{bottom:414.212400px;}
.y1f9{bottom:414.239600px;}
.y112c{bottom:414.247000px;}
.yd30{bottom:414.251300px;}
.y141f{bottom:414.251900px;}
.y55c{bottom:414.340900px;}
.yb{bottom:414.810000px;}
.yae1{bottom:414.991000px;}
.y7a5{bottom:415.040700px;}
.ycbd{bottom:415.122100px;}
.yd48{bottom:415.126900px;}
.yd8a{bottom:415.303500px;}
.y7cb{bottom:415.438800px;}
.y59c{bottom:415.574200px;}
.y1384{bottom:415.579100px;}
.y89d{bottom:415.588100px;}
.yf7a{bottom:415.588400px;}
.y12dd{bottom:415.623000px;}
.ye2a{bottom:415.808300px;}
.y8bb{bottom:415.911900px;}
.y9e9{bottom:415.912100px;}
.y1399{bottom:415.946750px;}
.y2df{bottom:416.126850px;}
.y6c1{bottom:416.180800px;}
.y6c0{bottom:416.257300px;}
.y1d9{bottom:416.287700px;}
.y454{bottom:416.408800px;}
.y13b7{bottom:416.422800px;}
.y10f1{bottom:416.693300px;}
.y32c{bottom:416.693800px;}
.y5b8{bottom:416.736700px;}
.y112{bottom:416.747400px;}
.y12c6{bottom:416.783500px;}
.y360{bottom:416.855000px;}
.y1108{bottom:417.122100px;}
.ya8a{bottom:417.181300px;}
.y87{bottom:417.265100px;}
.ybf1{bottom:417.574200px;}
.y14f6{bottom:418.257400px;}
.ydc2{bottom:418.271000px;}
.y7ac{bottom:418.348900px;}
.ycce{bottom:418.354500px;}
.y68d{bottom:418.408500px;}
.y16e{bottom:418.438800px;}
.y4bd{bottom:418.468800px;}
.y1085{bottom:418.472000px;}
.yef8{bottom:418.745900px;}
.yaff{bottom:418.967000px;}
.y11a3{bottom:419.257400px;}
.y146d{bottom:419.284400px;}
.y12fb{bottom:419.411300px;}
.y814{bottom:419.589900px;}
.y193{bottom:419.920900px;}
.y7e4{bottom:419.956700px;}
.y92c{bottom:420.070600px;}
.yaba{bottom:420.251000px;}
.yc7d{bottom:420.408800px;}
.y1570{bottom:420.904900px;}
.yf2{bottom:420.934600px;}
.yec9{bottom:420.972150px;}
.y3df{bottom:421.026600px;}
.y611{bottom:421.109900px;}
.ydc6{bottom:421.257400px;}
.yc30{bottom:421.383000px;}
.yb9f{bottom:421.582100px;}
.ya61{bottom:421.582200px;}
.y126c{bottom:421.582900px;}
.y14d5{bottom:421.615400px;}
.yb79{bottom:421.753400px;}
.y5f{bottom:421.813800px;}
.y75b{bottom:421.956700px;}
.ye48{bottom:422.078100px;}
.y4c9{bottom:422.092800px;}
.yf5c{bottom:422.278500px;}
.y309{bottom:422.363700px;}
.y6d1{bottom:422.400100px;}
.y27d{bottom:422.430600px;}
.y532{bottom:422.436800px;}
.y1086{bottom:422.472000px;}
.y2a0{bottom:422.506400px;}
.yead{bottom:422.904900px;}
.y57b{bottom:423.006300px;}
.y1365{bottom:423.092300px;}
.ycec{bottom:423.243500px;}
.y610{bottom:423.360000px;}
.yd5{bottom:423.424800px;}
.y1f7{bottom:423.739600px;}
.y159d{bottom:424.078100px;}
.y846{bottom:424.107800px;}
.y8d9{bottom:424.414900px;}
.yfa8{bottom:424.415900px;}
.y962{bottom:424.416700px;}
.y714{bottom:424.436400px;}
.y642{bottom:424.453100px;}
.y5fa{bottom:424.797900px;}
.y90b{bottom:425.588100px;}
.y2bf{bottom:425.589900px;}
.y1337{bottom:425.603900px;}
.y785{bottom:425.607300px;}
.yb68{bottom:425.685200px;}
.yc59{bottom:425.739200px;}
.yf1b{bottom:425.834900px;}
.y1284{bottom:425.927200px;}
.ya8{bottom:426.077900px;}
.y13f6{bottom:426.114200px;}
.ye8f{bottom:426.122100px;}
.y3bf{bottom:426.143900px;}
.y103d{bottom:426.265800px;}
.y143b{bottom:426.465800px;}
.y46c{bottom:426.912400px;}
.y99a{bottom:426.987000px;}
.y251{bottom:427.092100px;}
.y9a3{bottom:427.212400px;}
.y33d{bottom:427.250900px;}
.y141e{bottom:427.251900px;}
.yd6c{bottom:427.303900px;}
.y55b{bottom:427.340900px;}
.yfc9{bottom:427.747400px;}
.y1398{bottom:427.947150px;}
.ycbc{bottom:428.122100px;}
.yb33{bottom:428.181200px;}
.y19f{bottom:428.265300px;}
.y59b{bottom:428.574200px;}
.y1383{bottom:428.579100px;}
.y112b{bottom:428.581550px;}
.y89c{bottom:428.588100px;}
.y8ba{bottom:428.911900px;}
.y9e8{bottom:428.912100px;}
.y1d8{bottom:429.287700px;}
.y13b6{bottom:429.422800px;}
.ye27{bottom:429.485000px;}
.y7a4{bottom:429.504250px;}
.yb50{bottom:429.693300px;}
.y156{bottom:429.747400px;}
.y12c5{bottom:429.783500px;}
.y4bc{bottom:429.968550px;}
.y1107{bottom:430.122100px;}
.ya89{bottom:430.181300px;}
.y86{bottom:430.265100px;}
.y1260{bottom:430.413174px;}
.yca3{bottom:430.574200px;}
.y5b6{bottom:431.025300px;}
.y32b{bottom:431.030150px;}
.ydf9{bottom:431.193800px;}
.y14f5{bottom:431.257400px;}
.y7ab{bottom:431.348900px;}
.yccd{bottom:431.354500px;}
.y88a{bottom:431.406000px;}
.y68c{bottom:431.408500px;}
.y16d{bottom:431.438800px;}
.yef7{bottom:431.745900px;}
.y11a2{bottom:432.257400px;}
.y6bf{bottom:432.271400px;}
.y813{bottom:432.589900px;}
.y192{bottom:432.920900px;}
.y135{bottom:432.956700px;}
.yd89{bottom:432.972550px;}
.y2de{bottom:433.296200px;}
.y12a0{bottom:433.416700px;}
.y14d4{bottom:433.615800px;}
.y39{bottom:433.794700px;}
.yd47{bottom:433.796200px;}
.y5e{bottom:433.813500px;}
.y156f{bottom:433.904900px;}
.yf1{bottom:433.934600px;}
.y5b7{bottom:434.025300px;}
.y7ca{bottom:434.107800px;}
.ye28{bottom:434.235400px;}
.ydc5{bottom:434.257400px;}
.y35f{bottom:434.426300px;}
.yc4{bottom:434.581900px;}
.yb9e{bottom:434.582100px;}
.ya60{bottom:434.582200px;}
.yb78{bottom:434.753400px;}
.y21b{bottom:434.956700px;}
.y7a2{bottom:435.254000px;}
.y27c{bottom:435.430600px;}
.y422{bottom:435.506400px;}
.yeac{bottom:435.904900px;}
.y1364{bottom:436.092300px;}
.yceb{bottom:436.243500px;}
.y57a{bottom:436.423300px;}
.y308{bottom:436.699400px;}
.y1f6{bottom:436.739600px;}
.y6d0{bottom:436.912150px;}
.y1173{bottom:437.078100px;}
.y125f{bottom:437.083000px;}
.y125d{bottom:437.083395px;}
.y784{bottom:437.107300px;}
.y845{bottom:437.107800px;}
.y638{bottom:437.309950px;}
.y8f3{bottom:437.414900px;}
.y961{bottom:437.416700px;}
.y713{bottom:437.436400px;}
.y641{bottom:437.453100px;}
.y15c3{bottom:437.589900px;}
.y530{bottom:437.724350px;}
.y15ea{bottom:437.739900px;}
.y4c8{bottom:437.927800px;}
.y12fa{bottom:438.080600px;}
.y90a{bottom:438.588100px;}
.y2be{bottom:438.589900px;}
.y1336{bottom:438.603900px;}
.y1322{bottom:438.641200px;}
.yb67{bottom:438.685200px;}
.y92b{bottom:438.739600px;}
.y125e{bottom:438.810500px;}
.yf1a{bottom:438.834900px;}
.y1283{bottom:438.927200px;}
.ye26{bottom:438.985400px;}
.ya7{bottom:439.077900px;}
.y13f5{bottom:439.114200px;}
.ye8e{bottom:439.122100px;}
.y5f9{bottom:439.134150px;}
.y3be{bottom:439.143900px;}
.y103c{bottom:439.265800px;}
.yd6b{bottom:439.304300px;}
.y13da{bottom:439.465500px;}
.y143a{bottom:439.465800px;}
.yf5b{bottom:439.947550px;}
.y12dc{bottom:439.961500px;}
.y112a{bottom:440.081300px;}
.y8d8{bottom:440.249900px;}
.y33c{bottom:440.250900px;}
.y126b{bottom:440.251900px;}
.yf3c{bottom:440.287700px;}
.y55a{bottom:440.340900px;}
.y7a3{bottom:441.004000px;}
.ycbb{bottom:441.122100px;}
.y29f{bottom:441.175600px;}
.y19e{bottom:441.265300px;}
.y4bb{bottom:441.468300px;}
.y59a{bottom:441.574200px;}
.y1382{bottom:441.579100px;}
.y89b{bottom:441.588100px;}
.yd4{bottom:442.093800px;}
.y263{bottom:442.287700px;}
.y5ce{bottom:442.355900px;}
.y13b5{bottom:442.422800px;}
.yb4f{bottom:442.693300px;}
.y155{bottom:442.747400px;}
.y12c4{bottom:442.783500px;}
.y1106{bottom:443.122100px;}
.y85{bottom:443.265100px;}
.yca2{bottom:443.574200px;}
.y1d7{bottom:443.704700px;}
.y125c{bottom:443.753221px;}
.y1083{bottom:443.986000px;}
.y14f4{bottom:444.257400px;}
.y7aa{bottom:444.348900px;}
.yccc{bottom:444.354500px;}
.y68b{bottom:444.408500px;}
.y16c{bottom:444.438800px;}
.y5cd{bottom:444.606000px;}
.yef6{bottom:444.745900px;}
.y9e7{bottom:444.747100px;}
.yd88{bottom:444.972950px;}
.y11a1{bottom:445.257400px;}
.y32a{bottom:445.364700px;}
.y812{bottom:445.589900px;}
.y14d3{bottom:445.616200px;}
.y38{bottom:445.794400px;}
.y5d{bottom:445.813200px;}
.y191{bottom:445.920900px;}
.y35e{bottom:445.926050px;}
.y134{bottom:445.956700px;}
.ya88{bottom:446.015900px;}
.y250{bottom:446.069200px;}
.ye47{bottom:446.416700px;}
.y370{bottom:446.739200px;}
.y156e{bottom:446.904900px;}
.yf0{bottom:446.934600px;}
.y7c9{bottom:447.107800px;}
.ydc4{bottom:447.257400px;}
.y8b9{bottom:447.580900px;}
.yc3{bottom:447.581900px;}
.yb9d{bottom:447.582100px;}
.ya5f{bottom:447.582200px;}
.y6be{bottom:447.608300px;}
.yb77{bottom:447.753400px;}
.y21a{bottom:447.956700px;}
.y1084{bottom:447.986000px;}
.y307{bottom:448.199150px;}
.y6cf{bottom:448.411900px;}
.y129f{bottom:448.416700px;}
.y27b{bottom:448.430600px;}
.y421{bottom:448.506400px;}
.y783{bottom:448.607300px;}
.y637{bottom:448.809700px;}
.yeab{bottom:448.904900px;}
.y1363{bottom:449.092300px;}
.y52f{bottom:449.224100px;}
.ycea{bottom:449.243500px;}
.y15c2{bottom:449.589900px;}
.y707{bottom:449.739600px;}
.y579{bottom:449.840300px;}
.y844{bottom:450.107800px;}
.y122f{bottom:450.311999px;}
.ybd8{bottom:450.416700px;}
.y125b{bottom:450.423047px;}
.y640{bottom:450.453100px;}
.y1242{bottom:450.546096px;}
.y1247{bottom:450.546615px;}
.y1313{bottom:450.641600px;}
.ydf8{bottom:450.756200px;}
.y108e{bottom:450.881400px;}
.y2dd{bottom:451.194400px;}
.y1193{bottom:451.304700px;}
.y9bc{bottom:451.551000px;}
.y111{bottom:451.589900px;}
.y1335{bottom:451.603900px;}
.yb66{bottom:451.685200px;}
.y92a{bottom:451.739600px;}
.yf19{bottom:451.834900px;}
.y1282{bottom:451.927200px;}
.yf5a{bottom:451.947950px;}
.y13f4{bottom:452.114200px;}
.ye8d{bottom:452.122100px;}
.y103b{bottom:452.265800px;}
.y13d9{bottom:452.465500px;}
.y1439{bottom:452.465800px;}
.yb32{bottom:452.519800px;}
.ye24{bottom:452.662200px;}
.y4ba{bottom:452.968050px;}
.y8d7{bottom:453.249900px;}
.yfa7{bottom:453.250900px;}
.y960{bottom:453.251300px;}
.y126a{bottom:453.251900px;}
.yf3b{bottom:453.287700px;}
.y559{bottom:453.340900px;}
.y5f8{bottom:453.468700px;}
.ycba{bottom:454.122100px;}
.y146c{bottom:454.126900px;}
.y19d{bottom:454.265300px;}
.y599{bottom:454.574200px;}
.y1381{bottom:454.579100px;}
.y89a{bottom:454.588100px;}
.y12db{bottom:454.961500px;}
.y262{bottom:455.287700px;}
.y13b4{bottom:455.422800px;}
.y10f0{bottom:455.693300px;}
.y154{bottom:455.747400px;}
.y12c3{bottom:455.783500px;}
.y1105{bottom:456.122100px;}
.yca1{bottom:456.574200px;}
.y1d6{bottom:456.704700px;}
.y36f{bottom:456.738950px;}
.y329{bottom:456.864450px;}
.yd6a{bottom:456.973350px;}
.y122e{bottom:456.981825px;}
.y1233{bottom:456.982343px;}
.y125a{bottom:457.092873px;}
.y1241{bottom:457.215922px;}
.y1246{bottom:457.216441px;}
.y908{bottom:457.257400px;}
.y5b5{bottom:457.348900px;}
.y78d{bottom:457.408400px;}
.y68a{bottom:457.408500px;}
.ye25{bottom:457.412600px;}
.y16b{bottom:457.438800px;}
.y1397{bottom:457.616600px;}
.ybf0{bottom:457.747100px;}
.y37{bottom:457.794400px;}
.y5c{bottom:457.812900px;}
.yd46{bottom:458.134800px;}
.y11a0{bottom:458.257400px;}
.y811{bottom:458.589900px;}
.y33b{bottom:458.919900px;}
.y190{bottom:458.920900px;}
.y133{bottom:458.956700px;}
.y39e{bottom:459.247500px;}
.y306{bottom:459.698900px;}
.y889{bottom:459.744700px;}
.y156d{bottom:459.904900px;}
.yef{bottom:459.934600px;}
.y782{bottom:460.107300px;}
.y7c8{bottom:460.107800px;}
.y1129{bottom:460.112900px;}
.yccb{bottom:460.189100px;}
.ydc3{bottom:460.257400px;}
.y35d{bottom:460.260600px;}
.ya6{bottom:460.581900px;}
.y9e6{bottom:460.582100px;}
.ya5e{bottom:460.582200px;}
.y52d{bottom:460.724800px;}
.y909{bottom:460.757500px;}
.yd3{bottom:460.762800px;}
.y219{bottom:460.956700px;}
.yb4e{bottom:461.362300px;}
.y734{bottom:461.416700px;}
.y27a{bottom:461.430600px;}
.y420{bottom:461.506400px;}
.y15c1{bottom:461.589900px;}
.y2f{bottom:461.790300px;}
.y5ed{bottom:461.810200px;}
.y24f{bottom:461.904200px;}
.yeaa{bottom:461.904900px;}
.ye23{bottom:462.162600px;}
.yce9{bottom:462.243500px;}
.y108f{bottom:462.338000px;}
.y12f9{bottom:462.419100px;}
.y1f5{bottom:462.495900px;}
.yec8{bottom:462.642000px;}
.y6ce{bottom:462.923950px;}
.y6bd{bottom:462.945100px;}
.y843{bottom:463.107800px;}
.y636{bottom:463.145900px;}
.ybb8{bottom:463.173400px;}
.y578{bottom:463.257300px;}
.y14d2{bottom:463.285250px;}
.yef5{bottom:463.414900px;}
.y8b8{bottom:463.415900px;}
.y52e{bottom:463.574200px;}
.y122d{bottom:463.651650px;}
.y1232{bottom:463.652169px;}
.y1259{bottom:463.762699px;}
.y1240{bottom:463.885748px;}
.y1245{bottom:463.886267px;}
.yf59{bottom:463.948350px;}
.y110{bottom:464.589900px;}
.y1334{bottom:464.603900px;}
.y929{bottom:464.739600px;}
.y84{bottom:464.769100px;}
.yf18{bottom:464.834900px;}
.y1281{bottom:464.927200px;}
.y5f7{bottom:464.968450px;}
.y4c6{bottom:465.101000px;}
.y1450{bottom:465.114200px;}
.ye8c{bottom:465.122100px;}
.y13d8{bottom:465.465500px;}
.y1438{bottom:465.465800px;}
.y8f2{bottom:466.249900px;}
.y1269{bottom:466.251900px;}
.yf3a{bottom:466.287700px;}
.y558{bottom:466.340900px;}
.y36e{bottom:466.738700px;}
.ycb9{bottom:467.122100px;}
.y146b{bottom:467.126900px;}
.ya05{bottom:467.181200px;}
.y19c{bottom:467.265300px;}
.y4b9{bottom:467.302600px;}
.y3ff{bottom:467.347650px;}
.yb65{bottom:467.519800px;}
.y598{bottom:467.574200px;}
.y1380{bottom:467.579100px;}
.y1362{bottom:467.761600px;}
.y261{bottom:468.287700px;}
.y2dc{bottom:468.364850px;}
.y706{bottom:468.408800px;}
.y36d{bottom:468.501200px;}
.y3de{bottom:468.561000px;}
.y4c7{bottom:468.601100px;}
.y3dd{bottom:468.637500px;}
.y39d{bottom:468.747400px;}
.y12c2{bottom:468.783500px;}
.y712{bottom:468.940300px;}
.yd69{bottom:468.973750px;}
.y8d6{bottom:469.084900px;}
.yfa6{bottom:469.085900px;}
.y63f{bottom:469.122100px;}
.y8{bottom:469.392900px;}
.yca0{bottom:469.574200px;}
.y1396{bottom:469.617000px;}
.y5b{bottom:469.812600px;}
.y907{bottom:470.257400px;}
.ydf7{bottom:470.318600px;}
.y122c{bottom:470.321476px;}
.y1231{bottom:470.321995px;}
.y29e{bottom:470.348900px;}
.y78c{bottom:470.408400px;}
.y689{bottom:470.408500px;}
.y1258{bottom:470.432524px;}
.y16a{bottom:470.438800px;}
.y123f{bottom:470.555574px;}
.y1244{bottom:470.556093px;}
.y711{bottom:470.702800px;}
.y13f3{bottom:470.783500px;}
.y103a{bottom:470.934800px;}
.y1d5{bottom:471.121700px;}
.yd45{bottom:471.134800px;}
.y305{bottom:471.198650px;}
.y328{bottom:471.199000px;}
.y119f{bottom:471.257400px;}
.y810{bottom:471.589900px;}
.y781{bottom:471.607300px;}
.y33a{bottom:471.919900px;}
.yfc8{bottom:471.920600px;}
.y18f{bottom:471.920900px;}
.y132{bottom:471.956700px;}
.yb93{bottom:472.092000px;}
.yee{bottom:472.934600px;}
.y7c7{bottom:473.107800px;}
.y1081{bottom:473.181000px;}
.ya87{bottom:473.188300px;}
.y898{bottom:473.257400px;}
.y5ec{bottom:473.309950px;}
.y2e{bottom:473.376000px;}
.ya5{bottom:473.581900px;}
.y9e5{bottom:473.582100px;}
.ya5d{bottom:473.582200px;}
.y15c0{bottom:473.589900px;}
.y218{bottom:473.956700px;}
.y13b3{bottom:474.092000px;}
.yb4d{bottom:474.362300px;}
.y153{bottom:474.416700px;}
.y6cd{bottom:474.423700px;}
.y279{bottom:474.430600px;}
.y41f{bottom:474.506400px;}
.yd87{bottom:474.642400px;}
.y108d{bottom:474.791400px;}
.y946{bottom:474.963900px;}
.y52c{bottom:475.059350px;}
.y14d1{bottom:475.285650px;}
.y1af{bottom:476.107800px;}
.y1022{bottom:476.416700px;}
.y5f6{bottom:476.468200px;}
.y35c{bottom:476.570850px;}
.y888{bottom:476.744800px;}
.y899{bottom:476.757500px;}
.y122b{bottom:476.991302px;}
.y1230{bottom:476.991821px;}
.ye22{bottom:477.046500px;}
.y1257{bottom:477.102350px;}
.y1082{bottom:477.181000px;}
.y123e{bottom:477.225400px;}
.y1243{bottom:477.225919px;}
.y12f8{bottom:477.419100px;}
.y635{bottom:477.480450px;}
.y1f4{bottom:477.495500px;}
.y10f{bottom:477.589900px;}
.y1333{bottom:477.603900px;}
.y24e{bottom:477.739200px;}
.y83{bottom:477.769100px;}
.y1280{bottom:477.927200px;}
.ye8b{bottom:478.122100px;}
.y13d7{bottom:478.465500px;}
.y156c{bottom:478.574200px;}
.y36{bottom:478.798300px;}
.y4b8{bottom:478.802350px;}
.y3fe{bottom:478.847400px;}
.y6bc{bottom:479.035700px;}
.yef4{bottom:479.249900px;}
.y8b7{bottom:479.250900px;}
.y1542{bottom:479.251900px;}
.yf39{bottom:479.287700px;}
.y557{bottom:479.340900px;}
.yd2{bottom:479.431800px;}
.ycb8{bottom:480.122100px;}
.y19b{bottom:480.265300px;}
.y597{bottom:480.574200px;}
.yf17{bottom:480.669900px;}
.yce8{bottom:480.912800px;}
.y1192{bottom:480.974150px;}
.yf58{bottom:481.617400px;}
.y39c{bottom:481.747400px;}
.y12c1{bottom:481.783500px;}
.y5a{bottom:481.812300px;}
.y8d5{bottom:482.084900px;}
.yc2{bottom:482.085900px;}
.y1123{bottom:482.086000px;}
.y63e{bottom:482.122100px;}
.yd44{bottom:482.134800px;}
.y304{bottom:482.698400px;}
.y327{bottom:482.698750px;}
.y2db{bottom:482.699400px;}
.y780{bottom:483.107300px;}
.yfc7{bottom:483.120700px;}
.y29d{bottom:483.348900px;}
.y169{bottom:483.438800px;}
.y1256{bottom:483.772176px;}
.y144f{bottom:483.783500px;}
.y1039{bottom:483.934800px;}
.y1d4{bottom:484.121700px;}
.yd43{bottom:484.134800px;}
.y80f{bottom:484.589900px;}
.y39a{bottom:484.651500px;}
.y399{bottom:484.728000px;}
.y576{bottom:484.761300px;}
.y5eb{bottom:484.809700px;}
.y339{bottom:484.919900px;}
.yfc6{bottom:484.920600px;}
.y18e{bottom:484.920900px;}
.y131{bottom:484.956700px;}
.y733{bottom:485.132500px;}
.y66f{bottom:485.247500px;}
.yc9f{bottom:485.408800px;}
.y15bf{bottom:485.589900px;}
.y15e7{bottom:485.739900px;}
.y146a{bottom:485.796200px;}
.yed{bottom:485.934600px;}
.y7c6{bottom:486.107800px;}
.y688{bottom:486.243500px;}
.y897{bottom:486.257400px;}
.y137f{bottom:486.411300px;}
.y52b{bottom:486.559100px;}
.y9e4{bottom:486.582100px;}
.ya5c{bottom:486.582200px;}
.yd68{bottom:486.642800px;}
.y217{bottom:486.956700px;}
.y14d0{bottom:487.286050px;}
.yb31{bottom:487.362300px;}
.y46b{bottom:487.416700px;}
.y278{bottom:487.430600px;}
.ybb7{bottom:487.512000px;}
.y35b{bottom:488.070600px;}
.y577{bottom:488.261400px;}
.y634{bottom:488.980200px;}
.ya86{bottom:489.023300px;}
.yea9{bottom:489.078100px;}
.y1ae{bottom:489.107800px;}
.yb9c{bottom:489.416700px;}
.ydf6{bottom:489.881000px;}
.y6cc{bottom:490.143800px;}
.y4b7{bottom:490.302100px;}
.y10e{bottom:490.589900px;}
.y1332{bottom:490.603900px;}
.y82{bottom:490.769100px;}
.y5f5{bottom:490.802750px;}
.y127f{bottom:490.927200px;}
.ye8a{bottom:491.122100px;}
.y13d6{bottom:491.465500px;}
.ya04{bottom:491.519800px;}
.y928{bottom:491.912800px;}
.y1541{bottom:492.251900px;}
.yf38{bottom:492.287700px;}
.y1321{bottom:492.311450px;}
.ye1e{bottom:492.350400px;}
.ycb7{bottom:493.122100px;}
.y41e{bottom:493.175600px;}
.y19a{bottom:493.265300px;}
.y24d{bottom:493.574200px;}
.yf57{bottom:493.617800px;}
.y108c{bottom:493.806400px;}
.y59{bottom:493.812000px;}
.y6bb{bottom:494.032950px;}
.y326{bottom:494.198500px;}
.y2da{bottom:494.199150px;}
.y3fd{bottom:494.399150px;}
.y77f{bottom:494.607300px;}
.yb64{bottom:494.692300px;}
.y43b{bottom:494.747400px;}
.y12c0{bottom:494.783500px;}
.y2d{bottom:494.976000px;}
.y8d4{bottom:495.084900px;}
.ya4{bottom:495.085900px;}
.y1122{bottom:495.086000px;}
.y63d{bottom:495.122100px;}
.y556{bottom:495.175900px;}
.y7{bottom:496.062900px;}
.yfc4{bottom:496.120700px;}
.y29c{bottom:496.348900px;}
.y1038{bottom:496.934800px;}
.y303{bottom:497.034000px;}
.ye21{bottom:497.100800px;}
.yd42{bottom:497.134800px;}
.y906{bottom:497.429800px;}
.y80e{bottom:497.589900px;}
.y575{bottom:497.761300px;}
.y338{bottom:497.919900px;}
.yfc5{bottom:497.920600px;}
.y18d{bottom:497.920900px;}
.y130{bottom:497.956700px;}
.yd1{bottom:498.100800px;}
.y1255{bottom:498.146774px;}
.y119e{bottom:498.430800px;}
.yd67{bottom:498.643200px;}
.yec{bottom:498.934600px;}
.y7c5{bottom:499.107800px;}
.y5ea{bottom:499.145200px;}
.y1395{bottom:499.286450px;}
.yf16{bottom:499.338900px;}
.y732{bottom:499.467700px;}
.ybef{bottom:499.582100px;}
.ya5b{bottom:499.582200px;}
.y6b9{bottom:499.782700px;}
.y35{bottom:499.802900px;}
.y1d3{bottom:499.956700px;}
.yb30{bottom:500.362300px;}
.y39b{bottom:500.416700px;}
.y277{bottom:500.430600px;}
.y633{bottom:500.479950px;}
.y398{bottom:500.742100px;}
.y397{bottom:500.818600px;}
.y52a{bottom:500.893650px;}
.y6cb{bottom:501.643550px;}
.y4b6{bottom:501.801850px;}
.ye1d{bottom:501.850800px;}
.y168{bottom:502.107800px;}
.y5f4{bottom:502.302500px;}
.y107f{bottom:502.376200px;}
.y9e3{bottom:502.416700px;}
.y10d{bottom:503.589900px;}
.y1331{bottom:503.603900px;}
.y81{bottom:503.769100px;}
.ye89{bottom:504.122100px;}
.yf77{bottom:504.311850px;}
.y13d5{bottom:504.465500px;}
.y1254{bottom:504.816600px;}
.y1252{bottom:504.817739px;}
.y35a{bottom:504.930500px;}
.y14cf{bottom:504.955100px;}
.y887{bottom:505.083500px;}
.ye19{bottom:505.146100px;}
.y1540{bottom:505.251900px;}
.y6ba{bottom:505.532700px;}
.y325{bottom:505.698250px;}
.y2c{bottom:505.776000px;}
.y58{bottom:505.811700px;}
.y3fc{bottom:505.898900px;}
.y77e{bottom:506.107300px;}
.ycb6{bottom:506.122100px;}
.y199{bottom:506.265300px;}
.y1080{bottom:506.376200px;}
.y1253{bottom:506.544100px;}
.ye20{bottom:506.601200px;}
.y4e8{bottom:506.890500px;}
.ye1a{bottom:507.265600px;}
.ya85{bottom:507.692300px;}
.y43a{bottom:507.747400px;}
.ya3{bottom:508.085900px;}
.y63c{bottom:508.122100px;}
.y2d9{bottom:508.533700px;}
.y302{bottom:508.533750px;}
.y29b{bottom:509.348900px;}
.y15be{bottom:509.589900px;}
.y127e{bottom:509.596200px;}
.y1037{bottom:509.934800px;}
.yd41{bottom:510.134800px;}
.y80d{bottom:510.589900px;}
.yee3{bottom:510.643600px;}
.y137e{bottom:510.749900px;}
.y574{bottom:510.761300px;}
.y337{bottom:510.919900px;}
.y18c{bottom:510.920900px;}
.y12f{bottom:510.956700px;}
.yf56{bottom:511.286850px;}
.ye1c{bottom:511.351200px;}
.y1251{bottom:511.487565px;}
.y34{bottom:511.802600px;}
.yeb{bottom:511.934600px;}
.y7c4{bottom:512.107800px;}
.yf15{bottom:512.338900px;}
.y529{bottom:512.393400px;}
.y12b0{bottom:512.582100px;}
.ya5a{bottom:512.582200px;}
.y1d2{bottom:512.956700px;}
.y6ca{bottom:513.143300px;}
.y4b5{bottom:513.301600px;}
.yb2f{bottom:513.362300px;}
.y687{bottom:513.416700px;}
.y896{bottom:513.430400px;}
.y12bf{bottom:513.452800px;}
.y5e9{bottom:513.479750px;}
.y5f3{bottom:513.802250px;}
.ye18{bottom:514.646500px;}
.y632{bottom:514.814500px;}
.y167{bottom:515.107800px;}
.y3dc{bottom:515.272700px;}
.ybee{bottom:515.416700px;}
.ye1f{bottom:516.101600px;}
.yd66{bottom:516.312250px;}
.y359{bottom:516.430250px;}
.y2b{bottom:516.576000px;}
.yc1{bottom:516.589900px;}
.y1330{bottom:516.603900px;}
.y80{bottom:516.769100px;}
.yd0{bottom:516.769800px;}
.y396{bottom:516.832600px;}
.y395{bottom:516.909100px;}
.y14ce{bottom:516.955500px;}
.y3da{bottom:517.172700px;}
.y324{bottom:517.198000px;}
.y3fb{bottom:517.398650px;}
.y13d4{bottom:517.465500px;}
.y77d{bottom:517.607300px;}
.y57{bottom:517.811400px;}
.y123d{bottom:518.137935px;}
.y1250{bottom:518.157391px;}
.y1239{bottom:518.206746px;}
.ycfb{bottom:518.251300px;}
.y4e7{bottom:518.390250px;}
.y122a{bottom:518.526622px;}
.ycb5{bottom:519.122100px;}
.y198{bottom:519.265300px;}
.y3db{bottom:520.022800px;}
.y2d8{bottom:520.033450px;}
.y301{bottom:520.033500px;}
.ya84{bottom:520.692300px;}
.y24c{bottom:520.747400px;}
.ye1b{bottom:520.851600px;}
.ya2{bottom:521.085900px;}
.y6ad{bottom:521.086000px;}
.y63b{bottom:521.122100px;}
.y15bd{bottom:521.589900px;}
.y29a{bottom:522.348900px;}
.ybb6{bottom:522.354500px;}
.y127d{bottom:522.596200px;}
.ye14{bottom:522.692100px;}
.ye88{bottom:522.791400px;}
.y1036{bottom:522.934800px;}
.yd40{bottom:523.134800px;}
.yf55{bottom:523.287250px;}
.yb63{bottom:523.527300px;}
.y80c{bottom:523.589900px;}
.y33{bottom:523.802300px;}
.y8d3{bottom:523.919900px;}
.y18b{bottom:523.920900px;}
.y12d{bottom:523.956700px;}
.ye17{bottom:524.146900px;}
.y6c9{bottom:524.643050px;}
.y4b4{bottom:524.801350px;}
.y123c{bottom:524.808023px;}
.y124f{bottom:524.827216px;}
.y1238{bottom:524.876571px;}
.yea{bottom:524.934600px;}
.y5e8{bottom:524.979500px;}
.y7c3{bottom:525.107800px;}
.y1229{bottom:525.196448px;}
.y5f2{bottom:525.302000px;}
.ya59{bottom:525.582200px;}
.y1d1{bottom:525.956700px;}
.y631{bottom:526.314250px;}
.ya03{bottom:526.362300px;}
.y439{bottom:526.416700px;}
.y527{bottom:526.728100px;}
.y336{bottom:526.754900px;}
.yf14{bottom:526.755900px;}
.y12e{bottom:527.456800px;}
.y276{bottom:527.603900px;}
.y531{bottom:527.906900px;}
.y358{bottom:527.930000px;}
.y166{bottom:528.107800px;}
.y731{bottom:528.136800px;}
.yd65{bottom:528.312650px;}
.y3fa{bottom:528.898400px;}
.y14cd{bottom:528.955900px;}
.y528{bottom:528.959400px;}
.y77c{bottom:529.107300px;}
.yc0{bottom:529.589900px;}
.y132f{bottom:529.603900px;}
.y56{bottom:529.811100px;}
.y4e6{bottom:529.890000px;}
.y13d3{bottom:530.465500px;}
.y12af{bottom:531.251300px;}
.y123b{bottom:531.478112px;}
.y124e{bottom:531.497042px;}
.y323{bottom:531.532550px;}
.y2d7{bottom:531.533200px;}
.y300{bottom:531.533250px;}
.y1237{bottom:531.546397px;}
.y107d{bottom:531.571500px;}
.y1ad{bottom:531.607900px;}
.y1228{bottom:531.866274px;}
.y903{bottom:532.246200px;}
.y904{bottom:532.246300px;}
.y2bd{bottom:532.590000px;}
.y394{bottom:532.923100px;}
.y393{bottom:532.999700px;}
.y15bc{bottom:533.589900px;}
.ya83{bottom:533.692300px;}
.y15e4{bottom:533.739900px;}
.y6ac{bottom:534.086000px;}
.y63a{bottom:534.122100px;}
.y299{bottom:535.348900px;}
.ycf{bottom:535.438800px;}
.y107e{bottom:535.571500px;}
.y32{bottom:535.802300px;}
.y1035{bottom:535.934800px;}
.yd3f{bottom:536.134800px;}
.y6c8{bottom:536.142800px;}
.ye16{bottom:536.156700px;}
.y108a{bottom:536.416400px;}
.yb62{bottom:536.527300px;}
.y80b{bottom:536.589900px;}
.y5f1{bottom:536.801750px;}
.yea8{bottom:536.919900px;}
.y18a{bottom:536.920900px;}
.y12c{bottom:536.956700px;}
.y2{bottom:537.322488px;}
.ycb4{bottom:537.791400px;}
.y573{bottom:537.934600px;}
.y905{bottom:537.941600px;}
.y7c2{bottom:538.107800px;}
.y123a{bottom:538.148200px;}
.y124d{bottom:538.166868px;}
.y2a{bottom:538.176000px;}
.ybb5{bottom:538.189100px;}
.y1236{bottom:538.216223px;}
.y7f{bottom:538.273100px;}
.y1227{bottom:538.536100px;}
.y1d0{bottom:538.956700px;}
.y5e7{bottom:539.314050px;}
.ya02{bottom:539.362300px;}
.y1526{bottom:539.416700px;}
.y730{bottom:539.636550px;}
.y335{bottom:539.754900px;}
.yf13{bottom:539.755900px;}
.y13f2{bottom:539.791400px;}
.yd64{bottom:540.313050px;}
.y630{bottom:540.648800px;}
.yf54{bottom:540.956300px;}
.y165{bottom:541.107800px;}
.y127c{bottom:541.265500px;}
.ya58{bottom:541.416700px;}
.y526{bottom:541.527850px;}
.y357{bottom:541.539450px;}
.y55{bottom:541.810800px;}
.y4b3{bottom:541.970700px;}
.y3f9{bottom:542.023650px;}
.y4e5{bottom:542.519450px;}
.ya1{bottom:542.589900px;}
.y321{bottom:543.032250px;}
.y322{bottom:543.032300px;}
.y2d6{bottom:543.032950px;}
.y2ff{bottom:543.033000px;}
.y77b{bottom:543.442000px;}
.y13d2{bottom:543.465500px;}
.y14bb{bottom:544.251300px;}
.y124c{bottom:544.836694px;}
.y15bb{bottom:545.589900px;}
.yec7{bottom:545.981700px;}
.y197{bottom:546.438200px;}
.y524{bottom:547.277600px;}
.y355{bottom:547.289200px;}
.y3f7{bottom:547.773400px;}
.y4e3{bottom:548.269200px;}
.y298{bottom:548.348900px;}
.y1034{bottom:548.934800px;}
.y392{bottom:549.013700px;}
.ye87{bottom:549.130800px;}
.yd3e{bottom:549.134800px;}
.y902{bottom:549.246300px;}
.ya82{bottom:549.527300px;}
.y80a{bottom:549.589900px;}
.y38f{bottom:549.891750px;}
.y1f3{bottom:549.920900px;}
.y5e6{bottom:550.813800px;}
.y7e{bottom:551.273100px;}
.y1cf{bottom:551.956700px;}
.ye9{bottom:552.108200px;}
.y62f{bottom:552.148550px;}
.ye15{bottom:552.247200px;}
.y15b7{bottom:552.313450px;}
.ya01{bottom:552.362300px;}
.y8d2{bottom:552.754900px;}
.y639{bottom:552.791400px;}
.yf53{bottom:552.956700px;}
.y525{bottom:553.027600px;}
.y356{bottom:553.039200px;}
.y1089{bottom:553.243400px;}
.y3f8{bottom:553.523400px;}
.y6c6{bottom:553.650700px;}
.y54{bottom:553.810500px;}
.y895{bottom:553.942200px;}
.y4b2{bottom:553.971100px;}
.y4e4{bottom:554.019200px;}
.yce{bottom:554.107800px;}
.yf12{bottom:554.172900px;}
.y97e{bottom:554.791400px;}
.ya0{bottom:555.589900px;}
.y1226{bottom:555.839878px;}
.y1235{bottom:555.840396px;}
.y6c7{bottom:555.881900px;}
.y13d1{bottom:556.465500px;}
.y31{bottom:556.806200px;}
.y15ba{bottom:557.589900px;}
.yd63{bottom:557.982100px;}
.y1{bottom:558.522278px;}
.y29{bottom:559.776000px;}
.y320{bottom:560.201600px;}
.y2d5{bottom:560.202300px;}
.y77a{bottom:560.611300px;}
.y107b{bottom:560.766600px;}
.y297{bottom:561.348900px;}
.y1225{bottom:561.768900px;}
.y1033{bottom:561.934800px;}
.yd3d{bottom:562.134800px;}
.y5e5{bottom:562.313550px;}
.y274{bottom:562.445800px;}
.y809{bottom:562.589900px;}
.y12b{bottom:564.130400px;}
.y38e{bottom:564.226300px;}
.y107c{bottom:564.766800px;}
.yaa2{bottom:564.769400px;}
.y390{bottom:564.799100px;}
.y3d9{bottom:565.104200px;}
.ya00{bottom:565.362300px;}
.y127b{bottom:565.604100px;}
.yea7{bottom:565.754900px;}
.y53{bottom:565.810200px;}
.y62e{bottom:566.483100px;}
.y5ef{bottom:567.332800px;}
.y391{bottom:567.649200px;}
.y4b1{bottom:567.832800px;}
.y9f{bottom:568.589900px;}
.y275{bottom:569.046400px;}
.y15b9{bottom:569.589900px;}
.y5f0{bottom:569.695300px;}
.yd62{bottom:569.982500px;}
.y886{bottom:570.587500px;}
.y7c1{bottom:570.779800px;}
.y124b{bottom:573.144935px;}
.y31e{bottom:575.948100px;}
.y2d3{bottom:575.948400px;}
.y779{bottom:576.349400px;}
.y30{bottom:577.810200px;}
.y4b0{bottom:577.832800px;}
.y31f{bottom:578.310600px;}
.y2d4{bottom:578.310900px;}
.y5ee{bottom:578.332800px;}
.y7d{bottom:578.446400px;}
.y124a{bottom:579.073958px;}
.y12a{bottom:579.130000px;}
.y5e4{bottom:579.482900px;}
.yd12{bottom:579.590000px;}
.y0{bottom:579.722250px;}
.y296{bottom:580.018100px;}
.yaa1{bottom:580.604100px;}
.yd3c{bottom:580.804000px;}
.y9ff{bottom:581.197000px;}
.y28{bottom:581.376000px;}
.y9e{bottom:581.589900px;}
.y107a{bottom:581.656500px;}
.y15b8{bottom:581.739900px;}
.y572{bottom:581.946400px;}
.yd61{bottom:581.982900px;}
.y1249{bottom:585.002980px;}
.y234{bottom:586.446400px;}
.y893{bottom:589.211000px;}
.y894{bottom:589.211100px;}
.y5{bottom:597.275000px;}
.y9{bottom:634.903500px;}
.y4{bottom:701.684190px;}
.h54{height:7.075200px;}
.h5f{height:8.807053px;}
.h53{height:9.433600px;}
.h5d{height:13.001858px;}
.h55{height:13.324800px;}
.h57{height:13.331462px;}
.h5b{height:15.106582px;}
.h5c{height:15.168835px;}
.h5e{height:15.339834px;}
.h3{height:15.984000px;}
.h50{height:17.304000px;}
.h4f{height:18.572400px;}
.h19{height:19.110000px;}
.h8{height:19.264000px;}
.h42{height:19.605600px;}
.h56{height:19.900800px;}
.h28{height:20.188000px;}
.h4a{height:20.386000px;}
.h2{height:20.628420px;}
.h1d{height:20.694800px;}
.h4c{height:20.801200px;}
.he{height:20.832000px;}
.h58{height:21.000000px;}
.h5a{height:21.700000px;}
.h14{height:21.784000px;}
.h1f{height:21.896000px;}
.h41{height:23.072000px;}
.h20{height:23.250000px;}
.h45{height:23.899708px;}
.h18{height:24.085600px;}
.h1c{height:24.206000px;}
.h4b{height:25.094838px;}
.h11{height:25.480000px;}
.h40{height:25.956000px;}
.h47{height:26.734422px;}
.h15{height:27.300000px;}
.h43{height:27.900000px;}
.h3f{height:28.008000px;}
.h1a{height:28.348000px;}
.h48{height:28.440984px;}
.h49{height:28.679650px;}
.h29{height:28.833220px;}
.h27{height:28.840000px;}
.ha{height:29.120000px;}
.h4d{height:29.450000px;}
.h61{height:29.480000px;}
.h1b{height:29.564000px;}
.h16{height:29.716000px;}
.h46{height:30.811066px;}
.h60{height:30.880000px;}
.h10{height:31.000000px;}
.h1e{height:31.120000px;}
.hd{height:31.280000px;}
.h51{height:31.724000px;}
.h25{height:32.676000px;}
.hc{height:32.760000px;}
.h23{height:34.408000px;}
.h17{height:34.580000px;}
.h2e{height:36.000000px;}
.hb{height:36.400000px;}
.h13{height:37.536000px;}
.h59{height:40.040000px;}
.h22{height:40.456000px;}
.h12{height:42.000000px;}
.hf{height:42.672000px;}
.h24{height:43.568000px;}
.h5{height:48.328125px;}
.h9{height:50.960000px;}
.h1{height:55.009140px;}
.h3a{height:63.581000px;}
.h21{height:73.152000px;}
.h38{height:77.726000px;}
.h7{height:82.544000px;}
.h2c{height:96.019000px;}
.h39{height:97.417000px;}
.h2b{height:98.267000px;}
.h36{height:105.885000px;}
.h30{height:118.440000px;}
.h2a{height:122.831000px;}
.h3c{height:128.435000px;}
.h3e{height:128.599000px;}
.h32{height:139.545000px;}
.h34{height:140.829000px;}
.h2f{height:141.713000px;}
.h31{height:143.977000px;}
.h33{height:144.805000px;}
.h3d{height:151.632000px;}
.h35{height:154.598000px;}
.h37{height:158.690000px;}
.h3b{height:163.007000px;}
.h2d{height:163.025000px;}
.h26{height:190.370000px;}
.h52{height:215.435000px;}
.h4e{height:224.001000px;}
.h44{height:452.165000px;}
.h62{height:677.730000px;}
.h0{height:679.090000px;}
.h6{height:680.280000px;}
.h4{height:680.315000px;}
.w7{width:198.146000px;}
.wa{width:203.500000px;}
.we{width:203.501000px;}
.w8{width:208.855000px;}
.w5{width:211.397000px;}
.w2{width:215.433000px;}
.w10{width:218.772000px;}
.wf{width:219.726000px;}
.wc{width:222.590000px;}
.w4{width:225.188000px;}
.wd{width:226.407000px;}
.wb{width:229.606000px;}
.w3{width:249.899000px;}
.w6{width:250.146000px;}
.w11{width:256.841000px;}
.w9{width:258.507000px;}
.w13{width:288.889000px;}
.w14{width:311.958000px;}
.w12{width:366.266000px;}
.w15{width:452.725000px;}
.w1{width:453.543000px;}
.w0{width:455.449000px;}
.x2{left:-452.231610px;}
.x1{left:-15.726230px;}
.xad{left:-1.862000px;}
.x4{left:0.000000px;}
.x9a{left:1.270700px;}
.xcc{left:6.027300px;}
.x9e{left:7.352000px;}
.xb7{left:8.772000px;}
.x3{left:10.623000px;}
.x45{left:13.028900px;}
.x27{left:14.792600px;}
.xf{left:18.125100px;}
.x8{left:20.938100px;}
.xc6{left:22.318019px;}
.xb1{left:24.610000px;}
.x9f{left:26.595100px;}
.xaa{left:27.659000px;}
.xae{left:30.072900px;}
.xa0{left:32.191000px;}
.xa2{left:33.244000px;}
.xab{left:37.770000px;}
.x0{left:40.338220px;}
.xbc{left:41.814000px;}
.xa1{left:42.850000px;}
.xb{left:45.082700px;}
.x8f{left:47.082700px;}
.x2d{left:48.082700px;}
.x1a{left:49.501500px;}
.x7{left:50.752000px;}
.xa3{left:51.775000px;}
.x20{left:53.586600px;}
.xa5{left:55.316900px;}
.x26{left:56.420700px;}
.x4d{left:58.421121px;}
.xa6{left:61.837000px;}
.x8d{left:64.090778px;}
.x71{left:65.604700px;}
.xc{left:67.759800px;}
.xc5{left:69.091904px;}
.x38{left:70.259919px;}
.x98{left:72.519300px;}
.x99{left:73.871700px;}
.x95{left:76.281100px;}
.xb2{left:78.521000px;}
.xb0{left:80.486000px;}
.xa7{left:81.911000px;}
.xa4{left:83.826000px;}
.x6{left:85.142000px;}
.xac{left:86.266000px;}
.x9d{left:88.412000px;}
.x9{left:90.437000px;}
.xbb{left:91.503900px;}
.x47{left:92.937000px;}
.x46{left:94.774000px;}
.x1b{left:96.106300px;}
.xda{left:97.398200px;}
.x14{left:98.703600px;}
.xa9{left:100.502000px;}
.x16{left:101.776000px;}
.x7a{left:103.775600px;}
.xa{left:105.637100px;}
.x37{left:107.066700px;}
.xa8{left:108.341000px;}
.x7b{left:109.445257px;}
.xd7{left:110.534700px;}
.xb9{left:112.104000px;}
.x10{left:113.114200px;}
.x97{left:114.824000px;}
.x24{left:116.257300px;}
.x9b{left:117.786700px;}
.x93{left:119.992700px;}
.x77{left:121.122200px;}
.x25{left:122.156100px;}
.x3c{left:123.225500px;}
.x44{left:124.468600px;}
.x82{left:125.626600px;}
.x5a{left:127.393363px;}
.x49{left:128.710900px;}
.x28{left:130.122800px;}
.xba{left:132.284000px;}
.x3a{left:133.604100px;}
.x8b{left:134.629300px;}
.x35{left:135.791300px;}
.x3b{left:136.796400px;}
.xc2{left:137.890163px;}
.x39{left:138.994900px;}
.x66{left:140.131200px;}
.x5{left:141.447200px;}
.x5f{left:143.110200px;}
.xb8{left:144.817000px;}
.x21{left:146.171600px;}
.x11{left:147.352900px;}
.xdb{left:148.523500px;}
.x5d{left:149.694900px;}
.x22{left:151.571400px;}
.x72{left:152.830000px;}
.xb3{left:153.868000px;}
.x60{left:155.464300px;}
.x61{left:157.360300px;}
.x7f{left:158.469000px;}
.x62{left:159.998600px;}
.x13{left:162.437000px;}
.xaf{left:164.075900px;}
.x81{left:165.737600px;}
.x17{left:167.533900px;}
.x70{left:168.579800px;}
.x3d{left:170.430900px;}
.xb5{left:171.479000px;}
.x76{left:173.063100px;}
.x9c{left:175.099000px;}
.x3e{left:176.260600px;}
.x94{left:177.555700px;}
.xdd{left:178.773092px;}
.x18{left:181.667100px;}
.x63{left:182.984900px;}
.x1c{left:184.465300px;}
.xc4{left:185.527900px;}
.x19{left:187.828900px;}
.x4a{left:188.918100px;}
.xc1{left:190.669734px;}
.xb6{left:191.699000px;}
.x3f{left:192.921700px;}
.x50{left:194.449000px;}
.x2b{left:196.864800px;}
.x40{left:198.751300px;}
.x2c{left:200.568000px;}
.x86{left:202.121500px;}
.xb4{left:204.348000px;}
.x4f{left:205.645300px;}
.x5b{left:206.876200px;}
.x51{left:208.866600px;}
.x52{left:210.762700px;}
.x75{left:212.237100px;}
.x53{left:213.401000px;}
.xdc{left:215.311173px;}
.x41{left:216.798400px;}
.x80{left:218.432500px;}
.x42{left:220.623100px;}
.x29{left:222.857400px;}
.x31{left:227.234100px;}
.x2a{left:228.770400px;}
.xbd{left:231.460900px;}
.x88{left:232.845500px;}
.x73{left:234.807000px;}
.xc8{left:235.996500px;}
.x54{left:238.935300px;}
.x74{left:239.971000px;}
.xd9{left:241.142639px;}
.x64{left:242.570700px;}
.x1f{left:244.020700px;}
.x4e{left:246.281500px;}
.xc7{left:247.636249px;}
.x32{left:250.936300px;}
.xd4{left:253.047200px;}
.x84{left:256.766700px;}
.x34{left:261.864200px;}
.xd8{left:262.976000px;}
.xc9{left:264.388600px;}
.x91{left:267.186400px;}
.xd6{left:270.248000px;}
.x8a{left:273.183900px;}
.xd0{left:275.437800px;}
.x36{left:276.657400px;}
.x79{left:278.666000px;}
.x87{left:280.523600px;}
.x1e{left:282.325900px;}
.x5e{left:283.828172px;}
.x1d{left:286.046400px;}
.x65{left:289.259500px;}
.x89{left:291.213700px;}
.x43{left:296.144700px;}
.x48{left:297.236300px;}
.x6e{left:298.641400px;}
.xc0{left:302.066900px;}
.x55{left:304.821200px;}
.x8c{left:306.100200px;}
.x6b{left:307.547250px;}
.xd5{left:309.078200px;}
.x15{left:310.267400px;}
.x85{left:311.738350px;}
.x2f{left:312.738450px;}
.x2e{left:314.620400px;}
.x8e{left:317.291800px;}
.x4b{left:319.954800px;}
.x56{left:321.045400px;}
.x90{left:322.469700px;}
.x57{left:323.683700px;}
.x6c{left:325.798700px;}
.x58{left:327.039700px;}
.x4c{left:329.256600px;}
.x33{left:330.528100px;}
.xd{left:331.607800px;}
.x12{left:333.010900px;}
.xd3{left:336.300900px;}
.xdf{left:338.282300px;}
.x67{left:339.559800px;}
.xc3{left:343.127414px;}
.xcf{left:344.888700px;}
.x7d{left:347.411200px;}
.x59{left:349.307500px;}
.x92{left:351.454600px;}
.x7e{left:353.059400px;}
.x6d{left:355.474650px;}
.x83{left:356.577800px;}
.x68{left:357.629100px;}
.x69{left:359.525200px;}
.x23{left:362.326700px;}
.xca{left:363.450200px;}
.x6a{left:365.519400px;}
.x6f{left:368.923200px;}
.x30{left:372.469600px;}
.x7c{left:373.726100px;}
.x78{left:375.143500px;}
.xcd{left:376.479700px;}
.xd1{left:383.971100px;}
.xce{left:385.166200px;}
.x5c{left:387.620600px;}
.xbe{left:393.481700px;}
.xcb{left:394.870500px;}
.xd2{left:400.244200px;}
.xbf{left:405.248100px;}
.xe{left:424.926500px;}
.xde{left:427.667500px;}
.x96{left:433.412100px;}
.xe1{left:475.180770px;}
.xe0{left:531.245220px;}
@media print{
.v0{vertical-align:0.000000pt;}
.ls376{letter-spacing:-10.240000pt;}
.ls248{letter-spacing:-8.160000pt;}
.ls257{letter-spacing:-7.584000pt;}
.ls35{letter-spacing:-7.226667pt;}
.ls254{letter-spacing:-7.056000pt;}
.ls246{letter-spacing:-6.970667pt;}
.ls38{letter-spacing:-6.613333pt;}
.ls41{letter-spacing:-6.122667pt;}
.ls14b{letter-spacing:-3.298400pt;}
.ls288{letter-spacing:-2.373333pt;}
.ls2a7{letter-spacing:-2.277333pt;}
.ls371{letter-spacing:-2.267200pt;}
.ls35d{letter-spacing:-2.260267pt;}
.ls2a4{letter-spacing:-2.245333pt;}
.ls305{letter-spacing:-2.197333pt;}
.lscf{letter-spacing:-2.165333pt;}
.ls269{letter-spacing:-2.106667pt;}
.ls116{letter-spacing:-2.058667pt;}
.ls2a6{letter-spacing:-2.032000pt;}
.ls215{letter-spacing:-2.011467pt;}
.ls2f2{letter-spacing:-1.994667pt;}
.lsf8{letter-spacing:-1.968000pt;}
.ls214{letter-spacing:-1.965867pt;}
.ls275{letter-spacing:-1.930667pt;}
.lsea{letter-spacing:-1.925333pt;}
.ls1cd{letter-spacing:-1.920000pt;}
.ls358{letter-spacing:-1.899733pt;}
.ls2f1{letter-spacing:-1.877333pt;}
.ls1f5{letter-spacing:-1.834133pt;}
.ls33e{letter-spacing:-1.824000pt;}
.ls343{letter-spacing:-1.813333pt;}
.ls375{letter-spacing:-1.802667pt;}
.ls367{letter-spacing:-1.799467pt;}
.ls304{letter-spacing:-1.797333pt;}
.ls260{letter-spacing:-1.792000pt;}
.ls307{letter-spacing:-1.781333pt;}
.lsb5{letter-spacing:-1.765333pt;}
.ls30c{letter-spacing:-1.749333pt;}
.ls1cc{letter-spacing:-1.744000pt;}
.ls34f{letter-spacing:-1.728000pt;}
.ls2b1{letter-spacing:-1.722667pt;}
.ls366{letter-spacing:-1.717333pt;}
.ls30d{letter-spacing:-1.712000pt;}
.ls1c1{letter-spacing:-1.706667pt;}
.ls2e6{letter-spacing:-1.696000pt;}
.ls36d{letter-spacing:-1.690667pt;}
.ls36e{letter-spacing:-1.680000pt;}
.ls225{letter-spacing:-1.674667pt;}
.ls2d8{letter-spacing:-1.669333pt;}
.ls28a{letter-spacing:-1.664000pt;}
.ls226{letter-spacing:-1.658667pt;}
.ls2ee{letter-spacing:-1.648000pt;}
.ls2c3{letter-spacing:-1.637333pt;}
.lsff{letter-spacing:-1.632000pt;}
.ls361{letter-spacing:-1.626667pt;}
.ls228{letter-spacing:-1.621333pt;}
.ls227{letter-spacing:-1.610667pt;}
.ls12b{letter-spacing:-1.601067pt;}
.ls31c{letter-spacing:-1.600000pt;}
.ls1c0{letter-spacing:-1.594667pt;}
.ls2ea{letter-spacing:-1.584000pt;}
.ls353{letter-spacing:-1.578667pt;}
.ls289{letter-spacing:-1.573333pt;}
.ls36b{letter-spacing:-1.562667pt;}
.ls261{letter-spacing:-1.560533pt;}
.lsdb{letter-spacing:-1.557333pt;}
.ls1c8{letter-spacing:-1.552000pt;}
.ls267{letter-spacing:-1.545333pt;}
.ls216{letter-spacing:-1.540267pt;}
.ls35b{letter-spacing:-1.530667pt;}
.ls330{letter-spacing:-1.525333pt;}
.ls176{letter-spacing:-1.514933pt;}
.ls1ff{letter-spacing:-1.514667pt;}
.ls21c{letter-spacing:-1.509333pt;}
.ls1a1{letter-spacing:-1.504800pt;}
.ls29f{letter-spacing:-1.504000pt;}
.ls26a{letter-spacing:-1.498667pt;}
.ls68{letter-spacing:-1.493333pt;}
.ls117{letter-spacing:-1.488000pt;}
.ls188{letter-spacing:-1.482667pt;}
.ls2e5{letter-spacing:-1.477333pt;}
.ls2c7{letter-spacing:-1.472000pt;}
.ls162{letter-spacing:-1.461333pt;}
.lse9{letter-spacing:-1.456000pt;}
.ls6f{letter-spacing:-1.450667pt;}
.ls2b3{letter-spacing:-1.440000pt;}
.ls2cd{letter-spacing:-1.434667pt;}
.ls284{letter-spacing:-1.429333pt;}
.ls306{letter-spacing:-1.424000pt;}
.ls2b4{letter-spacing:-1.418667pt;}
.ls29d{letter-spacing:-1.413333pt;}
.ls66{letter-spacing:-1.408000pt;}
.ls1fb{letter-spacing:-1.402667pt;}
.ls60{letter-spacing:-1.397333pt;}
.ls286{letter-spacing:-1.392000pt;}
.ls63{letter-spacing:-1.386667pt;}
.ls2b9{letter-spacing:-1.381333pt;}
.ls205{letter-spacing:-1.376000pt;}
.ls58{letter-spacing:-1.370667pt;}
.ls383{letter-spacing:-1.368000pt;}
.ls2ef{letter-spacing:-1.365333pt;}
.ls22b{letter-spacing:-1.360000pt;}
.ls36a{letter-spacing:-1.354667pt;}
.ls1ec{letter-spacing:-1.352800pt;}
.lsc0{letter-spacing:-1.349333pt;}
.lsbd{letter-spacing:-1.344000pt;}
.lsdf{letter-spacing:-1.338667pt;}
.ls202{letter-spacing:-1.333333pt;}
.ls1d2{letter-spacing:-1.328000pt;}
.ls24e{letter-spacing:-1.322667pt;}
.ls153{letter-spacing:-1.317333pt;}
.lse0{letter-spacing:-1.312000pt;}
.ls287{letter-spacing:-1.306667pt;}
.ls12c{letter-spacing:-1.302133pt;}
.ls2d3{letter-spacing:-1.301333pt;}
.ls74{letter-spacing:-1.296000pt;}
.ls108{letter-spacing:-1.286933pt;}
.ls18a{letter-spacing:-1.285333pt;}
.ls33f{letter-spacing:-1.280000pt;}
.ls98{letter-spacing:-1.274667pt;}
.ls1f6{letter-spacing:-1.271733pt;}
.ls1f{letter-spacing:-1.269333pt;}
.ls7e{letter-spacing:-1.264000pt;}
.lsaf{letter-spacing:-1.258667pt;}
.ls111{letter-spacing:-1.253333pt;}
.ls20{letter-spacing:-1.248000pt;}
.ls8d{letter-spacing:-1.242667pt;}
.ls15a{letter-spacing:-1.237333pt;}
.lse{letter-spacing:-1.233067pt;}
.ls237{letter-spacing:-1.232000pt;}
.ls250{letter-spacing:-1.231200pt;}
.lsc9{letter-spacing:-1.226667pt;}
.ls219{letter-spacing:-1.221333pt;}
.ls5a{letter-spacing:-1.216000pt;}
.ls25b{letter-spacing:-1.210667pt;}
.ls2a9{letter-spacing:-1.205333pt;}
.ls23d{letter-spacing:-1.200800pt;}
.ls2c5{letter-spacing:-1.200000pt;}
.ls141{letter-spacing:-1.194667pt;}
.ls206{letter-spacing:-1.189333pt;}
.ls197{letter-spacing:-1.184000pt;}
.ls17d{letter-spacing:-1.178667pt;}
.lsb4{letter-spacing:-1.173333pt;}
.ls7b{letter-spacing:-1.168000pt;}
.ls10a{letter-spacing:-1.165333pt;}
.ls26e{letter-spacing:-1.162667pt;}
.ls14f{letter-spacing:-1.157333pt;}
.ls125{letter-spacing:-1.152000pt;}
.ls87{letter-spacing:-1.146667pt;}
.ls1ac{letter-spacing:-1.141333pt;}
.ls1d5{letter-spacing:-1.136000pt;}
.ls1bc{letter-spacing:-1.134933pt;}
.lsde{letter-spacing:-1.130667pt;}
.ls1f7{letter-spacing:-1.129867pt;}
.lsab{letter-spacing:-1.125333pt;}
.lsd9{letter-spacing:-1.124800pt;}
.ls232{letter-spacing:-1.120000pt;}
.ls203{letter-spacing:-1.114667pt;}
.ls15f{letter-spacing:-1.109333pt;}
.ls37e{letter-spacing:-1.104533pt;}
.ls165{letter-spacing:-1.104000pt;}
.lsc7{letter-spacing:-1.098667pt;}
.ls356{letter-spacing:-1.094400pt;}
.ls102{letter-spacing:-1.093333pt;}
.ls37f{letter-spacing:-1.089333pt;}
.ls65{letter-spacing:-1.088000pt;}
.ls2ac{letter-spacing:-1.082667pt;}
.ls2bf{letter-spacing:-1.077333pt;}
.ls23c{letter-spacing:-1.074133pt;}
.ls2f0{letter-spacing:-1.072000pt;}
.ls11b{letter-spacing:-1.069067pt;}
.ls4b{letter-spacing:-1.066667pt;}
.lsfe{letter-spacing:-1.061333pt;}
.ls1f1{letter-spacing:-1.056000pt;}
.ls8{letter-spacing:-1.053867pt;}
.ls61{letter-spacing:-1.050667pt;}
.ls7{letter-spacing:-1.049600pt;}
.lsf7{letter-spacing:-1.045333pt;}
.ls1c2{letter-spacing:-1.043733pt;}
.ls17f{letter-spacing:-1.040000pt;}
.ls22c{letter-spacing:-1.034667pt;}
.ls2f4{letter-spacing:-1.034218pt;}
.ls2a0{letter-spacing:-1.029333pt;}
.ls24a{letter-spacing:-1.024000pt;}
.ls273{letter-spacing:-1.018667pt;}
.lsf6{letter-spacing:-1.014347pt;}
.lsb1{letter-spacing:-1.013333pt;}
.ls1b9{letter-spacing:-1.008000pt;}
.ls139{letter-spacing:-1.003200pt;}
.ls21d{letter-spacing:-1.002667pt;}
.ls19f{letter-spacing:-0.998133pt;}
.lsa0{letter-spacing:-0.997333pt;}
.ls128{letter-spacing:-0.992000pt;}
.ls10{letter-spacing:-0.989867pt;}
.lsd4{letter-spacing:-0.988000pt;}
.ls83{letter-spacing:-0.986667pt;}
.ls2ae{letter-spacing:-0.981333pt;}
.ls223{letter-spacing:-0.977867pt;}
.ls56{letter-spacing:-0.976000pt;}
.ls2e7{letter-spacing:-0.970667pt;}
.lsd1{letter-spacing:-0.965333pt;}
.lsbc{letter-spacing:-0.960000pt;}
.ls107{letter-spacing:-0.957600pt;}
.lsa9{letter-spacing:-0.954667pt;}
.ls25c{letter-spacing:-0.949333pt;}
.ls47{letter-spacing:-0.944000pt;}
.ls43{letter-spacing:-0.938667pt;}
.ls1b4{letter-spacing:-0.937333pt;}
.ls145{letter-spacing:-0.933333pt;}
.ls79{letter-spacing:-0.928000pt;}
.ls294{letter-spacing:-0.922667pt;}
.ls121{letter-spacing:-0.922133pt;}
.ls14d{letter-spacing:-0.920000pt;}
.lsbe{letter-spacing:-0.917333pt;}
.ls16b{letter-spacing:-0.912000pt;}
.ls2d4{letter-spacing:-0.910933pt;}
.ls2e4{letter-spacing:-0.908267pt;}
.ls5f{letter-spacing:-0.906667pt;}
.ls109{letter-spacing:-0.901867pt;}
.lsfa{letter-spacing:-0.901333pt;}
.lsec{letter-spacing:-0.896000pt;}
.ls1ba{letter-spacing:-0.890667pt;}
.ls1e5{letter-spacing:-0.886667pt;}
.lsbb{letter-spacing:-0.885333pt;}
.ls190{letter-spacing:-0.880000pt;}
.ls1e3{letter-spacing:-0.876533pt;}
.ls161{letter-spacing:-0.874667pt;}
.lsd3{letter-spacing:-0.871467pt;}
.lsf9{letter-spacing:-0.869333pt;}
.lsed{letter-spacing:-0.864000pt;}
.ls318{letter-spacing:-0.861333pt;}
.ls1db{letter-spacing:-0.858667pt;}
.lsc6{letter-spacing:-0.853333pt;}
.ls1fc{letter-spacing:-0.848000pt;}
.ls174{letter-spacing:-0.846133pt;}
.ls17b{letter-spacing:-0.842667pt;}
.ls354{letter-spacing:-0.837333pt;}
.lse7{letter-spacing:-0.832000pt;}
.ls382{letter-spacing:-0.830933pt;}
.ls25{letter-spacing:-0.826667pt;}
.ls10b{letter-spacing:-0.825867pt;}
.lsb9{letter-spacing:-0.821333pt;}
.ls15c{letter-spacing:-0.816000pt;}
.ls70{letter-spacing:-0.810667pt;}
.ls163{letter-spacing:-0.805333pt;}
.ls1e6{letter-spacing:-0.800533pt;}
.lseb{letter-spacing:-0.800000pt;}
.ls302{letter-spacing:-0.795552pt;}
.ls6d{letter-spacing:-0.794667pt;}
.ls1de{letter-spacing:-0.790400pt;}
.ls28c{letter-spacing:-0.789333pt;}
.ls16d{letter-spacing:-0.784000pt;}
.ls27b{letter-spacing:-0.783467pt;}
.ls26b{letter-spacing:-0.778667pt;}
.ls264{letter-spacing:-0.775200pt;}
.ls1d1{letter-spacing:-0.773333pt;}
.lsf{letter-spacing:-0.768000pt;}
.ls270{letter-spacing:-0.762667pt;}
.ls22a{letter-spacing:-0.757333pt;}
.ls9f{letter-spacing:-0.752000pt;}
.ls349{letter-spacing:-0.749867pt;}
.ls1d4{letter-spacing:-0.746667pt;}
.ls1cf{letter-spacing:-0.744000pt;}
.ls218{letter-spacing:-0.741333pt;}
.ls179{letter-spacing:-0.739733pt;}
.ls5{letter-spacing:-0.738133pt;}
.ls18f{letter-spacing:-0.736000pt;}
.ls132{letter-spacing:-0.734667pt;}
.ls78{letter-spacing:-0.730667pt;}
.lsa2{letter-spacing:-0.725333pt;}
.ls1e{letter-spacing:-0.720000pt;}
.ls185{letter-spacing:-0.714667pt;}
.lsd{letter-spacing:-0.712533pt;}
.ls5b{letter-spacing:-0.709333pt;}
.ls249{letter-spacing:-0.704000pt;}
.ls1df{letter-spacing:-0.699200pt;}
.lsb8{letter-spacing:-0.698667pt;}
.ls11{letter-spacing:-0.695467pt;}
.ls1c4{letter-spacing:-0.694133pt;}
.ls21f{letter-spacing:-0.693333pt;}
.ls236{letter-spacing:-0.688000pt;}
.ls25f{letter-spacing:-0.686933pt;}
.ls23e{letter-spacing:-0.684000pt;}
.ls150{letter-spacing:-0.682667pt;}
.lsae{letter-spacing:-0.677333pt;}
.lsbf{letter-spacing:-0.672000pt;}
.ls276{letter-spacing:-0.668000pt;}
.lsa7{letter-spacing:-0.666667pt;}
.ls8f{letter-spacing:-0.661333pt;}
.ls2db{letter-spacing:-0.660800pt;}
.ls1ca{letter-spacing:-0.658667pt;}
.ls48{letter-spacing:-0.656000pt;}
.ls170{letter-spacing:-0.653600pt;}
.lsfc{letter-spacing:-0.650667pt;}
.ls1a4{letter-spacing:-0.645333pt;}
.ls106{letter-spacing:-0.643467pt;}
.ls62{letter-spacing:-0.640000pt;}
.lsfd{letter-spacing:-0.634667pt;}
.ls1c5{letter-spacing:-0.633333pt;}
.ls33{letter-spacing:-0.629333pt;}
.ls272{letter-spacing:-0.627200pt;}
.ls34{letter-spacing:-0.624000pt;}
.ls120{letter-spacing:-0.623200pt;}
.ls32{letter-spacing:-0.618667pt;}
.ls42{letter-spacing:-0.613333pt;}
.ls320{letter-spacing:-0.608533pt;}
.ls1fa{letter-spacing:-0.608000pt;}
.ls381{letter-spacing:-0.602933pt;}
.ls239{letter-spacing:-0.602667pt;}
.ls345{letter-spacing:-0.597333pt;}
.ls138{letter-spacing:-0.592800pt;}
.ls91{letter-spacing:-0.592000pt;}
.ls2e1{letter-spacing:-0.587733pt;}
.ls229{letter-spacing:-0.586667pt;}
.ls2e3{letter-spacing:-0.582667pt;}
.ls22{letter-spacing:-0.581333pt;}
.ls2df{letter-spacing:-0.577600pt;}
.ls1ae{letter-spacing:-0.576000pt;}
.ls104{letter-spacing:-0.572533pt;}
.ls290{letter-spacing:-0.570667pt;}
.ls2e2{letter-spacing:-0.567467pt;}
.ls126{letter-spacing:-0.565333pt;}
.lsd6{letter-spacing:-0.562400pt;}
.ls222{letter-spacing:-0.560000pt;}
.ls130{letter-spacing:-0.557333pt;}
.ls2a2{letter-spacing:-0.554667pt;}
.ls32d{letter-spacing:-0.552533pt;}
.ls105{letter-spacing:-0.552267pt;}
.lsa{letter-spacing:-0.550400pt;}
.ls3e{letter-spacing:-0.549333pt;}
.ls137{letter-spacing:-0.547200pt;}
.ls29b{letter-spacing:-0.544000pt;}
.ls1dc{letter-spacing:-0.542133pt;}
.ls100{letter-spacing:-0.541333pt;}
.ls28{letter-spacing:-0.538667pt;}
.ls31a{letter-spacing:-0.537067pt;}
.ls5d{letter-spacing:-0.533333pt;}
.ls19{letter-spacing:-0.532800pt;}
.lscc{letter-spacing:-0.532000pt;}
.ls2f6{letter-spacing:-0.530368pt;}
.ls2a8{letter-spacing:-0.528000pt;}
.ls357{letter-spacing:-0.526933pt;}
.ls18{letter-spacing:-0.523200pt;}
.ls245{letter-spacing:-0.522667pt;}
.ls20a{letter-spacing:-0.518933pt;}
.ls73{letter-spacing:-0.517333pt;}
.ls380{letter-spacing:-0.516800pt;}
.ls274{letter-spacing:-0.512000pt;}
.ls11c{letter-spacing:-0.511733pt;}
.ls2d7{letter-spacing:-0.507733pt;}
.lsd5{letter-spacing:-0.506667pt;}
.ls67{letter-spacing:-0.501333pt;}
.ls2f5{letter-spacing:-0.498544pt;}
.ls1e9{letter-spacing:-0.496533pt;}
.lse2{letter-spacing:-0.496000pt;}
.ls45{letter-spacing:-0.490667pt;}
.ls76{letter-spacing:-0.485333pt;}
.ls334{letter-spacing:-0.481600pt;}
.ls46{letter-spacing:-0.480000pt;}
.ls2cc{letter-spacing:-0.474667pt;}
.lsf5{letter-spacing:-0.471200pt;}
.ls7a{letter-spacing:-0.469333pt;}
.lsc{letter-spacing:-0.465067pt;}
.ls21b{letter-spacing:-0.464000pt;}
.ls204{letter-spacing:-0.458667pt;}
.ls6a{letter-spacing:-0.453333pt;}
.ls151{letter-spacing:-0.448000pt;}
.ls23f{letter-spacing:-0.445867pt;}
.lse3{letter-spacing:-0.442667pt;}
.ls147{letter-spacing:-0.440800pt;}
.ls1b2{letter-spacing:-0.437333pt;}
.ls1e8{letter-spacing:-0.435733pt;}
.ls3a{letter-spacing:-0.432000pt;}
.ls213{letter-spacing:-0.430667pt;}
.ls201{letter-spacing:-0.426667pt;}
.ls3b{letter-spacing:-0.421333pt;}
.lsc5{letter-spacing:-0.416000pt;}
.ls1a0{letter-spacing:-0.415467pt;}
.ls32f{letter-spacing:-0.414400pt;}
.ls2c0{letter-spacing:-0.410667pt;}
.ls32e{letter-spacing:-0.406933pt;}
.ls122{letter-spacing:-0.405333pt;}
.ls18b{letter-spacing:-0.400000pt;}
.ls303{letter-spacing:-0.396000pt;}
.ls1b6{letter-spacing:-0.395200pt;}
.ls2da{letter-spacing:-0.394667pt;}
.lsc8{letter-spacing:-0.389333pt;}
.ls24f{letter-spacing:-0.385067pt;}
.ls247{letter-spacing:-0.384000pt;}
.ls1a6{letter-spacing:-0.378667pt;}
.ls2dd{letter-spacing:-0.377067pt;}
.ls1e1{letter-spacing:-0.373333pt;}
.ls75{letter-spacing:-0.368000pt;}
.ls13b{letter-spacing:-0.362667pt;}
.ls31{letter-spacing:-0.357333pt;}
.lsc4{letter-spacing:-0.352000pt;}
.ls6b{letter-spacing:-0.346667pt;}
.ls19b{letter-spacing:-0.344533pt;}
.ls283{letter-spacing:-0.344000pt;}
.ls1a5{letter-spacing:-0.341333pt;}
.ls3d{letter-spacing:-0.336000pt;}
.ls11f{letter-spacing:-0.334400pt;}
.ls17a{letter-spacing:-0.330667pt;}
.ls19e{letter-spacing:-0.329333pt;}
.ls282{letter-spacing:-0.328533pt;}
.ls244{letter-spacing:-0.325333pt;}
.ls1e4{letter-spacing:-0.324267pt;}
.lsaa{letter-spacing:-0.320000pt;}
.lsce{letter-spacing:-0.316000pt;}
.ls140{letter-spacing:-0.314667pt;}
.lsf3{letter-spacing:-0.314133pt;}
.ls25e{letter-spacing:-0.313600pt;}
.ls37{letter-spacing:-0.309333pt;}
.ls7f{letter-spacing:-0.304000pt;}
.ls1bd{letter-spacing:-0.298933pt;}
.ls10e{letter-spacing:-0.298667pt;}
.ls317{letter-spacing:-0.293867pt;}
.ls64{letter-spacing:-0.293333pt;}
.ls1d9{letter-spacing:-0.288000pt;}
.ls12f{letter-spacing:-0.283733pt;}
.ls30e{letter-spacing:-0.283200pt;}
.ls16e{letter-spacing:-0.282667pt;}
.ls131{letter-spacing:-0.278667pt;}
.ls95{letter-spacing:-0.277333pt;}
.ls27{letter-spacing:-0.272000pt;}
.ls37c{letter-spacing:-0.268800pt;}
.ls22d{letter-spacing:-0.266667pt;}
.ls200{letter-spacing:-0.261333pt;}
.ls192{letter-spacing:-0.256000pt;}
.ls30f{letter-spacing:-0.254400pt;}
.ls233{letter-spacing:-0.250667pt;}
.ls184{letter-spacing:-0.245333pt;}
.ls1e0{letter-spacing:-0.243200pt;}
.lsa4{letter-spacing:-0.240000pt;}
.ls148{letter-spacing:-0.238133pt;}
.ls1d8{letter-spacing:-0.234667pt;}
.ls217{letter-spacing:-0.233067pt;}
.ls1b3{letter-spacing:-0.229333pt;}
.ls1e7{letter-spacing:-0.228000pt;}
.ls13c{letter-spacing:-0.224000pt;}
.ls30{letter-spacing:-0.218667pt;}
.ls166{letter-spacing:-0.213333pt;}
.ls1a2{letter-spacing:-0.212800pt;}
.ls191{letter-spacing:-0.208000pt;}
.ls17{letter-spacing:-0.206400pt;}
.ls181{letter-spacing:-0.202667pt;}
.lsef{letter-spacing:-0.197333pt;}
.ls12e{letter-spacing:-0.192533pt;}
.lsba{letter-spacing:-0.192000pt;}
.ls85{letter-spacing:-0.186667pt;}
.ls90{letter-spacing:-0.181333pt;}
.ls325{letter-spacing:-0.176000pt;}
.ls6{letter-spacing:-0.174933pt;}
.ls1f3{letter-spacing:-0.172267pt;}
.ls368{letter-spacing:-0.171733pt;}
.ls12a{letter-spacing:-0.170667pt;}
.lsf0{letter-spacing:-0.167200pt;}
.ls93{letter-spacing:-0.165333pt;}
.ls1d0{letter-spacing:-0.164000pt;}
.ls189{letter-spacing:-0.160000pt;}
.ls1be{letter-spacing:-0.154667pt;}
.ls143{letter-spacing:-0.149333pt;}
.ls1bb{letter-spacing:-0.146933pt;}
.ls8a{letter-spacing:-0.144000pt;}
.ls262{letter-spacing:-0.138667pt;}
.ls24{letter-spacing:-0.133333pt;}
.ls1f4{letter-spacing:-0.131733pt;}
.ls146{letter-spacing:-0.128000pt;}
.ls31e{letter-spacing:-0.127680pt;}
.ls92{letter-spacing:-0.122667pt;}
.ls133{letter-spacing:-0.121600pt;}
.ls1d{letter-spacing:-0.117333pt;}
.ls20f{letter-spacing:-0.116533pt;}
.ls9c{letter-spacing:-0.112000pt;}
.ls155{letter-spacing:-0.111467pt;}
.ls333{letter-spacing:-0.108267pt;}
.ls3c{letter-spacing:-0.106667pt;}
.ls172{letter-spacing:-0.101333pt;}
.ls171{letter-spacing:-0.096267pt;}
.ls182{letter-spacing:-0.096000pt;}
.ls158{letter-spacing:-0.093333pt;}
.ls2ab{letter-spacing:-0.090667pt;}
.ls255{letter-spacing:-0.089600pt;}
.ls173{letter-spacing:-0.086133pt;}
.ls26{letter-spacing:-0.085333pt;}
.ls12d{letter-spacing:-0.081067pt;}
.ls97{letter-spacing:-0.080000pt;}
.ls379{letter-spacing:-0.076800pt;}
.ls256{letter-spacing:-0.074667pt;}
.ls25a{letter-spacing:-0.069333pt;}
.lsa8{letter-spacing:-0.064000pt;}
.ls14e{letter-spacing:-0.058667pt;}
.lscb{letter-spacing:-0.056000pt;}
.ls149{letter-spacing:-0.055733pt;}
.ls1a9{letter-spacing:-0.053333pt;}
.ls33d{letter-spacing:-0.051200pt;}
.ls134{letter-spacing:-0.050667pt;}
.ls5e{letter-spacing:-0.048000pt;}
.ls31b{letter-spacing:-0.042667pt;}
.ls9{letter-spacing:-0.038400pt;}
.ls53{letter-spacing:-0.037333pt;}
.ls2fd{letter-spacing:-0.037126pt;}
.ls11d{letter-spacing:-0.035467pt;}
.ls44{letter-spacing:-0.032000pt;}
.ls20b{letter-spacing:-0.030400pt;}
.ls2{letter-spacing:-0.029867pt;}
.ls160{letter-spacing:-0.026667pt;}
.ls156{letter-spacing:-0.025333pt;}
.ls2fb{letter-spacing:-0.023204pt;}
.ls1b{letter-spacing:-0.022400pt;}
.ls8e{letter-spacing:-0.021333pt;}
.ls13a{letter-spacing:-0.020267pt;}
.ls2a5{letter-spacing:-0.019200pt;}
.ls2ff{letter-spacing:-0.018563pt;}
.ls2f8{letter-spacing:-0.017679pt;}
.ls14{letter-spacing:-0.016000pt;}
.ls154{letter-spacing:-0.015200pt;}
.ls1{letter-spacing:-0.014933pt;}
.ls15{letter-spacing:-0.014400pt;}
.ls2fe{letter-spacing:-0.013922pt;}
.ls69{letter-spacing:-0.012800pt;}
.ls20c{letter-spacing:-0.012000pt;}
.ls279{letter-spacing:-0.011733pt;}
.ls4f{letter-spacing:-0.011200pt;}
.ls13{letter-spacing:-0.010667pt;}
.ls135{letter-spacing:-0.010640pt;}
.lsd8{letter-spacing:-0.010133pt;}
.ls2f3{letter-spacing:-0.009600pt;}
.ls2fa{letter-spacing:-0.009281pt;}
.ls301{letter-spacing:-0.008839pt;}
.ls198{letter-spacing:-0.008400pt;}
.lsac{letter-spacing:-0.008000pt;}
.ls9a{letter-spacing:-0.007467pt;}
.ls31f{letter-spacing:-0.006720pt;}
.ls80{letter-spacing:-0.006400pt;}
.ls27a{letter-spacing:-0.005867pt;}
.ls285{letter-spacing:-0.005600pt;}
.ls12{letter-spacing:-0.005333pt;}
.lsd2{letter-spacing:-0.005067pt;}
.ls16{letter-spacing:-0.004800pt;}
.ls2fc{letter-spacing:-0.004641pt;}
.ls4{letter-spacing:-0.004267pt;}
.ls7d{letter-spacing:-0.004000pt;}
.ls34b{letter-spacing:-0.003733pt;}
.ls33b{letter-spacing:-0.002560pt;}
.ls0{letter-spacing:0.000000pt;}
.ls33a{letter-spacing:0.001707pt;}
.ls34e{letter-spacing:0.002809pt;}
.ls26d{letter-spacing:0.004000pt;}
.ls300{letter-spacing:0.004420pt;}
.ls2f9{letter-spacing:0.004641pt;}
.ls11e{letter-spacing:0.005067pt;}
.ls50{letter-spacing:0.005333pt;}
.ls308{letter-spacing:0.006400pt;}
.ls86{letter-spacing:0.007467pt;}
.ls118{letter-spacing:0.010133pt;}
.ls1c3{letter-spacing:0.010667pt;}
.ls323{letter-spacing:0.012800pt;}
.ls9e{letter-spacing:0.014933pt;}
.ls1e2{letter-spacing:0.016000pt;}
.ls35a{letter-spacing:0.019200pt;}
.ls1dd{letter-spacing:0.020267pt;}
.ls2f{letter-spacing:0.021333pt;}
.lsc3{letter-spacing:0.022400pt;}
.ls1f2{letter-spacing:0.025333pt;}
.ls297{letter-spacing:0.026667pt;}
.ls1c{letter-spacing:0.029867pt;}
.ls177{letter-spacing:0.030400pt;}
.ls2e{letter-spacing:0.032000pt;}
.ls1ea{letter-spacing:0.035467pt;}
.ls4e{letter-spacing:0.037333pt;}
.ls1fe{letter-spacing:0.042667pt;}
.lse8{letter-spacing:0.044800pt;}
.ls6c{letter-spacing:0.048000pt;}
.ls26f{letter-spacing:0.051200pt;}
.ls268{letter-spacing:0.052267pt;}
.ls152{letter-spacing:0.053333pt;}
.ls124{letter-spacing:0.055733pt;}
.ls4d{letter-spacing:0.058667pt;}
.ls52{letter-spacing:0.059733pt;}
.ls4c{letter-spacing:0.064000pt;}
.lscd{letter-spacing:0.068000pt;}
.ls10c{letter-spacing:0.069333pt;}
.ls210{letter-spacing:0.070933pt;}
.ls2b0{letter-spacing:0.074667pt;}
.ls115{letter-spacing:0.080000pt;}
.ls96{letter-spacing:0.085333pt;}
.ls169{letter-spacing:0.086133pt;}
.lsb{letter-spacing:0.089600pt;}
.lsfb{letter-spacing:0.090667pt;}
.lsb3{letter-spacing:0.096000pt;}
.ls25d{letter-spacing:0.101333pt;}
.ls1ce{letter-spacing:0.104533pt;}
.ls119{letter-spacing:0.106400pt;}
.ls180{letter-spacing:0.106667pt;}
.ls18c{letter-spacing:0.112000pt;}
.lsa6{letter-spacing:0.117333pt;}
.ls11a{letter-spacing:0.121600pt;}
.ls114{letter-spacing:0.122667pt;}
.ls103{letter-spacing:0.128000pt;}
.ls26c{letter-spacing:0.130667pt;}
.ls2bb{letter-spacing:0.133333pt;}
.ls2bc{letter-spacing:0.138667pt;}
.ls123{letter-spacing:0.141867pt;}
.ls81{letter-spacing:0.144000pt;}
.ls22e{letter-spacing:0.146933pt;}
.ls224{letter-spacing:0.149333pt;}
.ls1b7{letter-spacing:0.152000pt;}
.lsc1{letter-spacing:0.154667pt;}
.ls14a{letter-spacing:0.157067pt;}
.lsd0{letter-spacing:0.160000pt;}
.ls32c{letter-spacing:0.165333pt;}
.ls1c9{letter-spacing:0.170667pt;}
.lsc2{letter-spacing:0.176000pt;}
.ls136{letter-spacing:0.181333pt;}
.ls220{letter-spacing:0.186667pt;}
.ls352{letter-spacing:0.192000pt;}
.ls194{letter-spacing:0.197333pt;}
.ls2b2{letter-spacing:0.202667pt;}
.ls208{letter-spacing:0.208000pt;}
.ls207{letter-spacing:0.213333pt;}
.ls19c{letter-spacing:0.217867pt;}
.lse4{letter-spacing:0.218667pt;}
.ls310{letter-spacing:0.224000pt;}
.ls278{letter-spacing:0.229333pt;}
.ls335{letter-spacing:0.231467pt;}
.ls168{letter-spacing:0.233067pt;}
.ls29a{letter-spacing:0.234667pt;}
.ls199{letter-spacing:0.238133pt;}
.ls1bf{letter-spacing:0.240000pt;}
.lse5{letter-spacing:0.245333pt;}
.ls19a{letter-spacing:0.248267pt;}
.ls112{letter-spacing:0.250667pt;}
.ls295{letter-spacing:0.256000pt;}
.ls2c2{letter-spacing:0.261333pt;}
.ls24b{letter-spacing:0.266667pt;}
.ls1d6{letter-spacing:0.272000pt;}
.ls84{letter-spacing:0.277333pt;}
.ls1ef{letter-spacing:0.278667pt;}
.ls1b8{letter-spacing:0.280000pt;}
.ls1ab{letter-spacing:0.282667pt;}
.lsb2{letter-spacing:0.288000pt;}
.ls319{letter-spacing:0.288800pt;}
.ls281{letter-spacing:0.293333pt;}
.ls1d3{letter-spacing:0.298667pt;}
.ls1cb{letter-spacing:0.298933pt;}
.ls39{letter-spacing:0.304000pt;}
.lse1{letter-spacing:0.308000pt;}
.ls71{letter-spacing:0.309333pt;}
.ls28f{letter-spacing:0.314667pt;}
.ls1eb{letter-spacing:0.319200pt;}
.ls280{letter-spacing:0.320000pt;}
.ls1a8{letter-spacing:0.325333pt;}
.ls1aa{letter-spacing:0.330667pt;}
.lsf4{letter-spacing:0.334400pt;}
.ls2d1{letter-spacing:0.336000pt;}
.ls110{letter-spacing:0.341333pt;}
.ls2e0{letter-spacing:0.344000pt;}
.ls309{letter-spacing:0.346667pt;}
.ls7c{letter-spacing:0.352000pt;}
.ls19d{letter-spacing:0.354667pt;}
.ls2a{letter-spacing:0.357333pt;}
.ls16a{letter-spacing:0.359733pt;}
.ls29{letter-spacing:0.362667pt;}
.ls266{letter-spacing:0.364800pt;}
.ls23b{letter-spacing:0.368000pt;}
.ls2b6{letter-spacing:0.373333pt;}
.ls313{letter-spacing:0.374933pt;}
.ls24d{letter-spacing:0.378667pt;}
.ls72{letter-spacing:0.384000pt;}
.ls347{letter-spacing:0.389333pt;}
.ls2d{letter-spacing:0.394667pt;}
.ls2c8{letter-spacing:0.400000pt;}
.ls23a{letter-spacing:0.405333pt;}
.ls2c{letter-spacing:0.410667pt;}
.ls94{letter-spacing:0.416000pt;}
.ls20d{letter-spacing:0.420533pt;}
.ls2b{letter-spacing:0.421333pt;}
.ls211{letter-spacing:0.425600pt;}
.ls2b5{letter-spacing:0.426667pt;}
.ls242{letter-spacing:0.432000pt;}
.ls355{letter-spacing:0.437333pt;}
.ls10d{letter-spacing:0.442667pt;}
.ls1fd{letter-spacing:0.448000pt;}
.lsd7{letter-spacing:0.450933pt;}
.ls29c{letter-spacing:0.453333pt;}
.ls8c{letter-spacing:0.458667pt;}
.ls1ee{letter-spacing:0.461067pt;}
.ls337{letter-spacing:0.464000pt;}
.ls129{letter-spacing:0.469333pt;}
.ls1ed{letter-spacing:0.471200pt;}
.ls34d{letter-spacing:0.471932pt;}
.ls2de{letter-spacing:0.474667pt;}
.ls15e{letter-spacing:0.480000pt;}
.ls193{letter-spacing:0.481333pt;}
.ls40{letter-spacing:0.485333pt;}
.ls1b5{letter-spacing:0.486400pt;}
.ls331{letter-spacing:0.490667pt;}
.ls316{letter-spacing:0.491467pt;}
.ls3f{letter-spacing:0.496000pt;}
.lsda{letter-spacing:0.496533pt;}
.ls21e{letter-spacing:0.501333pt;}
.ls2aa{letter-spacing:0.506667pt;}
.ls311{letter-spacing:0.511733pt;}
.ls341{letter-spacing:0.512000pt;}
.ls238{letter-spacing:0.517333pt;}
.ls164{letter-spacing:0.522667pt;}
.ls240{letter-spacing:0.530133pt;}
.ls2f7{letter-spacing:0.530368pt;}
.ls1d7{letter-spacing:0.533333pt;}
.ls15b{letter-spacing:0.538667pt;}
.ls195{letter-spacing:0.544000pt;}
.ls16c{letter-spacing:0.549333pt;}
.ls34c{letter-spacing:0.553355pt;}
.ls144{letter-spacing:0.554667pt;}
.lsa1{letter-spacing:0.560000pt;}
.ls315{letter-spacing:0.562400pt;}
.ls9b{letter-spacing:0.565333pt;}
.lsca{letter-spacing:0.570667pt;}
.ls1c7{letter-spacing:0.572533pt;}
.ls231{letter-spacing:0.576000pt;}
.ls2ce{letter-spacing:0.581333pt;}
.lse6{letter-spacing:0.586667pt;}
.ls15d{letter-spacing:0.592000pt;}
.ls36c{letter-spacing:0.597333pt;}
.ls18e{letter-spacing:0.602667pt;}
.ls57{letter-spacing:0.608000pt;}
.ls234{letter-spacing:0.613333pt;}
.ls296{letter-spacing:0.618667pt;}
.ls2ed{letter-spacing:0.622933pt;}
.ls22f{letter-spacing:0.624000pt;}
.ls54{letter-spacing:0.629333pt;}
.ls2c6{letter-spacing:0.634667pt;}
.ls2ec{letter-spacing:0.635733pt;}
.ls235{letter-spacing:0.640000pt;}
.ls1ad{letter-spacing:0.645333pt;}
.ls241{letter-spacing:0.650667pt;}
.ls37b{letter-spacing:0.656000pt;}
.ls348{letter-spacing:0.661333pt;}
.ls30b{letter-spacing:0.666667pt;}
.lsa5{letter-spacing:0.672000pt;}
.ls263{letter-spacing:0.677333pt;}
.ls2d6{letter-spacing:0.679467pt;}
.ls89{letter-spacing:0.682667pt;}
.ls88{letter-spacing:0.688000pt;}
.ls13d{letter-spacing:0.693333pt;}
.ls175{letter-spacing:0.694133pt;}
.ls55{letter-spacing:0.698667pt;}
.ls212{letter-spacing:0.699200pt;}
.ls2af{letter-spacing:0.704000pt;}
.ls2ca{letter-spacing:0.709333pt;}
.ls178{letter-spacing:0.714400pt;}
.ls324{letter-spacing:0.714667pt;}
.ls2eb{letter-spacing:0.715200pt;}
.ls1a3{letter-spacing:0.720000pt;}
.ls142{letter-spacing:0.725333pt;}
.ls291{letter-spacing:0.730667pt;}
.lsdd{letter-spacing:0.736000pt;}
.ls1b0{letter-spacing:0.741333pt;}
.ls31d{letter-spacing:0.744000pt;}
.ls271{letter-spacing:0.746667pt;}
.ls259{letter-spacing:0.752000pt;}
.ls2d0{letter-spacing:0.757333pt;}
.lsdc{letter-spacing:0.762667pt;}
.ls365{letter-spacing:0.768000pt;}
.ls8b{letter-spacing:0.773333pt;}
.ls77{letter-spacing:0.778667pt;}
.ls314{letter-spacing:0.780267pt;}
.ls186{letter-spacing:0.784000pt;}
.ls196{letter-spacing:0.789333pt;}
.ls2cb{letter-spacing:0.794667pt;}
.ls27f{letter-spacing:0.798933pt;}
.ls17e{letter-spacing:0.800000pt;}
.ls159{letter-spacing:0.810667pt;}
.ls277{letter-spacing:0.816000pt;}
.ls16f{letter-spacing:0.820800pt;}
.ls9d{letter-spacing:0.821333pt;}
.ls1f0{letter-spacing:0.825867pt;}
.ls5c{letter-spacing:0.826667pt;}
.ls29e{letter-spacing:0.832000pt;}
.lsf1{letter-spacing:0.836000pt;}
.ls1a7{letter-spacing:0.837333pt;}
.ls59{letter-spacing:0.842667pt;}
.ls350{letter-spacing:0.848000pt;}
.ls2a3{letter-spacing:0.853333pt;}
.ls1f9{letter-spacing:0.858667pt;}
.ls4a{letter-spacing:0.864000pt;}
.ls346{letter-spacing:0.869333pt;}
.ls1af{letter-spacing:0.874667pt;}
.ls2d2{letter-spacing:0.880000pt;}
.ls37d{letter-spacing:0.885333pt;}
.ls377{letter-spacing:0.890667pt;}
.ls321{letter-spacing:0.896000pt;}
.ls2dc{letter-spacing:0.901333pt;}
.ls6e{letter-spacing:0.906667pt;}
.ls230{letter-spacing:0.912000pt;}
.lsf2{letter-spacing:0.917067pt;}
.ls370{letter-spacing:0.917333pt;}
.ls113{letter-spacing:0.928000pt;}
.ls2a1{letter-spacing:0.933333pt;}
.ls183{letter-spacing:0.938667pt;}
.ls21a{letter-spacing:0.944000pt;}
.lsa3{letter-spacing:0.954667pt;}
.ls298{letter-spacing:0.965333pt;}
.ls2d5{letter-spacing:0.970667pt;}
.ls332{letter-spacing:0.981333pt;}
.ls36{letter-spacing:0.986667pt;}
.ls344{letter-spacing:0.992000pt;}
.ls253{letter-spacing:0.993067pt;}
.ls30a{letter-spacing:0.997333pt;}
.ls299{letter-spacing:1.002667pt;}
.ls49{letter-spacing:1.008000pt;}
.ls32b{letter-spacing:1.013333pt;}
.ls2ad{letter-spacing:1.018667pt;}
.ls369{letter-spacing:1.034667pt;}
.ls340{letter-spacing:1.040000pt;}
.lsb0{letter-spacing:1.050667pt;}
.ls312{letter-spacing:1.069067pt;}
.ls360{letter-spacing:1.072000pt;}
.ls258{letter-spacing:1.093333pt;}
.ls28d{letter-spacing:1.098667pt;}
.ls157{letter-spacing:1.109333pt;}
.ls13e{letter-spacing:1.114667pt;}
.ls187{letter-spacing:1.120000pt;}
.ls18d{letter-spacing:1.125333pt;}
.ls322{letter-spacing:1.130667pt;}
.ls82{letter-spacing:1.141333pt;}
.ls2c9{letter-spacing:1.152000pt;}
.ls37a{letter-spacing:1.157333pt;}
.ls32a{letter-spacing:1.173333pt;}
.ls17c{letter-spacing:1.189333pt;}
.ls21{letter-spacing:1.200000pt;}
.ls342{letter-spacing:1.205333pt;}
.ls1c6{letter-spacing:1.205867pt;}
.ls28b{letter-spacing:1.221333pt;}
.ls13f{letter-spacing:1.226667pt;}
.ls2e8{letter-spacing:1.232000pt;}
.ls28e{letter-spacing:1.237333pt;}
.ls359{letter-spacing:1.242667pt;}
.lsb7{letter-spacing:1.248000pt;}
.ls2c1{letter-spacing:1.258667pt;}
.ls362{letter-spacing:1.264000pt;}
.ls2cf{letter-spacing:1.280000pt;}
.ls33c{letter-spacing:1.301333pt;}
.ls292{letter-spacing:1.317333pt;}
.ls1da{letter-spacing:1.322667pt;}
.ls363{letter-spacing:1.333333pt;}
.ls251{letter-spacing:1.347733pt;}
.ls1f8{letter-spacing:1.360000pt;}
.ls2b7{letter-spacing:1.376000pt;}
.ls378{letter-spacing:1.386667pt;}
.ls252{letter-spacing:1.428800pt;}
.ls329{letter-spacing:1.434667pt;}
.ls221{letter-spacing:1.450667pt;}
.ls167{letter-spacing:1.456000pt;}
.ls2bd{letter-spacing:1.461333pt;}
.ls35e{letter-spacing:1.477333pt;}
.ls34a{letter-spacing:1.493333pt;}
.ls326{letter-spacing:1.504000pt;}
.ls243{letter-spacing:1.525333pt;}
.ls336{letter-spacing:1.594667pt;}
.ls2b8{letter-spacing:1.600000pt;}
.ls127{letter-spacing:1.632000pt;}
.ls2c4{letter-spacing:1.648000pt;}
.ls35f{letter-spacing:1.669333pt;}
.ls1b1{letter-spacing:1.696000pt;}
.ls364{letter-spacing:1.706667pt;}
.ls328{letter-spacing:1.712000pt;}
.ls327{letter-spacing:1.717333pt;}
.ls2ba{letter-spacing:1.738667pt;}
.ls2e9{letter-spacing:1.765333pt;}
.ls35c{letter-spacing:1.786667pt;}
.ls27c{letter-spacing:1.844267pt;}
.ls27d{letter-spacing:1.855467pt;}
.ls27e{letter-spacing:1.862933pt;}
.lsb6{letter-spacing:1.877333pt;}
.ls2be{letter-spacing:1.882667pt;}
.ls265{letter-spacing:1.900000pt;}
.ls351{letter-spacing:1.962667pt;}
.ls209{letter-spacing:2.072000pt;}
.ls36f{letter-spacing:2.074667pt;}
.ls14c{letter-spacing:2.075733pt;}
.ls20e{letter-spacing:2.173600pt;}
.ls2d9{letter-spacing:2.288000pt;}
.ls373{letter-spacing:2.587200pt;}
.ls372{letter-spacing:2.598400pt;}
.ls374{letter-spacing:2.609600pt;}
.ls24c{letter-spacing:3.677333pt;}
.ls1a{letter-spacing:3.707200pt;}
.ls51{letter-spacing:3.714667pt;}
.ls101{letter-spacing:3.718400pt;}
.lsee{letter-spacing:3.722133pt;}
.ls3{letter-spacing:3.725867pt;}
.lsad{letter-spacing:3.729600pt;}
.ls99{letter-spacing:3.733333pt;}
.ls10f{letter-spacing:10.912000pt;}
.ls23{letter-spacing:15.477333pt;}
.ls293{letter-spacing:129.146667pt;}
.ls338{letter-spacing:313.987200pt;}
.ls339{letter-spacing:404.459733pt;}
.ws23{word-spacing:-11.418667pt;}
.ws530{word-spacing:-2.885333pt;}
.ws59a{word-spacing:-2.693333pt;}
.ws58a{word-spacing:-2.618667pt;}
.ws4a8{word-spacing:-2.549333pt;}
.ws4e6{word-spacing:-2.325333pt;}
.ws591{word-spacing:-2.187733pt;}
.ws4de{word-spacing:-2.000000pt;}
.ws134{word-spacing:-1.797333pt;}
.ws135{word-spacing:-1.792000pt;}
.ws25d{word-spacing:-1.786667pt;}
.wsdd{word-spacing:-1.781333pt;}
.ws230{word-spacing:-1.776000pt;}
.ws93{word-spacing:-1.770667pt;}
.ws160{word-spacing:-1.765333pt;}
.ws2c2{word-spacing:-1.760000pt;}
.ws7f{word-spacing:-1.754667pt;}
.ws262{word-spacing:-1.749333pt;}
.ws1a6{word-spacing:-1.744000pt;}
.ws10a{word-spacing:-1.738667pt;}
.ws3c1{word-spacing:-1.733333pt;}
.ws1a8{word-spacing:-1.728000pt;}
.wsf0{word-spacing:-1.722667pt;}
.ws2a{word-spacing:-1.717333pt;}
.ws30e{word-spacing:-1.712000pt;}
.ws130{word-spacing:-1.706667pt;}
.ws362{word-spacing:-1.702400pt;}
.ws18a{word-spacing:-1.701333pt;}
.ws31{word-spacing:-1.696000pt;}
.wsfa{word-spacing:-1.690667pt;}
.ws153{word-spacing:-1.687200pt;}
.ws1c{word-spacing:-1.685333pt;}
.ws302{word-spacing:-1.682133pt;}
.wse7{word-spacing:-1.680000pt;}
.ws207{word-spacing:-1.674667pt;}
.ws3ee{word-spacing:-1.672533pt;}
.ws26{word-spacing:-1.669333pt;}
.ws38e{word-spacing:-1.664000pt;}
.ws2d1{word-spacing:-1.661867pt;}
.wsd0{word-spacing:-1.658667pt;}
.ws1eb{word-spacing:-1.656800pt;}
.ws203{word-spacing:-1.653333pt;}
.ws294{word-spacing:-1.648000pt;}
.ws36a{word-spacing:-1.646667pt;}
.ws381{word-spacing:-1.642667pt;}
.wse9{word-spacing:-1.637333pt;}
.ws1e1{word-spacing:-1.632000pt;}
.ws313{word-spacing:-1.631467pt;}
.ws233{word-spacing:-1.626667pt;}
.ws24a{word-spacing:-1.626400pt;}
.wse2{word-spacing:-1.621333pt;}
.ws5aa{word-spacing:-1.620267pt;}
.ws1bb{word-spacing:-1.616267pt;}
.wsc9{word-spacing:-1.616000pt;}
.ws249{word-spacing:-1.611200pt;}
.wsb1{word-spacing:-1.610667pt;}
.ws3f9{word-spacing:-1.606133pt;}
.wsab{word-spacing:-1.605333pt;}
.ws264{word-spacing:-1.600000pt;}
.ws361{word-spacing:-1.596000pt;}
.ws278{word-spacing:-1.594667pt;}
.ws91{word-spacing:-1.589333pt;}
.ws3e{word-spacing:-1.584000pt;}
.ws336{word-spacing:-1.580800pt;}
.ws189{word-spacing:-1.578667pt;}
.ws28{word-spacing:-1.573333pt;}
.ws2a0{word-spacing:-1.570667pt;}
.ws173{word-spacing:-1.568000pt;}
.ws2cf{word-spacing:-1.565600pt;}
.ws104{word-spacing:-1.562667pt;}
.ws267{word-spacing:-1.557333pt;}
.ws567{word-spacing:-1.553067pt;}
.ws17b{word-spacing:-1.552000pt;}
.ws192{word-spacing:-1.550400pt;}
.ws27a{word-spacing:-1.546667pt;}
.ws3f0{word-spacing:-1.545600pt;}
.ws29f{word-spacing:-1.545333pt;}
.ws25{word-spacing:-1.541333pt;}
.ws335{word-spacing:-1.540267pt;}
.ws394{word-spacing:-1.536000pt;}
.ws30{word-spacing:-1.530667pt;}
.wsec{word-spacing:-1.525333pt;}
.ws334{word-spacing:-1.525067pt;}
.ws245{word-spacing:-1.520000pt;}
.ws39e{word-spacing:-1.514933pt;}
.ws18c{word-spacing:-1.514667pt;}
.wsa4{word-spacing:-1.509333pt;}
.ws1c8{word-spacing:-1.504000pt;}
.wsc0{word-spacing:-1.498667pt;}
.ws48{word-spacing:-1.493333pt;}
.ws200{word-spacing:-1.488000pt;}
.ws318{word-spacing:-1.484533pt;}
.ws110{word-spacing:-1.482667pt;}
.ws2bd{word-spacing:-1.479467pt;}
.ws19f{word-spacing:-1.477333pt;}
.ws20b{word-spacing:-1.474400pt;}
.ws53{word-spacing:-1.472000pt;}
.ws30a{word-spacing:-1.469333pt;}
.wsbd{word-spacing:-1.466667pt;}
.ws317{word-spacing:-1.464267pt;}
.ws76{word-spacing:-1.461333pt;}
.ws3cf{word-spacing:-1.459200pt;}
.ws58{word-spacing:-1.456000pt;}
.ws1b3{word-spacing:-1.450667pt;}
.ws3ce{word-spacing:-1.449067pt;}
.ws41{word-spacing:-1.445333pt;}
.ws1c3{word-spacing:-1.440000pt;}
.ws1f1{word-spacing:-1.438933pt;}
.wsb0{word-spacing:-1.434667pt;}
.ws2bf{word-spacing:-1.433867pt;}
.ws5a7{word-spacing:-1.430400pt;}
.ws312{word-spacing:-1.429333pt;}
.ws2a7{word-spacing:-1.424000pt;}
.ws21{word-spacing:-1.418667pt;}
.ws18{word-spacing:-1.416000pt;}
.ws2d2{word-spacing:-1.413600pt;}
.ws83{word-spacing:-1.413333pt;}
.ws345{word-spacing:-1.408000pt;}
.ws9{word-spacing:-1.403733pt;}
.ws1f0{word-spacing:-1.403467pt;}
.ws2fb{word-spacing:-1.402667pt;}
.ws197{word-spacing:-1.398400pt;}
.ws4b4{word-spacing:-1.397333pt;}
.ws1f4{word-spacing:-1.393333pt;}
.ws206{word-spacing:-1.392000pt;}
.ws1ef{word-spacing:-1.388267pt;}
.ws13b{word-spacing:-1.386667pt;}
.ws4f{word-spacing:-1.381333pt;}
.ws1d5{word-spacing:-1.378133pt;}
.ws347{word-spacing:-1.376000pt;}
.ws1b2{word-spacing:-1.370667pt;}
.ws1a4{word-spacing:-1.365333pt;}
.ws1bf{word-spacing:-1.362933pt;}
.ws11{word-spacing:-1.361067pt;}
.ws172{word-spacing:-1.360000pt;}
.ws215{word-spacing:-1.354667pt;}
.ws96{word-spacing:-1.349333pt;}
.ws350{word-spacing:-1.344000pt;}
.ws2d9{word-spacing:-1.338667pt;}
.wsb7{word-spacing:-1.333333pt;}
.ws3d1{word-spacing:-1.332533pt;}
.ws47e{word-spacing:-1.328000pt;}
.ws66{word-spacing:-1.322667pt;}
.ws1f8{word-spacing:-1.322400pt;}
.wsb3{word-spacing:-1.317333pt;}
.wsbb{word-spacing:-1.312000pt;}
.ws386{word-spacing:-1.307200pt;}
.ws138{word-spacing:-1.306667pt;}
.ws2f1{word-spacing:-1.304000pt;}
.ws1bc{word-spacing:-1.302133pt;}
.ws1f9{word-spacing:-1.301333pt;}
.ws74{word-spacing:-1.296000pt;}
.ws40d{word-spacing:-1.290667pt;}
.ws385{word-spacing:-1.286933pt;}
.ws50{word-spacing:-1.285333pt;}
.ws31b{word-spacing:-1.281867pt;}
.ws161{word-spacing:-1.280000pt;}
.ws31a{word-spacing:-1.276800pt;}
.ws229{word-spacing:-1.274667pt;}
.ws209{word-spacing:-1.271733pt;}
.ws7e{word-spacing:-1.269333pt;}
.ws4{word-spacing:-1.267200pt;}
.ws34{word-spacing:-1.264000pt;}
.ws55{word-spacing:-1.258667pt;}
.ws54{word-spacing:-1.253333pt;}
.ws1e8{word-spacing:-1.251467pt;}
.ws34c{word-spacing:-1.248000pt;}
.ws343{word-spacing:-1.242667pt;}
.ws199{word-spacing:-1.241333pt;}
.ws1dc{word-spacing:-1.237333pt;}
.ws2ff{word-spacing:-1.232000pt;}
.ws2bc{word-spacing:-1.226667pt;}
.ws5e{word-spacing:-1.221333pt;}
.ws31e{word-spacing:-1.216000pt;}
.ws155{word-spacing:-1.210933pt;}
.wse6{word-spacing:-1.210667pt;}
.ws12d{word-spacing:-1.205333pt;}
.ws330{word-spacing:-1.200800pt;}
.ws2cd{word-spacing:-1.200000pt;}
.ws1d1{word-spacing:-1.195733pt;}
.ws43c{word-spacing:-1.194667pt;}
.wsd{word-spacing:-1.190400pt;}
.ws5b{word-spacing:-1.189333pt;}
.ws43{word-spacing:-1.184000pt;}
.ws2b0{word-spacing:-1.180533pt;}
.ws14a{word-spacing:-1.178667pt;}
.ws5f{word-spacing:-1.173333pt;}
.ws201{word-spacing:-1.168000pt;}
.ws89{word-spacing:-1.162667pt;}
.ws210{word-spacing:-1.160267pt;}
.ws2a5{word-spacing:-1.157333pt;}
.ws37e{word-spacing:-1.152000pt;}
.ws156{word-spacing:-1.150133pt;}
.ws68{word-spacing:-1.146667pt;}
.ws12{word-spacing:-1.143467pt;}
.wsde{word-spacing:-1.141333pt;}
.ws109{word-spacing:-1.136000pt;}
.ws12e{word-spacing:-1.130667pt;}
.ws118{word-spacing:-1.125333pt;}
.ws4fa{word-spacing:-1.124800pt;}
.ws168{word-spacing:-1.120000pt;}
.ws4fe{word-spacing:-1.119733pt;}
.ws2ea{word-spacing:-1.114667pt;}
.ws502{word-spacing:-1.109600pt;}
.ws15f{word-spacing:-1.109333pt;}
.ws4bd{word-spacing:-1.104533pt;}
.ws127{word-spacing:-1.104000pt;}
.ws28e{word-spacing:-1.098667pt;}
.ws78{word-spacing:-1.093333pt;}
.ws1d6{word-spacing:-1.089333pt;}
.wscc{word-spacing:-1.088000pt;}
.ws2e0{word-spacing:-1.084267pt;}
.ws1d{word-spacing:-1.082667pt;}
.ws102{word-spacing:-1.077333pt;}
.wsb5{word-spacing:-1.072000pt;}
.wsdc{word-spacing:-1.066667pt;}
.ws4e8{word-spacing:-1.064000pt;}
.ws216{word-spacing:-1.061333pt;}
.ws27d{word-spacing:-1.058933pt;}
.ws2f4{word-spacing:-1.056000pt;}
.ws20a{word-spacing:-1.053867pt;}
.wsfe{word-spacing:-1.050667pt;}
.ws38f{word-spacing:-1.045333pt;}
.ws175{word-spacing:-1.040000pt;}
.ws142{word-spacing:-1.036000pt;}
.ws12f{word-spacing:-1.034667pt;}
.ws131{word-spacing:-1.029333pt;}
.ws3ad{word-spacing:-1.028533pt;}
.ws3f1{word-spacing:-1.024000pt;}
.ws120{word-spacing:-1.018667pt;}
.ws2df{word-spacing:-1.018400pt;}
.ws304{word-spacing:-1.013333pt;}
.wsa3{word-spacing:-1.008000pt;}
.ws8e{word-spacing:-1.002667pt;}
.ws36e{word-spacing:-0.997333pt;}
.ws36b{word-spacing:-0.993067pt;}
.wsa2{word-spacing:-0.992000pt;}
.ws26e{word-spacing:-0.986667pt;}
.ws1f7{word-spacing:-0.982933pt;}
.ws128{word-spacing:-0.981333pt;}
.ws1f2{word-spacing:-0.977867pt;}
.ws27{word-spacing:-0.976000pt;}
.ws1be{word-spacing:-0.972800pt;}
.ws178{word-spacing:-0.970667pt;}
.ws2fe{word-spacing:-0.965333pt;}
.ws258{word-spacing:-0.960000pt;}
.ws4d8{word-spacing:-0.956000pt;}
.ws214{word-spacing:-0.954667pt;}
.ws13c{word-spacing:-0.949333pt;}
.ws438{word-spacing:-0.944000pt;}
.ws191{word-spacing:-0.938667pt;}
.ws516{word-spacing:-0.933333pt;}
.ws231{word-spacing:-0.928000pt;}
.ws17c{word-spacing:-0.922667pt;}
.ws18f{word-spacing:-0.917333pt;}
.ws1f5{word-spacing:-0.917067pt;}
.ws30b{word-spacing:-0.912000pt;}
.ws393{word-spacing:-0.906667pt;}
.ws3ea{word-spacing:-0.901333pt;}
.ws10{word-spacing:-0.900267pt;}
.ws84{word-spacing:-0.896000pt;}
.wsa{word-spacing:-0.891733pt;}
.ws242{word-spacing:-0.890667pt;}
.ws37f{word-spacing:-0.885333pt;}
.ws28d{word-spacing:-0.880000pt;}
.wsb6{word-spacing:-0.874667pt;}
.ws205{word-spacing:-0.869333pt;}
.ws24b{word-spacing:-0.866400pt;}
.ws60{word-spacing:-0.864000pt;}
.ws67{word-spacing:-0.858667pt;}
.ws3ec{word-spacing:-0.853333pt;}
.wsf1{word-spacing:-0.848000pt;}
.ws6b{word-spacing:-0.842667pt;}
.ws14e{word-spacing:-0.837333pt;}
.ws562{word-spacing:-0.832000pt;}
.ws72{word-spacing:-0.826667pt;}
.ws315{word-spacing:-0.825867pt;}
.ws180{word-spacing:-0.821333pt;}
.ws13f{word-spacing:-0.820000pt;}
.wsc7{word-spacing:-0.816000pt;}
.ws1df{word-spacing:-0.810667pt;}
.wsff{word-spacing:-0.805333pt;}
.ws2ad{word-spacing:-0.800000pt;}
.ws4ba{word-spacing:-0.794667pt;}
.ws1d7{word-spacing:-0.790400pt;}
.ws11c{word-spacing:-0.789333pt;}
.ws40b{word-spacing:-0.784000pt;}
.ws450{word-spacing:-0.778667pt;}
.ws2c6{word-spacing:-0.775200pt;}
.ws41a{word-spacing:-0.773333pt;}
.ws1e5{word-spacing:-0.770133pt;}
.ws4c1{word-spacing:-0.769067pt;}
.ws38c{word-spacing:-0.768000pt;}
.ws25f{word-spacing:-0.762667pt;}
.ws408{word-spacing:-0.761600pt;}
.ws1ad{word-spacing:-0.757333pt;}
.ws86{word-spacing:-0.752000pt;}
.ws24d{word-spacing:-0.749867pt;}
.wsa0{word-spacing:-0.746667pt;}
.ws372{word-spacing:-0.741333pt;}
.ws6c{word-spacing:-0.736000pt;}
.ws256{word-spacing:-0.730667pt;}
.ws48e{word-spacing:-0.725333pt;}
.ws154{word-spacing:-0.724533pt;}
.ws2c1{word-spacing:-0.720000pt;}
.ws1ab{word-spacing:-0.714667pt;}
.wsb2{word-spacing:-0.709333pt;}
.ws3{word-spacing:-0.704000pt;}
.ws238{word-spacing:-0.698667pt;}
.ws281{word-spacing:-0.694133pt;}
.ws19c{word-spacing:-0.693333pt;}
.ws342{word-spacing:-0.688000pt;}
.ws1e3{word-spacing:-0.684000pt;}
.ws90{word-spacing:-0.682667pt;}
.ws113{word-spacing:-0.677333pt;}
.ws16b{word-spacing:-0.672000pt;}
.ws2dc{word-spacing:-0.668800pt;}
.ws1a0{word-spacing:-0.666667pt;}
.ws1e2{word-spacing:-0.663733pt;}
.ws2b7{word-spacing:-0.661333pt;}
.ws27e{word-spacing:-0.658667pt;}
.wscd{word-spacing:-0.656000pt;}
.ws306{word-spacing:-0.653600pt;}
.ws1db{word-spacing:-0.650667pt;}
.ws590{word-spacing:-0.649600pt;}
.ws133{word-spacing:-0.645333pt;}
.wsa1{word-spacing:-0.640000pt;}
.ws305{word-spacing:-0.638400pt;}
.wsb8{word-spacing:-0.634667pt;}
.ws122{word-spacing:-0.629333pt;}
.ws3da{word-spacing:-0.627200pt;}
.ws25c{word-spacing:-0.624000pt;}
.ws28c{word-spacing:-0.618667pt;}
.ws1a3{word-spacing:-0.613333pt;}
.ws1bd{word-spacing:-0.608000pt;}
.ws1ca{word-spacing:-0.602667pt;}
.ws94{word-spacing:-0.597333pt;}
.ws3eb{word-spacing:-0.592000pt;}
.ws158{word-spacing:-0.587733pt;}
.ws77{word-spacing:-0.586667pt;}
.ws2d0{word-spacing:-0.582667pt;}
.ws371{word-spacing:-0.581333pt;}
.ws13d{word-spacing:-0.576000pt;}
.ws2d{word-spacing:-0.570667pt;}
.ws368{word-spacing:-0.567467pt;}
.ws223{word-spacing:-0.565333pt;}
.wsd8{word-spacing:-0.560000pt;}
.ws1f{word-spacing:-0.554667pt;}
.ws4a1{word-spacing:-0.549333pt;}
.ws11a{word-spacing:-0.544000pt;}
.wsbc{word-spacing:-0.538667pt;}
.ws1e{word-spacing:-0.533333pt;}
.wsf2{word-spacing:-0.528000pt;}
.ws3fb{word-spacing:-0.522667pt;}
.ws369{word-spacing:-0.521867pt;}
.ws2b5{word-spacing:-0.517333pt;}
.wsac{word-spacing:-0.512000pt;}
.ws3a8{word-spacing:-0.511733pt;}
.wsae{word-spacing:-0.506667pt;}
.ws147{word-spacing:-0.501333pt;}
.ws2d5{word-spacing:-0.496000pt;}
.ws11f{word-spacing:-0.490667pt;}
.ws1c1{word-spacing:-0.485333pt;}
.ws2a1{word-spacing:-0.481333pt;}
.ws3cd{word-spacing:-0.480000pt;}
.wsd7{word-spacing:-0.474667pt;}
.ws348{word-spacing:-0.469333pt;}
.ws16d{word-spacing:-0.464000pt;}
.ws2ed{word-spacing:-0.458667pt;}
.ws17d{word-spacing:-0.453333pt;}
.ws10e{word-spacing:-0.448000pt;}
.ws36c{word-spacing:-0.445867pt;}
.ws390{word-spacing:-0.442667pt;}
.ws339{word-spacing:-0.440800pt;}
.ws418{word-spacing:-0.437333pt;}
.ws212{word-spacing:-0.432000pt;}
.ws338{word-spacing:-0.430667pt;}
.ws8b{word-spacing:-0.426667pt;}
.ws8c{word-spacing:-0.421333pt;}
.ws8a{word-spacing:-0.416000pt;}
.ws3ab{word-spacing:-0.410667pt;}
.ws85{word-spacing:-0.405333pt;}
.ws286{word-spacing:-0.400000pt;}
.ws8{word-spacing:-0.396800pt;}
.ws3f{word-spacing:-0.394667pt;}
.ws422{word-spacing:-0.389333pt;}
.ws2d6{word-spacing:-0.384000pt;}
.ws50f{word-spacing:-0.378667pt;}
.ws283{word-spacing:-0.373333pt;}
.ws470{word-spacing:-0.368000pt;}
.ws52c{word-spacing:-0.362667pt;}
.ws324{word-spacing:-0.359733pt;}
.ws3c5{word-spacing:-0.357333pt;}
.ws3a4{word-spacing:-0.352000pt;}
.ws358{word-spacing:-0.346667pt;}
.ws331{word-spacing:-0.339467pt;}
.ws101{word-spacing:-0.336000pt;}
.wsf4{word-spacing:-0.325333pt;}
.wse{word-spacing:-0.324267pt;}
.ws3a{word-spacing:-0.320000pt;}
.ws3cb{word-spacing:-0.309333pt;}
.ws587{word-spacing:-0.304000pt;}
.ws41b{word-spacing:-0.298667pt;}
.ws412{word-spacing:-0.293333pt;}
.wsdb{word-spacing:-0.282667pt;}
.ws31c{word-spacing:-0.278667pt;}
.ws44a{word-spacing:-0.277333pt;}
.ws3aa{word-spacing:-0.256000pt;}
.ws3a1{word-spacing:-0.250667pt;}
.ws32d{word-spacing:-0.240000pt;}
.ws145{word-spacing:-0.234667pt;}
.ws3b4{word-spacing:-0.229333pt;}
.wsc{word-spacing:-0.226133pt;}
.ws47a{word-spacing:-0.224000pt;}
.ws2c{word-spacing:-0.218667pt;}
.ws2b{word-spacing:-0.213333pt;}
.ws9d{word-spacing:-0.208000pt;}
.ws42{word-spacing:-0.202667pt;}
.ws4fc{word-spacing:-0.197600pt;}
.ws425{word-spacing:-0.197333pt;}
.ws568{word-spacing:-0.192000pt;}
.wse0{word-spacing:-0.186667pt;}
.ws53e{word-spacing:-0.181333pt;}
.ws3f8{word-spacing:-0.177333pt;}
.ws53f{word-spacing:-0.176000pt;}
.ws4f4{word-spacing:-0.170667pt;}
.ws140{word-spacing:-0.164000pt;}
.ws274{word-spacing:-0.160000pt;}
.ws5d{word-spacing:-0.154667pt;}
.ws2ba{word-spacing:-0.149333pt;}
.ws296{word-spacing:-0.144000pt;}
.ws3f7{word-spacing:-0.141867pt;}
.ws24{word-spacing:-0.138667pt;}
.ws471{word-spacing:-0.133333pt;}
.ws3ac{word-spacing:-0.128000pt;}
.ws1ae{word-spacing:-0.122667pt;}
.ws415{word-spacing:-0.119467pt;}
.ws4e9{word-spacing:-0.117333pt;}
.ws1ba{word-spacing:-0.116533pt;}
.ws528{word-spacing:-0.106667pt;}
.ws1dd{word-spacing:-0.101333pt;}
.ws8f{word-spacing:-0.090667pt;}
.ws36{word-spacing:-0.085333pt;}
.ws15d{word-spacing:-0.080000pt;}
.ws548{word-spacing:-0.074667pt;}
.ws578{word-spacing:-0.067200pt;}
.ws404{word-spacing:-0.064000pt;}
.ws58b{word-spacing:-0.059733pt;}
.ws5a{word-spacing:-0.058667pt;}
.ws583{word-spacing:-0.053333pt;}
.ws179{word-spacing:-0.052267pt;}
.ws544{word-spacing:-0.048000pt;}
.ws4ed{word-spacing:-0.042667pt;}
.ws144{word-spacing:-0.037333pt;}
.ws26b{word-spacing:-0.032000pt;}
.ws139{word-spacing:-0.029867pt;}
.ws523{word-spacing:-0.026667pt;}
.ws56b{word-spacing:-0.025600pt;}
.ws566{word-spacing:-0.025333pt;}
.wsfd{word-spacing:-0.022400pt;}
.ws27c{word-spacing:-0.021333pt;}
.ws4bf{word-spacing:-0.020267pt;}
.ws510{word-spacing:-0.019200pt;}
.ws2dd{word-spacing:-0.016000pt;}
.ws1cc{word-spacing:-0.015200pt;}
.wsca{word-spacing:-0.014933pt;}
.ws4cb{word-spacing:-0.013259pt;}
.ws4e0{word-spacing:-0.012800pt;}
.ws40{word-spacing:-0.010667pt;}
.ws1d2{word-spacing:-0.010133pt;}
.ws95{word-spacing:-0.007467pt;}
.ws405{word-spacing:-0.006933pt;}
.wsc1{word-spacing:-0.006400pt;}
.ws81{word-spacing:-0.005333pt;}
.ws1d4{word-spacing:-0.005067pt;}
.ws17{word-spacing:-0.004800pt;}
.ws4cf{word-spacing:-0.004641pt;}
.ws4d6{word-spacing:-0.004420pt;}
.ws117{word-spacing:-0.003733pt;}
.ws552{word-spacing:-0.002767pt;}
.ws551{word-spacing:-0.002372pt;}
.ws0{word-spacing:0.000000pt;}
.ws550{word-spacing:0.002372pt;}
.ws533{word-spacing:0.002560pt;}
.ws2{word-spacing:0.003733pt;}
.ws115{word-spacing:0.004000pt;}
.wsf{word-spacing:0.004267pt;}
.ws4d2{word-spacing:0.004641pt;}
.ws1a{word-spacing:0.004800pt;}
.ws19a{word-spacing:0.005067pt;}
.ws14{word-spacing:0.005333pt;}
.ws542{word-spacing:0.005600pt;}
.ws413{word-spacing:0.005867pt;}
.ws1b0{word-spacing:0.006400pt;}
.ws406{word-spacing:0.006933pt;}
.ws17a{word-spacing:0.007467pt;}
.ws35e{word-spacing:0.008000pt;}
.ws4d7{word-spacing:0.008839pt;}
.ws4d0{word-spacing:0.009281pt;}
.ws16{word-spacing:0.009600pt;}
.ws218{word-spacing:0.010133pt;}
.ws15{word-spacing:0.010667pt;}
.ws4c0{word-spacing:0.011200pt;}
.ws2b2{word-spacing:0.012000pt;}
.ws554{word-spacing:0.012800pt;}
.ws4d4{word-spacing:0.013922pt;}
.ws1{word-spacing:0.014933pt;}
.ws1d3{word-spacing:0.015200pt;}
.ws370{word-spacing:0.016000pt;}
.ws4c8{word-spacing:0.017067pt;}
.ws4ce{word-spacing:0.017679pt;}
.ws4d5{word-spacing:0.018563pt;}
.ws414{word-spacing:0.018667pt;}
.ws35b{word-spacing:0.020267pt;}
.ws4e5{word-spacing:0.021333pt;}
.ws34a{word-spacing:0.022400pt;}
.ws4d1{word-spacing:0.023204pt;}
.ws219{word-spacing:0.025333pt;}
.ws64{word-spacing:0.026667pt;}
.ws4be{word-spacing:0.030400pt;}
.ws55e{word-spacing:0.032000pt;}
.ws4d3{word-spacing:0.037126pt;}
.ws4a6{word-spacing:0.042667pt;}
.ws535{word-spacing:0.044800pt;}
.ws449{word-spacing:0.058667pt;}
.ws472{word-spacing:0.064000pt;}
.ws18e{word-spacing:0.074667pt;}
.ws569{word-spacing:0.080000pt;}
.ws565{word-spacing:0.090667pt;}
.ws409{word-spacing:0.101333pt;}
.ws376{word-spacing:0.106667pt;}
.ws5af{word-spacing:0.117333pt;}
.ws63{word-spacing:0.122667pt;}
.ws5ab{word-spacing:0.128000pt;}
.ws1b4{word-spacing:0.133333pt;}
.ws5be{word-spacing:0.138667pt;}
.ws5bd{word-spacing:0.144000pt;}
.ws476{word-spacing:0.149333pt;}
.ws4db{word-spacing:0.154667pt;}
.ws4c3{word-spacing:0.160000pt;}
.ws5c9{word-spacing:0.165333pt;}
.ws123{word-spacing:0.170667pt;}
.ws4ab{word-spacing:0.176000pt;}
.ws10b{word-spacing:0.181333pt;}
.ws20c{word-spacing:0.192533pt;}
.ws10c{word-spacing:0.197333pt;}
.ws2da{word-spacing:0.202667pt;}
.ws29c{word-spacing:0.207733pt;}
.wsf3{word-spacing:0.208000pt;}
.ws4c5{word-spacing:0.213333pt;}
.ws44e{word-spacing:0.218667pt;}
.ws45{word-spacing:0.229333pt;}
.wsc6{word-spacing:0.240000pt;}
.ws427{word-spacing:0.245333pt;}
.ws349{word-spacing:0.250667pt;}
.ws366{word-spacing:0.258400pt;}
.ws33b{word-spacing:0.261333pt;}
.ws9c{word-spacing:0.272000pt;}
.ws4cc{word-spacing:0.274199pt;}
.ws531{word-spacing:0.277333pt;}
.ws586{word-spacing:0.282667pt;}
.ws2c5{word-spacing:0.283733pt;}
.ws402{word-spacing:0.284000pt;}
.ws49a{word-spacing:0.288000pt;}
.ws2a2{word-spacing:0.288800pt;}
.ws448{word-spacing:0.293333pt;}
.ws3ef{word-spacing:0.298667pt;}
.ws152{word-spacing:0.298933pt;}
.ws27f{word-spacing:0.304000pt;}
.wscb{word-spacing:0.309333pt;}
.ws4ee{word-spacing:0.314667pt;}
.ws571{word-spacing:0.320000pt;}
.ws23d{word-spacing:0.325333pt;}
.ws546{word-spacing:0.336000pt;}
.ws184{word-spacing:0.341333pt;}
.ws108{word-spacing:0.346667pt;}
.ws536{word-spacing:0.357333pt;}
.ws9b{word-spacing:0.362667pt;}
.ws16c{word-spacing:0.368000pt;}
.ws4c2{word-spacing:0.373333pt;}
.ws279{word-spacing:0.378667pt;}
.wse1{word-spacing:0.384000pt;}
.ws30c{word-spacing:0.389333pt;}
.ws491{word-spacing:0.400000pt;}
.ws52e{word-spacing:0.405333pt;}
.ws466{word-spacing:0.410667pt;}
.ws539{word-spacing:0.416000pt;}
.ws526{word-spacing:0.421333pt;}
.ws15c{word-spacing:0.426667pt;}
.ws4d9{word-spacing:0.432000pt;}
.ws1b9{word-spacing:0.435733pt;}
.ws1aa{word-spacing:0.437333pt;}
.ws44b{word-spacing:0.442667pt;}
.ws1b8{word-spacing:0.445867pt;}
.ws496{word-spacing:0.458667pt;}
.ws3bd{word-spacing:0.464000pt;}
.ws33{word-spacing:0.469333pt;}
.ws1ea{word-spacing:0.476267pt;}
.ws514{word-spacing:0.490667pt;}
.ws4b9{word-spacing:0.496000pt;}
.ws352{word-spacing:0.501333pt;}
.ws159{word-spacing:0.501600pt;}
.ws2c3{word-spacing:0.506667pt;}
.ws26a{word-spacing:0.512000pt;}
.ws1a9{word-spacing:0.517333pt;}
.ws2ac{word-spacing:0.522667pt;}
.ws54a{word-spacing:0.528000pt;}
.ws16e{word-spacing:0.533333pt;}
.ws4aa{word-spacing:0.538667pt;}
.ws48c{word-spacing:0.544000pt;}
.ws40f{word-spacing:0.549333pt;}
.ws51e{word-spacing:0.554667pt;}
.ws37{word-spacing:0.560000pt;}
.ws5c1{word-spacing:0.565333pt;}
.ws5c2{word-spacing:0.570667pt;}
.ws3d0{word-spacing:0.572533pt;}
.ws3d7{word-spacing:0.576000pt;}
.ws5a9{word-spacing:0.581333pt;}
.ws310{word-spacing:0.586667pt;}
.ws453{word-spacing:0.592000pt;}
.ws498{word-spacing:0.602667pt;}
.wsf5{word-spacing:0.608000pt;}
.ws332{word-spacing:0.613067pt;}
.ws4c9{word-spacing:0.613333pt;}
.ws419{word-spacing:0.624000pt;}
.ws19d{word-spacing:0.629333pt;}
.ws4bb{word-spacing:0.636000pt;}
.ws82{word-spacing:0.640000pt;}
.ws4e4{word-spacing:0.645333pt;}
.ws579{word-spacing:0.650667pt;}
.ws308{word-spacing:0.653600pt;}
.ws580{word-spacing:0.661333pt;}
.ws417{word-spacing:0.666667pt;}
.ws185{word-spacing:0.672000pt;}
.ws3d9{word-spacing:0.677333pt;}
.ws47{word-spacing:0.682667pt;}
.ws273{word-spacing:0.688000pt;}
.wsa6{word-spacing:0.693333pt;}
.ws146{word-spacing:0.704000pt;}
.ws4f1{word-spacing:0.709333pt;}
.ws42f{word-spacing:0.714667pt;}
.ws29{word-spacing:0.720000pt;}
.ws22b{word-spacing:0.725333pt;}
.ws53d{word-spacing:0.730667pt;}
.ws2bb{word-spacing:0.736000pt;}
.ws323{word-spacing:0.744800pt;}
.ws18d{word-spacing:0.746667pt;}
.ws459{word-spacing:0.757333pt;}
.ws367{word-spacing:0.760000pt;}
.ws43e{word-spacing:0.762667pt;}
.ws54e{word-spacing:0.768000pt;}
.ws5ba{word-spacing:0.778667pt;}
.ws40a{word-spacing:0.789333pt;}
.ws298{word-spacing:0.794667pt;}
.ws4eb{word-spacing:0.800000pt;}
.wse8{word-spacing:0.810667pt;}
.ws29a{word-spacing:0.815733pt;}
.wsda{word-spacing:0.816000pt;}
.ws420{word-spacing:0.821333pt;}
.ws14d{word-spacing:0.832000pt;}
.ws543{word-spacing:0.837333pt;}
.ws2f5{word-spacing:0.842667pt;}
.ws486{word-spacing:0.848000pt;}
.ws48b{word-spacing:0.853333pt;}
.wsf8{word-spacing:0.858667pt;}
.ws295{word-spacing:0.864000pt;}
.ws51b{word-spacing:0.869333pt;}
.ws1a7{word-spacing:0.874667pt;}
.ws59e{word-spacing:0.880000pt;}
.wsc4{word-spacing:0.885333pt;}
.ws21e{word-spacing:0.890667pt;}
.ws59{word-spacing:0.896000pt;}
.ws169{word-spacing:0.901333pt;}
.ws521{word-spacing:0.906667pt;}
.ws325{word-spacing:0.906933pt;}
.ws45e{word-spacing:0.912000pt;}
.ws513{word-spacing:0.917333pt;}
.ws522{word-spacing:0.922667pt;}
.ws3e8{word-spacing:0.933333pt;}
.ws24f{word-spacing:0.937333pt;}
.ws250{word-spacing:0.942400pt;}
.ws45c{word-spacing:0.944000pt;}
.ws595{word-spacing:0.949333pt;}
.ws2f{word-spacing:0.954667pt;}
.ws319{word-spacing:0.957600pt;}
.ws2a6{word-spacing:0.960000pt;}
.ws3e7{word-spacing:0.965333pt;}
.ws426{word-spacing:0.970667pt;}
.wse3{word-spacing:0.976000pt;}
.ws285{word-spacing:0.981333pt;}
.ws43d{word-spacing:0.992000pt;}
.ws32e{word-spacing:0.993067pt;}
.ws346{word-spacing:0.997333pt;}
.ws2de{word-spacing:1.013333pt;}
.ws534{word-spacing:1.024000pt;}
.ws4b0{word-spacing:1.029333pt;}
.ws33e{word-spacing:1.040000pt;}
.ws441{word-spacing:1.045333pt;}
.ws4ac{word-spacing:1.061333pt;}
.ws2b1{word-spacing:1.064000pt;}
.ws4b3{word-spacing:1.066667pt;}
.ws41e{word-spacing:1.072000pt;}
.wsaf{word-spacing:1.077333pt;}
.ws500{word-spacing:1.079200pt;}
.ws3fd{word-spacing:1.082667pt;}
.ws143{word-spacing:1.084000pt;}
.ws12b{word-spacing:1.093333pt;}
.ws112{word-spacing:1.098667pt;}
.ws3c8{word-spacing:1.104000pt;}
.ws253{word-spacing:1.109333pt;}
.ws18b{word-spacing:1.114667pt;}
.ws50c{word-spacing:1.120000pt;}
.ws4c4{word-spacing:1.130667pt;}
.ws28f{word-spacing:1.136000pt;}
.ws303{word-spacing:1.140000pt;}
.ws2b3{word-spacing:1.141333pt;}
.ws5a1{word-spacing:1.146667pt;}
.ws97{word-spacing:1.162667pt;}
.ws475{word-spacing:1.168000pt;}
.ws3bf{word-spacing:1.178667pt;}
.ws3c0{word-spacing:1.184000pt;}
.ws38a{word-spacing:1.189333pt;}
.ws297{word-spacing:1.194667pt;}
.ws25a{word-spacing:1.200000pt;}
.ws3c6{word-spacing:1.205333pt;}
.ws71{word-spacing:1.210667pt;}
.ws564{word-spacing:1.221333pt;}
.ws87{word-spacing:1.237333pt;}
.ws329{word-spacing:1.241333pt;}
.ws598{word-spacing:1.242667pt;}
.ws237{word-spacing:1.248000pt;}
.ws487{word-spacing:1.253333pt;}
.ws57b{word-spacing:1.258667pt;}
.ws328{word-spacing:1.261600pt;}
.ws5c6{word-spacing:1.264000pt;}
.ws4e2{word-spacing:1.274667pt;}
.ws2a9{word-spacing:1.280000pt;}
.ws356{word-spacing:1.285333pt;}
.ws446{word-spacing:1.296000pt;}
.ws33d{word-spacing:1.301333pt;}
.ws2ce{word-spacing:1.312000pt;}
.ws59f{word-spacing:1.317333pt;}
.ws354{word-spacing:1.322667pt;}
.ws42b{word-spacing:1.328000pt;}
.ws252{word-spacing:1.333333pt;}
.ws532{word-spacing:1.338667pt;}
.ws1a5{word-spacing:1.344000pt;}
.ws5ae{word-spacing:1.349333pt;}
.ws45d{word-spacing:1.354667pt;}
.ws3a5{word-spacing:1.360000pt;}
.ws511{word-spacing:1.365333pt;}
.ws509{word-spacing:1.370667pt;}
.ws2e4{word-spacing:1.381333pt;}
.wsd2{word-spacing:1.392000pt;}
.wsf6{word-spacing:1.397333pt;}
.ws13{word-spacing:1.403733pt;}
.ws116{word-spacing:1.408000pt;}
.ws3e3{word-spacing:1.413333pt;}
.ws25b{word-spacing:1.424000pt;}
.ws3be{word-spacing:1.434667pt;}
.ws1ed{word-spacing:1.440000pt;}
.ws22a{word-spacing:1.445333pt;}
.ws473{word-spacing:1.450667pt;}
.ws538{word-spacing:1.456000pt;}
.ws5b7{word-spacing:1.461333pt;}
.ws236{word-spacing:1.466667pt;}
.ws4ef{word-spacing:1.472000pt;}
.ws3e4{word-spacing:1.482667pt;}
.ws3b0{word-spacing:1.488000pt;}
.ws163{word-spacing:1.493333pt;}
.ws92{word-spacing:1.498667pt;}
.ws254{word-spacing:1.504000pt;}
.ws2a3{word-spacing:1.509333pt;}
.ws5c4{word-spacing:1.514667pt;}
.ws4df{word-spacing:1.520000pt;}
.ws398{word-spacing:1.525333pt;}
.ws391{word-spacing:1.530667pt;}
.ws3d4{word-spacing:1.535200pt;}
.ws32{word-spacing:1.536000pt;}
.ws431{word-spacing:1.541333pt;}
.ws5b5{word-spacing:1.546667pt;}
.ws316{word-spacing:1.550400pt;}
.ws44f{word-spacing:1.552000pt;}
.ws111{word-spacing:1.557333pt;}
.ws593{word-spacing:1.568000pt;}
.ws58d{word-spacing:1.573333pt;}
.ws5a6{word-spacing:1.578667pt;}
.ws151{word-spacing:1.585867pt;}
.ws1b7{word-spacing:1.589333pt;}
.ws442{word-spacing:1.600000pt;}
.ws480{word-spacing:1.605333pt;}
.ws3e0{word-spacing:1.610667pt;}
.ws2e{word-spacing:1.616000pt;}
.ws48f{word-spacing:1.621333pt;}
.ws58c{word-spacing:1.632000pt;}
.ws106{word-spacing:1.637333pt;}
.ws377{word-spacing:1.642667pt;}
.ws22f{word-spacing:1.653333pt;}
.ws582{word-spacing:1.658667pt;}
.ws26d{word-spacing:1.664000pt;}
.ws257{word-spacing:1.669333pt;}
.ws195{word-spacing:1.672000pt;}
.ws4e3{word-spacing:1.674667pt;}
.ws49d{word-spacing:1.690667pt;}
.ws36f{word-spacing:1.696000pt;}
.ws2ab{word-spacing:1.701333pt;}
.ws3a2{word-spacing:1.717333pt;}
.ws14b{word-spacing:1.722667pt;}
.ws211{word-spacing:1.727733pt;}
.ws14c{word-spacing:1.728000pt;}
.wsed{word-spacing:1.733333pt;}
.ws2b4{word-spacing:1.738667pt;}
.ws266{word-spacing:1.744000pt;}
.ws53a{word-spacing:1.754667pt;}
.wsc5{word-spacing:1.760000pt;}
.ws50b{word-spacing:1.765333pt;}
.ws378{word-spacing:1.770667pt;}
.ws2f6{word-spacing:1.776000pt;}
.ws23a{word-spacing:1.786667pt;}
.ws384{word-spacing:1.792000pt;}
.ws3c2{word-spacing:1.813333pt;}
.ws171{word-spacing:1.818667pt;}
.ws170{word-spacing:1.824000pt;}
.ws5b4{word-spacing:1.829333pt;}
.ws440{word-spacing:1.840000pt;}
.ws43f{word-spacing:1.845333pt;}
.ws9a{word-spacing:1.850667pt;}
.ws50a{word-spacing:1.856000pt;}
.ws2b6{word-spacing:1.861333pt;}
.ws255{word-spacing:1.882667pt;}
.ws45a{word-spacing:1.888000pt;}
.ws58f{word-spacing:1.904000pt;}
.ws6e{word-spacing:1.909333pt;}
.ws4f2{word-spacing:1.930667pt;}
.ws503{word-spacing:1.946667pt;}
.ws4f3{word-spacing:1.957333pt;}
.wsad{word-spacing:1.962667pt;}
.ws4f7{word-spacing:1.968000pt;}
.ws494{word-spacing:1.984000pt;}
.ws12c{word-spacing:1.989333pt;}
.ws246{word-spacing:1.996267pt;}
.ws4d{word-spacing:2.000000pt;}
.ws307{word-spacing:2.001333pt;}
.ws4b{word-spacing:2.005333pt;}
.ws4a{word-spacing:2.010667pt;}
.ws7a{word-spacing:2.016000pt;}
.ws2e8{word-spacing:2.032000pt;}
.wsbe{word-spacing:2.037333pt;}
.ws291{word-spacing:2.042667pt;}
.ws559{word-spacing:2.048000pt;}
.ws525{word-spacing:2.058667pt;}
.ws5c{word-spacing:2.064000pt;}
.ws3e9{word-spacing:2.085333pt;}
.ws52f{word-spacing:2.090667pt;}
.wsba{word-spacing:2.106667pt;}
.wsdf{word-spacing:2.112000pt;}
.wsd1{word-spacing:2.117333pt;}
.ws4a7{word-spacing:2.122667pt;}
.ws17e{word-spacing:2.128000pt;}
.ws62{word-spacing:2.133333pt;}
.ws359{word-spacing:2.144000pt;}
.ws5b3{word-spacing:2.149333pt;}
.ws5b2{word-spacing:2.154667pt;}
.ws55f{word-spacing:2.165333pt;}
.ws208{word-spacing:2.173600pt;}
.ws515{word-spacing:2.176000pt;}
.ws506{word-spacing:2.186667pt;}
.ws46b{word-spacing:2.197333pt;}
.ws5bf{word-spacing:2.202667pt;}
.ws57c{word-spacing:2.229333pt;}
.ws52b{word-spacing:2.234667pt;}
.ws4ea{word-spacing:2.250667pt;}
.ws181{word-spacing:2.256000pt;}
.ws10d{word-spacing:2.266667pt;}
.ws2c4{word-spacing:2.272000pt;}
.ws80{word-spacing:2.282667pt;}
.ws1c6{word-spacing:2.293333pt;}
.ws61{word-spacing:2.298667pt;}
.ws421{word-spacing:2.304000pt;}
.ws4da{word-spacing:2.314667pt;}
.ws247{word-spacing:2.315467pt;}
.ws1ec{word-spacing:2.330667pt;}
.ws37c{word-spacing:2.346667pt;}
.ws227{word-spacing:2.352000pt;}
.ws188{word-spacing:2.357333pt;}
.ws505{word-spacing:2.362667pt;}
.ws22e{word-spacing:2.368000pt;}
.ws5a3{word-spacing:2.373333pt;}
.ws45b{word-spacing:2.378667pt;}
.ws33c{word-spacing:2.384000pt;}
.ws4b1{word-spacing:2.394667pt;}
.ws4b2{word-spacing:2.400000pt;}
.ws477{word-spacing:2.405333pt;}
.ws2e2{word-spacing:2.411733pt;}
.ws284{word-spacing:2.416000pt;}
.wsd9{word-spacing:2.421333pt;}
.wsa5{word-spacing:2.426667pt;}
.ws28a{word-spacing:2.432000pt;}
.ws2d7{word-spacing:2.437333pt;}
.ws490{word-spacing:2.442667pt;}
.ws259{word-spacing:2.453333pt;}
.ws2cc{word-spacing:2.458667pt;}
.ws512{word-spacing:2.469333pt;}
.ws493{word-spacing:2.485333pt;}
.ws48a{word-spacing:2.490667pt;}
.ws374{word-spacing:2.506667pt;}
.ws529{word-spacing:2.512000pt;}
.ws52a{word-spacing:2.517333pt;}
.wsf7{word-spacing:2.544000pt;}
.ws451{word-spacing:2.549333pt;}
.ws3c9{word-spacing:2.554667pt;}
.ws17f{word-spacing:2.560000pt;}
.ws23b{word-spacing:2.565333pt;}
.ws40e{word-spacing:2.570667pt;}
.ws4b5{word-spacing:2.576000pt;}
.ws49{word-spacing:2.581333pt;}
.ws469{word-spacing:2.602667pt;}
.ws56a{word-spacing:2.608000pt;}
.ws375{word-spacing:2.624000pt;}
.ws3b3{word-spacing:2.629333pt;}
.ws3bb{word-spacing:2.640000pt;}
.ws518{word-spacing:2.645333pt;}
.ws3f5{word-spacing:2.649867pt;}
.ws380{word-spacing:2.650667pt;}
.ws3e2{word-spacing:2.682667pt;}
.ws3e1{word-spacing:2.688000pt;}
.ws344{word-spacing:2.693333pt;}
.ws488{word-spacing:2.714667pt;}
.ws36d{word-spacing:2.725333pt;}
.ws495{word-spacing:2.730667pt;}
.ws4ca{word-spacing:2.736000pt;}
.ws4e7{word-spacing:2.741333pt;}
.ws3db{word-spacing:2.752000pt;}
.ws5bc{word-spacing:2.768000pt;}
.ws465{word-spacing:2.773333pt;}
.ws288{word-spacing:2.778667pt;}
.ws239{word-spacing:2.789333pt;}
.ws468{word-spacing:2.800000pt;}
.ws277{word-spacing:2.821333pt;}
.ws3a7{word-spacing:2.832000pt;}
.ws467{word-spacing:2.837333pt;}
.ws16a{word-spacing:2.848000pt;}
.ws3cc{word-spacing:2.853333pt;}
.ws19{word-spacing:2.860800pt;}
.ws1af{word-spacing:2.864000pt;}
.ws1a1{word-spacing:2.874667pt;}
.ws597{word-spacing:2.885333pt;}
.ws65{word-spacing:2.890667pt;}
.ws594{word-spacing:2.901333pt;}
.ws51c{word-spacing:2.906667pt;}
.ws57e{word-spacing:2.917333pt;}
.ws2e5{word-spacing:2.922667pt;}
.ws46a{word-spacing:2.944000pt;}
.ws558{word-spacing:2.954667pt;}
.ws4dc{word-spacing:2.960000pt;}
.ws2ae{word-spacing:2.970667pt;}
.ws462{word-spacing:2.976000pt;}
.ws28b{word-spacing:2.986667pt;}
.ws30d{word-spacing:3.008000pt;}
.ws4b6{word-spacing:3.013333pt;}
.ws1b1{word-spacing:3.018667pt;}
.wsbf{word-spacing:3.024000pt;}
.ws3ba{word-spacing:3.045333pt;}
.ws5c3{word-spacing:3.050667pt;}
.ws3b9{word-spacing:3.056000pt;}
.ws599{word-spacing:3.066667pt;}
.ws1ce{word-spacing:3.070400pt;}
.ws6{word-spacing:3.084800pt;}
.ws1cd{word-spacing:3.085600pt;}
.ws217{word-spacing:3.088000pt;}
.ws5{word-spacing:3.089067pt;}
.ws57a{word-spacing:3.093333pt;}
.ws7b{word-spacing:3.098667pt;}
.ws54b{word-spacing:3.104000pt;}
.ws340{word-spacing:3.109333pt;}
.wsa9{word-spacing:3.114667pt;}
.ws445{word-spacing:3.136000pt;}
.ws34f{word-spacing:3.152000pt;}
.ws41d{word-spacing:3.157333pt;}
.ws30f{word-spacing:3.162667pt;}
.ws26c{word-spacing:3.168000pt;}
.ws35d{word-spacing:3.173333pt;}
.ws3a3{word-spacing:3.178667pt;}
.ws3a9{word-spacing:3.189333pt;}
.ws41c{word-spacing:3.194667pt;}
.ws51f{word-spacing:3.210667pt;}
.ws489{word-spacing:3.216000pt;}
.ws508{word-spacing:3.221333pt;}
.ws474{word-spacing:3.226667pt;}
.ws39a{word-spacing:3.237333pt;}
.ws213{word-spacing:3.248000pt;}
.ws592{word-spacing:3.253333pt;}
.ws49e{word-spacing:3.269333pt;}
.ws4c7{word-spacing:3.274667pt;}
.ws7{word-spacing:3.281067pt;}
.ws55a{word-spacing:3.285333pt;}
.ws20f{word-spacing:3.288267pt;}
.ws289{word-spacing:3.290667pt;}
.ws31d{word-spacing:3.293333pt;}
.ws2ec{word-spacing:3.296000pt;}
.wsee{word-spacing:3.306667pt;}
.ws5b1{word-spacing:3.322667pt;}
.ws23c{word-spacing:3.328000pt;}
.ws435{word-spacing:3.333333pt;}
.ws452{word-spacing:3.338667pt;}
.ws15e{word-spacing:3.344000pt;}
.ws4ec{word-spacing:3.365333pt;}
.ws333{word-spacing:3.399733pt;}
.ws561{word-spacing:3.402667pt;}
.ws1f3{word-spacing:3.404800pt;}
.ws572{word-spacing:3.408000pt;}
.ws290{word-spacing:3.413333pt;}
.ws38b{word-spacing:3.418667pt;}
.ws504{word-spacing:3.429333pt;}
.ws196{word-spacing:3.430133pt;}
.ws57d{word-spacing:3.434667pt;}
.ws39b{word-spacing:3.440000pt;}
.ws3c3{word-spacing:3.445333pt;}
.ws275{word-spacing:3.450667pt;}
.ws35c{word-spacing:3.452000pt;}
.ws47c{word-spacing:3.456000pt;}
.ws524{word-spacing:3.488000pt;}
.ws3f2{word-spacing:3.504000pt;}
.ws4f0{word-spacing:3.509333pt;}
.ws7d{word-spacing:3.530667pt;}
.ws3ca{word-spacing:3.541333pt;}
.ws3dc{word-spacing:3.562667pt;}
.ws271{word-spacing:3.568000pt;}
.wsfb{word-spacing:3.573333pt;}
.ws190{word-spacing:3.578667pt;}
.ws57f{word-spacing:3.594667pt;}
.ws432{word-spacing:3.605333pt;}
.ws540{word-spacing:3.610667pt;}
.ws570{word-spacing:3.632000pt;}
.wse4{word-spacing:3.642667pt;}
.ws322{word-spacing:3.653067pt;}
.ws4af{word-spacing:3.653333pt;}
.wsd3{word-spacing:3.664000pt;}
.ws40c{word-spacing:3.669333pt;}
.ws5a8{word-spacing:3.674667pt;}
.ws5a4{word-spacing:3.685333pt;}
.ws54c{word-spacing:3.690667pt;}
.ws456{word-spacing:3.706667pt;}
.ws455{word-spacing:3.712000pt;}
.ws1c0{word-spacing:3.722667pt;}
.ws32f{word-spacing:3.724000pt;}
.ws166{word-spacing:3.744000pt;}
.ws265{word-spacing:3.760000pt;}
.ws34b{word-spacing:3.765333pt;}
.ws537{word-spacing:3.770667pt;}
.ws379{word-spacing:3.776000pt;}
.ws46d{word-spacing:3.781333pt;}
.ws3ff{word-spacing:3.786667pt;}
.ws2f0{word-spacing:3.796000pt;}
.ws1ac{word-spacing:3.797333pt;}
.ws5a2{word-spacing:3.802667pt;}
.ws457{word-spacing:3.813333pt;}
.ws5ad{word-spacing:3.818667pt;}
.ws44d{word-spacing:3.824000pt;}
.ws51{word-spacing:3.834667pt;}
.ws5c7{word-spacing:3.845333pt;}
.ws55d{word-spacing:3.850667pt;}
.ws4dd{word-spacing:3.856000pt;}
.ws55c{word-spacing:3.861333pt;}
.ws3a0{word-spacing:3.882667pt;}
.ws292{word-spacing:3.888000pt;}
.ws41f{word-spacing:3.898667pt;}
.ws59b{word-spacing:3.914667pt;}
.ws478{word-spacing:3.920000pt;}
.ws44c{word-spacing:3.936000pt;}
.ws3de{word-spacing:3.941333pt;}
.ws4b7{word-spacing:3.946667pt;}
.ws5c0{word-spacing:3.952000pt;}
.ws399{word-spacing:3.962667pt;}
.ws2be{word-spacing:3.967200pt;}
.ws4a2{word-spacing:3.973333pt;}
.ws263{word-spacing:3.978667pt;}
.ws37d{word-spacing:3.984000pt;}
.ws392{word-spacing:4.005333pt;}
.ws47b{word-spacing:4.010667pt;}
.ws5a0{word-spacing:4.016000pt;}
.ws483{word-spacing:4.021333pt;}
.ws4b8{word-spacing:4.026667pt;}
.ws388{word-spacing:4.032000pt;}
.ws585{word-spacing:4.037333pt;}
.ws1f6{word-spacing:4.038133pt;}
.ws497{word-spacing:4.053333pt;}
.ws10f{word-spacing:4.058667pt;}
.ws22{word-spacing:4.064000pt;}
.ws27b{word-spacing:4.069333pt;}
.ws581{word-spacing:4.074667pt;}
.ws560{word-spacing:4.085333pt;}
.ws2e7{word-spacing:4.106667pt;}
.ws124{word-spacing:4.112000pt;}
.ws234{word-spacing:4.128000pt;}
.ws228{word-spacing:4.132000pt;}
.ws463{word-spacing:4.133333pt;}
.ws5bb{word-spacing:4.138667pt;}
.ws5b0{word-spacing:4.144000pt;}
.ws4bc{word-spacing:4.148000pt;}
.ws311{word-spacing:4.154667pt;}
.ws2af{word-spacing:4.159733pt;}
.ws454{word-spacing:4.176000pt;}
.ws484{word-spacing:4.181333pt;}
.ws16f{word-spacing:4.184000pt;}
.ws1c9{word-spacing:4.186667pt;}
.ws183{word-spacing:4.197333pt;}
.ws56f{word-spacing:4.202667pt;}
.ws507{word-spacing:4.208000pt;}
.ws2c9{word-spacing:4.212000pt;}
.ws584{word-spacing:4.213333pt;}
.ws50e{word-spacing:4.218667pt;}
.ws4c6{word-spacing:4.224000pt;}
.ws3ed{word-spacing:4.229333pt;}
.ws187{word-spacing:4.234667pt;}
.ws485{word-spacing:4.250667pt;}
.ws3d5{word-spacing:4.256000pt;}
.ws519{word-spacing:4.272000pt;}
.ws59d{word-spacing:4.277333pt;}
.ws589{word-spacing:4.282667pt;}
.ws269{word-spacing:4.293333pt;}
.ws5ac{word-spacing:4.304000pt;}
.ws129{word-spacing:4.309333pt;}
.ws576{word-spacing:4.314667pt;}
.ws577{word-spacing:4.320000pt;}
.ws287{word-spacing:4.330667pt;}
.ws88{word-spacing:4.336000pt;}
.ws3d3{word-spacing:4.337067pt;}
.ws3bc{word-spacing:4.341333pt;}
.ws1de{word-spacing:4.357333pt;}
.ws8d{word-spacing:4.368000pt;}
.ws2ef{word-spacing:4.372000pt;}
.ws46c{word-spacing:4.384000pt;}
.ws4ae{word-spacing:4.389333pt;}
.ws4f6{word-spacing:4.394667pt;}
.ws39d{word-spacing:4.400000pt;}
.ws38d{word-spacing:4.405333pt;}
.ws54f{word-spacing:4.410667pt;}
.ws2db{word-spacing:4.418133pt;}
.ws35{word-spacing:4.421333pt;}
.ws141{word-spacing:4.424000pt;}
.ws337{word-spacing:4.438400pt;}
.ws114{word-spacing:4.440000pt;}
.ws3fa{word-spacing:4.442667pt;}
.ws9f{word-spacing:4.458667pt;}
.ws34e{word-spacing:4.474667pt;}
.ws35a{word-spacing:4.476000pt;}
.ws2e1{word-spacing:4.484000pt;}
.ws517{word-spacing:4.485333pt;}
.ws261{word-spacing:4.490667pt;}
.ws4f5{word-spacing:4.496000pt;}
.ws545{word-spacing:4.501333pt;}
.ws34d{word-spacing:4.506667pt;}
.ws2d8{word-spacing:4.512000pt;}
.wscf{word-spacing:4.522667pt;}
.ws23e{word-spacing:4.528000pt;}
.ws2f3{word-spacing:4.533333pt;}
.ws382{word-spacing:4.538667pt;}
.ws461{word-spacing:4.544000pt;}
.ws51a{word-spacing:4.554667pt;}
.ws45f{word-spacing:4.570667pt;}
.ws32c{word-spacing:4.597333pt;}
.ws5b8{word-spacing:4.602667pt;}
.ws482{word-spacing:4.613333pt;}
.ws4f9{word-spacing:4.620800pt;}
.ws49b{word-spacing:4.624000pt;}
.ws4f8{word-spacing:4.625867pt;}
.ws33f{word-spacing:4.629333pt;}
.ws3e6{word-spacing:4.640000pt;}
.ws3e5{word-spacing:4.650667pt;}
.ws588{word-spacing:4.656000pt;}
.ws2fc{word-spacing:4.666667pt;}
.ws42e{word-spacing:4.672000pt;}
.ws56c{word-spacing:4.677333pt;}
.ws51d{word-spacing:4.688000pt;}
.ws2a4{word-spacing:4.693333pt;}
.ws3d6{word-spacing:4.696800pt;}
.ws479{word-spacing:4.698667pt;}
.wsb{word-spacing:4.701867pt;}
.ws4a5{word-spacing:4.709333pt;}
.ws3fc{word-spacing:4.714667pt;}
.ws556{word-spacing:4.725333pt;}
.ws492{word-spacing:4.730667pt;}
.ws437{word-spacing:4.736000pt;}
.ws3d2{word-spacing:4.737333pt;}
.ws125{word-spacing:4.741333pt;}
.ws19e{word-spacing:4.746667pt;}
.ws428{word-spacing:4.752000pt;}
.ws3b7{word-spacing:4.757333pt;}
.ws1fe{word-spacing:4.762667pt;}
.ws423{word-spacing:4.768000pt;}
.ws194{word-spacing:4.772800pt;}
.ws575{word-spacing:4.773333pt;}
.ws3fe{word-spacing:4.778667pt;}
.ws351{word-spacing:4.784000pt;}
.ws1e7{word-spacing:4.788000pt;}
.ws20{word-spacing:4.789333pt;}
.ws9e{word-spacing:4.794667pt;}
.ws14f{word-spacing:4.800000pt;}
.ws50d{word-spacing:4.805333pt;}
.ws5a5{word-spacing:4.821333pt;}
.ws49c{word-spacing:4.832000pt;}
.ws49f{word-spacing:4.837333pt;}
.wsc3{word-spacing:4.848000pt;}
.ws56d{word-spacing:4.853333pt;}
.ws193{word-spacing:4.853867pt;}
.ws13a{word-spacing:4.858667pt;}
.ws32a{word-spacing:4.858933pt;}
.ws32b{word-spacing:4.864000pt;}
.ws248{word-spacing:4.869067pt;}
.ws1fd{word-spacing:4.869333pt;}
.ws52d{word-spacing:4.874667pt;}
.ws21f{word-spacing:4.880000pt;}
.ws2fa{word-spacing:4.885333pt;}
.ws3dd{word-spacing:4.890667pt;}
.wsd5{word-spacing:4.896000pt;}
.wsa8{word-spacing:4.901333pt;}
.ws387{word-spacing:4.906667pt;}
.ws4fb{word-spacing:4.909600pt;}
.ws573{word-spacing:4.912000pt;}
.ws574{word-spacing:4.917333pt;}
.ws29e{word-spacing:4.929867pt;}
.ws164{word-spacing:4.933333pt;}
.ws11b{word-spacing:4.938667pt;}
.ws20d{word-spacing:4.940000pt;}
.ws42c{word-spacing:4.944000pt;}
.ws309{word-spacing:4.945067pt;}
.ws53c{word-spacing:4.949333pt;}
.ws596{word-spacing:4.954667pt;}
.ws430{word-spacing:4.965333pt;}
.ws464{word-spacing:4.970667pt;}
.ws251{word-spacing:4.975467pt;}
.ws69{word-spacing:4.981333pt;}
.ws148{word-spacing:4.986667pt;}
.ws365{word-spacing:4.990667pt;}
.ws37a{word-spacing:4.992000pt;}
.ws24c{word-spacing:4.995733pt;}
.ws541{word-spacing:4.997333pt;}
.ws46{word-spacing:5.002667pt;}
.ws39f{word-spacing:5.008000pt;}
.ws56e{word-spacing:5.013333pt;}
.ws1d8{word-spacing:5.016000pt;}
.ws4a9{word-spacing:5.018667pt;}
.ws434{word-spacing:5.024000pt;}
.ws2d3{word-spacing:5.029333pt;}
.ws103{word-spacing:5.034667pt;}
.ws341{word-spacing:5.040000pt;}
.ws373{word-spacing:5.045333pt;}
.ws165{word-spacing:5.050667pt;}
.ws3f6{word-spacing:5.051467pt;}
.ws447{word-spacing:5.056000pt;}
.ws1c5{word-spacing:5.061333pt;}
.ws499{word-spacing:5.066667pt;}
.ws59c{word-spacing:5.072000pt;}
.ws397{word-spacing:5.077333pt;}
.ws2cb{word-spacing:5.082667pt;}
.ws39c{word-spacing:5.088000pt;}
.ws2ca{word-spacing:5.093333pt;}
.ws5b6{word-spacing:5.098667pt;}
.ws33a{word-spacing:5.102133pt;}
.ws3a6{word-spacing:5.104000pt;}
.ws1cb{word-spacing:5.109333pt;}
.ws126{word-spacing:5.114667pt;}
.ws2e3{word-spacing:5.117333pt;}
.ws547{word-spacing:5.120000pt;}
.ws6a{word-spacing:5.125333pt;}
.ws4fd{word-spacing:5.127467pt;}
.ws22c{word-spacing:5.130667pt;}
.ws443{word-spacing:5.136000pt;}
.ws555{word-spacing:5.141333pt;}
.ws75{word-spacing:5.146667pt;}
.ws2a8{word-spacing:5.152000pt;}
.ws79{word-spacing:5.157333pt;}
.ws527{word-spacing:5.162667pt;}
.wsfc{word-spacing:5.168000pt;}
.ws410{word-spacing:5.173333pt;}
.ws221{word-spacing:5.178667pt;}
.ws25e{word-spacing:5.189333pt;}
.ws15a{word-spacing:5.193333pt;}
.ws4a3{word-spacing:5.194667pt;}
.ws4ff{word-spacing:5.198400pt;}
.ws119{word-spacing:5.200000pt;}
.ws2c7{word-spacing:5.203467pt;}
.ws268{word-spacing:5.205333pt;}
.ws280{word-spacing:5.208533pt;}
.wsb4{word-spacing:5.210667pt;}
.wsd4{word-spacing:5.216000pt;}
.ws58e{word-spacing:5.221333pt;}
.ws162{word-spacing:5.226667pt;}
.ws327{word-spacing:5.228800pt;}
.ws3df{word-spacing:5.232000pt;}
.ws186{word-spacing:5.237333pt;}
.ws157{word-spacing:5.238933pt;}
.ws55b{word-spacing:5.242667pt;}
.ws2c0{word-spacing:5.248000pt;}
.ws167{word-spacing:5.253333pt;}
.ws42d{word-spacing:5.258667pt;}
.ws202{word-spacing:5.264000pt;}
.ws364{word-spacing:5.264267pt;}
.ws35f{word-spacing:5.269333pt;}
.ws47d{word-spacing:5.274667pt;}
.ws4a0{word-spacing:5.280000pt;}
.ws3c4{word-spacing:5.285333pt;}
.ws70{word-spacing:5.290667pt;}
.ws1fc{word-spacing:5.296000pt;}
.wsce{word-spacing:5.301333pt;}
.ws226{word-spacing:5.306667pt;}
.ws429{word-spacing:5.312000pt;}
.ws105{word-spacing:5.317333pt;}
.ws46f{word-spacing:5.322667pt;}
.ws54d{word-spacing:5.328000pt;}
.ws241{word-spacing:5.330133pt;}
.ws5c5{word-spacing:5.333333pt;}
.ws29d{word-spacing:5.335200pt;}
.ws3b1{word-spacing:5.338667pt;}
.ws2b8{word-spacing:5.344000pt;}
.ws276{word-spacing:5.349333pt;}
.ws4e1{word-spacing:5.354667pt;}
.ws198{word-spacing:5.355467pt;}
.ws6f{word-spacing:5.360000pt;}
.ws396{word-spacing:5.365333pt;}
.ws321{word-spacing:5.370667pt;}
.ws150{word-spacing:5.375733pt;}
.ws3b6{word-spacing:5.376000pt;}
.ws320{word-spacing:5.380800pt;}
.ws73{word-spacing:5.381333pt;}
.ws2eb{word-spacing:5.385867pt;}
.ws272{word-spacing:5.386667pt;}
.ws270{word-spacing:5.392000pt;}
.ws2f8{word-spacing:5.397333pt;}
.ws501{word-spacing:5.401067pt;}
.ws177{word-spacing:5.402667pt;}
.ws4a4{word-spacing:5.408000pt;}
.ws13e{word-spacing:5.413333pt;}
.ws44{word-spacing:5.418667pt;}
.wsf9{word-spacing:5.424000pt;}
.ws326{word-spacing:5.426400pt;}
.ws100{word-spacing:5.429333pt;}
.ws204{word-spacing:5.434667pt;}
.ws244{word-spacing:5.440000pt;}
.ws299{word-spacing:5.441600pt;}
.ws243{word-spacing:5.445333pt;}
.ws224{word-spacing:5.450667pt;}
.ws23f{word-spacing:5.451733pt;}
.ws2f9{word-spacing:5.456000pt;}
.ws235{word-spacing:5.461333pt;}
.ws19b{word-spacing:5.466667pt;}
.ws1ff{word-spacing:5.472000pt;}
.ws520{word-spacing:5.477333pt;}
.ws29b{word-spacing:5.482133pt;}
.ws460{word-spacing:5.482667pt;}
.ws2b9{word-spacing:5.488000pt;}
.ws7c{word-spacing:5.493333pt;}
.ws1e4{word-spacing:5.497333pt;}
.ws389{word-spacing:5.498667pt;}
.ws56{word-spacing:5.504000pt;}
.wse5{word-spacing:5.509333pt;}
.ws47f{word-spacing:5.514667pt;}
.ws1e0{word-spacing:5.520000pt;}
.wsd6{word-spacing:5.525333pt;}
.ws5b9{word-spacing:5.530667pt;}
.ws20e{word-spacing:5.532800pt;}
.ws43b{word-spacing:5.536000pt;}
.ws1e9{word-spacing:5.537867pt;}
.ws3b5{word-spacing:5.541333pt;}
.ws1d9{word-spacing:5.542933pt;}
.ws1c2{word-spacing:5.546667pt;}
.ws563{word-spacing:5.552000pt;}
.ws395{word-spacing:5.553067pt;}
.ws3b2{word-spacing:5.557333pt;}
.ws314{word-spacing:5.558133pt;}
.ws182{word-spacing:5.562667pt;}
.ws400{word-spacing:5.568000pt;}
.ws1d0{word-spacing:5.568267pt;}
.wsea{word-spacing:5.573333pt;}
.ws39{word-spacing:5.578667pt;}
.ws1cf{word-spacing:5.583467pt;}
.ws2e9{word-spacing:5.584000pt;}
.ws3b{word-spacing:5.594667pt;}
.ws549{word-spacing:5.600000pt;}
.ws240{word-spacing:5.603733pt;}
.wsaa{word-spacing:5.605333pt;}
.ws1e6{word-spacing:5.608800pt;}
.ws1a2{word-spacing:5.610667pt;}
.ws481{word-spacing:5.616000pt;}
.ws363{word-spacing:5.618933pt;}
.ws1c7{word-spacing:5.621333pt;}
.ws3f3{word-spacing:5.626667pt;}
.ws1da{word-spacing:5.629067pt;}
.ws38{word-spacing:5.632000pt;}
.wsb9{word-spacing:5.637333pt;}
.ws2d4{word-spacing:5.642667pt;}
.ws3af{word-spacing:5.644267pt;}
.ws424{word-spacing:5.648000pt;}
.ws1b6{word-spacing:5.653333pt;}
.ws31f{word-spacing:5.654400pt;}
.ws15b{word-spacing:5.658667pt;}
.ws24e{word-spacing:5.659467pt;}
.ws2aa{word-spacing:5.664000pt;}
.ws416{word-spacing:5.669333pt;}
.ws301{word-spacing:5.669600pt;}
.ws42a{word-spacing:5.674667pt;}
.ws300{word-spacing:5.679733pt;}
.wsa7{word-spacing:5.680000pt;}
.ws2c8{word-spacing:5.684800pt;}
.ws4e{word-spacing:5.685333pt;}
.ws3ae{word-spacing:5.689867pt;}
.ws2f2{word-spacing:5.690667pt;}
.ws222{word-spacing:5.696000pt;}
.ws11d{word-spacing:5.701333pt;}
.ws2fd{word-spacing:5.706667pt;}
.wsc8{word-spacing:5.712000pt;}
.ws2f7{word-spacing:5.717333pt;}
.ws3c7{word-spacing:5.722667pt;}
.ws98{word-spacing:5.728000pt;}
.ws136{word-spacing:5.733333pt;}
.ws1c4{word-spacing:5.738667pt;}
.ws176{word-spacing:5.744000pt;}
.ws403{word-spacing:5.749333pt;}
.ws436{word-spacing:5.754667pt;}
.ws411{word-spacing:5.760000pt;}
.ws225{word-spacing:5.765333pt;}
.ws174{word-spacing:5.770667pt;}
.ws357{word-spacing:5.776000pt;}
.ws458{word-spacing:5.781333pt;}
.ws355{word-spacing:5.786667pt;}
.ws282{word-spacing:5.792000pt;}
.ws401{word-spacing:5.797333pt;}
.ws353{word-spacing:5.802667pt;}
.ws1ee{word-spacing:5.808000pt;}
.ws137{word-spacing:5.813333pt;}
.ws293{word-spacing:5.818667pt;}
.ws444{word-spacing:5.824000pt;}
.ws149{word-spacing:5.829333pt;}
.ws132{word-spacing:5.834667pt;}
.ws11e{word-spacing:5.840000pt;}
.wsc2{word-spacing:5.845333pt;}
.ws48d{word-spacing:5.850667pt;}
.ws1fb{word-spacing:5.856000pt;}
.ws1b5{word-spacing:5.861333pt;}
.ws2ee{word-spacing:5.866667pt;}
.ws107{word-spacing:5.872000pt;}
.ws26f{word-spacing:5.877333pt;}
.ws260{word-spacing:5.882667pt;}
.ws121{word-spacing:5.888000pt;}
.ws12a{word-spacing:5.893333pt;}
.ws22d{word-spacing:5.898667pt;}
.wsef{word-spacing:5.904000pt;}
.ws3b8{word-spacing:5.909333pt;}
.ws46e{word-spacing:5.914667pt;}
.ws3d8{word-spacing:5.920000pt;}
.ws6d{word-spacing:5.925333pt;}
.wseb{word-spacing:5.930667pt;}
.ws37b{word-spacing:5.936000pt;}
.ws99{word-spacing:5.941333pt;}
.ws220{word-spacing:5.946667pt;}
.ws232{word-spacing:5.952000pt;}
.ws3c{word-spacing:5.957333pt;}
.ws433{word-spacing:5.962667pt;}
.ws3d{word-spacing:5.968000pt;}
.ws383{word-spacing:5.973333pt;}
.ws439{word-spacing:5.978667pt;}
.ws1fa{word-spacing:5.984000pt;}
.ws2e6{word-spacing:5.989333pt;}
.ws53b{word-spacing:5.994667pt;}
.ws43a{word-spacing:6.010667pt;}
.ws557{word-spacing:6.037333pt;}
.ws3f4{word-spacing:6.434667pt;}
.ws52{word-spacing:6.608000pt;}
.ws4c{word-spacing:8.613333pt;}
.ws4ad{word-spacing:8.634667pt;}
.ws360{word-spacing:9.920533pt;}
.ws57{word-spacing:12.106667pt;}
.ws553{word-spacing:15.410927pt;}
.ws4cd{word-spacing:17.496840pt;}
.ws5c8{word-spacing:22.378667pt;}
.ws21c{word-spacing:188.667467pt;}
.ws21b{word-spacing:215.419467pt;}
.ws21d{word-spacing:274.400533pt;}
.ws21a{word-spacing:294.945867pt;}
.ws407{word-spacing:624.929067pt;}
.ws1b{word-spacing:985.468800pt;}
._7{margin-left:-864.000000pt;}
._b6{margin-left:-445.632000pt;}
._c9{margin-left:-416.784769pt;}
._c7{margin-left:-273.254835pt;}
._b7{margin-left:-262.133333pt;}
._b5{margin-left:-234.080000pt;}
._c5{margin-left:-127.165261pt;}
._c8{margin-left:-91.940229pt;}
._d1{margin-left:-42.613333pt;}
._d2{margin-left:-35.626667pt;}
._cf{margin-left:-33.653333pt;}
._ce{margin-left:-31.893333pt;}
._cd{margin-left:-30.453333pt;}
._d3{margin-left:-29.013333pt;}
._d0{margin-left:-27.360000pt;}
._b4{margin-left:-25.081440pt;}
._c3{margin-left:-21.778942pt;}
._65{margin-left:-15.338391pt;}
._7e{margin-left:-11.413333pt;}
._ae{margin-left:-8.624000pt;}
._c{margin-left:-6.608000pt;}
._4b{margin-left:-5.188800pt;}
._b{margin-left:-3.485867pt;}
._a{margin-left:-2.094933pt;}
._8{width:1.448533pt;}
._9{width:3.808000pt;}
._66{width:5.265342pt;}
._67{width:7.747200pt;}
._6{width:9.718278pt;}
._5{width:11.368551pt;}
._95{width:13.158133pt;}
._64{width:14.576000pt;}
._7c{width:16.034409pt;}
._3{width:17.602925pt;}
._68{width:19.477574pt;}
._2{width:22.101450pt;}
._1{width:23.470566pt;}
._0{width:25.426447pt;}
._4{width:27.088945pt;}
._7a{width:33.808000pt;}
._b1{width:35.936000pt;}
._44{width:38.462400pt;}
._39{width:40.483200pt;}
._a6{width:42.854400pt;}
._46{width:44.371200pt;}
._5a{width:46.387200pt;}
._a7{width:48.076800pt;}
._54{width:51.134400pt;}
._a8{width:53.337600pt;}
._50{width:55.306667pt;}
._40{width:57.283200pt;}
._1d{width:58.684800pt;}
._33{width:60.120000pt;}
._52{width:62.368000pt;}
._15{width:64.291200pt;}
._49{width:66.662400pt;}
._ac{width:68.792533pt;}
._13{width:70.339200pt;}
._97{width:72.896000pt;}
._3b{width:74.725333pt;}
._18{width:77.877333pt;}
._1a{width:79.589333pt;}
._2d{width:82.240000pt;}
._11{width:84.544000pt;}
._7d{width:86.912000pt;}
._79{width:89.683200pt;}
._7b{width:91.731200pt;}
._17{width:94.684800pt;}
._4c{width:97.150933pt;}
._83{width:100.828204pt;}
._89{width:103.582487pt;}
._88{width:105.861758pt;}
._93{width:108.404936pt;}
._8e{width:112.472454pt;}
._82{width:113.926954pt;}
._78{width:117.025067pt;}
._87{width:118.359333pt;}
._81{width:121.144970pt;}
._90{width:123.359274pt;}
._86{width:126.240573pt;}
._c0{width:128.756993pt;}
._85{width:132.210599pt;}
._84{width:133.565606pt;}
._aa{width:137.627200pt;}
._8d{width:139.466735pt;}
._a1{width:140.846576pt;}
._9f{width:147.096528pt;}
._22{width:148.984533pt;}
._9e{width:151.327092pt;}
._80{width:153.802612pt;}
._92{width:157.708443pt;}
._91{width:160.918173pt;}
._7f{width:164.414678pt;}
._31{width:168.183467pt;}
._71{width:169.767467pt;}
._8f{width:171.595538pt;}
._62{width:178.169600pt;}
._8b{width:180.831149pt;}
._8c{width:182.199149pt;}
._c6{width:185.387647pt;}
._8a{width:187.215149pt;}
._bf{width:188.986099pt;}
._9a{width:196.855013pt;}
._bd{width:202.180267pt;}
._af{width:210.918933pt;}
._6e{width:216.080000pt;}
._9c{width:220.249713pt;}
._6d{width:228.938667pt;}
._57{width:233.810133pt;}
._a5{width:235.618576pt;}
._bc{width:238.169600pt;}
._a9{width:241.631467pt;}
._96{width:243.840000pt;}
._bb{width:245.555200pt;}
._ba{width:249.233067pt;}
._9d{width:253.626054pt;}
._98{width:259.421584pt;}
._72{width:261.210667pt;}
._77{width:262.693333pt;}
._a0{width:267.612187pt;}
._76{width:269.840000pt;}
._32{width:282.881600pt;}
._75{width:292.762667pt;}
._74{width:294.698667pt;}
._69{width:297.722667pt;}
._73{width:305.237333pt;}
._70{width:309.335467pt;}
._6b{width:318.090667pt;}
._6c{width:323.370667pt;}
._6a{width:328.917333pt;}
._58{width:332.040000pt;}
._b8{width:335.589333pt;}
._6f{width:339.914667pt;}
._56{width:342.638400pt;}
._be{width:348.706014pt;}
._2e{width:360.685867pt;}
._55{width:366.288000pt;}
._a2{width:368.841509pt;}
._b3{width:370.458667pt;}
._ca{width:378.735829pt;}
._a3{width:392.751109pt;}
._e{width:401.275200pt;}
._38{width:415.701333pt;}
._4f{width:421.579200pt;}
._2c{width:434.913600pt;}
._59{width:440.488533pt;}
._36{width:479.299200pt;}
._ad{width:485.972267pt;}
._d{width:488.020800pt;}
._94{width:510.232681pt;}
._a4{width:520.958043pt;}
._5e{width:523.790400pt;}
._cc{width:528.749333pt;}
._45{width:538.564800pt;}
._35{width:539.947200pt;}
._4d{width:550.456533pt;}
._2b{width:553.787733pt;}
._9b{width:570.268369pt;}
._99{width:572.090043pt;}
._60{width:575.288000pt;}
._b9{width:590.040000pt;}
._25{width:599.512533pt;}
._5d{width:610.790400pt;}
._24{width:622.536000pt;}
._53{width:625.392000pt;}
._26{width:648.821333pt;}
._61{width:651.721067pt;}
._23{width:659.284800pt;}
._c4{width:663.748267pt;}
._48{width:665.635200pt;}
._b0{width:696.126400pt;}
._34{width:700.274133pt;}
._37{width:703.435200pt;}
._4e{width:713.279467pt;}
._b2{width:716.408533pt;}
._30{width:719.227200pt;}
._28{width:745.872000pt;}
._ab{width:749.312533pt;}
._5f{width:760.291200pt;}
._3e{width:765.419733pt;}
._42{width:772.547733pt;}
._cb{width:779.675733pt;}
._16{width:784.660800pt;}
._3f{width:787.216533pt;}
._2a{width:809.924267pt;}
._47{width:814.354667pt;}
._43{width:840.393600pt;}
._21{width:902.872533pt;}
._51{width:912.704000pt;}
._3a{width:928.089600pt;}
._c2{width:938.865067pt;}
._1c{width:942.086400pt;}
._29{width:966.369600pt;}
._41{width:972.664533pt;}
._27{width:979.593600pt;}
._3d{width:981.475200pt;}
._1f{width:1027.349333pt;}
._1b{width:1041.528533pt;}
._20{width:1050.648000pt;}
._19{width:1066.021333pt;}
._5b{width:1067.385600pt;}
._5c{width:1076.846400pt;}
._1e{width:1102.939200pt;}
._2f{width:1139.409600pt;}
._14{width:1163.193600pt;}
._4a{width:1174.718400pt;}
._3c{width:1182.393600pt;}
._c1{width:1200.476267pt;}
._12{width:1238.869333pt;}
._10{width:1277.349333pt;}
._63{width:1356.595200pt;}
._f{width:1434.887467pt;}
.fs1d{font-size:12.800000pt;}
.fs24{font-size:16.130133pt;}
.fs1c{font-size:17.066667pt;}
.fs22{font-size:23.715200pt;}
.fs1e{font-size:25.600000pt;}
.fs20{font-size:25.612800pt;}
.fs21{font-size:27.667733pt;}
.fsd{font-size:28.000000pt;}
.fs23{font-size:28.094933pt;}
.fs2{font-size:32.000000pt;}
.fs15{font-size:33.600000pt;}
.fse{font-size:35.466667pt;}
.fs1{font-size:36.672747pt;}
.fs5{font-size:37.333333pt;}
.fs1f{font-size:38.400000pt;}
.fsa{font-size:40.000000pt;}
.fsc{font-size:41.066667pt;}
.fs7{font-size:42.666667pt;}
.fs1a{font-size:43.490133pt;}
.fs16{font-size:44.197333pt;}
.fs1b{font-size:46.407467pt;}
.fs9{font-size:48.000000pt;}
.fs18{font-size:49.854400pt;}
.fsb{font-size:50.666667pt;}
.fs19{font-size:53.036800pt;}
.fs8{font-size:53.333333pt;}
.fs13{font-size:54.524870pt;}
.fs12{font-size:56.000000pt;}
.fs17{font-size:57.456533pt;}
.fs11{font-size:58.666667pt;}
.fs3{font-size:64.000000pt;}
.fs10{font-size:69.333333pt;}
.fs6{font-size:74.666667pt;}
.fs0{font-size:97.794027pt;}
.fsf{font-size:128.000000pt;}
.fs4{font-size:149.333333pt;}
.fs14{font-size:224.000000pt;}
.y6{bottom:0.000000pt;}
.ye37{bottom:0.000452pt;}
.ye3c{bottom:0.307600pt;}
.y9a2{bottom:1.933333pt;}
.yb0c{bottom:2.182667pt;}
.yac8{bottom:2.333333pt;}
.yc8d{bottom:3.118533pt;}
.ybe6{bottom:3.346667pt;}
.yabd{bottom:4.280000pt;}
.y99d{bottom:4.299200pt;}
.y9a1{bottom:4.600000pt;}
.yb5d{bottom:4.738667pt;}
.yc8b{bottom:4.825200pt;}
.yb0b{bottom:4.849333pt;}
.ya52{bottom:4.954667pt;}
.yb27{bottom:4.961333pt;}
.yac7{bottom:5.000000pt;}
.y95f{bottom:5.306667pt;}
.yc74{bottom:5.729333pt;}
.yaec{bottom:6.708000pt;}
.ya7c{bottom:7.105333pt;}
.yf9b{bottom:7.541333pt;}
.ya51{bottom:7.621333pt;}
.y95e{bottom:7.973333pt;}
.y10a7{bottom:8.162933pt;}
.yc75{bottom:8.396000pt;}
.yc73{bottom:8.396133pt;}
.yaeb{bottom:9.374667pt;}
.yc7a{bottom:9.396000pt;}
.ya7b{bottom:9.772000pt;}
.yb44{bottom:10.074667pt;}
.yc79{bottom:12.062800pt;}
.y9da{bottom:12.534667pt;}
.ybd1{bottom:15.489333pt;}
.yc31{bottom:15.916133pt;}
.ybad{bottom:16.356000pt;}
.y9c2{bottom:16.668000pt;}
.yb2c{bottom:16.733333pt;}
.y9cb{bottom:17.545333pt;}
.yb0e{bottom:18.205333pt;}
.y10ab{bottom:18.241333pt;}
.yaca{bottom:18.356000pt;}
.y10a4{bottom:19.038667pt;}
.ya1f{bottom:19.105333pt;}
.yb2b{bottom:19.400000pt;}
.yb28{bottom:19.664000pt;}
.yb97{bottom:19.836000pt;}
.yb47{bottom:19.960000pt;}
.y10a5{bottom:20.105333pt;}
.y9ca{bottom:20.212000pt;}
.y9c3{bottom:20.668000pt;}
.y9c1{bottom:20.668667pt;}
.ya54{bottom:20.977333pt;}
.yb46{bottom:22.626667pt;}
.yaee{bottom:22.729333pt;}
.ya7e{bottom:23.128000pt;}
.y9e2{bottom:25.942667pt;}
.ybb4{bottom:26.096000pt;}
.y10aa{bottom:27.660533pt;}
.yb5c{bottom:28.072000pt;}
.ybac{bottom:28.356000pt;}
.ybb3{bottom:28.762667pt;}
.yc32{bottom:29.694800pt;}
.y9e1{bottom:29.942400pt;}
.yb0a{bottom:30.013333pt;}
.y216{bottom:30.434200pt;}
.yc70{bottom:30.662800pt;}
.yb99{bottom:31.534667pt;}
.yb09{bottom:32.680000pt;}
.y927{bottom:33.543533pt;}
.yb00{bottom:33.694667pt;}
.yabb{bottom:33.844000pt;}
.yb96{bottom:34.100000pt;}
.yb98{bottom:34.201333pt;}
.yc68{bottom:35.182800pt;}
.y9bf{bottom:35.191333pt;}
.ya48{bottom:36.465333pt;}
.y1ce{bottom:36.849533pt;}
.y10a9{bottom:37.079733pt;}
.ya{bottom:37.798000pt;}
.yae2{bottom:38.220133pt;}
.ya70{bottom:38.616000pt;}
.ybd5{bottom:39.284000pt;}
.ybd7{bottom:39.617333pt;}
.yc77{bottom:40.529333pt;}
.y596{bottom:41.248267pt;}
.ybe9{bottom:42.186800pt;}
.y152{bottom:42.483333pt;}
.ybd3{bottom:43.192000pt;}
.yc76{bottom:43.200000pt;}
.yc78{bottom:43.200133pt;}
.ybd4{bottom:43.284000pt;}
.ybd6{bottom:43.617333pt;}
.y215{bottom:43.767200pt;}
.y295{bottom:44.477733pt;}
.ybe8{bottom:44.853333pt;}
.y9a0{bottom:45.110400pt;}
.y24b{bottom:46.262867pt;}
.y885{bottom:46.263267pt;}
.ya16{bottom:46.478667pt;}
.y10a6{bottom:46.498933pt;}
.y999{bottom:46.838267pt;}
.y926{bottom:46.876533pt;}
.y151{bottom:47.150133pt;}
.y99f{bottom:47.777067pt;}
.yef3{bottom:47.870800pt;}
.y99c{bottom:48.011200pt;}
.ya57{bottom:49.114667pt;}
.y294{bottom:49.144400pt;}
.y95d{bottom:49.317333pt;}
.yd60{bottom:49.439867pt;}
.y6ab{bottom:49.750067pt;}
.y1cd{bottom:50.182533pt;}
.y4eb{bottom:50.187267pt;}
.y7c{bottom:50.397067pt;}
.yabe{bottom:50.577333pt;}
.y925{bottom:51.543333pt;}
.y95c{bottom:51.984000pt;}
.y8b6{bottom:52.036933pt;}
.yc94{bottom:52.046533pt;}
.y9c5{bottom:52.077333pt;}
.ya78{bottom:52.269333pt;}
.y438{bottom:52.864000pt;}
.y4a5{bottom:53.142533pt;}
.yacd{bottom:53.160000pt;}
.y95a{bottom:53.220533pt;}
.yc8c{bottom:53.843867pt;}
.y595{bottom:54.581267pt;}
.y1cc{bottom:54.849200pt;}
.ya77{bottom:54.936000pt;}
.yaf1{bottom:55.312000pt;}
.yab9{bottom:55.841333pt;}
.yc9d{bottom:56.184000pt;}
.y8b5{bottom:56.703600pt;}
.y945{bottom:56.846133pt;}
.ye62{bottom:56.975600pt;}
.y214{bottom:57.100200pt;}
.y858{bottom:57.540133pt;}
.yc3e{bottom:59.109333pt;}
.y7a9{bottom:59.220400pt;}
.y164{bottom:59.595867pt;}
.y150{bottom:59.596133pt;}
.y884{bottom:59.596267pt;}
.y3bd{bottom:59.632333pt;}
.ybe5{bottom:60.197333pt;}
.yc72{bottom:60.696133pt;}
.yec6{bottom:60.721200pt;}
.y99e{bottom:60.751200pt;}
.y53d{bottom:61.081333pt;}
.ya46{bottom:61.221333pt;}
.y62d{bottom:61.346933pt;}
.yb2e{bottom:61.844000pt;}
.y686{bottom:62.131333pt;}
.yb0f{bottom:62.276000pt;}
.y105d{bottom:62.338267pt;}
.yacb{bottom:62.426667pt;}
.y864{bottom:62.543867pt;}
.yb0d{bottom:62.609333pt;}
.yac9{bottom:62.760000pt;}
.yd5f{bottom:62.772867pt;}
.yc71{bottom:62.774800pt;}
.y27{bottom:62.828800pt;}
.y956{bottom:62.971467pt;}
.y13b1{bottom:62.999800pt;}
.y6aa{bottom:63.083067pt;}
.yc3d{bottom:63.109467pt;}
.y1079{bottom:63.218133pt;}
.y15b6{bottom:63.386867pt;}
.y4ea{bottom:63.520267pt;}
.yf37{bottom:63.549200pt;}
.y105e{bottom:63.671600pt;}
.y105c{bottom:63.672000pt;}
.y118e{bottom:63.835533pt;}
.yfc3{bottom:63.869200pt;}
.yffd{bottom:63.873200pt;}
.y7a8{bottom:63.887200pt;}
.y924{bottom:63.989333pt;}
.y1469{bottom:64.072933pt;}
.y9c4{bottom:64.078667pt;}
.y453{bottom:64.083200pt;}
.y998{bottom:64.171600pt;}
.y163{bottom:64.262533pt;}
.y14f{bottom:64.262933pt;}
.y883{bottom:64.263200pt;}
.y705{bottom:64.374000pt;}
.yb2d{bottom:64.510667pt;}
.y747{bottom:64.533200pt;}
.y9c0{bottom:64.648667pt;}
.y156b{bottom:64.987200pt;}
.ya55{bottom:65.048000pt;}
.yce7{bottom:65.113067pt;}
.yef2{bottom:65.204133pt;}
.ya53{bottom:65.381333pt;}
.ye13{bottom:65.572800pt;}
.yd11{bottom:65.637067pt;}
.y12f7{bottom:65.702000pt;}
.y53c{bottom:65.748000pt;}
.y1005{bottom:66.088400pt;}
.yc58{bottom:66.088533pt;}
.y40a{bottom:66.231400pt;}
.y7b{bottom:66.396667pt;}
.yf99{bottom:66.662000pt;}
.y685{bottom:66.798000pt;}
.yaef{bottom:66.801333pt;}
.yd2f{bottom:67.001867pt;}
.y49a{bottom:67.002533pt;}
.ybcf{bottom:67.019467pt;}
.yaed{bottom:67.134667pt;}
.y901{bottom:67.154800pt;}
.ya7f{bottom:67.198667pt;}
.ya81{bottom:67.265333pt;}
.y1cb{bottom:67.295667pt;}
.y842{bottom:67.448933pt;}
.ya7d{bottom:67.532000pt;}
.yb45{bottom:67.714667pt;}
.y6a9{bottom:67.749733pt;}
.y46a{bottom:67.862800pt;}
.y594{bottom:67.914267pt;}
.y4e9{bottom:68.186933pt;}
.yd10{bottom:68.303733pt;}
.y9db{bottom:68.461333pt;}
.yb92{bottom:68.531733pt;}
.y923{bottom:68.656133pt;}
.y4f9{bottom:68.670933pt;}
.y72f{bottom:68.791867pt;}
.y1437{bottom:69.218533pt;}
.y140c{bottom:69.664267pt;}
.y145c{bottom:69.664400pt;}
.y1021{bottom:69.878400pt;}
.y437{bottom:70.197333pt;}
.y213{bottom:70.433200pt;}
.y4a4{bottom:70.475867pt;}
.y149b{bottom:70.729333pt;}
.ybb2{bottom:70.777333pt;}
.y65c{bottom:71.029067pt;}
.y97d{bottom:71.432267pt;}
.y155b{bottom:71.434533pt;}
.yf76{bottom:71.442133pt;}
.y15e1{bottom:71.453200pt;}
.ybd2{bottom:71.822667pt;}
.ybae{bottom:71.910667pt;}
.yfed{bottom:72.093733pt;}
.y7fd{bottom:72.141867pt;}
.y129{bottom:72.293200pt;}
.y1484{bottom:72.347733pt;}
.yb61{bottom:72.506667pt;}
.y593{bottom:72.581067pt;}
.ybe2{bottom:72.777333pt;}
.y3bc{bottom:72.965333pt;}
.yc66{bottom:73.039733pt;}
.ybb1{bottom:73.444000pt;}
.ye46{bottom:73.474267pt;}
.y14aa{bottom:73.647467pt;}
.y1f2{bottom:73.695600pt;}
.y1589{bottom:73.857867pt;}
.y9d8{bottom:73.879733pt;}
.ya1e{bottom:73.956000pt;}
.y944{bottom:74.179467pt;}
.ye61{bottom:74.308933pt;}
.y1511{bottom:74.559200pt;}
.ya14{bottom:74.658800pt;}
.y189{bottom:74.801067pt;}
.y857{bottom:74.873467pt;}
.ya6e{bottom:75.036400pt;}
.y11ac{bottom:75.174800pt;}
.y293{bottom:75.639867pt;}
.yb9b{bottom:75.798667pt;}
.y14cc{bottom:75.861600pt;}
.y1153{bottom:75.862800pt;}
.yb25{bottom:76.031067pt;}
.yd5e{bottom:76.105867pt;}
.y1320{bottom:76.374400pt;}
.yc9a{bottom:76.401333pt;}
.y3f6{bottom:76.445067pt;}
.ye78{bottom:76.534667pt;}
.y62c{bottom:76.679933pt;}
.yec5{bottom:76.721733pt;}
.yabc{bottom:76.846667pt;}
.yab8{bottom:76.954133pt;}
.y153f{bottom:76.977867pt;}
.y9c9{bottom:77.195867pt;}
.y26{bottom:77.228800pt;}
.y14ef{bottom:77.232067pt;}
.y31d{bottom:77.375200pt;}
.yb01{bottom:77.430667pt;}
.y1121{bottom:77.475600pt;}
.yb95{bottom:77.504000pt;}
.yabf{bottom:77.581333pt;}
.y3bb{bottom:77.632000pt;}
.y9bb{bottom:78.026400pt;}
.ycfa{bottom:78.078000pt;}
.y9bd{bottom:78.214000pt;}
.y1128{bottom:78.278000pt;}
.yb9a{bottom:78.465333pt;}
.ya45{bottom:78.554667pt;}
.yde1{bottom:78.559200pt;}
.y141d{bottom:78.739467pt;}
.yc69{bottom:78.870800pt;}
.y14ba{bottom:78.991333pt;}
.y1032{bottom:78.991733pt;}
.y115f{bottom:78.992133pt;}
.y13b0{bottom:79.000333pt;}
.yc99{bottom:79.068000pt;}
.y478{bottom:79.298267pt;}
.yc8e{bottom:79.377200pt;}
.y15b5{bottom:79.387400pt;}
.y129e{bottom:79.441067pt;}
.yd5d{bottom:79.605867pt;}
.y1224{bottom:79.627600pt;}
.yc0a{bottom:79.642267pt;}
.yfde{bottom:79.653467pt;}
.y118d{bottom:79.836067pt;}
.y9c8{bottom:79.862533pt;}
.y863{bottom:79.877200pt;}
.yc9c{bottom:80.146667pt;}
.ya49{bottom:80.202667pt;}
.y1172{bottom:80.303733pt;}
.y955{bottom:80.304800pt;}
.y1525{bottom:80.503600pt;}
.y1078{bottom:80.551467pt;}
.y1ca{bottom:80.628667pt;}
.yf36{bottom:80.882533pt;}
.y105b{bottom:81.005333pt;}
.yfc2{bottom:81.202533pt;}
.yffc{bottom:81.206533pt;}
.y1468{bottom:81.406267pt;}
.y452{bottom:81.416533pt;}
.y409{bottom:81.564400pt;}
.y704{bottom:81.707333pt;}
.y746{bottom:81.866533pt;}
.yae3{bottom:81.956133pt;}
.y156a{bottom:82.320533pt;}
.ya71{bottom:82.353333pt;}
.y7a{bottom:82.396267pt;}
.yce6{bottom:82.446400pt;}
.y159c{bottom:82.517467pt;}
.y5b4{bottom:82.518933pt;}
.yef1{bottom:82.537467pt;}
.ye33{bottom:82.754995pt;}
.yc9b{bottom:82.813333pt;}
.ye12{bottom:82.906133pt;}
.y12f6{bottom:83.035333pt;}
.y778{bottom:83.271200pt;}
.y1004{bottom:83.421733pt;}
.yc57{bottom:83.421867pt;}
.y212{bottom:83.766200pt;}
.yf98{bottom:83.995333pt;}
.y751{bottom:84.155200pt;}
.yd2e{bottom:84.335200pt;}
.y499{bottom:84.335867pt;}
.ybce{bottom:84.352800pt;}
.y841{bottom:84.782267pt;}
.yee2{bottom:84.816733pt;}
.y3d8{bottom:84.948533pt;}
.y592{bottom:85.027200pt;}
.y469{bottom:85.196133pt;}
.y1c9{bottom:85.295467pt;}
.yc2f{bottom:85.371467pt;}
.yd0f{bottom:85.637067pt;}
.y808{bottom:85.647867pt;}
.yd86{bottom:85.700867pt;}
.yb91{bottom:85.865067pt;}
.y4f8{bottom:86.004267pt;}
.y72e{bottom:86.125200pt;}
.y1436{bottom:86.551867pt;}
.y140b{bottom:86.997600pt;}
.y145b{bottom:86.997733pt;}
.yc9e{bottom:87.164000pt;}
.y1020{bottom:87.211733pt;}
.yf75{bottom:87.442667pt;}
.y15e0{bottom:87.453200pt;}
.y13f1{bottom:87.465867pt;}
.y436{bottom:87.530667pt;}
.ybaf{bottom:87.577333pt;}
.y15e8{bottom:87.653200pt;}
.y2ac{bottom:87.690000pt;}
.y4a3{bottom:87.809200pt;}
.y149a{bottom:88.062667pt;}
.y65b{bottom:88.362400pt;}
.yb06{bottom:88.654533pt;}
.y97c{bottom:88.765600pt;}
.y155a{bottom:88.767867pt;}
.yac4{bottom:88.806667pt;}
.yf11{bottom:88.965467pt;}
.y997{bottom:89.064000pt;}
.yfec{bottom:89.427067pt;}
.y7fc{bottom:89.475200pt;}
.yb94{bottom:89.504000pt;}
.y128{bottom:89.626533pt;}
.y1483{bottom:89.681067pt;}
.y591{bottom:89.694000pt;}
.ye32{bottom:89.774747pt;}
.y137d{bottom:89.876400pt;}
.y2ab{bottom:90.040133pt;}
.ybe1{bottom:90.110667pt;}
.yc65{bottom:90.373067pt;}
.y14a9{bottom:90.980800pt;}
.y1f1{bottom:91.028933pt;}
.y11ab{bottom:91.174400pt;}
.y1588{bottom:91.191200pt;}
.y9d7{bottom:91.213067pt;}
.yb05{bottom:91.321333pt;}
.yb4c{bottom:91.341333pt;}
.ya4e{bottom:91.428000pt;}
.yac3{bottom:91.473333pt;}
.y943{bottom:91.512800pt;}
.ydf4{bottom:91.551333pt;}
.ye60{bottom:91.642267pt;}
.y13d0{bottom:91.661200pt;}
.y1510{bottom:91.892533pt;}
.ya13{bottom:91.992133pt;}
.y62b{bottom:92.012933pt;}
.y188{bottom:92.134400pt;}
.y856{bottom:92.206800pt;}
.ya6d{bottom:92.369733pt;}
.y131f{bottom:92.374933pt;}
.yc93{bottom:92.705200pt;}
.yec4{bottom:92.722267pt;}
.y292{bottom:92.973200pt;}
.yae8{bottom:93.180000pt;}
.y14cb{bottom:93.194933pt;}
.y1152{bottom:93.196133pt;}
.y14ee{bottom:93.232600pt;}
.ye45{bottom:93.254067pt;}
.ydbb{bottom:93.259067pt;}
.ydae{bottom:93.262333pt;}
.yb24{bottom:93.364400pt;}
.ya76{bottom:93.578667pt;}
.y7e3{bottom:93.676533pt;}
.y3f5{bottom:93.778400pt;}
.ye77{bottom:93.868000pt;}
.y260{bottom:93.897467pt;}
.yc89{bottom:93.977467pt;}
.ya4d{bottom:94.094667pt;}
.y12da{bottom:94.115600pt;}
.y119c{bottom:94.143200pt;}
.y8d1{bottom:94.181067pt;}
.y153e{bottom:94.311200pt;}
.y9de{bottom:94.360133pt;}
.y31c{bottom:94.708533pt;}
.y1120{bottom:94.808933pt;}
.y13af{bottom:95.000867pt;}
.y9ba{bottom:95.359733pt;}
.ycf9{bottom:95.411333pt;}
.y10c{bottom:95.462133pt;}
.y1127{bottom:95.611333pt;}
.y118c{bottom:95.836600pt;}
.yae7{bottom:95.846800pt;}
.ya44{bottom:95.888000pt;}
.yde0{bottom:95.892533pt;}
.y141c{bottom:96.072800pt;}
.ya75{bottom:96.245333pt;}
.y14b9{bottom:96.324667pt;}
.y1031{bottom:96.325067pt;}
.y115e{bottom:96.325467pt;}
.y477{bottom:96.631600pt;}
.y129d{bottom:96.774400pt;}
.y67a{bottom:96.895867pt;}
.y1312{bottom:96.953400pt;}
.y1223{bottom:96.960933pt;}
.y8f1{bottom:96.974000pt;}
.yc09{bottom:96.975600pt;}
.yfdd{bottom:96.986800pt;}
.y9dd{bottom:97.026667pt;}
.ybec{bottom:97.080000pt;}
.y211{bottom:97.099200pt;}
.y862{bottom:97.210533pt;}
.y1171{bottom:97.637067pt;}
.y954{bottom:97.638133pt;}
.y1c8{bottom:97.741600pt;}
.y1524{bottom:97.836933pt;}
.y1077{bottom:97.884800pt;}
.yf35{bottom:98.215867pt;}
.yfa3{bottom:98.293333pt;}
.y105a{bottom:98.338667pt;}
.y79{bottom:98.395867pt;}
.yfc1{bottom:98.535867pt;}
.yffb{bottom:98.539867pt;}
.y38d{bottom:98.699600pt;}
.y1467{bottom:98.739600pt;}
.y451{bottom:98.749867pt;}
.y8b4{bottom:98.756133pt;}
.y38c{bottom:98.801733pt;}
.yd2c{bottom:99.001867pt;}
.y703{bottom:99.040667pt;}
.y12ae{bottom:99.202400pt;}
.yb5a{bottom:99.337467pt;}
.yb4b{bottom:99.390667pt;}
.yce5{bottom:99.779733pt;}
.y159b{bottom:99.850800pt;}
.y5b3{bottom:99.852267pt;}
.yef0{bottom:99.870800pt;}
.y881{bottom:99.900400pt;}
.ye11{bottom:100.239467pt;}
.y9be{bottom:100.307333pt;}
.y12f5{bottom:100.368667pt;}
.y777{bottom:100.604533pt;}
.y1003{bottom:100.755067pt;}
.yc56{bottom:100.755200pt;}
.yee1{bottom:100.817267pt;}
.yfa2{bottom:100.960133pt;}
.ybe4{bottom:101.085333pt;}
.y6c5{bottom:101.332267pt;}
.ybf{bottom:101.405200pt;}
.y750{bottom:101.488533pt;}
.yd2d{bottom:101.668533pt;}
.yd2b{bottom:101.668800pt;}
.y498{bottom:101.669200pt;}
.ybcd{bottom:101.686133pt;}
.yd85{bottom:101.701400pt;}
.yb5e{bottom:101.738667pt;}
.y210{bottom:101.766000pt;}
.y840{bottom:102.115600pt;}
.y408{bottom:102.192400pt;}
.y406{bottom:102.192933pt;}
.y3d7{bottom:102.281867pt;}
.y1c7{bottom:102.408267pt;}
.y468{bottom:102.529467pt;}
.y14f2{bottom:102.538267pt;}
.y14f3{bottom:102.538400pt;}
.yb42{bottom:102.624933pt;}
.yc2e{bottom:102.704800pt;}
.y15b4{bottom:102.946133pt;}
.yd0e{bottom:102.970400pt;}
.y127a{bottom:102.971200pt;}
.y745{bottom:102.979867pt;}
.y807{bottom:102.981200pt;}
.yb90{bottom:103.198400pt;}
.y4f7{bottom:103.337600pt;}
.yb4a{bottom:103.390667pt;}
.yf74{bottom:103.443200pt;}
.y15df{bottom:103.453200pt;}
.y72d{bottom:103.458533pt;}
.y15ed{bottom:103.653200pt;}
.y9e0{bottom:103.679733pt;}
.y1435{bottom:103.885200pt;}
.y140a{bottom:104.330933pt;}
.y145a{bottom:104.331067pt;}
.y6c4{bottom:104.332267pt;}
.y101f{bottom:104.545067pt;}
.y882{bottom:104.567067pt;}
.yc92{bottom:104.705200pt;}
.y13f0{bottom:104.799200pt;}
.y435{bottom:104.864000pt;}
.y4a2{bottom:105.142533pt;}
.y1499{bottom:105.396000pt;}
.yb03{bottom:105.477333pt;}
.yac1{bottom:105.628000pt;}
.y65a{bottom:105.695733pt;}
.y407{bottom:105.992267pt;}
.y69f{bottom:106.061067pt;}
.y97b{bottom:106.098933pt;}
.y1559{bottom:106.101200pt;}
.yf10{bottom:106.298800pt;}
.y996{bottom:106.397333pt;}
.ye44{bottom:106.587067pt;}
.yfeb{bottom:106.760400pt;}
.yb29{bottom:106.776000pt;}
.y4e2{bottom:106.779733pt;}
.y7fb{bottom:106.808533pt;}
.y127{bottom:106.959867pt;}
.y1482{bottom:107.014400pt;}
.y11aa{bottom:107.174000pt;}
.y137c{bottom:107.209733pt;}
.y1569{bottom:107.212533pt;}
.y523{bottom:107.428000pt;}
.ybe0{bottom:107.444000pt;}
.ye3a{bottom:107.550267pt;}
.y9df{bottom:107.679733pt;}
.yc64{bottom:107.706400pt;}
.y922{bottom:107.859333pt;}
.ya4b{bottom:108.249333pt;}
.y9c6{bottom:108.264000pt;}
.y9c7{bottom:108.264133pt;}
.y14a8{bottom:108.314133pt;}
.y1f0{bottom:108.362267pt;}
.y131e{bottom:108.375467pt;}
.y1587{bottom:108.524533pt;}
.y9d6{bottom:108.546400pt;}
.ye39{bottom:108.731333pt;}
.y942{bottom:108.846133pt;}
.ydf3{bottom:108.884667pt;}
.yf97{bottom:108.887333pt;}
.y10ee{bottom:108.887867pt;}
.y13cf{bottom:108.994533pt;}
.y150f{bottom:109.225867pt;}
.y14ed{bottom:109.233133pt;}
.y62a{bottom:109.235800pt;}
.ydba{bottom:109.259600pt;}
.ydad{bottom:109.262867pt;}
.ya12{bottom:109.325467pt;}
.y187{bottom:109.467733pt;}
.ycca{bottom:109.475200pt;}
.y855{bottom:109.540133pt;}
.ya6c{bottom:109.703067pt;}
.yae5{bottom:110.001467pt;}
.y119b{bottom:110.143733pt;}
.y291{bottom:110.306533pt;}
.ya73{bottom:110.400000pt;}
.y14ca{bottom:110.528267pt;}
.y1151{bottom:110.529467pt;}
.yb23{bottom:110.697733pt;}
.y7e2{bottom:111.009867pt;}
.y3f4{bottom:111.111733pt;}
.ye76{bottom:111.201333pt;}
.y25f{bottom:111.230800pt;}
.yc88{bottom:111.310800pt;}
.y12d9{bottom:111.448933pt;}
.y8d0{bottom:111.514400pt;}
.y153d{bottom:111.644533pt;}
.y9dc{bottom:111.950667pt;}
.y31b{bottom:112.041867pt;}
.y111f{bottom:112.142267pt;}
.y9b9{bottom:112.693067pt;}
.ycb3{bottom:112.744667pt;}
.y10b{bottom:112.795467pt;}
.ybaa{bottom:112.874800pt;}
.y1126{bottom:112.944667pt;}
.y1311{bottom:112.953933pt;}
.yab7{bottom:113.185067pt;}
.yddf{bottom:113.225867pt;}
.y141b{bottom:113.406133pt;}
.y14b8{bottom:113.658000pt;}
.y1030{bottom:113.658400pt;}
.y115d{bottom:113.658800pt;}
.yc33{bottom:113.694800pt;}
.y476{bottom:113.964933pt;}
.y129c{bottom:114.107733pt;}
.y679{bottom:114.229200pt;}
.y1222{bottom:114.294267pt;}
.y8f0{bottom:114.307333pt;}
.yc08{bottom:114.308933pt;}
.yfdc{bottom:114.320133pt;}
.yae0{bottom:114.382267pt;}
.y78{bottom:114.395467pt;}
.y861{bottom:114.543867pt;}
.y25{bottom:114.844400pt;}
.y1170{bottom:114.970400pt;}
.y1523{bottom:115.170267pt;}
.y1076{bottom:115.218133pt;}
.yf34{bottom:115.549200pt;}
.y1059{bottom:115.672000pt;}
.yfc0{bottom:115.869200pt;}
.yffa{bottom:115.873200pt;}
.y1466{bottom:116.072933pt;}
.y450{bottom:116.083200pt;}
.y8b3{bottom:116.089467pt;}
.yec3{bottom:116.281000pt;}
.y702{bottom:116.374000pt;}
.ye5f{bottom:116.534667pt;}
.y12ad{bottom:116.535733pt;}
.yb59{bottom:116.670800pt;}
.yee0{bottom:116.817800pt;}
.ya43{bottom:117.000800pt;}
.y14e{bottom:117.034933pt;}
.yce4{bottom:117.113067pt;}
.y5b2{bottom:117.185600pt;}
.yeef{bottom:117.204133pt;}
.y880{bottom:117.233733pt;}
.ybb0{bottom:117.354667pt;}
.y405{bottom:117.525933pt;}
.ye10{bottom:117.572800pt;}
.yd84{bottom:117.701933pt;}
.y776{bottom:117.937867pt;}
.y69d{bottom:118.061067pt;}
.y1002{bottom:118.088400pt;}
.y10c1{bottom:118.235867pt;}
.y9d{bottom:118.326800pt;}
.y13ae{bottom:118.559600pt;}
.ybe{bottom:118.738533pt;}
.y953{bottom:118.751067pt;}
.y74f{bottom:118.821867pt;}
.y15b3{bottom:118.946667pt;}
.yd2a{bottom:119.002133pt;}
.y497{bottom:119.002533pt;}
.ybcc{bottom:119.019467pt;}
.y118b{bottom:119.395333pt;}
.yf73{bottom:119.443733pt;}
.y83f{bottom:119.448933pt;}
.y15de{bottom:119.453200pt;}
.y3d6{bottom:119.615200pt;}
.y467{bottom:119.862800pt;}
.yb41{bottom:119.958267pt;}
.yc2d{bottom:120.038133pt;}
.y38b{bottom:120.153733pt;}
.y38a{bottom:120.255733pt;}
.yd0d{bottom:120.303733pt;}
.y1279{bottom:120.304533pt;}
.y744{bottom:120.313200pt;}
.y806{bottom:120.314533pt;}
.yb8f{bottom:120.531733pt;}
.y4f6{bottom:120.670933pt;}
.y72c{bottom:120.791867pt;}
.y159a{bottom:120.964133pt;}
.y1361{bottom:121.023733pt;}
.yb10{bottom:121.038667pt;}
.y6c3{bottom:121.111867pt;}
.yb02{bottom:121.168000pt;}
.yacc{bottom:121.189333pt;}
.y1434{bottom:121.218533pt;}
.yac0{bottom:121.320000pt;}
.y3ab{bottom:121.378667pt;}
.y1409{bottom:121.664267pt;}
.yc55{bottom:121.868000pt;}
.y101e{bottom:121.878400pt;}
.yc91{bottom:122.066533pt;}
.y13ef{bottom:122.132533pt;}
.y2bc{bottom:122.394667pt;}
.y4a1{bottom:122.475867pt;}
.y69e{bottom:122.727867pt;}
.y1498{bottom:122.729333pt;}
.yb49{bottom:122.745333pt;}
.y10a2{bottom:122.950400pt;}
.y659{bottom:123.029067pt;}
.y11a9{bottom:123.173600pt;}
.y11a8{bottom:123.173867pt;}
.yc7c{bottom:123.329333pt;}
.y97a{bottom:123.432267pt;}
.y1558{bottom:123.434533pt;}
.ybe7{bottom:123.565333pt;}
.yf0f{bottom:123.632133pt;}
.y995{bottom:123.730667pt;}
.ya1c{bottom:123.785333pt;}
.ya56{bottom:123.810667pt;}
.ya4a{bottom:123.941333pt;}
.yfea{bottom:124.093733pt;}
.y6c2{bottom:124.111867pt;}
.y4e1{bottom:124.113067pt;}
.y7fa{bottom:124.141867pt;}
.y126{bottom:124.293200pt;}
.y137b{bottom:124.543067pt;}
.y1568{bottom:124.545867pt;}
.y629{bottom:124.568800pt;}
.y522{bottom:124.761333pt;}
.ybdf{bottom:124.777333pt;}
.y24a{bottom:124.984400pt;}
.y921{bottom:125.192667pt;}
.y14f1{bottom:125.205067pt;}
.ydb9{bottom:125.260133pt;}
.y12f4{bottom:125.261067pt;}
.ydac{bottom:125.263400pt;}
.yb48{bottom:125.412000pt;}
.yaf0{bottom:125.562667pt;}
.y14a7{bottom:125.647467pt;}
.yae4{bottom:125.693467pt;}
.y1ef{bottom:125.695600pt;}
.y1586{bottom:125.857867pt;}
.y9d5{bottom:125.879733pt;}
.ya80{bottom:125.961333pt;}
.ya72{bottom:126.092000pt;}
.y119a{bottom:126.144267pt;}
.ydf2{bottom:126.218000pt;}
.yf96{bottom:126.220667pt;}
.y10ed{bottom:126.221200pt;}
.y13ce{bottom:126.327867pt;}
.y150e{bottom:126.559200pt;}
.ya11{bottom:126.658800pt;}
.y186{bottom:126.801067pt;}
.ycc9{bottom:126.808533pt;}
.y854{bottom:126.873467pt;}
.ya6b{bottom:127.036400pt;}
.yc7b{bottom:127.329333pt;}
.y290{bottom:127.639867pt;}
.yb04{bottom:127.846667pt;}
.y1150{bottom:127.862800pt;}
.yac2{bottom:127.997333pt;}
.yb22{bottom:128.031067pt;}
.y7e1{bottom:128.343200pt;}
.ye75{bottom:128.534667pt;}
.y25e{bottom:128.564133pt;}
.yc87{bottom:128.644133pt;}
.y7a1{bottom:128.713867pt;}
.y12d8{bottom:128.782267pt;}
.yc63{bottom:128.819067pt;}
.y1310{bottom:128.954467pt;}
.y1459{bottom:129.223200pt;}
.y111e{bottom:129.475600pt;}
.yaa0{bottom:129.554133pt;}
.y434{bottom:129.756533pt;}
.y9b8{bottom:130.026400pt;}
.y69c{bottom:130.061067pt;}
.ycb2{bottom:130.078000pt;}
.y10a{bottom:130.128800pt;}
.y1125{bottom:130.278000pt;}
.y233{bottom:130.322467pt;}
.y52{bottom:130.375200pt;}
.y77{bottom:130.395067pt;}
.ye86{bottom:130.537867pt;}
.ydde{bottom:130.559200pt;}
.ya4c{bottom:130.618667pt;}
.y141a{bottom:130.739467pt;}
.y14b7{bottom:130.991333pt;}
.y102f{bottom:130.991733pt;}
.y115c{bottom:130.992133pt;}
.yc3c{bottom:131.022800pt;}
.y590{bottom:131.304133pt;}
.y129b{bottom:131.441067pt;}
.y678{bottom:131.562533pt;}
.y1221{bottom:131.627600pt;}
.y8ef{bottom:131.640667pt;}
.yc07{bottom:131.642267pt;}
.yfdb{bottom:131.653467pt;}
.y20f{bottom:131.852267pt;}
.y860{bottom:131.877200pt;}
.y1481{bottom:131.906800pt;}
.y131d{bottom:131.934200pt;}
.y24{bottom:132.177733pt;}
.yec2{bottom:132.281533pt;}
.y116f{bottom:132.303733pt;}
.yae6{bottom:132.372133pt;}
.y1522{bottom:132.503600pt;}
.y8cf{bottom:132.627733pt;}
.ya74{bottom:132.769333pt;}
.y14ec{bottom:132.791867pt;}
.y14f0{bottom:132.818333pt;}
.y404{bottom:132.858933pt;}
.yf33{bottom:132.882533pt;}
.y1058{bottom:133.005333pt;}
.y31a{bottom:133.155200pt;}
.yfbf{bottom:133.202533pt;}
.yff9{bottom:133.206533pt;}
.y1465{bottom:133.406267pt;}
.y44f{bottom:133.416533pt;}
.y8b2{bottom:133.422800pt;}
.y548{bottom:133.682400pt;}
.yc37{bottom:133.688000pt;}
.yd83{bottom:133.702467pt;}
.y701{bottom:133.707333pt;}
.y941{bottom:133.738133pt;}
.y12ac{bottom:133.869067pt;}
.yba9{bottom:133.987733pt;}
.yb58{bottom:134.004133pt;}
.yab6{bottom:134.297867pt;}
.y14d{bottom:134.368267pt;}
.yce3{bottom:134.446400pt;}
.y5b1{bottom:134.518933pt;}
.yf89{bottom:134.537467pt;}
.y13ad{bottom:134.560133pt;}
.y87f{bottom:134.567067pt;}
.ye0f{bottom:134.906133pt;}
.y775{bottom:135.271200pt;}
.y118a{bottom:135.395867pt;}
.y14c9{bottom:135.420267pt;}
.y1001{bottom:135.421733pt;}
.y15dd{bottom:135.453200pt;}
.yadf{bottom:135.495200pt;}
.y10c0{bottom:135.569200pt;}
.y9c{bottom:135.660133pt;}
.y3f3{bottom:136.004133pt;}
.ybd{bottom:136.071867pt;}
.y74e{bottom:136.155200pt;}
.yd29{bottom:136.335467pt;}
.y496{bottom:136.335867pt;}
.ybcb{bottom:136.352800pt;}
.yc36{bottom:136.354800pt;}
.y153c{bottom:136.536533pt;}
.yc98{bottom:136.658667pt;}
.y83e{bottom:136.782267pt;}
.y3d5{bottom:136.948533pt;}
.yb40{bottom:137.291600pt;}
.yc2c{bottom:137.371467pt;}
.ycf8{bottom:137.637067pt;}
.y9fe{bottom:137.637467pt;}
.y1278{bottom:137.637867pt;}
.y805{bottom:137.647867pt;}
.yb8e{bottom:137.865067pt;}
.y4f5{bottom:138.004267pt;}
.yc34{bottom:138.006800pt;}
.yd3b{bottom:138.098933pt;}
.y72b{bottom:138.125200pt;}
.y1599{bottom:138.297467pt;}
.y1360{bottom:138.357067pt;}
.yc17{bottom:138.550400pt;}
.y1433{bottom:138.551867pt;}
.y3aa{bottom:138.712000pt;}
.y475{bottom:138.857200pt;}
.y101d{bottom:139.211733pt;}
.yc97{bottom:139.325333pt;}
.yc35{bottom:139.462800pt;}
.y4a0{bottom:139.809200pt;}
.y10a1{bottom:140.283733pt;}
.y658{bottom:140.362400pt;}
.yea6{bottom:140.372800pt;}
.yedf{bottom:140.376533pt;}
.y979{bottom:140.765600pt;}
.y1557{bottom:140.767867pt;}
.yf0e{bottom:140.965467pt;}
.y994{bottom:141.064000pt;}
.ydc1{bottom:141.260667pt;}
.y743{bottom:141.426533pt;}
.yfe9{bottom:141.427067pt;}
.y4e0{bottom:141.446400pt;}
.y7f9{bottom:141.475200pt;}
.y389{bottom:141.607733pt;}
.y125{bottom:141.626533pt;}
.y388{bottom:141.709867pt;}
.y628{bottom:141.791667pt;}
.y137a{bottom:141.876400pt;}
.y1567{bottom:141.879200pt;}
.y521{bottom:142.094667pt;}
.y249{bottom:142.317733pt;}
.y15b2{bottom:142.505400pt;}
.y920{bottom:142.526000pt;}
.y11a7{bottom:142.953067pt;}
.y14a6{bottom:142.980800pt;}
.yf72{bottom:143.002467pt;}
.y1ee{bottom:143.028933pt;}
.y1585{bottom:143.191200pt;}
.y9d4{bottom:143.213067pt;}
.ydf1{bottom:143.551333pt;}
.yf95{bottom:143.554000pt;}
.y10ec{bottom:143.554533pt;}
.y13cd{bottom:143.661200pt;}
.y150d{bottom:143.892533pt;}
.ya10{bottom:143.992133pt;}
.y185{bottom:144.134400pt;}
.ycc8{bottom:144.141867pt;}
.y853{bottom:144.206800pt;}
.y466{bottom:144.755067pt;}
.y130f{bottom:144.955000pt;}
.y28f{bottom:144.973200pt;}
.yc8f{bottom:145.081200pt;}
.y114f{bottom:145.196133pt;}
.y134c{bottom:145.225467pt;}
.ya1d{bottom:145.270667pt;}
.y2bb{bottom:145.287067pt;}
.yb21{bottom:145.364400pt;}
.yd5c{bottom:145.457800pt;}
.y232{bottom:145.655467pt;}
.y7e0{bottom:145.676533pt;}
.ye74{bottom:145.868000pt;}
.y25d{bottom:145.897467pt;}
.yc86{bottom:145.977467pt;}
.y7a0{bottom:146.047200pt;}
.y12d7{bottom:146.115600pt;}
.y51{bottom:146.374800pt;}
.y76{bottom:146.394667pt;}
.y1408{bottom:146.556533pt;}
.y111d{bottom:146.808933pt;}
.y13ee{bottom:147.024933pt;}
.y9b7{bottom:147.359733pt;}
.ycb1{bottom:147.411333pt;}
.y109{bottom:147.462133pt;}
.y1104{bottom:147.548800pt;}
.y1124{bottom:147.611333pt;}
.y1497{bottom:147.621333pt;}
.ye85{bottom:147.871200pt;}
.yddd{bottom:147.892533pt;}
.y131c{bottom:147.934733pt;}
.y1419{bottom:148.072800pt;}
.y1c6{bottom:148.112267pt;}
.y14b6{bottom:148.324667pt;}
.y102e{bottom:148.325067pt;}
.y115b{bottom:148.325467pt;}
.yfa5{bottom:148.376000pt;}
.y952{bottom:148.535733pt;}
.y58f{bottom:148.637467pt;}
.y14eb{bottom:148.792400pt;}
.ydb8{bottom:148.818867pt;}
.ydab{bottom:148.822133pt;}
.y677{bottom:148.895867pt;}
.ye8{bottom:148.956533pt;}
.yc06{bottom:148.975600pt;}
.ye5e{bottom:148.986400pt;}
.yfda{bottom:148.986800pt;}
.y547{bottom:149.015400pt;}
.y20e{bottom:149.185600pt;}
.y85f{bottom:149.210533pt;}
.y23{bottom:149.511067pt;}
.ybde{bottom:149.669333pt;}
.y1199{bottom:149.703000pt;}
.y95b{bottom:149.714400pt;}
.y8ce{bottom:149.961067pt;}
.y403{bottom:150.028600pt;}
.y99b{bottom:150.132533pt;}
.yf32{bottom:150.215867pt;}
.yc96{bottom:150.276000pt;}
.y319{bottom:150.488533pt;}
.yfbe{bottom:150.535867pt;}
.yff8{bottom:150.539867pt;}
.y13ac{bottom:150.560667pt;}
.ya9f{bottom:150.666933pt;}
.y1464{bottom:150.739600pt;}
.y44e{bottom:150.749867pt;}
.yfa4{bottom:151.042667pt;}
.y940{bottom:151.071467pt;}
.y12ab{bottom:151.202400pt;}
.yb57{bottom:151.337467pt;}
.y1075{bottom:151.449600pt;}
.y15dc{bottom:151.453200pt;}
.y15e9{bottom:151.653200pt;}
.y14c{bottom:151.701600pt;}
.y5b0{bottom:151.852267pt;}
.yc39{bottom:151.868133pt;}
.yf88{bottom:151.870800pt;}
.y87e{bottom:151.900400pt;}
.yc3b{bottom:151.936000pt;}
.ye0e{bottom:152.239467pt;}
.y959{bottom:152.380533pt;}
.y774{bottom:152.604533pt;}
.y6a8{bottom:152.611467pt;}
.y6a7{bottom:152.713600pt;}
.y14c8{bottom:152.753600pt;}
.y8ee{bottom:152.754000pt;}
.y1000{bottom:152.755067pt;}
.y10bf{bottom:152.902533pt;}
.yc95{bottom:152.942533pt;}
.ya42{bottom:153.230800pt;}
.yeee{bottom:153.435067pt;}
.y74d{bottom:153.488533pt;}
.yd28{bottom:153.668800pt;}
.y495{bottom:153.669200pt;}
.y10d5{bottom:153.774667pt;}
.y153b{bottom:153.869867pt;}
.y83d{bottom:154.115600pt;}
.y3d4{bottom:154.281867pt;}
.yc38{bottom:154.534800pt;}
.yc3a{bottom:154.602800pt;}
.yb3f{bottom:154.624933pt;}
.yc2b{bottom:154.704800pt;}
.yd0c{bottom:154.970400pt;}
.y9fd{bottom:154.970800pt;}
.y804{bottom:154.981200pt;}
.yb8d{bottom:155.198400pt;}
.y4f4{bottom:155.337600pt;}
.y72a{bottom:155.458533pt;}
.yce2{bottom:155.559333pt;}
.y1598{bottom:155.630800pt;}
.y135f{bottom:155.690400pt;}
.yec1{bottom:155.840267pt;}
.yc16{bottom:155.883733pt;}
.y1432{bottom:155.885200pt;}
.y3a9{bottom:156.045333pt;}
.y129a{bottom:156.333067pt;}
.yede{bottom:156.377067pt;}
.y1220{bottom:156.519600pt;}
.yb60{bottom:156.528000pt;}
.y101c{bottom:156.545067pt;}
.y627{bottom:157.124667pt;}
.y116e{bottom:157.196133pt;}
.yd82{bottom:157.261200pt;}
.y1521{bottom:157.395600pt;}
.ybca{bottom:157.465600pt;}
.y11c9{bottom:157.530400pt;}
.y10a0{bottom:157.617067pt;}
.y401{bottom:157.694933pt;}
.y657{bottom:157.695733pt;}
.yea5{bottom:157.706133pt;}
.y12f3{bottom:157.712933pt;}
.y1057{bottom:157.897333pt;}
.y978{bottom:158.098933pt;}
.yc54{bottom:158.100267pt;}
.y1556{bottom:158.101200pt;}
.yc6a{bottom:158.228133pt;}
.y8b1{bottom:158.314800pt;}
.y144e{bottom:158.363467pt;}
.y993{bottom:158.397333pt;}
.y15b1{bottom:158.505933pt;}
.y700{bottom:158.599333pt;}
.y742{bottom:158.759867pt;}
.yfe8{bottom:158.760400pt;}
.y7f8{bottom:158.808533pt;}
.y1189{bottom:158.954600pt;}
.y124{bottom:158.959867pt;}
.yf71{bottom:159.003000pt;}
.y1379{bottom:159.209733pt;}
.y1566{bottom:159.212533pt;}
.y520{bottom:159.428000pt;}
.ya6f{bottom:159.488000pt;}
.yc90{bottom:159.514533pt;}
.y248{bottom:159.651067pt;}
.y91f{bottom:159.859333pt;}
.y1ed{bottom:160.362267pt;}
.ya1b{bottom:160.486667pt;}
.y1584{bottom:160.524533pt;}
.y9d3{bottom:160.546400pt;}
.ydf0{bottom:160.884667pt;}
.yf94{bottom:160.887333pt;}
.y10eb{bottom:160.887867pt;}
.y130e{bottom:160.955533pt;}
.y387{bottom:160.982000pt;}
.y231{bottom:160.988467pt;}
.y13cc{bottom:160.994533pt;}
.y150c{bottom:161.225867pt;}
.ya0f{bottom:161.325467pt;}
.yd5b{bottom:161.458333pt;}
.y184{bottom:161.467733pt;}
.ycc7{bottom:161.475200pt;}
.y852{bottom:161.540133pt;}
.y1458{bottom:161.674667pt;}
.y28e{bottom:162.306533pt;}
.y50{bottom:162.374400pt;}
.y75{bottom:162.394267pt;}
.y114e{bottom:162.529467pt;}
.y1277{bottom:162.529867pt;}
.y134b{bottom:162.558800pt;}
.y4df{bottom:162.559733pt;}
.yb20{bottom:162.697733pt;}
.y7df{bottom:163.009867pt;}
.y384{bottom:163.061867pt;}
.ye73{bottom:163.201333pt;}
.y25c{bottom:163.230800pt;}
.yc85{bottom:163.310800pt;}
.y79f{bottom:163.380533pt;}
.y12d6{bottom:163.448933pt;}
.ye38{bottom:163.479612pt;}
.y385{bottom:163.515333pt;}
.ye30{bottom:163.592028pt;}
.y131b{bottom:163.935267pt;}
.y900{bottom:164.086533pt;}
.y14a5{bottom:164.093733pt;}
.y111c{bottom:164.142267pt;}
.y9b{bottom:164.332133pt;}
.y546{bottom:164.348400pt;}
.y1480{bottom:164.358267pt;}
.y2ba{bottom:164.400200pt;}
.y9b6{bottom:164.693067pt;}
.y49f{bottom:164.701600pt;}
.ybc{bottom:164.743867pt;}
.ycb0{bottom:164.744667pt;}
.y14ea{bottom:164.792933pt;}
.y108{bottom:164.795467pt;}
.ydb7{bottom:164.819400pt;}
.ydaa{bottom:164.822667pt;}
.y1496{bottom:164.954667pt;}
.yc62{bottom:165.050133pt;}
.yddc{bottom:165.225867pt;}
.y402{bottom:165.361600pt;}
.y1418{bottom:165.406133pt;}
.y1c3{bottom:165.445467pt;}
.y1c5{bottom:165.445600pt;}
.y571{bottom:165.512733pt;}
.y14b5{bottom:165.658000pt;}
.y102d{bottom:165.658400pt;}
.y115a{bottom:165.658800pt;}
.y1198{bottom:165.703533pt;}
.yf0d{bottom:165.857467pt;}
.y951{bottom:165.869067pt;}
.y58e{bottom:165.970800pt;}
.y11ca{bottom:166.189488pt;}
.y676{bottom:166.229200pt;}
.ye5d{bottom:166.319733pt;}
.yfd9{bottom:166.320133pt;}
.y20d{bottom:166.518933pt;}
.y85e{bottom:166.543867pt;}
.y22{bottom:166.844400pt;}
.ybdd{bottom:167.002667pt;}
.y386{bottom:167.315333pt;}
.y15db{bottom:167.453200pt;}
.yf31{bottom:167.549200pt;}
.y15e6{bottom:167.653200pt;}
.ye31{bottom:167.657078pt;}
.yfbd{bottom:167.869200pt;}
.yff7{bottom:167.873200pt;}
.y1463{bottom:168.072933pt;}
.y44d{bottom:168.083200pt;}
.y12aa{bottom:168.535733pt;}
.y433{bottom:168.654133pt;}
.y1103{bottom:168.661733pt;}
.yb56{bottom:168.670800pt;}
.y82b{bottom:168.690933pt;}
.ye84{bottom:168.984533pt;}
.y14b{bottom:169.034933pt;}
.y5af{bottom:169.185600pt;}
.yf87{bottom:169.204133pt;}
.y87d{bottom:169.233733pt;}
.ye0d{bottom:169.572800pt;}
.y773{bottom:169.937867pt;}
.ya1a{bottom:170.034667pt;}
.y14c7{bottom:170.086933pt;}
.y8ed{bottom:170.087333pt;}
.yc05{bottom:170.088400pt;}
.y1c4{bottom:170.112400pt;}
.yba8{bottom:170.218800pt;}
.y10be{bottom:170.235867pt;}
.yc6c{bottom:170.244133pt;}
.yc6d{bottom:170.281467pt;}
.yab5{bottom:170.528800pt;}
.ya41{bottom:170.564133pt;}
.y74c{bottom:170.821867pt;}
.yd27{bottom:171.002133pt;}
.y494{bottom:171.002533pt;}
.y8cd{bottom:171.074400pt;}
.y10d4{bottom:171.108000pt;}
.y83c{bottom:171.448933pt;}
.y1074{bottom:171.449067pt;}
.yb08{bottom:171.569333pt;}
.yac6{bottom:171.718667pt;}
.yade{bottom:171.726133pt;}
.yec0{bottom:171.840800pt;}
.yb3e{bottom:171.958267pt;}
.yc2a{bottom:172.038133pt;}
.yd0b{bottom:172.303733pt;}
.y9fc{bottom:172.304133pt;}
.y803{bottom:172.314533pt;}
.yedd{bottom:172.377600pt;}
.y4f3{bottom:172.670933pt;}
.y729{bottom:172.791867pt;}
.y1597{bottom:172.964133pt;}
.y135e{bottom:173.023733pt;}
.yc15{bottom:173.217067pt;}
.y1431{bottom:173.218533pt;}
.yd81{bottom:173.261733pt;}
.y3a8{bottom:173.378667pt;}
.yc6e{bottom:173.606800pt;}
.y1299{bottom:173.666400pt;}
.y6ea{bottom:173.721600pt;}
.ye7{bottom:173.848533pt;}
.y121f{bottom:173.852933pt;}
.y101b{bottom:173.878400pt;}
.y474{bottom:173.975333pt;}
.y6a6{bottom:174.065600pt;}
.y13ab{bottom:174.119400pt;}
.yb07{bottom:174.236000pt;}
.y626{bottom:174.347533pt;}
.yac5{bottom:174.385333pt;}
.yc6f{bottom:174.437467pt;}
.ya50{bottom:174.562667pt;}
.y1520{bottom:174.728933pt;}
.y3f2{bottom:174.901733pt;}
.y109f{bottom:174.950400pt;}
.y1188{bottom:174.955133pt;}
.y656{bottom:175.029067pt;}
.yea4{bottom:175.039467pt;}
.y12f2{bottom:175.046267pt;}
.y1056{bottom:175.230667pt;}
.y318{bottom:175.380933pt;}
.y977{bottom:175.432267pt;}
.yc53{bottom:175.433600pt;}
.y1555{bottom:175.434533pt;}
.y144d{bottom:175.696800pt;}
.y992{bottom:175.730667pt;}
.y6ff{bottom:175.932667pt;}
.y93f{bottom:175.963467pt;}
.y741{bottom:176.093200pt;}
.yaea{bottom:176.094667pt;}
.y7f7{bottom:176.141867pt;}
.y123{bottom:176.293200pt;}
.yb8c{bottom:176.311200pt;}
.y230{bottom:176.321467pt;}
.ya7a{bottom:176.490667pt;}
.y1378{bottom:176.543067pt;}
.y1565{bottom:176.545867pt;}
.y51f{bottom:176.761333pt;}
.y130d{bottom:176.956067pt;}
.ya19{bottom:177.196000pt;}
.ya17{bottom:177.197333pt;}
.ya4f{bottom:177.229333pt;}
.yd5a{bottom:177.458867pt;}
.y1ec{bottom:177.695600pt;}
.y1583{bottom:177.857867pt;}
.y9d2{bottom:177.879733pt;}
.ydef{bottom:178.218000pt;}
.yf93{bottom:178.220667pt;}
.y10ea{bottom:178.221200pt;}
.y13cb{bottom:178.327867pt;}
.y4f{bottom:178.374000pt;}
.y74{bottom:178.393867pt;}
.y13b2{bottom:178.513467pt;}
.y150b{bottom:178.559200pt;}
.yae9{bottom:178.761333pt;}
.y153a{bottom:178.761867pt;}
.y183{bottom:178.801067pt;}
.ycc6{bottom:178.808533pt;}
.y1407{bottom:179.008000pt;}
.ya79{bottom:179.157333pt;}
.y3d3{bottom:179.173867pt;}
.ye2f{bottom:179.248933pt;}
.y8b0{bottom:179.428133pt;}
.y13ed{bottom:179.476267pt;}
.y1210{bottom:179.476616pt;}
.y28d{bottom:179.639867pt;}
.y2b9{bottom:179.733200pt;}
.y114d{bottom:179.862800pt;}
.y1276{bottom:179.863200pt;}
.yfe7{bottom:179.873200pt;}
.y134a{bottom:179.892133pt;}
.y131a{bottom:179.935800pt;}
.y7de{bottom:180.343200pt;}
.ye72{bottom:180.534667pt;}
.y25b{bottom:180.564133pt;}
.yc84{bottom:180.644133pt;}
.y79e{bottom:180.713867pt;}
.y12d5{bottom:180.782267pt;}
.y14e9{bottom:180.793467pt;}
.ydb6{bottom:180.819933pt;}
.yda9{bottom:180.823200pt;}
.y570{bottom:180.845733pt;}
.y91e{bottom:180.972667pt;}
.y60f{bottom:181.072667pt;}
.y8ff{bottom:181.419867pt;}
.y111b{bottom:181.475600pt;}
.y5e3{bottom:181.567200pt;}
.y9a{bottom:181.665467pt;}
.y147f{bottom:181.691600pt;}
.y15b0{bottom:182.064667pt;}
.ybb{bottom:182.077200pt;}
.y107{bottom:182.128800pt;}
.y1495{bottom:182.288000pt;}
.yfa0{bottom:182.290133pt;}
.ya0e{bottom:182.438267pt;}
.yddb{bottom:182.559200pt;}
.yf70{bottom:182.561733pt;}
.y1417{bottom:182.739467pt;}
.y1c2{bottom:182.778800pt;}
.y14b4{bottom:182.991333pt;}
.y1159{bottom:182.992133pt;}
.ye2d{bottom:183.044000pt;}
.yf0c{bottom:183.190800pt;}
.y58d{bottom:183.304133pt;}
.y15da{bottom:183.453200pt;}
.y465{bottom:183.652800pt;}
.ye5c{bottom:183.653067pt;}
.yfd8{bottom:183.653467pt;}
.yf0b{bottom:183.791467pt;}
.yb1f{bottom:183.810533pt;}
.y20c{bottom:183.852267pt;}
.y85d{bottom:183.877200pt;}
.y82a{bottom:184.023933pt;}
.y21{bottom:184.177733pt;}
.ybdc{bottom:184.336000pt;}
.y383{bottom:184.515867pt;}
.y247{bottom:184.543067pt;}
.yf30{bottom:184.882533pt;}
.y400{bottom:185.119867pt;}
.yfbc{bottom:185.202533pt;}
.yff6{bottom:185.206533pt;}
.y1462{bottom:185.406267pt;}
.y66e{bottom:185.416533pt;}
.y9b5{bottom:185.806000pt;}
.ycaf{bottom:185.857467pt;}
.y545{bottom:185.967600pt;}
.y432{bottom:185.987467pt;}
.yc61{bottom:186.162933pt;}
.ye83{bottom:186.317867pt;}
.y14a{bottom:186.368267pt;}
.y5ae{bottom:186.518933pt;}
.yf86{bottom:186.537467pt;}
.y87c{bottom:186.567067pt;}
.ya9e{bottom:186.897867pt;}
.ye0c{bottom:186.906133pt;}
.y950{bottom:186.982000pt;}
.y772{bottom:187.271200pt;}
.y120d{bottom:187.282241pt;}
.y120f{bottom:187.283067pt;}
.y1144{bottom:187.346867pt;}
.y14c6{bottom:187.420267pt;}
.ycf7{bottom:187.421733pt;}
.yba7{bottom:187.552133pt;}
.yab4{bottom:187.862133pt;}
.y74b{bottom:188.155200pt;}
.yd26{bottom:188.335467pt;}
.y493{bottom:188.335867pt;}
.y1191{bottom:188.378133pt;}
.y8cc{bottom:188.407733pt;}
.y10d3{bottom:188.441333pt;}
.y83b{bottom:188.782267pt;}
.yd80{bottom:189.262267pt;}
.yb3d{bottom:189.291600pt;}
.yc29{bottom:189.371467pt;}
.y120e{bottom:189.586400pt;}
.yd0a{bottom:189.637067pt;}
.y9fb{bottom:189.637467pt;}
.y802{bottom:189.647867pt;}
.y625{bottom:189.680533pt;}
.yc6b{bottom:189.818800pt;}
.y4f2{bottom:190.004267pt;}
.y13aa{bottom:190.119933pt;}
.y728{bottom:190.125200pt;}
.y135d{bottom:190.357067pt;}
.yc14{bottom:190.550400pt;}
.y1430{bottom:190.551867pt;}
.y3a7{bottom:190.712000pt;}
.y109e{bottom:190.950533pt;}
.y1298{bottom:190.999733pt;}
.y675{bottom:191.121200pt;}
.y121e{bottom:191.186267pt;}
.y8ec{bottom:191.200667pt;}
.y101a{bottom:191.211733pt;}
.y6e9{bottom:191.350800pt;}
.ya40{bottom:191.677467pt;}
.yce1{bottom:191.790667pt;}
.y151f{bottom:192.062267pt;}
.y3f1{bottom:192.235067pt;}
.y109d{bottom:192.283733pt;}
.y655{bottom:192.362400pt;}
.yea3{bottom:192.372800pt;}
.y12f1{bottom:192.379600pt;}
.y1055{bottom:192.564000pt;}
.y976{bottom:192.765600pt;}
.yc52{bottom:192.766933pt;}
.y1554{bottom:192.767867pt;}
.yadd{bottom:192.838933pt;}
.y44c{bottom:192.975600pt;}
.y144c{bottom:193.030133pt;}
.y991{bottom:193.064000pt;}
.y6fe{bottom:193.266000pt;}
.y740{bottom:193.426533pt;}
.y12a9{bottom:193.427733pt;}
.y7f6{bottom:193.475200pt;}
.ybc9{bottom:193.696533pt;}
.y1377{bottom:193.876400pt;}
.y1564{bottom:193.879200pt;}
.yb2a{bottom:193.886667pt;}
.y1596{bottom:194.077467pt;}
.y51e{bottom:194.094667pt;}
.y4e{bottom:194.373600pt;}
.y73{bottom:194.393467pt;}
.y354{bottom:194.959333pt;}
.y120c{bottom:195.088692pt;}
.y10bd{bottom:195.127867pt;}
.y1582{bottom:195.191200pt;}
.yebf{bottom:195.399533pt;}
.y6a5{bottom:195.519600pt;}
.ydee{bottom:195.551333pt;}
.yf92{bottom:195.554000pt;}
.y10e9{bottom:195.554533pt;}
.y13ca{bottom:195.661200pt;}
.y150a{bottom:195.892533pt;}
.yedc{bottom:195.936333pt;}
.y116d{bottom:196.093733pt;}
.y1539{bottom:196.095200pt;}
.y182{bottom:196.134400pt;}
.ycc5{bottom:196.141867pt;}
.y56f{bottom:196.178733pt;}
.ybeb{bottom:196.189333pt;}
.y1406{bottom:196.341333pt;}
.y3d2{bottom:196.507200pt;}
.y14e8{bottom:196.794000pt;}
.y13ec{bottom:196.809600pt;}
.ydc0{bottom:196.820467pt;}
.y28c{bottom:196.973200pt;}
.y114c{bottom:197.196133pt;}
.y1275{bottom:197.196533pt;}
.y1349{bottom:197.225467pt;}
.y2fe{bottom:197.622000pt;}
.y7dd{bottom:197.676533pt;}
.ybed{bottom:197.746667pt;}
.y851{bottom:197.771067pt;}
.ye71{bottom:197.868000pt;}
.y22f{bottom:197.877667pt;}
.y25a{bottom:197.897467pt;}
.y79d{bottom:198.047200pt;}
.y15af{bottom:198.065200pt;}
.y12d4{bottom:198.115600pt;}
.y91d{bottom:198.306000pt;}
.y1187{bottom:198.513867pt;}
.yf6f{bottom:198.562267pt;}
.yb5f{bottom:198.738667pt;}
.ye6{bottom:198.740533pt;}
.y4de{bottom:198.790400pt;}
.y2b8{bottom:198.848133pt;}
.ybea{bottom:198.856000pt;}
.y5e2{bottom:198.900533pt;}
.y99{bottom:198.998800pt;}
.y147e{bottom:199.024933pt;}
.yf9f{bottom:199.178933pt;}
.y829{bottom:199.356933pt;}
.yba{bottom:199.410533pt;}
.y15d9{bottom:199.453200pt;}
.y106{bottom:199.462133pt;}
.y1494{bottom:199.621333pt;}
.y15ec{bottom:199.653200pt;}
.ydda{bottom:199.892533pt;}
.y1416{bottom:200.072800pt;}
.y60e{bottom:200.186333pt;}
.y14a4{bottom:200.324667pt;}
.y1158{bottom:200.325467pt;}
.y130c{bottom:200.514800pt;}
.yf09{bottom:200.524533pt;}
.y8af{bottom:200.541467pt;}
.y58c{bottom:200.637467pt;}
.y93e{bottom:200.855467pt;}
.y464{bottom:200.986133pt;}
.ye5b{bottom:200.986400pt;}
.yfd7{bottom:200.986800pt;}
.yd59{bottom:201.017600pt;}
.yb5b{bottom:201.121333pt;}
.yf0a{bottom:201.124267pt;}
.y122{bottom:201.184667pt;}
.y20b{bottom:201.185600pt;}
.y544{bottom:201.300600pt;}
.y5cc{bottom:201.498533pt;}
.y20{bottom:201.511067pt;}
.ybdb{bottom:201.669333pt;}
.y246{bottom:201.876400pt;}
.yf2f{bottom:202.215867pt;}
.ye3b{bottom:202.224933pt;}
.y7c0{bottom:202.369133pt;}
.y8fe{bottom:202.533200pt;}
.yfbb{bottom:202.535867pt;}
.yff5{bottom:202.539867pt;}
.y1eb{bottom:202.588000pt;}
.y1143{bottom:202.679867pt;}
.y1461{bottom:202.739600pt;}
.y66d{bottom:202.749867pt;}
.ya18{bottom:202.857333pt;}
.y11e7{bottom:202.891481pt;}
.y120b{bottom:202.895143pt;}
.y11c6{bottom:203.031303pt;}
.y431{bottom:203.320800pt;}
.y49e{bottom:203.599200pt;}
.y5ad{bottom:203.852267pt;}
.yf85{bottom:203.870800pt;}
.ya9d{bottom:204.231200pt;}
.ye0b{bottom:204.239467pt;}
.ydb5{bottom:204.378667pt;}
.yda8{bottom:204.381933pt;}
.y771{bottom:204.604533pt;}
.y14c5{bottom:204.753600pt;}
.ycf6{bottom:204.755067pt;}
.y12be{bottom:204.755200pt;}
.yba6{bottom:204.885467pt;}
.y1102{bottom:204.892667pt;}
.y624{bottom:205.013533pt;}
.yab3{bottom:205.195467pt;}
.y102b{bottom:205.217067pt;}
.y1197{bottom:205.262800pt;}
.yd25{bottom:205.668800pt;}
.y492{bottom:205.669200pt;}
.y3{bottom:205.701840pt;}
.y10d2{bottom:205.774667pt;}
.y381{bottom:205.970000pt;}
.y83a{bottom:206.115600pt;}
.y13a9{bottom:206.120467pt;}
.yc04{bottom:206.319467pt;}
.y111a{bottom:206.367600pt;}
.y49d{bottom:206.599200pt;}
.y6e8{bottom:206.683800pt;}
.yc28{bottom:206.704800pt;}
.y801{bottom:206.981200pt;}
.y4f1{bottom:207.337600pt;}
.ye82{bottom:207.431200pt;}
.y727{bottom:207.458533pt;}
.y1c1{bottom:207.670800pt;}
.yc13{bottom:207.883733pt;}
.y102a{bottom:207.884133pt;}
.y142f{bottom:207.885200pt;}
.y1297{bottom:208.333067pt;}
.y674{bottom:208.454533pt;}
.y121d{bottom:208.519600pt;}
.y8eb{bottom:208.534000pt;}
.yfff{bottom:208.534667pt;}
.y1019{bottom:208.545067pt;}
.yce0{bottom:209.124000pt;}
.y151e{bottom:209.395600pt;}
.y8cb{bottom:209.521067pt;}
.y3f0{bottom:209.568400pt;}
.y109c{bottom:209.617067pt;}
.y654{bottom:209.695733pt;}
.yea2{bottom:209.706133pt;}
.y12f0{bottom:209.712933pt;}
.y1054{bottom:209.897333pt;}
.y975{bottom:210.098933pt;}
.yc51{bottom:210.100267pt;}
.yfa1{bottom:210.157733pt;}
.y144b{bottom:210.363467pt;}
.y4d{bottom:210.373200pt;}
.y72{bottom:210.393067pt;}
.y990{bottom:210.397333pt;}
.yb3c{bottom:210.404400pt;}
.y6fd{bottom:210.599333pt;}
.y12a8{bottom:210.761067pt;}
.ybc8{bottom:211.029867pt;}
.y1376{bottom:211.209733pt;}
.y149{bottom:211.260267pt;}
.yebe{bottom:211.400067pt;}
.y1595{bottom:211.410800pt;}
.y51d{bottom:211.428000pt;}
.y56e{bottom:211.511733pt;}
.y102c{bottom:211.883867pt;}
.yedb{bottom:211.936867pt;}
.y353{bottom:212.292667pt;}
.y10bc{bottom:212.461200pt;}
.y1581{bottom:212.524533pt;}
.yb8b{bottom:212.541600pt;}
.ya3f{bottom:212.790800pt;}
.y14e7{bottom:212.794533pt;}
.yd7f{bottom:212.821000pt;}
.yded{bottom:212.884667pt;}
.yf91{bottom:212.887333pt;}
.y10e8{bottom:212.887867pt;}
.y13c9{bottom:212.994533pt;}
.y74a{bottom:213.047467pt;}
.yc8a{bottom:213.094667pt;}
.y22e{bottom:213.210667pt;}
.y1509{bottom:213.225867pt;}
.y1061{bottom:213.227867pt;}
.y116c{bottom:213.427067pt;}
.y1538{bottom:213.428533pt;}
.y181{bottom:213.467733pt;}
.ycc4{bottom:213.475200pt;}
.y1405{bottom:213.674667pt;}
.y3d1{bottom:213.840533pt;}
.y13eb{bottom:214.142933pt;}
.y2b7{bottom:214.181133pt;}
.y1186{bottom:214.514400pt;}
.y9fa{bottom:214.529467pt;}
.y73f{bottom:214.539867pt;}
.y1348{bottom:214.558800pt;}
.y828{bottom:214.689933pt;}
.y2fd{bottom:214.955333pt;}
.y7dc{bottom:215.009867pt;}
.ye70{bottom:215.201333pt;}
.y259{bottom:215.230800pt;}
.y135c{bottom:215.249467pt;}
.y79c{bottom:215.380533pt;}
.y12d3{bottom:215.448933pt;}
.y15d8{bottom:215.453200pt;}
.yf3e{bottom:215.468000pt;}
.y3a6{bottom:215.604400pt;}
.y91c{bottom:215.639333pt;}
.y6a4{bottom:215.921533pt;}
.yfe6{bottom:216.104133pt;}
.y4dd{bottom:216.123733pt;}
.y5e1{bottom:216.233867pt;}
.y710{bottom:216.304133pt;}
.y98{bottom:216.332133pt;}
.y147d{bottom:216.358267pt;}
.y130b{bottom:216.515333pt;}
.y543{bottom:216.633600pt;}
.yb9{bottom:216.743867pt;}
.y94f{bottom:216.767200pt;}
.y105{bottom:216.795467pt;}
.y5cb{bottom:216.831533pt;}
.yf9e{bottom:216.913733pt;}
.y1493{bottom:216.954667pt;}
.yd58{bottom:217.018133pt;}
.ydd9{bottom:217.225867pt;}
.y14b3{bottom:217.658000pt;}
.y1157{bottom:217.658800pt;}
.y1553{bottom:217.659867pt;}
.y7bf{bottom:217.702133pt;}
.y120a{bottom:217.749949pt;}
.yf08{bottom:217.857867pt;}
.y58b{bottom:217.970800pt;}
.y1142{bottom:218.012867pt;}
.y463{bottom:218.319467pt;}
.ye5a{bottom:218.319733pt;}
.y7f5{bottom:218.367600pt;}
.y317{bottom:218.496667pt;}
.y20a{bottom:218.518933pt;}
.ya0d{bottom:218.668800pt;}
.y1563{bottom:218.771200pt;}
.yf3d{bottom:218.968133pt;}
.y245{bottom:219.209733pt;}
.y60d{bottom:219.299067pt;}
.yf2e{bottom:219.549200pt;}
.y8fd{bottom:219.866533pt;}
.yfba{bottom:219.869200pt;}
.yff4{bottom:219.873200pt;}
.yb1e{bottom:220.041467pt;}
.y93d{bottom:220.078133pt;}
.y66c{bottom:220.083200pt;}
.y85c{bottom:220.108667pt;}
.y623{bottom:220.346533pt;}
.ydb4{bottom:220.379200pt;}
.yda7{bottom:220.382467pt;}
.y430{bottom:220.654133pt;}
.yf84{bottom:221.204133pt;}
.y1f{bottom:221.511067pt;}
.ya9c{bottom:221.564533pt;}
.ye0a{bottom:221.572800pt;}
.y15ae{bottom:221.623933pt;}
.y28b{bottom:221.865600pt;}
.y770{bottom:221.937867pt;}
.y6e7{bottom:222.016800pt;}
.y9b4{bottom:222.036933pt;}
.y14c4{bottom:222.086933pt;}
.ycae{bottom:222.088400pt;}
.y1274{bottom:222.088533pt;}
.yf6e{bottom:222.121000pt;}
.y121{bottom:222.298000pt;}
.yc60{bottom:222.393600pt;}
.yab2{bottom:222.528800pt;}
.y87b{bottom:222.798000pt;}
.yd24{bottom:223.002133pt;}
.y491{bottom:223.002533pt;}
.y10d1{bottom:223.108000pt;}
.y1017{bottom:223.211867pt;}
.y6a2{bottom:223.587867pt;}
.ye5{bottom:223.632533pt;}
.yc03{bottom:223.652800pt;}
.y6a1{bottom:223.689867pt;}
.y1119{bottom:223.700933pt;}
.yc27{bottom:224.038133pt;}
.y4f0{bottom:224.670933pt;}
.ye81{bottom:224.764533pt;}
.y726{bottom:224.791867pt;}
.y1415{bottom:224.965067pt;}
.y1c0{bottom:225.004133pt;}
.yc12{bottom:225.217067pt;}
.y1029{bottom:225.217467pt;}
.y8ae{bottom:225.433467pt;}
.y1073{bottom:225.468533pt;}
.y1207{bottom:225.555261pt;}
.y1209{bottom:225.556400pt;}
.y1296{bottom:225.666400pt;}
.y1016{bottom:225.878400pt;}
.yfd6{bottom:225.878800pt;}
.y4c{bottom:226.372800pt;}
.y71{bottom:226.392667pt;}
.ycdf{bottom:226.457333pt;}
.y151d{bottom:226.728933pt;}
.y8ca{bottom:226.854400pt;}
.y3ef{bottom:226.901733pt;}
.y109b{bottom:226.950400pt;}
.y653{bottom:227.029067pt;}
.yea1{bottom:227.039467pt;}
.y12ef{bottom:227.046267pt;}
.y1052{bottom:227.230667pt;}
.y382{bottom:227.424000pt;}
.yd3a{bottom:227.432267pt;}
.yc50{bottom:227.433600pt;}
.yafe{bottom:227.462667pt;}
.ye42{bottom:227.519067pt;}
.y1460{bottom:227.631733pt;}
.y144a{bottom:227.696800pt;}
.y98f{bottom:227.730667pt;}
.y1208{bottom:227.859867pt;}
.y6fc{bottom:227.932667pt;}
.yeda{bottom:227.937400pt;}
.ycd{bottom:228.082533pt;}
.y12a7{bottom:228.094400pt;}
.ybc7{bottom:228.363200pt;}
.y10bb{bottom:228.461200pt;}
.y22d{bottom:228.543667pt;}
.y148{bottom:228.593600pt;}
.y1594{bottom:228.744133pt;}
.y51c{bottom:228.761333pt;}
.y14e6{bottom:228.795067pt;}
.yd7e{bottom:228.821533pt;}
.y56d{bottom:229.012067pt;}
.yadc{bottom:229.069867pt;}
.y2b6{bottom:229.514133pt;}
.y352{bottom:229.626000pt;}
.y8ea{bottom:229.647333pt;}
.y13a8{bottom:229.679200pt;}
.y10ba{bottom:229.794533pt;}
.y1580{bottom:229.857867pt;}
.yb8a{bottom:229.874933pt;}
.y1018{bottom:229.878667pt;}
.y827{bottom:230.022933pt;}
.ya3e{bottom:230.124133pt;}
.ydec{bottom:230.218000pt;}
.y10e7{bottom:230.221200pt;}
.y4af{bottom:230.290133pt;}
.y13c8{bottom:230.327867pt;}
.y1185{bottom:230.514933pt;}
.y1508{bottom:230.559200pt;}
.y1060{bottom:230.561200pt;}
.y116b{bottom:230.760400pt;}
.y1537{bottom:230.761867pt;}
.y180{bottom:230.801067pt;}
.ycc3{bottom:230.808533pt;}
.y1404{bottom:231.008000pt;}
.y3d0{bottom:231.173867pt;}
.y974{bottom:231.211733pt;}
.y1053{bottom:231.230800pt;}
.y6a3{bottom:231.254533pt;}
.y15d7{bottom:231.453200pt;}
.y13ea{bottom:231.476267pt;}
.y9f9{bottom:231.862800pt;}
.y44b{bottom:231.873200pt;}
.y1347{bottom:231.892133pt;}
.y5ca{bottom:232.164533pt;}
.y7db{bottom:232.343200pt;}
.y130a{bottom:232.515867pt;}
.ye6f{bottom:232.534667pt;}
.y9d9{bottom:232.556000pt;}
.y258{bottom:232.564133pt;}
.y79b{bottom:232.713867pt;}
.y14a3{bottom:232.776133pt;}
.y142e{bottom:232.777200pt;}
.y91b{bottom:232.972667pt;}
.y1141{bottom:233.345867pt;}
.y673{bottom:233.346800pt;}
.y1206{bottom:233.361712pt;}
.y121c{bottom:233.411867pt;}
.yfe5{bottom:233.437467pt;}
.y4dc{bottom:233.457067pt;}
.y41d{bottom:233.503133pt;}
.y5e0{bottom:233.567200pt;}
.y70f{bottom:233.637467pt;}
.y97{bottom:233.665467pt;}
.y147c{bottom:233.691600pt;}
.yb8{bottom:234.077200pt;}
.y94e{bottom:234.100533pt;}
.y104{bottom:234.128800pt;}
.y1492{bottom:234.288000pt;}
.ydd8{bottom:234.559200pt;}
.y60c{bottom:234.632067pt;}
.yebd{bottom:234.958800pt;}
.y14b2{bottom:234.991333pt;}
.y1156{bottom:234.992133pt;}
.y1552{bottom:234.993200pt;}
.yf07{bottom:235.191200pt;}
.y462{bottom:235.652800pt;}
.ye59{bottom:235.653067pt;}
.y542{bottom:235.786467pt;}
.y316{bottom:235.830000pt;}
.y209{bottom:235.852267pt;}
.ya0c{bottom:236.002133pt;}
.y1562{bottom:236.104533pt;}
.ydb3{bottom:236.379733pt;}
.yda6{bottom:236.383000pt;}
.y244{bottom:236.543067pt;}
.y56b{bottom:236.678400pt;}
.y8fc{bottom:237.199867pt;}
.yfb9{bottom:237.202533pt;}
.yff3{bottom:237.206533pt;}
.ybab{bottom:237.337333pt;}
.yb1d{bottom:237.374800pt;}
.y66b{bottom:237.416533pt;}
.y15ad{bottom:237.624467pt;}
.y42f{bottom:237.987467pt;}
.yf6d{bottom:238.121533pt;}
.yf83{bottom:238.537467pt;}
.ye41{bottom:238.728667pt;}
.ya9b{bottom:238.897867pt;}
.ye09{bottom:238.906133pt;}
.y76f{bottom:239.271200pt;}
.y93c{bottom:239.300800pt;}
.y9b3{bottom:239.370267pt;}
.ycad{bottom:239.421733pt;}
.y1273{bottom:239.421867pt;}
.y120{bottom:239.631333pt;}
.y6e6{bottom:239.646000pt;}
.yc5f{bottom:239.726933pt;}
.yab1{bottom:239.862133pt;}
.y5ac{bottom:240.083200pt;}
.y85b{bottom:240.108133pt;}
.y490{bottom:240.335867pt;}
.y12d2{bottom:240.341333pt;}
.y10d0{bottom:240.441333pt;}
.yd57{bottom:240.576867pt;}
.y622{bottom:240.652267pt;}
.y11c5{bottom:240.745190pt;}
.yc02{bottom:240.986133pt;}
.y1118{bottom:241.034267pt;}
.y11e6{bottom:241.123446pt;}
.y11e3{bottom:241.124138pt;}
.y1205{bottom:241.168163pt;}
.y483{bottom:241.243200pt;}
.yc26{bottom:241.371467pt;}
.y7be{bottom:241.403733pt;}
.y1072{bottom:241.468133pt;}
.y1ea{bottom:241.487600pt;}
.y1e{bottom:241.511067pt;}
.y958{bottom:241.761867pt;}
.ybe3{bottom:241.894667pt;}
.y4ef{bottom:242.004267pt;}
.ye80{bottom:242.097867pt;}
.y725{bottom:242.125200pt;}
.y1bf{bottom:242.337467pt;}
.y839{bottom:242.346533pt;}
.y4b{bottom:242.372400pt;}
.y70{bottom:242.392667pt;}
.yc11{bottom:242.550400pt;}
.y1028{bottom:242.550800pt;}
.y8ad{bottom:242.766800pt;}
.y58a{bottom:242.862800pt;}
.y109a{bottom:242.950400pt;}
.y1295{bottom:242.999733pt;}
.y14c3{bottom:243.200267pt;}
.y1015{bottom:243.211733pt;}
.yfd5{bottom:243.212133pt;}
.y540{bottom:243.452800pt;}
.y1101{bottom:243.790267pt;}
.ycde{bottom:243.790667pt;}
.y22c{bottom:243.876667pt;}
.y1190{bottom:243.937933pt;}
.y151c{bottom:244.062267pt;}
.y2fc{bottom:244.068667pt;}
.ye3e{bottom:244.103067pt;}
.y850{bottom:244.229467pt;}
.y3ee{bottom:244.235067pt;}
.y1099{bottom:244.283733pt;}
.y56c{bottom:244.345067pt;}
.y652{bottom:244.362400pt;}
.yea0{bottom:244.372800pt;}
.y12ee{bottom:244.379600pt;}
.yf2d{bottom:244.441200pt;}
.y1050{bottom:244.564000pt;}
.yd39{bottom:244.765600pt;}
.yc4f{bottom:244.766933pt;}
.ydbf{bottom:244.822067pt;}
.y2b5{bottom:244.847133pt;}
.yb76{bottom:244.892667pt;}
.yf52{bottom:244.951400pt;}
.y1449{bottom:245.030133pt;}
.y98e{bottom:245.064000pt;}
.y6fb{bottom:245.266000pt;}
.ycc{bottom:245.415867pt;}
.y12a6{bottom:245.427733pt;}
.y4ae{bottom:245.623133pt;}
.y13a7{bottom:245.679733pt;}
.ybc6{bottom:245.696533pt;}
.y34e{bottom:245.878533pt;}
.y147{bottom:245.926933pt;}
.y51b{bottom:246.094667pt;}
.yadb{bottom:246.403200pt;}
.yb3b{bottom:246.635333pt;}
.y8e9{bottom:246.980667pt;}
.yd09{bottom:246.980800pt;}
.y10b9{bottom:247.127867pt;}
.y157f{bottom:247.191200pt;}
.y1375{bottom:247.441200pt;}
.y15d6{bottom:247.453200pt;}
.ydeb{bottom:247.551333pt;}
.y13c7{bottom:247.661200pt;}
.y1507{bottom:247.892533pt;}
.yd23{bottom:247.894133pt;}
.y105f{bottom:247.894533pt;}
.y8c9{bottom:247.967733pt;}
.y116a{bottom:248.093733pt;}
.y1536{bottom:248.095200pt;}
.y17f{bottom:248.134400pt;}
.ycc2{bottom:248.141867pt;}
.y1403{bottom:248.341333pt;}
.y3cf{bottom:248.507200pt;}
.y1309{bottom:248.516400pt;}
.ye4{bottom:248.524533pt;}
.y11c4{bottom:248.550258pt;}
.y11c8{bottom:248.550950pt;}
.y1051{bottom:248.564133pt;}
.yafd{bottom:248.575467pt;}
.y13e9{bottom:248.809600pt;}
.y41c{bottom:248.836133pt;}
.y11e5{bottom:248.929897pt;}
.y11e2{bottom:248.930589pt;}
.y1204{bottom:248.974614pt;}
.yf90{bottom:249.118800pt;}
.y9f8{bottom:249.196133pt;}
.y44a{bottom:249.206533pt;}
.y1346{bottom:249.225467pt;}
.y380{bottom:249.404933pt;}
.y1593{bottom:249.857467pt;}
.ye6e{bottom:249.868000pt;}
.y257{bottom:249.897467pt;}
.y79a{bottom:250.047200pt;}
.y14a2{bottom:250.109467pt;}
.y142d{bottom:250.110533pt;}
.yfe4{bottom:250.770800pt;}
.y4db{bottom:250.790400pt;}
.y5df{bottom:250.900533pt;}
.yebc{bottom:250.959333pt;}
.y70e{bottom:250.970800pt;}
.yb89{bottom:250.988267pt;}
.y96{bottom:250.998800pt;}
.y147b{bottom:251.024933pt;}
.y541{bottom:251.119467pt;}
.ya3d{bottom:251.236933pt;}
.y5c9{bottom:251.278533pt;}
.y10e6{bottom:251.334000pt;}
.y94d{bottom:251.433867pt;}
.y103{bottom:251.462133pt;}
.yed9{bottom:251.496133pt;}
.y1491{bottom:251.621333pt;}
.y6a0{bottom:251.656133pt;}
.y826{bottom:251.662000pt;}
.ydd7{bottom:251.892533pt;}
.y749{bottom:251.945200pt;}
.y14b1{bottom:252.324667pt;}
.y1155{bottom:252.325467pt;}
.y1551{bottom:252.326533pt;}
.y14e5{bottom:252.353800pt;}
.yd7d{bottom:252.380267pt;}
.yf06{bottom:252.524533pt;}
.y461{bottom:252.986133pt;}
.ye58{bottom:252.986400pt;}
.y315{bottom:253.163333pt;}
.y208{bottom:253.185600pt;}
.y672{bottom:253.346800pt;}
.y1561{bottom:253.437867pt;}
.y7f4{bottom:253.485600pt;}
.y60b{bottom:253.744800pt;}
.y1184{bottom:254.073667pt;}
.y91a{bottom:254.086000pt;}
.yf6c{bottom:254.122067pt;}
.y135b{bottom:254.147067pt;}
.y748{bottom:254.295200pt;}
.y3a5{bottom:254.502000pt;}
.y351{bottom:254.518400pt;}
.yfb8{bottom:254.535867pt;}
.yff2{bottom:254.539867pt;}
.yb1c{bottom:254.708133pt;}
.y66a{bottom:254.749867pt;}
.y6e5{bottom:254.979000pt;}
.y1140{bottom:255.090933pt;}
.y42e{bottom:255.320800pt;}
.yf82{bottom:255.870800pt;}
.y621{bottom:255.985267pt;}
.ya9a{bottom:256.231200pt;}
.ye08{bottom:256.239467pt;}
.y11c3{bottom:256.357401pt;}
.y11c7{bottom:256.358092pt;}
.y482{bottom:256.576200pt;}
.yd56{bottom:256.577400pt;}
.y76e{bottom:256.604533pt;}
.y9b2{bottom:256.703600pt;}
.y11e4{bottom:256.736348pt;}
.y7bd{bottom:256.736733pt;}
.y11e1{bottom:256.737040pt;}
.ycac{bottom:256.755067pt;}
.y1272{bottom:256.755200pt;}
.y1203{bottom:256.781065pt;}
.y132e{bottom:256.995200pt;}
.yc5e{bottom:257.060267pt;}
.ya0b{bottom:257.115467pt;}
.yab0{bottom:257.195467pt;}
.y1414{bottom:257.416533pt;}
.y1071{bottom:257.467733pt;}
.y8fb{bottom:258.313200pt;}
.yc01{bottom:258.319467pt;}
.y1117{bottom:258.367600pt;}
.y4a{bottom:258.372000pt;}
.y93b{bottom:258.523467pt;}
.y1e9{bottom:258.820933pt;}
.y22b{bottom:259.209667pt;}
.ye7f{bottom:259.431200pt;}
.y724{bottom:259.458533pt;}
.y1be{bottom:259.670800pt;}
.yc10{bottom:259.883733pt;}
.y1027{bottom:259.884133pt;}
.ydb2{bottom:259.938467pt;}
.yda5{bottom:259.941733pt;}
.y145f{bottom:260.083200pt;}
.y2b4{bottom:260.180133pt;}
.y589{bottom:260.196133pt;}
.y1294{bottom:260.333067pt;}
.y766{bottom:260.383600pt;}
.y14c2{bottom:260.533600pt;}
.y1014{bottom:260.545067pt;}
.yfd4{bottom:260.545467pt;}
.y11f{bottom:260.744667pt;}
.y28a{bottom:260.763200pt;}
.y1196{bottom:260.822600pt;}
.y4ad{bottom:260.956133pt;}
.y1100{bottom:261.123600pt;}
.ycdd{bottom:261.124000pt;}
.y15ac{bottom:261.183200pt;}
.y151b{bottom:261.395600pt;}
.y2fb{bottom:261.402000pt;}
.y243{bottom:261.435067pt;}
.y84f{bottom:261.562800pt;}
.y3ed{bottom:261.568400pt;}
.y1098{bottom:261.617067pt;}
.y13a6{bottom:261.680267pt;}
.y651{bottom:261.695733pt;}
.ye9f{bottom:261.706133pt;}
.y12ed{bottom:261.712933pt;}
.yf2c{bottom:261.774533pt;}
.y104e{bottom:261.897333pt;}
.ye43{bottom:262.005200pt;}
.yd38{bottom:262.098933pt;}
.yb75{bottom:262.226000pt;}
.y1448{bottom:262.363467pt;}
.yc25{bottom:262.484400pt;}
.y6fa{bottom:262.599333pt;}
.yb7{bottom:262.749200pt;}
.y12a5{bottom:262.761067pt;}
.yf9d{bottom:262.938533pt;}
.ybc5{bottom:263.029867pt;}
.y34d{bottom:263.211867pt;}
.y146{bottom:263.260267pt;}
.y15d5{bottom:263.453200pt;}
.y15e5{bottom:263.653200pt;}
.y973{bottom:263.663600pt;}
.yada{bottom:263.736533pt;}
.yf51{bottom:264.064133pt;}
.yd08{bottom:264.314133pt;}
.y56a{bottom:264.433200pt;}
.y10b8{bottom:264.461200pt;}
.y1308{bottom:264.516933pt;}
.y157e{bottom:264.524533pt;}
.y1202{bottom:264.587516pt;}
.ydea{bottom:264.884667pt;}
.y13c6{bottom:264.994533pt;}
.yd22{bottom:265.227467pt;}
.y48f{bottom:265.227867pt;}
.y8c8{bottom:265.301067pt;}
.y10cf{bottom:265.333333pt;}
.y1169{bottom:265.427067pt;}
.y1394{bottom:265.432133pt;}
.y17e{bottom:265.467733pt;}
.ycc1{bottom:265.475200pt;}
.y1457{bottom:265.674667pt;}
.y3ce{bottom:265.840533pt;}
.y121b{bottom:265.863333pt;}
.y104f{bottom:265.897467pt;}
.y13e8{bottom:266.142933pt;}
.y98d{bottom:266.176933pt;}
.y9f7{bottom:266.529467pt;}
.y449{bottom:266.539867pt;}
.y1345{bottom:266.558800pt;}
.y7da{bottom:266.684400pt;}
.y4ee{bottom:266.896667pt;}
.yebb{bottom:266.959867pt;}
.y825{bottom:266.995000pt;}
.y1592{bottom:267.190800pt;}
.ye6d{bottom:267.201333pt;}
.y256{bottom:267.230800pt;}
.y799{bottom:267.380533pt;}
.y1374{bottom:267.440667pt;}
.ya2f{bottom:267.442800pt;}
.y142c{bottom:267.443867pt;}
.yed8{bottom:267.496667pt;}
.y8ac{bottom:267.658800pt;}
.yb3a{bottom:267.748267pt;}
.y41b{bottom:267.951667pt;}
.yfe3{bottom:268.104133pt;}
.y4da{bottom:268.123733pt;}
.y5de{bottom:268.233867pt;}
.y70d{bottom:268.304133pt;}
.yb88{bottom:268.321600pt;}
.y95{bottom:268.332133pt;}
.y14e4{bottom:268.354333pt;}
.y147a{bottom:268.358267pt;}
.yd7c{bottom:268.380800pt;}
.y102{bottom:268.795467pt;}
.y1490{bottom:268.954667pt;}
.y60a{bottom:269.077800pt;}
.yf8f{bottom:269.118267pt;}
.ydd6{bottom:269.225867pt;}
.y87a{bottom:269.254667pt;}
.y14b0{bottom:269.658000pt;}
.yc4e{bottom:269.658933pt;}
.y1550{bottom:269.659867pt;}
.yf05{bottom:269.857867pt;}
.y8e8{bottom:269.983200pt;}
.y1183{bottom:270.074200pt;}
.y6e4{bottom:270.312000pt;}
.y460{bottom:270.319467pt;}
.ye57{bottom:270.319733pt;}
.y5c8{bottom:270.391267pt;}
.y6f{bottom:270.400267pt;}
.y113f{bottom:270.423933pt;}
.y207{bottom:270.518933pt;}
.y2ce{bottom:270.770800pt;}
.y1560{bottom:270.771200pt;}
.y519{bottom:270.987067pt;}
.y620{bottom:271.318267pt;}
.y135a{bottom:271.480400pt;}
.y3a4{bottom:271.835333pt;}
.yfb7{bottom:271.869200pt;}
.yff1{bottom:271.873200pt;}
.y481{bottom:271.909200pt;}
.yb1b{bottom:272.041467pt;}
.y669{bottom:272.083200pt;}
.ye36{bottom:272.177200pt;}
.y42d{bottom:272.654133pt;}
.y1506{bottom:272.784533pt;}
.y12d1{bottom:272.792800pt;}
.y53f{bottom:272.861200pt;}
.y1535{bottom:272.987200pt;}
.yf81{bottom:273.204133pt;}
.y1402{bottom:273.233733pt;}
.ye3{bottom:273.416533pt;}
.y1070{bottom:273.467333pt;}
.y75a{bottom:273.492267pt;}
.ya99{bottom:273.564533pt;}
.y69b{bottom:273.637067pt;}
.y76d{bottom:273.937867pt;}
.y9b1{bottom:274.036933pt;}
.ycab{bottom:274.088400pt;}
.y12bd{bottom:274.088533pt;}
.y49{bottom:274.371600pt;}
.yc5d{bottom:274.393600pt;}
.ya0a{bottom:274.448800pt;}
.yaaf{bottom:274.528800pt;}
.y22a{bottom:274.542667pt;}
.y1413{bottom:274.749867pt;}
.ye3d{bottom:275.336267pt;}
.y2b3{bottom:275.513133pt;}
.y8fa{bottom:275.646533pt;}
.yc00{bottom:275.652800pt;}
.y51a{bottom:275.653867pt;}
.y1116{bottom:275.700933pt;}
.y7bc{bottom:275.849467pt;}
.ydb1{bottom:275.939000pt;}
.yda4{bottom:275.942267pt;}
.y1e8{bottom:276.154267pt;}
.y94c{bottom:276.325867pt;}
.ye7e{bottom:276.764533pt;}
.y723{bottom:276.791867pt;}
.y15ab{bottom:277.183733pt;}
.yc0f{bottom:277.217067pt;}
.y1026{bottom:277.217467pt;}
.y145e{bottom:277.416533pt;}
.y588{bottom:277.529467pt;}
.y1293{bottom:277.666400pt;}
.yf6b{bottom:277.680800pt;}
.y765{bottom:277.716933pt;}
.y93a{bottom:277.746133pt;}
.y14c1{bottom:277.866933pt;}
.y1013{bottom:277.878400pt;}
.yfd3{bottom:277.878800pt;}
.y37f{bottom:278.076800pt;}
.y11e{bottom:278.078000pt;}
.y289{bottom:278.096533pt;}
.y10a8{bottom:278.327600pt;}
.y1201{bottom:278.407549pt;}
.y10ff{bottom:278.456933pt;}
.ycdc{bottom:278.457333pt;}
.y151a{bottom:278.728933pt;}
.y2fa{bottom:278.735333pt;}
.y242{bottom:278.768400pt;}
.y84e{bottom:278.896133pt;}
.y3ec{bottom:278.901733pt;}
.y918{bottom:278.978400pt;}
.y650{bottom:279.029067pt;}
.ye9e{bottom:279.039467pt;}
.y12ec{bottom:279.046267pt;}
.yf2b{bottom:279.107867pt;}
.y6b8{bottom:279.212933pt;}
.y104c{bottom:279.230667pt;}
.yf50{bottom:279.397133pt;}
.yd37{bottom:279.432267pt;}
.y15d4{bottom:279.453200pt;}
.yb74{bottom:279.559333pt;}
.y1447{bottom:279.696800pt;}
.yb6{bottom:280.082533pt;}
.yd55{bottom:280.136133pt;}
.ybc4{bottom:280.363200pt;}
.y34c{bottom:280.545200pt;}
.y145{bottom:280.593600pt;}
.y1bd{bottom:280.784133pt;}
.y972{bottom:280.996933pt;}
.yad9{bottom:281.069867pt;}
.ye07{bottom:281.131867pt;}
.yd07{bottom:281.647467pt;}
.y273{bottom:281.725933pt;}
.y569{bottom:281.766533pt;}
.y10b7{bottom:281.794533pt;}
.y157d{bottom:281.857867pt;}
.yde9{bottom:282.218000pt;}
.y314{bottom:282.276667pt;}
.y13c5{bottom:282.327867pt;}
.y824{bottom:282.328000pt;}
.yd21{bottom:282.560800pt;}
.y48e{bottom:282.561200pt;}
.y132d{bottom:282.613067pt;}
.y10ce{bottom:282.666667pt;}
.y1097{bottom:282.729867pt;}
.y1168{bottom:282.760400pt;}
.y1393{bottom:282.765467pt;}
.y17d{bottom:282.801067pt;}
.ycc0{bottom:282.808533pt;}
.y4ab{bottom:282.816733pt;}
.y1456{bottom:283.008000pt;}
.y3cd{bottom:283.173867pt;}
.y104d{bottom:283.230800pt;}
.y41a{bottom:283.284667pt;}
.y13e7{bottom:283.476267pt;}
.yed7{bottom:283.497200pt;}
.y919{bottom:283.645200pt;}
.y9f6{bottom:283.862800pt;}
.y448{bottom:283.873200pt;}
.y1344{bottom:283.892133pt;}
.y512{bottom:284.165200pt;}
.y14e3{bottom:284.354867pt;}
.yd7b{bottom:284.381333pt;}
.y1591{bottom:284.524133pt;}
.ye6c{bottom:284.534667pt;}
.y255{bottom:284.564133pt;}
.y798{bottom:284.713867pt;}
.ya2e{bottom:284.776133pt;}
.y142b{bottom:284.777200pt;}
.yafc{bottom:284.806400pt;}
.y13a5{bottom:285.239000pt;}
.y1134{bottom:285.308600pt;}
.yfe2{bottom:285.437467pt;}
.y4d9{bottom:285.457067pt;}
.y70c{bottom:285.637467pt;}
.y94{bottom:285.665467pt;}
.y1479{bottom:285.691600pt;}
.y5c7{bottom:285.724267pt;}
.y113e{bottom:285.756933pt;}
.y121a{bottom:285.863333pt;}
.y1182{bottom:286.074733pt;}
.y101{bottom:286.128800pt;}
.y11fe{bottom:286.212200pt;}
.y1200{bottom:286.214000pt;}
.y6e{bottom:286.399867pt;}
.y5ab{bottom:286.540267pt;}
.ydd5{bottom:286.559200pt;}
.y879{bottom:286.588000pt;}
.y14af{bottom:286.991333pt;}
.yc4d{bottom:286.992267pt;}
.y154f{bottom:286.993200pt;}
.ya3c{bottom:287.467600pt;}
.y6f9{bottom:287.491333pt;}
.y10e5{bottom:287.564933pt;}
.y45f{bottom:287.652800pt;}
.ye56{bottom:287.653067pt;}
.y206{bottom:287.852267pt;}
.y6e3{bottom:287.941200pt;}
.y892{bottom:288.046667pt;}
.y2cd{bottom:288.104133pt;}
.y155f{bottom:288.104533pt;}
.y8c7{bottom:288.303733pt;}
.y11ff{bottom:288.517333pt;}
.yf9c{bottom:288.696533pt;}
.y8ab{bottom:288.772133pt;}
.y838{bottom:288.803600pt;}
.y1359{bottom:288.813733pt;}
.y3a3{bottom:289.168667pt;}
.yfb6{bottom:289.202533pt;}
.y114b{bottom:289.206533pt;}
.yb1a{bottom:289.374800pt;}
.y668{bottom:289.416533pt;}
.yb87{bottom:289.434933pt;}
.y106f{bottom:289.466933pt;}
.y350{bottom:289.637067pt;}
.y42c{bottom:289.987467pt;}
.y1505{bottom:290.117867pt;}
.y53e{bottom:290.194533pt;}
.y1534{bottom:290.320533pt;}
.y48{bottom:290.371600pt;}
.yf80{bottom:290.537467pt;}
.y2b2{bottom:290.846133pt;}
.y2b1{bottom:290.846333pt;}
.ya98{bottom:290.897867pt;}
.y69a{bottom:290.970400pt;}
.y7bb{bottom:291.182467pt;}
.y61f{bottom:291.187000pt;}
.y76c{bottom:291.271200pt;}
.y9b0{bottom:291.370267pt;}
.ycaa{bottom:291.421733pt;}
.y73e{bottom:291.432267pt;}
.yc5c{bottom:291.726933pt;}
.yd95{bottom:291.939533pt;}
.yda3{bottom:291.942800pt;}
.y609{bottom:291.970267pt;}
.y1412{bottom:292.083200pt;}
.y1d{bottom:292.442133pt;}
.y759{bottom:292.605600pt;}
.y480{bottom:292.639000pt;}
.y12d0{bottom:292.792800pt;}
.y8f9{bottom:292.979867pt;}
.ybff{bottom:292.986133pt;}
.y1115{bottom:293.034267pt;}
.y5dd{bottom:293.125867pt;}
.y94b{bottom:293.659200pt;}
.yf6a{bottom:293.681333pt;}
.y148f{bottom:293.846933pt;}
.y872{bottom:293.947933pt;}
.y11fd{bottom:294.018651pt;}
.yeed{bottom:294.117867pt;}
.y722{bottom:294.125200pt;}
.y229{bottom:294.310333pt;}
.yc0e{bottom:294.550400pt;}
.y1025{bottom:294.550800pt;}
.yf4f{bottom:294.730133pt;}
.yf04{bottom:294.749867pt;}
.y1292{bottom:294.999733pt;}
.y764{bottom:295.050267pt;}
.y1012{bottom:295.211733pt;}
.yfd2{bottom:295.212133pt;}
.y37e{bottom:295.410133pt;}
.y288{bottom:295.429867pt;}
.y15d3{bottom:295.453200pt;}
.ya09{bottom:295.561600pt;}
.yaae{bottom:295.641733pt;}
.y10fe{bottom:295.790267pt;}
.ycdb{bottom:295.790667pt;}
.y1519{bottom:296.062267pt;}
.y2f9{bottom:296.068667pt;}
.yd54{bottom:296.136667pt;}
.y84d{bottom:296.229467pt;}
.y3eb{bottom:296.235067pt;}
.y917{bottom:296.311733pt;}
.y64f{bottom:296.362400pt;}
.ye9d{bottom:296.372800pt;}
.y12eb{bottom:296.379600pt;}
.yf2a{bottom:296.441200pt;}
.y6b7{bottom:296.546267pt;}
.y104b{bottom:296.564000pt;}
.yd36{bottom:296.765600pt;}
.yb73{bottom:296.892667pt;}
.y939{bottom:296.968800pt;}
.y1446{bottom:297.030133pt;}
.y272{bottom:297.058933pt;}
.yb5{bottom:297.415867pt;}
.ybc3{bottom:297.696533pt;}
.ye7d{bottom:297.877867pt;}
.y34b{bottom:297.878533pt;}
.y144{bottom:297.926933pt;}
.y1bc{bottom:298.117467pt;}
.y4a9{bottom:298.149733pt;}
.ye2{bottom:298.308533pt;}
.y971{bottom:298.330267pt;}
.yad8{bottom:298.403200pt;}
.y132c{bottom:298.613600pt;}
.y419{bottom:298.617667pt;}
.y98c{bottom:298.628267pt;}
.yc24{bottom:298.715333pt;}
.y4ac{bottom:298.963333pt;}
.y14c0{bottom:298.980267pt;}
.yd06{bottom:298.980800pt;}
.y10b6{bottom:299.127867pt;}
.y157c{bottom:299.191200pt;}
.y1307{bottom:299.414533pt;}
.yed6{bottom:299.497733pt;}
.yde8{bottom:299.551333pt;}
.y13c4{bottom:299.661200pt;}
.y1ac{bottom:299.881333pt;}
.yd20{bottom:299.894133pt;}
.y48d{bottom:299.894533pt;}
.y7f3{bottom:299.942267pt;}
.y10cd{bottom:300.000000pt;}
.y1392{bottom:300.098800pt;}
.y14e2{bottom:300.355400pt;}
.ydbe{bottom:300.381867pt;}
.y3cc{bottom:300.507200pt;}
.y8e7{bottom:300.539867pt;}
.y1133{bottom:300.641600pt;}
.y15aa{bottom:300.742467pt;}
.y13e6{bottom:300.809600pt;}
.y1e7{bottom:301.046267pt;}
.y5c6{bottom:301.057267pt;}
.y113d{bottom:301.089933pt;}
.y9f5{bottom:301.196133pt;}
.y447{bottom:301.206533pt;}
.y13a4{bottom:301.239533pt;}
.y2d2{bottom:301.335733pt;}
.y511{bottom:301.388067pt;}
.y11bc{bottom:301.685448pt;}
.y11fc{bottom:301.825102pt;}
.yeba{bottom:301.857467pt;}
.ye6b{bottom:301.868000pt;}
.y254{bottom:301.897467pt;}
.y4aa{bottom:301.949733pt;}
.y11e0{bottom:302.021511pt;}
.y11d9{bottom:302.022894pt;}
.y797{bottom:302.047200pt;}
.ya2d{bottom:302.109467pt;}
.y142a{bottom:302.110533pt;}
.y6d{bottom:302.399467pt;}
.yfe1{bottom:302.770800pt;}
.y4d8{bottom:302.790400pt;}
.y11d{bottom:302.970400pt;}
.y93{bottom:302.998800pt;}
.y1478{bottom:303.024933pt;}
.y6e2{bottom:303.274200pt;}
.y313{bottom:303.390000pt;}
.y100{bottom:303.462133pt;}
.y2d1{bottom:303.685733pt;}
.y5aa{bottom:303.873600pt;}
.y878{bottom:303.921333pt;}
.yb39{bottom:303.978933pt;}
.y823{bottom:303.985867pt;}
.yc4c{bottom:304.325600pt;}
.y154e{bottom:304.326533pt;}
.ya3b{bottom:304.800933pt;}
.y6f8{bottom:304.824667pt;}
.y10e4{bottom:304.898267pt;}
.y45e{bottom:304.986133pt;}
.ye55{bottom:304.986400pt;}
.y205{bottom:305.185600pt;}
.y1c{bottom:305.242133pt;}
.y2cc{bottom:305.437467pt;}
.y155e{bottom:305.437867pt;}
.y106e{bottom:305.466533pt;}
.y1401{bottom:305.685733pt;}
.yafb{bottom:305.919333pt;}
.y518{bottom:306.105200pt;}
.y837{bottom:306.136933pt;}
.y1358{bottom:306.147067pt;}
.y3a2{bottom:306.502000pt;}
.y61e{bottom:306.520000pt;}
.yfb5{bottom:306.535867pt;}
.y114a{bottom:306.539867pt;}
.y667{bottom:306.749867pt;}
.y684{bottom:306.895333pt;}
.y681{bottom:306.895400pt;}
.y1319{bottom:307.055933pt;}
.y42b{bottom:307.320800pt;}
.y1504{bottom:307.451200pt;}
.y1167{bottom:307.652800pt;}
.y17c{bottom:307.693067pt;}
.yf7f{bottom:307.870800pt;}
.y1455{bottom:307.900400pt;}
.yd7a{bottom:307.940067pt;}
.yda2{bottom:307.943333pt;}
.y47f{bottom:307.972000pt;}
.y14ae{bottom:308.104133pt;}
.ya97{bottom:308.231200pt;}
.y76b{bottom:308.604533pt;}
.yca9{bottom:308.755067pt;}
.y1343{bottom:308.784133pt;}
.yc5b{bottom:309.060267pt;}
.y871{bottom:309.280933pt;}
.y11c2{bottom:309.490516pt;}
.y11bb{bottom:309.491899pt;}
.y11fb{bottom:309.631553pt;}
.y1181{bottom:309.633467pt;}
.y34f{bottom:309.636533pt;}
.y228{bottom:309.643333pt;}
.y11df{bottom:309.827962pt;}
.y11d8{bottom:309.829345pt;}
.y1010{bottom:309.878533pt;}
.y8aa{bottom:309.885467pt;}
.y7ba{bottom:310.295200pt;}
.ybfe{bottom:310.319467pt;}
.y1114{bottom:310.367600pt;}
.y5dc{bottom:310.459200pt;}
.yb19{bottom:310.487733pt;}
.y70b{bottom:310.529467pt;}
.y891{bottom:310.713467pt;}
.y94a{bottom:310.992533pt;}
.y7d9{bottom:311.251733pt;}
.ydd4{bottom:311.451200pt;}
.y15d2{bottom:311.453200pt;}
.y15e3{bottom:311.653200pt;}
.y758{bottom:311.718333pt;}
.yc0d{bottom:311.883733pt;}
.y1024{bottom:311.884133pt;}
.yf03{bottom:312.083200pt;}
.yd53{bottom:312.137200pt;}
.y1291{bottom:312.333067pt;}
.y763{bottom:312.383600pt;}
.y9af{bottom:312.483067pt;}
.y100f{bottom:312.545067pt;}
.yfd1{bottom:312.545467pt;}
.y37d{bottom:312.743467pt;}
.y287{bottom:312.763200pt;}
.y10fd{bottom:313.123600pt;}
.y2f8{bottom:313.402000pt;}
.y84c{bottom:313.562800pt;}
.y3ea{bottom:313.568400pt;}
.y12ea{bottom:313.712933pt;}
.y2b0{bottom:313.738800pt;}
.y587{bottom:313.760400pt;}
.yf29{bottom:313.774533pt;}
.yf4e{bottom:313.846267pt;}
.y6b6{bottom:313.879600pt;}
.y104a{bottom:313.897333pt;}
.y1373{bottom:313.897733pt;}
.y418{bottom:313.950667pt;}
.y8f8{bottom:314.093200pt;}
.yd35{bottom:314.098933pt;}
.y568{bottom:314.218533pt;}
.yb72{bottom:314.226000pt;}
.yb86{bottom:314.326933pt;}
.y132b{bottom:314.614133pt;}
.y241{bottom:314.999333pt;}
.ybc2{bottom:315.029867pt;}
.ye7c{bottom:315.211200pt;}
.y34a{bottom:315.211867pt;}
.y1533{bottom:315.212533pt;}
.y143{bottom:315.260267pt;}
.y1bb{bottom:315.450800pt;}
.y118f{bottom:315.498267pt;}
.y970{bottom:315.663600pt;}
.y98b{bottom:315.961600pt;}
.yc23{bottom:316.048667pt;}
.y4a8{bottom:316.133133pt;}
.ye06{bottom:316.250000pt;}
.yd05{bottom:316.314133pt;}
.y14e1{bottom:316.355933pt;}
.y1195{bottom:316.382400pt;}
.y10b5{bottom:316.461200pt;}
.y157b{bottom:316.524533pt;}
.y1011{bottom:316.545333pt;}
.y15a9{bottom:316.743000pt;}
.yde7{bottom:316.884667pt;}
.y1411{bottom:316.975600pt;}
.y13c3{bottom:316.994533pt;}
.y1ab{bottom:317.214667pt;}
.yd1f{bottom:317.227467pt;}
.y48c{bottom:317.227867pt;}
.yf69{bottom:317.240067pt;}
.y7f2{bottom:317.275600pt;}
.y11c1{bottom:317.296967pt;}
.y11ba{bottom:317.298350pt;}
.y10cc{bottom:317.333333pt;}
.y271{bottom:317.340733pt;}
.y1391{bottom:317.432133pt;}
.y11fa{bottom:317.438004pt;}
.y11de{bottom:317.634413pt;}
.y11d7{bottom:317.635796pt;}
.y3cb{bottom:317.840533pt;}
.y8e6{bottom:317.873200pt;}
.y1b{bottom:318.042133pt;}
.y938{bottom:318.082133pt;}
.y13e5{bottom:318.142933pt;}
.y47{bottom:318.377200pt;}
.y1e6{bottom:318.379600pt;}
.y6c{bottom:318.399067pt;}
.y9f4{bottom:318.529467pt;}
.y446{bottom:318.539867pt;}
.y6e1{bottom:318.607200pt;}
.y510{bottom:318.610933pt;}
.y1096{bottom:318.960933pt;}
.y721{bottom:319.017600pt;}
.y1590{bottom:319.190800pt;}
.ye6a{bottom:319.201333pt;}
.y253{bottom:319.230800pt;}
.y608{bottom:319.240733pt;}
.y822{bottom:319.318867pt;}
.y796{bottom:319.380533pt;}
.ya2c{bottom:319.442800pt;}
.y1429{bottom:319.443867pt;}
.yad7{bottom:319.516133pt;}
.y699{bottom:319.642000pt;}
.y145d{bottom:319.642267pt;}
.y502{bottom:319.895533pt;}
.y14bf{bottom:320.093600pt;}
.yfe0{bottom:320.104133pt;}
.y4d7{bottom:320.123733pt;}
.y5c5{bottom:320.170000pt;}
.ycda{bottom:320.682667pt;}
.yff{bottom:320.795467pt;}
.y1518{bottom:320.954667pt;}
.y1219{bottom:320.982533pt;}
.y5a9{bottom:321.206933pt;}
.y64e{bottom:321.254667pt;}
.ye9c{bottom:321.265200pt;}
.yb38{bottom:321.312267pt;}
.y106d{bottom:321.466133pt;}
.yc4b{bottom:321.658933pt;}
.y154d{bottom:321.659867pt;}
.y61d{bottom:321.853000pt;}
.ya3a{bottom:322.134267pt;}
.y6f7{bottom:322.158000pt;}
.y2d0{bottom:322.228133pt;}
.y10e3{bottom:322.231600pt;}
.y45d{bottom:322.319467pt;}
.ye54{bottom:322.319733pt;}
.y203{bottom:322.518933pt;}
.y2cb{bottom:322.770800pt;}
.y155d{bottom:322.771200pt;}
.yed5{bottom:323.056467pt;}
.yf8e{bottom:323.135600pt;}
.ye1{bottom:323.200533pt;}
.y47e{bottom:323.305000pt;}
.y1357{bottom:323.480400pt;}
.y4a6{bottom:323.799467pt;}
.y3a1{bottom:323.835333pt;}
.yfb4{bottom:323.869200pt;}
.y1149{bottom:323.873200pt;}
.yd79{bottom:323.940600pt;}
.y666{bottom:324.083200pt;}
.y312{bottom:324.503333pt;}
.y2cf{bottom:324.578133pt;}
.y42a{bottom:324.654133pt;}
.y1503{bottom:324.784533pt;}
.y13a3{bottom:324.798267pt;}
.y227{bottom:324.976333pt;}
.y17b{bottom:325.026400pt;}
.y11c0{bottom:325.103418pt;}
.y11b9{bottom:325.104801pt;}
.yf7e{bottom:325.204133pt;}
.y11f9{bottom:325.244455pt;}
.y11dd{bottom:325.440864pt;}
.y11d6{bottom:325.442247pt;}
.y7b9{bottom:325.628200pt;}
.y1180{bottom:325.634000pt;}
.y1400{bottom:325.685200pt;}
.y76a{bottom:325.937867pt;}
.y683{bottom:326.008067pt;}
.y680{bottom:326.008133pt;}
.yb4{bottom:326.087867pt;}
.yca8{bottom:326.088400pt;}
.y1342{bottom:326.117467pt;}
.y148e{bottom:326.298933pt;}
.yc5a{bottom:326.393600pt;}
.y204{bottom:326.518933pt;}
.y14a1{bottom:327.001733pt;}
.y100e{bottom:327.211867pt;}
.y15d1{bottom:327.453200pt;}
.ybfd{bottom:327.652800pt;}
.y1113{bottom:327.700933pt;}
.y5db{bottom:327.792533pt;}
.y70a{bottom:327.862800pt;}
.y12cf{bottom:327.911467pt;}
.y1477{bottom:327.917200pt;}
.yd52{bottom:328.137733pt;}
.y949{bottom:328.325867pt;}
.y7d8{bottom:328.585067pt;}
.ydd3{bottom:328.784533pt;}
.y10fc{bottom:329.123600pt;}
.yf4d{bottom:329.179267pt;}
.yc0c{bottom:329.217067pt;}
.yff0{bottom:329.217467pt;}
.y417{bottom:329.283667pt;}
.ya96{bottom:329.344133pt;}
.yf02{bottom:329.416533pt;}
.y1290{bottom:329.666400pt;}
.y762{bottom:329.716933pt;}
.y100d{bottom:329.878400pt;}
.y37c{bottom:330.076800pt;}
.y286{bottom:330.096533pt;}
.ye35{bottom:330.253321pt;}
.y73d{bottom:330.329867pt;}
.y10fb{bottom:330.456933pt;}
.y132a{bottom:330.614667pt;}
.y2f7{bottom:330.735333pt;}
.y757{bottom:330.831067pt;}
.y870{bottom:330.838000pt;}
.y1a{bottom:330.842133pt;}
.y3e9{bottom:330.901733pt;}
.y8a9{bottom:330.998800pt;}
.y836{bottom:331.028933pt;}
.y12e9{bottom:331.046267pt;}
.y2af{bottom:331.071867pt;}
.yf28{bottom:331.107867pt;}
.y6b5{bottom:331.212933pt;}
.y1049{bottom:331.230667pt;}
.y1372{bottom:331.231067pt;}
.y8f7{bottom:331.426533pt;}
.yd34{bottom:331.432267pt;}
.y12bc{bottom:331.433467pt;}
.y4a7{bottom:331.466133pt;}
.ydb0{bottom:331.498800pt;}
.yda1{bottom:331.502067pt;}
.y567{bottom:331.551867pt;}
.yb71{bottom:331.559333pt;}
.y119d{bottom:331.644933pt;}
.yb85{bottom:331.660267pt;}
.y92{bottom:331.670800pt;}
.ya08{bottom:331.792267pt;}
.yaad{bottom:331.871733pt;}
.y8c6{bottom:332.094267pt;}
.y14e0{bottom:332.356467pt;}
.ybc1{bottom:332.363200pt;}
.y916{bottom:332.542667pt;}
.y349{bottom:332.545200pt;}
.y1532{bottom:332.545867pt;}
.y142{bottom:332.593600pt;}
.y270{bottom:332.673733pt;}
.y1ba{bottom:332.784133pt;}
.y11bf{bottom:332.909869pt;}
.y11b8{bottom:332.911252pt;}
.y96f{bottom:332.996933pt;}
.y11f8{bottom:333.050906pt;}
.yf68{bottom:333.240600pt;}
.y11dc{bottom:333.247315pt;}
.y11d5{bottom:333.248698pt;}
.y1445{bottom:333.261600pt;}
.y98a{bottom:333.294933pt;}
.yd04{bottom:333.647467pt;}
.y10b4{bottom:333.794533pt;}
.y157a{bottom:333.857867pt;}
.yde6{bottom:334.218000pt;}
.y13c2{bottom:334.327867pt;}
.y46{bottom:334.376800pt;}
.y6b{bottom:334.398667pt;}
.y1aa{bottom:334.548000pt;}
.yd1e{bottom:334.560800pt;}
.y48b{bottom:334.561200pt;}
.y607{bottom:334.573733pt;}
.y7f1{bottom:334.608933pt;}
.y821{bottom:334.651867pt;}
.y10cb{bottom:334.666667pt;}
.y3ca{bottom:335.173867pt;}
.y501{bottom:335.228533pt;}
.y13e4{bottom:335.476267pt;}
.y5c4{bottom:335.503000pt;}
.y113c{bottom:335.535667pt;}
.y1e5{bottom:335.712933pt;}
.y50f{bottom:335.833800pt;}
.y445{bottom:335.873200pt;}
.ye7b{bottom:336.324533pt;}
.y795{bottom:336.713867pt;}
.ya2b{bottom:336.776133pt;}
.y1428{bottom:336.777200pt;}
.y698{bottom:336.975333pt;}
.yc22{bottom:337.161467pt;}
.y937{bottom:337.304800pt;}
.y14be{bottom:337.426933pt;}
.yfd0{bottom:337.437467pt;}
.y4d6{bottom:337.457067pt;}
.y106c{bottom:337.465733pt;}
.ycd9{bottom:338.016000pt;}
.y6e0{bottom:338.067733pt;}
.y84b{bottom:338.454800pt;}
.y5a8{bottom:338.540267pt;}
.y1390{bottom:338.545467pt;}
.y877{bottom:338.588000pt;}
.y47d{bottom:338.638000pt;}
.yb37{bottom:338.645600pt;}
.y555{bottom:338.984867pt;}
.y8e5{bottom:338.986533pt;}
.yc4a{bottom:338.992267pt;}
.yed4{bottom:339.057000pt;}
.yf8d{bottom:339.135200pt;}
.ya39{bottom:339.467600pt;}
.y6f6{bottom:339.491333pt;}
.y10e2{bottom:339.564933pt;}
.y9f3{bottom:339.642267pt;}
.y45c{bottom:339.652800pt;}
.ye53{bottom:339.653067pt;}
.y202{bottom:339.852267pt;}
.yd78{bottom:339.941133pt;}
.y2ca{bottom:340.104133pt;}
.y155c{bottom:340.104533pt;}
.ycbf{bottom:340.152267pt;}
.y15a8{bottom:340.301733pt;}
.y226{bottom:340.309333pt;}
.y1454{bottom:340.352400pt;}
.y11be{bottom:340.716320pt;}
.y11b7{bottom:340.717703pt;}
.ye34{bottom:340.760685pt;}
.y13a2{bottom:340.798800pt;}
.y1356{bottom:340.813733pt;}
.y11f7{bottom:340.857357pt;}
.y7b8{bottom:340.961200pt;}
.y61c{bottom:340.965733pt;}
.y1218{bottom:340.982000pt;}
.y11db{bottom:341.053766pt;}
.y11d4{bottom:341.055149pt;}
.y3a0{bottom:341.168667pt;}
.yfb3{bottom:341.202533pt;}
.y1148{bottom:341.206533pt;}
.y117f{bottom:341.634533pt;}
.y11c{bottom:341.867467pt;}
.y429{bottom:341.987467pt;}
.y1502{bottom:342.117867pt;}
.yafa{bottom:342.150267pt;}
.y161{bottom:342.319333pt;}
.y17a{bottom:342.359733pt;}
.y769{bottom:343.271200pt;}
.yb3{bottom:343.421200pt;}
.yca7{bottom:343.421733pt;}
.y1341{bottom:343.450800pt;}
.y15d0{bottom:343.453200pt;}
.y19{bottom:343.642133pt;}
.ye69{bottom:344.093733pt;}
.y252{bottom:344.122800pt;}
.y14ad{bottom:344.335867pt;}
.yf4c{bottom:344.512267pt;}
.ybfc{bottom:344.986133pt;}
.y1112{bottom:345.034267pt;}
.y682{bottom:345.120800pt;}
.y67f{bottom:345.120867pt;}
.y5da{bottom:345.125867pt;}
.y709{bottom:345.196133pt;}
.y311{bottom:345.616667pt;}
.y948{bottom:345.659200pt;}
.yfe{bottom:345.687467pt;}
.y1306{bottom:345.871200pt;}
.y7d7{bottom:345.918400pt;}
.ydd2{bottom:346.117867pt;}
.y756{bottom:346.164067pt;}
.y86f{bottom:346.171000pt;}
.y148d{bottom:346.298400pt;}
.y1166{bottom:346.550400pt;}
.yfef{bottom:346.550800pt;}
.y154c{bottom:346.551867pt;}
.y1329{bottom:346.615200pt;}
.yb18{bottom:346.718133pt;}
.yf01{bottom:346.749867pt;}
.y162{bottom:346.986133pt;}
.y128f{bottom:346.999733pt;}
.y761{bottom:347.050267pt;}
.y100c{bottom:347.211733pt;}
.y285{bottom:347.429867pt;}
.ydaf{bottom:347.499333pt;}
.yda0{bottom:347.502600pt;}
.y73c{bottom:347.663200pt;}
.ye2e{bottom:347.688400pt;}
.y10fa{bottom:347.790267pt;}
.y12ce{bottom:347.910933pt;}
.y26f{bottom:348.006733pt;}
.y2f6{bottom:348.068667pt;}
.ye0{bottom:348.092533pt;}
.y3e8{bottom:348.235067pt;}
.yeb9{bottom:348.314533pt;}
.y8a8{bottom:348.332133pt;}
.y835{bottom:348.362267pt;}
.y12e8{bottom:348.379600pt;}
.y416{bottom:348.396400pt;}
.yf27{bottom:348.441200pt;}
.y890{bottom:348.498400pt;}
.y11bd{bottom:348.522771pt;}
.y11b6{bottom:348.524154pt;}
.y1048{bottom:348.564000pt;}
.y1371{bottom:348.564400pt;}
.y11f6{bottom:348.663808pt;}
.y9ae{bottom:348.713067pt;}
.yd33{bottom:348.765600pt;}
.y12bb{bottom:348.766800pt;}
.y11da{bottom:348.860217pt;}
.y11d3{bottom:348.861600pt;}
.y566{bottom:348.885200pt;}
.y91{bottom:349.004133pt;}
.ya07{bottom:349.125600pt;}
.y1410{bottom:349.427600pt;}
.ybc0{bottom:349.696533pt;}
.y348{bottom:349.878533pt;}
.y1531{bottom:349.879200pt;}
.yc0b{bottom:350.329867pt;}
.y96e{bottom:350.330267pt;}
.y45{bottom:350.376800pt;}
.y6a{bottom:350.398267pt;}
.y989{bottom:350.628267pt;}
.y113b{bottom:350.868667pt;}
.yd03{bottom:350.980800pt;}
.y10b3{bottom:351.127867pt;}
.y50e{bottom:351.166800pt;}
.y1579{bottom:351.191200pt;}
.y49c{bottom:351.224267pt;}
.yde5{bottom:351.551333pt;}
.y158f{bottom:351.642267pt;}
.y13c1{bottom:351.661200pt;}
.y1a9{bottom:351.881333pt;}
.yd1d{bottom:351.894133pt;}
.y48a{bottom:351.894533pt;}
.y2ed{bottom:351.938267pt;}
.y2eb{bottom:351.938600pt;}
.y7f0{bottom:351.942267pt;}
.y10ca{bottom:352.000000pt;}
.y8c5{bottom:352.093733pt;}
.y8f6{bottom:352.539867pt;}
.yffe{bottom:352.545067pt;}
.yb70{bottom:352.672133pt;}
.yb84{bottom:352.773067pt;}
.y13e3{bottom:352.809600pt;}
.yaac{bottom:352.985067pt;}
.y1e4{bottom:353.046267pt;}
.y2ad{bottom:353.052533pt;}
.y444{bottom:353.206533pt;}
.y1444{bottom:353.261067pt;}
.y6df{bottom:353.400733pt;}
.y106b{bottom:353.465333pt;}
.ye7a{bottom:353.657867pt;}
.y606{bottom:353.689067pt;}
.y1b8{bottom:353.897067pt;}
.y794{bottom:354.047200pt;}
.ya2a{bottom:354.109467pt;}
.y1427{bottom:354.110533pt;}
.y697{bottom:354.308667pt;}
.y554{bottom:354.317867pt;}
.y500{bottom:354.391933pt;}
.yfcf{bottom:354.770800pt;}
.y4d5{bottom:354.790400pt;}
.y37b{bottom:354.969200pt;}
.yed3{bottom:355.057533pt;}
.yf8c{bottom:355.134800pt;}
.y517{bottom:355.228533pt;}
.ycd8{bottom:355.349333pt;}
.y10e1{bottom:355.564933pt;}
.y2ec{bottom:355.738400pt;}
.yad6{bottom:355.746533pt;}
.y5a7{bottom:355.873600pt;}
.y138f{bottom:355.878800pt;}
.y14df{bottom:355.915200pt;}
.y876{bottom:355.921333pt;}
.yd77{bottom:355.941667pt;}
.yb36{bottom:355.978933pt;}
.y2ae{bottom:356.202533pt;}
.y15a7{bottom:356.302267pt;}
.y8e4{bottom:356.319867pt;}
.yc49{bottom:356.325600pt;}
.y11f5{bottom:356.470259pt;}
.y936{bottom:356.527467pt;}
.y820{bottom:356.738267pt;}
.yf67{bottom:356.799333pt;}
.ya38{bottom:356.800933pt;}
.y10e0{bottom:356.898267pt;}
.y45b{bottom:356.986133pt;}
.ye52{bottom:356.986400pt;}
.y201{bottom:357.185600pt;}
.y2c9{bottom:357.437467pt;}
.y141{bottom:357.485600pt;}
.y516{bottom:357.578533pt;}
.y84a{bottom:357.677467pt;}
.y720{bottom:357.915200pt;}
.ya6a{bottom:358.088400pt;}
.y1355{bottom:358.147067pt;}
.y225{bottom:358.262200pt;}
.y586{bottom:358.332400pt;}
.y5c3{bottom:358.395467pt;}
.y1147{bottom:358.539867pt;}
.y14bd{bottom:358.540267pt;}
.y1b9{bottom:358.563733pt;}
.yc67{bottom:358.845333pt;}
.y11b{bottom:359.200800pt;}
.y428{bottom:359.320800pt;}
.y1501{bottom:359.451200pt;}
.y14a0{bottom:359.453200pt;}
.y61b{bottom:359.474733pt;}
.yaf9{bottom:359.483600pt;}
.y160{bottom:359.652667pt;}
.y179{bottom:359.693067pt;}
.y7b7{bottom:359.747267pt;}
.yf4b{bottom:359.845267pt;}
.y1517{bottom:359.852667pt;}
.y64d{bottom:360.153467pt;}
.ye9b{bottom:360.162800pt;}
.y665{bottom:360.314133pt;}
.y1453{bottom:360.351867pt;}
.y1476{bottom:360.368667pt;}
.y768{bottom:360.604533pt;}
.yca6{bottom:360.755067pt;}
.y1340{bottom:360.784133pt;}
.y1217{bottom:360.981467pt;}
.yf7d{bottom:361.435067pt;}
.y240{bottom:361.456133pt;}
.y86e{bottom:361.504000pt;}
.y14ac{bottom:361.669200pt;}
.ybfb{bottom:362.319467pt;}
.yfdf{bottom:362.329867pt;}
.y1111{bottom:362.367600pt;}
.y1318{bottom:362.615733pt;}
.ye05{bottom:362.706667pt;}
.y47c{bottom:362.742400pt;}
.y947{bottom:362.992533pt;}
.yfd{bottom:363.020800pt;}
.yd50{bottom:363.035333pt;}
.y1305{bottom:363.204533pt;}
.y7d6{bottom:363.251733pt;}
.y26e{bottom:363.339733pt;}
.ydd1{bottom:363.451200pt;}
.yd94{bottom:363.499867pt;}
.yd9f{bottom:363.503133pt;}
.y415{bottom:363.729400pt;}
.y1165{bottom:363.883733pt;}
.yfee{bottom:363.884133pt;}
.y154b{bottom:363.885200pt;}
.y18{bottom:364.001600pt;}
.yf00{bottom:364.083200pt;}
.ye68{bottom:364.093733pt;}
.y67e{bottom:364.233600pt;}
.y128e{bottom:364.333067pt;}
.y13a1{bottom:364.357533pt;}
.y6f5{bottom:364.383333pt;}
.y760{bottom:364.383600pt;}
.y100b{bottom:364.545067pt;}
.y73b{bottom:364.996533pt;}
.y117e{bottom:365.193267pt;}
.y2f5{bottom:365.402000pt;}
.y1095{bottom:365.418800pt;}
.ya95{bottom:365.575067pt;}
.yeb8{bottom:365.647867pt;}
.y834{bottom:365.695600pt;}
.y12e7{bottom:365.712933pt;}
.yf26{bottom:365.774533pt;}
.y1047{bottom:365.897333pt;}
.y1370{bottom:365.897733pt;}
.y223{bottom:365.928533pt;}
.y9ad{bottom:366.046400pt;}
.yfb2{bottom:366.094533pt;}
.yd32{bottom:366.098933pt;}
.y113a{bottom:366.201667pt;}
.y69{bottom:366.397867pt;}
.ya06{bottom:366.458933pt;}
.y310{bottom:366.730000pt;}
.y1069{bottom:367.064933pt;}
.y619{bottom:367.141067pt;}
.y9d1{bottom:367.211733pt;}
.y347{bottom:367.211867pt;}
.y1530{bottom:367.212533pt;}
.y2ea{bottom:367.271600pt;}
.y7b5{bottom:367.413600pt;}
.y6b4{bottom:367.444000pt;}
.yb17{bottom:367.831467pt;}
.y988{bottom:367.961600pt;}
.y10c9{bottom:368.000000pt;}
.yd02{bottom:368.314133pt;}
.y10b2{bottom:368.461200pt;}
.y1578{bottom:368.524533pt;}
.y49b{bottom:368.557600pt;}
.y6de{bottom:368.733733pt;}
.y10f9{bottom:368.903067pt;}
.y13c0{bottom:368.994533pt;}
.y755{bottom:369.056533pt;}
.y1a8{bottom:369.214667pt;}
.yd1c{bottom:369.227467pt;}
.y489{bottom:369.227867pt;}
.y7ef{bottom:369.275600pt;}
.y10c8{bottom:369.333333pt;}
.y140f{bottom:369.427067pt;}
.y8a7{bottom:369.445467pt;}
.y106a{bottom:369.464933pt;}
.y1068{bottom:369.467333pt;}
.y3c9{bottom:369.515067pt;}
.y4ff{bottom:369.724933pt;}
.yd51{bottom:369.998400pt;}
.y5d9{bottom:370.017867pt;}
.y708{bottom:370.088400pt;}
.y13e2{bottom:370.142933pt;}
.y1328{bottom:370.173933pt;}
.y50d{bottom:370.281533pt;}
.yaab{bottom:370.318400pt;}
.y1e3{bottom:370.379600pt;}
.y443{bottom:370.539867pt;}
.ybbf{bottom:370.809467pt;}
.yf78{bottom:371.058067pt;}
.y11f4{bottom:371.132082pt;}
.yf8b{bottom:371.134400pt;}
.y1b7{bottom:371.230400pt;}
.y793{bottom:371.380533pt;}
.ya29{bottom:371.442800pt;}
.y1426{bottom:371.443867pt;}
.y14de{bottom:371.915733pt;}
.y1194{bottom:371.942200pt;}
.y81f{bottom:372.071267pt;}
.yb2{bottom:372.093200pt;}
.yfce{bottom:372.104133pt;}
.y4d4{bottom:372.123733pt;}
.y13ff{bottom:372.141867pt;}
.y284{bottom:372.322267pt;}
.y515{bottom:372.341800pt;}
.ycd7{bottom:372.682667pt;}
.yf66{bottom:372.799867pt;}
.y605{bottom:372.801800pt;}
.ydf{bottom:372.984533pt;}
.y3e7{bottom:373.127467pt;}
.y5a6{bottom:373.206933pt;}
.y138e{bottom:373.212133pt;}
.y875{bottom:373.254667pt;}
.y36c{bottom:373.279933pt;}
.yb35{bottom:373.312267pt;}
.yc21{bottom:373.392533pt;}
.y553{bottom:373.430600pt;}
.y224{bottom:373.595200pt;}
.y8e3{bottom:373.653200pt;}
.y12ba{bottom:373.658800pt;}
.yc48{bottom:373.658933pt;}
.y565{bottom:373.777200pt;}
.yba5{bottom:373.857467pt;}
.ya37{bottom:374.134267pt;}
.y10df{bottom:374.231600pt;}
.y45a{bottom:374.319467pt;}
.ye51{bottom:374.319733pt;}
.y2c8{bottom:374.770800pt;}
.ye79{bottom:374.771200pt;}
.y61a{bottom:374.807733pt;}
.y140{bottom:374.818933pt;}
.y7b6{bottom:375.080267pt;}
.yf4a{bottom:375.178267pt;}
.y96d{bottom:375.222267pt;}
.y71f{bottom:375.248533pt;}
.y15cf{bottom:375.453200pt;}
.y935{bottom:375.750133pt;}
.y9f2{bottom:375.873200pt;}
.y14bc{bottom:375.873600pt;}
.y585{bottom:376.221733pt;}
.y427{bottom:376.654133pt;}
.y1500{bottom:376.784533pt;}
.y149f{bottom:376.786533pt;}
.y17{bottom:376.801600pt;}
.yaf8{bottom:376.816933pt;}
.y86d{bottom:376.837000pt;}
.yad5{bottom:376.859867pt;}
.y849{bottom:376.900133pt;}
.y15f{bottom:376.986000pt;}
.y178{bottom:377.026400pt;}
.y1516{bottom:377.186000pt;}
.y64c{bottom:377.486800pt;}
.ye9a{bottom:377.496133pt;}
.y90{bottom:377.676133pt;}
.y1475{bottom:377.702000pt;}
.y133f{bottom:378.117467pt;}
.y44{bottom:378.382800pt;}
.yed2{bottom:378.616267pt;}
.y23f{bottom:378.789467pt;}
.y11f1{bottom:378.934351pt;}
.y11f3{bottom:378.938533pt;}
.y915{bottom:379.000133pt;}
.y14ab{bottom:379.002533pt;}
.y414{bottom:379.062400pt;}
.y696{bottom:379.200667pt;}
.ya69{bottom:379.201333pt;}
.yd76{bottom:379.500400pt;}
.ybfa{bottom:379.652800pt;}
.y1110{bottom:379.700933pt;}
.y15a6{bottom:379.861000pt;}
.ye04{bottom:380.040000pt;}
.yfc{bottom:380.354133pt;}
.y13a0{bottom:380.358067pt;}
.y3ba{bottom:380.391067pt;}
.y3b9{bottom:380.493067pt;}
.y1304{bottom:380.537867pt;}
.y7d5{bottom:380.585067pt;}
.ydd0{bottom:380.784533pt;}
.y117d{bottom:381.193800pt;}
.y1164{bottom:381.217067pt;}
.y1023{bottom:381.217467pt;}
.y154a{bottom:381.218533pt;}
.y47b{bottom:381.234200pt;}
.y11f2{bottom:381.241867pt;}
.yeff{bottom:381.416533pt;}
.y1094{bottom:381.418400pt;}
.y1139{bottom:381.534667pt;}
.y6f4{bottom:381.716667pt;}
.y75f{bottom:381.716933pt;}
.yca5{bottom:381.868000pt;}
.y100a{bottom:381.878400pt;}
.y67d{bottom:381.979800pt;}
.y73a{bottom:382.329867pt;}
.y68{bottom:382.397867pt;}
.y2f4{bottom:382.735333pt;}
.y5c2{bottom:382.751333pt;}
.ya94{bottom:382.908400pt;}
.yeb7{bottom:382.981200pt;}
.y833{bottom:383.028933pt;}
.y1354{bottom:383.039467pt;}
.y12e6{bottom:383.046267pt;}
.yf25{bottom:383.107867pt;}
.y1046{bottom:383.230667pt;}
.y136f{bottom:383.231067pt;}
.yfb1{bottom:383.427867pt;}
.y1271{bottom:383.432267pt;}
.y6dd{bottom:384.066733pt;}
.y11a{bottom:384.092800pt;}
.y346{bottom:384.545200pt;}
.y152f{bottom:384.545867pt;}
.y987{bottom:385.294933pt;}
.y1067{bottom:385.466933pt;}
.ycf5{bottom:385.647467pt;}
.y514{bottom:385.674800pt;}
.y10b1{bottom:385.794533pt;}
.y26d{bottom:385.926600pt;}
.y1327{bottom:386.174467pt;}
.y88f{bottom:386.283333pt;}
.y13bf{bottom:386.327867pt;}
.y2e9{bottom:386.386867pt;}
.yd1b{bottom:386.560800pt;}
.y488{bottom:386.561200pt;}
.y7ee{bottom:386.608933pt;}
.y10c7{bottom:386.666667pt;}
.y11f0{bottom:386.740802pt;}
.y753{bottom:386.872267pt;}
.yd93{bottom:387.058600pt;}
.yd9e{bottom:387.061867pt;}
.yf8a{bottom:387.134000pt;}
.y9ac{bottom:387.159733pt;}
.y5d8{bottom:387.351200pt;}
.y81e{bottom:387.404267pt;}
.y1e2{bottom:387.712933pt;}
.yde4{bottom:387.782267pt;}
.y442{bottom:387.873200pt;}
.y957{bottom:387.885333pt;}
.y14dd{bottom:387.916267pt;}
.y513{bottom:388.024800pt;}
.y604{bottom:388.134800pt;}
.y1b6{bottom:388.563733pt;}
.y36b{bottom:388.612933pt;}
.y792{bottom:388.713867pt;}
.y552{bottom:388.763600pt;}
.ya28{bottom:388.776133pt;}
.y479{bottom:388.900533pt;}
.yb6f{bottom:388.903067pt;}
.yb16{bottom:388.944400pt;}
.yb83{bottom:389.004533pt;}
.y128d{bottom:389.225467pt;}
.y50c{bottom:389.394267pt;}
.yb1{bottom:389.426533pt;}
.yfcd{bottom:389.437467pt;}
.y4d3{bottom:389.457067pt;}
.y13fe{bottom:389.475200pt;}
.y16{bottom:389.601600pt;}
.y67b{bottom:389.646133pt;}
.y4fe{bottom:389.854467pt;}
.y2aa{bottom:390.008533pt;}
.ycd6{bottom:390.016000pt;}
.y754{bottom:390.022267pt;}
.yf49{bottom:390.511267pt;}
.y5a5{bottom:390.540267pt;}
.y8a6{bottom:390.558800pt;}
.y874{bottom:390.588000pt;}
.yb34{bottom:390.645600pt;}
.yc20{bottom:390.725867pt;}
.y8f5{bottom:390.986533pt;}
.yd31{bottom:390.991333pt;}
.y12b9{bottom:390.992133pt;}
.yc47{bottom:390.992267pt;}
.y564{bottom:391.110533pt;}
.yc83{bottom:391.190800pt;}
.yaaa{bottom:391.431733pt;}
.y15ce{bottom:391.453200pt;}
.ya36{bottom:391.467600pt;}
.y200{bottom:391.526800pt;}
.y10de{bottom:391.564933pt;}
.y459{bottom:391.652800pt;}
.ye50{bottom:391.653067pt;}
.y15ef{bottom:391.653200pt;}
.y13f{bottom:392.152267pt;}
.y86c{bottom:392.170000pt;}
.y96c{bottom:392.555600pt;}
.y71e{bottom:392.581867pt;}
.y148c{bottom:392.755067pt;}
.y3e6{bottom:393.127467pt;}
.y9f1{bottom:393.206533pt;}
.y1577{bottom:393.416533pt;}
.y37a{bottom:393.866800pt;}
.y11b2{bottom:393.956647pt;}
.y426{bottom:393.987467pt;}
.y584{bottom:394.111067pt;}
.y14ff{bottom:394.117867pt;}
.y149e{bottom:394.119867pt;}
.y15e{bottom:394.319333pt;}
.y138d{bottom:394.325467pt;}
.y177{bottom:394.359733pt;}
.y12cd{bottom:394.367600pt;}
.y43{bottom:394.382400pt;}
.y413{bottom:394.395400pt;}
.y11ce{bottom:394.509714pt;}
.y11d2{bottom:394.531710pt;}
.y11ef{bottom:394.547253pt;}
.yed1{bottom:394.616800pt;}
.y8e2{bottom:394.766533pt;}
.ye99{bottom:394.829467pt;}
.y934{bottom:394.972800pt;}
.y8f{bottom:395.009467pt;}
.y13e1{bottom:395.035333pt;}
.y133e{bottom:395.450800pt;}
.y222{bottom:395.469333pt;}
.yd75{bottom:395.500933pt;}
.y15a5{bottom:395.861533pt;}
.y618{bottom:395.905867pt;}
.y23e{bottom:396.122800pt;}
.y914{bottom:396.333467pt;}
.y1425{bottom:396.335867pt;}
.yf65{bottom:396.358600pt;}
.y7b4{bottom:396.454533pt;}
.y695{bottom:396.534000pt;}
.y47a{bottom:396.567200pt;}
.y767{bottom:396.835467pt;}
.y1138{bottom:396.867667pt;}
.ybf9{bottom:396.986133pt;}
.y110f{bottom:397.034267pt;}
.y67c{bottom:397.312800pt;}
.ye03{bottom:397.373333pt;}
.y1093{bottom:397.418000pt;}
.yfb{bottom:397.687467pt;}
.y1303{bottom:397.871200pt;}
.yde{bottom:397.876533pt;}
.y7d4{bottom:397.918400pt;}
.yaf7{bottom:397.929733pt;}
.yad4{bottom:397.972800pt;}
.y158e{bottom:398.098933pt;}
.ydcf{bottom:398.117867pt;}
.y8c4{bottom:398.549200pt;}
.y1163{bottom:398.550400pt;}
.y1549{bottom:398.551867pt;}
.yefe{bottom:398.749867pt;}
.ya15{bottom:398.910667pt;}
.y6f3{bottom:399.050000pt;}
.y6f1{bottom:399.050267pt;}
.y30f{bottom:399.181333pt;}
.y1009{bottom:399.211733pt;}
.ye67{bottom:399.212267pt;}
.y6dc{bottom:399.399733pt;}
.y2c7{bottom:399.663200pt;}
.y1443{bottom:399.717733pt;}
.ya93{bottom:400.241733pt;}
.yeb6{bottom:400.314533pt;}
.y832{bottom:400.362267pt;}
.y12e5{bottom:400.379600pt;}
.y136e{bottom:400.564400pt;}
.y1270{bottom:400.765600pt;}
.y26c{bottom:401.259600pt;}
.y1066{bottom:401.466533pt;}
.y30e{bottom:401.531333pt;}
.y752{bottom:401.538933pt;}
.y11b5{bottom:401.762406pt;}
.y11b1{bottom:401.763098pt;}
.y10b0{bottom:401.794533pt;}
.y3b8{bottom:401.845067pt;}
.y5c1{bottom:401.865467pt;}
.y345{bottom:401.878533pt;}
.y152e{bottom:401.879200pt;}
.y3b7{bottom:401.947067pt;}
.y1515{bottom:402.078000pt;}
.y1326{bottom:402.175000pt;}
.y11cd{bottom:402.316165pt;}
.y11ee{bottom:402.353704pt;}
.y64b{bottom:402.378800pt;}
.y15{bottom:402.401600pt;}
.y11d1{bottom:402.458696pt;}
.y81d{bottom:402.737267pt;}
.yd01{bottom:402.980800pt;}
.y1353{bottom:403.039467pt;}
.y6f2{bottom:403.050000pt;}
.yd92{bottom:403.059133pt;}
.yd9d{bottom:403.062400pt;}
.y10af{bottom:403.127867pt;}
.yf9a{bottom:403.133333pt;}
.y13be{bottom:403.661200pt;}
.yd1a{bottom:403.894133pt;}
.y487{bottom:403.894533pt;}
.y139f{bottom:403.916800pt;}
.y7ed{bottom:403.942267pt;}
.yfb0{bottom:404.541200pt;}
.y5d7{bottom:404.684533pt;}
.y50b{bottom:404.727267pt;}
.y117c{bottom:404.752533pt;}
.y1e1{bottom:405.046267pt;}
.yf79{bottom:405.074133pt;}
.y10f8{bottom:405.134133pt;}
.y4fd{bottom:405.187467pt;}
.y119{bottom:405.206133pt;}
.y441{bottom:405.206533pt;}
.y1a7{bottom:405.445600pt;}
.y2e8{bottom:405.499600pt;}
.yf48{bottom:405.844267pt;}
.y791{bottom:406.047200pt;}
.ya27{bottom:406.109467pt;}
.yb6e{bottom:406.236400pt;}
.yba4{bottom:406.308933pt;}
.yb82{bottom:406.337867pt;}
.y986{bottom:406.407867pt;}
.yb0{bottom:406.759867pt;}
.y664{bottom:406.770800pt;}
.y4d2{bottom:406.790400pt;}
.y13fd{bottom:406.808533pt;}
.ybbe{bottom:407.040533pt;}
.y603{bottom:407.247533pt;}
.y2a9{bottom:407.341867pt;}
.ycd5{bottom:407.349333pt;}
.y15cd{bottom:407.453200pt;}
.y86b{bottom:407.503000pt;}
.y10c6{bottom:407.779467pt;}
.y5a4{bottom:407.873600pt;}
.y551{bottom:407.878000pt;}
.y8a5{bottom:407.892133pt;}
.yf7c{bottom:407.892533pt;}
.y873{bottom:407.921333pt;}
.yf24{bottom:407.999867pt;}
.yc1f{bottom:408.059200pt;}
.y1045{bottom:408.123067pt;}
.y9ab{bottom:408.273067pt;}
.y12b8{bottom:408.325467pt;}
.y563{bottom:408.443867pt;}
.ya35{bottom:408.800933pt;}
.y10dd{bottom:408.898267pt;}
.y458{bottom:408.986133pt;}
.y12a4{bottom:408.986400pt;}
.y13e{bottom:409.485600pt;}
.yd4f{bottom:409.492000pt;}
.y11b4{bottom:409.568857pt;}
.y11b0{bottom:409.569549pt;}
.y96b{bottom:409.888933pt;}
.y71d{bottom:409.915200pt;}
.y148b{bottom:410.088400pt;}
.y11cc{bottom:410.122616pt;}
.y53b{bottom:410.133133pt;}
.y11ed{bottom:410.160155pt;}
.y42{bottom:410.382000pt;}
.y11d0{bottom:410.385681pt;}
.y67{bottom:410.403200pt;}
.y9f0{bottom:410.539867pt;}
.yed0{bottom:410.617333pt;}
.y1576{bottom:410.749867pt;}
.y379{bottom:411.200133pt;}
.y1216{bottom:411.218933pt;}
.y283{bottom:411.219867pt;}
.y425{bottom:411.320800pt;}
.y14fe{bottom:411.451200pt;}
.y149d{bottom:411.453200pt;}
.y36a{bottom:411.469333pt;}
.y14dc{bottom:411.475000pt;}
.yd74{bottom:411.501467pt;}
.y15d{bottom:411.652667pt;}
.y138c{bottom:411.658800pt;}
.y176{bottom:411.693067pt;}
.y583{bottom:412.000400pt;}
.y8e1{bottom:412.099867pt;}
.ye98{bottom:412.162800pt;}
.y3c8{bottom:412.191867pt;}
.y1137{bottom:412.200667pt;}
.yf64{bottom:412.359133pt;}
.y1474{bottom:412.368667pt;}
.yaa9{bottom:412.544533pt;}
.y133d{bottom:412.784133pt;}
.y1092{bottom:413.417600pt;}
.y23d{bottom:413.456133pt;}
.y412{bottom:413.508133pt;}
.y913{bottom:413.666800pt;}
.y1424{bottom:413.669200pt;}
.y7b3{bottom:413.787867pt;}
.y694{bottom:413.867333pt;}
.y6b3{bottom:413.900000pt;}
.ybf8{bottom:414.319467pt;}
.ye02{bottom:414.706667pt;}
.yfa{bottom:415.020800pt;}
.y1302{bottom:415.204533pt;}
.y7d3{bottom:415.251733pt;}
.y158d{bottom:415.432267pt;}
.ydce{bottom:415.451200pt;}
.y8c3{bottom:415.882533pt;}
.y1162{bottom:415.883733pt;}
.yc46{bottom:415.884267pt;}
.y1548{bottom:415.885200pt;}
.y933{bottom:416.086133pt;}
.y6f0{bottom:416.383600pt;}
.ye4f{bottom:416.545067pt;}
.y26b{bottom:416.592600pt;}
.y739{bottom:416.996533pt;}
.y1442{bottom:417.051067pt;}
.y11b3{bottom:417.375308pt;}
.y11af{bottom:417.376000pt;}
.y1065{bottom:417.466133pt;}
.ya92{bottom:417.575067pt;}
.y473{bottom:417.645867pt;}
.y671{bottom:417.646933pt;}
.yeb5{bottom:417.647867pt;}
.y831{bottom:417.695600pt;}
.y12e4{bottom:417.712933pt;}
.y136d{bottom:417.897733pt;}
.y11cb{bottom:417.929067pt;}
.y11ec{bottom:417.966606pt;}
.y81c{bottom:418.070267pt;}
.ycb{bottom:418.098533pt;}
.ya68{bottom:418.098933pt;}
.ycf4{bottom:418.099333pt;}
.y110e{bottom:418.147000pt;}
.y1317{bottom:418.175533pt;}
.y4c5{bottom:418.281600pt;}
.y11cf{bottom:418.312667pt;}
.y2f3{bottom:418.966933pt;}
.ydbd{bottom:419.059667pt;}
.yd9c{bottom:419.062933pt;}
.ye66{bottom:419.211733pt;}
.y344{bottom:419.211867pt;}
.y12cc{bottom:419.260000pt;}
.yb55{bottom:419.338800pt;}
.y1514{bottom:419.411333pt;}
.y15a4{bottom:419.420267pt;}
.y64a{bottom:419.712133pt;}
.y6db{bottom:419.797133pt;}
.y139e{bottom:419.917333pt;}
.ydc{bottom:420.102000pt;}
.yd00{bottom:420.314133pt;}
.y10ae{bottom:420.461200pt;}
.y117b{bottom:420.753067pt;}
.y2e7{bottom:420.832600pt;}
.y5c0{bottom:420.978200pt;}
.y13bd{bottom:420.994533pt;}
.yf47{bottom:421.177267pt;}
.yd19{bottom:421.227467pt;}
.y486{bottom:421.227867pt;}
.y7ec{bottom:421.275600pt;}
.y334{bottom:421.587067pt;}
.y128c{bottom:421.677600pt;}
.y5d6{bottom:422.017867pt;}
.y1e0{bottom:422.379600pt;}
.y118{bottom:422.539467pt;}
.y440{bottom:422.539867pt;}
.y602{bottom:422.580533pt;}
.y4fc{bottom:422.687667pt;}
.y14{bottom:422.761067pt;}
.ydd{bottom:422.768533pt;}
.ydb{bottom:422.773067pt;}
.y86a{bottom:422.836000pt;}
.yeec{bottom:423.009867pt;}
.yb43{bottom:423.097333pt;}
.y3b6{bottom:423.299200pt;}
.y790{bottom:423.380533pt;}
.y3b5{bottom:423.401200pt;}
.ya26{bottom:423.442800pt;}
.y15cc{bottom:423.453200pt;}
.yb6d{bottom:423.569733pt;}
.yc82{bottom:423.642267pt;}
.yb81{bottom:423.671200pt;}
.y8e{bottom:423.681467pt;}
.y50a{bottom:423.840000pt;}
.y88e{bottom:424.068267pt;}
.yaf{bottom:424.093200pt;}
.y663{bottom:424.104133pt;}
.y4d1{bottom:424.123733pt;}
.y13fc{bottom:424.141867pt;}
.ybbd{bottom:424.373867pt;}
.y2a8{bottom:424.675200pt;}
.ycd4{bottom:424.682667pt;}
.y1b5{bottom:424.794667pt;}
.yb15{bottom:425.175200pt;}
.y5a3{bottom:425.206933pt;}
.y8a4{bottom:425.225467pt;}
.yf7b{bottom:425.225867pt;}
.yf23{bottom:425.333200pt;}
.yc1e{bottom:425.392533pt;}
.y53a{bottom:425.466133pt;}
.y9aa{bottom:425.606400pt;}
.yfaf{bottom:425.654533pt;}
.y12b7{bottom:425.658800pt;}
.y1325{bottom:425.733733pt;}
.y11eb{bottom:425.773057pt;}
.y562{bottom:425.777200pt;}
.ya34{bottom:426.134267pt;}
.y10dc{bottom:426.231600pt;}
.y457{bottom:426.319467pt;}
.y12a3{bottom:426.319733pt;}
.y41{bottom:426.382000pt;}
.yd91{bottom:426.617867pt;}
.y152d{bottom:426.771200pt;}
.y13d{bottom:426.818933pt;}
.yd4e{bottom:426.825333pt;}
.y550{bottom:426.990733pt;}
.y1215{bottom:427.218533pt;}
.y96a{bottom:427.222267pt;}
.y71c{bottom:427.248533pt;}
.y148a{bottom:427.421733pt;}
.y14db{bottom:427.475533pt;}
.y13e0{bottom:427.486800pt;}
.y1136{bottom:427.533667pt;}
.y9ef{bottom:427.873200pt;}
.y221{bottom:427.921333pt;}
.y617{bottom:428.356533pt;}
.y378{bottom:428.533467pt;}
.y282{bottom:428.553200pt;}
.y149c{bottom:428.786533pt;}
.y411{bottom:428.841133pt;}
.y138b{bottom:428.992133pt;}
.y175{bottom:429.026400pt;}
.y10a3{bottom:429.417333pt;}
.ye97{bottom:429.496133pt;}
.y3c7{bottom:429.525200pt;}
.y1473{bottom:429.702000pt;}
.y582{bottom:429.889733pt;}
.y133c{bottom:430.117467pt;}
.y4fa{bottom:430.354000pt;}
.y23c{bottom:430.789467pt;}
.y1423{bottom:431.002533pt;}
.y693{bottom:431.200667pt;}
.y6b2{bottom:431.233333pt;}
.ybf7{bottom:431.652800pt;}
.y26a{bottom:431.925600pt;}
.y3e5{bottom:432.025067pt;}
.ye01{bottom:432.040000pt;}
.yf9{bottom:432.354133pt;}
.y7d2{bottom:432.585067pt;}
.y158c{bottom:432.765600pt;}
.ydcd{bottom:432.784533pt;}
.y8e0{bottom:433.213200pt;}
.y8c2{bottom:433.215867pt;}
.y1161{bottom:433.217067pt;}
.yc45{bottom:433.217600pt;}
.y1547{bottom:433.218533pt;}
.y932{bottom:433.419467pt;}
.y1064{bottom:433.465733pt;}
.y369{bottom:433.603400pt;}
.y6ef{bottom:433.716933pt;}
.ye4e{bottom:433.878400pt;}
.yaf6{bottom:434.160800pt;}
.yecf{bottom:434.176067pt;}
.yad3{bottom:434.203200pt;}
.y738{bottom:434.329867pt;}
.y1441{bottom:434.384400pt;}
.ya91{bottom:434.908400pt;}
.y472{bottom:434.979200pt;}
.y670{bottom:434.980267pt;}
.yefd{bottom:434.980800pt;}
.y830{bottom:435.028933pt;}
.y12e3{bottom:435.046267pt;}
.yd73{bottom:435.060200pt;}
.y6da{bottom:435.130133pt;}
.y136c{bottom:435.231067pt;}
.y15a3{bottom:435.420800pt;}
.yca4{bottom:435.432267pt;}
.ycf3{bottom:435.432667pt;}
.y81b{bottom:435.465133pt;}
.y110d{bottom:435.480400pt;}
.y4c4{bottom:435.504800pt;}
.y13{bottom:435.561067pt;}
.y1575{bottom:435.642267pt;}
.yf63{bottom:435.917867pt;}
.y1ff{bottom:436.094133pt;}
.y5bf{bottom:436.311200pt;}
.y14fd{bottom:436.343200pt;}
.yf46{bottom:436.510267pt;}
.y15c{bottom:436.544667pt;}
.y343{bottom:436.545200pt;}
.y1513{bottom:436.744667pt;}
.y117a{bottom:436.753600pt;}
.y333{bottom:436.920067pt;}
.y649{bottom:437.045467pt;}
.ycff{bottom:437.647467pt;}
.y601{bottom:437.913533pt;}
.y4fb{bottom:438.020667pt;}
.y869{bottom:438.169000pt;}
.y13bc{bottom:438.327867pt;}
.y66{bottom:438.410400pt;}
.y912{bottom:438.558800pt;}
.yd18{bottom:438.560800pt;}
.y2c6{bottom:438.561200pt;}
.y7eb{bottom:438.608933pt;}
.y985{bottom:438.859333pt;}
.y2f2{bottom:438.966400pt;}
.y128b{bottom:439.010933pt;}
.y509{bottom:439.173000pt;}
.ya67{bottom:439.211733pt;}
.y5d5{bottom:439.351200pt;}
.y15cb{bottom:439.453200pt;}
.y1df{bottom:439.712933pt;}
.y117{bottom:439.872800pt;}
.y43f{bottom:439.873200pt;}
.y2e6{bottom:439.945333pt;}
.y1301{bottom:440.096933pt;}
.yeeb{bottom:440.343200pt;}
.y11ae{bottom:440.447970pt;}
.ya25{bottom:440.776133pt;}
.y539{bottom:440.799133pt;}
.yb6c{bottom:440.903067pt;}
.yb80{bottom:441.004533pt;}
.y8d{bottom:441.014800pt;}
.yae{bottom:441.426533pt;}
.y662{bottom:441.437467pt;}
.y4d0{bottom:441.457067pt;}
.y1452{bottom:441.475200pt;}
.y10ad{bottom:441.574133pt;}
.ybbc{bottom:441.707200pt;}
.y1324{bottom:441.734267pt;}
.yde3{bottom:441.798400pt;}
.y1352{bottom:441.937467pt;}
.y2a7{bottom:442.008533pt;}
.ycd3{bottom:442.016000pt;}
.y54f{bottom:442.323733pt;}
.yb14{bottom:442.508533pt;}
.yeb4{bottom:442.539867pt;}
.y5a2{bottom:442.540267pt;}
.y8a3{bottom:442.558800pt;}
.yd90{bottom:442.618400pt;}
.yd9b{bottom:442.621667pt;}
.yf22{bottom:442.666533pt;}
.y3b4{bottom:442.673333pt;}
.yc1d{bottom:442.725867pt;}
.y1135{bottom:442.866667pt;}
.y1132{bottom:442.866733pt;}
.y9a9{bottom:442.939733pt;}
.yfae{bottom:442.987867pt;}
.y12b6{bottom:442.992133pt;}
.y561{bottom:443.110533pt;}
.y819{bottom:443.131467pt;}
.y1214{bottom:443.218133pt;}
.ya33{bottom:443.467600pt;}
.y139d{bottom:443.476067pt;}
.y456{bottom:443.652800pt;}
.y12a2{bottom:443.653067pt;}
.y10f7{bottom:444.032400pt;}
.y152c{bottom:444.104533pt;}
.y13c{bottom:444.152267pt;}
.yd4d{bottom:444.158667pt;}
.y969{bottom:444.555600pt;}
.y71b{bottom:444.581867pt;}
.y3b1{bottom:444.753200pt;}
.y1489{bottom:444.755067pt;}
.y13df{bottom:444.820133pt;}
.y9ee{bottom:445.206533pt;}
.y3b2{bottom:445.206667pt;}
.y220{bottom:445.254667pt;}
.y616{bottom:445.689867pt;}
.y377{bottom:445.866800pt;}
.y281{bottom:445.886533pt;}
.y9d0{bottom:446.119867pt;}
.y7b2{bottom:446.239867pt;}
.y138a{bottom:446.325467pt;}
.y174{bottom:446.359733pt;}
.yca{bottom:446.770533pt;}
.ye96{bottom:446.829467pt;}
.y3c6{bottom:446.858533pt;}
.y1044{bottom:447.021067pt;}
.y1472{bottom:447.035333pt;}
.y10db{bottom:447.344533pt;}
.y133b{bottom:447.450800pt;}
.y424{bottom:447.551867pt;}
.yda{bottom:447.665067pt;}
.y581{bottom:447.779067pt;}
.y410{bottom:447.953867pt;}
.y23b{bottom:448.122800pt;}
.y1422{bottom:448.335867pt;}
.y11ad{bottom:448.353333pt;}
.y12{bottom:448.361067pt;}
.y692{bottom:448.534000pt;}
.y6b1{bottom:448.566667pt;}
.yaa8{bottom:448.775200pt;}
.y368{bottom:448.936400pt;}
.ybf6{bottom:448.986133pt;}
.y3b3{bottom:449.006800pt;}
.y13fb{bottom:449.034267pt;}
.y3e4{bottom:449.358400pt;}
.ye00{bottom:449.373333pt;}
.y1063{bottom:449.465333pt;}
.yf8{bottom:449.687467pt;}
.y7d1{bottom:449.918400pt;}
.y158b{bottom:450.098933pt;}
.ydcc{bottom:450.117867pt;}
.yece{bottom:450.176600pt;}
.y6d9{bottom:450.463133pt;}
.y8df{bottom:450.546533pt;}
.y8c1{bottom:450.549200pt;}
.y1160{bottom:450.550400pt;}
.yc44{bottom:450.550933pt;}
.y1546{bottom:450.551867pt;}
.y81a{bottom:450.798133pt;}
.y269{bottom:450.968067pt;}
.y6ee{bottom:451.050267pt;}
.yd72{bottom:451.060733pt;}
.ye4d{bottom:451.211733pt;}
.y15a2{bottom:451.421333pt;}
.yad2{bottom:451.536533pt;}
.y10c5{bottom:451.570000pt;}
.y5be{bottom:451.644200pt;}
.y737{bottom:451.663200pt;}
.y12cb{bottom:451.711333pt;}
.y1440{bottom:451.717733pt;}
.yb54{bottom:451.790267pt;}
.y1a6{bottom:451.902267pt;}
.yf62{bottom:451.918400pt;}
.ya90{bottom:452.241733pt;}
.y332{bottom:452.253067pt;}
.y82f{bottom:452.362267pt;}
.y12e2{bottom:452.379600pt;}
.y136b{bottom:452.564400pt;}
.y4c3{bottom:452.727867pt;}
.y1179{bottom:452.754133pt;}
.yba3{bottom:452.765600pt;}
.ycf2{bottom:452.766000pt;}
.y600{bottom:453.246533pt;}
.y1fe{bottom:453.427467pt;}
.y868{bottom:453.502000pt;}
.y14fc{bottom:453.676533pt;}
.y342{bottom:453.878533pt;}
.y648{bottom:454.378800pt;}
.y40{bottom:454.389333pt;}
.y65{bottom:454.410000pt;}
.y508{bottom:454.506000pt;}
.ycfe{bottom:454.980800pt;}
.y1008{bottom:454.991333pt;}
.yaf5{bottom:455.273600pt;}
.y2e5{bottom:455.278333pt;}
.y15ca{bottom:455.453200pt;}
.yf45{bottom:455.623000pt;}
.y13bb{bottom:455.661200pt;}
.y911{bottom:455.892133pt;}
.yd17{bottom:455.894133pt;}
.y2c5{bottom:455.894533pt;}
.y7ea{bottom:455.942267pt;}
.y984{bottom:456.192667pt;}
.y128a{bottom:456.344267pt;}
.y983{bottom:456.392667pt;}
.y5d4{bottom:456.684533pt;}
.y1de{bottom:457.046267pt;}
.y800{bottom:457.206533pt;}
.y54e{bottom:457.656733pt;}
.y15b{bottom:457.658000pt;}
.yeea{bottom:457.676533pt;}
.y1323{bottom:457.734800pt;}
.yde2{bottom:457.798000pt;}
.ya24{bottom:458.109467pt;}
.y4ed{bottom:458.110533pt;}
.y931{bottom:458.311467pt;}
.yb7f{bottom:458.337867pt;}
.y8c{bottom:458.348133pt;}
.yd8f{bottom:458.618933pt;}
.yd9a{bottom:458.622200pt;}
.y267{bottom:458.634400pt;}
.yad{bottom:458.759867pt;}
.y661{bottom:458.770800pt;}
.y4cf{bottom:458.790400pt;}
.ybbb{bottom:459.040533pt;}
.y1213{bottom:459.217733pt;}
.y1212{bottom:459.218000pt;}
.y1351{bottom:459.270800pt;}
.y2a6{bottom:459.341867pt;}
.ycd2{bottom:459.349333pt;}
.y139c{bottom:459.476600pt;}
.y78e{bottom:459.611467pt;}
.yb13{bottom:459.841867pt;}
.yeb3{bottom:459.873200pt;}
.y8a2{bottom:459.892133pt;}
.y538{bottom:459.911867pt;}
.yc1c{bottom:460.059200pt;}
.y12b5{bottom:460.325467pt;}
.ya32{bottom:460.800933pt;}
.y116{bottom:460.986133pt;}
.y12a1{bottom:460.986400pt;}
.y11{bottom:461.161067pt;}
.y10f6{bottom:461.365733pt;}
.y152b{bottom:461.437867pt;}
.y13b{bottom:461.485600pt;}
.yd4c{bottom:461.492000pt;}
.y88d{bottom:461.853200pt;}
.y968{bottom:461.888933pt;}
.y71a{bottom:461.915200pt;}
.y1131{bottom:461.979467pt;}
.yb6b{bottom:462.016000pt;}
.y1488{bottom:462.088400pt;}
.y13de{bottom:462.153467pt;}
.y9ed{bottom:462.539867pt;}
.y21f{bottom:462.588000pt;}
.y615{bottom:463.023200pt;}
.y376{bottom:463.200133pt;}
.y40f{bottom:463.286867pt;}
.y9cf{bottom:463.453200pt;}
.y11ea{bottom:463.517379pt;}
.y7b1{bottom:463.573200pt;}
.y1389{bottom:463.658800pt;}
.y173{bottom:463.693067pt;}
.yf21{bottom:463.779867pt;}
.y9a8{bottom:464.052667pt;}
.yfad{bottom:464.101200pt;}
.yc9{bottom:464.103867pt;}
.y78b{bottom:464.137467pt;}
.ye95{bottom:464.162800pt;}
.y3c5{bottom:464.191867pt;}
.y560{bottom:464.223867pt;}
.y78f{bottom:464.278133pt;}
.y1043{bottom:464.354400pt;}
.y1471{bottom:464.368667pt;}
.y43e{bottom:464.765600pt;}
.y133a{bottom:464.784133pt;}
.y23a{bottom:465.456133pt;}
.y1062{bottom:465.464933pt;}
.ye65{bottom:465.667867pt;}
.y1421{bottom:465.669200pt;}
.y6d7{bottom:465.796133pt;}
.y691{bottom:465.867333pt;}
.ybda{bottom:465.868000pt;}
.y6b0{bottom:465.900000pt;}
.ye3f{bottom:466.058800pt;}
.yaa7{bottom:466.108533pt;}
.yecd{bottom:466.177133pt;}
.y3b0{bottom:466.207200pt;}
.y268{bottom:466.301067pt;}
.ybf5{bottom:466.319467pt;}
.y1451{bottom:466.367600pt;}
.y3e3{bottom:466.691733pt;}
.y5bd{bottom:466.977200pt;}
.y14da{bottom:467.034800pt;}
.yd71{bottom:467.061267pt;}
.y7d0{bottom:467.251733pt;}
.y471{bottom:467.431200pt;}
.y5a1{bottom:467.432267pt;}
.ydcb{bottom:467.451200pt;}
.y10c4{bottom:467.569600pt;}
.y331{bottom:467.586400pt;}
.y8c0{bottom:467.882533pt;}
.y140e{bottom:467.883733pt;}
.yc43{bottom:467.884267pt;}
.y1545{bottom:467.885200pt;}
.y6ed{bottom:468.383600pt;}
.ye4c{bottom:468.545067pt;}
.y5ff{bottom:468.579533pt;}
.yad1{bottom:468.869867pt;}
.y736{bottom:468.996533pt;}
.y12ca{bottom:469.044667pt;}
.y1a5{bottom:469.235600pt;}
.ya8f{bottom:469.575067pt;}
.y6d8{bottom:469.596133pt;}
.y82e{bottom:469.695600pt;}
.y12e1{bottom:469.712933pt;}
.y507{bottom:469.839000pt;}
.y4c2{bottom:469.951133pt;}
.yba2{bottom:470.098933pt;}
.ycf1{bottom:470.099333pt;}
.y3f{bottom:470.388933pt;}
.y64{bottom:470.409600pt;}
.y867{bottom:470.422867pt;}
.yd16{bottom:470.560933pt;}
.y2e4{bottom:470.611333pt;}
.y1fd{bottom:470.760800pt;}
.y818{bottom:470.781200pt;}
.yf44{bottom:470.956000pt;}
.y14fb{bottom:471.009867pt;}
.y341{bottom:471.211867pt;}
.y1b4{bottom:471.251733pt;}
.y11e9{bottom:471.422050pt;}
.y15c9{bottom:471.453200pt;}
.y365{bottom:471.582200pt;}
.ye40{bottom:471.583451pt;}
.y15eb{bottom:471.653200pt;}
.y8de{bottom:471.659867pt;}
.y110c{bottom:471.711333pt;}
.y647{bottom:471.712133pt;}
.ycfd{bottom:472.314133pt;}
.y1300{bottom:472.548400pt;}
.yd9{bottom:472.557067pt;}
.y1512{bottom:472.975600pt;}
.y54d{bottom:472.989733pt;}
.y910{bottom:473.225467pt;}
.yd15{bottom:473.227467pt;}
.y2c4{bottom:473.227867pt;}
.y7e9{bottom:473.275600pt;}
.y1289{bottom:473.677600pt;}
.y1316{bottom:473.735333pt;}
.y5d3{bottom:474.017867pt;}
.y1dd{bottom:474.379600pt;}
.y7ff{bottom:474.539867pt;}
.y580{bottom:474.561733pt;}
.yf7{bottom:474.579467pt;}
.ydbc{bottom:474.619467pt;}
.yd99{bottom:474.622733pt;}
.y15a1{bottom:474.980067pt;}
.yee9{bottom:475.009867pt;}
.y537{bottom:475.244867pt;}
.ya23{bottom:475.442800pt;}
.ya66{bottom:475.442933pt;}
.y4ec{bottom:475.443867pt;}
.yf61{bottom:475.477133pt;}
.yb7e{bottom:475.671200pt;}
.y660{bottom:476.104133pt;}
.y4ce{bottom:476.123733pt;}
.y1178{bottom:476.312867pt;}
.ybba{bottom:476.373867pt;}
.y1350{bottom:476.604133pt;}
.y143f{bottom:476.610133pt;}
.y2a5{bottom:476.675200pt;}
.yb12{bottom:477.175200pt;}
.yeb2{bottom:477.206533pt;}
.y982{bottom:477.305467pt;}
.yc1b{bottom:477.392533pt;}
.y136a{bottom:477.456400pt;}
.y930{bottom:477.534133pt;}
.y865{bottom:478.089200pt;}
.ya31{bottom:478.134267pt;}
.y115{bottom:478.319467pt;}
.y10f5{bottom:478.699067pt;}
.y15a{bottom:478.770800pt;}
.y152a{bottom:478.771200pt;}
.y139{bottom:478.818933pt;}
.y1211{bottom:478.997200pt;}
.y967{bottom:479.222267pt;}
.y719{bottom:479.248533pt;}
.y11e8{bottom:479.326721pt;}
.y1487{bottom:479.421733pt;}
.y78a{bottom:479.470800pt;}
.y9ec{bottom:479.873200pt;}
.y21e{bottom:479.921333pt;}
.yfcc{bottom:480.104267pt;}
.y614{bottom:480.356533pt;}
.y375{bottom:480.533467pt;}
.y13ba{bottom:480.553200pt;}
.yee4{bottom:480.594267pt;}
.y9ce{bottom:480.786533pt;}
.y7b0{bottom:480.906533pt;}
.y1388{bottom:480.992133pt;}
.y172{bottom:481.026400pt;}
.yf20{bottom:481.113200pt;}
.yefc{bottom:481.435867pt;}
.yc8{bottom:481.437200pt;}
.y13fa{bottom:481.485600pt;}
.ye94{bottom:481.496133pt;}
.y10{bottom:481.520533pt;}
.y3c4{bottom:481.525200pt;}
.y1042{bottom:481.687733pt;}
.y1470{bottom:481.702000pt;}
.y280{bottom:482.117467pt;}
.yd8e{bottom:482.177667pt;}
.yd4b{bottom:482.604933pt;}
.y239{bottom:482.789467pt;}
.ye64{bottom:483.001200pt;}
.y1420{bottom:483.002533pt;}
.y14d9{bottom:483.035333pt;}
.y6af{bottom:483.233333pt;}
.y1130{bottom:483.437867pt;}
.yaa6{bottom:483.441867pt;}
.y13a{bottom:483.485733pt;}
.ybf4{bottom:483.652800pt;}
.y5fe{bottom:483.912533pt;}
.y3e2{bottom:484.025067pt;}
.y6d6{bottom:484.238933pt;}
.ycd1{bottom:484.241733pt;}
.y7cf{bottom:484.585067pt;}
.y470{bottom:484.764533pt;}
.y5a0{bottom:484.765600pt;}
.y8a1{bottom:484.784133pt;}
.ydca{bottom:484.784533pt;}
.yfac{bottom:485.214533pt;}
.y8bf{bottom:485.215867pt;}
.y140d{bottom:485.217067pt;}
.y12b4{bottom:485.217467pt;}
.yc42{bottom:485.217600pt;}
.y1544{bottom:485.218533pt;}
.y10ac{bottom:485.364133pt;}
.y2f1{bottom:485.423067pt;}
.y6ec{bottom:485.716933pt;}
.y866{bottom:485.755867pt;}
.ye4b{bottom:485.878400pt;}
.y2e3{bottom:485.944333pt;}
.y5bc{bottom:486.089933pt;}
.y40e{bottom:486.179333pt;}
.yad0{bottom:486.203200pt;}
.yf43{bottom:486.289000pt;}
.y735{bottom:486.329867pt;}
.y12c9{bottom:486.378000pt;}
.y3e{bottom:486.388533pt;}
.y63{bottom:486.409200pt;}
.y1a4{bottom:486.568933pt;}
.ya8e{bottom:486.908400pt;}
.y367{bottom:486.914667pt;}
.y364{bottom:486.915200pt;}
.y690{bottom:486.980667pt;}
.y8b{bottom:487.020133pt;}
.y13dd{bottom:487.045867pt;}
.y12e0{bottom:487.046267pt;}
.y108b{bottom:487.303200pt;}
.ydf5{bottom:487.417333pt;}
.yac{bottom:487.431867pt;}
.yc81{bottom:487.432267pt;}
.ycf0{bottom:487.432667pt;}
.y15c8{bottom:487.453200pt;}
.y3af{bottom:487.609200pt;}
.yd13{bottom:487.894267pt;}
.y266{bottom:487.931600pt;}
.y1fc{bottom:488.094133pt;}
.y817{bottom:488.114533pt;}
.y54c{bottom:488.322733pt;}
.y14fa{bottom:488.343200pt;}
.y2f0{bottom:488.423067pt;}
.y340{bottom:488.545200pt;}
.y1b3{bottom:488.585067pt;}
.y8dd{bottom:488.993200pt;}
.y4c1{bottom:489.063867pt;}
.yecc{bottom:489.735867pt;}
.y12ff{bottom:489.881733pt;}
.yd8{bottom:489.890400pt;}
.y330{bottom:490.478800pt;}
.y90f{bottom:490.558800pt;}
.yd14{bottom:490.560800pt;}
.y2c3{bottom:490.561200pt;}
.y7e8{bottom:490.608933pt;}
.yd70{bottom:490.620000pt;}
.y506{bottom:490.841600pt;}
.y15a0{bottom:490.980600pt;}
.y1288{bottom:491.010933pt;}
.y10da{bottom:491.134533pt;}
.yba1{bottom:491.211733pt;}
.y1007{bottom:491.222267pt;}
.y5d2{bottom:491.351200pt;}
.yf60{bottom:491.477667pt;}
.yaf4{bottom:491.504533pt;}
.y1dc{bottom:491.712933pt;}
.y1574{bottom:491.873200pt;}
.yf6{bottom:491.912800pt;}
.y1177{bottom:492.313400pt;}
.yee8{bottom:492.343200pt;}
.y57f{bottom:492.451067pt;}
.ya22{bottom:492.776133pt;}
.ya65{bottom:492.776267pt;}
.yb7d{bottom:493.004533pt;}
.y65f{bottom:493.437467pt;}
.y4cd{bottom:493.457067pt;}
.ybb9{bottom:493.707200pt;}
.y134f{bottom:493.937467pt;}
.y2a4{bottom:494.008533pt;}
.y3ac{bottom:494.275467pt;}
.yf{bottom:494.320533pt;}
.y536{bottom:494.357600pt;}
.yb11{bottom:494.508533pt;}
.yeb1{bottom:494.539867pt;}
.yc1a{bottom:494.725867pt;}
.y1369{bottom:494.789733pt;}
.y126f{bottom:494.991333pt;}
.ya30{bottom:495.467600pt;}
.y10d9{bottom:495.554133pt;}
.y114{bottom:495.652800pt;}
.y1529{bottom:496.104533pt;}
.y138{bottom:496.152267pt;}
.y966{bottom:496.555600pt;}
.y718{bottom:496.581867pt;}
.y646{bottom:496.604133pt;}
.y1486{bottom:496.755067pt;}
.y92f{bottom:496.756800pt;}
.y1267{bottom:497.090400pt;}
.y9eb{bottom:497.206533pt;}
.y21d{bottom:497.254667pt;}
.y613{bottom:497.689867pt;}
.y374{bottom:497.866800pt;}
.y13b9{bottom:497.886533pt;}
.y9cd{bottom:498.119867pt;}
.yd8d{bottom:498.178200pt;}
.yd98{bottom:498.181467pt;}
.y7af{bottom:498.239867pt;}
.yb53{bottom:498.246933pt;}
.ybd9{bottom:498.319467pt;}
.y1387{bottom:498.325467pt;}
.y171{bottom:498.359733pt;}
.yf1f{bottom:498.446533pt;}
.y789{bottom:498.584133pt;}
.yefb{bottom:498.769200pt;}
.yc7{bottom:498.770533pt;}
.y13f9{bottom:498.818933pt;}
.ye93{bottom:498.829467pt;}
.y3c3{bottom:498.858533pt;}
.y1041{bottom:499.021067pt;}
.y139b{bottom:499.035867pt;}
.y5fd{bottom:499.245533pt;}
.y7fe{bottom:499.432267pt;}
.y6d5{bottom:499.571933pt;}
.y88c{bottom:499.638133pt;}
.y159{bottom:499.883733pt;}
.y238{bottom:500.122800pt;}
.y9a7{bottom:500.283200pt;}
.y1154{bottom:500.335067pt;}
.y196{bottom:500.335867pt;}
.y55f{bottom:500.454533pt;}
.yaa5{bottom:500.775200pt;}
.y3ae{bottom:500.942133pt;}
.ybf3{bottom:500.986133pt;}
.y1339{bottom:501.015600pt;}
.y3e1{bottom:501.358400pt;}
.y5bb{bottom:501.422933pt;}
.ydff{bottom:501.604267pt;}
.y7ce{bottom:501.918400pt;}
.y46f{bottom:502.097867pt;}
.y59f{bottom:502.098933pt;}
.y8a0{bottom:502.117467pt;}
.ydc9{bottom:502.117867pt;}
.y40d{bottom:502.179867pt;}
.y3d{bottom:502.388133pt;}
.y62{bottom:502.408800pt;}
.y2ef{bottom:502.535867pt;}
.y8be{bottom:502.549200pt;}
.y1146{bottom:502.550400pt;}
.y112f{bottom:502.550600pt;}
.y12b3{bottom:502.550800pt;}
.yc41{bottom:502.550933pt;}
.y6eb{bottom:503.050267pt;}
.ye4a{bottom:503.211733pt;}
.y15c7{bottom:503.453200pt;}
.yacf{bottom:503.536533pt;}
.y10f4{bottom:503.591067pt;}
.y15ee{bottom:503.653200pt;}
.y43d{bottom:503.663200pt;}
.y12c8{bottom:503.711333pt;}
.y1a3{bottom:503.902267pt;}
.ye63{bottom:504.114533pt;}
.y110b{bottom:504.162800pt;}
.ya8d{bottom:504.241733pt;}
.y6ae{bottom:504.346667pt;}
.y8a{bottom:504.353467pt;}
.yab{bottom:504.765200pt;}
.yc80{bottom:504.765600pt;}
.ycef{bottom:504.766000pt;}
.y2e2{bottom:505.057067pt;}
.ydfe{bottom:505.104400pt;}
.y1088{bottom:505.143467pt;}
.y85a{bottom:505.264933pt;}
.y1fb{bottom:505.427467pt;}
.y2ee{bottom:505.535867pt;}
.y14f9{bottom:505.676533pt;}
.yecb{bottom:505.736400pt;}
.y1268{bottom:505.749467pt;}
.y33f{bottom:505.878533pt;}
.y1b2{bottom:505.918400pt;}
.y82d{bottom:505.927200pt;}
.ydfc{bottom:505.929867pt;}
.y363{bottom:506.027933pt;}
.yfab{bottom:506.327867pt;}
.y10d8{bottom:506.386667pt;}
.y14d8{bottom:506.594067pt;}
.y146f{bottom:506.594400pt;}
.yd6f{bottom:506.620533pt;}
.y11a6{bottom:507.009867pt;}
.ye{bottom:507.120533pt;}
.y12fe{bottom:507.215067pt;}
.y54b{bottom:507.435467pt;}
.yf5f{bottom:507.478200pt;}
.y90e{bottom:507.892133pt;}
.y2c2{bottom:507.894533pt;}
.y7e7{bottom:507.942267pt;}
.y505{bottom:508.174667pt;}
.y4c0{bottom:508.179667pt;}
.y5d1{bottom:508.684533pt;}
.yaf3{bottom:508.837867pt;}
.y143e{bottom:509.062400pt;}
.yf42{bottom:509.181467pt;}
.y1573{bottom:509.206533pt;}
.yf5{bottom:509.246133pt;}
.y32f{bottom:509.592733pt;}
.yee7{bottom:509.676533pt;}
.y535{bottom:509.690600pt;}
.y981{bottom:509.756533pt;}
.y8dc{bottom:510.106533pt;}
.ya21{bottom:510.109467pt;}
.ya64{bottom:510.109600pt;}
.y1543{bottom:510.110533pt;}
.yb7c{bottom:510.337867pt;}
.y57e{bottom:510.340400pt;}
.y75e{bottom:510.608933pt;}
.y65e{bottom:510.770800pt;}
.y4cc{bottom:510.790400pt;}
.y1006{bottom:511.222267pt;}
.y134e{bottom:511.270800pt;}
.y2a3{bottom:511.341867pt;}
.yeb0{bottom:511.873200pt;}
.y12df{bottom:511.938267pt;}
.yc19{bottom:512.059200pt;}
.y1368{bottom:512.123067pt;}
.y455{bottom:512.986133pt;}
.y1528{bottom:513.437867pt;}
.y137{bottom:513.485600pt;}
.y965{bottom:513.888933pt;}
.y717{bottom:513.915200pt;}
.y788{bottom:513.917467pt;}
.y645{bottom:513.937467pt;}
.yd8c{bottom:514.178733pt;}
.yd97{bottom:514.182000pt;}
.y159f{bottom:514.539333pt;}
.yd7{bottom:514.782400pt;}
.y6d4{bottom:514.904933pt;}
.y139a{bottom:515.036400pt;}
.y373{bottom:515.200133pt;}
.y423{bottom:515.341867pt;}
.y9cc{bottom:515.453200pt;}
.y7ae{bottom:515.573200pt;}
.yb52{bottom:515.580267pt;}
.y170{bottom:515.693067pt;}
.yf1e{bottom:515.779867pt;}
.y1176{bottom:515.872133pt;}
.y1287{bottom:515.902933pt;}
.y10c3{bottom:515.929333pt;}
.yefa{bottom:516.102533pt;}
.yc6{bottom:516.103867pt;}
.y13f8{bottom:516.152267pt;}
.ye92{bottom:516.162800pt;}
.y3c2{bottom:516.191867pt;}
.y1040{bottom:516.354400pt;}
.y1db{bottom:516.604933pt;}
.y5ba{bottom:516.755933pt;}
.y158a{bottom:516.765600pt;}
.y158{bottom:517.217067pt;}
.y10d7{bottom:517.219333pt;}
.ycbe{bottom:517.265200pt;}
.y237{bottom:517.456133pt;}
.y9a6{bottom:517.616533pt;}
.y195{bottom:517.669200pt;}
.y55e{bottom:517.787867pt;}
.y112e{bottom:517.883600pt;}
.yd96{bottom:517.982000pt;}
.yaa4{bottom:518.108533pt;}
.y9ea{bottom:518.319467pt;}
.y3c{bottom:518.387733pt;}
.y61{bottom:518.408400pt;}
.yd4a{bottom:518.835867pt;}
.y7cd{bottom:519.251733pt;}
.y59e{bottom:519.432267pt;}
.y1386{bottom:519.438800pt;}
.y89f{bottom:519.450800pt;}
.ydc8{bottom:519.451200pt;}
.y15c6{bottom:519.453200pt;}
.y13dc{bottom:519.497733pt;}
.y15e2{bottom:519.653200pt;}
.y8bd{bottom:519.882533pt;}
.y12b2{bottom:519.884133pt;}
.yc40{bottom:519.884267pt;}
.yd{bottom:519.920533pt;}
.y40c{bottom:519.995600pt;}
.ya47{bottom:520.360000pt;}
.y265{bottom:520.383600pt;}
.y2e1{bottom:520.390067pt;}
.y113{bottom:520.545067pt;}
.yace{bottom:520.869867pt;}
.y10f3{bottom:520.924400pt;}
.y43c{bottom:520.996533pt;}
.y1338{bottom:521.015067pt;}
.y12c7{bottom:521.044667pt;}
.y366{bottom:521.360400pt;}
.y362{bottom:521.360933pt;}
.y110a{bottom:521.496133pt;}
.ya8c{bottom:521.575067pt;}
.y92e{bottom:521.648800pt;}
.y89{bottom:521.686800pt;}
.yeca{bottom:521.736933pt;}
.ye2c{bottom:521.899200pt;}
.yaa{bottom:522.098533pt;}
.yc7f{bottom:522.098933pt;}
.ycee{bottom:522.099333pt;}
.y5fc{bottom:522.138000pt;}
.y3ad{bottom:522.343733pt;}
.y612{bottom:522.582267pt;}
.y14d7{bottom:522.594600pt;}
.y859{bottom:522.598267pt;}
.y7a7{bottom:522.721600pt;}
.ydfb{bottom:522.759733pt;}
.y13b8{bottom:522.778933pt;}
.y14f8{bottom:523.009867pt;}
.ycd0{bottom:523.139333pt;}
.y1087{bottom:523.186667pt;}
.y68f{bottom:523.211333pt;}
.y1b1{bottom:523.251733pt;}
.y1145{bottom:523.663200pt;}
.y11a5{bottom:524.343200pt;}
.y1266{bottom:524.354099pt;}
.y12fd{bottom:524.548400pt;}
.y816{bottom:524.786533pt;}
.y32e{bottom:524.925733pt;}
.y30d{bottom:524.925867pt;}
.y30b{bottom:524.926200pt;}
.y90d{bottom:525.225467pt;}
.y2c1{bottom:525.227867pt;}
.y7e6{bottom:525.275600pt;}
.ycfc{bottom:525.878400pt;}
.y82c{bottom:525.926667pt;}
.y504{bottom:525.990267pt;}
.y5d0{bottom:526.017867pt;}
.ybd0{bottom:526.158667pt;}
.yaf2{bottom:526.171200pt;}
.y3e0{bottom:526.250800pt;}
.y10ef{bottom:526.320800pt;}
.y143d{bottom:526.395733pt;}
.y10c2{bottom:526.439067pt;}
.y1572{bottom:526.539867pt;}
.yf4{bottom:526.579467pt;}
.yb26{bottom:526.960000pt;}
.y46e{bottom:526.989867pt;}
.yee6{bottom:527.009867pt;}
.y980{bottom:527.089867pt;}
.y4bf{bottom:527.292400pt;}
.y8db{bottom:527.439867pt;}
.yfaa{bottom:527.441200pt;}
.ya20{bottom:527.442800pt;}
.ya63{bottom:527.442933pt;}
.y126e{bottom:527.443867pt;}
.yb7b{bottom:527.671200pt;}
.y10d6{bottom:527.729067pt;}
.y75d{bottom:527.942267pt;}
.yfcb{bottom:528.104133pt;}
.y4cb{bottom:528.123733pt;}
.y57d{bottom:528.229733pt;}
.y27f{bottom:528.574133pt;}
.y134d{bottom:528.604133pt;}
.y2a2{bottom:528.675200pt;}
.y30c{bottom:528.726000pt;}
.y1a1{bottom:528.795067pt;}
.y534{bottom:528.803333pt;}
.yeaf{bottom:529.206533pt;}
.y787{bottom:529.250800pt;}
.y12de{bottom:529.271600pt;}
.y1315{bottom:529.295133pt;}
.yc18{bottom:529.392533pt;}
.y1367{bottom:529.456400pt;}
.yd6e{bottom:530.179267pt;}
.y1fa{bottom:530.319467pt;}
.y54a{bottom:530.327867pt;}
.y159e{bottom:530.539867pt;}
.y33e{bottom:530.770800pt;}
.y1527{bottom:530.771200pt;}
.yf5e{bottom:531.036933pt;}
.y964{bottom:531.222267pt;}
.y716{bottom:531.248533pt;}
.yf40{bottom:531.262600pt;}
.y644{bottom:531.270800pt;}
.y1175{bottom:531.872667pt;}
.y372{bottom:532.533467pt;}
.y6d3{bottom:532.534133pt;}
.yc{bottom:532.720533pt;}
.y485{bottom:532.786533pt;}
.y7ad{bottom:532.906533pt;}
.yb6a{bottom:532.913600pt;}
.y1485{bottom:532.986133pt;}
.y16f{bottom:533.026400pt;}
.yf1d{bottom:533.113200pt;}
.y1286{bottom:533.236267pt;}
.y1265{bottom:533.247200pt;}
.y1263{bottom:533.247249pt;}
.yc5{bottom:533.437200pt;}
.y1a2{bottom:533.461467pt;}
.y21c{bottom:533.485600pt;}
.ye91{bottom:533.496133pt;}
.y3c1{bottom:533.525200pt;}
.y103f{bottom:533.687733pt;}
.yf41{bottom:534.237333pt;}
.y3b{bottom:534.387333pt;}
.y60{bottom:534.408400pt;}
.y40b{bottom:534.662267pt;}
.y236{bottom:534.789467pt;}
.y9a5{bottom:534.949867pt;}
.y194{bottom:535.002533pt;}
.y55d{bottom:535.121200pt;}
.y1091{bottom:535.258667pt;}
.yaa3{bottom:535.441867pt;}
.y15c5{bottom:535.453200pt;}
.y1264{bottom:535.550533pt;}
.ybf2{bottom:535.652800pt;}
.y65d{bottom:535.663200pt;}
.y1da{bottom:535.827600pt;}
.yd49{bottom:536.169200pt;}
.y848{bottom:536.353733pt;}
.y7cc{bottom:536.585067pt;}
.yb51{bottom:536.693067pt;}
.y59d{bottom:536.765600pt;}
.y1385{bottom:536.772133pt;}
.y89e{bottom:536.784133pt;}
.ydc7{bottom:536.784533pt;}
.y112d{bottom:536.996333pt;}
.y8bc{bottom:537.215867pt;}
.y12b1{bottom:537.217467pt;}
.yc3f{bottom:537.217600pt;}
.y88b{bottom:537.423067pt;}
.y264{bottom:537.716933pt;}
.yd8b{bottom:537.737467pt;}
.ye49{bottom:537.878400pt;}
.y1090{bottom:537.925333pt;}
.y7a6{bottom:538.054600pt;}
.y10f2{bottom:538.257733pt;}
.y157{bottom:538.329867pt;}
.y136{bottom:538.378000pt;}
.y14d6{bottom:538.595133pt;}
.y1109{bottom:538.829467pt;}
.ya8b{bottom:538.908400pt;}
.y88{bottom:539.020133pt;}
.y146e{bottom:539.046400pt;}
.yc7e{bottom:539.432267pt;}
.y13db{bottom:539.497200pt;}
.y2e0{bottom:539.502800pt;}
.y5b9{bottom:539.648400pt;}
.yd6{bottom:539.674400pt;}
.y32d{bottom:540.258733pt;}
.y30a{bottom:540.259200pt;}
.y14f7{bottom:540.343200pt;}
.yccf{bottom:540.472667pt;}
.y361{bottom:540.473667pt;}
.y68e{bottom:540.544667pt;}
.y1b0{bottom:540.585067pt;}
.y503{bottom:540.656933pt;}
.y92d{bottom:540.871467pt;}
.yef9{bottom:540.994533pt;}
.y11a4{bottom:541.676533pt;}
.ye2b{bottom:541.743867pt;}
.y12fc{bottom:541.881733pt;}
.y815{bottom:542.119867pt;}
.y1262{bottom:542.140350pt;}
.y2c0{bottom:542.561200pt;}
.y7e5{bottom:542.608933pt;}
.y4be{bottom:542.625400pt;}
.y143c{bottom:543.729067pt;}
.y1571{bottom:543.873200pt;}
.ydfd{bottom:543.901733pt;}
.yf3{bottom:543.912800pt;}
.y533{bottom:544.136333pt;}
.y39f{bottom:544.324667pt;}
.yee5{bottom:544.343200pt;}
.y97f{bottom:544.423200pt;}
.y8f4{bottom:544.773200pt;}
.yfa9{bottom:544.774533pt;}
.yba0{bottom:544.776133pt;}
.ya62{bottom:544.776267pt;}
.y126d{bottom:544.777200pt;}
.yb7a{bottom:545.004533pt;}
.y75c{bottom:545.275600pt;}
.y1314{bottom:545.295667pt;}
.yfca{bottom:545.437467pt;}
.y4ca{bottom:545.457067pt;}
.y27e{bottom:545.907467pt;}
.y2a1{bottom:546.008533pt;}
.y57c{bottom:546.119067pt;}
.y1a0{bottom:546.128400pt;}
.yd6d{bottom:546.179800pt;}
.yeae{bottom:546.539867pt;}
.yf3f{bottom:546.595600pt;}
.y1366{bottom:546.789733pt;}
.yced{bottom:546.991333pt;}
.yf5d{bottom:547.037467pt;}
.y1f8{bottom:547.652800pt;}
.y6d2{bottom:547.867133pt;}
.y1174{bottom:547.873200pt;}
.ye29{bottom:548.077733pt;}
.y46d{bottom:548.103200pt;}
.y847{bottom:548.143733pt;}
.y786{bottom:548.363600pt;}
.y8da{bottom:548.553200pt;}
.y963{bottom:548.555600pt;}
.y715{bottom:548.581867pt;}
.y643{bottom:548.604133pt;}
.ydfa{bottom:548.841867pt;}
.y371{bottom:549.866800pt;}
.y90c{bottom:550.117467pt;}
.y484{bottom:550.119867pt;}
.yb69{bottom:550.246933pt;}
.y549{bottom:550.331467pt;}
.y3a{bottom:550.387333pt;}
.yf1c{bottom:550.446533pt;}
.y1285{bottom:550.569600pt;}
.ya9{bottom:550.770533pt;}
.y13f7{bottom:550.818933pt;}
.ye90{bottom:550.829467pt;}
.y1234{bottom:550.857554pt;}
.y3c0{bottom:550.858533pt;}
.y5cf{bottom:550.910267pt;}
.y103e{bottom:551.021067pt;}
.y1261{bottom:551.033451pt;}
.y1248{bottom:551.034804pt;}
.y5fb{bottom:551.064200pt;}
.y15c4{bottom:551.453200pt;}
.y235{bottom:552.122800pt;}
.y9a4{bottom:552.283200pt;}
.y1f9{bottom:552.319467pt;}
.y112c{bottom:552.329333pt;}
.yd30{bottom:552.335067pt;}
.y141f{bottom:552.335867pt;}
.y55c{bottom:552.454533pt;}
.yb{bottom:553.080000pt;}
.yae1{bottom:553.321333pt;}
.y7a5{bottom:553.387600pt;}
.ycbd{bottom:553.496133pt;}
.yd48{bottom:553.502533pt;}
.yd8a{bottom:553.738000pt;}
.y7cb{bottom:553.918400pt;}
.y59c{bottom:554.098933pt;}
.y1384{bottom:554.105467pt;}
.y89d{bottom:554.117467pt;}
.yf7a{bottom:554.117867pt;}
.y12dd{bottom:554.164000pt;}
.ye2a{bottom:554.411067pt;}
.y8bb{bottom:554.549200pt;}
.y9e9{bottom:554.549467pt;}
.y1399{bottom:554.595667pt;}
.y2df{bottom:554.835800pt;}
.y6c1{bottom:554.907733pt;}
.y6c0{bottom:555.009733pt;}
.y1d9{bottom:555.050267pt;}
.y454{bottom:555.211733pt;}
.y13b7{bottom:555.230400pt;}
.y10f1{bottom:555.591067pt;}
.y32c{bottom:555.591733pt;}
.y5b8{bottom:555.648933pt;}
.y112{bottom:555.663200pt;}
.y12c6{bottom:555.711333pt;}
.y360{bottom:555.806667pt;}
.y1108{bottom:556.162800pt;}
.ya8a{bottom:556.241733pt;}
.y87{bottom:556.353467pt;}
.ybf1{bottom:556.765600pt;}
.y14f6{bottom:557.676533pt;}
.ydc2{bottom:557.694667pt;}
.y7ac{bottom:557.798533pt;}
.ycce{bottom:557.806000pt;}
.y68d{bottom:557.878000pt;}
.y16e{bottom:557.918400pt;}
.y4bd{bottom:557.958400pt;}
.y1085{bottom:557.962667pt;}
.yef8{bottom:558.327867pt;}
.yaff{bottom:558.622667pt;}
.y11a3{bottom:559.009867pt;}
.y146d{bottom:559.045867pt;}
.y12fb{bottom:559.215067pt;}
.y814{bottom:559.453200pt;}
.y193{bottom:559.894533pt;}
.y7e4{bottom:559.942267pt;}
.y92c{bottom:560.094133pt;}
.yaba{bottom:560.334667pt;}
.yc7d{bottom:560.545067pt;}
.y1570{bottom:561.206533pt;}
.yf2{bottom:561.246133pt;}
.yec9{bottom:561.296200pt;}
.y3df{bottom:561.368800pt;}
.y611{bottom:561.479867pt;}
.ydc6{bottom:561.676533pt;}
.yc30{bottom:561.844000pt;}
.yb9f{bottom:562.109467pt;}
.ya61{bottom:562.109600pt;}
.y126c{bottom:562.110533pt;}
.y14d5{bottom:562.153867pt;}
.yb79{bottom:562.337867pt;}
.y5f{bottom:562.418400pt;}
.y75b{bottom:562.608933pt;}
.ye48{bottom:562.770800pt;}
.y4c9{bottom:562.790400pt;}
.yf5c{bottom:563.038000pt;}
.y309{bottom:563.151600pt;}
.y6d1{bottom:563.200133pt;}
.y27d{bottom:563.240800pt;}
.y532{bottom:563.249067pt;}
.y1086{bottom:563.296000pt;}
.y2a0{bottom:563.341867pt;}
.yead{bottom:563.873200pt;}
.y57b{bottom:564.008400pt;}
.y1365{bottom:564.123067pt;}
.ycec{bottom:564.324667pt;}
.y610{bottom:564.480000pt;}
.yd5{bottom:564.566400pt;}
.y1f7{bottom:564.986133pt;}
.y159d{bottom:565.437467pt;}
.y846{bottom:565.477067pt;}
.y8d9{bottom:565.886533pt;}
.yfa8{bottom:565.887867pt;}
.y962{bottom:565.888933pt;}
.y714{bottom:565.915200pt;}
.y642{bottom:565.937467pt;}
.y5fa{bottom:566.397200pt;}
.y90b{bottom:567.450800pt;}
.y2bf{bottom:567.453200pt;}
.y1337{bottom:567.471867pt;}
.y785{bottom:567.476400pt;}
.yb68{bottom:567.580267pt;}
.yc59{bottom:567.652267pt;}
.yf1b{bottom:567.779867pt;}
.y1284{bottom:567.902933pt;}
.ya8{bottom:568.103867pt;}
.y13f6{bottom:568.152267pt;}
.ye8f{bottom:568.162800pt;}
.y3bf{bottom:568.191867pt;}
.y103d{bottom:568.354400pt;}
.y143b{bottom:568.621067pt;}
.y46c{bottom:569.216533pt;}
.y99a{bottom:569.316000pt;}
.y251{bottom:569.456133pt;}
.y9a3{bottom:569.616533pt;}
.y33d{bottom:569.667867pt;}
.y141e{bottom:569.669200pt;}
.yd6c{bottom:569.738533pt;}
.y55b{bottom:569.787867pt;}
.yfc9{bottom:570.329867pt;}
.y1398{bottom:570.596200pt;}
.ycbc{bottom:570.829467pt;}
.yb33{bottom:570.908267pt;}
.y19f{bottom:571.020400pt;}
.y59b{bottom:571.432267pt;}
.y1383{bottom:571.438800pt;}
.y112b{bottom:571.442067pt;}
.y89c{bottom:571.450800pt;}
.y8ba{bottom:571.882533pt;}
.y9e8{bottom:571.882800pt;}
.y1d8{bottom:572.383600pt;}
.y13b6{bottom:572.563733pt;}
.ye27{bottom:572.646667pt;}
.y7a4{bottom:572.672333pt;}
.yb50{bottom:572.924400pt;}
.y156{bottom:572.996533pt;}
.y12c5{bottom:573.044667pt;}
.y4bc{bottom:573.291400pt;}
.y1107{bottom:573.496133pt;}
.ya89{bottom:573.575067pt;}
.y86{bottom:573.686800pt;}
.y1260{bottom:573.884232pt;}
.yca3{bottom:574.098933pt;}
.y5b6{bottom:574.700400pt;}
.y32b{bottom:574.706867pt;}
.ydf9{bottom:574.925067pt;}
.y14f5{bottom:575.009867pt;}
.y7ab{bottom:575.131867pt;}
.yccd{bottom:575.139333pt;}
.y88a{bottom:575.208000pt;}
.y68c{bottom:575.211333pt;}
.y16d{bottom:575.251733pt;}
.yef7{bottom:575.661200pt;}
.y11a2{bottom:576.343200pt;}
.y6bf{bottom:576.361867pt;}
.y813{bottom:576.786533pt;}
.y192{bottom:577.227867pt;}
.y135{bottom:577.275600pt;}
.yd89{bottom:577.296733pt;}
.y2de{bottom:577.728267pt;}
.y12a0{bottom:577.888933pt;}
.y14d4{bottom:578.154400pt;}
.y39{bottom:578.392933pt;}
.yd47{bottom:578.394933pt;}
.y5e{bottom:578.418000pt;}
.y156f{bottom:578.539867pt;}
.yf1{bottom:578.579467pt;}
.y5b7{bottom:578.700400pt;}
.y7ca{bottom:578.810400pt;}
.ye28{bottom:578.980533pt;}
.ydc5{bottom:579.009867pt;}
.y35f{bottom:579.235067pt;}
.yc4{bottom:579.442533pt;}
.yb9e{bottom:579.442800pt;}
.ya60{bottom:579.442933pt;}
.yb78{bottom:579.671200pt;}
.y21b{bottom:579.942267pt;}
.y7a2{bottom:580.338667pt;}
.y27c{bottom:580.574133pt;}
.y422{bottom:580.675200pt;}
.yeac{bottom:581.206533pt;}
.y1364{bottom:581.456400pt;}
.yceb{bottom:581.658000pt;}
.y57a{bottom:581.897733pt;}
.y308{bottom:582.265867pt;}
.y1f6{bottom:582.319467pt;}
.y6d0{bottom:582.549533pt;}
.y1173{bottom:582.770800pt;}
.y125f{bottom:582.777333pt;}
.y125d{bottom:582.777860pt;}
.y784{bottom:582.809733pt;}
.y845{bottom:582.810400pt;}
.y638{bottom:583.079933pt;}
.y8f3{bottom:583.219867pt;}
.y961{bottom:583.222267pt;}
.y713{bottom:583.248533pt;}
.y641{bottom:583.270800pt;}
.y15c3{bottom:583.453200pt;}
.y530{bottom:583.632467pt;}
.y15ea{bottom:583.653200pt;}
.y4c8{bottom:583.903733pt;}
.y12fa{bottom:584.107467pt;}
.y90a{bottom:584.784133pt;}
.y2be{bottom:584.786533pt;}
.y1336{bottom:584.805200pt;}
.y1322{bottom:584.854933pt;}
.yb67{bottom:584.913600pt;}
.y92b{bottom:584.986133pt;}
.y125e{bottom:585.080667pt;}
.yf1a{bottom:585.113200pt;}
.y1283{bottom:585.236267pt;}
.ye26{bottom:585.313867pt;}
.ya7{bottom:585.437200pt;}
.y13f5{bottom:585.485600pt;}
.ye8e{bottom:585.496133pt;}
.y5f9{bottom:585.512200pt;}
.y3be{bottom:585.525200pt;}
.y103c{bottom:585.687733pt;}
.yd6b{bottom:585.739067pt;}
.y13da{bottom:585.954000pt;}
.y143a{bottom:585.954400pt;}
.yf5b{bottom:586.596733pt;}
.y12dc{bottom:586.615333pt;}
.y112a{bottom:586.775067pt;}
.y8d8{bottom:586.999867pt;}
.y33c{bottom:587.001200pt;}
.y126b{bottom:587.002533pt;}
.yf3c{bottom:587.050267pt;}
.y55a{bottom:587.121200pt;}
.y7a3{bottom:588.005333pt;}
.ycbb{bottom:588.162800pt;}
.y29f{bottom:588.234133pt;}
.y19e{bottom:588.353733pt;}
.y4bb{bottom:588.624400pt;}
.y59a{bottom:588.765600pt;}
.y1382{bottom:588.772133pt;}
.y89b{bottom:588.784133pt;}
.yd4{bottom:589.458400pt;}
.y263{bottom:589.716933pt;}
.y5ce{bottom:589.807867pt;}
.y13b5{bottom:589.897067pt;}
.yb4f{bottom:590.257733pt;}
.y155{bottom:590.329867pt;}
.y12c4{bottom:590.378000pt;}
.y1106{bottom:590.829467pt;}
.y85{bottom:591.020133pt;}
.yca2{bottom:591.432267pt;}
.y1d7{bottom:591.606267pt;}
.y125c{bottom:591.670961pt;}
.y1083{bottom:591.981333pt;}
.y14f4{bottom:592.343200pt;}
.y7aa{bottom:592.465200pt;}
.yccc{bottom:592.472667pt;}
.y68b{bottom:592.544667pt;}
.y16c{bottom:592.585067pt;}
.y5cd{bottom:592.808000pt;}
.yef6{bottom:592.994533pt;}
.y9e7{bottom:592.996133pt;}
.yd88{bottom:593.297267pt;}
.y11a1{bottom:593.676533pt;}
.y32a{bottom:593.819600pt;}
.y812{bottom:594.119867pt;}
.y14d3{bottom:594.154933pt;}
.y38{bottom:594.392533pt;}
.y5d{bottom:594.417600pt;}
.y191{bottom:594.561200pt;}
.y35e{bottom:594.568067pt;}
.y134{bottom:594.608933pt;}
.ya88{bottom:594.687867pt;}
.y250{bottom:594.758933pt;}
.ye47{bottom:595.222267pt;}
.y370{bottom:595.652267pt;}
.y156e{bottom:595.873200pt;}
.yf0{bottom:595.912800pt;}
.y7c9{bottom:596.143733pt;}
.ydc4{bottom:596.343200pt;}
.y8b9{bottom:596.774533pt;}
.yc3{bottom:596.775867pt;}
.yb9d{bottom:596.776133pt;}
.ya5f{bottom:596.776267pt;}
.y6be{bottom:596.811067pt;}
.yb77{bottom:597.004533pt;}
.y21a{bottom:597.275600pt;}
.y1084{bottom:597.314667pt;}
.y307{bottom:597.598867pt;}
.y6cf{bottom:597.882533pt;}
.y129f{bottom:597.888933pt;}
.y27b{bottom:597.907467pt;}
.y421{bottom:598.008533pt;}
.y783{bottom:598.143067pt;}
.y637{bottom:598.412933pt;}
.yeab{bottom:598.539867pt;}
.y1363{bottom:598.789733pt;}
.y52f{bottom:598.965467pt;}
.ycea{bottom:598.991333pt;}
.y15c2{bottom:599.453200pt;}
.y707{bottom:599.652800pt;}
.y579{bottom:599.787067pt;}
.y844{bottom:600.143733pt;}
.y122f{bottom:600.415998pt;}
.ybd8{bottom:600.555600pt;}
.y125b{bottom:600.564062pt;}
.y640{bottom:600.604133pt;}
.y1242{bottom:600.728129pt;}
.y1247{bottom:600.728820pt;}
.y1313{bottom:600.855467pt;}
.ydf8{bottom:601.008267pt;}
.y108e{bottom:601.175200pt;}
.y2dd{bottom:601.592533pt;}
.y1193{bottom:601.739600pt;}
.y9bc{bottom:602.068000pt;}
.y111{bottom:602.119867pt;}
.y1335{bottom:602.138533pt;}
.yb66{bottom:602.246933pt;}
.y92a{bottom:602.319467pt;}
.yf19{bottom:602.446533pt;}
.y1282{bottom:602.569600pt;}
.yf5a{bottom:602.597267pt;}
.y13f4{bottom:602.818933pt;}
.ye8d{bottom:602.829467pt;}
.y103b{bottom:603.021067pt;}
.y13d9{bottom:603.287333pt;}
.y1439{bottom:603.287733pt;}
.yb32{bottom:603.359733pt;}
.ye24{bottom:603.549600pt;}
.y4ba{bottom:603.957400pt;}
.y8d7{bottom:604.333200pt;}
.yfa7{bottom:604.334533pt;}
.y960{bottom:604.335067pt;}
.y126a{bottom:604.335867pt;}
.yf3b{bottom:604.383600pt;}
.y559{bottom:604.454533pt;}
.y5f8{bottom:604.624933pt;}
.ycba{bottom:605.496133pt;}
.y146c{bottom:605.502533pt;}
.y19d{bottom:605.687067pt;}
.y599{bottom:606.098933pt;}
.y1381{bottom:606.105467pt;}
.y89a{bottom:606.117467pt;}
.y12db{bottom:606.615333pt;}
.y262{bottom:607.050267pt;}
.y13b4{bottom:607.230400pt;}
.y10f0{bottom:607.591067pt;}
.y154{bottom:607.663200pt;}
.y12c3{bottom:607.711333pt;}
.y1105{bottom:608.162800pt;}
.yca1{bottom:608.765600pt;}
.y1d6{bottom:608.939600pt;}
.y36f{bottom:608.985267pt;}
.y329{bottom:609.152600pt;}
.yd6a{bottom:609.297800pt;}
.y122e{bottom:609.309099pt;}
.y1233{bottom:609.309791pt;}
.y125a{bottom:609.457163pt;}
.y1241{bottom:609.621230pt;}
.y1246{bottom:609.621921pt;}
.y908{bottom:609.676533pt;}
.y5b5{bottom:609.798533pt;}
.y78d{bottom:609.877867pt;}
.y68a{bottom:609.878000pt;}
.ye25{bottom:609.883467pt;}
.y16b{bottom:609.918400pt;}
.y1397{bottom:610.155467pt;}
.ybf0{bottom:610.329467pt;}
.y37{bottom:610.392533pt;}
.y5c{bottom:610.417200pt;}
.yd46{bottom:610.846400pt;}
.y11a0{bottom:611.009867pt;}
.y811{bottom:611.453200pt;}
.y33b{bottom:611.893200pt;}
.y190{bottom:611.894533pt;}
.y133{bottom:611.942267pt;}
.y39e{bottom:612.330000pt;}
.y306{bottom:612.931867pt;}
.y889{bottom:612.992933pt;}
.y156d{bottom:613.206533pt;}
.yef{bottom:613.246133pt;}
.y782{bottom:613.476400pt;}
.y7c8{bottom:613.477067pt;}
.y1129{bottom:613.483867pt;}
.yccb{bottom:613.585467pt;}
.ydc3{bottom:613.676533pt;}
.y35d{bottom:613.680800pt;}
.ya6{bottom:614.109200pt;}
.y9e6{bottom:614.109467pt;}
.ya5e{bottom:614.109600pt;}
.y52d{bottom:614.299733pt;}
.y909{bottom:614.343333pt;}
.yd3{bottom:614.350400pt;}
.y219{bottom:614.608933pt;}
.yb4e{bottom:615.149733pt;}
.y734{bottom:615.222267pt;}
.y27a{bottom:615.240800pt;}
.y420{bottom:615.341867pt;}
.y15c1{bottom:615.453200pt;}
.y2f{bottom:615.720400pt;}
.y5ed{bottom:615.746933pt;}
.y24f{bottom:615.872267pt;}
.yeaa{bottom:615.873200pt;}
.ye23{bottom:616.216800pt;}
.yce9{bottom:616.324667pt;}
.y108f{bottom:616.450667pt;}
.y12f9{bottom:616.558800pt;}
.y1f5{bottom:616.661200pt;}
.yec8{bottom:616.856000pt;}
.y6ce{bottom:617.231933pt;}
.y6bd{bottom:617.260133pt;}
.y843{bottom:617.477067pt;}
.y636{bottom:617.527867pt;}
.ybb8{bottom:617.564533pt;}
.y578{bottom:617.676400pt;}
.y14d2{bottom:617.713667pt;}
.yef5{bottom:617.886533pt;}
.y8b8{bottom:617.887867pt;}
.y52e{bottom:618.098933pt;}
.y122d{bottom:618.202201pt;}
.y1232{bottom:618.202892pt;}
.y1259{bottom:618.350265pt;}
.y1240{bottom:618.514331pt;}
.y1245{bottom:618.515023pt;}
.yf59{bottom:618.597800pt;}
.y110{bottom:619.453200pt;}
.y1334{bottom:619.471867pt;}
.y929{bottom:619.652800pt;}
.y84{bottom:619.692133pt;}
.yf18{bottom:619.779867pt;}
.y1281{bottom:619.902933pt;}
.y5f7{bottom:619.957933pt;}
.y4c6{bottom:620.134667pt;}
.y1450{bottom:620.152267pt;}
.ye8c{bottom:620.162800pt;}
.y13d8{bottom:620.620667pt;}
.y1438{bottom:620.621067pt;}
.y8f2{bottom:621.666533pt;}
.y1269{bottom:621.669200pt;}
.yf3a{bottom:621.716933pt;}
.y558{bottom:621.787867pt;}
.y36e{bottom:622.318267pt;}
.ycb9{bottom:622.829467pt;}
.y146b{bottom:622.835867pt;}
.ya05{bottom:622.908267pt;}
.y19c{bottom:623.020400pt;}
.y4b9{bottom:623.070133pt;}
.y3ff{bottom:623.130200pt;}
.yb65{bottom:623.359733pt;}
.y598{bottom:623.432267pt;}
.y1380{bottom:623.438800pt;}
.y1362{bottom:623.682133pt;}
.y261{bottom:624.383600pt;}
.y2dc{bottom:624.486467pt;}
.y706{bottom:624.545067pt;}
.y36d{bottom:624.668267pt;}
.y3de{bottom:624.748000pt;}
.y4c7{bottom:624.801467pt;}
.y3dd{bottom:624.850000pt;}
.y39d{bottom:624.996533pt;}
.y12c2{bottom:625.044667pt;}
.y712{bottom:625.253733pt;}
.yd69{bottom:625.298333pt;}
.y8d6{bottom:625.446533pt;}
.yfa6{bottom:625.447867pt;}
.y63f{bottom:625.496133pt;}
.y8{bottom:625.857200pt;}
.yca0{bottom:626.098933pt;}
.y1396{bottom:626.156000pt;}
.y5b{bottom:626.416800pt;}
.y907{bottom:627.009867pt;}
.ydf7{bottom:627.091467pt;}
.y122c{bottom:627.095302pt;}
.y1231{bottom:627.095994pt;}
.y29e{bottom:627.131867pt;}
.y78c{bottom:627.211200pt;}
.y689{bottom:627.211333pt;}
.y1258{bottom:627.243366pt;}
.y16a{bottom:627.251733pt;}
.y123f{bottom:627.407432pt;}
.y1244{bottom:627.408124pt;}
.y711{bottom:627.603733pt;}
.y13f3{bottom:627.711333pt;}
.y103a{bottom:627.913067pt;}
.y1d5{bottom:628.162267pt;}
.yd45{bottom:628.179733pt;}
.y305{bottom:628.264867pt;}
.y328{bottom:628.265333pt;}
.y119f{bottom:628.343200pt;}
.y810{bottom:628.786533pt;}
.y781{bottom:628.809733pt;}
.y33a{bottom:629.226533pt;}
.yfc8{bottom:629.227467pt;}
.y18f{bottom:629.227867pt;}
.y132{bottom:629.275600pt;}
.yb93{bottom:629.456000pt;}
.yee{bottom:630.579467pt;}
.y7c7{bottom:630.810400pt;}
.y1081{bottom:630.908000pt;}
.ya87{bottom:630.917733pt;}
.y898{bottom:631.009867pt;}
.y5ec{bottom:631.079933pt;}
.y2e{bottom:631.168000pt;}
.ya5{bottom:631.442533pt;}
.y9e5{bottom:631.442800pt;}
.ya5d{bottom:631.442933pt;}
.y15c0{bottom:631.453200pt;}
.y218{bottom:631.942267pt;}
.y13b3{bottom:632.122667pt;}
.yb4d{bottom:632.483067pt;}
.y153{bottom:632.555600pt;}
.y6cd{bottom:632.564933pt;}
.y279{bottom:632.574133pt;}
.y41f{bottom:632.675200pt;}
.yd87{bottom:632.856533pt;}
.y108d{bottom:633.055200pt;}
.y946{bottom:633.285200pt;}
.y52c{bottom:633.412467pt;}
.y14d1{bottom:633.714200pt;}
.y1af{bottom:634.810400pt;}
.y1022{bottom:635.222267pt;}
.y5f6{bottom:635.290933pt;}
.y35c{bottom:635.427800pt;}
.y888{bottom:635.659733pt;}
.y899{bottom:635.676667pt;}
.y122b{bottom:635.988403pt;}
.y1230{bottom:635.989095pt;}
.ye22{bottom:636.062000pt;}
.y1257{bottom:636.136467pt;}
.y1082{bottom:636.241333pt;}
.y123e{bottom:636.300533pt;}
.y1243{bottom:636.301225pt;}
.y12f8{bottom:636.558800pt;}
.y635{bottom:636.640600pt;}
.y1f4{bottom:636.660667pt;}
.y10f{bottom:636.786533pt;}
.y1333{bottom:636.805200pt;}
.y24e{bottom:636.985600pt;}
.y83{bottom:637.025467pt;}
.y1280{bottom:637.236267pt;}
.ye8b{bottom:637.496133pt;}
.y13d7{bottom:637.954000pt;}
.y156c{bottom:638.098933pt;}
.y36{bottom:638.397733pt;}
.y4b8{bottom:638.403133pt;}
.y3fe{bottom:638.463200pt;}
.y6bc{bottom:638.714267pt;}
.yef4{bottom:638.999867pt;}
.y8b7{bottom:639.001200pt;}
.y1542{bottom:639.002533pt;}
.yf39{bottom:639.050267pt;}
.y557{bottom:639.121200pt;}
.yd2{bottom:639.242400pt;}
.ycb8{bottom:640.162800pt;}
.y19b{bottom:640.353733pt;}
.y597{bottom:640.765600pt;}
.yf17{bottom:640.893200pt;}
.yce8{bottom:641.217067pt;}
.y1192{bottom:641.298867pt;}
.yf58{bottom:642.156533pt;}
.y39c{bottom:642.329867pt;}
.y12c1{bottom:642.378000pt;}
.y5a{bottom:642.416400pt;}
.y8d5{bottom:642.779867pt;}
.yc2{bottom:642.781200pt;}
.y1123{bottom:642.781333pt;}
.y63e{bottom:642.829467pt;}
.yd44{bottom:642.846400pt;}
.y304{bottom:643.597867pt;}
.y327{bottom:643.598333pt;}
.y2db{bottom:643.599200pt;}
.y780{bottom:644.143067pt;}
.yfc7{bottom:644.160933pt;}
.y29d{bottom:644.465200pt;}
.y169{bottom:644.585067pt;}
.y1256{bottom:645.029568pt;}
.y144f{bottom:645.044667pt;}
.y1039{bottom:645.246400pt;}
.y1d4{bottom:645.495600pt;}
.yd43{bottom:645.513067pt;}
.y80f{bottom:646.119867pt;}
.y39a{bottom:646.202000pt;}
.y399{bottom:646.304000pt;}
.y576{bottom:646.348400pt;}
.y5eb{bottom:646.412933pt;}
.y339{bottom:646.559867pt;}
.yfc6{bottom:646.560800pt;}
.y18e{bottom:646.561200pt;}
.y131{bottom:646.608933pt;}
.y733{bottom:646.843333pt;}
.y66f{bottom:646.996667pt;}
.yc9f{bottom:647.211733pt;}
.y15bf{bottom:647.453200pt;}
.y15e7{bottom:647.653200pt;}
.y146a{bottom:647.728267pt;}
.yed{bottom:647.912800pt;}
.y7c6{bottom:648.143733pt;}
.y688{bottom:648.324667pt;}
.y897{bottom:648.343200pt;}
.y137f{bottom:648.548400pt;}
.y52b{bottom:648.745467pt;}
.y9e4{bottom:648.776133pt;}
.ya5c{bottom:648.776267pt;}
.yd68{bottom:648.857067pt;}
.y217{bottom:649.275600pt;}
.y14d0{bottom:649.714733pt;}
.yb31{bottom:649.816400pt;}
.y46b{bottom:649.888933pt;}
.y278{bottom:649.907467pt;}
.ybb7{bottom:650.016000pt;}
.y35b{bottom:650.760800pt;}
.y577{bottom:651.015200pt;}
.y634{bottom:651.973600pt;}
.ya86{bottom:652.031067pt;}
.yea9{bottom:652.104133pt;}
.y1ae{bottom:652.143733pt;}
.yb9c{bottom:652.555600pt;}
.ydf6{bottom:653.174667pt;}
.y6cc{bottom:653.525067pt;}
.y4b7{bottom:653.736133pt;}
.y10e{bottom:654.119867pt;}
.y1332{bottom:654.138533pt;}
.y82{bottom:654.358800pt;}
.y5f5{bottom:654.403667pt;}
.y127f{bottom:654.569600pt;}
.ye8a{bottom:654.829467pt;}
.y13d6{bottom:655.287333pt;}
.ya04{bottom:655.359733pt;}
.y928{bottom:655.883733pt;}
.y1541{bottom:656.335867pt;}
.yf38{bottom:656.383600pt;}
.y1321{bottom:656.415267pt;}
.ye1e{bottom:656.467200pt;}
.ycb7{bottom:657.496133pt;}
.y41e{bottom:657.567467pt;}
.y19a{bottom:657.687067pt;}
.y24d{bottom:658.098933pt;}
.yf57{bottom:658.157067pt;}
.y108c{bottom:658.408533pt;}
.y59{bottom:658.416000pt;}
.y6bb{bottom:658.710600pt;}
.y326{bottom:658.931333pt;}
.y2da{bottom:658.932200pt;}
.y3fd{bottom:659.198867pt;}
.y77f{bottom:659.476400pt;}
.yb64{bottom:659.589733pt;}
.y43b{bottom:659.663200pt;}
.y12c0{bottom:659.711333pt;}
.y2d{bottom:659.968000pt;}
.y8d4{bottom:660.113200pt;}
.ya4{bottom:660.114533pt;}
.y1122{bottom:660.114667pt;}
.y63d{bottom:660.162800pt;}
.y556{bottom:660.234533pt;}
.y7{bottom:661.417200pt;}
.yfc4{bottom:661.494267pt;}
.y29c{bottom:661.798533pt;}
.y1038{bottom:662.579733pt;}
.y303{bottom:662.712000pt;}
.ye21{bottom:662.801067pt;}
.yd42{bottom:662.846400pt;}
.y906{bottom:663.239733pt;}
.y80e{bottom:663.453200pt;}
.y575{bottom:663.681733pt;}
.y338{bottom:663.893200pt;}
.yfc5{bottom:663.894133pt;}
.y18d{bottom:663.894533pt;}
.y130{bottom:663.942267pt;}
.yd1{bottom:664.134400pt;}
.y1255{bottom:664.195699pt;}
.y119e{bottom:664.574400pt;}
.yd67{bottom:664.857600pt;}
.yec{bottom:665.246133pt;}
.y7c5{bottom:665.477067pt;}
.y5ea{bottom:665.526933pt;}
.y1395{bottom:665.715267pt;}
.yf16{bottom:665.785200pt;}
.y732{bottom:665.956933pt;}
.ybef{bottom:666.109467pt;}
.ya5b{bottom:666.109600pt;}
.y6b9{bottom:666.376933pt;}
.y35{bottom:666.403867pt;}
.y1d3{bottom:666.608933pt;}
.yb30{bottom:667.149733pt;}
.y39b{bottom:667.222267pt;}
.y277{bottom:667.240800pt;}
.y633{bottom:667.306600pt;}
.y398{bottom:667.656133pt;}
.y397{bottom:667.758133pt;}
.y52a{bottom:667.858200pt;}
.y6cb{bottom:668.858067pt;}
.y4b6{bottom:669.069133pt;}
.ye1d{bottom:669.134400pt;}
.y168{bottom:669.477067pt;}
.y5f4{bottom:669.736667pt;}
.y107f{bottom:669.834933pt;}
.y9e3{bottom:669.888933pt;}
.y10d{bottom:671.453200pt;}
.y1331{bottom:671.471867pt;}
.y81{bottom:671.692133pt;}
.ye89{bottom:672.162800pt;}
.yf77{bottom:672.415800pt;}
.y13d5{bottom:672.620667pt;}
.y1254{bottom:673.088800pt;}
.y1252{bottom:673.090318pt;}
.y35a{bottom:673.240667pt;}
.y14cf{bottom:673.273467pt;}
.y887{bottom:673.444667pt;}
.ye19{bottom:673.528133pt;}
.y1540{bottom:673.669200pt;}
.y6ba{bottom:674.043600pt;}
.y325{bottom:674.264333pt;}
.y2c{bottom:674.368000pt;}
.y58{bottom:674.415600pt;}
.y3fc{bottom:674.531867pt;}
.y77e{bottom:674.809733pt;}
.ycb6{bottom:674.829467pt;}
.y199{bottom:675.020400pt;}
.y1080{bottom:675.168267pt;}
.y1253{bottom:675.392133pt;}
.ye20{bottom:675.468267pt;}
.y4e8{bottom:675.854000pt;}
.ye1a{bottom:676.354133pt;}
.ya85{bottom:676.923067pt;}
.y43a{bottom:676.996533pt;}
.ya3{bottom:677.447867pt;}
.y63c{bottom:677.496133pt;}
.y2d9{bottom:678.044933pt;}
.y302{bottom:678.045000pt;}
.y29b{bottom:679.131867pt;}
.y15be{bottom:679.453200pt;}
.y127e{bottom:679.461600pt;}
.y1037{bottom:679.913067pt;}
.yd41{bottom:680.179733pt;}
.y80d{bottom:680.786533pt;}
.yee3{bottom:680.858133pt;}
.y137e{bottom:680.999867pt;}
.y574{bottom:681.015067pt;}
.y337{bottom:681.226533pt;}
.y18c{bottom:681.227867pt;}
.y12f{bottom:681.275600pt;}
.yf56{bottom:681.715800pt;}
.ye1c{bottom:681.801600pt;}
.y1251{bottom:681.983420pt;}
.y34{bottom:682.403467pt;}
.yeb{bottom:682.579467pt;}
.y7c4{bottom:682.810400pt;}
.yf15{bottom:683.118533pt;}
.y529{bottom:683.191200pt;}
.y12b0{bottom:683.442800pt;}
.ya5a{bottom:683.442933pt;}
.y1d2{bottom:683.942267pt;}
.y6ca{bottom:684.191067pt;}
.y4b5{bottom:684.402133pt;}
.yb2f{bottom:684.483067pt;}
.y687{bottom:684.555600pt;}
.y896{bottom:684.573867pt;}
.y12bf{bottom:684.603733pt;}
.y5e9{bottom:684.639667pt;}
.y5f3{bottom:685.069667pt;}
.ye18{bottom:686.195333pt;}
.y632{bottom:686.419333pt;}
.y167{bottom:686.810400pt;}
.y3dc{bottom:687.030267pt;}
.ybee{bottom:687.222267pt;}
.ye1f{bottom:688.135467pt;}
.yd66{bottom:688.416333pt;}
.y359{bottom:688.573667pt;}
.y2b{bottom:688.768000pt;}
.yc1{bottom:688.786533pt;}
.y1330{bottom:688.805200pt;}
.y80{bottom:689.025467pt;}
.yd0{bottom:689.026400pt;}
.y396{bottom:689.110133pt;}
.y395{bottom:689.212133pt;}
.y14ce{bottom:689.274000pt;}
.y3da{bottom:689.563600pt;}
.y324{bottom:689.597333pt;}
.y3fb{bottom:689.864867pt;}
.y13d4{bottom:689.954000pt;}
.y77d{bottom:690.143067pt;}
.y57{bottom:690.415200pt;}
.y123d{bottom:690.850580pt;}
.y1250{bottom:690.876521pt;}
.y1239{bottom:690.942327pt;}
.ycfb{bottom:691.001733pt;}
.y4e7{bottom:691.187000pt;}
.y122a{bottom:691.368830pt;}
.ycb5{bottom:692.162800pt;}
.y198{bottom:692.353733pt;}
.y3db{bottom:693.363733pt;}
.y2d8{bottom:693.377933pt;}
.y301{bottom:693.378000pt;}
.ya84{bottom:694.256400pt;}
.y24c{bottom:694.329867pt;}
.ye1b{bottom:694.468800pt;}
.ya2{bottom:694.781200pt;}
.y6ad{bottom:694.781333pt;}
.y63b{bottom:694.829467pt;}
.y15bd{bottom:695.453200pt;}
.y29a{bottom:696.465200pt;}
.ybb6{bottom:696.472667pt;}
.y127d{bottom:696.794933pt;}
.ye14{bottom:696.922800pt;}
.ye88{bottom:697.055200pt;}
.y1036{bottom:697.246400pt;}
.yd40{bottom:697.513067pt;}
.yf55{bottom:697.716333pt;}
.yb63{bottom:698.036400pt;}
.y80c{bottom:698.119867pt;}
.y33{bottom:698.403067pt;}
.y8d3{bottom:698.559867pt;}
.y18b{bottom:698.561200pt;}
.y12d{bottom:698.608933pt;}
.ye17{bottom:698.862533pt;}
.y6c9{bottom:699.524067pt;}
.y4b4{bottom:699.735133pt;}
.y123c{bottom:699.744031pt;}
.y124f{bottom:699.769622pt;}
.y1238{bottom:699.835429pt;}
.yea{bottom:699.912800pt;}
.y5e8{bottom:699.972667pt;}
.y7c3{bottom:700.143733pt;}
.y1229{bottom:700.261931pt;}
.y5f2{bottom:700.402667pt;}
.ya59{bottom:700.776267pt;}
.y1d1{bottom:701.275600pt;}
.y631{bottom:701.752333pt;}
.ya03{bottom:701.816400pt;}
.y439{bottom:701.888933pt;}
.y527{bottom:702.304133pt;}
.y336{bottom:702.339867pt;}
.yf14{bottom:702.341200pt;}
.y12e{bottom:703.275733pt;}
.y276{bottom:703.471867pt;}
.y531{bottom:703.875867pt;}
.y358{bottom:703.906667pt;}
.y166{bottom:704.143733pt;}
.y731{bottom:704.182400pt;}
.yd65{bottom:704.416867pt;}
.y3fa{bottom:705.197867pt;}
.y14cd{bottom:705.274533pt;}
.y528{bottom:705.279200pt;}
.y77c{bottom:705.476400pt;}
.yc0{bottom:706.119867pt;}
.y132f{bottom:706.138533pt;}
.y56{bottom:706.414800pt;}
.y4e6{bottom:706.520000pt;}
.y13d3{bottom:707.287333pt;}
.y12af{bottom:708.335067pt;}
.y123b{bottom:708.637482pt;}
.y124e{bottom:708.662723pt;}
.y323{bottom:708.710067pt;}
.y2d7{bottom:708.710933pt;}
.y300{bottom:708.711000pt;}
.y1237{bottom:708.728530pt;}
.y107d{bottom:708.762000pt;}
.y1ad{bottom:708.810533pt;}
.y1228{bottom:709.155032pt;}
.y903{bottom:709.661600pt;}
.y904{bottom:709.661733pt;}
.y2bd{bottom:710.120000pt;}
.y394{bottom:710.564133pt;}
.y393{bottom:710.666267pt;}
.y15bc{bottom:711.453200pt;}
.ya83{bottom:711.589733pt;}
.y15e4{bottom:711.653200pt;}
.y6ac{bottom:712.114667pt;}
.y63a{bottom:712.162800pt;}
.y299{bottom:713.798533pt;}
.ycf{bottom:713.918400pt;}
.y107e{bottom:714.095333pt;}
.y32{bottom:714.403067pt;}
.y1035{bottom:714.579733pt;}
.yd3f{bottom:714.846400pt;}
.y6c8{bottom:714.857067pt;}
.ye16{bottom:714.875600pt;}
.y108a{bottom:715.221867pt;}
.yb62{bottom:715.369733pt;}
.y80b{bottom:715.453200pt;}
.y5f1{bottom:715.735667pt;}
.yea8{bottom:715.893200pt;}
.y18a{bottom:715.894533pt;}
.y12c{bottom:715.942267pt;}
.y2{bottom:716.429985pt;}
.ycb4{bottom:717.055200pt;}
.y573{bottom:717.246133pt;}
.y905{bottom:717.255467pt;}
.y7c2{bottom:717.477067pt;}
.y123a{bottom:717.530933pt;}
.y124d{bottom:717.555824pt;}
.y2a{bottom:717.568000pt;}
.ybb5{bottom:717.585467pt;}
.y1236{bottom:717.621631pt;}
.y7f{bottom:717.697467pt;}
.y1227{bottom:718.048133pt;}
.y1d0{bottom:718.608933pt;}
.y5e7{bottom:719.085400pt;}
.ya02{bottom:719.149733pt;}
.y1526{bottom:719.222267pt;}
.y730{bottom:719.515400pt;}
.y335{bottom:719.673200pt;}
.yf13{bottom:719.674533pt;}
.y13f2{bottom:719.721867pt;}
.yd64{bottom:720.417400pt;}
.y630{bottom:720.865067pt;}
.yf54{bottom:721.275067pt;}
.y165{bottom:721.477067pt;}
.y127c{bottom:721.687333pt;}
.ya58{bottom:721.888933pt;}
.y526{bottom:722.037133pt;}
.y357{bottom:722.052600pt;}
.y55{bottom:722.414400pt;}
.y4b3{bottom:722.627600pt;}
.y3f9{bottom:722.698200pt;}
.y4e5{bottom:723.359267pt;}
.ya1{bottom:723.453200pt;}
.y321{bottom:724.043000pt;}
.y322{bottom:724.043067pt;}
.y2d6{bottom:724.043933pt;}
.y2ff{bottom:724.044000pt;}
.y77b{bottom:724.589333pt;}
.y13d2{bottom:724.620667pt;}
.y14bb{bottom:725.668400pt;}
.y124c{bottom:726.448925pt;}
.y15bb{bottom:727.453200pt;}
.yec7{bottom:727.975600pt;}
.y197{bottom:728.584267pt;}
.y524{bottom:729.703467pt;}
.y355{bottom:729.718933pt;}
.y3f7{bottom:730.364533pt;}
.y4e3{bottom:731.025600pt;}
.y298{bottom:731.131867pt;}
.y1034{bottom:731.913067pt;}
.y392{bottom:732.018267pt;}
.ye87{bottom:732.174400pt;}
.yd3e{bottom:732.179733pt;}
.y902{bottom:732.328400pt;}
.ya82{bottom:732.703067pt;}
.y80a{bottom:732.786533pt;}
.y38f{bottom:733.189000pt;}
.y1f3{bottom:733.227867pt;}
.y5e6{bottom:734.418400pt;}
.y7e{bottom:735.030800pt;}
.y1cf{bottom:735.942267pt;}
.ye9{bottom:736.144267pt;}
.y62f{bottom:736.198067pt;}
.ye15{bottom:736.329600pt;}
.y15b7{bottom:736.417933pt;}
.ya01{bottom:736.483067pt;}
.y8d2{bottom:737.006533pt;}
.y639{bottom:737.055200pt;}
.yf53{bottom:737.275600pt;}
.y525{bottom:737.370133pt;}
.y356{bottom:737.385600pt;}
.y1089{bottom:737.657867pt;}
.y3f8{bottom:738.031200pt;}
.y6c6{bottom:738.200933pt;}
.y54{bottom:738.414000pt;}
.y895{bottom:738.589600pt;}
.y4b2{bottom:738.628133pt;}
.y4e4{bottom:738.692267pt;}
.yce{bottom:738.810400pt;}
.yf12{bottom:738.897200pt;}
.y97e{bottom:739.721867pt;}
.ya0{bottom:740.786533pt;}
.y1226{bottom:741.119837pt;}
.y1235{bottom:741.120529pt;}
.y6c7{bottom:741.175867pt;}
.y13d1{bottom:741.954000pt;}
.y31{bottom:742.408267pt;}
.y15ba{bottom:743.453200pt;}
.yd63{bottom:743.976133pt;}
.y1{bottom:744.696370pt;}
.y29{bottom:746.368000pt;}
.y320{bottom:746.935467pt;}
.y2d5{bottom:746.936400pt;}
.y77a{bottom:747.481733pt;}
.y107b{bottom:747.688800pt;}
.y297{bottom:748.465200pt;}
.y1225{bottom:749.025200pt;}
.y1033{bottom:749.246400pt;}
.yd3d{bottom:749.513067pt;}
.y5e5{bottom:749.751400pt;}
.y274{bottom:749.927733pt;}
.y809{bottom:750.119867pt;}
.y12b{bottom:752.173867pt;}
.y38e{bottom:752.301733pt;}
.y107c{bottom:753.022400pt;}
.yaa2{bottom:753.025867pt;}
.y390{bottom:753.065467pt;}
.y3d9{bottom:753.472267pt;}
.ya00{bottom:753.816400pt;}
.y127b{bottom:754.138800pt;}
.yea7{bottom:754.339867pt;}
.y53{bottom:754.413600pt;}
.y62e{bottom:755.310800pt;}
.y5ef{bottom:756.443733pt;}
.y391{bottom:756.865600pt;}
.y4b1{bottom:757.110400pt;}
.y9f{bottom:758.119867pt;}
.y275{bottom:758.728533pt;}
.y15b9{bottom:759.453200pt;}
.y5f0{bottom:759.593733pt;}
.yd62{bottom:759.976667pt;}
.y886{bottom:760.783333pt;}
.y7c1{bottom:761.039733pt;}
.y124b{bottom:764.193247pt;}
.y31e{bottom:767.930800pt;}
.y2d3{bottom:767.931200pt;}
.y779{bottom:768.465867pt;}
.y30{bottom:770.413600pt;}
.y4b0{bottom:770.443733pt;}
.y31f{bottom:771.080800pt;}
.y2d4{bottom:771.081200pt;}
.y5ee{bottom:771.110400pt;}
.y7d{bottom:771.261867pt;}
.y124a{bottom:772.098610pt;}
.y12a{bottom:772.173333pt;}
.y5e4{bottom:772.643867pt;}
.yd12{bottom:772.786667pt;}
.y0{bottom:772.963000pt;}
.y296{bottom:773.357467pt;}
.yaa1{bottom:774.138800pt;}
.yd3c{bottom:774.405333pt;}
.y9ff{bottom:774.929333pt;}
.y28{bottom:775.168000pt;}
.y9e{bottom:775.453200pt;}
.y107a{bottom:775.542000pt;}
.y15b8{bottom:775.653200pt;}
.y572{bottom:775.928533pt;}
.yd61{bottom:775.977200pt;}
.y1249{bottom:780.003973pt;}
.y234{bottom:781.928533pt;}
.y893{bottom:785.614667pt;}
.y894{bottom:785.614800pt;}
.y5{bottom:796.366667pt;}
.y9{bottom:846.538000pt;}
.y4{bottom:935.578920pt;}
.h54{height:9.433600pt;}
.h5f{height:11.742737pt;}
.h53{height:12.578133pt;}
.h5d{height:17.335811pt;}
.h55{height:17.766400pt;}
.h57{height:17.775283pt;}
.h5b{height:20.142110pt;}
.h5c{height:20.225113pt;}
.h5e{height:20.453111pt;}
.h3{height:21.312000pt;}
.h50{height:23.072000pt;}
.h4f{height:24.763200pt;}
.h19{height:25.480000pt;}
.h8{height:25.685333pt;}
.h42{height:26.140800pt;}
.h56{height:26.534400pt;}
.h28{height:26.917333pt;}
.h4a{height:27.181333pt;}
.h2{height:27.504560pt;}
.h1d{height:27.593067pt;}
.h4c{height:27.734933pt;}
.he{height:27.776000pt;}
.h58{height:28.000000pt;}
.h5a{height:28.933333pt;}
.h14{height:29.045333pt;}
.h1f{height:29.194667pt;}
.h41{height:30.762667pt;}
.h20{height:31.000000pt;}
.h45{height:31.866277pt;}
.h18{height:32.114133pt;}
.h1c{height:32.274667pt;}
.h4b{height:33.459783pt;}
.h11{height:33.973333pt;}
.h40{height:34.608000pt;}
.h47{height:35.645896pt;}
.h15{height:36.400000pt;}
.h43{height:37.200000pt;}
.h3f{height:37.344000pt;}
.h1a{height:37.797333pt;}
.h48{height:37.921312pt;}
.h49{height:38.239533pt;}
.h29{height:38.444293pt;}
.h27{height:38.453333pt;}
.ha{height:38.826667pt;}
.h4d{height:39.266667pt;}
.h61{height:39.306667pt;}
.h1b{height:39.418667pt;}
.h16{height:39.621333pt;}
.h46{height:41.081421pt;}
.h60{height:41.173333pt;}
.h10{height:41.333333pt;}
.h1e{height:41.493333pt;}
.hd{height:41.706667pt;}
.h51{height:42.298667pt;}
.h25{height:43.568000pt;}
.hc{height:43.680000pt;}
.h23{height:45.877333pt;}
.h17{height:46.106667pt;}
.h2e{height:48.000000pt;}
.hb{height:48.533333pt;}
.h13{height:50.048000pt;}
.h59{height:53.386667pt;}
.h22{height:53.941333pt;}
.h12{height:56.000000pt;}
.hf{height:56.896000pt;}
.h24{height:58.090667pt;}
.h5{height:64.437500pt;}
.h9{height:67.946667pt;}
.h1{height:73.345520pt;}
.h3a{height:84.774667pt;}
.h21{height:97.536000pt;}
.h38{height:103.634667pt;}
.h7{height:110.058667pt;}
.h2c{height:128.025333pt;}
.h39{height:129.889333pt;}
.h2b{height:131.022667pt;}
.h36{height:141.180000pt;}
.h30{height:157.920000pt;}
.h2a{height:163.774667pt;}
.h3c{height:171.246667pt;}
.h3e{height:171.465333pt;}
.h32{height:186.060000pt;}
.h34{height:187.772000pt;}
.h2f{height:188.950667pt;}
.h31{height:191.969333pt;}
.h33{height:193.073333pt;}
.h3d{height:202.176000pt;}
.h35{height:206.130667pt;}
.h37{height:211.586667pt;}
.h3b{height:217.342667pt;}
.h2d{height:217.366667pt;}
.h26{height:253.826667pt;}
.h52{height:287.246667pt;}
.h4e{height:298.668000pt;}
.h44{height:602.886667pt;}
.h62{height:903.640000pt;}
.h0{height:905.453333pt;}
.h6{height:907.040000pt;}
.h4{height:907.086667pt;}
.w7{width:264.194667pt;}
.wa{width:271.333333pt;}
.we{width:271.334667pt;}
.w8{width:278.473333pt;}
.w5{width:281.862667pt;}
.w2{width:287.244000pt;}
.w10{width:291.696000pt;}
.wf{width:292.968000pt;}
.wc{width:296.786667pt;}
.w4{width:300.250667pt;}
.wd{width:301.876000pt;}
.wb{width:306.141333pt;}
.w3{width:333.198667pt;}
.w6{width:333.528000pt;}
.w11{width:342.454667pt;}
.w9{width:344.676000pt;}
.w13{width:385.185333pt;}
.w14{width:415.944000pt;}
.w12{width:488.354667pt;}
.w15{width:603.633333pt;}
.w1{width:604.724000pt;}
.w0{width:607.265333pt;}
.x2{left:-602.975480pt;}
.x1{left:-20.968307pt;}
.xad{left:-2.482667pt;}
.x4{left:0.000000pt;}
.x9a{left:1.694267pt;}
.xcc{left:8.036400pt;}
.x9e{left:9.802667pt;}
.xb7{left:11.696000pt;}
.x3{left:14.164000pt;}
.x45{left:17.371867pt;}
.x27{left:19.723467pt;}
.xf{left:24.166800pt;}
.x8{left:27.917467pt;}
.xc6{left:29.757358pt;}
.xb1{left:32.813333pt;}
.x9f{left:35.460133pt;}
.xaa{left:36.878667pt;}
.xae{left:40.097200pt;}
.xa0{left:42.921333pt;}
.xa2{left:44.325333pt;}
.xab{left:50.360000pt;}
.x0{left:53.784293pt;}
.xbc{left:55.752000pt;}
.xa1{left:57.133333pt;}
.xb{left:60.110267pt;}
.x8f{left:62.776933pt;}
.x2d{left:64.110267pt;}
.x1a{left:66.002000pt;}
.x7{left:67.669333pt;}
.xa3{left:69.033333pt;}
.x20{left:71.448800pt;}
.xa5{left:73.755867pt;}
.x26{left:75.227600pt;}
.x4d{left:77.894828pt;}
.xa6{left:82.449333pt;}
.x8d{left:85.454371pt;}
.x71{left:87.472933pt;}
.xc{left:90.346400pt;}
.xc5{left:92.122538pt;}
.x38{left:93.679892pt;}
.x98{left:96.692400pt;}
.x99{left:98.495600pt;}
.x95{left:101.708133pt;}
.xb2{left:104.694667pt;}
.xb0{left:107.314667pt;}
.xa7{left:109.214667pt;}
.xa4{left:111.768000pt;}
.x6{left:113.522667pt;}
.xac{left:115.021333pt;}
.x9d{left:117.882667pt;}
.x9{left:120.582667pt;}
.xbb{left:122.005200pt;}
.x47{left:123.916000pt;}
.x46{left:126.365333pt;}
.x1b{left:128.141733pt;}
.xda{left:129.864267pt;}
.x14{left:131.604800pt;}
.xa9{left:134.002667pt;}
.x16{left:135.701333pt;}
.x7a{left:138.367467pt;}
.xa{left:140.849467pt;}
.x37{left:142.755600pt;}
.xa8{left:144.454667pt;}
.x7b{left:145.927009pt;}
.xd7{left:147.379600pt;}
.xb9{left:149.472000pt;}
.x10{left:150.818933pt;}
.x97{left:153.098667pt;}
.x24{left:155.009733pt;}
.x9b{left:157.048933pt;}
.x93{left:159.990267pt;}
.x77{left:161.496267pt;}
.x25{left:162.874800pt;}
.x3c{left:164.300667pt;}
.x44{left:165.958133pt;}
.x82{left:167.502133pt;}
.x5a{left:169.857817pt;}
.x49{left:171.614533pt;}
.x28{left:173.497067pt;}
.xba{left:176.378667pt;}
.x3a{left:178.138800pt;}
.x8b{left:179.505733pt;}
.x35{left:181.055067pt;}
.x3b{left:182.395200pt;}
.xc2{left:183.853550pt;}
.x39{left:185.326533pt;}
.x66{left:186.841600pt;}
.x5{left:188.596267pt;}
.x5f{left:190.813600pt;}
.xb8{left:193.089333pt;}
.x21{left:194.895467pt;}
.x11{left:196.470533pt;}
.xdb{left:198.031333pt;}
.x5d{left:199.593200pt;}
.x22{left:202.095200pt;}
.x72{left:203.773333pt;}
.xb3{left:205.157333pt;}
.x60{left:207.285733pt;}
.x61{left:209.813733pt;}
.x7f{left:211.292000pt;}
.x62{left:213.331467pt;}
.x13{left:216.582667pt;}
.xaf{left:218.767867pt;}
.x81{left:220.983467pt;}
.x17{left:223.378533pt;}
.x70{left:224.773067pt;}
.x3d{left:227.241200pt;}
.xb5{left:228.638667pt;}
.x76{left:230.750800pt;}
.x9c{left:233.465333pt;}
.x3e{left:235.014133pt;}
.x94{left:236.740933pt;}
.xdd{left:238.364123pt;}
.x18{left:242.222800pt;}
.x63{left:243.979867pt;}
.x1c{left:245.953733pt;}
.xc4{left:247.370533pt;}
.x19{left:250.438533pt;}
.x4a{left:251.890800pt;}
.xc1{left:254.226312pt;}
.xb6{left:255.598667pt;}
.x3f{left:257.228933pt;}
.x50{left:259.265333pt;}
.x2b{left:262.486400pt;}
.x40{left:265.001733pt;}
.x2c{left:267.424000pt;}
.x86{left:269.495333pt;}
.xb4{left:272.464000pt;}
.x4f{left:274.193733pt;}
.x5b{left:275.834933pt;}
.x51{left:278.488800pt;}
.x52{left:281.016933pt;}
.x75{left:282.982800pt;}
.x53{left:284.534667pt;}
.xdc{left:287.081564pt;}
.x41{left:289.064533pt;}
.x80{left:291.243333pt;}
.x42{left:294.164133pt;}
.x29{left:297.143200pt;}
.x31{left:302.978800pt;}
.x2a{left:305.027200pt;}
.xbd{left:308.614533pt;}
.x88{left:310.460667pt;}
.x73{left:313.076000pt;}
.xc8{left:314.662000pt;}
.x54{left:318.580400pt;}
.x74{left:319.961333pt;}
.xd9{left:321.523519pt;}
.x64{left:323.427600pt;}
.x1f{left:325.360933pt;}
.x4e{left:328.375333pt;}
.xc7{left:330.181665pt;}
.x32{left:334.581733pt;}
.xd4{left:337.396267pt;}
.x84{left:342.355600pt;}
.x34{left:349.152267pt;}
.xd8{left:350.634667pt;}
.xc9{left:352.518133pt;}
.x91{left:356.248533pt;}
.xd6{left:360.330667pt;}
.x8a{left:364.245200pt;}
.xd0{left:367.250400pt;}
.x36{left:368.876533pt;}
.x79{left:371.554667pt;}
.x87{left:374.031467pt;}
.x1e{left:376.434533pt;}
.x5e{left:378.437563pt;}
.x1d{left:381.395200pt;}
.x65{left:385.679333pt;}
.x89{left:388.284933pt;}
.x43{left:394.859600pt;}
.x48{left:396.315067pt;}
.x6e{left:398.188533pt;}
.xc0{left:402.755867pt;}
.x55{left:406.428267pt;}
.x8c{left:408.133600pt;}
.x6b{left:410.063000pt;}
.xd5{left:412.104267pt;}
.x15{left:413.689867pt;}
.x85{left:415.651133pt;}
.x2f{left:416.984600pt;}
.x2e{left:419.493867pt;}
.x8e{left:423.055733pt;}
.x4b{left:426.606400pt;}
.x56{left:428.060533pt;}
.x90{left:429.959600pt;}
.x57{left:431.578267pt;}
.x6c{left:434.398267pt;}
.x58{left:436.052933pt;}
.x4c{left:439.008800pt;}
.x33{left:440.704133pt;}
.xd{left:442.143733pt;}
.x12{left:444.014533pt;}
.xd3{left:448.401200pt;}
.xdf{left:451.043067pt;}
.x67{left:452.746400pt;}
.xc3{left:457.503218pt;}
.xcf{left:459.851600pt;}
.x7d{left:463.214933pt;}
.x59{left:465.743333pt;}
.x92{left:468.606133pt;}
.x7e{left:470.745867pt;}
.x6d{left:473.966200pt;}
.x83{left:475.437067pt;}
.x68{left:476.838800pt;}
.x69{left:479.366933pt;}
.x23{left:483.102267pt;}
.xca{left:484.600267pt;}
.x6a{left:487.359200pt;}
.x6f{left:491.897600pt;}
.x30{left:496.626133pt;}
.x7c{left:498.301467pt;}
.x78{left:500.191333pt;}
.xcd{left:501.972933pt;}
.xd1{left:511.961467pt;}
.xce{left:513.554933pt;}
.x5c{left:516.827467pt;}
.xbe{left:524.642267pt;}
.xcb{left:526.494000pt;}
.xd2{left:533.658933pt;}
.xbf{left:540.330800pt;}
.xe{left:566.568667pt;}
.xde{left:570.223333pt;}
.x96{left:577.882800pt;}
.xe1{left:633.574360pt;}
.xe0{left:708.326960pt;}
}
</style>
<script>
/*
 Copyright 2012 Mozilla Foundation 
 Copyright 2013 Lu Wang <coolwanglu@gmail.com>
 Apachine License Version 2.0 
*/
(function(){function b(a,b,e,f){var c=(a.className||"").split(/\s+/g);""===c[0]&&c.shift();var d=c.indexOf(b);0>d&&e&&c.push(b);0<=d&&f&&c.splice(d,1);a.className=c.join(" ");return 0<=d}if(!("classList"in document.createElement("div"))){var e={add:function(a){b(this.element,a,!0,!1)},contains:function(a){return b(this.element,a,!1,!1)},remove:function(a){b(this.element,a,!1,!0)},toggle:function(a){b(this.element,a,!0,!0)}};Object.defineProperty(HTMLElement.prototype,"classList",{get:function(){if(this._classList)return this._classList;
var a=Object.create(e,{element:{value:this,writable:!1,enumerable:!0}});Object.defineProperty(this,"_classList",{value:a,writable:!1,enumerable:!1});return a},enumerable:!0})}})();
</script>
<script>
(function(){/*
 pdf2htmlEX.js: Core UI functions for pdf2htmlEX 
 Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> and other contributors 
 https://github.com/coolwanglu/pdf2htmlEX/blob/master/share/LICENSE 
*/
var pdf2htmlEX=window.pdf2htmlEX=window.pdf2htmlEX||{},CSS_CLASS_NAMES={page_frame:"pf",page_content_box:"pc",page_data:"pi",background_image:"bi",link:"l",input_radio:"ir",__dummy__:"no comma"},DEFAULT_CONFIG={container_id:"page-container",sidebar_id:"sidebar",outline_id:"outline",loading_indicator_cls:"loading-indicator",preload_pages:3,render_timeout:100,scale_step:0.9,key_handler:!0,hashchange_handler:!0,view_history_handler:!0,__dummy__:"no comma"},EPS=1E-6;
function invert(a){var b=a[0]*a[3]-a[1]*a[2];return[a[3]/b,-a[1]/b,-a[2]/b,a[0]/b,(a[2]*a[5]-a[3]*a[4])/b,(a[1]*a[4]-a[0]*a[5])/b]}function transform(a,b){return[a[0]*b[0]+a[2]*b[1]+a[4],a[1]*b[0]+a[3]*b[1]+a[5]]}function get_page_number(a){return parseInt(a.getAttribute("data-page-no"),16)}function disable_dragstart(a){for(var b=0,c=a.length;b<c;++b)a[b].addEventListener("dragstart",function(){return!1},!1)}
function clone_and_extend_objs(a){for(var b={},c=0,e=arguments.length;c<e;++c){var h=arguments[c],d;for(d in h)h.hasOwnProperty(d)&&(b[d]=h[d])}return b}
function Page(a){if(a){this.shown=this.loaded=!1;this.page=a;this.num=get_page_number(a);this.original_height=a.clientHeight;this.original_width=a.clientWidth;var b=a.getElementsByClassName(CSS_CLASS_NAMES.page_content_box)[0];b&&(this.content_box=b,this.original_scale=this.cur_scale=this.original_height/b.clientHeight,this.page_data=JSON.parse(a.getElementsByClassName(CSS_CLASS_NAMES.page_data)[0].getAttribute("data-data")),this.ctm=this.page_data.ctm,this.ictm=invert(this.ctm),this.loaded=!0)}}
Page.prototype={hide:function(){this.loaded&&this.shown&&(this.content_box.classList.remove("opened"),this.shown=!1)},show:function(){this.loaded&&!this.shown&&(this.content_box.classList.add("opened"),this.shown=!0)},rescale:function(a){this.cur_scale=0===a?this.original_scale:a;this.loaded&&(a=this.content_box.style,a.msTransform=a.webkitTransform=a.transform="scale("+this.cur_scale.toFixed(3)+")");a=this.page.style;a.height=this.original_height*this.cur_scale+"px";a.width=this.original_width*this.cur_scale+
"px"},view_position:function(){var a=this.page,b=a.parentNode;return[b.scrollLeft-a.offsetLeft-a.clientLeft,b.scrollTop-a.offsetTop-a.clientTop]},height:function(){return this.page.clientHeight},width:function(){return this.page.clientWidth}};function Viewer(a){this.config=clone_and_extend_objs(DEFAULT_CONFIG,0<arguments.length?a:{});this.pages_loading=[];this.init_before_loading_content();var b=this;document.addEventListener("DOMContentLoaded",function(){b.init_after_loading_content()},!1)}
Viewer.prototype={scale:1,cur_page_idx:0,first_page_idx:0,init_before_loading_content:function(){this.pre_hide_pages()},initialize_radio_button:function(){for(var a=document.getElementsByClassName(CSS_CLASS_NAMES.input_radio),b=0;b<a.length;b++)a[b].addEventListener("click",function(){this.classList.toggle("checked")})},init_after_loading_content:function(){this.sidebar=document.getElementById(this.config.sidebar_id);this.outline=document.getElementById(this.config.outline_id);this.container=document.getElementById(this.config.container_id);
this.loading_indicator=document.getElementsByClassName(this.config.loading_indicator_cls)[0];for(var a=!0,b=this.outline.childNodes,c=0,e=b.length;c<e;++c)if("ul"===b[c].nodeName.toLowerCase()){a=!1;break}a||this.sidebar.classList.add("opened");this.find_pages();if(0!=this.pages.length){disable_dragstart(document.getElementsByClassName(CSS_CLASS_NAMES.background_image));this.config.key_handler&&this.register_key_handler();var h=this;this.config.hashchange_handler&&window.addEventListener("hashchange",
function(a){h.navigate_to_dest(document.location.hash.substring(1))},!1);this.config.view_history_handler&&window.addEventListener("popstate",function(a){a.state&&h.navigate_to_dest(a.state)},!1);this.container.addEventListener("scroll",function(){h.update_page_idx();h.schedule_render(!0)},!1);[this.container,this.outline].forEach(function(a){a.addEventListener("click",h.link_handler.bind(h),!1)});this.initialize_radio_button();this.render()}},find_pages:function(){for(var a=[],b={},c=this.container.childNodes,
e=0,h=c.length;e<h;++e){var d=c[e];d.nodeType===Node.ELEMENT_NODE&&d.classList.contains(CSS_CLASS_NAMES.page_frame)&&(d=new Page(d),a.push(d),b[d.num]=a.length-1)}this.pages=a;this.page_map=b},load_page:function(a,b,c){var e=this.pages;if(!(a>=e.length||(e=e[a],e.loaded||this.pages_loading[a]))){var e=e.page,h=e.getAttribute("data-page-url");if(h){this.pages_loading[a]=!0;var d=e.getElementsByClassName(this.config.loading_indicator_cls)[0];"undefined"===typeof d&&(d=this.loading_indicator.cloneNode(!0),
d.classList.add("active"),e.appendChild(d));var f=this,g=new XMLHttpRequest;g.open("GET",h,!0);g.onload=function(){if(200===g.status||0===g.status){var b=document.createElement("div");b.innerHTML=g.responseText;for(var d=null,b=b.childNodes,e=0,h=b.length;e<h;++e){var p=b[e];if(p.nodeType===Node.ELEMENT_NODE&&p.classList.contains(CSS_CLASS_NAMES.page_frame)){d=p;break}}b=f.pages[a];f.container.replaceChild(d,b.page);b=new Page(d);f.pages[a]=b;b.hide();b.rescale(f.scale);disable_dragstart(d.getElementsByClassName(CSS_CLASS_NAMES.background_image));
f.schedule_render(!1);c&&c(b)}delete f.pages_loading[a]};g.send(null)}void 0===b&&(b=this.config.preload_pages);0<--b&&(f=this,setTimeout(function(){f.load_page(a+1,b)},0))}},pre_hide_pages:function(){var a="@media screen{."+CSS_CLASS_NAMES.page_content_box+"{display:none;}}",b=document.createElement("style");b.styleSheet?b.styleSheet.cssText=a:b.appendChild(document.createTextNode(a));document.head.appendChild(b)},render:function(){for(var a=this.container,b=a.scrollTop,c=a.clientHeight,a=b-c,b=
b+c+c,c=this.pages,e=0,h=c.length;e<h;++e){var d=c[e],f=d.page,g=f.offsetTop+f.clientTop,f=g+f.clientHeight;g<=b&&f>=a?d.loaded?d.show():this.load_page(e):d.hide()}},update_page_idx:function(){var a=this.pages,b=a.length;if(!(2>b)){for(var c=this.container,e=c.scrollTop,c=e+c.clientHeight,h=-1,d=b,f=d-h;1<f;){var g=h+Math.floor(f/2),f=a[g].page;f.offsetTop+f.clientTop+f.clientHeight>=e?d=g:h=g;f=d-h}this.first_page_idx=d;for(var g=h=this.cur_page_idx,k=0;d<b;++d){var f=a[d].page,l=f.offsetTop+f.clientTop,
f=f.clientHeight;if(l>c)break;f=(Math.min(c,l+f)-Math.max(e,l))/f;if(d===h&&Math.abs(f-1)<=EPS){g=h;break}f>k&&(k=f,g=d)}this.cur_page_idx=g}},schedule_render:function(a){if(void 0!==this.render_timer){if(!a)return;clearTimeout(this.render_timer)}var b=this;this.render_timer=setTimeout(function(){delete b.render_timer;b.render()},this.config.render_timeout)},register_key_handler:function(){var a=this;window.addEventListener("DOMMouseScroll",function(b){if(b.ctrlKey){b.preventDefault();var c=a.container,
e=c.getBoundingClientRect(),c=[b.clientX-e.left-c.clientLeft,b.clientY-e.top-c.clientTop];a.rescale(Math.pow(a.config.scale_step,b.detail),!0,c)}},!1);window.addEventListener("keydown",function(b){var c=!1,e=b.ctrlKey||b.metaKey,h=b.altKey;switch(b.keyCode){case 61:case 107:case 187:e&&(a.rescale(1/a.config.scale_step,!0),c=!0);break;case 173:case 109:case 189:e&&(a.rescale(a.config.scale_step,!0),c=!0);break;case 48:e&&(a.rescale(0,!1),c=!0);break;case 33:h?a.scroll_to(a.cur_page_idx-1):a.container.scrollTop-=
a.container.clientHeight;c=!0;break;case 34:h?a.scroll_to(a.cur_page_idx+1):a.container.scrollTop+=a.container.clientHeight;c=!0;break;case 35:a.container.scrollTop=a.container.scrollHeight;c=!0;break;case 36:a.container.scrollTop=0,c=!0}c&&b.preventDefault()},!1)},rescale:function(a,b,c){var e=this.scale;this.scale=a=0===a?1:b?e*a:a;c||(c=[0,0]);b=this.container;c[0]+=b.scrollLeft;c[1]+=b.scrollTop;for(var h=this.pages,d=h.length,f=this.first_page_idx;f<d;++f){var g=h[f].page;if(g.offsetTop+g.clientTop>=
c[1])break}g=f-1;0>g&&(g=0);var g=h[g].page,k=g.clientWidth,f=g.clientHeight,l=g.offsetLeft+g.clientLeft,m=c[0]-l;0>m?m=0:m>k&&(m=k);k=g.offsetTop+g.clientTop;c=c[1]-k;0>c?c=0:c>f&&(c=f);for(f=0;f<d;++f)h[f].rescale(a);b.scrollLeft+=m/e*a+g.offsetLeft+g.clientLeft-m-l;b.scrollTop+=c/e*a+g.offsetTop+g.clientTop-c-k;this.schedule_render(!0)},fit_width:function(){var a=this.cur_page_idx;this.rescale(this.container.clientWidth/this.pages[a].width(),!0);this.scroll_to(a)},fit_height:function(){var a=this.cur_page_idx;
this.rescale(this.container.clientHeight/this.pages[a].height(),!0);this.scroll_to(a)},get_containing_page:function(a){for(;a;){if(a.nodeType===Node.ELEMENT_NODE&&a.classList.contains(CSS_CLASS_NAMES.page_frame)){a=get_page_number(a);var b=this.page_map;return a in b?this.pages[b[a]]:null}a=a.parentNode}return null},link_handler:function(a){var b=a.target,c=b.getAttribute("data-dest-detail");if(c){if(this.config.view_history_handler)try{var e=this.get_current_view_hash();window.history.replaceState(e,
"","#"+e);window.history.pushState(c,"","#"+c)}catch(h){}this.navigate_to_dest(c,this.get_containing_page(b));a.preventDefault()}},navigate_to_dest:function(a,b){try{var c=JSON.parse(a)}catch(e){return}if(c instanceof Array){var h=c[0],d=this.page_map;if(h in d){for(var f=d[h],h=this.pages[f],d=2,g=c.length;d<g;++d){var k=c[d];if(null!==k&&"number"!==typeof k)return}for(;6>c.length;)c.push(null);var g=b||this.pages[this.cur_page_idx],d=g.view_position(),d=transform(g.ictm,[d[0],g.height()-d[1]]),
g=this.scale,l=[0,0],m=!0,k=!1,n=this.scale;switch(c[1]){case "XYZ":l=[null===c[2]?d[0]:c[2]*n,null===c[3]?d[1]:c[3]*n];g=c[4];if(null===g||0===g)g=this.scale;k=!0;break;case "Fit":case "FitB":l=[0,0];k=!0;break;case "FitH":case "FitBH":l=[0,null===c[2]?d[1]:c[2]*n];k=!0;break;case "FitV":case "FitBV":l=[null===c[2]?d[0]:c[2]*n,0];k=!0;break;case "FitR":l=[c[2]*n,c[5]*n],m=!1,k=!0}if(k){this.rescale(g,!1);var p=this,c=function(a){l=transform(a.ctm,l);m&&(l[1]=a.height()-l[1]);p.scroll_to(f,l)};h.loaded?
c(h):(this.load_page(f,void 0,c),this.scroll_to(f))}}}},scroll_to:function(a,b){var c=this.pages;if(!(0>a||a>=c.length)){c=c[a].view_position();void 0===b&&(b=[0,0]);var e=this.container;e.scrollLeft+=b[0]-c[0];e.scrollTop+=b[1]-c[1]}},get_current_view_hash:function(){var a=[],b=this.pages[this.cur_page_idx];a.push(b.num);a.push("XYZ");var c=b.view_position(),c=transform(b.ictm,[c[0],b.height()-c[1]]);a.push(c[0]/this.scale);a.push(c[1]/this.scale);a.push(this.scale);return JSON.stringify(a)}};
pdf2htmlEX.Viewer=Viewer;})();
</script>
<script>
try{
pdf2htmlEX.defaultViewer = new pdf2htmlEX.Viewer({});
}catch(e){}
</script>
<title></title>
</head>
<body>
<div id="sidebar">
<div id="outline">
</div>
</div>
<div id="page-container">
<div id="pf1" class="pf w0 h0" data-page-no="1"><div class="pc pc1 w0 h0"><div class="t m0 x0 h1 y0 ff1 fs0 fc0 sc0 ls0 ws0">G U<span class="_ _0"> </span>I<span class="_ _1"> </span>D E L<span class="_ _1"> </span>I<span class="_ _1"> </span>N<span class="_ _1"> </span>E S<span class="_ _1"> </span> </div><div class="t m0 x0 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0">F<span class="_ _2"> </span>O R  <span class="_ _2"> </span>T<span class="_ _1"> </span>H<span class="_ _2"> </span>E<span class="_ _2"> </span> <span class="_ _2"> </span>T<span class="_ _2"> </span>R<span class="_ _0"> </span>E<span class="_ _0"> </span>A<span class="_ _3"> </span>T<span class="_ _1"> </span>M<span class="_ _2"> </span>E<span class="_ _2"> </span>N<span class="_ _0"> </span>T</div><div class="t m0 x0 h1 y2 ff1 fs0 fc0 sc0 ls0 ws0">O F  <span class="_ _2"> </span>M<span class="_ _0"> </span>A<span class="_ _0"> </span>L<span class="_ _1"> </span>A<span class="_ _1"> </span>R<span class="_ _4"> </span>I<span class="_ _0"> </span>A</div><div class="t m1 x1 h2 y3 ff1 fs1 fc0 sc0 ls0 ws0">G U<span class="_ _5"> </span>I<span class="_ _6"> </span>D E<span class="_ _6"> </span>L<span class="_ _6"> </span>I<span class="_ _6"> </span>N<span class="_ _6"> </span>E<span class="_ _6"> </span>S   F<span class="_ _6"> </span>O R  <span class="_ _6"> </span>T<span class="_ _6"> </span>H E<span class="_ _6"> </span>  T<span class="_ _6"> </span>R<span class="_ _6"> </span>E<span class="_ _6"> </span>A T<span class="_ _6"> </span>M<span class="_ _6"> </span>E<span class="_ _6"> </span>N<span class="_ _6"> </span>T   O<span class="_ _6"> </span>F   M<span class="_ _5"> </span>A<span class="_ _6"> </span>L<span class="_ _6"> </span>A<span class="_ _6"> </span>R<span class="_ _5"> </span>I<span class="_ _6"> </span>A</div><div class="t m0 x2 h3 y4 ff2 fs2 fc1 sc1 ls0 ws0">GTMcover-production.pdf   11.1.2006   7:10:05<span class="_ _7"></span><span class="fc2 sc0">GTMcover-production.pdf   11.1.2006   7:10:05</span></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,-666.361000,-1073.830000]}'></div></div>
<div id="pf2" class="pf w1 h4" data-page-no="2"><div class="pc pc2 w1 h4"><div class="t m0 x3 h5 y5 ff3 fs3 fc2 sc0 ls0 ws0"> </div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,-158.457000,-111.685000]}'></div></div>
<div id="pf3" class="pf w1 h4" data-page-no="3"><div class="pc pc3 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x5 h7 y7 ff4 fs4 fc3 sc0 ls1 ws0">G<span class="_ _8"></span>uidelines for </div><div class="t m0 x6 h7 y8 ff4 fs4 fc3 sc0 ls2 ws1">the treatment of malar<span class="_ _9"></span>ia</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4" class="pf w1 h4" data-page-no="4"><div class="pc pc4 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff5 fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x8 h9 ya ff6 fs6 fc4 sc0 ls1 ws0">ii</div><div class="t m0 x9 ha yb ff6 fs7 fc3 sc0 ls4 ws0">© W<span class="_ _a"></span>orld Health Organization, 2006</div><div class="t m0 x9 ha yc ff6 fs7 fc3 sc0 ls5 ws3">All rights reserved. Publications of the W<span class="_ _a"></span>orld Health Organization can be obtained fr<span class="_ _a"></span>om WHO Press,</div><div class="t m0 x9 ha yd ff6 fs7 fc3 sc0 ls6 ws4">World Health Or<span class="_ _a"></span>ganization, 20, avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3<span class="_ _a"></span>264;</div><div class="t m0 x9 ha ye ff6 fs7 fc3 sc0 ls4 ws5">fax: +41 22 791 4857; e-mail: <span class="ff7 ws0">bookorders@who.int</span><span class="ws6">). R<span class="_ _a"></span>equests for permission to reproduce or</span></div><div class="t m0 x9 ha yf ff6 fs7 fc3 sc0 ls4 ws7">translate <span class="_ _a"></span>WHO publications – whether for sale or for noncommercial distribution – should be</div><div class="t m0 x9 ha y10 ff6 fs7 fc3 sc0 ls7 ws8">addressed to <span class="_ _a"></span>WHO Press, at the above addr<span class="_ _a"></span>ess (fax: +41 22 791 4806; e-mail: <span class="ff7 ls8 ws0">permissions@who.int<span class="ff6">).</span></span></div><div class="t m0 x9 ha y11 ff6 fs7 fc3 sc0 ls9 ws9">The designations employed and the presentation of the material in this publication do not imply</div><div class="t m0 x9 ha y12 ff6 fs7 fc3 sc0 lsa wsa">the expression of any opinion whatsoever on the part of the W<span class="_ _a"></span>orld Health Organization concerning</div><div class="t m0 x9 ha y13 ff6 fs7 fc3 sc0 lsb wsb">the legal status of any country<span class="_ _b"></span>, territory<span class="_ _b"></span>, city or area or of its authorities, or concerning the</div><div class="t m0 x9 ha y14 ff6 fs7 fc3 sc0 ls4 ws0">delimitation of its frontiers or boundaries.</div><div class="t m0 x9 ha y15 ff6 fs7 fc3 sc0 lsc wsc">The mention of specific companies or of certain manufacturers’ pr<span class="_ _a"></span>oducts does not imply that they</div><div class="t m0 x9 ha y16 ff6 fs7 fc3 sc0 lsd wsd">are endorsed or recommended by the <span class="_ _a"></span>World Health Or<span class="_ _a"></span>ganization in preference to others of a similar</div><div class="t m0 x9 ha y17 ff6 fs7 fc3 sc0 lsc wse">nature that are not mentioned. Errors and omissions ex<span class="_ _a"></span>cepted, the names of proprietary products</div><div class="t m0 x9 ha y18 ff6 fs7 fc3 sc0 lsc wsf">are distinguished by initial capital letters.</div><div class="t m0 x9 ha y19 ff6 fs7 fc3 sc0 lse ws10">All reasonable precautions hav<span class="_ _a"></span>e been taken by the W<span class="_ _a"></span>orld Health Organization to verify the information</div><div class="t m0 x9 ha y1a ff6 fs7 fc3 sc0 lsf ws11">contained in this publication. Howeve<span class="_ _a"></span>r<span class="_ _b"></span>, the published material is being distributed without warranty</div><div class="t m0 x9 ha y1b ff6 fs7 fc3 sc0 ls10 ws12">of any kind, either express or implied. The r<span class="_ _a"></span>esponsibility for the interpretation and use of the material</div><div class="t m0 x9 ha y1c ff6 fs7 fc3 sc0 ls11 ws13">lies with the reader<span class="_ _b"></span>. In no event shall the W<span class="_ _b"></span>orld Health Organization be liable for damages arising</div><div class="t m0 x9 ha y1d ff6 fs7 fc3 sc0 ls11 ws0">from its use. The named authors alone ar<span class="_ _a"></span>e responsible for the views expressed in this publication.</div><div class="t m0 x9 hb y1e ff6 fs8 fc3 sc0 ls12 ws0">For technical information, please contact:</div><div class="t m0 x9 hb y1f ff6 fs8 fc3 sc0 ls13 ws14">Dr P<span class="_ _c"></span>. Olumese</div><div class="t m0 x9 hb y20 ff6 fs8 fc3 sc0 ls12 ws0">Global Malaria Progr<span class="_ _a"></span>amme </div><div class="t m0 x9 hb y21 ff6 fs8 fc3 sc0 ls12 ws0">W<span class="_ _a"></span>orld Health Organization</div><div class="t m0 x9 hb y22 ff6 fs8 fc3 sc0 ls13 ws14">20, avenue Appia – CH-1211 Genev<span class="_ _a"></span>a 27</div><div class="t m0 x9 hb y23 ff6 fs8 fc3 sc0 ls12 ws0">T<span class="_ _b"></span>el. +41 22 791 4424</div><div class="t m0 x9 hb y24 ff6 fs8 fc3 sc0 ls14 ws15">F<span class="_ _a"></span>ax +41 22 791 4824</div><div class="t m0 x9 hb y25 ff6 fs8 fc3 sc0 ls12 ws0">E-mail: olumesep@who.int</div><div class="t m0 x9 hc y26 ff6 fs9 fc3 sc0 ls15 ws16">Printed in Switzerland</div><div class="t m0 x9 hc y27 ff6 fs9 fc3 sc0 ls16 ws0">Design: B. Duret – Cov<span class="_ _a"></span>er: T<span class="_ _b"></span>. Cailler</div><div class="t m0 x9 hc y28 ff6 fs9 fc3 sc0 ls16 ws0">WHO Library Cataloguing-in-Publication Data</div><div class="t m0 xa hc y29 ff6 fs9 fc3 sc0 ls16 ws0">Guidelines for the treatment of malaria/W<span class="_ _a"></span>orld Health Organization. </div><div class="t m0 xa hc y2a ff6 fs9 fc3 sc0 ls0 ws17">Running title: <span class="_ _a"></span>WHO guidelines for the treatment of malaria.</div><div class="t m0 xa hc y2b ff6 fs9 fc3 sc0 ls17 ws18">1. Malaria – drug therapy<span class="_ _b"></span>. 2. Malaria – diagnosis. 3. Antimalarials – administr<span class="_ _a"></span>ation</div><div class="t m0 xa hc y2c ff6 fs9 fc3 sc0 ls0 ws19">and dosage. 4. Drug therapy<span class="_ _b"></span>, Combination. 5. Guidelines. I. <span class="_ _b"></span>Title. I<span class="_ _8"></span>I. T<span class="_ _a"></span>itle: WHO</div><div class="t m0 xa hc y2d ff6 fs9 fc3 sc0 ls16 ws0">guidelines for the treatment of malaria.</div><div class="t m0 xa hc y2e ff6 fs9 fc3 sc0 ls0 ws17">ISBN 92 4 154694 8<span class="_ _d"> </span>(NLM classification: W<span class="_ _a"></span>C 770)</div><div class="t m0 xa hc y2f ff6 fs9 fc3 sc0 ls15 ws16">ISBN 978 92 4 154694 2<span class="_ _e"> </span>WHO/HTM/MAL/2006.1108</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5" class="pf w1 h4" data-page-no="5"><div class="pc pc5 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb hd y30 ff8 fs8 fc4 sc0 ls12 ws0">Glossar<span class="_ _8"></span>y<span class="_ _f"> </span>v</div><div class="t m0 xb hd y31 ff8 fs8 fc4 sc0 ls12 ws0">Abbreviations<span class="_ _10"> </span>viii</div><div class="t m0 xb hd y32 ff8 fs8 fc4 sc0 ls12 ws0">1.<span class="_ _11"> </span>Introduction<span class="_ _12"> </span>1</div><div class="t m0 xc hc y33 ff9 fs9 fc3 sc0 ls18 ws0">1.1<span class="_ _13"> </span>Background<span class="_ _14"> </span>1</div><div class="t m0 xc hc y34 ff9 fs9 fc3 sc0 ls18 ws0">1.2<span class="_ _15"> </span>Objectives and target audience<span class="_ _16"> </span>2</div><div class="t m0 xc hc y35 ff9 fs9 fc3 sc0 ls18 ws0">1.3<span class="_ _15"> </span>Methods used in developing the guidelines and recommendations<span class="_ _17"> </span>3</div><div class="t m0 xb hd y36 ff8 fs8 fc4 sc0 ls12 ws0">2.<span class="_ _18"> </span>The clinical disease<span class="_ _19"> </span>5</div><div class="t m0 xb hd y37 ff8 fs8 fc4 sc0 ls13 ws14">3.<span class="_ _1a"> </span>T<span class="_ _b"></span>reatment objectives<span class="_ _1b"> </span>7</div><div class="t m0 xc hc y38 ff9 fs9 fc3 sc0 ls18 ws0">3.1<span class="_ _15"> </span>Uncomplicated malaria<span class="_ _1c"> </span>7</div><div class="t m0 xc hc y39 ff9 fs9 fc3 sc0 ls18 ws1a">3.2<span class="_ _1d"> </span>Severe malaria<span class="_ _1e"> </span>7</div><div class="t m0 xb hd y3a ff8 fs8 fc4 sc0 ls12 ws0">4.<span class="_ _18"> </span>Diagnosis of malaria <span class="_ _1f"> </span>8</div><div class="t m0 xc hc y3b ff9 fs9 fc3 sc0 ls18 ws0">4.1<span class="_ _15"> </span>Clinical diagnosis<span class="_ _20"> </span>8</div><div class="t m0 xc hc y3c ff9 fs9 fc3 sc0 ls18 ws0">4.2<span class="_ _1d"> </span>Par<span class="_ _a"></span>asitological diagnosis<span class="_ _21"> </span>9</div><div class="t m0 xc hc y3d ff9 fs9 fc3 sc0 ls18 ws1a">4.3<span class="_ _1d"> </span>Where malaria transmission is lo<span class="_ _a"></span>w–moderate and/or unstable <span class="_ _22"> </span>10</div><div class="t m0 xc hc y3e ff9 fs9 fc3 sc0 ls18 ws0">4.4<span class="_ _1d"> </span>In stable high-transmission settings <span class="_ _23"> </span>10</div><div class="t m0 xc hc y3f ff9 fs9 fc3 sc0 ls18 ws0">4.5<span class="_ _1d"> </span>Malaria parasite species identification <span class="_ _24"> </span>11</div><div class="t m0 xc hc y40 ff9 fs9 fc3 sc0 ls18 ws0">4.6<span class="_ _1d"> </span>In epidemics and complex emer<span class="_ _a"></span>gencies <span class="_ _25"> </span>11</div><div class="t m0 xb hd y41 ff8 fs8 fc4 sc0 ls12 ws0">5.<span class="_ _1a"> </span>Resistance to antimalarial medicines<span class="_ _26"> </span>12</div><div class="t m0 xc hc y42 ff9 fs9 fc3 sc0 ls18 ws0">5.1<span class="_ _15"> </span>Impact of resistance<span class="_ _27"> </span>12</div><div class="t m0 xc hc y43 ff9 fs9 fc3 sc0 ls18 ws0">5.2<span class="_ _1d"> </span>Global distribution of resistance<span class="_ _28"> </span>12</div><div class="t m0 xc hc y44 ff9 fs9 fc3 sc0 ls18 ws0">5.3<span class="_ _1d"> </span>Assessing resistance<span class="_ _29"> </span>13</div><div class="t m0 xb hd y45 ff8 fs8 fc4 sc0 ls12 ws0">6.<span class="_ _18"> </span>Antimalarial tr<span class="_ _a"></span>eatment policy <span class="_ _2a"> </span>14</div><div class="t m0 xc hc y46 ff9 fs9 fc3 sc0 ls18 ws0">6.1<span class="_ _15"> </span>Assessment of <span class="ffa">in vivo </span>ther<span class="_ _a"></span>apeutic efficacy<span class="_ _2b"> </span>14</div><div class="t m0 xc hc y47 ff9 fs9 fc3 sc0 ls18 ws0">6.2<span class="_ _1d"> </span>Criteria for antimalarial treatment policy change<span class="_ _2c"> </span>15</div><div class="t m0 xb hd y48 ff8 fs8 fc4 sc0 ls12 ws0">7.<span class="_ _2d"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffb">P<span class="_ _c"></span>. falciparum <span class="ff8">malaria<span class="_ _2e"> </span>16</span></span></div><div class="t m0 xc hc y49 ff9 fs9 fc3 sc0 ls18 ws0">7.1<span class="_ _15"> </span>Assessment<span class="_ _2f"> </span>16</div><div class="t m0 xc hc y4a ff9 fs9 fc3 sc0 ls18 ws0">7.2<span class="_ _1d"> </span>Antimalarial combination therapy<span class="_ _30"> </span>16</div><div class="t m0 xc hc y4b ff9 fs9 fc3 sc0 ls18 ws0">7.3<span class="_ _1d"> </span>The choice of ar<span class="_ _8"></span>temisinin based combination therapy options<span class="_ _31"> </span>20</div><div class="t m0 xc hc y4c ff9 fs9 fc3 sc0 ls18 ws0">7.4<span class="_ _1d"> </span>Practical aspects of treatment with recommended A<span class="_ _a"></span>CT<span class="_ _b"></span>s <span class="_ _32"> </span>23</div><div class="t m0 xc hc y4d ff9 fs9 fc3 sc0 ls18 ws0">7.5<span class="_ _33"> </span>Incorrect approaches to tr<span class="_ _a"></span>eatment<span class="_ _34"> </span>26</div><div class="t m0 xc hc y4e ff9 fs9 fc3 sc0 ls18 ws0">7.6<span class="_ _1d"> </span>Additional aspects of clinical management<span class="_ _35"> </span>27</div><div class="t m0 xc hc y4f ff9 fs9 fc3 sc0 ls18 ws0">7.7<span class="_ _33"> </span>Operational issues in treatment management<span class="_ _36"> </span>29</div><div class="t m0 xc hc y50 ff9 fs9 fc3 sc0 ls18 ws0">7.8<span class="_ _1d"> </span>Management of treatment failures<span class="_ _37"> </span>31</div><div class="t m0 xc hc y51 ff9 fs9 fc3 sc0 ls18 ws0">7.9<span class="_ _1d"> </span>T<span class="_ _a"></span>reatment in specific populations and situations <span class="_ _38"> </span>32</div><div class="t m0 xc hc y52 ff9 fs9 fc3 sc0 ls19 ws16">7.10<span class="_ _39"> </span>Coexisting morbidities<span class="_ _3a"> </span>38</div><div class="t m0 xd he y9 ffc fs5 fc3 sc0 ls1a ws0">Contents</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">iii</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6" class="pf w1 h4" data-page-no="6"><div class="pc pc6 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xf h9 ya ff9 fs6 fc4 sc0 ls1b ws0">iv</div><div class="t m0 x9 hd y30 ff8 fs8 fc4 sc0 ls12 ws0">8.<span class="_ _3b"> </span>T<span class="_ _b"></span>reatment of sever<span class="_ _a"></span>e falciparum malaria<span class="_ _25"> </span>41</div><div class="t m0 x10 hc y53 ff9 fs9 fc3 sc0 ls18 ws0">8.1<span class="_ _15"> </span>Definition<span class="_ _3c"> </span>41</div><div class="t m0 x10 hc y54 ff9 fs9 fc3 sc0 ls18 ws0">8.2<span class="_ _1d"> </span>T<span class="_ _b"></span>reatment objectiv<span class="_ _a"></span>es<span class="_ _29"> </span>41</div><div class="t m0 x10 hc y55 ff9 fs9 fc3 sc0 ls18 ws0">8.3<span class="_ _1d"> </span>Clinical assessment<span class="_ _3d"> </span>42</div><div class="t m0 x10 hc y56 ff9 fs9 fc3 sc0 ls18 ws1a">8.4<span class="_ _1d"> </span>Specific antimalarial tr<span class="_ _a"></span>eatment<span class="_ _3e"> </span>42</div><div class="t m0 x10 hc y57 ff9 fs9 fc3 sc0 ls18 ws0">8.5<span class="_ _1d"> </span>Pr<span class="_ _a"></span>actical aspects of treatment<span class="_ _3f"> </span>47</div><div class="t m0 x10 hc y58 ff9 fs9 fc3 sc0 ls18 ws0">8.6<span class="_ _40"> </span>Follo<span class="_ _a"></span>w-on treatment<span class="_ _41"> </span>48</div><div class="t m0 x10 hc y59 ff9 fs9 fc3 sc0 ls18 ws0">8.7<span class="_ _1d"> </span>Pre-referr<span class="_ _a"></span>al treatment options <span class="_ _42"> </span>49</div><div class="t m0 x10 hc y5a ff9 fs9 fc3 sc0 ls18 ws0">8.8<span class="_ _40"> </span>Adjunctive tr<span class="_ _a"></span>eatment<span class="_ _29"> </span>51</div><div class="t m0 x10 hc y5b ff9 fs9 fc3 sc0 ls18 ws1a">8.9<span class="_ _40"> </span>Continuing supportive care<span class="_ _43"> </span>53</div><div class="t m0 x10 hc y5c ff9 fs9 fc3 sc0 ls18 ws1a">8.10<span class="_ _44"> </span>Additional aspects of clinical management<span class="_ _45"> </span>54</div><div class="t m0 x10 hc y5d ff9 fs9 fc3 sc0 ls18 ws0">8.11<span class="_ _46"> </span>T<span class="_ _b"></span>reatment during pregnancy<span class="_ _47"> </span>58</div><div class="t m0 x10 hc y5e ff9 fs9 fc3 sc0 ls19 ws16">8.12<span class="_ _44"> </span>Management in epidemic situations<span class="_ _48"> </span>59</div><div class="t m0 x10 hc y5f ff9 fs9 fc3 sc0 ls19 ws1b">8.13<span class="_ _44"> </span>Hyperparasitaemia 60</div><div class="t m0 x9 hd y60 ff8 fs8 fc4 sc0 ls12 ws0">9.<span class="_ _18"> </span>T<span class="_ _b"></span>r<span class="_ _a"></span>eatment of malaria caused by <span class="ffb ls13">P<span class="_ _c"></span>. vivax<span class="ff8 ls14">, </span>P<span class="_ _c"></span>. o<span class="_ _a"></span>vale <span class="ff8">or </span><span class="ls12">P<span class="_ _c"></span>. malariae<span class="_ _49"> </span><span class="ff8 ls13">62</span></span></span></div><div class="t m0 x10 hc y61 ff9 fs9 fc3 sc0 ls18 ws0">9.1<span class="_ _15"> </span>Diagnosis<span class="_ _4a"> </span>62</div><div class="t m0 x10 hc y62 ff9 fs9 fc3 sc0 ls18 ws0">9.2<span class="_ _40"> </span>Susceptibility of <span class="ffa">P<span class="_ _4b"></span>. vivax<span class="ff9">, </span>P<span class="_ _c"></span>. ov<span class="_ _a"></span>ale <span class="ff9">and </span>P<span class="_ _c"></span>. malariae <span class="ff9">to antimalarials<span class="_ _4c"> </span>63</span></span></div><div class="t m0 x10 hc y63 ff9 fs9 fc3 sc0 ls18 ws0">9.3<span class="_ _40"> </span>T<span class="_ _a"></span>reatment of uncomplicated vivax malaria<span class="_ _4d"> </span>63</div><div class="t m0 x10 hc y64 ff9 fs9 fc3 sc0 ls18 ws0">9.4<span class="_ _40"> </span>T<span class="_ _a"></span>reatment of sever<span class="_ _a"></span>e vivax malaria<span class="_ _4e"> </span>66</div><div class="t m0 x10 hc y65 ff9 fs9 fc3 sc0 ls18 ws1a">9.5<span class="_ _40"> </span>T<span class="_ _a"></span>reatment of malaria caused by <span class="ffa ws0">P<span class="_ _c"></span>. ovale <span class="ff9">and </span>P<span class="_ _c"></span>. malariae<span class="_ _32"> </span><span class="ff9">66</span></span></div><div class="t m0 x10 hc y66 ff9 fs9 fc3 sc0 ls18 ws0">9.6<span class="_ _40"> </span>Monitoring therapeutic efficacy for vivax malaria<span class="_ _4f"> </span>66</div><div class="t m0 x9 hd y67 ff8 fs8 fc4 sc0 ls12 ws0">10.<span class="_ _50"> </span>Mixed malaria infections<span class="_ _51"> </span>68</div><div class="t m0 x9 hd y68 ff8 fs8 fc4 sc0 ls12 ws0">11.<span class="_ _52"> </span>Complex emergencies and epidemics <span class="_ _53"> </span>69</div><div class="t m0 x10 hc y69 ff9 fs9 fc3 sc0 ls18 ws0">11.1<span class="_ _54"> </span>Diagnosis<span class="_ _4a"> </span>69</div><div class="t m0 x10 hc y6a ff9 fs9 fc3 sc0 ls18 ws0">11.2<span class="_ _46"> </span>Use of rapid diagnostic tests in epidemic situations<span class="_ _55"> </span>69</div><div class="t m0 x10 hc y6b ff9 fs9 fc3 sc0 ls18 ws0">11.3<span class="_ _46"> </span>Management of uncomplicated malaria in epidemics<span class="_ _56"> </span>70</div><div class="t m0 x10 hc y6c ff9 fs9 fc3 sc0 ls18 ws0">11.4<span class="_ _46"> </span>Areas prone to mixed falciparum/viv<span class="_ _a"></span>ax malaria epidemics <span class="_ _57"> </span>70</div><div class="t m0 x10 hc y6d ff9 fs9 fc3 sc0 ls18 ws0">11.5<span class="_ _46"> </span>Use of gametocytocidal drugs to reduce transmission<span class="_ _58"> </span>71</div><div class="t m0 x10 hc y6e ff9 fs9 fc3 sc0 ls18 ws0">11.6<span class="_ _46"> </span>Anti-relapse therapy in viv<span class="_ _a"></span>ax malaria epidemics <span class="_ _59"> </span>71</div><div class="t m0 x10 hc y6f ff9 fs9 fc3 sc0 ls18 ws0">11.7<span class="_ _5a"> </span>Mass treatment<span class="_ _5b"> </span>71</div><div class="t m0 x10 hd y70 ff8 fs8 fc4 sc0 ls13 ws0">Annexes</div><div class="t m0 x10 hc y71 ff9 fs9 fc3 sc0 ls18 ws0">Annex 1. The guidelines dev<span class="_ _a"></span>elopment process<span class="_ _25"> </span>77</div><div class="t m0 x10 hc y72 ff9 fs9 fc3 sc0 ls18 ws17">Annex 2. Adaptation of WHO malaria tr<span class="_ _a"></span>eatment guidelines for use </div><div class="t m0 x11 hc y73 ff9 fs9 fc3 sc0 ls18 ws0">in countries<span class="_ _5c"> </span>83</div><div class="t m0 x10 hc y74 ff9 fs9 fc3 sc0 ls18 ws0">Annex 3. Pharmacology of antimalarial drugs<span class="_ _5d"> </span>87</div><div class="t m0 x10 hc y75 ff9 fs9 fc3 sc0 ls18 ws0">Annex 4. Antimalarials and malaria transmission<span class="_ _5e"> </span>133</div><div class="t m0 x10 hc y76 ff9 fs9 fc3 sc0 ls18 ws0">Annex 5. Malaria diagnosis<span class="_ _1c"> </span>147</div><div class="t m0 x10 hc y77 ff9 fs9 fc3 sc0 ls18 ws0">Annex 6. Resistance to antimalarials<span class="_ _5f"> </span>155</div><div class="t m0 x10 hc y78 ff9 fs9 fc3 sc0 ls18 ws0">Annex 7. Uncomplicated <span class="ffa">P<span class="_ _c"></span>. falciparum <span class="ff9">malaria<span class="_ _60"> </span>185</span></span></div><div class="t m0 x10 hc y79 ff9 fs9 fc3 sc0 ls18 ws0">Annex 8. Malaria treatment and HIV/AI<span class="_ _8"></span>DS<span class="_ _61"> </span>198</div><div class="t m0 x10 hc y7a ff9 fs9 fc3 sc0 ls18 ws0">Annex 9. T<span class="_ _b"></span>reatment of sever<span class="_ _a"></span>e <span class="ffa">P<span class="_ _c"></span>. falciparum <span class="ff9">malaria<span class="_ _36"> </span>207</span></span></div><div class="t m0 x10 hc y7b ff9 fs9 fc3 sc0 ls19 ws16">Annex 10. T<span class="_ _b"></span>reatment of <span class="ffa ws0">P<span class="_ _c"></span>. vivax<span class="ff9">, </span><span class="ls18">P<span class="_ _c"></span>. ov<span class="_ _a"></span>ale <span class="ff9">and </span>P<span class="_ _c"></span>. malariae <span class="ff9">infections<span class="_ _62"> </span>225</span></span></span></div><div class="t m0 x10 hc y7c ff9 fs9 fc3 sc0 ls18 ws0">Index<span class="_ _63"> </span>240</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7" class="pf w1 h4" data-page-no="7"><div class="pc pc7 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x12 he y9 ffc fs5 fc3 sc0 ls3 ws0">Glossary</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls0 ws0">v</div><div class="t m0 xb hf y7d ffe fs6 fc4 sc0 ls1c ws0">GLOSSAR<span class="_ _b"></span>Y</div><div class="t m0 xb hb y7e ff8 fs8 fc3 sc0 ls1d ws1c">Artemisinin-based combination therapy (ACT). <span class="ff9">A combination of ar<span class="_ _8"></span>temisinin</span></div><div class="t m0 xb hb y7f ff9 fs8 fc3 sc0 ls1e ws1d">or one if its derivativ<span class="_ _a"></span>es with an antimalarial or antimalarials of a different class.</div><div class="t m0 xb hb y80 ff8 fs8 fc3 sc0 ls1f ws1e">Asexual cycle.<span class="_ _6"> </span><span class="ff9 ls20 ws1f">The life-cy<span class="_ _a"></span>cle of the malaria parasite in host red blood cells (intra-</span></div><div class="t m0 xb hb y81 ff9 fs8 fc3 sc0 ls21 ws20">erythrocytic development) from mer<span class="_ _a"></span>ozoite invasion to schiz<span class="_ _a"></span>ont rupture</div><div class="t m0 xb hb y82 ff9 fs8 fc3 sc0 ls13 ws0">(merozoite <span class="_ _b"></span><span class="fff ls0">→<span class="_ _5"> </span><span class="ff9 ls12 ws21">ring stage </span>→<span class="_ _6"> </span><span class="ff9 ls12">trophozoite </span>→<span class="_ _6"> </span><span class="ff9 ls13">schizont <span class="_ _a"></span><span class="fff ls0">→<span class="_ _6"> </span><span class="ff9 ls12 ws21">merozoites). Duration</span></span></span></span></div><div class="t m0 xb hb y83 ff9 fs8 fc3 sc0 ls22 ws22">approximately 48 h in <span class="ffa">Plasmodium falciparum</span><span class="ws0">, <span class="_ _9"></span><span class="ffa">P<span class="_ _c"></span>.<span class="_ _64"> </span>ov<span class="_ _a"></span>ale<span class="_ _64"> </span><span class="ff9">and <span class="_ _9"></span></span>P<span class="_ _c"></span>.<span class="_ _3"> </span>viv<span class="_ _a"></span>ax<span class="ff9 ls23 ws23">;7<span class="_ _65"></span>2h<span class="_ _65"></span> i<span class="_ _65"></span>n</span></span></span></div><div class="t m0 xb h10 y84 ffa fs8 fc3 sc0 ls13 ws0">P<span class="_ _c"></span>. malariae.</div><div class="t m0 xb hb y85 ff8 fs8 fc3 sc0 ls12 ws24">Asexual parasitaemia.<span class="_ _6"> </span><span class="ff9">The presence in host red blood cells of asexual para-</span></div><div class="t m0 xb hb y86 ff9 fs8 fc3 sc0 ls12 ws25">sites. The lev<span class="_ _a"></span>el of asexual parasitaemia can be expressed in sev<span class="_ _a"></span>eral different</div><div class="t m0 xb hb y87 ff9 fs8 fc3 sc0 ls24 ws26">ways: the percentage of infected red blood cells, the number of infected cells</div><div class="t m0 xb hb y88 ff9 fs8 fc3 sc0 ls25 ws27">per unit volume of blood, the number of parasites seen in one micr<span class="_ _a"></span>oscopic field</div><div class="t m0 xb hb y89 ff9 fs8 fc3 sc0 ls12 ws28">in a high-power examination of a thick blood film, or the number of par<span class="_ _a"></span>asites</div><div class="t m0 xb hb y8a ff9 fs8 fc3 sc0 ls13 ws29">seen per 200–1000 white blood cells in a high-power examination of a thick</div><div class="t m0 xb hb y8b ff9 fs8 fc3 sc0 ls12 ws0">blood film.</div><div class="t m0 xb hb y8c ff8 fs8 fc3 sc0 ls26 ws2a">Cerebral malaria. <span class="ff9">Sev<span class="_ _a"></span>ere falciparum malaria with coma (Glasgow coma scale</span></div><div class="t m0 xb hb y8d fff fs8 fc3 sc0 ls0 ws0">&lt;<span class="ff9 ls12 ws2b">11, Blantyre coma scale </span>&lt;<span class="ff9 ls12 ws2b">3). Malaria with coma persisting for </span>&gt;<span class="ff9 ls12 ws2c">30 min after</span></div><div class="t m0 xb hb y8e ff9 fs8 fc3 sc0 ls12 ws0">a seizure is considered to be cer<span class="_ _a"></span>ebral malaria.</div><div class="t m0 xb hb y8f ff8 fs8 fc3 sc0 ls12 ws2d">Combination treatment (CT). <span class="ff9">A combination of two or more different classes</span></div><div class="t m0 xb hb y90 ff9 fs8 fc3 sc0 ls12 ws0">of antimalarial medicines with unrelated mechanisms of action.</div><div class="t m0 xb hb y91 ff8 fs8 fc3 sc0 ls14 ws0">Cure. <span class="ff9 ls12 ws2e">Elimination of the symptoms and asexual blood stages of the malaria</span></div><div class="t m0 xb hb y92 ff9 fs8 fc3 sc0 ls12 ws0">parasite that caused the patient or carer to seek tr<span class="_ _a"></span>eatment.</div><div class="t m0 xb hb y93 ff8 fs8 fc3 sc0 ls12 ws2f">Drug resistance. <span class="ff9 ls0">R<span class="_ _a"></span>educed susceptibility of the causal agent to a drug. WHO</span></div><div class="t m0 xb hb y94 ff9 fs8 fc3 sc0 ls27 ws30">defines resistance to antimalarials as the ability of a parasite str<span class="_ _a"></span>ain to sur<span class="_ _8"></span>vive</div><div class="t m0 xb hb y95 ff9 fs8 fc3 sc0 ls22 ws31">and/or multiply despite the administration and absorption of a medicine given</div><div class="t m0 xb hb y96 ff9 fs8 fc3 sc0 ls12 ws32">in doses equal to – or higher than – those usually recommended but within</div><div class="t m0 xb hb y97 ff9 fs8 fc3 sc0 ls12 ws33">the tolerance of the subject, with the caveat that the form of the drug activ<span class="_ _a"></span>e</div><div class="t m0 xb hb y98 ff9 fs8 fc3 sc0 ls28 ws34">against the parasite must be able to gain access to the parasite or the infected</div><div class="t m0 xb hb y99 ff9 fs8 fc3 sc0 ls12 ws35">red blood cell for the duration of the time necessary for its normal action.</div><div class="t m0 xb hb y9a ff9 fs8 fc3 sc0 ls12 ws36">Resistance to antimalarials arises because of the selection of par<span class="_ _a"></span>asites with</div><div class="t m0 xb hb y9b ff9 fs8 fc3 sc0 ls12 ws37">genetic mutations or gene amplifications that confer reduced susceptibility<span class="_ _c"></span>.</div><div class="t m0 xb hb y9c ff8 fs8 fc3 sc0 ls29 ws0">Gametocytes.<span class="_ _3"> </span><span class="ff9 ls2a ws38">Sexual stages of malaria parasites present in the host red</span></div><div class="t m0 xb hb y9d ff9 fs8 fc3 sc0 ls12 ws0">blood cells, which are infective to the anopheline mosquito<span class="_ _a"></span>. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8" class="pf w1 h4" data-page-no="8"><div class="pc pc8 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xf h9 ya ff9 fs6 fc4 sc0 ls1b ws0">vi</div><div class="t m0 x9 hb y9e ff8 fs8 fc3 sc0 ls2b ws0">Hypnozoites.<span class="_ _3"> </span><span class="ff9 ls2c ws39">Persistent liv<span class="_ _a"></span>er stages of <span class="ffa">P<span class="_ _c"></span>. vivax <span class="ff9 ws0">and <span class="_ _66"></span></span>P<span class="_ _c"></span>. ov<span class="_ _a"></span>ale <span class="ff9">malaria that</span></span></span></div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls12 ws3a">remain dormant in host hepatocytes for a fixed interval (3–45 w<span class="_ _a"></span>eeks) before</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls2d ws3b">maturing to hepatic schizonts. <span class="_ _a"></span>These then burst and release merozoites,</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls12 ws0">which infect red blood cells. Hypnozoites ar<span class="_ _a"></span>e the source of relapses.</div><div class="t m0 x9 hb ya2 ff8 fs8 fc3 sc0 ls2e ws3c">Malaria pigment (haemozoin). <span class="ff9 ls2f ws3d">A dark bro<span class="_ _a"></span>wn granular pigment formed by</span></div><div class="t m0 x9 hb ya3 ff9 fs8 fc3 sc0 ls30 ws3e">malaria parasites as a by-product of haemoglobin catabolism. <span class="_ _a"></span>The pigment is</div><div class="t m0 x9 hb ya4 ff9 fs8 fc3 sc0 ls12 ws0">evident in mature trophoz<span class="_ _a"></span>oites and schizonts. </div><div class="t m0 x9 hb ya5 ff8 fs8 fc3 sc0 ls13 ws0">Merozoites. <span class="ff9 ls12 ws3f">P<span class="_ _a"></span>arasites released into the host bloodstream when a hepatic or</span></div><div class="t m0 x9 hb ya6 ff9 fs8 fc3 sc0 ls12 ws0">erythrocytic schizont bursts. <span class="_ _a"></span>These then invade the red blood cells. </div><div class="t m0 x9 hb ya7 ff8 fs8 fc3 sc0 ls12 ws0">Monotherapy<span class="_ _c"></span>. <span class="ff9 ws40">Antimalarial treatment with a single medicine (either a single</span></div><div class="t m0 x9 hb ya8 ff9 fs8 fc3 sc0 ls31 ws41">active compound or a syner<span class="_ _a"></span>gistic combination of two compounds with related</div><div class="t m0 x9 hb ya9 ff9 fs8 fc3 sc0 ls12 ws0">mechanism of action).</div><div class="t m0 x9 hb yaa ffb fs8 fc3 sc0 ls12 ws0">Plasmodium. <span class="ff9 ws42">A genus of protozoan v<span class="_ _a"></span>er<span class="_ _8"></span>tebrate blood parasites that includes</span></div><div class="t m0 x9 hb yab ff9 fs8 fc3 sc0 ls32 ws43">the causal agents of malaria. <span class="ffa">Plasmodium falciparum</span><span class="ls33 ws0">, </span><span class="ffa ls34">P<span class="_ _c"></span>. malariae<span class="ff9 ls33 ws0">, <span class="_ _b"></span><span class="ffa ls35 ws44">P.<span class="_ _67"> </span> o<span class="_ _66"></span>v<span class="_ _66"></span>a<span class="_ _67"> </span>l<span class="_ _66"></span>e<span class="_ _3"> </span><span class="ff9 ls32 ws0">and</span></span></span></span></div><div class="t m0 x9 hb yac ffa fs8 fc3 sc0 ls13 ws0">P<span class="_ _c"></span>. vivax <span class="ff9 ls12">cause malaria in humans.</span></div><div class="t m0 x9 hb yad ff8 fs8 fc3 sc0 ls0 ws45">Pre-erythrocytic development.<span class="_ _6"> </span><span class="ff9 ls12">The life-cycle of the malaria parasite when it</span></div><div class="t m0 x9 hb yae ff9 fs8 fc3 sc0 ls36 ws46">first enters the host. Follo<span class="_ _a"></span>wing inoculation into a human by the female</div><div class="t m0 x9 hb yaf ff9 fs8 fc3 sc0 ls12 ws47">anopheline mosquito, sporozoites inv<span class="_ _a"></span>ade parenchyma cells in the host liver</div><div class="t m0 x9 hb yb0 ff9 fs8 fc3 sc0 ls37 ws48">and multiply within the hepatocytes for 5–12 days, forming hepatic schizonts.</div><div class="t m0 x9 hb yb1 ff9 fs8 fc3 sc0 ls12 ws49">These then burst liberating meroz<span class="_ _a"></span>oites into the bloodstream, which subse-</div><div class="t m0 x9 hb yb2 ff9 fs8 fc3 sc0 ls12 ws0">quently invade r<span class="_ _a"></span>ed blood cells.</div><div class="t m0 x9 hb yb3 ff8 fs8 fc3 sc0 ls13 ws4a">Radical cure. <span class="ff9 ws0">In <span class="ffa ws4b">P<span class="_ _c"></span>. vivax <span class="ff9 ls12 ws0">and<span class="_ _64"> </span></span><span class="ls38 ws4c">P.<span class="_ _66"></span> o<span class="_ _66"></span>v<span class="_ _66"></span>a<span class="_ _67"> </span>l<span class="_ _67"> </span>e<span class="_ _68"> </span><span class="ff9 ls12 ws4d">infections only<span class="_ _4b"></span>, this comprises cure as</span></span></span></span></div><div class="t m0 x9 hb yb4 ff9 fs8 fc3 sc0 ls12 ws0">defined abov<span class="_ _a"></span>e plus prevention of relapses. </div><div class="t m0 x9 hb yb5 ff8 fs8 fc3 sc0 ls26 ws2a">Rapid diagnostic test (RD<span class="_ _a"></span>T). <span class="ff9">An antigen-based stick, cassette or card test for</span></div><div class="t m0 x9 hb yb6 ff9 fs8 fc3 sc0 ls39 ws4e">malaria in which a coloured line indicates that plasmodial antigens have</div><div class="t m0 x9 hb yb7 ff9 fs8 fc3 sc0 ls12 ws0">been detected.</div><div class="t m0 x9 hb yb8 ff8 fs8 fc3 sc0 ls3a ws0">R<span class="_ _a"></span>ecrudescence.<span class="_ _6"> </span><span class="ff9 ls3b ws4f">The recurrence of asexual par<span class="_ _a"></span>asitaemia after treatment of the</span></div><div class="t m0 x9 hb yb9 ff9 fs8 fc3 sc0 ls12 ws50">infection with the same infection that caused the original illness (in endemic</div><div class="t m0 x9 hb yba ff9 fs8 fc3 sc0 ls13 ws51">areas now defined by molecular genotyping). <span class="_ _b"></span>This results from incomplete</div><div class="t m0 x9 hb ybb ff9 fs8 fc3 sc0 ls3c ws31">clearance of parasitaemia by tr<span class="_ _a"></span>eatment and is therefore different to a r<span class="_ _a"></span>elapse</div><div class="t m0 x9 hb ybc ff9 fs8 fc3 sc0 ls13 ws0">in <span class="ffa">P<span class="_ _c"></span>. vivax <span class="ff9 ls12">and </span><span class="ls38 ws52">P.<span class="_ _66"></span> o<span class="_ _66"></span>v<span class="_ _66"></span>a<span class="_ _67"> </span>l<span class="_ _66"></span>e<span class="_ _68"> </span></span><span class="ff9 ls12">infections.</span></span></div><div class="t m0 x9 hb ybd ff8 fs8 fc3 sc0 ls3d ws0">R<span class="_ _a"></span>ecurrence.<span class="_ _67"> </span><span class="ff9 ws53">The recurrence of asexual parasitaemia following tr<span class="_ _a"></span>eatment. This</span></div><div class="t m0 x9 hb ybe ff9 fs8 fc3 sc0 ls3e ws54">can be caused by a recrudescence, a relapse (in <span class="ffa ws55">P<span class="_ _c"></span>. viv<span class="_ _b"></span>ax <span class="ff9 ws0">and </span><span class="ws34">P<span class="_ _c"></span>. ov<span class="_ _a"></span>ale <span class="ff9 ws0">infections</span></span></span></div><div class="t m0 x9 hb ybf ff9 fs8 fc3 sc0 ls12 ws0">only) or a new infection.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9" class="pf w1 h4" data-page-no="9"><div class="pc pc9 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x12 he y9 ffc fs5 fc3 sc0 ls3 ws0">Glossary</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">vii</div><div class="t m0 xb hb y9e ff8 fs8 fc3 sc0 ls3f ws0">R<span class="_ _a"></span>elapse.<span class="_ _3"> </span><span class="ff9 ls40 ws56">The recurrence of asexual par<span class="_ _a"></span>asitaemia in <span class="ffa ls41 ws57">P.<span class="_ _67"> </span> v<span class="_ _66"></span>i<span class="_ _67"> </span>v<span class="_ _9"></span>a<span class="_ _67"> </span>x<span class="_ _1"> </span></span><span class="ws0">and <span class="_ _67"></span></span><span class="ffa">P<span class="_ _c"></span>. o<span class="_ _a"></span>vale</span></span></div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls12 ws58">malaria deriving from persisting liver stages. R<span class="_ _a"></span>elapse occurs when the blood</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls12 ws59">stage infection has been eliminated but hypnozoites persist in the liver and</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls12 ws5a">mature to form hepatic schizonts. After a v<span class="_ _a"></span>ariable interval of weeks (tropical</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls42 ws5b">strains) or months (temperate str<span class="_ _a"></span>ains) the hepatic schizonts burst and liberate</div><div class="t m0 xb hb yc1 ff9 fs8 fc3 sc0 ls12 ws0">merozoites into the bloodstr<span class="_ _a"></span>eam. </div><div class="t m0 xb hb ya4 ff8 fs8 fc3 sc0 ls12 ws5c">Ring stage. <span class="ff9">Y<span class="_ _4b"></span>oung usually ring-shaped intra-erythrocytic malaria parasites,</span></div><div class="t m0 xb hb yc2 ff9 fs8 fc3 sc0 ls12 ws0">before malaria pigment is evident under microscopy<span class="_ _c"></span>.</div><div class="t m0 xb hb ya6 ff8 fs8 fc3 sc0 ls12 ws0">Schizonts. <span class="ff9 ws5d">Mature malaria par<span class="_ _a"></span>asites in host liver cells (hepatic schizonts) or</span></div><div class="t m0 xb hb yc3 ff9 fs8 fc3 sc0 ls12 ws5e">red blood cells (erythrocytic schizonts) that ar<span class="_ _a"></span>e undergoing nuclear division.</div><div class="t m0 xb hb yc4 ff9 fs8 fc3 sc0 ls12 ws0">This process is called schizogony<span class="_ _c"></span>.</div><div class="t m0 xb hb ya9 ff8 fs8 fc3 sc0 ls33 ws5f">Selection pressur<span class="_ _a"></span>e. <span class="ff9 ls42 ws5b">Resistance to antimalarials emerges and spr<span class="_ _a"></span>eads because</span></div><div class="t m0 xb hb yc5 ff9 fs8 fc3 sc0 ls43 ws60">of the selective survival adv<span class="_ _a"></span>antage that resistant parasites hav<span class="_ _a"></span>e in the presence</div><div class="t m0 xb hb yc6 ff9 fs8 fc3 sc0 ls13 ws61">of antimalarials that they are resistant to<span class="_ _a"></span>. Selection pressure describes the</div><div class="t m0 xb hb yc7 ff9 fs8 fc3 sc0 ls12 ws27">intensity and magnitude of the selection process; the greater the pr<span class="_ _a"></span>opor<span class="_ _8"></span>tion</div><div class="t m0 xb hb yc8 ff9 fs8 fc3 sc0 ls12 ws62">of parasites in a given par<span class="_ _a"></span>asite population exposed to concentrations of an</div><div class="t m0 xb hb yc9 ff9 fs8 fc3 sc0 ls12 ws63">antimalarial that allow prolifer<span class="_ _a"></span>ation of resistant, but not sensitive par<span class="_ _a"></span>asites,</div><div class="t m0 xb hb yca ff9 fs8 fc3 sc0 ls12 ws0">the greater is the selection pressur<span class="_ _a"></span>e.</div><div class="t m0 xb hb ycb ff8 fs8 fc3 sc0 ls12 ws0">Sever<span class="_ _a"></span>e anaemia. <span class="ff9">Haemoglobin concentration of <span class="fff ls0">&lt;</span><span class="ls44 ws64">5 g/100 ml.</span></span></div><div class="t m0 xb hb yb1 ff8 fs8 fc3 sc0 ls12 ws65">Sever<span class="_ _a"></span>e falciparum malaria. <span class="ff9">Acute falciparum malaria with signs of severity</span></div><div class="t m0 xb hb yb2 ff9 fs8 fc3 sc0 ls12 ws0">and/or evidence of vital organ dysfunction. </div><div class="t m0 xb hb yb3 ff8 fs8 fc3 sc0 ls45 ws0">Spor<span class="_ _a"></span>ozoites. <span class="ff9 ls46 ws66">Motile malaria par<span class="_ _a"></span>asites that are infective to humans, inoculated</span></div><div class="t m0 xb hb yb4 ff9 fs8 fc3 sc0 ls47 ws67">by a feeding female anopheline mosquito. <span class="_ _a"></span>The sporozoites inv<span class="_ _a"></span>ade hepatocytes.</div><div class="t m0 xb hb yb5 ff8 fs8 fc3 sc0 ls48 ws68">T<span class="_ _b"></span>ransmission intensity<span class="_ _4b"></span>. <span class="ff9">The intensity of malaria tr<span class="_ _a"></span>ansmission measured by the</span></div><div class="t m0 xb hb yb6 ff9 fs8 fc3 sc0 ls49 ws69">frequency with which people living in an area ar<span class="_ _a"></span>e bitten by anopheline</div><div class="t m0 xb hb yb7 ff9 fs8 fc3 sc0 ls4a ws6a">mosquitoes carrying sporozoites. <span class="_ _a"></span>This is often expressed as the annual</div><div class="t m0 xb hb ycc ff9 fs8 fc3 sc0 ls12 ws33">entomological inoculation rate (EI<span class="_ _8"></span>R), which is the number of inoculations of</div><div class="t m0 xb hb ycd ff9 fs8 fc3 sc0 ls13 ws14">malaria parasites receiv<span class="_ _a"></span>ed by one person in one year<span class="_ _b"></span>. </div><div class="t m0 xb hb yba ff8 fs8 fc3 sc0 ls12 ws0">T<span class="_ _b"></span>rophozoites.<span class="_ _6"> </span><span class="ff9 ws6b">Stage of development of the malaria parasites within host r<span class="_ _a"></span>ed</span></div><div class="t m0 xb hb ybb ff9 fs8 fc3 sc0 ls4b ws6c">blood cells from the ring stage and before nuclear division. Matur<span class="_ _a"></span>e trophozoites</div><div class="t m0 xb hb ybc ff9 fs8 fc3 sc0 ls12 ws0">contain visible malaria pigment.</div><div class="t m0 xb hb ybd ff8 fs8 fc3 sc0 ls4c ws6d">Uncomplicated malaria<span class="ff9 ls4d">. Symptomatic infection with malaria par<span class="_ _a"></span>asitaemia</span></div><div class="t m0 xb hb ybe ff9 fs8 fc3 sc0 ls12 ws0">without signs of severity and/or evidence of vital or<span class="_ _a"></span>gan dysfunction.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa" class="pf w1 h4" data-page-no="a"><div class="pc pca w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x3 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">viii</div><div class="t m0 x9 hf y7d ffe fs6 fc4 sc0 ls4e ws0">ABBREVIATIONS</div><div class="t m0 x9 hb yce ff9 fs8 fc3 sc0 ls12 ws0">ACT<span class="_ _69"> </span>artemisinin-based combination therapy</div><div class="t m0 x9 hb ycf ff9 fs8 fc3 sc0 ls12 ws0">AL<span class="_ _6a"> </span>artemether-lumefantrine combination</div><div class="t m0 x9 hb yd0 ff9 fs8 fc3 sc0 ls12 ws0">AQ<span class="_ _6b"> </span>amodiaquine</div><div class="t m0 x9 hb yd1 ff9 fs8 fc3 sc0 ls12 ws0">AS<span class="_ _6c"> </span>artesunate</div><div class="t m0 x9 hb yd2 ff9 fs8 fc3 sc0 ls12 ws0">AS+AQ<span class="_ _6d"> </span>artesunate + amodiaquine combination</div><div class="t m0 x9 hb yd3 ff9 fs8 fc3 sc0 ls12 ws0">AS+MQ<span class="_ _6e"> </span>artesunate + mefloquine combination</div><div class="t m0 x9 hb yd4 ff9 fs8 fc3 sc0 ls12 ws0">AS+SP<span class="_ _57"> </span>ar<span class="_ _8"></span>tesunate + sulfadoxine-pyrimethamine combination</div><div class="t m0 x9 hb yd5 ff9 fs8 fc3 sc0 ls12 ws0">CI<span class="_ _6f"> </span>confidence interval</div><div class="t m0 x9 hb yd6 ff9 fs8 fc3 sc0 ls12 ws0">CQ<span class="_ _6b"> </span>chloroquine</div><div class="t m0 x9 hb yd7 ff9 fs8 fc3 sc0 ls12 ws0">EI<span class="_ _8"></span>R<span class="_ _70"> </span>entomological inoculation rate </div><div class="t m0 x9 hb yd8 ff9 fs8 fc3 sc0 ls12 ws0">HIV/AI<span class="_ _8"></span>DS<span class="_ _71"> </span>human immunodeficiency virus/</div><div class="t m0 x13 hb yd9 ff9 fs8 fc3 sc0 ls12 ws0">acquired immunodeficiency syndrome</div><div class="t m0 x9 hb yda ff9 fs8 fc3 sc0 ls12 ws0">HRP2<span class="_ _72"> </span>histidine-rich protein 2</div><div class="t m0 x9 hb ydb ff9 fs8 fc3 sc0 ls14 ws0">IC</div><div class="t m0 x14 h11 ydc ff9 fs5 fc3 sc0 ls4f ws0">50</div><div class="t m0 x13 hb ydd ff9 fs8 fc3 sc0 ls12 ws0">concentration pro<span class="_ _a"></span>viding 50% inhibition</div><div class="t m0 x9 hb yde ff9 fs8 fc3 sc0 ls12 ws0">MIC<span class="_ _69"> </span>minimum inhibitory concentration</div><div class="t m0 x9 hb ydf ff9 fs8 fc3 sc0 ls12 ws0">MQ<span class="_ _73"> </span>mefloquine</div><div class="t m0 x9 hb ye0 ff9 fs8 fc3 sc0 ls13 ws0">OR<span class="_ _6b"> </span>odds ratio</div><div class="t m0 x9 hb ye1 ff9 fs8 fc3 sc0 ls14 ws15">PCR<span class="_ _74"> </span>polymerase chain reaction</div><div class="t m0 x9 hb ye2 ffa fs8 fc3 sc0 ls0 ws0">p<span class="ff9 ls14">LDH<span class="_ _72"> </span></span><span class="ls13">parasite<span class="ff9 ls12">-lactate dehydrogenase</span></span></div><div class="t m0 x9 hb ye3 ff9 fs8 fc3 sc0 ls12 ws0">RCT<span class="_ _69"> </span>randomized contr<span class="_ _a"></span>olled trial</div><div class="t m0 x9 hb ye4 ff9 fs8 fc3 sc0 ls12 ws0">RDT<span class="_ _75"> </span>rapid diagnostic test </div><div class="t m0 x9 hb ye5 ff9 fs8 fc3 sc0 ls13 ws14">RR<span class="_ _6c"> </span>r<span class="_ _a"></span>elative risk </div><div class="t m0 x9 hb ye6 ff9 fs8 fc3 sc0 ls12 ws0">SP<span class="_ _6c"> </span>sulfadoxine–pyrimethamine</div><div class="t m0 x9 hb ye7 ff9 fs8 fc3 sc0 ls50 ws40">WHO<span class="_ _76"> </span>W<span class="_ _a"></span>orld Health Organization</div><div class="t m0 x9 hb ye8 ff9 fs8 fc3 sc0 ls12 ws0">WMD<span class="_ _77"> </span>weighted mean difference</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb" class="pf w1 h4" data-page-no="b"><div class="pc pcb w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x15 he y9 ffc fs5 fc3 sc0 ls51 ws0">1.<span class="_ _5"> </span>Introduction</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls0 ws0">1</div><div class="t m0 xb hf y7d ffe fs6 fc3 sc0 ls52 ws0">1.<span class="_ _33"> </span>I<span class="_ _8"></span>NTRODUCTION</div><div class="t m0 xb h12 ye9 ff10 fs6 fc4 sc0 ls53 ws0">1.1<span class="_ _78"> </span>Background</div><div class="t m0 xb hb yea ff9 fs8 fc3 sc0 ls12 ws6e">Malaria is an important cause of death and illness in children and adults in</div><div class="t m0 xb hb yeb ff9 fs8 fc3 sc0 ls12 ws5e">tropical countries. Mortality<span class="_ _4b"></span>, currently estimated at over a million people per</div><div class="t m0 xb hb yec ff9 fs8 fc3 sc0 ls54 ws6f">year<span class="_ _4b"></span>, has risen in recent years, probably due to increasing r<span class="_ _a"></span>esistance to</div><div class="t m0 xb hb yed ff9 fs8 fc3 sc0 ls55 ws70">antimalarial medicines. Malaria control requir<span class="_ _a"></span>es an integrated approach</div><div class="t m0 xb hb yee ff9 fs8 fc3 sc0 ls12 ws71">comprising prevention including v<span class="_ _a"></span>ector control and treatment with effectiv<span class="_ _a"></span>e</div><div class="t m0 xb hb yef ff9 fs8 fc3 sc0 ls56 ws72">antimalarials. The affor<span class="_ _a"></span>dable and widely available antimalarial chloroquine that</div><div class="t m0 xb hb yf0 ff9 fs8 fc3 sc0 ls57 ws73">was in the past a mainstay of malaria control is now ineffectiv<span class="_ _a"></span>e in most</div><div class="t m0 xb hb yf1 ff9 fs8 fc3 sc0 ls58 ws74">falciparum malaria endemic areas, and resistance to sulfado<span class="_ _a"></span>xine–pyrimethamine</div><div class="t m0 xb hb yf2 ff9 fs8 fc3 sc0 ls59 ws75">is increasing rapidly<span class="_ _c"></span>. The discov<span class="_ _a"></span>ery and development of the artemisinin</div><div class="t m0 xb hb yf3 ff9 fs8 fc3 sc0 ls32 ws43">derivativ<span class="_ _a"></span>es in China, and their evaluation in South-East Asia and other r<span class="_ _a"></span>egions,</div><div class="t m0 xb hb yf4 ff9 fs8 fc3 sc0 ls12 ws76">have pro<span class="_ _a"></span>vided a new class of highly effective antimalarials, and hav<span class="_ _a"></span>e already</div><div class="t m0 xb hb yf5 ff9 fs8 fc3 sc0 ls5a ws77">transformed the chemotherapy of malaria in South-East Asia. Artemisinin-based</div><div class="t m0 xb hb yf6 ff9 fs8 fc3 sc0 ls5b ws78">combination therapies (A<span class="_ _a"></span>CT<span class="_ _4b"></span>s) are now generally considered as the best curr<span class="_ _a"></span>ent</div><div class="t m0 xb hb yf7 ff9 fs8 fc3 sc0 ls12 ws0">treatment for uncomplicated falciparum malaria. </div><div class="t m0 xb hb yf8 ff9 fs8 fc3 sc0 ls5c ws79">These treatment guidelines recommend antimalarials for which ther<span class="_ _a"></span>e is</div><div class="t m0 xb hb yf9 ff9 fs8 fc3 sc0 ls12 ws7a">adequate evidence of efficacy and safety now<span class="_ _b"></span>, and which are unlikely to be</div><div class="t m0 xb hb yfa ff9 fs8 fc3 sc0 ls13 ws7b">affected by resistance in the near future. Much of the world’<span class="_ _4b"></span>s symptomatic</div><div class="t m0 xb hb yfb ff9 fs8 fc3 sc0 ls3f ws7c">malaria is treated in peripheral health centr<span class="_ _a"></span>es or remote villages, where</div><div class="t m0 xb hb yfc ff9 fs8 fc3 sc0 ls25 ws27">facilities are limited. <span class="_ _a"></span>The aim is therefore to pro<span class="_ _a"></span>vide simple and straightforward</div><div class="t m0 xb hb yfd ff9 fs8 fc3 sc0 ls12 ws7d">treatment recommendations based on sound evidence that can be applied</div><div class="t m0 xb hb yfe ff9 fs8 fc3 sc0 ls12 ws0">effectively in most settings.</div><div class="t m0 xb hb yff ff9 fs8 fc3 sc0 ls5d ws7e">These guidelines are based on a review of curr<span class="_ _a"></span>ent evidence and are developed</div><div class="t m0 xb hb y100 ff9 fs8 fc3 sc0 ls5e ws7f">in accordance with <span class="_ _a"></span>WHO’<span class="_ _b"></span>s standard methodology<span class="_ _c"></span>. Clinical evidence has been</div><div class="t m0 xb hb y101 ff9 fs8 fc3 sc0 ls12 ws80">assessed in an objective way using standard methods. <span class="_ _b"></span>The number of anti-</div><div class="t m0 xb hb y102 ff9 fs8 fc3 sc0 ls12 ws81">malarial drug trials published has doubled in the past seven years, so these</div><div class="t m0 xb hb y103 ff9 fs8 fc3 sc0 ls12 ws82">guidelines have a firmer evidence base than previous tr<span class="_ _a"></span>eatment recommen-</div><div class="t m0 xb hb y104 ff9 fs8 fc3 sc0 ls12 ws83">dations. Inevitably<span class="_ _4b"></span>, information gaps remain, howev<span class="_ _a"></span>er<span class="_ _b"></span>, and so the guidelines</div><div class="t m0 xb hb y105 ff9 fs8 fc3 sc0 ls5f ws84">will remain under regular r<span class="_ _a"></span>eview and will be updated as new evidence becomes</div><div class="t m0 xb hb y106 ff9 fs8 fc3 sc0 ls60 ws85">available. <span class="_ _b"></span>There are also difficulties when comparing results from differ<span class="_ _a"></span>ent areas,</div><div class="t m0 xb hb y107 ff9 fs8 fc3 sc0 ls61 ws86">as levels of drug resistance and backgr<span class="_ _a"></span>ound immunity vary<span class="_ _4b"></span>. Wher<span class="_ _a"></span>e transmission</div><div class="t m0 xb hb y108 ff9 fs8 fc3 sc0 ls12 ws60">levels and, consequently<span class="_ _c"></span>, immunity are high, the malaria symptoms are self-</div><div class="t m0 xb hb y109 ff9 fs8 fc3 sc0 ls12 ws87">limiting in many patients, in particular in adults, so that drugs that are only</div><div class="t m0 xb hb y10a ff9 fs8 fc3 sc0 ls12 ws88">partially effective may appear still to work well in many cases, misleading</div><div class="t m0 xb hb y10b ff9 fs8 fc3 sc0 ls62 ws89">patients and doctors alike. But in the same location, the young child who lacks</div><div class="t m0 xb hb y10c ff9 fs8 fc3 sc0 ls63 ws8a">immunity to illness caused by <span class="ffa ws8b">P<span class="_ _c"></span>. falciparum <span class="ff9 ws8c">may die if ineffective drugs are giv<span class="_ _a"></span>en. </span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc" class="pf w1 h4" data-page-no="c"><div class="pc pcc w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x8 h9 ya ff9 fs6 fc4 sc0 ls0 ws0">2</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls64 ws8d">The treatment recommendations giv<span class="_ _a"></span>en in these guidelines aim for effective</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls65 ws8e">treatment for the most vulnerable and ther<span class="_ _a"></span>efore take all the relev<span class="_ _a"></span>ant factors into</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls64 ws8f">account. These factors include labor<span class="_ _a"></span>atory measures, such as tests for <span class="ffa ws36">in vitro</span></div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls64 ws21">antimalarial susceptibility and validated molecular markers of r<span class="_ _a"></span>esistance, the</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls66 ws90">pharmacokinetic and pharmacodynamic properties of the different antimalarials,</div><div class="t m0 x9 hb yc1 ff9 fs8 fc3 sc0 ls67 ws91">and clinical trial results. Cost is a factor that has been taken into consideration</div><div class="t m0 x9 hb y10d ff9 fs8 fc3 sc0 ls64 ws92">in antimalarial treatment policy and practices. Ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, there are increasing</div><div class="t m0 x9 hb y10e ff9 fs8 fc3 sc0 ls64 ws93">international subsidies for antimalarials. Efficacy (both now and in the future)</div><div class="t m0 x9 hb y10f ff9 fs8 fc3 sc0 ls68 ws94">and safety have therefor<span class="_ _a"></span>e taken precedence when making the recommendations.</div><div class="t m0 x9 hb y110 ff9 fs8 fc3 sc0 ls64 ws76">The malaria treatment guidelines given belo<span class="_ _a"></span>w are brief; for those who wish to</div><div class="t m0 x9 hb y111 ff9 fs8 fc3 sc0 ls64 ws0">study the evidence base in more detail, a series of annexes is pr<span class="_ _a"></span>ovided. </div><div class="t m0 x9 h12 y112 ff10 fs6 fc4 sc0 ls0 ws95">1.2<span class="_ _78"> </span>Object<span class="_ _8"></span>ives and target audience</div><div class="t m0 x9 h13 y113 ff8 fs3 fc3 sc0 ls69 ws0">1.2.1<span class="_ _79"> </span>Objectives</div><div class="t m0 x9 hb y114 ff9 fs8 fc3 sc0 ls6a ws96">The purpose of this document is to pro<span class="_ _a"></span>vide comprehensible, global, evidence-</div><div class="t m0 x9 hb y115 ff9 fs8 fc3 sc0 ls12 ws97">based guidelines to help formulate policies and protocols for the treatment</div><div class="t m0 x9 hb y116 ff9 fs8 fc3 sc0 ls12 ws0">of malaria. Information is presented on the treatment of:</div><div class="t m0 x9 hb y117 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls25 ws27">uncomplicated malaria, including disease in special groups (young childr<span class="_ _a"></span>en,</span></div><div class="t m0 x16 hb y118 ff9 fs8 fc3 sc0 ls6b ws58">pregnant women, people who are HIV<span class="_ _b"></span>-positive, travellers from non-malaria</div><div class="t m0 x16 hb y119 ff9 fs8 fc3 sc0 ls12 ws98">endemic regions) and in epidemics and complex emergency situations;</div><div class="t m0 x9 hb y11a ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls13 ws14">severe malaria. </span></div><div class="t m0 x9 hb y11b ff9 fs8 fc3 sc0 ls6c ws99">The guidelines do not deal with preventiv<span class="_ _a"></span>e uses of antimalarials, such as</div><div class="t m0 x9 hb y11c ff9 fs8 fc3 sc0 ls12 ws0">intermittent preventiv<span class="_ _a"></span>e treatment or chemoprophylaxis. </div><div class="t m0 x9 h13 y11d ff8 fs3 fc3 sc0 ls69 ws0">1.2.2<span class="_ _2d"> </span>T<span class="_ _c"></span>arget audience</div><div class="t m0 x9 hb y11e ff9 fs8 fc3 sc0 ls12 ws9a">The guidelines are aimed primarily at policy-makers in ministries of health.</div><div class="t m0 x9 hb y11f ff9 fs8 fc3 sc0 ls12 ws0">The following groups should also find them useful:</div><div class="t m0 x9 hb y120 ff9 fs8 fc3 sc0 ls12 ws9b">•<span class="_ _7a"> </span>public health and policy specialists working in hospitals, ministries, non-</div><div class="t m0 x16 hb y121 ff9 fs8 fc3 sc0 ls12 ws0">gov<span class="_ _a"></span>ernmental organizations and primary health care services;</div><div class="t m0 x9 hb y122 ff9 fs8 fc3 sc0 ls12 ws0">•<span class="_ _7a"> </span>health professionals (doctors, nurses and paramedical officers).</div><div class="t m2 x9 hb y123 ff9 fs8 fc3 sc0 ls64 ws9c">The guidelines pro<span class="_ _a"></span>vide a framework for the development of specific and more</div><div class="t m2 x9 hb y124 ff9 fs8 fc3 sc0 ls64 ws9d">detailed treatment protocols that take into account national and local malaria</div><div class="t m2 x9 hb y125 ff9 fs8 fc3 sc0 ls6d ws74">drug resistance patterns and health service capacity (see Annex 2). They are not</div><div class="t m2 x9 hb y126 ff9 fs8 fc3 sc0 ls6e ws9e">intended to pro<span class="_ _a"></span>vide a comprehensive clinical management guide for the</div><div class="t m2 x9 hb y127 ff9 fs8 fc3 sc0 ls64 ws9f">treatment of malaria. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, where there are contro<span class="_ _a"></span>versies about specific</div><div class="t m2 x9 hb y128 ff9 fs8 fc3 sc0 ls64 wsa0">clinical practices, and evidence is currently av<span class="_ _b"></span>ailable to provide information to</div><div class="t m2 x9 hb y129 ff9 fs8 fc3 sc0 ls6f wsa1">guide decision-making about these practices, that information has been included.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd" class="pf w1 h4" data-page-no="d"><div class="pc pcd w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x15 he y9 ffc fs5 fc3 sc0 ls51 ws0">1.<span class="_ _5"> </span>Introduction</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls0 ws0">3</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls0 ws95">1.3<span class="_ _78"> </span>Methods used in developing the guidelines and</div><div class="t m0 x6 h12 y12b ff10 fs6 fc4 sc0 ls1 ws0">recommendations</div><div class="t m0 xb hb y12c ff9 fs8 fc3 sc0 ls70 wsa2">These guidelines have been dev<span class="_ _a"></span>eloped in accordance with the <span class="ffa ls6d wsa3">WHO Guidelines</span></div><div class="t m0 xb hb y12d ffa fs8 fc3 sc0 ls64 wsa4">for Guidelines Development<span class="ff9 ls0 ws0">.</span></div><div class="t m0 x13 h14 y12e ff11 fs5 fc4 sc0 ls0 ws0">1</div><div class="t m0 x17 hb y12d ff9 fs8 fc3 sc0 ls64 wsa4">In order to ensure that the guidelines ar<span class="_ _a"></span>e based</div><div class="t m0 xb hb y12f ff9 fs8 fc3 sc0 ls0 wsa5">on the best current evidence, <span class="_ _a"></span>WHO commissioned two academic centres to</div><div class="t m0 xb hb y130 ff9 fs8 fc3 sc0 ls12 wsa6">identify<span class="_ _4b"></span>, compile and critically review published and unpublished studies of</div><div class="t m0 xb hb y131 ff9 fs8 fc3 sc0 ls71 wsa7">antimalarial treatments. <span class="_ _a"></span>The collated evidence was then reviewed by the</div><div class="t m0 xb hb y132 ff9 fs8 fc3 sc0 ls12 wsa8">T<span class="_ _4b"></span>echnical Guidelines Development Group made up of a broad spectrum of</div><div class="t m0 xb hb y133 ff9 fs8 fc3 sc0 ls12 wsa9">experts on malaria, malaria control programmes, and treatment guidelines</div><div class="t m0 xb hb y134 ff9 fs8 fc3 sc0 ls72 wsaa">methodology<span class="_ _4b"></span>. A large number of external reviewers with a wide r<span class="_ _a"></span>ange of</div><div class="t m0 xb hb y135 ff9 fs8 fc3 sc0 ls12 ws0">expertise were also involved in dev<span class="_ _a"></span>eloping the guidelines.</div><div class="t m0 xb h13 y136 ff8 fs3 fc3 sc0 ls69 ws0">1.3.1<span class="_ _7b"> </span>E<span class="_ _a"></span>vidence considered </div><div class="t m0 xb hb y137 ff9 fs8 fc3 sc0 ls12 wsab">In assessing the available information on tr<span class="_ _a"></span>eatment options, four main types</div><div class="t m0 xb hb y138 ff9 fs8 fc3 sc0 ls13 wsac">of information were consider<span class="_ _a"></span>ed, and should also be considered by countries</div><div class="t m0 xb hb y139 ff9 fs8 fc3 sc0 ls12 wsad">seeking to adapt the guidelines.</div><div class="t m0 x18 h14 y13a ff11 fs5 fc4 sc0 ls0 ws0">2</div><div class="t m0 x19 hb y139 ff9 fs8 fc3 sc0 ls13 wsad">Wherever possible, systematic r<span class="_ _a"></span>eviews of</div><div class="t m0 xb hb y13b ff9 fs8 fc3 sc0 ls30 ws3e">randomized trials that dir<span class="_ _a"></span>ectly compare two or more treatment alternativ<span class="_ _a"></span>es in</div><div class="t m0 xb hb y13c ff9 fs8 fc3 sc0 ls73 ws50">large populations wer<span class="_ _a"></span>e identified and used as the basis for recommendations.</div><div class="t m0 xb hb y13d ff9 fs8 fc3 sc0 ls74 wsae">It is clear that such evidence does not exist for all options, but recommendations</div><div class="t m0 xb hb y13e ff9 fs8 fc3 sc0 ls12 wsaf">on these options still need to be made. Other information including studies</div><div class="t m0 xb hb y13f ff9 fs8 fc3 sc0 ls75 wsb0">measuring cure rates but not dir<span class="_ _a"></span>ectly comparing treatments, pharmacological</div><div class="t m0 xb hb y140 ff9 fs8 fc3 sc0 ls12 wsb1">assessments and surveillance data about resistance patterns have therefor<span class="_ _a"></span>e</div><div class="t m0 xb hb y141 ff9 fs8 fc3 sc0 ls12 ws0">also been considered. </div><div class="t m0 xb hb y142 ff9 fs8 fc3 sc0 ls12 wsb2">In relation to malaria, as with other diseases, systematic reviews ar<span class="_ _a"></span>e not the</div><div class="t m0 xb hb y143 ff9 fs8 fc3 sc0 ls76 wsb3">sole basis for decision-making: the large differences in tr<span class="_ _a"></span>ansmission intensity<span class="_ _4b"></span>,</div><div class="t m0 xb hb y144 ff9 fs8 fc3 sc0 ls77 wsb4">and thus baseline immunity<span class="_ _4b"></span>, in treatment populations and in resistance</div><div class="t m0 xb hb y145 ff9 fs8 fc3 sc0 ls78 wsb5">patterns all have major effects on treatment r<span class="_ _a"></span>esponses. Any statistical analysis</div><div class="t m0 xb hb y146 ff9 fs8 fc3 sc0 ls79 wsb6">that combines the results of individual studies has to take due account of these</div><div class="t m0 xb hb y147 ff9 fs8 fc3 sc0 ls7a wsb7">factors and be interpreted accordingly<span class="_ _c"></span>. However<span class="_ _4b"></span>, such analyses do not obviate</div><div class="t m0 xb hb y148 ff9 fs8 fc3 sc0 ls7b wsb8">the need for a systematic and comprehensive r<span class="_ _a"></span>eview of all available trials before</div><div class="t m0 xb hb y149 ff9 fs8 fc3 sc0 ls12 ws0">reaching decisions about treatment r<span class="_ _a"></span>ecommendations. </div><div class="t m0 xb hb y14a ff9 fs8 fc3 sc0 ls7c wsb9">T<span class="_ _b"></span>reatments for malaria, like those for many infectious diseases, must be</div><div class="t m0 xb hb y14b ff9 fs8 fc3 sc0 ls13 ws9d">considered from the perspectiv<span class="_ _a"></span>e of community or public health benefits and</div><div class="t m0 xb hb y14c ff9 fs8 fc3 sc0 ls12 wsba">harms as well as from that of the patient. In some instances, ther<span class="_ _a"></span>efore, the</div><div class="t m0 xb hb y14d ff9 fs8 fc3 sc0 ls45 wsbb">recommendations pro<span class="_ _a"></span>vided here are based on public health consider<span class="_ _a"></span>ations as</div><div class="t m0 xb hb y14e ff9 fs8 fc3 sc0 ls12 ws0">well as the potential individual benefits.</div><div class="t m0 xb h14 y14f ff11 fs5 fc4 sc0 ls0 ws0">1</div><div class="t m0 x1a h15 y150 ff9 fsa fc3 sc0 ls7d ws0">The process is described in detail in Annex 1.</div><div class="t m0 xb h14 y151 ff11 fs5 fc4 sc0 ls0 ws0">2</div><div class="t m0 x7 h15 y152 ff9 fsa fc3 sc0 ls7d ws0">A guide to assist country adaptation of these guidelines is provided in Annex 2. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe" class="pf w1 h4" data-page-no="e"><div class="pc pce w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x8 h9 ya ff9 fs6 fc4 sc0 ls0 ws0">4</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls7e wsbc">Cost-effectiveness studies hav<span class="_ _a"></span>e not been included in the information considered</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls3d wsbd">by the T<span class="_ _c"></span>echnical Guidelines Development Group at this stage for two reasons:</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls12 wsbe">there are v<span class="_ _a"></span>ery few completed, generalizable cost-effectiveness studies that</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls12 wsbf">relate to the main treatment options being consider<span class="_ _a"></span>ed and the price of the</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls7f wsc0">antimalarials concerned is extremely fluid, rendering such studies unr<span class="_ _a"></span>eliable.</div><div class="t m0 x9 hb yc1 ff9 fs8 fc3 sc0 ls5e ws7f">Howev<span class="_ _a"></span>er<span class="_ _b"></span>, as relev<span class="_ _a"></span>ant information becomes available, it will be considered for</div><div class="t m0 x9 hb y10d ff9 fs8 fc3 sc0 ls12 ws0">inclusion in future editions of the guidelines.</div><div class="t m0 x9 h13 y153 ff8 fs3 fc3 sc0 ls80 wsc1">1.3.2<span class="_ _11"> </span>Pr<span class="_ _a"></span>esentation of evidence</div><div class="t m0 x9 hb y154 ff9 fs8 fc3 sc0 ls81 wsc2">For clarity<span class="_ _c"></span>, these guidelines have adopted a simple descriptive approach;</div><div class="t m0 x9 hb y155 ff9 fs8 fc3 sc0 ls82 wsc3">this may be revised in future editions. <span class="_ _b"></span>They are presented as a central</div><div class="t m0 x9 hb y156 ff9 fs8 fc3 sc0 ls12 wsc4">unreferenced main document containing the r<span class="_ _a"></span>ecommendations. Summaries</div><div class="t m0 x9 hb y112 ff9 fs8 fc3 sc0 ls12 wsc5">of the recommendations are giv<span class="_ _a"></span>en in boxes. S<span class="_ _a"></span>ymbols for the evidence used</div><div class="t m0 x9 hb y157 ff9 fs8 fc3 sc0 ls12 ws0">as the basis of each recommendation (in order of lev<span class="_ _a"></span>el of evidence) are: </div><div class="t m0 x1b hb y158 ff8 fs8 fc3 sc0 ls0 ws0">S<span class="_ _1d"> </span><span class="ff9 ls12 wsc6">formal systematic reviews, such as a Cochrane Review<span class="_ _b"></span>, including more</span></div><div class="t m0 x10 hb y159 ff9 fs8 fc3 sc0 ls12 ws0">than one randomized contr<span class="_ _a"></span>olled trial;</div><div class="t m0 x1b hb y15a ff8 fs8 fc3 sc0 ls0 ws0">T<span class="_ _52"> </span><span class="ff9 ls12">comparative trials without formal systematic review;</span></div><div class="t m0 x1b hb y15b ff8 fs8 fc3 sc0 ls0 ws0">O<span class="_ _50"> </span><span class="ff9 ls12">observational studies (e.g. surveillance or pharmacological data);</span></div><div class="t m0 x1b hb y15c ff8 fs8 fc3 sc0 ls0 ws0">E<span class="_ _52"> </span><span class="ff9 ls12">expert opinion/consensus.</span></div><div class="t m0 x9 hb y15d ff9 fs8 fc3 sc0 ls83 wsc7">In addition, for each policy or treatment question leading to a recommendation,</div><div class="t m0 x9 hb y15e ff9 fs8 fc3 sc0 ls84 wsc8">a brief summary of evidence is provided in a separ<span class="_ _a"></span>ate evidence box. Full</div><div class="t m0 x9 hb y15f ff9 fs8 fc3 sc0 ls85 wsc9">reviews of the evidence and refer<span class="_ _a"></span>ences are pro<span class="_ _a"></span>vided in annexes. If pharmaco-</div><div class="t m0 x9 hb y160 ff9 fs8 fc3 sc0 ls3c ws31">kinetics studies have been included as part of the deliberations, this is noted</div><div class="t m0 x9 hb y161 ff9 fs8 fc3 sc0 ls12 ws0">in the main document.</div><div class="t m0 x1c h14 y162 ff11 fs5 fc4 sc0 ls0 ws0">3</div><div class="t m0 x9 h14 y163 ff11 fs5 fc4 sc0 ls0 ws0">3</div><div class="t m0 x1b h15 y164 ff9 fsa fc3 sc0 ls7d ws0">Details of the pharmacology of antimalarials are pro<span class="_ _a"></span>vided in Annex 3.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff" class="pf w1 h4" data-page-no="f"><div class="pc pcf w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x1d he y9 ffc fs5 fc3 sc0 ls3 ws0">2.<span class="_ _6"> </span>The clinic<span class="_ _8"></span>al disease</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls0 ws0">5</div><div class="t m0 xb hf y7d ffe fs6 fc3 sc0 ls86 wsca">2.<span class="_ _33"> </span>TH<span class="_ _8"></span>E CLI<span class="_ _8"></span>NIC<span class="_ _8"></span>AL DIS<span class="_ _8"></span>EA<span class="_ _8"></span>SE</div><div class="t m0 xb hb yce ff9 fs8 fc3 sc0 ls13 wscb">Malaria is caused by infection of red blood cells with protoz<span class="_ _a"></span>oan parasites of</div><div class="t m0 xb hb y165 ff9 fs8 fc3 sc0 ls12 wscc">the genus <span class="ffa ws0">Plasmodium</span><span class="ls14 wsb5">. The par<span class="_ _a"></span>asites are inoculated into the human host by</span></div><div class="t m0 xb hb y166 ff9 fs8 fc3 sc0 ls87 wscd">a feeding female anopheline mosquito. <span class="_ _a"></span>The four <span class="ffa ws0">Plasmodium </span>species that infect</div><div class="t m0 xb hb y167 ff9 fs8 fc3 sc0 ls88 wsce">humans are <span class="ffa ls89 ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>falciparum<span class="ff9">, <span class="_ _66"></span></span>P<span class="_ _c"></span>.<span class="_ _68"> </span>vivax<span class="ff9">, <span class="_ _9"></span></span>P<span class="_ _c"></span>.<span class="_ _2"> </span>o<span class="_ _a"></span>vale<span class="_ _3"> </span><span class="ff9 ls88">and <span class="_ _9"></span></span>P<span class="_ _c"></span>.<span class="_ _2"> </span>malariae<span class="ff9 ls88 wsce">. Occasional</span></span></div><div class="t m0 xb hb y168 ff9 fs8 fc3 sc0 ls12 wscf">infections with monkey malaria parasites, such as <span class="ffa ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>knowlesi,<span class="_ _7c"> </span><span class="ff9 wscf">also occur</span><span class="ls0">.</span></span></div><div class="t m0 xb hb y169 ff9 fs8 fc3 sc0 ls8a wsd0">The first symptoms of malaria are nonspecific and similar to the symptoms of</div><div class="t m0 xb hb y16a ff9 fs8 fc3 sc0 ls12 wsd1">a minor systemic viral illness. <span class="_ _a"></span>They comprise: headache, lassitude, fatigue,</div><div class="t m0 xb hb y16b ff9 fs8 fc3 sc0 ls13 wsd2">abdominal discomfort and muscle and joint aches, followed by fever<span class="_ _4b"></span>, chills,</div><div class="t m0 xb hb y16c ff9 fs8 fc3 sc0 ls12 wsd3">perspiration, anorexia, v<span class="_ _a"></span>omiting and worsening malaise. This is the typical</div><div class="t m0 xb hb y16d ff9 fs8 fc3 sc0 ls8b wsd4">picture of uncomplicated malaria. R<span class="_ _a"></span>esidents of endemic areas are often</div><div class="t m0 xb hb y16e ff9 fs8 fc3 sc0 ls12 wsd5">familiar with this combination of symptoms, and frequently self-diagnose. </div><div class="t m0 xb hb y16f ff9 fs8 fc3 sc0 ls8c wsd6">Malaria is therefore fr<span class="_ _a"></span>equently over<span class="_ _a"></span>diagnosed on the basis of symptoms</div><div class="t m0 xb hb y170 ff9 fs8 fc3 sc0 ls12 wsd7">alone. Infection with <span class="ffa ls14 ws0">P<span class="_ _c"></span>. vivax <span class="ff9 ls12">and </span><span class="ls38">P.<span class="_ _3"> </span>o v a<span class="_ _67"> </span>l e<span class="_ _67"> </span><span class="ff9 ls12 wsd7">, more than with other species, can</span></span></span></div><div class="t m0 xb hb y171 ff9 fs8 fc3 sc0 ls8d wsd8">be associated with well-defined malarial paro<span class="_ _a"></span>xysms, in which fever spikes, chills</div><div class="t m0 xb hb y172 ff9 fs8 fc3 sc0 ls12 ws2e">and rigors occur at regular intervals. At this stage, with no evidence of vital</div><div class="t m0 xb hb y173 ff9 fs8 fc3 sc0 ls12 wsd9">organ dysfunction, the case-fatality rate is lo<span class="_ _a"></span>w (circa 0.1% for <span class="ffa ls13 ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum</span></div><div class="t m0 xb hb y174 ff9 fs8 fc3 sc0 ls12 wsda">infections – the other human malarias are rar<span class="_ _a"></span>ely fatal) provided pr<span class="_ _a"></span>ompt and</div><div class="t m0 xb hb y175 ff9 fs8 fc3 sc0 ls12 wsdb">effective treatment is giv<span class="_ _a"></span>en. But if ineffective drugs are giv<span class="_ _a"></span>en or treatment is</div><div class="t m0 xb hb y176 ff9 fs8 fc3 sc0 ls3c ws31">delayed in falciparum malaria, the parasite bur<span class="_ _a"></span>den continues to increase and</div><div class="t m0 xb hb y177 ff9 fs8 fc3 sc0 ls8d wsd8">severe malaria may ensue. A patient may pr<span class="_ _a"></span>ogress from having minor symptoms</div><div class="t m0 xb hb y178 ff9 fs8 fc3 sc0 ls12 wsdc">to having severe disease within a few hours. <span class="_ _b"></span>This usually manifests with one</div><div class="t m0 xb hb y179 ff9 fs8 fc3 sc0 ls8e wsdd">or more of the following: coma (cer<span class="_ _a"></span>ebral malaria), metabolic acidosis, sever<span class="_ _a"></span>e</div><div class="t m0 xb hb y17a ff9 fs8 fc3 sc0 ls8f wsde">anaemia, hypoglycaemia and, in adults, acute renal failur<span class="_ _a"></span>e or acute pulmonary</div><div class="t m0 xb hb y17b ff9 fs8 fc3 sc0 ls12 wsdf">oedema. By this stage, mortality in people receiving treatment has risen to</div><div class="t m0 xb hb y17c ff9 fs8 fc3 sc0 ls12 ws0">15–20%. If untreated, sever<span class="_ _a"></span>e malaria is almost always fatal. </div><div class="t m0 xb hb y17d ff9 fs8 fc3 sc0 ls81 wsc2">The nature of the clinical disease depends very much on the pattern and</div><div class="t m0 xb hb y17e ff9 fs8 fc3 sc0 ls12 wse0">intensity of malaria transmission in the area of r<span class="_ _a"></span>esidence, which determines</div><div class="t m0 xb hb y17f ff9 fs8 fc3 sc0 ls12 wse1">the degree of protectiv<span class="_ _a"></span>e immunity acquired and, in turn, the clinical disease</div><div class="t m0 xb hb y180 ff9 fs8 fc3 sc0 ls90 wse2">profile. <span class="_ _a"></span>Where malaria transmission is “<span class="_ _b"></span>stable” – meaning where populations</div><div class="t m0 xb hb y181 ff9 fs8 fc3 sc0 ls12 wse3">are continuously exposed to a fairly constant rate of malarial inoculations –</div><div class="t m0 xb hb y182 ff9 fs8 fc3 sc0 ls12 wse4">and if the inoculation rates are high – entomological inoculation r<span class="_ _a"></span>ate (E<span class="_ _8"></span>I<span class="_ _8"></span>R)</div><div class="t m0 xb hb y183 fff fs8 fc3 sc0 ls0 ws0">&gt;<span class="ff9 ls13 wse5">10/year –, then partial immunity to the clinical disease and to its severe</span></div><div class="t m0 xb hb y184 ff9 fs8 fc3 sc0 ls91 wse6">manifestations is acquired early in childhood. In such situations, which prev<span class="_ _b"></span>ail</div><div class="t m0 xb hb y185 ff9 fs8 fc3 sc0 ls6b ws58">in much of sub-Saharan Africa and parts of Oceania, the acute clinical disease</div><div class="t m0 xb hb y186 ff9 fs8 fc3 sc0 ls92 wse7">described abov<span class="_ _a"></span>e is almost always confined to young children who suffer high</div><div class="t m0 xb hb y187 ff9 fs8 fc3 sc0 ls12 wse8">parasite densities and acute clinical disease. If untreated, this can pr<span class="_ _a"></span>ogress</div><div class="t m0 xb hb y188 ff9 fs8 fc3 sc0 ls93 wse9">very rapidly to sev<span class="_ _a"></span>ere malaria. In stable and high-transmission areas, adoles-</div><div class="t m0 xb hb y189 ff9 fs8 fc3 sc0 ls54 ws6f">cents and adults are partially immune and rarely suffer clinical disease,</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf10" class="pf w1 h4" data-page-no="10"><div class="pc pc10 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x8 h9 ya ff9 fs6 fc4 sc0 ls0 ws0">6</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls12 wsa4">although they continue to harbour low blood-parasite densities. Immunity is</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls94 wsea">reduced in pregnancy<span class="_ _c"></span>, and can be lost when individuals move out of the</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls13 ws14">transmission zone. </div><div class="t m0 x9 hb y18a ff9 fs8 fc3 sc0 ls4d wseb">In areas of unstable malaria, the situation prev<span class="_ _b"></span>ailing in much of Asia and</div><div class="t m0 x9 hb y18b ff9 fs8 fc3 sc0 ls95 wsec">Latin America and the remaining parts of the world where malaria is endemic,</div><div class="t m0 x9 hb y18c ff9 fs8 fc3 sc0 ls12 wscf">the rates of inoculation fluctuate greatly o<span class="_ _a"></span>ver seasons and years. EI<span class="_ _8"></span>Rs are</div><div class="t m0 x9 hb y18d ff9 fs8 fc3 sc0 ls12 ws0">usually <span class="_ _8"></span><span class="fff ls0">&lt;</span><span class="wsed">5/year and often </span><span class="fff ls0">&lt;</span><span class="wsed">1/year<span class="_ _4b"></span>. This retards the acquisition of immunity</span></div><div class="t m0 x9 hb y18e ff9 fs8 fc3 sc0 ls12 wsee">and results in people of all ages, adults and children alike, suffering acute</div><div class="t m0 x9 hb y18f ff9 fs8 fc3 sc0 ls85 wsc9">clinical malaria, with a high risk of progression to sev<span class="_ _a"></span>ere malaria if untreated.</div><div class="t m0 x9 hb y190 ff9 fs8 fc3 sc0 ls96 wsef">Epidemics may occur in areas of unstable malaria when inoculation rates</div><div class="t m0 x9 hb y191 ff9 fs8 fc3 sc0 ls97 wsf0">increase rapidly<span class="_ _c"></span>. Epidemics manifest as a very high incidence of malaria in all</div><div class="t m0 x9 hb y192 ff9 fs8 fc3 sc0 ls13 wsf1">age groups and can o<span class="_ _a"></span>verwhelm health services. Severe malaria is common if</div><div class="t m0 x9 hb y193 ff9 fs8 fc3 sc0 ls12 ws0">effective treatment is not made widely av<span class="_ _b"></span>ailable. </div><div class="t m0 x9 hb y194 ff9 fs8 fc3 sc0 ls98 wsf2">Thus in areas of high transmission, it is childr<span class="_ _a"></span>en who are at risk of severe malaria</div><div class="t m0 x9 hb y195 ff9 fs8 fc3 sc0 ls0 wsf3">and death, whereas in areas of lo<span class="_ _a"></span>w or unstable transmission, all age groups</div><div class="t m0 x9 hb y196 ff9 fs8 fc3 sc0 ls12 ws0">are at risk.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf11" class="pf w1 h4" data-page-no="11"><div class="pc pc11 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x1e he y9 ffc fs5 fc3 sc0 ls99 ws95">3.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment objectives</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls0 ws0">7</div><div class="t m0 xb hf y7d ffe fs6 fc3 sc0 ls86 ws0">3.<span class="_ _33"> </span>TR<span class="_ _8"></span>EA<span class="_ _a"></span>TMENT OBJECTIVE<span class="_ _8"></span>S</div><div class="t m0 xb h12 y197 ff10 fs6 fc4 sc0 ls9a ws95">3.1<span class="_ _78"> </span>Uncomplicated malar<span class="_ _8"></span>ia</div><div class="t m0 xb hb y198 ff9 fs8 fc3 sc0 ls12 wsf4">The objective of treating uncomplicated malaria is to cur<span class="_ _a"></span>e the infection. This</div><div class="t m0 xb hb y199 ff9 fs8 fc3 sc0 ls92 wse7">is important as it will help prevent progression to sev<span class="_ _a"></span>ere disease and prev<span class="_ _a"></span>ent</div><div class="t m0 xb hb y19a ff9 fs8 fc3 sc0 ls12 wsf5">additional morbidity associated with treatment failure. Cur<span class="_ _a"></span>e of the infection</div><div class="t m0 xb hb y19b ff9 fs8 fc3 sc0 ls12 wsf6">means eradication from the body of the infection that caused the illness. In</div><div class="t m0 xb hb y19c ff9 fs8 fc3 sc0 ls12 wsf7">treatment ev<span class="_ _a"></span>aluations in all settings, emerging evidence indicates that it is</div><div class="t m0 xb hb y19d ff9 fs8 fc3 sc0 ls12 wsf8">necessary to follow patients for long enough to document cure (see section</div><div class="t m0 xb hb y19e ff9 fs8 fc3 sc0 ls9b wsf9">6.1). In assessing drug efficacy in high-transmission settings, temporary</div><div class="t m0 xb hb y19f ff9 fs8 fc3 sc0 ls9c wsfa">suppression of infection for 14 days is not considered sufficient by the gr<span class="_ _a"></span>oup. </div><div class="t m0 xb hb y1a0 ff9 fs8 fc3 sc0 ls12 ws91">The public health goal of treatment is to reduce tr<span class="_ _a"></span>ansmission of the infection</div><div class="t m0 xb hb y1a1 ff9 fs8 fc3 sc0 ls12 ws0">to others, i.e. to reduce the infectious reservoir<span class="_ _4b"></span>.</div><div class="t m0 x1f h14 y1a2 ff11 fs5 fc4 sc0 ls0 ws0">4</div><div class="t m0 xb hb y1a3 ff9 fs8 fc3 sc0 ls12 wsfb">A secondary but equally impor<span class="_ _8"></span>tant objective of treatment is to pr<span class="_ _a"></span>event the</div><div class="t m0 xb hb y1a4 ff9 fs8 fc3 sc0 ls64 wsa4">emergence and spread of r<span class="_ _a"></span>esistance to antimalarials. T<span class="_ _c"></span>olerability<span class="_ _4b"></span>, the adverse</div><div class="t m0 xb hb y1a5 ff9 fs8 fc3 sc0 ls9d wsfc">effect profile and the speed of therapeutic r<span class="_ _a"></span>esponse are also important</div><div class="t m0 xb hb y1a6 ff9 fs8 fc3 sc0 ls12 ws0">considerations. </div><div class="t m0 xb h12 y1a7 ff10 fs6 fc4 sc0 ls9e wsfd">3.2<span class="_ _78"> </span>Se<span class="_ _8"></span>vere malaria</div><div class="t m0 xb hb y1a8 ff9 fs8 fc3 sc0 ls75 wsb0">The primary objective of antimalarial treatment in sev<span class="_ _a"></span>ere malaria is to prevent</div><div class="t m0 xb hb y1a9 ff9 fs8 fc3 sc0 ls9f wsfe">death. Prev<span class="_ _a"></span>ention of recrudescence and avoidance of minor adv<span class="_ _a"></span>erse effects are</div><div class="t m0 xb hb y1aa ff9 fs8 fc3 sc0 lsa0 wsff">secondary<span class="_ _4b"></span>. In treating cerebral malaria, prev<span class="_ _a"></span>ention of neurological deficit is also</div><div class="t m0 xb hb y1ab ff9 fs8 fc3 sc0 lsa1 ws100">an important objective. In the treatment of severe malaria in pr<span class="_ _a"></span>egnancy<span class="_ _4b"></span>,</div><div class="t m0 xb hb y1ac ff9 fs8 fc3 sc0 ls12 ws0">saving the life of the mother is the primary objective.</div><div class="t m0 xb h14 y163 ff11 fs5 fc4 sc0 ls0 ws0">4</div><div class="t m0 x20 h15 y164 ff9 fsa fc3 sc0 ls7d ws0">Further information on antimalarials and malaria transmission is provided in Annex 4.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf12" class="pf w1 h4" data-page-no="12"><div class="pc pc12 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x8 h9 ya ff9 fs6 fc4 sc0 ls0 ws0">8</div><div class="t m0 x9 hf y7d ffe fs6 fc3 sc0 ls9a ws0">4.<span class="_ _33"> </span>DIAG<span class="_ _8"></span>NOSIS OF MAL<span class="_ _8"></span>ARIA </div><div class="t m0 x9 hb yce ff9 fs8 fc3 sc0 ls75 wsb0">Prompt and accur<span class="_ _a"></span>ate diagnosis of malaria is par<span class="_ _8"></span>t of effective disease manage-</div><div class="t m0 x9 hb y165 ff9 fs8 fc3 sc0 ls12 ws101">ment and will, if implemented effectively<span class="_ _c"></span>, help to reduce unnecessary use of</div><div class="t m0 x9 hb y166 ff9 fs8 fc3 sc0 lsa2 ws0">antimalarials.</div><div class="t m0 x21 h14 y1ad ff11 fs5 fc4 sc0 ls0 ws0">5</div><div class="t m0 x22 hb y166 ff9 fs8 fc3 sc0 lsa2 ws102">High sensitivity of malaria diagnosis is important in all settings,</div><div class="t m0 x9 hb y167 ff9 fs8 fc3 sc0 lsa3 ws103">in particular for the most vulnerable population groups, such as young</div><div class="t m0 x9 hb y168 ff9 fs8 fc3 sc0 lsa4 ws104">children, in which the disease can be rapidly fatal. High specificity can r<span class="_ _a"></span>educe</div><div class="t m0 x9 hb y1ae ff9 fs8 fc3 sc0 ls44 ws93">unnecessary treatment with antimalarials and impro<span class="_ _a"></span>ve differential diagnosis</div><div class="t m0 x9 hb y1af ff9 fs8 fc3 sc0 ls12 ws0">of febrile illness.</div><div class="t m0 x9 hb y16b ff9 fs8 fc3 sc0 lsa5 ws105">The diagnosis of malaria is based on clinical criteria (clinical diagnosis)</div><div class="t m0 x9 hb y16c ff9 fs8 fc3 sc0 ls13 ws106">supplemented by the detection of parasites in the blood (parasitological or</div><div class="t m0 x9 hb y16d ff9 fs8 fc3 sc0 ls97 wsf0">confirmatory diagnosis). Clinical diagnosis alone has very low specificity and</div><div class="t m0 x9 hb y16e ff9 fs8 fc3 sc0 ls48 ws68">in many areas parasitological diagnosis is not curr<span class="_ _a"></span>ently available. <span class="_ _a"></span>The decision</div><div class="t m0 x9 hb y1b0 ff9 fs8 fc3 sc0 lsa6 ws107">to pro<span class="_ _a"></span>vide antimalarial treatment in these settings must be based on the</div><div class="t m0 x9 hb y1b1 ff9 fs8 fc3 sc0 ls12 ws108">prior probability of the illness being malaria. One needs to weigh the risk of</div><div class="t m0 x9 hb y1b2 ff9 fs8 fc3 sc0 lsa7 ws109">withholding antimalarial treatment from a patient with malaria against the risk</div><div class="t m0 x9 hb y1b3 ff9 fs8 fc3 sc0 ls44 ws93">associated with antimalarial treatment when given to a patient who does not</div><div class="t m0 x9 hb y1b4 ff9 fs8 fc3 sc0 ls12 ws0">have malaria.</div><div class="t m0 x9 h12 y1b5 ff10 fs6 fc4 sc0 ls9a ws0">4.1<span class="_ _78"> </span>Clinic<span class="_ _8"></span>al diagnosis</div><div class="t m0 x9 hb y1b6 ff9 fs8 fc3 sc0 ls9b wsf9">The signs and symptoms of malaria are nonspecific. Malaria is clinically</div><div class="t m0 x9 hb y1b7 ff9 fs8 fc3 sc0 lsa8 ws10a">diagnosed mostly on the basis of fever or history of fever<span class="_ _4b"></span>. The following <span class="_ _b"></span>WHO</div><div class="t m0 x9 hb y1b8 ff9 fs8 fc3 sc0 ls12 ws0">recommendations are still consider<span class="_ _a"></span>ed valid for clinical diagnosis.</div><div class="t m0 x23 h14 y1b9 ff11 fs5 fc4 sc0 ls0 ws0">6</div><div class="t m0 x9 hb y1ba ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls50 ws10b">In general, </span><span class="ff8 ls12 ws10c">in settings where the risk of malaria is lo<span class="_ _a"></span>w<span class="ff9 ls0 ws0">, </span><span class="ff9 fc3">clinical diagnosis</span></span></div><div class="t m0 x16 hb y1bb ff9 fs8 fc3 sc0 ls12 ws10d">of uncomplicated malaria should be based on the degree of exposure to</div><div class="t m0 x16 hb y1bc ff9 fs8 fc3 sc0 lsa9 wsf1">malaria and a history of fever in the previous 3 days with no features of other</div><div class="t m0 x16 hb y1bd ff9 fs8 fc3 sc0 ls13 ws0">severe diseases. </div><div class="t m0 x9 hb y1be ff8 fs8 fc4 sc0 ls12 ws10e">•<span class="_ _7a"> </span>In settings where the risk of malaria is high<span class="ff9 fc3">, clinical diagnosis should be</span></div><div class="t m0 x16 hb y1bf ff9 fs8 fc3 sc0 ls12 ws10f">based on a history of fever in the previous 24 h and/or the presence of</div><div class="t m0 x16 hb y1c0 ff9 fs8 fc3 sc0 lsaa ws110">anaemia, for which pallor of the palms appears to be the most reliable sign</div><div class="t m0 x16 hb y1c1 ff9 fs8 fc3 sc0 ls12 ws0">in young children.</div><div class="t m0 x9 hb y1c2 ff9 fs8 fc3 sc0 ls0 ws111">The WHO/UNICE<span class="_ _8"></span>F strategy for Integrated Management of Childhood Illness</div><div class="t m0 x9 hb y1c3 ff9 fs8 fc3 sc0 ls13 ws0">(IMCI)</div><div class="t m0 x24 h14 y1c4 ff11 fs5 fc4 sc0 ls0 ws0">7</div><div class="t m0 x25 hb y1c5 ff9 fs8 fc3 sc0 ls12 ws112">has also developed practical algorithms for management of the sick</div><div class="t m0 x9 hb y1c6 ff9 fs8 fc3 sc0 lsab ws113">child presenting with fever wher<span class="_ _a"></span>e there are no facilities for laboratory diagnosis.</div><div class="t m0 x9 h14 y1c7 ff11 fs5 fc4 sc0 ls0 ws0">5</div><div class="t m0 x14 h15 y1c8 ff9 fsa fc3 sc0 ls7d ws0">Further information on the diagnosis of malaria is provided in Annex 5.</div><div class="t m0 x9 h14 y1c9 ff11 fs5 fc4 sc0 ls0 ws0">6</div><div class="t m0 x14 h15 y1ca ff9 fsa fc3 sc0 ls6c ws114">WHO Exper<span class="_ _8"></span>t Committee on Malaria. T<span class="_ _b"></span>wentieth report. Geneva, <span class="_ _a"></span>World Health Organization, 2000</div><div class="t m0 x14 h15 y1cb ff9 fsa fc3 sc0 lsac ws115">(WHO T<span class="_ _4b"></span>echnical Repor<span class="_ _8"></span>t Series, No. 892).</div><div class="t m0 x9 h14 y1cc ff11 fs5 fc4 sc0 ls0 ws0">7</div><div class="t m0 x14 h15 y1cd ff9 fsa fc3 sc0 ls7d ws116">IMCI information package, 1999. Geneva, W<span class="_ _b"></span>orld Health Organization, 1999 (document WHO/CHS/</div><div class="t m0 x14 h15 y1ce ff9 fsa fc3 sc0 lsac ws0">CAH/98.1).</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf13" class="pf w1 h4" data-page-no="13"><div class="pc pc13 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x1e he y9 ffc fs5 fc3 sc0 lsad ws117">4.<span class="_ _5"> </span>Diagnosis of malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls0 ws0">9</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls86 wsca">4.2<span class="_ _78"> </span>Parasitological diagnosis</div><div class="t m0 xb hb y1cf ff9 fs8 fc3 sc0 lsae ws118">The introduction of A<span class="_ _a"></span>CT<span class="_ _4b"></span>s has increased the urgency of impro<span class="_ _a"></span>ving the specificity</div><div class="t m0 xb hb y1d0 ff9 fs8 fc3 sc0 ls12 ws119">of malaria diagnosis. The r<span class="_ _a"></span>elatively high cost of these drugs makes waste</div><div class="t m0 xb hb y1d1 ff9 fs8 fc3 sc0 lsaf ws11a">through unnecessary treatment of patients without parasitaemia unsustainable.</div><div class="t m0 xb hb y1d2 ff9 fs8 fc3 sc0 lsb0 ws11b">In addition to cost savings, parasitological diagnosis has the following</div><div class="t m0 xb hb y1d3 ff9 fs8 fc3 sc0 ls12 ws0">advantages:</div><div class="t m0 xb hb y1d4 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 lsb1 ws11c">impro<span class="_ _a"></span>ved patient care in parasite-positiv<span class="_ _a"></span>e patients owing to greater certainty</span></div><div class="t m0 x26 hb y1d5 ff9 fs8 fc3 sc0 ls12 ws0">that the patient has malaria;</div><div class="t m0 xb hb y1d6 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 lsb2 ws11d">identification of parasite-negative patients in whom another diagnosis</span></div><div class="t m0 x26 hb y1d7 ff9 fs8 fc3 sc0 ls12 ws0">must be sought;</div><div class="t m0 xb hb y1d8 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls81 ws11e">prevention of unnecessary exposure to antimalarials, ther<span class="_ _a"></span>eby reducing</span></div><div class="t m0 x26 hb y1d9 ff9 fs8 fc3 sc0 ls12 ws0">side-effects, drug interactions and selection pressur<span class="_ _a"></span>e;</div><div class="t m0 xb hb y1da ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">impro<span class="_ _a"></span>ved health information;</span></div><div class="t m0 xb hb y1db ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">confirmation of treatment failures.</span></div><div class="t m0 xb hb y1dc ff9 fs8 fc3 sc0 ls45 wsbb">The two methods in use for parasitological diagnosis are light micr<span class="_ _a"></span>oscopy and</div><div class="t m0 xb hb y1dd ff9 fs8 fc3 sc0 ls30 ws3e">rapid diagnostic tests (RDT<span class="_ _4b"></span>s). Light microscopy has the adv<span class="_ _a"></span>antage of low cost</div><div class="t m0 xb hb y1de ff9 fs8 fc3 sc0 ls13 ws11f">and high sensitivity and specificity when used by well-trained staff<span class="_ _a"></span>. RDT<span class="_ _4b"></span>s for</div><div class="t m0 xb hb y1df ff9 fs8 fc3 sc0 ls12 ws120">detection of parasite antigen are gener<span class="_ _a"></span>ally more expensive, but the prices of</div><div class="t m0 xb hb y1e0 ff9 fs8 fc3 sc0 lsb3 ws121">some of these products have r<span class="_ _a"></span>ecently decreased to an extent that makes</div><div class="t m0 xb hb y1e1 ff9 fs8 fc3 sc0 lsb4 ws122">their deployment cost-effective in some settings. <span class="_ _b"></span>Their sensitivity and specificity</div><div class="t m0 xb hb y1e2 ff9 fs8 fc3 sc0 ls12 ws123">are v<span class="_ _a"></span>ariable, and their vulnerability to high temperatures and humidity is an</div><div class="t m0 xb hb y1e3 ff9 fs8 fc3 sc0 lsb5 ws43">important constraint. Despite these concerns, RDT<span class="_ _4b"></span>s make it possible to expand the</div><div class="t m0 xb hb y1e4 ff9 fs8 fc3 sc0 ls76 wsb3">use of confirmatory diagnosis. Deployment of these tests, as with microscopy<span class="_ _c"></span>,</div><div class="t m0 xb hb y1e5 ff9 fs8 fc3 sc0 lsb6 ws124">must be accompanied by quality assurance. Pr<span class="_ _a"></span>actical experience and</div><div class="t m0 xb hb y1e6 ff9 fs8 fc3 sc0 lsb7 ws125">operational evidence from lar<span class="_ _a"></span>ge-scale implementation are limited and,</div><div class="t m0 xb hb y1e7 ff9 fs8 fc3 sc0 ls12 ws126">therefore, their intr<span class="_ _a"></span>oduction should be carefully monitored and ev<span class="_ _a"></span>aluated.</div><div class="t m0 xb hb y1e8 ff9 fs8 fc3 sc0 lsb8 ws127">The results of parasitological diagnosis should be av<span class="_ _b"></span>ailable within a shor<span class="_ _8"></span>t time</div><div class="t m0 xb hb y1e9 ff9 fs8 fc3 sc0 lsb9 ws128">(less than 2 h) of the patient presenting. If this is not possible, the patient must</div><div class="t m0 xb hb y1ea ff9 fs8 fc3 sc0 ls12 ws0">be treated on the basis of a clinical diagnosis. </div><div class="t m0 xb h13 y1eb ff8 fs3 fc3 sc0 ls80 ws0">4.2.1<span class="_ _2d"> </span>The choice betw<span class="_ _a"></span>een RDT<span class="_ _c"></span>s and microscopy</div><div class="t m0 xb hb y1ec ff9 fs8 fc3 sc0 ls64 ws129">The choice between RDT<span class="_ _4b"></span>s and microscopy depends on local circumstances,</div><div class="t m0 xb hb y1ed ff9 fs8 fc3 sc0 ls64 ws28">including the skills available, the usefulness of micr<span class="_ _a"></span>oscopy for other diseases</div><div class="t m0 xb hb y1ee ff9 fs8 fc3 sc0 ls64 ws24">found in the area, and the case-load. <span class="_ _a"></span>Where the case-load of fever patients is</div><div class="t m0 xb hb y1ef ff9 fs8 fc3 sc0 lsba ws12a">high, microscopy is likely to be less expensive than RDT<span class="_ _c"></span>s. Microscopy has</div><div class="t m0 xb hb y1f0 ff9 fs8 fc3 sc0 ls64 ws12b">further advantages in that it can be used for speciation and quantification of</div><div class="t m0 xb hb y1f1 ff9 fs8 fc3 sc0 ls64 ws12c">parasites, and identification of other causes of fever<span class="_ _4b"></span>. However<span class="_ _4b"></span>, most malaria</div><div class="t m0 xb hb y1f2 ff9 fs8 fc3 sc0 lsbb ws12d">patients are treated outside the health services, for example, in the community<span class="_ _4b"></span>,</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf14" class="pf w1 h4" data-page-no="14"><div class="pc pc14 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x27 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">10</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 lsbc ws12e">in the home or by private pr<span class="_ _a"></span>oviders; microscopy is gener<span class="_ _a"></span>ally not feasible in such</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls64 ws0">circumstances, but RDT<span class="_ _4b"></span>s may be.</div><div class="t m0 x9 hb y1f3 ff9 fs8 fc3 sc0 lsbd ws12f">The following conclusions and recommendations ar<span class="_ _a"></span>e based on evidence summa-</div><div class="t m0 x9 hb y18a ff9 fs8 fc3 sc0 lsbe ws76">rized by recent <span class="_ _a"></span>WHO consultations, especially the T<span class="_ _c"></span>echnical Consultation on the</div><div class="t m0 x9 hb y18b ff9 fs8 fc3 sc0 lsbf ws130">Role of P<span class="_ _a"></span>arasitological Diagnosis in Malaria Case Management in Areas of High</div><div class="t m0 x9 hb y18c ff9 fs8 fc3 sc0 lsc0 ws131">T<span class="_ _b"></span>ransmission, held in Geneva fr<span class="_ _a"></span>om 25 to 26 October 2004 (report in preparation). </div><div class="t m0 x9 h12 y1f4 ff10 fs6 fc4 sc0 ls86 wsca">4.3<span class="_ _78"> </span>W<span class="_ _8"></span>here malar<span class="_ _8"></span>ia transmission is low to moderate</div><div class="t m0 x28 h12 y1f5 ff10 fs6 fc4 sc0 ls1 ws0">and/or unstable </div><div class="t m0 x9 hb y1f6 ff9 fs8 fc3 sc0 lsc1 ws132">Parasitological confirmation of the diagnosis of malaria is r<span class="_ _a"></span>ecommended.</div><div class="t m0 x9 hb y1f7 ff9 fs8 fc3 sc0 ls13 ws133">This should be pro<span class="_ _a"></span>vided by microscopy or<span class="_ _b"></span>, where not av<span class="_ _a"></span>ailable, RDT<span class="_ _4b"></span>s. Low to</div><div class="t m0 x9 hb y1f8 ff9 fs8 fc3 sc0 ls13 ws134">moderate transmission settings</div><div class="t m0 x29 h14 y1f9 ff11 fs5 fc4 sc0 ls0 ws0">8</div><div class="t m0 x2a hb y1f8 ff9 fs8 fc3 sc0 ls13 ws135">include many urban areas in Africa, and the</div><div class="t m0 x9 hb y1fa ff9 fs8 fc3 sc0 ls12 ws0">low transmission season in ar<span class="_ _a"></span>eas with seasonal malaria.</div><div class="t m0 x9 hb y1fb ff9 fs8 fc3 sc0 ls12 ws6b">In settings where malaria incidence is very lo<span class="_ _a"></span>w, par<span class="_ _a"></span>asitological diagnosis for</div><div class="t m0 x9 hb y1fc ff9 fs8 fc3 sc0 ls12 ws136">all fever cases may lead to considerable expenditur<span class="_ _a"></span>e to detect only a few</div><div class="t m0 x9 hb y1fd ff9 fs8 fc3 sc0 lsc2 ws137">patients who are actually suffering from malaria. In such settings, health</div><div class="t m0 x9 hb y1fe ff9 fs8 fc3 sc0 ls12 ws138">workers should be trained to identify<span class="_ _c"></span>, through the history<span class="_ _b"></span>, patients that have</div><div class="t m0 x9 hb y1ff ff9 fs8 fc3 sc0 ls12 ws0">been exposed to malaria risk before they conduct a parasitological test. </div><div class="t m0 x9 h12 y200 ff10 fs6 fc4 sc0 lsc3 ws139">4.4<span class="_ _78"> </span>In stable high-transmission settings </div><div class="t m0 x9 hb y201 ff9 fs8 fc3 sc0 ls12 wsf4">Malaria is usually the most common cause of fever in children under 5 y<span class="_ _a"></span>ears</div><div class="t m0 x9 hb y202 ff9 fs8 fc3 sc0 ls12 ws13a">of age in these areas. Antimalarial treatment should ther<span class="_ _a"></span>efore be given to</div><div class="t m0 x9 hb y203 ff9 fs8 fc3 sc0 lsaa ws110">children with fever (<span class="ff10 ls0 ws0">&gt;<span class="_ _a"></span><span class="ff9 lsc4">37.5</span></span></div><div class="t m0 x2b h11 y204 ff9 fs5 fc3 sc0 ls0 ws0">o</div><div class="t m0 x2c hb y203 ff9 fs8 fc3 sc0 lsaa ws110">C) or a history of fever and no other obvious cause.</div><div class="t m0 x9 hb y205 ff9 fs8 fc3 sc0 ls64 wsa4">Malaria is the most likely cause of their illness and there is as yet no evidence</div><div class="t m0 x9 hb y206 ff9 fs8 fc3 sc0 lsc5 ws13b">to show that the benefits of parasitological diagnosis in this highly vulner<span class="_ _a"></span>able</div><div class="t m0 x9 hb y207 ff9 fs8 fc3 sc0 lsa4 ws104">group outweigh the risks of not tr<span class="_ _a"></span>eating false negatives. In children of 5 years</div><div class="t m0 x9 hb y208 ff9 fs8 fc3 sc0 lsc6 ws13c">of age and abov<span class="_ _a"></span>e, malaria becomes progressively less likely as a cause of fev<span class="_ _a"></span>er<span class="_ _b"></span>,</div><div class="t m0 x9 hb y209 ff9 fs8 fc3 sc0 lsc7 ws3">as immunity is acquired. In these older children and in adults, malaria diagnosis</div><div class="t m0 x9 hb y20a ff9 fs8 fc3 sc0 ls8e wsdd">should be based on a parasitological confirmation. Par<span class="_ _a"></span>asitological diagnosis</div><div class="t m0 x9 hb y20b ff9 fs8 fc3 sc0 lsc8 ws83">should be promoted in pregnant women, to impr<span class="_ _a"></span>ove the differ<span class="_ _a"></span>ential diagnosis</div><div class="t m0 x9 hb y20c ff9 fs8 fc3 sc0 lsb8 ws127">of fever and to reduce unnecessary use of antimalarials in pregnancy<span class="_ _c"></span>. Parasito-</div><div class="t m0 x9 hb y20d ff9 fs8 fc3 sc0 lsc9 ws13d">logical diagnosis is also particularly impor<span class="_ _8"></span>tant in settings with a high prevalence</div><div class="t m0 x9 hb y20e ff9 fs8 fc3 sc0 lsca ws13e">of HIV/AI<span class="_ _8"></span>DS because of the high incidence of febrile disease that is not</div><div class="t m0 x9 hb y20f ff9 fs8 fc3 sc0 ls12 ws0">malaria in HIV-infected patients. </div><div class="t m0 x9 h14 y210 ff11 fs5 fc4 sc0 ls0 ws0">8</div><div class="t m0 x14 h15 y211 ff9 fsa fc3 sc0 lscb ws74">T<span class="_ _b"></span>ransmission intensity is conventionally expressed in terms of EI<span class="_ _8"></span>R (see section 2). There is as yet no</div><div class="t m0 x14 h15 y212 ff9 fsa fc3 sc0 lscc ws13f">consensus on criteria for determining the thresholds between high, and low to moder<span class="_ _a"></span>ate transmission</div><div class="t m0 x14 h15 y213 ff9 fsa fc3 sc0 ls7d ws140">settings. Suggested criteria include: the proportion of all children under 5 years of age with patent</div><div class="t m0 x14 h15 y214 ff9 fsa fc3 sc0 lscd ws141">parasitaemia, and the incidence of individuals with the spleen palpable below the umbilicus in</div><div class="t m0 x14 h15 y215 ff9 fsa fc3 sc0 lsce ws142">children aged 2–9 years. <span class="_ _a"></span>The IMCI guidelines recommend that areas in which fewer than 5% of young</div><div class="t m0 x14 h15 y216 ff9 fsa fc3 sc0 ls7d ws143">children with fever hav<span class="_ _a"></span>e malaria parasitaemia should be considered as low-transmission settings. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf15" class="pf w1 h4" data-page-no="15"><div class="pc pc15 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x1e he y9 ffc fs5 fc3 sc0 lsad ws117">4.<span class="_ _5"> </span>Diagnosis of malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">11</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls1c ws144">4.5<span class="_ _78"> </span>Malaria parasite species identific<span class="_ _8"></span>ation </div><div class="t m0 xb hb y1cf ff9 fs8 fc3 sc0 ls14 ws145">In areas where two or mor<span class="_ _a"></span>e species of malaria parasites are common, only a</div><div class="t m0 xb hb y1d0 ff9 fs8 fc3 sc0 ls45 wsbb">parasitological method will permit a species diagnosis. <span class="_ _a"></span>Where mono-infection</div><div class="t m0 xb hb y1d1 ff9 fs8 fc3 sc0 ls12 ws0">with <span class="ffa ls13 ws146">P<span class="_ _c"></span>. vivax <span class="ff9 ls12">is common and microscopy is not av<span class="_ _a"></span>ailable, it is recommended</span></span></div><div class="t m0 xb hb y1d2 ff9 fs8 fc3 sc0 lscf ws147">that a combination RDT which contains a pan-malarial antigen is used. Alternativ<span class="_ _a"></span>ely<span class="_ _4b"></span>,</div><div class="t m0 xb hb y1d3 ff9 fs8 fc3 sc0 ls12 ws148">RDT<span class="_ _4b"></span>s specific for falciparum malaria may be used, and treatment for vivax</div><div class="t m0 xb hb y217 ff9 fs8 fc3 sc0 lsd0 ws149">malaria given only to cases with a negativ<span class="_ _a"></span>e test result but a high clinical</div><div class="t m0 xb hb y218 ff9 fs8 fc3 sc0 ls33 ws5f">suspicion of malaria. Wher<span class="_ _a"></span>e <span class="ffa">P<span class="_ _c"></span>. vivax, P<span class="_ _c"></span>.malariae <span class="ff9 ws0">or <span class="_ _a"></span><span class="ffa">P<span class="_ _c"></span>.ov<span class="_ _a"></span>ale <span class="ff9 ls34 ws14a">occur almost always</span></span></span></span></div><div class="t m0 xb hb y219 ff9 fs8 fc3 sc0 ls12 ws14b">as a co-infection with <span class="ffa ls38 ws0">P.  <span class="_ _6"> </span></span>falciparum, an RDT detecting <span class="ffa ls13 ws14c">P<span class="_ _c"></span>. falciparum <span class="ff9 ls12 ws14b">alone is</span></span></div><div class="t m0 xb hb y21a ff9 fs8 fc3 sc0 ls87 wscd">sufficient. Anti-relapse treatment with primaquine should only be giv<span class="_ _a"></span>en to cases</div><div class="t m0 xb hb y21b ff9 fs8 fc3 sc0 ls12 ws0">with confirmed diagnosis of vivax malaria.</div><div class="t m0 xb h12 y21c ff10 fs6 fc4 sc0 ls9a ws0">4.6<span class="_ _78"> </span>In epidemics and complex emergencies </div><div class="t m0 xb hb y21d ff9 fs8 fc3 sc0 ls12 ws14d">In epidemic and complex emergency situations, facilities for parasitological</div><div class="t m0 xb hb y21e ff9 fs8 fc3 sc0 lsd1 ws14e">diagnosis may be unavailable or inadequate to cope with the case-load. In such</div><div class="t m0 xb hb y21f ff9 fs8 fc3 sc0 ls12 ws14f">circumstances, it is impractical and unnecessary to demonstrate par<span class="_ _a"></span>asites</div><div class="t m0 xb hb y220 ff9 fs8 fc3 sc0 lsa9 wsf1">before treatment in all cases of fev<span class="_ _a"></span>er<span class="_ _b"></span>. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, there is a role for parasitological</div><div class="t m0 xb hb y221 ff9 fs8 fc3 sc0 ls12 ws0">diagnosis even in these situations (see section 11.1).</div><div class="t m0 xb hd y222 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on parasitological diagnosis</div><div class="t m0 x2d h16 y223 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x2e h16 y224 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x2f h16 y225 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y226 ff9 fsb fc3 sc0 lsd2 ws150">In areas of low to moder<span class="_ _a"></span>ate transmission, prompt parasitological</div><div class="t m3 x2d h17 y227 ff9 fsb fc3 sc0 lsd2 ws151">confirmation of the diagnosis is recommended before tr<span class="_ _a"></span>eatment is</div><div class="t m3 x2d h17 y228 ff9 fsb fc3 sc0 lsd2 ws152">started. This should be achieved through micr<span class="_ _a"></span>oscopy or<span class="_ _b"></span>, where not</div><div class="t m3 x2d h17 y229 ff9 fsb fc3 sc0 lsd2 ws0">available, RDT<span class="_ _c"></span>s.</div><div class="t m3 xd h16 y226 ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x2d h17 y22a ff9 fsb fc3 sc0 lsd2 ws153">In areas of high stable malaria transmission, the prior pr<span class="_ _a"></span>obability of</div><div class="t m3 x2d h17 y22b ff9 fsb fc3 sc0 lsd4 ws154">fever in a child being caused by malaria is high. Children under 5 y<span class="_ _a"></span>ears</div><div class="t m3 x2d h17 y22c ff9 fsb fc3 sc0 lsd5 ws155">of age should therefore be tr<span class="_ _a"></span>eated on the basis of a clinical diagnosis</div><div class="t m3 x2d h17 y22d ff9 fsb fc3 sc0 lsd6 ws156">of malaria. In older children and adults including in pregnant women,</div><div class="t m3 x2d h17 y22e ff9 fsb fc3 sc0 lsd7 ws157">a parasitological diagnosis is recommended befor<span class="_ _a"></span>e treatment is</div><div class="t m3 x2d h17 y22f ff9 fsb fc3 sc0 lsd8 ws0">started.</div><div class="t m3 xd h16 y22a ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x2d h17 y230 ff9 fsb fc3 sc0 lsd9 ws158">In all suspected cases of severe malaria, a par<span class="_ _a"></span>asitological confirmation</div><div class="t m3 x2d h17 y231 ff9 fsb fc3 sc0 lsd2 ws159">of the diagnosis of malaria is recommended. In the absence of or a</div><div class="t m3 x2d h17 y232 ff9 fsb fc3 sc0 lsda ws15a">delay in obtaining parasitological diagnosis, patients should be</div><div class="t m3 x2d h17 y233 ff9 fsb fc3 sc0 lsd2 ws0">treated for sever<span class="_ _a"></span>e malaria on clinical grounds.</div><div class="t m3 xd h16 y230 ff8 fsb fc3 sc0 ls0 ws0">E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf16" class="pf w1 h4" data-page-no="16"><div class="pc pc16 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x27 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">12</div><div class="t m0 x9 hf y7d ffe fs6 fc3 sc0 ls0 ws95">5.<span class="_ _33"> </span>R<span class="_ _8"></span>E<span class="_ _8"></span>SI<span class="_ _8"></span>ST<span class="_ _b"></span>ANCE <span class="_ _a"></span>TO ANTIMALARIAL M<span class="_ _8"></span>EDICI<span class="_ _8"></span>NE<span class="_ _8"></span>S</div><div class="t m0 x30 h14 y234 ff11 fs5 fc4 sc0 ls0 ws0">9</div><div class="t m0 x9 hb yce ff9 fs8 fc3 sc0 ls12 ws15b">Resistance has arisen to all classes of antimalarials ex<span class="_ _a"></span>cept, as yet, to the</div><div class="t m0 x9 hb y165 ff9 fs8 fc3 sc0 ls12 ws15c">artemisinin derivatives. <span class="_ _a"></span>This has increased the global malaria burden and is</div><div class="t m0 x9 hb y166 ff9 fs8 fc3 sc0 ls12 ws4f">a major threat to malaria control. <span class="_ _b"></span>Widespread and indiscriminate use of anti-</div><div class="t m0 x9 hb y167 ff9 fs8 fc3 sc0 ls12 ws15d">malarials places a strong selective pr<span class="_ _a"></span>essure on malaria parasites to dev<span class="_ _a"></span>elop</div><div class="t m0 x9 hb y168 ff9 fs8 fc3 sc0 ls12 ws15e">high levels of resistance. R<span class="_ _a"></span>esistance can be prevented, or its onset slo<span class="_ _a"></span>wed</div><div class="t m0 x9 hb y1ae ff9 fs8 fc3 sc0 lsdb ws15f">considerably<span class="_ _c"></span>, by combining antimalarials with different mechanisms of action and</div><div class="t m0 x9 hb y1af ff9 fs8 fc3 sc0 ls34 ws14a">ensuring very high cure rates thr<span class="_ _a"></span>ough full adherence to correct dose regimens.</div><div class="t m0 x9 h12 y19e ff10 fs6 fc4 sc0 ls9a ws0">5.1<span class="_ _78"> </span>Impact of resistance</div><div class="t m0 x9 hb y235 ff9 fs8 fc3 sc0 ls12 ws8f">Initially<span class="_ _4b"></span>, at low levels of r<span class="_ _a"></span>esistance and with a low prev<span class="_ _a"></span>alence of malaria, the</div><div class="t m0 x9 hb y236 ff9 fs8 fc3 sc0 ls53 ws160">impact of resistance to antimalarials is insidious. <span class="_ _a"></span>The initial symptoms of the</div><div class="t m0 x9 hb y237 ff9 fs8 fc3 sc0 ls12 ws161">infection resolve and the patient appears to be better for some w<span class="_ _a"></span>eeks. When</div><div class="t m0 x9 hb y238 ff9 fs8 fc3 sc0 lsdc ws162">symptoms recur<span class="_ _4b"></span>, usually more than two weeks later<span class="_ _4b"></span>, anaemia may have</div><div class="t m0 x9 hb y239 ff9 fs8 fc3 sc0 ls12 ws163">worsened and there is a greater pr<span class="_ _a"></span>obability of carrying gametocytes (which</div><div class="t m0 x9 hb y23a ff9 fs8 fc3 sc0 ls12 ws164">in turn carry the resistance genes) and transmitting malaria. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, the</div><div class="t m0 x9 hb y23b ff9 fs8 fc3 sc0 ls12 ws165">patient and the treatment pro<span class="_ _a"></span>vider may interpret this as a newly acquired</div><div class="t m0 x9 hb y23c ff9 fs8 fc3 sc0 ls12 wsc5">infection. At this stage, unless clinical drug trials are conducted, resistance</div><div class="t m0 x9 hb y23d ff9 fs8 fc3 sc0 ls12 ws166">may go unrecognized. As r<span class="_ _a"></span>esistance worsens the inter<span class="_ _8"></span>val between primary</div><div class="t m0 x9 hb y23e ff9 fs8 fc3 sc0 lsdd ws167">infection and recrudescence shortens, until eventually symptoms fail to</div><div class="t m0 x9 hb y23f ff9 fs8 fc3 sc0 ls12 ws168">resolve follo<span class="_ _a"></span>wing treatment. At this stage, malaria incidence may rise in low-</div><div class="t m0 x9 hb y240 ff9 fs8 fc3 sc0 ls12 ws0">transmission settings and mortality is likely to rise in all settings. </div><div class="t m0 x9 h12 y241 ff10 fs6 fc4 sc0 ls9a ws0">5.2<span class="_ _78"> </span>Global distribut<span class="_ _8"></span>ion of resistance</div><div class="t m0 x9 hb y242 ff9 fs8 fc3 sc0 ls12 ws169">Resistance to antimalarials has been documented for <span class="ffa ls13 ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum, P<span class="_ _c"></span>.<span class="_ _64"> </span>viv<span class="_ _a"></span>ax</span></div><div class="t m0 x9 hb y243 ff9 fs8 fc3 sc0 ls12 ws0">and, recently<span class="_ _c"></span>, <span class="ffa ls13">P<span class="_ _c"></span>.<span class="_ _64"> </span>malariae.</span></div><div class="t m0 x9 hb y244 ff9 fs8 fc3 sc0 ls13 ws0">In <span class="_ _9"></span><span class="ffa">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum<span class="ff9 ls12 ws16a">, resistance has been obser<span class="_ _8"></span>ved to almost all currently used</span></span></div><div class="t m0 x9 hb y245 ff9 fs8 fc3 sc0 lsde ws16b">antimalarials (amodiaquine, chloroquine, mefloquine, quinine and sulfadoxine–</div><div class="t m0 x9 hb y246 ff9 fs8 fc3 sc0 ls12 ws16c">pyrimethamine) except for artemisinin and its derivatives. <span class="_ _b"></span>The geographical</div><div class="t m0 x9 hb y247 ff9 fs8 fc3 sc0 ls12 ws0">distributions and rates of spread hav<span class="_ _a"></span>e varied considerably<span class="_ _c"></span>. </div><div class="t m0 x9 hb y248 ffa fs8 fc3 sc0 lsc0 ws0">P<span class="_ _c"></span>. vivax <span class="ff9 lsdf ws16d">has dev<span class="_ _a"></span>eloped resistance rapidly to sulfadoxine–pyrimethamine in many</span></div><div class="t m0 x9 hb y249 ff9 fs8 fc3 sc0 lse0 ws11f">areas. Chloroquine r<span class="_ _a"></span>esistance is confined largely to Indonesia, East <span class="_ _a"></span>Timor<span class="_ _b"></span>, Papua</div><div class="t m0 x9 hb y24a ff9 fs8 fc3 sc0 ls12 ws16e">New Guinea and other parts of Oceania. There are also documented r<span class="_ _a"></span>epor<span class="_ _8"></span>ts</div><div class="t m0 x9 h14 y163 ff11 fs5 fc4 sc0 ls0 ws0">9</div><div class="t m0 x14 h15 y164 ff9 fsa fc3 sc0 lse1 ws16f">Further information on the emergence, spread and prev<span class="_ _a"></span>ention of resistance to antimalarials is</div><div class="t m0 x14 h15 y24b ff9 fsa fc3 sc0 ls7d ws0">provided in Annex 6.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf17" class="pf w1 h4" data-page-no="17"><div class="pc pc17 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x31 he y9 ffc fs5 fc3 sc0 ls3 ws0">5.<span class="_ _5"> </span>Resistance to antimalarial medicines</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">13</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls13 ws170">from Peru. <span class="ffa ls14 ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>viv<span class="_ _a"></span>ax<span class="_ _64"> </span><span class="ff9 ls12 ws171">remains sensitiv<span class="_ _a"></span>e to chloroquine in South-East Asia, the</span></span></div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 lse2 ws138">Indian subcontinent, the K<span class="_ _a"></span>orean peninsula, the Middle East, north-east Africa,</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls12 ws0">and most of South and Central America.</div><div class="t m0 xb h12 y24c ff10 fs6 fc4 sc0 ls9a ws0">5.3<span class="_ _78"> </span>Assessing resistance</div><div class="t m0 xb hb y24d ff9 fs8 fc3 sc0 lse3 ws172">The following methods are av<span class="_ _b"></span>ailable for assessing resistance to antimalarials:</div><div class="t m0 xb hb y24e ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="ffa fc3 ls13">in vivo <span class="ff9 ls12">assessment of therapeutic efficacy (see section 6.1),</span></span></div><div class="t m0 xb hb y24f ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="ffa fc3 ls13">in vitro <span class="ff9 ls12">studies of parasite susceptibility to drugs in cultur<span class="_ _a"></span>e,</span></span></div><div class="t m0 xb hb y250 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">molecular genotyping.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf18" class="pf w1 h4" data-page-no="18"><div class="pc pc18 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x27 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">14</div><div class="t m0 x9 hf y7d ffe fs6 fc3 sc0 ls0 ws173">6.<span class="_ _33"> </span>ANTI<span class="_ _8"></span>MALAR<span class="_ _8"></span>IAL TRE<span class="_ _8"></span>A<span class="_ _b"></span>TMENT POLIC<span class="_ _8"></span>Y </div><div class="t m0 x9 hb yce ff9 fs8 fc3 sc0 lse4 ws174">National antimalarial treatment policies should aim to offer antimalarials</div><div class="t m0 x9 hb y165 ff9 fs8 fc3 sc0 ls12 ws175">that are highly effective. <span class="_ _b"></span>The main determinant of policy change is the thera-</div><div class="t m0 x9 hb y166 ff9 fs8 fc3 sc0 ls63 ws8a">peutic efficacy and the consequent effectiveness of the antimalarial in use. Other</div><div class="t m0 x9 hb y167 ff9 fs8 fc3 sc0 lse5 ws176">important determinants include: changing patterns of malaria-associated</div><div class="t m0 x9 hb y168 ff9 fs8 fc3 sc0 lse6 ws177">morbidity and mortality; consumer and provider dissatisfaction with the</div><div class="t m0 x9 hb y1ae ff9 fs8 fc3 sc0 lse7 ws178">current policy; and the av<span class="_ _a"></span>ailability of new products, strategies and approaches. </div><div class="t m0 x9 h12 y19d ff10 fs6 fc4 sc0 ls9a ws0">6.1<span class="_ _78"> </span>Assessment of <span class="ff12 lse8 ws179">in vivo </span><span class="ls1 ws17a">therapeut<span class="_ _8"></span>ic efficac<span class="_ _8"></span>y</span></div><div class="t m0 x9 hb y251 ff9 fs8 fc3 sc0 ls9b wsc3">This involv<span class="_ _a"></span>es the assessment of clinical and parasitological outcomes of</div><div class="t m0 x9 hb y235 ff9 fs8 fc3 sc0 ls25 ws17b">treatment o<span class="_ _a"></span>ver a certain period following the star<span class="_ _8"></span>t of treatment, to check for the</div><div class="t m0 x9 hb y236 ff9 fs8 fc3 sc0 lse9 ws17c">reappearance of par<span class="_ _a"></span>asites in the blood. Reappearance indicates r<span class="_ _a"></span>educed parasite</div><div class="t m0 x9 hb y237 ff9 fs8 fc3 sc0 lsaf ws168">sensitivity to the treatment drug. As a significant proportion of treatment failures</div><div class="t m0 x9 hb y238 ff9 fs8 fc3 sc0 lsea ws17d">do not appear until after day 14, shorter obser<span class="_ _8"></span>vation periods lead to a considerable</div><div class="t m0 x9 hb y239 ff9 fs8 fc3 sc0 ls34 ws7f">ov<span class="_ _a"></span>erestimation of the efficacy of the tested drug. This is a particular problem at</div><div class="t m0 x9 hb y23a ff9 fs8 fc3 sc0 ls22 ws17e">low levels of r<span class="_ _a"></span>esistance and with low failure r<span class="_ _a"></span>ates. The current r<span class="_ _a"></span>ecommended</div><div class="t m0 x9 hb y23b ff9 fs8 fc3 sc0 ls22 ws17f">duration of follow-up is ≥28 days in ar<span class="_ _a"></span>eas of high as well as low to moderate</div><div class="t m0 x9 hb y23c ff9 fs8 fc3 sc0 lsdb ws180">transmission. Assessment o<span class="_ _a"></span>ver only 14 days, the period previously recommended</div><div class="t m0 x9 hb y23d ff9 fs8 fc3 sc0 ls22 ws181">in areas of high transmission, is no longer consider<span class="_ _a"></span>ed sufficient. Antimalarial</div><div class="t m0 x9 hb y23e ff9 fs8 fc3 sc0 ls22 ws6e">treatment should also be assessed on the basis of parasitological cur<span class="_ _a"></span>e rates.</div><div class="t m0 x9 hb y23f ff9 fs8 fc3 sc0 ls8a ws182">Where possible, blood or plasma levels of the antimalarial should also be</div><div class="t m0 x9 hb y240 ff9 fs8 fc3 sc0 ls22 ws183">measured in prospectiv<span class="_ _a"></span>e assessments so that drug resistance can be distin-</div><div class="t m0 x9 hb y252 ff9 fs8 fc3 sc0 ls22 ws0">guished from treatment failur<span class="_ _a"></span>es due to pharmacokinetic reasons. </div><div class="t m0 x9 hb y253 ff9 fs8 fc3 sc0 ls22 ws184">In high-transmission settings reinfection is inevitable, but cur<span class="_ _a"></span>e of malaria (i.e.</div><div class="t m0 x9 hb y254 ff9 fs8 fc3 sc0 ls22 ws12c">prevention of r<span class="_ _a"></span>ecrudescences) is impor<span class="_ _8"></span>tant as it benefits both the patient, by</div><div class="t m0 x9 hb y255 ff9 fs8 fc3 sc0 ls22 ws185">reducing anaemia, and the community<span class="_ _c"></span>, by slowing the emergence and spread</div><div class="t m0 x9 hb y256 ff9 fs8 fc3 sc0 lsc2 ws186">of resistance. In the past, “<span class="_ _b"></span>clinical” and “parasitological” cur<span class="_ _a"></span>e rates were</div><div class="t m0 x9 hb y257 ff9 fs8 fc3 sc0 ls22 ws1e">regarded separ<span class="_ _a"></span>ately<span class="_ _4b"></span>, but with increasing appreciation of the adverse effects of</div><div class="t m0 x9 hb y258 ff9 fs8 fc3 sc0 ls22 ws187">treatment failure, the two ar<span class="_ _a"></span>e now considered together<span class="_ _4b"></span>. Persistence of para-</div><div class="t m0 x9 hb y259 ff9 fs8 fc3 sc0 ls22 ws188">sitaemia without fever following tr<span class="_ _a"></span>eatment has previously not been regarded</div><div class="t m0 x9 hb y25a ff9 fs8 fc3 sc0 ls13 wsf9">seriously in high-transmission situations. <span class="_ _a"></span>This still represents a treatment</div><div class="t m0 x9 hb y25b ff9 fs8 fc3 sc0 lseb ws189">failure and is associated with anaemia. Slowly eliminated antimalarials pr<span class="_ _a"></span>ovide</div><div class="t m0 x9 hb y25c ff9 fs8 fc3 sc0 lsec ws110">the additional benefit of suppressing malaria infections that are newly acquir<span class="_ _a"></span>ed</div><div class="t m0 x9 hb y25d ff9 fs8 fc3 sc0 ls22 ws18a">during the period in which residual antimalarial drug levels persist in the body<span class="_ _c"></span>.</div><div class="t m0 x9 hb y25e ff9 fs8 fc3 sc0 ls22 ws18b">On the other hand, these residual drug levels do pr<span class="_ _a"></span>ovide a selection pressur<span class="_ _a"></span>e</div><div class="t m0 x9 hb y25f ff9 fs8 fc3 sc0 lsed ws18c">for resistance. In these treatment r<span class="_ _a"></span>ecommendations, the curative efficacy of the</div><div class="t m0 x9 hb y260 ff9 fs8 fc3 sc0 ls22 ws0">antimalarials has taken precedence o<span class="_ _a"></span>ver these considerations.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf19" class="pf w1 h4" data-page-no="19"><div class="pc pc19 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x32 he y9 ffc fs5 fc3 sc0 lsee ws2">6.<span class="_ _5"> </span>Antimalarial treatment policy</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">15</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls9a ws0">6.2<span class="_ _78"> </span>Criter<span class="_ _8"></span>ia for antimalarial t<span class="_ _8"></span>reatment polic<span class="_ _8"></span>y change</div><div class="t m0 xb hb y1cf ff9 fs8 fc3 sc0 ls12 ws18d">These malaria treatment guidelines recommend that antimalarial tr<span class="_ _a"></span>eatment</div><div class="t m0 xb hb y1d0 ff9 fs8 fc3 sc0 ls12 ws18e">policy should be changed at treatment failure r<span class="_ _a"></span>ates considerably lower than</div><div class="t m0 xb hb y1d1 ff9 fs8 fc3 sc0 ls5e ws7f">those recommended previously<span class="_ _c"></span>. This major change reflects the av<span class="_ _a"></span>ailability of</div><div class="t m0 xb hb y1d2 ff9 fs8 fc3 sc0 ls12 ws13b">highly effective drugs, and the recognition both of the consequences of drug</div><div class="t m0 xb hb y1d3 ff9 fs8 fc3 sc0 lsbb ws18f">resistance, in terms of morbidity and mortality<span class="_ _4b"></span>, and the impor<span class="_ _8"></span>tance of high cure</div><div class="t m0 xb hb y217 ff9 fs8 fc3 sc0 ls12 ws0">rates in malaria control.</div><div class="t m0 xb hb y261 ff9 fs8 fc3 sc0 ls1e ws1d">It is now recommended that a change of first-line tr<span class="_ _a"></span>eatment should be initiated</div><div class="t m0 xb hb y262 ff9 fs8 fc3 sc0 ls13 ws27">if the total failure proportion exceeds 10%. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, it is acknowledged that</div><div class="t m0 xb hb y263 ff9 fs8 fc3 sc0 ls13 ws190">a decision to change may be influenced by a number of additional factors,</div><div class="t m0 xb hb y1d8 ff9 fs8 fc3 sc0 lsef wsab">including the prev<span class="_ _a"></span>alence and geographical distribution of reported treatment</div><div class="t m0 xb hb y1d9 ff9 fs8 fc3 sc0 ls3c ws31">failures, health service provider and/or patient dissatisfaction with the treat-</div><div class="t m0 xb hb y264 ff9 fs8 fc3 sc0 ls12 ws191">ment, the political and economical context, and the availability of affor<span class="_ _a"></span>dable</div><div class="t m0 xb hb y265 ff9 fs8 fc3 sc0 ls12 ws0">alternatives to the commonly used treatment.</div><div class="t m0 xb hd y266 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on changing antimalarial treatment policy </div><div class="t m0 x2d h16 y267 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x2e h16 y268 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x2f h16 y269 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y26a ff9 fsb fc3 sc0 lsf0 ws192">In therapeutic efficacy assessments, the cure r<span class="_ _a"></span>ate should be defined</div><div class="t m3 x2d h17 y26b ff9 fsb fc3 sc0 lsf1 ws193">parasitologically<span class="_ _4b"></span>, based on a minimum of 28 days of follow-up.</div><div class="t m3 x2d h17 y26c ff9 fsb fc3 sc0 lsf2 ws194">Molecular genotyping using PCR technology should be used to</div><div class="t m3 x2d h17 y26d ff9 fsb fc3 sc0 lsd2 ws195">distinguish recrudescent parasites fr<span class="_ _a"></span>om newly acquired infections.</div><div class="t m3 x33 h16 y26a ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x2d h17 y26e ff9 fsb fc3 sc0 lsd2 ws196">Review and change of the antimalarial treatment policy should be</div><div class="t m3 x2d h17 y26f ff9 fsb fc3 sc0 lsf3 ws197">initiated when the cure rate with the curr<span class="_ _a"></span>ent recommended medicine</div><div class="t m3 x2d h17 y270 ff9 fsb fc3 sc0 lsf4 ws198">falls below 90% (as assessed through monitoring of ther<span class="_ _a"></span>apeutic</div><div class="t m3 x2d h17 y271 ff9 fsb fc3 sc0 lsd2 ws0">efficacy).</div><div class="t m3 x33 h16 y26e ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x2d h17 y272 ff9 fsb fc3 sc0 lsf5 ws199">A new recommended antimalarial medicine adopted as policy should</div><div class="t m3 x2d h17 y273 ff9 fsb fc3 sc0 lsd8 ws19a">have an aver<span class="_ _a"></span>age cure rate <span class="fff ls0 ws0">≥<span class="_ _67"> </span></span>95% as assessed in clinical trials.</div><div class="t m3 x33 h16 y272 ff8 fsb fc3 sc0 ls0 ws0">E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf1a" class="pf w1 h4" data-page-no="1a"><div class="pc pc1a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x27 h9 ya ff9 fs6 fc4 sc0 ls9a ws0">16</div><div class="t m0 x9 hf y7d ffe fs6 fc3 sc0 ls86 wsca">7.<span class="_ _33"> </span>TR<span class="_ _8"></span>EA<span class="_ _a"></span>TMENT OF UNC<span class="_ _a"></span>OMPLIC<span class="_ _9"></span>A<span class="_ _b"></span>TED</div><div class="t m0 x10 hf y274 ff13 fs6 fc3 sc0 ls1 ws0">P<span class="_ _c"></span>. F<span class="_ _a"></span>ALCIP<span class="_ _b"></span>ARUM <span class="ffe">MAL<span class="_ _8"></span>ARIA</span></div><div class="t m0 x34 h18 y275 ff8 fsc fc4 sc0 lsf6 ws0">10</div><div class="t m0 x9 h12 y276 ff10 fs6 fc4 sc0 ls1 ws0">7.1<span class="_ _78"> </span>Assessment</div><div class="t m0 x9 hb y277 ff9 fs8 fc3 sc0 ls3d ws19b">Uncomplicated malaria is defined as symptomatic malaria without signs of</div><div class="t m0 x9 hb y278 ff9 fs8 fc3 sc0 lsf7 wse2">severity or evidence of vital or<span class="_ _a"></span>gan dysfunction. In acute falciparum malaria there</div><div class="t m0 x9 hb y279 ff9 fs8 fc3 sc0 lsf8 ws19c">is a continuum from mild to sever<span class="_ _a"></span>e malaria. Y<span class="_ _b"></span>oung children and non-immune adults</div><div class="t m0 x9 hb y27a ff9 fs8 fc3 sc0 lsf9 ws19d">with malaria may deteriorate rapidly<span class="_ _c"></span>. Detailed definitions of severe malaria are</div><div class="t m0 x9 hb y27b ff9 fs8 fc3 sc0 lsf9 ws19e">available (see section 8.1) to guide pr<span class="_ _a"></span>actitioners and for epidemiological and</div><div class="t m0 x9 hb y27c ff9 fs8 fc3 sc0 lsd1 ws18a">research purposes but, in pr<span class="_ _a"></span>actice, any patient whom the attending physician or</div><div class="t m0 x9 hb y27d ff9 fs8 fc3 sc0 lsf9 ws19f">health care worker suspects of having sever<span class="_ _a"></span>e malaria should be treated as such</div><div class="t m0 x9 hb y27e ff9 fs8 fc3 sc0 lsfa ws160">initially<span class="_ _4b"></span>. The risks of under<span class="_ _b"></span>-treating severe malaria consider<span class="_ _a"></span>ably exceed those of</div><div class="t m0 x9 hb y27f ff9 fs8 fc3 sc0 lsf9 ws14">giving parenteral or r<span class="_ _a"></span>ectal treatment to a patient who does not need it.</div><div class="t m0 x9 h12 y280 ff10 fs6 fc4 sc0 lsc3 ws139">7.2<span class="_ _78"> </span>Antimalarial combination therapy</div><div class="t m0 x9 hb y281 ff9 fs8 fc3 sc0 ls12 ws1a0">T<span class="_ _4b"></span>o counter the threat of resistance of <span class="ffa ls13 ws0">P<span class="_ _c"></span>. falciparum <span class="ff9 ls12 ws16b">to monother<span class="_ _a"></span>apies, and to</span></span></div><div class="t m0 x9 hb y282 ff9 fs8 fc3 sc0 ls12 ws1a1">impro<span class="_ _a"></span>ve treatment outcome, combinations of antimalarials are no<span class="_ _a"></span>w recom-</div><div class="t m0 x9 hb y283 ff9 fs8 fc3 sc0 ls12 ws0">mended by WHO for the tr<span class="_ _a"></span>eatment of falciparum malaria.</div><div class="t m0 x9 h13 y284 ff8 fs3 fc3 sc0 ls80 ws0">7.2.1<span class="_ _7d"> </span>Definition</div><div class="t m0 x9 hb y285 ff9 fs8 fc3 sc0 lsfb ws1a2">Antimalarial combination therapy is the simultaneous use of two or more</div><div class="t m0 x9 hb y286 ff9 fs8 fc3 sc0 ls64 ws1a3">blood schizontocidal drugs with independent modes of action and thus unre-</div><div class="t m0 x9 hb y287 ff9 fs8 fc3 sc0 lsa2 ws1a4">lated biochemical targets in the parasite. <span class="_ _b"></span>The concept is based on the potential</div><div class="t m0 x9 hb y288 ff9 fs8 fc3 sc0 ls64 ws1a5">of two or more simultaneously administered schiz<span class="_ _a"></span>ontocidal drugs with inde-</div><div class="t m0 x9 hb y289 ff9 fs8 fc3 sc0 ls6b ws1a6">pendent modes of action to impro<span class="_ _a"></span>ve therapeutic efficacy and also to delay the</div><div class="t m0 x9 hb y28a ff9 fs8 fc3 sc0 ls64 ws1a7">development of resistance to the individual components of the combination.</div><div class="t m0 x9 h13 y28b ff8 fs3 fc3 sc0 ls80 ws0">7.2.2<span class="_ _18"> </span>What is not considered to be combination therapy</div><div class="t m0 x9 hb y28c ff9 fs8 fc3 sc0 lsfc ws1a8">Drug combinations such as sulfadoxine–pyrimethamine, sulfalene–pyrimetha-</div><div class="t m0 x9 hb y28d ff9 fs8 fc3 sc0 ls22 ws1a9">mine, proguanil-dapsone, chlorproguanil-dapsone and ato<span class="_ _a"></span>vaquone-pr<span class="_ _a"></span>oguanil</div><div class="t m0 x9 hb y28e ff9 fs8 fc3 sc0 ls22 ws1aa">rely on synergy betw<span class="_ _a"></span>een the two components. The drug tar<span class="_ _a"></span>gets in the malaria</div><div class="t m0 x9 hb y28f ff9 fs8 fc3 sc0 lsfd ws1a6">parasite are linked. <span class="_ _b"></span>These combinations are operationally considered as single</div><div class="t m0 x9 hb y290 ff9 fs8 fc3 sc0 lsfe wsb3">products and treatment with them is not consider<span class="_ _a"></span>ed to be antimalarial combina-</div><div class="t m0 x9 hb y291 ff9 fs8 fc3 sc0 ls22 ws1ab">tion therapy<span class="_ _c"></span>. Multiple-drug therapies that include a non-antimalarial medicine</div><div class="t m0 x9 hb y292 ff9 fs8 fc3 sc0 lsff wsa0">to enhance the antimalarial effect of a blood schizontocidal drug (e.g. chloroquine</div><div class="t m0 x9 hb y293 ff9 fs8 fc3 sc0 ls22 ws14">and chlorpheniramine) are also not antimalarial combination ther<span class="_ _a"></span>apy<span class="_ _4b"></span>. </div><div class="t m0 x9 h14 y294 ff11 fs5 fc4 sc0 ls100 ws0">10</div><div class="t m0 x35 h15 y295 ff9 fsa fc3 sc0 ls7d ws0">Further information is provided in Annex 7.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf1b" class="pf w1 h4" data-page-no="1b"><div class="pc pc1b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls2 ws0">17</div><div class="t m0 xb h13 y296 ff8 fs3 fc3 sc0 ls80 ws0">7.2.3<span class="_ _2d"> </span>R<span class="_ _b"></span>ationale for antimalarial combination therapy</div><div class="t m0 xb hb y297 ff9 fs8 fc3 sc0 ls12 ws1ac">The rationale for combining antimalarials with different modes of action is</div><div class="t m0 xb hb y298 ff9 fs8 fc3 sc0 ls12 wsdc">twofold: (1) the combination is often more effective; and (2) in the r<span class="_ _a"></span>are event</div><div class="t m0 xb hb y299 ff9 fs8 fc3 sc0 lsf7 ws1ad">that a mutant parasite that is resistant to one of the drugs arises de no<span class="_ _a"></span>vo during</div><div class="t m0 xb hb y29a ff9 fs8 fc3 sc0 ls13 ws1ae">the course of the infection, the parasite will be killed by the other drug. <span class="_ _a"></span>This</div><div class="t m0 xb hb y29b ff9 fs8 fc3 sc0 ls7f wsc0">mutual protection is thought to prev<span class="_ _a"></span>ent or delay the emergence of resistance.</div><div class="t m0 xb hb y29c ff9 fs8 fc3 sc0 ls12 ws1af">T<span class="_ _4b"></span>o realize the two adv<span class="_ _a"></span>antages, the par<span class="_ _8"></span>tner drugs in a combination must be</div><div class="t m0 xb hb y29d ff9 fs8 fc3 sc0 ls102 wsb2">independently effective. <span class="_ _a"></span>The possible disadvantages of combination tr<span class="_ _a"></span>eatments</div><div class="t m0 xb hb y29e ff9 fs8 fc3 sc0 ls12 ws172">are the potential for increased risk of adv<span class="_ _a"></span>erse effects and the increased cost. </div><div class="t m0 xb h13 y29f ff8 fs3 fc3 sc0 ls69 ws1b0">7.2.4<span class="_ _18"> </span>Ar<span class="_ _8"></span>temisinin-based combination therapy (ACT) </div><div class="t m0 xb hb y2a0 ff9 fs8 fc3 sc0 ls12 ws1b1">Artemisinin and its derivatives (artesunate, ar<span class="_ _8"></span>temether<span class="_ _b"></span>, artemotil, dihydro-</div><div class="t m0 xb hb y2a1 ff9 fs8 fc3 sc0 ls12 ws1b2">artemisinin) produce rapid clearance of parasitaemia and r<span class="_ _a"></span>apid resolution of</div><div class="t m0 xb hb y2a2 ff9 fs8 fc3 sc0 lsc4 ws1b3">symptoms. They r<span class="_ _a"></span>educe parasite numbers by a factor of approximately 10 000</div><div class="t m0 xb hb y2a3 ff9 fs8 fc3 sc0 ls12 ws1b4">in each asexual cycle, which is more than other curr<span class="_ _a"></span>ent antimalarials (which</div><div class="t m0 xb hb y2a4 ff9 fs8 fc3 sc0 ls103 ws1b5">reduce parasite numbers 100- to 1000-fold per cy<span class="_ _a"></span>cle). Ar<span class="_ _8"></span>temisinin and its</div><div class="t m0 xb hb y2a5 ff9 fs8 fc3 sc0 lsa9 wsf1">derivativ<span class="_ _a"></span>es are eliminated rapidly<span class="_ _c"></span>. When given in combination with rapidly elim-</div><div class="t m0 xb hb y2a6 ff9 fs8 fc3 sc0 ls12 ws169">inated compounds (tetracyclines, clindamy<span class="_ _a"></span>cin), a 7-day course of treatment</div><div class="t m0 xb hb y2a7 ff9 fs8 fc3 sc0 lsa2 ws102">with an artemisinin compound is required; but when given in combination with</div><div class="t m0 xb hb y2a8 ff9 fs8 fc3 sc0 ls12 ws1b6">slowly eliminated antimalarials, shorter courses of treatment (3 days) are</div><div class="t m0 xb hb y2a9 ff9 fs8 fc3 sc0 ls12 ws1b7">effective. <span class="_ _a"></span>The evidence of their superiority in comparison to monotherapies</div><div class="t m0 xb hb y2aa ff9 fs8 fc3 sc0 ls12 ws0">has been clearly documented.</div><div class="t m0 xb h19 y2ab ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x1a h15 y2ac ff9 fsa fc3 sc0 lsac ws115">See also Annex 7.1. </div><div class="t m0 x2d hd y2ad ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE: trials comparing monotherapies with A<span class="_ _a"></span>CT<span class="_ _b"></span>s</div><div class="t m0 x36 h11 y2ae ff9 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x2d h1a y2af ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y2af ff14 fsb fc3 sc0 lsd2 ws0">single drug (oral AQ, MQ or SP) compar<span class="_ _a"></span>ed with single drug in</div><div class="t m3 x2d h1b y2b0 ff14 fsb fc3 sc0 lsd8 ws19a">combination with AS (both oral)</div><div class="t m3 x38 h1b y2b1 ff14 fsb fc5 sc0 ls104 ws1b8">Summary of RCT<span class="_ _b"></span>s:</div><div class="t m4 x39 h17 y2b2 ff9 fsb fc3 sc0 ls105 ws1b9">one meta-analysis of 11 RCT<span class="_ _4b"></span>s has been conducted. This found</div><div class="t m4 x38 h17 y2b3 ff9 fsb fc3 sc0 ls105 ws1ba">a clear benefit of adding 3 days of AS to AQ, MQ or SP for uncomplicated malaria.</div><div class="t m4 x38 h17 y2b4 ff9 fsb fc3 sc0 ls106 ws1bb">The combination treatment resulted in fewer par<span class="_ _a"></span>asitological failures at day 28 and</div><div class="t m4 x38 h17 y2b5 ff9 fsb fc3 sc0 ls107 ws1bc">reduced gametocyte carriage compared to the baseline v<span class="_ _a"></span>alue. Adding AS treatment</div><div class="t m4 x38 h17 y2b6 ff9 fsb fc3 sc0 ls105 ws1bd">for 1 day (6 RCT<span class="_ _4b"></span>s) was also associated with fewer treatment failures by day 28 but</div><div class="t m4 x38 h17 y2b7 ff9 fsb fc3 sc0 ls108 ws1be">was significantly less effective than the 3-day regimen (OR: 0.34; 95% CI: 0.24–0.47;</div><div class="t m4 x38 h17 y2b8 ffa fsb fc3 sc0 ls0 ws0">p<span class="_ _67"> </span><span class="fff">&lt;<span class="_ _67"> </span><span class="ff9 ls105">0.0001).</span></span></div><div class="t m3 x38 h1b y2b9 ff14 fsb fc5 sc0 ls109 ws1bf">Exper<span class="_ _8"></span>t comment:</div><div class="t m4 x3a h17 y2b9 ff9 fsb fc3 sc0 ls10a ws1bf">the addition of AS to standard monotherapy significantly reduces</div><div class="t m4 x38 h17 y2ba ff9 fsb fc3 sc0 ls10b ws19a">treatment failure, r<span class="_ _a"></span>ecrudescence and gametocyte carriage.</div><div class="t m3 x38 h1b y2bb ff14 fsb fc5 sc0 ls105 ws0">Basis of decision:</div><div class="t m4 x3b h17 y2bb ff9 fsb fc3 sc0 ls10b ws0">systematic review<span class="_ _b"></span>.</div><div class="t m0 x2d h16 y2bc ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y2bc ff9 fsb fc3 sc0 lsd2 ws0">replace monotherapy with or<span class="_ _a"></span>al ACT<span class="_ _4b"></span>s given for 3 days.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf1c" class="pf w1 h4" data-page-no="1c"><div class="pc pc1c w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x27 h9 ya ff9 fs6 fc4 sc0 ls2 ws0">18</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls10c ws38">In 3-day ACT<span class="_ _64"> </span>regimens, the ar<span class="_ _8"></span>temisinin component is present in the body</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls64 ws1c0">during only two asexual parasite life-cycles (each lasting 2 days, ex<span class="_ _a"></span>cept for</div><div class="t m0 x9 hb ya0 ffa fs8 fc3 sc0 ls10d ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>malariae<span class="_ _3"> </span><span class="ff9 ws167">infections). This exposure to 3 days of artemisinin treatment</span></div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls10e ws1c1">reduces the number of parasites in the body by a factor of appr<span class="_ _a"></span>oximately one</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls7f wsd0">hundred million (10</div><div class="t m0 x3d h11 y2bd ff9 fs5 fc3 sc0 ls0 ws0">4</div><div class="t m0 x3e hb yc0 fff fs8 fc3 sc0 ls0 ws0">×<span class="_ _6"> </span><span class="ff9 ls67">10</span></div><div class="t m0 x3f h11 y2bd ff9 fs5 fc3 sc0 ls0 ws0">4</div><div class="t m0 x40 hb yc0 ff9 fs8 fc3 sc0 ls10f ws0">=1<span class="_ _7e"></span>0</div><div class="t m0 x41 h11 y2bd ff9 fs5 fc3 sc0 ls0 ws0">8</div><div class="t m0 x42 hb yc0 ff9 fs8 fc3 sc0 ls64 ws26">). Howev<span class="_ _a"></span>er<span class="_ _b"></span>, complete clearance of parasites is</div><div class="t m0 x9 hb yc1 ff9 fs8 fc3 sc0 ls63 ws3">dependent on the partner medicine being effective and persisting at parasiticidal</div><div class="t m0 x9 hb y10d ff9 fs8 fc3 sc0 lsc1 ws1c2">concentrations until all the infecting parasites hav<span class="_ _a"></span>e been killed. Thus the</div><div class="t m0 x9 hb y10e ff9 fs8 fc3 sc0 ls64 ws89">partner compounds need to be relatively slowly eliminated. As a result of this</div><div class="t m0 x9 hb y10f ff9 fs8 fc3 sc0 ls110 ws6f">the artemisinin component is “protected” from resistance by the partner</div><div class="t m0 x9 hb y110 ff9 fs8 fc3 sc0 lsfc ws1c3">medicine pro<span class="_ _a"></span>vided it is efficacious and the par<span class="_ _8"></span>tner medicine is par<span class="_ _8"></span>tly protected</div><div class="t m0 x9 hb y111 ff9 fs8 fc3 sc0 ls111 ws14e">by the artemisinin derivative. Courses of A<span class="_ _a"></span>CT<span class="_ _4b"></span>s of 1–2 days are not recommended;</div><div class="t m0 x9 hb y2be ff9 fs8 fc3 sc0 ls64 ws77">they are less efficacious, and pro<span class="_ _a"></span>vide less protection of the slowly eliminated</div><div class="t m0 x9 hb y2bf ff9 fs8 fc3 sc0 ls64 ws0">partner antimalarial.</div><div class="t m0 x9 hb y2c0 ff9 fs8 fc3 sc0 ls112 ws1c4">The artemisinin compounds are active against all four species of malaria</div><div class="t m0 x9 hb y2c1 ff9 fs8 fc3 sc0 ls113 ws1c5">parasites that infect humans and are gener<span class="_ _a"></span>ally well tolerated. <span class="_ _a"></span>The only</div><div class="t m0 x9 hb y2c2 ff9 fs8 fc3 sc0 ls91 wse6">significant adverse effect to emer<span class="_ _a"></span>ge from extensive clinical trials has been rar<span class="_ _a"></span>e</div><div class="t m0 x9 hb y2c3 ff9 fs8 fc3 sc0 ls7b wsb8">(circa 1:3000) type 1 hypersensitivity reactions (manifested initially by urticaria).</div><div class="t m0 x9 hb y2c4 ff9 fs8 fc3 sc0 ls114 ws1b5">These drugs also have the adv<span class="_ _a"></span>antage from a public health perspective of</div><div class="t m0 x9 hb y2c5 ff9 fs8 fc3 sc0 ls12 ws1c6">reducing gametocyte carriage and thus the transmissibility of malaria. <span class="_ _b"></span>This</div><div class="t m0 x9 hb y2c6 ff9 fs8 fc3 sc0 ls12 ws0">contributes to malaria control in areas of lo<span class="_ _a"></span>w endemicity<span class="_ _4b"></span>.</div><div class="t m0 x9 h13 y2c7 ff8 fs3 fc3 sc0 ls80 ws0">7.2.5<span class="_ _2d"> </span>Non-artemisinin based combination therapy</div><div class="t m0 x9 hb y2c8 ff9 fs8 fc3 sc0 ls115 ws1c7">Non-artemisinin based combinations (non-ACT<span class="_ _4b"></span>s) include sulfadoxine–pyri-</div><div class="t m0 x9 hb y2c9 ff9 fs8 fc3 sc0 ls64 ws1c8">methamine with chloroquine (SP+CQ) or amodiaquine (SP+AQ). Ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, the</div><div class="t m0 x9 hb y2ca ff9 fs8 fc3 sc0 ls64 ws1c9">prev<span class="_ _a"></span>ailing high levels of resistance hav<span class="_ _a"></span>e compromised the efficacy of these</div><div class="t m0 x9 hb y2cb ff9 fs8 fc3 sc0 ls116 ws1ca">combinations. Ther<span class="_ _a"></span>e is no convincing evidence that S<span class="ls117">P+CQ provides any additional</span></div><div class="t m0 x9 hb y2cc ff9 fs8 fc3 sc0 lsaa ws93">benefit ov<span class="_ _a"></span>er SP<span class="_ _c"></span>, so this combination is not recommended; SP+AQ can be more</div><div class="t m0 x9 hb y2cd ff9 fs8 fc3 sc0 ls64 ws1cb">effective than either drug alone, but needs to be considered in the light of</div><div class="t m0 x9 hb y2ce ff9 fs8 fc3 sc0 ls64 ws0">comparison with ACT<span class="_ _c"></span>s. The evidence is summarized next page. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf1d" class="pf w1 h4" data-page-no="1d"><div class="pc pc1d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls9a ws0">19</div><div class="t m0 xb h19 y2cf ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x1a h15 y2d0 ff9 fsa fc3 sc0 lsac ws115">See also Annex 7.2.   </div><div class="t m0 xb h19 y2d1 ff9 fsd fc3 sc0 ls0 ws0">b</div><div class="t m0 x1a h15 y2d2 ff9 fsa fc3 sc0 ls7d ws0">Efficacy <span class="fff ls0">&gt;</span><span class="lsac">80%.</span></div><div class="t m0 x2d hd y2d3 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE: trials comparing monotherapies with non-A<span class="_ _a"></span>CT<span class="_ _b"></span>s</div><div class="t m0 x43 h11 y2d4 ff9 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x2d h1a y2d5 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y2d5 ff14 fsb fc3 sc0 ls118 ws1cc">oral SP+CQ compared with or<span class="_ _a"></span>al SP</div><div class="t m3 x38 h17 y2d6 ff14 fsb fc5 sc0 ls104 ws1cd">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 lsd2 ws1ce">no RCT<span class="_ _c"></span>s with repor<span class="_ _8"></span>ted results for day 28 outcomes. Five</span></div><div class="t m3 x38 h17 y2d7 ff9 fsb fc3 sc0 ls119 ws1cf">subsequent RCT<span class="_ _4b"></span>s found insufficient evidence of any difference in rates of</div><div class="t m3 x38 h17 y2d8 ff9 fsb fc3 sc0 ls11a ws1d0">treatment failure at days 14 and 21, r<span class="_ _a"></span>espectively<span class="_ _4b"></span>, between CQ+SP and SP</div><div class="t m3 x38 h17 y2d9 ff9 fsb fc3 sc0 lsd2 ws0">alone, and gave no information on adverse ev<span class="_ _a"></span>ents.</div><div class="t m3 x38 h17 y2da ff14 fsb fc5 sc0 ls11b ws1d1">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 ls11c">increasing resistance to CQ in all settings means that neither</span></div><div class="t m3 x38 h17 y2db ff9 fsb fc3 sc0 lsd2 ws0">of the options is recommended.</div><div class="t m3 x38 h17 y2dc ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 ls11d">RCT<span class="_ _4b"></span>.</span></div><div class="t m0 x2d h16 y2dd ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y2dd ff9 fsb fc3 sc0 lsd2 ws0">do not use CQ+SP<span class="_ _c"></span>.</div><div class="t m0 x2d h1a y2de ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y2de ff14 fsb fc3 sc0 ls11e ws1d2">oral SP+AQ compar<span class="_ _a"></span>ed with oral AQ or oral SP</div><div class="t m3 x38 h17 y2df ff14 fsb fc5 sc0 ls104 ws1d3">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 lsd2 ws0">one systematic review of SP+A<span class="_ _a"></span>Q compared with AQ alone</span></div><div class="t m3 x38 h17 y2e0 ff9 fsb fc3 sc0 ls0 ws1d4">with day 28 follow-up found no significant difference in day 28 outcomes. </div><div class="t m3 x38 h17 y2e1 ff9 fsb fc3 sc0 ls11f ws1d5">Three subsequent RCT<span class="_ _4b"></span>s also found no significant differences in cure r<span class="_ _a"></span>ates and</div><div class="t m3 x38 h17 y2e2 ff9 fsb fc3 sc0 lsd8 ws0">levels of adverse ev<span class="_ _a"></span>ents. </div><div class="t m3 x38 h17 y2e3 ff9 fsb fc3 sc0 ls120 ws1d6">One systematic review of SP+AQ compar<span class="_ _a"></span>ed with SP alone, found no significant</div><div class="t m3 x38 h17 y2e4 ff9 fsb fc3 sc0 ls121 ws1d7">difference in rates of day 28 cur<span class="_ _a"></span>e or adverse events. One subsequent RCT<span class="_ _67"> </span>found</div><div class="t m3 x38 h17 y2e5 ff9 fsb fc3 sc0 lsd2 ws1d8">higher rates of day 28 cure and mid-adv<span class="_ _a"></span>erse events with the combination</div><div class="t m3 x38 h17 y2e6 ff9 fsb fc3 sc0 lsd2 ws0">compared to SP alone. </div><div class="t m3 x38 h17 y2e7 ff14 fsb fc5 sc0 ls122 ws1d9">Exper<span class="_ _8"></span>t comment:<span class="_ _3"> </span><span class="ff9 fc3 ls123">in some areas where A<span class="_ _a"></span>Q+SP has been deployed, failure</span></div><div class="t m3 x38 h17 y2e8 ff9 fsb fc3 sc0 lsd2 ws0">rates of this combination have incr<span class="_ _a"></span>eased rapidly<span class="_ _4b"></span>.</div><div class="t m3 x38 h17 y2e9 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">systematic review<span class="_ _b"></span>.</span></div><div class="t m0 x2d h16 y2ea ff8 fsb fc4 sc0 ls124 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x44 h17 y2ea ff9 fsb fc3 sc0 ls124 ws1da">if more effective medicines (A<span class="_ _a"></span>CT<span class="_ _4b"></span>s) are not available and A<span class="_ _a"></span>Q</div><div class="t m3 x2d h17 y2eb ff9 fsb fc3 sc0 lsd8 ws0">and SP are effectiv<span class="_ _a"></span>e,</div><div class="t m3 x3c h1c y2ec ff9 fse fc3 sc0 ls0 ws0">b</div><div class="t m3 x28 h17 y2ed ff9 fsb fc3 sc0 lsd2 ws0">AQ+SP<span class="_ _6"> </span>may be used as an interim measure.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf1e" class="pf w1 h4" data-page-no="1e"><div class="pc pc1e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">20</div><div class="t m0 x9 h19 y2ee ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x46 h15 y2ef ff9 fsa fc3 sc0 lsac ws115">See also Annex 7.3.</div><div class="t m0 x9 h19 y2f0 ff9 fsd fc3 sc0 ls0 ws0">b</div><div class="t m0 x46 h15 y2f1 ff9 fsa fc3 sc0 ls7d ws0">Efficacy <span class="fff ls0">&gt;</span><span class="lsac">80%.</span></div><div class="t m0 x9 h12 y2f2 ff10 fs6 fc4 sc0 ls86 wsca">7.3<span class="_ _78"> </span>The choice of ar<span class="_ _8"></span>temisinin-based combination</div><div class="t m0 x28 h12 y2f3 ff10 fs6 fc4 sc0 ls1 ws17a">therapy options</div><div class="t m0 x9 hb y2f4 ff9 fs8 fc3 sc0 ls125 ws1db">Although there ar<span class="_ _a"></span>e some minor differences in oral absorption and bioav<span class="_ _a"></span>ailability</div><div class="t m0 x9 hb y2f5 ff9 fs8 fc3 sc0 ls8a wsd0">between the different artemisinin derivativ<span class="_ _a"></span>es, there is no evidence that these</div><div class="t m0 x9 hb y2f6 ff9 fs8 fc3 sc0 ls126 ws1dc">differences are clinically significant in curr<span class="_ _a"></span>ent formulations. It is the properties</div><div class="t m0 x9 hb y2f7 ff9 fs8 fc3 sc0 ls12 ws1dd">of the partner medicine that determine the effectiveness and choice of com-</div><div class="t m0 x9 hb y2f8 ff9 fs8 fc3 sc0 ls127 ws1de">bination. ACT<span class="_ _c"></span>s with amodiaquine, atovaquone-pr<span class="_ _a"></span>oguanil, chloroquine,</div><div class="t m0 x9 hb y2f9 ff9 fs8 fc3 sc0 ls128 ws1df">clindamycin, doxy<span class="_ _a"></span>cycline, lumefantrine, mefloquine, piperaquine, pyronaridine,</div><div class="t m0 x9 hb y2fa ff9 fs8 fc3 sc0 ls129 ws1e0">proguanil-dapsone, sulfadoxine–pyrimethamine and tetr<span class="_ _a"></span>acycline have all</div><div class="t m0 x9 hb y2fb ff9 fs8 fc3 sc0 ls12a ws1e1">been evaluated in trials carried out acr<span class="_ _a"></span>oss the malaria-affected regions of the</div><div class="t m0 x9 hb y2fc ff9 fs8 fc3 sc0 ls12 ws0">world. Some of these are studies for product dev<span class="_ _a"></span>elopment. </div><div class="t m0 x9 hb y2fd ff9 fs8 fc3 sc0 ls6b ws58">Though there are still gaps in our kno<span class="_ _a"></span>wledge, there is reasonable evidence on</div><div class="t m0 x9 hb y2fe ff9 fs8 fc3 sc0 ls12 ws0">safety and efficacy on which to base recommendations. </div><div class="t m0 x47 hd y2d3 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE: trials comparing ACT<span class="_ _4b"></span>s with non-ACT<span class="_ _4b"></span>s</div><div class="t m0 x48 h11 y2d4 ff9 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x47 h1a y2d5 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x22 h1b y2d5 ff14 fsb fc3 sc0 lsd2 ws0">oral ACT<span class="_ _c"></span>s compared with oral non-artesunate combinations</div><div class="t m3 x24 h1b y2d6 ff14 fsb fc5 sc0 ls12b ws1e2">Summary of RCT<span class="_ _b"></span>s:</div><div class="t m5 x18 h17 y2ff ff9 fsb fc3 sc0 ls12c ws1e3">1 RCT compar<span class="_ _a"></span>ed A<span class="_ _8"></span>S(for 3 days)+SP with A<span class="_ _a"></span>Q+SP<span class="_ _c"></span>. The total failure</div><div class="t m5 x24 h17 y300 ff9 fsb fc3 sc0 ls12d ws1e4">excluding new infections at day 28 was similar in the 2 groups (13% in the</div><div class="t m5 x24 h17 y301 ff9 fsb fc3 sc0 ls5a ws1e5">AS+SP group compared to 22% in the A<span class="_ _a"></span>Q+SP group; OR: 0.59; 95% CI: 0.29–1.18);</div><div class="t m5 x24 h17 y302 ff9 fsb fc3 sc0 ls12e ws1e6">total number of recurrent infections, including r<span class="_ _a"></span>einfections, was higher with</div><div class="t m5 x24 h17 y303 ff9 fsb fc3 sc0 ls12f ws19a">AS+SP (29% with AS+S<span class="_ _8"></span>P<span class="_ _c"></span>, 17% with AQ+SP<span class="_ _c"></span>, OR:<span class="_ _5"> </span>0.49; 95% CI: 0.27–0.87).</div><div class="t m3 x24 h1b y304 ff14 fsb fc5 sc0 ls130 ws1e7">Exper<span class="_ _8"></span>t comment:</div><div class="t m5 x18 h17 y304 ff9 fsb fc3 sc0 ls131 ws1e7">the abov<span class="_ _a"></span>e result is probably due to the efficacy of A<span class="_ _a"></span>Q that</div><div class="t m5 x24 h17 y305 ff9 fsb fc3 sc0 ls132 ws1e8">remains high, while SP failur<span class="_ _a"></span>e is on the increase. In areas where A<span class="_ _a"></span>Q+SP has been</div><div class="t m5 x24 h17 y306 ff9 fsb fc3 sc0 ls133 ws1e9">adopted as first-line treatment, the impression is that ther<span class="_ _a"></span>e has been rapid</div><div class="t m5 x24 h17 y307 ff9 fsb fc3 sc0 ls131 ws1ea">development of resistance to A<span class="_ _a"></span>Q. This also makes both A<span class="_ _a"></span>Q and SP unav<span class="_ _a"></span>ailable</div><div class="t m5 x24 h17 y308 ff9 fsb fc3 sc0 ls131 ws0">for use as an ACT<span class="_ _6"> </span>component.</div><div class="t m3 x24 h1b y309 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision:</div><div class="t m5 x18 h17 y309 ff9 fsb fc3 sc0 ls131 ws0">expert opinion.</div><div class="t m0 x47 h16 y30a ff8 fsb fc4 sc0 ls134 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x17 h17 y30a ff9 fsb fc3 sc0 ls134 ws1eb">if more effective A<span class="_ _a"></span>CT<span class="_ _4b"></span>s are not available and both A<span class="_ _a"></span>Q and SP are</div><div class="t m3 x47 h17 y30b ff9 fsb fc3 sc0 lsd8 ws0">effective,</div><div class="t m3 x49 h1c y30c ff9 fse fc3 sc0 ls135 ws0">b </div><div class="t m3 x3a h17 y30d ff9 fsb fc3 sc0 lsd2 ws0">then AQ+SP<span class="_ _6"> </span>may be used as an interim measure. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf1f" class="pf w1 h4" data-page-no="1f"><div class="pc pc1f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">21</div><div class="t m0 xb h19 y30e ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x1a h15 y30f ff9 fsa fc3 sc0 lsac ws115">See also Annex 7.4</div><div class="t m0 xb hb y310 ff9 fs8 fc3 sc0 ls12 ws0">The following A<span class="_ _a"></span>CT<span class="_ _4b"></span>s are currently recommended (alphabetical order):</div><div class="t m0 xb hb y311 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">artemether-lumefantrine, </span></div><div class="t m0 xb hb y312 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">artesunate + amodiaquine,</span></div><div class="t m0 xb hb y313 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">artesunate + mefloquine, </span></div><div class="t m0 xb hb y314 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">artesunate + sulfadoxine–pyrimethamine.</span></div><div class="t m0 xb hb y315 ff8 fs8 fc3 sc0 ls12 ws0">Note: <span class="_ _8"></span><span class="ff9 ws1ec">amodiaquine + sulfadoxine–pyrimethamine may be considered as an</span></div><div class="t m0 xb hb y316 ff9 fs8 fc3 sc0 ls12 ws1ed">interim option where A<span class="_ _a"></span>CT<span class="_ _4b"></span>s cannot be made available, pro<span class="_ _a"></span>vided that efficacy</div><div class="t m0 xb hb y317 ff9 fs8 fc3 sc0 ls12 ws0">of both is high. </div><div class="t m0 xb h13 y318 ff8 fs3 fc3 sc0 ls80 ws0">7.3.1<span class="_ _79"> </span>R<span class="_ _a"></span>ationale for the exclusion of certain antimalarials</div><div class="t m0 xb hb y319 ff9 fs8 fc3 sc0 ls136 ws1ee">Several av<span class="_ _b"></span>ailable drugs that were considered by the T<span class="_ _c"></span>echnical Guidelines</div><div class="t m0 xb hb y31a ff9 fs8 fc3 sc0 ls12 ws0">Development Group ar<span class="_ _a"></span>e currently not recommended.</div><div class="t m0 xb hb y31b ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 lse4 ws174">Chlorproguanil-dapsone has not yet been ev<span class="_ _a"></span>aluated as an ACT<span class="_ _7c"> </span>par<span class="_ _8"></span>tner</span></div><div class="t m0 x26 hb y31c ff9 fs8 fc3 sc0 ls12a ws1e1">drug, so there is insufficient evidence of both efficacy and safety to recom-</div><div class="t m0 x26 hb y31d ff9 fs8 fc3 sc0 ls12 ws0">mend it as a combination partner<span class="_ _b"></span>. </div><div class="t m0 x2d hd y31e ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE: trials comparing ACT<span class="_ _4b"></span>s</div><div class="t m0 x4a h11 y31f ff9 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x2d h1a y320 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y320 ff14 fsb fc3 sc0 ls11e ws1d2">oral AL, AS+AQ, AS+MQ, A<span class="_ _8"></span>S+SP</div><div class="t m3 x38 h1b y321 ff14 fsb fc5 sc0 ls104 ws1ef">Summary of RCT<span class="_ _b"></span>s:</div><div class="t m6 x39 h17 y322 ff9 fsb fc3 sc0 ls131 ws1f0">AL 6-dose r<span class="_ _a"></span>egimen compared with 4-dose regimen; 6 doses</div><div class="t m6 x38 h17 y323 ff9 fsb fc3 sc0 ls131 ws1bd">resulted in higher cure r<span class="_ _a"></span>ate in 1 trial in Thailand (RR: 0.19; 95% CI: 0.06–0.62). </div><div class="t m6 x38 h17 y324 ff9 fsb fc3 sc0 ls137 ws1f1">AS+MQ compared with AL 6-dose r<span class="_ _a"></span>egimen; systematic review including 2 small</div><div class="t m6 x38 h17 y325 ff9 fsb fc3 sc0 ls131 ws1f2">RCT<span class="_ _4b"></span>s from Thailand. Higher pr<span class="_ _a"></span>opor<span class="_ _8"></span>tion of patients with parasitaemia at day 28</div><div class="t m6 x38 h17 y326 ff9 fsb fc3 sc0 ls131 ws1f3">with AL but differ<span class="_ _a"></span>ence not statistically significant. One additional RCT in Lao</div><div class="t m6 x38 h17 y327 ff9 fsb fc3 sc0 ls138 ws1f4">People<span class="_ _a"></span>’<span class="_ _b"></span>s Democratic Republic also r<span class="_ _a"></span>epor<span class="_ _8"></span>ted higher proportions of patients with</div><div class="t m6 x38 h17 y328 ff9 fsb fc3 sc0 ls131 ws0">parasitaemia at day 42 with AL<span class="_ _6"> </span>but also not statistically significant. </div><div class="t m6 x38 h17 y329 ff9 fsb fc3 sc0 ls11b ws1f5">AS+AQ compared with AL<span class="_ _67"> </span>6-dose regimen; 1 trial in <span class="_ _a"></span>T<span class="_ _4b"></span>anzania found a significantly</div><div class="t m6 x38 h17 y32a ff9 fsb fc3 sc0 ls131 ws0">higher proportion of parasitological failures on day 28 with AS+AQ.</div><div class="t m6 x38 h17 y32b ff9 fsb fc3 sc0 ls131 ws0">No trials of AL compar<span class="_ _a"></span>ed with AS+S<span class="_ _8"></span>P<span class="_ _c"></span>.</div><div class="t m3 x38 h1b y32c ff14 fsb fc5 sc0 ls130 ws1f6">Exper<span class="_ _8"></span>t comment:</div><div class="t m6 x35 h17 y32c ff9 fsb fc3 sc0 ls131 ws1f6">the efficacy of ACT<span class="_ _c"></span>s with AQ or SP as partner medicines is</div><div class="t m6 x38 h17 y32d ff9 fsb fc3 sc0 ls139 ws1f7">insufficient where cure r<span class="_ _a"></span>ates with these medicines as monotherapies is less than</div><div class="t m6 x38 h17 y32e ff9 fsb fc3 sc0 ls131 ws1f8">80%. The efficacy of AL<span class="_ _67"> </span>and AS+MQ generally exceeds 90% except at the <span class="_ _a"></span>Thai-</div><div class="t m6 x38 h17 y32f ff9 fsb fc3 sc0 ls131 ws0">Cambodian border<span class="_ _4b"></span>, where AL failure r<span class="_ _a"></span>ate was 15%.</div><div class="t m3 x38 h1b y330 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision:</div><div class="t m5 x3b h17 y330 ff9 fsb fc3 sc0 ls131 ws0">expert opinion.</div><div class="t m0 x2d h16 y331 ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendations </div><div class="t m7 x2d h17 y332 ff8 fsb fc3 sc0 ls13a ws0">1.<span class="_ _4c"> </span><span class="ff9 lsd8 ws19a">Use the following ACT<span class="_ _4b"></span>s: AL (6-dose r<span class="_ _a"></span>egimen), A<span class="_ _8"></span>S+AQ, AS+MQ, AS+SP<span class="_ _4b"></span>. </span></div><div class="t m7 x2d h17 y333 ff8 fsb fc3 sc0 ls13a ws0">2.<span class="_ _7b"> </span><span class="ff9 lsd8 ws19a">In areas with A<span class="_ _a"></span>Q and SP resistance exceeding 20% (PCR-corr<span class="_ _a"></span>ected at day 28 of</span></div><div class="t m7 x38 h17 y334 ff9 fsb fc3 sc0 lsd2 ws0">follow-up), use AS+MQ or AL.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf20" class="pf w1 h4" data-page-no="20"><div class="pc pc20 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">22</div><div class="t m0 x9 hb y9e ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls13b ws1c3">Atov<span class="_ _a"></span>aquone-proguanil has been shown to be safe and effectiv<span class="_ _a"></span>e as a combi-</span></div><div class="t m0 x16 hb y9f ff9 fs8 fc3 sc0 ls67 ws1f9">nation partner in one large study<span class="_ _4b"></span>, but is not included in these recommenda-</div><div class="t m0 x16 hb ya0 ff9 fs8 fc3 sc0 ls12 ws0">tions for deployment in endemic areas because of its v<span class="_ _a"></span>ery high cost.</div><div class="t m0 x9 hb y335 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws14c">Halofantrine has not yet been ev<span class="_ _a"></span>aluated as an ACT partner medicine and</span></div><div class="t m0 x16 hb y336 ff9 fs8 fc3 sc0 ls12 ws0">is not included in these recommendations because of safety concerns.</div><div class="t m0 x9 hb y337 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls50 ws1fa">Dihydroartemisinin (ar<span class="_ _8"></span>tenimol)-piperaquine has been shown to be safe</span></div><div class="t m0 x16 hb y338 ff9 fs8 fc3 sc0 ls12 ws1fb">and effective in lar<span class="_ _a"></span>ge trials in Asia, but is not included in these recom-</div><div class="t m0 x16 hb y339 ff9 fs8 fc3 sc0 ls12 wsb0">mendations as it is not yet av<span class="_ _a"></span>ailable as a formulation manufactured under</div><div class="t m0 x16 hb y33a ff9 fs8 fc3 sc0 ls3c ws31">good manufacturing practices, and has not yet been ev<span class="_ _a"></span>aluated sufficiently</div><div class="t m0 x16 hb y33b ff9 fs8 fc3 sc0 ls12 ws0">in Africa and South America.</div><div class="t m0 x9 hb y33c ff9 fs8 fc3 sc0 ls13c ws189">Several other new antimalarial compounds ar<span class="_ _a"></span>e in development but do not yet</div><div class="t m0 x9 hb y33d ff9 fs8 fc3 sc0 ls12 ws0">have a sufficient clinical evidence to support recommendation here.</div><div class="t m0 x9 h13 y33e ff8 fs3 fc3 sc0 ls80 ws0">7.3.2<span class="_ _2d"> </span>Deplo<span class="_ _a"></span>yment considerations affecting choice</div><div class="t m0 x9 hb y33f ff9 fs8 fc3 sc0 ls13d ws1fc">Although for many countries, artemether<span class="_ _a"></span>-lumefantrine and ar<span class="_ _8"></span>tesunate +</div><div class="t m0 x9 hb y340 ff9 fs8 fc3 sc0 ls13e ws1fd">mefloquine may give the highest cure r<span class="_ _a"></span>ates, there may be problems of</div><div class="t m0 x9 hb y341 ff9 fs8 fc3 sc0 ls13f ws1fe">affordability and av<span class="_ _a"></span>ailability of these products. Also, there is curr<span class="_ _a"></span>ently</div><div class="t m0 x9 hb y342 ff9 fs8 fc3 sc0 ls12 ws1ff">insufficient safety and tolerability data on artesunate + mefloquine at the</div><div class="t m0 x9 hb y343 ff9 fs8 fc3 sc0 ls39 ws4e">recommended dose of 25mg/kg in African children to support its recom-</div><div class="t m0 x9 hb y344 ff9 fs8 fc3 sc0 ls140 ws200">mendation there. <span class="_ _a"></span>T<span class="_ _b"></span>rials with mefloquine monotherapy (25mg/kg) have raised</div><div class="t m0 x9 hb y345 ff9 fs8 fc3 sc0 lsf ws12f">concerns of tolerability in African children. Countries may ther<span class="_ _a"></span>efore opt instead</div><div class="t m0 x9 hb y346 ff9 fs8 fc3 sc0 ls141 ws1bd">to use artesunate + amodiaquine and ar<span class="_ _8"></span>tesunate + sulfadoxine–pyrimethamine,</div><div class="t m0 x9 hb y347 ff9 fs8 fc3 sc0 lsfd ws201">which may have low<span class="_ _a"></span>er cure rates because of resistance. A<span class="_ _a"></span>lthough still effective</div><div class="t m0 x9 hb y348 ff9 fs8 fc3 sc0 ls142 ws202">in some areas, sulfadoxine–pyrimethamine and amodiaquine ar<span class="_ _a"></span>e widely</div><div class="t m0 x9 hb y349 ff9 fs8 fc3 sc0 ls143 ws203">available as monother<span class="_ _a"></span>apies, providing continued selection pr<span class="_ _a"></span>essure, and it is</div><div class="t m0 x9 hb y34a ff9 fs8 fc3 sc0 ls144 ws204">likely that resistance will continue to worsen despite deployment of the</div><div class="t m0 x9 hb y34b ff9 fs8 fc3 sc0 lsca ws44">corresponding A<span class="_ _a"></span>CT<span class="_ _4b"></span>s. This may be a particular problem in settings where</div><div class="t m0 x9 hb y34c ff9 fs8 fc3 sc0 ls145 ws205">sulfadoxine–pyrimethamine is being used for intermittent prev<span class="_ _a"></span>entive treatment</div><div class="t m0 x9 hb y34d ff9 fs8 fc3 sc0 ls12 ws206">in pregnancy; artesunate + sulfadoxine–pyrimethamine should probably not</div><div class="t m0 x9 hb y34e ff9 fs8 fc3 sc0 ls12 ws0">be used in such settings.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf21" class="pf w1 h4" data-page-no="21"><div class="pc pc21 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">23</div><div class="t m0 xb hd y9e ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on treatment for uncomplicated</div><div class="t m0 xb hd y9f ff8 fs8 fc3 sc0 ls12 ws0">falciparum malaria</div><div class="t m0 xb h12 y34f ff10 fs6 fc4 sc0 ls9a ws0">7.4<span class="_ _78"> </span>P<span class="_ _a"></span>ractic<span class="_ _8"></span>al aspects of t<span class="_ _8"></span>reatment with</div><div class="t m0 x6 h12 y350 ff10 fs6 fc4 sc0 ls9a ws0">recommended A<span class="_ _b"></span>CT<span class="_ _c"></span>s </div><div class="t m0 xb h13 y351 ff8 fs3 fc3 sc0 ls69 ws0">7.4.1<span class="_ _7d"> </span>Artemether<span class="_ _a"></span>-lumefantrine</div><div class="t m0 xb hb y352 ff9 fs8 fc3 sc0 ls142 ws202">This is currently av<span class="_ _a"></span>ailable as co-formulated tablets containing 20<span class="_ _68"> </span>mg of</div><div class="t m0 xb hb y353 ff9 fs8 fc3 sc0 ls146 ws207">artemether and 120<span class="_ _5"> </span>mg of lumefantrine. The total recommended treatment is</div><div class="t m0 xb hb y354 ff9 fs8 fc3 sc0 ls12 ws0">a 6-dose regimen of artemether<span class="_ _a"></span>-lumefantrine twice a day for 3 days.</div><div class="t m0 x2d h16 y355 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x2f h16 y356 ff8 fsb fc0 sc0 lsd2 ws0">LEVEL<span class="_ _67"> </span>OF</div><div class="t m0 x15 h16 y357 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y358 ff9 fsb fc3 sc0 lsd2 ws208">The treatment of choice for uncomplicated falciparum malaria is a</div><div class="t m3 x2d h17 y359 ff9 fsb fc3 sc0 ls147 ws209">combination of two or more antimalarials with different mechanisms</div><div class="t m3 x2d h17 y35a ff9 fsb fc3 sc0 lsd2 ws0">of action.</div><div class="t m3 x4b h16 y358 ff8 fsb fc3 sc0 lsd8 ws20a">S, T<span class="_ _b"></span>, O</div><div class="t m3 x2d h17 y35b ff9 fsb fc3 sc0 lsd6 ws156">ACT<span class="_ _c"></span>s are the recommended treatments for uncomplicated falciparum</div><div class="t m3 x2d h17 y35c ff9 fsb fc3 sc0 lsd2 ws0">malaria. </div><div class="t m3 x4c h16 y35b ff8 fsb fc3 sc0 lsd8 ws0">S </div><div class="t m3 x2d h17 y35d ff9 fsb fc3 sc0 lsd2 ws0">The following A<span class="_ _a"></span>CT<span class="_ _4b"></span>s are currently recommended:</div><div class="t m3 x20 h17 y35e ff9 fsb fc3 sc0 ls148 ws20b">– artemether-lumefantrine, artesunate + amodiaquine, ar<span class="_ _8"></span>tesunate</div><div class="t m3 x4d h17 y35f ff9 fsb fc3 sc0 lsd2 ws0">+ mefloquine, artesunate + sulfadoxine-pyrimethamine.</div><div class="t m3 x4b h16 y35d ff8 fsb fc3 sc0 lsd8 ws20a">S, T<span class="_ _b"></span>, O</div><div class="t m3 x2d h17 y360 ff9 fsb fc3 sc0 ls149 ws1eb">The choice of ACT<span class="_ _67"> </span>in a country or region will be based on the level of</div><div class="t m3 x2d h17 y361 ff9 fsb fc3 sc0 lsd2 ws0">resistance of the partner medicine in the combination:</div><div class="t m3 x20 h17 y362 ff9 fsb fc3 sc0 lsd2 ws20c">–<span class="_ _67"> </span>in areas of multidrug resistance (South-East Asia), artesunate +</div><div class="t m3 x4d h17 y363 ff9 fsb fc3 sc0 lsd2 ws0">mefloquine or artemether-lumefantrine</div><div class="t m3 x20 h17 y364 ff9 fsb fc3 sc0 lsd2 ws20d">–<span class="_ _67"> </span>in Africa, artemether-lumefantrine, artesunate + amodiaquine;</div><div class="t m3 x4d h17 y365 ff9 fsb fc3 sc0 lsd2 ws0">artesunate + sulfadoxine-pyrimethamine.</div><div class="t m3 x4c h16 y366 ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x4c h16 y367 ff8 fsb fc3 sc0 ls0 ws0">S</div><div class="t m3 x2d h17 y368 ff9 fsb fc3 sc0 lsd2 ws1f2">The artemisinin derivative components of the combination must be</div><div class="t m3 x2d h17 y369 ff9 fsb fc3 sc0 lsd2 ws0">given for at least 3 days for an optimum effect.</div><div class="t m3 x4c h16 y368 ff8 fsb fc3 sc0 ls0 ws0">S</div><div class="t m3 x2d h17 y36a ff9 fsb fc3 sc0 ls14a ws20e">Artemether-lumefantrine should be used with a 6-dose r<span class="_ _a"></span>egimen.<span class="_ _7f"> </span><span class="ff8 ls14b ws20f">T,<span class="_ _9"></span> E</span></div><div class="t m3 x2d h17 y36b ff9 fsb fc3 sc0 ls105 ws210">Amodiaquine + sulfadoxine-pyrimethamine may be considered as an</div><div class="t m3 x2d h17 y36c ff9 fsb fc3 sc0 lsd2 ws211">interim option in situations where ACT<span class="_ _c"></span>s cannot be made available.</div><div class="t m3 x4c h16 y36b ff8 fsb fc3 sc0 ls0 ws0">E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf22" class="pf w1 h4" data-page-no="22"><div class="pc pc22 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">24</div><div class="t m0 x9 hd y9e ff15 fs5 fc4 sc0 ls14c ws0">T<span class="_ _b"></span>able 1.<span class="_ _3b"> </span><span class="ff8 fs8 fc3 ls12">Dosing schedule for artemether<span class="_ _b"></span>-lumefantrine</span></div><div class="t m0 x9 h19 y36d ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x1b h15 y36e ff9 fsa fc3 sc0 ls14d ws212">The regimen can be expressed more simply for ease of use at the pr<span class="_ _a"></span>ogramme level as follows: the second</div><div class="t m0 x1b h15 y36f ff9 fsa fc3 sc0 ls7d wse1">dose on the first day should be given any time between 8 h and 12 h after the first dose. Dosage on</div><div class="t m0 x1b h15 y370 ff9 fsa fc3 sc0 ls7d ws0">the second and third days is twice a day (morning and evening).</div><div class="t m0 x9 hb y371 ff9 fs8 fc3 sc0 ls12 ws213">An advantage of this combination is that lumefantrine is not av<span class="_ _b"></span>ailable as a</div><div class="t m0 x9 hb y372 ff9 fs8 fc3 sc0 ls13 ws214">monotherapy and has never been used by itself for the tr<span class="_ _a"></span>eatment of malaria.</div><div class="t m0 x9 hb y373 ff9 fs8 fc3 sc0 ls14e ws1a6">Recent evidence indicates that the ther<span class="_ _a"></span>apeutic response and safety profile in</div><div class="t m0 x9 hb y374 ff9 fs8 fc3 sc0 lsc1 ws132">young children of less than 10 kg is similar to that in older children, and</div><div class="t m0 x9 hb y375 ff9 fs8 fc3 sc0 ls14f ws133">artemether-lumefantrine is no<span class="_ _a"></span>w recommended for patients <span class="fff ls0 ws0">≥<span class="_ _6"> </span></span>5 kg. L<span class="_ _a"></span>umefantrine</div><div class="t m0 x9 hb y376 ff9 fs8 fc3 sc0 ls13 wsdc">absorption is enhanced by co-administration with fat. L<span class="_ _a"></span>ow blood levels, with</div><div class="t m0 x9 hb y377 ff9 fs8 fc3 sc0 ls150 ws168">resultant treatment failur<span class="_ _a"></span>e, could potentially result from inadequate fat intake,</div><div class="t m0 x9 hb y378 ff9 fs8 fc3 sc0 ls12 ws42">and so it is essential that patients or carers are informed of the need to take</div><div class="t m0 x9 hb y379 ff9 fs8 fc3 sc0 ls151 ws215">this ACT<span class="_ _67"> </span>with milk or fat-containing food – par<span class="_ _8"></span>ticularly on the second and third</div><div class="t m0 x9 hb y37a ff9 fs8 fc3 sc0 ls12 ws0">days of treatment.</div><div class="t m0 x9 h13 y37b ff8 fs3 fc3 sc0 ls80 ws0">7.4.2<span class="_ _18"> </span>Ar<span class="_ _8"></span>tesunate + amodiaquine</div><div class="t m0 x9 hb y37c ff9 fs8 fc3 sc0 ls152 ws6f">This is currently av<span class="_ _a"></span>ailable as separate scored tablets containing 50<span class="_ _3"> </span>mg of</div><div class="t m0 x9 hb y37d ff9 fs8 fc3 sc0 ls153 ws216">artesunate and 153<span class="_ _5"> </span>mg base of amodiaquine, respectively<span class="_ _c"></span>. Co-formulated tablets</div><div class="t m0 x9 hb y37e ff9 fs8 fc3 sc0 ls22 ws217">are under development. <span class="_ _b"></span>The total recommended treatment is 4<span class="_ _7c"> </span>mg/kg bw of</div><div class="t m0 x9 hb y37f ff9 fs8 fc3 sc0 ls22 wsc0">artesunate and 10<span class="_ _5"> </span>mg base/kg bw of amodiaquine given once a day for 3 days. </div><div class="t m0 x9 hd y380 ff15 fs5 fc4 sc0 ls14c ws0">T<span class="_ _b"></span>able 2.<span class="_ _13"> </span><span class="ff8 fs8 fc3 ls12">Dosing schedule for artesunate + amodiaquine</span></div><div class="t m8 x47 h1b y381 ff11 fsb fc3 sc0 lsd8 ws0">Age</div><div class="t m8 x4e h1b y382 ff11 fsb fc3 sc0 lsd2 ws0">Dose in mg (No. of tablets)</div><div class="t m8 x4f h1b y381 ff11 fsb fc3 sc0 lsd2 ws1d4">Artesunate (50 mg)<span class="_ _80"> </span>Amodiaquine (153 mg)</div><div class="t m8 x2b h1b y383 ff11 fsb fc3 sc0 lsd8 ws0">Day 1<span class="_ _2d"> </span>Day 2<span class="_ _18"> </span>Day 3<span class="_ _11"> </span>Day 1<span class="_ _1a"> </span>Day 2<span class="_ _1a"> </span>Day 3</div><div class="t m3 x47 h17 y384 ff9 fsb fc3 sc0 lsd2 ws0">5–11 months </div><div class="t m3 x50 h17 y385 ff9 fsb fc3 sc0 lsd8 ws0">25 (</div><div class="t m3 x51 h1c y386 ff9 fse fc3 sc0 ls0 ws0">1</div><div class="t m3 x52 h17 y385 ff9 fsb fc3 sc0 ls0 ws0">/</div><div class="t m3 x53 h1c y387 ff9 fse fc3 sc0 ls0 ws0">2</div><div class="t m3 x41 h17 y385 ff9 fsb fc3 sc0 ls0 ws0">)</div><div class="t m3 x54 h17 y384 ff9 fsb fc3 sc0 lsd8 ws0">25<span class="_ _80"> </span>25</div><div class="t m3 x55 h17 y385 ff9 fsb fc3 sc0 lsd8 ws0">76 (</div><div class="t m3 x4b h1c y386 ff9 fse fc3 sc0 ls0 ws0">1</div><div class="t m3 x56 h17 y385 ff9 fsb fc3 sc0 ls0 ws0">/</div><div class="t m3 x57 h1c y387 ff9 fse fc3 sc0 ls0 ws0">2</div><div class="t m3 x58 h17 y385 ff9 fsb fc3 sc0 ls0 ws0">)</div><div class="t m3 x59 h17 y384 ff9 fsb fc3 sc0 lsd8 ws0">76<span class="_ _80"> </span>76</div><div class="t m3 x47 h17 y388 fff fsb fc3 sc0 ls0 ws0">≥<span class="_ _67"> </span><span class="ff9 lsd8 ws19a">1–6 years</span></div><div class="t m3 x2b h17 y389 ff9 fsb fc3 sc0 lsd2 ws1d4">50 (1)<span class="_ _81"> </span><span class="ls154 ws0">50<span class="_ _80"> </span>50<span class="_ _82"> </span><span class="lsd2">153 (1)<span class="_ _83"> </span><span class="lsd8">153<span class="_ _84"> </span>153</span></span></span></div><div class="t m3 x47 h17 y38a fff fsb fc3 sc0 ls0 ws0">≥<span class="_ _9"></span><span class="ff9 ls13a ws218">7–13 years</span></div><div class="t m3 x50 h17 y38b ff9 fsb fc3 sc0 ls11d ws219">100 (2)<span class="_ _4c"> </span><span class="ls155 ws0">100<span class="_ _85"> </span>100<span class="_ _4c"> </span><span class="lsd2">306 (2)<span class="_ _79"> </span><span class="lsd8">306<span class="_ _86"> </span>306</span></span></span></div><div class="t m3 x47 h17 y38c fff fsb fc3 sc0 ls0 ws0">&gt;<span class="_ _9"></span><span class="ff9 ls156 ws1d3">13 years</span></div><div class="t m3 x3f h17 y38d ff9 fsb fc3 sc0 lsd8 ws0">200 (4)<span class="_ _79"> </span>200<span class="_ _86"> </span>200<span class="_ _4c"> </span><span class="ls13a ws218">612 (4)<span class="_ _17"> </span></span><span class="ls134">612<span class="_ _85"> </span>612</span></div><div class="t m8 x47 h1b y38e ff11 fsb fc3 sc0 lsd2 ws1d4">Body weight in kg </div><div class="t m8 x5a h1b y38f ff11 fsb fc3 sc0 lsd2 ws1d4">(age in years)</div><div class="t m8 x5b h1b y390 ff11 fsb fc3 sc0 lsd2 ws0">No. of tablets at appro<span class="_ _a"></span>ximate timing of dosing</div><div class="t m8 x5c h1d y391 ff11 fse fc3 sc0 ls0 ws0">a</div><div class="t m8 x2c h1b y392 ff11 fsb fc3 sc0 lsd8 ws0">0 h<span class="_ _85"> </span><span class="ls154">8 h<span class="_ _87"> </span></span>24 h<span class="_ _88"> </span><span class="ls154">36 h<span class="_ _88"> </span></span>48 h<span class="_ _89"> </span>60 h</div><div class="t m3 x47 h17 y393 ff9 fsb fc3 sc0 lsd2 ws21a">5–14 (<span class="fff ls0 ws0">&lt;<span class="_ _9"></span><span class="ff9 ls154">3)</span></span></div><div class="t m3 x4f h17 y394 ff9 fsb fc3 sc0 ls0 ws0">1<span class="_ _8a"> </span>1<span class="_ _8a"> </span>1<span class="_ _8a"> </span>1<span class="_ _8a"> </span>1<span class="_ _8a"> </span>1</div><div class="t m3 x47 h17 y395 ff9 fsb fc3 sc0 lsd2 ws21b">15–24 (<span class="fff ls0 ws0">≥<span class="_ _9"></span><span class="ff9 lsd8">3–8)</span></span></div><div class="t m3 x4f h17 y396 ff9 fsb fc3 sc0 ls0 ws0">2<span class="_ _8b"> </span>2<span class="_ _8b"> </span>2<span class="_ _8b"> </span>2<span class="_ _8b"> </span>2<span class="_ _8b"> </span>2</div><div class="t m3 x47 h17 y397 ff9 fsb fc3 sc0 lsd2 ws21c">25–34 (<span class="fff ls0 ws0">≥<span class="_ _9"></span></span><span class="ws0">9–14)</span></div><div class="t m3 x4f h17 y398 ff9 fsb fc3 sc0 ls0 ws0">3<span class="_ _8b"> </span>3<span class="_ _8b"> </span>3<span class="_ _8c"> </span>3<span class="_ _8b"> </span>3<span class="_ _8b"> </span>3</div><div class="t m3 x47 h17 y399 fff fsb fc3 sc0 ls0 ws0">&gt;<span class="_ _9"></span><span class="ff9 lsd8 ws21d">34 (</span>&gt;<span class="_ _66"> </span><span class="ff9 lsd8">1 4)</span></div><div class="t m3 x4f h17 y39a ff9 fsb fc3 sc0 ls0 ws0">4<span class="_ _8b"> </span>4<span class="_ _8b"> </span>4<span class="_ _8b"> </span>4<span class="_ _8b"> </span>4<span class="_ _8b"> </span>4</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf23" class="pf w1 h4" data-page-no="23"><div class="pc pc23 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">25</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls24 ws26">This combination is sufficiently efficacious only where 28-day cure r<span class="_ _a"></span>ates with</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls12 ws21e">amodiaquine monotherapy exceed 80%. R<span class="_ _a"></span>esistance is likely to worsen with</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls143 ws203">continued availability of chlor<span class="_ _a"></span>oquine and amodiaquine monotherapies. More</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls157 ws21f">information on the safety of artesunate + amodiaquine is needed from</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls12 ws0">prospective pharmaco<span class="_ _a"></span>vigilance programmes.</div><div class="t m0 xb h13 y39b ff8 fs3 fc3 sc0 ls80 ws0">7.4.3<span class="_ _1a"> </span>Ar<span class="_ _8"></span>tesunate + sulfadoxine–pyrimethamine</div><div class="t m0 xb hb y39c ff9 fs8 fc3 sc0 ls12 ws220">This is currently av<span class="_ _a"></span>ailable as separate scored tablets containing 50 mg of</div><div class="t m0 xb hb y39d ff9 fs8 fc3 sc0 ls12 ws90">artesunate, and tablets containing 500 mg of sulfadoxine and 25<span class="_ _64"> </span>mg of pyri-</div><div class="t m0 xb hb y154 ff9 fs8 fc3 sc0 ls92 ws0">methamine.</div><div class="t m0 x46 h14 y39e ff11 fs5 fc4 sc0 ls158 ws0">11</div><div class="t m0 x16 hb y154 ff9 fs8 fc3 sc0 ls92 wse7">The total recommended treatment is 4 mg/kg bw of artesunate</div><div class="t m0 xb hb y155 ff9 fs8 fc3 sc0 ls159 ws221">given once a day for 3 days and a single administration of sulfado<span class="_ _a"></span>xine-</div><div class="t m0 xb hb y156 ff9 fs8 fc3 sc0 ls12 ws0">pyrimethamine (25/1.25<span class="_ _64"> </span>mg base/kg bw) on day 1. </div><div class="t m0 xb hd y39f ff15 fs5 fc4 sc0 ls14c ws0">T<span class="_ _b"></span>able 3.<span class="_ _13"> </span><span class="ff8 fs8 fc3 ls12">Dosing schedule for artesunate + sulfadoxine-pyrimethamine</span></div><div class="t m0 xb hb y3a0 ff9 fs8 fc3 sc0 ls73 ws50">While a single dose of sulfadoxine–pyrimethamine is sufficient, it is necessary</div><div class="t m0 xb hb y3a1 ff9 fs8 fc3 sc0 lse2 ws138">for artesunate to be given for 3 days for satisfactory efficacy<span class="_ _b"></span>. <span class="_ _a"></span>This combination</div><div class="t m0 xb hb y3a2 ff9 fs8 fc3 sc0 lsb2 ws222">is sufficiently efficacious only where 28-day cure r<span class="_ _a"></span>ates with sulfadoxine–</div><div class="t m0 xb hb y3a3 ff9 fs8 fc3 sc0 ls15a ws223">pyrimethamine alone exceed 80%. R<span class="_ _a"></span>esistance is likely to worsen with continued</div><div class="t m0 xb hb y3a4 ff9 fs8 fc3 sc0 ls15b ws224">availability of sulfado<span class="_ _a"></span>xine–pyrimethamine, sulfalene–pyrimethamine and</div><div class="t m0 xb hb y3a5 ff9 fs8 fc3 sc0 ls12 ws0">cotrimoxazole (trimethoprim-sulfametho<span class="_ _a"></span>xazole). </div><div class="t m0 xb h13 y3a6 ff8 fs3 fc3 sc0 ls80 ws0">7.4.4<span class="_ _18"> </span>Ar<span class="_ _8"></span>tesunate + mefloquine</div><div class="t m0 xb hb y3a7 ff9 fs8 fc3 sc0 ls12 ws225">This is currently av<span class="_ _a"></span>ailable as separate scored tablets containing 50<span class="_ _68"> </span>mg of</div><div class="t m0 xb hb y3a8 ff9 fs8 fc3 sc0 ls89 ws226">artesunate and 250<span class="_ _2"> </span>mg base of mefloquine, r<span class="_ _a"></span>espectively<span class="_ _4b"></span>. Co-formulated</div><div class="t m0 xb hb y3a9 ff9 fs8 fc3 sc0 ls4c ws6d">tablets are under development but ar<span class="_ _a"></span>e not available at present. <span class="_ _b"></span>The total</div><div class="t m0 xb hb y3aa ff9 fs8 fc3 sc0 ls12 ws7b">recommended treatment is 4 mg/kg b<span class="_ _a"></span>w of ar<span class="_ _8"></span>tesunate given once a day for</div><div class="t m0 xb hb y3ab ff9 fs8 fc3 sc0 ls12 ws227">3 days and 25 mg base/kg bw of mefloquine usually split ov<span class="_ _a"></span>er 2 or 3 days. </div><div class="t m8 x2d h1b y3ac ff11 fsb fc3 sc0 lsd8 ws0">Age</div><div class="t m8 x2b h1b y3ad ff11 fsb fc3 sc0 lsd2 ws0">Dose in mg (No. of tablets)</div><div class="t m8 x5d h1b y3ac ff11 fsb fc3 sc0 lsd2 ws1d4">Artesunate (50 mg)</div><div class="t m8 x4e h1b y3ae ff11 fsb fc3 sc0 lsd2 ws0">Sulfadoxine-pyrimethamine</div><div class="t m8 x5e h1b y3af ff11 fsb fc3 sc0 lsd2 ws0">(500/25)</div><div class="t m8 x5f h1b y3b0 ff11 fsb fc3 sc0 lsd8 ws0">Day 1<span class="_ _49"> </span>Day 2<span class="_ _15"> </span>Day 3<span class="_ _85"> </span>Day 1<span class="_ _86"> </span>Day 2<span class="_ _15"> </span>Day 3</div><div class="t m3 x2d h17 y3b1 ff9 fsb fc3 sc0 lsd2 ws0">5–11 months </div><div class="t m3 x5 h17 y3b2 ff9 fsb fc3 sc0 lsd8 ws0">25 (</div><div class="t m3 x60 h1c y3b3 ff9 fse fc3 sc0 ls0 ws0">1</div><div class="t m3 x61 h17 y3b2 ff9 fsb fc3 sc0 ls0 ws0">/</div><div class="t m3 x62 h1c y3b4 ff9 fse fc3 sc0 ls0 ws0">2</div><div class="t m3 x13 h17 y3b2 ff9 fsb fc3 sc0 ls0 ws0">)</div><div class="t m3 x63 h17 y3b1 ff9 fsb fc3 sc0 lsd8 ws0">25<span class="_ _8d"> </span>25</div><div class="t m3 x64 h17 y3b2 ff9 fsb fc3 sc0 ls13a ws218">250/12.5 (</div><div class="t m3 x1e h1c y3b3 ff9 fse fc3 sc0 ls0 ws0">1</div><div class="t m3 x1e h17 y3b2 ff9 fsb fc3 sc0 ls0 ws0">/</div><div class="t m3 x1d h1c y3b4 ff9 fse fc3 sc0 ls0 ws0">2</div><div class="t m3 x65 h17 y3b2 ff9 fsb fc3 sc0 ls0 ws0">)</div><div class="t m3 x15 h17 y3b1 ff9 fsb fc3 sc0 ls0 ws0">–<span class="_ _31"> </span>–</div><div class="t m3 x2d h17 y3b5 fff fsb fc3 sc0 ls0 ws0">≥<span class="_ _9"></span><span class="ff9 lsd8 ws19a">1–6 years</span></div><div class="t m3 x5f h17 y3b6 ff9 fsb fc3 sc0 lsd2 ws1d4">50 (1)<span class="_ _88"> </span><span class="ls154 ws0">50<span class="_ _8d"> </span>50<span class="_ _81"> </span><span class="lsd8">500/25 (1)<span class="_ _85"> </span><span class="ls0">–<span class="_ _31"> </span>–</span></span></span></div><div class="t m3 x2d h17 y3b7 fff fsb fc3 sc0 ls0 ws0">≥<span class="_ _9"></span><span class="ff9 ls13a ws218">7–13 years</span></div><div class="t m3 x5 h17 y3b8 ff9 fsb fc3 sc0 ls11d ws219">100 (2)<span class="_ _2d"> </span><span class="ls155 ws0">100<span class="_ _78"> </span>100<span class="_ _4c"> </span><span class="ls156 ws1d3">1000/50 (2)<span class="_ _78"> </span></span><span class="ls0">–<span class="_ _71"> </span>–</span></span></div><div class="t m3 x2d h17 y3b9 fff fsb fc3 sc0 ls0 ws0">&gt;<span class="_ _9"></span><span class="ff9 ls156 ws1d3">13 years</span></div><div class="t m3 x66 h17 y3ba ff9 fsb fc3 sc0 lsd8 ws0">200 (4)<span class="_ _3b"> </span>200<span class="_ _8e"> </span>200<span class="_ _17"> </span>1500/75 (3)<span class="_ _78"> </span><span class="ls0">–<span class="_ _71"> </span>–</span></div><div class="t m0 xb h14 y3bb ff11 fs5 fc4 sc0 ls4f ws0">11</div><div class="t m0 x20 h15 y3bc ff9 fsa fc3 sc0 ls7d ws228">A similar medicine with tablets containing 500<span class="_ _68"> </span>mg of sulfalene and 25<span class="_ _68"> </span>mg of pyrimethamine is</div><div class="t m0 x20 h15 y3bd ff9 fsa fc3 sc0 ls7d ws0">considered to be equivalent to sulfado<span class="_ _a"></span>xine-pyrimethamine.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf24" class="pf w1 h4" data-page-no="24"><div class="pc pc24 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">26</div><div class="t m0 x9 hd y9e ff15 fs5 fc4 sc0 ls14c ws117">T<span class="_ _b"></span>able 4.<span class="_ _49"> </span><span class="ff8 fs8 fc3 ls12 ws0">Dosing schedule for ar<span class="_ _8"></span>tesunate + mefloquine</span></div><div class="t m0 x9 hb y3be ff9 fs8 fc3 sc0 ls15c ws229">T<span class="_ _b"></span>wo different doses of mefloquine have been ev<span class="_ _b"></span>aluated, 15 mg base/kg bw and</div><div class="t m0 x9 hb y3bf ff9 fs8 fc3 sc0 ls64 ws22a">25 mg base/kg bw<span class="_ _b"></span>. The lo<span class="_ _a"></span>wer dose is associated with inferior efficacy and is</div><div class="t m0 x9 hb y3c0 ff9 fs8 fc3 sc0 ls24 ws132">not recommended. <span class="_ _a"></span>T<span class="_ _4b"></span>o reduce acute vomiting and optimize absorption, the</div><div class="t m0 x9 hb y3c1 ff9 fs8 fc3 sc0 ls64 wsd9">25 mg/kg dose is usually split and given either as 15 mg/kg (usually on the</div><div class="t m0 x9 hb y3c2 ff9 fs8 fc3 sc0 ls7f ws22b">second day) followed by 10 mg/kg one day later<span class="_ _4b"></span>, or as 8.3 mg/kg per day for</div><div class="t m0 x9 hb y3c3 ff9 fs8 fc3 sc0 ls4c wsb9">3<span class="_ _68"> </span>days. Pending development of a co-formulated pr<span class="_ _a"></span>oduct, malaria control</div><div class="t m0 x9 hb y3c4 ff9 fs8 fc3 sc0 lsca ws22c">programmes will hav<span class="_ _a"></span>e to decide on the optimum operational strategy of</div><div class="t m0 x9 hb y3c5 ff9 fs8 fc3 sc0 lsef ws22d">mefloquine dosing for their populations. Mefloquine is associated with an</div><div class="t m0 x9 hb y3c6 ff9 fs8 fc3 sc0 ls15d ws1cb">increased incidence of nausea, vomiting, dizziness, dysphoria and sleep</div><div class="t m0 x9 hb y3c7 ff9 fs8 fc3 sc0 ls64 wsb0">disturbance in clinical trials, but these are seldom debilitating and in general,</div><div class="t m0 x9 hb y3c8 ff9 fs8 fc3 sc0 ls64 ws0">where this A<span class="_ _a"></span>CT has been deployed, it has been w<span class="_ _a"></span>ell tolerated. </div><div class="t m0 x9 h12 y3c9 ff10 fs6 fc4 sc0 ls1b ws1">7.5<span class="_ _78"> </span>Incorrect approaches to treat<span class="_ _8"></span>ment</div><div class="t m0 x9 hb y3ca ff9 fs8 fc3 sc0 ls15e wse5">In endemic regions, some semi-immune malaria patients could be cured</div><div class="t m0 x9 hb y3cb ff9 fs8 fc3 sc0 ls15f ws19c">using partial treatment with effective medicines (i.e. use of regimens that would</div><div class="t m0 x9 hb y3cc ff9 fs8 fc3 sc0 ls12 ws22e">be unsatisfactory in patients with no immunity). This had led in the past to</div><div class="t m0 x9 hb y3cd ff9 fs8 fc3 sc0 ls12 ws22f">different recommendations for patients consider<span class="_ _a"></span>ed to be semi-immune and</div><div class="t m0 x9 hb y3ce ff9 fs8 fc3 sc0 ls160 ws230">those considered to be non-immune. Another potentially dangerous pr<span class="_ _a"></span>actice</div><div class="t m0 x9 hb y3cf ff9 fs8 fc3 sc0 ls161 ws231">is to give only the first dose of the treatment course for patients with suspected</div><div class="t m0 x9 hb y3d0 ff9 fs8 fc3 sc0 ls4e ws232">but unconfirmed malaria, with the intention of giving full treatment if the</div><div class="t m0 x9 hb y3d1 ff9 fs8 fc3 sc0 ls8f wsde">diagnosis is eventually confirmed. Neither practice is r<span class="_ _a"></span>ecommended. If malaria</div><div class="t m0 x9 hb y3d2 ff9 fs8 fc3 sc0 ls12 ws233">is suspected and the decision to treat is made, then a full effective tr<span class="_ _a"></span>eatment</div><div class="t m0 x9 hb y3d3 ff9 fs8 fc3 sc0 ls13 ws14">is required whether or not the diagnosis is confirmed by a test.</div><div class="t m0 x9 hb y3d4 ff9 fs8 fc3 sc0 ls162 ws122">With the exception of artemether<span class="_ _a"></span>-lumefantrine, the partner medicines of all other</div><div class="t m0 x9 hb y3d5 ff9 fs8 fc3 sc0 ls64 ws234">ACT<span class="_ _c"></span>s have been previously used as monotherapies, and still continue to be</div><div class="t m0 x9 hb y3d6 ff9 fs8 fc3 sc0 ls163 ws50">available as such in many countries. <span class="_ _b"></span>Their continued use as monotherapies can</div><div class="t m0 x9 hb y3d7 ff9 fs8 fc3 sc0 ls13c ws6d">potentially compromise the v<span class="_ _a"></span>alue of ACT<span class="_ _c"></span>s by selecting for drug resistance.</div><div class="t m0 x9 hb y3d8 ff9 fs8 fc3 sc0 ls64 ws235">The withdrawal of artemisinins and other monotherapies is recommended. </div><div class="t m8 x47 h1b y392 ff11 fsb fc3 sc0 lsd8 ws0">Age</div><div class="t m8 x4e h1b y3d9 ff11 fsb fc3 sc0 lsd2 ws0">Dose in mg (No. of tablets)</div><div class="t m8 x4f h1b y392 ff11 fsb fc3 sc0 lsd2 ws1d4">Artesunate (50 mg)<span class="_ _71"> </span><span class="ws0">Mefloquine (250 mg)</span></div><div class="t m8 x2b h1b y394 ff11 fsb fc3 sc0 lsd8 ws0">Day 1<span class="_ _2d"> </span>Day 2<span class="_ _18"> </span>Day 3<span class="_ _11"> </span>Day 1<span class="_ _1a"> </span>Day 2<span class="_ _1a"> </span>Day 3</div><div class="t m3 x47 h17 y396 ff9 fsb fc3 sc0 lsd2 ws0">5–11 months </div><div class="t m3 x50 h17 y3da ff9 fsb fc3 sc0 lsd8 ws0">25 (</div><div class="t m3 x51 h1c y3db ff9 fse fc3 sc0 ls0 ws0">1</div><div class="t m3 x52 h17 y3da ff9 fsb fc3 sc0 ls0 ws0">/</div><div class="t m3 x53 h1c y3dc ff9 fse fc3 sc0 ls0 ws0">2</div><div class="t m3 x41 h17 y3da ff9 fsb fc3 sc0 ls0 ws0">)</div><div class="t m3 x54 h17 y396 ff9 fsb fc3 sc0 lsd8 ws0">25<span class="_ _80"> </span>25<span class="_ _8f"> </span><span class="ls0">–</span></div><div class="t m3 x67 h17 y3da ff9 fsb fc3 sc0 ls11d ws219">125 (</div><div class="t m3 x68 h1c y3db ff9 fse fc3 sc0 ls0 ws0">1</div><div class="t m3 x69 h17 y3da ff9 fsb fc3 sc0 ls0 ws0">/</div><div class="t m3 x23 h1c y3dc ff9 fse fc3 sc0 ls0 ws0">2</div><div class="t m3 x6a h17 y3da ff9 fsb fc3 sc0 ls0 ws0">)</div><div class="t m3 x5c h17 y396 ff9 fsb fc3 sc0 ls0 ws0">–</div><div class="t m3 x47 h17 y397 fff fsb fc3 sc0 ls0 ws0">≥<span class="_ _9"></span><span class="ff9 lsd8 ws19a">1–6 years</span></div><div class="t m3 x2b h17 y398 ff9 fsb fc3 sc0 lsd2 ws1d4">50 (1)<span class="_ _81"> </span><span class="ls154 ws0">50<span class="_ _80"> </span>50<span class="_ _8f"> </span><span class="ls0">–<span class="_ _81"> </span><span class="lsd2">250 (1)<span class="_ _90"> </span></span>–</span></span></div><div class="t m3 x47 h17 y399 fff fsb fc3 sc0 ls0 ws0">≥<span class="_ _9"></span><span class="ff9 ls13a ws218">7–13 years</span></div><div class="t m3 x50 h17 y39a ff9 fsb fc3 sc0 ls11d ws219">100 (2)<span class="_ _4c"> </span><span class="ls155 ws0">100<span class="_ _85"> </span>100<span class="_ _91"> </span><span class="ls0">–<span class="_ _87"> </span><span class="lsd8">500 (2)<span class="_ _1d"> </span><span class="lsd2">250 (1)</span></span></span></span></div><div class="t m3 x47 h17 y3dd fff fsb fc3 sc0 ls0 ws0">&gt;<span class="_ _9"></span><span class="ff9 ls156 ws1d3">13 years</span></div><div class="t m3 x3f h17 y3de ff9 fsb fc3 sc0 lsd8 ws0">200 (4)<span class="_ _79"> </span>200<span class="_ _86"> </span>200<span class="_ _92"> </span><span class="ls0">–<span class="_ _93"> </span><span class="ls11d ws219">1000 (4)<span class="_ _46"> </span></span></span>500 (2)</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf25" class="pf w1 h4" data-page-no="25"><div class="pc pc25 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls2 ws0">27</div><div class="t m0 xb hd y9e ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on treatment approaches </div><div class="t m0 xb hd y9f ff8 fs8 fc3 sc0 ls12 ws0">that should be avoided</div><div class="t m0 xb h12 y3df ff10 fs6 fc4 sc0 ls9a ws0">7.6<span class="_ _78"> </span>Additional aspects of c<span class="_ _8"></span>linical management</div><div class="t m0 xb h13 y3e0 ff8 fs3 fc3 sc0 ls80 ws0">7.6.1<span class="_ _11"> </span>Can the patient take oral medication?</div><div class="t m0 xb hb y3e1 ff9 fs8 fc3 sc0 ls12 wsa6">Some patients cannot tolerate oral tr<span class="_ _a"></span>eatment, and will require parenter<span class="_ _a"></span>al or</div><div class="t m0 xb hb y3e2 ff9 fs8 fc3 sc0 ls164 ws19b">rectal administration for 1–2 days until they can swallo<span class="_ _a"></span>w and retain oral</div><div class="t m0 xb hb y3e3 ff9 fs8 fc3 sc0 ls12 ws236">medication reliably<span class="_ _c"></span>. Although such patients may not show signs of severity<span class="_ _4b"></span>,</div><div class="t m0 xb hb y3e4 ff9 fs8 fc3 sc0 ls33 ws5f">they should receive the same antimalarial dose r<span class="_ _a"></span>egimens as for severe malaria</div><div class="t m0 xb hb y3e5 ff9 fs8 fc3 sc0 ls13 ws14">(see section 8.4 ). </div><div class="t m0 xb h13 y3e6 ff8 fs3 fc3 sc0 ls80 ws0">7.6.2<span class="_ _18"> </span>Does the patient have v<span class="_ _a"></span>er<span class="_ _8"></span>y high parasitaemia</div><div class="t m0 x6 h13 y3e7 ff8 fs3 fc3 sc0 ls80 ws0">(hyperparasitaemia)?</div><div class="t m0 xb hb y3e8 ff9 fs8 fc3 sc0 ls3c ws31">Some patients may have no signs of sev<span class="_ _a"></span>erity but on examination of the blood</div><div class="t m0 xb hb y3e9 ff9 fs8 fc3 sc0 ls12 ws1e1">film are found to have v<span class="_ _a"></span>ery high parasitaemia. The risks associated with high</div><div class="t m0 xb hb y3ea ff9 fs8 fc3 sc0 ls12 ws237">parasitaemia v<span class="_ _a"></span>ary depending on the age of the patient and on transmission</div><div class="t m0 xb hb y3eb ff9 fs8 fc3 sc0 ls12 ws133">intensity<span class="_ _4b"></span>. Thus cut-off v<span class="_ _a"></span>alues and definitions of hyperparasitaemia also v<span class="_ _a"></span>ary<span class="_ _b"></span>.</div><div class="t m0 xb hb y3ec ff9 fs8 fc3 sc0 ls12 ws91">Patients with high parasitaemias ar<span class="_ _a"></span>e at an increased risk of treatment failure</div><div class="t m0 xb hb y3ed ff9 fs8 fc3 sc0 ls165 ws238">and of developing sev<span class="_ _a"></span>ere malaria, and therefore hav<span class="_ _a"></span>e an increased risk of dying.</div><div class="t m0 xb hb y3ee ff9 fs8 fc3 sc0 ls12 ws239">These patients can be treated with the oral A<span class="_ _a"></span>CT<span class="_ _4b"></span>s recommended for uncom-</div><div class="t m0 xb hb y3ef ff9 fs8 fc3 sc0 ls12 ws23a">plicated malaria. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, they require close monitoring to ensur<span class="_ _a"></span>e that the</div><div class="t m0 xb hb y3f0 ff9 fs8 fc3 sc0 ls12 ws23b">drugs are retained and that signs of sev<span class="_ _a"></span>erity do not develop, and they may</div><div class="t m0 xb hb y3f1 ff9 fs8 fc3 sc0 ls166 ws91">require a longer course of tr<span class="_ _a"></span>eatment to ensure cure. Details of definitions and</div><div class="t m0 xb hb y3f2 ff9 fs8 fc3 sc0 ls12 ws0">management are pro<span class="_ _a"></span>vided in sections 8.1 and 8.15. </div><div class="t m0 xb h13 y3f3 ff8 fs3 fc3 sc0 ls80 ws0">7.6.3<span class="_ _1a"> </span>Use of antipyretics </div><div class="t m0 xb hb y3f4 ff9 fs8 fc3 sc0 ls12 ws23c">Fev<span class="_ _a"></span>er is a cardinal feature of malaria, and is associated with constitutional</div><div class="t m0 xb hb y3f5 ff9 fs8 fc3 sc0 ls12 ws23d">symptoms of lassitude, weakness, headache, anorexia and often nausea. In</div><div class="t m0 xb hb y3f6 ff9 fs8 fc3 sc0 ls167 ws23e">young children, high fev<span class="_ _a"></span>ers are associated with vomiting, including of</div><div class="t m0 x2d h16 y3f7 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x15 h16 y3f8 ff8 fsb fc0 sc0 lsd2 ws0">LEVEL<span class="_ _67"> </span>OF</div><div class="t m0 x6b h16 y3f9 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y3fa ff9 fsb fc3 sc0 ls168 ws23f">Partial treatments should not be given even when patients ar<span class="_ _a"></span>e</div><div class="t m3 x2d h17 y3fb ff9 fsb fc3 sc0 ls169 ws240">considered to be semi-immune or the diagnosis is uncertain. A</div><div class="t m3 x2d h17 y3fc ff9 fsb fc3 sc0 lsd2 ws196">full course of effective treatment should always be giv<span class="_ _a"></span>en once a</div><div class="t m3 x2d h17 y3fd ff9 fsb fc3 sc0 lsd2 ws0">decision to give antimalarial treatment has been r<span class="_ _a"></span>eached.</div><div class="t m3 x6c h16 y3fa ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x2d h17 y3fe ff9 fsb fc3 sc0 ls16a ws241">The artemisinins and par<span class="_ _8"></span>tner medicines of ACT<span class="_ _4b"></span>s should not be</div><div class="t m3 x2d h17 y3ff ff9 fsb fc3 sc0 lsd2 ws0">available as monother<span class="_ _a"></span>apies.</div><div class="t m3 x6c h16 y3fe ff8 fsb fc3 sc0 ls0 ws0">E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf26" class="pf w1 h4" data-page-no="26"><div class="pc pc26 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls2 ws0">28</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls16b ws242">medication, and seizures. <span class="_ _a"></span>T<span class="_ _b"></span>reatment is with antipyretics and, if necessary<span class="_ _4b"></span>, tepid</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls12 ws4d">sponging. Care should be taken to ensure that the water is not too cool as,</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls4d ws6d">paradoxically<span class="_ _c"></span>, this may raise the core temperatur<span class="_ _a"></span>e by inducing cutaneous</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls4d ws6d">vasoconstriction. P<span class="_ _a"></span>aracetamol (acetaminophen) 15 mg/kg bw every 4 h is</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls12 ws243">widely used; it is safe and well tolerated giv<span class="_ _a"></span>en orally or as a suppository<span class="_ _4b"></span>.</div><div class="t m0 x9 hb yc1 ff9 fs8 fc3 sc0 ls16c ws244">Ibuprofen (5 mg/kg bw) has been used successfully as an alternativ<span class="_ _a"></span>e in</div><div class="t m0 x9 hb y10d ff9 fs8 fc3 sc0 lsfd ws201">malaria and other childhood fevers, although there is less experience with this</div><div class="t m0 x9 hb y10e ff9 fs8 fc3 sc0 lsd1 ws14e">compound. Acetylsalicylic acid (aspirin) should not be used in children because</div><div class="t m0 x9 hb y10f ff9 fs8 fc3 sc0 ls16d ws120">of the risks of Reye<span class="_ _a"></span>’<span class="_ _4b"></span>s syndrome. There has been some concern that antipyr<span class="_ _a"></span>etics</div><div class="t m0 x9 hb y110 ff9 fs8 fc3 sc0 ls12 ws42">might attenuate the host defence against malaria, as their use is associated</div><div class="t m0 x9 hb y111 ff9 fs8 fc3 sc0 ls91 wse6">with delayed parasite clear<span class="_ _a"></span>ance. However<span class="_ _4b"></span>, this appears to result from delaying</div><div class="t m0 x9 hb y2be ff9 fs8 fc3 sc0 ls16e ws245">cytoadherence, which is likely to be beneficial. <span class="_ _a"></span>There is no reason to withhold</div><div class="t m0 x9 hb y2bf ff9 fs8 fc3 sc0 ls12 ws0">antipyretics in malaria.</div><div class="t m0 x9 hd y400 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on management of fever</div><div class="t m0 x47 h16 y401 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x68 h16 y402 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x6d h16 y403 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y404 ff9 fsb fc3 sc0 lsd2 ws246">An antipyretic medicine and physical methods for fever r<span class="_ _a"></span>eduction</div><div class="t m3 x47 h17 y405 ff9 fsb fc3 sc0 lsd2 ws247">should be administered to children with fev<span class="_ _a"></span>er<span class="_ _b"></span>. This is particularly</div><div class="t m3 x47 h17 y406 ff9 fsb fc3 sc0 lsd2 ws0">important in children when core temperature is <span class="fff ls0">≥<span class="_ _9"></span></span><span class="lsd8">38.5</span></div><div class="t m3 x43 h1c y407 ff9 fse fc3 sc0 ls0 ws0">o</div><div class="t m3 x6e h17 y408 ff9 fsb fc3 sc0 ls154 ws0">C.</div><div class="t m3 x6f h16 y404 ff8 fsb fc3 sc0 lsd2 ws0">S, E</div><div class="t m3 x47 h17 y409 ff9 fsb fc3 sc0 ls16f ws248">Paracetamol (acetaminophen) and ibupr<span class="_ _a"></span>ofen are the preferred</div><div class="t m3 x47 h17 y40a ff9 fsb fc3 sc0 lsd2 ws0">options for reducing fever<span class="_ _4b"></span>.</div><div class="t m3 x6f h16 y409 ff8 fsb fc3 sc0 lsd2 ws0">S, E</div><div class="t m0 x47 hd y40b ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:<span class="_ _1"> </span>trials of routine use of antipyretics in uncomplicated</div><div class="t m0 x5f hd y40c ff8 fs8 fc0 sc0 ls12 ws0">falciparum malaria</div><div class="t m0 x47 h1a y40d ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x22 h1b y40d ff14 fsb fc3 sc0 lsd2 ws0">oral paracetamol, or<span class="_ _a"></span>al nonsteroidal antiinflammatory drugs,</div><div class="t m3 x47 h1b y40e ff14 fsb fc3 sc0 lsd2 ws1d4">mechanical methods</div><div class="t m3 x24 h17 y40f ff14 fsb fc5 sc0 ls170 ws249">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls171 wse2">a systematic review of 12 trials (<span class="ffa ls172 ws0">n <span class="_ _b"></span><span class="ff9 ls173 ws24a">= 1509) in children using</span></span></span></div><div class="t m3 x24 h17 y410 ff9 fsb fc3 sc0 lsd2 ws0">paracetamol. </div><div class="t m3 x24 h17 y411 ff9 fsb fc3 sc0 ls174 ws24b">Systematic review of 3 r<span class="_ _a"></span>andomised trials in adults did not provide any evidence</div><div class="t m3 x24 h17 y412 ff9 fsb fc3 sc0 lsd2 ws0">that antipyretic medicines prolonged illness. </div><div class="t m3 x24 h17 y413 ff9 fsb fc3 sc0 ls175 ws24c">In 2 trials, where all children r<span class="_ _a"></span>eceived an antipyretic medicine, physical</div><div class="t m3 x24 h17 y414 ff9 fsb fc3 sc0 ls12e ws245">methods resulted in a higher proportion of children without fever at one hour</div><div class="t m3 x24 h17 y415 ff9 fsb fc3 sc0 ls0 ws0">(<span class="ffa ls13a">n </span><span class="lsd8 ws20a">= 125, RR: 11.76; 95% CI: 3.39–40.79). In a thir<span class="_ _a"></span>d trial (<span class="ffa ls13a ws0">n </span>= 130), which only</span></div><div class="t m3 x24 h17 y416 ff9 fsb fc3 sc0 lsd2 ws0">reported mean change in temperature, no difference was detected.</div><div class="t m3 x24 h17 y417 ff14 fsb fc5 sc0 ls176 ws24d">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 ls107">symptomatic treatment of fev<span class="_ _a"></span>er is indicated and is par<span class="_ _8"></span>ticularly</span></div><div class="t m3 x24 h17 y418 ff9 fsb fc3 sc0 ls177 ws24e">important in small children in whom fever can cause seizures and induce</div><div class="t m3 x24 h17 y419 ff9 fsb fc3 sc0 lsd2 ws24f">vomiting (more likely if cor<span class="_ _a"></span>e temperature is <span class="fff ls0 ws0">&gt;<span class="_ _9"></span></span><span class="ws250">38 °C). Mechanical antipyretic</span></div><div class="t m3 x24 h17 y41a ff9 fsb fc3 sc0 ls178 ws251">measures, such as exposure and fanning cause a tr<span class="_ _a"></span>ansient reduction in</div><div class="t m3 x24 h17 y41b ff9 fsb fc3 sc0 ls179 ws1be">temperature, or<span class="_ _a"></span>al antipyretics may be more effective for r<span class="_ _a"></span>educing temperature.</div><div class="t m0 x47 h16 y41c ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x70 h17 y41c ff9 fsb fc3 sc0 lsd2 ws0">use paracetamol or ibuprofen for tr<span class="_ _a"></span>eating fever (particularly if</div><div class="t m3 x47 h17 y41d ff9 fsb fc3 sc0 lsd8 ws0">temperature is <span class="fff ls0">&gt;<span class="_ _67"> </span></span><span class="lsd2">38.5 °C). Mechanical methods hav<span class="_ _a"></span>e an additive effect. </span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf27" class="pf w1 h4" data-page-no="27"><div class="pc pc27 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">29</div><div class="t m0 xb h13 y296 ff8 fs3 fc3 sc0 ls80 ws0">7.6.4<span class="_ _18"> </span>Use of antiemetics </div><div class="t m0 xb hb y297 ff9 fs8 fc3 sc0 ls125 ws1db">V<span class="_ _a"></span>omiting is common in acute malaria and may be severe. Antiemetics ar<span class="_ _a"></span>e widely</div><div class="t m0 xb hb y298 ff9 fs8 fc3 sc0 ls44 ws93">used. Ther<span class="_ _a"></span>e have been no studies of their efficacy in malaria, and no compar-</div><div class="t m0 xb hb y299 ff9 fs8 fc3 sc0 lse2 ws138">isons between different antiemetic compounds, although ther<span class="_ _a"></span>e is no evidence</div><div class="t m0 xb hb y29a ff9 fs8 fc3 sc0 ls12 ws0">that they are harmful.</div><div class="t m0 xb h13 y41e ff8 fs3 fc3 sc0 ls80 ws0">7.6.5<span class="_ _1a"> </span>Management of seizures</div><div class="t m0 xb hb y41f ff9 fs8 fc3 sc0 ls15f ws19c">Generalized seizur<span class="_ _a"></span>es are more common in children with falciparum malaria than</div><div class="t m0 xb hb y420 ff9 fs8 fc3 sc0 lsf9 ws215">in those with the other malarias. This suggests an o<span class="_ _a"></span>verlap between the cer<span class="_ _a"></span>ebral</div><div class="t m0 xb hb y421 ff9 fs8 fc3 sc0 ls12 ws252">pathology resulting from malaria and febrile convulsions. Sometimes these</div><div class="t m0 xb hb y422 ff9 fs8 fc3 sc0 ls12 ws253">seizures are the pr<span class="_ _a"></span>odrome of cerebral malaria. If the seizur<span class="_ _a"></span>e is ongoing, the</div><div class="t m0 xb hb y2a0 ff9 fs8 fc3 sc0 ls12 ws127">airway should be maintained and anticonvulsants given (parenter<span class="_ _a"></span>al or rectal</div><div class="t m0 xb hb y2a1 ff9 fs8 fc3 sc0 ls12 ws254">benzodiazepines or intramuscular par<span class="_ _a"></span>aldehyde). If it has stopped, the child</div><div class="t m0 xb hb y2a2 ff9 fs8 fc3 sc0 ls12 ws255">should be treated as indicated in section 7.6.3 if core temper<span class="_ _a"></span>ature is abov<span class="_ _a"></span>e</div><div class="t m0 xb hb y2a3 ff9 fs8 fc3 sc0 ls92 ws0">38.5</div><div class="t m0 x71 h11 y423 ff9 fs5 fc3 sc0 ls0 ws0">o</div><div class="t m0 x38 hb y2a3 ff9 fs8 fc3 sc0 ls1d ws1c">C. Ther<span class="_ _a"></span>e is no evidence that prophylactic anticonvulsants are beneficial</div><div class="t m0 xb hb y2a4 ff9 fs8 fc3 sc0 ls12 ws0">in otherwise uncomplicated malaria.</div><div class="t m0 xb h12 y424 ff10 fs6 fc4 sc0 ls9a ws0">7.7<span class="_ _78"> </span>Operational issues in t<span class="_ _8"></span>reatment management</div><div class="t m0 xb hb y425 ff9 fs8 fc3 sc0 ls12 ws256">T<span class="_ _4b"></span>o optimize the benefit of deploying A<span class="_ _a"></span>CT<span class="_ _4b"></span>s, and to have an impact on malaria,</div><div class="t m0 xb hb y426 ff9 fs8 fc3 sc0 ls17a ws53">it will be necessary to deploy them as widely as possible – this means at most</div><div class="t m0 xb hb y427 ff9 fs8 fc3 sc0 ls47 ws67">peripheral health clinics and health centres, and in the community<span class="_ _c"></span>. Deployment</div><div class="t m0 xb hb y428 ff9 fs8 fc3 sc0 ls12 ws257">through the formal public health delivery system alone will not reach many</div><div class="t m0 xb hb y429 ff9 fs8 fc3 sc0 ls73 ws50">of those who need treatment. In sever<span class="_ _a"></span>al countries, they must also be available</div><div class="t m0 xb hb y42a ff9 fs8 fc3 sc0 ls17b ws258">through the priv<span class="_ _a"></span>ate sector<span class="_ _b"></span>. Ultimately<span class="_ _4b"></span>, effective treatment needs to be av<span class="_ _a"></span>ailable</div><div class="t m0 xb hb y42b ff9 fs8 fc3 sc0 ls12 ws259">at community or household level in such a way that there is no financial or</div><div class="t m0 xb hb y42c ff9 fs8 fc3 sc0 ls12 ws25a">physical barrier to access. The str<span class="_ _a"></span>ategy to secure full access must be based</div><div class="t m0 xb hb y42d ff9 fs8 fc3 sc0 ls166 ws91">on an analysis of the national and local health systems, and will often require</div><div class="t m0 xb hb y42e ff9 fs8 fc3 sc0 ls12 ws25b">adjustment based on programme monitoring and oper<span class="_ _a"></span>ational research. <span class="_ _a"></span>The</div><div class="t m0 xb hb y42f ff9 fs8 fc3 sc0 lsa1 ws100">dissemination of clear national treatment guidelines, use of appropriate</div><div class="t m0 xb hb y430 ff9 fs8 fc3 sc0 ls93 wse9">information, education and communication materials, monitoring both of the</div><div class="t m0 xb hb y431 ff9 fs8 fc3 sc0 ls17c ws14f">deployment process, access and co<span class="_ _a"></span>verage and pr<span class="_ _a"></span>ovision of adequately</div><div class="t m0 xb hb y432 ff9 fs8 fc3 sc0 ls85 wsc9">packaged and presented antimalarials are needed to optimiz<span class="_ _a"></span>e the benefits of</div><div class="t m0 xb hb y433 ff9 fs8 fc3 sc0 ls12 ws0">pro<span class="_ _a"></span>viding these new effective treatments widely<span class="_ _c"></span>. </div><div class="t m0 xb h13 y434 ff8 fs3 fc3 sc0 ls80 ws0">7.7.1<span class="_ _7b"> </span>Health education</div><div class="t m0 xb hb y435 ff9 fs8 fc3 sc0 lsd1 ws14e">At all levels, from the hospital to the community<span class="_ _c"></span>, education is vital to optimizing</div><div class="t m0 xb hb y436 ff9 fs8 fc3 sc0 ls17d ws25c">antimalarial treatment. Clear guidelines in the language understood by the local</div><div class="t m0 xb hb y437 ff9 fs8 fc3 sc0 ls14 ws25d">users, posters, wall charts, educational videos and other teaching materials,</div><div class="t m0 xb hb y438 ff9 fs8 fc3 sc0 ls17e ws25e">public awareness campaigns, education of and pro<span class="_ _a"></span>vision of information</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf28" class="pf w1 h4" data-page-no="28"><div class="pc pc28 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">30</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls17f ws25f">materials to shopkeepers and other dispensers can all impro<span class="_ _a"></span>ve the understand-</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls180 ws260">ing of malaria and the likelihood of impro<span class="_ _a"></span>ved prescribing and adherence,</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls12 ws261">appropriate referr<span class="_ _a"></span>al, and minimizing the unnecessary use of antimalarials.</div><div class="t m0 x9 h13 y439 ff8 fs3 fc3 sc0 ls80 ws0">7.7.2<span class="_ _11"> </span>Adherence to tr<span class="_ _a"></span>eatment</div><div class="t m0 x9 hb y43a ff9 fs8 fc3 sc0 ls12 ws262">T<span class="_ _4b"></span>o achieve the desired ther<span class="_ _a"></span>apeutic effectiveness, a drug must be intrinsically</div><div class="t m0 x9 hb y43b ff9 fs8 fc3 sc0 ls12 ws263">efficacious and must be taken in the correct doses at the proper intervals.</div><div class="t m0 x9 hb y39c ff9 fs8 fc3 sc0 ls181 ws264">Patient adherence is a major determinant of the r<span class="_ _a"></span>esponse to antimalarials, as</div><div class="t m0 x9 hb y39d ff9 fs8 fc3 sc0 ls12 ws175">most treatments are taken at home without medical supervision. Ther<span class="_ _a"></span>e have</div><div class="t m0 x9 hb y154 ff9 fs8 fc3 sc0 ls15a ws223">been few studies of adherence. <span class="_ _a"></span>These suggest that 3-day regimens of medicines</div><div class="t m0 x9 hb y155 ff9 fs8 fc3 sc0 ls182 ws130">such as ACT<span class="_ _c"></span>s are adhered to reasonably well, pr<span class="_ _a"></span>ovided that patients or carers</div><div class="t m0 x9 hb y156 ff9 fs8 fc3 sc0 ls12 ws105">are given an adequate explanation at the time of pr<span class="_ _a"></span>escribing. Prescribers,</div><div class="t m0 x9 hb y112 ff9 fs8 fc3 sc0 ls12 ws265">shopkeepers or vendors should therefor<span class="_ _a"></span>e give a clear and comprehensible</div><div class="t m0 x9 hb y157 ff9 fs8 fc3 sc0 ls12 ws266">explanation of how to use the medicines. Co-formulation is probably a v<span class="_ _a"></span>ery</div><div class="t m0 x9 hb y43c ff9 fs8 fc3 sc0 ls12 ws12f">important contributor to adherence. User<span class="_ _a"></span>-friendly packaging, such as blister</div><div class="t m0 x9 hb y43d ff9 fs8 fc3 sc0 ls45 wsbb">packs, also encourage completion of the treatment course and corr<span class="_ _a"></span>ect dosing.</div><div class="t m0 x9 h13 y43e ff8 fs3 fc3 sc0 ls80 ws0">7.7.3<span class="_ _7d"> </span>Quality assur<span class="_ _a"></span>ance of antimalarial medicines</div><div class="t m0 x9 hb y43f ff9 fs8 fc3 sc0 ls75 wsb0">Many of the antimalarials available in malaria endemic ar<span class="_ _a"></span>eas are substandard</div><div class="t m0 x9 hb y440 ff9 fs8 fc3 sc0 ls17b ws258">in that the manufacturing processes have been unsatisfactory<span class="_ _c"></span>, or their pharma-</div><div class="t m0 x9 hb y441 ff9 fs8 fc3 sc0 ls12 ws14e">ceutical properties do not meet the required pharmacopoeial specifications.</div><div class="t m0 x9 hb y442 ff9 fs8 fc3 sc0 ls6c ws99">Counterfeit tablets and ampoules containing no antimalarials are a major</div><div class="t m0 x9 hb y443 ff9 fs8 fc3 sc0 ls183 ws165">problem in some areas. <span class="_ _b"></span>These may result in fatal delays in appropriate</div><div class="t m0 x9 hb y444 ff9 fs8 fc3 sc0 ls161 ws231">treatment, and may also give rise to a mistaken impr<span class="_ _a"></span>ession of resistance. <span class="_ _a"></span>WHO,</div><div class="t m0 x9 hb y445 ff9 fs8 fc3 sc0 ls184 ws267">in collaboration with other United Nations agencies, has established an <span class="ls165 ws0">inter-</span></div><div class="t m0 x9 hb y446 ff9 fs8 fc3 sc0 ls185 ws11e">national mechanism to pre-qualify manufacturers of artemisinin compounds</div><div class="t m0 x9 hb y447 ff9 fs8 fc3 sc0 ls186 ws268">and ACT<span class="_ _c"></span>s on the basis of compliance with internationally-recommended</div><div class="t m0 x9 hb y448 ff9 fs8 fc3 sc0 ls12 ws221">standards of manufacturing and quality<span class="_ _c"></span>.<span class="_ _2"> </span>It is the responsibility of <span class="_ _a"></span>nat<span class="_ _a"></span>i<span class="ls22 ws0">onal</span></div><div class="t m0 x9 hb y449 ff9 fs8 fc3 sc0 ls187 ws269">ministries of Health and regulatory authorities to ensure the quality of</div><div class="t m0 x9 hb y44a ff9 fs8 fc3 sc0 ls12 ws26a">antimalarials pro<span class="_ _a"></span>vided through both the public and private sectors, thr<span class="_ _a"></span>ough</div><div class="t m0 x9 hb y44b ff9 fs8 fc3 sc0 ls12 ws0">regulation, inspection and law enforcement.</div><div class="t m0 x9 h13 y44c ff8 fs3 fc3 sc0 ls80 ws0">7.7.4<span class="_ _11"> </span>Pharmaco<span class="_ _a"></span>vigilance</div><div class="t m0 x9 hb y44d ff9 fs8 fc3 sc0 ls62 ws1b3">Rare but serious adv<span class="_ _a"></span>erse effects are often not detected in clinical trials and can</div><div class="t m0 x9 hb y44e ff9 fs8 fc3 sc0 ls64 ws26b">only be detected through pharmaco<span class="_ _a"></span>vigilance systems operating in situations</div><div class="t m0 x9 hb y44f ff9 fs8 fc3 sc0 ls64 ws26c">of wide population use. Ther<span class="_ _a"></span>e are few data from prospectiv<span class="_ _a"></span>e Phase IV post-</div><div class="t m0 x9 hb y450 ff9 fs8 fc3 sc0 ls188 ws1bd">marketing studies on rare but potentially serious adv<span class="_ _a"></span>erse effects of antimalarials.</div><div class="t m0 x9 hb y451 ff9 fs8 fc3 sc0 ls17f wsfe">Chloroquine has the best-documented adverse effect pr<span class="_ _a"></span>ofile. The safety profiles</div><div class="t m0 x9 hb y452 ff9 fs8 fc3 sc0 lsf9 ws1a7">of the artemisinin derivatives, mefloquine and sulfadoxine–pyrimethamine ar<span class="_ _a"></span>e</div><div class="t m0 x9 hb y453 ff9 fs8 fc3 sc0 ls7a wse2">supported by a reasonable evidence base, but mainly from large clinical trials.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf29" class="pf w1 h4" data-page-no="29"><div class="pc pc29 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">31</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls189 ws1b5">The neurotoxicity observed in animals treated with artemisinin derivativ<span class="_ _a"></span>es</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls64 ws32">has prompted large pr<span class="_ _a"></span>ospective assessments in humans, but no evidence of</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls64 ws8d">neurotoxicity has been found. Concerns o<span class="_ _a"></span>ver the risk of sev<span class="_ _a"></span>ere liver or skin</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls5a wsb6">reactions to sulfadoxine-pyrimethamine tr<span class="_ _a"></span>eatment have receded with incr<span class="_ _a"></span>easing</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls64 ws26d">numbers of negative reports. More data are needed on the new<span class="_ _a"></span>er drugs and</div><div class="t m0 xb hb yc1 ff9 fs8 fc3 sc0 ls18a wsff">on amodiaquine as well. <span class="_ _a"></span>There is also an urgent need to obtain more information</div><div class="t m0 xb hb y10d ff9 fs8 fc3 sc0 ls64 ws1c">on the safety of antimalarials, in particular the ACT<span class="_ _4b"></span>s, in pregnancy<span class="_ _4b"></span>. It is recom-</div><div class="t m0 xb hb y10e ff9 fs8 fc3 sc0 ls18b wsfa">mended that countries or regions should consider establishing pharmaco<span class="_ _a"></span>vigi-</div><div class="t m0 xb hb y10f ff9 fs8 fc3 sc0 ls64 ws0">lance systems if they have not already done so<span class="_ _a"></span>. </div><div class="t m0 xb h12 y155 ff10 fs6 fc4 sc0 ls9a ws0">7.8<span class="_ _78"> </span>Management of treatment failures</div><div class="t m0 xb h13 y454 ff8 fs3 fc3 sc0 ls80 wsc1">7.8.1<span class="_ _2d"> </span>F<span class="_ _b"></span>ailure within 14 days</div><div class="t m0 xb hb y1fa ff9 fs8 fc3 sc0 ls15c ws26e">T<span class="_ _b"></span>reatment failure within 14 days of receiving an A<span class="_ _a"></span>CT is v<span class="_ _a"></span>ery unusual. Of 39 trials</div><div class="t m0 xb hb y455 ff9 fs8 fc3 sc0 ls47 ws67">of artemisinin or its derivatives, which together enrolled 6124 patients, 3<span class="_ _a"></span>2 trials</div><div class="t m0 xb hb y114 ff9 fs8 fc3 sc0 ls18c ws26f">(4917 patients) had no failures at all by day 14. In the remaining 7 trials,</div><div class="t m0 xb hb y115 ff9 fs8 fc3 sc0 ls15d ws270">failure rates at day 14 r<span class="_ _a"></span>anged from 1% to 7%. The majority of tr<span class="_ _a"></span>eatment</div><div class="t m0 xb hb y116 ff9 fs8 fc3 sc0 ls12 ws271">failures occur after 2 weeks of initial tr<span class="_ _a"></span>eatment. In many cases failures are</div><div class="t m0 xb hb y456 ff9 fs8 fc3 sc0 ls85 wsc9">missed because patients presenting with malaria are not asked whether they</div><div class="t m0 xb hb y457 ff9 fs8 fc3 sc0 ls18d ws13a">have receiv<span class="_ _a"></span>ed antimalarial treatment within the preceding 1–2 months.</div><div class="t m0 xb hb y458 ff9 fs8 fc3 sc0 ls18e ws272">Recurr<span class="_ _a"></span>ence of falciparum malaria can be the result of a reinfection, or a</div><div class="t m0 xb hb y459 ff9 fs8 fc3 sc0 ls12 ws72">recrudescence (i.e. failure). In an individual patient it may not be possible to</div><div class="t m0 xb hb y45a ff9 fs8 fc3 sc0 lsfd ws201">distinguish recrudescence from r<span class="_ _a"></span>einfection, although if fever and parasitaemia</div><div class="t m0 xb hb y45b ff9 fs8 fc3 sc0 ls12 ws273">fail to resolve or r<span class="_ _a"></span>ecur within 2 weeks of treatment then this is considered a</div><div class="t m0 xb hb y45c ff9 fs8 fc3 sc0 ls14 ws274">failure of treatment. <span class="_ _b"></span>Wherever possible treatment failure must be confirmed</div><div class="t m0 xb hb y45d ff9 fs8 fc3 sc0 ls96 wsef">parasitologically – prefer<span class="_ _a"></span>ably by blood slide examination (as H<span class="_ _8"></span>RP2-based</div><div class="t m0 xb hb y45e ff9 fs8 fc3 sc0 ls12 ws275">tests may remain positive for w<span class="_ _a"></span>eeks after the initial infection even without</div><div class="t m0 xb hb y45f ff9 fs8 fc3 sc0 ls12 ws22c">recrudescence). <span class="_ _a"></span>This may require transferring the patient to a facility with</div><div class="t m0 xb hb y460 ff9 fs8 fc3 sc0 ls17d ws25c">microscopy; transfer may be necessary anyway to obtain second-line treatment.</div><div class="t m0 xb hb y461 ff9 fs8 fc3 sc0 ls18f wsdc">T<span class="_ _b"></span>reatment failures may result fr<span class="_ _a"></span>om drug resistance, poor adherence or unusual</div><div class="t m0 xb hb y462 ff9 fs8 fc3 sc0 ls25 ws27">pharmacokinetic properties in that individual. It is impor<span class="_ _8"></span>tant to determine from</div><div class="t m0 xb hb y463 ff9 fs8 fc3 sc0 ls12a ws1e1">the patient’<span class="_ _4b"></span>s histor<span class="_ _8"></span>y whether he or she vomited previous tr<span class="_ _a"></span>eatment or did not</div><div class="t m0 xb hb y464 ff9 fs8 fc3 sc0 ls47 ws67">complete a full course. T<span class="_ _4b"></span>reatment failures within 14 days should be treated with</div><div class="t m0 xb hb y465 ff9 fs8 fc3 sc0 ls12 ws0">a second-line antimalarial (see section 7.8.3).</div><div class="t m0 xb h13 y466 ff8 fs3 fc3 sc0 ls69 ws0">7.8.2<span class="_ _3b"> </span>F<span class="_ _b"></span>ailure after 14 days</div><div class="t m0 xb hb y467 ff9 fs8 fc3 sc0 ls50 ws1fa">Recurr<span class="_ _a"></span>ence of fever and parasitaemia more than 2 w<span class="_ _a"></span>eeks after treatment,</div><div class="t m0 xb hb y468 ff9 fs8 fc3 sc0 ls190 ws17c">which could result either from r<span class="_ _a"></span>ecrudescence or new infection, can be retreated</div><div class="t m0 xb hb y469 ff9 fs8 fc3 sc0 ls182 ws130">with the first-line ACT<span class="_ _4b"></span>. Parasitological confirmation is desirable but not a pre-</div><div class="t m0 xb hb y46a ff9 fs8 fc3 sc0 ls12 ws7f">condition. If it is a recrudescence, then the first-line treatment should still be</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf2a" class="pf w1 h4" data-page-no="2a"><div class="pc pc2a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">32</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls12 ws276">effective in most cases. <span class="_ _a"></span>This simplifies operational management and drug</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls12 ws1aa">deployment. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, reuse of mefloquine within 28 days of first treatment</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls13 ws135">is associated with an increased risk of neuropsy<span class="_ _a"></span>chiatric sequelae and, in this</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls12 ws277">particular case, second-line treatment should be given. If there is a further</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls12 ws9b">recurrence, then malaria should be confirmed par<span class="_ _a"></span>asitologically and second-</div><div class="t m0 x9 hb yc1 ff9 fs8 fc3 sc0 ls12 ws0">line treatment given. </div><div class="t m0 x9 h13 y46b ff8 fs3 fc3 sc0 ls80 ws0">7.8.3<span class="_ _18"> </span>R<span class="_ _b"></span>ecommended second-line antimalarial treatments</div><div class="t m0 x9 hb y39d ff9 fs8 fc3 sc0 ls191 ws278">On the basis of the evidence from current pr<span class="_ _a"></span>actice and the consensus opinion</div><div class="t m0 x9 hb y154 ff9 fs8 fc3 sc0 ls12 ws279">of the Guidelines Development Group<span class="_ _a"></span>, the following second-line treatments</div><div class="t m0 x9 hb y155 ff9 fs8 fc3 sc0 ls12 ws0">are recommended, in or<span class="_ _a"></span>der of preference: </div><div class="t m0 x9 hb y46c ff9 fs8 fc4 sc0 ls0 ws0">• <span class="fc3 ls12">alternative A<span class="_ _a"></span>CT known to be effectiv<span class="_ _a"></span>e in the region,</span></div><div class="t m0 x9 hb y46d ff9 fs8 fc4 sc0 ls0 ws0">• <span class="fc3 ls12">artesunate + tetracycline or doxycy<span class="_ _a"></span>cline or clindamycin,</span></div><div class="t m0 x9 hb y46e ff9 fs8 fc4 sc0 ls0 ws0">• <span class="fc3 ls12">quinine + tetracycline or do<span class="_ _a"></span>xycycline or clindamycin.</span></div><div class="t m0 x9 hb y46f ff9 fs8 fc3 sc0 ls192 ws27a">The alternative A<span class="_ _a"></span>CT has the adv<span class="_ _a"></span>antages of simplicity<span class="_ _4b"></span>, and where available, co-</div><div class="t m0 x9 hb y470 ff9 fs8 fc3 sc0 ls12 ws27b">formulation to impro<span class="_ _a"></span>ve adherence. <span class="_ _a"></span>The 7-day quinine regimes are not well</div><div class="t m0 x9 hb y471 ff9 fs8 fc3 sc0 ls12 ws0">tolerated and adherence is likely to be poor if tr<span class="_ _a"></span>eatment is not obser<span class="_ _8"></span>ved.</div><div class="t m0 x9 hd y472 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on second-line antimalarial treatment </div><div class="t m0 x9 hd y473 ff8 fs8 fc3 sc0 ls12 ws0">for uncomplicated falciparum malaria</div><div class="t m0 x9 h12 y474 ff10 fs6 fc4 sc0 ls9a ws0">7.9<span class="_ _78"> </span>T<span class="_ _c"></span>reatment in specific populat<span class="_ _8"></span>ions and situations </div><div class="t m0 x9 h13 y475 ff8 fs3 fc3 sc0 ls80 ws0">7.9.1<span class="_ _11"> </span>Pregnant women</div><div class="t m0 x9 hb y476 ff9 fs8 fc3 sc0 ls12 ws27c">Pregnant women with symptomatic acute malaria ar<span class="_ _a"></span>e a high-risk group, and</div><div class="t m0 x9 hb y477 ff9 fs8 fc3 sc0 ls102 ws50">must receive effectiv<span class="_ _a"></span>e antimalarials. Malaria in pregnancy is associated with low</div><div class="t m0 x9 hb y478 ff9 fs8 fc3 sc0 ls22 ws14d">birth weight, increased anaemia and, in low-transmission areas, an incr<span class="_ _a"></span>eased</div><div class="t m0 x47 h16 y479 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x68 h16 y47a ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x6d h16 y47b ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y47c ff9 fsb fc3 sc0 lsd2 ws0">Alternative A<span class="_ _a"></span>CT known to be effectiv<span class="_ _a"></span>e in the region.<span class="_ _94"> </span><span class="ff8 ls0">O</span></div><div class="t m3 x47 h17 y47d ff9 fsb fc3 sc0 ls170 ws27d">Artesunate (2 mg/kg bw once a day) + tetracycline (4 mg/kg bw four</div><div class="t m3 x47 h17 y47e ff9 fsb fc3 sc0 ls8 ws27e">times a day) or doxycy<span class="_ _a"></span>cline (3.5<span class="_ _5"> </span>mg/kg bw once a day) or clindamycin</div><div class="t m3 x47 h17 y47f ff9 fsb fc3 sc0 lsd8 ws27f">(10 mg/kg bw twice a day). Any of these combinations to be given</div><div class="t m3 x47 h17 y480 ff9 fsb fc3 sc0 lsd8 ws0">for 7 days.</div><div class="t m3 x30 h16 y47d ff8 fsb fc3 sc0 ls0 ws0">O</div><div class="t m3 x47 h17 y481 ff9 fsb fc3 sc0 ls193 ws280">Quinine (10<span class="_ _68"> </span>mg salt/kg bw three times a day) + tetr<span class="_ _a"></span>acycline or</div><div class="t m3 x47 h17 y482 ff9 fsb fc3 sc0 lsd2 ws281">doxycy<span class="_ _a"></span>cline or clindamycin. Any of these combinations to be given</div><div class="t m3 x47 h17 y483 ff9 fsb fc3 sc0 lsd8 ws0">for 7 days.</div><div class="t m3 x30 h16 y481 ff8 fsb fc3 sc0 ls0 ws0">O</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf2b" class="pf w1 h4" data-page-no="2b"><div class="pc pc2b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">33</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls194 ws282">risk of severe malaria. In high-tr<span class="_ _a"></span>ansmission settings, despite the adverse</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls12 ws1f">effects on fetal growth, malaria is usually asymptomatic in pr<span class="_ _a"></span>egnancy<span class="_ _4b"></span>. There</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls12 ws283">is insufficient information on the safety and efficacy of most antimalarials in</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls12 ws284">pregnancy<span class="_ _c"></span>, par<span class="_ _8"></span>ticularly for exposure in the first trimester<span class="_ _b"></span>, and so treatment</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls153 ws1c1">recommendations are differ<span class="_ _a"></span>ent to those for non-pregnant adults. Organogenesis</div><div class="t m0 xb hb yc1 ff9 fs8 fc3 sc0 ls12 ws285">occurs mainly in the first trimester and this is therefore the time of gr<span class="_ _a"></span>eatest</div><div class="t m0 xb hb y10d ff9 fs8 fc3 sc0 ls12 wsd2">concern for potential teratogenicity<span class="_ _c"></span>, although ner<span class="_ _8"></span>vous system development</div><div class="t m0 xb hb y10e ff9 fs8 fc3 sc0 ls126 ws1dc">continues throughout pregnancy<span class="_ _c"></span>. The antimalarials considered safe in the first</div><div class="t m0 xb hb y10f ff9 fs8 fc3 sc0 ls145 ws205">trimester of pregnancy are quinine, chlor<span class="_ _a"></span>oquine, proguanil, pyrimethamine and</div><div class="t m0 xb hb y110 ff9 fs8 fc3 sc0 lsd0 ws149">sulfadoxine–pyrimethamine. Of these, quinine remains the most effectiv<span class="_ _a"></span>e</div><div class="t m0 xb hb y111 ff9 fs8 fc3 sc0 ls5e ws7f">and can be used in all trimesters of pregnancy including the first trimester<span class="_ _4b"></span>. In</div><div class="t m0 xb hb y2be ff9 fs8 fc3 sc0 ls6b ws58">reality women often do not declare their pr<span class="_ _a"></span>egnancies in the first trimester and</div><div class="t m0 xb hb y2bf ff9 fs8 fc3 sc0 ls126 ws1dc">so, early pregnancies will often be exposed inadvertently to the available first-</div><div class="t m0 xb hb y484 ff9 fs8 fc3 sc0 ls12 ws286">line treatment. Inadvertent exposure to antimalarials is not an indication for</div><div class="t m0 xb hb y485 ff9 fs8 fc3 sc0 ls12 ws0">termination of the pregnancy<span class="_ _c"></span>. </div><div class="t m0 xb hb y2c2 ff9 fs8 fc3 sc0 ls24 ws26">There is increasing experience with artemisinin derivativ<span class="_ _a"></span>es in the second and</div><div class="t m0 xb hb y2c3 ff9 fs8 fc3 sc0 ls13 ws287">third trimesters (ov<span class="_ _a"></span>er 1000 documented pregnancies). <span class="_ _a"></span>There have been no</div><div class="t m0 xb hb y2c4 ff9 fs8 fc3 sc0 ls12 ws288">adverse effects on the mother or fetus. <span class="_ _a"></span>The current assessment of benefits</div><div class="t m0 xb hb y2c5 ff9 fs8 fc3 sc0 lsa2 ws102">compared with potential risks suggests that the artemisinin derivatives should</div><div class="t m0 xb hb y2c6 ff9 fs8 fc3 sc0 ls12 ws289">be used to treat uncomplicated falciparum malaria in the second and third</div><div class="t m0 xb hb y486 ff9 fs8 fc3 sc0 ls70 wsa2">trimesters of pregnancy<span class="_ _c"></span>, but should not be used in the first trimester until more</div><div class="t m0 xb hb y487 ff9 fs8 fc3 sc0 ls16e ws245">information becomes available. <span class="_ _b"></span>The choice of combination par<span class="_ _8"></span>tner is difficult.</div><div class="t m0 xb hb y488 ff9 fs8 fc3 sc0 ls12 ws28a">Mefloquine has been associated with an increased risk of stillbirth in large</div><div class="t m0 xb hb y489 ff9 fs8 fc3 sc0 ls26 ws2a">observational studies in Thailand, but not in Malawi. Amodiaquine, chlorpr<span class="_ _a"></span>o-</div><div class="t m0 xb hb y48a ff9 fs8 fc3 sc0 ls12 ws28b">guanil-dapsone, halofantrine, lumefantrine and piperaquine have not been</div><div class="t m0 xb hb y48b ff9 fs8 fc3 sc0 ls195 ws244">evaluated sufficiently to permit positiv<span class="_ _a"></span>e recommendations. Sulfadoxine–</div><div class="t m0 xb hb y48c ff9 fs8 fc3 sc0 ls196 ws119">pyrimethamine is safe but may be ineffective in many areas because of</div><div class="t m0 xb hb y48d ff9 fs8 fc3 sc0 ls197 ws28c">increasing resistance. Clindamy<span class="_ _a"></span>cin is also safe, but both medicines (clindamycin</div><div class="t m0 xb hb y48e ff9 fs8 fc3 sc0 ls12 ws28d">and the artemisinin par<span class="_ _8"></span>tner) must be given for 7 days. Primaquine and tetra-</div><div class="t m0 xb hb y48f ff9 fs8 fc3 sc0 ls12 ws0">cyclines should not be used in pregnancy<span class="_ _c"></span>. </div><div class="t m0 xb hb y490 ff9 fs8 fc3 sc0 ls64 ws28e">Despite these many uncertainties, effective treatment must not be delayed in</div><div class="t m0 xb hb y491 ff9 fs8 fc3 sc0 ls64 ws28f">pregnant women. Given the disadv<span class="_ _b"></span>antages of quinine, i.e. the long course of</div><div class="t m0 xb hb y492 ff9 fs8 fc3 sc0 ls64 ws290">treatment, and the increased risk of hypogly<span class="_ _a"></span>caemia in the second and third</div><div class="t m0 xb hb y493 ff9 fs8 fc3 sc0 ls64 ws291">trimesters, ACT<span class="_ _c"></span>s are considered suitable alternatives for these trimesters. In</div><div class="t m0 xb hb y494 ff9 fs8 fc3 sc0 ls64 ws292">practice, if first-line treatment with an artemisinin combination is all that is</div><div class="t m0 xb hb y495 ff9 fs8 fc3 sc0 ls1d ws293">immediately available to tr<span class="_ _a"></span>eat in the first trimester of pregnancy pregnant</div><div class="t m0 xb hb y496 ff9 fs8 fc3 sc0 ls64 ws294">women who have symptomatic malaria, then this should be giv<span class="_ _a"></span>en. Pharmaco-</div><div class="t m0 xb hb y497 ff9 fs8 fc3 sc0 ls64 ws295">vigilance programmes to document the outcome of pr<span class="_ _a"></span>egnancies where there</div><div class="t m0 xb hb y498 ff9 fs8 fc3 sc0 ls126 wsec">has been exposure to A<span class="_ _a"></span>CT<span class="_ _4b"></span>s, and if possible documentation of the development</div><div class="t m0 xb hb y499 ff9 fs8 fc3 sc0 ls64 ws296">of the infant, are encouraged so that futur<span class="_ _a"></span>e recommendations can stand on a</div><div class="t m0 xb hb y49a ff9 fs8 fc3 sc0 ls64 ws0">firmer footing.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf2c" class="pf w1 h4" data-page-no="2c"><div class="pc pc2c w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">34</div><div class="t m0 x9 hd y49b ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on the treatment of uncomplicated</div><div class="t m0 x9 hd y49c ff8 fs8 fc3 sc0 ls12 ws0">falciparum malaria in pregnancy</div><div class="t m0 x9 h19 y49d ff9 fsd fc3 sc0 ls198 ws0">a </div><div class="t m0 x46 h15 y49e ff9 fsa fc3 sc0 ls7d ws0">If clindamycin is unavailable or unaffor<span class="_ _a"></span>dable, then the monotherapy should be given.</div><div class="t m0 x9 h13 y49f ff8 fs3 fc3 sc0 ls80 ws0">7.9.2<span class="_ _18"> </span>Lactating women</div><div class="t m0 x9 hb y4a0 ff9 fs8 fc3 sc0 ls12 ws297">The amounts of antimalarials that enter breast milk and are ther<span class="_ _a"></span>efore likely</div><div class="t m0 x9 hb y4a1 ff9 fs8 fc3 sc0 ls13 ws9f">to be consumed by the breast-feeding infant are r<span class="_ _a"></span>elatively small. The only</div><div class="t m0 x9 hb y4a2 ff9 fs8 fc3 sc0 ls12 ws298">exception to this is dapsone, relativ<span class="_ _a"></span>ely large amounts of which are ex<span class="_ _a"></span>creted</div><div class="t m0 x9 hb y4a3 ff9 fs8 fc3 sc0 ls12 ws33">in breast milk (14% of the adult dose), and pending further data this should</div><div class="t m0 x9 hb y4a4 ff9 fs8 fc3 sc0 ls96 wsef">not be prescribed. <span class="_ _a"></span>T<span class="_ _4b"></span>etracyclines are also contraindicated because of their</div><div class="t m0 x9 hb y4a5 ff9 fs8 fc3 sc0 ls12 ws0">effect on the infant’<span class="_ _4b"></span>s bones and teeth.</div><div class="t m0 x47 h16 y4a6 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x68 h16 y4a7 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x6d h16 y4a8 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m8 x47 h1b y4a9 ff11 fsb fc3 sc0 lsd2 ws0">First trimester:</div><div class="t m3 x72 h17 y4a9 ff9 fsb fc3 sc0 lsd2 ws0">quinine + clindamycin</div><div class="t m3 x73 h1c y4aa ff9 fse fc3 sc0 ls0 ws0">a</div><div class="t m3 x74 h17 y4a9 ff9 fsb fc3 sc0 lsd8 ws19a">to be given for 7 days.</div><div class="t m3 x47 h17 y4ab ff9 fsb fc3 sc0 lsd2 ws0">ACT<span class="_ _6"> </span>should be used if it is the only effective treatment av<span class="_ _b"></span>ailable.</div><div class="t m3 x6f h16 y4ac ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m8 x47 h1b y4ad ff11 fsb fc3 sc0 ls199 ws23f">Second and third trimesters:</div><div class="t m3 x75 h17 y4ad ff9 fsb fc3 sc0 ls19a ws299">ACT<span class="_ _64"> </span>known to be effective in the</div><div class="t m3 x47 h17 y4ae ff9 fsb fc3 sc0 lsd2 ws29a">country/region or artesunate + clindamycin to be given for 7 days</div><div class="t m3 x47 h17 y4af ff9 fsb fc3 sc0 lsd2 ws0">or quinine + clindamycin to be given for 7 days.</div><div class="t m3 x6f h16 y4ad ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m0 x47 hd y4b0 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:<span class="_ _1"> </span>trials on the use of antimalarial medicines for the treatment</div><div class="t m0 x5f hd y4b1 ff8 fs8 fc0 sc0 ls12 ws0">of uncomplicated malaria in pregnant women</div><div class="t m0 x47 h1a y4b2 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x22 h1b y4b2 ff14 fsb fc3 sc0 lsd8 ws19a">oral AS+MQ, oral CQ alone, oral quinine, oral quinine +</div><div class="t m3 x47 h1b y4b3 ff14 fsb fc3 sc0 lsd2 ws0">clindamycin</div><div class="t m3 x24 h17 y4b4 ff14 fsb fc5 sc0 ls19b ws29b">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls19c ws1ff">four randomiz<span class="_ _a"></span>ed and two quasi-randomized trials with</span></div><div class="t m3 x24 h17 y4b5 ff9 fsb fc3 sc0 lsd2 ws29c">513 pregnant participants. There wer<span class="_ _a"></span>e fewer treatment failures with AS+MQ</div><div class="t m3 x24 h17 y4b6 ff9 fsb fc3 sc0 ls19d ws29d">than with quinine in one trial (day 63: RR: 0.09; 95% CI: 0.02–0.38; 106</div><div class="t m3 x24 h17 y4b7 ff9 fsb fc3 sc0 lsd2 ws29e">participants). Data for other comparisons are scant. Where trials r<span class="_ _a"></span>epor<span class="_ _8"></span>ted</div><div class="t m3 x24 h17 y4b8 ff9 fsb fc3 sc0 ls19e ws1ef">adverse outcomes, there w<span class="_ _a"></span>ere no differences reported between treatments in</div><div class="t m3 x24 h17 y4b9 ff9 fsb fc3 sc0 lsd2 ws0">terms of effect on the mother or the fetus.</div><div class="t m3 x24 h17 y4ba ff14 fsb fc5 sc0 ls19f ws29f">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 ls147">systematic summaries of safety suggest that the artemisinin</span></div><div class="t m3 x24 h17 y4bb ff9 fsb fc3 sc0 ls1a0 ws2a0">derivativ<span class="_ _a"></span>es are safe in the second and third trimesters of pregnancy<span class="_ _c"></span>. One large</div><div class="t m3 x24 h17 y4bc ff9 fsb fc3 sc0 ls1a1 ws2a1">observational study in Thailand suggests an incr<span class="_ _a"></span>eased risk of stillbir<span class="_ _8"></span>th associated</div><div class="t m3 x24 h17 y4bd ff9 fsb fc3 sc0 ls131 ws2a2">with MQ but this was not found in a study conducted in Malawi. Ther<span class="_ _a"></span>e are as</div><div class="t m3 x24 h17 y4be ff9 fsb fc3 sc0 ls131 ws24a">yet insufficient safety data about the use of artemisinin derivatives in the first</div><div class="t m3 x24 h17 y4bf ff9 fsb fc3 sc0 ls131 ws0">trimester of pregnancy<span class="_ _4b"></span>.</div><div class="t m3 x24 h17 y4c0 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">exper<span class="_ _8"></span>t opinion.</span></div><div class="t m0 x47 h16 y4c1 ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendations:</div><div class="t m3 x76 h17 y4c1 ff9 fsb fc3 sc0 lsd2 ws0">for the first trimester of pregnancy: quinine +/– clindamycin. </div><div class="t m3 x47 h17 y4c2 ff9 fsb fc3 sc0 lsd2 ws0">For second and thir<span class="_ _a"></span>d trimesters: </div><div class="t m7 x47 h16 y4c3 ff8 fsb fc3 sc0 ls13a ws0">1.</div><div class="t m3 x24 h17 y4c3 ff9 fsb fc3 sc0 lsd2 ws0">the ACT<span class="_ _6"> </span>being used in the country/region, or </div><div class="t m7 x47 h16 y4c4 ff8 fsb fc3 sc0 ls13a ws0">2.</div><div class="t m3 x24 h17 y4c4 ff9 fsb fc3 sc0 lsd2 ws0">artesunate + clindamycin, </div><div class="t m7 x47 h16 y4c5 ff8 fsb fc3 sc0 ls13a ws0">3.</div><div class="t m3 x24 h17 y4c5 ff9 fsb fc3 sc0 lsd2 ws0">quinine + clindamycin.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf2d" class="pf w1 h4" data-page-no="2d"><div class="pc pc2d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">35</div><div class="t m0 xb hd y9e ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on the treatment of uncomplicated</div><div class="t m0 xb hd y9f ff8 fs8 fc3 sc0 ls12 ws0">falciparum malaria in lactating women</div><div class="t m0 xb h13 y4c6 ff8 fs3 fc3 sc0 ls80 ws0">7.9.3<span class="_ _1a"> </span>Infants</div><div class="t m0 x77 h14 y4c7 ff11 fs5 fc4 sc0 ls1a2 ws0">12</div><div class="t m0 xb h1e y4c8 ff14 fs8 fc3 sc0 ls12 ws0">Choice of antimalarial drug</div><div class="t m0 xb hb y4c9 ff9 fs8 fc3 sc0 ls22 ws205">In endemic countries, malaria is common in infants and children under 2 years</div><div class="t m0 xb hb y4ca ff9 fs8 fc3 sc0 ls12 ws2a3">of age. Immunity acquired from the mother wanes after 3–6 months of age,</div><div class="t m0 xb hb y4cb ff9 fs8 fc3 sc0 ls12 ws253">and the case-fatality rate of sever<span class="_ _a"></span>e malaria in infants is higher than in older</div><div class="t m0 xb hb y4cc ff9 fs8 fc3 sc0 lsc0 ws17d">children. F<span class="_ _a"></span>ur<span class="_ _8"></span>thermore, there are important differences between infants <span class="lsea">and older</span></div><div class="t m0 xb hb y4cd ff9 fs8 fc3 sc0 ls1a3 ws2a4">children in the pharmacokinetics of many medicines. Accurate dosing is</div><div class="t m0 xb hb y4ce ff9 fs8 fc3 sc0 ls55 ws70">particularly impor<span class="_ _8"></span>tant in infants. Despite this, few clinical studies focus</div><div class="t m0 xb hb y4cf ff9 fs8 fc3 sc0 ls1a4 ws2a5">specifically on this age range, partly because of ethical considerations relating</div><div class="t m0 xb hb y4d0 ff9 fs8 fc3 sc0 ls12 ws2a6">to the recruitment of very young childr<span class="_ _a"></span>en to clinical trials, and also because</div><div class="t m0 xb hb y4d1 ff9 fs8 fc3 sc0 ls1a5 ws76">of the difficulty of repeated blood sampling. In the majority of clinical studies,</div><div class="t m0 xb hb y4d2 ff9 fs8 fc3 sc0 ls186 ws268">subgroup analysis is not used to distinguish between infants and older</div><div class="t m0 xb hb y4d3 ff9 fs8 fc3 sc0 ls1a6 ws2a7">children. Infants are mor<span class="_ _a"></span>e likely to vomit or regur<span class="_ _a"></span>gitate antimalarial treatment</div><div class="t m0 xb hb y4d4 ff9 fs8 fc3 sc0 lsef wsab">than older children or adults. <span class="_ _a"></span>T<span class="_ _4b"></span>aste, volume, consistency and gastrointestinal</div><div class="t m0 xb hb y4d5 ff9 fs8 fc3 sc0 ls1a7 ws2a8">tolerability are important determinants of whether the child retains the</div><div class="t m0 xb hb y4d6 ff9 fs8 fc3 sc0 ls14f ws133">treatment. Mothers often need advice on techniques of medicine administration</div><div class="t m0 xb hb y4d7 ff9 fs8 fc3 sc0 ls12 ws2a9">and the importance of administering the medicine again if it is immediately</div><div class="t m0 xb hb y4d8 ff9 fs8 fc3 sc0 ls1a8 ws2aa">regurgitated. <span class="_ _b"></span>With the increasing failure of chloroquine and sulfado<span class="_ _a"></span>xine–</div><div class="t m0 xb hb y4d9 ff9 fs8 fc3 sc0 ls12 ws2ab">pyrimethamine as front-line antimalarials, the challenge is now to find safe</div><div class="t m0 xb hb y4da ff9 fs8 fc3 sc0 ls1a9 ws262">alternatives in this age group<span class="_ _a"></span>. Fortunately the ar<span class="_ _8"></span>temisinin derivativ<span class="_ _a"></span>es appear</div><div class="t m0 xb hb y4db ff9 fs8 fc3 sc0 ls12 ws45">to be safe in, and well tolerated by young childr<span class="_ _a"></span>en, and so the choice of ACT</div><div class="t m0 xb hb y4dc ff9 fs8 fc3 sc0 ls13 ws2ac">will be determined largely by the safety and tolerability of the partner drug.</div><div class="t m0 xb hb y4dd ff9 fs8 fc3 sc0 ls12 ws2ad">The limited information available does not indicate particular problems with</div><div class="t m0 xb hb y4de ff9 fs8 fc3 sc0 ls12 ws0">currently recommended A<span class="_ _a"></span>CT<span class="_ _4b"></span>s in infancy<span class="_ _4b"></span>.</div><div class="t m0 xb h1e y4df ff14 fs8 fc3 sc0 ls12 ws0">Dosing</div><div class="t m0 xb hb y4e0 ff9 fs8 fc3 sc0 ls1aa ws15b">Although dosing based on body area is r<span class="_ _a"></span>ecommended for many drugs in</div><div class="t m0 xb hb y4e1 ff9 fs8 fc3 sc0 ls12 ws2ae">young children, for the sake of simplicity<span class="_ _c"></span>, dosing of antimalarials has been</div><div class="t m0 xb hb y4e2 ff9 fs8 fc3 sc0 ls12 ws205">traditionally based on weight. <span class="_ _a"></span>The weight-adjusted doses of antimalarials in</div><div class="t m0 x2d h16 y4e3 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TION</div><div class="t m0 x2f h16 y4e4 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x15 h16 y4e5 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y4e6 ff9 fsb fc3 sc0 lsd2 ws2af">Lactating women should receive standar<span class="_ _a"></span>d antimalarial treatment</div><div class="t m3 x2d h17 y4e7 ff9 fsb fc3 sc0 lscc ws2b0">(including ACT<span class="_ _c"></span>s) except for tetracyclines and dapsone, which should</div><div class="t m3 x2d h17 y4e8 ff9 fsb fc3 sc0 lsd2 ws0">be withheld during lactation.</div><div class="t m3 x4c h16 y4e6 ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m0 xb h14 y4e9 ff11 fs5 fc4 sc0 ls1a2 ws0">12</div><div class="t m0 x20 h15 y4ea ff9 fsa fc3 sc0 ls7d ws2b1">A detailed review of the available data on safety of antimalarials in infants is pr<span class="_ _a"></span>ovided in Annex 3,</div><div class="t m0 x20 h15 y4eb ff9 fsa fc3 sc0 ls14 ws2b2">section A3.17.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf2e" class="pf w1 h4" data-page-no="2e"><div class="pc pc2e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">36</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls12 wsc4">infants are similar to those used in adults. F<span class="_ _a"></span>or the majority of antimalarials,</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls12 ws2b3">howev<span class="_ _a"></span>er<span class="_ _b"></span>, the lack of an infant formulation necessitates the division of adult</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls12 ws2b4">tablets, which leads to inaccurate dosing. <span class="_ _a"></span>There is a need to develop infant</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls30 ws3e">formulations for a range of antimalarials in order to impr<span class="_ _a"></span>ove the accur<span class="_ _a"></span>acy and</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls12 ws0">reliability of dosing.</div><div class="t m0 x9 hb y18c ff9 fs8 fc3 sc0 ls5b ws1df">Delay in treating falciparum malaria may have fatal consequences, particularly</div><div class="t m0 x9 hb y18d ff9 fs8 fc3 sc0 ls10e ws5e">for more sever<span class="_ _a"></span>e infections. Every effort should be made to give oral treatment</div><div class="t m0 x9 hb y18e ff9 fs8 fc3 sc0 ls1ab ws12c">and ensure that it is retained. In situations wher<span class="_ _a"></span>e it is not possible to give</div><div class="t m0 x9 hb y18f ff9 fs8 fc3 sc0 ls16d ws6c">parenteral tr<span class="_ _a"></span>eatment, a sick infant who vomits antimalarial medicine treatment</div><div class="t m0 x9 hb y190 ff9 fs8 fc3 sc0 ls84 ws2b5">repeatedly<span class="_ _c"></span>, has a seizure or is too weak to swallow reliably should be giv<span class="_ _a"></span>en</div><div class="t m0 x9 hb y191 ff9 fs8 fc3 sc0 ls172 ws21">artesunate by the rectal route, pending transfer to a facility where par<span class="_ _a"></span>enteral</div><div class="t m0 x9 hb y192 ff9 fs8 fc3 sc0 ls84 ws2b6">treatment is possible. Large trials assessing the impact of this str<span class="_ _a"></span>ategy on</div><div class="t m0 x9 hb y193 ff9 fs8 fc3 sc0 ls84 ws22f">mortality have recently been undertaken in remote rural areas, but results</div><div class="t m0 x9 hb y2c0 ff9 fs8 fc3 sc0 ls8c ws137">are not yet av<span class="_ _a"></span>ailable. Pharmacological and trial evidence concerning the</div><div class="t m0 x9 hb y2c1 ff9 fs8 fc3 sc0 ls84 ws134">rectal administration of artesunate and other antimalarial drugs is provided</div><div class="t m0 x9 hb y2c2 ff9 fs8 fc3 sc0 ls84 ws14">in section 8.7.</div><div class="t m0 x9 hd y4ec ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on treatment of uncomplicated falciparum</div><div class="t m0 x9 hd y4ed ff8 fs8 fc3 sc0 ls12 ws0">malaria in infants and young children</div><div class="t m0 x9 h13 y4ee ff8 fs3 fc3 sc0 ls69 ws0">7.9.4<span class="_ _18"> </span>T<span class="_ _4b"></span>ravellers </div><div class="t m0 x9 hb y4ef ff9 fs8 fc3 sc0 ls1a6 ws2a7">T<span class="_ _b"></span>ravellers who acquire malaria ar<span class="_ _a"></span>e often non-immune adults either from cities</div><div class="t m0 x9 hb y4f0 ff9 fs8 fc3 sc0 ls12 ws101">with little or no transmission within endemic countries, or visitors from non-</div><div class="t m0 x9 hb y4f1 ff9 fs8 fc3 sc0 ls1ac ws2b7">endemic countries. Both are likely to be at a higher risk of malaria and its conse-</div><div class="t m0 x9 hb y4f2 ff9 fs8 fc3 sc0 ls4b wsbb">quences because they have no immunity to malaria. <span class="_ _a"></span>Within the malaria endemic</div><div class="t m0 x9 hb y4f3 ff9 fs8 fc3 sc0 ls1ad ws2b8">country they should in principle be treated according to national policy<span class="_ _c"></span>.</div><div class="t m0 x9 hb y4f4 ff9 fs8 fc3 sc0 ls12 ws2b9">T<span class="_ _b"></span>ravellers who return to a non-endemic country and then dev<span class="_ _a"></span>elop malaria</div><div class="t m0 x9 hb y4f5 ff9 fs8 fc3 sc0 ls12 ws2ba">present particular problems and, have a high case fatality rate. Doctors may</div><div class="t m0 x9 hb y4f6 ff9 fs8 fc3 sc0 ls12 ws2bb">be unfamiliar with malaria and the diagnosis may be delayed, relev<span class="_ _a"></span>ant anti-</div><div class="t m0 x9 hb y4f7 ff9 fs8 fc3 sc0 lsc1 ws149">malarials may not be registered and/or ther<span class="_ _a"></span>efore available. If the patient</div><div class="t m0 x9 hb y4f8 ff9 fs8 fc3 sc0 ls1ae ws2bc">falls ill far from a major health facility<span class="_ _c"></span>, availability of antimalarials can be a life-</div><div class="t m0 x9 hb y4f9 ff9 fs8 fc3 sc0 ls1af ws126">threatening issue despite registr<span class="_ _a"></span>ation. On the other hand prevention of</div><div class="t m0 x47 h16 y4fa ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x69 h16 y4fb ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x68 h16 y4fc ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y4fd ff9 fsb fc3 sc0 lsd2 ws2bd">The acutely ill child requires car<span class="_ _a"></span>eful clinical monitoring as they may</div><div class="t m3 x47 h17 y4fe ff9 fsb fc3 sc0 lsd2 ws1d4">deteriorate rapidly<span class="_ _c"></span>.</div><div class="t m3 x78 h16 y4fd ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x47 h17 y4ff ff9 fsb fc3 sc0 lsd2 ws2be">ACT<span class="_ _c"></span>s should be used as first-line treatment for infants and young</div><div class="t m3 x47 h17 y500 ff9 fsb fc3 sc0 lsd2 ws0">children.</div><div class="t m3 x6a h16 y4ff ff8 fsb fc3 sc0 lsd2 ws0">T<span class="_ _b"></span>, O, E</div><div class="t m3 x47 h17 y501 ff9 fsb fc3 sc0 ls131 ws2bf">Referral to a health centr<span class="_ _a"></span>e or hospital is indicated for young children</div><div class="t m3 x47 h17 y502 ff9 fsb fc3 sc0 lsd2 ws0">who cannot swallow antimalarials reliably<span class="_ _c"></span>.</div><div class="t m3 x78 h16 y501 ff8 fsb fc3 sc0 ls0 ws0">E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf2f" class="pf w1 h4" data-page-no="2f"><div class="pc pc2f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _64"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls2 ws0">37</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls1b0 ws2c0">emergence of resistance and tr<span class="_ _a"></span>ansmission are of less relev<span class="_ _a"></span>ance outside</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls12 ws14">malaria endemic areas. <span class="_ _a"></span>Thus monotherapy may be given if it can be assured</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls12 ws2c1">to be effective. F<span class="_ _a"></span>ur<span class="_ _8"></span>thermore cost of treatment is usually not a limiting factor<span class="_ _4b"></span>.</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls7a wsb7">The principles underlying the recommendations given belo<span class="_ _a"></span>w are that effective</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls1b1 ws269">medicines should be used to treat trav<span class="_ _a"></span>ellers; if the patient has taken</div><div class="t m0 xb hb yc1 ff9 fs8 fc3 sc0 ls1b2 ws1a4">chemoprophylaxis, then the same medicine should not be used for treatment.</div><div class="t m0 xb hb y10d ff9 fs8 fc3 sc0 ls12 ws2c2">The treatment for <span class="ffa ls14 ws0">P<span class="_ _c"></span>. viv<span class="_ _b"></span>ax<span class="ff9">, </span><span class="ls38">P.<span class="_ _3"> </span>o v a<span class="_ _67"> </span>l e<span class="_ _7c"> </span><span class="ff9 ls12">and </span><span class="ls13">P<span class="_ _c"></span>. malariae<span class="_ _6"> </span><span class="ff9 ls12 ws2c2">in trav<span class="_ _a"></span>ellers should be the</span></span></span></span></div><div class="t m0 xb hb y10e ff9 fs8 fc3 sc0 ls12 ws2c3">same as for these infections in patients from endemic areas (see section 9). </div><div class="t m0 xb hb y18f ff9 fs8 fc3 sc0 ls12 ws2c4">In the management of severe malaria outside endemic ar<span class="_ _a"></span>eas, there may be</div><div class="t m0 xb hb y190 ff9 fs8 fc3 sc0 ls1b3 ws28">delays in obtaining artesunate, ar<span class="_ _8"></span>temether or quinine. If parenteral quinidine</div><div class="t m0 xb hb y191 ff9 fs8 fc3 sc0 ls4d ws6d">is available but other par<span class="_ _a"></span>enteral drugs are not, then this should be given</div><div class="t m0 xb hb y192 ff9 fs8 fc3 sc0 ls12 ws0">with careful clinical and electrocar<span class="_ _a"></span>diographic monitoring (see section 8).</div><div class="t m0 x2d hd y503 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:  treatment of uncomplicated malaria in trav<span class="_ _a"></span>ellers returning to</div><div class="t m0 x14 hd y504 ff8 fs8 fc0 sc0 ls12 ws0">non-endemic areas</div><div class="t m0 x2d h1a y505 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y505 ff14 fsb fc3 sc0 lsd2 ws0">atov<span class="_ _a"></span>aquone–proguanil, halofantrine, quinine, quinine +</div><div class="t m3 x2d h1b y506 ff14 fsb fc3 sc0 lsd8 ws0">clindamycin, artemether<span class="_ _a"></span>-lumefantrine</div><div class="t m3 x38 h17 y507 ff14 fsb fc5 sc0 ls104 ws152">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 lsd8 ws2c5">three RCT<span class="_ _a"></span>S (total 259 patients) report effective treatment</span></div><div class="t m3 x38 h17 y508 ff9 fsb fc3 sc0 ls1b4 ws2c6">with all interventions listed although the ar<span class="_ _8"></span>temether<span class="_ _a"></span>-lumefantrine regimen was</div><div class="t m3 x38 h17 y509 ff9 fsb fc3 sc0 ls1b5 ws2c7">only 4 doses and therefore less effectiv<span class="_ _a"></span>e. In one trial using halofantrine</div><div class="t m3 x38 h17 y50a ff9 fsb fc3 sc0 lsd2 ws0">significant prolongation of the QT<span class="_ _6"> </span>inter<span class="_ _8"></span>val was noted.</div><div class="t m3 x38 h17 y50b ff14 fsb fc5 sc0 ls1b6 ws20e">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 ls1b7 ws1e9">halofantrine is not recommended because of significant</span></div><div class="t m3 x38 h17 y50c ff9 fsb fc3 sc0 lsd2 ws0">cardiotoxicity compar<span class="_ _a"></span>ed to other treatments.</div><div class="t m3 x38 h17 y50d ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd8 ws19a">RCT<span class="_ _4b"></span>s and exper<span class="_ _8"></span>t opinion.</span></div><div class="t m0 x2d h16 y50e ff8 fsb fc4 sc0 ls118 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x44 h17 y50e ff9 fsb fc3 sc0 ls11e ws2c8">the following antimalarials are suitable for use in tr<span class="_ _a"></span>avellers</div><div class="t m3 x2d h17 y50f ff9 fsb fc3 sc0 lsd2 ws0">returning to non-endemic countries:</div><div class="t m3 x4d h17 y510 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _5a"> </span>ar<span class="_ _8"></span>temether<span class="_ _a"></span>-lumefantrine (6-dose regimen), </div><div class="t m3 x4d h17 y511 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _5a"> </span>atovaquone–pr<span class="_ _a"></span>oguanil,</div><div class="t m3 x4d h17 y512 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _5a"> </span>quinine + doxycycline or clindamycin. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf30" class="pf w1 h4" data-page-no="30"><div class="pc pc30 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls2 ws0">38</div><div class="t m0 x9 hd y9e ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on the treatment of falciparum malaria</div><div class="t m0 x9 hd y9f ff8 fs8 fc3 sc0 ls12 ws0">in non-immune travellers</div><div class="t m0 x9 h19 y513 ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x14 h15 y514 ff9 fsa fc3 sc0 ls1b8 ws2c9">Halofantrine is not recommended as first-line treatment for uncomplicated malaria because of</div><div class="t m0 x14 h15 y515 ff9 fsa fc3 sc0 ls7d ws0">cardiotoxicity<span class="_ _4b"></span>.</div><div class="t m0 x9 h19 y516 ff9 fsd fc3 sc0 ls0 ws0">b</div><div class="t m0 x14 h15 y517 ff9 fsa fc3 sc0 ls7d ws0">Doxycycline should not be used in childr<span class="_ _a"></span>en under 8 years of age.</div><div class="t m0 x9 h12 y518 ff10 fs6 fc4 sc0 lsc3 ws139">7.10<span class="_ _1a"> </span>Coexisting mor<span class="_ _8"></span>bidities</div><div class="t m0 x9 h13 y519 ff8 fs3 fc3 sc0 ls80 ws0">7.10.1<span class="_ _1d"> </span>HIV infection</div><div class="t m0 x2b h14 y51a ff11 fs5 fc4 sc0 ls1a2 ws0">13</div><div class="t m0 x9 hb y51b ff9 fs8 fc3 sc0 ls64 ws2ca">Increasing numbers of people in malaria endemic areas ar<span class="_ _a"></span>e living with H<span class="_ _8"></span>IV</div><div class="t m0 x9 hb y51c ff9 fs8 fc3 sc0 ls64 ws2cb">infection. It is becoming increasingly apparent that, as HIV progresses and</div><div class="t m0 x9 hb y51d ff9 fs8 fc3 sc0 ls64 ws2cc">immunosuppression worsens, the manifestations of malaria also worsen. In</div><div class="t m0 x9 hb y51e ff9 fs8 fc3 sc0 lsb8 ws206">pregnant women, the adverse effects on birth weight are increased. In patients</div><div class="t m0 x9 hb y51f ff9 fs8 fc3 sc0 ls1b9 ws1d">with partial immunity to malaria, the severity of the infection is increased. Ther<span class="_ _a"></span>e</div><div class="t m0 x9 hb y520 ff9 fs8 fc3 sc0 ls1ba ws2cd">is insufficient information at the present time on how HIV infection modifies the</div><div class="t m0 x9 hb y521 ff9 fs8 fc3 sc0 ls64 ws2ce">therapeutic response to antimalarials. Ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, increasing parasite burdens</div><div class="t m0 x9 hb y522 ff9 fs8 fc3 sc0 ls64 ws26b">and reduced host immunity<span class="_ _c"></span>, both of which occur with H<span class="_ _8"></span>IV infection, are asso-</div><div class="t m0 x9 hb y523 ff9 fs8 fc3 sc0 ls64 ws2bc">ciated with increased treatment failur<span class="_ _a"></span>e rates. At this time, there is insufficient</div><div class="t m0 x47 h16 y524 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x68 h16 y525 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x6d h16 y526 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y527 ff9 fsb fc3 sc0 lsd2 ws0">For tr<span class="_ _a"></span>avellers returning to non-endemic countries:</div><div class="t m3 x79 h1c y528 ff9 fse fc3 sc0 ls0 ws0">a</div><div class="t m3 x7a h17 y529 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _67"> </span>atov<span class="_ _a"></span>aquone–proguanil (15/6 mg/kg, usual adult dose,</div><div class="t m3 x7b h17 y52a ff9 fsb fc3 sc0 lsd2 ws0">4 tablets once a day for 3 days);</div><div class="t m3 x7a h17 y52b ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _67"> </span>artemether–lumefantrine (adult dose, 4 tablets twice a day for</div><div class="t m3 x7b h17 y52c ff9 fsb fc3 sc0 lsd8 ws0">3 days);</div><div class="t m3 x7a h17 y52d ff9 fsb fc3 sc0 lsd8 ws19a">–<span class="_ _67"> </span>quinine (10 mg salt/kg bw every 8<span class="_ _64"> </span>h) + do<span class="_ _a"></span>xycycline</div><div class="t m3 x6e h1c y52e ff9 fse fc3 sc0 ls0 ws0">b</div><div class="t m3 x7b h17 y52f ff9 fsb fc3 sc0 lsd8 ws19a">(3.5 mg/kg bw once a day) or clindamycin (10<span class="_ _95"> </span>mg/kg bw twice</div><div class="t m3 x7b h17 y530 ff9 fsb fc3 sc0 lsd2 ws0">a day); all drugs to be given for 7 days </div><div class="t m3 x6f h16 y531 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m3 x47 h17 y532 ff9 fsb fc3 sc0 lsd8 ws19a">For sev<span class="_ _a"></span>ere malaria:</div><div class="t m3 x7a h17 y533 ff9 fsb fc3 sc0 ls1bb ws2cf">–<span class="_ _67"> </span>the antimalarial treatment of sever<span class="_ _a"></span>e malaria in travellers is the</div><div class="t m3 x7b h17 y534 ff9 fsb fc3 sc0 lsd2 ws0">same as shown in section 8;</div><div class="t m3 x7a h17 y535 ff9 fsb fc3 sc0 ls1bc ws2d0">– trav<span class="_ _a"></span>ellers with severe malaria should be managed in an intensiv<span class="_ _a"></span>e</div><div class="t m3 x7b h17 y536 ff9 fsb fc3 sc0 lsd2 ws0">care unit;</div><div class="t m3 x7a h17 y537 ff9 fsb fc3 sc0 ls11e ws2c8">–<span class="_ _67"> </span>haemofiltration or haemodialysis should be started early in</div><div class="t m3 x7b h17 y538 ff9 fsb fc3 sc0 lsd2 ws0">acute renal failure or sev<span class="_ _a"></span>ere metabolic acidosis;</div><div class="t m3 x7a h17 y539 ff9 fsb fc3 sc0 ls134 ws2d1">–<span class="_ _67"> </span>positive pressur<span class="_ _a"></span>e ventilation should be started early if there is</div><div class="t m3 x7b h17 y53a ff9 fsb fc3 sc0 ls1bd ws2d2">any breathing pattern abnormality<span class="_ _4b"></span>, intractable seizure or acute</div><div class="t m3 x7b h17 y53b ff9 fsb fc3 sc0 lsd8 ws0">respiratory distress syndr<span class="_ _a"></span>ome.</div><div class="t m3 x6f h16 y532 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m0 x9 h14 y53c ff11 fs5 fc4 sc0 ls1a2 ws0">13</div><div class="t m0 x14 h15 y53d ff9 fsa fc3 sc0 ls7d ws0">Further information on malaria treatment and HIV/AI<span class="_ _8"></span>DS is provided in Annex 8.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf31" class="pf w1 h4" data-page-no="31"><div class="pc pc31 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _95"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">39</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls1be ws1fb">information to modify the general malaria treatment r<span class="_ _a"></span>ecommendations for</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 lsa5 ws2d3">patients with HIV/AI<span class="_ _8"></span>DS. Current U<span class="_ _8"></span>NAI<span class="_ _8"></span>DS/WHO recommendations on the</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls1bf ws235">prophylaxis of opportunistic infections with cotrimoxazole (trimethoprim-</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls4d ws2d4">sulfamethoxazole) in people living with HIV/AI<span class="_ _8"></span>DS remain unchanged (see</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls1c0 ws2d5">below). How<span class="_ _a"></span>ever<span class="_ _4b"></span>, treatment with sulfadoxine–pyrimethamine should not be given</div><div class="t m0 xb hb yc1 ff9 fs8 fc3 sc0 ls1c1 ws2d6">to patients on cotrimoxazole as ther<span class="_ _a"></span>e is probably an increased risk of sulfa-related</div><div class="t m0 xb hb y10d ff9 fs8 fc3 sc0 ls64 ws92">adverse effects (and in any case as both medicines hav<span class="_ _a"></span>e similar antimalarial</div><div class="t m0 xb hb y10e ff9 fs8 fc3 sc0 ls64 ws2d7">activity<span class="_ _4b"></span>, the malaria infection is likely to be resistant to sulfadoxine–pyrime-</div><div class="t m0 xb hb y10f ff9 fs8 fc3 sc0 ls17c ws2d8">thamine). Depending on the malaria transmission setting, HIV<span class="_ _a"></span>-infected</div><div class="t m0 xb hb y110 ff9 fs8 fc3 sc0 ls9f ws2d9">individuals are at increased risk of asymptomatic par<span class="_ _a"></span>asitaemia, clinical malaria</div><div class="t m0 xb hb y111 ff9 fs8 fc3 sc0 ls1a5 ws262">or severe and complicated malaria. <span class="_ _b"></span>Therefore, they have an even gr<span class="_ _a"></span>eater need</div><div class="t m0 xb hb y2be ff9 fs8 fc3 sc0 ls64 ws0">for malaria control measures than individuals not infected with HIV<span class="_ _4b"></span>. </div><div class="t m0 xb hd y53e ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of the recommendations on treatment of uncomplicated</div><div class="t m0 xb hd y53f ff8 fs8 fc3 sc0 ls12 ws0">falciparum malaria in patients with HIV infection</div><div class="t m0 x2d h16 y540 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x2f h16 y541 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x15 h16 y542 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y543 ff9 fsb fc3 sc0 ls19a ws299">Patients with HIV infection who develop malaria should receive</div><div class="t m3 x2d h17 y544 ff9 fsb fc3 sc0 lsd2 ws2da">standard antimalarial treatment r<span class="_ _a"></span>egimens as recommended in the</div><div class="t m3 x2d h17 y545 ff9 fsb fc3 sc0 lsd2 ws0">relev<span class="_ _a"></span>ant sections of the guidelines.</div><div class="t m3 x4c h16 y543 ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x2d h17 y546 ff9 fsb fc3 sc0 lsd2 ws2db">T<span class="_ _b"></span>reatment or intermittent preventiv<span class="_ _a"></span>e treatment with sulfadoxine-</div><div class="t m3 x2d h17 y547 ff9 fsb fc3 sc0 ls1c2 ws2dc">pyrimethamine should not be given to HIV<span class="_ _a"></span>-infected patients receiving</div><div class="t m3 x2d h17 y548 ff9 fsb fc3 sc0 lsd2 ws0">cotrimoxazole (trimethoprim-sulfametho<span class="_ _a"></span>xazole) prophylaxis.</div><div class="t m3 x4c h16 y546 ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m0 x2d hd y549 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:  treatment of malaria in patients co-infected with HIV</div><div class="t m0 x2d h1e y54a ffb fsb fc4 sc0 lsd2 ws0">Interventions: <span class="ff14 fs8 fc3 ls1c3 ws2dd">oral A<span class="_ _a"></span>CT<span class="_ _4b"></span>s, oral SP</span></div><div class="t m3 x38 h17 y54b ff14 fsb fc5 sc0 ls104 ws1d3">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 lsd2 ws0">none.</span></div><div class="t m3 x38 h17 y54c ff14 fsb fc5 sc0 ls130 ws2de">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 lsd2">observational studies suggest that malaria is more sev<span class="_ _a"></span>ere</span></div><div class="t m3 x38 h17 y54d ff9 fsb fc3 sc0 ls1c4 ws2df">in patients co-infected with HIV<span class="_ _b"></span>. There is concern that sev<span class="_ _a"></span>ere adverse reactions</div><div class="t m3 x38 h17 y54e ff9 fsb fc3 sc0 ls1c5 ws2e0">to sulfonamides may be more frequent in HIV patients receiving cotrimoxazole</div><div class="t m3 x38 h17 y54f ff9 fsb fc3 sc0 ls1c6 ws2e1">(trimethoprim-sulfamethoxazole) for pr<span class="_ _a"></span>ophylaxis against oppor<span class="_ _8"></span>tunistic</div><div class="t m3 x38 h17 y550 ff9 fsb fc3 sc0 lsd2 ws0">infections who are treated with SP<span class="_ _6"> </span>for malaria.</div><div class="t m3 x38 h17 y551 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">exper<span class="_ _8"></span>t opinion.</span></div><div class="t m0 x2d h16 y552 ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y552 ff9 fsb fc3 sc0 lsd2 ws2e2">there is insufficient evidence to recommend modifications to</div><div class="t m3 x2d h17 y553 ff9 fsb fc3 sc0 lsd2 ws0">antimalarial treatment regimens in patients infected with HIV<span class="_ _4b"></span>.</div><div class="t m3 x2d h17 y554 ff9 fsb fc3 sc0 ls1c7 ws2e3">SP should be avoided for malaria tr<span class="_ _a"></span>eatment in H<span class="_ _8"></span>IV<span class="_ _b"></span>-infected patients receiving</div><div class="t m3 x2d h17 y555 ff9 fsb fc3 sc0 lsd2 ws0">cotrimoxazole pr<span class="_ _a"></span>ophylaxis. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf32" class="pf w1 h4" data-page-no="32"><div class="pc pc32 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">40</div><div class="t m0 x9 h13 y296 ff8 fs3 fc3 sc0 ls80 ws0">7.10.2<span class="_ _54"> </span>Severe malnutrition</div><div class="t m0 x9 hb y297 ff9 fs8 fc3 sc0 ls12 ws2e4">Malaria and malnutrition frequently coexist. <span class="_ _a"></span>There are only a few studies of</div><div class="t m0 x9 hb y298 ff9 fs8 fc3 sc0 ls1a5 ws76">antimalarial medicine disposition in people with malnutrition, although many</div><div class="t m0 x9 hb y299 ff9 fs8 fc3 sc0 ls12 ws2e5">antimalarial drug efficacy studies have been conducted in populations and</div><div class="t m0 x9 hb y29a ff9 fs8 fc3 sc0 ls13 ws2e6">settings where malnutrition was prev<span class="_ _b"></span>alent (see Annex 3, section A3.17.2). </div><div class="t m0 x9 h1e y556 ff14 fs8 fc3 sc0 ls12 ws0">Changes in drug kinetics in malnutrition</div><div class="t m0 x9 hb y557 ff9 fs8 fc3 sc0 ls12 ws238">Drug absorption may be reduced owing to diarrhoea and v<span class="_ _a"></span>omiting, rapid gut</div><div class="t m0 x9 hb y558 ff9 fs8 fc3 sc0 ls12 ws2e7">transit and atrophy of the bo<span class="_ _a"></span>wel mucosa. Absorption of intramuscular and</div><div class="t m0 x9 hb y559 ff9 fs8 fc3 sc0 ls12 ws2e8">possibly intrarectal drugs may be slo<span class="_ _a"></span>wer and diminished muscle mass may</div><div class="t m0 x9 hb y55a ff9 fs8 fc3 sc0 ls8e wsdd">make it difficult to administer repeated intramuscular injections. <span class="_ _b"></span>The volume</div><div class="t m0 x9 hb y55b ff9 fs8 fc3 sc0 ls12 ws2e9">of distribution of some drugs would be expected to be larger and plasma</div><div class="t m0 x9 hb y55c ff9 fs8 fc3 sc0 ls28 ws34">concentrations low<span class="_ _a"></span>er<span class="_ _b"></span>. Hypoalbuminaemia, resulting from decr<span class="_ _a"></span>eased synthesis</div><div class="t m0 x9 hb y55d ff9 fs8 fc3 sc0 ls3c ws31">as dietary deficiency occurs, could lead to an increase in the concentration of</div><div class="t m0 x9 hb y55e ff9 fs8 fc3 sc0 lsae ws118">unbound drug; this may increase metabolic clearance, but hepatic dysfunction</div><div class="t m0 x9 hb y55f ff9 fs8 fc3 sc0 ls12 ws0">may reduce the metabolism of some drugs.</div><div class="t m0 x9 h1e y560 ff14 fs8 fc3 sc0 ls12 ws0">Antimalarial drugs and protein energy malnutrition</div><div class="t m0 x9 hb y561 ff9 fs8 fc3 sc0 ls1c8 ws2ea">There are limited studies of the effect of malnutrition on chlor<span class="_ _a"></span>oquine, doxycycline,</div><div class="t m0 x9 hb y562 ff9 fs8 fc3 sc0 ls12 wsaa">quinine, sulfadoxine–pyrimethamine and tetracy<span class="_ _a"></span>cline, and not all of these</div><div class="t m0 x9 hb y563 ff9 fs8 fc3 sc0 ls22 ws5e">studies were conducted in patients with malaria. <span class="_ _a"></span>There is insufficient evidence</div><div class="t m0 x9 hb y564 ff9 fs8 fc3 sc0 ls88 wsce">to suggest that the dosages in mg/kg bw of any antimalarial should be</div><div class="t m0 x9 hb y565 ff9 fs8 fc3 sc0 ls12 ws0">changed in patients with malnutrition. </div><div class="t m0 x9 hb y566 ff9 fs8 fc3 sc0 ls12 ws181">There are no studies in malnourished patients of amodiaquine, artemisinin</div><div class="t m0 x9 hb y567 ff9 fs8 fc3 sc0 ls1c9 ws137">derivativ<span class="_ _a"></span>es, ar<span class="_ _8"></span>temether<span class="_ _b"></span>-lumefantrine, atovaquone–proguanil, clindamy<span class="_ _a"></span>cin,</div><div class="t m0 x9 hb y568 ff9 fs8 fc3 sc0 ls12 ws0">mefloquine or primaquine.</div><div class="t m0 x9 hd y569 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of the recommendations on treatment of uncomplicated</div><div class="t m0 x9 hd y56a ff8 fs8 fc3 sc0 ls12 ws0">falciparum malaria in malnourished patients</div><div class="t m0 x47 h16 y56b ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TION </div><div class="t m0 x68 h16 y56c ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x6d h16 y56d ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y56e ff9 fsb fc3 sc0 ls1ca ws20a">Although there ar<span class="_ _a"></span>e many reasons why drug kinetics may be different</div><div class="t m3 x47 h17 y56f ff9 fsb fc3 sc0 ls1cb ws2eb">in malnourished patients as compared with those who are well</div><div class="t m3 x47 h17 y570 ff9 fsb fc3 sc0 lsd2 ws2de">nourished, there is insufficient evidence to change current mg/kg</div><div class="t m3 x47 h17 y571 ff9 fsb fc3 sc0 lsd2 ws0">bw dosing recommendations.</div><div class="t m3 x7c h16 y56e ff8 fsb fc3 sc0 ls0 ws0">E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf33" class="pf w1 h4" data-page-no="33"><div class="pc pc33 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x18 he y9 ffc fs5 fc3 sc0 ls101 ws17a">7.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of uncomplicated <span class="ffd ls3 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _95"> </span><span class="ffc lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">41</div><div class="t m0 xb hf y7d ffe fs6 fc3 sc0 ls1 ws17a">8.<span class="_ _33"> </span>TR<span class="_ _8"></span>EA<span class="_ _a"></span>TMENT OF SEVERE FAL<span class="_ _b"></span>CI<span class="_ _8"></span>P<span class="_ _b"></span>ARU<span class="_ _8"></span>M MALAR<span class="_ _8"></span>IA</div><div class="t m0 x7d h14 y572 ff11 fs5 fc4 sc0 ls9a ws0">14</div><div class="t m0 xb h12 y573 ff10 fs6 fc4 sc0 lsc3 ws0">8.1<span class="_ _78"> </span>Definition</div><div class="t m0 xb hb y574 ff9 fs8 fc3 sc0 lsf7 ws1ad">In a patient with <span class="ffa ws0">P<span class="_ _c"></span>. falciparum <span class="ff9 ws1ad">asexual parasitaemia and no other obvious cause</span></span></div><div class="t m0 xb hb y575 ff9 fs8 fc3 sc0 ls12 ws2ec">of their symptoms, the presence of one or more of the follo<span class="_ _a"></span>wing clinical or</div><div class="t m0 xb hb y576 ff9 fs8 fc3 sc0 ls12 ws2c3">laboratory features classifies the patient as suffering from sev<span class="_ _a"></span>ere malaria</div><div class="t m0 x7e h14 y577 ff11 fs5 fc4 sc0 ls9a ws0">15</div><div class="t m0 x69 hb y576 ff9 fs8 fc3 sc0 ls0 ws0">:</div><div class="t m0 xb hb y578 ff14 fs8 fc3 sc0 ls12 ws0">Clinical manifestation:<span class="_ _4c"> </span>– <span class="ff9">Pr<span class="_ _a"></span>ostration</span></div><div class="t m0 x7f hb y579 ff9 fs8 fc3 sc0 ls12 ws0">– Impaired consciousness</div><div class="t m0 x7f hb y57a ff9 fs8 fc3 sc0 ls12 ws0">– Respir<span class="_ _a"></span>atory distress (acidotic breathing)</div><div class="t m0 x7f hb y57b ff9 fs8 fc3 sc0 ls12 ws0">– Multiple convulsions</div><div class="t m0 x7f hb y57c ff9 fs8 fc3 sc0 ls12 ws0">– Circulatory collapse</div><div class="t m0 x7f hb y57d ff9 fs8 fc3 sc0 ls14 ws15">– Pulmonary oedema (radiological)</div><div class="t m0 x7f hb y57e ff9 fs8 fc3 sc0 ls12 ws0">– Abnormal bleeding</div><div class="t m0 x7f hb y57f ff9 fs8 fc3 sc0 ls12 ws0">– Jaundice</div><div class="t m0 x7f hb y580 ff9 fs8 fc3 sc0 ls12 ws0">– Haemoglobinuria</div><div class="t m0 xb hb y581 ff14 fs8 fc3 sc0 ls13 ws14">Laboratory test:<span class="_ _96"> </span>– <span class="ff9 ls14 ws15">Severe anaemia</span></div><div class="t m0 x7f hb y582 ff9 fs8 fc3 sc0 ls12 ws81">– Hypoglycaemia</div><div class="t m0 x7f hb y583 ff9 fs8 fc3 sc0 ls12 ws0">– Acidosis</div><div class="t m0 x7f hb y584 ff9 fs8 fc3 sc0 ls12 ws0">– Renal impairment</div><div class="t m0 x7f hb y585 ff9 fs8 fc3 sc0 ls12 ws81">– Hyperlactataemia</div><div class="t m0 x7f hb y586 ff9 fs8 fc3 sc0 ls12 ws81">– Hyperparasitaemia</div><div class="t m0 xb h12 y587 ff10 fs6 fc4 sc0 ls0 wsca">8.2<span class="_ _78"> </span>T<span class="_ _c"></span>reatment objectives</div><div class="t m0 xb hb y588 ff9 fs8 fc3 sc0 ls182 ws130">The main objective is to prev<span class="_ _a"></span>ent the patient from dying, secondary objectives</div><div class="t m0 xb hb y589 ff9 fs8 fc3 sc0 ls22 ws5e">are prev<span class="_ _a"></span>ention of recrudescence, transmission or emer<span class="_ _a"></span>gence of resistance and</div><div class="t m0 xb hb y58a ff9 fs8 fc3 sc0 ls12 ws0">prevention of disabilities. </div><div class="t m0 xb hb y58b ff9 fs8 fc3 sc0 ls1c8 ws72">The mortality of untreated severe malaria is thought to approach 100%. <span class="_ _b"></span>With anti-</div><div class="t m0 xb hb y58c ff9 fs8 fc3 sc0 ls1cc wsb8">malarial treatment the mortality falls to 15–20% over<span class="_ _a"></span>all, although within the broad</div><div class="t m0 xb hb y58d ff9 fs8 fc3 sc0 ls1cd ws2ed">definition are syndromes associated with mortality rates that are lo<span class="_ _a"></span>wer (e.g. severe</div><div class="t m0 xb hb y58e ff9 fs8 fc3 sc0 ls6a ws2ee">anaemia) and higher (metabolic acidosis). Death from sever<span class="_ _a"></span>e malaria often</div><div class="t m0 xb hb y58f ff9 fs8 fc3 sc0 ls22 ws93">occurs within hours of admission to hospital or clinic, and so it is essential that</div><div class="t m0 xb hb y590 ff9 fs8 fc3 sc0 ls22 ws263">therapeutic concentrations of antimalarial ar<span class="_ _a"></span>e achieved as soon as possible. </div><div class="t m0 xb h14 y591 ff11 fs5 fc4 sc0 ls9a ws0">14</div><div class="t m0 x20 h15 y592 ff9 fsa fc3 sc0 ls7d ws0">Further information is provided in Annex 9. </div><div class="t m0 xb h14 y593 ff11 fs5 fc4 sc0 ls1ce ws0">15</div><div class="t m0 x20 h15 y594 ff9 fsa fc3 sc0 ls1cf ws2ef">Full details of the definition and prognostic factors ar<span class="_ _a"></span>e provided in<span class="_ _5"> </span>WHO Severe falciparum malaria.</div><div class="t m0 x20 h15 y595 ffa fsa fc3 sc0 ls1d0 ws2f0">T<span class="_ _b"></span>ransactions of the Royal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff9">, 2000:94(Suppl. 1):1–90, and</span></div><div class="t m0 x20 h15 y596 ffa fsa fc3 sc0 ls16b ws2f1">Management of severe malaria: a practical handbook<span class="_ _a"></span><span class="ff9">, 2nd ed. Geneva, W<span class="_ _a"></span>orld Health Organization, 2000.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf34" class="pf w1 h4" data-page-no="34"><div class="pc pc34 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">42</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls1d1 ws131">Management of severe malaria comprises four main ar<span class="_ _a"></span>eas: clinical assessment</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls1d2 wsd7">of the patient, specific antimalarial treatment, adjunctive ther<span class="_ _a"></span>apy and suppor<span class="_ _8"></span>tive</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls13 ws0">care. </div><div class="t m0 x9 h12 y24c ff10 fs6 fc4 sc0 ls9a ws95">8.3<span class="_ _78"> </span>Clinic<span class="_ _8"></span>al assessment</div><div class="t m0 x9 hb y24d ff9 fs8 fc3 sc0 ls1d3 ws2f2">Severe malaria is a medical emer<span class="_ _a"></span>gency<span class="_ _4b"></span>. The airway should be secured in</div><div class="t m0 x9 hb y597 ff9 fs8 fc3 sc0 ls12 ws282">unconscious patients and breathing and circulation assessed. <span class="_ _a"></span>The patient</div><div class="t m0 x9 hb y598 ff9 fs8 fc3 sc0 ls167 ws2f3">should be weighed or body weight estimated so that drugs, including</div><div class="t m0 x9 hb y599 ff9 fs8 fc3 sc0 ls12 ws5e">antimalarials and fluids can be given on a body weight basis. An intr<span class="_ _a"></span>avenous</div><div class="t m0 x9 hb y59a ff9 fs8 fc3 sc0 ls12 ws29">cannula should be inserted and immediate measurements of blood glucose</div><div class="t m0 x9 hb y59b ff9 fs8 fc3 sc0 ls39 ws4e">(stick test), haematocrit/haemoglobin, parasitaemia and, in adults, renal</div><div class="t m0 x9 hb y59c ff9 fs8 fc3 sc0 ls70 wsa2">function should be taken. A detailed clinical examination should be conducted,</div><div class="t m0 x9 hb y59d ff9 fs8 fc3 sc0 lsb9 ws128">with particular note of the level of consciousness and record of the coma score.</div><div class="t m0 x9 hb y59e ff9 fs8 fc3 sc0 ls1d4 ws2f4">Several coma scor<span class="_ _a"></span>es have been advocated. <span class="_ _a"></span>The Glasgow coma scale is suitable</div><div class="t m0 x9 hb y59f ff9 fs8 fc3 sc0 ls0 ws45">for adults, and the simple Blantyre modification or children<span class="_ _b"></span>’<span class="_ _b"></span>s Glasgow coma</div><div class="t m0 x9 hb y5a0 ff9 fs8 fc3 sc0 ls12 ws1c6">scale are easily performed in children. Unconscious patients should hav<span class="_ _a"></span>e a</div><div class="t m0 x9 hb y5a1 ff9 fs8 fc3 sc0 ls1d5 ws1a0">lumbar puncture for cerebr<span class="_ _a"></span>ospinal fluid analysis to exclude bacterial meningitis. </div><div class="t m0 x9 hb y5a2 ff9 fs8 fc3 sc0 ls12 ws2f5">The degree of acidosis is an important determinant of outcome; the plasma</div><div class="t m0 x9 hb y5a3 ff9 fs8 fc3 sc0 ls16e ws245">bicarbonate or venous lactate lev<span class="_ _a"></span>el should therefore be measured if possible.</div><div class="t m0 x9 hb y5a4 ff9 fs8 fc3 sc0 ls12 ws2f6">If facilities are av<span class="_ _a"></span>ailable, ar<span class="_ _8"></span>terial or capillary blood pH and gases should be</div><div class="t m0 x9 hb y5a5 ff9 fs8 fc3 sc0 ls1d6 ws2f7">measured in patients who are unconscious, hyperventilating or in shock.</div><div class="t m0 x9 hb y5a6 ff9 fs8 fc3 sc0 ls12 ws2f8">Blood should be taken for cross-match, and (if possible) full blood count,</div><div class="t m0 x9 hb y5a7 ff9 fs8 fc3 sc0 ls16e ws245">platelet count, clotting studies, blood culture and full biochemistry should be</div><div class="t m0 x9 hb y5a8 ff9 fs8 fc3 sc0 ls1d7 ws2f9">conducted. The assessment of fluid balance is critical in sev<span class="_ _a"></span>ere malaria.</div><div class="t m0 x9 hb y5a9 ff9 fs8 fc3 sc0 ls1d8 ws173">Respir<span class="_ _a"></span>atory distress, in par<span class="_ _8"></span>ticular with acidotic breathing in sever<span class="_ _a"></span>ely anaemic</div><div class="t m0 x9 hb y5aa ff9 fs8 fc3 sc0 lsba wsb1">children, often indicates hypo<span class="_ _a"></span>volaemia and requires pr<span class="_ _a"></span>ompt rehydration and,</div><div class="t m0 x9 hb y5ab ff9 fs8 fc3 sc0 ls13 ws14">where indicated, blood transfusion (see also section 8.10.3).</div><div class="t m0 x9 h12 y5ac ff10 fs6 fc4 sc0 ls9a ws0">8.4<span class="_ _78"> </span>Sp<span class="_ _8"></span>ecific antimalarial t<span class="_ _8"></span>reatment</div><div class="t m0 x9 hb y5ad ff9 fs8 fc3 sc0 ls12 ws2fa">It is essential that antimalarial treatment in full doses is given as soon as</div><div class="t m0 x9 hb y5ae ff9 fs8 fc3 sc0 ls18b ws2fb">possible in severe malaria. <span class="_ _b"></span>T<span class="_ _b"></span>wo classes of drugs are currently available for the</div><div class="t m0 x9 hb y5af ff9 fs8 fc3 sc0 ls12 ws19d">parenteral tr<span class="_ _a"></span>eatment of severe malaria: the cinchona alkaloids (quinine and</div><div class="t m0 x9 hb y5b0 ff9 fs8 fc3 sc0 ls187 ws1fd">quinidine) and the artemisinin derivatives (artesunate, ar<span class="_ _8"></span>temether and</div><div class="t m0 x9 hb y5b1 ff9 fs8 fc3 sc0 ls30 ws3e">artemotil). Although there are a few areas where chlor<span class="_ _a"></span>oquine is still effective,</div><div class="t m0 x9 hb y5b2 ff9 fs8 fc3 sc0 ls1d9 ws18c">parenteral chlor<span class="_ _a"></span>oquine is no longer recommended for the treatment of sever<span class="_ _a"></span>e</div><div class="t m0 x9 hb y5b3 ff9 fs8 fc3 sc0 ls1da ws2fc">malaria because of widespread resistance. Intr<span class="_ _a"></span>amuscular sulfadoxine–</div><div class="t m0 x9 hb y5b4 ff9 fs8 fc3 sc0 ls12 ws0">pyrimethamine is also not recommended. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf35" class="pf w1 h4" data-page-no="35"><div class="pc pc35 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">43</div><div class="t m0 xb h13 y296 ff8 fs3 fc3 sc0 ls80 ws0">8.4.1<span class="_ _18"> </span>Quinine</div><div class="t m0 xb hb y297 ff9 fs8 fc3 sc0 ls12 ws2fd">Quinine treatment for sever<span class="_ _a"></span>e malaria was established before modern trial</div><div class="t m0 xb hb y298 ff9 fs8 fc3 sc0 ls64 ws10d">methods were dev<span class="_ _a"></span>eloped. Several salts of quinine hav<span class="_ _a"></span>e been formulated for</div><div class="t m0 xb hb y299 ff9 fs8 fc3 sc0 ls18b wsfa">parenteral use, but the dihy<span class="_ _a"></span>drochloride is the most widely used. Peak concen-</div><div class="t m0 xb hb y29a ff9 fs8 fc3 sc0 lsaa ws93">trations following intr<span class="_ _a"></span>amuscular quinine in severe malaria ar<span class="_ _a"></span>e similar to those</div><div class="t m0 xb hb y29b ff9 fs8 fc3 sc0 lsab ws2fe">following intrav<span class="_ _a"></span>enous infusion. Pharmacokinetic modelling studies suggest that</div><div class="t m0 xb hb y29c ff9 fs8 fc3 sc0 lsd1 ws118">a loading dose of quinine of twice the maintenance dose (i.e. 20 mg salt/kg<span class="_ _5"> </span>bw)</div><div class="t m0 xb hb y29d ff9 fs8 fc3 sc0 ls1db ws2ff">reduces the time to reach ther<span class="_ _a"></span>apeutic plasma concentrations. After the first day</div><div class="t m0 xb hb y29e ff9 fs8 fc3 sc0 ls64 wsdc">of treatment, the total daily maintenance dose of quinine is 30 mg salt/kg bw</div><div class="t m0 xb hb y5b5 ff9 fs8 fc3 sc0 ls64 ws0">(usually divided into three equal administrations at 8 h inter<span class="_ _8"></span>vals).</div><div class="t m0 x2d hd y5b6 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:  trials on dosage and route of administration of quinine</div><div class="t m0 x33 h1f y5b7 ff8 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x2d h1a y5b8 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y5b8 ff14 fsb fc3 sc0 lsd2 ws0">high first dose of quinine (loading dose 20 mg/kg bw) compared</div><div class="t m3 x2d h1b y5b9 ff14 fsb fc3 sc0 lsd2 ws0">with non-loading dose regimen</div><div class="t m3 x38 h17 y5ba ff14 fsb fc5 sc0 ls1dc ws300">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls1dd ws301">a systematic review of two small trials sho<span class="_ _a"></span>wed shorter</span></div><div class="t m3 x38 h17 y5bb ff9 fsb fc3 sc0 lsd2 ws302">parasite and fever clear<span class="_ _a"></span>ance time with high first-dose regimens but the trials</div><div class="t m3 x38 h17 y5bc ff9 fsb fc3 sc0 lsd2 ws0">were too small to sho<span class="_ _a"></span>w an impact on mor<span class="_ _8"></span>tality<span class="_ _4b"></span>.</div><div class="t m3 x38 h17 y5bd ff14 fsb fc5 sc0 ls1de ws20b">Pharmacokinetic studies: <span class="ff9 fc3 ls148">a 20 mg salt/kg bw loading dose results in effective</span></div><div class="t m3 x38 h17 y5be ff9 fsb fc3 sc0 lsd8 ws303">blood levels of quinine being reached by the end of a 4-h infusion or within</div><div class="t m3 x38 h17 y5bf ff9 fsb fc3 sc0 ls1df ws304">4 h of i.m. administration. If a loading dose is not given, therapeutic concentra-</div><div class="t m3 x38 h17 y5c0 ff9 fsb fc3 sc0 lsd8 ws19a">tions may not be reached in the first 12 h of treatment.</div><div class="t m3 x38 h17 y5c1 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">pharmacokinetic studies.</span></div><div class="t m0 x2d h16 y5c2 ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y5c2 ff9 fsb fc3 sc0 lsd2 ws0">use a loading dose of quinine of 20 mg salt/kg bw<span class="_ _a"></span>.</div><div class="t m0 x2d h1a y5c3 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y5c3 ff14 fsb fc3 sc0 lsd8 ws19a">quinine i.m. compared with quinine by i.v<span class="_ _4b"></span>. infusion</div><div class="t m3 x38 h17 y5c4 ff14 fsb fc5 sc0 ls104 ws305">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 lsd2 ws306">one small trial of limited pow<span class="_ _a"></span>er did not demonstrate large</span></div><div class="t m3 x38 h17 y5c5 ff9 fsb fc3 sc0 lsd8 ws0">differences.</div><div class="t m3 x38 h17 y5c6 ff14 fsb fc5 sc0 ls130 ws307">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 lsd2">peak plasma concentrations are similar for both routes of</span></div><div class="t m3 x38 h17 y5c7 ff9 fsb fc3 sc0 lsd2 ws308">administration. How<span class="_ _a"></span>ever<span class="_ _b"></span>, quinine i.m. may be erratically absorbed in sev<span class="_ _a"></span>ere</div><div class="t m3 x38 h17 y5c8 ff9 fsb fc3 sc0 lsd2 ws0">malaria, particularly in patients with shock.</div><div class="t m3 x38 h17 y5c9 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">pharmacokinetic studies.</span></div><div class="t m0 x2d h16 y5ca ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y5ca ff9 fsb fc3 sc0 lsd2 ws309">rate-controlled i.v<span class="_ _4b"></span>. infusion is the preferred route of quinine</div><div class="t m3 x2d h17 y5cb ff9 fsb fc3 sc0 ls1e0 ws30a">administration, but if this cannot be given safely<span class="_ _c"></span>, then i.m. injection is a satisfactory</div><div class="t m3 x2d h17 y5cc ff9 fsb fc3 sc0 lsd2 ws0">alternative.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf36" class="pf w1 h4" data-page-no="36"><div class="pc pc36 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">44</div><div class="t m0 x9 h19 y5cd ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x46 h15 y5ce ff9 fsa fc3 sc0 lsac ws115">See also Annex 9.1–9.3.</div><div class="t m0 x9 h13 y5cf ff8 fs3 fc3 sc0 ls69 ws1b0">8.4.2<span class="_ _13"> </span>Artemisinin derivativ<span class="_ _a"></span>es</div><div class="t m0 x9 hb y5d0 ff9 fs8 fc3 sc0 ls3c ws1ee">V<span class="_ _b"></span>arious ar<span class="_ _8"></span>temisinin derivativ<span class="_ _a"></span>es have been used in the treatment of sev<span class="_ _a"></span>ere</div><div class="t m0 x9 hb y5d1 ff9 fs8 fc3 sc0 ls17d ws30b">malaria including artemether<span class="_ _b"></span>, ar<span class="_ _8"></span>temisinin (rectal), artemotil and ar<span class="_ _8"></span>tesunate. The</div><div class="t m0 x9 hb y5d2 ff9 fs8 fc3 sc0 ls64 ws262">pharmacokinetic properties of ar<span class="_ _8"></span>tesunate are superior to those of artemether</div><div class="t m0 x9 hb y5d3 ff9 fs8 fc3 sc0 ls64 ws30c">and artemotil as it is water soluble and can be given either by intravenous or</div><div class="t m0 x9 hb y5d4 ff9 fs8 fc3 sc0 ls1e1 ws2a">intramuscular injection. Randomised trials comparing artesunate and quinine</div><div class="t m0 x9 hb y5d5 ff9 fs8 fc3 sc0 ls64 ws30d">from South-East Asia show clear evidence of benefit with artesunate. In the</div><div class="t m0 x9 hb y5d6 ff9 fs8 fc3 sc0 ls1a6 ws30e">largest multi-centre trial, which enr<span class="_ _a"></span>olled 1461 patients (including 202 children</div><div class="t m0 x9 hb y5d7 fff fs8 fc3 sc0 ls0 ws0">&lt;<span class="ff9 lsc1 ws1c2">15 years old), mortality was reduced by 34.7% compared to the quinine</span></div><div class="t m0 x9 hb y5d8 ff9 fs8 fc3 sc0 ls64 ws30f">group<span class="_ _a"></span>. The results of this and smaller trials ar<span class="_ _a"></span>e consistent and suggest that</div><div class="t m0 x9 hb y5d9 ff9 fs8 fc3 sc0 ls64 ws0">artesunate is the treatment of choice for adults with severe malaria. </div><div class="t m0 x9 hb y5da ff9 fs8 fc3 sc0 ls12 ws310">There are, ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, still insufficient data for children, par<span class="_ _8"></span>ticularly from high</div><div class="t m0 x9 hb y5db ff9 fs8 fc3 sc0 ls2e ws3c">transmission settings to make the same conclusion. An individual patient</div><div class="t m0 x9 hb y5dc ff9 fs8 fc3 sc0 ls12 ws311">data meta-analysis of trials comparing artemether and quinine showed no</div><div class="t m0 x9 hb y5dd ff9 fs8 fc3 sc0 ls12 ws0">difference in mortality in African children. </div><div class="t m0 x9 hb y5de ff9 fs8 fc3 sc0 ls14e ws1a6">Although artesunate has better pharmacokinetic proper<span class="_ _8"></span>ties than artemether</div><div class="t m0 x9 hb y5df ff9 fs8 fc3 sc0 ls1e2 ws3d">or artemotil, there are relatively few published compar<span class="_ _a"></span>ative clinical trials.</div><div class="t m0 x9 hb y5e0 ff9 fs8 fc3 sc0 ls126 ws1dc">Concerns have been raised, r<span class="_ _a"></span>egarding the possibility that the intrinsic benefits</div><div class="t m0 x9 hb y5e1 ff9 fs8 fc3 sc0 ls1e1 ws312">of artemether as an antimalarial may have been negated by its erratic absorp-</div><div class="t m0 x9 hb y5e2 ff9 fs8 fc3 sc0 ls13c ws189">tion following intramuscular injection. Artemotil is very similar to artemether<span class="_ _b"></span>,</div><div class="t m0 x9 hb y5e3 ff9 fs8 fc3 sc0 ls12 ws0">but very few trials have been conducted.</div><div class="t m0 x47 h1a y5e4 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x22 h1b y5e4 ff14 fsb fc3 sc0 lsd8 ws19a">quinine, rectal compared with quinine by i.m or i.v<span class="_ _4b"></span>. infusion</div><div class="t m3 x24 h17 y5e5 ff14 fsb fc5 sc0 ls104 ws2c6">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 lsd2 ws1d7">one systematic review of 8 trials detected no differ<span class="_ _a"></span>ence in</span></div><div class="t m3 x24 h17 y5e6 ff9 fsb fc3 sc0 lsd2 ws313">effect on parasites, clinical illness between the rectal gr<span class="_ _a"></span>oup and either i.m or</div><div class="t m3 x24 h17 y5e7 ff9 fsb fc3 sc0 lsd2 ws314">i.v<span class="_ _b"></span>. groups. Some studies ho<span class="_ _a"></span>wever excluded patients with sev<span class="_ _a"></span>ere malaria.</div><div class="t m3 x24 h17 y5e8 ff14 fsb fc5 sc0 ls1e3 ws1ef">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 ls1e4">quinine dihydrochloride is locally irritant, quinine gluconate</span></div><div class="t m3 x24 h17 y5e9 ff9 fsb fc3 sc0 lsd2 ws0">is less irritant.</div><div class="t m3 x24 h17 y5ea ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">systematic review<span class="_ _b"></span>.</span></div><div class="t m0 x47 h16 y5eb ff8 fsb fc4 sc0 ls109 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x81 h17 y5eb ff9 fsb fc3 sc0 ls1e5 ws315">there is insufficient evidence to recommend r<span class="_ _a"></span>ectal administration</div><div class="t m3 x47 h17 y5ec ff9 fsb fc3 sc0 lsd2 ws316">of quinine unless parenteral administr<span class="_ _a"></span>ation is not possible and no other effective</div><div class="t m3 x47 h17 y5ed ff9 fsb fc3 sc0 lsd2 ws0">options are av<span class="_ _a"></span>ailable.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf37" class="pf w1 h4" data-page-no="37"><div class="pc pc37 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">45</div><div class="t m0 x2d hd y5ee ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:  trials of treatment of sever<span class="_ _a"></span>e malaria with ar<span class="_ _8"></span>temisinin</div><div class="t m0 x14 hd y5ef ff8 fs8 fc0 sc0 ls12 ws0">derivativ<span class="_ _a"></span>es compared to quinine</div><div class="t m0 x73 h1f y5f0 ff8 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x2d h1a y4b2 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y4b2 ff14 fsb fc3 sc0 lsd2 ws0">AS i.v<span class="_ _b"></span>. compared with quinine i.v<span class="_ _b"></span>. infusion</div><div class="t m3 x38 h17 y5f1 ff14 fsb fc5 sc0 ls1e6 ws317">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls1e7 ws318">multi-centre trials enr<span class="_ _a"></span>olling 1461 patients, with mor<span class="_ _8"></span>tality in</span></div><div class="t m3 x38 h17 y5f2 ff9 fsb fc3 sc0 lsd2 ws319">the AS vs QN being 15% vs 22%. There was a relativ<span class="_ _a"></span>e reduction in mortality</div><div class="t m3 x38 h17 y5f3 ff9 fsb fc3 sc0 ls147 ws31a">of 34.7% (95% CI: 18.5–47.6%; <span class="ffa ls0 ws0">p <span class="fff">=<span class="_ _6"> </span></span></span><span class="ls1e8 ws31b">0.002) in the AS group. QN was associated</span></div><div class="t m3 x38 h17 y5f4 ff9 fsb fc3 sc0 lsd2 ws31c">with hypoglycaemia (RR: 3.2, <span class="ffa ls0 ws0">p <span class="fff">=<span class="_ _95"> </span></span></span>0.009). Clear evidence of mortality benefit</div><div class="t m3 x38 h17 y5f5 ff9 fsb fc3 sc0 lsd2 ws0">with artesunate.</div><div class="t m3 x38 h17 y5f6 ff14 fsb fc5 sc0 ls130 ws31d">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 lsd2">trials mainly in Asian adults, more information needed in</span></div><div class="t m3 x38 h17 y5f7 ff9 fsb fc3 sc0 ls1e9 ws31e">children in higher transmission settings. <span class="_ _a"></span>There are no RCT<span class="_ _c"></span>s comparing A<span class="_ _8"></span>S with</div><div class="t m3 x38 h17 y5f8 ff9 fsb fc3 sc0 lsd2 ws0">artemether i.m.</div><div class="t m3 x38 h17 y5f9 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 ls11d">RCT</span></div><div class="t m0 x2d h16 y5fa ff8 fsb fc4 sc0 ls1ea ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x44 h17 y5fa ff9 fsb fc3 sc0 ls1ea ws31f">AS is the recommended first choice in areas of low-malaria</div><div class="t m3 x2d h17 y5fb ff9 fsb fc3 sc0 lsd2 ws0">transmission.</div><div class="t m0 x2d h1a y5fc ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y5fc ff14 fsb fc3 sc0 lsd2 ws0">artemether i.m. compared with quinine i.v<span class="_ _b"></span>. infusion</div><div class="t m3 x38 h17 y5fd ff14 fsb fc5 sc0 ls1e0 ws320">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls1eb ws321">systematic review of 11 RCT<span class="_ _c"></span>s; analysis across all trials</span></div><div class="t m3 x38 h17 y5fe ff9 fsb fc3 sc0 lsd2 ws322">showed lo<span class="_ _a"></span>wer mor<span class="_ _8"></span>tality with artemether<span class="_ _b"></span>, but this was not significant in an</div><div class="t m3 x38 h17 y5ff ff9 fsb fc3 sc0 lsd2 ws323">analysis of adequately concealed trials (RR: 0.8; 95% CI: 0.52–1.25). W<span class="_ _a"></span>ithin</div><div class="t m3 x38 h17 y600 ff9 fsb fc3 sc0 lsd2 ws20c">these, in an individual patient data analysis of 1919 adults and children, the</div><div class="t m3 x38 h17 y601 ff9 fsb fc3 sc0 ls1ec ws324">odds ratio for deaths in artemether recipients was 0.8 (95% CI: 0.62–1.02). In the</div><div class="t m3 x38 h17 y602 ff9 fsb fc3 sc0 lsd2 ws325">prospectively defined subgr<span class="_ _a"></span>oup analysis of adults with multisystem failure,</div><div class="t m3 x38 h17 y603 ff9 fsb fc3 sc0 lsd2 ws0">there was a significant difference in mortality in favour of artemether<span class="_ _b"></span>.</div><div class="t m3 x38 h17 y604 ff14 fsb fc5 sc0 ls130 ws326">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 lsd2">ar<span class="_ _8"></span>temether i.m. is erratically absorbed in sever<span class="_ _a"></span>e malaria</span></div><div class="t m3 x38 h17 y605 ff9 fsb fc3 sc0 lsd2 ws0">particularly in patients with shock.</div><div class="t m3 x38 h17 y606 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2 ws1d4">systematic review<span class="_ _b"></span>.</span></div><div class="t m0 x2d h16 y607 ff8 fsb fc4 sc0 ls1ed ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x82 h17 y607 ff9 fsb fc3 sc0 ls1ee ws327">artemether i.m. is an acceptable alternative to quinine i.v<span class="_ _b"></span>.</div><div class="t m3 x2d h17 y608 ff9 fsb fc3 sc0 lsd2 ws0">infusion.</div><div class="t m0 x2d h1a y609 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y609 ff14 fsb fc3 sc0 lsd8 ws19a">artemotil i.m. compared with quinine by i.v<span class="_ _b"></span>. infusion</div><div class="t m3 x38 h17 y60a ff14 fsb fc5 sc0 ls104 ws328">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 lsd2 ws329">systematic review of two trials; the trials had insufficient</span></div><div class="t m3 x38 h17 y60b ff9 fsb fc3 sc0 lsd2 ws0">power to sho<span class="_ _a"></span>w a difference.</div><div class="t m3 x38 h17 y60c ff14 fsb fc5 sc0 ls1ef ws32a">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 ls1f0 ws32b">insufficient clinical trials and pharmacokinetic data to</span></div><div class="t m3 x38 h17 y60d ff9 fsb fc3 sc0 lsd2 ws0">warrant a recommendation.</div><div class="t m3 x38 h17 y60e ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2 ws1d4">systematic review<span class="_ _b"></span>.</span></div><div class="t m0 x2d h16 y60f ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y60f ff9 fsb fc3 sc0 lsd2 ws0">do not use artemotil unless alternatives are not available.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf38" class="pf w1 h4" data-page-no="38"><div class="pc pc38 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">46</div><div class="t m0 x9 h19 y610 ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x46 h15 y611 ff9 fsa fc3 sc0 lsac ws115">See also Annex 9.4–9.7.</div><div class="t m0 x9 h13 y612 ff8 fs3 fc3 sc0 ls80 ws0">8.4.3<span class="_ _13"> </span>Quinidine</div><div class="t m0 x9 hb y613 ff9 fs8 fc3 sc0 ls157 ws32c">Quinidine commonly causes hypotension and concentration-dependent</div><div class="t m0 x9 hb y614 ff9 fs8 fc3 sc0 ls18b wsfa">prolongation of ventricular r<span class="_ _a"></span>epolarization (QT prolongation). Quinidine is thus</div><div class="t m0 x9 hb y615 ff9 fs8 fc3 sc0 ls1f1 ws12f">considered more to<span class="_ _a"></span>xic than quinine and should only be used if none of the other</div><div class="t m0 x9 hb y616 ff9 fs8 fc3 sc0 ls64 ws32d">effective parenter<span class="_ _a"></span>al drugs are available. Electr<span class="_ _a"></span>ocardiographic monitoring and</div><div class="t m0 x9 hb y617 ff9 fs8 fc3 sc0 ls64 ws0">frequent assessment of vital signs are r<span class="_ _a"></span>equired if quinidine is used.</div><div class="t m0 x9 hd y618 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on the treatment of sev<span class="_ _a"></span>ere malaria</div><div class="t m0 x47 h16 y619 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x83 h16 y61a ff8 fsb fc0 sc0 lsd2 ws0">LEVEL<span class="_ _67"> </span>OF</div><div class="t m0 x6d h16 y61b ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y61c ff9 fsb fc3 sc0 lsd8 ws19a">Severe malaria is a medical emer<span class="_ _a"></span>gency<span class="_ _4b"></span>. </div><div class="t m3 x47 h17 y61d ff9 fsb fc3 sc0 lsd2 ws32e">After rapid clinical assessment and confirmation of the diagnosis,</div><div class="t m3 x47 h17 y61e ff9 fsb fc3 sc0 lsd2 ws32f">full doses of parenteral antimalarial tr<span class="_ _a"></span>eatment should be star<span class="_ _8"></span>ted</div><div class="t m3 x47 h17 y61f ff9 fsb fc3 sc0 ls11c ws330">without delay with whichever effective antimalarial is first av<span class="_ _b"></span>ailable.</div><div class="t m3 x30 h16 y61c ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x47 h17 y620 ff9 fsb fc3 sc0 ls149 ws2d1">Artesunate 2.4<span class="_ _5"> </span>mg/kg bw i.v<span class="_ _b"></span>. or i.m. given on admission (time =<span class="_ _5"> </span>0),</div><div class="t m3 x47 h17 y621 ff9 fsb fc3 sc0 lsd8 ws331">then at 12 h and 24<span class="_ _95"> </span>h, then once a day is the recommended choice</div><div class="t m3 x47 h17 y622 ff9 fsb fc3 sc0 lsd2 ws0">in low transmission ar<span class="_ _a"></span>eas or outside malaria endemic areas</div><div class="t m3 x30 h16 y620 ff8 fsb fc3 sc0 ls0 ws0">S</div><div class="t m3 x47 h17 y623 ff9 fsb fc3 sc0 lsd2 ws332">For childr<span class="_ _a"></span>en in high transmission areas, the following antimalarial</div><div class="t m3 x47 h17 y624 ff9 fsb fc3 sc0 ls1f2 ws24e">medicines are recommended as ther<span class="_ _a"></span>e is insufficient evidence to</div><div class="t m3 x47 h17 y625 ff9 fsb fc3 sc0 lsd2 ws333">recommend any of these antimalarial medicines ov<span class="_ _a"></span>er another for</div><div class="t m3 x47 h17 y626 ff9 fsb fc3 sc0 lsd8 ws19a">severe malaria:</div><div class="t m3 x7a h17 y627 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _67"> </span>artesunate 2.4<span class="_ _95"> </span>mg/kg bw i.v<span class="_ _b"></span>. or i.m. given on admission</div><div class="t m3 x7b h17 y628 ff9 fsb fc3 sc0 lsd8 ws19a">(time = 0), then at 12 h and 24<span class="_ _95"> </span>h, then once a day;</div><div class="t m3 x7a h17 y629 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _67"> </span>artemether 3.2 mg/kg bw i.m. given on admission then</div><div class="t m3 x7b h17 y62a ff9 fsb fc3 sc0 lsd2 ws0">1.6 mg/kg bw per day;</div><div class="t m3 x7a h17 y62b ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _67"> </span>quinine 20 mg salt/kg bw on admission (i.v<span class="_ _b"></span>. infusion or</div><div class="t m3 x7b h17 y62c ff9 fsb fc3 sc0 lsd8 ws19a">divided i.m. injection), then 10 mg/kg bw every 8 h; infusion</div><div class="t m3 x7b h17 y62d ff9 fsb fc3 sc0 lsd2 ws0">rate should not exceed 5 mg salt/kg bw per hour<span class="_ _4b"></span>.</div><div class="t m3 x69 h16 y623 ff8 fsb fc3 sc0 lsd8 ws19a">S, T<span class="_ _4b"></span>, O, E</div><div class="t m0 x47 h1a y5e4 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x22 h1b y5e4 ff14 fsb fc3 sc0 lsd8 ws19a">artemisinin derivatives, rectal, compar<span class="_ _a"></span>ed with quinine by i.v<span class="_ _b"></span>.</div><div class="t m3 x47 h1b y62e ff14 fsb fc3 sc0 lsd2 ws0">infusion</div><div class="t m3 x24 h17 y62f ff14 fsb fc5 sc0 ls179 ws334">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls1f3 ws335">systematic review of thr<span class="_ _a"></span>ee trials; the trials had insufficient</span></div><div class="t m3 x24 h17 y630 ff9 fsb fc3 sc0 lsd2 ws0">power to sho<span class="_ _a"></span>w a difference. </div><div class="t m3 x24 h17 y631 ff9 fsb fc3 sc0 ls1f4 ws336">Howev<span class="_ _a"></span>er<span class="_ _b"></span>, rectal artesunate has superior effect in reducing parasite densities</div><div class="t m3 x24 h17 y632 ff9 fsb fc3 sc0 lsd2 ws337">compared to quinine (i.v<span class="_ _4b"></span>. or i.m.) at 12 and 24 hours after administration.</div><div class="t m3 x24 h17 y633 ff14 fsb fc5 sc0 ls1f5 ws338">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 ls1f6 ws339">pharmacokinetic studies suggest highly variable but adequate</span></div><div class="t m3 x24 h17 y634 ff9 fsb fc3 sc0 ls1f7 ws2d0">absorption of rectal artemisinin and rectal artesunate. Rectal formulations have</div><div class="t m3 x24 h17 y635 ff9 fsb fc3 sc0 lsd8 ws19a">been developed for pre-r<span class="_ _a"></span>eferral use.</div><div class="t m3 x24 h17 y636 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">systematic review<span class="_ _b"></span>.</span></div><div class="t m0 x47 h16 y637 ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x70 h17 y637 ff9 fsb fc3 sc0 lsd2 ws33a">use artemisinins rectally for complete treatment only when</div><div class="t m3 x47 h17 y638 ff9 fsb fc3 sc0 lsd2 ws0">parenteral antimalarial tr<span class="_ _a"></span>eatment is not possible.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf39" class="pf w1 h4" data-page-no="39"><div class="pc pc39 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls2 ws0">47</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls9a ws0">8.5<span class="_ _78"> </span>P<span class="_ _a"></span>ractic<span class="_ _8"></span>al aspects of t<span class="_ _8"></span>reatment</div><div class="t m0 xb h13 y639 ff8 fs3 fc3 sc0 ls69 ws0">8.5.1<span class="_ _1a"> </span>Ar<span class="_ _9"></span>temisinins </div><div class="t m0 xb hb y63a ff9 fs8 fc3 sc0 ls4b ws6c">Artemisinin is formulated as a suppositor<span class="_ _8"></span>y for rectal administration. Artemether</div><div class="t m0 xb hb y63b ff9 fs8 fc3 sc0 ls12 ws33b">and artemotil are formulated in oil and are given by intramuscular injection.</div><div class="t m0 xb hb y63c ff9 fs8 fc3 sc0 ls12 ws33c">They are both absorbed erratically<span class="_ _c"></span>, par<span class="_ _8"></span>ticularly in very severely ill patients.</div><div class="t m0 xb hb y63d ff9 fs8 fc3 sc0 ls71 wsa7">Artesunate is soluble in water and can be given either by intravenous or</div><div class="t m0 xb hb y63e ff9 fs8 fc3 sc0 ls7c wsb9">intramuscular injection. <span class="_ _a"></span>There are also rectal formulations of artesunate,</div><div class="t m0 xb hb y63f ff9 fs8 fc3 sc0 ls12 ws0">artemether and dihydroar<span class="_ _8"></span>temisinin. </div><div class="t m0 xb hb y640 ff9 fs8 fc3 sc0 ls12 ws33d">The dosing of artemisinin derivatives has been largely empirical. <span class="_ _b"></span>The doses</div><div class="t m0 xb hb y641 ff9 fs8 fc3 sc0 ls12 ws33e">recommended here ar<span class="_ _a"></span>e those that have been most widely studied. The only</div><div class="t m0 xb hb y642 ff9 fs8 fc3 sc0 ls1af ws126">recent change is the higher maintenance dose of parenter<span class="_ _a"></span>al ar<span class="_ _8"></span>tesunate</div><div class="t m0 xb hb y643 ff9 fs8 fc3 sc0 ls1af ws1cb">recommended (2.4<span class="_ _68"> </span>mg/kg bw), which is based on pharmacokinetic and</div><div class="t m0 xb hb y644 ff9 fs8 fc3 sc0 ls1f8 ws33f">pharmacodynamic studies and by extrapolation from studies with or<span class="_ _a"></span>al</div><div class="t m0 xb hb y645 ff9 fs8 fc3 sc0 ls24 ws26">artesunate. E<span class="_ _8"></span>xper<span class="_ _8"></span>t opinion is that the previously recommended maintenance</div><div class="t m0 xb hb y646 ff9 fs8 fc3 sc0 ls12 ws0">dose of 1.2<span class="_ _95"> </span>mg/kg bw may have been insufficient in some patients.</div><div class="t m0 xb hb y647 ff9 fs8 fc3 sc0 ls12 ws340">Artesunate is dispensed as a powder of ar<span class="_ _8"></span>tesunic acid. This is dissolv<span class="_ _a"></span>ed in</div><div class="t m0 xb hb y648 ff9 fs8 fc3 sc0 ls12 ws341">sodium bicarbonate (5%) to form sodium artesunate. The solution is then</div><div class="t m0 xb hb y649 ff9 fs8 fc3 sc0 ls1f9 ws22c">diluted in approximately 5 ml of 5% dextrose and given by intrav<span class="_ _a"></span>enous</div><div class="t m0 xb hb y64a ff9 fs8 fc3 sc0 ls1d3 ws2f2">injection or by intramuscular injection to the anterior thigh. <span class="_ _a"></span>The solution</div><div class="t m0 xb hb y64b ff9 fs8 fc3 sc0 ls93 wse9">should be prepared fr<span class="_ _a"></span>eshly for each administration and should not be stored. </div><div class="t m0 xb hb y64c ff9 fs8 fc3 sc0 ls12 wsfa">Artemether and ar<span class="_ _8"></span>temotil are dispensed dissolved in oil (groundnut, sesame</div><div class="t m0 xb hb y64d ff9 fs8 fc3 sc0 ls13 ws14">seed) and given by i.m. injection into the anterior thigh. </div><div class="t m0 xb h13 y64e ff8 fs3 fc3 sc0 ls80 ws0">8.5.2<span class="_ _97"> </span>Quinine </div><div class="t m0 xb hb y64f ff9 fs8 fc3 sc0 ls184 ws220">Whereas many antimalarials are pr<span class="_ _a"></span>escribed in terms of base, for historical</div><div class="t m0 xb hb y650 ff9 fs8 fc3 sc0 ls1fa ws110">reasons quinine doses are often r<span class="_ _a"></span>ecommended in terms of salt (usually sulfate</div><div class="t m0 xb hb y651 ff9 fs8 fc3 sc0 ls1fb ws342">for oral use and dihydr<span class="_ _a"></span>ochloride for parenteral use). Recommendations for doses</div><div class="t m0 xb hb y652 ff9 fs8 fc3 sc0 ls64 ws5e">of this and other antimalarials should state clearly whether the salt or base is</div><div class="t m0 xb hb y653 ff9 fs8 fc3 sc0 ls64 ws5b">being referred to (doses with differ<span class="_ _a"></span>ent salts must have the same base equiva-</div><div class="t m0 xb hb y654 ff9 fs8 fc3 sc0 ls1fc ws343">lents). Quinine must never be giv<span class="_ _a"></span>en by intravenous injection, as lethal hypoten-</div><div class="t m0 xb hb y655 ff9 fs8 fc3 sc0 ls10e ws344">sion may result. Quinine dihydr<span class="_ _a"></span>ochloride should be given by rate-controlled</div><div class="t m0 xb hb y656 ff9 fs8 fc3 sc0 ls150 ws345">infusion in saline or dextrose solutions at a rate not ex<span class="_ _a"></span>ceeding 5<span class="_ _5"> </span>mg salt/kg bw</div><div class="t m0 xb hb y657 ff9 fs8 fc3 sc0 ls1fd ws167">per hour<span class="_ _b"></span>. If this is not possible then it should be given by intramuscular</div><div class="t m0 xb hb y658 ff9 fs8 fc3 sc0 ls64 ws116">injection to the anterior thigh, not the buttock (to avoid sciatic nerve injury).</div><div class="t m0 xb hb y659 ff9 fs8 fc3 sc0 ls64 ws346">The first dose should be split, 10<span class="_ _95"> </span>mg/kg bw to each thigh. Undiluted quinine</div><div class="t m0 xb hb y65a ff9 fs8 fc3 sc0 ls64 ws252">dihydrochloride at a concentr<span class="_ _a"></span>ation of 300<span class="_ _64"> </span>mg/ml is acidic (pH<span class="_ _64"> </span>2) and painful</div><div class="t m0 xb hb y65b ff9 fs8 fc3 sc0 ls5b ws4f">when given by intramuscular injection, so it is best either formulated or diluted</div><div class="t m0 xb hb y65c ff9 fs8 fc3 sc0 ls1fe ws15b">to concentrations of 60–100<span class="_ _68"> </span>mg/ml for intramuscular injection. Gluconate</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf3a" class="pf w1 h4" data-page-no="3a"><div class="pc pc3a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls2 ws0">48</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls1ff ws13d">salts are less acidic and better tolerated than the dihy<span class="_ _a"></span>drochloride salt when given</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls10e ws14">by the intramuscular and rectal r<span class="_ _a"></span>outes. </div><div class="t m0 x9 hb y1f3 ff9 fs8 fc3 sc0 lsd1 ws14e">As the first dose (loading dose) is the most important in the treatment of severe</div><div class="t m0 x9 hb y18a ff9 fs8 fc3 sc0 ls22 ws5e">malaria, this should be reduced only if there is clear evidence of adequate pr<span class="_ _a"></span>e-</div><div class="t m0 x9 hb y18b ff9 fs8 fc3 sc0 ls12 ws1fe">treatment before pr<span class="_ _a"></span>esentation. Although quinine can cause hypotension if</div><div class="t m0 x9 hb y18c ff9 fs8 fc3 sc0 ls1e ws1d">administered rapidly<span class="_ _c"></span>, and overdose is associated with blindness and deafness,</div><div class="t m0 x9 hb y18d ff9 fs8 fc3 sc0 ls200 ws25">these adverse effects are r<span class="_ _a"></span>are in the treatment of sev<span class="_ _a"></span>ere malaria. The dangers</div><div class="t m0 x9 hb y18e ff9 fs8 fc3 sc0 lsd5 ws74">of insufficient treatment (i.e. death from malaria) ex<span class="_ _a"></span>ceed those from excessive</div><div class="t m0 x9 hb y18f ff9 fs8 fc3 sc0 ls97 wsf0">treatment initially<span class="_ _c"></span>. After the second day of parenteral treatment, if there is no</div><div class="t m0 x9 hb y190 ff9 fs8 fc3 sc0 lsa1 ws100">clinical impro<span class="_ _a"></span>vement or in acute renal failure, the maintenance doses of</div><div class="t m0 x9 hb y191 ff9 fs8 fc3 sc0 ls7e wsbc">quinine given by infusion should be reduced by one-thir<span class="_ _a"></span>d to avoid accumulation.</div><div class="t m0 x9 h13 y112 ff8 fs3 fc3 sc0 ls80 ws0">8.5.3<span class="_ _3b"> </span>Adjustment of dosing in renal failure or hepatic</div><div class="t m0 x28 h13 y65d ff8 fs3 fc3 sc0 ls80 ws0">dysfunction</div><div class="t m0 x9 hb y65e ff9 fs8 fc3 sc0 ls201 ws347">The dosage of artemisinin derivatives does not need adjustment in vital organ</div><div class="t m0 x9 hb y65f ff9 fs8 fc3 sc0 ls202 ws348">dysfunction. Quinine (and quinidine) levels may accumulate in sev<span class="_ _a"></span>ere vital organ</div><div class="t m0 x9 hb y660 ff9 fs8 fc3 sc0 ls39 ws4e">dysfunction. If there is no clinical impro<span class="_ _a"></span>vement or the patient remains in</div><div class="t m0 x9 hb y661 ff9 fs8 fc3 sc0 ls3e ws54">acute renal failure the dose should be r<span class="_ _a"></span>educed by one-third after 48 h. Dosage</div><div class="t m0 x9 hb y662 ff9 fs8 fc3 sc0 ls12 ws161">adjustments are not necessary if patients are receiving either haemodialysis</div><div class="t m0 x9 hb y663 ff9 fs8 fc3 sc0 ls12 ws349">or haemofiltration. Dosage adjustment by one-third is necessary in patients</div><div class="t m0 x9 hb y664 ff9 fs8 fc3 sc0 ls12 ws0">with hepatic dysfunction.</div><div class="t m0 x9 h12 y665 ff10 fs6 fc4 sc0 ls53 ws34a">8.6<span class="_ _78"> </span>F<span class="_ _4b"></span>ol<span class="_ _8"></span>low-on treatment</div><div class="t m0 x9 hb y666 ff9 fs8 fc3 sc0 ls203 ws27">Follo<span class="_ _a"></span>wing initial parenteral treatment, once the patient can toler<span class="_ _a"></span>ate oral therapy<span class="_ _c"></span>,</div><div class="t m0 x9 hb y667 ff9 fs8 fc3 sc0 ls64 ws14d">it is essential to continue and complete treatment with an effective or<span class="_ _a"></span>al anti-</div><div class="t m0 x9 hb y668 ff9 fs8 fc3 sc0 ls64 ws11e">malarial. Current practice is to continue the same medicine or<span class="_ _a"></span>ally as given</div><div class="t m0 x9 hb y669 ff9 fs8 fc3 sc0 ls64 ws34b">parenterally to complete a full 7 days of tr<span class="_ _a"></span>eatment. In non-pregnant adults,</div><div class="t m0 x9 hb y66a ff9 fs8 fc3 sc0 ls64 ws71">doxycy<span class="_ _a"></span>cline is added to either quinine, ar<span class="_ _8"></span>tesunate or ar<span class="_ _8"></span>temether and should</div><div class="t m0 x9 hb y66b ff9 fs8 fc3 sc0 ls17b ws34c">also be given for 7 days. Do<span class="_ _a"></span>xycycline is preferr<span class="_ _a"></span>ed to other tetracyclines because</div><div class="t m0 x9 hb y66c ff9 fs8 fc3 sc0 ls64 ws34d">it can be given once daily<span class="_ _c"></span>, and does not accumulate in renal failure. But as</div><div class="t m0 x9 hb y66d ff9 fs8 fc3 sc0 ls13f ws34e">treatment with doxy<span class="_ _a"></span>cycline only starts when the patient has recover<span class="_ _a"></span>ed</div><div class="t m0 x9 hb y66e ff9 fs8 fc3 sc0 ls64 ws34f">sufficiently<span class="_ _4b"></span>, the doxycy<span class="_ _a"></span>cline course finishes after the quinine, ar<span class="_ _8"></span>temether or</div><div class="t m0 x9 hb y44d ff9 fs8 fc3 sc0 lsbc ws12e">artesunate course. Where av<span class="_ _a"></span>ailable, clindamycin may be substituted in children</div><div class="t m0 x9 hb y44e ff9 fs8 fc3 sc0 lsc7 wsa2">and pregnant women, as doxy<span class="_ _a"></span>cycline cannot be given to these gr<span class="_ _a"></span>oups. Although</div><div class="t m0 x9 hb y44f ff9 fs8 fc3 sc0 ls192 ws3c">following parenter<span class="_ _a"></span>al treatment with a full course of oral A<span class="_ _a"></span>CT (artesunate +</div><div class="t m0 x9 hb y450 ff9 fs8 fc3 sc0 ls64 ws16e">amodiaquine or artemether-lumefantrine) is theor<span class="_ _a"></span>etically a good alternative,</div><div class="t m0 x9 hb y451 ff9 fs8 fc3 sc0 ls64 ws0">this has not been evaluated in clinical trials. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf3b" class="pf w1 h4" data-page-no="3b"><div class="pc pc3b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">49</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls204 ws350">The recommendation from experts’<span class="_ _67"> </span>opinion is to complete treatment in severe</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls13 ws351">malaria following parenter<span class="_ _a"></span>al drug administration by giving a full course of</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls12 ws1a6">combination therapy<span class="_ _c"></span>, ACT or quinine + clindamycin or do<span class="_ _a"></span>xycycline. R<span class="_ _a"></span>egimens</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 lsfd ws201">containing mefloquine should be avoided if the patient presented initially with</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 lsf7 ws1ad">impaired consciousness. <span class="_ _a"></span>This is because of an increased incidence of neuropsy-</div><div class="t m0 xb hb yc1 ff9 fs8 fc3 sc0 ls31 ws41">chiatric complications associated with mefloquine following cerebr<span class="_ _a"></span>al malaria. </div><div class="t m0 xb h12 y39c ff10 fs6 fc4 sc0 ls0 wsca">8.7<span class="_ _78"> </span>P<span class="_ _a"></span>re-referral t<span class="_ _8"></span>reatment options</div><div class="t m0 x84 h14 y66f ff11 fs5 fc4 sc0 ls1 ws0">16</div><div class="t m0 xb hb y599 ff9 fs8 fc3 sc0 ls12 ws2c1">The risk of death from sever<span class="_ _a"></span>e malaria is greatest in the first 24 h, yet in most</div><div class="t m0 xb hb y59a ff9 fs8 fc3 sc0 ls205 ws8b">malaria endemic countries, the transit time between r<span class="_ _a"></span>eferral and arrival at appr<span class="_ _a"></span>o-</div><div class="t m0 xb hb y59b ff9 fs8 fc3 sc0 lsd0 ws149">priate health facilities is usually prolonged thus delaying the commence-</div><div class="t m0 xb hb y59c ff9 fs8 fc3 sc0 lsfd ws201">ment of appropriate antimalarial treatment, during which time the patient may</div><div class="t m0 xb hb y59d ff9 fs8 fc3 sc0 ls12 ws146">deteriorate or die. It is recommended that patients ar<span class="_ _a"></span>e treated with the first</div><div class="t m0 xb hb y59e ff9 fs8 fc3 sc0 lseb ws8e">dose of one of the recommended treatments by the par<span class="_ _a"></span>enteral route if possible</div><div class="t m0 xb hb y59f ff9 fs8 fc3 sc0 lsf7 ws1ad">or by the intra-rectal r<span class="_ _a"></span>oute before referral (unless the r<span class="_ _a"></span>eferral time is very short).</div><div class="t m0 xb hb y5a0 ff9 fs8 fc3 sc0 ls74 wsae">This could be intramuscular artemether<span class="_ _b"></span>, ar<span class="_ _8"></span>tesunate or quinine, or a rectal formu-</div><div class="t m0 xb hb y5a1 ff9 fs8 fc3 sc0 ls12 ws0">lation of artemisinin or ar<span class="_ _8"></span>tesunate.</div><div class="t m0 xb hd y670 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on pre-referr<span class="_ _a"></span>al treatment for sever<span class="_ _a"></span>e</div><div class="t m0 xb hd y671 ff8 fs8 fc3 sc0 ls12 ws0">falciparum malaria</div><div class="t m0 xb h13 y672 ff8 fs3 fc3 sc0 ls80 ws0">8.7.1<span class="_ _2d"> </span>Pre-referr<span class="_ _a"></span>al and continued treatment with </div><div class="t m0 x6 h13 y673 ff8 fs3 fc3 sc0 ls80 ws0">rectal artemisinins</div><div class="t m0 xb hb y674 ff9 fs8 fc3 sc0 ls187 ws1fd">The administration of an artemisinin by the rectal route as pre-r<span class="_ _a"></span>eferral</div><div class="t m0 xb hb y675 ff9 fs8 fc3 sc0 ls12 ws0">treatment is feasible even at the community lev<span class="_ _a"></span>el. </div><div class="t m0 xb hb y676 ff9 fs8 fc3 sc0 ls140 ws200">There is insufficient evidence to show whether r<span class="_ _a"></span>ectal ar<span class="_ _8"></span>tesunate is as good as</div><div class="t m0 xb hb y677 ff9 fs8 fc3 sc0 ls12 wsaf">intravenous or intr<span class="_ _a"></span>amuscular options in the management of severe malaria.</div><div class="t m0 xb hb y678 ff9 fs8 fc3 sc0 ls12 ws286">The recommendation, therefor<span class="_ _a"></span>e, is to use ar<span class="_ _8"></span>tesunate or ar<span class="_ _8"></span>temisinin suppos-</div><div class="t m0 xb hb y679 ff9 fs8 fc3 sc0 ls1d3 ws2f2">itories only as pre-referr<span class="_ _a"></span>al treatment and to refer the patient to a facility</div><div class="t m0 xb hb y67a ff9 fs8 fc3 sc0 ls93 wse9">where complete parenter<span class="_ _a"></span>al treatment with artesunate, quinine or ar<span class="_ _8"></span>temether</div><div class="t m0 x2d h16 y67b ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x2f h16 y67c ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x85 h16 y67d ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y67e ff9 fsb fc3 sc0 lsd2 ws0">The following may be given:</div><div class="t m3 x4d h17 y67f ff9 fsb fc3 sc0 lsd8 ws19a">–<span class="_ _67"> </span>artesunate or ar<span class="_ _8"></span>temisinin by rectal administration</div><div class="t m3 x4d h17 y680 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _67"> </span>artesunate or ar<span class="_ _8"></span>temether i.m.</div><div class="t m3 x4d h17 y681 ff9 fsb fc3 sc0 lsd2 ws0">–<span class="_ _67"> </span>quinine i.m.</div><div class="t m3 x6c h16 y682 ff8 fsb fc3 sc0 ls14b ws20f">T,<span class="_ _9"></span> E</div><div class="t m3 x4c h16 y683 ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m3 x6c h16 y684 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m0 xb h14 y685 ff11 fs5 fc4 sc0 ls1 ws0">16</div><div class="t m0 x20 h15 y686 ff9 fsa fc3 sc0 ls7d ws0">Further infromation is provided in Annex 9.8</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf3c" class="pf w1 h4" data-page-no="3c"><div class="pc pc3c w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">50</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls13 ws1dd">can be instituted. If, ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, referral is impossible, rectal treatment should</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls12 ws352">be continued until the patient can tolerate oral medication, at which point a</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls146 ws207">full course of the recommended A<span class="_ _a"></span>CT for uncomplicated malaria in the locality</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls12 ws0">can be administered.</div><div class="t m0 x9 h13 y687 ff8 fs3 fc3 sc0 ls80 ws0">8.7.2<span class="_ _3b"> </span>Dosing for antimalarials given by suppositor<span class="_ _8"></span>y</div><div class="t m0 x9 h1e y688 ff14 fs8 fc3 sc0 ls12 ws0">Artemisinin derivatives</div><div class="t m0 x9 hb y689 ff9 fs8 fc3 sc0 ls172 ws353">Artemisinin suppositories are not widely available. Doses used have been</div><div class="t m0 x9 hb y68a ff9 fs8 fc3 sc0 ls10e ws354">variable and empiric: 10–40 mg/kg bw (at 0, 4 or 12, 24, 48 and 72<span class="_ _64"> </span>h). Some</div><div class="t m0 x9 hb y68b ff9 fs8 fc3 sc0 ls26 ws355">studies have giv<span class="_ _a"></span>en a maintenance dose of one- to two-thirds of the initial</div><div class="t m0 x9 hb y68c ff9 fs8 fc3 sc0 lsaa ws93">dose. Artesunate suppositories* are given in a dose of 10 mg/kg bw daily<span class="_ _4b"></span>. The</div><div class="t m0 x9 hb y68d ff9 fs8 fc3 sc0 lsb1 ws102">individual suppositories contain either 50, 100 or 400 mg of ar<span class="_ _8"></span>tesunate. Recom-</div><div class="t m0 x9 hb y68e ff9 fs8 fc3 sc0 ls64 ws356">mendations for artesunate suppositories for pre-referral treatment of sev<span class="_ _a"></span>ere</div><div class="t m0 x9 hb y68f ff9 fs8 fc3 sc0 ls64 ws0">malaria are pro<span class="_ _a"></span>vided in T<span class="_ _c"></span>ables 5 and 6.</div><div class="t m0 x9 h1e y690 ff14 fs8 fc3 sc0 ls13 ws14">Initial (pre-referr<span class="_ _a"></span>al) treatment with rectal artesunate</div><div class="t m0 x9 hb y691 ff9 fs8 fc3 sc0 ls13 ws234">The appropriate single dose of artesunate given by suppository should be</div><div class="t m0 x9 hb y692 ff9 fs8 fc3 sc0 ls166 ws91">administered rectally as soon as the pr<span class="_ _a"></span>esumptive diagnosis of sever<span class="_ _a"></span>e malaria</div><div class="t m0 x9 hb y693 ff9 fs8 fc3 sc0 ls206 ws1a3">is made. In the event that an artesunate suppository is expelled from the rectum</div><div class="t m0 x9 hb y694 ff9 fs8 fc3 sc0 ls4e ws232">within 30<span class="_ _68"> </span>min of inser<span class="_ _8"></span>tion, a second suppository should be inser<span class="_ _8"></span>ted and,</div><div class="t m0 x9 hb y695 ff9 fs8 fc3 sc0 ls85 wsc9">especially in young children, the buttocks should be held together<span class="_ _4b"></span>, for 10<span class="_ _5"> </span>min</div><div class="t m0 x9 hb y696 ff9 fs8 fc3 sc0 ls12 ws0">to ensure retention of the r<span class="_ _a"></span>ectal dose of ar<span class="_ _8"></span>tesunate.</div><div class="t m0 x9 hb y697 ff8 fs8 fc3 sc0 ls207 ws357">F<span class="_ _a"></span>or adults: <span class="ff9 ls208">one or more artesunate suppositories inser<span class="_ _8"></span>ted in the rectum,</span></div><div class="t m0 x9 hb y698 ff9 fs8 fc3 sc0 ls12 ws358">dose as indicated in T<span class="_ _c"></span>able 5. The dose should be given once and follo<span class="_ _a"></span>wed as</div><div class="t m0 x9 hb y699 ff9 fs8 fc3 sc0 ls13 ws14">soon as possible by definitive therapy for malaria.</div><div class="t m0 x9 hd y69a ff15 fs5 fc4 sc0 ls209 ws0">T<span class="_ _b"></span>able 5.<span class="_ _13"> </span><span class="ff8 fs8 fc3 ls12">Dosage* for initial (pre-referral) tr<span class="_ _a"></span>eatment in adult patients</span></div><div class="t m0 x28 hd y69b ff8 fs8 fc3 sc0 ls13 ws14">(aged ≥<span class="_ _66"></span>16 years)</div><div class="t m0 x9 h15 y69c ff9 fsa fc3 sc0 ls0 ws0">*<span class="_ _4"> </span><span class="ffa ls7d ws359">It should be noted that the clinical trial data with rectal artesunate relate to a single suppository</span></div><div class="t m0 x14 h20 y69d ffa fsa fc3 sc0 ls1e2 ws35a">formulation and presentation</div><div class="t m0 x3f h14 y69e ff11 fs5 fc4 sc0 ls20a ws0">17</div><div class="t m0 x86 h20 y69d ffa fsa fc3 sc0 ls1e2 ws35a">which has well characterized absorption kinetics and so cannot</div><div class="t m0 x14 h20 y69f ffa fsa fc3 sc0 ls7d ws0">necessarily be extrapolated to other rectal formulations of artesunate.</div><div class="t m8 x47 h1b y6a0 ff11 fsb fc3 sc0 lsd2 ws1d4">W<span class="_ _a"></span>eight (kg)<span class="_ _98"> </span><span class="lsd8 ws0">Artesunate dose<span class="_ _92"> </span></span>Regimen (single dose)</div><div class="t m3 x47 h17 y6a1 fff fsb fc3 sc0 ls0 ws0">&lt;<span class="_ _9"></span><span class="ff9 ls154">40</span></div><div class="t m3 x5b h17 y6a2 ff9 fsb fc3 sc0 ls20b ws35b">10 mg/kg bw</div><div class="t m3 x87 h17 y6a3 ff9 fsb fc3 sc0 lsd8 ws19a">Use appropriate no. of 100-mg</div><div class="t m3 x87 h17 y6a4 ff9 fsb fc3 sc0 lsd2 ws0">rectal suppositories (see <span class="_ _a"></span>T<span class="_ _4b"></span>able 6)</div><div class="t m3 x47 h17 y6a5 ff9 fsb fc3 sc0 ls20b ws0">40–59<span class="_ _99"> </span><span class="lsd8">400 mg<span class="_ _9a"> </span><span class="lsd2">One 400-mg suppository </span></span></div><div class="t m3 x47 h17 y6a6 ff9 fsb fc3 sc0 lsd8 ws0">60–80<span class="_ _9b"> </span>800 mg<span class="_ _9a"> </span><span class="lsd2">T<span class="_ _b"></span>wo 400-mg suppositories</span></div><div class="t m3 x47 h17 y6a7 fff fsb fc3 sc0 ls0 ws0">&gt;<span class="_ _9"></span><span class="ff9 ls13a">80</span></div><div class="t m3 x41 h17 y6a8 ff9 fsb fc3 sc0 ls156 ws1d3">1200 mg<span class="_ _8a"> </span><span class="lsd8 ws19a">Three 400-mg suppositories</span></div><div class="t m0 x9 h14 y6a9 ff11 fs5 fc4 sc0 ls100 ws0">17</div><div class="t m0 x14 h15 y6aa ff9 fsa fc3 sc0 lsac ws35c">This product is being developed by the UNDP/U<span class="_ _8"></span>NICE<span class="_ _8"></span>F/World Bank/WHO Special Pr<span class="_ _a"></span>ogramme for</div><div class="t m0 x14 h15 y6ab ff9 fsa fc3 sc0 ls7d ws0">Research and <span class="_ _a"></span>T<span class="_ _a"></span>raining in T<span class="_ _b"></span>ropical Diseases.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf3d" class="pf w1 h4" data-page-no="3d"><div class="pc pc3d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">51</div><div class="t m0 xb hb y9e ff8 fs8 fc3 sc0 ls12 ws2c2">F<span class="_ _a"></span>or children: <span class="ff9">one or more artesunate suppositories inser<span class="_ _8"></span>ted in the rectum as</span></div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls12 ws2ed">indicated in T<span class="_ _c"></span>able 6. The dose should be given once and follo<span class="_ _a"></span>wed as soon as</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls13 ws14">possible by definitive therapy for malaria.</div><div class="t m0 xb hd y6ac ff15 fs5 fc4 sc0 ls14c ws0">T<span class="_ _b"></span>able 6.<span class="_ _49"> </span><span class="ff8 fs8 fc3 ls12">Dosage for initial (pre-referral) tr<span class="_ _a"></span>eatment in children </span></div><div class="t m0 x6 hd y6ad ff8 fs8 fc3 sc0 ls12 ws0">(aged 2–15 years) and weighing at least 5 kg </div><div class="t m0 xb h1e y6ae ff14 fs8 fc3 sc0 ls13 ws0">Quinine</div><div class="t m0 xb hb y6af ff9 fs8 fc3 sc0 ls1d ws1c">The intrarectal dose used in tr<span class="_ _a"></span>eatment trials in Africa was either 12<span class="_ _5"> </span>mg/kg bw</div><div class="t m0 xb hb y6b0 ff9 fs8 fc3 sc0 ls1a6 ws2a7">quinine base every 12 h without a loading dose, or 8<span class="_ _5"> </span>mg/kg bw every 8<span class="_ _5"> </span>h, also</div><div class="t m0 xb hb y6b1 ff9 fs8 fc3 sc0 lsaa ws110">without a loading dose. The r<span class="_ _a"></span>etention and absorption of quinine is dependent</div><div class="t m0 xb hb y6b2 ff9 fs8 fc3 sc0 ls12 ws145">on pH. Results with gluconate salts (pH 4.5) cannot be extr<span class="_ _a"></span>apolated to more</div><div class="t m0 xb hb y6b3 ff9 fs8 fc3 sc0 ls12 ws0">acidic solutions (such as the dihydrochloride salt, pH 2).</div><div class="t m0 xb h12 y6b4 ff10 fs6 fc4 sc0 ls0 wsca">8.8<span class="_ _78"> </span>Adjunctive treatment</div><div class="t m0 xb hb y6b5 ff9 fs8 fc3 sc0 ls12 ws35d">In an attempt to reduce the unacceptably high mortality of severe malaria,</div><div class="t m0 xb hb y6b6 ff9 fs8 fc3 sc0 ls81 wsc2">various adjunctiv<span class="_ _a"></span>e treatments for the complications of malaria have been</div><div class="t m0 xb hb y6b7 ff9 fs8 fc3 sc0 ls1ad ws2b8">evaluated in clinical trials. <span class="_ _b"></span>These are summarized in T<span class="_ _c"></span>able 7 and fur<span class="_ _8"></span>ther</div><div class="t m0 xb hb y6b8 ff9 fs8 fc3 sc0 ls13 ws14">information is given in sections 8.9 and 8.10.</div><div class="t m8 x2d h1b y6b9 ff11 fsb fc3 sc0 lsd2 ws1d4">W<span class="_ _a"></span>eight (kg)<span class="_ _79"> </span><span class="lsd8 ws0">Age</span></div><div class="t m8 x76 h1b y6ba ff11 fsb fc3 sc0 lsd8 ws0">Artesunate</div><div class="t m8 x76 h1b y6bb ff11 fsb fc3 sc0 lsd2 ws1d4">dose (mg)</div><div class="t m8 x73 h1b y6b9 ff11 fsb fc3 sc0 lsd2 ws1d4">Regimen (single dose)</div><div class="t m3 x2d h17 y6bc ff9 fsb fc3 sc0 lsd2 ws0">5–8.9<span class="_ _57"> </span><span class="ls154 ws218">0–12 months<span class="_ _9c"> </span><span class="ws0">50<span class="_ _91"> </span></span></span>One 50-mg suppository</div><div class="t m3 x2d h17 y6bd ff9 fsb fc3 sc0 lsd2 ws0">9–19<span class="_ _9d"> </span><span class="ls154 ws218">13–42 months<span class="_ _8c"> </span></span><span class="ls155">100<span class="_ _9e"> </span><span class="ls154 ws218">One 100-mg suppository</span></span></div><div class="t m3 x2d h17 y6be ff9 fsb fc3 sc0 lsd2 ws0">20–29<span class="_ _9c"> </span>43–60 months<span class="_ _8f"> </span><span class="lsd8">200<span class="_ _22"> </span><span class="ls154 ws218">T<span class="_ _b"></span>wo 100-mg suppositories</span></span></div><div class="t m3 x2d h17 y6bf ff9 fsb fc3 sc0 lsd2 ws0">30–39<span class="_ _9c"> </span><span class="ls13a ws218">6–13 years<span class="_ _9d"> </span></span><span class="lsd8">300<span class="_ _9f"> </span><span class="ls154 ws218">Three 100-mg suppositories</span></span></div><div class="t m3 x2d h17 y6c0 fff fsb fc3 sc0 ls0 ws0">&gt;<span class="_ _9"></span><span class="ff9 ls154">40<span class="_ _a0"> </span></span>&gt;<span class="_ _9"></span><span class="ff9 lsd8">14 years</span></div><div class="t m3 x50 h17 y6c1 ff9 fsb fc3 sc0 lsd8 ws0">400<span class="_ _9f"> </span><span class="lsd2">One 400-mg suppository</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf3e" class="pf w1 h4" data-page-no="3e"><div class="pc pc3e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">52</div><div class="t m0 x9 hd y9e ff15 fs5 fc4 sc0 ls14c ws0">T<span class="_ _b"></span>able 7.<span class="_ _97"> </span><span class="ff8 fs8 fc3 ls12">Immediate clinical management of severe manifestations and</span></div><div class="t m0 x9 hd y9f ff8 fs8 fc3 sc0 ls12 ws0">complications of falciparum malaria</div><div class="t m0 x9 h19 y6c2 ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x46 h15 y6c3 ff9 fsa fc3 sc0 ls7d ws0">It is assumed that appropriate antimalarial treatment will have been started in all cases.</div><div class="t m0 x9 h19 y6c4 ff9 fsd fc3 sc0 ls0 ws0">b</div><div class="t m0 x46 h15 y6c5 ff9 fsa fc3 sc0 ls20c ws35e">Prevent by av<span class="_ _a"></span>oiding excess hydration.</div><div class="t m9 x47 h1b y6c6 ff11 fsb fc3 sc0 lsd2 ws0">Manifestation/complication</div><div class="t m8 x51 h1b y6c6 ff11 fsb fc3 sc0 lsd2 ws1d4">Immediate management</div><div class="t m8 x55 h1d y6c7 ff11 fse fc3 sc0 ls0 ws0">a</div><div class="t m3 x47 h17 y6c8 ff9 fsb fc3 sc0 lsd2 ws0">Coma (cerebral malaria)<span class="_ _a1"> </span><span class="ls20d ws35f">Maintain airway<span class="_ _4b"></span>, place patient on his or her side,</span></div><div class="t m3 x51 h17 y6c9 ff9 fsb fc3 sc0 ls20e ws360">exclude other treatable causes of coma (e.g.</div><div class="t m3 x51 h17 y6ca ff9 fsb fc3 sc0 ls20f ws361">hypoglycaemia, bacterial meningitis); avoid harmful</div><div class="t m3 x51 h17 y6cb ff9 fsb fc3 sc0 lsd2 ws1cc">ancillary treatment such as corticosteroids, heparin</div><div class="t m3 x51 h17 y6cc ff9 fsb fc3 sc0 lsd2 ws0">and adrenaline; intubate if necessary<span class="_ _4b"></span>.</div><div class="t m3 x47 h17 y6cd ff9 fsb fc3 sc0 lsd2 ws0">Hyperpyrexia<span class="_ _a2"> </span><span class="lsd8 ws362">Administer tepid sponging, fanning, cooling blanket</span></div><div class="t m3 x51 h17 y6ce ff9 fsb fc3 sc0 lsd2 ws0">and antipyretic drugs.</div><div class="t m3 x47 h17 y6cf ff9 fsb fc3 sc0 lsd2 ws0">Convulsions<span class="_ _a3"> </span><span class="ls210 ws363">Maintain airways; treat promptly with intr<span class="_ _a"></span>avenous</span></div><div class="t m3 x51 h17 y6d0 ff9 fsb fc3 sc0 ls211 ws364">or rectal diazepam or intramuscular par<span class="_ _a"></span>aldehyde.</div><div class="t m3 x47 h17 y6d1 ff9 fsb fc3 sc0 lsd2 ws0">Hypoglycaemia (blood</div><div class="t m3 x47 h17 y6d2 ff9 fsb fc3 sc0 lsd2 ws0">glucose concentration of</div><div class="t m3 x47 h17 y6d3 fff fsb fc3 sc0 ls0 ws0">&lt;<span class="_ _9"></span><span class="ff9 lsd2">2.2<span class="_ _95"> </span>mmol/l; </span>&lt;<span class="ff9 ls20b">40<span class="_ _95"> </span>mg/100ml)</span></div><div class="t m3 x51 h17 y6d1 ff9 fsb fc3 sc0 ls212 ws365">Check blood glucose, correct hypoglycaemia and</div><div class="t m3 x51 h17 y6d2 ff9 fsb fc3 sc0 lsd2 ws0">maintain with glucose-containing infusion.</div><div class="t m3 x47 h17 y6d4 ff9 fsb fc3 sc0 ls154 ws218">Severe anaemia</div><div class="t m3 x47 h17 y6d5 ff9 fsb fc3 sc0 lsd2 ws0">(haemoglobin <span class="fff ls0">&lt;<span class="_ _9"></span></span><span class="ls156 ws1d3">5<span class="_ _95"> </span>g/100ml or</span></div><div class="t m3 x47 h17 y6d6 ff9 fsb fc3 sc0 lsd2 ws0">packed cell volume <span class="fff ls0">&lt;<span class="_ _9"></span></span><span class="lsd8">15%)</span></div><div class="t m3 x51 h17 y6d4 ff9 fsb fc3 sc0 lsd2 ws0">T<span class="_ _b"></span>ransfuse with screened fresh whole blood </div><div class="t m3 x47 h17 y6d7 ff9 fsb fc3 sc0 lsd2 ws0">Acute pulmonary oedema</div><div class="t m3 x4a h1c y6d8 ff9 fse fc3 sc0 ls0 ws0">b</div><div class="t m6 x51 h17 y6d7 ff9 fsb fc3 sc0 lsd2 ws366">Prop patient up at an angle of 45</div><div class="t ma x4c h1c y6d8 ff9 fse fc3 sc0 ls0 ws0">o</div><div class="t m6 x12 h17 y6d7 ff9 fsb fc3 sc0 lsd8 ws366">, give oxygen, giv<span class="_ _a"></span>e</div><div class="t m6 x51 h17 y6d9 ff9 fsb fc3 sc0 lsd2 ws367">a diuretic, stop intrav<span class="_ _a"></span>enous fluids, intubate and add</div><div class="t m6 x51 h17 y6da ff9 fsb fc3 sc0 ls213 ws31b">positive end-expiratory pressur<span class="_ _a"></span>e/continuous positive</div><div class="t m6 x51 h17 y6db ff9 fsb fc3 sc0 lsd2 ws0">airway pressure in life-thr<span class="_ _a"></span>eatening hypoxaemia.</div><div class="t m3 x47 h17 y6dc ff9 fsb fc3 sc0 lsd2 ws0">Acute renal failure</div><div class="t m6 x51 h17 y6dc ff9 fsb fc3 sc0 ls214 ws368">Exclude pre-renal causes, check fluid balance and urinary</div><div class="t m6 x51 h17 y6dd ff9 fsb fc3 sc0 ls215 ws369">sodium; if in established renal failure add haemofiltr<span class="_ _a"></span>ation</div><div class="t m6 x51 h17 y6de ff9 fsb fc3 sc0 ls10b ws36a">or haemodialysis, or if unavailable, peritoneal dialysis.</div><div class="t m6 x51 h17 y6df ff9 fsb fc3 sc0 ls216 ws36b">The benefits of diuretics/dopamine in acute renal failur<span class="_ _a"></span>e</div><div class="t m6 x51 h17 y6e0 ff9 fsb fc3 sc0 ls10b ws0">are not pro<span class="_ _a"></span>ven.</div><div class="t m3 x47 h17 y6e1 ff9 fsb fc3 sc0 ls154 ws218">Spontaneous bleeding </div><div class="t m3 x47 h17 y6e2 ff9 fsb fc3 sc0 lsd2 ws0">and coagulopathy</div><div class="t m3 x51 h17 y6e1 ff9 fsb fc3 sc0 ls217 ws2bd">T<span class="_ _b"></span>ransfuse with screened fresh whole blood (cryopr<span class="_ _a"></span>e-</div><div class="t m3 x51 h17 y6e2 ff9 fsb fc3 sc0 ls1f6 ws36c">cipitate, fresh frozen plasma and platelets if av<span class="_ _b"></span>ailable);</div><div class="t m3 x51 h17 y6e3 ff9 fsb fc3 sc0 lsd2 ws0">give vitamin K injection.</div><div class="t m3 x47 h17 y6e4 ff9 fsb fc3 sc0 lsd2 ws0">Metabolic acidosis<span class="_ _9d"> </span>Exclude or treat hypoglycaemia, hypo<span class="_ _a"></span>volaemia and</div><div class="t m3 x51 h17 y6e5 ff9 fsb fc3 sc0 lsd2 ws0">septicaemia. If severe add haemofiltr<span class="_ _a"></span>ation or</div><div class="t m3 x51 h17 y6e6 ff9 fsb fc3 sc0 lsd2 ws0">haemodialysis.</div><div class="t m3 x47 h17 y6e7 ff9 fsb fc3 sc0 lsd2 ws0">Shock<span class="_ _a4"> </span>Suspect septicaemia, take blood for cultures; give</div><div class="t m3 x51 h17 y6e8 ff9 fsb fc3 sc0 lsd2 ws0">parenteral antimicr<span class="_ _a"></span>obials, correct haemodynamic</div><div class="t m3 x51 h17 y6e9 ff9 fsb fc3 sc0 lsd2 ws0">disturbances.</div><div class="t m3 x47 h17 y6ea ff9 fsb fc3 sc0 lsd2 ws0">Hyperparasitaemia <span class="_ _a5"> </span><span class="lsd8 ws19a">See section 8.14. </span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf3f" class="pf w1 h4" data-page-no="3f"><div class="pc pc3f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">53</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls9e wsfd">8.9<span class="_ _78"> </span>Continuing suppor<span class="_ _8"></span>tive care</div><div class="t m0 xb hb y1cf ff9 fs8 fc3 sc0 ls8f ws312">Patients with sever<span class="_ _a"></span>e malaria require intensiv<span class="_ _a"></span>e nursing, in an intensive care unit</div><div class="t m0 xb hb y1d0 ff9 fs8 fc3 sc0 ls2a ws2b8">if possible. Follo<span class="_ _a"></span>wing the initial assessment and the star<span class="_ _8"></span>t of antimalarial</div><div class="t m0 xb hb y1d1 ff9 fs8 fc3 sc0 ls60 ws19c">treatment, clinical observations should be made as frequently as possible. <span class="_ _a"></span>These</div><div class="t m0 xb hb y1d2 ff9 fs8 fc3 sc0 ls218 ws96">should include recording of vital signs, with an accur<span class="_ _a"></span>ate assessment of respira-</div><div class="t m0 xb hb y1d3 ff9 fs8 fc3 sc0 ls64 ws1ad">tory rate and pattern, coma score, and urine output. Blood glucose should be</div><div class="t m0 xb hb y217 ff9 fs8 fc3 sc0 lsc7 wsa2">checked, using rapid stick tests every 4 h if possible, par<span class="_ _8"></span>ticularly in unconscious</div><div class="t m0 xb hb y218 ff9 fs8 fc3 sc0 ls64 ws36d">patients. Convulsions should be treated promptly with intr<span class="_ _a"></span>avenous or rectal</div><div class="t m0 xb hb y219 ff9 fs8 fc3 sc0 ls64 ws0">diazepam or intramuscular par<span class="_ _a"></span>aldehyde.</div><div class="t m0 xb hb y263 ff9 fs8 fc3 sc0 ls163 ws36e">Fluid requirements should be assessed individually<span class="_ _c"></span>. Adults with severe malaria</div><div class="t m0 xb hb y1d8 ff9 fs8 fc3 sc0 ls12 wsb1">are very vulnerable to fluid o<span class="_ _b"></span>verload and there is a thin dividing line between</div><div class="t m0 xb hb y1d9 ff9 fs8 fc3 sc0 ls43 ws60">underhydration, and thus worsening r<span class="_ _a"></span>enal impairment, and overhydr<span class="_ _a"></span>ation, with</div><div class="t m0 xb hb y264 ff9 fs8 fc3 sc0 ls12 ws36f">the risk of precipitating pulmonary oedema. If the patient becomes oliguric</div><div class="t m0 xb hb y265 ff9 fs8 fc3 sc0 ls0 ws0">(<span class="fff">&lt;<span class="_ _66"> </span></span><span class="ls1ba ws30b">0.4<span class="_ _5"> </span>ml of urine/kg bw per hour) despite adequate rehydration, and the blood</span></div><div class="t m0 xb hb y6eb ff9 fs8 fc3 sc0 ls12 ws370">urea or creatinine ar<span class="_ _a"></span>e rising or already high, then fluids should be restricted</div><div class="t m0 xb hb y6ec ff9 fs8 fc3 sc0 ls9c wsfa">to replace insensible losses only<span class="_ _c"></span>. Children, on the other hand, are more likely</div><div class="t m0 xb hb y6ed ff9 fs8 fc3 sc0 ls12 ws12f">to be dehydrated and may r<span class="_ _a"></span>espond well to a bolus of fluid. The fluid regimen</div><div class="t m0 xb hb y6ee ff9 fs8 fc3 sc0 lsa2 ws102">must also be tailored around infusion of the antimalarial drugs. Centr<span class="_ _a"></span>al venous</div><div class="t m0 xb hb y6ef ff9 fs8 fc3 sc0 ls12 ws25f">pressure should be maintained at 0–5 cm. If the venous pressur<span class="_ _a"></span>e is elevated</div><div class="t m0 xb hb y6f0 ff9 fs8 fc3 sc0 ls0 ws2e6">(usually because of excessive fluid administr<span class="_ _a"></span>ation), the patient should be</div><div class="t m0 xb hb y6f1 ff9 fs8 fc3 sc0 ls12 ws216">nursed with the head raised at an angle of 45</div><div class="t m0 x88 h11 y6f2 ff9 fs5 fc3 sc0 ls0 ws0">o</div><div class="t m0 x54 hb y6f3 ff9 fs8 fc3 sc0 ls12 ws216">and, if necessary<span class="_ _4b"></span>, intravenous</div><div class="t m0 xb hb y6f4 ff9 fs8 fc3 sc0 ls219 ws371">furosemide should be given. If av<span class="_ _b"></span>ailable, heamofiltration should be star<span class="_ _8"></span>ted early</div><div class="t m0 xb hb y6f5 ff9 fs8 fc3 sc0 lsfe ws372">for acute renal failure or sev<span class="_ _a"></span>ere metabolic acidosis unresponsiv<span class="_ _a"></span>e to rehydration.</div><div class="t m0 xb hb y6f6 ff9 fs8 fc3 sc0 ls21a ws373">If blood glucose is <span class="fff ls0 ws0">&lt;<span class="_ _66"> </span></span>2.2<span class="_ _2"> </span>mmol/l then hypogly<span class="_ _a"></span>caemia should be treated</div><div class="t m0 xb hb y6f7 ff9 fs8 fc3 sc0 ls165 ws238">immediately (0.3–0.5 g/kg bw of glucose). Hypoglycaemia should be suspected</div><div class="t m0 xb hb y6f8 ff9 fs8 fc3 sc0 ls12 ws374">in any patient who deteriorates suddenly<span class="_ _c"></span>. Stick tests may overestimate the</div><div class="t m0 xb hb y6f9 ff9 fs8 fc3 sc0 ls12 ws375">frequency of hypoglycaemia, so labor<span class="_ _a"></span>atory confirmation may be necessar<span class="_ _8"></span>y<span class="_ _4b"></span>.</div><div class="t m0 xb hb y6fa ff9 fs8 fc3 sc0 ls16b ws242">Patients with acute pulmonary oedema should be nursed in an upright position</div><div class="t m0 xb hb y6fb ff9 fs8 fc3 sc0 ls12 ws376">and given o<span class="_ _a"></span>xygen, and filling pressures on the right side of the heart should</div><div class="t m0 xb hb y6fc ff9 fs8 fc3 sc0 ls12 ws1a0">be reduced with whichever tr<span class="_ _a"></span>eatments are available (loop diur<span class="_ _a"></span>etics, opiates,</div><div class="t m0 xb hb y6fd ff9 fs8 fc3 sc0 ls21b ws2d9">venodilators, v<span class="_ _a"></span>enesection, haemofiltration, dialysis). The right-sided pr<span class="_ _a"></span>essure</div><div class="t m0 xb hb y6fe ff9 fs8 fc3 sc0 ls12 ws377">should be reduced to the low<span class="_ _a"></span>est level compatible with an adequate cardiac</div><div class="t m0 xb hb y6ff ff9 fs8 fc3 sc0 ls12 ws378">output. Positive pr<span class="_ _a"></span>essure ventilation should be started (if available) early if</div><div class="t m0 xb hb y700 ff9 fs8 fc3 sc0 ls12 ws0">the patient becomes hypoxic.</div><div class="t m0 xb hb y701 ff9 fs8 fc3 sc0 ls64 ws379">Few<span class="_ _a"></span>er than 5% of patients with severe malaria develop clinically significant</div><div class="t m0 xb hb y702 ff9 fs8 fc3 sc0 ls37 wsdd">disseminated intrav<span class="_ _a"></span>ascular coagulation. These patients should be giv<span class="_ _a"></span>en fresh</div><div class="t m0 xb hb y703 ff9 fs8 fc3 sc0 lsaa ws93">blood transfusions and vitamin K. Patients with secondary pneumonia should</div><div class="t m0 xb hb y704 ff9 fs8 fc3 sc0 ls64 ws37a">be given empirical treatment with a thir<span class="_ _a"></span>d-generation cephalosporin, unless</div><div class="t m0 xb hb y705 ff9 fs8 fc3 sc0 ls21c ws371">admitted with clear evidence of aspiration, in which case penicillin or clindamycin</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf40" class="pf w1 h4" data-page-no="40"><div class="pc pc40 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">54</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls1d8 ws37b">is adequate. Children with persistent fever despite par<span class="_ _a"></span>asite clearance may</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls64 ws37c">have a systematic <span class="ffa ws0">Salmonella<span class="_ _95"> </span></span><span class="ws227">infection, although in the majority of cases of</span></div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls21d wscc">persistent fever no other pathogen is identified after parasite clear<span class="_ _a"></span>ance. Urinary</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls192 ws3c">tract infections are common in catheteriz<span class="_ _a"></span>ed patients. Antibiotic treatments</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls64 ws0">should take account of likely local antibiotic sensitivity patterns.</div><div class="t m0 x9 h12 y43b ff10 fs6 fc4 sc0 ls9a ws0">8.10<span class="_ _1a"> </span>Additional aspects of c<span class="_ _8"></span>linical management</div><div class="t m0 x9 h13 y706 ff8 fs3 fc3 sc0 ls69 ws0">8.10.1<span class="_ _54"> </span>Diagnosis</div><div class="t m0 x9 hb y707 ff9 fs8 fc3 sc0 ls12 ws7e">The differential diagnosis of fever in a sev<span class="_ _a"></span>erely ill patient is broad. Coma and</div><div class="t m0 x9 hb y1f6 ff9 fs8 fc3 sc0 ls200 ws25">fever may result fr<span class="_ _a"></span>om meningoencephalitis or malaria. Cerebral malaria is not</div><div class="t m0 x9 hb y1f7 ff9 fs8 fc3 sc0 ls12 ws37d">associated with signs of meningeal irritation (neck stiffness, photophobia,</div><div class="t m0 x9 hb y1f8 ff9 fs8 fc3 sc0 ls21e ws2b9">K<span class="_ _a"></span>ernig sign) but the patient may be opisthotonic. As untreated bacterial</div><div class="t m0 x9 hb y1fa ff9 fs8 fc3 sc0 ls44 ws93">meningitis is almost invariably fatal, a diagnostic lumbar punctur<span class="_ _a"></span>e should be</div><div class="t m0 x9 hb y455 ff9 fs8 fc3 sc0 lsfc ws37e">performed to exclude this condition. <span class="_ _a"></span>There is also considerable clinical o<span class="_ _a"></span>verlap</div><div class="t m0 x9 hb y114 ff9 fs8 fc3 sc0 ls8e wsdd">between septicaemia, pneumonia and sever<span class="_ _a"></span>e malaria – and these conditions</div><div class="t m0 x9 hb y115 ff9 fs8 fc3 sc0 ls6c ws99">may coexist. In malaria endemic areas particularly<span class="_ _4b"></span>, where parasitaemia is</div><div class="t m0 x9 hb y116 ff9 fs8 fc3 sc0 ls3a ws1b2">common in the young age group<span class="_ _a"></span>, it is often impossible to rule out septicaemia</div><div class="t m0 x9 hb y456 ff9 fs8 fc3 sc0 ls202 ws348">in a shocked or severely ill obtunded child. <span class="_ _b"></span>Where possible, blood should always</div><div class="t m0 x9 hb y457 ff9 fs8 fc3 sc0 lsbe ws37f">be taken on admission for culture, and if there is any doubt, empirical antibiotic</div><div class="t m0 x9 hb y458 ff9 fs8 fc3 sc0 ls12 ws24">treatment should be started immediately along with antimalarial treatment.</div><div class="t m0 x9 h13 y708 ff8 fs3 fc3 sc0 ls69 ws0">8.10.2<span class="_ _a6"> </span>Other treatments</div><div class="t m0 x9 hb y709 ff9 fs8 fc3 sc0 ls12 ws188">Many other supportive strategies and interventions have been proposed in</div><div class="t m0 x9 hb y70a ff9 fs8 fc3 sc0 ls13 wsde">severe malaria, but v<span class="_ _a"></span>ery few are suppor<span class="_ _8"></span>ted by evidence of benefit, and many</div><div class="t m0 x9 hb y70b ff9 fs8 fc3 sc0 ls12 ws0">have pro<span class="_ _a"></span>ved harmful. </div><div class="t m0 x9 hb y70c ff9 fs8 fc3 sc0 ls1c9 ws293">Heparin, prostacyclin, defer<span class="_ _a"></span>oxamine, pentoxifylline, lo<span class="_ _a"></span>w molecular weight</div><div class="t m0 x9 hb y70d ff9 fs8 fc3 sc0 ls12 ws37">dextran, urea, high-dose corticosteroids, acetylsalicylic acid, defero<span class="_ _a"></span>xamine,</div><div class="t m0 x9 hb y70e ff9 fs8 fc3 sc0 ls45 wsbb">anti-tumour necrosis factor antibody<span class="_ _c"></span>, cyclosporin, dichloroacetate, adrenaline</div><div class="t m0 x9 hb y70f ff9 fs8 fc3 sc0 lsf9 ws41">and hyperimmune serum have all been suggested – but none of these is recom-</div><div class="t m0 x9 hb y710 ff9 fs8 fc3 sc0 ls12 ws17c">mended. Evidence on use of corticosteroids is summarized in the box belo<span class="_ _a"></span>w<span class="_ _b"></span>. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf41" class="pf w1 h4" data-page-no="41"><div class="pc pc41 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">55</div><div class="t m0 xb h19 y711 ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x1a h15 y712 ff9 fsa fc3 sc0 lsac ws115">See also Annex 9.9.</div><div class="t m0 xb hb y713 ff9 fs8 fc3 sc0 ls8d wsd8">Severe metabolic acidosis is common but apart from correction of hypo<span class="_ _a"></span>volaemia</div><div class="t m0 xb hb y714 ff9 fs8 fc3 sc0 ls12 ws1b3">and anaemia, no specific treatment is of pro<span class="_ _a"></span>ven v<span class="_ _a"></span>alue. Significant electrolyte</div><div class="t m0 xb hb y715 ff9 fs8 fc3 sc0 ls3a ws1b2">abnormalities are relativ<span class="_ _a"></span>ely unusual, and potassium supplementation is often</div><div class="t m0 xb hb y716 ff9 fs8 fc3 sc0 ls21f ws15f">not required in the acute phase. <span class="_ _b"></span>The optimum fluid resuscitation regimens, the</div><div class="t m0 xb hb y717 ff9 fs8 fc3 sc0 ls12 ws380">thresholds for blood transfusion, the r<span class="_ _a"></span>ole of exchange transfusion, and the</div><div class="t m0 xb hb y718 ff9 fs8 fc3 sc0 lse3 ws172">management of seizures remain ar<span class="_ _a"></span>eas of uncer<span class="_ _8"></span>tainty<span class="_ _4b"></span>, and these are discussed</div><div class="t m0 xb hb y719 ff9 fs8 fc3 sc0 lsbf ws12e">in more detail below<span class="_ _4b"></span>. The optimum body positioning in comatose patients, and</div><div class="t m0 xb hb y71a ff9 fs8 fc3 sc0 ls12 ws381">the timing and type of feeding in patients who remain unconscious for <span class="fff ls0 ws0">&gt;<span class="_ _67"> </span><span class="ff9 ls14">24 h</span></span></div><div class="t m0 xb hb y71b ff9 fs8 fc3 sc0 ls7e wsbc">have not been studied. It is generally agr<span class="_ _a"></span>eed that early ventilation for respir<span class="_ _a"></span>atory</div><div class="t m0 xb hb y71c ff9 fs8 fc3 sc0 ls208 ws357">abnormalities and early management of renal failure or sev<span class="_ _a"></span>ere metabolic</div><div class="t m0 xb hb y71d ff9 fs8 fc3 sc0 lsc6 ws13c">acidosis are beneficial. In acute renal failur<span class="_ _a"></span>e, haemofiltration is associated with</div><div class="t m0 xb hb y71e ff9 fs8 fc3 sc0 ls12 ws22d">a lower mortality<span class="_ _4b"></span>, and more rapid correction of biochemical abnormalities</div><div class="t m0 xb hb y71f ff9 fs8 fc3 sc0 ls12 ws14">compared with peritoneal dialysis. <span class="_ _a"></span>There have been no comparativ<span class="_ _a"></span>e trials of</div><div class="t m0 xb hb y720 ff9 fs8 fc3 sc0 ls12 ws0">haemodialysis and haemofiltration.</div><div class="t m0 xb h13 y721 ff8 fs3 fc3 sc0 ls69 ws0">8.10.3<span class="_ _46"> </span>Fluid therapy </div><div class="t m0 xb hb y722 ff9 fs8 fc3 sc0 ls8f wsde">Patients, especially children with sev<span class="_ _a"></span>ere malaria may be dehydrated. Ho<span class="_ _a"></span>wever<span class="_ _4b"></span>,</div><div class="t m0 xb hb y723 ff9 fs8 fc3 sc0 ls27 ws30">the degree of fluid depletion v<span class="_ _a"></span>aries considerably<span class="_ _4b"></span>. As a result, it is not possible</div><div class="t m0 xb hb y724 ff9 fs8 fc3 sc0 ls143 ws203">to give general r<span class="_ _a"></span>ecommendations on fluid replacement. Each patient must be</div><div class="t m0 xb hb y725 ff9 fs8 fc3 sc0 ls20 ws1f">individually assessed and fluid resuscitation based on estimated deficit. In high-</div><div class="t m0 xb hb y726 ff9 fs8 fc3 sc0 ls17a ws53">transmission settings where sev<span class="_ _a"></span>ere malaria is confined to childhood, children</div><div class="t m0 xb hb y727 ff9 fs8 fc3 sc0 lsc2 ws137">commonly present with sever<span class="_ _a"></span>e anaemia and hyper<span class="_ _8"></span>ventilation (sometimes</div><div class="t m0 xb hb y728 ff9 fs8 fc3 sc0 ls220 ws353">termed “respir<span class="_ _a"></span>atory distress”). In the past this was ascribed to “<span class="_ _a"></span>anaemic</div><div class="t m0 xb hb y729 ff9 fs8 fc3 sc0 ls221 ws382">heart failure” (i.e. pulmonary oedema), and sometimes diuretics were</div><div class="t m0 xb hb y72a ff9 fs8 fc3 sc0 ls6d wsa3">administered. It is now clear that this syndr<span class="_ _a"></span>ome is not a result of anaemic heart</div><div class="t m0 xb hb y72b ff9 fs8 fc3 sc0 lsa5 ws105">failure, but results fr<span class="_ _a"></span>om severe metabolic acidosis and anaemia, and so</div><div class="t m0 xb hb y72c ff9 fs8 fc3 sc0 ls1e2 ws383">should be treated by blood transfusion. In gener<span class="_ _a"></span>al children tolerate rapid</div><div class="t m0 xb hb y72d ff9 fs8 fc3 sc0 ls222 ws343">fluid resuscitation better than adults, and are less likely to dev<span class="_ _a"></span>elop pulmonary</div><div class="t m0 xb hb y72e ff9 fs8 fc3 sc0 ls12 ws384">oedema. In adults, there is a very thin dividing line between o<span class="_ _a"></span>verhydr<span class="_ _a"></span>ation,</div><div class="t m0 xb hb y72f ff9 fs8 fc3 sc0 ls12 wsf4">which may produce pulmonary oedema, and underhydration contributing to</div><div class="t m0 x2d hd y5ee ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:  trials of routine use of corticosteroids (e.g. dexamethasone)</div><div class="t m0 x14 hd y5ef ff8 fs8 fc0 sc0 ls12 ws0">in the treatment of sever<span class="_ _a"></span>e falciparum malaria</div><div class="t m0 x89 h1f y5f0 ff8 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x2d h1a y4b2 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y4b2 ff14 fsb fc3 sc0 lsd2 ws0">corticosteroids i.v<span class="_ _b"></span>.</div><div class="t m3 x38 h17 y730 ff14 fsb fc5 sc0 ls223 ws385">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls122 ws386">one systematic review and no additional trials. No significant</span></div><div class="t m3 x38 h17 y731 ff9 fsb fc3 sc0 lsd2 ws0">difference in mortality; increased risk of gastrointestinal bleeding.</div><div class="t m3 x38 h17 y5f3 ff14 fsb fc5 sc0 ls130 ws0">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 lsd2">no additional information.</span></div><div class="t m3 x38 h17 y732 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2 ws1d4">systematic review<span class="_ _b"></span>.</span></div><div class="t m0 x2d h16 y733 ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y733 ff9 fsb fc3 sc0 lsd2 ws0">do not use corticosteroids.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf42" class="pf w1 h4" data-page-no="42"><div class="pc pc42 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls9a ws0">56</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls12 ws387">shock and worsening acidosis and renal impairment. Careful and fr<span class="_ _a"></span>equent</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls1aa ws15b">evaluations of the jugular v<span class="_ _a"></span>enous pressure, peripheral perfusion, v<span class="_ _a"></span>enous</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 lsbb ws18f">filling, skin turgor and urine output should be made. <span class="_ _a"></span>Where there is uncertainty</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls12 ws388">ov<span class="_ _a"></span>er the jugular venous pressure, and if nursing facilities permit, a centr<span class="_ _a"></span>al</div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls1e ws1d">venous catheter should be inserted and the central venous pressur<span class="_ _a"></span>e measured</div><div class="t m0 x9 hb yc1 ff9 fs8 fc3 sc0 ls224 ws11e">directly<span class="_ _c"></span>. The optimum rate of resuscitation, the r<span class="_ _a"></span>ole of colloids compared</div><div class="t m0 x9 hb y10d ff9 fs8 fc3 sc0 ls48 ws68">with crystalloids, and the optimum electrolyte composition of the replacement</div><div class="t m0 x9 hb y10e ff9 fs8 fc3 sc0 ls12 ws0">fluid have not been determined. </div><div class="t m0 x9 h13 y734 ff8 fs3 fc3 sc0 ls69 ws0">8.10.4<span class="_ _a6"> </span>Blood transfusion</div><div class="t m0 x9 hb y155 ff9 fs8 fc3 sc0 ls1ac ws1dc">Severe malaria is associated with r<span class="_ _a"></span>apid development of anaemia as infected and</div><div class="t m0 x9 hb y156 ff9 fs8 fc3 sc0 ls26 ws389">uninfected erythrocytes are remo<span class="_ _a"></span>ved from the cir<span class="_ _a"></span>culation. In areas of high</div><div class="t m0 x9 hb y112 ff9 fs8 fc3 sc0 ls1d4 ws1e1">stable transmission, sever<span class="_ _a"></span>e anaemia in young children is the principal manifes-</div><div class="t m0 x9 hb y157 ff9 fs8 fc3 sc0 ls22 ws354">tation of severe falciparum malaria. Ideally fr<span class="_ _a"></span>esh blood should be transfused,</div><div class="t m0 x9 hb y43c ff9 fs8 fc3 sc0 ls22 ws38a">and the patient’<span class="_ _4b"></span>s relatives are often willing donors. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, in most settings</div><div class="t m0 x9 hb y43d ff9 fs8 fc3 sc0 ls225 ws3">cross-matched virus-free blood is in short supply<span class="_ _4b"></span>. As with fluid resuscitation, there</div><div class="t m0 x9 hb y735 ff9 fs8 fc3 sc0 ls22 wse4">have not been enough studies to pro<span class="_ _a"></span>vide strong evidence-based recommen-</div><div class="t m0 x9 hb y736 ff9 fs8 fc3 sc0 ls226 ws2c1">dations, so the recommendations given her<span class="_ _a"></span>e are based on expert opinion. In high-</div><div class="t m0 x9 hb y737 ff9 fs8 fc3 sc0 ls22 ws38b">transmission settings, blood transfusion is r<span class="_ _a"></span>ecommended for children with a</div><div class="t m0 x9 hb y738 ff9 fs8 fc3 sc0 ls227 ws38c">haemoglobin level of <span class="fff ls0 ws0">&lt;<span class="_ _9"></span></span><span class="ls228 ws1ad">5 g/100 ml (haematocrit <span class="fff ls0 ws0">&lt;<span class="_ _9"></span></span></span>15%). Mor<span class="_ _8"></span>tality as a direct result</div><div class="t m0 x9 hb y739 ff9 fs8 fc3 sc0 ls22 ws25b">of anaemia rises at lower haemoglobin lev<span class="_ _a"></span>els. In low-transmission settings, a</div><div class="t m0 x9 hb y2c7 ff9 fs8 fc3 sc0 ls22 ws38d">threshold of 20% (haemoglobin 7<span class="_ _7c"> </span>g/100ml) is recommended. These general</div><div class="t m0 x9 hb y73a ff9 fs8 fc3 sc0 ls185 ws38e">recommendations still need to be tailored to the individual, as the pathological</div><div class="t m0 x9 hb y73b ff9 fs8 fc3 sc0 ls22 ws36e">consequences of rapid development of anaemia ar<span class="_ _a"></span>e worse than those of acute</div><div class="t m0 x9 hb y73c ff9 fs8 fc3 sc0 ls28 ws232">on chronic anaemia, where ther<span class="_ _a"></span>e has been adaptation and a compensatory</div><div class="t m0 x9 hb y73d ff9 fs8 fc3 sc0 ls229 ws14">right shift in the oxygen dissociation curve (Annex 9.10).</div><div class="t m0 x9 h13 y73e ff8 fs3 fc3 sc0 ls80 ws0">8.10.5<span class="_ _5a"> </span>Exchange blood tr<span class="_ _a"></span>ansfusion (EBT) </div><div class="t m0 x9 hb y449 ff9 fs8 fc3 sc0 ls12 ws28d">There have been many anecdotal r<span class="_ _a"></span>epor<span class="_ _8"></span>ts and several series claiming benefit</div><div class="t m0 x9 hb y44a ff9 fs8 fc3 sc0 ls95 wsec">for EBT in sev<span class="_ _a"></span>ere malaria but no comparative trials, and ther<span class="_ _a"></span>e is no consensus</div><div class="t m0 x9 hb y44b ff9 fs8 fc3 sc0 lsfc ws37e">on whether it reduces mortality or how it might work. The r<span class="_ _a"></span>ationale for E<span class="_ _8"></span>BT<span class="_ _67"> </span>has</div><div class="t m0 x9 hb y73f ff9 fs8 fc3 sc0 ls12 ws0">been variously pr<span class="_ _a"></span>oposed as:</div><div class="t m0 x9 hb y740 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 lsa0 wsff">remo<span class="_ _a"></span>ving infected red blood cells from the circulation and therefor<span class="_ _a"></span>e lowering</span></div><div class="t m0 x16 hb y741 ff9 fs8 fc3 sc0 ls22a ws38f">the parasite burden (although only the cir<span class="_ _a"></span>culating relatively non-pathogenic</div><div class="t m0 x16 hb y742 ff9 fs8 fc3 sc0 ls12 ws9e">stages are remo<span class="_ _a"></span>ved – and this is also achieved r<span class="_ _a"></span>apidly with ar<span class="_ _8"></span>temisinin</div><div class="t m0 x16 hb y743 ff9 fs8 fc3 sc0 ls13 ws0">derivativ<span class="_ _a"></span>es);</div><div class="t m0 x9 hb y744 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws1c8">reducing rapidly both the antigen load and the bur<span class="_ _a"></span>den of parasite-derived</span></div><div class="t m0 x16 hb y745 ff9 fs8 fc3 sc0 ls13 ws14">toxins, metabolites and to<span class="_ _a"></span>xic mediators produced by the host; </div><div class="t m0 x9 hb y746 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls13 ws340">replacing the rigid unparasitiz<span class="_ _a"></span>ed red cells by more deformable cells and</span></div><div class="t m0 x16 hb y747 ff9 fs8 fc3 sc0 ls12 ws0">therefore alleviating micr<span class="_ _a"></span>ocirculatory obstruction. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf43" class="pf w1 h4" data-page-no="43"><div class="pc pc43 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">57</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls22b ws390">EBT r<span class="_ _a"></span>equires intensive nursing and a relativ<span class="_ _a"></span>ely large volume of blood, and carries</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls54 ws6f">significant risks. Ther<span class="_ _a"></span>e is no consensus on the indications, benefits and</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls18a ws2b5">dangers involv<span class="_ _a"></span>ed, or on practical details such as the volume of blood that should</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls40 ws56">be exchanged. It is therefor<span class="_ _a"></span>e not possible to make any recommendation</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls12 ws0">regarding the use of EBT<span class="_ _4b"></span>.</div><div class="t m0 xb h13 y39b ff8 fs3 fc3 sc0 ls80 ws0">8.10.6<span class="_ _39"> </span>Use of anticonvulsants</div><div class="t m0 xb hb y39c ff9 fs8 fc3 sc0 ls22c ws38c">Seizures are common in cer<span class="_ _a"></span>ebral malaria, particularly in children. The treatment</div><div class="t m0 xb hb y39d ff9 fs8 fc3 sc0 ls85 wsc9">of convulsions in cerebral malaria with intr<span class="_ _a"></span>avenous (or<span class="_ _4b"></span>, if not possible, rectal)</div><div class="t m0 xb hb y154 ff9 fs8 fc3 sc0 ls182 ws130">benzodiazepines or intramuscular par<span class="_ _a"></span>aldehyde is similar to that for repeated</div><div class="t m0 xb hb y155 ff9 fs8 fc3 sc0 lsfc ws37e">seizures from any cause. In a lar<span class="_ _a"></span>ge double-blind placebo-controlled ev<span class="_ _a"></span>aluation</div><div class="t m0 xb hb y156 ff9 fs8 fc3 sc0 ls12 ws1a3">of a single intramuscular injection of 20 mg/kg bw of phenobarbital (pheno-</div><div class="t m0 xb hb y112 ff9 fs8 fc3 sc0 ls14e ws1a6">barbitone) in children with cerebr<span class="_ _a"></span>al malaria there was a reduction in seizures</div><div class="t m0 xb hb y157 ff9 fs8 fc3 sc0 ls9f wsfe">but a significant increase in mortality in phenobarbital recipients. This r<span class="_ _a"></span>esulted</div><div class="t m0 xb hb y43c ff9 fs8 fc3 sc0 ls12 ws285">from respir<span class="_ _a"></span>atory arrest, and was associated with additional benzodiazepine</div><div class="t m0 xb hb y43d ff9 fs8 fc3 sc0 ls24 ws26">use. Clearly the 20 mg/kg dose of phenobarbital should not be given without</div><div class="t m0 xb hb y735 ff9 fs8 fc3 sc0 ls12 ws391">respiratory support, but it is not known, whether a lower dose would be ef-</div><div class="t m0 xb hb y736 ff9 fs8 fc3 sc0 ls12 ws392">fective and safer or whether<span class="_ _4b"></span>, if ventilation is given, mortality would not be</div><div class="t m0 xb hb y737 ff9 fs8 fc3 sc0 ls21b ws2d9">increased. In the absence of further information, prophylactic anticonvulsants</div><div class="t m0 xb hb y738 ff9 fs8 fc3 sc0 ls12 ws0">are not recommended.</div><div class="t m0 xb h19 y748 ff9 fsd fc3 sc0 ls0 ws0">a</div><div class="t m0 x1a h15 y749 ff9 fsa fc3 sc0 lsac ws115">See also Annex 9.11. </div><div class="t m0 xb h13 y74a ff8 fs3 fc3 sc0 ls80 ws0">8.10.7<span class="_ _a7"> </span>Concomitant use of antibiotics </div><div class="t m0 xb hb y74b ff9 fs8 fc3 sc0 ls12 ws120">The threshold for administering antibiotic treatment should be lo<span class="_ _a"></span>w in severe</div><div class="t m0 xb hb y74c ff9 fs8 fc3 sc0 ls17b ws258">malaria. Septicaemia and severe malaria ar<span class="_ _a"></span>e associated and there is diagnostic</div><div class="t m0 xb hb y74d ff9 fs8 fc3 sc0 lsa8 ws10a">ov<span class="_ _a"></span>erlap, particularly in children. Unexplained deterioration may result from a</div><div class="t m0 xb hb y74e ff9 fs8 fc3 sc0 lsec ws393">supervening bacterial infection. Although enteric bacteria (notably <span class="ffa ws0">Salmonella<span class="ff9 ls0">)</span></span></div><div class="t m0 xb hb y74f ff9 fs8 fc3 sc0 ls25 ws27">have predominated in most trial series, a v<span class="_ _b"></span>ariety of bacteria have been cultured</div><div class="t m0 xb hb y750 ff9 fs8 fc3 sc0 ls22d ws394">from the blood of patients diagnosed as having sever<span class="_ _a"></span>e malaria, and so broad-</div><div class="t m0 xb hb y751 ff9 fs8 fc3 sc0 ls12 ws0">spectrum antibiotic treatment should be given initially<span class="_ _c"></span>.</div><div class="t m0 x2d hd y752 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE:<span class="_ _1"> </span>trials on use of phenobarbital for the treatment of</div><div class="t m0 x14 hd y753 ff8 fs8 fc0 sc0 ls12 ws0">convulsions in severe falciparum malaria</div><div class="t m0 x8a h1f y754 ff8 fs5 fc0 sc0 ls0 ws0">a</div><div class="t m0 x2d h1a y755 ffb fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x37 h1b y755 ff14 fsb fc3 sc0 lsd2 ws0">phenobarbital i.v<span class="_ _b"></span>.</div><div class="t m3 x38 h17 y756 ff14 fsb fc5 sc0 ls1a0 ws395">Summary of RCT<span class="_ _b"></span>s: <span class="ff9 fc3 ls22e ws1d9">systematic review of thr<span class="_ _a"></span>ee trials. In the two trials with</span></div><div class="t m3 x38 h17 y757 ff9 fsb fc3 sc0 lsd2 ws0">adequate blinding, death was more common with phenobarbital.</div><div class="t m3 x38 h17 y758 ff14 fsb fc5 sc0 ls130 ws0">Exper<span class="_ _8"></span>t comment: <span class="ff9 fc3 lsd2">no additional information.</span></div><div class="t m3 x38 h17 y759 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2 ws1d4">systematic review<span class="_ _b"></span>.</span></div><div class="t m0 x2d h16 y75a ff8 fsb fc4 sc0 lsd2 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x3c h17 y75a ff9 fsb fc3 sc0 lsd2 ws0">avoid routine use of phenobarbital.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf44" class="pf w1 h4" data-page-no="44"><div class="pc pc44 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls2 ws0">58</div><div class="t m0 x9 h12 y12a ff10 fs6 fc4 sc0 ls9a ws0">8.11<span class="_ _1a"> </span>T<span class="_ _c"></span>reatment during pregnanc<span class="_ _8"></span>y</div><div class="t m0 x9 hb y1cf ff9 fs8 fc3 sc0 ls6b ws58">Pregnant women, particularly in the second and third trimesters of pregnancy</div><div class="t m0 x9 hb y1d0 ff9 fs8 fc3 sc0 ls5d ws7e">are more likely to dev<span class="_ _a"></span>elop severe malaria than other adults, often complicated</div><div class="t m0 x9 hb y1d1 ff9 fs8 fc3 sc0 lsfe ws372">by pulmonary oedema and hypoglycaemia. Maternal mortality is approximately</div><div class="t m0 x9 hb y1d2 ff9 fs8 fc3 sc0 ls1be ws294">50%, which is higher than in non-pregnant adults. F<span class="_ _a"></span>etal death and premature</div><div class="t m0 x9 hb y1d3 ff9 fs8 fc3 sc0 ls218 ws216">labour are common. <span class="_ _a"></span>The role of early Caesarean section for the viable live fetus</div><div class="t m0 x9 hb y217 ff9 fs8 fc3 sc0 ls218 ws216">is unpro<span class="_ _a"></span>ven, but is recommended by many authorities. Obstetric advice should</div><div class="t m0 x9 hb y218 ff9 fs8 fc3 sc0 ls12 ws392">be sought at an early stage, the paediatricians alerted, and blood glucose</div><div class="t m0 x9 hb y219 ff9 fs8 fc3 sc0 lse3 ws172">checked frequently<span class="_ _c"></span>. Hypoglycaemia should be expected and is often recurrent</div><div class="t m0 x9 hb y21a ff9 fs8 fc3 sc0 ls3c ws31">if the patient is receiving quinine. Antimalarials should be given in full doses.</div><div class="t m0 x9 hb y21b ff9 fs8 fc3 sc0 ls26 ws2a">Severe malaria may also pr<span class="_ _a"></span>esent immediately following delivery<span class="_ _c"></span>. Postpar<span class="_ _8"></span>tum</div><div class="t m0 x9 hb y75b ff9 fs8 fc3 sc0 ls22f ws396">bacterial infection is a common complication in these cases. F<span class="_ _a"></span>alciparum</div><div class="t m0 x9 hb y75c ff9 fs8 fc3 sc0 ls230 ws397">malaria has also been associated with severe mid-trimester haemolytic</div><div class="t m0 x9 hb y75d ff9 fs8 fc3 sc0 ls1e1 ws312">anaemia in Nigeria. This often r<span class="_ _a"></span>equires transfusion, in addition to antimalarial</div><div class="t m0 x9 hb y75e ff9 fs8 fc3 sc0 ls12 ws0">treatment and folate supplementation. </div><div class="t m0 x9 hb y6ec ff9 fs8 fc3 sc0 ls71 wsa7">Parenter<span class="_ _a"></span>al antimalarials should be given to pregnant women with sev<span class="_ _a"></span>ere</div><div class="t m0 x9 hb y6ed ff9 fs8 fc3 sc0 ls16b ws242">malaria in full doses without delay<span class="_ _4b"></span>. Ar<span class="_ _8"></span>tesunate or ar<span class="_ _8"></span>temether are preferr<span class="_ _a"></span>ed over</div><div class="t m0 x9 hb y6ee ff9 fs8 fc3 sc0 ls1c9 ws293">quinine in the second and third trimesters because quinine is associated</div><div class="t m0 x9 hb y6ef ff9 fs8 fc3 sc0 ls12 ws354">with recurrent hypogly<span class="_ _a"></span>caemia. Recent evidence shows that in non pr<span class="_ _a"></span>egnant</div><div class="t m0 x9 hb y6f0 ff9 fs8 fc3 sc0 ls231 ws13e">adults with severe malaria in ar<span class="_ _a"></span>eas of low transmission, artesunate was</div><div class="t m0 x9 hb y6f1 ff9 fs8 fc3 sc0 ls13 ws398">superior to quinine, reducing mortality by 35% compared to quinine, which</div><div class="t m0 x9 hb y75f ff9 fs8 fc3 sc0 ls12 ws38f">makes artesunate the preferred option in the second and third trimesters. In</div><div class="t m0 x9 hb y760 ff9 fs8 fc3 sc0 ls200 ws25">the first trimester<span class="_ _4b"></span>, the risk of hypoglycaemia associated with quinine is lower<span class="_ _4b"></span>,</div><div class="t m0 x9 hb y761 ff9 fs8 fc3 sc0 ls91 wse6">and the uncertainties over the safety of the artemisinin derivatives ar<span class="_ _a"></span>e greater<span class="_ _b"></span>.</div><div class="t m0 x9 hb y762 ff9 fs8 fc3 sc0 ls12 ws399">Howev<span class="_ _a"></span>er<span class="_ _b"></span>, weighing these risks against the abov<span class="_ _a"></span>e evidence in favour of the</div><div class="t m0 x9 hb y763 ff9 fs8 fc3 sc0 ls15b ws224">efficacy of artesunate, and until more evidence becomes available, both</div><div class="t m0 x9 hb y764 ff9 fs8 fc3 sc0 ls17a ws53">artesunate and quinine may be considered as options. T<span class="_ _b"></span>reatment must not be</div><div class="t m0 x9 hb y765 ff9 fs8 fc3 sc0 ls10d ws1c2">delayed so if only one of the drugs artesunate, ar<span class="_ _8"></span>temether or quinine is</div><div class="t m0 x9 hb y766 ff9 fs8 fc3 sc0 ls12 ws0">available it should be started immediately<span class="_ _4b"></span>. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf45" class="pf w1 h4" data-page-no="45"><div class="pc pc45 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls9a ws0">59</div><div class="t m0 xb h12 y767 ff10 fs6 fc4 sc0 ls9a ws0">8.12<span class="_ _1a"> </span>Management in epidemic situations</div><div class="t m0 xb hb y768 ff9 fs8 fc3 sc0 ls56 ws2ea">Management of severe falciparum malaria in epidemic situations will often take</div><div class="t m0 xb hb y769 ff9 fs8 fc3 sc0 ls64 ws39a">place in temporary clinics or in situations in which staff shortages and high</div><div class="t m0 xb hb y76a ff9 fs8 fc3 sc0 ls64 ws355">workloads make intensive care monitoring difficult. Drug tr<span class="_ _a"></span>eatment should</div><div class="t m0 xb hb y76b ff9 fs8 fc3 sc0 ls229 ws1c8">therefore be as simple and safe as possible, with simple dosing schedules and</div><div class="t m0 xb hb y76c ff9 fs8 fc3 sc0 lsc9 ws60">a minimum need for monitoring. Artesunate has been shown to reduce mortality</div><div class="t m0 xb hb y76d ff9 fs8 fc3 sc0 ls232 ws178">of severe malaria, but with the curr<span class="_ _a"></span>ent ar<span class="_ _8"></span>tesunate formulation, drawing the drug</div><div class="t m0 xb hb y76e ff9 fs8 fc3 sc0 ls233 ws232">into a syringe takes two dissolution-dilution steps. In some circumstances</div><div class="t m0 xb hb y76f ff9 fs8 fc3 sc0 ls15d ws1cb">this may not be possible. Parenter<span class="_ _a"></span>al quinine requires either intrav<span class="_ _a"></span>enous</div><div class="t m0 xb hb y770 ff9 fs8 fc3 sc0 lsc9 ws60">infusions or a three times a day intramuscular r<span class="_ _a"></span>egimen, plus monitoring of blood</div><div class="t m0 xb hb y771 ff9 fs8 fc3 sc0 ls13b ws1a8">glucose. Thus the simple once a day r<span class="_ _a"></span>egimens and the ease of drawing up and</div><div class="t m0 xb hb y772 ff9 fs8 fc3 sc0 ls64 ws39b">administering intramuscular artemether make this a suitable alternative for</div><div class="t m0 xb hb y773 ff9 fs8 fc3 sc0 ls1a7 ws32b">severe malaria in most epidemic situations. Experience with artesunate</div><div class="t m0 xb hb y774 ff9 fs8 fc3 sc0 ls64 ws376">suppositories in epidemic situations is limited. Their use may be appr<span class="_ _a"></span>opriate</div><div class="t m0 xb hb y775 ff9 fs8 fc3 sc0 ls234 ws39c">in severely ill patients who ar<span class="_ _a"></span>e unable to swallow oral medication when</div><div class="t m0 xb hb y776 ff9 fs8 fc3 sc0 ls10e ws2c1">intramuscular artemether (or quinine by intravenous infusion) is unav<span class="_ _a"></span>ailable.</div><div class="t m0 xb hb y777 ff9 fs8 fc3 sc0 ls10e ws39d">If artesunate suppositories are used, patients should be moved as soon as</div><div class="t m0 xb hb y778 ff9 fs8 fc3 sc0 ls61 ws175">possible to a facility where intramuscular or intr<span class="_ _a"></span>avenous therapy can be started.</div><div class="t m0 x2d hd y779 ff8 fs8 fc0 sc0 ls12 ws0">EVIDENCE: treatment for sever<span class="_ _a"></span>e falciparum malaria in pregnant women</div><div class="t m0 x2d hb y77a ff8 fsb fc4 sc0 lsd2 ws0">Interventions: <span class="ff9 fs8 fc3 ls12">A<span class="_ _8"></span>S, ar<span class="_ _8"></span>temether<span class="_ _4b"></span>, quinine (all parenteral)</span></div><div class="t m3 x38 h1b y77b ff14 fsb fc5 sc0 ls104 ws1d3">Summary of RCT<span class="_ _b"></span>s:</div><div class="t m0 x39 hb y77b ff9 fs8 fc3 sc0 ls12 ws0">none. </div><div class="t m3 x38 h1b y77c ff14 fsb fc5 sc0 ls130 ws39e">Exper<span class="_ _8"></span>t comment: </div><div class="t m0 x8b hb y77c ff9 fs8 fc3 sc0 ls12 ws278">complications of severe malaria ar<span class="_ _a"></span>e more frequent in</div><div class="t m0 x38 hb y77d ff9 fs8 fc3 sc0 ls185 wscc">pregnant women than in non-pregnant adults. Artesunate reduces the</div><div class="t m0 x38 hb y77e ff9 fs8 fc3 sc0 ls12 ws39f">mortality of severe malaria in non pregnant adults compared with</div><div class="t m0 x38 hb y77f ff9 fs8 fc3 sc0 ls12 ws3a0">quinine in low transmission situations. <span class="_ _b"></span>The ar<span class="_ _8"></span>temisinin derivatives</div><div class="t m0 x38 hb y780 ff9 fs8 fc3 sc0 ls12 ws3a1">(artesunate and ar<span class="_ _8"></span>temether) may also have safety advantages com-</div><div class="t m0 x38 hb y781 ff9 fs8 fc3 sc0 ls12 ws3a2">pared with quinine in the second and third trimesters of pr<span class="_ _a"></span>egnancy</div><div class="t m0 x38 hb y782 ff9 fs8 fc3 sc0 ls235 ws276">because they do not cause recurrent hypogly<span class="_ _a"></span>caemia. In the first</div><div class="t m0 x38 hb y783 ff9 fs8 fc3 sc0 ls37 ws48">trimester<span class="_ _4b"></span>, the risk of hypoglycaemia associated with quinine is lower<span class="_ _4b"></span>,</div><div class="t m0 x38 hb y784 ff9 fs8 fc3 sc0 ls236 ws2ea">and the uncertainties over the safety of the artemisinin derivatives ar<span class="_ _a"></span>e</div><div class="t m0 x38 hb y785 ff9 fs8 fc3 sc0 ls13 ws0">greater<span class="_ _4b"></span>.</div><div class="t m3 x38 h17 y786 ff14 fsb fc5 sc0 ls105 ws0">Basis of decision: <span class="ff9 fc3 lsd2">exper<span class="_ _8"></span>t opinion.</span></div><div class="t m0 x2d hb y787 ff8 fsb fc4 sc0 ls10b ws0">R<span class="_ _a"></span>ecommendation: <span class="ff9 fs8 fc3 lsc6 ws13c">use the parenter<span class="_ _a"></span>al antimalarial treatment locally available</span></div><div class="t m0 x2d hb y788 ff9 fs8 fc3 sc0 ls6e ws397">for severe malaria in full doses. <span class="_ _b"></span>Where available, AS is the first, and</div><div class="t m0 x2d hb y789 ff9 fs8 fc3 sc0 ls12 ws0">artemether the second option in the second and third trimesters. </div><div class="t m0 x2d hb y78a ff9 fs8 fc3 sc0 ls87 wscd">In the first trimester<span class="_ _4b"></span>, until more evidence becomes available, both artesunate</div><div class="t m0 x2d hb y78b ff9 fs8 fc3 sc0 ls12 ws0">and quinine may be considered as options.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf46" class="pf w1 h4" data-page-no="46"><div class="pc pc46 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">60</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls17b ws34c">When the patient cannot be mov<span class="_ _a"></span>ed, continued treatment with rectal artesunate</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls64 ws2ea">is appropriate until oral drugs can be taken. It is essential that a full course of</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls64 ws0">antimalarial treatment is completed.</div><div class="t m0 x9 h13 y439 ff8 fs3 fc3 sc0 ls80 ws0">8.12.1<span class="_ _54"> </span>T<span class="_ _b"></span>reatment during pr<span class="_ _a"></span>egnancy in epidemic situations </div><div class="t m0 x9 hb y43a ff9 fs8 fc3 sc0 ls236 ws2fb">In epidemic settings where the need for simplicity is paramount, intr<span class="_ _a"></span>amuscular</div><div class="t m0 x9 hb y43b ff9 fs8 fc3 sc0 ls237 ws67">artemether is the drug of choice for severe malaria in all trimesters of pregnancy<span class="_ _c"></span>. </div><div class="t m0 x9 hd y78c ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendation on treatment of sev<span class="_ _a"></span>ere falciparum malaria </div><div class="t m0 x9 hd y78d ff8 fs8 fc3 sc0 ls12 ws0">in pregnant women in epidemic situations</div><div class="t m0 x9 h12 y78e ff10 fs6 fc4 sc0 ls86 ws0">8.13<span class="_ _1a"> </span>Hyper<span class="_ _8"></span>parasitaemia</div><div class="t m0 x54 h14 y78f ff11 fs5 fc4 sc0 ls1 ws0">18</div><div class="t m0 x9 hb y790 ff9 fs8 fc3 sc0 ls97 wsf0">Patients with high parasite counts ar<span class="_ _a"></span>e known to be at increased risk of dying,</div><div class="t m0 x9 hb y791 ff9 fs8 fc3 sc0 ls12 ws3a3">although the relationship between par<span class="_ _a"></span>asite counts and prognosis varies at</div><div class="t m0 x9 hb y792 ff9 fs8 fc3 sc0 ls85 wsc9">different levels of malaria endemicity<span class="_ _c"></span>. Many hyperparasitaemic patients have</div><div class="t m0 x9 hb y793 ff9 fs8 fc3 sc0 ls12 ws78">evidence of vital organ dysfunction but there is a lar<span class="_ _a"></span>ge subgroup in which no</div><div class="t m0 x9 hb y794 ff9 fs8 fc3 sc0 ls238 ws1ff">other manifestations of severe disease ar<span class="_ _a"></span>e present. These patients hav<span class="_ _a"></span>e</div><div class="t m0 x9 hb y795 ff9 fs8 fc3 sc0 ls12 ws237">symptoms and signs compatible with a diagnosis of uncomplicated malaria</div><div class="t m0 x9 hb y796 ff9 fs8 fc3 sc0 ls12 ws3a4">in association with a high parasite count (sometimes termed uncomplicated</div><div class="t m0 x9 hb y797 ff9 fs8 fc3 sc0 ls12 ws3a5">hyperparasitaemia). <span class="_ _a"></span>The relevance for tr<span class="_ _a"></span>eatment is firstly the increased risk</div><div class="t m0 x9 hb y798 ff9 fs8 fc3 sc0 ls3a ws1b2">of progressing to sev<span class="_ _a"></span>ere malaria, and secondly the generally higher treatment</div><div class="t m0 x9 hb y799 ff9 fs8 fc3 sc0 ls239 ws2cd">failure rates. <span class="_ _b"></span>This is of par<span class="_ _8"></span>ticular concern as resistance to antimalarials is most</div><div class="t m0 x9 hb y79a ff9 fs8 fc3 sc0 lsf ws12f">likely to arise in patients with heavy parasite burdens and little or no immunity<span class="_ _c"></span>.</div><div class="t m0 x9 hb y79b ff9 fs8 fc3 sc0 ls12 ws3a6">In a low-transmission ar<span class="_ _a"></span>ea in nor<span class="_ _8"></span>th-west Thailand, the o<span class="_ _a"></span>verall mortality of</div><div class="t m0 x9 hb y79c ff9 fs8 fc3 sc0 lsfd ws201">uncomplicated falciparum malaria was 0.1%, but in patients with parasitaemia</div><div class="t m0 x9 hb y79d ff9 fs8 fc3 sc0 ls13 ws0">of <span class="_ _9"></span><span class="fff ls0">&gt;<span class="_ _8"></span></span><span class="ls12 ws3a7">4% it was 3%. In areas of moderate or high tr<span class="_ _a"></span>ansmission, much higher</span></div><div class="t m0 x9 hb y79e ff9 fs8 fc3 sc0 ls28 ws34">parasitaemias are often w<span class="_ _a"></span>ell tolerated, howev<span class="_ _a"></span>er<span class="_ _b"></span>. There is not enough evidence</div><div class="t m0 x9 hb y79f ff9 fs8 fc3 sc0 ls12 wsf9">to pro<span class="_ _a"></span>vide a firm recommendation on the definition of hyperparasitaemia,</div><div class="t m0 x9 hb y7a0 ff9 fs8 fc3 sc0 ls23a ws0">although <span class="_ _66"></span><span class="fff ls0">≥<span class="_ _66"></span></span><span class="ws2e9">5% parasitaemia in a low-transmission setting and </span><span class="fff ls0">≥</span><span class="ls23b ws1c7">10% in a</span></div><div class="t m0 x9 hb y7a1 ff9 fs8 fc3 sc0 ls12 ws0">higher transmission setting are commonly used. </div><div class="t m0 x47 h16 y7a2 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TION</div><div class="t m0 x83 h16 y7a3 ff8 fsb fc0 sc0 lsd2 ws0">LEVEL<span class="_ _67"> </span>OF</div><div class="t m0 x6d h16 y7a4 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y7a5 ff9 fsb fc3 sc0 ls156 ws153">Artesunate by the intravenous route is the treatment of choice, but</div><div class="t m3 x47 h17 y7a6 ff9 fsb fc3 sc0 ls23c ws305">if not possible, artemether by the intramuscular route is the preferred</div><div class="t m3 x47 h17 y7a7 ff9 fsb fc3 sc0 ls23d ws3a8">alternative for sever<span class="_ _a"></span>e malaria in pregnancy during a malaria epidemic.</div><div class="t m3 x7c h16 y7a5 ff8 fsb fc3 sc0 ls0 ws0">E</div><div class="t m0 x9 h14 y7a8 ff11 fs5 fc4 sc0 ls1 ws0">18</div><div class="t m0 x14 h15 y7a9 ff9 fsa fc3 sc0 ls7d ws0">Further information is provided in Annex 9.12</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf47" class="pf w1 h4" data-page-no="47"><div class="pc pc47 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls9a ws0">61</div><div class="t m0 xb h13 y296 ff8 fs3 fc3 sc0 ls80 wsc1">8.13.1<span class="_ _a8"> </span>T<span class="_ _4b"></span>reatment of hyperparasitaemia</div><div class="t m0 xb hb y297 ff9 fs8 fc3 sc0 ls16d ws120">Available evidence indicates that use of or<span class="_ _a"></span>al treatment under close supervision</div><div class="t m0 xb hb y298 ff9 fs8 fc3 sc0 ls12 ws205">is effective in the treatment of patients with hyperpar<span class="_ _a"></span>asitaemia who have no</div><div class="t m0 xb hb y299 ff9 fs8 fc3 sc0 ls12 ws3a9">other features of sever<span class="_ _a"></span>e malaria. Parenteral tr<span class="_ _a"></span>eatment should, howev<span class="_ _a"></span>er<span class="_ _b"></span>, be</div><div class="t m0 xb hb y29a ff9 fs8 fc3 sc0 ls1b0 ws2c0">substituted at any time if there is concern. <span class="_ _a"></span>The rapidity of action of the</div><div class="t m0 xb hb y29b ff9 fs8 fc3 sc0 ls79 ws1b3">artemisinin derivatives makes them ideal drugs. <span class="_ _a"></span>The standard treatment course</div><div class="t m0 xb hb y29c ff9 fs8 fc3 sc0 ls58 ws212">should be given, as there is insufficient information on the safety of higher doses</div><div class="t m0 xb hb y29d ff9 fs8 fc3 sc0 ls13 ws3aa">of the partner drug. Alternatively<span class="_ _4b"></span>, the first dose of ar<span class="_ _8"></span>temisinin derivativ<span class="_ _a"></span>e can</div><div class="t m0 xb hb y29e ff9 fs8 fc3 sc0 ls13 ws1e">be given parenter<span class="_ _a"></span>ally or rectally to ensure adequate absorption, follow<span class="_ _a"></span>ed by</div><div class="t m0 xb hb y5b5 ff9 fs8 fc3 sc0 ls50 ws1fa">a full course of ACT<span class="_ _4b"></span>. Mefloquine-containing regimens in which the tablets</div><div class="t m0 xb hb y7aa ff9 fs8 fc3 sc0 lsab ws113">are dispensed separately should be giv<span class="_ _a"></span>en such that mefloquine is given on days</div><div class="t m0 xb hb y7ab ff9 fs8 fc3 sc0 ls12 ws3ab">2 and 3, rather than day 1, when it is better tolerated, with a lo<span class="_ _a"></span>wer incidence</div><div class="t m0 xb hb y7ac ff9 fs8 fc3 sc0 ls12 ws0">of early vomiting.</div><div class="t m0 xb hb y7ad ff9 fs8 fc3 sc0 ls64 ws3ac">The optimum duration of treatment for hyperpar<span class="_ _a"></span>asitaemia is still unresolved.</div><div class="t m0 xb hb y7ae ff9 fs8 fc3 sc0 lsc8 ws18a">Data to support the suggestion that patients should be treated conser<span class="_ _8"></span>vativ<span class="_ _a"></span>ely</div><div class="t m0 xb hb y7af ff9 fs8 fc3 sc0 ls64 ws189">with 7 days of an artemisinin derivative, plus a full course of partner medicine</div><div class="t m0 xb hb y7b0 ff9 fs8 fc3 sc0 ls64 ws1af">(e.g. artesunate 7 days + mefloquine 25<span class="_ _3"> </span>mg/kg bw divided ov<span class="_ _a"></span>er 2 days) are</div><div class="t m0 xb hb y7b1 ff9 fs8 fc3 sc0 ls64 ws48">lacking. A longer ACT<span class="_ _67"> </span>course than is recommended for uncomplicated malaria</div><div class="t m0 xb hb y7b2 ff9 fs8 fc3 sc0 ls141 ws84">may not be possible in places where only fixed-dose combinations ar<span class="_ _a"></span>e available. </div><div class="t m0 xb hd y7b3 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on the treatment of hyperparasitaemia </div><div class="t m0 xb hd y7b4 ff8 fs8 fc3 sc0 ls12 ws0">in falciparum malaria</div><div class="t m0 x2d h16 y7b5 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x8c h16 y7b6 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x55 h16 y7b7 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x2d h17 y7b8 ff9 fsb fc3 sc0 ls23e ws3ad">Hyperparasitaemic patients with no other signs of sev<span class="_ _a"></span>ere disease</div><div class="t m3 x2d h17 y7b9 ff9 fsb fc3 sc0 ls0 ws3ae">should be treated with oral artemisinin derivativ<span class="_ _a"></span>es under the</div><div class="t m3 x2d h17 y7ba ff9 fsb fc3 sc0 lsd2 ws0">following conditions:</div><div class="t m3 x4d h17 y7bb ff9 fsb fc3 sc0 ls1e6 ws30b">– patients must be monitor<span class="_ _a"></span>ed closely for the first 48<span class="_ _5"> </span>h after the</div><div class="t m3 x8d h17 y7bc ff9 fsb fc3 sc0 lsd2 ws0">start of treatment,</div><div class="t m3 x4d h17 y7bd ff9 fsb fc3 sc0 lsd2 ws3af">–<span class="_ _67"> </span>if the patient does not retain oral medication, par<span class="_ _a"></span>enteral</div><div class="t m3 x8d h17 y7be ff9 fsb fc3 sc0 lsd2 ws0">treatment should be given without delay<span class="_ _c"></span>.</div><div class="t m3 x8e h16 y7b8 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m3 x2d h17 y7bf ff9 fsb fc3 sc0 ls147 ws209">Non-immune patients with parasitaemia of <span class="fff ls0 ws0">&gt;<span class="_ _9"></span></span><span class="ls23f">20% should receive</span></div><div class="t m3 x8f h17 y7c0 ff9 fsb fc3 sc0 lsd2 ws0">parenteral antimalarial tr<span class="_ _a"></span>eatment.</div><div class="t m3 x90 h16 y7bf ff8 fsb fc3 sc0 ls0 ws0">E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf48" class="pf w1 h4" data-page-no="48"><div class="pc pc48 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">62</div><div class="t m0 x9 hf y7d ffe fs6 fc3 sc0 ls9e wsfd">9.<span class="_ _33"> </span>TR<span class="_ _8"></span>EA<span class="_ _a"></span>TMENT<span class="_ _64"> </span>OF MAL<span class="_ _8"></span>ARIA C<span class="_ _8"></span>AUS<span class="_ _8"></span>ED B<span class="_ _a"></span>Y <span class="ff13 ls1b ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>VIV<span class="_ _a"></span>A<span class="_ _8"></span>X<span class="ffe ls0">,</span></span></div><div class="t m0 x10 hf y274 ff13 fs6 fc3 sc0 ls1 ws0">P<span class="_ _c"></span>.<span class="_ _95"> </span>OV<span class="_ _a"></span>ALE <span class="ffe ls240">OR </span><span class="ls9a">P<span class="_ _c"></span>.<span class="_ _95"> </span>MALAR<span class="_ _8"></span>IAE</span></div><div class="t m0 x91 h14 y7c1 ff11 fs5 fc4 sc0 ls1 ws0">19</div><div class="t m0 x9 hb y7c2 ffa fs8 fc3 sc0 ls7a ws0">P<span class="_ _c"></span>. vivax<span class="ff9 ws2d9">, the second most important species causing human malaria, accounts</span></div><div class="t m0 x9 hb y7c3 ff9 fs8 fc3 sc0 ls18f wsdc">for about 40% of malaria cases worldwide and is the dominant malaria species</div><div class="t m0 x9 hb y7c4 ff9 fs8 fc3 sc0 ls6d ws3e">outside Africa. It is prev<span class="_ _a"></span>alent in endemic areas in the Middle East, Asia, Oceania</div><div class="t m0 x9 hb y7c5 ff9 fs8 fc3 sc0 ls12 ws3b0">and Central and South America. In Africa, it is rar<span class="_ _a"></span>e except in the Horn and it</div><div class="t m0 x9 hb y7c6 ff9 fs8 fc3 sc0 lsc0 ws17d">is almost absent in W<span class="_ _b"></span>est Africa. In most areas where <span class="ffa ls22b ws0">P<span class="_ _c"></span>. vivax <span class="ff9 ws10e">is pr<span class="_ _a"></span>evalent, malaria</span></span></div><div class="t m0 x9 hb y7c7 ff9 fs8 fc3 sc0 ls47 ws67">transmission rates ar<span class="_ _a"></span>e low<span class="_ _a"></span>, and the affected populations therefore achiev<span class="_ _a"></span>e little</div><div class="t m0 x9 hb y7c8 ff9 fs8 fc3 sc0 ls17f ws25f">immunity to this parasite. Consequently<span class="_ _c"></span>, people of all ages are at risk. The other</div><div class="t m0 x9 hb y7c9 ff9 fs8 fc3 sc0 ls22 ws5e">two human malaria parasite species <span class="ffa ws0">P<span class="_ _c"></span>. malariae<span class="_ _6"> </span><span class="ff9">and <span class="_ _a"></span><span class="ffa">P<span class="_ _c"></span>. ov<span class="_ _a"></span>ale <span class="ff9 ws2bc">are gener<span class="_ _a"></span>ally less</span></span></span></span></div><div class="t m0 x9 hb y7ca ff9 fs8 fc3 sc0 lsab ws113">prev<span class="_ _a"></span>alent but are distributed worldwide especially in the tropical areas of Africa.</div><div class="t m0 x9 hb y7cb ff9 fs8 fc3 sc0 ls12 ws12e">Among the four species of <span class="ffa ws0">Plasmodium </span>that affect humans, only <span class="ffa ls14 ws0">P<span class="_ _c"></span>. viv<span class="_ _b"></span>ax <span class="ff9 ls12">and</span></span></div><div class="t m0 x9 hb y7cc ffa fs8 fc3 sc0 ls241 ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>ov<span class="_ _a"></span>ale<span class="_ _3"> </span><span class="ff9 ws3b1">form hypnozoites, parasite stages in the liver that can result in</span></div><div class="t m0 x9 hb y7cd ff9 fs8 fc3 sc0 ls125 ws1db">multiple relapses of infection, weeks to months after the primary infection. <span class="_ _a"></span>Thus</div><div class="t m0 x9 hb y7ce ff9 fs8 fc3 sc0 lsde ws16b">a single infection causes repeated bouts of illness. <span class="_ _a"></span>This affects the development</div><div class="t m0 x9 hb y7cf ff9 fs8 fc3 sc0 ls48 ws68">and schooling of children and debilitates adults, thereby impairing human and</div><div class="t m0 x9 hb y7d0 ff9 fs8 fc3 sc0 ls242 ws3b2">economic development in affected populations. <span class="_ _a"></span>The objective of treating</div><div class="t m0 x9 hb y7d1 ff9 fs8 fc3 sc0 lsc4 ws1b3">malaria caused by <span class="ffa ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff9 ls1a5">and <span class="_ _b"></span><span class="ffa">P<span class="_ _c"></span>. ovale<span class="_ _6"> </span><span class="ff9 ws76">is to cure both the blood stage and the</span></span></span></span></div><div class="t m0 x9 hb y7d2 ff9 fs8 fc3 sc0 ls13 ws2de">liver stage infections, and thereby pr<span class="_ _a"></span>event both relapse and r<span class="_ _a"></span>ecrudescence.</div><div class="t m0 x9 hb y7d3 ff9 fs8 fc3 sc0 ls12 ws3b3">This is called radical cure. Infection with <span class="ffa ls14 ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>vivax <span class="_ _8"></span><span class="ff9 ls12 ws3b3">during pregnancy<span class="_ _4b"></span>, as with</span></span></div><div class="t m0 x9 hb y7d4 ffa fs8 fc3 sc0 ls243 ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>falciparum<span class="ff9 ws9f">, reduces birth weight. In primigravidae, the reduction is</span></div><div class="t m0 x9 hb y7d5 ff9 fs8 fc3 sc0 lse7 ws178">approximately two-thir<span class="_ _a"></span>ds of that associated with <span class="ffa ws0">P<span class="_ _c"></span>. falciparum <span class="ff9 lsc6 ws13c">(110 g compared</span></span></div><div class="t m0 x9 hb y7d6 ff9 fs8 fc3 sc0 ls5d ws7e">to 170 g), but this adverse effect does not decline with successive pregnancies</div><div class="t m0 x9 hb y7d7 ff9 fs8 fc3 sc0 ls12 ws27c">as with <span class="ffa ls13 ws0">P<span class="_ _c"></span>.<span class="_ _95"> </span>falciparum <span class="ff9 ls12 ws2dd">infections. Indeed, in the one large series in which this</span></span></div><div class="t m0 x9 hb y7d8 ff9 fs8 fc3 sc0 ls12 ws3b4">was studied, it increased. R<span class="_ _a"></span>eduction in bir<span class="_ _8"></span>th weight (<span class="fff ls0 ws0">&lt;<span class="_ _66"></span></span><span class="ls13">2500<span class="_ _95"> </span>g) increases the</span></div><div class="t m0 x9 hb y7d9 ff9 fs8 fc3 sc0 ls12 ws0">risk of neonatal death.</div><div class="t m0 x9 h12 y7da ff10 fs6 fc4 sc0 ls9a ws0">9.1<span class="_ _78"> </span>Diagnosis</div><div class="t m0 x9 hb y7db ff9 fs8 fc3 sc0 lsa1 ws100">The clinical features of uncomplicated malaria are too non-specific for a</div><div class="t m0 x9 hb y7dc ff9 fs8 fc3 sc0 ls1d ws1c">clinical diagnosis of the species of malaria infection to be made. Diagnosis of</div><div class="t m0 x9 hb y7dd ffa fs8 fc3 sc0 ls242 ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>vivax<span class="_ _3"> </span><span class="ff9 ls10d ws3b5">malaria is based on microscopy<span class="_ _c"></span>. Although rapid diagnostic tests</span></div><div class="t m0 x9 hb y7de ff9 fs8 fc3 sc0 ls244 ws19f">based on immunochromatographic methods ar<span class="_ _a"></span>e available for the detection of</div><div class="t m0 x9 hb y7df ff9 fs8 fc3 sc0 ls172 ws18a">non-falciparum malaria, their sensitivities below parasite densities of 500/μl</div><div class="t m0 x9 hb y7e0 ff9 fs8 fc3 sc0 ls12 ws1b3">are low<span class="_ _4b"></span>. Their relativ<span class="_ _a"></span>ely high cost is a fur<span class="_ _8"></span>ther impediment to their wide use in</div><div class="t m0 x9 hb y7e1 ff9 fs8 fc3 sc0 lsd0 ws149">endemic areas. Molecular markers for genotyping <span class="ffa lsc1 ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>vivax<span class="_ _7c"> </span><span class="ff9 lsd0 ws149">parasites have</span></span></div><div class="t m0 x9 hb y7e2 ff9 fs8 fc3 sc0 ls245 ws161">been developed to assist epidemiological and treatment studies but these ar<span class="_ _a"></span>e</div><div class="t m0 x9 hb y7e3 ff9 fs8 fc3 sc0 ls12 ws0">still under evaluation. </div><div class="t m0 x9 h14 y294 ff11 fs5 fc4 sc0 ls1 ws0">19</div><div class="t m0 x14 h15 y295 ff9 fsa fc3 sc0 lsac ws115">Further information is provided in Annex 10.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf49" class="pf w1 h4" data-page-no="49"><div class="pc pc49 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x80 he y9 ffc fs5 fc3 sc0 lsad ws117">8.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of severe falciparum malaria</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1 ws0">63</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls9e wsfd">9.2<span class="_ _78"> </span>Susceptibilit<span class="_ _8"></span>y of <span class="ff12 ls9c ws0">P<span class="_ _7e"></span>. vivax,<span class="_ _5"> </span>P<span class="_ _7e"></span>.<span class="_ _95"> </span>ovale <span class="ff10 ls1">and <span class="ff12">P<span class="_ _7e"></span>. malariae</span></span></span></div><div class="t m0 x6 h12 y12b ff10 fs6 fc4 sc0 ls1 ws0">to antimalarials</div><div class="t m0 xb hb y12c ff9 fs8 fc3 sc0 ls64 ws3b6">There are v<span class="_ _a"></span>ery few recent data on the <span class="ffa ws73">in vivo <span class="ff9">susceptibility of </span><span class="ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>ovale <span class="_ _9"></span><span class="ff9">and</span></span></span></div><div class="t m0 xb hb y12d ffa fs8 fc3 sc0 ls64 ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>malariae<span class="_ _7c"> </span><span class="ff9 ws3b7">to antimalarials. Both species are regarded as very sensitive to</span></div><div class="t m0 xb hb y12f ff9 fs8 fc3 sc0 ls7a wse2">chloroquine, although there is a single r<span class="_ _a"></span>ecent report of chloroquine resistance</div><div class="t m0 xb hb y130 ff9 fs8 fc3 sc0 ls1c3 ws0">in <span class="_ _66"></span><span class="ffa">P<span class="_ _c"></span>.<span class="_ _68"> </span>malariae. <span class="_ _66"></span><span class="ff9 ws2f2">E<span class="_ _8"></span>xperience indicates that </span>P<span class="_ _c"></span>.<span class="_ _68"> </span>ovale <span class="_ _9"></span><span class="ff9">and <span class="_ _66"></span></span>P<span class="_ _c"></span>.<span class="_ _68"> </span>malariae<span class="_ _68"> </span><span class="ff9 ws2f2">are also</span></span></div><div class="t m0 xb hb y131 ff9 fs8 fc3 sc0 ls126 wsec">susceptible to amodiaquine, mefloquine and the artemisinin derivatives. <span class="_ _a"></span>Their</div><div class="t m0 xb hb y132 ff9 fs8 fc3 sc0 ls62 ws1b3">susceptibility to antifolate antimalarials such as sulfadoxine-pyrimethamine is</div><div class="t m0 xb hb y133 ff9 fs8 fc3 sc0 ls75 ws1a8">less certain. <span class="ffa ls246 ws0">P.<span class="_ _68"> </span>v i<span class="_ _67"> </span>v a<span class="_ _67"> </span>x<span class="_ _64"> </span></span><span class="ls13b">susceptibility has been studied extensively<span class="_ _4b"></span>, and now that</span></div><div class="t m0 xb hb y134 ff9 fs8 fc3 sc0 ls191 ws3b8">short-term culture methodologies have been standardized, clinical studies</div><div class="t m0 xb hb y135 ff9 fs8 fc3 sc0 ls7f ws3b9">have been supported by <span class="ffa ls10e ws3ba">in vitro <span class="ff9 ws0">observations. <span class="_ _9"></span><span class="ffa">P<span class="_ _c"></span>.<span class="_ _64"> </span>vivax<span class="_ _64"> </span><span class="ff9 ws3ba">is still generally very</span></span></span></span></div><div class="t m0 xb hb y7e4 ff9 fs8 fc3 sc0 ls22b ws256">sensitive to chloroquine, although r<span class="_ _a"></span>esistance is prevalent and incr<span class="_ _a"></span>easing in some</div><div class="t m0 xb hb y7e5 ff9 fs8 fc3 sc0 ls64 ws2b3">areas, notably Oceania, Indonesia and Peru (see Annex A.6.4). R<span class="_ _a"></span>esistance to</div><div class="t m0 xb hb y7e6 ff9 fs8 fc3 sc0 ls127 ws27b">pyrimethamine has increased rapidly in some ar<span class="_ _a"></span>eas, and sulfadoxine-</div><div class="t m0 xb hb y7e7 ff9 fs8 fc3 sc0 lsb2 ws13e">pyrimethamine is consequently ineffective. <span class="_ _a"></span>There are insufficient data on</div><div class="t m0 xb hb y7e8 ff9 fs8 fc3 sc0 ls64 ws127">current susceptibility to proguanil and chlorpr<span class="_ _a"></span>oguanil, although resistance to</div><div class="t m0 xb hb y7e9 ff9 fs8 fc3 sc0 ls91 wsc0">proguanil was selected rapidly when it was first used in <span class="ffa ws0">P<span class="_ _c"></span>.viv<span class="_ _a"></span>ax <span class="_ _a"></span><span class="ff9 wsc0">endemic areas.</span></span></div><div class="t m0 xb hb y7ea ff9 fs8 fc3 sc0 ls64 ws3bb">In general, <span class="ffa ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>vivax<span class="_ _95"> </span><span class="ff9 ws3bb">is sensitive to all the other antimalarial drugs; it is more</span></span></div><div class="t m0 xb hb y7eb ff9 fs8 fc3 sc0 ls64 ws3bc">sensitive than <span class="ffa ws0">P<span class="_ _c"></span>.<span class="_ _7c"> </span>falciparum<span class="_ _7c"> </span><span class="ff9 ws3bc">to the ar<span class="_ _8"></span>temisinin derivatives, and slightly less</span></span></div><div class="t m0 xb hb y7ec ff9 fs8 fc3 sc0 ls64 ws3bd">sensitive to mefloquine (although mefloquine is still effectiv<span class="_ _a"></span>e). In contrast to</div><div class="t m0 xb hb y7ed ffa fs8 fc3 sc0 ls64 ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum<span class="ff9 ws3be">, asexual stages of </span>P<span class="_ _c"></span>.<span class="_ _64"> </span>vivax <span class="ff9 ws3be">are susceptible to primaquine. Thus</span></div><div class="t m0 xb hb y7ee ff9 fs8 fc3 sc0 ls64 ws135">chloroquine + primaquine can be considered as a combination tr<span class="_ _a"></span>eatment. The</div><div class="t m0 xb hb y7ef ff9 fs8 fc3 sc0 ls64 ws26d">only drugs with significant activity against the hypnozoites are the 8-amino-</div><div class="t m0 xb hb y7f0 ff9 fs8 fc3 sc0 ls64 ws2b7">quinolines (bulaquine, primaquine, tafenoquine). Ther<span class="_ _a"></span>e is no standardized in</div><div class="t m0 xb hb y7f1 ff9 fs8 fc3 sc0 ls165 ws26e">vitro method of drug assessment for hypnozoiticidal activity<span class="_ _c"></span>. <span class="ffa">In vivo </span><span class="ws0">assessment</span></div><div class="t m0 xb hb y7f2 ff9 fs8 fc3 sc0 ls64 ws3bf">suggests that tolerance of <span class="ffa ws0">P<span class="_ _c"></span>.<span class="_ _95"> </span>vivax <span class="ff9 ws3c0">to primaquine in East Asia and Oceania is</span></span></div><div class="t m0 xb hb y7f3 ff9 fs8 fc3 sc0 ls64 ws0">greater than elsewhere.</div><div class="t m0 xb h12 y7f4 ff10 fs6 fc4 sc0 ls9a ws0">9.3<span class="_ _78"> </span>T<span class="_ _c"></span>reatment of uncomplicated vivax malaria</div><div class="t m0 xb h13 y7f5 ff8 fs3 fc3 sc0 ls80 ws0">9.3.1<span class="_ _2d"> </span>Blood stage infection</div><div class="t m0 xb hb y7f6 ff9 fs8 fc3 sc0 ls8a wsd0">There have been few<span class="_ _a"></span>er studies on the treatment of malaria caused by <span class="ffa ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax</span></div><div class="t m0 xb hb y7f7 ff9 fs8 fc3 sc0 ls1d6 ws2f7">than of falciparum malaria – only 11% of 435 published before 2004. F<span class="_ _a"></span>or</div><div class="t m0 xb hb y7f8 ff9 fs8 fc3 sc0 ls15e ws56">chloroquine-sensitive viv<span class="_ _b"></span>ax malaria (i.e. in most places where <span class="ffa ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>vivax<span class="_ _3"> </span><span class="ff9 ls129">is</span></span></div><div class="t m0 xb hb y7f9 ff9 fs8 fc3 sc0 ls42 ws5b">prev<span class="_ _a"></span>alent) the conventional oral chloroquine dose of 25 mg base/kg bw is well</div><div class="t m0 xb hb y7fa ff9 fs8 fc3 sc0 ls91 wse6">tolerated and effective. Some hav<span class="_ _a"></span>e advocated low<span class="_ _a"></span>er total doses, but this is not</div><div class="t m0 xb hb y7fb ff9 fs8 fc3 sc0 ls25 ws27">recommended as it might encourage the emer<span class="_ _a"></span>gence of resistance. Chloroquine</div><div class="t m0 xb hb y7fc ff9 fs8 fc3 sc0 ls92 wse7">is given in an initial dose of 10 mg base/kg bw followed by either 5 mg/kg bw</div><div class="t m0 xb hb y7fd ff9 fs8 fc3 sc0 ls14 ws1c1">at 6 h, 24<span class="_ _95"> </span>h and 48<span class="_ _95"> </span>h or<span class="_ _b"></span>, more commonly<span class="_ _4b"></span>, by 10<span class="_ _95"> </span>mg/kg bw on the second day</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4a" class="pf w1 h4" data-page-no="4a"><div class="pc pc4a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1 ws0">64</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 ls1be ws294">and 5 mg/kg bw on the third day<span class="_ _4b"></span>. It is also clear that if ACT tr<span class="_ _a"></span>eatment is given,</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls1e1 ws312">the response is as good as or better than in falciparum malaria<span class="ffa ls247 ws0">. <span class="_ _a"></span><span class="ff9 ls1e1">The<span class="_ _6"> </span>exception</span></span></div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls12 ws379">to this is a regimen containing sulfadoxine-pyrimethamine. It appears that</div><div class="t m0 x9 hb ya1 ffa fs8 fc3 sc0 ls6b ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff9 ls1a5 ws76">has dev<span class="_ _a"></span>eloped resistance to sulfadoxine-pyrimethamine more r<span class="_ _a"></span>apidly</span></div><div class="t m0 x9 hb yc0 ff9 fs8 fc3 sc0 ls12 ws3c1">than has <span class="ffa ls13 ws0">P<span class="_ _c"></span>. falciparum,<span class="_ _6"> </span><span class="ff9 ls12 ws3c1">so that artesunate + sulfadoxine-pyrimethamine may</span></span></div><div class="t m0 x9 hb yc1 ff9 fs8 fc3 sc0 ls12 ws0">not be effective against <span class="ffa ls14">P<span class="_ _c"></span>. vivax <span class="ff9 ls12">in many areas.</span></span></div><div class="t m0 x9 h13 y46b ff8 fs3 fc3 sc0 ls80 ws0">Chloroquine-resistant viv<span class="_ _b"></span>ax malaria</div><div class="t m0 x9 hb y39d ff9 fs8 fc3 sc0 ls27 ws30">There are r<span class="_ _a"></span>elatively few data on treatment responses in chlor<span class="_ _a"></span>oquine-resistant</div><div class="t m0 x9 hb y154 ff9 fs8 fc3 sc0 lsb8 ws127">vivax malaria. S<span class="_ _a"></span>tudies from Indonesia indicate that amodiaquine is efficacious,</div><div class="t m0 x9 hb y155 ff9 fs8 fc3 sc0 ls1ae ws2bc">and there is some evidence that mefloquine and quinine can also be used. <span class="_ _a"></span>The</div><div class="t m0 x9 hb y156 ff9 fs8 fc3 sc0 ls12 ws1c5">artemisinin derivatives would also be expected to be highly effective, and</div><div class="t m0 x9 hb y112 ff9 fs8 fc3 sc0 ls5b ws78">artemether-lumefantrine could be an alternativ<span class="_ _a"></span>e treatment. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, there are</div><div class="t m0 x9 hb y157 ff9 fs8 fc3 sc0 ls12 ws0">insufficient clinical data to confirm this.</div><div class="t m0 x9 h13 y7fe ff8 fs3 fc3 sc0 ls80 ws0">9.3.2<span class="_ _3b"> </span>Liver stage infection</div><div class="t m0 x9 hb y7ff ff9 fs8 fc3 sc0 ls233 ws232">T<span class="_ _4b"></span>o achieve radical cur<span class="_ _a"></span>e, relapses must be prevented by giving primaquine.</div><div class="t m0 x9 hb y800 ff9 fs8 fc3 sc0 ls64 ws3c2">The frequency and pattern of relapses v<span class="_ _b"></span>aries geographically<span class="_ _4b"></span>, however<span class="_ _4b"></span>. It has</div><div class="t m0 x9 hb y43f ff9 fs8 fc3 sc0 ls1c8 wsbc">become clear in recent years that wher<span class="_ _a"></span>eas 50–60% of <span class="ffa ls248 ws0">P.<span class="_ _3"> </span>v<span class="_ _67"> </span>i<span class="_ _66"></span>v<span class="_ _66"></span>a<span class="_ _67"> </span>x<span class="_ _7c"> </span></span>infections in South-</div><div class="t m0 x9 hb y440 ff9 fs8 fc3 sc0 ls64 ws3c3">East Asia relapse, the frequency is lo<span class="_ _a"></span>wer in Indonesia (30%) and the Indian</div><div class="t m0 x9 hb y441 ff9 fs8 fc3 sc0 ls222 ws30">subcontinent (15–20%). Some <span class="ffa ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff9 ws30">infections in the K<span class="_ _b"></span>orean peninsula (now</span></span></div><div class="t m0 x9 hb y442 ff9 fs8 fc3 sc0 lsbf ws21">the most northerly of human malarias) have an incubation period of nearly one</div><div class="t m0 x9 hb y443 ff9 fs8 fc3 sc0 ls94 ws3c4">year<span class="_ _4b"></span>. Thus the preventiv<span class="_ _a"></span>e efficacy of primaquine must be set against the</div><div class="t m0 x9 hb y444 ff9 fs8 fc3 sc0 ls249 ws13b">prev<span class="_ _a"></span>alent relapse frequency<span class="_ _c"></span>. It appears that the total dose of 8-aminoquinoline</div><div class="t m0 x9 hb y445 ff9 fs8 fc3 sc0 ls3a wsd0">given is the main determinant of curativ<span class="_ _a"></span>e efficacy against liver<span class="_ _b"></span>-stage infection.</div><div class="t m0 x9 hb y446 ff9 fs8 fc3 sc0 ls24a wsdc">There is no evidence that the short courses of primaquine widely recommended</div><div class="t m0 x9 hb y447 ff9 fs8 fc3 sc0 ls1a5 ws262">(such as 5-day regimens) have any efficacy<span class="_ _c"></span>. Primaquine should be given for 14</div><div class="t m0 x9 hb y448 ff9 fs8 fc3 sc0 ls64 ws3c5">days. The usual adult or<span class="_ _a"></span>al dose is 15<span class="_ _95"> </span>mg base (0.25 mg/kg bw per day) but in</div><div class="t m0 x9 hb y449 ff9 fs8 fc3 sc0 ls64 ws110">South-East Asia, particularly Indonesia, and in Oceania, higher doses (0.5<span class="_ _5"> </span>mg</div><div class="t m0 x9 hb y44a ff9 fs8 fc3 sc0 ls64 ws3c6">base/kg bw per day) are r<span class="_ _a"></span>equired. Primaquine causes abdominal discomfort</div><div class="t m0 x9 hb y44b ff9 fs8 fc3 sc0 ls64 ws0">when taken on an empty stomach; it should always be taken with food. </div><div class="t m0 x9 hb y801 ff9 fs8 fc3 sc0 ls8a wsd0">There has been debate as to whether primaquine should be given in endemic</div><div class="t m0 x9 hb y802 ff9 fs8 fc3 sc0 ls24b ws3c7">areas. R<span class="_ _a"></span>epeated vivax malaria relapses ar<span class="_ _a"></span>e debilitating at any age, but if</div><div class="t m0 x9 hb y803 ff9 fs8 fc3 sc0 ls12 ws3c8">reinfection is very frequent, then the risks of widespr<span class="_ _a"></span>ead use of primaquine</div><div class="t m0 x9 hb y804 ff9 fs8 fc3 sc0 lsaa ws110">may exceed the benefits. In low-tr<span class="_ _a"></span>ansmission areas, the benefits of deploying</div><div class="t m0 x9 hb y805 ff9 fs8 fc3 sc0 ls1be ws294">primaquine are considered to ex<span class="_ _a"></span>ceed the risks, but in areas of sustained high</div><div class="t m0 x9 hb y806 ff9 fs8 fc3 sc0 ls12 ws1ab">transmission (such as on the island of New Guinea), <span class="ffa ls13">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff9 ls12">infection is very</span></span></div><div class="t m0 x9 hb y807 ff9 fs8 fc3 sc0 ls12 ws3c9">frequent, immunity is acquired, and the risks of widespr<span class="_ _a"></span>ead deployment of</div><div class="t m0 x9 hb y808 ff9 fs8 fc3 sc0 ls12 ws0">primaquine are considered to outw<span class="_ _a"></span>eigh the benefits.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4b" class="pf w1 h4" data-page-no="4b"><div class="pc pc4b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x35 he y9 ffc fs5 fc3 sc0 ls3 ws0">9.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of malaria caused by <span class="ffd ls24c">P<span class="_ _4b"></span>. vivax,<span class="_ _6"> </span>P<span class="_ _4b"></span>. ovale <span class="ffc ls3">or </span><span class="lsad">P<span class="_ _c"></span>. malariae</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls9a ws0">65</div><div class="t m0 xb h1e y9e ff14 fs8 fc3 sc0 ls12 ws0">Primaquine and glucose-6-phosphate dehydrogenase deficiency</div><div class="t m0 xb hb y809 ff9 fs8 fc3 sc0 ls12 ws2e">The inherited sex-linked deficiency in glucose-6-phosphate dehydrogenase</div><div class="t m0 xb hb y80a ff9 fs8 fc3 sc0 ls12 ws3ca">(G6PD) is associated with some protection against falciparum malaria, but</div><div class="t m0 xb hb y80b ff9 fs8 fc3 sc0 ls1a7 ws2a8">increased susceptibility to oxidant haemolysis. <span class="_ _b"></span>The prevalence of G6PD</div><div class="t m0 xb hb y80c ff9 fs8 fc3 sc0 ls58 ws212">deficiency varies but can be as high as 30%. <span class="_ _b"></span>There are many different genotypes,</div><div class="t m0 xb hb y80d ff9 fs8 fc3 sc0 ls12 ws3cb">each with different levels of deficiency<span class="_ _c"></span>. Primaquine is an oxidant and causes</div><div class="t m0 xb hb y80e ff9 fs8 fc3 sc0 lsa8 ws10a">variable haemolysis in G6PD-deficient individuals. F<span class="_ _a"></span>ortunately primaquine is</div><div class="t m0 xb hb y80f ff9 fs8 fc3 sc0 ls94 wsea">eliminated rapidly and so haemolysis is self-limiting pro<span class="_ _a"></span>vided no fur<span class="_ _8"></span>ther</div><div class="t m0 xb hb y810 ff9 fs8 fc3 sc0 ls12 ws3cc">medicine is taken. Screening for G6PD deficiency is not generally av<span class="_ _b"></span>ailable</div><div class="t m0 xb hb y811 ff9 fs8 fc3 sc0 ls126 ws1dc">outside hospitals, although rapid tests are under dev<span class="_ _a"></span>elopment. Many patients</div><div class="t m0 xb hb y812 ff9 fs8 fc3 sc0 ls48 ws68">are therefor<span class="_ _a"></span>e unaware of their G6PD status. If a patient is known to be sev<span class="_ _a"></span>erely</div><div class="t m0 xb hb y813 ff9 fs8 fc3 sc0 ls24d ws1a2">G6PD deficient then primaquine should not be given. F<span class="_ _a"></span>or the majority of</div><div class="t m0 xb hb y814 ff9 fs8 fc3 sc0 ls12 ws2e">patients with mild variants of the deficiency<span class="_ _c"></span>, primaquine should be given in</div><div class="t m0 xb hb y815 ff9 fs8 fc3 sc0 ls24e ws3cd">a dose of 0.75 mg base/kg bw once a week for 8 weeks. If significant haemolysis</div><div class="t m0 xb hb y816 ff9 fs8 fc3 sc0 ls12 ws0">occurs on treatment then primaquine should be stopped.</div><div class="t m0 xb hd y817 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on the treatment of uncomplicated viv<span class="_ _a"></span>ax</div><div class="t m0 xb hd y818 ff8 fs8 fc3 sc0 ls12 ws0">malaria </div><div class="t m0 x8f h16 y819 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x8c h16 y81a ff8 fsb fc0 sc0 lsd2 ws0">LEVEL<span class="_ _67"> </span>OF</div><div class="t m0 x55 h16 y81b ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x8f h17 y81c ff9 fsb fc3 sc0 ls70 ws3ce">Chloroquine 25 mg base/kg bw divided over 3 days, combined with</div><div class="t m3 x8f h17 y81d ff9 fsb fc3 sc0 ls105 ws27e">primaquine 0.25 mg base/kg bw, taken with food once daily for 14</div><div class="t m3 x8f h17 y81e ff9 fsb fc3 sc0 ls1e6 ws3cf">days is the treatment of choice for chloroquine-sensitiv<span class="_ _a"></span>e infections.</div><div class="t m3 x8f h17 y81f ff9 fsb fc3 sc0 ls105 ws3d0">In Oceania and South-East Asia the dose of primaquine should be</div><div class="t m3 x8f h17 y820 ff9 fsb fc3 sc0 ls105 ws0">0.5 mg/kg bw<span class="_ _a"></span>.</div><div class="t m3 x8e h16 y81c ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m3 x8f h17 y821 ff9 fsb fc3 sc0 ls24f ws3d1">Amodiaquine (30 mg base/kg bw divided over 3 days as 10 mg/kg</div><div class="t m3 x8f h17 y822 ff9 fsb fc3 sc0 ls213 ws385">bw single daily doses) combined with primaquine should be given</div><div class="t m3 x8f h17 y823 ff9 fsb fc3 sc0 lsd2 ws0">for chloroquine-resistant viv<span class="_ _a"></span>ax malaria.</div><div class="t m3 x8e h16 y821 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m3 x8f h17 y824 ff9 fsb fc3 sc0 lsd2 ws3d2">In moderate G6PD deficiency<span class="_ _4b"></span>, primaquine 0.75<span class="_ _3"> </span>mg base/kg bw</div><div class="t m3 x8f h17 y825 ff9 fsb fc3 sc0 ls250 ws2a1">should be given once a week for 8 weeks. In sev<span class="_ _a"></span>ere G6PD deficiency<span class="_ _4b"></span>,</div><div class="t m3 x8f h17 y826 ff9 fsb fc3 sc0 lsd2 ws0">primaquine should not be given.</div><div class="t m3 x8e h16 y824 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m3 x8f h17 y827 ff9 fsb fc3 sc0 ls251 ws3d3">Where ACT<span class="_ _64"> </span>has been adopted as the first-line treatment for</div><div class="t m3 x8f h17 y828 ffa fsb fc3 sc0 lsd8 ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum<span class="_ _95"> </span><span class="ff9 lsd2 ws3d4">malaria, it may also be used for </span><span class="ls154">P<span class="_ _c"></span>.<span class="_ _64"> </span>vivax <span class="ff9 lsd2 ws3d4">malaria in</span></span></div><div class="t m3 x8f h17 y829 ff9 fsb fc3 sc0 ls252 ws3d5">combination with primaquine for radical cure. Artesunate +</div><div class="t m3 x8f h17 y82a ff9 fsb fc3 sc0 ls253 ws3d6">sulfadoxine-pyrimethamine is the exception as it will not be</div><div class="t m3 x8f h17 y82b ff9 fsb fc3 sc0 lsd2 ws0">effective against <span class="ffa ls154">P<span class="_ _c"></span>. vivax <span class="ff9 lsd2">in many places.</span></span></div><div class="t m3 x8e h16 y827 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4c" class="pf w1 h4" data-page-no="4c"><div class="pc pc4c w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls0 ws0">66</div><div class="t m0 x9 h12 y12a ff10 fs6 fc4 sc0 ls0 ws95">9.4<span class="_ _78"> </span>T<span class="_ _c"></span>reatment of severe vivax malar<span class="_ _8"></span>ia</div><div class="t m0 x9 hb y1cf ff9 fs8 fc3 sc0 ls151 ws0">Although <span class="_ _a"></span><span class="ffa ls254">P.<span class="_ _3"> </span>v<span class="_ _67"> </span>i v<span class="_ _67"> </span>a x<span class="_ _3"> </span><span class="ff9 ls151 ws215">malaria is considered to be a benign malaria, with a v<span class="_ _a"></span>ery low</span></span></div><div class="t m0 x9 hb y1d0 ff9 fs8 fc3 sc0 ls12 ws3d7">case-fatality ratio, it may still cause a sever<span class="_ _a"></span>e and debilitating febrile illness.</div><div class="t m0 x9 hb y1d1 ff9 fs8 fc3 sc0 ls85 wsc9">It can also very occasionally result in sev<span class="_ _a"></span>ere disease as in falciparum malaria.</div><div class="t m0 x9 hb y1d2 ff9 fs8 fc3 sc0 ls4c ws3d8">Severe viv<span class="_ _b"></span>ax malaria manifestations that have been reported are cerebral</div><div class="t m0 x9 hb y1d3 ff9 fs8 fc3 sc0 ls141 ws1bd">malaria, severe anaemia, sev<span class="_ _a"></span>ere thrombocytopenia and pancytopenia, jaundice,</div><div class="t m0 x9 hb y217 ff9 fs8 fc3 sc0 ls12 wse1">spleen rupture, acute renal failur<span class="_ _a"></span>e and acute respiratory distress syndrome.</div><div class="t m0 x9 hb y218 ff9 fs8 fc3 sc0 ls21 ws20">Severe anaemia and acute pulmonary oedema are not uncommon. <span class="_ _b"></span>The</div><div class="t m0 x9 hb y219 ff9 fs8 fc3 sc0 ls12 ws32c">underlying mechanisms of severe manifestations ar<span class="_ _a"></span>e not well understood. </div><div class="t m0 x9 hb y263 ff9 fs8 fc3 sc0 ls200 ws25">Prompt and effectiv<span class="_ _a"></span>e treatment and case management should be the same as</div><div class="t m0 x9 hb y1d8 ff9 fs8 fc3 sc0 ls12 ws0">for severe and complicated falciparum malaria (see section 8). </div><div class="t m0 x9 h12 y82c ff10 fs6 fc4 sc0 ls9a ws0">9.5<span class="_ _78"> </span>T<span class="_ _c"></span>reatment of malaria c<span class="_ _8"></span>aused by <span class="ff12 ls255">P<span class="_ _7e"></span>.<span class="_ _5"> </span>ovale</span></div><div class="t m0 x28 h12 y82d ff10 fs6 fc4 sc0 ls1 ws0">and <span class="ff12">P<span class="_ _7e"></span>.<span class="_ _5"> </span>malar<span class="_ _8"></span>iae</span></div><div class="t m0 x9 hb y82e ff9 fs8 fc3 sc0 ls32 ws5b">Resistance of <span class="ffa ws0">P<span class="_ _c"></span>. o<span class="_ _a"></span>vale<span class="_ _6"> </span><span class="ff9">and <span class="_ _a"></span><span class="ffa">P<span class="_ _c"></span>. malariae <span class="ff9 ws43">to antimalarials is not well char<span class="_ _a"></span>acterized</span></span></span></span></div><div class="t m0 x9 hb y82f ff9 fs8 fc3 sc0 ls13 ws217">and infections caused by these two species are considered to be gener<span class="_ _a"></span>ally</div><div class="t m0 x9 hb y830 ff9 fs8 fc3 sc0 ls5b ws78">sensitive to chloroquine. Only one study<span class="_ _c"></span>, conducted in Indonesia, has reported</div><div class="t m0 x9 hb y831 ff9 fs8 fc3 sc0 ls256 ws1a8">resistance to chloroquine in <span class="ffa ls97 ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>malariae<span class="ff9 ls256 ws1a8">. The recommended tr<span class="_ _a"></span>eatment for the</span></span></div><div class="t m0 x9 hb y832 ff9 fs8 fc3 sc0 ls83 wsc7">relapsing malaria caused by <span class="ffa ls257 ws0">P.<span class="_ _3"> </span>o v<span class="_ _67"> </span>a l<span class="_ _67"> </span>e<span class="_ _7c"> </span></span><span class="ls56 ws72">is the same as that given to achieve radical</span></div><div class="t m0 x9 hb y833 ff9 fs8 fc3 sc0 ls45 wsbb">cure in viv<span class="_ _a"></span>ax malaria, i.e. with chloroquine and primaquine. <span class="ffa ws0">P<span class="_ _c"></span>. malariae<span class="_ _6"> </span><span class="ff9">should</span></span></div><div class="t m0 x9 hb y834 ff9 fs8 fc3 sc0 ls12 ws2c2">be treated with the standard r<span class="_ _a"></span>egimen of chloroquine as for vivax malaria, but</div><div class="t m0 x9 hb y835 ff9 fs8 fc3 sc0 lsc4 ws1b3">it does not require r<span class="_ _a"></span>adical cure with primaquine as no hypnozoites are formed</div><div class="t m0 x9 hb y836 ff9 fs8 fc3 sc0 ls12 ws0">in infection with this species. </div><div class="t m0 x9 hb y837 ffa fs8 fc3 sc0 ls38 ws0">P. o<span class="_ _67"> </span>v a l<span class="_ _67"> </span>e<span class="_ _68"> </span><span class="ff9 ls12 ws1ed">mainly occurs in areas of high stable transmission wher<span class="_ _a"></span>e the risk of</span></div><div class="t m0 x9 hb y838 ff9 fs8 fc3 sc0 ls12 ws3d9">re-infection is high. In such settings, primaquine treatment is not indicated. </div><div class="t m0 x9 h12 y839 ff10 fs6 fc4 sc0 ls9a ws3da">9.6<span class="_ _78"> </span>Monitoring therap<span class="_ _8"></span>eutic efficac<span class="_ _8"></span>y for vivax malar<span class="_ _8"></span>ia</div><div class="t m0 x9 hb y83a ff9 fs8 fc3 sc0 ls12 ws3db">The antimalarial sensitivity of vivax malaria needs monitoring, to tr<span class="_ _a"></span>ack and</div><div class="t m0 x9 hb y83b ff9 fs8 fc3 sc0 ls12 ws3dc">respond to emerging r<span class="_ _a"></span>esistance to chloroquine. <span class="_ _a"></span>The 28-day <span class="ffa ls13 ws271">in vivo </span>test for</div><div class="t m0 x9 hb y83c ffa fs8 fc3 sc0 ls258 ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>vivax<span class="_ _3"> </span><span class="ff9 ws3dd">is similar to that for </span>P<span class="_ _c"></span>.<span class="_ _68"> </span>falciparum<span class="_ _3"> </span><span class="ff9 ws3dd">(see Annex 6), although the</span></div><div class="t m0 x9 hb y83d ff9 fs8 fc3 sc0 ls12 wsf5">interpretation is slightly different. Genotyping may distinguish a r<span class="_ _a"></span>einfection</div><div class="t m0 x9 hb y83e ff9 fs8 fc3 sc0 ls12 ws3de">from a recrudescence and fr<span class="_ _a"></span>om acquisition of a new infection, but it is not</div><div class="t m0 x9 hb y83f ff9 fs8 fc3 sc0 ls5b ws78">possible to distinguish reliably between a r<span class="_ _a"></span>elapse and a recrudescence as they</div><div class="t m0 x9 hb y840 ff9 fs8 fc3 sc0 ls259 ws3df">derive from the same infection. If par<span class="_ _a"></span>asitaemia recurs within 16 days of</div><div class="t m0 x9 hb y841 ff9 fs8 fc3 sc0 ls12 ws283">administering treatment then relapse is unlikely<span class="_ _c"></span>, but after that time, relapse</div><div class="t m0 x9 hb y842 ff9 fs8 fc3 sc0 ls0 ws2e6">cannot be distinguished from a recrudescence. Any <span class="ffa ls12 ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>viv<span class="_ _a"></span>ax<span class="_ _3"> </span><span class="ff9 ls50 ws1fa">infection that</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4d" class="pf w1 h4" data-page-no="4d"><div class="pc pc4d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x35 he y9 ffc fs5 fc3 sc0 ls3 ws0">9.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of malaria caused by <span class="ffd ls24c">P<span class="_ _4b"></span>. vivax,<span class="_ _6"> </span>P<span class="_ _4b"></span>. ovale <span class="ffc ls3">or </span><span class="lsad">P<span class="_ _c"></span>. malariae</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls1b ws0">67</div><div class="t m0 xb hb y9e ff9 fs8 fc3 sc0 ls12 ws3e0">recurs within 28 days, whatever its origin, must be r<span class="_ _a"></span>esistant to chloroquine</div><div class="t m0 xb hb y9f ff9 fs8 fc3 sc0 ls48 ws68">(or any other slowly eliminated antimalarial) pro<span class="_ _a"></span>vided adequate treatment has</div><div class="t m0 xb hb ya0 ff9 fs8 fc3 sc0 ls204 ws350">been given. In the case of chloroquine, adequate absorption can be confirmed</div><div class="t m0 xb hb ya1 ff9 fs8 fc3 sc0 ls13 wsc7">by measurement of the whole blood concentration at the time of r<span class="_ _a"></span>ecurrence.</div><div class="t m0 xb hb yc0 ff9 fs8 fc3 sc0 ls13 ws0">Any <span class="_ _66"></span><span class="ffa ls14">P<span class="_ _c"></span>.<span class="_ _68"> </span>vivax<span class="_ _7c"> </span><span class="ff9 ls12 wsf9">infection that has grown <span class="ffa ls13">in viv<span class="_ _a"></span>o <span class="ff9 ls12">through a chloroquine blood</span></span></span></span></div><div class="t m0 xb hb yc1 ff9 fs8 fc3 sc0 ls12 ws0">concentration <span class="_ _a"></span><span class="fff ls0">≥<span class="_ _66"></span><span class="ff9 ls13 wsab">100 ng/ml must be chloroquine resistant. Shor<span class="_ _8"></span>t-term <span class="ffa wsb1">in vitro</span></span></span></div><div class="t m0 xb hb y10d ff9 fs8 fc3 sc0 ls13 ws3e1">culture allows assessment of <span class="ffa">in vitr<span class="_ _a"></span>o <span class="ff9 ls12 ws3e2">susceptibility<span class="_ _4b"></span>. There are no molecular</span></span></div><div class="t m0 xb hb y10e ff9 fs8 fc3 sc0 ls247 ws21">markers yet identified for chloroquine r<span class="_ _a"></span>esistance. Antifolate resistance can be</div><div class="t m0 xb hb y10f ff9 fs8 fc3 sc0 ls13 ws3e3">monitored by molecular genotyping of the gene that encodes dihydr<span class="_ _a"></span>ofolate</div><div class="t m0 xb hb y110 ff9 fs8 fc3 sc0 ls12 ws0">reductase (<span class="ffa">Pvdhfr</span><span class="ls13">). </span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4e" class="pf w1 h4" data-page-no="4e"><div class="pc pc4e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls1b ws0">68</div><div class="t m0 x9 hf y7d ffe fs6 fc3 sc0 ls0 ws95">10.<span class="_ _2"> </span>MIXED MAL<span class="_ _8"></span>ARIA I<span class="_ _8"></span>NF<span class="_ _8"></span>ECTIONS</div><div class="t m0 x9 hb yce ff9 fs8 fc3 sc0 ls15b ws136">Mixed malaria infections are common. In <span class="_ _b"></span>Thailand, despite low levels of</div><div class="t m0 x9 hb y165 ff9 fs8 fc3 sc0 ls25a ws1b3">malaria transmission, one-third of patients with acute <span class="ffa ws0">P<span class="_ _c"></span>. falciparum<span class="_ _6"> </span><span class="ff9">infection</span></span></div><div class="t m0 x9 hb y166 ff9 fs8 fc3 sc0 ls3b ws28e">are co-infected with <span class="ffa ls201 ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax<span class="ff9 ls3b ws28e">, and 8% of patients with acute vivax malaria have</span></span></div><div class="t m0 x9 hb y167 ff9 fs8 fc3 sc0 ls1ab ws0">simultaneous <span class="_ _8"></span><span class="ffa">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum<span class="_ _95"> </span><span class="ff9 ws3e4">infection. Mixed infections are underestimated</span></span></div><div class="t m0 x9 hb y168 ff9 fs8 fc3 sc0 ls1d6 ws3e5">by routine microscopy<span class="_ _c"></span>. Cryptic <span class="ffa ws0">P<span class="_ _c"></span>.<span class="_ _68"> </span>falciparum<span class="_ _3"> </span><span class="ff9 ls1ab ws3e6">infections can be rev<span class="_ _a"></span>ealed in</span></span></div><div class="t m0 x9 hb y1ae ff9 fs8 fc3 sc0 ls1ab ws2fb">approximately 75% of cases by the RDT<span class="_ _c"></span>s based on the histidine-rich protein</div><div class="t m0 x9 hb y1af ff9 fs8 fc3 sc0 ls1fc ws16b">2 (HR<span class="_ _8"></span>P2) antigen, but such antigen tests are much less useful (because of their</div><div class="t m0 x9 hb y843 ff9 fs8 fc3 sc0 ls13c ws74">lower sensitivity) in detecting cryptic viv<span class="_ _a"></span>ax malaria. ACT<span class="_ _c"></span>s are effective against</div><div class="t m0 x9 hb y844 ff9 fs8 fc3 sc0 ls1ab ws3e7">all malaria species and are the treatment of choice. R<span class="_ _a"></span>adical treatment with</div><div class="t m0 x9 hb y845 ff9 fs8 fc3 sc0 ls1ab ws120">primaquine should be given to patients with confirmed <span class="ffa ls1d6 ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff9">and <span class="_ _a"></span><span class="ffa">P<span class="_ _c"></span>. ovale</span></span></span></div><div class="t m0 x9 hb y846 ff9 fs8 fc3 sc0 lsd0 ws207">infections except in high transmission settings wher<span class="_ _a"></span>e the risk of re-infection</div><div class="t m0 x9 hb y847 ff9 fs8 fc3 sc0 ls84 ws14">is high.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4f" class="pf w1 h4" data-page-no="4f"><div class="pc pc4f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x35 he y9 ffc fs5 fc3 sc0 ls3 ws0">9.<span class="_ _6"> </span>T<span class="_ _b"></span>reatment of malaria caused by <span class="ffd ls24c">P<span class="_ _4b"></span>. vivax,<span class="_ _6"> </span>P<span class="_ _4b"></span>. ovale <span class="ffc ls3">or </span><span class="lsad">P<span class="_ _c"></span>. malariae</span></span></div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls0 ws0">69</div><div class="t m0 xb hf y7d ffe fs6 fc3 sc0 ls1b ws17a">11.<span class="_ _2"> </span>C<span class="_ _b"></span>O<span class="_ _8"></span>MPLE<span class="_ _8"></span>X E<span class="_ _8"></span>ME<span class="_ _8"></span>RGE<span class="_ _8"></span>NCIE<span class="_ _8"></span>S AN<span class="_ _8"></span>D E<span class="_ _8"></span>PI<span class="_ _8"></span>DE<span class="_ _8"></span>MICS </div><div class="t m0 xb hb yce ff9 fs8 fc3 sc0 lsdf ws16d">When large numbers of people are displaced within malaria endemic ar<span class="_ _a"></span>eas there</div><div class="t m0 xb hb y165 ff9 fs8 fc3 sc0 ls166 ws91">is an increased risk of a malaria epidemic, especially when people living in an</div><div class="t m0 xb hb y166 ff9 fs8 fc3 sc0 ls10c ws3d8">area with little or no malaria transmission mo<span class="_ _a"></span>ve to an endemic area (e.g.</div><div class="t m0 xb hb y167 ff9 fs8 fc3 sc0 ls15c ws26e">displacement from highland to lowland ar<span class="_ _a"></span>eas). The lack of protectiv<span class="_ _a"></span>e immunity<span class="_ _4b"></span>,</div><div class="t m0 xb hb y168 ff9 fs8 fc3 sc0 ls12 ws3e8">concentration of population, breakdo<span class="_ _a"></span>wn in public health activities and diffi-</div><div class="t m0 xb hb y1ae ff9 fs8 fc3 sc0 ls205 ws8e">culties in accessing insecticides, insecticide-treated nets and effective tr<span class="_ _a"></span>eatment,</div><div class="t m0 xb hb y1af ff9 fs8 fc3 sc0 lsbc ws6b">all conspire to fuel epidemic malaria, in which morbidity and mortality are often</div><div class="t m0 xb hb y843 ff9 fs8 fc3 sc0 ls12 ws2f4">high. Such circumstances are also ideal for the dev<span class="_ _a"></span>elopment of resistance to</div><div class="t m0 xb hb y844 ff9 fs8 fc3 sc0 ls12 ws3e9">antimalarials. For these r<span class="_ _a"></span>easons, par<span class="_ _8"></span>ticular effor<span class="_ _8"></span>ts must be made to deliver</div><div class="t m0 xb hb y845 ff9 fs8 fc3 sc0 ls12 ws0">effective antimalarial treatment to the population at risk. </div><div class="t m0 xb h12 y848 ff10 fs6 fc4 sc0 ls9a ws0">11.1<span class="_ _1a"> </span>Diagnosis</div><div class="t m0 xb hb y238 ff9 fs8 fc3 sc0 ls21a ws373">In epidemic and complex emergency situations, facilities for laboratory</div><div class="t m0 xb hb y239 ff9 fs8 fc3 sc0 lsfa ws3ea">diagnosis may be either unavailable or so o<span class="_ _a"></span>verwhelmed with the case-load that</div><div class="t m0 xb hb y23a ff9 fs8 fc3 sc0 ls218 ws216">parasite-based diagnosis is impossible. In such circumstances, it is impr<span class="_ _a"></span>actical</div><div class="t m0 xb hb y23b ff9 fs8 fc3 sc0 ls25b ws3eb">and unnecessary to demonstrate parasites before tr<span class="_ _a"></span>eatment in all cases of fever<span class="_ _b"></span>.</div><div class="t m0 xb hb y23c ff9 fs8 fc3 sc0 ls25c ws3ec">Once an epidemic of malaria has been confirmed, and if case numbers are high,</div><div class="t m0 xb hb y23d ff9 fs8 fc3 sc0 ls237 ws2d">treatment based solely on the clinical history is appropriate in most cases, using</div><div class="t m0 xb hb y23e ff9 fs8 fc3 sc0 ls12 ws3ed">a full treatment course. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, parasite-based diagnosis is essential to:</div><div class="t m0 xb hb y849 ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">diagnose the cause of an epidemic of febrile illness, </span></div><div class="t m0 xb hb y84a ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">monitor and confirm the end of an epidemic, </span></div><div class="t m0 xb hb y84b ff9 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls5d ws7e">follow progr<span class="_ _a"></span>ess in infants, pregnant women, and those with sever<span class="_ _a"></span>e malaria.</span></div><div class="t m0 xb hb y84c ff9 fs8 fc3 sc0 ls12 wsda">As the epidemic wanes, the proportion of fever cases investigated parasito-</div><div class="t m0 xb hb y84d ff9 fs8 fc3 sc0 ls12 wsf4">logically can be increased. It is important to monitor the clinical response to</div><div class="t m0 xb hb y84e ff9 fs8 fc3 sc0 ls12 ws2b5">treatment wherev<span class="_ _a"></span>er possible, bearing in mind that other infections may also</div><div class="t m0 xb hb y84f ff9 fs8 fc3 sc0 ls25d ws121">be present. In mixed falciparum/viv<span class="_ _b"></span>ax epidemics, parasitaemia should be</div><div class="t m0 xb hb y850 ff9 fs8 fc3 sc0 ls12 ws0">monitored in order to determine a species-specific tr<span class="_ _a"></span>eatment.</div><div class="t m0 xb h12 y851 ff10 fs6 fc4 sc0 ls25e ws0">11.2<span class="_ _1a"> </span>Use <span class="_ _b"></span><span class="ls25f ws3ee">of rapid diagnostic tests in epidemic situations</span></div><div class="t m0 xb hb y852 ff9 fs8 fc3 sc0 lse0 wsdc">RDT<span class="_ _4b"></span>s offer the advantage of simplicity and speed in epidemic situations, but heat</div><div class="t m0 xb hb y853 ff9 fs8 fc3 sc0 ls22 ws3a1">stability may be a problem and false-negative r<span class="_ _a"></span>esults may be seen. A negative</div><div class="t m0 xb hb y854 ff9 fs8 fc3 sc0 ls17b ws394">result should not automatically preclude tr<span class="_ _a"></span>eatment, especially in severe clinical</div><div class="t m0 xb hb y855 ff9 fs8 fc3 sc0 ls260 ws77">disease. Current experience with RDT<span class="_ _4b"></span>s indicates that they are useful for confirming</div><div class="t m0 xb hb y856 ff9 fs8 fc3 sc0 ls34 ws7f">the cause and end-point of malaria epidemics, but they should not be relied on</div><div class="t m0 xb hb y857 ff9 fs8 fc3 sc0 ls22 ws3ef">as the sole basis for treatment. <span class="_ _a"></span>They should also be backed up with adequate</div><div class="t m0 xb hb y858 ff9 fs8 fc3 sc0 ls22 ws14">quality assurance, including temperatur<span class="_ _a"></span>e stability testing.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf50" class="pf w1 h4" data-page-no="50"><div class="pc pc50 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls2 ws0">70</div><div class="t m0 x9 h12 y12a ff10 fs6 fc4 sc0 ls9a ws0">11.3</div><div class="t m8 x28 h12 y12a ff10 fs6 fc4 sc0 ls261 ws3f0">Management of uncomplicated malar<span class="_ _8"></span>ia in epidemics</div><div class="t m0 x9 hb y1cf ff9 fs8 fc3 sc0 ls12 ws30e">Malaria epidemics are emergencies in which populations at risk in epidemic-</div><div class="t m0 x9 hb y1d0 ff9 fs8 fc3 sc0 ls12 ws2a7">prone areas ar<span class="_ _a"></span>e mainly non-immune or only par<span class="_ _8"></span>tially immune. The principles</div><div class="t m0 x9 hb y1d1 ff9 fs8 fc3 sc0 ls200 ws25">of treatment are the same as elsewher<span class="_ _a"></span>e (see section 7); the antimalarial to be</div><div class="t m0 x9 hb y1d2 ff9 fs8 fc3 sc0 ls25d ws121">used in epidemics (and complex emergencies) must be highly efficacious</div><div class="t m0 x9 hb y1d3 ff9 fs8 fc3 sc0 ls0 ws0">(<span class="fff">≥<span class="_ _66"></span></span><span class="ls12 ws2d">95% cure), safe and well tolerated so that adher<span class="_ _a"></span>ence to treatment is high.</span></div><div class="t m0 x9 hb y217 ff9 fs8 fc3 sc0 ls12 ws0">Complete courses of treatment should always be given in all cir<span class="_ _a"></span>cumstances. </div><div class="t m0 x9 hb y261 ff9 fs8 fc3 sc0 ls12 ws3f1">The rapid and reliable antimalarial effects of A<span class="_ _a"></span>CT<span class="_ _4b"></span>s and their gametocytocidal</div><div class="t m0 x9 hb y262 ff9 fs8 fc3 sc0 ls12 ws3f2">properties, which reduce transmission, make them ideal for treatment in a</div><div class="t m0 x9 hb y263 ff9 fs8 fc3 sc0 ls15a ws223">malaria epidemic. An active search should be made for febrile patients to ensur<span class="_ _a"></span>e</div><div class="t m0 x9 hb y1d8 ff9 fs8 fc3 sc0 ls12 ws23a">that, as many cases as possible are treated, r<span class="_ _a"></span>ather than relying on patients</div><div class="t m0 x9 hb y1d9 ff9 fs8 fc3 sc0 ls12 ws0">to come to a clinic.</div><div class="t m0 x9 hd y859 ff8 fs8 fc3 sc0 ls12 ws0">Summar<span class="_ _8"></span>y of recommendations on treatment of uncomplicated malaria </div><div class="t m0 x9 hd y85a ff8 fs8 fc3 sc0 ls12 ws0">in epidemic situations</div><div class="t m0 x9 h12 y85b ff10 fs6 fc4 sc0 ls1 ws17a">11.4<span class="_ _1a"> </span>Areas prone to mixed falcipar<span class="_ _8"></span>um/vivax malaria</div><div class="t m0 x28 h12 y85c ff10 fs6 fc4 sc0 ls9a ws0">epidemics </div><div class="t m0 x9 hb y85d ff9 fs8 fc3 sc0 ls24 ws207">Resistance of <span class="ffa ls262 ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>vivax <span class="_ _a"></span><span class="ff9 ls24 ws26">to chloroquine has been reported from South-East Asia</span></span></div><div class="t m0 x9 hb y85e ff9 fs8 fc3 sc0 ls88 wsce">and Oceania but is probably limited in distribution. <span class="_ _a"></span>There is insufficient</div><div class="t m0 x9 hb y85f ff9 fs8 fc3 sc0 ls29 ws3f3">knowledge at present to allo<span class="_ _a"></span>w specific recommendations to be made for</div><div class="t m0 x9 hb y860 ff9 fs8 fc3 sc0 ls13b ws1c3">treatment of <span class="ffa ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff9 ws41">epidemics in ar<span class="_ _a"></span>eas of suspected resistance. ACT<span class="_ _c"></span>s (except</span></span></div><div class="t m0 x9 hb y861 ff9 fs8 fc3 sc0 lsfa ws3ea">artesunate + sulfadoxine-pyrimethamine) should be used for treatment as they</div><div class="t m0 x9 hb y862 ff9 fs8 fc3 sc0 ls263 ws226">are highly effective against all malaria species. In ar<span class="_ _a"></span>eas with pure vivax</div><div class="t m0 x9 hb y863 ff9 fs8 fc3 sc0 ls12 ws214">epidemics, and where drug resistance has not been r<span class="_ _a"></span>epor<span class="_ _8"></span>ted, chloroquine is</div><div class="t m0 x9 hb y864 ff9 fs8 fc3 sc0 ls153 ws1c1">the most appropriate drug once the cause of the epidemic has been established.</div><div class="t m0 x47 h16 y865 ff8 fsb fc0 sc0 lsd2 ws0">RECOMMEND<span class="_ _a"></span>A<span class="_ _a"></span>TIONS</div><div class="t m0 x92 h16 y866 ff8 fsb fc0 sc0 lsd3 ws0">LEV<span class="_ _8"></span>EL O<span class="_ _8"></span>F</div><div class="t m0 x59 h16 y867 ff8 fsb fc0 sc0 lsd2 ws0">EVIDENCE</div><div class="t m3 x47 h17 y868 ff9 fsb fc3 sc0 ls12f ws362">ACT<span class="_ _c"></span>s are recommended for antimalarial treatment in epidemics in</div><div class="t m3 x47 h17 y869 ff9 fsb fc3 sc0 ls264 ws155">all areas with the exception of countries in Centr<span class="_ _a"></span>al America and the</div><div class="t m3 x47 h17 y86a ff9 fsb fc3 sc0 ls265 ws3f4">Island of Hispaniola, where chloroquine and sulfado<span class="_ _a"></span>xine-</div><div class="t m3 x47 h17 y86b ff9 fsb fc3 sc0 ls131 ws3f5">pyrimethamine still have a very high efficacy against falciparum</div><div class="t m3 x47 h17 y86c ff9 fsb fc3 sc0 ls266 ws3f6">malaria. Chloroquine 25<span class="_ _3"> </span>mg base/kg bw divided over 3 days,</div><div class="t m3 x47 h17 y86d ff9 fsb fc3 sc0 ls131 ws3f7">combined with primaquine 0.25 mg base/kg bw, taken with food</div><div class="t m3 x47 h17 y86e ff9 fsb fc3 sc0 ls131 ws3f8">once a day for 14 days is the treatment of choice for chloroquine-</div><div class="t m3 x47 h17 y86f ff9 fsb fc3 sc0 ls267 ws0">sensitive <span class="ffa">P<span class="_ _c"></span>. vivax <span class="_ _a"></span><span class="ff9 ws36c">infections. In Oceania and South-East Asia the dose</span></span></div><div class="t m3 x47 h17 y870 ff9 fsb fc3 sc0 ls131 ws0">of primaquine should be 0.5 mg/kg bw<span class="_ _a"></span>.</div><div class="t m3 x23 h16 y868 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div><div class="t m3 x47 h17 y871 ff9 fsb fc3 sc0 lsd2 ws362">In situations where ACT<span class="_ _c"></span>s are not immediately available, the most</div><div class="t m3 x47 h17 y872 ff9 fsb fc3 sc0 ls155 ws3f9">effective alternative should be used until A<span class="_ _a"></span>CT<span class="_ _4b"></span>s become available.</div><div class="t m3 x23 h16 y871 ff8 fsb fc3 sc0 lsd2 ws0">O, E</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf51" class="pf w1 h4" data-page-no="51"><div class="pc pc51 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x29 he y9 ffc fs5 fc3 sc0 ls3 ws2">11.<span class="_ _5"> </span>Complex emergencies and epidemics</div><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls2 ws0">71</div><div class="t m0 xb h12 y12a ff10 fs6 fc4 sc0 ls9a ws0">11.5<span class="_ _1a"> </span>Use of gametocy<span class="_ _8"></span>tocidal dr<span class="_ _8"></span>ugs to reduce</div><div class="t m0 x6 h12 y12b ff10 fs6 fc4 sc0 ls268 ws0">transmission</div><div class="t m0 xb hb y12c ff9 fs8 fc3 sc0 lsf9 ws12e">ACT<span class="_ _c"></span>s reduce gametocyte carriage markedly<span class="_ _4b"></span>, and therefore reduce tr<span class="_ _a"></span>ansmission.</div><div class="t m0 xb hb y12d ff9 fs8 fc3 sc0 lsf9 ws3fa">This is very v<span class="_ _a"></span>aluable in epidemic control. In the only randomized comparison</div><div class="t m0 xb hb y12f ff9 fs8 fc3 sc0 lsf9 ws3fb">reported, ACT<span class="_ _4b"></span>s had a greater effect than primaquine on gametocyte carriage. In</div><div class="t m0 xb hb y130 ff9 fs8 fc3 sc0 lsf9 ws3fc">circumstances where an A<span class="_ _a"></span>CT is not used, a single <span class="fc6 ws0">oral <span class="_ _9"></span></span>dose of primaquine of</div><div class="t m0 xb hb y131 ff9 fs8 fc3 sc0 lsf9 ws2a8">0.75<span class="_ _3"> </span>mg base/kg bw (45<span class="_ _3"> </span>mg base maximal for adults) combined with a fully</div><div class="t m0 xb hb y132 ff9 fs8 fc3 sc0 ls70 ws99">effective blood schizonticide could be used to r<span class="_ _a"></span>educe transmission pro<span class="_ _a"></span>vided</div><div class="t m0 xb hb y133 ff9 fs8 fc3 sc0 ls228 ws38f">that it is possible to achieve high co<span class="_ _a"></span>verage (<span class="fff ls0 ws0">&gt;<span class="_ _66"></span></span>85%) of the population infected with</div><div class="t m0 xb hb y134 ff9 fs8 fc3 sc0 ls182 ws162">malaria. This str<span class="_ _a"></span>ategy has been widely used in South-East Asia and South</div><div class="t m0 xb hb y135 ff9 fs8 fc3 sc0 ls269 wsd8">America, although its impact has not been well documented. <span class="_ _a"></span>The single primaquine</div><div class="t m0 xb hb y7e4 ff9 fs8 fc3 sc0 lsf9 ws1ad">dose was well tolerated and prior testing for G6PD deficiency was not r<span class="_ _a"></span>equired.</div><div class="t m0 xb hb y7e5 ff9 fs8 fc3 sc0 ls26a ws201">There is no experience with its use in Africa, where ther<span class="_ _a"></span>e is the highest prevalence</div><div class="t m0 xb hb y7e6 ff9 fs8 fc3 sc0 lsf9 ws3fd">of G6PD deficiency in the world. Primaquine should not be given in pr<span class="_ _a"></span>egnancy<span class="_ _4b"></span>.</div><div class="t m0 xb hb y7e7 ff9 fs8 fc3 sc0 lsf9 ws2c1">Whether there is any additional benefit in combining primaquine with an A<span class="_ _a"></span>CT is</div><div class="t m0 xb hb y7e8 ff9 fs8 fc3 sc0 lsf9 ws14">unknown. <span class="_ _a"></span>There is insufficient evidence to recommend this.</div><div class="t m0 xb h12 y13c ff10 fs6 fc4 sc0 ls86 wsca">11.6<span class="_ _1a"> </span>Anti-relapse therapy in vivax malaria epidemics </div><div class="t m0 xb hb y873 ff9 fs8 fc3 sc0 ls25c ws3ec">Anti-relapse therapy for viv<span class="_ _b"></span>ax malaria is impractical in most epidemic situations</div><div class="t m0 xb hb y874 ff9 fs8 fc3 sc0 ls26b ws3f1">because of the duration of treatment and poor compliance. If adequate r<span class="_ _a"></span>ecords</div><div class="t m0 xb hb y875 ff9 fs8 fc3 sc0 ls1d4 ws2f4">are kept, it can be given in the post-epidemic period to patients who hav<span class="_ _a"></span>e been</div><div class="t m0 xb hb y876 ff9 fs8 fc3 sc0 ls9c wsfa">treated with blood schizonticides. Primaquine 0.25–0.5 mg base/kg bw daily</div><div class="t m0 xb hb y877 ff9 fs8 fc3 sc0 lsfc ws37e">doses should be given for 14 days, as there is no evidence that shorter courses</div><div class="t m0 xb hb y64e ff9 fs8 fc3 sc0 ls12 ws116">are effective. Compliance with r<span class="_ _a"></span>adical (anti-relapse) treatment is often poor</div><div class="t m0 xb hb y878 ff9 fs8 fc3 sc0 ls22d ws394">and the drug should ideally be given under supervision, which is very difficult</div><div class="t m0 xb hb y879 ff9 fs8 fc3 sc0 ls12 ws3e4">in epidemic situations. Appropriate health education should be pro<span class="_ _a"></span>vided to</div><div class="t m0 xb hb y87a ff9 fs8 fc3 sc0 ls12 ws0">assist malaria control and encourage adher<span class="_ _a"></span>ence.</div><div class="t m0 xb h12 y87b ff10 fs6 fc4 sc0 ls1 ws0">11.7<span class="_ _1a"> </span>Mass treatment</div><div class="t m0 xb hb y87c ff9 fs8 fc3 sc0 ls12 ws3fe">Mass treatment (mass drug administration) of all or a lar<span class="_ _a"></span>ge section of the</div><div class="t m0 xb hb y87d ff9 fs8 fc3 sc0 ls85 wsc9">population whether symptoms are present or not) has been carried out in the</div><div class="t m0 xb hb y87e ff9 fs8 fc3 sc0 ls12 ws3ff">past, usually in conjunction with insecticide residual spraying, as a way of</div><div class="t m0 xb hb y87f ff9 fs8 fc3 sc0 ls48 ws68">controlling epidemics. Analysis of 19 mass drug administration pr<span class="_ _a"></span>ojects during</div><div class="t m0 xb hb y880 ff9 fs8 fc3 sc0 ls2b ws400">the period 1932–1999 did not draw definitiv<span class="_ _a"></span>e conclusions because study</div><div class="t m0 xb hb y881 ff9 fs8 fc3 sc0 ls220 ws401">designs were so v<span class="_ _a"></span>ariable.</div><div class="t m0 x60 h14 y882 ff11 fs5 fc4 sc0 ls26c ws0">20</div><div class="t m0 x81 hb y881 ff9 fs8 fc3 sc0 ls220 ws353">Many projects wer<span class="_ _a"></span>e unsuccessful, although a</div><div class="t m0 xb h14 y883 ff11 fs5 fc4 sc0 ls9a ws0">20</div><div class="t m0 x20 h15 y884 ff9 fsa fc3 sc0 ls7d ws402">von Seidlein L, Greenwood BM. Mass administration of antimalarial drugs. <span class="ffa">T<span class="_ _b"></span>rends in Parasitology<span class="ff9 ls0 ws0">,</span></span></div><div class="t m0 x20 h15 y885 ff9 fsa fc3 sc0 ls26d ws0">2003, 19:790–796.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf52" class="pf w1 h4" data-page-no="52"><div class="pc pc52 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ffd fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff9 fs6 fc4 sc0 ls2 ws0">72</div><div class="t m0 x9 hb y9e ff9 fs8 fc3 sc0 lsa7 ws109">reduction in parasite pr<span class="_ _a"></span>evalence and some transient r<span class="_ _a"></span>eduction in mor<span class="_ _8"></span>tality and</div><div class="t m0 x9 hb y9f ff9 fs8 fc3 sc0 ls33 ws5f">morbidity occurred in some cases. R<span class="_ _a"></span>educed transmission was seen only in one</div><div class="t m0 x9 hb ya0 ff9 fs8 fc3 sc0 ls12 ws21">study<span class="_ _4b"></span>, in V<span class="_ _4b"></span>anuatu, where the population concerned was relatively small, well</div><div class="t m0 x9 hb ya1 ff9 fs8 fc3 sc0 ls12 ws0">defined and controlled. </div><div class="t m0 x9 hb y18b ff9 fs8 fc3 sc0 ls12 ws403">There is no convincing evidence for the benefits of mass treatment. Mass</div><div class="t m0 x9 hb y18c ff9 fs8 fc3 sc0 ls26e wsa1">treatment of symptomatic febrile patients is considered appr<span class="_ _a"></span>opriate in epidemic</div><div class="t m0 x9 hb y18d ff9 fs8 fc3 sc0 ls12 ws200">and complex emergency situations. <span class="_ _a"></span>Whenever this strategy is adopted, a full</div><div class="t m0 x9 hb y18e ff9 fs8 fc3 sc0 ls12 ws0">treatment course should be given. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf53" class="pf w1 h4" data-page-no="53"><div class="pc pc53 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xe h9 ya ff9 fs6 fc4 sc0 ls2 ws0">73</div><div class="t m0 x93 h21 y886 ffe fsf fc4 sc0 ls26f ws404">LIST<span class="_ _1"> </span>OF AN<span class="_ _8"></span>N<span class="_ _8"></span>E<span class="_ _8"></span>X<span class="_ _8"></span>E<span class="_ _9"></span>S</div><div class="t m0 xb h22 y887 ff11 fs10 fc4 sc0 ls270 ws0">Annex 1. <span class="_ _18"> </span>The guidelines development process<span class="_ _a9"> </span>77</div><div class="t m0 xb h22 y888 ff11 fs10 fc4 sc0 ls270 ws0">Annex 2. <span class="_ _13"> </span>Adaptation of <span class="ff14 ws405">WHO malaria tr<span class="_ _a"></span>eatment </span></div><div class="t m0 x37 h22 y889 ff14 fs10 fc4 sc0 ls270 ws0">guidelines <span class="ff11">for use in countries<span class="_ _4f"> </span>83</span></div><div class="t m0 xb h22 y88a ff11 fs10 fc4 sc0 ls270 ws0">Annex 3. <span class="_ _13"> </span>Pharmacology of antimalarial drugs<span class="_ _77"> </span>87</div><div class="t m0 xb h22 y88b ff11 fs10 fc4 sc0 ls270 ws406">Annex 4. <span class="_ _13"> </span>Antimalarials and malaria tr<span class="_ _a"></span>ansmission<span class="_ _aa"> </span>133</div><div class="t m0 xb h22 y88c ff11 fs10 fc4 sc0 ls270 ws0">Annex 5. <span class="_ _13"> </span>Malaria diagnosis<span class="_ _ab"> </span>147</div><div class="t m0 xb h22 y88d ff11 fs10 fc4 sc0 ls270 ws0">Annex 6. <span class="_ _ac"> </span>R<span class="_ _a"></span>esistance to antimalarials<span class="_ _ad"> </span>155</div><div class="t m0 xb h22 y88e ff11 fs10 fc4 sc0 ls270 ws0">Annex 7. <span class="_ _97"> </span>Uncomplicated <span class="ff14">P<span class="_ _ae"></span>. falciparum <span class="ff11">malaria<span class="_ _af"> </span>185</span></span></div><div class="t m0 xb h22 y88f ff11 fs10 fc4 sc0 ls270 ws406">Annex 8. <span class="_ _49"> </span>Malaria treatment and HIV/AI<span class="_ _8"></span>DS<span class="_ _6c"> </span>199</div><div class="t m0 xb h22 y890 ff11 fs10 fc4 sc0 ls270 ws0">Annex 9. <span class="_ _ac"> </span>T<span class="_ _4b"></span>reatment of severe <span class="ff14">P<span class="_ _ae"></span>. falciparum <span class="ff11">malaria<span class="_ _13"> </span>207</span></span></div><div class="t m0 xb h22 y891 ff11 fs10 fc4 sc0 ls270 ws0">Annex 10. <span class="_ _39"> </span>T<span class="_ _b"></span>reatment of <span class="ff14">P<span class="_ _ae"></span>. viv<span class="_ _a"></span>ax, P<span class="_ _ae"></span>. ov<span class="_ _a"></span>ale <span class="ff11">and </span></span></div><div class="t m0 x37 h22 y892 ff14 fs10 fc4 sc0 ls270 ws0">P<span class="_ _ae"></span>. malariae <span class="ff11 ws407">infections 225</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf54" class="pf w1 h4" data-page-no="54"><div class="pc pc54 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf55" class="pf w1 h4" data-page-no="55"><div class="pc pc55 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 y893 ff11 fs10 fc7 sc0 ls270 ws0">Annex 1. </div><div class="t m0 x37 h22 y894 ff11 fs10 fc0 sc0 ls270 ws0">The guidelines development pr<span class="_ _a"></span>ocess<span class="_ _b0"> </span><span class="fc4">77</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf56" class="pf w1 h4" data-page-no="56"><div class="pc pc56 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf57" class="pf w1 h4" data-page-no="57"><div class="pc pc57 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x2c he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 1 - <span class="_ _a"></span>The guidelines development process</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls53 ws0">77</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 1</div><div class="t m0 x95 hf y895 ff18 fs6 fc3 sc0 ls9e ws139">THE GU<span class="_ _8"></span>I<span class="_ _8"></span>DELI<span class="_ _8"></span>NE<span class="_ _9"></span>S DEVEL<span class="_ _a"></span>OPME<span class="_ _8"></span>NT<span class="_ _64"> </span>PROCE<span class="_ _8"></span>SS</div><div class="t m0 xb h12 y896 ff19 fs6 fc4 sc0 ls9a ws0">A1.1<span class="_ _33"> </span>T<span class="_ _c"></span>reat<span class="_ _8"></span>ment recommendations</div><div class="t m0 xb hb y897 ff17 fs8 fc3 sc0 ls203 ws0">The <span class="ff1a ws19c">WHO Guidelines for the <span class="_ _a"></span>T<span class="_ _b"></span>reatment of Malaria <span class="ff17">were developed in accor<span class="_ _a"></span>dance</span></span></div><div class="t m0 xb hb y898 ff17 fs8 fc3 sc0 ls190 ws17c">with the guidance established by WHO for the formulation of such guidelines.</div><div class="t m0 x6d h14 y899 ff1b fs5 fc4 sc0 ls272 ws0">21</div><div class="t m0 xb hb y89a ff17 fs8 fc3 sc0 ls7c wsb9">The development process was undertaken at a technical consultation on</div><div class="t m0 xb hb y89b ff17 fs8 fc3 sc0 ls13 ws2e8">malaria treatment guidelines and by the <span class="_ _a"></span>T<span class="_ _4b"></span>echnical Guidelines Development</div><div class="t m0 xb hb y89c ff17 fs8 fc3 sc0 lsfc ws37e">Group<span class="_ _a"></span>, chaired by Professor Nick <span class="_ _a"></span>White (par<span class="_ _8"></span>ticipants are listed below). Conflict</div><div class="t m0 xb hb y89d ff17 fs8 fc3 sc0 ls12 ws409">of interest statements wer<span class="_ _a"></span>e received from all participants, and no conflict of</div><div class="t m0 xb hb y89e ff17 fs8 fc3 sc0 ls47 ws67">interest was declared by any of the participants. The first technical consultation</div><div class="t m0 xb hb y89f ff17 fs8 fc3 sc0 ls12 ws40a">was convened in April 2004, at which the tar<span class="_ _a"></span>get audience for the guidelines</div><div class="t m0 xb hb y8a0 ff17 fs8 fc3 sc0 ls273 ws40b">was defined and the scope of the guidelines and key questions to be addressed</div><div class="t m0 xb hb y8a1 ff17 fs8 fc3 sc0 ls12 ws0">were determined. </div><div class="t m0 xb hb y8a2 ff17 fs8 fc3 sc0 ls12 ws40c">Follo<span class="_ _a"></span>wing the first meeting, contracts for systematic search and reviews of</div><div class="t m0 xb hb y8a3 ff17 fs8 fc3 sc0 ls6b ws58">relev<span class="_ _a"></span>ant evidence were awarded to r<span class="_ _a"></span>esearch groups from two institutions: the</div><div class="t m0 xb hb y8a4 ff17 fs8 fc3 sc0 ls274 ws40d">Liverpool School of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine, Liverpool, England and Mahidol Univer-</div><div class="t m0 xb hb y8a5 ff17 fs8 fc3 sc0 ls92 wse7">sity<span class="_ _4b"></span>, Bangkok, Thailand. <span class="_ _a"></span>The search strategies employ<span class="_ _a"></span>ed included a search of</div><div class="t m0 xb hb y8a6 ff17 fs8 fc3 sc0 ls12 ws0">the following databases:</div><div class="t m0 xb hb y8a7 ff1c fs8 fc4 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 fc3 ls22">the Cochrane Infectious Diseases Group trials r<span class="_ _a"></span>egister (up to June 2004),* </span></div><div class="t m0 xb hb y8a8 ff1c fs8 fc4 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 fc3 ls12">the Cochrane Central R<span class="_ _a"></span>egister of Controlled <span class="_ _a"></span>T<span class="_ _b"></span>rials (CE<span class="_ _8"></span>NTRAL) published</span></div><div class="t m0 x26 hb y8a9 ff17 fs8 fc3 sc0 ls13 ws14">in The Cochr<span class="_ _a"></span>ane Library (Issue 2, 2004),* </div><div class="t m0 xb hb y8aa ff1c fs8 fc4 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 fc3 ls12">ME<span class="_ _8"></span>DLI<span class="_ _8"></span>NE (1966 to June 2004), </span></div><div class="t m0 xb hb y8ab ff1c fs8 fc4 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 fc3 ls12">EM<span class="_ _8"></span>BAS<span class="_ _8"></span>E (1980 to June 2004), </span></div><div class="t m0 xb hb y8ac ff1c fs8 fc4 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 fc3 ls14 ws15">LIL<span class="_ _8"></span>ACS (1982 to June 2004). </span></div><div class="t m0 xb hb y8ad ff17 fs8 fc3 sc0 ls9c wsfa">The evidence for RCT<span class="_ _4b"></span>s was assembled in collaboration with Clinical Evidence,</div><div class="t m0 xb hb y8ae ff17 fs8 fc3 sc0 ls12 ws0">a product of BMJ Knowledge.</div><div class="t m0 xb hb y8af ff17 fs8 fc3 sc0 ls12 ws0">The following search terms we<span class="_ _a"></span>re used:</div><div class="t m0 xb hb y8b0 ff1c fs8 fc4 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 fc3 ls12">malaria (free text),</span></div><div class="t m0 xb hb y8b1 ff1c fs8 fc4 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 fc3 ls12">malaria (controlled vocabulary<span class="_ _c"></span>, M<span class="_ _8"></span>E<span class="_ _8"></span>SH or E<span class="_ _8"></span>MTREE).</span></div><div class="t m0 xb hb y8b2 ff17 fs8 fc3 sc0 ls12 ws40e">The terms were used in combination with the search str<span class="_ _a"></span>ategy for retrieving</div><div class="t m0 xb hb y8b3 ff17 fs8 fc3 sc0 ls275 ws6c">randomized and contr<span class="_ _a"></span>olled clinical trials developed by The Cochr<span class="_ _a"></span>ane Collaboration.</div><div class="t m0 xb hb y8b4 ff17 fs8 fc3 sc0 ls1e2 ws3d">K<span class="_ _a"></span>ey words relativ<span class="_ _a"></span>e to currently available antimalarial drugs w<span class="_ _a"></span>ere used for</div><div class="t m0 xb h11 y8b5 ff17 fs5 fc4 sc0 ls4f ws0">21</div><div class="t m0 x20 h15 y8b6 ff1a fsa fc3 sc0 ls276 ws1e3">Guidelines for guidelines. <span class="ff17">Geneva, <span class="_ _a"></span>World Health Organization, 2003 (document EIP/GPE/EQC/2003.1).</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf58" class="pf w1 h4" data-page-no="58"><div class="pc pc58 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls53 ws0">78</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls12 ws263">each section of the review<span class="_ _b"></span>. <span class="_ _a"></span>Where indicated, specific authors and research</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls12 ws40f">groups wer<span class="_ _a"></span>e contacted for more information on published work and work in</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls13 ws0">progress.</div><div class="t m0 x9 hb y18a ff17 fs8 fc3 sc0 ls160 ws230">In formulating recommendations, evidence was graded in or<span class="_ _a"></span>der of priority as</div><div class="t m0 x9 hb y18b ff17 fs8 fc3 sc0 ls12 ws0">follows:</div><div class="t m0 x9 hb ya3 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls93 wse9">formal systematic reviews, such as Cochrane r<span class="_ _a"></span>eviews, including more than</span></div><div class="t m0 x16 hb ya4 ff17 fs8 fc3 sc0 ls12 ws0">one randomized contr<span class="_ _a"></span>ol trial,</div><div class="t m0 x9 hb y8b7 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">comparative trials without formal systematic r<span class="_ _a"></span>eview<span class="_ _a"></span>,</span></div><div class="t m0 x9 hb y8b8 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">observational studies (e.g. surveillance, pharmacological data),</span></div><div class="t m0 x9 hb y8b9 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">expert opinion/consensus.</span></div><div class="t m0 x9 hb y8ba ff17 fs8 fc3 sc0 ls44 ws93">The T<span class="_ _c"></span>echnical Guidelines Development Group held its first meeting in August</div><div class="t m0 x9 hb y8bb ff17 fs8 fc3 sc0 ls14e ws1a6">2004 and produced a preliminary draft that was pr<span class="_ _a"></span>esented and revised at the</div><div class="t m0 x9 hb y8bc ff17 fs8 fc3 sc0 ls277 ws410">second technical consultation in October 2004. The r<span class="_ _a"></span>evised draft of the</div><div class="t m0 x9 hb y8bd ff17 fs8 fc3 sc0 ls278 ws411">guidelines was sent out for external peer review in No<span class="_ _a"></span>vember 2004. At a</div><div class="t m0 x9 hb y8be ff17 fs8 fc3 sc0 lsbe ws37f">subsequent meeting of the T<span class="_ _c"></span>echnical Guidelines Development Group in January</div><div class="t m0 x9 hb y8bf ff17 fs8 fc3 sc0 lsae ws118">2005, the document was revised further in the light of comments received. <span class="_ _a"></span>The</div><div class="t m0 x9 hb y8c0 ff17 fs8 fc3 sc0 ls12 ws1ed">Guidelines development process and publication was fully funded by <span class="_ _b"></span>WHO.</div><div class="t m0 x9 hb y8c1 ff17 fs8 fc3 sc0 ls12 ws412">It is planned that the evidence will be reviewed on an annual basis, and that</div><div class="t m0 x9 hb y8c2 ff17 fs8 fc3 sc0 ls126 ws1dc">the guidelines will be updated periodically<span class="_ _4b"></span>. Similarly a mechanism for peroidic</div><div class="t m0 x9 hb y8c3 ff17 fs8 fc3 sc0 ls12 ws16a">monitoring and evaluating the use of the tr<span class="_ _a"></span>eatment guidelines in countries</div><div class="t m0 x9 hb y8c4 ff17 fs8 fc3 sc0 ls12 ws0">would be established.</div><div class="t m0 x9 h12 y8c5 ff19 fs6 fc4 sc0 ls0 ws95">A1.2<span class="_ _33"> </span>Members of the <span class="_ _a"></span>T<span class="_ _c"></span>echnical Guidelines</div><div class="t m0 x28 h12 y8c6 ff19 fs6 fc4 sc0 ls1 ws0">Development Group</div><div class="t m0 x9 h23 y8c7 ff1e fs11 fc8 sc0 ls279 ws0">T<span class="_ _4b"></span>emporar<span class="_ _8"></span>y advisers</div><div class="t m0 x9 hb y8c8 ff17 fs8 fc3 sc0 ls12 ws0">Dr D. Baza, National Malaria Control Pr<span class="_ _a"></span>ogramme Manager<span class="_ _b"></span>, Ministry</div><div class="t m0 x7a hb y8c9 ff17 fs8 fc3 sc0 ls12 ws0">of Health, Burundi</div><div class="t m0 x9 hb y8ca ff17 fs8 fc3 sc0 ls12 ws0">Dr D. Bethell*, F<span class="_ _a"></span>aculty of T<span class="_ _b"></span>ropical Medicine, Mahidol University<span class="_ _c"></span>, </div><div class="t m0 x7a hb y8cb ff17 fs8 fc3 sc0 ls12 ws2ea">Bangkok, Thailand</div><div class="t m0 x9 hb y8cc ff17 fs8 fc3 sc0 ls12 ws0">Professor A. Bjorkman, Division of Infectious Diseases, K<span class="_ _a"></span>arolinska</div><div class="t m0 x7a hb y8cd ff17 fs8 fc3 sc0 ls8e ws370">University Hospital, Stockholm, Sw<span class="_ _a"></span>eden</div><div class="t m0 x9 hb y8ce ff17 fs8 fc3 sc0 ls12 ws0">Professor M. Boulos, Hospital das Clinicas da F<span class="_ _b"></span>aculdade de Medicina</div><div class="t m0 x7a hb y8cf ff17 fs8 fc3 sc0 ls12 ws0">da Universidade de São Paulo, São P<span class="_ _a"></span>aulo, Brazil</div><div class="t m0 x9 hb y8d0 ff17 fs8 fc3 sc0 ls12 ws0">Professor M. A. F<span class="_ _b"></span>aiz, Depar<span class="_ _8"></span>tment of Medicine, Dhaka Medical College,</div><div class="t m0 x7a hb y8d1 ff17 fs8 fc3 sc0 ls12 ws0">Bangladesh</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf59" class="pf w1 h4" data-page-no="59"><div class="pc pc59 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x2c he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 1 - <span class="_ _a"></span>The guidelines development process</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">79</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls12 ws0">Professor P<span class="_ _ae"></span>. G<span class="_ _8"></span>arner*, Liverpool School of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine, </div><div class="t m0 x4d hb y9f ff17 fs8 fc3 sc0 ls12 ws0">Liverpool, England</div><div class="t m0 xb hb y8d2 ff17 fs8 fc3 sc0 ls13 ws14">Professor O. Gaye, Service de Parasitologie, F<span class="_ _a"></span>aculté de Médecine,</div><div class="t m0 x4d hb y335 ff17 fs8 fc3 sc0 ls13 ws14">Université Cheikh Anta Diop<span class="_ _a"></span>, Dakar<span class="_ _a"></span>-Fann, Senegal</div><div class="t m0 xb hb y8d3 ff17 fs8 fc3 sc0 ls12 ws0">Dr T<span class="_ _4b"></span>. Ghebremeskel, National Malaria Progr<span class="_ _a"></span>amme Manager<span class="_ _b"></span>, Ministry</div><div class="t m0 x4d hb y337 ff17 fs8 fc3 sc0 ls13 ws14">of Health, Asmara, Eritrea</div><div class="t m0 xb hb y8d4 ff17 fs8 fc3 sc0 ls12 ws0">Dr S. Hill*, Discipline of Clinical Pharmacology<span class="_ _4b"></span>, Faculty of Medicine &amp;</div><div class="t m0 x4d hb y8d5 ff17 fs8 fc3 sc0 ls12 ws0">Health Sciences, University of New<span class="_ _a"></span>castle, Newcastle Mater Hospital,</div><div class="t m0 x4d hb y8d6 ff17 fs8 fc3 sc0 ls12 ws0">Newcastle, Australia</div><div class="t m0 xb hb y8d7 ff17 fs8 fc3 sc0 ls12 ws0">Dr K. Jones*, Clinical Research F<span class="_ _b"></span>ellow, Liv<span class="_ _a"></span>erpool School of T<span class="_ _4b"></span>ropical</div><div class="t m0 x4d hb y8d8 ff17 fs8 fc3 sc0 ls12 ws0">Medicine, Liverpool, England</div><div class="t m0 xb hb y8d9 ff17 fs8 fc3 sc0 ls12 ws0">Dr S. Lutalo, Consultant Physician, Har<span class="_ _a"></span>are Central Hospital, </div><div class="t m0 x4d hb y8da ff17 fs8 fc3 sc0 ls12 ws0">Harare, Zimbab<span class="_ _a"></span>we</div><div class="t m0 xb hb y8db ff17 fs8 fc3 sc0 ls12 ws0">Dr A. McCarthy<span class="_ _b"></span>, Director<span class="_ _4b"></span>, T<span class="_ _b"></span>ropical Medicine and International Division of</div><div class="t m0 x4d hb y8dc ff17 fs8 fc3 sc0 ls12 ws0">Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Canada</div><div class="t m0 xb hb y8dd ff17 fs8 fc3 sc0 ls12 ws0">Dr O. Mokuolu*, Consultant Paediatrician, University of Ilorin <span class="_ _b"></span>T<span class="_ _b"></span>eaching</div><div class="t m0 x4d hb y8de ff17 fs8 fc3 sc0 ls12 ws0">Hospital, Ilorin, Nigeria</div><div class="t m0 xb hb y8df ff17 fs8 fc3 sc0 ls12 ws0">Dr S. Nyirenda, Consultant Physician, Department of Medicine, </div><div class="t m0 x4d hb y8e0 ff17 fs8 fc3 sc0 ls12 ws0">University <span class="_ _a"></span>T<span class="_ _4b"></span>eaching Hospital, Lusaka, Zambia</div><div class="t m0 xb hb y8e1 ff17 fs8 fc3 sc0 ls13 ws14">Dr E. Tjitr<span class="_ _a"></span>a*, Senior Researcher<span class="_ _4b"></span>, National Institute of Health </div><div class="t m0 x4d hb y8e2 ff17 fs8 fc3 sc0 ls12 ws0">&amp; Development, Ministry of Health, Jakarta, Indonesia</div><div class="t m0 xb hb y8e3 ff17 fs8 fc3 sc0 ls13 ws14">Dr L.S. V<span class="_ _4b"></span>estergaard, Laboratory of Parasitic Diseases, S<span class="_ _a"></span>tatens Serum</div><div class="t m0 x4d hb y8e4 ff17 fs8 fc3 sc0 ls12 ws0">Institut, and Department of International Health, University of</div><div class="t m0 x4d hb y8e5 ff17 fs8 fc3 sc0 ls12 ws0">Copenhagen, Copenhagen, Denmark</div><div class="t m0 xb hb y8e6 ff17 fs8 fc3 sc0 ls13 ws14">Professor N. <span class="_ _a"></span>White* (<span class="ff1a ws0">Chairman<span class="ff17 ls12">) F<span class="_ _a"></span>aculty of T<span class="_ _b"></span>ropical Medicine, </span></span></div><div class="t m0 x4d hb y8e7 ff17 fs8 fc3 sc0 ls12 ws0">Mahidol University<span class="_ _c"></span>, Bangkok, Thailand</div><div class="t m0 xb h23 y8e8 ff1e fs11 fc8 sc0 ls27a ws413">WHO Secretariat</div><div class="t m0 xb hb y8e9 ff17 fs8 fc3 sc0 ls12 ws0">Dr D. Bell, Malaria and Parasitic Diseases, <span class="_ _b"></span>WHO Regional Office for </div><div class="t m0 x4d hb y8ea ff17 fs8 fc3 sc0 ls12 ws0">the W<span class="_ _b"></span>estern Pacific, Manila, Philippines</div><div class="t m0 xb hb y8eb ff17 fs8 fc3 sc0 ls12 ws0">Dr A. Bosman, Roll Back Malaria Department, W<span class="_ _b"></span>orld Health Organization,</div><div class="t m0 x4d hb y8ec ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 xb hb y8ed ff17 fs8 fc3 sc0 ls12 ws0">Dr C. Delacollette, Roll Back Malaria Department, W<span class="_ _b"></span>orld Health</div><div class="t m0 x4d hb y8ee ff17 fs8 fc3 sc0 ls14 ws15">Organization, Genev<span class="_ _a"></span>a, Switzerland</div><div class="t m0 xb hb y8ef ff17 fs8 fc3 sc0 ls12 ws0">Dr M. Gomes, UN<span class="_ _8"></span>DP/U<span class="_ _8"></span>N<span class="_ _8"></span>ICEF/World Bank/WHO Special Pr<span class="_ _a"></span>ogramme for</div><div class="t m0 x4d hb y8f0 ff17 fs8 fc3 sc0 ls12 ws0">Research and <span class="_ _b"></span>T<span class="_ _a"></span>raining in <span class="_ _a"></span>T<span class="_ _b"></span>ropical Diseases, W<span class="_ _a"></span>orld Health Organization,</div><div class="t m0 x4d hb y8f1 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5a" class="pf w1 h4" data-page-no="5a"><div class="pc pc5a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls2 ws0">80</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls12 ws0">Dr R. Gray<span class="_ _c"></span>, Essential Drugs and Medicine, W<span class="_ _a"></span>orld Health Organization,</div><div class="t m0 x7a hb y9f ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8d2 ff17 fs8 fc3 sc0 ls12 ws0">Dr K.N. Mendis*, Roll Back Malaria Department, W<span class="_ _b"></span>orld Health Organization,</div><div class="t m0 x7a hb y335 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8d3 ff17 fs8 fc3 sc0 ls91 ws370">Dr F<span class="_ _4b"></span>. Nafo-T<span class="_ _b"></span>raoré, R<span class="ls12 ws0">oll Back Malaria Department, W<span class="_ _a"></span>orld Health Organization,</span></div><div class="t m0 x7a hb y337 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8d4 ff17 fs8 fc3 sc0 ls12 ws0">Dr B.L. Nahlen, Roll Back Malaria Department, W<span class="_ _b"></span>orld Health Organization,</div><div class="t m0 x7a hb y8d5 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8f2 ff17 fs8 fc3 sc0 ls13 ws14">Dr P<span class="_ _c"></span>.E. Olumese* (<span class="ff1a ls160 ws0">Secretary<span class="ff17 ls12">), Roll Back Malaria Department, W<span class="_ _b"></span>orld Health</span></span></div><div class="t m0 x7a hb y8d7 ff17 fs8 fc3 sc0 ls14 ws15">Organization, Genev<span class="_ _a"></span>a, Switzerland</div><div class="t m0 x9 hb y8f3 ff17 fs8 fc3 sc0 ls12 ws0">Dr C. Ondari*, Essential Drugs and Medicine, W<span class="_ _b"></span>orld Health Organization,</div><div class="t m0 x7a hb y8d9 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8f4 ff17 fs8 fc3 sc0 ls12 ws0">Dr R. Ridley*, U<span class="_ _8"></span>NDP/U<span class="_ _8"></span>N<span class="_ _8"></span>ICEF/World Bank/WHO Special Pr<span class="_ _a"></span>ogramme for</div><div class="t m0 x7a hb y8db ff17 fs8 fc3 sc0 ls12 ws0">Research and <span class="_ _b"></span>T<span class="_ _a"></span>raining in <span class="_ _a"></span>T<span class="_ _b"></span>ropical Diseases, W<span class="_ _a"></span>orld Health Organization,</div><div class="t m0 x7a hb y8dc ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8dd ff17 fs8 fc3 sc0 ls12 ws0">Dr A.E.C. Rietveld*, R<span class="_ _a"></span>oll Back Malaria Depar<span class="_ _8"></span>tment, W<span class="_ _b"></span>orld Health</div><div class="t m0 x7a hb y8de ff17 fs8 fc3 sc0 ls14 ws15">Organization, Genev<span class="_ _a"></span>a, Switzerland</div><div class="t m0 x9 hb y8df ff17 fs8 fc3 sc0 ls12 ws0">Dr P<span class="_ _c"></span>. Ringwald, Roll Back Malaria Department, W<span class="_ _b"></span>orld Health Organization,</div><div class="t m0 x7a hb y8e0 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8e1 ff17 fs8 fc3 sc0 ls0 ws81">Dr I. Sanou, Malaria, WHO R<span class="_ _a"></span>egional Office for Africa, Harare, Zimbabw<span class="_ _a"></span>e.</div><div class="t m0 x9 hb y8f5 ff17 fs8 fc3 sc0 ls12 ws0">Dr A. Schapira, Roll Back Malaria Department, W<span class="_ _b"></span>orld Health Organization,</div><div class="t m0 x7a hb y8e3 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8f6 ff17 fs8 fc3 sc0 ls0 ws81">Dr T<span class="_ _4b"></span>. Sukwa*, Malaria, WHO R<span class="_ _a"></span>egional Office for Africa, Harare, Zimbabwe</div><div class="t m0 x9 hb y8f7 ff17 fs8 fc3 sc0 ls12 ws0">Dr T<span class="_ _4b"></span>. T<span class="_ _c"></span>antorres, Evidence and Information for Policy<span class="_ _c"></span>, World Health</div><div class="t m0 x7a hb y8f8 ff17 fs8 fc3 sc0 ls14 ws15">Organization, Genev<span class="_ _a"></span>a, Switzerland</div><div class="t m0 x9 hb y8f9 ff17 fs8 fc3 sc0 ls12 ws0">Dr W<span class="_ _4b"></span>. T<span class="_ _c"></span>aylor<span class="_ _b"></span>, U<span class="_ _8"></span>NDP/U<span class="_ _8"></span>N<span class="_ _8"></span>ICEF/World Bank/WHO Special Progr<span class="_ _a"></span>amme for</div><div class="t m0 x7a hb y8fa ff17 fs8 fc3 sc0 ls12 ws0">Research and <span class="_ _b"></span>T<span class="_ _a"></span>raining in <span class="_ _a"></span>T<span class="_ _b"></span>ropical Diseases, W<span class="_ _a"></span>orld Health Organization,</div><div class="t m0 x7a hb y8fb ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8fc ff17 fs8 fc3 sc0 ls12 ws0">Dr Y<span class="_ _4b"></span>. T<span class="_ _c"></span>ouré, U<span class="_ _8"></span>N<span class="_ _8"></span>DP/U<span class="_ _8"></span>NICE<span class="_ _8"></span>F/W<span class="_ _a"></span>orld Bank/WHO Special Programme for</div><div class="t m0 x7a hb y8fd ff17 fs8 fc3 sc0 ls12 ws0">Research and <span class="_ _b"></span>T<span class="_ _a"></span>raining in <span class="_ _a"></span>T<span class="_ _b"></span>ropical Diseases, W<span class="_ _a"></span>orld Health Organization,</div><div class="t m0 x7a hb y8fe ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 hb y8ff ff17 fs8 fc3 sc0 ls12 ws0">Dr W<span class="_ _4b"></span>.M. W<span class="_ _b"></span>ere, Roll Back Malaria Department, W<span class="_ _a"></span>orld Health Organization,</div><div class="t m0 x7a hb y900 ff17 fs8 fc3 sc0 ls8e ws15">Geneva, Switz<span class="_ _a"></span>erland</div><div class="t m0 x9 h15 y901 ff17 fsa fc3 sc0 ls7d ws0">* Members of the Guidelines drafting committee. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5b" class="pf w1 h4" data-page-no="5b"><div class="pc pc5b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 y902 ff1b fs10 fc7 sc0 ls270 ws0">Annex 2. <span class="_ _ac"> </span><span class="fc0">Adaptation of <span class="ff1f ws405">WHO malaria treatment </span></span></div><div class="t m0 x37 h22 y903 ff1f fs10 fc0 sc0 ls270 ws0">guidelines <span class="ff1b ws405">for use in countries</span></div><div class="t m0 x96 h22 y904 ff1b fs10 fc4 sc0 ls27b ws0">83</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5c" class="pf w1 h4" data-page-no="5c"><div class="pc pc5c w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5d" class="pf w1 h4" data-page-no="5d"><div class="pc pc5d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x97 he y9 ff16 fs5 fc3 sc0 ls27c ws414">Annex 2 - Adaptation of <span class="ff1d ls27d ws17a">WHO malaria treatment guidelines </span><span class="ls27e ws0">for use in countries</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls2 ws0">83</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 2</div><div class="t m0 x98 h24 y895 ff18 fs6 fc3 sc0 ls9a ws0">ADAPT<span class="_ _b"></span>A<span class="_ _b"></span>TION OF <span class="ff1f ls1ce ws415">WHO MAL<span class="_ _9"></span>ARIA <span class="_ _b"></span>TR<span class="_ _8"></span>EA<span class="_ _b"></span>T<span class="_ _a"></span>ME<span class="_ _8"></span>NT</span></div><div class="t m0 x46 h24 y905 ff1f fs6 fc3 sc0 ls27f ws0">GUIDEL<span class="_ _a"></span>INES<span class="_ _7c"> </span><span class="ff18 lsc3 ws139">FOR USE I<span class="_ _8"></span>N COUNTRI<span class="_ _8"></span>E<span class="_ _8"></span>S </span></div><div class="t m0 xb h12 y906 ff19 fs6 fc4 sc0 ls53 ws0">A2.1<span class="_ _52"> </span>Background </div><div class="t m0 xb hb y907 ff17 fs8 fc3 sc0 ls280 ws416">WHO has recently convened technical consultations aimed at dev<span class="_ _a"></span>eloping</div><div class="t m0 xb hb y908 ff17 fs8 fc3 sc0 ls12 ws0">guidelines for the treatment of malaria.</div><div class="t m0 x51 h14 y909 ff1b fs5 fc4 sc0 ls4f ws0">22</div><div class="t m0 xb hb y90a ff17 fs8 fc3 sc0 ls1c9 ws293">The guidelines are generic in nature and should ther<span class="_ _a"></span>efore be adapted by</div><div class="t m0 xb hb y90b ff17 fs8 fc3 sc0 lsed ws191">regions and countries alike to take account of local conditions, especially when</div><div class="t m0 xb hb y90c ff17 fs8 fc3 sc0 ls12 ws0">formulating implementation and scale-up strategies. </div><div class="t m0 xb hb y90d ff17 fs8 fc3 sc0 lsb2 ws11d">A number of malaria endemic countries have not yet elabor<span class="_ _a"></span>ated national</div><div class="t m0 xb hb y90e ff17 fs8 fc3 sc0 ls191 ws278">malaria treatment guidelines, although treatment pr<span class="_ _a"></span>otocols may be available</div><div class="t m0 xb hb y90f ff17 fs8 fc3 sc0 lsc7 ws3">at the health-care pro<span class="_ _a"></span>vider level. F<span class="_ _a"></span>ur<span class="_ _8"></span>thermore, existing national guidelines need</div><div class="t m0 xb hb y910 ff17 fs8 fc3 sc0 ls273 ws172">to be updated as many countries, especially in sub-Saharan Africa, are adopting</div><div class="t m0 xb hb y911 ff17 fs8 fc3 sc0 ls24e ws3cd">and starting to implement policies specifying the use of ar<span class="_ _8"></span>temisinin combination</div><div class="t m0 xb hb y912 ff17 fs8 fc3 sc0 ls13 ws14">therapies (A<span class="_ _a"></span>CT<span class="_ _4b"></span>s). </div><div class="t m0 xb hb y913 ff17 fs8 fc3 sc0 ls229 ws31e">This annex pro<span class="_ _a"></span>vides orientation and guidance on the process countries should</div><div class="t m0 xb hb y914 ff17 fs8 fc3 sc0 ls12 ws187">follow in adapting the content of the generic malaria treatment guidelines</div><div class="t m0 xb hb y915 ff17 fs8 fc3 sc0 ls12 ws0">pro<span class="_ _a"></span>vided in the main document.</div><div class="t m0 xb h12 y916 ff19 fs6 fc4 sc0 ls1 ws0">A2.2<span class="_ _52"> </span>The development process </div><div class="t m0 xb hb y917 ff17 fs8 fc3 sc0 ls281 ws222">The ministry of health should take the lead in the process of developing</div><div class="t m0 xb hb y918 ff17 fs8 fc3 sc0 ls12 ws0">national malaria treatment guidelines.</div><div class="t m0 x4f h14 y919 ff1b fs5 fc4 sc0 ls1 ws0">23</div><div class="t m0 xb hb y91a ff17 fs8 fc3 sc0 ls12 ws0">The proposed steps include the following.</div><div class="t m0 xb hb y91b ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff1a ls12 ws417">A national workshop on the malaria treatment guidelines <span class="ff17">is the first step</span></span></div><div class="t m0 x26 hb y91c ff17 fs8 fc3 sc0 ls12 ws1de">at country level. <span class="_ _a"></span>This workshop will review any current national malaria</div><div class="t m0 x26 hb y91d ff17 fs8 fc3 sc0 lsa2 ws102">treatment guidelines, identify specific issues that need to be addressed and</div><div class="t m0 x26 hb y91e ff17 fs8 fc3 sc0 ls12 ws0">pro<span class="_ _a"></span>vide major policy recommendations.</div><div class="t m0 xb hb y91f ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff1a lsc5 ws207">Drafting/updating the national malaria treatment guidelines<span class="ff17">. F<span class="_ _a"></span>ollowing the</span></span></div><div class="t m0 x26 hb y920 ff17 fs8 fc3 sc0 ls64 ws391">national workshop, the national malaria case management committee (or</div><div class="t m0 x26 hb y921 ff17 fs8 fc3 sc0 ls64 ws2d9">its equivalent) should spearhead the dev<span class="_ _a"></span>elopment of new national malaria</div><div class="t m0 x26 hb y922 ff17 fs8 fc3 sc0 ls91 wsc0">treatment guidelines in accordance with the standar<span class="_ _a"></span>d outline set out below<span class="_ _b"></span>. </div><div class="t m0 xb h11 y923 ff17 fs5 fc4 sc0 ls4f ws0">22</div><div class="t m0 x20 h15 y924 ff17 fsa fc3 sc0 ls7d ws0">The guidelines development process is described in Annex 1.</div><div class="t m0 xb h11 y925 ff17 fs5 fc4 sc0 ls282 ws0">23</div><div class="t m0 x20 h15 y926 ff17 fsa fc3 sc0 ls283 wsa3">The preparation of the treatment guidelines is only one component of implementation of antimalarial</div><div class="t m0 x20 h15 y927 ff17 fsa fc3 sc0 ls7d ws0">treatment policy<span class="_ _4b"></span>.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5e" class="pf w1 h4" data-page-no="5e"><div class="pc pc5e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls2 ws0">84</div><div class="t m0 x9 hb y9e ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff1a ls218 ws216">A consensus workshop on the national malaria treatment guidelines <span class="ff17 ws0">should</span></span></div><div class="t m0 x16 hb y9f ff17 fs8 fc3 sc0 ls12 ws16b">then be arranged to present, discuss and adopt the dr<span class="_ _a"></span>aft national malaria</div><div class="t m0 x16 hb ya0 ff17 fs8 fc3 sc0 ls12 ws0">treatment guidelines.</div><div class="t m0 x9 hb y335 ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff1a ls1d ws1c">Finalization and dissemination. <span class="ff17">The national malaria tr<span class="_ _a"></span>eatment guidelines</span></span></div><div class="t m0 x16 hb y336 ff17 fs8 fc3 sc0 ls12 ws0">are finalized, officially endorsed and disseminated. </div><div class="t m0 x9 h12 y928 ff19 fs6 fc4 sc0 ls1 ws0">A2.3<span class="_ _52"> </span>The content</div><div class="t m0 x9 hb y929 ff17 fs8 fc3 sc0 ls12 ws418">It is recommended that national malaria treatment guidelines ar<span class="_ _a"></span>e presented</div><div class="t m0 x9 hb y92a ff17 fs8 fc3 sc0 ls21b ws2d9">in a similar way as WHO Guidelines on the <span class="_ _b"></span>T<span class="_ _a"></span>reatment of Malaria. <span class="_ _a"></span>The following</div><div class="t m0 x9 hb y92b ff17 fs8 fc3 sc0 ls12 ws0">outline is suggested:</div><div class="t m0 x14 hb y92c ff17 fs8 fc3 sc0 ls12 ws0">1.<span class="_ _44"> </span>General introduction</div><div class="t m0 x10 hb y92d ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 ls12">Epidemiological situation and parasite distribution</span></div><div class="t m0 x10 hb y92e ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 ls12">National drug resistance pattern</span></div><div class="t m0 x14 hb y92f ff17 fs8 fc3 sc0 ls12 ws0">2.<span class="_ _7a"> </span>Diagnosis of malaria</div><div class="t m0 x10 hb y930 ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 ls12">Clinical diagnosis</span></div><div class="t m0 x10 hb y931 ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 ls12">Role of parasitological diagnosis</span></div><div class="t m0 x14 hb y932 ff17 fs8 fc3 sc0 ls12 ws358">3.<span class="_ _7a"> </span>T<span class="_ _b"></span>reatment of <span class="ff1a ls13 ws0">P<span class="_ _c"></span>. falciparum <span class="ff17 ls12 ws358">malaria or the most pr<span class="_ _a"></span>evalent species in the</span></span></div><div class="t m0 x10 hb y933 ff17 fs8 fc3 sc0 ls12 ws0">country</div><div class="t m0 x10 hb y934 ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 ls12">Uncomplicated malaria</span></div><div class="t m0 x44 hb y935 ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">definition</span></div><div class="t m0 x44 hb y936 ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">tr<span class="_ _a"></span>eatment objectives</span></div><div class="t m0 x44 hb y937 ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">tr<span class="_ _a"></span>eatment recommendations</span></div><div class="t m0 x44 hb y938 ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">tr<span class="_ _a"></span>eatment in specific populations and situations</span></div><div class="t m0 x10 hb y939 ff1c fs8 fc3 sc0 ls0 ws0">•<span class="_ _b1"> </span><span class="ff17 ls14 ws15">Severe malaria</span></div><div class="t m0 x44 hb y93a ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">definition</span></div><div class="t m0 x44 hb y93b ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">tr<span class="_ _a"></span>eatment objectives</span></div><div class="t m0 x44 hb y93c ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">tr<span class="_ _a"></span>eatment recommendations</span></div><div class="t m0 x44 hb y93d ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">pr<span class="_ _a"></span>e-referral treatment options</span></div><div class="t m0 x44 hb y93e ff1c fs8 fc3 sc0 ls0 ws0">− <span class="ff17 ls12">management in epidemic situations</span></div><div class="t m0 x14 hb y93f ff17 fs8 fc3 sc0 ls13 ws14">4.<span class="_ _7a"> </span>T<span class="_ _4b"></span>reatment of malaria caused by other species </div><div class="t m0 x14 hb y940 ff17 fs8 fc3 sc0 ls12 ws419">5.<span class="_ _7a"> </span>Disease management at the different lev<span class="_ _a"></span>els of the health care delivery</div><div class="t m0 x10 hb y941 ff17 fs8 fc3 sc0 ls13 ws0">system</div><div class="t m0 x14 hb y942 ff17 fs8 fc3 sc0 lseb ws8e">6.<span class="_ _7a"> </span>Annexes – Relev<span class="_ _b"></span>ant annexes should be attached to provide more detailed</div><div class="t m0 x10 hb y943 ff17 fs8 fc3 sc0 ls284 ws283">information on, for example, dosages of drugs, specific data on therapeutic</div><div class="t m0 x10 hb y944 ff17 fs8 fc3 sc0 ls16d ws120">efficacy of antimalarial medicines in the country<span class="_ _4b"></span>, other available evidence</div><div class="t m0 x10 hb y945 ff17 fs8 fc3 sc0 ls12 ws0">for treatment recommendation, etc.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5f" class="pf w1 h4" data-page-no="5f"><div class="pc pc5f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 y946 ff1b fs10 fc7 sc0 ls270 ws0">Annex 3. <span class="_ _13"> </span><span class="fc0">Pharmacology of antimalarial drugs<span class="_ _b2"> </span><span class="fc4">87</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf60" class="pf w1 h4" data-page-no="60"><div class="pc pc60 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf61" class="pf w1 h4" data-page-no="61"><div class="pc pc61 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls53 ws0">87</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 3</div><div class="t m0 x99 hf y895 ff18 fs6 fc3 sc0 ls9a ws0">PHARMAC<span class="_ _b"></span>OLOGY OF ANTIMALAR<span class="_ _8"></span>IAL DRUGS</div><div class="t m0 xb h12 y896 ff19 fs6 fc4 sc0 ls53 ws0">A3.1<span class="_ _52"> </span>Chloroquine</div><div class="t m0 xb hb y897 ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 436.0 </div><div class="t m0 xb hb y947 ff17 fs8 fc3 sc0 ls12 ws222">Chloroquine is a 4-aminoquinoline that has been used extensively for the</div><div class="t m0 xb hb y948 ff17 fs8 fc3 sc0 ls185 wscc">treatment and prev<span class="_ _a"></span>ention of malaria. Widespr<span class="_ _a"></span>ead resistance has now r<span class="_ _a"></span>endered</div><div class="t m0 xb hb y949 ff17 fs8 fc3 sc0 ls1d ws1c">it virtually useless against <span class="ff1a wsfa">P<span class="_ _c"></span>. falciparum <span class="ff17 ws1c">infections in most par<span class="_ _8"></span>ts of the world,</span></span></div><div class="t m0 xb hb y94a ff17 fs8 fc3 sc0 ls12 ws77">although it still maintains considerable efficacy for the treatment of <span class="ff1a ls14 ws0">P<span class="_ _ae"></span>. vivax,</span></div><div class="t m0 xb hb y94b ff1a fs8 fc3 sc0 ls38 ws0">P.<span class="_ _3"> </span>o<span class="_ _67"> </span>v a l<span class="_ _67"> </span>e<span class="_ _3"> </span><span class="ff17 ls12">and </span><span class="ls13">P<span class="_ _c"></span>. malariae <span class="ff17 ls12 ws10c">infections. As with other 4-aminoquinolines, it does</span></span></div><div class="t m0 xb hb y94c ff17 fs8 fc3 sc0 ls12 ws0">not produce radical cur<span class="_ _a"></span>e. </div><div class="t m0 xb hb y94d ff17 fs8 fc3 sc0 ls12 ws30">Chloroquine interferes with par<span class="_ _a"></span>asite haem detoxification <span class="ff1a ls13">(1, 2)<span class="ff17">. Resistance is</span></span></div><div class="t m0 xb hb y94e ff17 fs8 fc3 sc0 ls12 ws6b">related to genetic changes in transporters (PfCR<span class="_ _a"></span>T<span class="_ _b"></span>, PfM<span class="_ _8"></span>DR), which reduce the</div><div class="t m0 xb hb y94f ff17 fs8 fc3 sc0 ls12 ws41a">concentrations of chloroquine at its site of action, the par<span class="_ _a"></span>asite food vacuole.</div><div class="t m0 xb h25 y950 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m2 xb hb y951 ff17 fs8 fc4 sc0 ls0 ws0">•</div><div class="t m0 x26 hb y951 ff17 fs8 fc3 sc0 ls244 ws19f">T<span class="_ _4b"></span>ablets containing 100 mg or 150 mg of chloroquine base as hydrochloride,</div><div class="t m0 x26 hb y952 ff17 fs8 fc3 sc0 ls12 ws0">phosphate or sulfate.</div><div class="t m0 xb h25 y953 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb y954 ff17 fs8 fc3 sc0 ls286 ws3ab">Chloroquine is rapidly and almost completely absorbed fr<span class="_ _a"></span>om the gastrointestinal</div><div class="t m0 xb hb y955 ff17 fs8 fc3 sc0 ls34 ws14a">tract when taken orally<span class="_ _c"></span>, although peak plasma concentrations can vary consid-</div><div class="t m0 xb hb y956 ff17 fs8 fc3 sc0 lsc6 ws13c">erably<span class="_ _c"></span>. Absorption is also very rapid following intramuscular and subcutaneous</div></div><div class="c xb y957 w2 h26"><div class="t m0 x9a h27 y958 ff20 fs8 fc4 sc0 ls0 ws0">CI<span class="_ _b3"> </span><span class="fc8">N</span></div><div class="t m0 x98 h27 y959 ff20 fs8 fc8 sc0 ls0 ws0">HN</div><div class="t m0 x35 h27 y95a ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x9b h27 y959 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x28 h28 y95b ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x3e h27 y95c ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x19 h28 y95d ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x7b h27 y95e ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x24 h28 y95f ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x93 h27 y95e ff20 fs8 fc3 sc0 ls0 ws0">C</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf62" class="pf w1 h4" data-page-no="62"><div class="pc pc62 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls53 ws0">88</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls274 ws0">administration <span class="_ _a"></span><span class="ff1a">(3–5)<span class="ff17 ws40d">. Chloroquine is extensively distributed into body tissues,</span></span></div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls12 ws41b">including the placenta and breast milk, and has an enormous total apparent</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 lsa2 ws203">volume of distribution. <span class="_ _a"></span>The relatively small v<span class="_ _a"></span>olume of distribution of the central</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls287 ws381">compartment means that transiently cardiotoxic levels may occur follo<span class="_ _a"></span>wing intra-</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls288 ws0">venous ad<span class="_ _8"></span>m<span class="_ _8"></span><span class="ls219 ws371">inistration unless the rate of parenter<span class="_ _a"></span>al delivery is strictly controlled.</span></div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls289 ws78">Some 60% of chloroquine is bound to plasma proteins, and the drug is eliminated</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls12 ws17b">slowly from the body via the kidneys, with an estimated terminal elimination</div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 ls81 wsc2">half-life of 1–2 months. Chloroquine is metabolized in the liv<span class="_ _a"></span>er<span class="_ _b"></span>, mainly to</div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 ls12 ws41c">monodesethylchloroquine, which has similar activity against <span class="ff1a ls13 ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum<span class="ff17">. </span></span></div><div class="t m0 x9 h25 y960 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb y961 ff17 fs8 fc3 sc0 ls12 ws41d">Chloroquine has a low safety mar<span class="_ _a"></span>gin and is very dangerous in o<span class="_ _a"></span>verdosage.</div><div class="t m0 x9 hb y962 ff17 fs8 fc3 sc0 ls21b ws2d9">Larger doses of chloroquine ar<span class="_ _a"></span>e used for the treatment of rheumatoid arthritis</div><div class="t m0 x9 hb y963 ff17 fs8 fc3 sc0 ls256 ws1a8">than for malaria, so adverse effects are seen mor<span class="_ _a"></span>e frequently in patients with</div><div class="t m0 x9 hb y964 ff17 fs8 fc3 sc0 ls12 ws41e">arthritis. The drug is generally well tolerated. <span class="_ _b"></span>The principle limiting adverse</div><div class="t m0 x9 hb y965 ff17 fs8 fc3 sc0 ls12 ws3a7">effects in practice are the unpleasant taste, which may upset childr<span class="_ _a"></span>en, and</div><div class="t m0 x9 hb y966 ff17 fs8 fc3 sc0 ls70 wsa2">pruritus, which may be severe in dark-skinned patients <span class="ff1a ws0">(6)</span>. Other less common</div><div class="t m0 x9 hb y967 ff17 fs8 fc3 sc0 ls12 ws244">side effects include headache, various skin eruptions and gastr<span class="_ _a"></span>ointestinal</div><div class="t m0 x9 hb y968 ff17 fs8 fc3 sc0 ls12 ws41f">disturbances, such as nausea, vomiting and diarrhoea. More r<span class="_ _a"></span>arely central</div><div class="t m0 x9 hb y969 ff17 fs8 fc3 sc0 ls9b wsf9">nervous system toxicity including, convulsions and mental changes may</div><div class="t m0 x9 hb y96a ff17 fs8 fc3 sc0 ls12 ws256">occur<span class="_ _b"></span>. Chronic use (<span class="ff1c ls0 ws0">&gt;</span>5 years continuous use as pr<span class="_ _a"></span>ophylaxis) may lead to eye</div><div class="t m0 x9 hb y96b ff17 fs8 fc3 sc0 ls12 ws28b">disorders, including keratopathy and r<span class="_ _a"></span>etinopathy<span class="_ _4b"></span>. Other uncommon effects</div><div class="t m0 x9 hb y96c ff17 fs8 fc3 sc0 ls12 ws420">include myopathy<span class="_ _4b"></span>, reduced hearing, photosensitivity and loss of hair<span class="_ _4b"></span>. Blood</div><div class="t m0 x9 hb y96d ff17 fs8 fc3 sc0 ls12 ws0">disorders, such as aplastic anaemia, are extr<span class="_ _a"></span>emely uncommon <span class="ff1a ls14">(7)</span><span class="ls0">.</span></div><div class="t m0 x9 hb y96e ff17 fs8 fc3 sc0 ls12 ws97">Acute ov<span class="_ _a"></span>erdosage is extremely dangerous and death can occur within a few</div><div class="t m0 x9 hb y96f ff17 fs8 fc3 sc0 ls7a wsb7">hours. The patient may pr<span class="_ _a"></span>ogress from feeling dizzy and dro<span class="_ _a"></span>wsy with headache</div><div class="t m0 x9 hb y970 ff17 fs8 fc3 sc0 ls28a ws1ab">and gastrointestinal upset, to developing sudden visual disturbance, convulsions,</div><div class="t m0 x9 hb y971 ff17 fs8 fc3 sc0 ls24b ws3c7">hypokalaemia, hypotension and cardiac arrhythmias. <span class="_ _a"></span>There is no specific</div><div class="t m0 x9 hb y972 ff17 fs8 fc3 sc0 ls10c ws3d8">treatment, although diazepam and epinephrine (adr<span class="_ _a"></span>enaline) administered</div><div class="t m0 x9 hb y973 ff17 fs8 fc3 sc0 ls12 ws0">together are beneficial <span class="ff1a ls13">(8, 9)</span><span class="ls0">.</span></div><div class="t m0 x9 h25 y974 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb y975 ff17 fs8 fc3 sc0 ls12 ws421">Major interactions are v<span class="_ _a"></span>ery unusual. There is a theor<span class="_ _a"></span>etical increased risk of</div><div class="t m0 x9 hb y976 ff17 fs8 fc3 sc0 ls12 ws422">arrhythmias when chloroquine is given with halofantrine or other drugs that</div><div class="t m0 x9 hb y977 ff17 fs8 fc3 sc0 ls196 ws119">prolong the electrocar<span class="_ _a"></span>diograph QT interval; a possible incr<span class="_ _a"></span>eased risk of</div><div class="t m0 x9 hb y978 ff17 fs8 fc3 sc0 ls39 ws4e">convulsions with mefloquine; reduced absorption with antacids; reduced</div><div class="t m0 x9 hb y979 ff17 fs8 fc3 sc0 ls222 ws343">metabolism and clearance with cimetidine; an increased risk of acute dystonic</div><div class="t m0 x9 hb y97a ff17 fs8 fc3 sc0 ls28b ws423">reactions with metronidaz<span class="_ _a"></span>ole; reduced bioavailability of ampicillin and</div><div class="t m0 x9 hb y97b ff17 fs8 fc3 sc0 ls16e ws245">praziquantel; reduced ther<span class="_ _a"></span>apeutic effect of thyroxine; a possible antagonistic</div><div class="t m0 x9 hb y97c ff17 fs8 fc3 sc0 ls21f ws15f">effect on the antiepileptic effects of carbamazepine and sodium v<span class="_ _a"></span>alproate; and</div><div class="t m0 x9 hb y97d ff17 fs8 fc3 sc0 ls12 ws0">increased plasma concentrations of cy<span class="_ _a"></span>closporine. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf63" class="pf w1 h4" data-page-no="63"><div class="pc pc63 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">89</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls9a ws0">A3.2<span class="_ _33"> </span>Amodiaquine</div><div class="t m0 xb hb y97e ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 355.9 </div><div class="t m0 xb hb y97f ff17 fs8 fc3 sc0 ls110 ws424">Amodiaquine is a Mannich base 4-aminoquinoline with a mode of action</div><div class="t m0 xb hb y980 ff17 fs8 fc3 sc0 ls28c ws304">similar to that of chloroquine. It is effective against some chlor<span class="_ _a"></span>oquine-resistant</div><div class="t m0 xb hb y981 ff17 fs8 fc3 sc0 ls13 ws14">strains of <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum, <span class="ff17 ls12">although there is cr<span class="_ _a"></span>oss-resistance. </span></span></div><div class="t m0 xb h25 y982 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t mb xb h29 y983 ff1c fs13 fc3 sc0 ls0 ws0">•<span class="_ _b4"></span><span class="fc1 sc2">•</span></div><div class="t m0 x26 hb y984 ff17 fs8 fc3 sc0 ls28d ws3dd">T<span class="_ _4b"></span>ablets containing 200 mg of amodiaquine base as hydrochloride or</div><div class="t m0 x26 hb y985 ff17 fs8 fc3 sc0 ls12 ws0">153.1 mg of base as chlorohydr<span class="_ _a"></span>ate.</div><div class="t m0 xb h25 y986 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb y987 ff17 fs8 fc3 sc0 ls110 ws424">Amodiaquine hydrochloride is r<span class="_ _a"></span>eadily absorbed from the gastrointestinal</div><div class="t m0 xb hb y988 ff17 fs8 fc3 sc0 ls12 ws425">tract. It is rapidly conv<span class="_ _a"></span>er<span class="_ _8"></span>ted in the liver to the active metabolite desethylam-</div><div class="t m0 xb hb y989 ff17 fs8 fc3 sc0 ls12 ws426">odiaquine, which contributes nearly all of the antimalarial effect <span class="ff1a lsa8 ws0">(10)</span><span class="ws2ba">. There</span></div><div class="t m0 xb hb y98a ff17 fs8 fc3 sc0 ls12 ws427">are insufficient data on the terminal plasma elimination half-life of desethy-</div><div class="t m0 xb hb y98b ff17 fs8 fc3 sc0 ls28e ws428">lamodiaquine. Both amodiaquine and desethylamodiaquine have been</div><div class="t m0 xb hb y98c ff17 fs8 fc3 sc0 ls12 ws0">detected in the urine several months after administr<span class="_ _a"></span>ation.</div><div class="t m0 xb h25 y98d ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb y98e ff17 fs8 fc3 sc0 ls263 ws429">The adverse effects of amodiaquine are similar to those of chlor<span class="_ _a"></span>oquine.</div><div class="t m0 xb hb y98f ff17 fs8 fc3 sc0 ls28f ws42a">Amodiaquine is associated with less pruritus and is more palatable than</div><div class="t m0 xb hb y990 ff17 fs8 fc3 sc0 ls76 wsb3">chloroquine, but is associated with a much higher risk of agranulocytosis and,</div><div class="t m0 xb hb y991 ff17 fs8 fc3 sc0 ls12 ws42b">to a lesser degree, of hepatitis when used for prophylaxis <span class="ff1a ws0">(11)</span>. <span class="_ _b"></span>The risk of a</div><div class="t m0 xb hb y992 ff17 fs8 fc3 sc0 ls12 ws42c">serious adverse reaction with pr<span class="_ _a"></span>ophylactic use (which is no longer recom-</div><div class="t m0 xb hb y993 ff17 fs8 fc3 sc0 ls290 ws2ff">mended) appears to be between 1 in 1000 and 1 in 5000. It is not clear whether</div><div class="t m0 xb hb y994 ff17 fs8 fc3 sc0 ls115 ws3b8">the risks are low<span class="_ _a"></span>er when amodiaquine is used to treat malaria. Follo<span class="_ _a"></span>wing</div><div class="t m0 xb hb y995 ff17 fs8 fc3 sc0 ls7e wsbc">ov<span class="_ _a"></span>erdose cardiotoxicity appears to be less fr<span class="_ _a"></span>equent than with chloroquine. Large</div><div class="t m0 xb hb y996 ff17 fs8 fc3 sc0 ls291 ws42d">doses of amodiaquine have been reported to cause syncope, spasticity<span class="_ _4b"></span>,</div><div class="t m0 xb hb y997 ff17 fs8 fc3 sc0 ls12 ws0">convulsions and involuntary mov<span class="_ _a"></span>ements.</div><div class="t m0 xb h25 y998 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions </div><div class="t m0 xb hb y999 ff17 fs8 fc3 sc0 ls12 ws0">There are insufficient data.</div></div><div class="c xb y99a w3 h2a"><div class="t m0 x9a h27 y99b ff20 fs8 fc4 sc0 ls0 ws0">CI<span class="_ _b3"> </span><span class="fc8">N</span></div><div class="t m0 x9c h27 y99c ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x60 h27 y99d ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 x98 h27 y99e ff20 fs8 fc8 sc0 ls0 ws0">HN</div><div class="t m0 x53 h27 y99f ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x31 h28 y9a0 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x50 h27 y9a1 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x5b h28 y9a2 ff20 fs5 fc3 sc0 ls0 ws0">3</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf64" class="pf w1 h4" data-page-no="64"><div class="pc pc64 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls1 ws0">90</div><div class="t m0 x9 h12 y12a ff19 fs6 fc4 sc0 ls53 ws0">A3.3<span class="_ _52"> </span>Sulfadoxine</div><div class="t m0 x9 hb y97e ff17 fs8 fc3 sc0 ls14 ws15">Molecular weight: 310.3 </div><div class="t m0 x9 hb y9a3 ff17 fs8 fc3 sc0 ls12 ws116">Sulfadoxine is a slowly eliminated sulfonamide. It is v<span class="_ _a"></span>ery slightly soluble in</div><div class="t m0 x9 hb y9a4 ff17 fs8 fc3 sc0 ls181 ws264">water<span class="_ _b"></span>. Sulfonamides are structural analogues and competitiv<span class="_ _a"></span>e antagonists of</div><div class="t m0 x9 hb y9a5 ff1a fs8 fc3 sc0 ls0 ws0">p<span class="ff17 lse6 ws177">-aminobenzoic acid. They ar<span class="_ _a"></span>e competitive inhibitors of dihydropter<span class="_ _a"></span>oate</span></div><div class="t m0 x9 hb y9a6 ff17 fs8 fc3 sc0 ls292 ws42e">synthase, the bacterial enzyme responsible for the incorporation of <span class="ff1a ls0 ws0">p<span class="ff17">-</span></span></div><div class="t m0 x9 hb y9a7 ff17 fs8 fc3 sc0 ls12 ws0">aminobenzoic acid in the synthesis of folic acid.</div><div class="t m0 x9 h25 y9a8 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 x9 hb y9a9 ff17 fs8 fc3 sc0 ls12 wsbb">Sulfadoxine is used in a fixed-dose combination of 20 parts sulfadoxine with</div><div class="t m0 x9 hb y9aa ff17 fs8 fc3 sc0 ls192 ws27a">1 part pyrimethamine and may be administered orally or by the intramuscular</div><div class="t m0 x9 hb y9ab ff17 fs8 fc3 sc0 ls12 ws0">route: </div><div class="t m0 x9 hb y9ac ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 wscf">T<span class="_ _4b"></span>ablets containing 500 mg of sulfadoxine and 25 mg of pyrimethamine.</span></div><div class="t m0 x9 hb y9ad ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws390">Ampoules containing 500 mg of sulfadoxine and 25 mg of pyrimethamine</span></div><div class="t m0 x16 hb y9ae ff17 fs8 fc3 sc0 ls12 ws0">in 2.5 ml of injectable solution for intramuscular use. </div><div class="t m0 x9 h25 y9af ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 hb y9b0 ff17 fs8 fc3 sc0 ls84 ws42f">Sulfadoxine is readily absorbed fr<span class="_ _a"></span>om the gastrointestinal tract. P<span class="_ _a"></span>eak blood</div><div class="t m0 x9 hb y9b1 ff17 fs8 fc3 sc0 ls84 ws123">concentrations occur about 4 h after an oral dose. <span class="_ _b"></span>The terminal elimination</div><div class="t m0 x9 hb y9b2 ff17 fs8 fc3 sc0 ls191 ws138">half-life is 4–9 days. Around 90–95% is bound to plasma proteins. It is widely</div><div class="t m0 x9 hb y9b3 ff17 fs8 fc3 sc0 ls1ab ws2f5">distributed to body tissues and fluids, passes into the fetal circulation and</div><div class="t m0 x9 hb y9b4 ff17 fs8 fc3 sc0 lsc6 ws1a0">is detectable in breast milk. <span class="_ _a"></span>The drug is excreted in urine, primarily unchanged. </div><div class="t m0 x9 h25 y9b5 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb y9b6 ff17 fs8 fc3 sc0 lsaa ws110">Sulfadoxine shares the adv<span class="_ _a"></span>erse effect profile of other sulfonamides, although</div><div class="t m0 x9 hb y9b7 ff17 fs8 fc3 sc0 ls1d3 ws2f2">allergic reactions can be sev<span class="_ _a"></span>ere because of its slow elimination. Nausea,</div><div class="t m0 x9 hb y9b8 ff17 fs8 fc3 sc0 ls2b ws182">vomiting, anorexia and diarrhoea may occur<span class="_ _4b"></span>. Crystalluria causing lumbar</div><div class="t m0 x9 hb y9b9 ff17 fs8 fc3 sc0 ls12 ws12f">pain, haematuria and oliguria is rare compar<span class="_ _a"></span>ed with more rapidly eliminated</div><div class="t m0 x9 hb y9ba ff17 fs8 fc3 sc0 ls75 wsb0">sulphonamides. Hypersensitivity reactions may effect differ<span class="_ _a"></span>ent organ system.</div><div class="t m0 x9 hb y9bb ff17 fs8 fc3 sc0 lsa2 ws102">Cutaneous manifestations can be severe and include pruritus, photosensitivity</div></div><div class="c x9 y9bc w4 h2b"><div class="t m0 x9d h27 y9bd ff20 fs8 fca sc0 ls0 ws0">S</div><div class="t m0 x38 h27 y9be ff20 fs8 fc9 sc0 ls293 ws0">OO</div><div class="t m0 x5f h27 y9bf ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x18 h27 y9c0 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x4 h27 y9c1 ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 x9e h28 y9c2 ff20 fs5 fc8 sc0 ls0 ws0">2</div><div class="t m0 x3 h27 y9c3 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xa h27 y9c4 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xa h27 y9c5 ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 x44 h27 y9c6 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x13 h27 y9c7 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x2c h27 y9c8 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x75 h28 y9c9 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x13 h27 y9ca ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x9c h28 y9cb ff20 fs5 fc3 sc0 ls0 ws0">3</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf65" class="pf w1 h4" data-page-no="65"><div class="pc pc65 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">91</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 lsf7 ws1ad">reactions, exfoliative dermatitis, erythema nodosum, to<span class="_ _a"></span>xic epidermal necrolysis</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls12 ws10d">and Stevens-Johnson syndr<span class="_ _a"></span>ome <span class="ff1a ls53 ws0">(12)</span>. T<span class="_ _b"></span>reatment with sulfado<span class="_ _a"></span>xine should be</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls75 wsb0">stopped in any patient developing a rash because of the risk of sev<span class="_ _a"></span>ere allergic</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls1a8 ws0">reactions <span class="_ _9"></span><span class="ff1a ls281">(13)</span><span class="ws15b">. Hypersensitivity to sulfadoxine may also cause interstitial</span></div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls294 ws28d">nephritis, lumbar pain, haematuria and oliguria. This is due to crystal formation</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls13 ws21f">in the urine (crystalluria) and may be avoided by keeping the patient well</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls12 ws43">hydrated to maintain a high urine output. Alkalinization of the urine will also</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 ls12 ws121">make the crystals more soluble. Blood disorders that have been r<span class="_ _a"></span>epor<span class="_ _8"></span>ted</div><div class="t m0 xb hb y10f ff17 fs8 fc3 sc0 ls81 wsc2">include agranulocytosis, aplastic anaemia, thrombocytopenia, leukopenia</div><div class="t m0 xb hb y110 ff17 fs8 fc3 sc0 ls32 ws43">and hypoprothrombinaemia. Acute haemolytic anaemia is a r<span class="_ _a"></span>are complication,</div><div class="t m0 xb hb y111 ff17 fs8 fc3 sc0 ls12 ws2cb">which may be antibody mediated or associated with glucose-6-phosphate</div><div class="t m0 xb hb y2be ff17 fs8 fc3 sc0 ls31 ws41">dehydrogenase (G6PD) deficiency<span class="_ _c"></span>. Other adverse effects, which may be mani-</div><div class="t m0 xb hb y2bf ff17 fs8 fc3 sc0 ls256 ws1a8">festations of a generalized hypersensitivity r<span class="_ _a"></span>eaction include fever<span class="_ _b"></span>, interstitial</div><div class="t m0 xb hb y484 ff17 fs8 fc3 sc0 ls22 ws63">nephritis, a syndrome resembling serum sickness, hepatitis, my<span class="_ _a"></span>ocarditis, pul-</div><div class="t m0 xb hb y485 ff17 fs8 fc3 sc0 ls294 ws0">monary <span class="lsc4 ws1b3">eosinophilia, fibrosing alv<span class="_ _a"></span>eolitis, peripheral neuropathy and systemic</span></div><div class="t m0 xb hb y9cc ff17 fs8 fc3 sc0 ls28f ws42a">vasculitis, including polyarteritis nodosa. Anaphylaxis has been reported</div><div class="t m0 xb hb y9cd ff17 fs8 fc3 sc0 ls12 ws340">only rarely<span class="_ _c"></span>. Other adverse reactions that have been r<span class="_ _a"></span>epor<span class="_ _8"></span>ted include hypo-</div><div class="t m0 xb hb y9ce ff17 fs8 fc3 sc0 ls295 ws136">glycaemia, jaundice in neonates, aseptic meningitis, dro<span class="_ _a"></span>wsiness, fatigue,</div><div class="t m0 xb hb y9cf ff17 fs8 fc3 sc0 ls15c ws26e">headache, ataxia, dizziness, drowsiness, convulsions, neur<span class="_ _a"></span>opathies, psychosis</div><div class="t m0 xb hb y9d0 ff17 fs8 fc3 sc0 ls12 ws0">and pseudomembranous colitis.</div><div class="t m0 xb h12 y2c7 ff19 fs6 fc4 sc0 ls9a ws0">A3.4<span class="_ _33"> </span>P<span class="_ _9"></span>yrimethamine</div><div class="t m0 xb hb y9d1 ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 248.7 </div><div class="t m0 xb hb y9d2 ff17 fs8 fc3 sc0 ls1ac ws2b7">Pyrimethamine is a diaminopyrimidine used in combination with a sulfonamide,</div><div class="t m0 xb hb y9d3 ff17 fs8 fc3 sc0 lsba wsb1">usually sulfadoxine or dapsone. It exerts its antimalarial activity by inhibiting</div><div class="t m0 xb hb y9d4 ff17 fs8 fc3 sc0 ls12 ws120">plasmodial dihydrofolate r<span class="_ _a"></span>eductase thus indirectly blocking the synthesis of</div><div class="t m0 xb hb y9d5 ff17 fs8 fc3 sc0 ls12 ws1a7">nucleic acids in the malaria parasite. It is a slow-acting blood schiz<span class="_ _a"></span>ontocide</div><div class="t m0 xb hb y9d6 ff17 fs8 fc3 sc0 ls296 ws321">and is also possibly active against pre-erythrocytic forms of the malaria</div><div class="t m0 xb hb y9d7 ff17 fs8 fc3 sc0 ls12 ws3b8">parasite and inhibits sporoz<span class="_ _a"></span>oite development in the mosquito vector<span class="_ _4b"></span>. It is</div><div class="t m0 xb hb y9d8 ff17 fs8 fc3 sc0 ls12 wsf2">effective against all four human malarials, although resistance has emer<span class="_ _a"></span>ged</div></div><div class="c xb y9d9 w5 h2c"><div class="t m0 x39 h27 y9da ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 x9f h27 y9db ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xb h27 y9dc ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x46 h27 y9dd ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x37 h28 y9de ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x4 h27 y9df ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 x9e h28 y9e0 ff20 fs5 fc8 sc0 ls0 ws0">2</div><div class="t m0 x3 h27 y9df ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xb h27 y9e1 ff20 fs8 fc8 sc0 ls0 ws0">NH</div><div class="t m0 x4d h28 y9e2 ff20 fs5 fc8 sc0 ls0 ws0">2</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf66" class="pf w1 h4" data-page-no="66"><div class="pc pc66 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls1 ws0">92</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls12 ws17e">rapidly<span class="_ _c"></span>. Pyrimethamine is also used in the treatment of toxoplasmosis, and</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls112 ws1c4">isosporiasis and as prophylaxis against <span class="ff1a">Pneumocystis carinii </span><span class="ws0">pneumonia.</span></div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 lsa8 ws10a">Pyrimethamine is no longer used alone as an antimalarial, only in synergistic</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls22d ws394">combination with slowly eliminated sulfonamides for treatment (sulfado<span class="_ _a"></span>xine,</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls12 ws0">sulfalene) or with dapsone for prophylaxis.</div><div class="t m0 x9 h25 y9e3 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations </div><div class="t m0 x9 hb y9e4 ff17 fs8 fc3 sc0 ls136 ws1ee">Pyrimethamine is currently used mainly in a fixed-dose combination with</div><div class="t m0 x9 hb y9e5 ff17 fs8 fc3 sc0 ls12 ws430">slowly eliminated sulfonamides, either of 20 parts sulfadoxine with 1 part</div><div class="t m0 x9 hb y9e6 ff17 fs8 fc3 sc0 ls12 ws0">pyrimethamine for which there are or<span class="_ _a"></span>al and parenteral formulations: </div><div class="t m0 x9 hb y9e7 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 wscf">T<span class="_ _4b"></span>ablets containing 500 mg of sulfadoxine and 25 mg of pyrimethamine.</span></div><div class="t m0 x9 hb y9e8 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws390">Ampoules containing 500 mg of sulfadoxine and 25 mg of pyrimethamine</span></div><div class="t m0 x16 hb y9e9 ff17 fs8 fc3 sc0 ls12 ws0">in 2.5 ml of injectable solution for intramuscular use.</div><div class="t m0 x9 h25 y9ea ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 hb y9eb ff17 fs8 fc3 sc0 ls166 ws91">Pyrimethamine is almost completely absorbed from the gastrointestinal tr<span class="_ _a"></span>act</div><div class="t m0 x9 hb y9ec ff17 fs8 fc3 sc0 ls12 ws431">and peak plasma concentrations occur 2–6 h after an oral dose. It is mainly</div><div class="t m0 x9 hb y9ed ff17 fs8 fc3 sc0 ls12 ws432">concentrated in the kidneys, lungs, liver and spleen, and about 80–90% is</div><div class="t m0 x9 hb y9ee ff17 fs8 fc3 sc0 ls12 ws33d">bound to plasma proteins. It is metabolized in the liv<span class="_ _a"></span>er and slowly excreted</div><div class="t m0 x9 hb y9ef ff17 fs8 fc3 sc0 lsaa ws110">via the kidneys. The plasma half-life is ar<span class="_ _a"></span>ound 4 days. Pyrimethamine crosses</div><div class="t m0 x9 hb y9f0 ff17 fs8 fc3 sc0 ls297 ws433">the blood-brain barrier and the placenta and is detectable in breast milk.</div><div class="t m0 x9 hb y9f1 ff17 fs8 fc3 sc0 ls12 ws348">Absorption of the intramuscular prepar<span class="_ _a"></span>ation is incomplete and insufficiently</div><div class="t m0 x9 hb y9f2 ff17 fs8 fc3 sc0 ls12 ws0">reliable for this formulation to be recommended <span class="ff1a ls13">(14)</span><span class="ls0">.</span></div><div class="t m0 x9 h25 y9f3 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb y9f4 ff17 fs8 fc3 sc0 ls256 ws1a8">Pyrimethamine is generally very well toler<span class="_ _a"></span>ated. Administration for prolonged</div><div class="t m0 x9 hb y9f5 ff17 fs8 fc3 sc0 ls26b ws3f1">periods may cause depression of haematopoiesis due to interference with folic</div><div class="t m0 x9 hb y9f6 ff17 fs8 fc3 sc0 ls290 ws2ff">acid metabolism. Skin rashes and hypersensitivity reactions also occur<span class="_ _4b"></span>. Larger</div><div class="t m0 x9 hb y9f7 ff17 fs8 fc3 sc0 ls298 ws434">doses may cause gastrointestinal symptoms such as atrophic glossitis,</div><div class="t m0 x9 hb y9f8 ff17 fs8 fc3 sc0 ls151 ws215">abdominal pain and vomiting, haematological effects including megaloblastic</div><div class="t m0 x9 hb y9f9 ff17 fs8 fc3 sc0 ls299 ws148">anaemia, leukopenia, thrombocytopenia and pancytopenia, and central</div><div class="t m0 x9 hb y9fa ff17 fs8 fc3 sc0 ls12 ws0">nervous system effects such as headache and dizziness.</div><div class="t m0 x9 hb y9fb ff17 fs8 fc3 sc0 ls12 ws435">Acute ov<span class="_ _a"></span>erdosage of pyrimethamine can cause gastrointestinal effects and</div><div class="t m0 x9 hb y9fc ff17 fs8 fc3 sc0 ls23a ws2e9">stimulation of the central nervous system with vomiting, excitability and</div><div class="t m0 x9 hb y9fd ff17 fs8 fc3 sc0 ls18c ws26f">convulsions. T<span class="_ _c"></span>achycardia, respir<span class="_ _a"></span>atory depression, circulatory collapse and</div><div class="t m0 x9 hb y9fe ff17 fs8 fc3 sc0 ls12 ws0">death may follow<span class="_ _4b"></span>. T<span class="_ _b"></span>reatment of ov<span class="_ _a"></span>erdosage is suppor<span class="_ _8"></span>tive.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf67" class="pf w1 h4" data-page-no="67"><div class="pc pc67 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">93</div><div class="t m0 xb h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 xb hb ya00 ff17 fs8 fc3 sc0 ls12 ws134">Administration of pyrimethamine with other folate antagonists such as cotri-</div><div class="t m0 xb hb ya01 ff17 fs8 fc3 sc0 ls29a ws436">moxazole, trimethoprim, methotr<span class="_ _a"></span>exate or with phenytoin may exacerbate</div><div class="t m0 xb hb ya02 ff17 fs8 fc3 sc0 ls13c ws189">bone marrow depr<span class="_ _a"></span>ession. Given with some benzodiazepines, ther<span class="_ _a"></span>e is a risk of</div><div class="t m0 xb hb ya03 ff17 fs8 fc3 sc0 ls12 ws0">hepatotoxicity<span class="_ _c"></span>.</div><div class="t m0 xb h12 ya04 ff19 fs6 fc4 sc0 ls1 ws0">A3.5<span class="_ _52"> </span>Mefloquine</div><div class="t m0 xb hb ya05 ff17 fs8 fc3 sc0 ls13 ws14">Molecular weight: 378.3 </div><div class="t m0 xb hb ya06 ff17 fs8 fc3 sc0 ls143 ws203">Mefloquine is a 4-methanolquinoline and is related to quinine. It is soluble in</div><div class="t m0 xb hb ya07 ff17 fs8 fc3 sc0 lsbb ws18f">alcohol but only very slightly soluble in water<span class="_ _b"></span>. It should be protected fr<span class="_ _a"></span>om light.</div><div class="t m0 xb hb ya08 ff17 fs8 fc3 sc0 ls12 ws0">The drug is effective against all forms of malaria. </div><div class="t m0 xb h25 ya09 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb ya0a ff17 fs8 fc3 sc0 ls189 ws381">Mefloquine is administered by mouth as the hydr<span class="_ _a"></span>ochloride salt (250 mg base</div><div class="t m0 xb hb ya0b ff17 fs8 fc3 sc0 ls12 ws0">equivalent to 27<span class="_ _a"></span>4 mg hydrochloride salt): </div><div class="t m0 xb hb ya0c ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls166 ws91">T<span class="_ _4b"></span>ablets containing either 250 mg salt (United States of America) or 250 mg</span></div><div class="t m0 x26 hb ya0d ff17 fs8 fc3 sc0 ls13 ws14">base (elsewhere).</div><div class="t m0 xb h25 ya0e ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb ya0f ff17 fs8 fc3 sc0 ls25b ws3eb">Mefloquine is reasonably well absorbed fr<span class="_ _a"></span>om the gastrointestinal tract but there</div><div class="t m0 xb hb ya10 ff17 fs8 fc3 sc0 lsae ws118">is marked interindividual variation in the time r<span class="_ _a"></span>equired to achieve peak plasma</div><div class="t m0 xb hb ya11 ff17 fs8 fc3 sc0 ls29b ws55">concentrations. Splitting the 25 mg/kg dose into two parts given at an interval</div><div class="t m0 xb hb ya12 ff17 fs8 fc3 sc0 ls12 ws437">of 6–24 h augments absorption and impro<span class="_ _a"></span>ves tolerability <span class="ff1a ls13 ws0">(15)</span>. Mefloquine</div><div class="t m0 xb hb ya13 ff17 fs8 fc3 sc0 lsef wsab">undergoes enterohepatic r<span class="_ _a"></span>ecycling. It is appro<span class="_ _a"></span>ximately 98% bound to plasma</div><div class="t m0 xb hb ya14 ff17 fs8 fc3 sc0 ls204 ws350">proteins and is widely distributed throughout the body<span class="_ _c"></span>. The pharmacokinetics</div></div><div class="c xb ya15 w2 h2d"><div class="t m0 xa0 h27 ya16 ff20 fs8 fc9 sc0 ls0 ws0">HO</div><div class="t m0 x9a h27 ya17 ff20 fs8 fca sc0 ls0 ws0">F</div><div class="t m0 x8 h27 ya18 ff20 fs8 fca sc0 ls0 ws0">F</div><div class="t m0 xa1 h27 ya19 ff20 fs8 fca sc0 ls0 ws0">F</div><div class="t m0 x9d h27 ya1a ff20 fs8 fca sc0 ls0 ws0">F</div><div class="t m0 x97 h27 ya1b ff20 fs8 fca sc0 ls0 ws0">F</div><div class="t m0 x7b h27 ya1c ff20 fs8 fca sc0 ls0 ws0">F</div><div class="t m0 x4d h27 ya1d ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x6 h27 ya1e ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x38 h27 ya1f ff20 fs8 fc8 sc0 ls0 ws0">HN</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf68" class="pf w1 h4" data-page-no="68"><div class="pc pc68 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls1 ws0">94</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls1db ws438">of mefloquine may be altered by malaria infection with reduced absorption and</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls1c3 ws439">accelerated clearance <span class="ff1a ls8e ws43a">(16, 17)</span>. <span class="_ _b"></span>When administered with ar<span class="_ _8"></span>tesunate, blood</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls29c ws43b">concentrations are incr<span class="_ _a"></span>eased, probably as an indirect effect of increased</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls1fa ws43c">absorption resulting from mor<span class="_ _a"></span>e rapid resolution of symptoms <span class="ff1a ws0">(15)</span>. Mefloquine</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls12 ws12f">is excreted in small amounts in br<span class="_ _a"></span>east milk. It has a long elimination half-life</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls12 ws297">of around 21 days, which is shortened in malaria to about 14 days, possibly</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls29d ws422">because of interrupted enterohepatic cycling <span class="ff1a ws0">(18–20)</span>. Mefloquine is metaboliz<span class="_ _a"></span>ed</div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 ls12 ws43d">in the liver and excr<span class="_ _a"></span>eted mainly in the bile and faeces. Its pharmacokinetics</div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 ls72 wsaa">show enantioselectivity after administration of the r<span class="_ _a"></span>acemic mixture, with</div><div class="t m0 x9 hb y110 ff17 fs8 fc3 sc0 ls103 ws1fb">higher peak plasma concentrations and area under the curve v<span class="_ _a"></span>alues, and</div><div class="t m0 x9 hb y111 ff17 fs8 fc3 sc0 ls17a ws53">lower v<span class="_ _a"></span>olume of distribution and total clearance of the SR enantiomer than its</div><div class="t m0 x9 hb y2be ff17 fs8 fc3 sc0 ls50 ws40">RS antipode <span class="ff1a ls13 ws0">(21–23)<span class="ff17 ls0">.</span></span></div><div class="t m0 x9 h25 y963 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb ya20 ff17 fs8 fc3 sc0 ls112 ws1c4">Minor adverse effects are common follo<span class="_ _a"></span>wing mefloquine treatment, most</div><div class="t m0 x9 hb ya21 ff17 fs8 fc3 sc0 ls16e ws245">frequently nausea, vomiting, abdominal pain, anor<span class="_ _a"></span>exia, diarrhoea, headache,</div><div class="t m0 x9 hb ya22 ff17 fs8 fc3 sc0 lsed ws191">dizziness, loss of balance, dysphoria, somnolence and sleep disorders, notably</div><div class="t m0 x9 hb ya23 ff17 fs8 fc3 sc0 lsd0 ws149">insomnia and abnormal dreams. Neuropsy<span class="_ _a"></span>chiatric disturbances (seizures,</div><div class="t m0 x9 hb ya24 ff17 fs8 fc3 sc0 ls2d ws3b">encephalopathy<span class="_ _4b"></span>, psychosis) occur in appro<span class="_ _a"></span>ximately 1 in 10 000 travellers</div><div class="t m0 x9 hb ya25 ff17 fs8 fc3 sc0 ls12 ws422">receiving mefloquine prophylaxis, 1 in 1000 patients tr<span class="_ _a"></span>eated in Asia, 1 in 200</div><div class="t m0 x9 hb ya26 ff17 fs8 fc3 sc0 ls29e ws79">patients treated in Africa, and 1 in 20 patients following sev<span class="_ _a"></span>ere malaria</div><div class="t m0 x9 hb ya27 ff1a fs8 fc3 sc0 ls13 ws0">(24–27)<span class="ff17 ls12 wscb">. Other side effects reported rarely include skin rashes, pruritus and</span></div><div class="t m0 x9 hb ya28 ff17 fs8 fc3 sc0 ls1d5 ws1a0">urticaria, hair loss, muscle weakness, liver function disturbances and very rarely</div><div class="t m0 x9 hb ya29 ff17 fs8 fc3 sc0 ls89 ws226">thrombocytopenia and leukopenia. Cardio<span class="_ _a"></span>vascular effects hav<span class="_ _a"></span>e included</div><div class="t m0 x9 hb ya2a ff17 fs8 fc3 sc0 ls12 ws33d">postural hypotension, brady<span class="_ _a"></span>cardia and, rarely<span class="_ _c"></span>, hyper<span class="_ _8"></span>tension, tachycardia or</div><div class="t m0 x9 hb ya2b ff17 fs8 fc3 sc0 ls12 ws127">palpitations and minor changes in the electrocardiogr<span class="_ _a"></span>am. Fatalities hav<span class="_ _a"></span>e not</div><div class="t m0 x9 hb ya2c ff17 fs8 fc3 sc0 ls15a ws223">been reported following ov<span class="_ _a"></span>erdosage, although cardiac, hepatic and neurological</div><div class="t m0 x9 hb ya2d ff17 fs8 fc3 sc0 ls12 wsfb">symptoms may be seen. Mefloquine should not be given with halofantrine</div><div class="t m0 x9 hb ya2e ff17 fs8 fc3 sc0 ls12 ws2f5">because it exacerbates QT pr<span class="_ _a"></span>olongation. There is no evidence of an adv<span class="_ _a"></span>erse</div><div class="t m0 x9 hb ya2f ff17 fs8 fc3 sc0 ls12 ws0">interaction with quinine <span class="ff1a ls1c3">(28)</span><span class="ls0">.</span></div><div class="t m0 x9 h25 y974 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb y975 ff17 fs8 fc3 sc0 ls12 ws43e">There is a possible increase in the risk of arrhythmias if mefloquine is giv<span class="_ _a"></span>en</div><div class="t m0 x9 hb y976 ff17 fs8 fc3 sc0 lsfc ws37e">together with beta blockers, calcium channel blockers, amiodarone, pimozide,</div><div class="t m0 x9 hb y977 ff17 fs8 fc3 sc0 ls12 ws1c5">digoxin or antidepressants; ther<span class="_ _a"></span>e is also a possible increase in the risk of</div><div class="t m0 x9 hb y978 ff17 fs8 fc3 sc0 lsfb ws22d">convulsions with chloroquine and quinine. Mefloquine concentrations ar<span class="_ _a"></span>e</div><div class="t m0 x9 hb y979 ff17 fs8 fc3 sc0 ls159 ws221">increased when given with ampicillin, tetr<span class="_ _a"></span>acycline and metoclopramide.</div><div class="t m0 x9 hb y97a ff17 fs8 fc3 sc0 ls12 ws0">Caution should be observed with alcohol.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf69" class="pf w1 h4" data-page-no="69"><div class="pc pc69 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">95</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls0 ws95">A3.6<span class="_ _33"> </span>Ar<span class="_ _8"></span>temisinin and its der<span class="_ _8"></span>ivatives</div><div class="t m0 xb h2e y639 ff19 fs3 fc3 sc0 ls80 ws0">A3.6.1<span class="_ _a7"> </span>Ar<span class="_ _8"></span>temisinin</div><div class="t m0 xb hb y12c ff17 fs8 fc3 sc0 ls13 ws14">Molecular weight: 282.3 </div><div class="t m0 xb hb ya30 ff17 fs8 fc3 sc0 ls12 ws1a9">Artemisinin, also known as qinghaosu, is a sesquiterpene lactone extracted</div><div class="t m0 xb hb ya31 ff17 fs8 fc3 sc0 ls13 ws43f">from the leaves of <span class="ff1a">Artemisia annua </span><span class="ls12 ws440">(sweet wormwood). It has been used in</span></div><div class="t m0 xb hb ya32 ff17 fs8 fc3 sc0 ls12 ws419">China for the treatment of fever for o<span class="_ _a"></span>ver a thousand years. It is a potent and</div><div class="t m0 xb hb ya33 ff17 fs8 fc3 sc0 ls55 ws70">rapidly acting blood schizontocide and is activ<span class="_ _a"></span>e against all <span class="ff1a ws0">Plasmodium</span></div><div class="t m0 xb hb ya34 ff17 fs8 fc3 sc0 ls12 ws441">species. It has an unusually broad activity against asexual parasites, killing</div><div class="t m0 xb hb ya35 ff17 fs8 fc3 sc0 ls3c ws31">all stages from young rings to schizonts. In <span class="ff1a ws0">P<span class="_ _ae"></span>. falciparum<span class="_ _6"> </span><span class="ff17 ws31">malaria, artemisinin</span></span></div><div class="t m0 xb hb ya36 ff17 fs8 fc3 sc0 ls12 ws38d">also kills the gametocytes – including the stage 4 gametocytes, which are</div><div class="t m0 xb hb ya37 ff17 fs8 fc3 sc0 ls7f wsc0">otherwise sensitive only to primaquine. Artemisinin and its derivatives inhibit</div><div class="t m0 xb hb ya38 ff17 fs8 fc3 sc0 ls1be ws294">an essential calcium adenosine triphosphatase, PfA<span class="_ _b"></span>TPase 6 <span class="ff1a ws0">(29)</span><span class="ws203">. Artemisinin</span></div><div class="t m0 xb hb ya39 ff17 fs8 fc3 sc0 ls224 ws11e">has now lar<span class="_ _a"></span>gely given way to the more potent dihydr<span class="_ _a"></span>oar<span class="_ _8"></span>temisinin and its</div><div class="t m0 xb hb ya3a ff17 fs8 fc3 sc0 ls37 ws48">derivativ<span class="_ _a"></span>es, ar<span class="_ _8"></span>temether<span class="_ _b"></span>, artemotil and ar<span class="_ _8"></span>tesunate. The three latter deriv<span class="_ _a"></span>atives</div><div class="t m0 xb hb ya3b ff17 fs8 fc3 sc0 ls1ab ws2fd">are converted back <span class="ff1a ws11d">in vivo </span>to dihydr<span class="_ _a"></span>oar<span class="_ _8"></span>temisinin. These drugs should be</div><div class="t m0 xb hb ya3c ff17 fs8 fc3 sc0 ls12 ws0">given as combination therapy to pr<span class="_ _a"></span>otect them from resistance. </div><div class="t m0 xb h25 ya3d ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb ya3e ff17 fs8 fc3 sc0 ls31 ws41">A wide variety of formulations for or<span class="_ _a"></span>al, parenteral and rectal use ar<span class="_ _a"></span>e available.</div><div class="t m0 xb hb ya3f ff17 fs8 fc3 sc0 ls12 ws0">These include:</div><div class="t m0 xb hb ya40 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">T<span class="_ _4b"></span>ablets and capsules containing 250 mg of ar<span class="_ _8"></span>temisinin. </span></div><div class="t m0 xb hb ya41 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls13 ws442">Suppositories containing 100 mg, 200 mg, 300 mg, 400 mg or 500 mg of</span></div><div class="t m0 x26 hb ya42 ff17 fs8 fc3 sc0 ls12 ws0">artemisinin.</div><div class="t m0 xb h25 ya43 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb ya44 ff17 fs8 fc3 sc0 ls160 ws136">Peak plasma concentrations occur ar<span class="_ _a"></span>ound 3 h and 11 h following oral and</div><div class="t m0 xb hb ya45 ff17 fs8 fc3 sc0 ls64 ws439">rectal administration r<span class="_ _a"></span>espectively <span class="ff1a ws0">(30)</span>. Artemisinin is conver<span class="_ _8"></span>ted to inactive</div><div class="t m0 xb hb ya46 ff17 fs8 fc3 sc0 ls22d ws3d">metabolites via the cytochrome P450 enzyme CYP2B6 and other enzymes.</div></div><div class="c xb ya47 w2 h2f"><div class="t m0 xa2 h27 ya48 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xa3 h27 ya49 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x38 h27 ya4a ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xa4 h27 ya4b ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x9 h27 ya4c ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x21 h27 ya4d ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x7f h28 ya4e ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xa5 h27 ya4f ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa6 h28 ya50 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x71 h27 ya4f ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x38 h27 ya51 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 xa7 h28 ya52 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xa8 h27 ya53 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x9d h27 ya54 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x38 h27 ya55 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa8 h27 ya56 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x4 h30 ya57 ff21 fs14 fc8 sc0 ls0 ws0">Ä</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6a" class="pf w1 h4" data-page-no="6a"><div class="pc pc6a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls0 ws0">96</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls28 ws17b">Artemisinin is a potent inducer of its own metabolism. The elimination half-life</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls64 ws0">is approximately 1 h <span class="ff1a">(31)</span>. </div><div class="t m0 x9 h25 ya58 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb ya59 ff17 fs8 fc3 sc0 ls200 ws433">Artemisinin and its derivatives are safe and r<span class="_ _a"></span>emarkably well tolerated <span class="ff1a ls27 ws0">(32,</span></div><div class="t m0 x9 hb ya5a ff1a fs8 fc3 sc0 ls10e ws0">33)<span class="ff17 wsb0">. Ther<span class="_ _a"></span>e have been reports of mild gastrointestinal disturbances, dizziness,</span></div><div class="t m0 x9 hb ya5b ff17 fs8 fc3 sc0 ls191 ws3b8">tinnitus, reticulocytopenia, neutropenia, elev<span class="_ _b"></span>ated liver enzyme values, and</div><div class="t m0 x9 hb ya5c ff17 fs8 fc3 sc0 ls34 wsbd">electrocardiogr<span class="_ _a"></span>aphic abnormalities, including bradycardia and pr<span class="_ _a"></span>olongation of</div><div class="t m0 x9 hb ya5d ff17 fs8 fc3 sc0 ls161 ws31e">the QT interval, although most studies hav<span class="_ _a"></span>e not found any electrocardiographic</div><div class="t m0 x9 hb ya5e ff17 fs8 fc3 sc0 ls29f ws77">abnormalities. The only potentially serious adv<span class="_ _a"></span>erse effect reported with this class</div><div class="t m0 x9 hb ya5f ff17 fs8 fc3 sc0 ls1e ws1b2">of drugs is type 1 hypersensitivity reactions in appro<span class="_ _a"></span>ximately 1 in 3000 patients</div><div class="t m0 x9 hb ya60 ff1a fs8 fc3 sc0 ls17a ws0">(34)<span class="ff17 ls244 ws160">. Neurotoxicity has been r<span class="_ _a"></span>epor<span class="_ _8"></span>ted in animal studies, par<span class="_ _8"></span>ticularly with very</span></div><div class="t m0 x9 hb ya61 ff17 fs8 fc3 sc0 ls9b ws443">high doses of intramuscular artemotil and ar<span class="_ _8"></span>temether<span class="_ _b"></span>, but has not been</div><div class="t m0 x9 hb ya62 ff17 fs8 fc3 sc0 ls92 ws444">substantiated in humans <span class="ff1a ls262 ws0">(35–37)</span>. Similarly<span class="_ _4b"></span>, evidence of death of embryos</div><div class="t m0 x9 hb ya63 ff17 fs8 fc3 sc0 ls122 ws1c">and morphological abnormalities in early pregnancy have been demonstr<span class="_ _a"></span>ated</div><div class="t m0 x9 hb ya64 ff17 fs8 fc3 sc0 ls2a0 ws216">in animal studies (37a). Artemisinin has not been evaluated in the first trimester</div><div class="t m0 x9 hb ya65 ff17 fs8 fc3 sc0 ls1f ws180">of pregnancy so should be avoided in first trimester patients with uncomplicated</div><div class="t m0 x9 hb ya66 ff17 fs8 fc3 sc0 ls64 ws0">malaria until more information is av<span class="_ _a"></span>ailable.</div><div class="t m0 x9 h25 ya67 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb ya68 ff17 fs8 fc3 sc0 ls12 ws0">None known.</div><div class="t m0 x9 h2e ya69 ff19 fs3 fc3 sc0 ls69 ws0">A3.6.2<span class="_ _a7"> </span>Ar<span class="_ _8"></span>temether</div><div class="t m0 x9 hb ya6a ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 298.4 </div><div class="t m0 x9 hb ya6b ff17 fs8 fc3 sc0 ls12 ws1f9">Artemether is the methyl ether of dihydroar<span class="_ _8"></span>temisinin. It is more lipid soluble</div><div class="t m0 x9 hb ya6c ff17 fs8 fc3 sc0 ls12 ws1f9">than artemisinin or ar<span class="_ _8"></span>tesunate. It can be given as an oil-based intramuscular</div><div class="t m0 x9 hb ya6d ff17 fs8 fc3 sc0 ls1f9 ws22c">injection or orally<span class="_ _c"></span>. It is also coformulated with lumefantrine (previously</div><div class="t m0 x9 hb ya6e ff17 fs8 fc3 sc0 ls12 ws0">referred to as benflumetol) for combination ther<span class="_ _a"></span>apy<span class="_ _4b"></span>. </div></div><div class="c x9 ya6f w2 h31"><div class="t m0 x1a h27 ya70 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xc h27 ya71 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x9d h27 ya72 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xa9 h27 ya73 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x37 h27 ya74 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x13 h27 ya75 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x9c h28 ya76 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xaa h27 ya77 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa2 h28 ya78 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xab h27 ya77 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x99 h27 ya79 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa7 h28 ya7a ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xa4 h27 ya79 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xac h27 ya7b ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x14 h28 ya7c ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x44 h27 ya7d ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa h27 ya7e ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x9d h27 ya7f ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x44 h27 ya80 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xad h30 ya81 ff21 fs14 fc8 sc0 ls0 ws0">Ä</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6b" class="pf w1 h4" data-page-no="6b"><div class="pc pc6b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">97</div><div class="t m0 xb h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb ya00 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">Capsules containing 40 mg of artemether<span class="_ _b"></span>.</span></div><div class="t m0 xb hb ya82 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">T<span class="_ _4b"></span>ablets containing 50 mg of ar<span class="_ _8"></span>temether<span class="_ _b"></span>.</span></div><div class="t m0 xb hb ya83 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls129 ws1e0">Ampoules of injectable solution for intramuscular injection containing</span></div><div class="t m0 x26 hb ya84 ff17 fs8 fc3 sc0 ls12 wsed">80 mg of artemether in 1 ml for adults or 40 mg of ar<span class="_ _8"></span>temether in 1 ml for</div><div class="t m0 x26 hb ya85 ff17 fs8 fc3 sc0 ls12 ws0">paediatric use.</div><div class="t m0 xb hb ya86 ff17 fs8 fc3 sc0 ls12 ws0">In a coformulation with lumefantrine:</div><div class="t m0 xb hb ya87 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">T<span class="_ _4b"></span>ablets containing 20 mg of ar<span class="_ _8"></span>temether and 120 mg of lumefantrine.</span></div><div class="t m0 xb h25 ya88 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb ya89 ff17 fs8 fc3 sc0 ls136 ws1ee">Peak plasma concentrations occur ar<span class="_ _a"></span>ound 2–3 h after oral administration</div><div class="t m0 xb hb ya8a ff1a fs8 fc3 sc0 ls1e1 ws0">(38)<span class="ff17 ls13b ws1c3">. Follo<span class="_ _a"></span>wing intramuscular injection, absorption is very v<span class="_ _a"></span>ariable, especially</span></div><div class="t m0 xb hb ya8b ff17 fs8 fc3 sc0 ls290 ws2ff">in children with poor peripheral perfusion: peak plasma concentr<span class="_ _a"></span>ations gener-</div><div class="t m0 xb hb ya8c ff17 fs8 fc3 sc0 ls34 ws14a">ally occur after around 6 h but absorption is slow and err<span class="_ _a"></span>atic and times to peak</div><div class="t m0 xb hb ya8d ff17 fs8 fc3 sc0 ls12 ws445">can be 18 h or longer in some cases <span class="ff1a ws0">(39–41)</span>. Artemether is metabolized to</div><div class="t m0 xb hb ya8e ff17 fs8 fc3 sc0 ls7a wsb7">dihydroartemisinin, the active metabolite. After intramuscular administr<span class="_ _a"></span>ation,</div><div class="t m0 xb hb ya8f ff17 fs8 fc3 sc0 ls26e wsa1">artemether predominates, whereas after oral administration dihydr<span class="_ _a"></span>oar<span class="_ _8"></span>temisinin</div><div class="t m0 xb hb ya90 ff17 fs8 fc3 sc0 ls43 ws60">predominates. Biotransformation is mediated via the cytochr<span class="_ _a"></span>ome P450 enzyme</div><div class="t m0 xb hb ya91 ff17 fs8 fc3 sc0 lsa9 wsf1">CYP3A4. Autoinduction of metabolism is less than with ar<span class="_ _8"></span>temisinin. Ar<span class="_ _8"></span>temether</div><div class="t m0 xb hb ya92 ff17 fs8 fc3 sc0 ls12 ws446">is 95% bound to plasma proteins. <span class="_ _a"></span>The elimination half-life is approximately</div><div class="t m0 xb hb ya93 ff17 fs8 fc3 sc0 ls88 wsce">1 h, but following intramuscular administr<span class="_ _a"></span>ation the elimination phase is</div><div class="t m0 xb hb ya94 ff17 fs8 fc3 sc0 ls2a1 ws447">prolonged because of continued absorption. No dose modifications are</div><div class="t m0 xb hb ya95 ff17 fs8 fc3 sc0 ls12 ws0">necessary in renal or hepatic impairment.</div><div class="t m0 xb h25 ya96 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb ya97 ff17 fs8 fc3 sc0 ls2a2 ws34c">In all species of animals tested, intramuscular artemether and ar<span class="_ _8"></span>temotil cause</div><div class="t m0 xb hb ya98 ff17 fs8 fc3 sc0 ls7f wsc0">an unusual selective pattern of neuronal damage to certain brain stem nuclei.</div><div class="t m0 xb hb ya99 ff17 fs8 fc3 sc0 ls2a3 ws443">Neurotoxicity in experimental animals is r<span class="_ _a"></span>elated to the sustained blood</div><div class="t m0 xb hb ya9a ff17 fs8 fc3 sc0 ls184 ws267">concentrations that follow intr<span class="_ _a"></span>amuscular administration <span class="ff1a ws0">(42)</span>, since it is much</div><div class="t m0 xb hb ya9b ff17 fs8 fc3 sc0 ls12 ws448">less frequent when the same doses are giv<span class="_ _a"></span>en orally<span class="_ _4b"></span>, or with similar doses of</div><div class="t m0 xb hb ya9c ff17 fs8 fc3 sc0 ls72 wsaa">water<span class="_ _b"></span>-soluble drugs such as ar<span class="_ _8"></span>tesunate. Clinical, neurophysiological and</div><div class="t m0 xb hb ya9d ff17 fs8 fc3 sc0 ls22b ws390">pathological studies in humans have not shown similar findings with ther<span class="_ _a"></span>apeutic</div><div class="t m0 xb hb ya9e ff17 fs8 fc3 sc0 ls87 wscd">use of these compounds <span class="ff1a ws0">(40)</span>. T<span class="_ _c"></span>oxicity is otherwise similar to that of artemisinin.</div><div class="t m0 xb h25 ya9f ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 xb hb yaa0 ff17 fs8 fc3 sc0 ls12 ws0">None known. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6c" class="pf w1 h4" data-page-no="6c"><div class="pc pc6c w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x45 h9 ya ff17 fs6 fc4 sc0 ls1b ws0">98</div><div class="t m0 x9 h2e yaa1 ff19 fs3 fc3 sc0 ls69 ws0">A3.6.3<span class="_ _a7"> </span>Ar<span class="_ _8"></span>tesunate</div><div class="t m0 x9 hb yaa2 ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 384.4 </div><div class="t m0 x9 hb yaa3 ff17 fs8 fc3 sc0 ls12 ws449">Artesunate is the sodium salt of the hemisuccinate ester of ar<span class="_ _8"></span>temisinin. It is</div><div class="t m0 x9 hb yaa4 ff17 fs8 fc3 sc0 ls256 ws1a8">soluble in water but has poor stability in aqueous solutions at neutral or acid</div><div class="t m0 x9 hb yaa5 ff17 fs8 fc3 sc0 ls12 ws449">pH. In the injectable form, artesunic acid is drawn up in sodium bicarbonate</div><div class="t m0 x9 hb yaa6 ff17 fs8 fc3 sc0 ls12 ws3bf">to form sodium artesunate immediately before injection. Ar<span class="_ _8"></span>tesunate can be</div><div class="t m0 x9 hb yaa7 ff17 fs8 fc3 sc0 ls13 ws5b">given orally<span class="_ _c"></span>, rectally or by the intramuscular or intrav<span class="_ _a"></span>enous routes. Ther<span class="_ _a"></span>e are</div><div class="t m0 x9 hb yaa8 ff17 fs8 fc3 sc0 ls12 ws0">no coformulations currently av<span class="_ _a"></span>ailable.</div><div class="t m0 x9 h25 yaa9 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 x9 hb yaaa ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">T<span class="_ _4b"></span>ablets containing 50 mg or 200 mg of sodium ar<span class="_ _8"></span>tesunate. </span></div><div class="t m0 x9 hb yaab ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls2a4 ws3">Ampoules: intramuscular or intrav<span class="_ _a"></span>enous injection containing 60 mg of anhydrous</span></div><div class="t m0 x16 hb yaac ff17 fs8 fc3 sc0 lsf9 ws44a">artesunic acid with a separate ampoule of 5% sodium bicarbonate<span class="_ _5"> </span><span class="ls12 ws0">solution. </span></div><div class="t m0 x9 hb yaad ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls13 ws14">Rectal capsules containing 100 mg or 400 mg of sodium artesunate.</span></div><div class="t m0 x9 h25 yaae ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 hb yaaf ff17 fs8 fc3 sc0 ls12 ws44b">Artesunate is rapidly absorbed, with peak plasma levels occurring 1.5 h and</div><div class="t m0 x9 hb yab0 ff17 fs8 fc3 sc0 lsf9 ws44c">2<span class="_ _7c"> </span>h<span class="_ _8"></span> and 0.5 h after oral, rectal and intramuscular administration, r<span class="_ _a"></span>espectively</div><div class="t m0 x9 hb yab1 ff1a fs8 fc3 sc0 ls233 ws0">(43–47)<span class="ff17 ls234 ws3b6">. <span class="_ _a"></span>It is almost entirely converted to dihydroartemisinin, the active</span></div><div class="t m0 x9 hb yab2 ff17 fs8 fc3 sc0 ls110 ws0">metabolite <span class="_ _66"></span><span class="ff1a">(30)</span><span class="ws2d4">. Elimination of ar<span class="_ _8"></span>tesunate is very rapid, and antimalarial</span></div><div class="t m0 x9 hb yab3 ff17 fs8 fc3 sc0 ls125 ws1db">activity is determined by dihydroartemisinin elimination (half-life approximately</div><div class="t m0 x9 hb yab4 ff17 fs8 fc3 sc0 ls76 ws0">45 min) <span class="_ _b"></span><span class="ff1a">(40)<span class="ff17 wsb3">. The extent of protein binding is unkno<span class="_ _a"></span>wn. No dose modifications</span></span></div><div class="t m0 x9 hb yab5 ff17 fs8 fc3 sc0 ls12 ws0">are necessary in renal or hepatic impairment.</div><div class="t m0 x9 h25 yab6 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb yab7 ff17 fs8 fc3 sc0 ls12 ws0">As for artemisinin.</div><div class="t m0 x9 h25 yab8 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yab9 ff17 fs8 fc3 sc0 ls12 ws0">None known.</div></div><div class="c x9 yaba w6 h32"><div class="t m0 xa h27 yabb ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xac h27 yabc ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xae h27 yabd ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x4 h27 yabe ff20 fs8 fc9 sc0 ls0 ws0">HO</div><div class="t m0 x44 h27 yabf ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x5f h27 yac0 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x61 h27 yac1 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xaf h27 yac2 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x42 h27 yac3 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x88 h28 yac4 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x28 h27 yac5 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x3b h28 yac6 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x66 h27 yac5 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x5f h27 yac7 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x60 h28 yac8 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x18 h27 yac9 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x13 h27 yaca ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x5f h27 yacb ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x18 h27 yacc ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x1a h30 yacd ff21 fs14 fc8 sc0 ls0 ws0">Ä</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6d" class="pf w1 h4" data-page-no="6d"><div class="pc pc6d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls0 ws0">99</div><div class="t m0 xb h2e yaa1 ff19 fs3 fc3 sc0 ls2a5 ws0">A3.6.4<span class="_ _a7"> </span>Dihydroartemisinin</div><div class="t m0 xb hb yaa2 ff17 fs8 fc3 sc0 ls0 ws81">Molecular weight: 284.4 </div><div class="t m0 xb hb yace ff17 fs8 fc3 sc0 lseb ws40d">Dihydroartemisinin is the main active metabolite of the artemisinin derivatives,</div><div class="t m0 xb hb yacf ff17 fs8 fc3 sc0 ls249 ws13b">but can also be given orally and r<span class="_ _a"></span>ectally as a drug in its own right. It is relativ<span class="_ _a"></span>ely</div><div class="t m0 xb hb yad0 ff17 fs8 fc3 sc0 ls7a wse2">insoluble in water<span class="_ _4b"></span>, and requires formulation with suitable excipients to ensure</div><div class="t m0 xb hb yad1 ff17 fs8 fc3 sc0 ls290 ws245">adequate absorption. It achieves cure r<span class="_ _a"></span>ates similar to those of oral artesunate.</div><div class="t m0 xb hb yad2 ff17 fs8 fc3 sc0 ls64 ws8e">A fixed-dose formulation with piperaquine is curr<span class="_ _a"></span>ently undergoing ev<span class="_ _a"></span>aluation</div><div class="t m0 xb hb yad3 ff17 fs8 fc3 sc0 ls64 ws0">as a promising new artemisinin-based combination therapy (ACT).</div><div class="t m0 xb h25 yad4 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb yad5 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">T<span class="_ _4b"></span>ablets containing 20 mg, 60 mg or 80 mg of dihydroartemisinin.</span></div><div class="t m0 xb hb yad6 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">Suppositories containing 80 mg of dihydroartemisinin.</span></div><div class="t m0 xb h25 yad7 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb yad8 ff17 fs8 fc3 sc0 lsbf ws12e">Dihydroartemisinin is rapidly absorbed following oral administr<span class="_ _a"></span>ation, reaching</div><div class="t m0 xb hb yad9 ff17 fs8 fc3 sc0 ls12 ws22e">peak levels after around 2.5 h. Absorption via the r<span class="_ _a"></span>ectal route is somewhat</div><div class="t m0 xb hb yada ff17 fs8 fc3 sc0 ls12 ws44d">slower<span class="_ _4b"></span>, with peak levels occurring around 4 h after administr<span class="_ _a"></span>ation. Plasma</div><div class="t m0 xb hb yadb ff17 fs8 fc3 sc0 ls12 ws44e">protein binding is around 55%. Elimination half-life is appr<span class="_ _a"></span>oximately 45 min</div><div class="t m0 xb hb yadc ff17 fs8 fc3 sc0 ls12 ws0">via intestinal and hepatic glucuronidation <span class="ff1a ls14">(48)</span><span class="ls13">. </span></div><div class="t m0 xb h25 yadd ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb yade ff17 fs8 fc3 sc0 ls12 ws0">As for artemisinin.</div><div class="t m0 xb h25 yadf ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 xb hb yae0 ff17 fs8 fc3 sc0 ls12 ws0">None known.</div></div><div class="c xb yae1 w7 h33"><div class="t m0 xab h27 yae2 ff20 fs8 fc9 sc0 ls0 ws0">HO</div><div class="t m0 x8d h27 yae3 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xa4 h27 yae4 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x1b h27 yae5 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x7a h27 yae6 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x7f h27 yae7 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x3d h28 yae8 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x38 h27 yae9 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x95 h28 yaea ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xb0 h27 yae9 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xa7 h27 yaeb ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x46 h28 yaec ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x93 h27 yaed ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa9 h27 yaee ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa4 h27 yaef ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x77 h27 yaf0 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xad h30 yaf1 ff21 fs14 fc8 sc0 ls0 ws0">Ä</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6e" class="pf w1 h4" data-page-no="6e"><div class="pc pc6e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">100</div><div class="t m0 x9 h2e yaa1 ff19 fs3 fc3 sc0 ls80 ws0">A3.6.5<span class="_ _a7"> </span>Ar<span class="_ _8"></span>temotil </div><div class="t m0 x9 hb yaa2 ff17 fs8 fc3 sc0 ls13 ws14">Molecular weight: 312.4 </div><div class="t m0 x9 hb yaf2 ff17 fs8 fc3 sc0 ls5d ws7e">Artemotil, previously known as arteether<span class="_ _b"></span>, is the ethyl ether of ar<span class="_ _8"></span>temisinin, and</div><div class="t m0 x9 hb yaf3 ff17 fs8 fc3 sc0 ls26 ws2a">is closely related to the more widely used artemether<span class="_ _b"></span>. It is oil-based so water</div><div class="t m0 x9 hb yaf4 ff17 fs8 fc3 sc0 ls13 ws14">insoluble. It is given by intramuscular injection only<span class="_ _c"></span>.</div><div class="t m0 x9 h25 yaf5 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 x9 hb yaf6 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws32c">Ampoules containing 150 mg of artemotil in 2 ml of injectable solution.</span></div><div class="t m0 x9 h25 yaf7 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 hb yaf8 ff17 fs8 fc3 sc0 lsaf ws11a">There is less published information on artemotil than for ar<span class="_ _8"></span>temether<span class="_ _b"></span>. Absorption</div><div class="t m0 x9 hb yaf9 ff17 fs8 fc3 sc0 ls12 ws44f">is slower and mor<span class="_ _a"></span>e erratic, with some patients having undetectable plasma</div><div class="t m0 x9 hb yafa ff17 fs8 fc3 sc0 ls12 ws0">artemotil until more than 24 h after administration.</div><div class="t m0 x9 h25 yafb ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb yafc ff17 fs8 fc3 sc0 ls12 ws0">As for artemisinin.</div><div class="t m0 x9 h25 yafd ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yafe ff17 fs8 fc3 sc0 ls12 ws0">None known.</div></div><div class="c x9 yaff w8 h34"><div class="t m0 x2d h27 yb00 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xc h27 yb01 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xac h27 yb02 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xa9 h27 yb03 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x37 h27 yb04 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x13 h27 yb05 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x9c h28 yb06 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x99 h27 yb07 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xb0 h28 yb08 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xa4 h27 yb07 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x9a h27 yb09 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x9e h28 yb0a ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x3 h27 yb09 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x6 h27 yb0b ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x14 h28 yb0c ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x44 h27 yb0d ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa h27 yb0e ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xac h27 yb0f ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x44 h27 yb10 ff20 fs8 fc3 sc0 ls0 ws0">C</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6f" class="pf w1 h4" data-page-no="6f"><div class="pc pc6f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">101</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls1 ws0">A3.7<span class="_ _52"> </span>Lumefantrine (benflumetol)</div><div class="t m0 xb hb y97e ff17 fs8 fc3 sc0 ls0 ws81">Molecular weight: 528.9 </div><div class="t m0 xb hb yb11 ff17 fs8 fc3 sc0 ls13 ws135">Lumefantrine belongs to the aryl aminoalcohol group of antimalarials, which</div><div class="t m0 xb hb yb12 ff17 fs8 fc3 sc0 ls26b ws3f1">also includes quinine, mefloquine and halofantrine. It has a similar mechanism</div><div class="t m0 xb hb yb13 ff17 fs8 fc3 sc0 ls12 wsec">of action. Lumefantrine is a r<span class="_ _a"></span>acemic fluorine derivative dev<span class="_ _a"></span>eloped in China. It</div><div class="t m0 xb hb yb14 ff17 fs8 fc3 sc0 ls22 ws5e">is only available in an or<span class="_ _a"></span>al preparation coformulated with artemether<span class="_ _b"></span>. This A<span class="_ _a"></span>CT</div><div class="t m0 xb hb yb15 ff17 fs8 fc3 sc0 ls12 ws0">is highly effective against multidrug-resistant <span class="ff1a ls13">P<span class="_ _ae"></span>. falciparum<span class="ff17 ls0">.</span></span></div><div class="t m0 xb h25 yb16 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb yb17 ff17 fs8 fc3 sc0 ls13 ws14">Available only in an or<span class="_ _a"></span>al preparation coformulated with artemether: </div><div class="t m0 xb hb yb18 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">T<span class="_ _4b"></span>ablets containing 20 mg of ar<span class="_ _8"></span>temether and 120 mg of lumefantrine.</span></div><div class="t m0 xb h25 yb19 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb yb1a ff17 fs8 fc3 sc0 ls29a ws436">Oral bioav<span class="_ _a"></span>ailability is variable and is highly dependant on administration</div><div class="t m0 xb hb yb1b ff17 fs8 fc3 sc0 ls98 wsf2">with fatty foods <span class="ff1a">(38, 49)</span><span class="ls18a ws2b5">. Absorption increases by 108% after a meal and is low<span class="_ _a"></span>er</span></div><div class="t m0 xb hb yb1c ff17 fs8 fc3 sc0 ls24a ws450">in patients with acute malaria than in convalescing patients. P<span class="_ _a"></span>eak plasma levels</div><div class="t m0 xb hb yb1d ff17 fs8 fc3 sc0 ls13 ws109">occur approximately 10 h after administr<span class="_ _a"></span>ation. The terminal elimination half-</div><div class="t m0 xb hb yb1e ff17 fs8 fc3 sc0 ls12 ws0">life is around 3 days. </div><div class="t m0 xb h25 yb1f ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb yb20 ff17 fs8 fc3 sc0 ls1ab ws2fd">Despite similarities with the structure and pharmacokinetic properties of</div><div class="t m0 xb hb yb21 ff17 fs8 fc3 sc0 ls12 ws451">halofantrine, lumefantrine does not significantly prolong the electrocar<span class="_ _a"></span>dio-</div><div class="t m0 xb hb yb22 ff17 fs8 fc3 sc0 ls2a6 ws122">graphic QT<span class="_ _67"> </span>interval, and has no other significant toxicity <span class="ff1a ws0">(50). </span>In fact the drug seems</div><div class="t m0 xb hb yb23 ff17 fs8 fc3 sc0 ls12 ws452">to be remarkably well toler<span class="_ _a"></span>ated. Reported side effects are generally mild –</div><div class="t m0 xb hb yb24 ff17 fs8 fc3 sc0 ls21e ws2b9">nausea, abdominal discomfort, headache and dizziness – and cannot be</div><div class="t m0 xb hb yb25 ff17 fs8 fc3 sc0 ls12 ws0">distinguished from symptoms of acute malaria.</div></div><div class="c xb yb26 w9 h35"><div class="t m0 x66 h27 yb27 ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 x6 h27 yb28 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xa4 h27 yb29 ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 xa4 h27 yb2a ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 x73 h27 yb29 ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 x4 h27 yb2b ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x9e h28 yb2c ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x3 h27 yb2b ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xf h27 yb2d ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xb1 h28 yb2e ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xaa h27 yb2d ff20 fs8 fc3 sc0 ls0 ws0">C</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf70" class="pf w1 h4" data-page-no="70"><div class="pc pc70 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">102</div><div class="t m0 x9 h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb ya00 ff17 fs8 fc3 sc0 ls9d ws21f">The manufacturer of artemether<span class="_ _a"></span>-lumefantrine recommends avoiding the</div><div class="t m0 x9 hb ya01 ff17 fs8 fc3 sc0 ls61 ws175">following: grapefruit juice; antiarrhythmics, such as amiodar<span class="_ _a"></span>one, disopyramide,</div><div class="t m0 x9 hb ya02 ff17 fs8 fc3 sc0 ls262 ws11e">flecainide, procainamide and quinidine; antibacterials, such as macrolides</div><div class="t m0 x9 hb ya03 ff17 fs8 fc3 sc0 ls129 ws3df">and quinolones; all antidepressants; antifungals such as imidazoles and</div><div class="t m0 x9 hb yb2f ff17 fs8 fc3 sc0 ls64 ws23b">triazoles; terfenadine; other antimalarials; all antipsychotic drugs; and beta</div><div class="t m0 x9 hb yb30 ff17 fs8 fc3 sc0 ls64 ws3c8">blockers, such as metoprolol and sotalol. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, there is no evidence that</div><div class="t m0 x9 hb yb31 ff17 fs8 fc3 sc0 ls64 ws0">co-administration with these drugs would be harmful. </div><div class="t m0 x9 h12 yb32 ff19 fs6 fc4 sc0 ls9a ws0">A3.8<span class="_ _33"> </span>Primaquine</div><div class="t m0 x9 hb yb33 ff17 fs8 fc3 sc0 ls13 ws14">Molecular weight: 259.4 </div><div class="t m0 x9 hb yb34 ff17 fs8 fc3 sc0 ls1e1 ws312">Primaquine is an 8-aminoquinoline and is effective against intr<span class="_ _a"></span>ahepatic forms</div><div class="t m0 x9 hb yb35 ff17 fs8 fc3 sc0 lsc5 ws13b">of all types of malaria parasite. It is used to pro<span class="_ _a"></span>vide radical cure of <span class="ff1a ws0">P<span class="_ _ae"></span>. viv<span class="_ _a"></span>ax <span class="ff17">and</span></span></div><div class="t m0 x9 hb yb36 ff1a fs8 fc3 sc0 ls5b ws0">P<span class="_ _c"></span>. o<span class="_ _a"></span>vale<span class="_ _6"> </span><span class="ff17 ws78">malaria, in combination with a blood schizontocide for the erythrocytic</span></div><div class="t m0 x9 hb yb37 ff17 fs8 fc3 sc0 ls12 ws3f">parasites. Primaquine is also gametocytocidal against <span class="ff1a ls13 ws0">P<span class="_ _ae"></span>. falciparum <span class="ff17 ls12 ws3f">and has</span></span></div><div class="t m0 x9 hb yb38 ff17 fs8 fc3 sc0 ls1fb ws3f">significant blood stage activity against <span class="ff1a">P<span class="_ _c"></span>. vivax <span class="ff17">(and some against asexual stages</span></span></div><div class="t m0 x9 hb yb39 ff17 fs8 fc3 sc0 ls13 ws0">of <span class="ff1a ws14">P<span class="_ _c"></span>. falciparum<span class="ff17 ls12 ws0">). The mechanism of action is unkno<span class="_ _a"></span>wn. </span></span></div><div class="t m0 x9 h25 yb3a ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 x9 hb yb3b ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls2a7 ws422">T<span class="_ _4b"></span>ablets containing 5.0 mg, 7.5 mg or 15.0 mg of primaquine base as diphosphate.</span></div><div class="t m0 x9 h25 yb3c ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 hb yb3d ff17 fs8 fc3 sc0 ls12 ws30c">Primaquine is readily absorbed fr<span class="_ _a"></span>om the gastrointestinal tract. Peak plasma</div><div class="t m0 x9 hb yb3e ff17 fs8 fc3 sc0 lsed ws7e">concentrations occur around 1–2 h after administr<span class="_ _a"></span>ation and then decline, with<span class="_ _5"> </span>a</div><div class="t m0 x9 hb yb3f ff17 fs8 fc3 sc0 ls12 ws453">reported elimination half-life of 3–6 h <span class="ff1a ls13 ws0">(51)</span><span class="ws310">. Primaquine is widely distributed</span></div><div class="t m0 x9 hb yb40 ff17 fs8 fc3 sc0 ls12 ws3ab">into body tissues. It is rapidly metabolized in the liv<span class="_ _a"></span>er<span class="_ _b"></span>. The major metabolite</div><div class="t m0 x9 hb yb41 ff17 fs8 fc3 sc0 ls12 ws454">is carboxyprimaquine, which may accumulate in the plasma with repeated</div><div class="t m0 x9 hb yb42 ff17 fs8 fc3 sc0 ls12 ws0">administration. </div></div><div class="c x9 yb43 w8 h36"><div class="t m0 xa0 h27 yb44 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xa8 h27 yb45 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x9a h27 yb46 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x9e h28 yb47 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x3 h27 yb46 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xa4 h27 yb48 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x1b h28 yb49 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x5 h27 yb4a ff20 fs8 fc8 sc0 ls0 ws0">NH</div><div class="t m0 x60 h28 yb4b ff20 fs5 fc8 sc0 ls0 ws0">2</div><div class="t m0 x8d h27 yb4c ff20 fs8 fc8 sc0 ls0 ws0">HN</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf71" class="pf w1 h4" data-page-no="71"><div class="pc pc71 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">103</div><div class="t m0 xb h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb ya00 ff17 fs8 fc3 sc0 ls64 ws3b0">The most important adverse effects are haemolytic anaemia in patients with</div><div class="t m0 xb hb ya01 ff17 fs8 fc3 sc0 ls33 ws76">G6PD deficiency<span class="_ _4b"></span>, other defects of the erythrocytic pentose phosphate pathway</div><div class="t m0 xb hb ya02 ff17 fs8 fc3 sc0 ls64 ws455">of glucose metabolism, or some other types of haemoglobinopathy <span class="ff1a ws0">(52)</span><span class="ws456">. In</span></div><div class="t m0 xb hb ya03 ff17 fs8 fc3 sc0 ls64 ws457">patients with the African variant of G6PD deficiency<span class="_ _c"></span>, the standard course of</div><div class="t m0 xb hb yb2f ff17 fs8 fc3 sc0 ls2a8 ws104">primaquine generally produces a benign self-limiting anaemia. In the Mediter-</div><div class="t m0 xb hb yb30 ff17 fs8 fc3 sc0 ls28 ws17b">ranean and Asian v<span class="_ _a"></span>ariants, haemolysis may be much more severe. <span class="_ _b"></span>Therapeutic</div><div class="t m0 xb hb yb31 ff17 fs8 fc3 sc0 ls64 ws273">doses may also cause abdominal pain if administered on an empty stomach.</div><div class="t m0 xb hb yb4d ff17 fs8 fc3 sc0 ls97 ws458">Larger doses can cause nausea and v<span class="_ _a"></span>omiting. Methaemoglobinaemia may</div><div class="t m0 xb hb yb4e ff17 fs8 fc3 sc0 ls64 ws0">occur<span class="_ _b"></span>. Other uncommon effects include mild anaemia and leukocytosis.</div><div class="t m0 xb hb yb4f ff17 fs8 fc3 sc0 ls49 ws2a4">Overdosage may r<span class="_ _a"></span>esult in leukopenia, agranulocytosis, gastrointestinal</div><div class="t m0 xb hb yb50 ff17 fs8 fc3 sc0 ls1be ws1fb">symptoms, haemolytic anaemia and methaemoglobinaemia with cyanosis.</div><div class="t m0 xb h25 yb51 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 xb hb yb52 ff17 fs8 fc3 sc0 ls12 ws29">Drugs liable to increase the risk of haemolysis or bone marro<span class="_ _a"></span>w suppression</div><div class="t m0 xb hb yb53 ff17 fs8 fc3 sc0 ls12 ws0">should be avoided. </div><div class="t m0 xb h12 yb54 ff19 fs6 fc4 sc0 ls53 ws0">A3.9<span class="_ _52"> </span>Atovaquone</div><div class="t m0 xb hb yb55 ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 366.8 </div><div class="t m0 xb hb yb56 ff17 fs8 fc3 sc0 ls64 ws1ae">Atov<span class="_ _a"></span>aquone is a hydro<span class="_ _a"></span>xynaphthoquinone antiparasitic drug active against all</div><div class="t m0 xb hb yb57 ff1a fs8 fc3 sc0 ls18b ws0">Plasmodium<span class="_ _6"> </span><span class="ff17 wsfa">species. It also inhibits pre-erythrocytic development in the liv<span class="_ _a"></span>er<span class="_ _b"></span>,</span></div><div class="t m0 xb hb yb58 ff17 fs8 fc3 sc0 ls274 ws189">and oocyst development in the mosquito<span class="_ _a"></span>. It is combined with proguanil for the</div><div class="t m0 xb hb yb59 ff17 fs8 fc3 sc0 ls64 ws12d">treatment of malaria – with which it is synergistic. Ato<span class="_ _a"></span>vaquone interfer<span class="_ _a"></span>es with</div><div class="t m0 xb hb yb5a ff17 fs8 fc3 sc0 ls64 ws0">cytochrome electron tr<span class="_ _a"></span>anspor<span class="_ _8"></span>t.</div></div><div class="c xb yb5b wa h37"><div class="t m0 x9d h27 yb5c ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 xa5 h27 yb5d ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xa5 h27 yb5e ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x81 h27 yb5f ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 xb0 h27 yb60 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xa8 h27 yb61 ff20 fs8 fc3 sc0 ls0 ws0">H</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf72" class="pf w1 h4" data-page-no="72"><div class="pc pc72 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">104</div><div class="t m0 x9 h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 x9 hb ya00 ff17 fs8 fc3 sc0 ls12 ws43c">Atov<span class="_ _a"></span>aquone is available for the tr<span class="_ _a"></span>eatment of malaria in a co-formulation with</div><div class="t m0 x9 hb ya01 ff17 fs8 fc3 sc0 ls12 ws0">proguanil:</div><div class="t m0 x9 hb yb62 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls299 ws148">Film-coated tablets containing 250 mg of atov<span class="_ _a"></span>aquone and 100 mg of</span></div><div class="t m0 x16 hb yb63 ff17 fs8 fc3 sc0 ls12 ws0">proguanil hydr<span class="_ _a"></span>ochloride for adults.</div><div class="t m0 x9 hb ya85 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws459">T<span class="_ _4b"></span>ablets containing 62.5 mg of atov<span class="_ _a"></span>aquone and 25 mg of proguanil hydro-</span></div><div class="t m0 x16 hb yb64 ff17 fs8 fc3 sc0 ls12 ws0">chloride for paediatric use.</div><div class="t m0 x9 h25 yb65 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 hb yb66 ff17 fs8 fc3 sc0 ls2a9 ws94">Atov<span class="_ _a"></span>aquone is poorly absorbed from the gastrointestinal tr<span class="_ _a"></span>act but bioavailability</div><div class="t m0 x9 hb yb67 ff17 fs8 fc3 sc0 ls13 ws45a">following oral administr<span class="_ _a"></span>ation can be improv<span class="_ _a"></span>ed by taking the drug with fatty</div><div class="t m0 x9 hb yb68 ff17 fs8 fc3 sc0 ls12 ws45b">foods. Bioavailabillity is r<span class="_ _a"></span>educed in patients with AI<span class="_ _8"></span>DS. Atov<span class="_ _a"></span>aquone is 99%</div><div class="t m0 x9 hb yb69 ff17 fs8 fc3 sc0 ls12 ws45c">bound to plasma proteins and has a plasma half-life of around 66–70 h due</div><div class="t m0 x9 hb yb6a ff17 fs8 fc3 sc0 ls12 ws45d">to enterohepatic recy<span class="_ _a"></span>cling. It is excreted almost exclusiv<span class="_ _a"></span>ely in the faeces as</div><div class="t m0 x9 hb yb52 ff17 fs8 fc3 sc0 ls129 ws1e0">unchanged drug. Plasma concentrations are significantly r<span class="_ _a"></span>educed in late</div><div class="t m0 x9 hb yb53 ff17 fs8 fc3 sc0 ls12 ws0">pregnancy <span class="ff1a ls13">(53)</span><span class="ls0">.</span></div><div class="t m0 x9 h25 yb6b ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb yb6c ff17 fs8 fc3 sc0 ls29b ws27a">Atov<span class="_ _a"></span>aquone is generally very well toler<span class="_ _a"></span>ated <span class="ff1a ws0">(54)</span>. Skin rashes, headache, fever<span class="_ _4b"></span>,</div><div class="t m0 x9 hb yb6d ff17 fs8 fc3 sc0 ls64 ws45e">insomnia, nausea, diarrhoea, vomiting, raised liv<span class="_ _a"></span>er enzymes, hyponatraemia</div><div class="t m0 x9 hb yb6e ff17 fs8 fc3 sc0 ls6f wsa1">and, very rarely<span class="_ _c"></span>, haematological disturbances, such as anaemia and neutropenia,</div><div class="t m0 x9 hb yb6f ff17 fs8 fc3 sc0 ls64 ws0">have all been reported. </div><div class="t m0 x9 h25 yb70 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yb71 ff17 fs8 fc3 sc0 ls12 ws358">Reduced plasma concentr<span class="_ _a"></span>ations may occur with concomitant administration</div><div class="t m0 x9 hb yb72 ff17 fs8 fc3 sc0 ls12 ws45f">of metoclopramide, tetracy<span class="_ _a"></span>cline and possibly also acyclovir<span class="_ _4b"></span>, antidiarrhoeal</div><div class="t m0 x9 hb yb73 ff17 fs8 fc3 sc0 ls37 ws48">drugs, benzodiazepines, cephalosporins, laxatives, opioids and par<span class="_ _a"></span>acetamol.</div><div class="t m0 x9 hb yb74 ff17 fs8 fc3 sc0 ls2aa ws460">Atov<span class="_ _a"></span>aquone decreases the metabolism of zidovudine and cotrimo<span class="_ _a"></span>xazole.</div><div class="t m0 x9 hb yb75 ff17 fs8 fc3 sc0 ls2ab ws30e">Theoretically<span class="_ _c"></span>, it may displace other highly protein-bound drugs from plasma-</div><div class="t m0 x9 hb yb76 ff17 fs8 fc3 sc0 ls12 ws0">protein binding sites.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf73" class="pf w1 h4" data-page-no="73"><div class="pc pc73 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">105</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls1 ws0">A3.10<span class="_ _1"> </span>Proguanil</div><div class="t m0 xb hb y97e ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 253.7 </div><div class="t m0 xb hb yb77 ff17 fs8 fc3 sc0 ls64 ws461">Proguanil is a biguanide compound that is metabolized in the body via the</div><div class="t m0 xb hb yb78 ff17 fs8 fc3 sc0 ls24b ws204">polymorphic cytochrome P450 enzyme CYP2C19 to the active metabolite,</div><div class="t m0 xb hb yb79 ff17 fs8 fc3 sc0 lse2 ws278">cycloguanil. Appro<span class="_ _a"></span>ximately 3% of Caucasian and African populations and 20%</div><div class="t m0 xb hb yb7a ff17 fs8 fc3 sc0 ls64 ws272">of Oriental people are “poor metaboliz<span class="_ _a"></span>ers” and have considerably reduced</div><div class="t m0 xb hb yb7b ff17 fs8 fc3 sc0 ls27 ws383">biotransformation of proguanil to cy<span class="_ _a"></span>cloguanil <span class="ff1a">(55, 56)</span>. C<span class="_ _a"></span>ycloguanil inhibits</div><div class="t m0 xb hb yb7c ff17 fs8 fc3 sc0 ls64 ws1c">plasmodial dihydrofolate r<span class="_ _a"></span>eductase. The parent compound has weak intrinsic</div><div class="t m0 xb hb yb7d ff17 fs8 fc3 sc0 ls1e2 ws4e">antimalarial activity through an unknown mechanism. It is possibly activ<span class="_ _a"></span>e</div><div class="t m0 xb hb yb7e ff17 fs8 fc3 sc0 ls2ac wsa3">against pre-erythrocytic forms of the parasite and is a slo<span class="_ _a"></span>w blood schizontocide.</div><div class="t m0 xb hb yb7f ff17 fs8 fc3 sc0 ls50 ws222">Proguanil also has spor<span class="_ _a"></span>ontocidal activity<span class="_ _4b"></span>, rendering the gametocytes non-</div><div class="t m0 xb hb yb80 ff17 fs8 fc3 sc0 ls64 ws266">infective to the mosquito v<span class="_ _a"></span>ector<span class="_ _b"></span>. Proguanil is given as the hydr<span class="_ _a"></span>ochloride salt</div><div class="t m0 xb hb yb81 ff17 fs8 fc3 sc0 lsb1 ws102">in combination with atov<span class="_ _a"></span>aquone. It is not used alone for treatment as resistance</div><div class="t m0 xb hb yb82 ff17 fs8 fc3 sc0 ls64 ws1bd">to proguanil develops v<span class="_ _a"></span>ery quickly<span class="_ _4b"></span>. Cy<span class="_ _a"></span>cloguanil was formerly administered as</div><div class="t m0 xb hb yb83 ff17 fs8 fc3 sc0 ls64 ws14">an oily suspension of the embonate by intramuscular injection.</div><div class="t m0 xb h25 yb84 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb yb85 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls7a wsb7">T<span class="_ _4b"></span>ablets of 100 mg of proguanil hydrochloride containing 87 mg of pr<span class="_ _a"></span>oguanil</span></div><div class="t m0 x26 hb yb86 ff17 fs8 fc3 sc0 ls13 ws0">base.</div><div class="t m0 xb hb yb87 ff17 fs8 fc3 sc0 ls12 ws0">In co-formulation with atov<span class="_ _a"></span>aquone:</div><div class="t m0 xb hb yb88 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls299 ws148">Film-coated tablets containing 250 mg of atov<span class="_ _a"></span>aquone and 100 mg of</span></div><div class="t m0 x26 hb yb89 ff17 fs8 fc3 sc0 ls12 ws0">proguanil hydr<span class="_ _a"></span>ochloride for adults.</div><div class="t m0 xb hb yb8a ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws462">T<span class="_ _4b"></span>ablet containing 62.5 mg of atov<span class="_ _a"></span>aquone and 25 mg of proguanil hydro-</span></div><div class="t m0 x26 hb yb8b ff17 fs8 fc3 sc0 ls12 ws0">chloride for paediatric use.</div><div class="t m0 xb h25 yb8c ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb yb8d ff17 fs8 fc3 sc0 ls12 ws463">Proguanil is r<span class="_ _a"></span>eadily absorbed from the gastrointestinal tract follo<span class="_ _a"></span>wing oral</div><div class="t m0 xb hb yb8e ff17 fs8 fc3 sc0 ls146 ws207">administration. Peak plasma lev<span class="_ _a"></span>els occur at about 4 h, and are reduced in the</div><div class="t m0 xb hb yb8f ff17 fs8 fc3 sc0 ls2ad ws464">third trimester of pregnancy<span class="_ _c"></span>. Around 75% is bound to plasma proteins.</div><div class="t m0 xb hb yb90 ff17 fs8 fc3 sc0 ls1a3 ws35f">Proguanil is metabolized in the liv<span class="_ _a"></span>er to the active antifolate metabolite,</div><div class="t m0 xb hb yb91 ff17 fs8 fc3 sc0 ls27 ws30">cycloguanil, and peak plasma levels of cy<span class="_ _a"></span>cloguanil occur 1 h after those of the</div><div class="t m0 xb hb yb92 ff17 fs8 fc3 sc0 ls12 ws465">parent drug. <span class="_ _a"></span>The elimination half-lives of both proguanil and cycloguanil is</div></div><div class="c xb yb93 wb h38"><div class="t m0 xb2 h27 yb94 ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 xb2 h27 yb95 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x24 h27 yb94 ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 x24 h27 yb95 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xb3 h27 yb94 ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 xb3 h27 yb95 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x46 h27 yb96 ff20 fs8 fc8 sc0 ls0 ws0">NH<span class="_ _84"> </span>NH</div><div class="t m0 x9a h27 yb97 ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 x76 h27 yb98 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x1c h28 yb99 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x3f h27 yb9a ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 xb4 h28 yb9b ff20 fs5 fc3 sc0 ls0 ws0">3</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf74" class="pf w1 h4" data-page-no="74"><div class="pc pc74 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">106</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls12 ws466">approximately 20 h <span class="ff1a ls13">(57, 58)</span>. Elimination is about 50% in the urine, of which</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 lsf ws12f">60% is unchanged drug and 30% cycloguanil, and a further amount is excreted</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls12 ws467">in the faeces. Small amounts are present in br<span class="_ _a"></span>east milk. The elimination of</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls24b ws3c7">cycloguanil is determined by that of the parent compound. <span class="_ _b"></span>The biotrans-</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls34 ws14a">formation of proguanil to cycloguanil via CYP2C19 is reduced in pr<span class="_ _a"></span>egnancy and</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls12 ws0">women taking the oral contraceptiv<span class="_ _a"></span>e pill <span class="ff1a ls8e ws370">(59, 60)</span><span class="ls13">. </span></div><div class="t m0 x9 h25 yb9c ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb y9e5 ff17 fs8 fc3 sc0 ls1fa ws43c">Apart from mild gastric intolerance, diarrhoea, occasional aphthous ulceration</div><div class="t m0 x9 hb y9e6 ff17 fs8 fc3 sc0 ls12 ws468">and hair loss, there are few adv<span class="_ _a"></span>erse effects associated with usual doses of</div><div class="t m0 x9 hb yb9d ff17 fs8 fc3 sc0 lsed ws191">proguanil hydr<span class="_ _a"></span>ochloride. Haematological changes (megaloblastic anaemia and</div><div class="t m0 x9 hb yb9e ff17 fs8 fc3 sc0 ls12 ws3">pancytopenia) have been reported in patients with severe r<span class="_ _a"></span>enal impairment.</div><div class="t m0 x9 hb yb9f ff17 fs8 fc3 sc0 ls12 ws3dd">Overdosage may pr<span class="_ _a"></span>oduce epigastric discomfor<span class="_ _8"></span>t, vomiting and haematuria.</div><div class="t m0 x9 hb yba0 ff17 fs8 fc3 sc0 ls1fa ws43c">Proguanil should be used cautiously in patients with r<span class="_ _a"></span>enal impairment and the</div><div class="t m0 x9 hb ya20 ff17 fs8 fc3 sc0 ls12 ws0">dose reduced according to the degr<span class="_ _a"></span>ee of impairment.</div><div class="t m0 x9 h25 yba1 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yba2 ff17 fs8 fc3 sc0 ls2ae ws180">Interactions may occur with concomitant administration of warfarin. Absorption</div><div class="t m0 x9 hb yba3 ff17 fs8 fc3 sc0 ls162 ws12d">of proguanil is reduced with concomitant administr<span class="_ _a"></span>ation of magnesium trisilicate.</div><div class="t m0 x9 h12 yba4 ff19 fs6 fc4 sc0 ls2 ws0">A3.11<span class="_ _1"> </span>Chlor<span class="_ _8"></span>proguanil</div><div class="t m0 x9 hb yba5 ff17 fs8 fc3 sc0 ls0 ws81">Molecular weight: 288.2 </div><div class="t m0 x9 hb yba6 ff17 fs8 fc3 sc0 ls234 ws3b6">Chlorproguanil is a biguanide and is given as the hy<span class="_ _a"></span>drochloride salt. Its</div><div class="t m0 x9 hb yba7 ff17 fs8 fc3 sc0 lsf ws12f">actions and properties are very similar to those of proguanil. It is av<span class="_ _a"></span>ailable only</div><div class="t m0 x9 hb yba8 ff17 fs8 fc3 sc0 ls12 ws469">in combination with a sulfone such as dapsone (co-formulated as Lapdap).</div><div class="t m0 x9 h25 yba9 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 hb ybaa ff17 fs8 fc3 sc0 ls12 ws0">Similar to those of proguanil <span class="ff1a">(61)</span><span class="ls0">.</span></div></div><div class="c x9 ybab wc h39"><div class="t m0 xb2 h27 ybac ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 xb2 h27 ybad ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x24 h27 ybac ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 x24 h27 ybad ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x72 h27 ybac ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 x72 h27 ybad ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x46 h27 ybae ff20 fs8 fc8 sc0 ls0 ws0">NH<span class="_ _84"> </span>NH</div><div class="t m0 x9a h27 ybaf ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 x0 h27 ybb0 ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 xb5 h27 ybb1 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x63 h28 ybb2 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xb6 h27 ybb3 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 xb4 h28 ybb4 ff20 fs5 fc3 sc0 ls0 ws0">3</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf75" class="pf w1 h4" data-page-no="75"><div class="pc pc75 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">107</div><div class="t m0 xb h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb ya00 ff17 fs8 fc3 sc0 ls12 ws0">As for proguanil.</div><div class="t m0 xb h25 ybb5 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 xb hb ybb6 ff17 fs8 fc3 sc0 ls12 ws0">As for proguanil.</div><div class="t m0 xb h12 ybb7 ff19 fs6 fc4 sc0 ls1 ws0">A3.12<span class="_ _1"> </span>Dapsone</div><div class="t m0 xb hb ybb8 ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 248.3 </div><div class="t m0 xb hb ybb9 ff17 fs8 fc3 sc0 ls1a6 ws2a7">Dapsone is a sulfone widely used for the treatment of leprosy<span class="_ _c"></span>, and sometimes</div><div class="t m0 xb hb ybba ff17 fs8 fc3 sc0 ls12 ws353">also for treatment or prophylaxis of <span class="ff1a">Pneumocystis carinii </span>pneumonia, and</div><div class="t m0 xb hb ybbb ff17 fs8 fc3 sc0 ls12 wsa6">treatment of toxoplasmosis, cutaneous leishmaniasis, actinomy<span class="_ _a"></span>cetoma and</div><div class="t m0 xb hb ybbc ff17 fs8 fc3 sc0 ls12 ws254">dermatitis herpetiformis. For malaria, dapsone is giv<span class="_ _a"></span>en in combination with</div><div class="t m0 xb hb ybbd ff17 fs8 fc3 sc0 ls12 ws46a">another antimalarial. It is coformulated with chlorproguanil (as Lapdap™).</div><div class="t m0 xb hb ybbe ff17 fs8 fc3 sc0 ls12 ws0">Dapsone inhibits plasmodial dihydropter<span class="_ _a"></span>oate synthase.</div><div class="t m0 xb h25 ybbf ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb ybc0 ff17 fs8 fc3 sc0 ls12 ws15f">Dapsone is almost completely absorbed from the gastrointestinal tr<span class="_ _a"></span>act, with</div><div class="t m0 xb hb ybc1 ff17 fs8 fc3 sc0 ls12 ws46b">peak plasma concentrations occurring 2–8 h after an oral dose. Dapsone is</div><div class="t m0 xb hb ybc2 ff17 fs8 fc3 sc0 ls204 ws350">50–80% bound to plasma proteins, as is almost 100% of monoacetyldapsone,</div><div class="t m0 xb hb ybc3 ff17 fs8 fc3 sc0 ls244 ws19f">its major metabolite. Dapsone undergoes enterohepatic r<span class="_ _a"></span>ecycling. It is widely</div><div class="t m0 xb hb ybc4 ff17 fs8 fc3 sc0 ls12 ws1a7">distributed to body tissues, including breast milk and saliv<span class="_ _a"></span>a. Its elimination</div><div class="t m0 xb hb ybc5 ff17 fs8 fc3 sc0 ls13 ws46c">half-life is 10–50 h. Dapsone is metabolized by acetylation, which exhibits</div><div class="t m0 xb hb ybc6 ff17 fs8 fc3 sc0 ls1fc ws214">genetic polymorphism. Hydro<span class="_ _a"></span>xylation is the other metabolic pathway<span class="_ _4b"></span>, resulting</div><div class="t m0 xb hb ybc7 ff17 fs8 fc3 sc0 ls7a wsb7">in hydro<span class="_ _a"></span>xylamine dapsone, which may be responsible for dapsone-associated</div><div class="t m0 xb hb ybc8 ff17 fs8 fc3 sc0 ls12 ws46d">methaemoglobinaemia and haemolysis. Dapsone is mainly excreted in the</div><div class="t m0 xb hb ybc9 ff17 fs8 fc3 sc0 ls12 ws0">urine, only 20% as unchanged drug.</div><div class="t m0 xb h25 ybca ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb ybcb ff17 fs8 fc3 sc0 ls2af ws3c4">V<span class="_ _b"></span>arying degrees of haemolysis and methaemoglobinaemia are the most</div><div class="t m0 xb hb ybcc ff17 fs8 fc3 sc0 ls1fc ws214">frequently reported adverse effects and occur in most patients given mor<span class="_ _a"></span>e than</div><div class="t m0 xb hb ybcd ff17 fs8 fc3 sc0 ls1b3 ws28">200 mg of dapsone daily<span class="_ _4b"></span>. Doses of up to 100 mg daily do not cause significant</div><div class="t m0 xb hb ybce ff17 fs8 fc3 sc0 ls26e wsa1">haemolysis but patients deficient in G6PD are affected by doses of <span class="ff16 ls0 ws0">&gt;<span class="_ _a"></span><span class="ff17 ls14f ws1db">50 mg daily<span class="_ _4b"></span>.</span></span></div><div class="t m0 xb hb ybcf ff17 fs8 fc3 sc0 ls4e ws232">Haemolytic anaemia has been reported following ingestion of dapsone in</div></div><div class="c xb ybd0 wd h3a"><div class="t m0 x14 h27 ybd1 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x14 h27 ybd2 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x14 h27 ybd3 ff20 fs8 fca sc0 ls0 ws0">S</div><div class="t m0 x9a h27 ybd4 ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 xb7 h28 ybd5 ff20 fs5 fc8 sc0 ls0 ws0">2</div><div class="t m0 x45 h27 ybd4 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x63 h27 ybd6 ff20 fs8 fc8 sc0 ls0 ws0">NH</div><div class="t m0 x2b h28 ybd7 ff20 fs5 fc8 sc0 ls0 ws0">2</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf76" class="pf w1 h4" data-page-no="76"><div class="pc pc76 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1b ws0">108</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls2b0 ws46e">breast milk. Agranulocytosis has been r<span class="_ _a"></span>epor<span class="_ _8"></span>ted following use of dapsone</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls90 wse2">and pyrimethamine together as malaria prophylaxis – particularly when used</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls12 ws1e0">twice weekly<span class="_ _4b"></span>. Aplastic anaemia has also been reported. Rashes, including</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls12 ws46f">pruritus and fixed-drug reactions may occur but serious cutaneous hyper-</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls12 ws223">sensitivity is rare. “Dapsone syndr<span class="_ _a"></span>ome” consists of rash, fev<span class="_ _a"></span>er<span class="_ _b"></span>, jaundice and</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls164 ws19b">eosinophilia, and has been reported in a few patients using dapsone as</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls126 ws1dc">malaria prophylaxis, but mainly in leprosy patients on long tr<span class="_ _a"></span>eatment courses.</div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 ls207 ws357">Other rare adv<span class="_ _a"></span>erse effects include anorexia, nausea, vomiting, headache,</div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 ls12 ws0">hepatitis, hypoalbuminaemia and psychosis.</div><div class="t m0 x9 h25 ybd8 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yb9e ff17 fs8 fc3 sc0 ls73 ws50">There is an increased risk of dapsone to<span class="_ _a"></span>xicity with concomitant administration</div><div class="t m0 x9 hb yb9f ff17 fs8 fc3 sc0 ls12 ws3f">of probenecid<span class="ff1a ls14 ws0">, </span><span class="ws422">trimethoprim and ampr<span class="_ _a"></span>enovir<span class="_ _b"></span>. L<span class="_ _a"></span>evels of dapsone are reduced</span></div><div class="t m0 x9 hb yba0 ff17 fs8 fc3 sc0 ls12 ws0">with rifampicin.</div><div class="t m0 x9 h12 ybd9 ff19 fs6 fc4 sc0 ls9a ws0">A3.13<span class="_ _1"> </span>Q<span class="_ _8"></span>uinine</div><div class="t m0 x9 hb ybda ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 324.4 </div><div class="t m0 x9 hb ybdb ff17 fs8 fc3 sc0 ls12 wsc4">Quinine is an alkaloid derived from the bark of the <span class="ff1a ls13 ws0">Cinchona </span>tree. F<span class="_ _a"></span>our anti-</div><div class="t m0 x9 hb ybdc ff17 fs8 fc3 sc0 ls12 wsd7">malarial alkaloids can be derived from the bark: quinine (the main alkaloid),</div><div class="t m0 x9 hb ybdd ff17 fs8 fc3 sc0 ls2d ws3b">quinidine, cinchonine and cinchonidine. Quinine is the L-stereoisomer of</div><div class="t m0 x9 hb ybde ff17 fs8 fc3 sc0 ls12 ws0">quinidine. </div><div class="t m0 x9 hb ybdf ff17 fs8 fc3 sc0 ls29f ws77">Quinine acts principally on the mature trophoz<span class="_ _a"></span>oite stage of parasite development</div><div class="t m0 x9 hb ybe0 ff17 fs8 fc3 sc0 ls64 ws2c2">and does not prevent sequestr<span class="_ _a"></span>ation or fur<span class="_ _8"></span>ther development of circulating ring</div><div class="t m0 x9 hb ybe1 ff17 fs8 fc3 sc0 ls203 ws128">stages of <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum<span class="ff17 ws128">. Like other structur<span class="_ _a"></span>ally similar antimalarials, quinine also</span></span></div><div class="t m0 x9 hb ybe2 ff17 fs8 fc3 sc0 ls64 ws1fc">kills the sexual stages of <span class="ff1a wsce">P<span class="_ _c"></span>. vivax, P<span class="_ _ae"></span>. malariae <span class="ff17 ws0">and<span class="_ _3"> </span><span class="ff1a">P<span class="_ _c"></span>.<span class="_ _7c"> </span>ovale<span class="ff17 ws1fc">, but not mature</span></span></span></span></div></div><div class="c x9 ybe3 we h3b"><div class="t m0 xa4 h27 ybe4 ff20 fs8 fc9 sc0 ls0 ws0">HO</div><div class="t m0 xa2 h27 ybe5 ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x7b h27 ybe6 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xb8 h27 ybe7 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x9a h27 ybe8 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x9e h28 ybe9 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x3 h27 ybe8 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xa h27 ybea ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 xb9 h28 ybeb ff20 fs5 fc3 sc0 ls0 ws0">2</div><div class="t m0 x97 h27 ybea ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x5f h27 ybec ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x3d h27 ybed ff20 fs8 fc3 sc0 ls0 ws0">H</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf77" class="pf w1 h4" data-page-no="77"><div class="pc pc77 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">109</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls2b1 ws470">gametocytes of <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum<span class="ff17 ws470">. It does not kill the pre-erythrocytic stages of malaria</span></span></div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls64 ws2cc">parasites. <span class="_ _a"></span>The mechanisms of its antimalarial actions are thought to involv<span class="_ _a"></span>e</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls64 wsfa">inhibition of parasite haem detoxification in the food v<span class="_ _b"></span>acuole, but are not well</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls64 ws0">understood. </div><div class="t m0 xb h25 ybee ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb ybef ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls160 ws230">T<span class="_ _4b"></span>ablets of quinine hydrochloride, quinine dihydr<span class="_ _a"></span>ochloride, quinine sulfate</span></div><div class="t m0 x26 hb y9e4 ff17 fs8 fc3 sc0 ls180 ws26f">and quinine bisulfate containing 82%, 82%, 82.6% and 59.2% quinine</div><div class="t m0 x26 hb y9e5 ff17 fs8 fc3 sc0 ls13 ws0">base, respectively<span class="_ _c"></span>.</div><div class="t m0 xb hb ybf0 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls27 ws30">Injectable solutions of quinine hydrochloride, quinine dihydr<span class="_ _a"></span>ochloride and</span></div><div class="t m0 x26 hb y9e7 ff17 fs8 fc3 sc0 ls34 ws14a">quinine sulfate containing 82%, 82% and 82.6% quinine base, respectively<span class="_ _c"></span>. </div><div class="t m0 xb h25 ybf1 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb ybf2 ff17 fs8 fc3 sc0 ls201 ws347">The pharmacokinetic properties of quinine are altered significantly by malaria</div><div class="t m0 xb hb y9ea ff17 fs8 fc3 sc0 ls90 wse2">infection, with reductions in apparent v<span class="_ _a"></span>olume of distribution and clearance in</div><div class="t m0 xb hb ybf3 ff17 fs8 fc3 sc0 ls14 ws471">proportion to disease severity <span class="ff1a ls12 ws24">(16, 62)<span class="ff17">. In children under 2 years of age with</span></span></div><div class="t m0 xb hb ybf4 ff17 fs8 fc3 sc0 ls12 ws472">severe malaria, concentr<span class="_ _a"></span>ations are slightly higher than in older children and</div><div class="t m0 xb hb ybf5 ff17 fs8 fc3 sc0 lsc1 ws0">adults <span class="_ _66"></span><span class="ff1a ls114">(63)</span><span class="ws132">. There is no evidence for dose-dependent kinetics. Quinine is</span></div><div class="t m0 xb hb ybf6 ff17 fs8 fc3 sc0 ls12 ws473">rapidly and almost completely absorbed from the gastr<span class="_ _a"></span>ointestinal tract and</div><div class="t m0 xb hb ybf7 ff17 fs8 fc3 sc0 ls150 ws168">peak plasma concentrations occur 1–3 h after oral administr<span class="_ _a"></span>ation of the sulfate</div><div class="t m0 xb hb ybf8 ff17 fs8 fc3 sc0 ls12 ws474">or bisulfate <span class="ff1a ls13 ws0">(64)</span>. It is well absorbed after intramuscular injection in sev<span class="_ _a"></span>ere</div><div class="t m0 xb hb ybf9 ff17 fs8 fc3 sc0 ls244 ws0">malaria <span class="_ _a"></span><span class="ff1a ws19f">(65, 66)<span class="ff17">. Plasma-protein binding, mainly to alpha 1-acid glycoprotein,</span></span></div><div class="t m0 xb hb ybfa ff17 fs8 fc3 sc0 ls12 ws475">is 80% in healthy subjects but rises to around 90% in patients with malaria</div><div class="t m0 xb hb ybfb ff1a fs8 fc3 sc0 ls220 ws0">(67–69)<span class="ff17 ls2b2 ws355">. Quinine is widely distributed throughout the body including the</span></div><div class="t m0 xb hb ybfc ff17 fs8 fc3 sc0 ls12 ws253">cerebrospinal fluid (2–7% of plasma v<span class="_ _b"></span>alues), breast milk (approximate 30%</div><div class="t m0 xb hb ybfd ff17 fs8 fc3 sc0 ls66 ws3f">of maternal plasma concentrations) and the placenta <span class="ff1a ls2b3 ws0">(70)</span><span class="ws286">. Extensive metabolism</span></div><div class="t m0 xb hb ybfe ff17 fs8 fc3 sc0 ls12 ws476">via the cytochrome P450 enzyme CYP3A4 occurs in the liver and elimination</div><div class="t m0 xb hb ybff ff17 fs8 fc3 sc0 ls12 ws1b1">of more polar metabolites is mainly renal <span class="ff1a ls13">(71, 72)</span>. <span class="_ _b"></span>The initial metabolite 3-</div><div class="t m0 xb hb yc00 ff17 fs8 fc3 sc0 ls44 ws93">hydro<span class="_ _a"></span>xyquinine contributes approximately 10% of the antimalarial activity of</div><div class="t m0 xb hb yc01 ff17 fs8 fc3 sc0 ls12 ws3d9">the parent compound, but may accumulate in renal failur<span class="_ _a"></span>e <span class="ff1a ls14 ws0">(73)</span><span class="ws185">. E<span class="_ _8"></span>xcretion is</span></div><div class="t m0 xb hb yc02 ff17 fs8 fc3 sc0 ls3e ws54">increased in acid urine. <span class="_ _a"></span>The mean elimination half-life is around 11 h in healthy</div><div class="t m0 xb hb yc03 ff17 fs8 fc3 sc0 lsc4 ws1b3">subjects, 16 h in uncomplicated malaria and 18 h in severe malaria <span class="ff1a ws0">(62)</span>. Small</div><div class="t m0 xb hb yc04 ff17 fs8 fc3 sc0 ls12 ws0">amounts appear in the bile and saliva.</div><div class="t m0 xb h25 yc05 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb yc06 ff17 fs8 fc3 sc0 ls3d wsbd">Administration of quinine or its salts regularly causes a complex of symptoms</div><div class="t m0 xb hb yc07 ff17 fs8 fc3 sc0 ls220 ws353">known as cinchonism, which is characteriz<span class="_ _a"></span>ed in its mild form by tinnitus,</div><div class="t m0 xb hb yc08 ff17 fs8 fc3 sc0 ls262 ws38e">impaired high tone hearing, headache, nausea, dizziness and dysphoria, and</div><div class="t m0 xb hb yc09 ff17 fs8 fc3 sc0 ls2a8 ws161">sometimes disturbed vision <span class="ff1a ws0">(7)</span><span class="ws229">. More sever<span class="_ _a"></span>e manifestations include vomiting,</span></div><div class="t m0 xb hb yc0a ff17 fs8 fc3 sc0 ls12 wsd2">abdominal pain, diarrhoea and severe v<span class="_ _a"></span>er<span class="_ _8"></span>tigo. Hypersensitivity r<span class="_ _a"></span>eactions to</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf78" class="pf w1 h4" data-page-no="78"><div class="pc pc78 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xb7 h9 ya ff17 fs6 fc4 sc0 ls1 ws0">110</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls12 ws477">quinine range from urticaria, bronchospasm, flushing of the skin and fever<span class="_ _4b"></span>,</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls21d ws2ad">through antibody-mediated thrombocytopenia and haemolytic anaemia, to life-</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls12 ws1c5">threatening haemolytic-uraemic syndr<span class="_ _a"></span>ome. Massive haemolysis with renal</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls236 ws2ea">failure (“black water fever”) has been linked epidemiologically and historically</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls15c ws26e">to quinine, but its etiology remains uncertain <span class="ff1a ls25 ws0">(74)</span>. The most important adverse</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls90 wse2">effect in the treatment of sever<span class="_ _a"></span>e malaria is hyperinsulinaemic hypoglycaemia</div><div class="t m0 x9 hb y10d ff1a fs8 fc3 sc0 lsa2 ws0">(75)<span class="ff17 ws1d">. This is particularly common in pregnancy (50% of quinine-treated women</span></div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 ls12 ws478">with severe malaria in late pr<span class="_ _a"></span>egnancy). Intramuscular injections of quinine</div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 ls12 ws1e">dihydrochloride ar<span class="_ _a"></span>e acidic (pH 2) and cause pain, focal necrosis and in some</div><div class="t m0 x9 hb y110 ff17 fs8 fc3 sc0 ls7f wsc0">cases abscess formation, and in endemic areas are a common cause of sciatic</div><div class="t m0 x9 hb y111 ff17 fs8 fc3 sc0 ls274 ws40d">nerve palsy<span class="_ _4b"></span>. Hypotension and cardiac arrest may result fr<span class="_ _a"></span>om rapid intravenous</div><div class="t m0 x9 hb y2be ff17 fs8 fc3 sc0 lsfa ws3ea">injection. Intravenous quinine should be giv<span class="_ _a"></span>en only by infusion, never injection.</div><div class="t m0 x9 hb y2bf ff17 fs8 fc3 sc0 ls31 ws41">Quinine causes an approximately 10% pr<span class="_ _a"></span>olongation of the electrocardiograph</div><div class="t m0 x9 hb y484 ff17 fs8 fc3 sc0 ls12 ws2a4">QT interval – mainly as a r<span class="_ _a"></span>esult of slight QRS widening <span class="ff1a ls13 ws0">(75)</span><span class="ws479">. The effect on</span></div><div class="t m0 x9 hb y485 ff17 fs8 fc3 sc0 ls12 ws47a">ventricular repolarization is much less than that with quinidine. Quinine has</div><div class="t m0 x9 hb y9cc ff17 fs8 fc3 sc0 ls32 ws43">been used as an abortifacient, but there is no evidence that it causes abor<span class="_ _8"></span>tion,</div><div class="t m0 x9 hb y9cd ff17 fs8 fc3 sc0 ls12 ws0">premature labour or fetal abnormalities in ther<span class="_ _a"></span>apeutic use. </div><div class="t m0 x9 hb y2c4 ff17 fs8 fc3 sc0 ls1fc ws343">Overdosage of quinine may cause oculoto<span class="_ _a"></span>xicity<span class="_ _4b"></span>, including blindness from direct</div><div class="t m0 x9 hb y2c5 ff17 fs8 fc3 sc0 ls151 ws381">retinal toxicity<span class="_ _c"></span>, and cardiotoxicity<span class="_ _c"></span>, and can be fatal <span class="_ _8"></span><span class="ff1a ws0">(76)</span>. Cardiotoxic effects ar<span class="_ _a"></span>e</div><div class="t m0 x9 hb y2c6 ff17 fs8 fc3 sc0 ls64 ws47b">less frequent than those of quinidine and include conduction disturbances,</div><div class="t m0 x9 hb y486 ff17 fs8 fc3 sc0 ls92 ws444">arrhythmias, angina, hypotension leading to cardiac arrest and cir<span class="_ _a"></span>culatory</div><div class="t m0 x9 hb y487 ff17 fs8 fc3 sc0 ls64 ws9d">failure. <span class="_ _a"></span>T<span class="_ _b"></span>reatment is largely supportive, with attention being given to mainte-</div><div class="t m0 x9 hb y488 ff17 fs8 fc3 sc0 ls2b4 ws16b">nance of blood pressure, glucose and r<span class="_ _a"></span>enal function, and to treating arrhythmias.</div><div class="t m0 x9 h25 yc0b ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yc0c ff17 fs8 fc3 sc0 ls1b3 wseb">There is a theoretical concern that drugs that may pr<span class="_ _a"></span>olong the QT interval</div><div class="t m0 x9 hb yc0d ff17 fs8 fc3 sc0 ls64 ws453">should not be given with quinine, although whether or not quinine increases</div><div class="t m0 x9 hb yc0e ff17 fs8 fc3 sc0 ls64 ws47c">the risk of iatrogenic ventricular tachyarrhythmia has not been established.</div><div class="t m0 x9 hb yc0f ff17 fs8 fc3 sc0 ls2b5 ws47d">Antiarrhythmics, such as flecainide and amiodarone, should probably be</div><div class="t m0 x9 hb yc10 ff17 fs8 fc3 sc0 ls7a wse2">avoided. <span class="_ _a"></span>There might be an increased risk of v<span class="_ _a"></span>entricular arrhythmias with anti-</div><div class="t m0 x9 hb yc11 ff17 fs8 fc3 sc0 lsf9 ws5e">histamines such as terfenadine, and with antipsychotic drugs such as pimozide</div><div class="t m0 x9 hb yc12 ff17 fs8 fc3 sc0 lsc4 ws10a">and thioridazine. Halofantrine, which causes marked QT pr<span class="_ _a"></span>olongation, should</div><div class="t m0 x9 hb yc13 ff17 fs8 fc3 sc0 ls270 ws47e">be avoided but combination with other antimalarials, such as lumefantrine and</div><div class="t m0 x9 hb yc14 ff17 fs8 fc3 sc0 ls64 ws119">mefloquine is safe. Quinine increases the plasma concentration of digo<span class="_ _a"></span>xin.</div><div class="t m0 x9 hb yc15 ff17 fs8 fc3 sc0 ls37 wsdd">Cimetidine inhibits quinine metabolism, causing increased quinine levels and</div><div class="t m0 x9 hb yc16 ff17 fs8 fc3 sc0 ls218 ws96">rifampicin increases metabolic clearance leading to lo<span class="_ _a"></span>w plasma concentrations</div><div class="t m0 x9 hb yc17 ff17 fs8 fc3 sc0 ls64 ws0">and an increased therapeutic failur<span class="_ _a"></span>e rate (77).</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf79" class="pf w1 h4" data-page-no="79"><div class="pc pc79 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">111</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls1 ws0">A3.14<span class="_ _1"> </span>T<span class="_ _c"></span>etrac<span class="_ _8"></span>yc<span class="_ _8"></span>line</div><div class="t m0 xb hb y97e ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 444.4 </div><div class="t m0 xb hb yc18 ff17 fs8 fc3 sc0 ls12 ws47f">The tetracyclines ar<span class="_ _a"></span>e a group of antibiotics originally derived from certain</div><div class="t m0 xb hb yc19 ff1a fs8 fc3 sc0 ls12 ws0">Streptomy<span class="_ _a"></span>ces<span class="_ _95"> </span><span class="ff17 ws480">species, but used mostly in synthetic form. T<span class="_ _4b"></span>etracycline itself</span></div><div class="t m0 xb hb yc1a ff17 fs8 fc3 sc0 ls2b6 ws481">may be administered orally or intr<span class="_ _a"></span>avenously as the hydrochloride salt or</div><div class="t m0 xb hb yc1b ff17 fs8 fc3 sc0 ls2b7 ws482">phosphate complex. Both are water soluble, although the intrav<span class="_ _a"></span>enous</div><div class="t m0 xb hb yc1c ff17 fs8 fc3 sc0 ls2c ws39">preparation is only stable for a few hours. <span class="_ _b"></span>T<span class="_ _b"></span>etracyclines are inhibitors of</div><div class="t m0 xb hb yc1d ff17 fs8 fc3 sc0 ls7f wsc0">aminoacyl-tRNA binding during protein synthesis. They have a br<span class="_ _a"></span>oad range of</div><div class="t m0 xb hb yc1e ff17 fs8 fc3 sc0 lsaa ws110">uses, including treatment of some bacterial infections: <span class="ff1a ws0">Chlamydia<span class="ff17">, <span class="_ _b"></span><span class="ff1a">Rickettsia<span class="ff17 ls0">,</span></span></span></span></div><div class="t m0 xb hb yc1f ff1a fs8 fc3 sc0 ls2b8 ws0">My<span class="_ _a"></span>coplasma<span class="ff17 ws46c">, L<span class="_ _b"></span>yme disease, <span class="ff1a ws0">Brucella</span>, tularaemia, plague and cholera.</span></div><div class="t m0 xb hb yc20 ff17 fs8 fc3 sc0 ls12 ws483">Doxycy<span class="_ _a"></span>cline is a synthetic tetracycline with a longer half-life, which makes</div><div class="t m0 xb hb yc21 ff17 fs8 fc3 sc0 ls12 ws0">dosing schedules easier<span class="_ _b"></span>.</div><div class="t m0 xb h25 yc22 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb yc23 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls1a8 ws2aa">Capsules and tablets containing 250 mg of tetracycline hy<span class="_ _a"></span>drochloride,</span></div><div class="t m0 x26 hb yc24 ff17 fs8 fc3 sc0 ls12 ws0">equivalent to 231 mg of tetr<span class="_ _a"></span>acycline base.</div><div class="t m0 xb h25 yc25 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb yc26 ff17 fs8 fc3 sc0 ls1fd ws3b5">Some 60–80% of tetracycline is absorbed fr<span class="_ _a"></span>om the gastrointestinal tract</div><div class="t m0 xb hb yc27 ff17 fs8 fc3 sc0 ls277 ws410">following oral administr<span class="_ _a"></span>ation. Absorption is reduced by the presence of</div><div class="t m0 xb hb yc28 ff17 fs8 fc3 sc0 ls2b9 ws8c">divalent and triv<span class="_ _b"></span>alent metal ions with which it forms stable, insoluble complexes.</div><div class="t m0 xb hb yc29 ff17 fs8 fc3 sc0 ls153 ws1c1">Thus absorption may be impaired with food or milk. F<span class="_ _a"></span>ormulation with phosphate</div><div class="t m0 xb hb yc2a ff17 fs8 fc3 sc0 ls6f ws231">may impro<span class="_ _a"></span>ve absorption. Peak plasma concentrations occur 1–3 h after ingestion.</div><div class="t m0 xb hb yc2b ff17 fs8 fc3 sc0 ls180 ws260">T<span class="_ _4b"></span>etracycline is 20–65% bound to plasma proteins. It is widely distributed</div><div class="t m0 xb hb yc2c ff17 fs8 fc3 sc0 ls12 ws417">throughout the body<span class="_ _c"></span>, although less so than the more lipophilic doxycycline.</div><div class="t m0 xb hb yc2d ff17 fs8 fc3 sc0 ls6a ws96">High concentrations are pr<span class="_ _a"></span>esent in breast milk (around 60% of plasma levels),</div><div class="t m0 xb hb yc2e ff17 fs8 fc3 sc0 ls12 ws85">and also diffuse readily across the placenta, and ar<span class="_ _a"></span>e retained in sites of new</div><div class="t m0 xb hb yc2f ff17 fs8 fc3 sc0 ls22b ws138">bone formation and teeth development. <span class="_ _a"></span>The half-life of tetracycline is around 8 h;</div></div><div class="c xb yc30 wf h3c"><div class="t m0 x3d h27 yc31 ff20 fs8 fc9 sc0 ls0 ws0">O<span class="_ _b5"></span>O<span class="_ _b6"></span>O<span class="_ _b7"></span>OH<span class="_ _b8"> </span>OH</div><div class="t m0 x7b h27 yc32 ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 x76 h27 yc33 ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 xa0 h27 yc34 ff20 fs8 fc9 sc0 ls0 ws0">HO</div><div class="t m0 xba h27 yc35 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x38 h27 yc36 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 xa4 h28 yc37 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x22 h27 yc38 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 xaf h28 yc39 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x7a h27 yc3a ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x7b h28 yc3b ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x10 h27 yc3a ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xb9 h27 yc3c ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x4a h27 yc3d ff20 fs8 fc8 sc0 ls0 ws0">NH</div><div class="t m0 x86 h28 yc3e ff20 fs5 fc8 sc0 ls0 ws0">2</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7a" class="pf w1 h4" data-page-no="7a"><div class="pc pc7a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xb7 h9 ya ff17 fs6 fc4 sc0 ls1 ws0">112</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls13 ws46c">40–70% is excreted in the urine via glomerular filtr<span class="_ _a"></span>ation. The remainder is</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls203 ws342">excreted in the faeces and bile. Enter<span class="_ _a"></span>ohepatic recycling slows do<span class="_ _a"></span>wn elimination.</div><div class="t m0 x9 h25 ya58 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb ya59 ff17 fs8 fc3 sc0 ls2b6 ws481">All the tetracy<span class="_ _a"></span>clines have similar adverse effect profiles. Gastrointestinal</div><div class="t m0 x9 hb ya5a ff17 fs8 fc3 sc0 ls24b ws3c7">effects, such as nausea, vomiting and diarrhoea, are common, especially</div><div class="t m0 x9 hb ya5b ff17 fs8 fc3 sc0 ls12 ws484">with higher doses, and are due to mucosal irritation. Dry mouth, glossitis,</div><div class="t m0 x9 hb ya5c ff17 fs8 fc3 sc0 ls12 ws1aa">stomatitis, dysphagia and oesophageal ulceration have also been r<span class="_ _a"></span>epor<span class="_ _8"></span>ted.</div><div class="t m0 x9 hb ya5d ff17 fs8 fc3 sc0 ls2ba ws485">Over<span class="_ _a"></span>growth of <span class="ff1a ws0">Candida<span class="_ _3"> </span></span>and other bacteria occurs, presumably due to</div><div class="t m0 x9 hb ya5e ff17 fs8 fc3 sc0 ls12 ws25f">disturbances in gastrointestinal flora as a r<span class="_ _a"></span>esult of incomplete absorption of</div><div class="t m0 x9 hb ya5f ff17 fs8 fc3 sc0 ls12 ws223">the drug. This effect is seen less fr<span class="_ _a"></span>equently with doxycycline, which is better</div><div class="t m0 x9 hb ya60 ff17 fs8 fc3 sc0 ls12 ws486">absorbed. Pseudomembranous colitis, hepatotoxicity and pancr<span class="_ _a"></span>eatitis have</div><div class="t m0 x9 hb ya61 ff17 fs8 fc3 sc0 ls12 ws0">also been reported.</div><div class="t m0 x9 hb yc3f ff17 fs8 fc3 sc0 ls236 ws2fb">T<span class="_ _4b"></span>etracyclines accumulate in patients with renal impairment and this may cause</div><div class="t m0 x9 hb yc40 ff17 fs8 fc3 sc0 ls2bb ws400">renal failure. In contr<span class="_ _a"></span>ast doxycycline accumulates less and is pr<span class="_ _a"></span>eferred in</div><div class="t m0 x9 hb yc41 ff17 fs8 fc3 sc0 lse3 ws294">patient with renal impairment. <span class="_ _a"></span>The use of out-of-date tetracycline can result in</div><div class="t m0 x9 hb yc42 ff17 fs8 fc3 sc0 ls2d ws226">the development of a rev<span class="_ _a"></span>ersible Fanconi-type syndr<span class="_ _a"></span>ome characterized by</div><div class="t m0 x9 hb yc43 ff17 fs8 fc3 sc0 ls64 ws21f">polyuria and polydipsia with nausea, glycosuria, aminoaciduria, hypophos-</div><div class="t m0 x9 hb yc44 ff17 fs8 fc3 sc0 ls6b ws1a6">phataemia, hypokalaemia, and hyperuricaemia with acidosis and proteinuria.</div><div class="t m0 x9 hb yc45 ff17 fs8 fc3 sc0 ls64 ws487">These effects have been attributed to the presence of degr<span class="_ _a"></span>adation products,</div><div class="t m0 x9 hb yc46 ff17 fs8 fc3 sc0 ls64 ws0">in particular anhydroepitetracycline. </div><div class="t m0 x9 hb yc47 ff17 fs8 fc3 sc0 ls12 ws488">T<span class="_ _4b"></span>etracyclines are deposited in deciduous and permanent teeth during their</div><div class="t m0 x9 hb yc48 ff17 fs8 fc3 sc0 ls71 wsa7">formation and cause discoloration and enamel hypoplasia. <span class="_ _a"></span>They are also</div><div class="t m0 x9 hb yc49 ff17 fs8 fc3 sc0 ls12 ws489">deposited in calcifying areas in bone and the nails and interfere with bone</div><div class="t m0 x9 hb yc4a ff17 fs8 fc3 sc0 ls12 ws21e">growth in y<span class="_ _a"></span>oung infants or pregnant women. Raised intracr<span class="_ _a"></span>anial pressure in</div><div class="t m0 x9 hb yc4b ff17 fs8 fc3 sc0 ls200 ws25">adults and infants has also been documented. T<span class="_ _c"></span>etracyclines use in pregnancy</div><div class="t m0 x9 hb yc4c ff17 fs8 fc3 sc0 ls200 ws25">has also been associated with acute fatty liver<span class="_ _4b"></span>. T<span class="_ _4b"></span>etracyclines should therefor<span class="_ _a"></span>e</div><div class="t m0 x9 hb yc4d ff17 fs8 fc3 sc0 ls12 ws40b">not be given to pregnant or lactating women, or childr<span class="_ _a"></span>en of less than 8 years</div><div class="t m0 x9 hb yc4e ff17 fs8 fc3 sc0 ls13 ws14">of age.</div><div class="t m0 x9 hb yc4f ff17 fs8 fc3 sc0 ls64 ws48a">Hypersensitivity reactions occur<span class="_ _4b"></span>, although they are less common than for ß-</div><div class="t m0 x9 hb yc50 ff17 fs8 fc3 sc0 ls71 ws270">lactam antibiotics. Rashes, fix<span class="_ _a"></span>ed drug reactions, drug fever<span class="_ _4b"></span>, angioedema,</div><div class="t m0 x9 hb yc51 ff17 fs8 fc3 sc0 ls14 ws2f7">urticaria, pericarditis and asthma have all been reported. Photosensitivity</div><div class="t m0 x9 hb yc52 ff17 fs8 fc3 sc0 ls64 ws48b">may develop and, rar<span class="_ _a"></span>ely<span class="_ _4b"></span>, haemolytic anaemia, eosinophilia, neutropenia and</div><div class="t m0 x9 hb yc53 ff17 fs8 fc3 sc0 ls26a ws3eb">thrombocytopenia. Pr<span class="_ _a"></span>e-existing systemic lupus erythematosus may be worsened</div><div class="t m0 x9 hb yc54 ff17 fs8 fc3 sc0 lsd5 ws3e">and tetracyclines ar<span class="_ _a"></span>e contraindicated in patients with the established disease.</div><div class="t m0 x9 h25 yc55 ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yc56 ff17 fs8 fc3 sc0 ls181 ws264">There is reduced absorption of tetr<span class="_ _a"></span>acyclines with concomitant administration</div><div class="t m0 x9 hb yc57 ff17 fs8 fc3 sc0 ls12 ws48c">of cations, such as aluminium, bismuth, calcium, iron, zinc and magnesium.</div><div class="t m0 x9 hb yc58 ff17 fs8 fc3 sc0 ls2bc ws48d">Administration with antacids, iron pr<span class="_ _a"></span>eparations, dairy products and some</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7b" class="pf w1 h4" data-page-no="7b"><div class="pc pc7b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">113</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls12a ws1e1">other foods should therefore be av<span class="_ _a"></span>oided. Nephrotoxicity may be exacerbated</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls2bd ws23e">with diuretics, methoxyflur<span class="_ _a"></span>ane or other potentially nephrotoxic drugs.</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls6e ws2cb">Potentially hepatotoxic drugs should be av<span class="_ _a"></span>oided. T<span class="_ _4b"></span>etracyclines pr<span class="_ _a"></span>oduce</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls12 ws1bd">increased concentrations of digo<span class="_ _a"></span>xin, lithium and theophylline, and decrease</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls2be ws2e7">plasma atov<span class="_ _a"></span>aquone concentrations and also the effectiveness of or<span class="_ _a"></span>al</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls12 ws178">contraceptives. <span class="_ _b"></span>They may antagonize the actions of penicillins so should not</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls12 ws0">be given concomitantly<span class="_ _c"></span>.</div><div class="t m0 xb h12 y39d ff19 fs6 fc4 sc0 ls53 ws0">A3.15<span class="_ _1"> </span>Doxyc<span class="_ _8"></span>ycline</div><div class="t m0 xb hb y59a ff17 fs8 fc3 sc0 ls13 ws14">(See also tetracycline)</div><div class="t m0 xb hb yc59 ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 444.4</div><div class="t m0 xb hb yc5a ff17 fs8 fc3 sc0 ls2bf ws48e">Doxycy<span class="_ _a"></span>cline is a tetracycline deriv<span class="_ _a"></span>ative with uses similar to those of tetracy<span class="_ _a"></span>cline.</div><div class="t m0 xb hb yc5b ff17 fs8 fc3 sc0 lse3 ws172">It may be preferred to tetr<span class="_ _a"></span>acycline because of its longer half-life, more reliable</div><div class="t m0 xb hb yc5c ff17 fs8 fc3 sc0 ls1a5 ws76">absorption and better safety profile in patients with renal insufficiency<span class="_ _c"></span>, where</div><div class="t m0 xb hb yc5d ff17 fs8 fc3 sc0 ls2bb ws1fb">it may be used with caution. It is relatively water insoluble but v<span class="_ _a"></span>ery lipid</div><div class="t m0 xb hb yc5e ff17 fs8 fc3 sc0 ls12 ws255">soluble. It may be given orally or intr<span class="_ _a"></span>avenously<span class="_ _4b"></span>. It is available as the hy<span class="_ _a"></span>dro-</div><div class="t m0 xb hb yc5f ff17 fs8 fc3 sc0 ls186 ws268">chloride salt or phosphate complex, or as a complex prepared fr<span class="_ _a"></span>om the</div><div class="t m0 xb hb yc60 ff17 fs8 fc3 sc0 ls12 ws0">hydrochloride and calcium chloride.</div><div class="t m0 xb h25 yc61 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb yc62 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls2a0 ws41a">Capsules and tablets containing 100 mg of doxycy<span class="_ _a"></span>cline salt as hydrochloride.</span></div><div class="t m0 xb h25 yc63 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb yc64 ff17 fs8 fc3 sc0 ls2a9 ws37f">Doxycy<span class="_ _a"></span>cline is readily and almost completely absorbed from the gastrointestinal</div><div class="t m0 xb hb yc65 ff17 fs8 fc3 sc0 ls2c0 wse7">tract and absorption is not affected significantly by the presence of food. P<span class="_ _a"></span>eak</div><div class="t m0 xb hb yc66 ff17 fs8 fc3 sc0 lsfa ws5b">plasma concentrations occur 2 h after administration. Some 80–95% is pr<span class="_ _a"></span>otein-</div></div><div class="c xb yc67 w10 h3d"><div class="t m0 xbb h27 yc68 ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 x17 h27 yc69 ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 xb9 h27 yc6a ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 xbb h27 yc6b ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 xf h27 yc6c ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 x26 h27 yc6d ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x35 h27 yc6e ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x3d h27 yc6f ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 xba h27 yc70 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 xb9 h27 yc71 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x95 h27 yc72 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x7a h27 yc73 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x7b h28 yc74 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xb9 h27 yc75 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 xbc h27 yc76 ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x2d h28 yc77 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xa3 h27 yc78 ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x60 h27 yc79 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x17 h28 yc7a ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x50 h27 yc7b ff20 fs8 fc8 sc0 ls0 ws0">NH</div><div class="t m0 x5b h28 yc7c ff20 fs5 fc8 sc0 ls0 ws0">2</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7c" class="pf w1 h4" data-page-no="7c"><div class="pc pc7c w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xb7 h9 ya ff17 fs6 fc4 sc0 ls1 ws0">114</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls10e ws160">bound and half-life is 10–24 h <span class="ff1a ws0">(78)</span><span class="ws93">. It is widely distributed in body tissues and</span></div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls10e wsf8">fluids. In patients with normal renal function, 40% of doxy<span class="_ _a"></span>cycline is excreted</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 lsa9 ws109">in the urine, although more if the urine is alkalinized. It may accumulate in r<span class="_ _a"></span>enal</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls64 ws0">failure. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, the majority of the dose is excreted in the faeces.</div><div class="t m0 x9 h25 ybee ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 x9 hb ybef ff17 fs8 fc3 sc0 ls12 ws97">As for tetracycline. Gastrointestinal effects are few<span class="_ _a"></span>er than with tetracycline,</div><div class="t m0 x9 hb y9e4 ff17 fs8 fc3 sc0 ls12 ws48f">although oesophageal ulceration can still be a problem if insufficient water</div><div class="t m0 x9 hb y9e5 ff17 fs8 fc3 sc0 ls12 ws16b">is taken with tablets or capsules. Ther<span class="_ _a"></span>e is less accumulation in patients with</div><div class="t m0 x9 hb y9e6 ff17 fs8 fc3 sc0 ls12 ws490">renal impairment. Doxy<span class="_ _a"></span>cycline should not be given to pr<span class="_ _a"></span>egnant or lactating</div><div class="t m0 x9 hb yb9d ff17 fs8 fc3 sc0 ls12 ws0">women, or children aged up to 8 years.</div><div class="t m0 x9 h25 yc7d ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 x9 hb yc7e ff17 fs8 fc3 sc0 ls205 ws8b">Doxycy<span class="_ _a"></span>cline has a lower affinity for binding with calcium than other tetracy<span class="_ _a"></span>clines,</div><div class="t m0 x9 hb yc7f ff17 fs8 fc3 sc0 ls24 ws26">so may be taken with food or milk. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, antacids and iron may still affect</div><div class="t m0 x9 hb yc80 ff17 fs8 fc3 sc0 ls96 wsef">absorption. Metabolism may be accelerated by drugs that induce hepatic</div><div class="t m0 x9 hb yc81 ff17 fs8 fc3 sc0 ls12 ws491">enzymes, such as carbamazepine, phenytoin, phenobarbital and rifampicin,</div><div class="t m0 x9 hb yba2 ff17 fs8 fc3 sc0 ls13 ws14">and by chronic alcohol use.</div><div class="t m0 x9 h12 yc82 ff19 fs6 fc4 sc0 ls9a ws0">A3.16<span class="_ _1"> </span>C<span class="_ _8"></span>lindamycin</div><div class="t m0 x9 hb yc83 ff17 fs8 fc3 sc0 ls12 ws0">Molecular weight: 425.0 </div><div class="t m0 x9 hb yc84 ff17 fs8 fc3 sc0 ls2c1 ws492">Clindamycin is a lincosamide antibiotic, i.e. a chlorinated deriv<span class="_ _a"></span>ative of</div><div class="t m0 x9 hb yc85 ff17 fs8 fc3 sc0 ls12 ws493">lincomycin. It is very soluble in water<span class="_ _4b"></span>. It inhibits the early stages of protein</div><div class="t m0 x9 hb yc86 ff17 fs8 fc3 sc0 ls1da ws2fc">synthesis by a mechanism similar to that of the macrolides. It may be</div><div class="t m0 x9 hb yc87 ff17 fs8 fc3 sc0 ls13 ws494">administered by mouth as capsules containing the hydr<span class="_ _a"></span>ochloride or as oral</div><div class="t m0 x9 hb yc88 ff17 fs8 fc3 sc0 lsc9 ws13d">liquid preparations containing the palmitate hy<span class="_ _a"></span>drochloride. Clindamycin is given</div><div class="t m0 x9 hb yc89 ff17 fs8 fc3 sc0 ls8e wsdd">parenterally as the phosphate either by the intr<span class="_ _a"></span>amuscular or the intravenous</div></div><div class="c x9 yc8a w11 h3e"><div class="t m0 x5d h27 yc8b ff20 fs8 fc9 sc0 ls0 ws0">HO</div><div class="t m0 x28 h27 yc8c ff20 fs8 fc9 sc0 ls0 ws0">HO</div><div class="t m0 x40 h27 yc8d ff20 fs8 fc9 sc0 ls0 ws0">OH</div><div class="t m0 x4a h27 yc8e ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x10 h27 yc8f ff20 fs8 fc9 sc0 ls0 ws0">O</div><div class="t m0 x21 h27 yc90 ff20 fs8 fc4 sc0 ls0 ws0">CI</div><div class="t m0 x95 h27 yc91 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x35 h27 yc92 ff20 fs8 fc8 sc0 ls0 ws0">N</div><div class="t m0 x35 h27 yc93 ff20 fs8 fc8 sc0 ls0 ws0">H</div><div class="t m0 x42 h27 yc94 ff20 fs8 fca sc0 ls0 ws0">S</div><div class="t m0 x95 h27 yc95 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x9d h28 yc96 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x1c h27 yc97 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x2b h28 yc98 ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 xbd h27 yc99 ff20 fs8 fc3 sc0 ls0 ws0">CH</div><div class="t m0 x1f h28 yc9a ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x9a h27 yc9b ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x9e h28 yc9c ff20 fs5 fc3 sc0 ls0 ws0">3</div><div class="t m0 x3 h27 yc9b ff20 fs8 fc3 sc0 ls0 ws0">C</div><div class="t m0 x98 h27 yc9d ff20 fs8 fc3 sc0 ls0 ws0">H</div><div class="t m0 x7b h27 yc9e ff20 fs8 fc3 sc0 ls0 ws0">H</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7d" class="pf w1 h4" data-page-no="7d"><div class="pc pc7d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">115</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls12 ws495">route. It is used for the treatment of anaer<span class="_ _a"></span>obic and Gram-positive bacterial</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls12 ws496">infections, babesiosis, toxoplasmosis and <span class="ff1a">Pneumocystis carinii </span><span class="ws0">pneumonia.</span></div><div class="t m0 xb h25 ya58 ff1f fs12 fc4 sc0 ls285 ws0">F<span class="_ _a"></span>ormulations</div><div class="t m0 xb hb ya59 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls2c2 ws98">Capsules containing 75 mg, 150 mg or 300 mg of clindamycin base as</span></div><div class="t m0 x26 hb ya5a ff17 fs8 fc3 sc0 ls12 ws0">hydrochloride.</div><div class="t m0 xb h25 yc9f ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 xb hb yca0 ff17 fs8 fc3 sc0 ls75 wsf0">About 90% of a dose is absorbed following oral administr<span class="_ _a"></span>ation. Food does not</div><div class="t m0 xb hb yca1 ff17 fs8 fc3 sc0 ls64 ws9e">impede absorption but may delay it. Clindamycin phosphate and palmitate</div><div class="t m0 xb hb yca2 ff17 fs8 fc3 sc0 ls128 ws28e">hydrochloride ar<span class="_ _a"></span>e rapidly hydrolysed to form the free drug. P<span class="_ _a"></span>eak concentrations</div><div class="t m0 xb hb yca3 ff17 fs8 fc3 sc0 ls1b2 ws203">may be reached within 1 h in children and 3 h in adults. It is widely distributed,</div><div class="t m0 xb hb ybf1 ff17 fs8 fc3 sc0 ls64 ws12f">although not into the cerebrospinal fluid. It cr<span class="_ _a"></span>osses the placenta and appears</div><div class="t m0 xb hb yc7e ff17 fs8 fc3 sc0 ls2c3 ws17d">in breast milk. It is 90% bound to plasma proteins and accumulates in leukocytes,</div><div class="t m0 xb hb yc7f ff17 fs8 fc3 sc0 ls93 ws2ee">macrophages and bile. <span class="_ _a"></span>The half-life is 2–3 h but this may be prolonged in</div><div class="t m0 xb hb yc80 ff17 fs8 fc3 sc0 ls2c4 ws497">neonates and patients with renal impairment. Clindamycin under<span class="_ _a"></span>goes</div><div class="t m0 xb hb yc81 ff17 fs8 fc3 sc0 ls96 ws481">metabolism to the active <span class="ff1a ls0 ws0">N</span>-demethyl and sulfoxide metabolites, and also</div><div class="t m0 xb hb yba2 ff17 fs8 fc3 sc0 ls2c5 ws242">some inactive metabolites. About 10% of a dose is excr<span class="_ _a"></span>eted in the urine as active</div><div class="t m0 xb hb yba3 ff17 fs8 fc3 sc0 ls64 ws1dc">drug or metabolites and about 4% in the faeces. The r<span class="_ _a"></span>emainder is excreted as</div><div class="t m0 xb hb yca4 ff17 fs8 fc3 sc0 ls291 ws464">inactive metabolites. Excretion is slo<span class="_ _a"></span>w and takes place over many days.</div><div class="t m0 xb hb ya68 ff17 fs8 fc3 sc0 ls10e ws14">Clindamycin is not effectively r<span class="_ _a"></span>emoved fr<span class="_ _a"></span>om the body by dialysis.</div><div class="t m0 xb h25 yca5 ff1f fs12 fc4 sc0 ls285 ws0">T<span class="_ _c"></span>oxicity</div><div class="t m0 xb hb yca6 ff17 fs8 fc3 sc0 lsdf ws86">Diarrhoea occurs in 2–20% of patients. In some, pseudomembranous colitis may</div><div class="t m0 xb hb yca7 ff17 fs8 fc3 sc0 ls64 ws498">develop during or after treatment, which can be fatal. Other r<span class="_ _a"></span>epor<span class="_ _8"></span>ted gastro-</div><div class="t m0 xb hb yca8 ff17 fs8 fc3 sc0 ls126 wsec">intestinal effects include nausea, vomiting, abdominal pain and an unpleasant</div><div class="t m0 xb hb yca9 ff17 fs8 fc3 sc0 ls1d1 wsb3">taste in the mouth. Around 10% of patients develop a hypersensitivity r<span class="_ _a"></span>eaction.</div><div class="t m0 xb hb ycaa ff17 fs8 fc3 sc0 ls64 ws462">This may take the form of skin rash, urticaria or anaphylaxis. Other adverse</div><div class="t m0 xb hb ycab ff17 fs8 fc3 sc0 ls31 ws3c1">effects include leukopenia, agranulocytosis, eosinophilia, thrombocytopenia,</div><div class="t m0 xb hb ycac ff17 fs8 fc3 sc0 ls2c6 ws499">erythema multiforme, polyar<span class="_ _8"></span>thritis, jaundice and hepatic damage. Some</div><div class="t m0 xb hb ycad ff17 fs8 fc3 sc0 ls128 ws28e">parenteral formulations contain benzyl alcohol, which may cause fatal “<span class="_ _b"></span>gasping</div><div class="t m0 xb hb ycae ff17 fs8 fc3 sc0 ls64 ws0">syndrome<span class="_ _a"></span>” in neonates.</div><div class="t m0 xb h25 ycaf ff1f fs12 fc4 sc0 ls285 ws0">Drug interactions</div><div class="t m0 xb hb ycb0 ff17 fs8 fc3 sc0 ls12 ws49a">Clindamycin may enhance the effects of drugs with neuromuscular blocking</div><div class="t m0 xb hb ycb1 ff17 fs8 fc3 sc0 ls12 ws49b">activity and there is a potential danger of respir<span class="_ _a"></span>atory depression. Additive</div><div class="t m0 xb hb ycb2 ff17 fs8 fc3 sc0 lsa8 ws10a">respiratory depressant effects may also occur with opioids. Clindamy<span class="_ _a"></span>cin may</div><div class="t m0 xb hb ycb3 ff17 fs8 fc3 sc0 ls12 ws0">antagonize the activity of parasympathomimetics.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7e" class="pf w1 h4" data-page-no="7e"><div class="pc pc7e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xb7 h9 ya ff17 fs6 fc4 sc0 ls9a ws0">116</div><div class="t m0 x9 h12 y12a ff19 fs6 fc4 sc0 ls1 ws17a">A3.17<span class="_ _1"> </span>P<span class="_ _9"></span>harmacolog<span class="_ _8"></span>y of ant<span class="_ _8"></span>imalarials in special groups</div><div class="t m0 x28 h12 y12b ff19 fs6 fc4 sc0 ls1 ws0">and conditions</div><div class="t m0 x9 h2e ycb4 ff19 fs3 fc3 sc0 ls0 wsc1">A3.17.1<span class="_ _7c"> </span>Safet<span class="_ _8"></span>y and tolerabilit<span class="_ _8"></span>y of antimalar<span class="_ _8"></span>ials in infants</div><div class="t m0 x9 hb ycb5 ff17 fs8 fc3 sc0 ls64 ws28c">Infants under 12 months of age constitute a significant proportion of patients</div><div class="t m0 x9 hb ycb6 ff17 fs8 fc3 sc0 ls2c7 ws28c">in malaria endemic countries. Y<span class="_ _4b"></span>et few studies focus specifically on this age range,</div><div class="t m0 x9 hb ycb7 ff17 fs8 fc3 sc0 ls1d9 ws2e6">partly because of ethical dilemmas and also owing to technical difficulties</div><div class="t m0 x9 hb ycb8 ff17 fs8 fc3 sc0 ls6b ws1a6">with sampling. V<span class="_ _4b"></span>er<span class="_ _8"></span>y young children cannot report adverse effects themselv<span class="_ _a"></span>es,</div><div class="t m0 x9 hb ycb9 ff17 fs8 fc3 sc0 ls200 ws433">so detection of these is dependent upon parents and health professionals</div><div class="t m0 x9 hb ycba ff17 fs8 fc3 sc0 lsbc ws12e">making observations. In addition, pre-marketing clinical trials for new drugs are</div><div class="t m0 x9 hb ycbb ff17 fs8 fc3 sc0 ls3b ws26">not represented by important subpopulations including infants <span class="ff1a ws0">(79)</span><span class="ws207">, yet there</span></div><div class="t m0 x9 hb ycbc ff17 fs8 fc3 sc0 ls64 ws17c">are potentially important pharmacokinetic differences in infants compared to</div><div class="t m0 x9 hb ycbd ff17 fs8 fc3 sc0 ls64 ws0">older children and adults <span class="ff1a">(80)</span>. </div><div class="t m0 x9 h25 ycbe ff1f fs12 fc4 sc0 ls285 ws0">Drug absorption</div><div class="t m0 x9 hb y138 ff17 fs8 fc3 sc0 ls64 ws1a6">The gastric pH at birth is usually 6–8 but within a few hours falls to 2 and then</div><div class="t m0 x9 hb y139 ff17 fs8 fc3 sc0 ls64 ws49c">rises again until virtual achlorhydria occurs for several days. As the gastric</div><div class="t m0 x9 hb y13b ff17 fs8 fc3 sc0 ls64 ws45">mucosa develops, the acidity increases again until 3 y<span class="_ _a"></span>ears of age when adult</div><div class="t m0 x9 hb y13c ff17 fs8 fc3 sc0 ls9c ws137">values ar<span class="_ _a"></span>e attained. The gastric emptying time is prolonged (up to 8 h) in</div><div class="t m0 x9 hb y13d ff17 fs8 fc3 sc0 ls262 ws11e">neonates and approaches adult v<span class="_ _a"></span>alues only after 6 months. Intramuscular</div><div class="t m0 x9 hb y13e ff17 fs8 fc3 sc0 ls287 ws40b">injections can also be problematic in young childr<span class="_ _a"></span>en. Infants with acute or severe</div><div class="t m0 x9 hb y13f ff17 fs8 fc3 sc0 ls1db ws2ff">malaria may become extremely “<span class="_ _b"></span>shut down” whereby visceral, muscle and skin</div><div class="t m0 x9 hb y140 ff17 fs8 fc3 sc0 ls2f wsa7">blood flow is reduced. <span class="_ _b"></span>This may result in slow<span class="_ _a"></span>, erratic or incomplete drug</div><div class="t m0 x9 hb y141 ff17 fs8 fc3 sc0 ls64 ws473">absorption and the consequent delay in achieving therapeutic drug levels at</div><div class="t m0 x9 hb ycbf ff17 fs8 fc3 sc0 ls64 ws0">a time when speed and adequacy of drug delivery are crucial.</div><div class="t m0 x9 h25 y878 ff1f fs12 fc4 sc0 ls285 ws0">Distribution</div><div class="t m0 x9 hb ycc0 ff17 fs8 fc3 sc0 ls12 ws49d">Relativ<span class="_ _a"></span>ely large total and extracellular body water compartments in infancy</div><div class="t m0 x9 hb ycc1 ff17 fs8 fc3 sc0 ls143 ws203">lead to larger apparent v<span class="_ _a"></span>olumes of distribution. T<span class="_ _c"></span>otal body lipids rise steadily</div><div class="t m0 x9 hb ycc2 ff17 fs8 fc3 sc0 ls12 ws417">after birth for the first 9 months of life but then decrease until adolescence.</div><div class="t m0 x9 hb ycc3 ff17 fs8 fc3 sc0 ls12a ws1e1">These changes in body composition can modulate volume of distribution and</div><div class="t m0 x9 hb ycc4 ff17 fs8 fc3 sc0 lsef wsab">clearance. Liver mass per body w<span class="_ _a"></span>eight is higher in infants than adults and the</div><div class="t m0 x9 hb ycc5 ff17 fs8 fc3 sc0 ls13 ws3b4">liver under<span class="_ _a"></span>goes rapid growth during the first 2 years. <span class="_ _b"></span>The brain is dispropor-</div><div class="t m0 x9 hb ycc6 ff17 fs8 fc3 sc0 ls2ad ws464">tionately large in young childr<span class="_ _a"></span>en, and the blood brain barrier relativ<span class="_ _a"></span>ely</div><div class="t m0 x9 hb ycc7 ff17 fs8 fc3 sc0 ls50 ws1fa">immature, making a further contribution to volume of distribution. Finally</div><div class="t m0 x9 hb ycc8 ff17 fs8 fc3 sc0 ls297 ws433">drug distribution is also affected by lower pr<span class="_ _a"></span>otein binding in infancy with</div><div class="t m0 x9 hb ycc9 ff17 fs8 fc3 sc0 ls12 wsaf">more free drug and thus incr<span class="_ _a"></span>eased clearance. The former might also lead to</div><div class="t m0 x9 hb ycca ff17 fs8 fc3 sc0 ls12 ws0">a greater risk of toxicity<span class="_ _c"></span>.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7f" class="pf w1 h4" data-page-no="7f"><div class="pc pc7f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">117</div><div class="t m0 xb h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">Drug metabolism</div><div class="t m0 xb hb ya00 ff17 fs8 fc3 sc0 ls64 ws49e">The cytochrome P450 mixed function o<span class="_ _a"></span>xidase system is the most impor<span class="_ _8"></span>tant</div><div class="t m0 xb hb ya01 ff17 fs8 fc3 sc0 ls64 ws447">biotransformation system incorporating many enzymes and isoenzymes. In</div><div class="t m0 xb hb ya02 ff17 fs8 fc3 sc0 ls2c8 wsce">general, these enzyme systems are immatur<span class="_ _a"></span>e at bir<span class="_ _8"></span>th. Ther<span class="_ _a"></span>e is therefore</div><div class="t m0 xb hb ya03 ff17 fs8 fc3 sc0 ls64 wsec">relatively slo<span class="_ _a"></span>w clearance of most metabolized drugs in the first 2–3 months of</div><div class="t m0 xb hb yb2f ff17 fs8 fc3 sc0 ls64 ws422">life. Between 2 and 6 months clearance is mor<span class="_ _a"></span>e rapid than in adults and even</div><div class="t m0 xb hb yb30 ff17 fs8 fc3 sc0 ls1d8 ws37b">more so for most drugs from 6 months to 2 y<span class="_ _a"></span>ears (elimination half-life for</div><div class="t m0 xb hb yb31 ff17 fs8 fc3 sc0 lsdb ws1e">metabolized drugs in infants aged 6 months to 2 years is 0.6 times that in adults).</div><div class="t m0 xb h25 yccb ff1f fs12 fc4 sc0 ls4f ws0">Renal clear<span class="_ _a"></span>ance</div><div class="t m0 xb hb yccc ff17 fs8 fc3 sc0 ls12 ws43d">Glomerular filtration rate only r<span class="_ _a"></span>eaches surface-area-adjusted adult levels at</div><div class="t m0 xb hb yccd ff17 fs8 fc3 sc0 ls2c9 ws49f">around 6 months of age. <span class="_ _a"></span>Thus for drugs that rely on renal elimination,</div><div class="t m0 xb hb ycce ff17 fs8 fc3 sc0 ls2a2 ws34c">elimination half-lives in v<span class="_ _a"></span>ery young infants may be up to 2–3 times longer than</div><div class="t m0 xb hb yccf ff17 fs8 fc3 sc0 ls12 wse6">in adults. After 2 months, half-lives are shorter (0.35–0.5 times adult values)</div><div class="t m0 xb hb ycd0 ff17 fs8 fc3 sc0 ls12 ws0">until about 2 years of age.</div><div class="t m0 xb h2e ycd1 ff19 fs3 fc3 sc0 ls80 wsc1">A3.17.2<span class="_ _7c"> </span>Malnutr<span class="_ _8"></span>ition and antimalar<span class="_ _8"></span>ials </div><div class="t m0 xb hb ycd2 ff17 fs8 fc3 sc0 ls29b ws55">Malaria and malnutrition frequently coexist. <span class="_ _a"></span>The relationship between malaria</div><div class="t m0 xb hb ycd3 ff17 fs8 fc3 sc0 ls278 ws411">and nutritional status is complex and has been the subject of debate for</div><div class="t m0 xb hb ycd4 ff17 fs8 fc3 sc0 ls4b ws372">many years <span class="ff1a ws0">(81)</span>. Given that a significant pr<span class="_ _a"></span>opor<span class="_ _8"></span>tion of the world’<span class="_ _b"></span>s malnourished</div><div class="t m0 xb hb ycd5 ff17 fs8 fc3 sc0 ls12 ws81">children live in malaria endemic countries <span class="ff1a lsa8 ws0">(82) </span>it is important to understand</div><div class="t m0 xb hb ycd6 ff17 fs8 fc3 sc0 ls2ca ws4a0">how antimalarial drug disposition may be affected when malnutrition is</div><div class="t m0 xb hb ycd7 ff17 fs8 fc3 sc0 ls0 ws2e6">severe. <span class="_ _b"></span>This section outlines the physiological changes that occur in mal-</div><div class="t m0 xb hb ycd8 ff17 fs8 fc3 sc0 ls111 ws4a1">nourished patients and discusses how these may influence the pharmacokinetic</div><div class="t m0 xb hb ycd9 ff17 fs8 fc3 sc0 ls12 ws3e3">properties of antimalarials, drawing on the few studies of antimalarial drug</div><div class="t m0 xb hb ycda ff17 fs8 fc3 sc0 ls12 ws0">disposition in malnutrition that are av<span class="_ _a"></span>ailable</div><div class="t m0 xb hb ycdb ff1e fs8 fc3 sc0 ls2b6 ws0">Note: <span class="_ _66"></span><span class="ff17 ls23b ws1c7">in reviewing the literature it was appar<span class="_ _a"></span>ent that many studies were</span></div><div class="t m0 xb hb ycdc ff17 fs8 fc3 sc0 ls12 ws4a2">conducted in populations and settings where some degree of malnutrition</div><div class="t m0 xb hb ycdd ff17 fs8 fc3 sc0 ls12 ws176">would have been expected. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, this was only rarely mentioned as a</div><div class="t m0 xb hb ycde ff17 fs8 fc3 sc0 lsa1 ws100">possible confounder for drug efficacy<span class="_ _4b"></span>, although there was an occasional</div><div class="t m0 xb hb ycdf ff17 fs8 fc3 sc0 ls102 wsb2">comment that obviously malnourished patients appeared to r<span class="_ _a"></span>espond differently</div><div class="t m0 xb hb yce0 ff17 fs8 fc3 sc0 lse7 ws178">to treatment than did other patients <span class="ff1a ls17b ws0">(83)<span class="ff17 ws2fe">. Sever<span class="_ _a"></span>al ongoing studies are planning</span></span></div><div class="t m0 xb hb yce1 ff17 fs8 fc3 sc0 ls12 ws0">to look specifically at treatment outcomes in this group of patients.</div><div class="t m0 xb h25 yce2 ff1f fs12 fc4 sc0 ls285 ws0">Definitions</div><div class="t m0 xb hb yce3 ff17 fs8 fc3 sc0 ls28 ws34">There are differ<span class="_ _a"></span>ent ways of classifying malnutrition. Earlier studies employ the</div><div class="t m0 xb hb yce4 ff17 fs8 fc3 sc0 ls2cb ws4a3">W<span class="_ _a"></span>ellcome classification: where body weight is given as a percentage of</div><div class="t m0 xb hb yce5 ff17 fs8 fc3 sc0 ls2cc ws47e">standard weight (50th percentile of the Harvar<span class="_ _a"></span>d value): underweight 80–60%;</div><div class="t m0 xb hb yce6 ff17 fs8 fc3 sc0 ls6a ws96">marasmus 60%; kwashiorkor 80–60% + oedema; marasmic kwashiorkor 60%</div><div class="t m0 xb hb yce7 ff17 fs8 fc3 sc0 ls140 ws200">+ oedema. Other studies refer to low w<span class="_ _a"></span>eight-for<span class="_ _a"></span>-height (wasting); low weight-</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf80" class="pf w1 h4" data-page-no="80"><div class="pc pc80 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xb7 h9 ya ff17 fs6 fc4 sc0 ls1 ws0">118</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 lsec ws393">for<span class="_ _b"></span>-age (underweight); or low height-for<span class="_ _a"></span>-age (stunting) and use anthropometric</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls30 ws3e">indicators and reference standar<span class="_ _a"></span>ds. Protein-energy malnutrition is defined as</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls12 ws98">a range of pathological conditions arising from coincident lack, in v<span class="_ _b"></span>ar<span class="_ _8"></span>ying</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls14e ws1a6">proportions, of protein and calories, occurring most frequently in infants and</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls12 ws0">young children and commonly associated with infections <span class="ff1a ls14">(84)</span><span class="ls13">. </span></div><div class="t m0 x9 h25 y9e3 ff1f fs12 fc4 sc0 ls285 ws0">Pharmacokinetics</div><div class="t m0 x9 h23 yce8 ff1e fs11 fc8 sc0 ls27a ws0">Absorption</div><div class="t m0 x9 hb yce9 ff17 fs8 fc3 sc0 ls2c9 ws49f">Anorexia, diarrhoea and vomiting ar<span class="_ _a"></span>e common. Anorexia will affect the</div><div class="t m0 x9 hb ycea ff17 fs8 fc3 sc0 ls12 ws233">absorption of drugs requiring concomitant administration of fatty foods, and</div><div class="t m0 x9 hb yceb ff17 fs8 fc3 sc0 ls12 wsae">oral bioav<span class="_ _a"></span>ailability will be reduced in vomiting patients or those with a rapid</div><div class="t m0 x9 hb ycec ff17 fs8 fc3 sc0 ls2cd ws470">transit time. Atrophy of the bo<span class="_ _a"></span>wel mucosa, which occurs in severe pr<span class="_ _a"></span>otein-energy</div><div class="t m0 x9 hb yced ff17 fs8 fc3 sc0 ls12 ws0">malnutrition, will also hinder absorption.</div><div class="t m0 x9 hb ycee ff17 fs8 fc3 sc0 ls2ce ws4a4">Children with oedematous low<span class="_ _a"></span>er limbs may be expected to have altered</div><div class="t m0 x9 hb ycef ff17 fs8 fc3 sc0 ls2cf ws4a5">absorption from intramuscular injections. P<span class="_ _a"></span>atients with protein-energy</div><div class="t m0 x9 hb ycf0 ff17 fs8 fc3 sc0 lse5 ws176">malnutrition frequently have poor peripher<span class="_ _a"></span>al perfusion due to circulatory</div><div class="t m0 x9 hb ycf1 ff17 fs8 fc3 sc0 ls13b ws1c3">insufficiency associated with bradycar<span class="_ _a"></span>dia, hypotension and a reduced cardiac</div><div class="t m0 x9 hb ycf2 ff17 fs8 fc3 sc0 ls12 ws96">output. Thus absorption of intr<span class="_ _a"></span>amuscular and possibly intrarectal drugs may</div><div class="t m0 x9 hb ycf3 ff17 fs8 fc3 sc0 lsfc ws37e">be expected to be slower than in patients without pr<span class="_ _a"></span>otein-energy malnutrition.</div><div class="t m0 x9 hb ycf4 ff17 fs8 fc3 sc0 ls15c ws26e">Diminished muscle mass may make repeated intramuscular injections difficult. </div><div class="t m0 x9 h23 ycf5 ff1e fs11 fc8 sc0 ls27a ws0">Distribution</div><div class="t m0 x9 hb yca6 ff17 fs8 fc3 sc0 lsc4 ws1b3">T<span class="_ _4b"></span>otal body water increases in proportion to the degree of malnutrition, mainly</div><div class="t m0 x9 hb yca7 ff17 fs8 fc3 sc0 lsa4 ws104">owing to an expansion of the extracellular fluid (most ob<span class="_ _a"></span>vious in oedematous</div><div class="t m0 x9 hb yca8 ff17 fs8 fc3 sc0 ls12 ws4a6">patients). Thus the v<span class="_ _a"></span>olume of distribution of some drugs can be expected to</div><div class="t m0 x9 hb yca9 ff17 fs8 fc3 sc0 ls12 ws455">be larger and plasma concentrations lo<span class="_ _a"></span>wer<span class="_ _b"></span>. Albumin is the most important</div><div class="t m0 x9 hb ycaa ff17 fs8 fc3 sc0 ls5e ws7f">plasma protein for binding of many drugs, but in protein-ener<span class="_ _a"></span>gy malnutrition</div><div class="t m0 x9 hb ycab ff17 fs8 fc3 sc0 ls12 ws272">hypoalbuminaemia results from decr<span class="_ _a"></span>eased synthesis as dietary deficiency</div><div class="t m0 x9 hb ycac ff17 fs8 fc3 sc0 ls1a6 ws2a7">occurs. W<span class="_ _a"></span>ith highly bound drugs this could in theory lead to an increase in the</div><div class="t m0 x9 hb ycad ff17 fs8 fc3 sc0 ls1d1 ws131">amount of unbound drug, which may increase both the elimination, since more</div><div class="t m0 x9 hb ycae ff17 fs8 fc3 sc0 lsbf ws12e">drug is available for metabolism, and potential to<span class="_ _a"></span>xicity<span class="_ _4b"></span>. There ar<span class="_ _a"></span>e other plasma</div><div class="t m0 x9 hb ycf6 ff17 fs8 fc3 sc0 ls13 wsae">proteins less sever<span class="_ _a"></span>ely affected by decreased synthesis, and if these are able</div><div class="t m0 x9 hb ycf7 ff17 fs8 fc3 sc0 lse3 ws172">to bind some free drug, then the increase in fr<span class="_ _a"></span>ee fraction might not be as great</div><div class="t m0 x9 hb yc05 ff17 fs8 fc3 sc0 ls12 ws0">as anticipated.</div><div class="t m0 x9 h23 ycf8 ff1e fs11 fc8 sc0 ls27a ws0">Metabolism</div><div class="t m0 x9 hb ycb3 ff17 fs8 fc3 sc0 ls153 ws216">F<span class="_ _a"></span>atty infiltration occurs but jaundice is uncommon unless septicaemia is present.</div><div class="t m0 x9 hb ycf9 ff17 fs8 fc3 sc0 ls22 ws4a7">Liver function tests may be abnormal and urea cy<span class="_ _a"></span>cle enzymes are decreased.</div><div class="t m0 x9 hb ycfa ff17 fs8 fc3 sc0 ls260 ws77">Children with kwashiorkor excr<span class="_ _a"></span>eted a higher proportion of unchanged chloroquine</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf81" class="pf w1 h4" data-page-no="81"><div class="pc pc81 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">119</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls17a ws176">before therapy than in the r<span class="_ _a"></span>ecovery phase <span class="ff1a ws0">(85)</span><span class="ws403">. <span class="_ _a"></span>This suggests that hepatic</span></div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls56 ws2fb">function was inadequate during the acute phase of kwashiorkor<span class="_ _b"></span>. Animal studies</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls17a ws176">have demonstrated that some enzyme systems, such as cytochr<span class="_ _a"></span>ome P450,</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls22 ws0">have decreased activity in the pr<span class="_ _a"></span>esence of significant malnutrition. </div><div class="t m0 xb h23 ycfb ff1e fs11 fc8 sc0 ls27a ws0">Elimination</div><div class="t m0 xb hb ybef ff17 fs8 fc3 sc0 ls206 ws1a3">Owing to the reduction in cardiac output, the kidneys r<span class="_ _a"></span>eceive less than the usual</div><div class="t m0 xb hb y9e4 ff17 fs8 fc3 sc0 ls40 ws56">25% of renal blood flow<span class="_ _4b"></span>. Glomerular filtration rate, renal blood flo<span class="_ _a"></span>w and</div><div class="t m0 xb hb y9e5 ff17 fs8 fc3 sc0 ls13 wsa3">tubular function have all been shown to be inadequate, and compounded by</div><div class="t m0 xb hb y9e6 ff17 fs8 fc3 sc0 ls2d0 ws3df">concomitant dehydration. Drugs dependent on r<span class="_ _a"></span>enal excretion might be</div><div class="t m0 xb hb yb9d ff17 fs8 fc3 sc0 ls92 wse7">expected to have elev<span class="_ _a"></span>ated plasma concentrations under such circumstances.</div><div class="t m0 xb hb yb9e ff17 fs8 fc3 sc0 ls21e ws2b9">Abnormal excretion of drugs into bile has also been described in sev<span class="_ _a"></span>ere</div><div class="t m0 xb hb yb9f ff17 fs8 fc3 sc0 ls12 ws0">protein-energy malnutrition. </div><div class="t m0 xb h25 ycfc ff1f fs12 fc4 sc0 ls285 ws0">Antimalarials and protein-energy malnutrition</div><div class="t m0 xb h23 y9eb ff1e fs11 fc8 sc0 ls27a ws0">Chloroquine</div><div class="t m0 xb hb ycfd ff17 fs8 fc3 sc0 lse4 ws225">Few data ar<span class="_ _a"></span>e available for chloroquine kinetics in malnourished patients.</div><div class="t m0 xb hb ycfe ff17 fs8 fc3 sc0 ls187 ws1fd">Children with kwashiorkor excr<span class="_ _a"></span>eted a higher ratio of chloroquine to its</div><div class="t m0 xb hb ycff ff17 fs8 fc3 sc0 ls229 ws31e">metabolites before nutritional rehabilitation <span class="ff1a ws0">(85)</span>. P<span class="_ _a"></span>resumably the metabolism</div><div class="t m0 xb hb yd00 ff17 fs8 fc3 sc0 ls2b9 ws8c">of chloroquine by the liver was affected adv<span class="_ _a"></span>ersely in protein-energy malnutrition.</div><div class="t m0 xb hb yd01 ff17 fs8 fc3 sc0 ls12 ws1f9">In a study of chloroquine pharmacokinetics in five childr<span class="_ _a"></span>en with kwashiorkor</div><div class="t m0 xb hb ycf5 ff17 fs8 fc3 sc0 ls12 wsbd">(but without malaria), peak plasma concentrations of the drug wer<span class="_ _a"></span>e approxi-</div><div class="t m0 xb hb yd02 ff17 fs8 fc3 sc0 ls2d1 ws1b6">mately one-third of the v<span class="_ _a"></span>alues for healthy controls (mean 40 + 30 ng/ml</div><div class="t m0 xb hb yd03 ff17 fs8 fc3 sc0 ls247 ws21">compared to 134 + 99 ng/ml), but the times to peak levels and the elimination</div><div class="t m0 xb hb yd04 ff17 fs8 fc3 sc0 ls15b ws243">half-lives wer<span class="_ _a"></span>e not significantly different, indicating reduced absorption.</div><div class="t m0 xb hb yd05 ff17 fs8 fc3 sc0 lsa2 ws102">There was also reduced metabolism of chlor<span class="_ _a"></span>oquine to its metabolite, desethyl-</div><div class="t m0 xb hb yd06 ff17 fs8 fc3 sc0 ls163 ws36e">chloroquine, which suggested some impairment of drug metabolism. How<span class="_ _a"></span>ever<span class="_ _4b"></span>,</div><div class="t m0 xb hb yd07 ff17 fs8 fc3 sc0 ls2d2 ws1cb">the study did not consider plasma protein binding or drug distribution.</div><div class="t m0 xb hb yd08 ff17 fs8 fc3 sc0 ls1a9 ws262">Currently there ar<span class="_ _a"></span>e no recommendations for dose alterations in patients with</div><div class="t m0 xb hb yd09 ff17 fs8 fc3 sc0 ls12 ws0">protein-energy malnutrition <span class="ff1a ls13">(86)</span><span class="ls0">.</span></div><div class="t m0 xb h23 y9fa ff1e fs11 fc8 sc0 ls27a ws0">Quinine</div><div class="t m0 xb hb yd0a ff17 fs8 fc3 sc0 ls103 ws1b5">Three studies examining the kinetics of quinine in malnourished patients</div><div class="t m0 xb hb yd0b ff17 fs8 fc3 sc0 ls12 ws8a">have been published. <span class="_ _a"></span>The first from Nigeria compared the pharmacokinetics</div><div class="t m0 xb hb yd0c ff17 fs8 fc3 sc0 ls6c ws99">of an oral dose of quinine 10 mg/kg in six children with kwashiorkor and</div><div class="t m0 xb hb ycf8 ff17 fs8 fc3 sc0 ls13b ws1c3">seven normal controls who w<span class="_ _a"></span>ere attending a malaria follow-up clinic <span class="ff1a ls1e1 ws0">(87)</span><span class="ls75 ws4a8">. The</span></div><div class="t m0 xb hb yd0d ff17 fs8 fc3 sc0 ls12 ws3e4">children wer<span class="_ _a"></span>e aged 1–3 years. V<span class="_ _4b"></span>alues for total plasma proteins and albumin</div><div class="t m0 xb hb yd0e ff17 fs8 fc3 sc0 ls46 ws66">for children with kwashiorkor wer<span class="_ _a"></span>e 74% and 67% of those for control children.</div><div class="t m0 xb hb yd0f ff17 fs8 fc3 sc0 ls70 wsa2">Absorption of quinine was slower in the kwashiorkor gr<span class="_ _a"></span>oup than in the controls</div><div class="t m0 xb hb yd10 ff17 fs8 fc3 sc0 ls2d3 ws147">(mean time to maximum concentration (t</div><div class="t m0 x4f h11 yd11 ff17 fs5 fc3 sc0 ls2d4 ws0">max</div><div class="t m0 x80 hb yd10 ff17 fs8 fc3 sc0 ls2d3 ws2d5">) 2.5 ± 0.3 h compared to 1.5 ± 0.6 h);</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf82" class="pf w1 h4" data-page-no="82"><div class="pc pc82 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">120</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls2d5 ws4a9">maximum plasma concentration (C</div><div class="t m0 x1f h11 yd12 ff17 fs5 fc3 sc0 ls2d6 ws0">max</div><div class="t m0 x84 hb y9e ff17 fs8 fc3 sc0 ls2d5 ws4a9">) was also lower (1.7 ± 0.5 <span class="ff1c ls0 ws0">μ</span><span class="ws0">mol/l</span></div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls270 ws38f">compared to 2.4 + 0.3 <span class="ff1c ls0 ws0">μ</span><span class="ws175">mol/l). R<span class="_ _a"></span>ate of clearance of quinine in kwashiorkor was</span></div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls67 ws1f9">less than one-third of the v<span class="_ _a"></span>alue for well-nourished patients (31.5 ± 8.5 mg/min</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls2c2 ws98">compared to 108.5 ± 34.8 mg/min) and the elimination half-life was also</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls12 ws1e">longer (15.0 ± 4.4 h compared to 8.0 ± 1.3 h). <span class="_ _a"></span>The authors concluded that the</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls12 ws1e1">combination of malabsorption, reduced plasma protein binding and r<span class="_ _a"></span>educed</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 lse4 ws174">metabolism in the liver was responsible for the differ<span class="_ _a"></span>ences obser<span class="_ _8"></span>ved. No</div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 ls12 ws0">dose alterations wer<span class="_ _a"></span>e suggested.</div><div class="t m0 x9 hb y18f ff17 fs8 fc3 sc0 ls12 ws4aa">The second study<span class="_ _4b"></span>, in Gabon, compared eight children with non-kwashiorkor</div><div class="t m0 x9 hb y190 ff17 fs8 fc3 sc0 ls29d ws422">global malnutrition (defined as having a ratio of left mid-arm circumfer<span class="_ _a"></span>ence:head</div><div class="t m0 x9 hb y191 ff17 fs8 fc3 sc0 ls1c9 ws0">circumference <span class="_ _9"></span><span class="ff1c ls0">&lt;<span class="_ _6"> </span></span><span class="ws293">0.279) with seven childr<span class="_ _a"></span>en with normal nutritional status</span></div><div class="t m0 x9 hb y192 ff1a fs8 fc3 sc0 ls2c ws0">(88)<span class="ff17 ls2b ws400">. The childr<span class="_ _a"></span>en were aged 9–60 months. Only two were subsequently</span></div><div class="t m0 x9 hb y193 ff17 fs8 fc3 sc0 ls81 wsc2">confirmed to have malaria, although all had been febrile at presentation.</div><div class="t m0 x9 hb y2c0 ff17 fs8 fc3 sc0 ls204 ws350">Mean serum albumin levels in the two groups w<span class="_ _a"></span>ere 28.7 and 31.0 respectively<span class="_ _c"></span>.</div><div class="t m0 x9 hb y2c1 ff17 fs8 fc3 sc0 ls23a ws2e9">Each child received a loading dose of 16 mg/kg quinine base (25 mg/kg</div><div class="t m0 x9 hb y2c2 ff17 fs8 fc3 sc0 ls12 ws4ab">quinine resorcine hydr<span class="_ _a"></span>ochloride; Quinimax) by deep intramuscular injection</div><div class="t m0 x9 hb y2c3 ff17 fs8 fc3 sc0 ls18f wsdc">followed by 8 mg/kg at 12 h. <span class="_ _a"></span>The t</div><div class="t m0 x31 h11 yd13 ff17 fs5 fc3 sc0 ls2d7 ws0">max</div><div class="t m0 x74 hb yd14 ff17 fs8 fc3 sc0 lsa2 ws102">was significantly shorter in malnourished</div><div class="t m0 x9 hb yd15 ff17 fs8 fc3 sc0 ls2d3 ws1a4">children (1.1 ± 0.4 h compared to 2.2 ± 1.2 h). No differ<span class="_ _a"></span>ence was obser<span class="_ _8"></span>ved for C</div><div class="t m0 xbe h11 yd16 ff17 fs5 fc3 sc0 ls2d4 ws0">max</div><div class="t m0 xbf hb yd15 ff17 fs8 fc3 sc0 ls0 ws0">,</div><div class="t m0 x9 hb yd17 ff17 fs8 fc3 sc0 ls12 ws4ac">volume of distribution or protein binding. Clear<span class="_ _a"></span>ance was significantly faster</div><div class="t m0 x9 hb yd18 ff17 fs8 fc3 sc0 ls2d8 wsb2">for malnourished children (4.4 ± 3.6 ml/min/kg compared to 2.3 ± 1.4 ml/min/kg),</div><div class="t m0 x9 hb yd19 ff17 fs8 fc3 sc0 ls22a ws38f">and half-life shorter (6.3 ± 1.8 h compared to 10.1 ± 3.4 h). Concentration at 12 h</div><div class="t m0 x9 hb yd1a ff17 fs8 fc3 sc0 ls2d9 ws4ad">was lower in malnourished childr<span class="_ _a"></span>en (3.3 ± 1.6 mg/ml compared to</div><div class="t m0 x9 hb yd1b ff17 fs8 fc3 sc0 ls12 ws1ca">5.3 ± 1.6 mg/l). Ther<span class="_ _a"></span>e was a significant correlation between elimination half-</div><div class="t m0 x9 hb yd1c ff17 fs8 fc3 sc0 ls12 ws3b0">life and left mid-arm:head circumference. <span class="_ _a"></span>The ratio between the area under</div><div class="t m0 x9 hb yd1d ff17 fs8 fc3 sc0 ls12 ws4ae">the curve for hydroxyquinine, the main metabolite of quinine, and that for</div><div class="t m0 x9 hb yd1e ff17 fs8 fc3 sc0 ls12 ws16b">quinine was significantly higher in the malnourished group and significantly</div><div class="t m0 x9 hb yd1f ff17 fs8 fc3 sc0 ls12 ws48a">correlated with left mid-arm:head circumfer<span class="_ _a"></span>ence ratio, indicating increased</div><div class="t m0 x9 hb yd20 ff17 fs8 fc3 sc0 ls3e ws54">metabolism of quinine in malnourished patients. The authors suggest that the</div><div class="t m0 x9 hb yd21 ff17 fs8 fc3 sc0 ls12 ws3ea">administration interval should be reduced to 8 h in malnourished childr<span class="_ _a"></span>en in</div><div class="t m0 x9 hb yd22 ff17 fs8 fc3 sc0 ls12 ws292">order to obtain plasma concentrations of quinine similar to those found in</div><div class="t m0 x9 hb yd23 ff17 fs8 fc3 sc0 ls12 ws0">children with normal nutrition.</div><div class="t m0 x9 hb yd24 ff17 fs8 fc3 sc0 ls1ab ws11d">In the third study<span class="_ _4b"></span>, from Niger<span class="_ _4b"></span>, 40 children were divided into four groups:</div><div class="t m0 x9 hb yd25 ff17 fs8 fc3 sc0 ls2a9 ws94">normally nourished children with or without cerebr<span class="_ _a"></span>al malaria, and malnourished</div><div class="t m0 x9 hb yd26 ff17 fs8 fc3 sc0 ls206 ws28c">children (<span class="ff1c ls0 ws0">&gt;<span class="_ _a"></span><span class="ff17 ls206 ws1a3">2 SD below the median value for at least two of the follo<span class="_ _a"></span>wing: weight-</span></span></div><div class="t m0 x9 hb yd27 ff17 fs8 fc3 sc0 ls229 ws31e">for<span class="_ _b"></span>-height, weight-for-age and height-for<span class="_ _b"></span>-age) with or without cerebral malaria</div><div class="t m0 x9 hb yd28 ff1a fs8 fc3 sc0 ls2ac ws0">(89)<span class="ff17 ls2bf ws48e">. The age r<span class="_ _a"></span>ange studied was 24–72 months. Patients with kwashiorkor were</span></div><div class="t m0 x9 hb yd29 ff17 fs8 fc3 sc0 ls48 ws68">excluded. All patients r<span class="_ _a"></span>eceived 4.7 mg/kg quinine base (as 8 mg/kg Quinimax)</div><div class="t m0 x9 hb yd2a ff17 fs8 fc3 sc0 ls26b ws3f1">by intravenous infusion o<span class="_ _a"></span>ver 4 h. Infusions wer<span class="_ _a"></span>e repeated every 8 h for children</div><div class="t m0 x9 hb yd2b ff17 fs8 fc3 sc0 ls12 ws4af">with cerebral malaria. C</div><div class="t m0 xb6 h11 yd2c ff17 fs5 fc3 sc0 ls9a ws0">max</div><div class="t m0 x5b hb yd2d ff17 fs8 fc3 sc0 ls12 ws4af">was highest in malnourished children, and was</div><div class="t m0 x9 hb yd2e ff17 fs8 fc3 sc0 ls12 ws4b0">higher in those without malaria than with malaria (8.5 ± 4.7 mg/l compared</div><div class="t m0 x9 hb yd2f ff17 fs8 fc3 sc0 ls67 ws1f9">to 7.7 ± 2.0 mg/l); it was lowest in the contr<span class="_ _a"></span>ol groups without and with malaria</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf83" class="pf w1 h4" data-page-no="83"><div class="pc pc83 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">121</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls5b ws78">(3.0 ± 2.1 mg/l and 6.6 ± 3.0 mg/l). Ther<span class="_ _a"></span>e were no differences between the ar<span class="_ _a"></span>ea</div><div class="t m0 xb h9 y9f ff17 fs8 fc3 sc0 ls12 ws4b1">under the curve for 0<span class="fs6 ls0 ws0">–</span><span class="ws4b2">8 h and elimination half-life for the two malnutrition</span></div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls28 ws34">groups and controls with malaria, but all w<span class="_ _a"></span>ere higher than for controls without</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls12 ws4b3">malaria. Conversely plasma clearance of quinine and v<span class="_ _a"></span>olume of distribution</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls12 wsb3">were smaller in these thr<span class="_ _a"></span>ee groups than in controls without malaria. Alpha 1-</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 lsaf ws11a">glycoprotein plasma concentr<span class="_ _a"></span>ations and protein-bound fraction of the drug wer<span class="_ _a"></span>e</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls12 wsef">increased in the three gr<span class="_ _a"></span>oups. Malnourished children had slower par<span class="_ _a"></span>asite</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 ls12 ws212">clearance but the difference was not significant. <span class="_ _b"></span>The authors concluded that</div><div class="t m0 xb hb y10f ff17 fs8 fc3 sc0 ls55 ws70">severe global malnutrition and cer<span class="_ _a"></span>ebral malaria have a similar effect on</div><div class="t m0 xb hb y110 ff17 fs8 fc3 sc0 ls71 wsa7">quinine pharmacokinetics in children and that cerebr<span class="_ _a"></span>al malaria-mediated</div><div class="t m0 xb hb y111 ff17 fs8 fc3 sc0 ls6d wsa3">modifications of quinine disposition are not potentiated. <span class="_ _a"></span>They recommend that</div><div class="t m0 xb hb y2be ff17 fs8 fc3 sc0 ls122 ws4b4">current dosing schedules should not be altered for childr<span class="_ _a"></span>en with malnutrition.</div><div class="t m0 xb h23 yd30 ff1e fs11 fc8 sc0 ls27a ws0">Sulfadoxine-pyrimethamine</div><div class="t m0 xb hb ya20 ff17 fs8 fc3 sc0 ls2ca ws4a0">No studies exist of sulfadoxine-pyrimethamine kinetics in malnourished</div><div class="t m0 xb hb ya21 ff17 fs8 fc3 sc0 ls42 ws5b">patients. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, observational data from Rwandan r<span class="_ _a"></span>efugee children showed</div><div class="t m0 xb hb ya22 ff17 fs8 fc3 sc0 ls17d ws25c">that malnourished children (defined as weight-for<span class="_ _b"></span>-height <span class="ff1c ls0 ws0">&lt;<span class="_ _67"> </span></span><span class="ws122">80% of the refer<span class="_ _a"></span>ence</span></div><div class="t m0 xb hb ya23 ff17 fs8 fc3 sc0 ls12 ws1b7">median with or without oedema) were mor<span class="_ _a"></span>e likely to have treatment failure</div><div class="t m0 xb hb ya24 ff17 fs8 fc3 sc0 ls10e ws1c8">than children without malnutrition (86% compared to 58% <span class="ff1a ls37 ws0">(83)</span>. Higher initial</div><div class="t m0 xb hb ya25 ff17 fs8 fc3 sc0 ls12 ws431">parasite counts and host immunity<span class="_ _c"></span>, as well as pharmacokinetic differences,</div><div class="t m0 xb hb ya26 ff17 fs8 fc3 sc0 ls12 ws0">may also have contributed to this finding.</div><div class="t m0 xb h23 yd31 ff1e fs11 fc8 sc0 ls279 ws0">T<span class="_ _4b"></span>etracycline</div><div class="t m0 xb hb yd32 ff17 fs8 fc3 sc0 ls12 ws275">A number of small studies have been conducted on tetracy<span class="_ _a"></span>cline kinetics in</div><div class="t m0 xb hb yd33 ff17 fs8 fc3 sc0 ls24e ws3cd">malnourished adults from India. One study compared the kinetics of intr<span class="_ _a"></span>avenous</div><div class="t m0 xb hb yd34 ff17 fs8 fc3 sc0 ls2da ws345">and oral tetracy<span class="_ _a"></span>cline in malnourished and normal adult males <span class="ff1a ws0">(90)</span><span class="ws83">. Compared</span></div><div class="t m0 xb hb yd35 ff17 fs8 fc3 sc0 lsae ws118">to the control group<span class="_ _a"></span>, malnourished patients had lower protein binding, shorter</div><div class="t m0 xb hb yd36 ff17 fs8 fc3 sc0 ls189 ws381">elimination half-life and reduced volume of distribution. <span class="_ _b"></span>The authors suggest</div><div class="t m0 xb hb yd37 ff17 fs8 fc3 sc0 lse5 ws176">that in order to keep levels of tetr<span class="_ _a"></span>acycline abov<span class="_ _a"></span>e the minimum inhibitory</div><div class="t m0 xb hb yd38 ff17 fs8 fc3 sc0 ls97 wsf0">concentration, the dose interval should be reduced. A similar conclusion was</div><div class="t m0 xb hb yd39 ff17 fs8 fc3 sc0 ls273 ws40b">reached by another study that also found more r<span class="_ _a"></span>apid distribution of tetracycline</div><div class="t m0 xb hb yd3a ff17 fs8 fc3 sc0 ls12 ws4b5">and faster clearance in the malnourished group <span class="ff1a ws0">(91)</span>. <span class="_ _b"></span>The same author<span class="_ _b"></span>, in a</div><div class="t m0 xb hb y975 ff17 fs8 fc3 sc0 ls12 ws168">separate study<span class="_ _c"></span>, also looked at absorption of oral compared with intravenous</div><div class="t m0 xb hb y976 ff17 fs8 fc3 sc0 ls12 ws4b6">tetracycline in v<span class="_ _b"></span>arious types of malnutrition. Oral absorption was slower in</div><div class="t m0 xb hb y977 ff17 fs8 fc3 sc0 ls12 ws283">patients with protein-energy-malnutrition and pellagr<span class="_ _a"></span>a than in patients with</div><div class="t m0 xb hb y978 ff17 fs8 fc3 sc0 ls12 ws15c">anaemia or vitamin B complex deficiency patients and healthy controls. In a</div><div class="t m0 xb hb y979 ff17 fs8 fc3 sc0 ls47 ws67">third study<span class="_ _c"></span>, patients with nutritional oedema were found to have increased C</div><div class="t m0 x92 h11 yd3b ff17 fs5 fc3 sc0 ls2db ws0">max</div><div class="t m0 xb hb y97a ff17 fs8 fc3 sc0 ls2dc ws2cb">and area under the curve values, and r<span class="_ _a"></span>educed clearance and volume of</div><div class="t m0 xb hb y97b ff17 fs8 fc3 sc0 ls12 ws238">distribution compared with healthy controls (i.e. some differ<span class="_ _a"></span>ences with non-</div><div class="t m0 xb hb y97c ff17 fs8 fc3 sc0 ls12 ws0">oedema malnutrition patients) <span class="ff1a ls13">(92)</span><span class="ls0">.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf84" class="pf w1 h4" data-page-no="84"><div class="pc pc84 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">122</div><div class="t m0 x9 h23 yd3c ff1e fs11 fc8 sc0 ls27a ws0">Doxycy<span class="_ _a"></span>cline</div><div class="t m0 x9 hb yd3d ff17 fs8 fc3 sc0 ls12 wsd2">There is a single study examining the kinetics of doxy<span class="_ _a"></span>cycline given or<span class="_ _a"></span>ally to</div><div class="t m0 x9 hb yd3e ff17 fs8 fc3 sc0 ls12 ws4b7">adult patients in India <span class="ff1a ls13 ws0">(93)</span><span class="ws3de">. Area under the curve, elimination half-life and</span></div><div class="t m0 x9 hb yd3f ff17 fs8 fc3 sc0 ls12 ws4b8">plasma protein binding wer<span class="_ _a"></span>e reduced, and clearance increased in the mal-</div><div class="t m0 x9 hb yd40 ff17 fs8 fc3 sc0 ls12 ws297">nourished group<span class="_ _a"></span>. Renal clearance was similar in controls and malnourished</div><div class="t m0 x9 hb yd41 ff17 fs8 fc3 sc0 ls12 ws4b9">patients. The authors surmised that incr<span class="_ _a"></span>eased total body clearance of doxy-</div><div class="t m0 x9 hb yd42 ff17 fs8 fc3 sc0 ls12 ws200">cycline might be due to higher metabolism in malnourished patients. Steady</div><div class="t m0 x9 hb yd43 ff17 fs8 fc3 sc0 ls28 ws34">state plasma C</div><div class="t m0 x5d h11 yd44 ff17 fs5 fc3 sc0 ls2dd ws0">min</div><div class="t m0 x13 hb yd43 ff17 fs8 fc3 sc0 ls28 ws34">levels wer<span class="_ _a"></span>e lower than in healthy patients but still within the</div><div class="t m0 x9 hb yd45 ff17 fs8 fc3 sc0 ls21d ws2ad">therapeutic range. A change in dose r<span class="_ _a"></span>ecommendation does not seem necessary</div><div class="t m0 x9 hb yd46 ff17 fs8 fc3 sc0 ls12 ws0">given these findings.</div><div class="t m0 x9 h23 yd47 ff1e fs11 fc8 sc0 ls27a ws0">Other antimalarials</div><div class="t m0 x9 hb yd48 ff17 fs8 fc3 sc0 ls85 wsc9">There are no studies of the kinetics of clindamy<span class="_ _a"></span>cin, amodiaquine, ar<span class="_ _8"></span>temisinin</div><div class="t m0 x9 hb yd49 ff17 fs8 fc3 sc0 ls2de ws47f">derivativ<span class="_ _a"></span>es (dihydroartemisinin), ar<span class="_ _8"></span>temether<span class="_ _a"></span>-lumefantrine, mefloquine or</div><div class="t m0 x9 hb yd4a ff17 fs8 fc3 sc0 ls12 ws0">primaquine kinetics in malnourished patients.</div><div class="t m0 x9 h25 yd4b ff1f fs12 fc4 sc0 ls285 ws0">Conclusion</div><div class="t m0 x9 hb yd4c ff17 fs8 fc3 sc0 ls2cd ws470">There are many r<span class="_ _a"></span>easons why pharmacokinetics may be different in malnourished</div><div class="t m0 x9 hb yd4d ff17 fs8 fc3 sc0 ls1b9 ws4ba">patients compared to those who are w<span class="_ _a"></span>ell nourished. However<span class="_ _4b"></span>, with the possible</div><div class="t m0 x9 hb yd4e ff17 fs8 fc3 sc0 ls12 ws36">exception of quinine, there ar<span class="_ _a"></span>e insufficient data available for specific dosing</div><div class="t m0 x9 hb yd4f ff17 fs8 fc3 sc0 ls12 ws0">changes to be recommended.</div><div class="t m0 x9 h12 yd50 ff19 fs6 fc4 sc0 ls1 ws0">A3.18<span class="_ _1"> </span>References</div><div class="t m0 xb6 h14 yd51 ff1b fs5 fc4 sc0 ls9a ws0">24</div><div class="t mc x9 h17 yd52 ff17 fsb fc3 sc0 ls105 ws0">1.<span class="_ _46"> </span>Krugliak M, Ginsburg H. Studies on the antimalarial mode of action of quinoline-</div><div class="t mc x7a h17 yd53 ff17 fsb fc3 sc0 ls105 ws0">containing drugs: time-dependence and irreversibility of drug action, and</div><div class="t mc x7a h17 yd54 ff17 fsb fc3 sc0 ls105 ws1d4">interactions with compounds that alter the function of the parasite<span class="_ _a"></span>’<span class="_ _b"></span>s food</div><div class="t mc x7a h17 yd55 ff17 fsb fc3 sc0 ls105 ws0">vacuole. <span class="ff1a">Life Sciences</span><span class="lsd6 ws218">, 1991, 49:1213–1219.</span></div><div class="t mc x9 h17 yd56 ff17 fsb fc3 sc0 ls105 ws0">2.<span class="_ _44"> </span>Bray PG et al. Access to hematin: the basis of chloroquine resistance. <span class="ff1a">Molecular</span></div><div class="t mc x7a h17 yd57 ff1a fsb fc3 sc0 ls105 ws0">Pharmacology<span class="ff17 ls2df ws219">, 1998, 54:170–179. </span></div><div class="t mc x9 h17 yd58 ff17 fsb fc3 sc0 ls130 ws19a">3.<span class="_ _44"> </span>Gustafsson LL et al. Disposition of chloroquine in man after single intr<span class="_ _a"></span>avenous</div><div class="t mc x7a h17 yd59 ff17 fsb fc3 sc0 ls130 ws0">and oral doses. <span class="ff1a">British Journal of Clinical Pharmacology</span>, 1983, 15:471–479.</div><div class="t mc x9 h17 yd5a ff17 fsb fc3 sc0 ls130 ws0">4.<span class="_ _44"> </span>Walker O et al. Plasma chloroquine and desethylchlor<span class="_ _a"></span>oquine concentrations in</div><div class="t mc x7a h17 yd5b ff17 fsb fc3 sc0 ls130 ws0">children during and after chloroquine tr<span class="_ _a"></span>eatment for malaria. <span class="ff1a">British Journal of</span></div><div class="t mc x7a h17 yd5c ff1a fsb fc3 sc0 ls130 ws0">Clinical Pharmacology<span class="ff17 ws218">, 1983:16:701–705.</span></div><div class="t m0 x9 h19 yd5d ff17 fsd fc4 sc0 ls198 ws0">24</div><div class="t m0 x14 h15 yd5e ff17 fsa fc3 sc0 ls7d ws4bb">Further information on the chemistry and pharmacology of antimalarials can be obtained from the</div><div class="t m0 x14 h15 yd5f ff17 fsa fc3 sc0 ls2e0 ws4bc">web site of the United States National Library of Medicines, Specialized Information Services,</div><div class="t m0 x14 h15 yd60 ff17 fsa fc3 sc0 ls7d ws0">ChemIDplus Advanced: http://chem.sis.nlm.nih.gov/chemidplus.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf85" class="pf w1 h4" data-page-no="85"><div class="pc pc85 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">123</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>White NJ et al. Chloroquine treatment of sev<span class="_ _a"></span>ere malaria in children.</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">Pharmacokinetics, toxicity<span class="_ _4b"></span>, and new dosage recommendations. <span class="ff1a">New England</span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Journal of Medicine<span class="ff17">, 1988, 319:1493–1500.</span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>Mnyika KS, Kihamia CM. Chloroquine-induced pruritus: its impact on chloroquine</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">utilization in malaria control in Dar es Salaam. <span class="ff1a">Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x4d h17 yd66 ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17">, 1991, 94:27–31.</span></div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">7.<span class="_ _39"> </span>T<span class="_ _4b"></span>aylor WR, <span class="_ _a"></span>White NJ. Antimalarial drug toxicity: a review<span class="_ _b"></span>. <span class="ff1a">Drug Safety</span>, 2004,</div><div class="t mc x4d h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">27:25–61.</div><div class="t mc xb h17 yd69 ff17 fsb fc3 sc0 ls105 ws0">8.<span class="_ _44"> </span>Riou B et al. T<span class="_ _4b"></span>reatment of severe chloroquine poisoning. <span class="ff1a">New England Journal of</span></div><div class="t mc x4d h17 yd6a ff1a fsb fc3 sc0 ls105 ws0">Medicine<span class="ff17">, 1988, 318:1–6.</span></div><div class="t mc xb h17 yd6b ff17 fsb fc3 sc0 ls105 ws0">9.<span class="_ _44"> </span>Clemessy JL et al. T<span class="_ _4b"></span>reatment of acute chloroquine poisoning: a 5-year experience.</div><div class="t mc x4d h17 yd6c ff1a fsb fc3 sc0 ls105 ws0">Critical Care Medicine<span class="ff17">, 1996, 24:1189–1195.</span></div><div class="t mc xb h17 yd6d ff17 fsb fc3 sc0 ls105 ws0">10.<span class="_ _68"> </span>Winstanley P<span class="_ _b"></span>A et al. The disposition of amodiaquine in Zambians and Nigerians</div><div class="t mc x4d h17 yd6e ff17 fsb fc3 sc0 ls105 ws0">with malaria. <span class="ff1a">British Journal of Clinical Pharmacology</span><span class="ws218">, 1990, 29:695–701. </span></div><div class="t mc xb h17 yd6f ff17 fsb fc3 sc0 ls105 ws0">11.<span class="_ _0"> </span>Hatton CS et al. Fr<span class="_ _a"></span>equency of severe neutropenia associated with amodiaquine</div><div class="t mc x4d h17 yd70 ff17 fsb fc3 sc0 ls105 ws0">prophylaxis against malaria. <span class="ff1a">Lancet</span>, 1986, 1:411–414.</div><div class="t mc xb h17 yd71 ff17 fsb fc3 sc0 ls105 ws19a">12.<span class="_ _68"> </span>Miller KD et al. Sever<span class="_ _a"></span>e cutaneous reactions among American travelers using</div><div class="t mc x4d h17 yd72 ff17 fsb fc3 sc0 ls105 ws0">pyrimethamine-sulfadoxine (F<span class="_ _a"></span>ansidar) for malaria prophylaxis. <span class="ff1a">American Journal</span></div><div class="t mc x4d h17 yd73 ff1a fsb fc3 sc0 ls105 ws0">of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 1986, 35:451–458.</span></div><div class="t mc xb h17 yd74 ff17 fsb fc3 sc0 ls105 ws0">13.<span class="_ _68"> </span>Bjorkman A, Phillips-Howard P<span class="_ _b"></span>A. Adverse reactions to sulfa drugs: implications</div><div class="t mc x4d h17 yd75 ff17 fsb fc3 sc0 ls105 ws0">for malaria chemotherapy<span class="_ _4b"></span>. <span class="ff1a ws19a">Bulletin of the W<span class="_ _b"></span>orld Health Organization<span class="ff17 ws0">, 1991,</span></span></div><div class="t mc x4d h17 yd76 ff17 fsb fc3 sc0 ls105 ws0">69:297–304.</div><div class="t mc xb h17 yd77 ff17 fsb fc3 sc0 ls105 ws0">14.<span class="_ _3"> </span>Winstanley P<span class="_ _a"></span>A et al. The disposition of oral and intr<span class="_ _a"></span>amuscular</div><div class="t mc x4d h17 yd78 ff17 fsb fc3 sc0 ls105 ws0">pyrimethamine/sulphadoxine in K<span class="_ _b"></span>enyan children with high parasitaemia but</div><div class="t mc x4d h17 yd79 ff17 fsb fc3 sc0 ls105 ws0">clinically non-severe falciparum malaria. <span class="ff1a">British Journal of Clinical Pharmacology</span><span class="ls0">,</span></div><div class="t mc x4d h17 yd7a ff17 fsb fc3 sc0 ls105 ws0">1992, 33:143–148.</div><div class="t mc xb h17 yd7b ff17 fsb fc3 sc0 ls105 ws0">15.<span class="_ _68"> </span>Price R et al. Pharmacokinetics of mefloquine combined with artesunate in</div><div class="t mc x4d h17 yd7c ff17 fsb fc3 sc0 ls105 ws1d4">children with acute falciparum malaria. <span class="ff1a ws0">Antimicrobial Agents and Chemother<span class="_ _a"></span>apy<span class="ff17 ls0">,</span></span></div><div class="t mc x4d h17 yd7d ff17 fsb fc3 sc0 ls137 ws1d4">1999, 43:341–346.</div><div class="t mc xb h17 yd7e ff17 fsb fc3 sc0 ls137 ws0">16.<span class="_ _3"> </span>Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine.</div><div class="t mc x4d h17 yd7f ff17 fsb fc3 sc0 ls137 ws0">Clinical implications. <span class="ff1a">Clinical Pharmacokinetics</span>, 1996, 30:263–299</div><div class="t mc xb h17 yd80 ff17 fsb fc3 sc0 ls137 ws0">17.<span class="_ _68"> </span>Simpson JA et al. Population pharmacokinetics of mefloquine in patients with</div><div class="t mc x4d h17 yd81 ff17 fsb fc3 sc0 ls137 ws0">acute falciparum malaria. <span class="ff1a">Clinical Pharmacology and Ther<span class="_ _a"></span>apeutics<span class="ff17">, 1999,</span></span></div><div class="t mc x4d h17 yd82 ff17 fsb fc3 sc0 ls137 ws0">66:472–484.</div><div class="t mc xb h17 yd83 ff17 fsb fc3 sc0 ls137 ws0">18.<span class="_ _3"> </span>Slutsker LM et al. Mefloquine therapy for <span class="ff1a">Plasmodium falciparum </span>malaria in</div><div class="t mc x4d h17 yd84 ff17 fsb fc3 sc0 ls137 ws0">children under 5 years of age in Malawi: in viv<span class="_ _a"></span>o/in vitro efficacy and correlation</div><div class="t mc x4d h17 yd85 ff17 fsb fc3 sc0 ls137 ws1d4">of drug concentration with parasitological outcome. <span class="ff1a ws0">Bulletin of the <span class="_ _b"></span>World Health</span></div><div class="t mc x4d h17 yd86 ff1a fsb fc3 sc0 ls130 ws0">Organization<span class="ff17 ls137 ws1d4">, 1990, 68:53–59.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf86" class="pf w1 h4" data-page-no="86"><div class="pc pc86 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">124</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">19.<span class="_ _3"> </span>Karbwang J et al. Pharmacokinetics and pharmacodynamics of mefloquine in Thai</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">patients with acute falciparum malaria. <span class="ff1a">Bulletin of the W<span class="_ _b"></span>orld Health</span></div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Organization<span class="ff17 ws19a">, 1991, 69:207–212.</span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">20.<span class="_ _5"> </span>Nosten F et al. Mefloquine pharmacokinetics and resistance in children with</div><div class="t mc x7a h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">acute falciparum malaria. <span class="ff1a">British Journal of Clinical Pharmacology</span>, 1991,</div><div class="t mc x7a h17 yd66 ff17 fsb fc3 sc0 ls105 ws0">31:556–559.</div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls105 ws1d4">21.<span class="_ _3"> </span>Svensson US et al. Population pharmacokinetic and pharmacodynamic modelling</div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">of artemisinin and mefloquine enantiomers in patients with falciparum malaria.</div><div class="t mc x7a h17 yd87 ff1a fsb fc3 sc0 ls105 ws0">European Journal of Clinical Pharmacology<span class="ff17">, 2002, 58:339–351.</span></div><div class="t mc x9 h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">22.<span class="_ _5"> </span>Gimenez F et al. Stereoselective pharmacokinetics of mefloquine in healthy</div><div class="t mc x7a h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">Caucasians after multiple doses. <span class="ff1a">Journal of Pharmaceutical Sciences</span>, 1994,</div><div class="t mc x7a h17 yd89 ff17 fsb fc3 sc0 ls2e1 ws0">83:824–827.</div><div class="t mc x9 h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">23.<span class="_ _95"> </span>Bourahla A et al. Ster<span class="_ _a"></span>eoselective pharmacokinetics of mefloquine in young</div><div class="t mc x7a h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">children. <span class="ff1a">Eur<span class="_ _a"></span>opean Journal of Clinical Pharmacology<span class="ff17 ws1d4">, 1996, 50:241–244.</span></span></div><div class="t mc x9 h17 yd8c ff17 fsb fc3 sc0 ls105 ws0">24.<span class="_ _5"> </span>Bem J<span class="_ _8"></span>L, K<span class="_ _a"></span>err L, Stuerchler D. Mefloquine prophylaxis: an o<span class="_ _a"></span>verview of</div><div class="t mc x7a h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">spontaneous reports of severe psychiatric r<span class="_ _a"></span>eactions and convulsions. <span class="ff1a">Journal of</span></div><div class="t mc x7a h17 yd8e ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls104 ws35b">, 1992, 95:167–179.</span></div><div class="t mc x9 h17 yd8f ff17 fsb fc3 sc0 ls105 ws0">25.<span class="_ _95"> </span>ter Kuile FO et al. Mefloquine treatment of acute falciparum malaria: a</div><div class="t mc x7a h17 yd90 ff17 fsb fc3 sc0 ls105 ws0">prospective study of non-serious adv<span class="_ _a"></span>erse effects in 3673 patients. <span class="ff1a">Bulletin of the</span></div><div class="t mc x7a h17 yd91 ff1a fsb fc3 sc0 ls105 ws0">W<span class="_ _a"></span>orld Health Organization<span class="ff17 lsd6 ws218">, 1995, 73:631–642.</span></div><div class="t mc x9 h17 yd92 ff17 fsb fc3 sc0 ls105 ws0">26.<span class="_ _5"> </span>Phillips-Howard P<span class="_ _b"></span>A, ter Kuile FO. CNS adverse events associated with</div><div class="t mc x7a h17 yd93 ff17 fsb fc3 sc0 ls105 ws0">antimalarial agents. F<span class="_ _a"></span>act or fiction? <span class="ff1a">Drug Safety</span><span class="ls104 ws35b">, 1995, 12:370–383.</span></div><div class="t mc x9 h17 yd94 ff17 fsb fc3 sc0 ls105 ws0">27.<span class="_ _95"> </span>Mai NTH et al. Post-malaria neurological syndrome. <span class="ff1a">Lancet</span><span class="lsd6 ws218">, 1996, 348:917–921.</span></div><div class="t mc x9 h17 yd78 ff17 fsb fc3 sc0 ls105 ws0">28. Supanaranond W et al. Lack of a significant adv<span class="_ _a"></span>erse cardiov<span class="_ _a"></span>ascular effect of</div><div class="t mc x7a h17 yd79 ff17 fsb fc3 sc0 ls105 ws0">combined quinine and mefloquine therapy for uncomplicated malaria.</div><div class="t mc x7a h17 yd7a ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene<span class="ff17">, 1997,</span></div><div class="t mc x7a h17 yd95 ff17 fsb fc3 sc0 ls105 ws0">91:694–696.</div><div class="t mc x9 h17 yd7c ff17 fsb fc3 sc0 ls105 ws0">29.<span class="_ _5"> </span>Eckstein-Ludwig U et al. Artemisinins target the SE<span class="_ _8"></span>RC<span class="_ _8"></span>A of <span class="ff1a">Plasmodium</span></div><div class="t mc x7a h17 yd7d ff1a fsb fc3 sc0 ls105 ws0">falciparum<span class="ff17">. </span>Nature<span class="ff17 ws1d4">, 2003, 424:957–961.</span></div><div class="t mc x9 h17 yd7e ff17 fsb fc3 sc0 ls105 ws0">30.<span class="_ _95"> </span>Navar<span class="_ _a"></span>atnam V et al. Pharmacokinetics of artemisinin-type compounds. <span class="ff1a">Clinical</span></div><div class="t mc x7a h17 yd7f ff1a fsb fc3 sc0 ls105 ws0">Pharmacokinetics<span class="ff17 ws19a">, 2000, 39:255–270.</span></div><div class="t mc x9 h17 yd80 ff17 fsb fc3 sc0 ls105 ws0">31.<span class="_ _68"> </span>Ashton M, Nguyen DS, Nguyen <span class="_ _a"></span>VH, et al. Ar<span class="_ _8"></span>temisinin kinetics and dynamics</div><div class="t mc x7a h17 yd81 ff17 fsb fc3 sc0 ls105 ws0">during oral and rectal tr<span class="_ _a"></span>eatment of uncomplicated malaria. <span class="ff1a">Clinical Pharmacology</span></div><div class="t mc x7a h17 yd82 ff1a fsb fc3 sc0 ls105 ws20a">and Therapeutics<span class="ff17 ls2e2 ws1d3">, 1998, 63:482–493.</span></div><div class="t mc x9 h17 yd83 ff17 fsb fc3 sc0 ls105 ws0">32.<span class="_ _95"> </span>Ribeiro IR, Olliaro P<span class="_ _c"></span>. Safety of artemisinin and its derivatives. A review of</div><div class="t mc x7a h17 yd84 ff17 fsb fc3 sc0 ls105 ws1d4">published and unpublished clinical trials. <span class="ff1a ws27d">Medicine T<span class="_ _b"></span>ropical (Mars)<span class="_ _8"></span><span class="ff17 ws0">, 1998, 58(3</span></span></div><div class="t mc x7a h17 yd85 ff17 fsb fc3 sc0 ls105 ws0">Suppl.):50–53.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf87" class="pf w1 h4" data-page-no="87"><div class="pc pc87 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">125</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">33.<span class="_ _95"> </span>Price R et al. Adverse effects in patients with acute falciparum malaria treated</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">with artemisinin derivatives. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls0">,</span></span></div><div class="t mc x4d h17 yd63 ff17 fsb fc3 sc0 ls137 ws1d4">1999, 60:547–555.</div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls137 ws0">34.<span class="_ _95"> </span>L<span class="_ _a"></span>eonardi E et al. Severe aller<span class="_ _a"></span>gic reactions to oral artesunate: a report of two</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls137 ws0">cases. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene<span class="ff17">, 2001,</span></span></div><div class="t mc x4d h17 yd66 ff17 fsb fc3 sc0 ls2df ws0">95:182–183.</div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">35.<span class="_ _95"> </span>van <span class="_ _a"></span>V<span class="_ _a"></span>ugt M et al. A case-control auditory evaluation of patients tr<span class="_ _a"></span>eated with</div><div class="t mc x4d h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">artemisinin derivatives for multidrug-resistant <span class="ff1a">Plasmodium falciparum </span>malaria.</div><div class="t mc x4d h17 yd87 ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17 ws1d4">, 2000, 62:65–69.</span></div><div class="t mc xb h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">36.<span class="_ _95"> </span>Kissinger E et al. Clinical and neurophysiological study of the effects of multiple</div><div class="t mc x4d h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">doses of artemisinin on brain-stem function in Vietnamese patients. <span class="ff1a">American</span></div><div class="t mc x4d h17 yd89 ff1a fsb fc3 sc0 ls105 ws0">Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 2000, 63:48–55.</span></div><div class="t mc xb h17 yd8a ff17 fsb fc3 sc0 ls105 ws1d4">37.<span class="_ _95"> </span>Hien TT et al. Neuropathological assessment of artemether<span class="_ _a"></span>-treated sever<span class="_ _a"></span>e</div><div class="t mc x4d h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">malaria. <span class="ff1a">Lancet</span><span class="ws1d4">, 2003, 362:295–296. </span></div><div class="t mc xb h17 yd8c ff17 fsb fc3 sc0 ls170 ws0">37</div><div class="t mc x20 h1c yd96 ff17 fse fc3 sc0 ls0 ws0">a</div><div class="t mc x4d h17 yd97 ff1a fsb fc3 sc0 ls105 ws0">Assessment of the safety of artemisinin compounds in pregnancy<span class="_ _4b"></span>. <span class="_ _8"></span><span class="ff17 ws4bd">Geneva, W<span class="_ _b"></span>orld</span></div><div class="t mc x4d h17 yd98 ff17 fsb fc3 sc0 ls105 ws1d4">Health Organization, 2003 (document <span class="_ _a"></span>WHO/CDS/MAL/2003.1094).</div><div class="t mc xb h17 yd99 ff17 fsb fc3 sc0 ls105 ws0">38.<span class="_ _5"> </span>Ezzet F<span class="_ _4b"></span>, Mull R, Karbwang J. Population pharmacokinetics and therapeutic</div><div class="t mc x4d h17 yd9a ff17 fsb fc3 sc0 ls105 ws19a">response of CGP 56697 (artemether + benflumetol) in malaria patients. <span class="ff1a ws0">British</span></div><div class="t mc x4d h17 yd9b ff1a fsb fc3 sc0 ls105 ws0">Journal of Clinical Pharmacology<span class="ff17 ws1d4">, 1998, 46:553–561.</span></div><div class="t mc xb h17 yd9c ff17 fsb fc3 sc0 ls105 ws0">39.<span class="_ _95"> </span>Murphy SA et al. <span class="_ _a"></span>The disposition of intramuscular artemether in children with</div><div class="t mc x4d h17 yd9d ff17 fsb fc3 sc0 ls105 ws0">cerebral malaria; a pr<span class="_ _a"></span>eliminary study<span class="_ _b"></span>. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of</span></div><div class="t mc x4d h17 yd9e ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 1997, 91:331–334.</span></div><div class="t mc xb h17 yd9f ff17 fsb fc3 sc0 ls105 ws1d4">40.<span class="_ _5"> </span>Hien TT et al. Compar<span class="_ _a"></span>ative pharmacokinetics of intramuscular artesunate and</div><div class="t mc x4d h17 yda0 ff17 fsb fc3 sc0 ls105 ws0">artemether in patients with severe falciparum malaria. <span class="ff1a">Antimicrobial Agents and</span></div><div class="t mc x4d h17 yda1 ff1a fsb fc3 sc0 ls105 ws0">Chemotherapy<span class="ff17">, 2004, 48:4234–4239.</span></div><div class="t mc xb h17 yda2 ff17 fsb fc3 sc0 ls105 ws0">41.<span class="_ _3"> </span>Mithwani S et al. Population pharmacokinetics of ar<span class="_ _8"></span>temether and dihydro-</div><div class="t mc x4d h17 yda3 ff17 fsb fc3 sc0 ls105 ws0">artemisinin following single intramuscular dosing of artemether in African</div><div class="t mc x4d h17 yda4 ff17 fsb fc3 sc0 ls105 ws0">children with sever<span class="_ _a"></span>e falciparum malaria. <span class="ff1a">British Journal of Clinical Pharmacology</span><span class="ls0">,</span></div><div class="t mc x4d h17 yda5 ff17 fsb fc3 sc0 ls105 ws0">2004, 57:146–152.</div><div class="t mc xb h17 yda6 ff17 fsb fc3 sc0 ls105 ws0">42.<span class="_ _5"> </span>Brewer T<span class="_ _a"></span>G et al. Neurotoxicity in animals due to arteether and ar<span class="_ _8"></span>temether<span class="_ _b"></span>.</div><div class="t mc x4d h17 yda7 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene<span class="ff17">, 1994, 88</span></div><div class="t mc x4d h17 yda8 ff17 fsb fc3 sc0 ls105 ws1d4">(Suppl. 1):S33–36.</div><div class="t mc xb h17 yda9 ff17 fsb fc3 sc0 ls105 ws0">43.<span class="_ _95"> </span>Bethell DB et al. Pharmacokinetics of oral artesunate in children with moderately</div><div class="t mc x4d h17 ydaa ff17 fsb fc3 sc0 lsd6 ws0">severe <span class="ff1a ls105">Plasmodium falciparum <span class="ff17">malaria. </span>T<span class="_ _4b"></span>ransactions of the Royal Society of</span></div><div class="t mc x4d h17 ydab ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 1997, 91:195–198.</span></div><div class="t mc xb h17 ydac ff17 fsb fc3 sc0 ls105 ws0">44.<span class="_ _5"> </span>Batty KT et al. A pharmacokinetic and pharmacodynamic study of intravenous vs</div><div class="t mc x4d h17 ydad ff17 fsb fc3 sc0 ls105 ws0">oral artesunate in uncomplicated falciparum malaria. <span class="ff1a">British Journal of Clinical</span></div><div class="t mc x4d h17 ydae ff1a fsb fc3 sc0 ls105 ws0">Pharmacology<span class="ff17 lsd6 ws218">, 1998, 45:123–129.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf88" class="pf w1 h4" data-page-no="88"><div class="pc pc88 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">126</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">45.<span class="_ _95"> </span>Newton PN et al. Antimalarial bioavailability and disposition of artesunate in</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">acute falciparum malaria. <span class="ff1a">Antimicrobial Agents and Chemotherapy</span>, 2000,</div><div class="t mc x7a h17 yd63 ff17 fsb fc3 sc0 ls105 ws0">44:972–997.</div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">46.<span class="_ _5"> </span>Krishna S et al. Bioavailability and preliminary clinical efficacy of intrarectal</div><div class="t mc x7a h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">artesunate in Ghanaian children with moderate malaria. <span class="ff1a">Antimicrobial Agents</span></div><div class="t mc x7a h17 yd66 ff1a fsb fc3 sc0 ls105 ws0">and Chemotherapy<span class="ff17">, 2001, 45:509–516.</span></div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">47.<span class="_ _95"> </span>Ilett KF et al. The pharmacokinetic properties of intramuscular artesunate and</div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">rectal dihydroartemisinin in uncomplicated falciparum malaria. <span class="ff1a">British Journal of</span></div><div class="t mc x7a h17 yd87 ff1a fsb fc3 sc0 ls105 ws0">Clinical Pharmacology<span class="ff17">, 2002, 53:23–30.</span></div><div class="t mc x9 h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">48. Newton PN et al. Comparison of oral ar<span class="_ _8"></span>tesunate and dihydroartemisinin</div><div class="t mc x7a h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">antimalarial bioavailabilities in acute falciparum malaria. <span class="ff1a">Antimicr<span class="_ _a"></span>obial Agents</span></div><div class="t mc x7a h17 yd89 ff1a fsb fc3 sc0 ls105 ws0">and Chemotherapy<span class="ff17 lsd6 ws218">, 2002, 46:1125–1127.</span></div><div class="t mc x9 h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">49.<span class="_ _5"> </span>White N<span class="_ _8"></span>J, van <span class="_ _a"></span>V<span class="_ _b"></span>ugt M, Ezzet F<span class="_ _4b"></span>. Clinical pharmacokinetics and pharmacodynamics</div><div class="t mc x7a h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">of artemether-lumefantrine. <span class="ff1a">Clinical Pharmacokinetics</span><span class="ls104 ws35b">, 1999, 37:105–125.</span></div><div class="t mc x9 h17 yd8c ff17 fsb fc3 sc0 ls105 ws0">50.<span class="_ _95"> </span>van <span class="_ _b"></span>Vugt M et al. No evidence of car<span class="_ _a"></span>diotoxicity during antimalarial treatment with</div><div class="t mc x7a h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">artemether-lumefantrine. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls0">,</span></span></div><div class="t mc x7a h17 yd8e ff17 fsb fc3 sc0 ls130 ws218">1999, 61:964–967.</div><div class="t mc x9 h17 yd8f ff17 fsb fc3 sc0 ls130 ws0">51.<span class="_ _68"> </span>Mihaly GW et al. Pharmacokinetics of primaquine in man: identification of the</div><div class="t mc x7a h17 yd90 ff17 fsb fc3 sc0 ls130 ws0">carboxylic acid deriv<span class="_ _a"></span>ative as a major plasma metabolite. <span class="ff1a">British Journal of Clinical</span></div><div class="t mc x7a h17 yd91 ff1a fsb fc3 sc0 ls130 ws0">Pharmacology<span class="ff17 ws218">, 1984, 17:441–446.</span></div><div class="t mc x9 h17 yd92 ff17 fsb fc3 sc0 ls130 ws0">52.<span class="_ _95"> </span>Chan TK, <span class="_ _a"></span>T<span class="_ _4b"></span>odd D, T<span class="_ _c"></span>so SC. Drug-induced haemolysis in glucose-6-phosphate</div><div class="t mc x7a h17 yd93 ff17 fsb fc3 sc0 ls130 ws0">dehydrogenase deficiency<span class="_ _c"></span>. <span class="_ _8"></span><span class="ff1a">British Medical Journal</span><span class="ws218">, 1976, 2:1227–1229.</span></div><div class="t mc x9 h17 yd94 ff17 fsb fc3 sc0 ls130 ws0">53.<span class="_ _95"> </span>McGready R et al. The pharmacokinetics of ato<span class="_ _a"></span>vaquone and pr<span class="_ _a"></span>oguanil in</div><div class="t mc x7a h17 ydaf ff17 fsb fc3 sc0 ls137 ws1d4">pregnant women with acute falciparum malaria. <span class="ff1a ws0">Eur<span class="_ _a"></span>opean Journal of Clinical</span></div><div class="t mc x7a h17 ydb0 ff1a fsb fc3 sc0 ls137 ws0">Pharmacology<span class="ff17 ws1d2">, 2003, 59:545–552.</span></div><div class="t mc x9 h17 yd7a ff17 fsb fc3 sc0 ls137 ws0">54.<span class="_ _95"> </span>Sabchareon A et al. Efficacy and pharmacokinetics of ato<span class="_ _a"></span>vaquone and proguanil</div><div class="t mc x7a h17 yd95 ff17 fsb fc3 sc0 ls137 ws0">in children with multidrug-resistant <span class="ff1a">Plasmodium falciparum </span>malaria.</div><div class="t mc x7a h17 ydb1 ff1a fsb fc3 sc0 ls137 ws0">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene<span class="ff17">, 1998,</span></div><div class="t mc x7a h17 ydb2 ff17 fsb fc3 sc0 ls137 ws0">92:201–206.</div><div class="t mc x9 h17 ydb3 ff17 fsb fc3 sc0 ls137 ws0">55.<span class="_ _95"> </span>Helsby NA et al. The pharmacokinetics and activation of pr<span class="_ _a"></span>oguanil in man:</div><div class="t mc x7a h17 ydb4 ff17 fsb fc3 sc0 ls137 ws0">consequences of variability in drug metabolism. <span class="ff1a">British Journal of Clinical</span></div><div class="t mc x7a h17 ydb5 ff1a fsb fc3 sc0 ls137 ws0">Pharmacology<span class="ff17 lsd6 ws218">, 1990, 30:593–598.</span></div><div class="t mc x9 h17 ydb6 ff17 fsb fc3 sc0 ls105 ws0">56.<span class="_ _95"> </span>Kaneko A et al. Pr<span class="_ _a"></span>oguanil disposition and toxicity in malaria patients from</div><div class="t mc x7a h17 ydb7 ff17 fsb fc3 sc0 ls105 ws0">V<span class="_ _b"></span>anuatu with high frequencies of CYP2C19 mutations. <span class="ff1a">Pharmacogenetics</span><span class="ws1d4">, 1999,</span></div><div class="t mc x7a h17 ydb8 ff17 fsb fc3 sc0 ls104 ws0">9:317–326.</div><div class="t mc x9 h17 ydb9 ff17 fsb fc3 sc0 ls105 ws0">57.<span class="_ _64"> </span>W<span class="_ _a"></span>attanagoon Y et al. Single dose pharmacokinetics of proguanil and its</div><div class="t mc x7a h17 ydba ff17 fsb fc3 sc0 ls105 ws0">metabolites in healthy subjects. <span class="ff1a">British Journal of Clinical Pharmacology</span>, 1987,</div><div class="t mc x7a h17 ydbb ff17 fsb fc3 sc0 ls105 ws0">24:775–780.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf89" class="pf w1 h4" data-page-no="89"><div class="pc pc89 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">127</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">58.<span class="_ _5"> </span>Hussein Z et al. Population pharmacokinetics of proguanil in patients with acute</div><div class="t mc x4d h17 yd62 ff1a fsb fc3 sc0 ls105 ws0">P<span class="_ _c"></span>. falciparum <span class="ff17">malaria after combined therapy with atov<span class="_ _a"></span>aquone. <span class="ff1a">British Journal of</span></span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Clinical Pharmacology<span class="ff17">, 1996, 42:589–597.</span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">59.<span class="_ _95"> </span>W<span class="_ _a"></span>angboonskul J et al. Single dose pharmacokinetics of proguanil and its</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">metabolites in pregnancy<span class="_ _4b"></span>. <span class="ff1a">European Journal of Clinical Pharmacology</span>, 1993,</div><div class="t mc x4d h17 yd66 ff17 fsb fc3 sc0 ls105 ws0">44:247–251.</div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">60.<span class="_ _5"> </span>McGready R et al. Pregnancy and use of oral contr<span class="_ _a"></span>aceptives reduces the</div><div class="t mc x4d h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">biotransformation of proguanil to cy<span class="_ _a"></span>cloguanil. <span class="ff1a">European Journal of Clinical</span></div><div class="t mc x4d h17 yd87 ff1a fsb fc3 sc0 ls105 ws0">Pharmacology<span class="ff17 ls1dc ws1d2">, 2003, 59:553–557.</span></div><div class="t mc xb h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">61.<span class="_ _3"> </span>V<span class="_ _a"></span>eenendaal J<span class="_ _8"></span>R, Edstein MD, Rieckmann KH. Pharmacokinetics of chlorproguanil</div><div class="t mc x4d h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">in man after a single oral dose of Lapudrine. <span class="ff1a">Chemotherapy</span><span class="ws1d4">, 1988, 34:275–283.</span></div><div class="t mc xb h17 yd6c ff17 fsb fc3 sc0 ls105 ws0">62.<span class="_ _5"> </span>White N<span class="_ _8"></span>J et al. Quinine pharmacokinetics and toxicity in cerebr<span class="_ _a"></span>al and</div><div class="t mc x4d h17 yd8a ff17 fsb fc3 sc0 ls105 ws1d4">uncomplicated falciparum malaria. <span class="ff1a ws0">American Journal of Medicine</span><span class="ls2e3 ws4be">, 1982,</span></div><div class="t mc x4d h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">73:564–572.</div><div class="t mc xb h17 yd8c ff17 fsb fc3 sc0 ls105 ws0">63.<span class="_ _95"> </span>v<span class="_ _a"></span>an Hensbroek MB et al. Quinine pharmacokinetics in young children with severe</div><div class="t mc x4d h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">malaria. <span class="ff1a">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 1996, 54:237–242.</span></span></div><div class="t mc xb h17 ydbc ff17 fsb fc3 sc0 ls105 ws0">64.<span class="_ _5"> </span>Supanaranond W et al. Disposition of oral quinine in acute falciparum malaria.</div><div class="t mc x4d h17 yd8f ff1a fsb fc3 sc0 ls105 ws0">European Journal of Clinical Pharmacology<span class="ff17 ws1d4">, 1991, 40:49–52.</span></div><div class="t mc xb h17 yd73 ff17 fsb fc3 sc0 ls105 ws0">65.<span class="_ _95"> </span>W<span class="_ _a"></span>aller D et al. The pharmacokinetic properties of intramuscular quinine in</div><div class="t mc x4d h17 ydbd ff17 fsb fc3 sc0 ls105 ws0">Gambian children with severe falciparum malaria. <span class="ff1a">T<span class="_ _b"></span>ransactions of the R<span class="_ _a"></span>oyal</span></div><div class="t mc x4d h17 yd92 ff1a fsb fc3 sc0 ls105 ws0">Society of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 1990. 84:488–491.</span></div><div class="t mc xb h17 yd76 ff17 fsb fc3 sc0 ls105 ws0">66. White N<span class="_ _8"></span>J. Optimal regimens of parenteral quinine. <span class="ff1a">T<span class="_ _b"></span>ransactions of the R<span class="_ _a"></span>oyal</span></div><div class="t mc x4d h17 yd94 ff1a fsb fc3 sc0 ls105 ws0">Society of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 1995, 89:462–464.</span></div><div class="t mc xb h17 yd78 ff17 fsb fc3 sc0 ls105 ws0">67.<span class="_ _95"> </span>Silamut K et al. Binding of quinine to plasma proteins in falciparum malaria.</div><div class="t mc x4d h17 yd79 ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17 lscc ws4bf">, 1985, 34:681–686.</span></div><div class="t mc xb h17 ydbe ff17 fsb fc3 sc0 ls137 ws1d4">68. Silamut K et al. Alpha 1-acid glycoprotein (or<span class="_ _a"></span>osomucoid) and plasma protein</div><div class="t mc x4d h17 yd7b ff17 fsb fc3 sc0 ls137 ws1d4">binding of quinine in falciparum malaria. <span class="ff1a ws0">British Journal of Clinical Pharmacology<span class="ff17 ls0">,</span></span></div><div class="t mc x4d h17 yd7c ff17 fsb fc3 sc0 ls105 ws0">1991, 32:311–315.</div><div class="t mc xb h17 ydbf ff17 fsb fc3 sc0 ls105 ws19a">69. Mansor SM et al. Effect of <span class="ff1a ws0">Plasmodium falciparum </span><span class="ws1d4">malaria infection on the</span></div><div class="t mc x4d h17 yd7e ff17 fsb fc3 sc0 ls105 ws0">plasma concentration of alpha 1-acid glycopr<span class="_ _a"></span>otein and the binding of quinine in</div><div class="t mc x4d h17 yd7f ff17 fsb fc3 sc0 ls105 ws0">Malawian children. <span class="ff1a">British Journal of Clinical Pharmacology</span><span class="lsd6 ws218">, 1991, 32:317–321.</span></div><div class="t mc xb h17 yd80 ff17 fsb fc3 sc0 ls105 ws0">70.<span class="_ _95"> </span>Phillips R<span class="_ _8"></span>E et al. Quinine pharmacokinetics and toxicity in pregnant and lactating</div><div class="t mc x4d h17 yd81 ff17 fsb fc3 sc0 ls105 ws0">women with falciparum malaria. <span class="ff1a">British Journal of Clinical Pharmacology</span>, 1986,</div><div class="t mc x4d h17 yd82 ff17 fsb fc3 sc0 ls1dc ws0">21:677–683.</div><div class="t mc xb h17 yd83 ff17 fsb fc3 sc0 ls105 ws0">71.<span class="_ _68"> </span>Hall AP et al. Human plasma and urine quinine levels following tablets, capsules,</div><div class="t mc x4d h17 yd84 ff17 fsb fc3 sc0 ls105 ws0">and intravenous infusion. <span class="ff1a">Clinical Pharmacology and <span class="_ _b"></span>Therapeutics<span class="ff17 ws19a">, 1973,</span></span></div><div class="t mc x4d h17 yd85 ff17 fsb fc3 sc0 ls105 ws0">14:580–585.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8a" class="pf w1 h4" data-page-no="8a"><div class="pc pc8a w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">128</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls130 ws19a">72.<span class="_ _95"> </span>Pukrittayakamee S et al. A study of the factors affecting the metabolic clearance</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls130 ws0">of quinine in malaria. <span class="ff1a">European Journal of Clinical Pharmacology</span>, 1997,</div><div class="t mc x7a h17 yd63 ff17 fsb fc3 sc0 ls130 ws0">52:487–493.</div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls130 ws0">73.<span class="_ _95"> </span>Newton PN et al. Pharmacokinetics of quinine and 3-hydroxyquinine in sever<span class="_ _a"></span>e</div><div class="t mc x7a h17 yd65 ff17 fsb fc3 sc0 ls130 ws0">falciparum malaria with acute renal failure. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Ro<span class="_ _a"></span>yal Society of</span></div><div class="t mc x7a h17 yd66 ff1a fsb fc3 sc0 ls130 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls137">, 1999, 93:69–72.</span></div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls137 ws0">74.<span class="_ _95"> </span>Bruce-Chwatt LJ. Quinine and the mystery of blackwater fever<span class="_ _b"></span>. <span class="ff1a">Acta Leidensia</span><span class="ls0">,</span></div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">1987, 55:181–196.</div><div class="t mc x9 h17 yd69 ff17 fsb fc3 sc0 ls105 ws0">75.<span class="_ _64"> </span>White NJ, Looareesuwan S, <span class="_ _a"></span>Warr<span class="_ _a"></span>ell DA. Quinine and quinidine: a comparison of</div><div class="t mc x7a h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">EKG effects during the treatment of malaria. <span class="ff1a">Journal of Car<span class="_ _a"></span>diovascular</span></div><div class="t mc x7a h17 yd88 ff1a fsb fc3 sc0 ls105 ws0">Pharmacology<span class="ff17 ls2df ws219">, 1983, 5:173–175.</span></div><div class="t mc x9 h17 yd6c ff17 fsb fc3 sc0 ls105 ws0">76.<span class="_ _95"> </span>Boland M<span class="_ _8"></span>E, Roper SM, Henry JA. Complications of quinine poisoning. <span class="ff1a">Lancet</span><span class="ls0">,</span></div><div class="t mc x7a h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">1985, 1:384–385.</div><div class="t mc x9 h17 yd6e ff17 fsb fc3 sc0 ls105 ws19a">77.<span class="_ _64"> </span>Pukrittayakamee S et al. Adverse effect of rifampicin on quinine efficacy in</div><div class="t mc x7a h17 yd8c ff17 fsb fc3 sc0 ls105 ws1d4">uncomplicated falciparum malaria. <span class="ff1a ws0">Antimicrobial Agents and Chemotherapy<span class="_ _c"></span>,</span></div><div class="t mc x7a h17 yd8d ff17 fsb fc3 sc0 ls105 ws1d4">2003, 47:1509-1513.</div><div class="t mc x9 h17 ydbc ff17 fsb fc3 sc0 ls105 ws0">78.<span class="_ _95"> </span>Newton PN et al. The Pharmacokinetics of or<span class="_ _a"></span>al doxycycline during combination</div><div class="t mc x7a h17 yd8f ff17 fsb fc3 sc0 ls105 ws0">treatment of sever<span class="_ _a"></span>e falciparum malaria. <span class="ff1a">Antimicrobial Agents and Chemotherapy</span><span class="ls0">,</span></div><div class="t mc x7a h17 yd90 ff17 fsb fc3 sc0 ls137 ws1d4">2005, 49:1622–1625.</div><div class="t mc x9 h17 ydbd ff17 fsb fc3 sc0 ls137 ws0">79.<span class="_ _95"> </span>Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: special safety</div><div class="t mc x7a h17 yd92 ff17 fsb fc3 sc0 ls137 ws0">considerations in drug development and pharmaco<span class="_ _a"></span>vigilance. <span class="ff1a">Drug Safety</span>, 2004,</div><div class="t mc x7a h17 yd93 ff17 fsb fc3 sc0 ls137 ws0">27:535–554.</div><div class="t mc x9 h17 yd94 ff17 fsb fc3 sc0 ls137 ws0">80. Ginsberg G et al. Pediatric pharmacokinetic data: implications for environmental</div><div class="t mc x7a h17 ydaf ff17 fsb fc3 sc0 ls137 ws0">risk assessment for children. <span class="ff1a">Pediatrics<span class="_ _a"></span><span class="ff17">, 2004, 113(4 Suppl.):973–983.</span></span></div><div class="t mc x9 h17 yd79 ff17 fsb fc3 sc0 ls137 ws0">81.<span class="_ _3"> </span>Shankar AH. Nutritional modulation of malaria morbidity and mor<span class="_ _8"></span>tality<span class="_ _4b"></span>. <span class="ff1a">Journal of</span></div><div class="t mc x7a h17 yd7a ff1a fsb fc3 sc0 ls137 ws0">Infectious Diseases<span class="ff17 lsd6 ws218">, 2000, 182(Suppl. 1):S37–S53.</span></div><div class="t mc x9 h17 yd7b ff17 fsb fc3 sc0 ls105 ws0">82. de Onis M et al. The worldwide magnitude of protein-energy malnutrition: an</div><div class="t mc x7a h17 yd7c ff17 fsb fc3 sc0 ls105 ws1d4">ov<span class="_ _a"></span>er<span class="_ _8"></span>view from the WHO Global Database on Child Gr<span class="_ _a"></span>owth. <span class="ff1a ws0">Bulletin of the W<span class="_ _b"></span>orld</span></div><div class="t mc x7a h17 yd7d ff1a fsb fc3 sc0 ls105 ws0">Health Organization<span class="ff17">, 1993, 71:703–712.</span></div><div class="t mc x9 h17 yd7e ff17 fsb fc3 sc0 ls105 ws19a">83.<span class="_ _5"> </span>Wolday D et al. Sensitivity of <span class="ff1a ws0">Plasmodium falciparum in vivo </span><span class="ws1d4">to chlor<span class="_ _a"></span>oquine and</span></div><div class="t mc x7a h17 yd7f ff17 fsb fc3 sc0 ls105 ws0">pyrimethamine-sulfadoxine in Rwandan patients in a r<span class="_ _a"></span>efugee camp in Zaire.</div><div class="t mc x7a h17 ydc0 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene<span class="ff17 ls2e2 ws1d3">, 1995,</span></div><div class="t mc x7a h17 ydb6 ff17 fsb fc3 sc0 ls137 ws0">89:654–656.</div><div class="t mc x9 h17 yd82 ff17 fsb fc3 sc0 ls137 ws0">84. Wellcome <span class="_ _a"></span>T<span class="_ _b"></span>rust Working P<span class="_ _a"></span>ar<span class="_ _8"></span>ty<span class="_ _4b"></span>. Classification of infantile malnutrition. <span class="ff1a">Lancet</span><span class="ls0">,</span></div><div class="t mc x7a h17 ydc1 ff17 fsb fc3 sc0 ls137 ws1d4">1970, 2:302–303.</div><div class="t mc x9 h17 yd84 ff17 fsb fc3 sc0 ls137 ws0">85.<span class="_ _5"> </span>Whar<span class="_ _8"></span>ton BA, McChesney EW<span class="_ _b"></span>. Chloroquine metabolism in kwashiorkor<span class="_ _b"></span>. <span class="ff1a">Journal of</span></div><div class="t mc x7a h17 yd85 ff1a fsb fc3 sc0 ls137 ws0">T<span class="_ _b"></span>ropical Pediatrics<span class="ff17 ls2e2 ws1d3">, 1970, 16:130–132.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8b" class="pf w1 h4" data-page-no="8b"><div class="pc pc8b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x86 he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 3 - Pharmacolog<span class="_ _8"></span>y of antimalarial drugs</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">129</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">86. Walker O et al. Single dose disposition of chlor<span class="_ _a"></span>oquine in kwashiorkor and normal</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">children – evidence for decreased absorption in kwashiorkor<span class="_ _4b"></span>. <span class="ff1a">British Journal of</span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Clinical Pharmacology<span class="ff17 ws19a">, 1987, 23:467–472.</span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">87.<span class="_ _95"> </span>Salako LA, Sowunmi A, Akinbami FO. Pharmacokinetics of quinine in African</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">children suffering from kwashiorkor<span class="_ _4b"></span>. <span class="ff1a">British Journal of Clinical Pharmacology</span><span class="ls0">,</span></div><div class="t mc x4d h17 yd66 ff17 fsb fc3 sc0 ls137 ws1d4">1989, 28:197–201.</div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls137 ws1d4">88. T<span class="_ _b"></span>reluyer JM et al. Metabolism of quinine in children with global malnutrition.</div><div class="t mc x4d h17 yd68 ff1a fsb fc3 sc0 ls137 ws0">Pediatric R<span class="_ _a"></span>esearch<span class="ff17 ls130 ws19a">, 1996, 40:558–563.</span></div><div class="t mc xb h17 yd69 ff17 fsb fc3 sc0 ls130 ws0">89. Pussard E et al. Quinine disposition in globally malnourished children with</div><div class="t mc x4d h17 yd6a ff17 fsb fc3 sc0 ls130 ws0">cerebral malaria. <span class="ff1a">Clinical Pharmacology and <span class="_ _a"></span>Therapeutics<span class="ff17 ws19a">, 1999, 65:500–510.</span></span></div><div class="t mc xb h17 yd6b ff17 fsb fc3 sc0 ls130 ws0">90.<span class="_ _5"> </span>Shastri RA, Krishnaswamy K. Undernutrition and tetracycline half life. <span class="ff1a">Clinica</span></div><div class="t mc x4d h17 yd6c ff1a fsb fc3 sc0 ls130 ws0">Chimica Acta<span class="ff17 ls137 ws1d4">, 1976 66:157–164.</span></div><div class="t mc xb h17 yd6d ff17 fsb fc3 sc0 ls137 ws0">91.<span class="_ _3"> </span>Raghuram T<span class="_ _b"></span>C, Krishnaswamy K. T<span class="_ _4b"></span>etracycline kinetics in undernourished subjects.</div><div class="t mc x4d h17 yd6e ff1a fsb fc3 sc0 ls137 ws0">International Journal of Clinical Pharmacology<span class="_ _4b"></span>, Therapy<span class="_ _c"></span>, and T<span class="_ _4b"></span>oxicology<span class="ff17">, 1981,</span></div><div class="t mc x4d h17 yd8c ff17 fsb fc3 sc0 ls130 ws0">19:409–413.</div><div class="t mc xb h17 yd70 ff17 fsb fc3 sc0 ls130 ws0">92.<span class="_ _5"> </span>Raghuram T<span class="_ _b"></span>C, Krishnaswamy K. T<span class="_ _4b"></span>etracycline absorption in malnutrition. <span class="ff1a">Drug-</span></div><div class="t mc x4d h17 ydbc ff1a fsb fc3 sc0 ls130 ws0">Nutrition Interactions<span class="ff17">, 1981, 1:23–29.</span></div><div class="t mc xb h17 yd72 ff17 fsb fc3 sc0 ls130 ws0">93.<span class="_ _95"> </span>Raghur<span class="_ _a"></span>am T<span class="_ _a"></span>C, Krishnaswamy K. Pharmacokinetics and plasma steady state</div><div class="t mc x4d h17 yd73 ff17 fsb fc3 sc0 ls130 ws19a">levels of doxy<span class="_ _a"></span>cycline in undernutrition. <span class="ff1a ws0">British Journal of Clinical Pharmacology<span class="ff17 ls0">,</span></span></div><div class="t mc x4d h17 ydbd ff17 fsb fc3 sc0 lsd6 ws218">1982, 14:785–789.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8c" class="pf w1 h4" data-page-no="8c"><div class="pc pc8c w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8d" class="pf w1 h4" data-page-no="8d"><div class="pc pc8d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 ydc2 ff1b fs10 fc7 sc0 ls270 ws0">Annex 4. <span class="_ _ac"> </span><span class="fc0">Antimalarials and malaria transmission<span class="_ _b9"> </span><span class="fc4 ls2e4">133</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8e" class="pf w1 h4" data-page-no="8e"><div class="pc pc8e w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8f" class="pf w1 h4" data-page-no="8f"><div class="pc pc8f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4a he y9 ff16 fs5 fc3 sc0 ls51 ws4c0">Annex 4 - Antimalarials and malaria transmission</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">133</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws4c1">ANNEX 4</div><div class="t m0 xa6 hf y895 ff18 fs6 fc3 sc0 ls9e wsfd">ANTIMAL<span class="_ _8"></span>ARIALS AN<span class="_ _8"></span>D MALAR<span class="_ _8"></span>IA <span class="_ _a"></span>TRANSM<span class="_ _8"></span>ISSION</div><div class="t m0 xb h12 y896 ff19 fs6 fc4 sc0 ls9e wsfd">A4.1<span class="_ _33"> </span>Principles of malaria transmission</div><div class="t m0 xb hb y897 ff17 fs8 fc3 sc0 lsa2 ws203">Malaria is spread from person to person by mosquitoes belonging to the genus</div><div class="t m0 xb hb y898 ff1a fs8 fc3 sc0 ls234 ws0">Anopheles<span class="ff17 ws73">. The female mosquito is infected by the sexual stages of the</span></div><div class="t m0 xb hb ydc3 ff17 fs8 fc3 sc0 ls12 ws4c2">parasite, the gametocytes, when it bites a malaria-infected person to take a</div><div class="t m0 xb hb ydc4 ff17 fs8 fc3 sc0 ls12 ws4c3">blood meal. The gametocytes under<span class="_ _a"></span>go fur<span class="_ _8"></span>ther development in the insect for</div><div class="t m0 xb hb ydc5 ff17 fs8 fc3 sc0 ls22 ws5e">a period of 6–12 days, after which they are capable of infecting a human, again</div><div class="t m0 xb hb ydc6 ff17 fs8 fc3 sc0 ls12 ws0">through the bite of the mosquito<span class="_ _a"></span>. </div><div class="t m0 xb hb ydc7 ff17 fs8 fc3 sc0 ls18b wsfa">The intensity of malaria transmission in an area is the r<span class="_ _a"></span>ate at which people are</div><div class="t m0 xb hb ydc8 ff17 fs8 fc3 sc0 ls249 ws13b">inoculated with malaria parasites by mosquitoes. It is usually expressed as the</div><div class="t m0 xb hb ydc9 ff17 fs8 fc3 sc0 ls2e5 ws1a3">annual entomological inoculation rate (EI<span class="_ _8"></span>R), i.e. the average number of infectious</div><div class="t m0 xb hb ydca ff17 fs8 fc3 sc0 lsa9 ws109">bites by malaria-infected mosquitoes delivered to an individual human r<span class="_ _a"></span>esident</div><div class="t m0 xb hb ydcb ff17 fs8 fc3 sc0 ls2e6 ws3f">in the area in the period of one year<span class="_ _4b"></span>. It is the E<span class="_ _8"></span>I<span class="_ _8"></span>R that determines, to a large extent,</div><div class="t m0 xb hb ydcc ff17 fs8 fc3 sc0 ls10e ws135">the epidemiology of malaria and the pattern of clinical disease in that locality<span class="_ _4b"></span>.</div><div class="t m0 xb hb ydcd ff17 fs8 fc3 sc0 ls172 ws353">The high end of the malaria transmission range is found in a few parts of</div><div class="t m0 xb hb ydce ff17 fs8 fc3 sc0 ls10e ws4c4">tropical Africa, where EIRs of 500–1000 can be reached <span class="ff1a ws0">(1)</span>. At the low end of</div><div class="t m0 xb hb ydcf ff17 fs8 fc3 sc0 ls10e ws422">the range are EIRs of 0.01 or below, as found in the temper<span class="_ _a"></span>ate climates of the</div><div class="t m0 xb hb ydd0 ff17 fs8 fc3 sc0 ls2e7 ws168">Caucasus and Central Asia where malaria tr<span class="_ _a"></span>ansmission is only barely sustained.</div><div class="t m0 xb hb ydd1 ff17 fs8 fc3 sc0 ls64 wse1">Between these extremes ar<span class="_ _a"></span>e situations of unstable seasonal malaria such as</div><div class="t m0 xb hb ydd2 ff17 fs8 fc3 sc0 ls64 ws22b">in much of Asia and Latin America where EI<span class="_ _8"></span>Rs lie below 10, and often around</div><div class="t m0 xb hb ydd3 ff17 fs8 fc3 sc0 lse7 ws55">1–2, and situations of stable but still seasonal malaria as in much of W<span class="_ _b"></span>est Africa</div><div class="t m0 xb hb ydd4 ff17 fs8 fc3 sc0 ls7f ws15">where the EI<span class="_ _8"></span>R is in the range 10–100. </div><div class="t m0 xb hb ydd5 ff17 fs8 fc3 sc0 ls6c ws99">The proportion of infected mosquitoes in a locality is itself related to the</div><div class="t m0 xb hb ydd6 ff17 fs8 fc3 sc0 ls200 ws25">number of infected and infectious humans living there. <span class="_ _a"></span>Therefore, low<span class="_ _a"></span>ering of</div><div class="t m0 xb hb ydd7 ff17 fs8 fc3 sc0 ls12 ws26c">the infectivity of infected persons to the mosquito vector will contribute to</div><div class="t m0 xb hb ydd8 ff17 fs8 fc3 sc0 ls12 ws44a">lowering of malaria tr<span class="_ _a"></span>ansmission, and eventually to reducing the prev<span class="_ _b"></span>alence</div><div class="t m0 xb hb ydd9 ff17 fs8 fc3 sc0 lse6 ws177">of malaria and the incidence of disease in that locality<span class="_ _4b"></span>. The relationship</div><div class="t m0 xb hb ydda ff17 fs8 fc3 sc0 ls12 ws4b1">between the EI<span class="_ _8"></span>R and the prevalence of malaria is, ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, complex and is</div><div class="t m0 xb hb yddb ff17 fs8 fc3 sc0 ls12 ws120">affected by the nature of immunity to malaria, its acquisition and loss and to</div><div class="t m0 xb hb yddc ff17 fs8 fc3 sc0 ls45 wsbb">whether or not there is effective drug tr<span class="_ _a"></span>eatment. The hypothetical relationship</div><div class="t m0 xb hb yddd ff17 fs8 fc3 sc0 ls2e8 ws3b7">represented in figur<span class="_ _a"></span>e A4.1 assumes no drug treatment. In areas of low</div><div class="t m0 xb hb ydde ff17 fs8 fc3 sc0 ls2bc ws48d">transmission, where EIRs are below 1 or 2, a reduction in the inoculation</div><div class="t m0 xb hb yddf ff17 fs8 fc3 sc0 ls12 ws4c5">rates will result in an almost pr<span class="_ _a"></span>opor<span class="_ _8"></span>tionate reduction in the prev<span class="_ _a"></span>alence (and</div><div class="t m0 xb hb yde0 ff17 fs8 fc3 sc0 ls26e wsa1">incidence rate) of malaria. At EI<span class="_ _8"></span>Rs in excess of 10, the reductions in transmission</div><div class="t m0 xb hb yde1 ff17 fs8 fc3 sc0 ls24d ws1a2">need to be increasingly large if they ar<span class="_ _a"></span>e to make a significant impact on</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf90" class="pf w1 h4" data-page-no="90"><div class="pc pc90 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">134</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls166 ws91">malaria prev<span class="_ _a"></span>alence. In high-transmission settings where there is gr<span class="_ _a"></span>eat redun-</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls1a8 ws2aa">dancy in the infectious reservoir<span class="_ _4b"></span>, the impact of reducing transmission on</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls14f ws133">disease incidence is not at all obvious, and has been the subject of considerable</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls1b9 ws4ba">debate. The experience with major interventions, such as the use of insecticide-</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls2e9 ws4c6">treated nets, suggests, how<span class="_ _a"></span>ever<span class="_ _4b"></span>, that effective transmission-reducing</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls12 ws0">interventions will always be beneficial with respect to mortality <span class="ff1a ls13">(2, 3)</span><span class="ls0">.</span></div><div class="t m0 x9 h3f yde2 ff22 fs5 fc4 sc0 ls209 ws0">Figure A4.1<span class="_ _49"> </span><span class="ff1b fs9 fc3 ls16">Relationship between inoculation rate and par<span class="_ _a"></span>asite prevalence</span></div><div class="t m0 x5 h3f yde3 ff1b fs9 fc3 sc0 ls16 ws0">(assumes that all infections are untreated)</div><div class="t m0 x9 h12 yde4 ff19 fs6 fc4 sc0 lsc3 ws139">A4.2<span class="_ _33"> </span>Effects of antimalar<span class="_ _8"></span>ials on malaria transmission</div><div class="t m0 x9 hb yde5 ff17 fs8 fc3 sc0 ls22 ws104">Antimalarials can help bring about a reduction in malaria transmission by their</div><div class="t m0 x9 hb yde6 ff17 fs8 fc3 sc0 ls34 ws7f">effect on parasite infectivity<span class="_ _c"></span>. This can be a direct effect on the gametocytes, the</div><div class="t m0 x9 hb yde7 ff17 fs8 fc3 sc0 ls15f ws7e">infective stages found in human infections (gametocytocidal effect) or<span class="_ _4b"></span>, when the</div><div class="t m0 x9 hb yde8 ff17 fs8 fc3 sc0 ls22 ws2da">drug is taken up in the blood meal of the mosquito, an effect on the parasite<span class="_ _a"></span>’<span class="_ _b"></span>s</div><div class="t m0 x9 hb yde9 ff17 fs8 fc3 sc0 lse5 ws410">development in the insect (sporonticidal effect) (T<span class="_ _c"></span>able A4.1; Figure A4.2).</div><div class="t m0 x9 hb ydea ff17 fs8 fc3 sc0 lseb ws189">Chloroquine acts against young gametocytes but has no suppr<span class="_ _a"></span>essive effects on</div><div class="t m0 x9 hb ydeb ff17 fs8 fc3 sc0 ls22 ws19c">mature infective forms <span class="ff1a ws0">(4)</span>. Chlor<span class="_ _a"></span>oquine has even been shown to be capable of</div><div class="t m0 x9 hb ydec ff17 fs8 fc3 sc0 ls103 ws70">enhancing the infectivity of gametocytes to the mosquito <span class="ff1a ls114 ws0">(5)</span>. In contrast,</div><div class="t m0 x9 hb yded ff17 fs8 fc3 sc0 lsbf ws130">sulfadoxine-pyrimethamine increases gametocyte carriage but, pr<span class="_ _a"></span>ovided there</div><div class="t m0 x9 hb ydee ff17 fs8 fc3 sc0 ls22 ws4c7">is no resistance, reduces the infectivity of gametocytes to mosquitoes <span class="ff1a ws0">(5–7)<span class="ff17 ls0">.</span></span></div><div class="t m0 x9 hb ydef ff17 fs8 fc3 sc0 ls47 wsb0">Artemisinins are the most potent gametocytocidal drugs among those currently</div><div class="t m0 x9 hb ydf0 ff17 fs8 fc3 sc0 ls22 ws7a">being used to treat an asexual blood infection <span class="ff1a ws0">(8–11)</span>. <span class="_ _a"></span>They destroy immature</div><div class="t m0 x9 hb ydf1 ff17 fs8 fc3 sc0 ls2ea ws4ba">gametocytes, preventing new infectiv<span class="_ _a"></span>e gametocytes from entering the circulation,</div><div class="t m0 x9 hb ydf2 ff17 fs8 fc3 sc0 ls22 ws201">but their effects on mature gametocytes are less and so they will not affect the</div><div class="t m0 x9 hb ydf3 ff17 fs8 fc3 sc0 ls13 wsf9">infectivity of those already present in the cir<span class="_ _a"></span>culation at the time a patient</div><div class="t m0 x9 hb ydf4 ff17 fs8 fc3 sc0 ls22 ws0">presents for treatment <span class="ff1a">(11).</span></div></div><div class="t m0 x72 h40 ydf5 ff23 fs9 fc3 sc0 ls2eb ws1a">Annual entomologicalinoculation r<span class="_ _a"></span>ate</div><div class="t m0 x7a h41 ydf6 ff20 fs7 fc3 sc0 ls2ec ws0">100</div><div class="t m0 x37 h41 ydf7 ff20 fs7 fc3 sc0 ls2ec ws0">80</div><div class="t m0 x37 h41 ydf8 ff20 fs7 fc3 sc0 ls2ec ws0">60</div><div class="t m0 x37 h41 ydf9 ff20 fs7 fc3 sc0 ls2ec ws0">40</div><div class="t m0 x37 h41 ydfa ff20 fs7 fc3 sc0 ls2ec ws0">20</div><div class="t m0 xb9 h41 ydfb ff20 fs7 fc3 sc0 ls0 ws0">0</div><div class="t m0 x24 h41 ydfc ff20 fs7 fc3 sc0 ls235 ws0">0.1<span class="_ _ba"> </span>1<span class="_ _bb"> </span>10<span class="_ _bc"> </span>100<span class="_ _bd"> </span>1000</div><div class="t m1 xa9 h41 ydfd ff23 fs7 fc3 sc0 ls2ed ws4c8">% Par<span class="_ _a"></span>asite prevalence</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf91" class="pf w1 h4" data-page-no="91"><div class="pc pc91 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4a he y9 ff16 fs5 fc3 sc0 ls51 ws4c0">Annex 4 - Antimalarials and malaria transmission</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">135</div><div class="t m0 xb hd y9e ff22 fs5 fc4 sc0 ls14c ws0">T<span class="_ _b"></span>able A4.1<span class="_ _0"> </span><span class="ff1e fs8 fc3 ls12">Effects of some commonly used antimalarials on the infectivity</span></div><div class="t m0 xa4 hd y9f ff1e fs8 fc3 sc0 ls13 ws0">of <span class="ff24 ls12">P<span class="_ _c"></span>. falciparum <span class="ff1e">to the mosquito</span></span></div><div class="t m0 xb h19 ydfe ff17 fsd fc4 sc0 ls0 ws0">a</div><div class="t m0 x20 h15 ydff ff17 fsa fc3 sc0 ls7d ws0">+/– no over<span class="_ _a"></span>all effect; + moderate effect; ++ high effect; +++ very high effect</div><div class="t m0 xb hb ye00 ff17 fs8 fc3 sc0 ls22 ws4c9">Primaquine, an 8-aminoquinoline antimalarial that has been widely used as a</div><div class="t m0 xb hb ye01 ff17 fs8 fc3 sc0 ls33 ws262">hypnozoiticidal drug, is the only antimalarial medicine that had been deployed</div><div class="t m0 xb hb ye02 ff17 fs8 fc3 sc0 ls1fb ws27">in the treatment of <span class="ff1a">P<span class="_ _c"></span>. falciparum <span class="ff17">infections specifically for its effects on infectivity<span class="_ _c"></span>.</span></span></div><div class="t m0 xb hb ye03 ff17 fs8 fc3 sc0 ls43 ws1c3">It acts on mature infective gametocytes in the cir<span class="_ _a"></span>culation and accelerates game-</div><div class="t m0 xb hb ye04 ff17 fs8 fc3 sc0 ls2ee ws256">tocyte clearance <span class="ff1a ls2ef ws0">(11)</span>, as opposed to artemisinins which mainly inhibit gametocyte</div><div class="t m0 xb hb ye05 ff17 fs8 fc3 sc0 ls22 ws0">development. </div><div class="t m0 xb h12 ye06 ff19 fs6 fc4 sc0 ls9e wsfd">A4.3<span class="_ _33"> </span>T<span class="_ _8"></span>he use of antimalarials to reduce infectivit<span class="_ _8"></span>y </div><div class="t m0 xb h2e ye07 ff19 fs3 fc3 sc0 ls80 ws0">A4.3.1<span class="_ _a7"> </span>Choice of dr<span class="_ _8"></span>ugs</div><div class="t m0 xb hb ye08 ff17 fs8 fc3 sc0 ls2f0 ws278">Artemisinin derivatives, as indicated earlier<span class="_ _4b"></span>, have specific and significant activity</div><div class="t m0 xb hb ye09 ff17 fs8 fc3 sc0 ls202 wsb7">against gametocytes (T<span class="_ _4b"></span>able A3.1). Effective treatment of a malaria blood infection</div><div class="t m0 xb hb ye0a ff17 fs8 fc3 sc0 lsf9 ws18a">with any antimalarial will, nevertheless, remov<span class="_ _a"></span>e the source of new gametocytes</div><div class="t m0 xb hb ye0b ff17 fs8 fc3 sc0 ls2f1 ws11c">by eliminating the asexual blood stages from which gametocytes derive. <span class="_ _b"></span>The faster</div><div class="t m0 xb hb ye0c ff17 fs8 fc3 sc0 ls161 ws135">the clearance of asexual blood parasites by a drug, the gr<span class="_ _a"></span>eater will be its impact</div><div class="t m0 xb hb ye0d ff17 fs8 fc3 sc0 ls2b9 ws50">on infectivity<span class="_ _4b"></span>. In <span class="ff1a">P<span class="_ _c"></span>. vivax, P<span class="_ _ae"></span>. malariae <span class="ff17 ws0">and <span class="ff1a">P<span class="_ _c"></span>. o<span class="_ _b"></span>vale <span class="ff17 ws50">infections, in which gametocytes</span></span></span></span></div><div class="t m0 xb hb ye0e ff17 fs8 fc3 sc0 ls237 wsb0">have a short developmental period and are short-lived, effective treatment of the</div><div class="t m0 xb hb ye0f ff17 fs8 fc3 sc0 lsed ws22f">asexual blood infection alone (without the addition of gametocytocidal drugs)</div><div class="t m0 xb hb ye10 ff17 fs8 fc3 sc0 lsed ws1c2">will be sufficient to abolish further infectivity to mosquitoes. <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>falciparum <span class="_ _66"></span><span class="ff17 ls190">is</span></span></div><div class="t m0 xb hb ye11 ff17 fs8 fc3 sc0 ls2f2 ws16b">different because its gametocytes take longer to develop – about 12 days to matur<span class="_ _a"></span>e</div><div class="t m0 xb hb ye12 ff17 fs8 fc3 sc0 lsf9 ws4ca">from a young par<span class="_ _a"></span>asite (merozoite) – and the mature gametocytes may remain</div><div class="t m0 xb hb ye13 ff17 fs8 fc3 sc0 ls7e ws2fb">infective in the peripheral cir<span class="_ _a"></span>culation for up to several weeks after the patient has</div><div class="t m8 x2d h3f ye14 ff1b fs9 fc3 sc0 ls2f3 ws0">Drug</div><div class="t m8 xb9 h3f ye15 ff1b fs9 fc3 sc0 ls16 ws0">Effect of treatment</div><div class="t m8 xb9 h3f ye16 ff1b fs9 fc3 sc0 ls16 ws0">Gametocytocidal<span class="_ _be"> </span>Sporonticidal</div><div class="t m8 xc0 h3f ye17 ff1b fs9 fc3 sc0 ls16 ws0">Overall effect</div><div class="t m8 xc0 h3f ye18 ff1b fs9 fc3 sc0 ls16 ws0">on suppressing</div><div class="t m8 xc0 h3f ye19 ff1b fs9 fc3 sc0 ls16 ws0">infectivity</div><div class="t m8 x67 h42 ye1a ff1b fs15 fc3 sc0 ls0 ws0">a</div><div class="t m8 xb9 h3f ye1b ff1b fs9 fc3 sc0 ls16 ws0">Viability of</div><div class="t m8 xb9 h3f ye1c ff1b fs9 fc3 sc0 ls2f3 ws0">young</div><div class="t m8 xb9 h3f ye1d ff1b fs9 fc3 sc0 ls2f3 ws0">sequestered</div><div class="t m8 xb9 h3f ye1e ff1b fs9 fc3 sc0 ls16 ws0">gametocytes</div><div class="t m8 x9c h3f ye1b ff1b fs9 fc3 sc0 ls16 ws0">Viability of</div><div class="t m8 x9c h3f ye1c ff1b fs9 fc3 sc0 ls16 ws0">mature</div><div class="t m8 x9c h3f ye1d ff1b fs9 fc3 sc0 ls2a5 ws0">circulating</div><div class="t m8 x9c h3f ye1e ff1b fs9 fc3 sc0 ls16 ws0">gametocytes</div><div class="t m8 x54 h3f ye1f ff1b fs9 fc3 sc0 ls16 ws0">Infectivity of</div><div class="t m8 x54 h3f ye20 ff1b fs9 fc3 sc0 ls16 ws0">gametocytes to</div><div class="t m8 x54 h3f ye21 ff1b fs9 fc3 sc0 ls16 ws0">mosquitoes</div><div class="t md x2d hc ye22 ff17 fs9 fc3 sc0 ls16 ws0">Chloroquine<span class="_ _8e"> </span><span class="ls2f3">Reduces<span class="_ _bf"> </span></span>No effect <span class="ff1a ls15">(4)<span class="_ _93"> </span></span>Enhances (5)<span class="_ _83"> </span><span class="ls0">+</span></div><div class="t md x2d hc ye23 ff17 fs9 fc3 sc0 ls16 ws0">Sulfadoxine-</div><div class="t md x2d hc ye24 ff17 fs9 fc3 sc0 ls16 ws0">pyrimethamine</div><div class="t md xb9 hc ye25 ff17 fs9 fc3 sc0 ls16 ws0">No effect<span class="_ _62"> </span><span class="ls2f3">Increases <span class="ff1a">(5–7)</span></span></div><div class="t md x54 hc ye23 ff17 fs9 fc3 sc0 ls2f3 ws0">Suppresses</div><div class="t md x54 h43 ye24 ff1a fs9 fc3 sc0 ls2f3 ws0">(5–7)</div><div class="t md xc0 hc ye25 ff17 fs9 fc3 sc0 ls2f3 ws0">+/–</div><div class="t md x2d hc ye26 ff17 fs9 fc3 sc0 ls16 ws0">Artemisinin</div><div class="t md x2d hc ye27 ff17 fs9 fc3 sc0 ls2f3 ws0">derivativ<span class="_ _a"></span>es</div><div class="t md xb9 hc ye26 ff17 fs9 fc3 sc0 ls2f3 ws1a">Reduces greatly</div><div class="t md xb9 hc ye27 ff17 fs9 fc3 sc0 ls16 ws0">(8–11) </div><div class="t md x9c hc ye28 ff17 fs9 fc3 sc0 ls16 ws0">Little effect <span class="ff1a">(11)<span class="_ _54"> </span></span><span class="ls0">Unkno<span class="_ _a"></span>wn<span class="_ _71"> </span><span class="ls16">+++</span></span></div><div class="t md x2d hc ye29 ff17 fs9 fc3 sc0 ls16 ws0">Primaquine<span class="_ _c0"> </span><span class="ls0">Unknown</span></div><div class="t md x9c hc ye2a ff17 fs9 fc3 sc0 ls2f3 ws1a">Reduces greatly</div><div class="t md x9c h43 ye2b ff1a fs9 fc3 sc0 ls16 ws0">(11)</div><div class="t md x54 hc ye29 ff17 fs9 fc3 sc0 ls0 ws0">Unknown<span class="_ _71"> </span><span class="ls16">+++</span></div><div class="t md x2d hc ye2c ff17 fs9 fc3 sc0 ls16 ws0">Quinine <span class="ff1a ls15">(4)<span class="_ _85"> </span></span>No effect<span class="_ _8b"> </span>No effect<span class="_ _62"> </span>No effect<span class="_ _62"> </span>None </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf92" class="pf w1 h4" data-page-no="92"><div class="pc pc92 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">136</div></div><div class="c xbc ye2d w12 h44"><div class="t me x3c h45 ye2e ff25 fs16 fc3 sc0 ls0 ws0">MEROZOITES</div><div class="t m1 xaf h46 ye2f ff26 fs17 fc3 sc0 ls2f4 ws0">In</div><div class="t m1 x94 h46 ye30 ff26 fs17 fc3 sc0 ls2f4 ws0">human</div><div class="t m1 xc1 h46 ye31 ff26 fs17 fc3 sc0 ls2f4 ws0">blood</div><div class="t m1 x8f h46 ye32 ff26 fs17 fc3 sc0 ls2f4 ws0">When  </div><div class="t m1 x4d h46 ye32 ff26 fs17 fc3 sc0 ls2f4 ws0">sensitive</div><div class="t m1 x5a h46 ye33 ff26 fs17 fc3 sc0 ls2f4 ws0">When  </div><div class="t m1 xc2 h46 ye33 ff26 fs17 fc3 sc0 ls2f4 ws0">resistant</div><div class="t m1 x33 h46 ye34 ff26 fs17 fc3 sc0 ls2f4 ws0">In the </div><div class="t m1 xc3 h46 ye35 ff26 fs17 fc3 sc0 ls2f4 ws0">mosquito</div><div class="t me x19 h45 ye36 ff25 fs16 fc3 sc0 ls0 ws4cb">YOUNG GAMETOCYTE  </div><div class="t me x2b h45 ye36 ff25 fs16 fc3 sc0 ls0 ws0">SEQUESTED IN TISSUES</div><div class="t me x20 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Chloroquine*</div><div class="t me x8d h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Amodiaquine*</div><div class="t me x98 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Sulfadoxine- </div><div class="t me xb0 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">pyrimethamine*</div><div class="t me x9 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Artemisinin  </div><div class="t me x14 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">derivatives*</div><div class="t me x61 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Sulfadoxine- </div><div class="t me x81 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">pyrimethamine*</div><div class="t me xc1 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Artemisinin  </div><div class="t me x40 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">derivatives</div><div class="t me x8a h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Primaquine</div><div class="t me x23 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Chloroquine</div><div class="t me x33 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">Sulfadoxine- </div><div class="t me x67 h45 ye37 ff25 fs16 fc3 sc0 ls0 ws0">pyrimethamine*</div><div class="t me x97 h45 ye38 ff25 fs16 fc3 sc0 ls0 ws0">SCHIZONT</div><div class="t m1 x37 h47 ye39 ff26 fs18 fc3 sc0 ls2f5 ws4cc">+  </div><div class="t m1 x11 h47 ye3a ff26 fs18 fc3 sc0 ls2f5 ws0">+ </div><div class="t mf xc4 h48 ye3a ff26 fs19 fc3 sc0 ls2f6 ws0">- </div><div class="t mf xc5 h48 ye3a ff26 fs19 fc3 sc0 ls2f6 ws0">- </div><div class="t mf x34 h48 ye3a ff26 fs19 fc3 sc0 ls2f6 ws0">- </div><div class="t mf x57 h48 ye3a ff26 fs19 fc3 sc0 ls2f6 ws0">- </div><div class="t m1 x92 h47 ye3a ff26 fs18 fc3 sc0 ls0 ws0">+</div><div class="t m1 x3 h49 ye3b ff25 fs19 fc3 sc0 ls2f7 ws4cd">PARASITE DEVELOPMENT </div><div class="t m10 x3 h49 ye3c ff25 fs19 fc3 sc0 ls0 ws0">ANTIMALARIAL DRUGS  </div><div class="t m10 xc6 h49 ye3c ff25 fs19 fc3 sc0 ls0 ws0">AND THEIR EFFECTS*</div><div class="t m1 xb7 h4a ye3d ff27 fs1a fc3 sc0 ls0 ws0"></div><div class="t m1 xc6 h45 ye3e ff20 fs16 fc3 sc0 ls0 ws0">Some will re-enter </div><div class="t m1 xa0 h45 ye3e ff20 fs16 fc3 sc0 ls0 ws0">erythroc<span class="_ _8"></span>ytes and develop </div><div class="t m1 x0 h45 ye3e ff20 fs16 fc3 sc0 ls2f8 ws4ce">into schizonts (asexual cycle)</div><div class="t m11 xb1 h4b ye3f ff23 fs1b fc3 sc0 ls2f9 ws4cf">• <span class="_ _a"></span>T<span class="_ _a"></span>reatment of the asexual blood </div><div class="t m11 xa2 h4b ye40 ff23 fs1b fc3 sc0 ls2f9 ws4cf">infection will abolish the source </div><div class="t m11 xa1 h4b ye40 ff23 fs1b fc3 sc0 ls2fa ws4d0">of gametocytes.</div><div class="t m11 x4d h4b ye3f ff23 fs1b fc3 sc0 ls2fa ws4d0">• However<span class="_ _b"></span>,<span class="_ _a"></span> young gametocytes </div><div class="t m11 xc h4b ye40 ff23 fs1b fc3 sc0 ls2fb ws4d1">already present will continue to </div><div class="t m11 xb2 h4b ye40 ff23 fs1b fc3 sc0 ls2fc ws4d2">mature and become infective </div><div class="t m11 x9d h4b ye40 ff23 fs1b fc3 sc0 ls2fd ws4d3">weeks later<span class="_ _a"></span>.</div><div class="t m11 x7a h4b ye3f ff23 fs1b fc3 sc0 ls2fc ws4d2">• <span class="_ _a"></span>The continued use of a failing </div><div class="t m11 x10 h4b ye40 ff23 fs1b fc3 sc0 ls2fc ws4d2">drug will increase </div><div class="t m11 x25 h4b ye40 ff23 fs1b fc3 sc0 ls0 ws0">gametocytogenesis and  </div><div class="t m11 xba h4b ye40 ff23 fs1b fc3 sc0 ls2fc ws4d2">gametocytes will contain and </div><div class="t m11 x5 h4b ye40 ff23 fs1b fc3 sc0 ls2fa ws4d0">transmit drug-resistant genes.</div><div class="t m11 x61 h4b ye3f ff23 fs1b fc3 sc0 ls0 ws0">• Sulfadoxine-pyrimethamine  </div><div class="t m11 x17 h4b ye40 ff23 fs1b fc3 sc0 ls0 ws0">enhances gametocytogenesis.</div><div class="t m11 x63 h4b ye3f ff23 fs1b fc3 sc0 ls2fe ws4d4">• Artemisinin derivatives and, to </div><div class="t m11 x3f h4b ye40 ff23 fs1b fc3 sc0 ls2fe ws4d4">a far lesser extent,<span class="_ _b"></span> chloroquine </div><div class="t m11 x86 h4b ye40 ff23 fs1b fc3 sc0 ls0 ws0">will act against young </div><div class="t m11 x75 h4b ye40 ff23 fs1b fc3 sc0 ls2fe ws4d4">gametocytes,<span class="_ _b"></span> and thereby </div><div class="t m11 x29 h4b ye40 ff23 fs1b fc3 sc0 ls2fc ws4d2">reduce the number of mature </div><div class="t m11 xbd h4b ye40 ff23 fs1b fc3 sc0 ls2fc ws4d2">infective gametocytes.</div><div class="t m11 xc7 h4b ye3f ff23 fs1b fc3 sc0 ls0 ws0">• Primaquine is the only drug </div><div class="t m11 x84 h4b ye40 ff23 fs1b fc3 sc0 ls2ff ws4d5">known to act on mature </div><div class="t m11 x91 h4b ye40 ff23 fs1b fc3 sc0 ls2ff ws4d5">gametocytes (which are </div><div class="t m11 x36 h4b ye40 ff23 fs1b fc3 sc0 ls2fa ws4d0">present in the circulation at  </div><div class="t m11 x1d h4b ye40 ff23 fs1b fc3 sc0 ls2fa ws4d0">the time  the patient presents </div><div class="t m11 x43 h4b ye40 ff23 fs1b fc3 sc0 ls2ff ws4d5">for treatment).</div><div class="t m11 x85 h4b ye3f ff23 fs1b fc3 sc0 ls2fa ws4d0">• <span class="_ _a"></span>The parasite undergoes </div><div class="t m11 x56 h4b ye40 ff23 fs1b fc3 sc0 ls2fc ws4d2">fertilisation and fur<span class="_ _8"></span>ther </div><div class="t m11 x33 h4b ye40 ff23 fs1b fc3 sc0 ls0 ws0">development in the midgut,<span class="_ _b"></span> </div><div class="t m11 x67 h4b ye40 ff23 fs1b fc3 sc0 ls0 ws0">and  the salivary glands of  </div><div class="t m11 x59 h4b ye40 ff23 fs1b fc3 sc0 ls2ff ws4d5">the mosquito.</div><div class="t m1 xb8 h45 ye41 ff20 fs16 fc3 sc0 ls300 ws4d6">Some will re-enter erythrocytes </div><div class="t m1 x72 h45 ye41 ff20 fs16 fc3 sc0 ls301 ws4d7">and develop into gametocytes</div><div class="t m1 xc8 h45 ye42 ff20 fs16 fc3 sc0 ls302 ws0">8–10 days</div><div class="t me x84 h45 ye43 ff25 fs16 fc3 sc0 ls0 ws0">MATURE GAMETOCYTE IN </div><div class="t me xc9 h45 ye43 ff25 fs16 fc3 sc0 ls0 ws0">PERIPHERAL CIRCULATION, </div><div class="t me x8a h45 ye43 ff25 fs16 fc3 sc0 ls0 ws0">INFECTIVE TO MOSQUITOES </div><div class="t me x87 h45 ye43 ff25 fs16 fc3 sc0 ls0 ws0">FOR 10-14 DAYS</div></div><div class="c x4 y6 w1 h6"><div class="t m0 x26 h15 ye44 ff17 fsa fc3 sc0 ls303 ws4d8">*<span class="_ _4"> </span>When parasites are sensitive to the drug unless otherwise stated. Positiv<span class="_ _a"></span>e and negative arrows indicate the effect</div><div class="t m0 x8d h15 ye45 ff17 fsa fc3 sc0 ls7d ws0">of the drug, enhancement (+) and suppression (-) respectively<span class="_ _4b"></span>, on the parasite stage or its development.</div><div class="t m0 x26 h3f ye46 ff22 fs5 fc4 sc0 ls14c ws117">Figure A4.2 <span class="_ _54"> </span><span class="ff1b fs9 fc3 ls16 ws0">T<span class="_ _a"></span>ransmission of <span class="ff1f">Plasmodium falciparum </span>and the effects of antimalarials</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf93" class="pf w1 h4" data-page-no="93"><div class="pc pc93 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4a he y9 ff16 fs5 fc3 sc0 ls51 ws4c0">Annex 4 - Antimalarials and malaria transmission</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">137</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 lsf9 ws15c">been successfully treated for the asexual blood infection. In order to terminate</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls25 ws3c">infectivity of <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _7c"> </span>falciparum<span class="ff17 ws3c">, the infection needs to be treated with drugs that</span></span></div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls15a ws312">have specific activity against gametocytes, i.e. either A<span class="_ _a"></span>CT<span class="_ _4b"></span>s that destroy immature</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls160 ws79">gametocytes, or by the addition of primaquine to the treatment regime to</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls304 ws205">eradicate mature gametocytes. It is not kno<span class="_ _a"></span>wn whether the use of primaquine with</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls1fc ws439">ACT<span class="_ _c"></span>s would result in a fur<span class="_ _8"></span>ther suppression of infectivity<span class="_ _c"></span>, although it appears</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls305 ws348">possible in principle, given that the two drugs act on different dev<span class="_ _a"></span>elopmental stages</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 lsf9 ws0">of gametocytes.</div><div class="t m0 xb h2e y734 ff19 fs3 fc3 sc0 ls80 ws0">A4.3.2<span class="_ _a7"> </span>T<span class="_ _8"></span>he effect on transmission of using tr<span class="_ _8"></span>ansmission-</div><div class="t m0 x9d h2e ye47 ff19 fs3 fc3 sc0 ls80 ws0">blocking medicines</div><div class="t m0 xb h23 ye48 ff1e fs11 fc8 sc0 ls27a ws0">Situations of low to moderate tr<span class="_ _a"></span>ansmission</div><div class="t m0 xb hb ye49 ff17 fs8 fc3 sc0 ls62 ws89">The most direct consequences of low<span class="_ _a"></span>ering the infectivity of patients by the use</div><div class="t m0 xb hb y113 ff17 fs8 fc3 sc0 ls1fe ws220">of drugs are to be seen in areas of lo<span class="_ _a"></span>w transmission, where symptomatic</div><div class="t m0 xb hb ye4a ff17 fs8 fc3 sc0 ls191 ws278">patients constitute the majority of the infectious reservoir<span class="_ _b"></span>. Here, a strategy to</div><div class="t m0 xb hb ye4b ff17 fs8 fc3 sc0 ls12 wsd7">shorten the period of infectivity of patients, if it could be achieved on a wide</div><div class="t m0 xb hb ye4c ff17 fs8 fc3 sc0 ls1b9 ws4ba">scale, would have a significant impact on the parasite r<span class="_ _a"></span>eser<span class="_ _8"></span>voir of infection and,</div><div class="t m0 xb hb ye4d ff17 fs8 fc3 sc0 lsd0 ws149">therefore, on malaria tr<span class="_ _a"></span>ansmission. A reduction in transmission would, in</div><div class="t m0 xb hb ye4e ff17 fs8 fc3 sc0 ls5d ws7e">these situations, result in an almost proportionate reduction in the prev<span class="_ _a"></span>alence</div><div class="t m0 xb hb ye4f ff17 fs8 fc3 sc0 ls12 ws0">of infection and incidence of disease. </div><div class="t m0 xb hb ye50 ff17 fs8 fc3 sc0 ls2bf ws1f9">In areas of low to moder<span class="_ _a"></span>ate transmission, therefore, the pr<span class="_ _a"></span>ovision of prompt and</div><div class="t m0 xb hb ye51 ff17 fs8 fc3 sc0 ls237 ws68">effective treatment to malaria patients is important both as a means of achieving</div><div class="t m0 xb hb ye52 ff17 fs8 fc3 sc0 ls22 ws4d9">the public health goal of reducing transmission, and attaining the ther<span class="_ _a"></span>apeutic</div><div class="t m0 xb hb ye53 ff17 fs8 fc3 sc0 ls201 ws11e">goal of reducing morbidity<span class="_ _c"></span>. Also impor<span class="_ _8"></span>tant in these situations is the use of</div><div class="t m0 xb hb ye54 ff17 fs8 fc3 sc0 lsfa ws19f">specific gametocytocidal drugs. Ther<span class="_ _a"></span>e are anecdotal accounts from areas of lo<span class="_ _a"></span>w</div><div class="t m0 xb hb ye55 ff17 fs8 fc3 sc0 ls306 ws214">transmission with inadequate health services that offer little access to treatment,</div><div class="t m0 xb hb ye56 ff17 fs8 fc3 sc0 ls22 ws4da">of patients presenting with extremely high par<span class="_ _a"></span>asite prevalence r<span class="_ _a"></span>ates (<span class="ff1c ls0 ws0">&gt;<span class="ff17 ls1fa">70%),</span></span></div><div class="t m0 xb hb ye57 ff17 fs8 fc3 sc0 ls22 ws4db">approaching those found in areas of intense tr<span class="_ _a"></span>ansmission (Figure A4.1). When</div><div class="t m0 xb hb ye58 ff17 fs8 fc3 sc0 ls141 ws43">treatment centres w<span class="_ _a"></span>ere established in such areas and early and effective malaria</div><div class="t m0 xb hb ye59 ff17 fs8 fc3 sc0 lsfc ws1a8">treatment was pro<span class="_ _a"></span>vided to patients, parasite prev<span class="_ _a"></span>alence and disease incidence</div><div class="t m0 xb hb ye5a ff17 fs8 fc3 sc0 ls28c ws91">rates decreased dr<span class="_ _a"></span>amatically<span class="_ _4b"></span>. One well-documented example is from the north-</div><div class="t m0 xb hb ye5b ff17 fs8 fc3 sc0 ls65 ws40d">western border of <span class="_ _a"></span>Thailand where high incidence rates of <span class="ff1a ws0">P<span class="_ _ae"></span>. falciparum <span class="_ _a"></span><span class="ff17">prevailed</span></span></div><div class="t m0 xb hb ye5c ff17 fs8 fc3 sc0 ls48 wsf0">in the face of increasing resistance to mefloquine, the antimalarial in use at the</div><div class="t m0 xb hb ye5d ff17 fs8 fc3 sc0 ls22 ws2a5">time. Ther<span class="_ _a"></span>e, the deployment of artesunate in combination with mefloquine led</div><div class="t m0 xb hb ye5e ff17 fs8 fc3 sc0 ls22 ws0">to a significant decline in the incidence of the disease <span class="ff1a ls1fa">(12)</span><span class="ls0">.</span></div><div class="t m0 xb h23 ye5f ff1e fs11 fc8 sc0 ls27a ws0">Situations of intense transmission</div><div class="t m0 xb hb ye60 ff17 fs8 fc3 sc0 ls145 ws41">In high-transmission settings, infected but asymptomatic persons constitute an</div><div class="t m0 xb hb ye61 ff17 fs8 fc3 sc0 ls22 ws4dc">important par<span class="_ _8"></span>t of the infectious reser<span class="_ _8"></span>voir<span class="_ _4b"></span>. Even though treated cases (mainly</div><div class="t m0 xb hb ye62 ff17 fs8 fc3 sc0 lsdb ws180">children) have higher densities of gametocytes, and effectiv<span class="_ _a"></span>eness of transmission</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf94" class="pf w1 h4" data-page-no="94"><div class="pc pc94 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1b ws0">138</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls189 wsea">is positively related to gametocyte density<span class="_ _c"></span>, a treatment strategy to reduce</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls307 ws94">infectivity of patients whose contribution to the reservoir of infection is only partial</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls9f ws233">is not likely to have a major impact on transmission. <span class="_ _b"></span>This, together with the fact</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls2b4 ws258">that a much greater reduction in tr<span class="_ _a"></span>ansmission rates needs to be achieved in order</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls22 ws49">to reduce parasite pr<span class="_ _a"></span>evalence (and incidence of disease), makes the case for</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 lsef ws481">introducing an infectivity-suppressing component to the drug tr<span class="_ _a"></span>eatment of</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls22 ws4dd">patients less compelling as a strategy for reducing the incidence of disease.</div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 lsae ws18a">Howev<span class="_ _a"></span>er<span class="_ _b"></span>, the potentially important role of medication in reducing transmission</div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 ls22 ws381">must not be ov<span class="_ _a"></span>erlooked even in these situations. As intensified malaria control</div><div class="t m0 x9 hb y110 ff17 fs8 fc3 sc0 ls184 ws15b">efforts deploying highly effective interventions, such as use of insecticide-</div><div class="t m0 x9 hb y111 ff17 fs8 fc3 sc0 ls79 ws1b3">treated mosquito nets and indoor residual spr<span class="_ _a"></span>aying with insecticides, get under</div><div class="t m0 x9 hb y2be ff17 fs8 fc3 sc0 ls117 ws242">way<span class="_ _4b"></span>, malaria inoculation rates could fall considerably <span class="ff1a ls15a ws0">(13)</span><span class="ls68 ws4de">. T<span class="_ _b"></span>ransmission-reducing</span></div><div class="t m0 x9 hb y2bf ff17 fs8 fc3 sc0 ls22 ws4df">drug regimes will then have a gr<span class="_ _a"></span>eater role to play<span class="_ _4b"></span>, and will complement other</div><div class="t m0 x9 hb y484 ff17 fs8 fc3 sc0 ls22 ws0">methods to achieve an impact on mortality and the incidence of malaria. </div><div class="t m0 x9 hd y2c1 ff1e fs8 fc3 sc0 ls12 ws0">The use of antimalarial drugs to reduce infectivity:</div><div class="t m0 x9 hb ye63 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="ff1e fc3 ls12">is essential in low-transmission settings,</span></div><div class="t m0 x9 hb ye64 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="ff1e fc3 ls190 wsd2">will be beneficial in high-transmission settings if used in conjunction with</span></div><div class="t m0 x16 hd ye65 ff1e fs8 fc3 sc0 ls12 ws0">other effective transmission-blocking interventions. </div><div class="t m0 x9 h12 ye66 ff19 fs6 fc4 sc0 ls86 wsca">A4.4<span class="_ _33"> </span>D<span class="_ _9"></span>ynamics of dr<span class="_ _8"></span>ug pressure and transmission </div><div class="t m0 x28 h12 ye67 ff19 fs6 fc4 sc0 ls9a ws0">of dr<span class="_ _8"></span>ug-resistant genes</div><div class="t m0 x9 h2e ye68 ff19 fs3 fc3 sc0 ls308 ws4e0">A4.4.1<span class="_ _a7"> </span>T<span class="_ _8"></span>he continued use of a failing drug wil<span class="_ _8"></span>l confer a</div><div class="t m0 xba h2e ye69 ff19 fs3 fc3 sc0 ls0 wsc1">selective transmission advantage to resistant parasites </div><div class="t m0 x9 hb ye6a ff17 fs8 fc3 sc0 ls64 ws55">It has been shown that when resistance to a drug is pr<span class="_ _a"></span>evalent in a locality<span class="_ _c"></span>, the</div><div class="t m0 x9 hb ye6b ff17 fs8 fc3 sc0 ls309 ws4e1">continued use of that drug will confer a selective adv<span class="_ _a"></span>antage to parasites</div><div class="t m0 x9 hb ye6c ff17 fs8 fc3 sc0 ls9c ws137">carrying resistance genes, and will lead to higher rates of transmission of</div><div class="t m0 x9 hb ye6d ff17 fs8 fc3 sc0 ls17e wsa8">drug-resistant parasites. <span class="_ _b"></span>This will result in the rapid spread of the drug</div><div class="t m0 x9 hb ye6e ff17 fs8 fc3 sc0 ls64 ws3b4">resistance through two mechanisms. First the use of the drug leads to higher</div><div class="t m0 x9 hb ye6f ff17 fs8 fc3 sc0 ls12 ws2fd">numbers of circulating gametocytes in the resistant infections than in the</div><div class="t m0 x9 hb ye70 ff17 fs8 fc3 sc0 ls10e ws4e2">sensitive ones <span class="ff1a ls7f ws356">(5, 6, 9, 10, 14, 15)</span><span class="ls64">. <span class="_ _a"></span>The failing drug may reduce asexual para-</span></div><div class="t m0 x9 hb ye71 ff17 fs8 fc3 sc0 ls22 wsa4">sitaemias initially to an extent that they may be undetectable even by PCR, but</div><div class="t m0 x9 hb ye72 ff17 fs8 fc3 sc0 ls64 ws4db">it induces the production of detectable numbers of gametocytes carrying the</div><div class="t m0 x9 hb ye73 ff17 fs8 fc3 sc0 ls1ae ws18c">resistant genes. R<span class="_ _a"></span>esistance is associated with recrudescence. The subsequent</div><div class="t m0 x9 hb ye74 ff17 fs8 fc3 sc0 ls76 wsab">recrudescence is associated with higher rates of gametocyte carriage than the</div><div class="t m0 x9 hb ye75 ff17 fs8 fc3 sc0 ls66 ws90">primary infection. The recrudescence with r<span class="_ _a"></span>esistance parasites is also more likely</div><div class="t m0 x9 hb ye76 ff17 fs8 fc3 sc0 ls21a ws3b7">to fail treatment and recrudesce again than the primary infection. <span class="_ _a"></span>Thus</div><div class="t m0 x9 hb ye77 ff17 fs8 fc3 sc0 lse5 ws2f9">cumulatively the resistant infection gener<span class="_ _a"></span>ates more gametocytes than an</div><div class="t m0 x9 hb ye78 ff17 fs8 fc3 sc0 lsff ws2ed">infection with sensitive parasites. Secondly<span class="_ _c"></span>, gametocytes carrying resistant genes</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf95" class="pf w1 h4" data-page-no="95"><div class="pc pc95 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4a he y9 ff16 fs5 fc3 sc0 ls51 ws4c0">Annex 4 - Antimalarials and malaria transmission</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">139</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls64 ws377">have been shown to be mor<span class="_ _a"></span>e infectious to mosquitoes. They pr<span class="_ _a"></span>oduce higher</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls2ef ws48e">densities of parasites (oocysts) in the mosquitoes, and infect a higher proportion</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls126 wsec">of mosquitoes than those carrying sensitive genes <span class="ff1a">(6, 7, 11)</span>. Molecular studies</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls2f0 ws120">on the transmission of two <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>falciparum<span class="_ _6"> </span><span class="ff17 ws120">genes linked to chloroquine resistance,</span></span></div><div class="t m0 xb hb yc0 ff1a fs8 fc3 sc0 ls46 ws0">pfcrt <span class="ff17">and <span class="_ _a"></span><span class="ff1a">pfmdr<span class="ff17 wsc9">, showed that gametocytes carrying the former produced mor<span class="_ _a"></span>e</span></span></span></div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls204 ws1e1">oocysts and were also mor<span class="_ _a"></span>e infectious to mosquitoes than gametocytes of the</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls64 ws0">sensitive genotype <span class="ff1a">(15)</span><span class="ls0">.</span></div><div class="t m0 xb h2e y153 ff19 fs3 fc3 sc0 ls308 ws4e0">A4.4.2<span class="_ _a7"> </span>Re<span class="_ _8"></span>versal of transmission advantage by artemisinins</div><div class="t m0 xb hb y154 ff17 fs8 fc3 sc0 lsaa ws110">The use of drugs in combination, specifically with artemisinin derivatives, will</div><div class="t m0 xb hb y155 ff17 fs8 fc3 sc0 ls6b ws58">remo<span class="_ _a"></span>ve the survival advantage conferr<span class="_ _a"></span>ed on parasites resistant to a particular</div><div class="t m0 xb hb y156 ff17 fs8 fc3 sc0 ls13 ws272">drug by the use of that drug as monotherapy <span class="ff1a ls8e ws2f8">(10, 15, 16)</span><span class="ls12 ws73">. <span class="_ _a"></span>This is because</span></div><div class="t m0 xb hb y112 ff17 fs8 fc3 sc0 ls6a ws96">artemisinins are very effective in clearing blood parasites and also in reducing</div><div class="t m0 xb hb y157 ff17 fs8 fc3 sc0 ls16b ws242">gametocyte prev<span class="_ _a"></span>alence and density <span class="ff1a ls2e7 ws0">(10)</span>, and therefore infectivity<span class="_ _c"></span>. But high cure</div><div class="t m0 xb hb y43c ff17 fs8 fc3 sc0 ls12 ws4e3">rates are needed to pr<span class="_ _a"></span>event recrudescence with its greater carriage, and so</div><div class="t m0 xb hb y43d ff17 fs8 fc3 sc0 lsf7 ws1ad">it is inadvisable to combine an artemisinin derivative with a failing partner drug.</div><div class="t m0 xb hb y735 ff17 fs8 fc3 sc0 ls62 ws89">Artemisinins have a shor<span class="_ _8"></span>t <span class="ff1a">in vivo </span>half-life so that their gametocytocidal activity</div><div class="t m0 xb hb y736 ff17 fs8 fc3 sc0 ls1f1 wsa0">will soon cease, leaving the parasites exposed to the failing partner drug, which</div><div class="t m0 xb hb y737 ff17 fs8 fc3 sc0 ls12 ws4e4">has a longer <span class="ff1a ls13">in vivo </span>half-life. <span class="_ _a"></span>There is a high failure rate and tr<span class="_ _a"></span>ansmission of</div><div class="t m0 xb hb y738 ff17 fs8 fc3 sc0 ls3c ws31">resistance parasites is not pr<span class="_ _a"></span>evented <span class="ff1a ls92 wse7">(9, 10, 15). </span><span class="ls172 ws18a">The clear adv<span class="_ _b"></span>antage of using</span></div><div class="t m0 xb hb y739 ff17 fs8 fc3 sc0 ls24b ws3c7">artemisinins in combination with an effective par<span class="_ _8"></span>tners drug is that it will</div><div class="t m0 xb hb y2c7 ff17 fs8 fc3 sc0 ls12 ws0">delay the selection and spread of drug-resistant genes <span class="ff1a ls160 ws4e5">(10–12, 15, 16)</span><span class="ls13">. </span></div><div class="t m0 xb hd ye79 ff1e fs8 fc3 sc0 ls12 ws0">The implications are as follows.</div><div class="t m0 xb hb ye7a ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="ff1e fc3 ls12 ws3aa">Once drug resistance has emerged in a locality<span class="_ _c"></span>, the continued use of the</span></div><div class="t m0 x26 hd ye7b ff1e fs8 fc3 sc0 ls12 ws0">failing drug will result in:</div><div class="t m0 x26 hd ye7c ff1e fs8 fc3 sc0 ls12 ws8f">–<span class="_ _7a"> </span>the rapid spread of drug resistance in the area because the use of the</div><div class="t m0 xc hd ye7d ff1e fs8 fc3 sc0 ls12 ws0">drug confers a transmission adv<span class="_ _a"></span>antage to resistant parasites;</div><div class="t m0 x26 hd ye7e ff1e fs8 fc3 sc0 ls31 ws41">–<span class="_ _b1"> </span>the prev<span class="_ _b"></span>alence of infections in which only gametocytes may be present</div><div class="t m0 xc hd ye7f ff1e fs8 fc3 sc0 ls12 wse2">in the peripheral circulation; the continued use of the drug can lead to</div><div class="t m0 xc hd ye80 ff1e fs8 fc3 sc0 ls12 ws12e">low-grade asexual par<span class="_ _a"></span>asitaemias with a high rate of differentiation to</div><div class="t m0 xc hd ye81 ff1e fs8 fc3 sc0 ls30a ws148">gametocytes; such infections must be considered as active drug-</div><div class="t m0 xc hd ye82 ff1e fs8 fc3 sc0 lsbd ws2d9">resistant infections and be treated with an effectiv<span class="_ _a"></span>e second-line medicine. </div><div class="t m0 xb hd ye83 ff1e fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls172 ws18a">Early treatment of malaria patients with an effective antimalarial has the</span></div><div class="t m0 x26 hd ye84 ff1e fs8 fc3 sc0 ls12 ws0">greatest chance of limiting the spread of drug-r<span class="_ _a"></span>esistant parasites. </div><div class="t m0 xb hd ye85 ff1e fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls111 ws4a1">The use of an artemisinin derivative with an effective partner drug will delay</span></div><div class="t m0 x26 hd ye86 ff1e fs8 fc3 sc0 ls12 ws0">the selection and spread of drug resistance. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf96" class="pf w1 h4" data-page-no="96"><div class="pc pc96 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">140</div><div class="t m0 x9 h12 y12a ff19 fs6 fc4 sc0 ls1 ws17a">A4.5<span class="_ _52"> </span>The role of transmission-blocking inter<span class="_ _9"></span>ventions</div><div class="t m0 x28 h12 y12b ff19 fs6 fc4 sc0 ls9a ws0">and antimalarials in cur<span class="_ _8"></span>tailing the spread of dr<span class="_ _8"></span>ug</div><div class="t m0 x28 h12 ye87 ff19 fs6 fc4 sc0 ls9a ws0">resistance </div><div class="t m0 x9 h2e ye88 ff19 fs3 fc3 sc0 ls80 ws0">A4.5.1<span class="_ _a7"> </span>T<span class="_ _4b"></span>ransmission control</div><div class="t m0 x9 hb ye89 ff17 fs8 fc3 sc0 ls163 ws36e">A reduction in transmission will curtail the spread of parasites of both sensitiv<span class="_ _a"></span>e</div><div class="t m0 x9 hb ye8a ff17 fs8 fc3 sc0 ls30b ws46f">and resistant strains<span class="ff1a ls0 ws0">.<span class="_ _3"> </span></span>Howev<span class="_ _a"></span>er<span class="_ _b"></span>, there is evidence to suggest that, in the</div><div class="t m0 x9 hb ye8b ff17 fs8 fc3 sc0 ls12 ws33">absence of drug pressure, r<span class="_ _a"></span>esistant parasites are at a survival disadv<span class="_ _a"></span>antage</div><div class="t m0 x9 hb ye8c ff17 fs8 fc3 sc0 ls13 ws23d">compared to sensitive str<span class="_ _a"></span>ains, i.e. in the absence of selection by the drug to</div><div class="t m0 x9 hb ye8d ff17 fs8 fc3 sc0 ls1a9 ws262">which they are resistant, drug-r<span class="_ _a"></span>esistant parasites tend to be intrinsically less</div><div class="t m0 x9 hb ye8e ff17 fs8 fc3 sc0 ls12 ws12d">able to be transmitted than are drug-sensitiv<span class="_ _a"></span>e parasites <span class="ff1a ls53 ws14a">(17, 18)</span><span class="ws4e6">. These more</span></div><div class="t m0 x9 hb ye8f ff17 fs8 fc3 sc0 ls75 wsb0">stringent transmission conditions will, therefor<span class="_ _a"></span>e, tend to selectively eliminate</div><div class="t m0 x9 hb ye90 ff17 fs8 fc3 sc0 ls12 ws24">drug-resistant parasites <span class="ff1a ws0">(19)</span><span class="ls14 ws3ac">. <span class="_ _b"></span>This expectation is suppor<span class="_ _8"></span>ted by obser<span class="_ _8"></span>vations</span></div><div class="t m0 x9 hb ye91 ff17 fs8 fc3 sc0 ls291 ws42d">in Zimbabwe, where house spr<span class="_ _a"></span>aying with insecticides to reduce malaria</div><div class="t m0 x9 hb ye92 ff17 fs8 fc3 sc0 ls45 wsbb">transmission was associated with reductions in the amount of drug r<span class="_ _a"></span>esistance</div><div class="t m0 x9 hb ye93 ff17 fs8 fc3 sc0 ls12 ws44e">in the malaria parasites <span class="ff1a ls13 ws0">(20)</span>. Likewise, in low-tr<span class="_ _a"></span>ansmission settings in India</div><div class="t m0 x9 hb ye94 ff17 fs8 fc3 sc0 ls12 ws478">and Sri Lanka, the replacement of the failing chloroquine with an effectiv<span class="_ _a"></span>e</div><div class="t m0 x9 hb ye95 ff17 fs8 fc3 sc0 ls201 ws347">antimalarial, in combination with intense entomological transmission control,</div><div class="t m0 x9 hb ye96 ff17 fs8 fc3 sc0 ls129 ws1e0">led to significant reductions, and in some instances even elimination, of</div><div class="t m0 x9 hb ye97 ff17 fs8 fc3 sc0 ls53 ws0">chloroquine-resistant <span class="_ _b"></span><span class="ff1a">P<span class="_ _c"></span>. falciparum<span class="ff17 ws160">. In w<span class="_ _a"></span>estern Thailand where, in the 1990s,</span></span></div><div class="t m0 x9 hb ye98 ff17 fs8 fc3 sc0 ls76 wsb3">increasing levels of mefloquine r<span class="_ _a"></span>esistance were associated with rising malaria</div><div class="t m0 x9 hb ye99 ff17 fs8 fc3 sc0 ls30 ws3e">incidence, the deployment of combination therapy for malaria tr<span class="_ _a"></span>eatment with</div><div class="t m0 x9 hb ye9a ff17 fs8 fc3 sc0 lsfc ws37e">mefloquine and artesunate was associated with an increased <span class="ff1a">in vitro </span><span class="ws0">suscepti-</span></div><div class="t m0 x9 hb ye9b ff17 fs8 fc3 sc0 ls12 ws0">bility of <span class="ff1a ls13">P<span class="_ _c"></span>. falciparum <span class="ff17 ls12">to mefloquine </span><span class="ls53">(12)<span class="ff17 ls0">.</span></span></span></div><div class="t m0 x9 h2e ye9c ff19 fs3 fc3 sc0 ls80 ws0">A4.5.2<span class="_ _a7"> </span>Antimalar<span class="_ _8"></span>ials</div><div class="t m0 x9 hb ye9d ff17 fs8 fc3 sc0 ls281 ws222">In contrast to transmission contr<span class="_ _a"></span>ol methods, such as residual insecticide</div><div class="t m0 x9 hb ye9e ff17 fs8 fc3 sc0 lsb9 ws128">spraying and the use of insecticide-treated nets – which ar<span class="_ _a"></span>e constantly in effect</div><div class="t m0 x9 hb ye9f ff17 fs8 fc3 sc0 ls102 wsb2">against the entire parasite population thr<span class="_ _a"></span>ough the killing of the vector mosquito</div><div class="t m0 x9 hb yea0 ff17 fs8 fc3 sc0 ls12 ws4e7">and the prevention of biting – tr<span class="_ _a"></span>eatment with antimalarials affects only the</div><div class="t m0 x9 hb yea1 ff17 fs8 fc3 sc0 ls92 wse7">parasites in an infected person at the time of treatment. In high-tr<span class="_ _a"></span>ansmission</div><div class="t m0 x9 hb yea2 ff17 fs8 fc3 sc0 ls15c ws26e">situations, this is a relatively r<span class="_ _a"></span>are event because the pr<span class="_ _a"></span>opor<span class="_ _8"></span>tion of persons who</div><div class="t m0 x9 hb yea3 ff17 fs8 fc3 sc0 ls76 wsb3">are ill among those who are infected is quite small, and applies only to a small</div><div class="t m0 x9 hb yea4 ff17 fs8 fc3 sc0 ls12 ws3a2">fraction of the parasite population. <span class="_ _b"></span>Therefore, the impact of drug treatment</div><div class="t m0 x9 hb yea5 ff17 fs8 fc3 sc0 ls12 ws428">as a means of curtailing the spread of resistant parasites may be small in</div><div class="t m0 x9 hb yea6 ff17 fs8 fc3 sc0 ls12 ws0">comparison to that of vector control methods. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf97" class="pf w1 h4" data-page-no="97"><div class="pc pc97 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4a he y9 ff16 fs5 fc3 sc0 ls51 ws4c0">Annex 4 - Antimalarials and malaria transmission</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">141</div><div class="t m0 xb hd y9e ff1e fs8 fc3 sc0 ls12 ws0">The implications are as follows:</div><div class="t m0 xb hb yea7 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="ff1e fc3 ls15a ws223">The implementation of transmission control thr<span class="_ _a"></span>ough vector control methods</span></div><div class="t m0 x26 hd y8d2 ff1e fs8 fc3 sc0 ls12 ws0">will help reduce the spread of drug r<span class="_ _a"></span>esistance. </div><div class="t m0 xb hb yea8 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="ff1e fc3 ls129 ws1e0">The use of infectivity-suppressing medicines will be synergistic with</span></div><div class="t m0 x26 hd y8d3 ff1e fs8 fc3 sc0 ls12 ws0">mosquito control methods.</div><div class="t m0 xb h12 yea9 ff19 fs6 fc4 sc0 ls9a ws0">A4.6<span class="_ _33"> </span>Conc<span class="_ _9"></span>lusion</div><div class="t m0 xb hb yeaa ff17 fs8 fc3 sc0 ls232 ws90">In situations of low malaria transmission, antimalarials hav<span class="_ _a"></span>e been and are being</div><div class="t m0 xb hb yeab ff17 fs8 fc3 sc0 ls247 ws21">used for the specific purpose of reducing infectivity to mosquitoes – a notable</div><div class="t m0 xb hb yeac ff17 fs8 fc3 sc0 ls62 ws89">example being the use of primaquine in the treatment of <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>falciparum <span class="ff17">malaria.</span></span></div><div class="t m0 xb hb yead ff17 fs8 fc3 sc0 ls53 ws160">In areas of intense transmission, ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, suppression of parasite infectivity</div><div class="t m0 xb hb yeae ff17 fs8 fc3 sc0 ls2ab ws30e">has previously not been regar<span class="_ _a"></span>ded as a significant goal of treatment. Now<span class="_ _b"></span>, the</div><div class="t m0 xb hb yeaf ff17 fs8 fc3 sc0 lsaa ws110">situation has changed. Artemisinin derivatives (which are gametocytocidal as</div><div class="t m0 xb hb yeb0 ff17 fs8 fc3 sc0 ls12 ws31e">well as destro<span class="_ _a"></span>ying asexual stages of the parasite) are being widely deploy<span class="_ _a"></span>ed</div><div class="t m0 xb hb yeb1 ff17 fs8 fc3 sc0 ls165 ws238">for the treatment of malarial disease, including in areas of intense tr<span class="_ _a"></span>ansmission.</div><div class="t m0 xb hb yeb2 ff17 fs8 fc3 sc0 ls12 ws11f">This will allow the impact of anti-infective drugs on the r<span class="_ _a"></span>eser<span class="_ _8"></span>voir of infection</div><div class="t m0 xb hb yeb3 ff17 fs8 fc3 sc0 ls33 ws5f">and transmission rates to be ev<span class="_ _b"></span>aluated across the entire range of transmission</div><div class="t m0 xb hb yeb4 ff17 fs8 fc3 sc0 ls12 ws0">intensities. </div><div class="t m0 xb hb yeb5 ff17 fs8 fc3 sc0 ls12 wsff">Reducing tr<span class="_ _a"></span>ansmission is fundamental to the cur<span class="_ _8"></span>tailment of drug resistance,</div><div class="t m0 xb hb yeb6 ff17 fs8 fc3 sc0 ls12 ws470">and antimalarials can help achieve this, at least in some situations. <span class="_ _a"></span>This has</div><div class="t m0 xb hb yeb7 ff17 fs8 fc3 sc0 ls25a ws3c1">implications for malaria treatment policy and also for drug development. <span class="_ _b"></span>The</div><div class="t m0 xb hb yeb8 ff17 fs8 fc3 sc0 ls2c ws39">ability to suppress parasite infectivity should be included in the pr<span class="_ _a"></span>oduct</div><div class="t m0 xb hb yeb9 ff17 fs8 fc3 sc0 ls1e1 ws312">profile of compounds that are being ev<span class="_ _b"></span>aluated as potential new antimalarials.</div><div class="t m0 xb h12 yeba ff19 fs6 fc4 sc0 ls1 ws0">A4.7<span class="_ _52"> </span>References</div><div class="t mc xb h17 yebb ff17 fsb fc3 sc0 ls105 ws0">1.<span class="_ _46"> </span>Hay S<span class="_ _8"></span>I et al. Annual <span class="ff1a">Plasmodium falciparum </span>entomological inoculation rates</div><div class="t mc x4d h17 yebc ff17 fsb fc3 sc0 ls105 ws0">(EI<span class="_ _8"></span>R) across Africa: literature survey<span class="_ _4b"></span>, Internet access and review<span class="_ _b"></span>. <span class="ff1a">T<span class="_ _b"></span>ransactions of</span></div><div class="t mc x4d h17 yebd ff1a fsb fc3 sc0 ls105 ws0">the Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 lsd6 ws218">, 2000, 94:113–127.</span></div><div class="t mc xb h17 yebe ff17 fsb fc3 sc0 ls105 ws0">2.<span class="_ _44"> </span>Lengeler C, Smith <span class="_ _a"></span>T<span class="_ _b"></span>A, Armstrong-Schellenberg J. Focus on the effect of bed nets</div><div class="t mc x4d h17 yebf ff17 fsb fc3 sc0 ls105 ws0">on malaria morbidity and mortality<span class="_ _b"></span>. <span class="ff1a ws4e8">Parasitology T<span class="_ _c"></span>oday<span class="ff17 ls2e2 ws1d3">, 1997, 13:123–124.</span></span></div><div class="t mc xb h17 yec0 ff17 fsb fc3 sc0 ls105 ws0">3.<span class="_ _44"> </span>Molineaux L. Malaria and mor<span class="_ _8"></span>tality: some epidemiological considerations.</div><div class="t mc x4d h17 yec1 ff1a fsb fc3 sc0 ls105 ws0">Annals of T<span class="_ _4b"></span>ropical Medicine and Parasitology<span class="ff17 lsd6 ws218">, 1997, 91:811–825.</span></div><div class="t mc xb h17 yec2 ff17 fsb fc3 sc0 ls105 ws0">4.<span class="_ _44"> </span>Bruce-Chwatt L. <span class="ff1a">Chemotherapy of malaria</span>, 2nd ed. Geneva, <span class="_ _a"></span>World Health</div><div class="t mc x4d h17 yec3 ff17 fsb fc3 sc0 ls105 ws0">Organization, 1981:261. </div><div class="t mc xb h17 yec4 ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>Hogh B et al. <span class="_ _a"></span>The differing impact of chloroquine and pyrimethamine/sulfadoxine</div><div class="t mc x4d h17 yec5 ff17 fsb fc3 sc0 ls105 ws0">upon the infectivity of malaria species to the mosquito vector<span class="_ _4b"></span>. <span class="ff1a">American Journal</span></div><div class="t mc x4d h17 yec6 ff1a fsb fc3 sc0 ls105 ws0">of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17 ls104 ws35b">, 1998, 58:176–182.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf98" class="pf w1 h4" data-page-no="98"><div class="pc pc98 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">142</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>Robert V et al. Gametocytemia and infectivity to mosquitoes of patients with</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated, <span class="ff1a">Plasmodium falciparum </span>malaria attacks treated with chloroquine</div><div class="t mc x7a h17 yd63 ff17 fsb fc3 sc0 ls105 ws0">or sulfadoxine plus pyrimethamine. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yec7 ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17 lsd6 ws218">, 2000, 62:210–216.</span></div><div class="t mc x9 h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">7.<span class="_ _39"> </span>von Seidlein L<span class="_ _67"> </span>et al. Risk factors for gametocyte carriage in G<span class="_ _8"></span>ambian children.</div><div class="t mc x7a h17 yd66 ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 2001, 65:523–527.</span></div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">8.<span class="_ _44"> </span>von Seidlein L<span class="_ _67"> </span>et al. A randomized controlled trial of artemether/benflumetol,</div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">a new antimalarial, and pyrimethamine/sulfadoxine in the treatment of</div><div class="t mc x7a h17 yd87 ff17 fsb fc3 sc0 ls105 ws1d4">uncomplicated falciparum malaria in African children. <span class="ff1a ws0">American Journal of</span></div><div class="t mc x7a h17 yec8 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 1998, 58:638–644.</span></div><div class="t mc x9 h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">9.<span class="_ _44"> </span>T<span class="_ _4b"></span>argett G et al. Ar<span class="_ _8"></span>tesunate reduces but does not prev<span class="_ _a"></span>ent post-treatment</div><div class="t mc x7a h17 yd89 ff17 fsb fc3 sc0 ls105 ws0">transmission of <span class="ff1a">Plasmodium falciparum </span>to <span class="ff1a">Anopheles gambiae</span>. <span class="ff1a">Journal of</span></div><div class="t mc x7a h17 yec9 ff1a fsb fc3 sc0 ls105 ws0">Infectious Diseases<span class="ff17 ls2e2 ws1d3">, 2001, 183:1254–1259.</span></div><div class="t mc x9 h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">10.<span class="_ _68"> </span>Drakeley CJ et al. Addition of artesunate to chloroquine for treatment of</div><div class="t mc x7a h17 yeca ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum <span class="ff17">malaria in Gambian children causes a significant but</span></div><div class="t mc x7a h17 yecb ff17 fsb fc3 sc0 ls105 ws0">short-lived reduction in infectiousness for mosquitoes. <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yecc ff1a fsb fc3 sc0 ls105 ws0">International Health<span class="ff17">, 2004, 9:53–61.</span></div><div class="t mc x9 h17 yecd ff17 fsb fc3 sc0 ls105 ws19a">11.<span class="_ _0"> </span>Pukrittayakamee S et al. Activities of artesunate and primaquine against</div><div class="t mc x7a h17 yece ff17 fsb fc3 sc0 ls105 ws0">asexual- and sexual-stage parasites in falciparum malaria. <span class="ff1a">Antimicrobial Agents</span></div><div class="t mc x7a h17 yecf ff1a fsb fc3 sc0 ls105 ws0">and Chemotherapy<span class="ff17 lsd6 ws218">, 2004, 48:1329–1334.</span></div><div class="t mc x9 h17 yed0 ff17 fsb fc3 sc0 ls105 ws0">12.<span class="_ _68"> </span>Nosten F et al. Effects of artesunate-mefloquine combination on incidence of</div><div class="t mc x7a h17 yed1 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum <span class="ff17">malaria and mefloquine resistance in western <span class="_ _a"></span>Thailand:</span></div><div class="t mc x7a h17 yed2 ff17 fsb fc3 sc0 ls105 ws0">a prospective study<span class="_ _c"></span>. <span class="ff1a">Lancet</span>, 2000, 356:297–302.</div><div class="t mc x9 h17 yed3 ff17 fsb fc3 sc0 ls105 ws0">13.<span class="_ _68"> </span>Killeem G et al. The potential impact of integr<span class="_ _a"></span>ated malaria transmission control</div><div class="t mc x7a h17 yed4 ff17 fsb fc3 sc0 ls105 ws19a">on entomologic inoculation rate in highly endemic areas. <span class="ff1a ws0">American Journal of</span></div><div class="t mc x7a h17 yed5 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 2000, 62:545–551.</span></div><div class="t mc x9 h17 yed6 ff17 fsb fc3 sc0 ls105 ws0">14.<span class="_ _3"> </span>Handunnetti SM et al. Features of recrudescent chloroquine-r<span class="_ _a"></span>esistant</div><div class="t mc x7a h17 yed7 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum <span class="ff17">infections confer a survival advantage on par<span class="_ _a"></span>asites, and</span></div><div class="t mc x7a h17 yed8 ff17 fsb fc3 sc0 ls105 ws0">have implications for disease control. <span class="ff1a">T<span class="_ _4b"></span>ransactions of the Royal Society of</span></div><div class="t mc x7a h17 yed9 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ws218">, 1996, 90:563–567.</span></div><div class="t mc x9 h17 yeda ff17 fsb fc3 sc0 ls105 ws0">15.<span class="_ _68"> </span>Hallett RL<span class="_ _6"> </span>et al. Combination therapy counter<span class="_ _a"></span>acts the enhanced transmission of</div><div class="t mc x7a h17 yedb ff17 fsb fc3 sc0 ls105 ws0">drug-resistant malaria parasites to mosquitoes. <span class="ff1a">Antimicr<span class="_ _a"></span>obial Agents and</span></div><div class="t mc x7a h17 yedc ff1a fsb fc3 sc0 ls105 ws0">Chemotherapy<span class="ff17">, 2004, 48:3940–3943.</span></div><div class="t mc x9 h17 yedd ff17 fsb fc3 sc0 ls105 ws0">16.<span class="_ _3"> </span>White N<span class="_ _8"></span>J, Olliaro PL. Str<span class="_ _a"></span>ategies for the prevention of antimalarial drug resistance:</div><div class="t mc x7a h17 yede ff17 fsb fc3 sc0 ls105 ws0">rationale for combination chemotherapy for malaria. <span class="ff1a ws4e8">P<span class="_ _a"></span>arasitology T<span class="_ _4b"></span>oday<span class="ff17 ws1d4">, 1996,</span></span></div><div class="t mc x7a h17 yedf ff17 fsb fc3 sc0 ls105 ws0">12:399–401.</div><div class="t mc x9 h17 yee0 ff17 fsb fc3 sc0 ls105 ws19a">17.<span class="_ _68"> </span>De Roode JC et al. Competitive release of drug r<span class="_ _a"></span>esistance following drug</div><div class="t mc x7a h17 yee1 ff17 fsb fc3 sc0 ls105 ws0">treatment of mixed <span class="ff1a">Plasmodium chabaudi </span>infections. <span class="ff1a">Malaria Journal</span>, 2004,</div><div class="t mc x7a h17 yee2 ff17 fsb fc3 sc0 ls105 ws0">3:33–42.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf99" class="pf w1 h4" data-page-no="99"><div class="pc pc99 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4a he y9 ff16 fs5 fc3 sc0 ls51 ws4c0">Annex 4 - Antimalarials and malaria transmission</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">143</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">18.<span class="_ _3"> </span>De Roode JC et al. Host heterogeneity is a determinant of competitive ex<span class="_ _a"></span>clusion</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">or coexistence in genetically diverse malaria infections. <span class="ff1a">Pr<span class="_ _a"></span>oceedings of the Royal</span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Society of London B, Biological Sciences<span class="ff17 ls104 ws35b">, 2004, 271:1073–1080.</span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">19.<span class="_ _3"> </span>Molyneux DH et al. T<span class="_ _b"></span>ransmission control and drug resistance in malaria: a crucial</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">interaction. <span class="ff1a ws4e8">Par<span class="_ _a"></span>asitology T<span class="_ _4b"></span>oday<span class="ff17 ws0">, 1999, 15:238–240.</span></span></div><div class="t mc xb h17 yee3 ff17 fsb fc3 sc0 ls105 ws0">20.<span class="_ _5"> </span>Mharakurwa S et al. Association of house spraying with suppressed levels of</div><div class="t mc x4d h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">drug resistance in Zimbabwe. <span class="ff1a">Malaria Journal</span>, 2004, 3:35.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9a" class="pf w1 h4" data-page-no="9a"><div class="pc pc9a w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9b" class="pf w1 h4" data-page-no="9b"><div class="pc pc9b w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 yee4 ff1b fs10 fc7 sc0 ls270 ws0">Annex 5.<span class="_ _7d"> </span><span class="fc0">Malaria diagnosis<span class="_ _c1"> </span><span class="fc4">147</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9c" class="pf w1 h4" data-page-no="9c"><div class="pc pc9c w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9d" class="pf w1 h4" data-page-no="9d"><div class="pc pc9d w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc9 he y9 ff16 fs5 fc3 sc0 lsee ws17a">Annex 5 - Malaria diagnosis</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">147</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 5</div><div class="t m0 x66 hf y895 ff18 fs6 fc3 sc0 ls9e wsfd">MALAR<span class="_ _8"></span>IA DIAGNOS<span class="_ _8"></span>IS</div><div class="t m0 xb h12 y896 ff19 fs6 fc4 sc0 ls9a ws0">A5.1<span class="_ _33"> </span>S<span class="_ _8"></span>y<span class="_ _8"></span>mptom-based (c<span class="_ _8"></span>linical) diagnosis </div><div class="t m0 xb hb y897 ff17 fs8 fc3 sc0 ls205 ws8e">The signs and symptoms of malaria, such as fever<span class="_ _4b"></span>, chills, headache and anorexia,</div><div class="t m0 xb hb y898 ff17 fs8 fc3 sc0 ls22 ws49a">are non-specific and are common to many diseases and conditions. Malaria is</div><div class="t m0 xb hb ydc3 ff17 fs8 fc3 sc0 ls206 ws5b">a common cause of fever and illness in endemic areas <span class="ff1a">(1, 2), but </span>it is not possible</div><div class="t m0 xb hb ydc4 ff17 fs8 fc3 sc0 ls22 ws442">to apply any one set of clinical criteria to the diagnosis of all types of malaria</div><div class="t m0 xb hb ydc5 ff17 fs8 fc3 sc0 ls22 ws2cd">in all patient populations. The appr<span class="_ _a"></span>opriateness of par<span class="_ _8"></span>ticular clinical diagnostic</div><div class="t m0 xb hb ydc6 ff17 fs8 fc3 sc0 ls22 ws376">criteria varies fr<span class="_ _a"></span>om area to area according to the intensity of tr<span class="_ _a"></span>ansmission, the</div><div class="t m0 xb hb yee5 ff17 fs8 fc3 sc0 ls1cc wsb8">species of malaria parasite, other prev<span class="_ _b"></span>ailing causes of fever<span class="_ _b"></span>, and the health ser<span class="_ _8"></span>vice</div><div class="t m0 xb hb yee6 ff17 fs8 fc3 sc0 ls28c ws0">infrastructure <span class="_ _b"></span><span class="ff1a lseb">(3)<span class="ff17 ls28c ws91">. One of the factors leading to a change in the clinical epidemi-</span></span></div><div class="t m0 xb hb yee7 ff17 fs8 fc3 sc0 ls22 ws5e">ology of malaria in some areas is the prev<span class="_ _b"></span>alence of H<span class="_ _8"></span>IV/AI<span class="_ _8"></span>DS. This disease can</div><div class="t m0 xb hb yee8 ff17 fs8 fc3 sc0 ls204 ws107">increase the risk of acquiring malaria or the progr<span class="_ _a"></span>ession to severe malaria,</div><div class="t m0 xb hb yee9 ff17 fs8 fc3 sc0 ls22 ws4e9">depending on malaria transmission in the area and the age of the patient. <span class="_ _b"></span>The</div><div class="t m0 xb hb yeea ff17 fs8 fc3 sc0 ls22 ws0">prev<span class="_ _a"></span>alence of H<span class="_ _8"></span>IV/AI<span class="_ _8"></span>DS can also lead to an increase in the incidence of febrile</div><div class="t m0 xb hb yeeb ff17 fs8 fc3 sc0 ls22 ws4ea">disease that is not malaria, and can therefore cause further difficulties in the</div><div class="t m0 xb hb yeec ff17 fs8 fc3 sc0 ls22 ws0">symptom-based diagnosis of malaria <span class="ff1a">(4)</span>. </div><div class="t m0 xb hb ydcf ff17 fs8 fc3 sc0 ls22 ws3e0">T<span class="_ _b"></span>wo different studies in <span class="_ _a"></span>The Gambia have shown that a sensitivity of 70–88%</div><div class="t m0 xb hb ydd0 ff17 fs8 fc3 sc0 ls22 ws3ff">and a specificity of 63–82% for malaria diagnosis could be achieved using a</div><div class="t m0 xb hb ydd1 ff17 fs8 fc3 sc0 ls22 ws160">weighting and scoring system for clinical signs and symptoms. <span class="_ _a"></span>These methods</div><div class="t m0 xb hb ydd2 ff17 fs8 fc3 sc0 ls30c ws122">may be too complicated to implement and supervise under operational conditions</div><div class="t m0 xb hb ydd3 ff17 fs8 fc3 sc0 lsb1 ws1a4">in the field, and many of the key symptoms and signs of malaria in one area may</div><div class="t m0 xb hb ydd4 ff17 fs8 fc3 sc0 ls2e6 ws90">not be applicable elsewhere. F<span class="_ _a"></span>or instance, reduced feeding in a child is more likely</div><div class="t m0 xb hb yeed ff17 fs8 fc3 sc0 ls22 ws14">to indicate malaria in The Gambia than in Ethiopia <span class="ff1a ws0">(5, 6)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb ydd6 ff17 fs8 fc3 sc0 ls237 wsb0">Fev<span class="_ _a"></span>er alone is as effective a criterion for diagnosis as clinical algorithms; a review</div><div class="t m0 xb hb ydd7 ff17 fs8 fc3 sc0 ls30d ws214">of 10 studies indicated that use of the more restrictiv<span class="_ _a"></span>e criteria of clinical algorithms</div><div class="t m0 xb hb ydd8 ff17 fs8 fc3 sc0 lsf9 ws2bc">resulted in only trivial savings in drug costs compared with use of a fev<span class="_ _a"></span>er<span class="_ _a"></span>-based</div><div class="t m0 xb hb ydd9 ff17 fs8 fc3 sc0 lsf9 ws4eb">diagnosis, even in areas of lo<span class="_ _a"></span>w malaria prev<span class="_ _a"></span>alence. In areas of high prev<span class="_ _a"></span>alence</div><div class="t m0 xb hb ydda ff17 fs8 fc3 sc0 lsf9 ws14">it greatly increases the pr<span class="_ _a"></span>obability of missing malaria infections <span class="ff1a ws0">(7)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb h12 yeee ff19 fs6 fc4 sc0 ls1b ws1">A5.2<span class="_ _52"> </span>Light microscopy </div><div class="t m0 xb hb yeef ff17 fs8 fc3 sc0 lsa6 ws107">In addition to pro<span class="_ _a"></span>viding a diagnosis with a high degree of sensitivity and</div><div class="t m0 xb hb yef0 ff17 fs8 fc3 sc0 lsa8 ws10a">specificity when performed well, microscopy allo<span class="_ _a"></span>ws quantification of malaria</div><div class="t m0 xb hb yef1 ff17 fs8 fc3 sc0 ls4e ws232">parasites and identification of the infecting species. It is inexpensive, the</div><div class="t m0 xb hb yef2 ff17 fs8 fc3 sc0 ls12 ws16c">cost varying from US$ 0.40–0.70 per slide and is consider<span class="_ _a"></span>ed to be the “<span class="_ _a"></span>gold</div><div class="t m0 xb hb yef3 ff17 fs8 fc3 sc0 ls140 ws200">standard” against which the sensitivity and specificity of other methods must</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9e" class="pf w1 h4" data-page-no="9e"><div class="pc pc9e w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1b ws0">148</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls10c ws3d8">be assessed. A skilled microscopist is able to detect asexual parasites at</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls28 ws34">densities of fewer than 10 per <span class="ff1c ls0 ws0">μ</span><span class="ls2a8 ws229">l of blood but under typical field conditions the</span></div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls9c wsfa">limit of sensitivity is approximately 100 par<span class="_ _a"></span>asites per <span class="ff1c ls0 ws0">μ<span class="ff17 ls3c">l <span class="ff1a">(8)</span><span class="ws31">. Light micr<span class="_ _a"></span>oscopy</span></span></span></div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls12 ws0">has important advantages: </div><div class="t m0 x9 hb y336 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws4ec">low direct costs if the infr<span class="_ _a"></span>astructure to maintain the service is available,</span></div><div class="t m0 x9 hb y337 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">high sensitivity if the quality of microscopy is high,</span></div><div class="t m0 x9 hb y8d4 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">differentiation between plasmodia species,</span></div><div class="t m0 x9 hb yef4 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">determination of parasite densities,</span></div><div class="t m0 x9 hb yef5 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">can be used to diagnose many other conditions.</span></div><div class="t m0 x9 hb yef6 ff17 fs8 fc3 sc0 ls189 ws381">It can be difficult to maintain good quality of microscopy<span class="_ _c"></span>, for various reasons:</div><div class="t m0 x9 hb yef7 ff17 fs8 fc3 sc0 ls12 ws4ab">the need for adequate training and supervision of laboratory staff; the need</div><div class="t m0 x9 hb yef8 ff17 fs8 fc3 sc0 ls146 ws207">to rely on electricity at night time; delays in pro<span class="_ _a"></span>viding results to patients; and</div><div class="t m0 x9 hb yef9 ff17 fs8 fc3 sc0 ls1e1 ws312">the need for maintaining quality assurance and control of labor<span class="_ _a"></span>atory ser<span class="_ _8"></span>vices.</div><div class="t m0 x9 hb yefa ff17 fs8 fc3 sc0 ls1a8 ws2aa">Numerous attempts have been made to impr<span class="_ _a"></span>ove malaria micr<span class="_ _a"></span>oscopy<span class="_ _4b"></span>, but</div><div class="t m0 x9 hb yefb ff17 fs8 fc3 sc0 ls2f ws3d">none has pro<span class="_ _a"></span>ven superior to the classical method of Giemsa-staining and</div><div class="t m0 x9 hb yefc ff17 fs8 fc3 sc0 ls262 ws38e">oil-immersion microscopy for performance in typical health-care settings <span class="ff1a ws0">(9)<span class="ff17 ls8a">. </span></span></div><div class="t m0 x9 h12 yefd ff19 fs6 fc4 sc0 ls86 wsca">A5.3<span class="_ _33"> </span>R<span class="_ _8"></span>apid diagnostic tests </div><div class="t m0 x9 hb yefe ff17 fs8 fc3 sc0 ls13 ws4ed">Rapid diagnostic tests (RDT<span class="_ _4b"></span>s) are immunochromatogr<span class="_ _a"></span>aphic tests that detect</div><div class="t m0 x9 hb yeff ff17 fs8 fc3 sc0 ls12 ws2f">parasite-specific antigens in a finger<span class="_ _b"></span>-prick blood sample. Some tests detect</div><div class="t m0 x9 hb yf00 ff17 fs8 fc3 sc0 ls12 wsac">only one species (<span class="ff1a">Plasmodium falciparum</span>), others detect one or more of the</div><div class="t m0 x9 hb yf01 ff17 fs8 fc3 sc0 ls115 ws3b8">other three species of human malaria parasites (<span class="ff1a ls2b0 ws0">P<span class="_ _ae"></span>.<span class="_ _2"> </span>viv<span class="_ _b"></span>ax<span class="ff17">, <span class="_ _67"></span></span>P<span class="_ _c"></span>.<span class="_ _68"> </span>malariae<span class="_ _3"> </span><span class="ff17 ls115">and</span></span></div><div class="t m0 x9 hb yf02 ff1a fs8 fc3 sc0 ls2b0 ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>ov<span class="_ _a"></span>ale<span class="ff17">) <span class="_ _66"></span></span><span class="ls2e">(10–12)</span><span class="ff17 ws3b8">. R<span class="_ _8"></span>DT<span class="_ _4b"></span>s are av<span class="_ _a"></span>ailable commercially in different formats, as</span></div><div class="t m0 x9 hb yf03 ff17 fs8 fc3 sc0 lsef wsab">dipsticks, cassettes or cards. Cassettes and cards ar<span class="_ _a"></span>e easier to use in difficult</div><div class="t m0 x9 hb yf04 ff17 fs8 fc3 sc0 ls12 ws0">conditions outside health facilities. </div><div class="t m0 x9 hb yf05 ff17 fs8 fc3 sc0 ls2ef ws418">RDT<span class="_ _4b"></span>s are simple to perform and interpret, and do not requir<span class="_ _a"></span>e electricity or special</div><div class="t m0 x9 hb yf06 ff17 fs8 fc3 sc0 ls1fb ws286">equipment. WHO r<span class="_ _a"></span>ecommends that such tests should have a sensitivity of <span class="ff1c ls0 ws0">&gt;<span class="_ _67"> </span><span class="ff17 ls162">95%</span></span></div><div class="t m0 x9 hb yf07 ff17 fs8 fc3 sc0 ls204 ws350">in detecting plasmodia at densities of more than 100 parasites per μl of blood.</div><div class="t m0 x9 hb yf08 ff17 fs8 fc3 sc0 ls12 ws4ee">Progr<span class="_ _a"></span>amme and project managers should make their own choice among the</div><div class="t m0 x9 hb yf09 ff17 fs8 fc3 sc0 ls140 ws200">many products av<span class="_ _a"></span>ailable, using the criteria recommended by WHO </div><div class="t m0 xca hc yf0a ff17 fs9 fc4 sc0 ls30e ws0">(www<span class="_ _b"></span>.wpro.</div><div class="t m0 x9 hc yf0b ff17 fs9 fc4 sc0 ls30f ws0">who.int/rdt)</div><div class="t m0 xc2 hb yf0c ff17 fs8 fc3 sc0 ls16e ws245">as there is as yet no international mechanism for pr<span class="_ _a"></span>e-qualification</div><div class="t m0 x9 hb yf0d ff17 fs8 fc3 sc0 ls13 ws0">of RDT<span class="_ _4b"></span>s.</div><div class="t m0 x9 hb yf0e ff17 fs8 fc3 sc0 ls205 ws8b">Current tests are based on the detection of histidine-rich pr<span class="_ _a"></span>otein 2 (H<span class="_ _8"></span>RP2), which</div><div class="t m0 x9 hb yf0f ff17 fs8 fc3 sc0 ls12 ws4ef">is specific for <span class="ff1a ls13">P<span class="_ _c"></span>. falciparum<span class="ff17 ls12">, pan-specific or species-specific parasite lactate</span></span></div><div class="t m0 x9 hb yf10 ff17 fs8 fc3 sc0 lse6 ws177">dehydrogenase (pLDH), or other pan-specific antigens such as aldolase.</div><div class="t m0 x9 hb yf11 ff17 fs8 fc3 sc0 ls6c ws99">These antigens have different char<span class="_ _a"></span>acteristics, which may affect suitability</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9f" class="pf w1 h4" data-page-no="9f"><div class="pc pc9f w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc9 he y9 ff16 fs5 fc3 sc0 lsee ws17a">Annex 5 - Malaria diagnosis</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">149</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls12 ws4f0">for use in different situations, and this should be taken into account when</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 lseb ws8e">developing RDT policy<span class="_ _c"></span>. These tests have many potential adv<span class="_ _b"></span>antages, including: </div><div class="t m0 xb hb yf12 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">the ability to pro<span class="_ _a"></span>vide rapid results, </span></div><div class="t m0 xb hb yf13 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws35f">fewer requir<span class="_ _a"></span>ements for training and skilled personnel (a general health</span></div><div class="t m0 x26 hb yf14 ff17 fs8 fc3 sc0 ls12 ws0">worker can be trained in one day),</div><div class="t m0 xb hb yf15 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls310 ws225">reinforcement of patient confidence in the diagnosis and in the health</span></div><div class="t m0 x26 hb yf16 ff17 fs8 fc3 sc0 ls12 ws0">service in general. </div><div class="t m0 xb hb yf17 ff17 fs8 fc3 sc0 ls12 ws0">There are also potential disadv<span class="_ _b"></span>antages, including:</div><div class="t m0 xb hb yf18 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws4f1">the likelihood of misinterpreting a positive r<span class="_ _a"></span>esult as indicating malaria in</span></div><div class="t m0 x26 hb yf19 ff17 fs8 fc3 sc0 ls95 wsec">patients with parasitaemia incidental to another illness, in particular when</div><div class="t m0 x26 hb yf1a ff17 fs8 fc3 sc0 ls122 ws4b4">host immunity is high; the inability in the case of some RDT<span class="_ _4b"></span>s, to distinguish</div><div class="t m0 x26 hb yf1b ff17 fs8 fc3 sc0 ls44 ws93">new infections from a recently and effectiv<span class="_ _a"></span>ely treated infection; this is due</div><div class="t m0 x26 hb yf1c ff17 fs8 fc3 sc0 ls5d ws7e">to the persistence of certain target antigens (e.g. H<span class="_ _8"></span>RP2) in the blood for 1–3</div><div class="t m0 x26 hb yf1d ff17 fs8 fc3 sc0 ls12 ws1ca">weeks after effective tr<span class="_ _a"></span>eatment. The persistence of PfHRP2 in blood for at</div><div class="t m0 x26 hb yf1e ff17 fs8 fc3 sc0 lsc2 ws137">least one week after treatment can be used in the diagnosis of sev<span class="_ _a"></span>ere</div><div class="t m0 x26 hb yf1f ff17 fs8 fc3 sc0 ls200 ws25">malaria in low transmission ar<span class="_ _a"></span>eas where artemisinin derivatives are widely</div><div class="t m0 x26 hb yf20 ff17 fs8 fc3 sc0 ls12 ws4f2">available. P<span class="_ _a"></span>atients may have cleared peripher<span class="_ _a"></span>al parasitaemia because of</div><div class="t m0 x26 hb yf21 ff17 fs8 fc3 sc0 ls12 ws3e2">inadequate self treatment, but the PfHRP2 test will be strongly positive. </div><div class="t m0 xb hb yf22 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls64 ws1b2">unpredictable sensitivity in the field <span class="ff1a ls37 ws0">(13–20),<span class="_ _6"> </span></span>mainly because test perform-</span></div><div class="t m0 x26 hb yf23 ff17 fs8 fc3 sc0 ls64 ws279">ance is greatly affected by adverse envir<span class="_ _a"></span>onmental conditions such as high</div><div class="t m0 x26 hb yf24 ff17 fs8 fc3 sc0 ls64 ws0">temperature and humidity<span class="_ _c"></span>.</div><div class="t m0 xb hb yf25 ff17 fs8 fc3 sc0 lsde ws113">Published sensitivities of RDT<span class="_ _4b"></span>s for <span class="ff1a ls232 ws342">P<span class="_ _c"></span>. falciparum <span class="ff17 ws90">range from comparable to those</span></span></div><div class="t m0 xb hb yf26 ff17 fs8 fc3 sc0 ls42 ws5b">of good field microscopy (<span class="ff1c ls0 ws0">&gt;</span><span class="ls34 ws14a">90% at 100–500 par<span class="_ _a"></span>asites/<span class="ff1c ls0 ws0">μ</span><span class="ls42 ws5b">l of blood) to very poor</span></span></div><div class="t m0 xb hb yf27 ff17 fs8 fc3 sc0 lsc4 ws1b3">(40–50%) for some widely used products. Sensitivities are gener<span class="_ _a"></span>ally lower for</div><div class="t m0 xb hb yf28 ff17 fs8 fc3 sc0 ls28 ws34">other species. The r<span class="_ _a"></span>easons for poor sensitivity are not clear<span class="_ _b"></span>. They may include:</div><div class="t m0 xb hb yf29 ff17 fs8 fc3 sc0 ls2c6 ws4e1">poor test manufacture, damage due to exposure to high temper<span class="_ _a"></span>ature or</div><div class="t m0 xb hb yf2a ff17 fs8 fc3 sc0 ls182 ws130">humidity<span class="_ _4b"></span>, incorrect handling by end-users, possible geographical v<span class="_ _a"></span>ariation in</div><div class="t m0 xb hb yf2b ff17 fs8 fc3 sc0 ls184 ws267">the test antigen, and poor comparative micr<span class="_ _a"></span>oscopy<span class="_ _95"> </span><span class="ff1a ls27 ws0">(12)</span><span class="ls233">. Several studies have</span></div><div class="t m0 xb hb yf2c ff17 fs8 fc3 sc0 ls44 ws93">shown that health workers, volunteers and priv<span class="_ _b"></span>ate sector providers can, with</div><div class="t m0 xb hb yf2d ff17 fs8 fc3 sc0 ls12 ws4f3">some support and follow-up, learn to use RDT<span class="_ _4b"></span>s correctly with relativ<span class="_ _a"></span>e ease.</div><div class="t m0 xb hb yf2e ff17 fs8 fc3 sc0 ls25 ws27">The use of a confirmatory diagnosis with either microscopy or RDT<span class="_ _4b"></span>s is expected</div><div class="t m0 xb hb yf2f ff17 fs8 fc3 sc0 ls13 ws17b">to reduce the o<span class="_ _a"></span>veruse of antimalarials by ensuring that treatment is targeted</div><div class="t m0 xb hb yf30 ff17 fs8 fc3 sc0 lsca ws44">on patients with confirmed malaria infections as opposed to treating all</div><div class="t m0 xb hb yf31 ff17 fs8 fc3 sc0 ls12 ws2a">patients with fever<span class="_ _4b"></span>. There is, ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, little documented evidence that this is</div><div class="t m0 xb hb yf32 ff17 fs8 fc3 sc0 ls13 ws4f4">so. <span class="_ _a"></span>The main problem is that pro<span class="_ _a"></span>viders of care, although they may be willing</div><div class="t m0 xb hb yf33 ff17 fs8 fc3 sc0 ls1d8 ws173">to perform diagnostic tests, do not always comply with the results, especially</div><div class="t m0 xb hb yf34 ff17 fs8 fc3 sc0 ls294 ws28d">when they are negative. Being awar<span class="_ _a"></span>e that delay in providing effectiv<span class="_ _a"></span>e treatment</div><div class="t m0 xb hb yf35 ff17 fs8 fc3 sc0 lsfa ws3ea">can be fatal for a malaria patient, they are often reluctant to withhold tr<span class="_ _a"></span>eatment</div><div class="t m0 xb hb yf36 ff17 fs8 fc3 sc0 ls0 ws4f5">on the basis of a negative result. <span class="_ _b"></span>WHO is currently suppor<span class="_ _8"></span>ting operational</div><div class="t m0 xb hb yf37 ff17 fs8 fc3 sc0 ls12 ws0">research pr<span class="_ _a"></span>ojects designed to address these issues.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa0" class="pf w1 h4" data-page-no="a0"><div class="pc pca0 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">150</div><div class="t m0 x9 h12 y12a ff19 fs6 fc4 sc0 ls9a ws0">A5.4<span class="_ _33"> </span>Immunodiagnosis and PCR-based molecular</div><div class="t m0 x28 h12 y12b ff19 fs6 fc4 sc0 ls1 ws0">detection methods</div><div class="t m0 x9 hb y12c ff17 fs8 fc3 sc0 ls64 wsa4">Detection of antibodies to parasites, which may be useful for epidemiological</div><div class="t m0 x9 hb y12d ff17 fs8 fc3 sc0 ls12 ws4f6">studies, is neither sensitive, specific, nor rapid enough to be of use in the</div><div class="t m0 x9 hb y12f ff17 fs8 fc3 sc0 ls12 ws0">management of patients suspected of having malaria <span class="ff1a ls13">(21)</span><span class="ls0">.</span></div><div class="t m0 x9 hb yf38 ff17 fs8 fc3 sc0 ls12 ws384">T<span class="_ _4b"></span>echniques to detect parasite DNA based on the polymerase chain reaction</div><div class="t m0 x9 hb yf39 ff17 fs8 fc3 sc0 ls13 ws4f7">(PCR) are highly sensitive and v<span class="_ _a"></span>ery useful for detecting mixed infections, in</div><div class="t m0 x9 hb yf3a ff17 fs8 fc3 sc0 ls12 ws3bd">particular at low parasite densities. They ar<span class="_ _a"></span>e also useful for studies on drug</div><div class="t m0 x9 hb yf3b ff17 fs8 fc3 sc0 ls14e ws1a6">resistance and other specialized epidemiological inv<span class="_ _a"></span>estigations <span class="ff1a lsa8 ws0">(22)</span>, but are</div><div class="t m0 x9 hb yf3c ff17 fs8 fc3 sc0 ls12 ws0">not generally av<span class="_ _a"></span>ailable in malaria endemic areas. </div><div class="t m0 x9 h19 yf3d ff17 fsd fc4 sc0 ls0 ws0">a</div><div class="t m0 x46 h15 yf3e ff17 fsa fc3 sc0 lsac ws115">See also references (7) and (23).</div><div class="t m0 x47 h16 yf3f ff1e fsb fc0 sc0 lsd2 ws0">What are the effects of treatment based on clinical diagnosis compar<span class="_ _a"></span>ed with</div><div class="t m0 x47 h16 yf40 ff1e fsb fc0 sc0 lsd2 ws0">treatment based on diagnosis with the use of malaria microscopy or RD<span class="_ _a"></span>T<span class="_ _4b"></span>s?</div><div class="t m0 xcb h4c yf41 ff1e fse fc0 sc0 ls0 ws0">a</div><div class="t m0 x47 h1a yf42 ff24 fsb fc4 sc0 lsd2 ws0">Interventions:</div><div class="t m3 x22 h1b yf42 ff1f fsb fc3 sc0 lsd2 ws0">use of RDT<span class="_ _4b"></span>s or microscopy for diagnosis</div><div class="t m3 x97 h17 yf43 ff1f fsb fc5 sc0 ls311 ws4f8">Summary of RCT<span class="_ _b"></span>s: <span class="ff17 fc3 ls312 ws4f9">despite the existence of a number of studies on the</span></div><div class="t m3 x97 h17 yf44 ff17 fsb fc3 sc0 ls2e1 ws4fa">sensitivity and specificity of various methods for diagnosing malaria, ther<span class="_ _a"></span>e are</div><div class="t m3 x97 h17 yf45 ff17 fsb fc3 sc0 lsd2 ws0">no RCT<span class="_ _4b"></span>s on the impact of a confirmatory diagnosis as an inter<span class="_ _8"></span>vention.</div><div class="t m3 x97 h17 yf46 ff1f fsb fc5 sc0 ls313 ws1fe">Exper<span class="_ _8"></span>t comment: <span class="ff17 fc3 lsf2 ws194">treatment of all people with fev<span class="_ _a"></span>er leads to overuse of</span></div><div class="t m3 x97 h17 yf47 ff17 fsb fc3 sc0 ls314 ws4fb">antimalarials in most settings. W<span class="_ _a"></span>ith the introduction of more expensive</div><div class="t m3 x97 h17 yf48 ff17 fsb fc3 sc0 lsd2 ws4fc">antimalarials, there is a need to target tr<span class="_ _a"></span>eatment more effectively on people</div><div class="t m3 x97 h17 yf49 ff17 fsb fc3 sc0 ls315 ws4fd">with malaria infections by using confirmatory testing. This will have the</div><div class="t m3 x97 h17 yf4a ff17 fsb fc3 sc0 lsd2 ws4fe">additional benefits of improving patient car<span class="_ _a"></span>e and providing better epidemio-</div><div class="t m3 x97 h17 yf4b ff17 fsb fc3 sc0 ls316 ws4ff">logical surveillance data. However<span class="_ _4b"></span>, in young children in areas of intense</div><div class="t m3 x97 h17 yf4c ff17 fsb fc3 sc0 ls317 ws21">transmission, it is believed that the risk associated with r<span class="_ _a"></span>elying on a parasito-</div><div class="t m3 x97 h17 yf4d ff17 fsb fc3 sc0 lsd2 ws500">logical diagnosis (death owing to a false negative r<span class="_ _a"></span>esult) may outweigh the</div><div class="t m3 x97 h17 yf4e ff17 fsb fc3 sc0 lsd2 ws0">benefits.</div><div class="t m0 x47 h16 yf4f ff1e fsb fc4 sc0 ls318 ws0">R<span class="_ _a"></span>ecommendation:</div><div class="t m3 x81 h17 yf4f ff17 fsb fc3 sc0 ls174 ws24b">except for children in ar<span class="_ _a"></span>eas of intense transmission, confirmatory</div><div class="t m3 x47 h17 yf50 ff17 fsb fc3 sc0 ls319 ws501">(parasitological) testing should be introduced and used to supplement clinical</div><div class="t m3 x47 h17 yf51 ff17 fsb fc3 sc0 lsd2 ws0">criteria in diagnosis.</div><div class="t m3 x47 h17 yf52 ff17 fsb fc3 sc0 lsd2 ws0">Controlled trials and operational r<span class="_ _a"></span>esearch in various settings are ur<span class="_ _a"></span>gently needed.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa1" class="pf w1 h4" data-page-no="a1"><div class="pc pca1 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc9 he y9 ff16 fs5 fc3 sc0 lsee ws17a">Annex 5 - Malaria diagnosis</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">151</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls1 ws0">A5.5<span class="_ _52"> </span>References</div><div class="t mc xb h17 yf53 ff17 fsb fc3 sc0 ls105 ws0">1.<span class="_ _46"> </span>Marsh K et al. Clinical algorithm for malaria in Africa. <span class="ff1a">Lancet</span><span class="ws1d4">, 1996,</span></div><div class="t mc x4d h17 yf54 ff17 fsb fc3 sc0 ls2e2 ws0">347:1327–1329.</div><div class="t mc xb h17 yf55 ff17 fsb fc3 sc0 ls105 ws0">2.<span class="_ _44"> </span>Redd SC et al. Clinical algorithm for treatment of <span class="ff1a">Plasmodium falciparum </span>in</div><div class="t mc x4d h17 yf56 ff17 fsb fc3 sc0 ls105 ws0">children. <span class="ff1a">Lancet</span>, 347:223–227.</div><div class="t mc xb h17 yf57 ff1a fsb fc3 sc0 ls105 ws1d4">3.<span class="_ _44"> </span>WHO E<span class="_ _8"></span>xper<span class="_ _8"></span>t Committee on Malaria. T<span class="_ _4b"></span>wentieth report.<span class="_ _5"> </span><span class="ff17 ws4bd">Geneva, W<span class="_ _a"></span>orld <span class="_ _8"></span>Health</span></div><div class="t mc x4d h17 yf58 ff17 fsb fc3 sc0 ls105 ws1d4">Organization, 2000 (WHO <span class="_ _a"></span>T<span class="_ _4b"></span>echnical Repor<span class="_ _8"></span>t Series, No. 892).</div><div class="t mc xb h17 yf59 ff17 fsb fc3 sc0 ls105 ws1d4">4.<span class="_ _44"> </span>Nwanyanwu OC et al. Malaria and human immunodeficiency virus infection</div><div class="t mc x4d h17 yf5a ff17 fsb fc3 sc0 ls105 ws0">among male employees of a sugar estate in Malawi. <span class="ff1a">T<span class="_ _b"></span>ransactions of the R<span class="_ _a"></span>oyal</span></div><div class="t mc x4d h17 yf5b ff1a fsb fc3 sc0 ls105 ws0">Society of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 1997, 91:567–569.</span></div><div class="t mc xb h17 yf5c ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>Bojang KA, Obaro S, Morison LA. A prospective ev<span class="_ _a"></span>aluation of a clinical algorithm</div><div class="t mc x4d h17 yf5d ff17 fsb fc3 sc0 ls105 ws0">for the diagnosis of malaria in Gambian children. <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x4d h17 yf5e ff1a fsb fc3 sc0 ls105 ws0">International Health<span class="ff17">, 2000, 5:231–236.</span></div><div class="t mc xb h17 yf5f ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>Olaleye BO et al. Clinical predictors of malaria in Gambian children with fever or</div><div class="t mc x4d h17 yf60 ff17 fsb fc3 sc0 ls105 ws0">a history of fever<span class="_ _b"></span>. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x4d h17 yf61 ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17">, 1998, 92:300–304.</span></div><div class="t mc xb h17 yf62 ff17 fsb fc3 sc0 ls105 ws0">7.<span class="_ _39"> </span>Chandramohan D, Jaffar S, Greenwood B. Use of clinical algorithms for</div><div class="t mc x4d h17 yf63 ff17 fsb fc3 sc0 ls105 ws0">diagnosing malaria. <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and International Health<span class="ff17">, 2002, 7, 45–52.</span></span></div><div class="t mc xb h17 yf64 ff17 fsb fc3 sc0 ls105 ws1d4">8.<span class="_ _44"> </span>W<span class="_ _a"></span>orld Health Organization. Malaria diagnosis. Memorandum from a <span class="_ _a"></span>WHO</div><div class="t mc x4d h17 yf65 ff17 fsb fc3 sc0 ls105 ws0">meeting. <span class="ff1a ws19a">Bulletin of the W<span class="_ _b"></span>orld Health Organization<span class="ff17 ws0">, 1988, 66:575.</span></span></div><div class="t mc xb h17 yf66 ff17 fsb fc3 sc0 ls105 ws19a">9.<span class="_ _44"> </span>Kawamoto F<span class="_ _4b"></span>, Billingsley PF<span class="_ _4b"></span>. Rapid diagnosis of malaria by fluorescence</div><div class="t mc x4d h17 yf67 ff17 fsb fc3 sc0 ls105 ws0">microscopy<span class="_ _4b"></span>. <span class="ff1a ws4e8">Parasitology T<span class="_ _c"></span>oday<span class="ff17 ws1d4">, 1992, 8:69–71.</span></span></div><div class="t mc xb h17 yf68 ff1a fsb fc3 sc0 ls105 ws19a">10.<span class="_ _68"> </span>Malaria diagnosis: new perspectives<span class="ff17 ws0">. Genev<span class="_ _a"></span>a, W<span class="_ _b"></span>orld Health Organization, 2000</span></div><div class="t mc x4d h17 yf69 ff17 fsb fc3 sc0 ls105 ws502">(document WHO/CDS/RBM/2000.14).</div><div class="t mc xb h17 yf6a ff1a fsb fc3 sc0 ls105 ws0">11.<span class="_ _0"> </span>Malaria rapid diagnosis: making it work<span class="ff17">. Geneva, <span class="_ _b"></span>World Health Organization,</span></div><div class="t mc x4d h17 yf6b ff17 fsb fc3 sc0 ls31a ws1cc">2003 (document RS/2003/GE/05(PH<span class="_ _8"></span>L)).</div><div class="t mc xb h17 yf6c ff1a fsb fc3 sc0 ls105 ws0">12.<span class="_ _68"> </span>The use of rapid diagnostic tests<span class="ff17 ws1d4">. Genev<span class="_ _a"></span>a, Roll Back Malaria, <span class="_ _a"></span>WHO Regional</span></div><div class="t mc x4d h17 yf6d ff17 fsb fc3 sc0 ls105 ws0">Office for the W<span class="_ _b"></span>estern Pacific and U<span class="_ _8"></span>NDP/World Bank/WHO/UN<span class="_ _8"></span>ICEF Special</div><div class="t mc x4d h17 yf6e ff17 fsb fc3 sc0 ls105 ws0">Progr<span class="_ _a"></span>amme for Research and <span class="_ _a"></span>T<span class="_ _b"></span>raining in T<span class="_ _b"></span>ropical Diseases, 2004.</div><div class="t mc xb h17 yf6f ff17 fsb fc3 sc0 ls105 ws19a">13.<span class="_ _68"> </span>Gaye O et al. Diagnosis of <span class="ff1a ws0">Plasmodium falciparum <span class="ff17">malaria using ParaSight F<span class="_ _c"></span>, ICT</span></span></div><div class="t mc x4d h17 yf70 ff17 fsb fc3 sc0 ls105 ws19a">malaria PF and malaria IgG CELISA assays. <span class="ff1a ws0">Parasite<span class="ff17">, 1998, 5: 189–192.</span></span></div><div class="t mc xb h17 yf71 ff17 fsb fc3 sc0 ls105 ws0">14.<span class="_ _3"> </span>Ricci L et al. Ev<span class="_ _a"></span>aluation of OptiMAL Assay test to detect imported malaria in Italy<span class="_ _4b"></span>.</div><div class="t mc x4d h17 yf72 ff1a fsb fc3 sc0 ls105 ws0">New Microbiology<span class="ff17">, 2000, 23: 391–398.</span></div><div class="t mc xb h17 yf73 ff17 fsb fc3 sc0 ls105 ws19a">15.<span class="_ _68"> </span>Iqbal J et al. Diagnosis of imported malaria by <span class="ff1a ws0">Plasmodium <span class="ff17">lactate</span></span></div><div class="t mc x4d h17 yf74 ff17 fsb fc3 sc0 ls105 ws0">dehydrogenase (pLDH) and histidine-rich protein 2 (PfHRP-2)-based</div><div class="t mc x4d h17 yf75 ff17 fsb fc3 sc0 ls105 ws0">immunocapture assays. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls0">,</span></span></div><div class="t mc x4d h17 yf76 ff17 fsb fc3 sc0 ls105 ws0">2001, 64:20–23.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa2" class="pf w1 h4" data-page-no="a2"><div class="pc pca2 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">152</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">16.<span class="_ _3"> </span>Rubio JM et al. Limited level of accuracy pro<span class="_ _a"></span>vided by available rapid diagnosis</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws19a">tests for malaria enhances the need for PCR-based reference labor<span class="_ _a"></span>atories.</div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Journal of Clinical Microbiology<span class="ff17 ws19a">, 39: 2736–2737.</span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">17.<span class="_ _68"> </span>Coleman R et al. Field evaluation of the ICT Malaria Pf/Pv immunochr<span class="_ _a"></span>omato-</div><div class="t mc x7a h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">graphic test for the detection of asymptomatic malaria in a <span class="ff1a">Plasmodium</span></div><div class="t mc x7a h17 yd66 ff1a fsb fc3 sc0 ls105 ws0">falciparum<span class="ff17 ls0">/</span><span class="ls130">viv<span class="_ _a"></span>ax <span class="ff17">endemic area in Thailand. </span>American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical</span></div><div class="t mc x7a h17 yf77 ff1a fsb fc3 sc0 ls130 ws0">Medicine and Hygiene<span class="ff17 ws19a">, 2002, 66:379–383.</span></div><div class="t mc x9 h17 yd68 ff17 fsb fc3 sc0 ls130 ws0">18.<span class="_ _3"> </span>Craig MH et al. Field and laboratory comparative evaluation of ten r<span class="_ _a"></span>apid malaria</div><div class="t mc x7a h17 yd87 ff17 fsb fc3 sc0 ls130 ws0">diagnostic tests. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yec8 ff1a fsb fc3 sc0 ls130 ws0">Hygiene<span class="ff17">, 2002, 96:258–265.</span></div><div class="t mc x9 h17 yd88 ff17 fsb fc3 sc0 ls130 ws0">19.<span class="_ _3"> </span>Huong N<span class="_ _8"></span>M et al. Comparison of three antigen detection methods for diagnosis</div><div class="t mc x7a h17 yd89 ff17 fsb fc3 sc0 ls130 ws0">and therapeutic monitoring of malaria: a field study from southern <span class="_ _a"></span>Vietnam.</div><div class="t mc x7a h17 yec9 ff1a fsb fc3 sc0 ls130 ws0">T<span class="_ _b"></span>ropical Medicine and International Health<span class="ff17">, 7:304–308.</span></div><div class="t mc x9 h17 yd8b ff17 fsb fc3 sc0 ls130 ws0">20.<span class="_ _5"> </span>Mason DP et al. A comparison of two rapid field immunochromatographic tests to</div><div class="t mc x7a h17 yeca ff17 fsb fc3 sc0 ls130 ws0">expert microscopy in the diagnosis of malaria. <span class="ff1a ws27d">Acta T<span class="_ _a"></span>ropica<span class="ff17 ls2e2 ws1d3">, 2002, 82: 51–59.</span></span></div><div class="t mc x9 h17 yd8d ff17 fsb fc3 sc0 ls137 ws1d4">21.<span class="_ _3"> </span>Voller A. <span class="_ _a"></span>The immunodiagnosis of malaria. In: W<span class="_ _b"></span>ernsdorfer WH, McGregor I.</div><div class="t mc x7a h17 yd8e ff1a fsb fc3 sc0 ls130 ws0">Malaria<span class="ff17 ws19a">, V<span class="_ _b"></span>ol.1. Edinburgh, Churchill Livingstone, 1988:815–827.</span></div><div class="t mc x9 h17 yd8f ff17 fsb fc3 sc0 ls130 ws0">22.<span class="_ _5"> </span>Bates I, Iboro J, Barnish G. Challenges in monitoring the impact of inter<span class="_ _8"></span>ventions</div><div class="t mc x7a h17 yd90 ff17 fsb fc3 sc0 ls130 ws0">against malaria using diagnostics. In: <span class="ff1a">Reducing malaria<span class="_ _a"></span>’<span class="_ _b"></span>s burden. E<span class="_ _a"></span>vidence of</span></div><div class="t mc x7a h17 yd91 ff1a fsb fc3 sc0 ls130 ws0">effectiveness for decision-makers<span class="ff17">. <span class="_ _a"></span>Washington DC, Global Health Council,</span></div><div class="t mc x7a h17 yed0 ff17 fsb fc3 sc0 ls137 ws1d4">2003:33–39 (Global Health Council T<span class="_ _c"></span>echnical Repor<span class="_ _8"></span>t).</div><div class="t mc x9 h4d yd93 ff1a fsb fc3 sc0 ls10b ws19a">23.<span class="_ _95"> </span>Role of parasitological diagnosis in malaria case management in areas of high</div><div class="t mc x7a h4d yf78 ff1a fsb fc3 sc0 ls10b ws0">transmission. Summary of the outcomes of a WHO <span class="_ _b"></span>T<span class="_ _b"></span>echnical Consultation held in</div><div class="t mc x7a h17 yed3 ff1a fsb fc3 sc0 ls10b ws0">Geneva, 25–26 October 2004. <span class="ff17">Genev<span class="_ _a"></span>a, W<span class="_ _b"></span>orld Health Organization (in preparation).</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa3" class="pf w1 h4" data-page-no="a3"><div class="pc pca3 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 yf79 ff1b fs10 fc7 sc0 ls270 ws0">Annex 6. <span class="_ _ac"> </span><span class="fc0 ws405">R<span class="_ _a"></span>esistance to antimalarials<span class="_ _c2"> </span><span class="fc4 ws0">155</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa4" class="pf w1 h4" data-page-no="a4"><div class="pc pca4 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa5" class="pf w1 h4" data-page-no="a5"><div class="pc pca5 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">155</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 6</div><div class="t m0 xa hf y895 ff18 fs6 fc3 sc0 ls0 ws173">RE<span class="_ _8"></span>S<span class="_ _8"></span>IST<span class="_ _b"></span>ANCE TO ANTIMAL<span class="_ _8"></span>ARIALS </div><div class="t m0 xb h12 y896 ff19 fs6 fc4 sc0 ls53 ws0">A6.1<span class="_ _52"> </span>Introduction</div><div class="t m0 xb hb y897 ff17 fs8 fc3 sc0 ls12 ws14a">There are curr<span class="_ _a"></span>ently no bedside tests for determining the susceptibility of the</div><div class="t m0 xb hb y898 ff17 fs8 fc3 sc0 ls91 wse6">malaria parasite to antimalarials. Monitoring is therefor<span class="_ _a"></span>e needed to determine</div><div class="t m0 xb hb ydc3 ff17 fs8 fc3 sc0 ls12 ws472">geographical trends in susceptibility and the emer<span class="_ _a"></span>gence and spread of drug</div><div class="t m0 xb hb ydc4 ff17 fs8 fc3 sc0 ls12 ws503">resistance. <span class="_ _a"></span>The information obtained will help guide treatment choices and</div><div class="t m0 xb hb ydc5 ff17 fs8 fc3 sc0 ls12 ws0">predictions about future r<span class="_ _a"></span>esistance patterns.</div><div class="t m0 xb hb yf7a ff17 fs8 fc3 sc0 ls1d4 ws2f4">The greatest problem with drug r<span class="_ _a"></span>esistance occur with <span class="ff1a">P<span class="_ _c"></span>. falciparum<span class="ff17">. Resistance</span></span></div><div class="t m0 xb hb ydc7 ff17 fs8 fc3 sc0 ls13 ws0">of <span class="ff1a">P<span class="_ _c"></span>.<span class="_ _64"> </span>falciparum <span class="ff17 ls12 ws356">is of par<span class="_ _8"></span>ticular concern because of the enormous burden of</span></span></div><div class="t m0 xb hb ydc8 ff17 fs8 fc3 sc0 ls1d2 wsd7">disease caused by this species, its lethal potential, the propensity for epidemics,</div><div class="t m0 xb hb ydc9 ff17 fs8 fc3 sc0 ls12 ws350">and the cost of candidate replacement drugs for areas with established drug</div><div class="t m0 xb hb ydca ff17 fs8 fc3 sc0 ls8f wsde">resistance. Chloroquine r<span class="_ _a"></span>esistance does occur in <span class="ff1a ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax, <span class="ff17 wsde">especially in western</span></span></div><div class="t m0 xb hb ydcb ff17 fs8 fc3 sc0 ls97 wsf0">Oceania, but there are v<span class="_ _a"></span>ery few repor<span class="_ _8"></span>ts of resistance in <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>malariae<span class="_ _6"> </span><span class="ff17">or </span><span class="ws1a8">P<span class="_ _ae"></span>. ovale</span></span></div><div class="t m0 xb hb ydcc ff17 fs8 fc3 sc0 ls13 ws14">(although there have also been v<span class="_ _a"></span>ery few studies). </div><div class="t m0 xb hb yf7b ff17 fs8 fc3 sc0 lsfe ws372">This annex defines resistance, examines how it arises and spr<span class="_ _a"></span>eads, summarizes</div><div class="t m0 xb hb yf7c ff17 fs8 fc3 sc0 ls9f wsfe">its current global distribution and describes ways in which it can be monitored.</div><div class="t m0 xb h12 yf7d ff19 fs6 fc4 sc0 ls9e ws0">A6.2<span class="_ _33"> </span>Definition</div><div class="t m0 xb hb yf7e ff17 fs8 fc3 sc0 ls12 ws504">Antimalarial drug resistance is defined as the ability of a parasite str<span class="_ _a"></span>ain to</div><div class="t m0 xb hb yf7f ff17 fs8 fc3 sc0 ls12 ws450">survive and/or multiply despite the proper administration and absorption of</div><div class="t m0 xb hb yf80 ff17 fs8 fc3 sc0 ls12 ws44e">an antimalarial drug in the dose normally recommended. Drug resistance to</div><div class="t m0 xb hb yf81 ff17 fs8 fc3 sc0 ls12 ws2c3">an antimalarial compound results in a right shift in the concentration–effect</div><div class="t m0 xb hb yf82 ff17 fs8 fc3 sc0 lsfd ws201">(dose–response) relationship (Figur<span class="_ _a"></span>e A6.1). As the pharmacokinetic properties</div><div class="t m0 xb hb yf83 ff17 fs8 fc3 sc0 lsfd ws201">of antimalarials vary widely in different individuals, the definition of r<span class="_ _a"></span>esistance</div><div class="t m0 xb hb yf84 ff17 fs8 fc3 sc0 ls10c ws3d8">should probably also include a “normal” plasma concentr<span class="_ _a"></span>ation profile for</div><div class="t m0 xb hb yf85 ff17 fs8 fc3 sc0 ls6c ws99">the active drug concerned or<span class="_ _4b"></span>, in the case of a prodrug (a drug that is not</div><div class="t m0 xb hb yf86 ff17 fs8 fc3 sc0 ls61 ws86">active in the ingested form and requir<span class="_ _a"></span>es chemical conversion through metabolic</div><div class="t m0 xb hb yf87 ff17 fs8 fc3 sc0 ls81 wsc2">processes to become pharmacologically active), a “<span class="_ _a"></span>normal” profile of the</div><div class="t m0 xb hb yf88 ff17 fs8 fc3 sc0 ls146 ws207">biologically active metabolite. Antimalarial drug resistance is not necessarily</div><div class="t m0 xb hb yf89 ff17 fs8 fc3 sc0 ls12 ws505">the same as malaria “treatment failure<span class="_ _a"></span>”, which is a failure to clear malarial</div><div class="t m0 xb hb yeef ff17 fs8 fc3 sc0 ls31b ws2c2">parasitaemia and/or resolv<span class="_ _a"></span>e clinical symptoms despite the administration of</div><div class="t m0 xb hb yef0 ff17 fs8 fc3 sc0 ls12 ws442">an antimalarial. So while drug resistance may lead to treatment failur<span class="_ _a"></span>e, not</div><div class="t m0 xb hb yef1 ff17 fs8 fc3 sc0 ls42 ws5b">all treatment failures ar<span class="_ _a"></span>e caused by drug resistance. T<span class="_ _4b"></span>reatment failure can also</div><div class="t m0 xb hb yef2 ff17 fs8 fc3 sc0 ls2b9 ws8c">be the result of incorrect dosing, pr<span class="_ _a"></span>oblems of treatment adherence (compliance),</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa6" class="pf w1 h4" data-page-no="a6"><div class="pc pca6 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">156</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls83 wsc7">poor drug quality<span class="_ _4b"></span>, interactions with other drugs, compromised drug absorption,</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls3f ws7c">or misdiagnosis of the patient. Apart from leading to inappropriate case</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls12 ws16a">management, all these factors may also accelerate the spread of true drug</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls13 ws14">resistance by exposure of the par<span class="_ _a"></span>asites to inadequate drug levels.</div><div class="t m0 x9 h3f yf8a ff22 fs5 fc4 sc0 ls209 ws0">Figure A6.1 <span class="ff1b fs9 fc3 ls16">R<span class="_ _a"></span>esistance is a rightward shift in the concentration–effect relationship</span></div><div class="t m0 x28 h3f yf8b ff1b fs9 fc3 sc0 ls16 ws0">for a particular parasite population. This may be a parallel shift (B) from</div><div class="t m0 x28 h3f yf8c ff1b fs9 fc3 sc0 ls2f3 ws1a">the “normal” profile (A) or<span class="_ _4b"></span>, in some circumstances, the slope changes,</div><div class="t m0 x28 h3f yf8d ff1b fs9 fc3 sc0 ls16 ws0">and/or the maximum achievable effect is r<span class="_ _a"></span>educed (C). The effect is</div><div class="t m0 x28 h3f yf8e ff1b fs9 fc3 sc0 ls16 ws0">parasite killing </div><div class="t m0 x9 h12 yf8f ff19 fs6 fc4 sc0 ls0 ws95">A6.3<span class="_ _33"> </span>T<span class="_ _8"></span>he emergence and spread of antimalarial</div><div class="t m0 x28 h12 yf90 ff19 fs6 fc4 sc0 ls9a ws0">resistance</div><div class="t m0 x9 hb yf91 ff17 fs8 fc3 sc0 ls2b0 ws3f3">The development of resistance can be consider<span class="_ _a"></span>ed in two par<span class="_ _8"></span>ts: the initial</div><div class="t m0 x9 hb yf92 ff17 fs8 fc3 sc0 ls1a8 ws3b6">genetic event, which produces the r<span class="_ _a"></span>esistant mutant; and the subsequent</div><div class="t m0 x9 hb yf93 ff17 fs8 fc3 sc0 ls64 wsd7">selection process in which the survival adv<span class="_ _a"></span>antage in the presence of the drug</div><div class="t m0 x9 hb yf94 ff17 fs8 fc3 sc0 ls64 ws207">leads to preferential tr<span class="_ _a"></span>ansmission of resistant mutants and thus the spread of</div><div class="t m0 x9 hb yf95 ff17 fs8 fc3 sc0 ls64 ws506">resistance. In the absence of the antimalarial, resistant mutants may hav<span class="_ _a"></span>e a</div><div class="t m0 x9 hb yf96 ff17 fs8 fc3 sc0 ls31c ws11f">survival disadvantage. <span class="_ _b"></span>This “fitness cost” of the resistance mechanism may result</div><div class="t m0 x9 hb yf97 ff17 fs8 fc3 sc0 ls64 ws507">in a decline in the prev<span class="_ _a"></span>alence of resistance once drug pressure is r<span class="_ _a"></span>emoved. </div><div class="t m0 x9 hb yf98 ff17 fs8 fc3 sc0 ls2da ws345">Resistance to one drug may select for r<span class="_ _a"></span>esistance to another where the mecha-</div><div class="t m0 x9 hb yf99 ff17 fs8 fc3 sc0 lsbc ws6b">nisms of resistance are similar (cr<span class="_ _a"></span>oss-resistance). Ther<span class="_ _a"></span>e are many parallels with</div></div><div class="c xbb yf9a w13 h4e"><div class="t m0 xbb h40 yf9b ff23 fs9 fc3 sc0 ls1a3 ws0">Log conc<span class="_ _a"></span>entration</div><div class="t m0 xcc h40 yf9c ff20 fs9 fc3 sc0 ls31d ws0">Effect</div><div class="t m0 x5a h40 yf9d ff20 fs9 fc3 sc0 ls1a3 ws0">Emax</div><div class="t m0 x77 h40 yf9e ff20 fs9 fc3 sc0 ls0 ws0">A</div><div class="t m0 x72 h40 yf9f ff20 fs9 fc3 sc0 ls0 ws0">B</div><div class="t m0 x18 h40 yfa0 ff20 fs9 fc3 sc0 ls0 ws0">C</div><div class="t m0 xc7 h40 yfa1 ff20 fs9 fc3 sc0 ls1a3 ws0">Emax</div><div class="t m0 x18 h40 yfa2 ff20 fs9 fc3 sc0 ls1a3 ws0">EC</div><div class="t m0 xc1 h28 yfa3 ff20 fs5 fc3 sc0 lsa1 ws0">50</div><div class="t m0 x14 h40 yfa4 ff20 fs9 fc3 sc0 ls1a3 ws0">EC</div><div class="t m0 xa8 h28 yfa5 ff20 fs5 fc3 sc0 lsa1 ws0">50</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa7" class="pf w1 h4" data-page-no="a7"><div class="pc pca7 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">157</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls13b ws1c3">antibiotic resistance, in particular resistance to antituberculosis drugs where,</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls22a ws38f">as for malaria, transferable r<span class="_ _a"></span>esistance genes are not involv<span class="_ _a"></span>ed in the emergence</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls22 ws508">of resistance <span class="ff1a ws0">(1–3)</span><span class="ws474">. In experimental models, drug-resistant mutations can be</span></div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 lse3 ws1b5">selected without mosquito passage (i.e. without meiotic recombination) by</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls70 ws173">exposure of large numbers of malaria par<span class="_ _a"></span>asites (either <span class="ff1a">in vitro</span>, in animals, or as</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls33 ws262">was done in the past, in volunteers) to subtherapeutic drug concentr<span class="_ _a"></span>ations <span class="ff1a ls62 ws0">(4)<span class="ff17">. </span></span></div><div class="t m0 xb hb y18d ff17 fs8 fc3 sc0 ls12 wse8">V<span class="_ _b"></span>arious factors determine the propensity for antimalarial drug resistance to</div><div class="t m0 xb hb y18e ff17 fs8 fc3 sc0 ls12 ws0">develop <span class="ff1a ls13">(5)</span><span class="ls0">:</span></div><div class="t m0 xb hb yfa6 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">the intrinsic frequency with which the genetic changes occur<span class="_ _4b"></span>,</span></div><div class="t m0 xb hb yfa7 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls97 wsf0">the degree of resistance (the shift in the concentr<span class="_ _a"></span>ation-effect relationship,</span></div><div class="t m0 x26 hb y33c ff17 fs8 fc3 sc0 ls13 ws14">(Figure A6.1) conferred by the genetic change,</div><div class="t m0 xb hb yfa8 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">the fitness cost of the resistance mechanism,</span></div><div class="t m0 xb hb yfa9 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws304">the proportion of all transmissible infections that are exposed to the drug</span></div><div class="t m0 x26 hb yfaa ff17 fs8 fc3 sc0 ls12 ws0">(the selection pressure),</div><div class="t m0 xb hb yfab ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">the number of parasites exposed to the drug,</span></div><div class="t m0 xb hb yfac ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">the concentrations of drug to which these parasites ar<span class="_ _a"></span>e exposed ,</span></div><div class="t m0 xb hb yfad ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls16e ws245">the pharmacokinetic and pharmacodynamic properties of the antimalarial,</span></div><div class="t m0 xb hb yfae ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 lsf7 ws1ad">individual (dosing, duration, adherence) and community (quality<span class="_ _c"></span>, availability<span class="_ _4b"></span>,</span></div><div class="t m0 x26 hb yfaf ff17 fs8 fc3 sc0 ls12 ws0">distribution) patterns of drug use,</div><div class="t m0 xb hb yfb0 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12">the immunity profile of the community and the individual,</span></div><div class="t m0 xb hb yfb1 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls29a ws436">the simultaneous presence of other antimalarials or substances in the</span></div><div class="t m0 x26 hb yfb2 ff17 fs8 fc3 sc0 ls12 ws0">blood to which the parasite is not resistant.</div><div class="t m0 xb hb yfb3 ff17 fs8 fc3 sc0 ls64 wsc6">The emergence of resistance can be thought of in terms of the pr<span class="_ _a"></span>oduct of the</div><div class="t m0 xb hb yfb4 ff17 fs8 fc3 sc0 ls64 ws11e">probabilities of <span class="ff1a">de no<span class="_ _a"></span>vo <span class="ff17 ws132">emergence (a rar<span class="_ _a"></span>e event) and subsequent spread.</span></span></div><div class="t m0 xb hb yfb5 ff17 fs8 fc3 sc0 ls6b ws1a6">Resistant par<span class="_ _a"></span>asites, if present, will be selected when parasites are exposed to</div><div class="t m0 xb hb yfb6 ff17 fs8 fc3 sc0 ls64 wsdf">“<span class="_ _a"></span>selective<span class="_ _a"></span>” (subtherapeutic) drug concentrations. “Selective<span class="_ _a"></span>” in this context</div><div class="t m0 xb hb yfb7 ff17 fs8 fc3 sc0 ls64 ws509">means a concentration of drug that will eradicate the sensitiv<span class="_ _a"></span>e parasites but</div><div class="t m0 xb hb yfb8 ff17 fs8 fc3 sc0 ls64 ws50a">still allow gro<span class="_ _a"></span>wth of the resistant parasite population such that it ev<span class="_ _a"></span>entually</div><div class="t m0 xb hb yfb9 ff17 fs8 fc3 sc0 ls1a9 ws436">transmits to another person. Because <span class="ff1a">de no<span class="_ _a"></span>vo <span class="ff17">resistance arises randomly</span></span></div><div class="t m0 xb hb yfba ff17 fs8 fc3 sc0 lsae ws83">among malaria parasites, non-immune patients infected with large numbers of</div><div class="t m0 xb hb yfbb ff17 fs8 fc3 sc0 ls180 ws3b">parasites who receiv<span class="_ _a"></span>e inadequate treatment (either because of poor drug</div><div class="t m0 xb hb yfbc ff17 fs8 fc3 sc0 ls2c2 ws244">quality<span class="_ _4b"></span>, poor adherence, vomiting of an or<span class="_ _a"></span>al treatment, etc.) are a potent</div><div class="t m0 xb hb yfbd ff17 fs8 fc3 sc0 ls29 ws3b1">source of <span class="ff1a">de nov<span class="_ _a"></span>o <span class="ff17">resistance. <span class="_ _a"></span>This emphasizes the impor<span class="_ _8"></span>tance of correct</span></span></div><div class="t m0 xb hb yfbe ff17 fs8 fc3 sc0 ls18b wsfa">prescribing, and good adherence to pr<span class="_ _a"></span>escribed drug regimens, and also pro<span class="_ _a"></span>vi-</div><div class="t m0 xb hb yfbf ff17 fs8 fc3 sc0 ls64 ws1df">sion of treatment regimens that ar<span class="_ _a"></span>e still highly effective in hyperparasitaemic</div><div class="t m0 xb hb yfc0 ff17 fs8 fc3 sc0 ls64 ws15b">patients. The principle specific immune r<span class="_ _a"></span>esponse that controls the primary</div><div class="t m0 xb hb yfc1 ff17 fs8 fc3 sc0 ls64 ws178">symptomatic infection in falciparum malaria is directed by the v<span class="_ _a"></span>ariant surface</div><div class="t m0 xb hb yfc2 ff17 fs8 fc3 sc0 ls64 ws469">antigen (PfEM<span class="_ _8"></span>P1). The parasite population ev<span class="_ _b"></span>ades this immune response by</div><div class="t m0 xb hb yfc3 ff17 fs8 fc3 sc0 ls185 ws347">switching its surface antigen in a specific sequence of changes. The pr<span class="_ _a"></span>obability</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa8" class="pf w1 h4" data-page-no="a8"><div class="pc pca8 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">158</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls1fa ws110">of selecting a resistant parasite fr<span class="_ _a"></span>om the primary infection is the product of the</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls64 ws0">switch rate and the rate of formation of viable r<span class="_ _a"></span>esistant parasites.</div><div class="t m0 x9 hb y1f3 ff17 fs8 fc3 sc0 ls3c ws31">The subsequent spread of resistant mutant malaria par<span class="_ _a"></span>asites is facilitated by</div><div class="t m0 x9 hb y18a ff17 fs8 fc3 sc0 ls12 ws50b">the widespread use of drugs with long elimination phases. <span class="_ _a"></span>These provide a</div><div class="t m0 x9 hb y18b ff17 fs8 fc3 sc0 ls17e ws25e">“<span class="_ _a"></span>selective filter”, allowing infection by the r<span class="_ _a"></span>esistant parasites while the</div><div class="t m0 x9 hb y18c ff17 fs8 fc3 sc0 ls1d8 ws173">residual antimalarial activity prev<span class="_ _a"></span>ents infection by sensitive parasites. Slo<span class="_ _a"></span>wly</div><div class="t m0 x9 hb y18d ff17 fs8 fc3 sc0 lsba wsb1">eliminated drugs such as mefloquine (terminal elimination half-life (T</div><div class="t m0 xcd h4f yfc4 ff28 fs15 fc3 sc0 ls31e ws0">1/2</div><div class="t m0 xce hb yfc5 ff1c fs8 fc3 sc0 ls0 ws0">β<span class="_ _6"> </span><span class="ff17 lsef">2–3</span></div><div class="t m0 x9 hb yfc6 ff17 fs8 fc3 sc0 ls12 ws33e">weeks) or chloroquine (T</div><div class="t m0 x50 h4f yfc7 ff28 fs15 fc3 sc0 ls31f ws0">1/2</div><div class="t m0 xb4 hb yfc6 ff1c fs8 fc3 sc0 ls0 ws0">β<span class="_ _95"> </span><span class="ff17 ls12 ws33e">1–2 months) persist in the blood and pro<span class="_ _a"></span>vide a</span></div><div class="t m0 x9 hb yfc8 ff17 fs8 fc3 sc0 ls12 ws0">selective filter for months after drug administration has ceased. </div><div class="t m0 x9 h2e y155 ff19 fs3 fc3 sc0 ls0 wsc1">A6.3.1<span class="_ _a7"> </span>T<span class="_ _4b"></span>ransmission intensit<span class="_ _8"></span>y and the selection and spread</div><div class="t m0 xba h2e yfc9 ff19 fs3 fc3 sc0 ls80 ws0">of resistance</div><div class="t m0 x9 hb yfca ff17 fs8 fc3 sc0 ls1ab ws2fd">The recrudescence and subsequent transmission of an infection that has</div><div class="t m0 x9 hb yfcb ff17 fs8 fc3 sc0 ls13 ws50c">generated a <span class="ff1a ls64">de no<span class="_ _a"></span>vo <span class="ff17 ls12">resistant malaria parasite is essential for resistance to</span></span></div><div class="t m0 x9 hb y65e ff17 fs8 fc3 sc0 ls12 ws172">be propagated <span class="ff1a ls13 ws0">(5)</span>. Gametocytes carrying the resistance genes will not reach</div><div class="t m0 x9 hb y65f ff17 fs8 fc3 sc0 ls13c ws189">transmissible densities until the resistant biomass has expanded to numbers</div><div class="t m0 x9 hb y660 ff17 fs8 fc3 sc0 ls1db ws438">close to those producing illness (<span class="ff1c ls0 ws0">&gt;<span class="_ _9"></span><span class="ff17 ls4b">10</span></span></div><div class="t m0 x54 h11 yfcc ff17 fs5 fc3 sc0 ls320 ws0">7 </div><div class="t m0 x64 hb y660 ff17 fs8 fc3 sc0 ls1db ws0">parasites) <span class="_ _a"></span><span class="ff1a">(6)<span class="ff17 ws438">. Thus to prev<span class="_ _a"></span>ent resistance</span></span></div><div class="t m0 x9 hb y661 ff17 fs8 fc3 sc0 ls145 ws205">spreading from an infection that has gener<span class="_ _a"></span>ated <span class="ff1a ls5a">de novo </span>resistance, gametocyte</div><div class="t m0 x9 hb y662 ff17 fs8 fc3 sc0 ls238 ws1ff">production from the r<span class="_ _a"></span>ecrudescent resistant infection must be prevented.</div><div class="t m0 x9 hb y663 ff17 fs8 fc3 sc0 ls12 ws473">There has been debate as to whether resistance arises mor<span class="_ _a"></span>e rapidly in low-</div><div class="t m0 x9 hb y664 ff17 fs8 fc3 sc0 ls12 ws279">or high-transmission settings <span class="ff1a ls13">(7, 8)</span>, but aside from theor<span class="_ _a"></span>etical calculations,</div><div class="t m0 x9 hb yfcd ff17 fs8 fc3 sc0 ls12 ws389">epidemiological studies clearly implicate low-transmission settings as the</div><div class="t m0 x9 hb yfce ff17 fs8 fc3 sc0 ls7f wsc0">source of drug resistance. Chlor<span class="_ _a"></span>oquine resistance and high-level sulfadoxine-</div><div class="t m0 x9 hb yfcf ff17 fs8 fc3 sc0 ls9c wsfa">pyrimethamine resistance in <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum <span class="_ _b"></span><span class="ff17 wsfa">both originated in South-East Asia</span></span></div><div class="t m0 x9 hb yfd0 ff17 fs8 fc3 sc0 ls12 ws0">and subsequently spread to Africa <span class="ff1a ls13">(9)</span><span class="ls0">.</span></div><div class="t m0 x9 hb yfd1 ff17 fs8 fc3 sc0 ls16e ws245">In low-transmission ar<span class="_ _a"></span>eas, the majority of malaria infections are symptomatic</div><div class="t m0 x9 hb yfd2 ff17 fs8 fc3 sc0 ls22a ws38f">and selection therefore takes place in the context of tr<span class="_ _a"></span>eatment. Relatively lar<span class="_ _a"></span>ge</div><div class="t m0 x9 hb yfd3 ff17 fs8 fc3 sc0 lsa1 ws100">numbers of parasites in an individual usually encounter antimalarials at</div><div class="t m0 x9 hb yfd4 ff17 fs8 fc3 sc0 ls12 ws213">concentrations that are maximally effectiv<span class="_ _a"></span>e. But in a variable proportion of</div><div class="t m0 x9 hb yfd5 ff17 fs8 fc3 sc0 ls2bc ws48d">patients, for the reasons mentioned earlier<span class="_ _4b"></span>, blood concentrations are low</div><div class="t m0 x9 hb yfd6 ff17 fs8 fc3 sc0 ls12 ws0">and may select for resistance. </div><div class="t m0 x9 hb yfd7 ff17 fs8 fc3 sc0 ls64 ws23b">In high-transmission areas, the majority of infections ar<span class="_ _a"></span>e asymptomatic and</div><div class="t m0 x9 hb yfd8 ff17 fs8 fc3 sc0 ls7b ws17c">infections are acquired r<span class="_ _a"></span>epeatedly throughout life. Symptomatic and sometimes</div><div class="t m0 x9 hb yfd9 ff17 fs8 fc3 sc0 lsf7 ws38f">fatal malaria occurs in the first years of life, but thereafter it is incr<span class="_ _a"></span>easingly likely</div><div class="t m0 x9 hb yfda ff17 fs8 fc3 sc0 ls2cc wsc9">to be asymptomatic. This r<span class="_ _a"></span>eflects a state of imperfect immunity (premunition),</div><div class="t m0 x9 hb yfdb ff17 fs8 fc3 sc0 ls321 ws50d">where the infection is controlled, usually at lev<span class="_ _a"></span>els below those causing</div><div class="t m0 x9 hb yfdc ff17 fs8 fc3 sc0 ls42 ws19f">symptoms. The r<span class="_ _a"></span>ate at which premunition is acquired depends on the intensity</div><div class="t m0 x9 hb yfdd ff17 fs8 fc3 sc0 ls64 ws50e">of transmission. In the context of intense malaria transmission, people still</div><div class="t m0 x9 hb yfde ff17 fs8 fc3 sc0 ls161 ws31e">receive antimalarial tr<span class="_ _a"></span>eatments throughout their lives (often inappr<span class="_ _a"></span>opriately for</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa9" class="pf w1 h4" data-page-no="a9"><div class="pc pca9 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">159</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls30d ws50f">other febrile infections), but these “treatments” are lar<span class="_ _a"></span>gely unrelated to the peaks</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls10e ws26d">of parasitaemia, thereby r<span class="_ _a"></span>educing the probability of selection for resistance. </div><div class="t m0 xb hb y1f3 ff17 fs8 fc3 sc0 ls45 ws264">Immunity considerably reduces the emer<span class="_ _a"></span>gence of resistance <span class="ff1a ws0">(9)</span>. Host defence</div><div class="t m0 xb hb y18a ff17 fs8 fc3 sc0 ls3c ws1ee">contributes a major antiparasitic effect, and any spontaneously generated</div><div class="t m0 xb hb y18b ff17 fs8 fc3 sc0 ls322 ws45f">drug-resistant mutant malaria parasite must contend not only with the</div><div class="t m0 xb hb y18c ff17 fs8 fc3 sc0 ls64 ws4ba">concentrations of antimalarial present, but also with host immunity<span class="_ _c"></span>. This kills</div><div class="t m0 xb hb y18d ff17 fs8 fc3 sc0 ls87 ws438">parasites regar<span class="_ _a"></span>dless of their antimalarial resistance, and reduces the probability</div><div class="t m0 xb hb y18e ff17 fs8 fc3 sc0 ls64 ws147">of parasite survival (independently of drugs) at all stages of the transmission</div><div class="t m0 xb hb y18f ff17 fs8 fc3 sc0 ls64 ws19e">cycle. F<span class="_ _a"></span>or the blood stage infection, immunity acts in a similar way to anti-</div><div class="t m0 xb hb y190 ff17 fs8 fc3 sc0 ls64 ws1bd">malarials both to eliminate the rare <span class="ff1a">de no<span class="_ _a"></span>vo <span class="ff17">resistant mutants and stop them</span></span></div><div class="t m0 xb hb y191 ff17 fs8 fc3 sc0 ls64 ws509">being transmitted (i.e. like a combination therapy), and also to impr<span class="_ _a"></span>ove cur<span class="_ _a"></span>e</div><div class="t m0 xb hb y192 ff17 fs8 fc3 sc0 ls64 ws50c">rates with failing drugs (i.e. drugs falling to resistance) ther<span class="_ _a"></span>eby reducing the</div><div class="t m0 xb hb y193 ff17 fs8 fc3 sc0 ls28f ws272">relative tr<span class="_ _a"></span>ansmission advantage of resistant par<span class="_ _a"></span>asites. Even if a r<span class="_ _a"></span>esistant</div><div class="t m0 xb hb y2c0 ff17 fs8 fc3 sc0 ls64 ws230">mutant does survive the initial drug treatment and multiplies, the chance that</div><div class="t m0 xb hb y2c1 ff17 fs8 fc3 sc0 ls28 ws17b">this will result in sufficient gametocytes for transmission is r<span class="_ _a"></span>educed as a result</div><div class="t m0 xb hb y2c2 ff17 fs8 fc3 sc0 ls64 ws420">of asexual stage immunity (which reduces the multiplication rate and lo<span class="_ _a"></span>wers</div><div class="t m0 xb hb y2c3 ff17 fs8 fc3 sc0 ls95 ws439">the density at which the infection is controlled) and transmission-blocking</div><div class="t m0 xb hb y2c4 ff17 fs8 fc3 sc0 ls1fe ws1b6">immunity<span class="_ _4b"></span>. Furthermore, other parasite genotypes are likely to be pr<span class="_ _a"></span>esent,</div><div class="t m0 xb hb y2c5 ff17 fs8 fc3 sc0 lse9 wsb8">competing with the resistant parasites for r<span class="_ _a"></span>ed cells, and increasing the possibility</div><div class="t m0 xb hb y2c6 ff17 fs8 fc3 sc0 ls1be ws1fb">of outbreeding of multigenic resistance mechanisms or competition in the</div><div class="t m0 xb hb y486 ff17 fs8 fc3 sc0 ls64 ws0">feeding anopheline mosquito <span class="ff1a lsc4">(10)</span><span class="ls10e">. </span></div><div class="t m0 xb h2e y73a ff19 fs3 fc3 sc0 ls323 ws510">A6.3.2<span class="_ _a7"> </span>Antimalar<span class="_ _8"></span>ial pharmacodynamics and the selection</div><div class="t m0 x9d h2e yfdf ff19 fs3 fc3 sc0 ls80 ws0">of resistance</div><div class="t m0 xb hb yfd0 ff17 fs8 fc3 sc0 ls12 ws3e0">The genetic events that confer antimalarial drug resistance (while r<span class="_ _a"></span>etaining</div><div class="t m0 xb hb yfe0 ff17 fs8 fc3 sc0 ls22b ws390">parasite viability) are spontaneous and r<span class="_ _a"></span>are. They ar<span class="_ _a"></span>e thought to be independent</div><div class="t m0 xb hb yfe1 ff17 fs8 fc3 sc0 ls2c5 ws1ca">of the drug. The r<span class="_ _a"></span>esistance mechanisms that have been described are mutations</div><div class="t m0 xb hb yfe2 ff17 fs8 fc3 sc0 ls8e wsdd">in genes or changes in the copy number of genes relating to the drug’<span class="_ _4b"></span>s target</div><div class="t m0 xb hb yfe3 ff17 fs8 fc3 sc0 ls67 ws1f9">or pumps that affect intraparasitic concentr<span class="_ _a"></span>ations of the drug. A single genetic</div><div class="t m0 xb hb yfe4 ff17 fs8 fc3 sc0 ls17b ws258">event may be all that is requir<span class="_ _a"></span>ed, or multiple unlinked events may be necessary</div><div class="t m0 xb hb yfe5 ff17 fs8 fc3 sc0 ls126 ws0">(epistasis). <span class="ff1a">P<span class="_ _ae"></span>. falciparum<span class="_ _6"> </span><span class="ff17 ws343">parasites from South-East Asia seem constitutionally</span></span></div><div class="t m0 xb hb yfe6 ff17 fs8 fc3 sc0 ls12 ws0">to have an increased pr<span class="_ _a"></span>opensity to develop drug resistance. </div><div class="t m0 xb h25 yfe7 ff1f fs12 fc4 sc0 ls285 ws0">Aminoquinolines</div><div class="t m0 xb hb yfe8 ff17 fs8 fc3 sc0 lse4 ws174">Chloroquine resistance in <span class="ff1a ws0">P<span class="_ _ae"></span>.<span class="_ _68"> </span>falciparum <span class="_ _66"></span><span class="ff17 ws174">may be multigenic and is initially</span></span></div><div class="t m0 xb hb yfe9 ff17 fs8 fc3 sc0 ls14 ws511">conferred by mutations in a gene that encodes a transporter (PfCR<span class="_ _a"></span>T). PfCRT</div><div class="t m0 xb hb yfea ff17 fs8 fc3 sc0 ls21b ws2d9">may be an anion channel pumping chloroquine out from the food v<span class="_ _b"></span>acuole. The</div><div class="t m0 xb hb yfeb ff17 fs8 fc3 sc0 ls12 ws96">initial mutation, which confers a moderate level of chlor<span class="_ _a"></span>oquine resistance, is</div><div class="t m0 xb hb yfec ff17 fs8 fc3 sc0 ls287 ws2d5">replacement of a lysine with threonine at codon 76. P<span class="_ _a"></span>ositions 72 to 76 are critical</div><div class="t m0 xb hb yfed ff17 fs8 fc3 sc0 ls3c ws31">for the binding of desethylamodiaquine (the biologically active metabolite of</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfaa" class="pf w1 h4" data-page-no="aa"><div class="pc pcaa w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">160</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls1d ws1c">amodiaquine) and also verapamil (which may r<span class="_ _a"></span>everse chloroquine r<span class="_ _a"></span>esistance</div><div class="t m0 x9 hb y9f ff1a fs8 fc3 sc0 ls13 ws2cc">in vitro<span class="ff17 ls14 ws512">). Eleven other PfCR<span class="_ _b"></span>T mutations have been described to date. <span class="_ _a"></span>These</span></div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls1a9 ws262">additional mutations may contribute to aminoquinoline resistance, although</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls219 ws371">the precise mechanisms have not y<span class="_ _a"></span>et been determined. Amodiaquine resistance</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls1b0 ws2c0">is linked to chloroquine resistance, but is not w<span class="_ _a"></span>ell characterized. In the</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls17f ws25f">presence of PfCR<span class="_ _b"></span>T mutations, point mutations in a second transporter (PfM<span class="_ _8"></span>DR1)</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls7c wsb9">modulate the level of <span class="ff1a">P<span class="_ _c"></span>. falciparum <span class="ff17 ws0">resistance <span class="_ _9"></span></span><span class="ws38">in vitro<span class="ff17">. Parasites that ar<span class="_ _a"></span>e</span></span></span></div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 ls13 ws425">highly resistant to chloroquine often hav<span class="_ _a"></span>e L<span class="_ _b"></span>ys76Thr and Ala220Ser in PfCRT<span class="_ _4b"></span>,</div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 ls0 ws437">and Asn86T<span class="_ _b"></span>yr in PfM<span class="_ _8"></span>DR. The r<span class="_ _a"></span>ole of PfM<span class="_ _8"></span>DR1 mutations in determining the</div><div class="t m0 x9 hb y110 ff17 fs8 fc3 sc0 ls18c ws26f">therapeutic response follo<span class="_ _a"></span>wing chloroquine treatment is still unclear<span class="_ _4b"></span>. The</div><div class="t m0 x9 hb y111 ff17 fs8 fc3 sc0 ls12 ws0">cause of chloroquine resistance in <span class="ff1a ls14">P<span class="_ _ae"></span>. vivax <span class="ff17 ls12">has not been found yet</span>. </span></div><div class="t m0 x9 h25 y962 ff1f fs12 fc4 sc0 ls285 ws0">Mefloquine</div><div class="t m0 x9 hb yba0 ff17 fs8 fc3 sc0 ls12 ws15d">Resistance to mefloquine and other structur<span class="_ _a"></span>ally related aryl-amino-alcohols</div><div class="t m0 x9 hb ya20 ff17 fs8 fc3 sc0 ls13 ws0">in <span class="ff1a">P<span class="_ _c"></span>.<span class="_ _95"> </span>falciparum<span class="_ _95"> </span><span class="ff17 ls12 ws513">results from amplifications (i.e. duplications not mutations)</span></span></div><div class="t m0 x9 hb ya21 ff17 fs8 fc3 sc0 ls13 ws0">in <span class="_ _66"></span><span class="ff1a ls12">Pfmdr<span class="ff17 ws42a">, which encodes an energy-demanding </span><span class="ls0">p</span><span class="ff17 ws42a">-glycopr<span class="_ _a"></span>otein pump. This</span></span></div><div class="t m0 x9 hb ya22 ff17 fs8 fc3 sc0 ls2ac ws2c1">explains approximately two-thir<span class="_ _a"></span>ds of the variance in susceptibility<span class="_ _c"></span>. Interestingly<span class="_ _4b"></span>,</div><div class="t m0 x9 hb ya23 ff17 fs8 fc3 sc0 ls1e ws1d">it appears that generally only the “wild type<span class="_ _a"></span>” (PfM<span class="_ _8"></span>DR Asn86) amplifies, so that</div><div class="t m0 x9 hb ya24 ff17 fs8 fc3 sc0 ls12 ws514">in the transition from chlor<span class="_ _a"></span>oquine resistance, back mutation from mutant to</div><div class="t m0 x9 hb ya25 ff17 fs8 fc3 sc0 ls160 ws230">wild type precedes amplification. Gene duplication is particularly frequent in</div><div class="t m0 x9 hb ya26 ff17 fs8 fc3 sc0 ls278 ws0">the <span class="_ _66"></span><span class="ff1a">P<span class="_ _c"></span>.<span class="_ _3"> </span>falciparum<span class="_ _3"> </span><span class="ff17 ws411">genome. It is a much more common genetic event than</span></span></div><div class="t m0 x9 hb ya27 ff17 fs8 fc3 sc0 ls262 ws38e">mutation. The lo<span class="_ _a"></span>w background frequency of gene amplification suggests that</div><div class="t m0 x9 hb ya28 ff17 fs8 fc3 sc0 ls3d wsbd">it may well confer a fitness disadv<span class="_ _a"></span>antage in the absence of selective pressure. </div><div class="t m0 x9 hb yfee ff17 fs8 fc3 sc0 ls12 ws515">The products of these v<span class="_ _a"></span>arious genetic events result in reduced intr<span class="_ _a"></span>acellular</div><div class="t m0 x9 hb yfef ff17 fs8 fc3 sc0 ls1ab ws2fd">concentrations of the antimalarial quinolines in the parasite (the r<span class="_ _a"></span>elative</div><div class="t m0 x9 hb yff0 ff17 fs8 fc3 sc0 ls12 ws0">importance of reduced uptake and increased efflux remains unresolv<span class="_ _a"></span>ed). </div><div class="t m0 x9 h25 ybff ff1f fs12 fc4 sc0 ls285 ws0">Antifolate antimalarials</div><div class="t m0 x9 hb yff1 ff17 fs8 fc3 sc0 lsfe ws372">For the antifolate antimalarials (pyrimethamine, and the biguanides cy<span class="_ _a"></span>cloguanil</div><div class="t m0 x9 hb yff2 ff17 fs8 fc3 sc0 ls245 ws161">and chlorcycloguanil – the activ<span class="_ _a"></span>e metabolites of proguanil and chlorproguanil,</div><div class="t m0 x9 hb yff3 ff17 fs8 fc3 sc0 ls161 ws516">respectively) r<span class="_ _a"></span>esistance in <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum<span class="_ _6"> </span><span class="ff17">and </span>P<span class="_ _ae"></span>. vivax <span class="_ _a"></span><span class="ff17 ws516">results from the sequential</span></span></div><div class="t m0 x9 hb yff4 ff17 fs8 fc3 sc0 ls20 ws1f">acquisition of mutations in the gene <span class="ff1a ws0">(dhfr) </span>that encodes dihydr<span class="_ _a"></span>ofolate reductase</div><div class="t m0 x9 hb yff5 ff17 fs8 fc3 sc0 ls324 ws47d">(DHF<span class="_ _8"></span>R). Each mutation confers a stepwise reduction in susceptibility<span class="_ _4b"></span>. In</div><div class="t m0 x9 hb yff6 ff1a fs8 fc3 sc0 ls325 ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>falciparum<span class="ff17 ws233">, the initial mutation is almost invariably at position 108 (usually</span></div><div class="t m0 x9 hb yff7 ff17 fs8 fc3 sc0 ls326 ws517">serine to asparagine), which confers only a ten-fold reduction in drug</div><div class="t m0 x9 hb yff8 ff17 fs8 fc3 sc0 ls3f ws7c">susceptibility<span class="_ _4b"></span>, and does not affect therapeutic responses to sulfado<span class="_ _a"></span>xine-</div><div class="t m0 x9 hb yff9 ff17 fs8 fc3 sc0 ls12 ws44e">pyrimethamine. This has little clinical r<span class="_ _a"></span>elevance initially<span class="_ _c"></span>, but then mutations</div><div class="t m0 x9 hb yffa ff17 fs8 fc3 sc0 ls28c ws304">arise at positions 51 and 59, conferring increasing resistance to pyrimethamine</div><div class="t m0 x9 hb yffb ff17 fs8 fc3 sc0 ls1d4 ws2f4">containing medicines. Infections with triple mutants are relativ<span class="_ _a"></span>ely resistant but</div><div class="t m0 x9 hb yffc ff17 fs8 fc3 sc0 ls12 ws518">some therapeutic response is usually seen. <span class="_ _b"></span>The acquisition of a four<span class="_ _8"></span>th and</div><div class="t m0 x9 hb yffd ff17 fs8 fc3 sc0 ls241 ws3b1">devastating mutation at position 164 (isoleucine to leucine) r<span class="_ _a"></span>enders the</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfab" class="pf w1 h4" data-page-no="ab"><div class="pc pcab w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">161</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls13d ws1fc">available antifolates completely ineffectiv<span class="_ _a"></span>e <span class="ff1a ws0">(11)</span>. Interestingly<span class="_ _4b"></span>, mutations</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls2c ws39">conferring moderate pyrimethamine resistance do not necessarily confer</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls37 ws48">cycloguanil resistance, and vice v<span class="_ _a"></span>ersa. For example, mutations at positions 16</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls13 ws50">(alanine to valine) plus 108 (serine to thr<span class="_ _a"></span>eonine) confer high-level resistance</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls160 ws230">to cycloguanil but not to pyrimethamine.<span class="_ _67"></span>In gener<span class="_ _a"></span>al, the biguanides are more</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls12 ws3ea">active than pyrimethamine against the resistant mutants (and they ar<span class="_ _a"></span>e more</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls1fc ws214">effective clinically too), but they are ineffectiv<span class="_ _a"></span>e against parasites with the DHFR</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 ls327 ws519">mutation at position 164. <span class="ff1a ls328 ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax <span class="_ _9"></span><span class="ff17 ls327 ws519">shares similar antifolate resistance</span></span></div><div class="t m0 xb hb y10f ff17 fs8 fc3 sc0 ls28 ws34">mechanisms through serial acquisition of mutations in PvDHFR. The sequence</div><div class="t m0 xb hb y110 ff17 fs8 fc3 sc0 ls12 ws21f">of acquisition associated with increasing resistance is usually mutation at</div><div class="t m0 xb hb y111 ff17 fs8 fc3 sc0 ls13 ws14">position 117 or 58, followed by mutation at positions 57, 61 and then 13.</div><div class="t m0 xb h25 y962 ff1f fs12 fc4 sc0 ls285 ws0">Sulfonamide and sulfone</div><div class="t m0 xb hb yba0 ff17 fs8 fc3 sc0 ls192 ws27a">The marked synergy with sulfonamides and sulfones is v<span class="_ _a"></span>ery impor<span class="_ _8"></span>tant for the</div><div class="t m0 xb hb ya20 ff17 fs8 fc3 sc0 ls26e wsa1">antimalarial activity of sulfa-pyrimethamine or sulfone-biguanide combinations.</div><div class="t m0 xb hb ya21 ff17 fs8 fc3 sc0 ls329 ws0">In <span class="_ _9"></span><span class="ff1a">P<span class="_ _c"></span>.<span class="_ _3"> </span>falciparum<span class="ff17 ws51a">, sulfonamide and sulfone resistance also develops by</span></span></div><div class="t m0 xb hb ya22 ff17 fs8 fc3 sc0 ls1a9 ws262">progressiv<span class="_ _a"></span>e acquisition of mutations in the gene encoding the target enzyme</div><div class="t m0 xb hb ya23 ff17 fs8 fc3 sc0 ls13 ws51b">PfDHPS<span class="_ _67"> </span>(which is a bifunctional protein with the enzyme PPPK). Specifically</div><div class="t m0 xb hb ya24 ff17 fs8 fc3 sc0 ls13 ws28e">altered amino acid residues hav<span class="_ _a"></span>e been found at positions 436, 437, 540, 581</div><div class="t m0 xb hb ya25 ff17 fs8 fc3 sc0 ls1a5 ws76">and 613 in the PfDHPS domain. The mutations at positions 581 and 631 do not</div><div class="t m0 xb hb ya26 ff17 fs8 fc3 sc0 ls75 wsb0">occur in isolation, but always following an initial mutation (usually at position</div><div class="t m0 xb hb ya27 ff17 fs8 fc3 sc0 ls274 ws40d">437, alanine to glycine). Mutations in <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>vivax <span class="_ _b"></span><span class="ff17 lsd5 ws1f9">DHPS (at positions 383 and 553)</span></span></div><div class="t m0 xb hb ya28 ff17 fs8 fc3 sc0 ls12 ws0">also appear to contribute to resistance.</div><div class="t m0 xb h25 yffe ff1f fs12 fc4 sc0 ls285 ws0">Atov<span class="_ _a"></span>aquone-proguanil</div><div class="t m0 xb hb yd34 ff17 fs8 fc3 sc0 ls2a9 ws94">Resistance to ato<span class="_ _a"></span>vaquone results fr<span class="_ _a"></span>om point mutations in the gene <span class="ff1a ws0">(cytB)</span>, which</div><div class="t m0 xb hb yd35 ff17 fs8 fc3 sc0 ls5a ws77">encodes cytochrome b<span class="_ _a"></span>. In the atovaquone-pr<span class="_ _a"></span>oguanil combination, it is proguanil</div><div class="t m0 xb hb yd36 ff17 fs8 fc3 sc0 ls12 ws5c">itself probably acting on the mitochondrial membrane r<span class="_ _a"></span>ather than the <span class="ff1a ws0">dhfr<span class="ff17 ls0">-</span></span></div><div class="t m0 xb hb yd37 ff17 fs8 fc3 sc0 lsed ws191">inhibiting proguanil metabolite cycloguanil that appears to be important in this</div><div class="t m0 xb hb yd38 ff17 fs8 fc3 sc0 ls294 ws58">combination. Whether and ho<span class="_ _a"></span>w resistance develops to the mitochondrial action</div><div class="t m0 xb hb yd39 ff17 fs8 fc3 sc0 ls12 ws0">of proguanil is not known.</div><div class="t m0 xb h25 yfff ff1f fs12 fc4 sc0 ls285 ws0">Artemisinins</div><div class="t m0 xb hb ycf7 ff17 fs8 fc3 sc0 ls190 wse6">Although a target for the artemisinins has recently been identified <span class="ff1a ls0 ws0">(<span class="ff17 lsbb">PfA<span class="_ _4b"></span>TPase<span class="ff1a">6)</span><span class="ls0">,</span></span></span></div><div class="t m0 xb hb yc05 ff17 fs8 fc3 sc0 ls200 ws433">preliminary studies have not so far associated polymorphisms in the gene</div><div class="t m0 xb hb y1000 ff17 fs8 fc3 sc0 ls32a ws23e">encoding this enzyme with reduced susceptibility of malaria parasites.</div><div class="t m0 xb hb y1001 ff17 fs8 fc3 sc0 lsba ws12a">Amplification in PfMDR does reduce ar<span class="_ _8"></span>temisinin susceptibility <span class="ff1a ls181 wsef">in vitro<span class="ff17 lsef">, but</span></span></div><div class="t m0 xb hb y1002 ff17 fs8 fc3 sc0 ls325 ws26f">not to a degree that causes <span class="ff1a ls90">in vivo </span>r<span class="_ _a"></span>esistance. This has lead to erroneous</div><div class="t m0 xb hb y1003 ff17 fs8 fc3 sc0 ls10e ws51c">claims that artemisinin resistance was being selected by widespread use of</div><div class="t m0 xb hb y1004 ff17 fs8 fc3 sc0 ls2bb ws400">artemisinin derivatives, whereas in fact the selection pr<span class="_ _a"></span>essure came from</div><div class="t m0 xb hb y1005 ff17 fs8 fc3 sc0 ls64 ws0">mefloquine use. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfac" class="pf w1 h4" data-page-no="ac"><div class="pc pcac w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">162</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls64 ws3ab">The mutation frequencies derived fr<span class="_ _a"></span>om <span class="ff1a">in vitro </span>studies are often much higher</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls273 wsb5">than those derived from observations <span class="ff1a ls22c ws216">in viv<span class="_ _a"></span>o (12)<span class="ff17 ls273 wsb5">. The absence of host defences</span></span></div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls32b ws51d">and differences in antimalarial concentration pr<span class="_ _a"></span>ofiles contribute to this</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls110 ws6f">discrepancy<span class="_ _c"></span>. The highest rates of emergence of r<span class="_ _a"></span>esistance <span class="ff1a">in vivo </span>are for</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls4a ws49f">pyrimethamine and atov<span class="_ _a"></span>aquone. In the case of atov<span class="_ _a"></span>aquone, it has been</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls9f ws2d9">estimated that one in three patients with symptomatic falciparum “<span class="_ _b"></span>contained”,</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls16d ws138">at presentation, a spontaneously arising ato<span class="_ _a"></span>vaquone-resistant mutant par<span class="_ _a"></span>asite</div><div class="t m0 x9 hb y10e ff1a fs8 fc3 sc0 ls1d4 ws0">(5)<span class="ff17 ls218 ws96">. For drugs such as chlor<span class="_ _a"></span>oquine or ar<span class="_ _8"></span>temisinin, the genetic events conferring</span></div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 lsab ws2fe">resistance are much r<span class="_ _a"></span>arer<span class="_ _b"></span>. These genetic ev<span class="_ _a"></span>ents may result in moderate changes</div><div class="t m0 x9 hb y110 ff17 fs8 fc3 sc0 ls64 ws51e">in drug susceptibility<span class="_ _4b"></span>, such that the drug still remains effective (e.g. as in the</div><div class="t m0 x9 hb y111 ff17 fs8 fc3 sc0 ls64 ws90">108AsnDHF<span class="_ _8"></span>R mutation for pyrimethamine resistance) or<span class="_ _4b"></span>, less commonly<span class="_ _b"></span>, very</div><div class="t m0 x9 hb y2be ff17 fs8 fc3 sc0 ls24e ws38c">large reductions in susceptibility such that achiev<span class="_ _b"></span>able concentrations of the drug</div><div class="t m0 x9 hb y2bf ff17 fs8 fc3 sc0 ls64 ws48f">are completely ineffective (e.g. as the cytochr<span class="_ _a"></span>ome B mutations giving rise to</div><div class="t m0 x9 hb y484 ff17 fs8 fc3 sc0 ls64 ws0">atov<span class="_ _a"></span>aquone resistance) <span class="ff1a ls37">(13–16)</span><span class="ls10e">. </span></div><div class="t m0 x9 h2e y1006 ff19 fs3 fc3 sc0 ls69 ws1b0">A6.3.3<span class="_ _a7"> </span>Antimalar<span class="_ _8"></span>ial pharmacokinetics and the selection </div><div class="t m0 xba h2e y1007 ff19 fs3 fc3 sc0 ls80 ws0">of resistance</div><div class="t m0 x9 h25 y1008 ff1f fs12 fc4 sc0 ls285 ws0">Absorption and disposition</div><div class="t m0 x9 hb ye4e ff17 fs8 fc3 sc0 ls1ba ws200">The probability of selecting a <span class="ff1a ls239">de nov<span class="_ _a"></span>o <span class="ff17 lsbb ws48">mutation that is resistant to antimalarials</span></span></div><div class="t m0 x9 hb ye4f ff17 fs8 fc3 sc0 ls22 ws2b7">during the initial phase of treatment depends on the per<span class="_ _b"></span>-parasite frequency of</div><div class="t m0 x9 hb y1009 ff17 fs8 fc3 sc0 ls22 ws51f">the genetic event, the number of parasites pr<span class="_ _a"></span>esent, immunity in the infected</div><div class="t m0 x9 hb y100a ff17 fs8 fc3 sc0 lsa8 ws520">individual, and the relationship between the drug lev<span class="_ _a"></span>els achieved and the</div><div class="t m0 x9 hb y100b ff17 fs8 fc3 sc0 ls229 ws169">degree of resistance conferr<span class="_ _a"></span>ed by the mutant parasite. Obviously<span class="_ _4b"></span>, if the range</div><div class="t m0 x9 hb y100c ff17 fs8 fc3 sc0 ls32c ws2c0">of blood concentrations achieved in the patient consider<span class="_ _a"></span>ably exceeds the</div><div class="t m0 x9 hb y100d ff17 fs8 fc3 sc0 ls28c ws91">concentrations giving 90% inhibition of multiplication (IC</div><div class="t m0 x4b h11 y100e ff17 fs5 fc3 sc0 ls32d ws0">90 </div><div class="t m0 x58 hb y100d ff17 fs8 fc3 sc0 ls28c ws91">values) for the most</div><div class="t m0 x9 hb y100f ff17 fs8 fc3 sc0 ls22 wsb3">resistant mutant (IC</div><div class="t m0 x3d h11 y1010 ff17 fs5 fc3 sc0 ls32e ws0">90</div><div class="t m0 x94 h11 y1011 ff17 fs5 fc3 sc0 ls0 ws0">R</div><div class="t m0 x18 hb y100f ff17 fs8 fc3 sc0 ls22 wsb3">), then resistance cannot be selected in the acute phase</div><div class="t m0 x9 hb y1012 ff17 fs8 fc3 sc0 ls45 wsef">of treatment as even the r<span class="_ _a"></span>esistant mutants are prev<span class="_ _a"></span>ented from multiplying.</div><div class="t m0 x9 hb y1013 ff17 fs8 fc3 sc0 ls188 ws84">Conversely<span class="_ _c"></span>, if the degree of resistance provided by the genetic ev<span class="_ _a"></span>ent is very small,</div><div class="t m0 x9 hb y1014 ff17 fs8 fc3 sc0 ls22 ws78">the window of opportunity for selection may be negligible. Provided that ther<span class="_ _a"></span>e</div><div class="t m0 x9 hb y1015 ff17 fs8 fc3 sc0 ls22 ws521">is such a window of selection then the broader the r<span class="_ _a"></span>ange of peak antimalarial</div><div class="t m0 x9 hb y1016 ff17 fs8 fc3 sc0 ls22 ws2da">concentrations and the closer the median v<span class="_ _a"></span>alue approaches IC</div><div class="t m0 xcf h11 y1017 ff17 fs5 fc3 sc0 ls32e ws0">90</div><div class="t m0 x92 h11 y1018 ff17 fs5 fc3 sc0 ls32f ws0">R </div><div class="t m0 x68 hb y1016 ff17 fs8 fc3 sc0 ls22 ws2da">, the greater</div><div class="t m0 x9 hb y1019 ff17 fs8 fc3 sc0 ls22 ws522">the probability of selecting a resistant mutant in a patient. P<span class="_ _a"></span>eak drug concen-</div><div class="t m0 x9 hb y101a ff17 fs8 fc3 sc0 ls22 ws3bf">trations are determined by absorption, distribution v<span class="_ _a"></span>olume and dose. Several</div><div class="t m0 x9 hb y101b ff17 fs8 fc3 sc0 ls22 ws523">antimalarials (notably lumefantrine, halofantrine, atov<span class="_ _a"></span>aquone and, to a lesser</div><div class="t m0 x9 hb y101c ff17 fs8 fc3 sc0 ls64 ws2fd">extent, mefloquine) are lipophilic, hydr<span class="_ _a"></span>ophobic and very variably absorbed</div><div class="t m0 x9 hb y101d ff17 fs8 fc3 sc0 lsbb ws48">(interindividual variation in bioav<span class="_ _b"></span>ailability up to 20-fold) <span class="ff1a lsbe ws76">(17, 18)</span>. Interindividual</div><div class="t m0 x9 hb y101e ff17 fs8 fc3 sc0 ls22 ws25f">variation in distribution v<span class="_ _a"></span>olumes tends to be lower (usually less than fiv<span class="_ _a"></span>e-fold)</div><div class="t m0 x9 hb y101f ff17 fs8 fc3 sc0 ls14e ws520">but, taken together with variable absorption, the outcome is consider<span class="_ _a"></span>able</div><div class="t m0 x9 hb y1020 ff17 fs8 fc3 sc0 ls22 ws524">interindividual variation in peak antimalarial blood concentr<span class="_ _a"></span>ations. The main</div><div class="t m0 x9 hb y1021 ff17 fs8 fc3 sc0 ls22 ws1ab">sources of underdosing globally ar<span class="_ _a"></span>e incorrect self-medication because of poor</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfad" class="pf w1 h4" data-page-no="ad"><div class="pc pcad w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">163</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls2af ws4a5">adherence to the correctly pr<span class="_ _a"></span>escribed drug regimen, poor quality drugs,</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls22 ws133">uncontrolled drug av<span class="_ _a"></span>ailability and purchase of incorrect dose regimens, use of</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls4b wsbb">substandard drugs purchased in shops or markets, and incorr<span class="_ _a"></span>ect administration</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls22 ws36f">in the home. The acute infection is the principal sour<span class="_ _a"></span>ce of <span class="ff1a ls64">de novo </span><span class="ws0">r<span class="_ _a"></span>esistance</span></div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls330 ws3ec">selection. Quality assured drugs, education, correct pr<span class="_ _a"></span>escribing, good adherence,</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls24b ws75">and optimized packaging and formulations therefor<span class="_ _a"></span>e play pivotal roles in</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls22 ws0">preventing the emer<span class="_ _a"></span>gence of antimalarial drug resistance. </div><div class="t m0 xb h25 y1022 ff1f fs12 fc4 sc0 ls285 ws0">Drug elimination rates </div><div class="t m0 xb hb y9e6 ff17 fs8 fc3 sc0 ls12 ws17d">In some areas of the world, transmission intensities may be as high as thr<span class="_ _a"></span>ee</div><div class="t m0 xb hb yb9d ff17 fs8 fc3 sc0 ls13d ws1fc">infectious bites per person per day<span class="_ _4b"></span>. In this context, a person who takes</div><div class="t m0 xb hb yb9e ff17 fs8 fc3 sc0 ls21f ws15f">antimalarial treatment for symptomatic malaria exposes not only the parasites</div><div class="t m0 xb hb yb9f ff17 fs8 fc3 sc0 ls22d ws394">causing that infection to the drug, but also any newly acquired infections that</div><div class="t m0 xb hb yba0 ff17 fs8 fc3 sc0 ls12 ws3c7">emerge from the liv<span class="_ _a"></span>er during the drug’<span class="_ _b"></span>s elimination phase; the longer the</div><div class="t m0 xb hb ya20 ff17 fs8 fc3 sc0 ls1c9 ws293">terminal elimination half-life, the greater the exposure. <span class="_ _b"></span>The length of the</div><div class="t m0 xb hb ya21 ff17 fs8 fc3 sc0 ls274 ws40d">terminal elimination half-life is an important determinant of the propensity for</div><div class="t m0 xb hb ya22 ff17 fs8 fc3 sc0 ls16c ws244">an antimalarial to select for resistance <span class="ff1a ws0">(19–21)</span>. Some rapidly eliminated</div><div class="t m0 xb hb ya23 ff17 fs8 fc3 sc0 ls189 ws381">antimalarials (e.g. the artemisinin derivatives) never pr<span class="_ _a"></span>esent an intermediate</div><div class="t m0 xb hb ya24 ff17 fs8 fc3 sc0 ls2da ws345">drug concentration to infecting malaria parasites because they ar<span class="_ _a"></span>e eliminated</div><div class="t m0 xb hb ya25 ff17 fs8 fc3 sc0 ls12 ws84">completely within the two-day life-cycle of the asexual parasite. Others (e.g.</div><div class="t m0 xb hb ya26 ff17 fs8 fc3 sc0 ls172 ws18a">mefloquine, chloroquine) have elimination half-liv<span class="_ _a"></span>es of weeks or months and</div><div class="t m0 xb hb ya27 ff17 fs8 fc3 sc0 ls12 ws0">present a lengthy selection opportunity<span class="_ _4b"></span>. </div><div class="t m0 xb hb y1023 ff17 fs8 fc3 sc0 ls15b ws224">With the exception of the artemisinin derivativ<span class="_ _a"></span>es, maximum antimalarial</div><div class="t m0 xb hb yfee ff17 fs8 fc3 sc0 ls13 ws525">parasite reduction r<span class="_ _a"></span>atios (kill rates) do not exceed 1000-fold per cycle <span class="ff1a ws0">(22)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb yfef ff17 fs8 fc3 sc0 ls2cc ws47e">Follo<span class="_ _a"></span>wing hepatic schizogony<span class="_ _4b"></span>, exposure of at least two asexual cycles (4 days)</div><div class="t m0 xb hb yff0 ff17 fs8 fc3 sc0 ls94 ws400">to therapeutic drug concentrations is ther<span class="_ _a"></span>efore required to er<span class="_ _a"></span>adicate the</div><div class="t m0 xb hb y1024 ff17 fs8 fc3 sc0 ls12 ws40">blood stage parasites emerging fr<span class="_ _a"></span>om the liver<span class="_ _4b"></span>. Even with maximum kill rates</div><div class="t m0 xb hb y1025 ff17 fs8 fc3 sc0 ls22a ws38f">in the sensitive parasites and maximum gr<span class="_ _a"></span>owth rates in the r<span class="_ _a"></span>esistant parasites,</div><div class="t m0 xb hb y1026 ff17 fs8 fc3 sc0 ls12 ws13e">the resistant parasites only “<span class="_ _b"></span>overtake” the sensitive par<span class="_ _a"></span>asites in the third</div><div class="t m0 xb hb y1027 ff17 fs8 fc3 sc0 ls20 ws1f">asexual cycle. <span class="_ _a"></span>Thus rapidly eliminated drugs (such as the artemisinin derivatives</div><div class="t m0 xb hb y1028 ff17 fs8 fc3 sc0 lsaa ws110">or quinine) cannot select during the elimination phase. Obviously<span class="_ _4b"></span>, the greater</div><div class="t m0 xb hb y1029 ff17 fs8 fc3 sc0 lsc4 ws1b3">the degree of resistance conferr<span class="_ _a"></span>ed by the resistance mutation – i.e. the higher</div><div class="t m0 xb hb y102a ff17 fs8 fc3 sc0 ls256 ws3c1">the IC</div><div class="t m0 xc5 h11 y102b ff17 fs5 fc3 sc0 lscb ws0">90</div><div class="t m0 x95 h11 y102c ff17 fs5 fc3 sc0 ls0 ws0">R</div><div class="t m0 xa7 hb yc13 ff17 fs8 fc3 sc0 ls256 ws3c1">relative to the IC</div><div class="t m0 x5d h11 y102b ff17 fs5 fc3 sc0 lscb ws0">90</div><div class="t m0 x7f hb yc13 ff17 fs8 fc3 sc0 ls256 ws1a8">for susceptible parasites (IC</div><div class="t m0 xd0 h11 y102b ff17 fs5 fc3 sc0 lscb ws0">90</div><div class="t m0 x1e h11 y102c ff17 fs5 fc3 sc0 ls0 ws0">S</div><div class="t m0 x1d hb yc13 ff17 fs8 fc3 sc0 ls256 ws1a8">) – the wider is the</div><div class="t m0 xb hb yc14 ff17 fs8 fc3 sc0 ls12 ws0">window of selection opportunity<span class="_ _4b"></span>.</div><div class="t m0 xb hb y102d ff17 fs8 fc3 sc0 ls237 ws67">Patent gametocytaemia is more likely in r<span class="_ _a"></span>ecrudescent than in primary infections.</div><div class="t m0 xb hb y102e ff17 fs8 fc3 sc0 ls141 ws3ea">Therefore, if <span class="ff1a">de no<span class="_ _a"></span>vo <span class="ff17">resistance ar<span class="_ _a"></span>ose in an acute symptomatic treated infection,</span></span></div><div class="t m0 xb hb y102f ff17 fs8 fc3 sc0 ls331 wsb4">the transmission probability fr<span class="_ _a"></span>om the subsequent recrudescent infection</div><div class="t m0 xb hb y1030 ff17 fs8 fc3 sc0 ls66 ws90">(bearing the new resistance genes) would be higher than from an infection newly</div><div class="t m0 xb hb y1031 ff17 fs8 fc3 sc0 ls64 wsde">acquired during the elimination phase of the antimalarial given for a pr<span class="_ _a"></span>evious</div><div class="t m0 xb hb y1032 ff17 fs8 fc3 sc0 ls64 ws0">infection, even if it attained the same parasite densities <span class="ff1a">(23)</span><span class="ls0">.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfae" class="pf w1 h4" data-page-no="ae"><div class="pc pcae w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">164</div><div class="t m0 x9 h2e yaa1 ff19 fs3 fc3 sc0 ls80 ws0">A6.3.4<span class="_ _a7"> </span>S<span class="_ _8"></span>pread of resistance</div><div class="t m0 x9 hb y1033 ff17 fs8 fc3 sc0 ls12 ws38b">Several mathematical models hav<span class="_ _a"></span>e been devised to examine the spread of</div><div class="t m0 x9 hb y1034 ff17 fs8 fc3 sc0 lsfa ws3ea">antimalarial drug resistance <span class="ff1a ls16b">(10, 21, 24, 25)<span class="ff17">. Spread of r<span class="_ _a"></span>esistance is determined</span></span></div><div class="t m0 x9 hb y1035 ff17 fs8 fc3 sc0 ls13 ws526">by the reproductiv<span class="_ _a"></span>e advantage conferred by the r<span class="_ _a"></span>esistance mechanism. This</div><div class="t m0 x9 hb y1036 ff17 fs8 fc3 sc0 ls12 ws484">derives from the incr<span class="_ _a"></span>eased gametocyte carriage associated with treatment</div><div class="t m0 x9 hb y1037 ff17 fs8 fc3 sc0 ls160 ws230">failure (both from the primary infection and the subsequent recrudescences)</div><div class="t m0 x9 hb y1038 ff17 fs8 fc3 sc0 ls12 ws10a">– the “<span class="_ _a"></span>donors”, and then the selective pressur<span class="_ _a"></span>e from residual concentrations</div><div class="t m0 x9 hb y1039 ff17 fs8 fc3 sc0 ls56 ws72">of slowly eliminated antimalarial in potential recipients. A long elimination half-</div><div class="t m0 x9 hb y103a ff17 fs8 fc3 sc0 ls12 ws0">life results in long periods of post-treatment chemopr<span class="_ _a"></span>ophylaxis. </div><div class="t m0 x9 hb y103b ff17 fs8 fc3 sc0 ls9f wsfe">Resistance encoded by multiple mutations at a single locus may be consider<span class="_ _a"></span>ed</div><div class="t m0 x9 hb y103c ff17 fs8 fc3 sc0 ls161 ws231">in two ov<span class="_ _a"></span>erlapping phases. The first phase, in which the drug is better tolerated</div><div class="t m0 x9 hb y103d ff17 fs8 fc3 sc0 lsc5 ws13b">by the parasites but therapeutic doses still usually clear the infection, and the</div><div class="t m0 x9 hb y103e ff17 fs8 fc3 sc0 ls12 wsb0">second phase, when clinical failures start to occur<span class="_ _b"></span>. This second phase is very</div><div class="t m0 x9 hb y103f ff17 fs8 fc3 sc0 ls1a4 ws2a5">rapid and it is essential that surveillance programmes ar<span class="_ _a"></span>e in place and capable</div><div class="t m0 x9 hb y1040 ff17 fs8 fc3 sc0 ls12 ws2c1">of monitoring the change from the first to the second phase. In areas of high</div><div class="t m0 x9 hb y1041 ff17 fs8 fc3 sc0 ls6c ws99">transmission, the first phase may occur faster<span class="_ _4b"></span>, but the subsequent phase</div><div class="t m0 x9 hb y1042 ff17 fs8 fc3 sc0 ls5c ws527">slower<span class="_ _4b"></span>. Combination therapy significantly slows the rate of ev<span class="_ _a"></span>olution of</div><div class="t m0 x9 hb y1043 ff17 fs8 fc3 sc0 ls12 ws528">resistance, but it should be instigated before significant r<span class="_ _a"></span>esistance to either</div><div class="t m0 x9 hb y1044 ff17 fs8 fc3 sc0 ls12 ws0">component is present.</div><div class="t m0 x9 h2e y1045 ff19 fs3 fc3 sc0 ls323 ws510">A6.3.5<span class="_ _a7"> </span>Prevention of resistance by use of combination therapy</div><div class="t m0 x9 hb y1046 ff17 fs8 fc3 sc0 ls222 ws343">The theory underlying combination treatment of tuberculosis, leprosy and HIV</div><div class="t m0 x9 hb y1047 ff17 fs8 fc3 sc0 ls12 ws529">infection is well known, and has r<span class="_ _a"></span>ecently been applied to malaria <span class="ff1a ls13 ws52a">(4, 5, 24,</span></div><div class="t m0 x9 hb y1048 ff1a fs8 fc3 sc0 ls12 ws0">26–29)<span class="ff17 ws52b">. If two drugs with different modes of action, and therefor<span class="_ _a"></span>e different</span></div><div class="t m0 x9 hb y1049 ff17 fs8 fc3 sc0 ls332 ws39f">resistance mechanisms, are used in combination, then the per<span class="_ _b"></span>-parasite</div><div class="t m0 x9 hb y104a ff17 fs8 fc3 sc0 ls310 ws225">probability of developing r<span class="_ _a"></span>esistance to both drugs is the product of their</div><div class="t m0 x9 hb y104b ff17 fs8 fc3 sc0 ls12 ws253">individual per<span class="_ _b"></span>-parasite probabilities. For example, if the per<span class="_ _b"></span>-parasite proba-</div><div class="t m0 x9 hb y104c ff17 fs8 fc3 sc0 ls13 ws3c5">bilities of developing resistance to drug A and drug B ar<span class="_ _a"></span>e both 1 in 10</div><div class="t m0 xcd h11 y104d ff17 fs5 fc3 sc0 ls333 ws0">12</div><div class="t m0 xd1 hb y104c ff17 fs8 fc3 sc0 ls12 ws52c">, then</div><div class="t m0 x9 hb y104e ff17 fs8 fc3 sc0 ls13e ws52d">a simultaneously resistant mutant will arise spontaneously in 1 in 10</div><div class="t m0 xd2 h11 y104f ff17 fs5 fc3 sc0 ls314 ws0">24</div><div class="t m0 x9 hb y1050 ff17 fs8 fc3 sc0 ls2da ws345">parasites. As it is postulated that there ar<span class="_ _a"></span>e approximately 10</div><div class="t m0 xd3 h11 y1051 ff17 fs5 fc3 sc0 ls334 ws0">17</div><div class="t m0 xcf hb y1050 ff17 fs8 fc3 sc0 lsc8 ws21">parasites in the</div><div class="t m0 x9 hb y1052 ff17 fs8 fc3 sc0 ls1aa ws15b">entire world, and a cumulative total of less than 10</div><div class="t m0 x2e h11 y1053 ff17 fs5 fc3 sc0 ls335 ws0">20 </div><div class="t m0 x6c hb y1052 ff17 fs8 fc3 sc0 ls1aa ws1b6">in one year<span class="_ _4b"></span>, such a</div><div class="t m0 x9 hb y1054 ff17 fs8 fc3 sc0 lsc0 ws17d">simultaneously resistant parasite would arise spontaneously r<span class="_ _a"></span>oughly once every</div><div class="t m0 x9 hb y1055 ff17 fs8 fc3 sc0 ls336 ws4f6">10 000 years – pro<span class="_ _a"></span>vided the drugs always confronted the parasites in</div><div class="t m0 x9 hb y1056 ff17 fs8 fc3 sc0 lse7 ws178">combination. Thus the lo<span class="_ _a"></span>wer the <span class="ff1a ls232">de nov<span class="_ _a"></span>o <span class="ff17 lse7">per<span class="_ _a"></span>-parasite probability of developing</span></span></div><div class="t m0 x9 hb y1057 ff17 fs8 fc3 sc0 ls12 ws0">resistance, the greater the delay in the emer<span class="_ _a"></span>gence of resistance. </div><div class="t m0 x9 hb y1058 ff17 fs8 fc3 sc0 ls17b ws34c">Stable resistance to the artemisinin derivativ<span class="_ _a"></span>es has not yet been identified, and</div><div class="t m0 x9 hb y1059 ff17 fs8 fc3 sc0 ls15c ws229">cannot yet be induced in the laboratory<span class="_ _4b"></span>, which suggests that it may be very rar<span class="_ _a"></span>e</div><div class="t m0 x9 hb y105a ff17 fs8 fc3 sc0 ls22c ws0">indeed. <span class="ff1a ws2f4">De no<span class="_ _a"></span>vo <span class="ff17">resistance to chlor<span class="_ _a"></span>oquine is also very rare, and appears to hav<span class="_ _a"></span>e</span></span></div><div class="t m0 x9 hb y105b ff17 fs8 fc3 sc0 ls64 ws108">arisen and spread only twice in the world during the first decade of intensive</div><div class="t m0 x9 hb y105c ff17 fs8 fc3 sc0 ls21c ws371">use in the 1950</div><div class="t m0 x5d hc y105d ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 x60 hb y105e ff1a fs8 fc3 sc0 ls21c ws0">(30)<span class="ff17 ws77">. On the other hand, resistance to antifolate and ato<span class="_ _a"></span>vaquone</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfaf" class="pf w1 h4" data-page-no="af"><div class="pc pcaf w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">165</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls2a8 ws104">arises relatively fr<span class="_ _a"></span>equently (e.g. antifolate resistance rose to high lev<span class="_ _a"></span>els within</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls64 ws350">two years of the initial deployment of pr<span class="_ _a"></span>oguanil in peninsular Malaya in 1947)</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls292 ws46c">and can be induced readily in experimental models <span class="ff1a">(14, 27)</span>. Against a</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls76 wsab">background of chloroquine r<span class="_ _a"></span>esistance, mefloquine resistance arose o<span class="_ _a"></span>ver a six-</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls64 ws0">year period on the north-west border of Thailand <span class="ff1a">(31)</span>. </div><div class="t m0 xb hb y18c ff17 fs8 fc3 sc0 ls2b0 ws3f3">The ideal pharmacokinetic properties for an antimalarial have been much</div><div class="t m0 xb hb y18d ff17 fs8 fc3 sc0 ls64 ws4dd">debated. Rapid elimination ensures that the r<span class="_ _a"></span>esidual concentrations do not</div><div class="t m0 xb hb y18e ff17 fs8 fc3 sc0 ls6a wse9">pro<span class="_ _a"></span>vide a selective filter for resistant parasites, but drugs with this pr<span class="_ _a"></span>oper<span class="_ _8"></span>ty (if</div><div class="t m0 xb hb y18f ff17 fs8 fc3 sc0 ls70 ws161">used alone) must be given for at least 7 days, and adherence to 7-day r<span class="_ _a"></span>egimens</div><div class="t m0 xb hb y190 ff17 fs8 fc3 sc0 ls1db ws2ff">is poor<span class="_ _b"></span>. In order to be effective in a 3-day r<span class="_ _a"></span>egimen, elimination half-lives usually</div><div class="t m0 xb hb y191 ff17 fs8 fc3 sc0 ls185 ws347">need to exceed 24 h. Artemisinin derivatives ar<span class="_ _a"></span>e par<span class="_ _8"></span>ticularly effective in combi-</div><div class="t m0 xb hb y192 ff17 fs8 fc3 sc0 ls65 ws8e">nations with other antimalarials because of their very high killing rates (parasite</div><div class="t m0 xb hb y193 ff17 fs8 fc3 sc0 ls337 ws186">reduction rate ar<span class="_ _a"></span>ound 10 000-fold per cycle), lack of adverse effects and</div><div class="t m0 xb hb y2c0 ff17 fs8 fc3 sc0 ls64 ws191">absence of significant resistance <span class="ff1a ws0">(5)</span>. Combinations of artemisinin derivatives</div><div class="t m0 xb hb y2c1 ff17 fs8 fc3 sc0 ls64 ws52e">(which are eliminated very rapidly) giv<span class="_ _a"></span>en for 3 days, with a slowly eliminated</div><div class="t m0 xb hb y2c2 ff17 fs8 fc3 sc0 ls3d ws7f">drug such as mefloquine, pro<span class="_ _a"></span>vide complete protection against the emergence</div><div class="t m0 xb hb y2c3 ff17 fs8 fc3 sc0 ls64 ws237">of resistance to the artemisinin derivatives if adher<span class="_ _a"></span>ence is good, but they do</div><div class="t m0 xb hb y2c4 ff17 fs8 fc3 sc0 ls1d2 ws25f">leave the slowly eliminated “tail” of mefloquine unpr<span class="_ _a"></span>otected. Perhaps resistance</div><div class="t m0 xb hb y2c5 ff17 fs8 fc3 sc0 ls10e ws3be">could arise within the residual parasites that hav<span class="_ _a"></span>e not yet been killed by the</div><div class="t m0 xb hb y2c6 ff17 fs8 fc3 sc0 ls26e ws231">artemisinin derivative. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, the number of parasites exposed to mefloquine</div><div class="t m0 xb hb y486 ff17 fs8 fc3 sc0 ls184 ws220">alone is a tiny fraction (less than 0.00001%) of those present in the acute</div><div class="t m0 xb hb y487 ff17 fs8 fc3 sc0 ls64 ws102">symptomatic infection. Furthermore, these residual par<span class="_ _a"></span>asites “see<span class="_ _a"></span>” relatively</div><div class="t m0 xb hb y488 ff17 fs8 fc3 sc0 ls244 ws160">high levels of mefloquine and, ev<span class="_ _a"></span>en if susceptibility was reduced, these levels</div><div class="t m0 xb hb y489 ff17 fs8 fc3 sc0 lsc8 ws18a">may be sufficient to eradicate the infection (Figure A6.2). <span class="_ _b"></span>The long mefloquine</div><div class="t m0 xb hb y48a ff17 fs8 fc3 sc0 ls2bf ws304">tail does, howev<span class="_ _a"></span>er<span class="_ _b"></span>, pro<span class="_ _a"></span>vide a selective filter for resistant parasites acquir<span class="_ _a"></span>ed from</div><div class="t m0 xb hb y48b ff17 fs8 fc3 sc0 ls64 ws52f">elsewhere, and therefor<span class="_ _a"></span>e contributes to the spread of resistance once it has</div><div class="t m0 xb hb y48c ff17 fs8 fc3 sc0 lse0 ws450">developed. Y<span class="_ _4b"></span>et on the nor<span class="_ _8"></span>th-west border of <span class="_ _a"></span>Thailand, an area of low tr<span class="_ _a"></span>ansmission</div><div class="t m0 xb hb y48d ff17 fs8 fc3 sc0 ls64 ws1f">where mefloquine resistance had alr<span class="_ _a"></span>eady developed, systematic deployment</div><div class="t m0 xb hb y48e ff17 fs8 fc3 sc0 ls63 ws3">of the artesunate-mefloquine combination was dramatically effective in stopping</div><div class="t m0 xb hb y48f ff17 fs8 fc3 sc0 lsaa ws93">resistance and also in reducing the incidence of malaria <span class="ff1a">(31, 3<span class="_ _a"></span>2)<span class="ff17 ws530">. This <span class="_ _8"></span>strategy</span></span></div><div class="t m0 xb hb y105f ff17 fs8 fc3 sc0 ls64 ws1a3">is thought to be effective at prev<span class="_ _a"></span>enting the emergence of resistance at higher</div><div class="t m0 xb hb y1060 ff17 fs8 fc3 sc0 ls1c3 ws2f2">levels of transmission, wher<span class="_ _a"></span>e high-biomass infections still constitutes the</div><div class="t m0 xb hb y1061 ff17 fs8 fc3 sc0 ls64 ws0">major source of <span class="ff1a">de nov<span class="_ _a"></span>o <span class="ff17">resistance. </span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb0" class="pf w1 h4" data-page-no="b0"><div class="pc pcb0 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">166</div><div class="t m0 x9 h3f y1062 ff22 fs5 fc4 sc0 ls14c ws0">Figure A6.2<span class="_ _52"> </span><span class="ff1b fs9 fc3 ls16">The ar<span class="_ _8"></span>tesunate + mefloquine combination. If no ar<span class="_ _8"></span>tesunate is given,</span></div><div class="t m0 x5 h3f y1063 ff1b fs9 fc3 sc0 ls2a8 ws0">then the number of parasites exposed to mefloquine alone is given </div><div class="t m0 x5 h3f y1064 ff1b fs9 fc3 sc0 ls2a8 ws16">by the area of A; <span class="ls16 ws0">with the combination administered for 3 days, the</span></div><div class="t m0 x5 h3f y1065 ff1b fs9 fc3 sc0 ls2f3 ws1a">number of parasites exposed to mefloquine alone is given by the ar<span class="_ _a"></span>ea</div><div class="t m0 x5 h3f y1066 ff1b fs9 fc3 sc0 ls16 ws0">of B (100 million times fewer). F<span class="_ _b"></span>ur<span class="_ _8"></span>thermore, mefloquine levels are</div><div class="t m0 x5 h3f y1067 ff1b fs9 fc3 sc0 ls16 ws0">higher (m to n) when confronting B than when confronting the same</div><div class="t m0 x5 h3f y1068 ff1b fs9 fc3 sc0 ls16 ws0">number of parasites (B</div><div class="t m0 x2a h42 y1069 ff1b fs15 fc3 sc0 ls0 ws0">1</div><div class="t m0 xbd h3f y106a ff1b fs9 fc3 sc0 ls16 ws0">) if no artesunate is given (x to y). If a parasite</div><div class="t m0 x5 h3f y106b ff1b fs9 fc3 sc0 ls16 ws0">containing a <span class="ff1f ls2f3">de nov<span class="_ _a"></span>o <span class="ff1b ls16">mefloquine-resistant mutation were to occur<span class="_ _4b"></span>,</span></span></div><div class="t m0 x5 h3f y106c ff1b fs9 fc3 sc0 ls16 ws0">then such a parasite should still be susceptible to artesunate. Thus</div><div class="t m0 x5 h3f y106d ff1b fs9 fc3 sc0 ls2f3 ws1a">the probability of selecting a resistant mutant is r<span class="_ _a"></span>educed by 100</div><div class="t m0 x5 h3f y106e ff1b fs9 fc3 sc0 ls16 ws1a">million times, as only a maximum of 100 000 pa<span class="_ _a"></span>ra<span class="ls2a8">sites ar<span class="_ _a"></span>e exposed to</span></div><div class="t m0 x5 h3f y106f ff1b fs9 fc3 sc0 ls2a8 ws0">mefloquine alone after the fourth day (i.e. in the third cycle), and any</div><div class="t m0 x5 h3f y1070 ff1b fs9 fc3 sc0 ls2a8 ws1a">artesunate-resistant parasite selected by artesunate initially would</div><div class="t m0 x5 h3f y1071 ff1b fs9 fc3 sc0 ls2a8 ws16">always be <span class="_ _8"></span><span class="ls2f3 ws1a">killed by the accompanying mefloquine. As a result, the</span></div><div class="t m0 x5 h3f y1072 ff1b fs9 fc3 sc0 ls16 ws0">combination is more effective, r<span class="_ _a"></span>educes transmission and prevents </div><div class="t m0 x5 h3f y1073 ff1b fs9 fc3 sc0 ls16 ws0">the emergence of resistance to both drugs.</div><div class="t m0 x9 h12 y1074 ff19 fs6 fc4 sc0 ls9a ws0">A6.4<span class="_ _33"> </span>A summar<span class="_ _9"></span>y of the global distr<span class="_ _8"></span>ibution </div><div class="t m0 x28 h12 y1075 ff19 fs6 fc4 sc0 ls0 ws95">of antimalarial dr<span class="_ _8"></span>ug resistance</div><div class="t m0 x9 hb y1076 ff17 fs8 fc3 sc0 ls31b ws2c2">Resistance to antimalarials has been a particular problem with <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>falciparum<span class="ff17 ls0">,</span></span></div><div class="t m0 x9 hb y1077 ff17 fs8 fc3 sc0 ls12 ws3e0">in which widespread resistance to chlor<span class="_ _a"></span>oquine, sulfadoxine-pyrimethamine</div><div class="t m0 x9 hb y1078 ff17 fs8 fc3 sc0 ls14 ws25d">and mefloquine has been observed (Figure A6.3). Antifolate and chloroquine</div><div class="t m0 x9 hb y1079 ff17 fs8 fc3 sc0 ls2a9 ws94">resistance has developed in <span class="ff1a ws1ca">P<span class="_ _ae"></span>. vivax <span class="ff17 ws94">in sever<span class="_ _a"></span>al areas, and chloroquine resistance</span></span></div></div><div class="t m0 xa h40 y107a ff20 fs9 fc3 sc0 ls1a3 ws0">T<span class="_ _b"></span>otal Parasit<span class="_ _a"></span>e</div><div class="t m0 x9 h40 y107b ff20 fs9 fc3 sc0 ls1a3 ws0">10</div><div class="t m0 xa9 h50 y107c ff20 fs2 fc3 sc0 ls15e ws0">12</div><div class="t m0 x9 h40 y107d ff20 fs9 fc3 sc0 ls1a3 ws0">10</div><div class="t m0 xa9 h50 y107e ff20 fs2 fc3 sc0 ls15e ws0">10</div><div class="t m0 x46 h40 y107f ff20 fs9 fc3 sc0 ls1a3 ws0">10</div><div class="t m0 x7a h50 y1080 ff20 fs2 fc3 sc0 ls0 ws0">8</div><div class="t m0 x46 h40 y1081 ff20 fs9 fc3 sc0 ls1a3 ws0">10</div><div class="t m0 x7a h50 y1082 ff20 fs2 fc3 sc0 ls0 ws0">6</div><div class="t m0 x46 h40 y1083 ff20 fs9 fc3 sc0 ls1a3 ws0">10</div><div class="t m0 x7a h50 y1084 ff20 fs2 fc3 sc0 ls0 ws0">4</div><div class="t m0 x46 h40 y1085 ff20 fs9 fc3 sc0 ls1a3 ws0">10</div><div class="t m0 x7a h50 y1086 ff20 fs2 fc3 sc0 ls0 ws0">2</div><div class="t m0 x16 h40 y1087 ff20 fs9 fc3 sc0 ls0 ws0">0</div><div class="t m0 x25 h40 y1088 ff20 fs9 fc3 sc0 ls338 ws0">01<span class="_ _b"></span>2<span class="_ _65"></span>3<span class="_ _c3"></span>4</div><div class="t m0 x81 h27 y1089 ff20 fs8 fc3 sc0 ls0 ws0">m</div><div class="t m0 x1c h27 y108a ff25 fs8 fc3 sc0 ls2cb ws14">Drug concen<span class="_ _a"></span>tration</div><div class="t m0 xc8 h27 y108b ff25 fs8 fc3 sc0 ls2cb ws0">W<span class="_ _b"></span>eeks</div><div class="t m0 x1e h27 y896 ff20 fs8 fc3 sc0 ls2cb ws0">Detection threshold</div><div class="t m0 x29 h27 y108c ff20 fs8 fc3 sc0 ls0 ws0">n</div><div class="t m0 xd4 h27 y108d ff20 fs8 fc3 sc0 ls0 ws0">x</div><div class="t m0 xd5 h27 y108e ff20 fs8 fc3 sc0 ls0 ws0">y</div><div class="t m0 x1c h51 y108f ff20 fs11 fc3 sc0 ls0 ws0">A</div><div class="t m0 x18 h51 y1090 ff20 fs11 fc3 sc0 ls339 ws0">BB</div><div class="t m0 xd6 h41 y1091 ff20 fs7 fc3 sc0 ls0 ws0">1</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb1" class="pf w1 h4" data-page-no="b1"><div class="pc pcb1 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">167</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls13 ws0">in <span class="ff1a">P<span class="_ _c"></span>. malariae <span class="ff17 ls12 ws531">has also recently been reported. No significant resistance has</span></span></div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls12 ws532">yet been observed to ar<span class="_ _8"></span>temisinin and its derivativ<span class="_ _a"></span>es despite their extensive</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls12 ws0">deployment in sever<span class="_ _a"></span>al par<span class="_ _8"></span>ts of Asia.</div><div class="t m0 xb h3f y1092 ff22 fs5 fc4 sc0 ls209 ws0">Figure A6.3<span class="_ _52"> </span><span class="ff1b fs9 fc3 ls16">Malaria transmission areas and the distribution of reported</span></div><div class="t m0 x1b h3f y1093 ff1b fs9 fc3 sc0 ls16 ws0">resistance or treatment failur<span class="_ _a"></span>es with selected antimalarial drugs,</div><div class="t m0 x1b h3f y1094 ff1b fs9 fc3 sc0 ls2f3 ws1a">September 2004 (mefloquine resistance in Africa is currently being</div><div class="t m0 x1b h3f y1095 ff1b fs9 fc3 sc0 ls2f3 ws1a">further reviewed)</div><div class="t m0 xb h2e y1096 ff19 fs3 fc3 sc0 ls80 ws0">A6.4.1<span class="_ _a7"> </span><span class="ff29">Plasmodium falcipar<span class="_ _8"></span>um </span>resistance</div><div class="t m0 xb h25 y1097 ff1f fs12 fc4 sc0 ls285 ws0">Chloroquine</div><div class="t m0 xb hb y1098 ff17 fs8 fc3 sc0 lsa4 ws104">The first reports of chloroquine resistance occurred in <span class="_ _a"></span>Thailand and Colombia</div><div class="t m0 xb hb y1099 ff17 fs8 fc3 sc0 ls13 ws47">in the late 1950</div><div class="t m0 xd7 hc y109a ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 x24 hb y1099 ff17 fs8 fc3 sc0 ls12 ws185">, around 12 years after the drug’<span class="_ _4b"></span>s introduction. By 1980, all</div><div class="t m0 xb hb y109b ff17 fs8 fc3 sc0 ls200 ws25">endemic areas in South America wer<span class="_ _a"></span>e affected, and by 1989, most of Asia and</div><div class="t m0 xb hb y109c ff17 fs8 fc3 sc0 ls12 ws359">Oceania. In Africa, chloroquine resistance emer<span class="_ _a"></span>ged in 1978 in the east, and</div><div class="t m0 xb hb y109d ff17 fs8 fc3 sc0 ls12 ws35">gradually spread w<span class="_ _a"></span>estwards through the 1980</div><div class="t m0 x64 hc y109e ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 xc7 hb y109d ff17 fs8 fc3 sc0 ls12 ws35">. Resistance has no<span class="_ _a"></span>w been</div><div class="t m0 xb hb y109f ff17 fs8 fc3 sc0 ls12 ws68">documented in all falciparum-endemic areas except Centr<span class="_ _a"></span>al America and the</div><div class="t m0 xb hb y10a0 ff17 fs8 fc3 sc0 ls12 ws0">Caribbean <span class="ff1a ls13">(33)</span><span class="ws1b4">. Recent molecular studies fav<span class="_ _a"></span>our impor<span class="_ _8"></span>tation of chloroquine</span></div><div class="t m0 xb hb y10a1 ff17 fs8 fc3 sc0 ls5c ws527">resistance to Africa from East Asia <span class="ff1a ws79">(34, 35)</span>. Chlor<span class="_ _a"></span>oquine resistance has</div><div class="t m0 xb hb y10a2 ff17 fs8 fc3 sc0 lsc4 ws1b3">emerged independently less than ten times in the past 50 years (Figur<span class="_ _a"></span>e A6.4).</div></div><div class="c xb y10a3 w14 h52"><div class="t m0 x79 h53 y10a4 ff28 fs1c fc3 sc0 ls33a ws0">Source: </div><div class="t m0 x65 h54 y10a5 ff28 fs1d fc3 sc0 ls0 ws0">©</div><div class="t m0 x89 h53 y10a4 ff28 fs1c fc3 sc0 ls33a ws0">WHO, 2005</div><div class="t m0 x3b h55 y10a6 ff2a fs1e fc3 sc0 ls33b ws533">Areas where malaria transmission occurs (high/low)</div><div class="t m0 x3b h55 y10a7 ff2a fs1e fc3 sc0 ls33b ws533">Malaria-free areas</div><div class="t m0 x0 h56 y10a8 ff2b fs1f fc3 sc0 ls0 ws0">Malaria transmission areas and reported <span class="ff2c">P. falciparum</span> resistance, 2004</div><div class="t m0 x3b h55 y10a9 ff2d fs1e fc3 sc0 ls33b ws533">P. falciparum <span class="ff2a">chloroquine resistance</span></div><div class="t m0 x3b h55 y10aa ff2d fs1e fc3 sc0 ls33b ws533">P. falciparum s<span class="ff2a">ulfadoxine-pyrimethamine resistance</span></div><div class="t m0 x3b h55 y10ab ff2d fs1e fc3 sc0 ls33b ws533">P. falciparum <span class="ff2a">mefloquine treatment failures</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb2" class="pf w1 h4" data-page-no="b2"><div class="pc pcb2 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">168</div><div class="t m0 x9 h3f y10ac ff22 fs5 fc4 sc0 ls209 ws0">Figure A6.4<span class="_ _52"> </span><span class="ff1b fs9 fc3 ls16">Distribution of chloroquine r<span class="_ _a"></span>esistance in <span class="ff1f">Plasmodium falciparum</span></span></div><div class="t m0 x9 h25 y10ad ff1f fs12 fc4 sc0 ls285 ws0">Sulfadoxine-pyrimethamine</div><div class="t m0 x9 hb y10ae ff17 fs8 fc3 sc0 ls33c ws51d">Resistance to pyrimethamine emer<span class="_ _a"></span>ged rapidly after its deployment for</div><div class="t m0 x9 hb y10af ff17 fs8 fc3 sc0 lsc1 ws132">treatment, prophylaxis and, in some ar<span class="_ _a"></span>eas, mass treatment in the 1950</div><div class="t m0 xd2 hc y10b0 ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 xbf hb y10af ff17 fs8 fc3 sc0 ls0 ws0">.</div><div class="t m0 x9 hb y10b1 ff17 fs8 fc3 sc0 ls1d6 ws2f7">Resistance to both components of sulfado<span class="_ _a"></span>xine-pyrimethamine was noted</div><div class="t m0 x9 hb y10b2 ff17 fs8 fc3 sc0 ls12 ws1c">shortly after this drug was introduced over a decade later<span class="_ _4b"></span>. In South-East Asia</div><div class="t m0 x9 hb y10b3 ff17 fs8 fc3 sc0 ls12 ws132">this occurred on the <span class="_ _a"></span>Thai-Cambodian border in the mid-1960s. Resistance</div><div class="t m0 x9 hb y10b4 ff17 fs8 fc3 sc0 ls12 ws10e">became an operational problem in the same ar<span class="_ _a"></span>ea within the few years of the</div><div class="t m0 x9 hb y10b5 ff17 fs8 fc3 sc0 ls64 wsa4">introduction of sulfadoxine-pyrimethamine to the malaria contr<span class="_ _a"></span>ol programme</div><div class="t m0 x9 hb y10b6 ff17 fs8 fc3 sc0 ls12 ws7e">in 1975 <span class="ff1a ls13 ws0">(36)</span>. High-level resistance is found in many parts of South-East Asia,</div><div class="t m0 x9 hb y10b7 ff17 fs8 fc3 sc0 lsa6 ws107">southern China and the Amazon basin, and lower lev<span class="_ _a"></span>els of resistance are</div><div class="t m0 x9 hb y10b8 ff17 fs8 fc3 sc0 ls1d2 wsd7">seen on the coast of South America and in southern Asia and Oceania. In eastern</div><div class="t m0 x9 hb y10b9 ff17 fs8 fc3 sc0 ls13b ws1c3">Africa, sulfadoxine-pyrimethamine sensitivity was observed to be declining in</div><div class="t m0 x9 hb y10ba ff17 fs8 fc3 sc0 lse2 ws138">the 1980</div><div class="t m0 x5a hc y10bb ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 xba hb y10ba ff17 fs8 fc3 sc0 ls67 ws138">and resistance has progr<span class="_ _a"></span>essed westwards across Africa relentlessly</div><div class="t m0 x9 hb y10bc ff17 fs8 fc3 sc0 ls1ae ws2bc">ov<span class="_ _a"></span>er the last decade. Clinical failure rates of more than 25% hav<span class="_ _a"></span>e already been</div><div class="t m0 x9 hb y10bd ff17 fs8 fc3 sc0 ls12 ws0">reported in Liberia <span class="ff1a ls31b">(37)</span>, Guinea Bissau <span class="ff1a ls14">(38) </span>and Malawi <span class="ff1a ls13">(39)</span><span class="ls0">.</span></div><div class="t m0 x9 hb y10be ff17 fs8 fc3 sc0 ls12 ws238">Many areas now hav<span class="_ _a"></span>e high-level resistance with high-tr<span class="_ _a"></span>eatment failure rates</div><div class="t m0 x9 hb y10bf ff17 fs8 fc3 sc0 ls1d ws1c">in children. R<span class="_ _a"></span>ecent molecular evidence suggests a common South-East Asian</div><div class="t m0 x9 hb y10c0 ff17 fs8 fc3 sc0 ls4a ws6a">origin of the resistant <span class="ff1a">P<span class="_ _c"></span>. falciparum <span class="ff17">parasites no<span class="_ _a"></span>w prevalent in much of</span></span></div><div class="t m0 x9 hb y10c1 ff17 fs8 fc3 sc0 ls12 ws0">southern and Central Africa (triple <span class="ff1a">dhfr </span>mutant) <span class="ff1a ls13 ws14">(9, 40–42) </span>(Figure A6.5). </div></div><div class="t m0 x2c h57 y10c2 ff2a fs20 fc3 sc0 ls0 ws0">Countries with at least one study indicating chloroquine total failure rate &gt; 10%</div><div class="t m0 x2c h57 y10c3 ff2a fs20 fc3 sc0 ls0 ws0">No recent data available</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb3" class="pf w1 h4" data-page-no="b3"><div class="pc pcb3 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">169</div><div class="t m0 xb h3f y10c4 ff22 fs5 fc4 sc0 ls209 ws0">Figure A6.5<span class="_ _15"> </span><span class="ff1b fs9 fc3 ls16">Distribution of sulfadoxine-pyrimethamine resistance in</span></div><div class="t m0 x1b h3f y10c5 ff1f fs9 fc3 sc0 ls16 ws0">Plasmodium falciparum</div><div class="t m0 xb h25 y10c6 ff1f fs12 fc4 sc0 ls285 ws0">Mefloquine</div><div class="t m0 xb hb y10c7 ff17 fs8 fc3 sc0 ls12 ws80">Mefloquine resistance was first observed on the Thai-Cambodian and <span class="_ _b"></span>Thai-</div><div class="t m0 xb hb y10c8 ff17 fs8 fc3 sc0 ls191 ws278">Burmese borders in the late 1980</div><div class="t m0 x63 hc y10c9 ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 x4a hb y10c8 ff1a fs8 fc3 sc0 ls166 ws278">(43, 44) <span class="ff17 ls191">and the monotherapy is no longer</span></div><div class="t m0 xb hb y10ca ff17 fs8 fc3 sc0 ls146 ws207">effective there. Migr<span class="_ _a"></span>ant gem miners returning from Cambodia may hav<span class="_ _a"></span>e been</div><div class="t m0 xb hb y10cb ff17 fs8 fc3 sc0 ls12 ws3fb">the means of spread of mefloquine resistance to India and Bangladesh <span class="ff1a ls13 ws0">(45)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb y10cc ff17 fs8 fc3 sc0 ls12 ws447">Isolated cases of mefloquine resistance have also been r<span class="_ _a"></span>epor<span class="_ _8"></span>ted from the</div><div class="t m0 xb hb y10cd ff17 fs8 fc3 sc0 ls6a ws96">Amazon basin, and <span class="ff1a">in vitro </span>studies in Africa hav<span class="_ _a"></span>e identified some <span class="ff1a">P<span class="_ _c"></span>. falciparum</span></div><div class="t m0 xb hb y10ce ff17 fs8 fc3 sc0 ls1a6 ws2a7">strains with low mefloquine sensitivity<span class="_ _c"></span>. Overall, clinical mefloquine resistance</div><div class="t m0 xb hb y10cf ff17 fs8 fc3 sc0 ls12 ws0">outside South-East Asia is rare (Figur<span class="_ _a"></span>e A6.6).</div><div class="t m0 xb hb y10d0 ff17 fs8 fc3 sc0 ls12 ws3e4">The main determinant of mefloquine resistance is amplification of the gene</div><div class="t m0 xb hb y10d1 ff17 fs8 fc3 sc0 ls0 ws0">(<span class="ff1a">Pfmdr</span><span class="ws2e6">) that encodes the multidrug transporter </span><span class="ff1a">(46)</span><span class="ws2e6">. Amplification occurs</span></div><div class="t m0 xb hb y10d2 ff17 fs8 fc3 sc0 ls12 ws38d">only for the “wild type” allele explaining the inv<span class="_ _a"></span>erse relationship between</div><div class="t m0 xb hb y10d3 ff17 fs8 fc3 sc0 ls6e ws2cb">sensitivity to chloroquine (the <span class="ff1a ws0">Pfmdr <span class="_ _9"></span></span>T<span class="_ _b"></span>yr86 mutation is associated with</div><div class="t m0 xb hb y10d4 ff17 fs8 fc3 sc0 ls5e ws7f">reduced sensitivity) and to mefloquine (and to the structurally r<span class="_ _a"></span>elated drugs,</div><div class="t m0 xb hb y10d5 ff17 fs8 fc3 sc0 ls12 ws0">quinine and halofantrine) <span class="ff1a ls13">(15)<span class="ff17">. </span></span></div></div><div class="t m0 xb3 h57 y10d6 ff2a fs20 fc3 sc0 ls0 ws0">Countries with at least one study indicating pyrimethamine -sulfadoxine total failure rate &gt; 10%</div><div class="t m0 xb3 h57 y10d7 ff2a fs20 fc3 sc0 ls0 ws0">Pyrimethamine -sulfadoxine total failure rate &lt; 10%</div><div class="t m0 xb3 h57 y10d8 ff2a fs20 fc3 sc0 ls0 ws0">No failure reported</div><div class="t m0 xb3 h57 y10d9 ff2a fs20 fc3 sc0 ls0 ws0">No recent data available</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb4" class="pf w1 h4" data-page-no="b4"><div class="pc pcb4 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1b ws0">170</div><div class="t m0 x9 h3f y10da ff22 fs5 fc4 sc0 ls209 ws0">Figure A6.6<span class="_ _52"> </span><span class="ff1b fs9 fc3 ls16">Distribution of mefloquine resistance in <span class="ff1f">Plasmodium falciparum</span></span></div><div class="t m0 x9 h25 y10db ff1f fs12 fc4 sc0 ls4f ws0">Quinine</div><div class="t m0 x9 hb y10dc ff17 fs8 fc3 sc0 ls13 ws1f">The first reports of possible quinine resistance occurred in Brazil almost 100</div><div class="t m0 x9 hb y10dd ff17 fs8 fc3 sc0 ls189 ws381">years ago. E<span class="_ _a"></span>ven today<span class="_ _c"></span>, however<span class="_ _4b"></span>, clinical resistance to quinine monotherapy is</div><div class="t m0 x9 hb y10de ff17 fs8 fc3 sc0 ls22f ws396">reported only sporadically in South-East Asia and western Oceania, and</div><div class="t m0 x9 hb y10df ff17 fs8 fc3 sc0 ls1a6 ws2a7">resistance in Africa and South America is much less frequent. <span class="_ _b"></span>Widespread use</div><div class="t m0 x9 hb y10e0 ff17 fs8 fc3 sc0 ls204 ws350">of quinine in Thailand in the 1980</div><div class="t m0 x31 hc y10e1 ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 x88 hb y10e0 ff17 fs8 fc3 sc0 ls21b ws2d9">led to significant reduction in its sensitivity</div><div class="t m0 x9 hb y10e2 ff1a fs8 fc3 sc0 ls30 ws0">(45)<span class="ff17 ws91">. Quinine is therefore no<span class="_ _a"></span>w used in combination with an antibiotic, usually</span></div><div class="t m0 x9 hb y10e3 ff17 fs8 fc3 sc0 ls12 ws534">tetracycline, do<span class="_ _a"></span>xycycline or clindamycin, and is r<span class="_ _a"></span>eser<span class="_ _8"></span>ved for cases of sever<span class="_ _a"></span>e</div><div class="t m0 x9 hb y10e4 ff17 fs8 fc3 sc0 ls85 ws0">malaria. <span class="_ _a"></span><span class="ff1a">Pfmdr1 <span class="ff17 wsc9">mutations associated with chlor<span class="_ _a"></span>oquine resistance have been</span></span></div><div class="t m0 x9 hb y10e5 ff17 fs8 fc3 sc0 ls12 ws0">believed to be associated with reduced susceptibility to quinine <span class="ff1a ls13">(47, 48)</span><span class="ls0">.</span></div><div class="t m0 x9 h25 y10e6 ff1f fs12 fc4 sc0 ls285 ws0">Artemisinin</div><div class="t m0 x9 hb y10e7 ff17 fs8 fc3 sc0 lsa0 wsff">Except in an animal model, there have been no confirmed r<span class="_ _a"></span>epor<span class="_ _8"></span>ts of ar<span class="_ _8"></span>temisinin</div><div class="t m0 x9 hb y10e8 ff17 fs8 fc3 sc0 lse6 ws177">resistance in malaria parasites that infect humans. <span class="_ _b"></span>The pharmacological</div><div class="t m0 x9 hb y10e9 ff17 fs8 fc3 sc0 ls2b ws400">characteristics of the drug, namely short elimination half-life, rapidity of</div><div class="t m0 x9 hb y10ea ff17 fs8 fc3 sc0 ls12 ws2f6">action and ability to reduce gametocyte carriage, should delay the onset of</div><div class="t m0 x9 hb y10eb ff17 fs8 fc3 sc0 ls17c ws9e">significant resistance. Artemisinin derivatives ar<span class="_ _a"></span>e associated with high</div><div class="t m0 x9 hb y10ec ff17 fs8 fc3 sc0 ls75 wsb0">recrudescence rates (~10%) after monother<span class="_ _a"></span>apy<span class="_ _4b"></span>, so are usually combined with</div><div class="t m0 x9 hb y10ed ff17 fs8 fc3 sc0 ls241 ws3b1">longer<span class="_ _b"></span>-acting antimalarials for clinical treatment. These recrudescences,</div><div class="t m0 x9 hb y10ee ff17 fs8 fc3 sc0 ls12 ws0">howev<span class="_ _a"></span>er<span class="_ _b"></span>, are not a result of r<span class="_ _a"></span>esistance. </div></div><div class="t m0 x40 h57 y10ef ff2a fs20 fc3 sc0 ls0 ws0">Countries with at least one study indicating mefloquine total failure rate &gt; 10%</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb5" class="pf w1 h4" data-page-no="b5"><div class="pc pcb5 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">171</div><div class="t m0 xb h25 y9ff ff1f fs12 fc4 sc0 ls285 ws0">Multidrug resistance</div><div class="t m0 xb hb ya00 ff17 fs8 fc3 sc0 ls57 ws73">Multidrug resistance is generally defined as r<span class="_ _a"></span>esistance to three or more</div><div class="t m0 xb hb ya01 ff17 fs8 fc3 sc0 ls12 ws185">antimalarial compounds from different chemical classes. Gener<span class="_ _a"></span>ally<span class="_ _4b"></span>, the first</div><div class="t m0 xb hb ya02 ff17 fs8 fc3 sc0 ls12 wsd6">two classes are 4-aminoquinolines (e.g. chloroquine) and antifolates (e.g.</div><div class="t m0 xb hb ya03 ff17 fs8 fc3 sc0 ls1ab ws2fd">sulfadoxine-pyrimethamine). <span class="_ _a"></span>The precise amount of resistance needed in</div><div class="t m0 xb hb yb2f ff17 fs8 fc3 sc0 ls12 ws4b">order for a drug to be considered as failing is not univ<span class="_ _a"></span>ersally agreed. Some</div><div class="t m0 xb hb yb30 ff17 fs8 fc3 sc0 ls0 ws4ab">consider clinical cure rates of less than 75% to be the minimum r<span class="_ _a"></span>equired for</div><div class="t m0 xb hb yb31 ff17 fs8 fc3 sc0 ls2d ws3b">classification as failure, while the current r<span class="_ _a"></span>ecommendations aim for cure</div><div class="t m0 xb hb yb4d ff17 fs8 fc3 sc0 ls13 ws14">rates o<span class="_ _a"></span>ver 90%.</div><div class="t m0 xb hb y10f0 ff17 fs8 fc3 sc0 ls76 wsb3">Established multidrug resistance occurs in South-East Asia (particularly along</div><div class="t m0 xb hb yb4f ff17 fs8 fc3 sc0 ls14e ws1a6">the borders of <span class="_ _a"></span>Thailand with Burma and Cambodia) and in the Amazon basin.</div><div class="t m0 xb hb yb50 ff17 fs8 fc3 sc0 ls12 ws123">In Thailand, mefloquine monother<span class="_ _a"></span>apy was replaced with the combination of</div><div class="t m0 xb hb y10f1 ff17 fs8 fc3 sc0 ls247 ws21">high-dose mefloquine and artesunate given for 3 days. Mefloquine resistance</div><div class="t m0 xb hb y10f2 ff17 fs8 fc3 sc0 ls8e ws2b">has been reduced by the use of this combination, as cure r<span class="_ _a"></span>ates of more than</div><div class="t m0 xb hb y10f3 ff17 fs8 fc3 sc0 ls13 ws393">95% have been sustained for o<span class="_ _a"></span>ver 10 years, and susceptibility to mefloquine</div><div class="t m0 xb hb y10f4 ff17 fs8 fc3 sc0 ls12 ws0">has actually impro<span class="_ _a"></span>ved despite extensive deployment of the combination.</div><div class="t m0 xb hb y10f5 ff17 fs8 fc3 sc0 ls90 wse2">Several ar<span class="_ _a"></span>eas are at risk of multidrug resistance, as resistance to chlor<span class="_ _a"></span>oquine</div><div class="t m0 xb hb y10f6 ff17 fs8 fc3 sc0 ls12 ws88">and sulfadoxine-pyrimethamine is already widespr<span class="_ _a"></span>ead. Progressiv<span class="_ _a"></span>e loss of</div><div class="t m0 xb hb y10f7 ff17 fs8 fc3 sc0 ls12 ws0">sulfadoxine-pyrimethamine efficacy should be taken as a warning sign. </div><div class="t m0 xb h2e y10f8 ff19 fs3 fc3 sc0 ls80 ws0">A6.4.2<span class="_ _a7"> </span><span class="ff29 ls33d ws535">Plasmodium vivax<span class="_ _95"> </span></span>resistance</div><div class="t m0 xb h25 y10f9 ff1f fs12 fc4 sc0 ls285 ws0">Chloroquine</div><div class="t m0 xb hb y10fa ff17 fs8 fc3 sc0 ls33e ws1f">Resistance of <span class="ff1a ws0">P<span class="_ _ae"></span>. vivax <span class="ff17 ws1f">is r<span class="_ _a"></span>are and generally limited to chloroquine r<span class="_ _a"></span>esistance, which</span></span></div><div class="t m0 xb hb y10fb ff17 fs8 fc3 sc0 ls22 ws536">was first reported in the late 1980</div><div class="t m0 x63 hc y10fc ff17 fs9 fc3 sc0 ls0 ws0">s</div><div class="t m0 x19 hb y10fb ff17 fs8 fc3 sc0 ls22 ws536">in Papua New Guinea and Indonesia. F<span class="_ _a"></span>ocal</div><div class="t m0 xb hb y10fd ff17 fs8 fc3 sc0 ls227 ws38c">true chloroquine resistance (with whole blood chlor<span class="_ _a"></span>oquine + desethylchloroquine</div><div class="t m0 xb hb y10fe ff17 fs8 fc3 sc0 ls37 ws98">concentrations of <span class="ff1c ls0 ws0">&gt;</span><span class="ws3c7">100 ng/ml on the day of failure) or pr<span class="_ _a"></span>ophylactic and/or</span></div><div class="t m0 xb hb y10ff ff17 fs8 fc3 sc0 ls76 ws22d">treatment failure not necessarily r<span class="_ _a"></span>elated to true resistance, have since also</div><div class="t m0 xb hb y1100 ff17 fs8 fc3 sc0 ls33f ws28e">been observed in Brazil, Colombia, Ethiopia, Guatemala, Guyana, India, Republic</div><div class="t m0 xb hb y1101 ff17 fs8 fc3 sc0 ls22 ws14">of K<span class="_ _a"></span>orea, Myanmar<span class="_ _4b"></span>, Solomon Islands, Thailand and <span class="_ _a"></span>T<span class="_ _b"></span>urkey<span class="_ _4b"></span>. </div><div class="t m0 xb h2e y1102 ff19 fs3 fc3 sc0 ls80 ws0">A6.4.3<span class="_ _a7"> </span><span class="ff29">Plasmodium malar<span class="_ _8"></span>iae </span>resistance</div><div class="t m0 xb h25 y1103 ff1f fs12 fc4 sc0 ls285 ws0">Chloroquine</div><div class="t m0 xb hb y1104 ff17 fs8 fc3 sc0 ls12 ws1c">Resistance of <span class="ff1a ls13 ws0">P<span class="_ _ae"></span>. malaria<span class="ff17 ls12 wse7">e to chloroquine was observed recently in Indonesia. </span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb6" class="pf w1 h4" data-page-no="b6"><div class="pc pcb6 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">172</div><div class="t m0 x9 h12 y12a ff19 fs6 fc4 sc0 ls9a ws0">A6.5<span class="_ _33"> </span>Monitor<span class="_ _8"></span>ing of antimalar<span class="_ _8"></span>ial dr<span class="_ _8"></span>ug resistance</div><div class="t m0 x9 h2e y639 ff19 fs3 fc3 sc0 ls80 wsc1">A6.5.1<span class="_ _a7"> </span>Monitor<span class="_ _8"></span>ing methods</div><div class="t m0 x9 hb y63a ff17 fs8 fc3 sc0 ls46 ws66">The rapid spread of antimalarial drug r<span class="_ _a"></span>esistance over the last few decades has</div><div class="t m0 x9 hb y63b ff17 fs8 fc3 sc0 ls12 ws96">increased the need for monitoring, in order to ensur<span class="_ _a"></span>e proper management of</div><div class="t m0 x9 hb y63c ff17 fs8 fc3 sc0 ls245 ws161">clinical cases, allow for early detection of changing patterns of resistance, and</div><div class="t m0 x9 hb y63d ff17 fs8 fc3 sc0 ls12 ws458">suggest where national malaria treatment policies should be r<span class="_ _a"></span>evised. The</div><div class="t m0 x9 hb y63e ff17 fs8 fc3 sc0 ls4c ws3d8">monitoring procedures av<span class="_ _b"></span>ailable include therapeutic efficacy testing (also</div><div class="t m0 x9 hb y63f ff17 fs8 fc3 sc0 ls12 ws14c">known as <span class="ff1a ls13">in vivo </span><span class="ws14b">testing). <span class="_ _b"></span>This involves the repeated assessment of clinical</span></div><div class="t m0 x9 hb y1105 ff17 fs8 fc3 sc0 ls12 ws33">and parasitological outcomes of treatment – during a fix<span class="_ _a"></span>ed period of follow-</div><div class="t m0 x9 hb y1106 ff17 fs8 fc3 sc0 ls12 ws451">up – in order to detect any reappear<span class="_ _a"></span>ance of symptoms and signs of clinical</div><div class="t m0 x9 hb y1107 ff17 fs8 fc3 sc0 ls1b3 ws28">malaria and/or parasites in the blood, which would indicate reduced par<span class="_ _a"></span>asite</div><div class="t m0 x9 hb y1108 ff17 fs8 fc3 sc0 ls12 ws18a">sensitivity with the particular drug. Other methods include <span class="ff1a ls13">in vitro <span class="ff17">studies of</span></span></div><div class="t m0 x9 hb y1109 ff17 fs8 fc3 sc0 ls12 ws9b">parasite susceptibility to drugs in culture, and studies of point mutations or</div><div class="t m0 x9 hb y110a ff17 fs8 fc3 sc0 ls163 ws36e">duplications in parasite resistance genes with molecular methods (polymer<span class="_ _a"></span>ase</div><div class="t m0 x9 hb y110b ff17 fs8 fc3 sc0 ls13 ws537">chain reaction, PCR). Animal models are also used, although not r<span class="_ _a"></span>outinely<span class="_ _4b"></span>. </div><div class="t m0 x9 h23 y110c ff24 fs11 fc8 sc0 ls27a ws0">In vivo <span class="ff1e">tests</span></div><div class="t m0 x9 h25 y110d ff1f fs12 fc4 sc0 ls285 ws0">(a) Ther<span class="_ _a"></span>apeutic efficacy testing and the WHO standard pr<span class="_ _a"></span>otocol for </div><div class="t m0 x9 h25 y110e ff1b fs12 fc4 sc0 ls285 ws0">P<span class="_ _c"></span>. falciparum</div><div class="t m0 x9 hb y110f ff17 fs8 fc3 sc0 ls1b9 ws4ba">Fr<span class="_ _a"></span>om a programmatic point of view<span class="_ _b"></span>, data on therapeutic efficacy are most useful</div><div class="t m0 x9 hb y1110 ff17 fs8 fc3 sc0 ls12 ws538">in deciding whether or not a drug is still appropriate as first-line treatment.</div><div class="t m0 x9 hb y1111 ff17 fs8 fc3 sc0 ls1b3 ws28">Therapeutic efficacy studies are r<span class="_ _a"></span>elatively simple to conduct, and the require-</div><div class="t m0 x9 hb y1112 ff17 fs8 fc3 sc0 ls3a ws1b2">ments in terms of training of staff and technical facilities are ther<span class="_ _a"></span>efore limited.</div><div class="t m0 x9 hb y1113 ff17 fs8 fc3 sc0 ls94 wsea">Howev<span class="_ _a"></span>er<span class="_ _b"></span>, the results can be affected by misdiagnosis and incorrect drug</div><div class="t m0 x9 hb y1114 ff17 fs8 fc3 sc0 ls12 ws4c4">administration. In order to interpr<span class="_ _a"></span>et and allow for comparison of the results</div><div class="t m0 x9 hb y1115 ff17 fs8 fc3 sc0 ls12 ws539">within and between regions, and to follo<span class="_ _a"></span>w trends ov<span class="_ _a"></span>er time, studies need to</div><div class="t m0 x9 hb y1116 ff17 fs8 fc3 sc0 lsa8 ws10a">be conducted according to similar procedur<span class="_ _a"></span>es and standards. WHO ther<span class="_ _a"></span>efore</div><div class="t m0 x9 hb y1117 ff17 fs8 fc3 sc0 ls192 ws27a">recommends the use of the <span class="_ _a"></span>WHO standard protocol, which pro<span class="_ _a"></span>vides guidance</div><div class="t m0 x9 hb y1118 ff17 fs8 fc3 sc0 ls60 ws85">on how best to obtain the minimum necessary information about the therapeutic</div><div class="t m0 x9 hb y1119 ff17 fs8 fc3 sc0 ls12 ws30c">responses to an antimalarial so as to allow informed decision-making on its</div><div class="t m0 x9 hb y111a ff17 fs8 fc3 sc0 ls13 ws0">future use <span class="ff1a">(49)</span>. </div><div class="t m0 x9 hb y111b ff17 fs8 fc3 sc0 ls12 ws53a">The protocol is designed for use in the assessment of antimalarial drugs or</div><div class="t m0 x9 hb y111c ff17 fs8 fc3 sc0 ls70 wsa2">drug combinations used routinely for treatment of uncomplicated <span class="ff1a ws0">P<span class="_ _ae"></span>. falciparum</span></div><div class="t m0 x9 hb y111d ff17 fs8 fc3 sc0 ls18b ws2fb">malaria (chloroquine, sulfadoxine-pyrimethamine, amodiaquine, artemisinin-</div><div class="t m0 x9 hb y111e ff17 fs8 fc3 sc0 ls12 ws53b">based combination therapies and others). It comprises a simple, one-arm</div><div class="t m0 x9 hb y111f ff17 fs8 fc3 sc0 ls12 ws48">prospective ev<span class="_ _b"></span>aluation of clinical and parasitological treatment responses in</div><div class="t m0 x9 hb y1120 ff17 fs8 fc3 sc0 ls340 ws53c">children aged 6–59 months, in whom the level of acquir<span class="_ _a"></span>ed immunity is</div><div class="t m0 x9 hb y1121 ff17 fs8 fc3 sc0 ls53 ws160">relatively lo<span class="_ _a"></span>w and therefore has only a minor influence on the outcome of the</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb7" class="pf w1 h4" data-page-no="b7"><div class="pc pcb7 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">173</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls12 ws493">test. T<span class="_ _c"></span>o ensure a reasonable specificity of the malaria diagnosis in areas of</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls1d ws1c">intense transmission, only individuals with a parasite density ≥ 2000 asexual</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 lsb1 ws0">parasites/<span class="ff1c ls0">μ<span class="_ _a"></span><span class="ff17 ls1b9 ws4ba">l of blood should be included in studies. In areas of low to moderate</span></span></div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls12 ws14c">transmission, individuals with ≥<span class="_ _6"> </span>1000 asexual parasites/<span class="ff1c ls0 ws0">μ</span>l can be included.</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls12 wsc2">Further methodological and operational considerations in r<span class="_ _a"></span>elation to case</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls341 ws520">definition, sample size calculations, ethical concerns and the criteria for</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls6b ws58">inclusion and exclusion, some of which some relate only to specific drugs, ar<span class="_ _a"></span>e</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 ls12 ws0">explained in detail in the protocol.</div><div class="t m0 xb hb y18f ff17 fs8 fc3 sc0 lsa2 ws102">The recommended duration of follo<span class="_ _a"></span>w-up is ≥ 28 days in ar<span class="_ _a"></span>eas of intense as well</div><div class="t m0 xb hb y190 ff17 fs8 fc3 sc0 ls12 ws1b6">as low to moderate tr<span class="_ _a"></span>ansmission. As a significant proportion of treatment</div><div class="t m0 xb hb y191 ff17 fs8 fc3 sc0 ls12 ws212">failures do not appear until after day 14, shorter obser<span class="_ _8"></span>vation periods lead to</div><div class="t m0 xb hb y192 ff17 fs8 fc3 sc0 ls0 ws2e6">a considerable o<span class="_ _a"></span>verestimation of the efficacy of the tested drug. <span class="_ _a"></span>This is a</div><div class="t m0 xb hb y193 ff17 fs8 fc3 sc0 ls12 ws72">particular problem at low levels of resistance and with lo<span class="_ _a"></span>w failure rates <span class="ff1a ls13 ws0">(50)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb y2c0 ff17 fs8 fc3 sc0 ls12 ws53d">As the objective of treatment is cur<span class="_ _a"></span>e of the infection, and cure rates of more</div><div class="t m0 xb hb y2c1 ff17 fs8 fc3 sc0 ls12 ws45d">than 90% are requir<span class="_ _a"></span>ed, the cure rate must be adequately characteriz<span class="_ _a"></span>ed. For</div><div class="t m0 xb hb y2c2 ff17 fs8 fc3 sc0 ls12 ws53e">relatively effectiv<span class="_ _a"></span>e, slowly eliminated antimalarials, half the recrudescences</div><div class="t m0 xb hb y2c3 ff17 fs8 fc3 sc0 ls208 ws458">may occur after 28 days. For tr<span class="_ _a"></span>eatment with drugs such as amodiaquine,</div><div class="t m0 xb hb y2c4 ff17 fs8 fc3 sc0 lsa7 ws109">chloroquine and sulfadoxine-pyrimethamine, a 28-day follo<span class="_ _a"></span>w-up is considered</div><div class="t m0 xb hb y2c5 ff17 fs8 fc3 sc0 ls12 wsa2">appropriate; follow-up periods of 42 days and 63 days ar<span class="_ _a"></span>e recommended for</div><div class="t m0 xb hb y2c6 ff17 fs8 fc3 sc0 ls12 ws53f">artemether-lumefantrine and mefloquine, r<span class="_ _a"></span>espectively <span class="ff1a ls13 ws0">(51)</span><span class="ws74">. These follow-up</span></div><div class="t m0 xb hb y486 ff17 fs8 fc3 sc0 ls56 ws72">periods will capture most but often not all recrudescent infections – particularly</div><div class="t m0 xb hb y487 ff17 fs8 fc3 sc0 ls13 ws44e">at low levels of r<span class="_ _a"></span>esistance. Studies even of <span class="ff1c ls0 ws0">&gt;<span class="_ _6"> </span></span><span class="ls1c3 ws10c">28 days of duration risk loss to</span></div><div class="t m0 xb hb y488 ff17 fs8 fc3 sc0 ls342 ws351">follow-up and should be accompanied by molecular assessments (PCR</div><div class="t m0 xb hb y489 ff17 fs8 fc3 sc0 ls15c ws26e">genotyping) so as to distinguish recrudescence from r<span class="_ _a"></span>einfection. If sur<span class="_ _8"></span>veillance</div><div class="t m0 xb hb y48a ff17 fs8 fc3 sc0 ls12 wsb2">programmes do not hav<span class="_ _a"></span>e access to molecular techniques, studies of 14 days</div><div class="t m0 xb hb y48b ff17 fs8 fc3 sc0 ls13 ws169">of duration without PCR adjustments can still pro<span class="_ _a"></span>vide useful information on</div><div class="t m0 xb hb y48c ff17 fs8 fc3 sc0 ls2ef ws418">failing drugs (i.e. to justify their replacement) – but they cannot be used to justify</div><div class="t m0 xb hb y48d ff17 fs8 fc3 sc0 ls343 wsf1">inclusion or continued recommendation. In areas of lo<span class="_ _a"></span>w to moderate transmission,</div><div class="t m0 xb hb y48e ff17 fs8 fc3 sc0 ls12 ws58">the use of molecular methods is recommended, but is not strictly essential if</div><div class="t m0 xb hb y48f ff17 fs8 fc3 sc0 ls235 ws276">the likelihood of reinfection is relativ<span class="_ _a"></span>ely small. PCR genotyping involves</div><div class="t m0 xb hb y105f ff17 fs8 fc3 sc0 ls12 ws531">comparison of polymorphic parasite genes, usually those encoding v<span class="_ _a"></span>ariable</div><div class="t m0 xb hb y1060 ff17 fs8 fc3 sc0 ls2b4 ws2d6">blocks within PfMSP2, and also sometimes PfMSP1 and PfGLURP<span class="_ _c"></span>, in whole blood</div><div class="t m0 xb hb y1061 ff17 fs8 fc3 sc0 ls12 ws0">samples taken during the acute and recurrent infections.</div><div class="t m0 xb hb y493 ff17 fs8 fc3 sc0 ls0 ws4a">The WHO standar<span class="_ _a"></span>d protocol classifies outcomes of efficacy studies into the</div><div class="t m0 xb hb y494 ff17 fs8 fc3 sc0 ls152 ws37b">following four categories: early treatment failur<span class="_ _a"></span>e, late clinical failure, late</div><div class="t m0 xb hb y495 ff17 fs8 fc3 sc0 ls12 ws540">parasitological failure, and adequate clinical and par<span class="_ _a"></span>asitological response.</div><div class="t m0 xb hb y496 ff17 fs8 fc3 sc0 ls0 ws44e">These classifications rely on the presence or absence of fev<span class="_ _a"></span>er or other signs</div><div class="t m0 xb hb y497 ff17 fs8 fc3 sc0 ls238 ws1ff">of clinical malaria and/or presence of parasitaemia during the course of</div><div class="t m0 xb hb y498 ff17 fs8 fc3 sc0 ls79 wsb6">follow-up (T<span class="_ _c"></span>able A6.1). The therapeutic response is classified as early tr<span class="_ _a"></span>eatment</div><div class="t m0 xb hb y499 ff17 fs8 fc3 sc0 ls2b0 ws46e">failure if the patient develops clinical or par<span class="_ _a"></span>asitological symptoms during</div><div class="t m0 xb hb y49a ff17 fs8 fc3 sc0 ls12 ws2d5">the first 3 days of follow-up<span class="_ _a"></span>. The response is classified as late clinical failur<span class="_ _a"></span>e</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb8" class="pf w1 h4" data-page-no="b8"><div class="pc pcb8 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1b ws0">174</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls32c ws444">if symptoms develop during the follow-up period (fr<span class="_ _a"></span>om day 4 to day 28),</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls12 ws1e">without previously meeting the criteria for early treatment failur<span class="_ _a"></span>e. It is a late</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls181 ws264">parasitological failure if only par<span class="_ _a"></span>asitaemia reappear without any symptom, in</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls190 ws17c">the period from day 7 to day 28. Adequate clinical and parasitological r<span class="_ _a"></span>esponse</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls8f wsde">is defined as the absence of symptoms and of parasitaemia on day 28, without</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls12 ws4a1">any of the criteria for the other three categories having been met previously<span class="_ _c"></span>. </div><div class="t m0 x9 h58 y1122 ff22 fs5 fc4 sc0 ls14c ws0">T<span class="_ _b"></span>able A6.1</div><div class="t m8 x28 hd y1122 ff1e fs8 fc3 sc0 ls91 ws14">Classification of treatment outcomes in studies of antimalarial drug</div><div class="t m8 x28 hd y1123 ff1e fs8 fc3 sc0 ls91 ws0">efficacy in areas of low<span class="_ _b"></span>, moderate and intense transmission <span class="ff1f">(49)</span></div><div class="t m0 x9 hb y1124 ff17 fs8 fc3 sc0 ls172 ws18a">For simplicity<span class="_ _c"></span>, the outcome of efficacy studies can be summarized as “<span class="_ _a"></span>clinical</div><div class="t m0 x9 hb y1125 ff17 fs8 fc3 sc0 ls12 ws101">failure<span class="_ _a"></span>”, which is equal to the sum of early treatment failure and late clinical</div><div class="t m0 x9 hb y1126 ff17 fs8 fc3 sc0 ls284 ws283">failure, and as “total failure<span class="_ _a"></span>”, which is equal to the sum of early treatment failure,</div><div class="t m0 x9 hb y1127 ff17 fs8 fc3 sc0 ls9c wsfa">late clinical failure and late parasitological failur<span class="_ _a"></span>e. The rates of clinical failur<span class="_ _a"></span>e</div><div class="t m0 x9 hb y1128 ff17 fs8 fc3 sc0 lsd0 ws149">and total failure are used to define cut-off points for drug policy change,</div><div class="t m8 xbb h1b y1129 ff1b fsb fc3 sc0 lsd2 ws1d4">T<span class="_ _b"></span>reatment outcome<span class="_ _84"> </span>Symptoms and signs</div><div class="t m3 xbb h17 y112a ff17 fsb fc3 sc0 lsd2 ws0">Early treatment failure<span class="_ _17"> </span>• Development of danger signs or severe malaria on</div><div class="t m3 x3f h17 y112b ff17 fsb fc3 sc0 lsd2 ws0">days 1–3 in the presence of parasitaemia</div><div class="t m3 x3f h17 y112c ff17 fsb fc3 sc0 lsd2 ws0">• Parasitaemia on day 2 higher than the day 0 count</div><div class="t m3 x3f h17 y112d ff17 fsb fc3 sc0 lsd8 ws19a">irrespective of axillary temperatur<span class="_ _a"></span>e</div><div class="t m3 x3f h17 y112e ff17 fsb fc3 sc0 lsd2 ws0">• Parasitaemia on day 3 with axillary temperatur<span class="_ _a"></span>e</div><div class="t m3 x3f h17 y112f ff17 fsb fc3 sc0 lsd8 ws0">≥<span class="_ _67"> </span>37.5 °C </div><div class="t m3 x3f h17 y1130 ff17 fsb fc3 sc0 lsd2 ws0">• Parasitaemia on day 3 that is ≥<span class="_ _67"> </span>25% of count on day 0.</div><div class="t m3 xbb h17 y1131 ff17 fsb fc3 sc0 lsd2 ws0">Late treatment failure</div><div class="t m3 xbb h17 y1132 ff17 fsb fc3 sc0 lsd2 ws0">•<span class="_ _2"> </span>Late clinical failure</div><div class="t m3 xbb h17 y1133 ff17 fsb fc3 sc0 lsd2 ws0">•<span class="_ _2"> </span>Late parasitological</div><div class="t m3 xa9 h17 y1134 ff17 fsb fc3 sc0 lsd2 ws0">failure</div><div class="t m3 x3f h17 y1135 ff17 fsb fc3 sc0 lsd2 ws0">• Development of danger signs or sever<span class="_ _a"></span>e malaria after</div><div class="t m3 x3f h17 y1136 ff17 fsb fc3 sc0 lsd2 ws0">day 3 in the presence of parasitaemia, without</div><div class="t m3 x3f h17 y1137 ff17 fsb fc3 sc0 lsd2 ws0">previously meeting any of the criteria of early treatment</div><div class="t m3 x3f h17 y1138 ff17 fsb fc3 sc0 lsd2 ws0">failure</div><div class="t m3 x3f h17 y1139 ff17 fsb fc3 sc0 lsd2 ws0">• Presence of par<span class="_ _a"></span>asitaemia and axillary temperature</div><div class="t m3 x3f h17 y113a ff17 fsb fc3 sc0 lsd2 ws0">≥<span class="_ _66"></span>37.5 °C (or history of fever) on any day from day 4 to</div><div class="t m3 x3f h17 y113b ff17 fsb fc3 sc0 lsd2 ws0">day 28, without previously meeting any of the criteria of</div><div class="t m3 x3f h17 y113c ff17 fsb fc3 sc0 lsd2 ws0">early treatment failure.</div><div class="t m3 x3f h17 y113d ff17 fsb fc3 sc0 lsd2 ws0">• Presence of par<span class="_ _a"></span>asitaemia on any day from day 7 to day</div><div class="t m3 x3f h17 y113e ff17 fsb fc3 sc0 lsd2 ws0">28 and axillary temperature <span class="ff1c ls0">&lt;<span class="_ _67"> </span></span><span class="lsd8 ws19a">37.5 °C, without previously</span></div><div class="t m3 x3f h17 y113f ff17 fsb fc3 sc0 lsd2 ws0">meeting any of the criteria of early treatment failure or</div><div class="t m3 x3f h17 y1140 ff17 fsb fc3 sc0 lsd2 ws0">late clinical failure.</div><div class="t m3 xbb h17 y1141 ff17 fsb fc3 sc0 lsd2 ws0">Adequate clinical and</div><div class="t m3 xbb h17 y1142 ff17 fsb fc3 sc0 lsd2 ws0">parasitological response</div><div class="t m3 x3f h17 y1141 ff17 fsb fc3 sc0 lsd2 ws0">• Absence of parasitaemia on day 28 irrespectiv<span class="_ _a"></span>e of</div><div class="t m3 x3f h17 y1142 ff17 fsb fc3 sc0 lsd2 ws0">axillary temperature without previously meeting any of</div><div class="t m3 x3f h17 y1143 ff17 fsb fc3 sc0 lsd2 ws0">the criteria of early treatment failure, late clinical failur<span class="_ _a"></span>e</div><div class="t m3 x3f h17 y1144 ff17 fsb fc3 sc0 lsd2 ws0">or late parasitological failure.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb9" class="pf w1 h4" data-page-no="b9"><div class="pc pcb9 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">175</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls0 ws392">using the standard <span class="_ _a"></span>WHO protocol. It should be noted that the most recent</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls2b5 ws182">classification of therapeutic responses described abo<span class="_ _a"></span>ve differs from that</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls344 ws541">used previously; late parasitological tr<span class="_ _a"></span>eatment responses are now also</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls1a8 ws2aa">considered as an indicator of drug efficacy<span class="_ _c"></span>, as persistent parasitaemia is</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls194 ws282">associated with increased risk of clinical malaria, anaemia and increased</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls1b2 ws1a4">gametocyte carriage <span class="ff1a ws0">(52)</span><span class="ws1b2">. The pr<span class="_ _a"></span>otocol provides guidance on ho<span class="_ _a"></span>w to calculate</span></div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls12 ws0">and present efficacy test results. </div><div class="t m0 xb hb y18e ff17 fs8 fc3 sc0 ls12 ws3b8">If feasible, any judgement of the therapeutic efficacy of a drug should be</div><div class="t m0 xb hb y18f ff17 fs8 fc3 sc0 ls14 ws25d">accompanied by measurements of blood drug concentrations, to ensur<span class="_ _a"></span>e that</div><div class="t m0 xb hb y190 ff17 fs8 fc3 sc0 ls12 wsb9">therapeutic drug levels w<span class="_ _a"></span>ere reached; subtherapeutic lev<span class="_ _a"></span>els confound the</div><div class="t m0 xb hb y191 ff17 fs8 fc3 sc0 ls25d ws121">efficacy result. <span class="_ _a"></span>With modern techniques, antimalarial drug concentrations</div><div class="t m0 xb hb y192 ff17 fs8 fc3 sc0 ls2a8 ws229">can often be analysed in small samples of blood dried on filter paper; samples</div><div class="t m0 xb hb y193 ff17 fs8 fc3 sc0 ls12 ws0">can be sent to a central pharmacological laboratory for analysis.</div><div class="t m0 xb h25 y1145 ff1f fs12 fc4 sc0 ls4f ws0">(b) <span class="ff1b ls285">In vivo <span class="ff1f">assessment of resistance in </span>P<span class="_ _ae"></span>. malariae</span></div><div class="t m0 xb hb y1146 ff17 fs8 fc3 sc0 ls12 ws0">Protocols similar to those used for <span class="ff1a ls13">P<span class="_ _ae"></span>. falciparum <span class="ff17 ls12">can be used.</span></span></div><div class="t m0 xb h25 ybf5 ff1f fs12 fc4 sc0 ls4f ws0">(c) <span class="ff1b ls285">In vivo <span class="ff1f">assessment of resistance in </span><span class="ls4f">P<span class="_ _ae"></span>. vivax <span class="ff1f ls285">and </span><span class="ws542">P<span class="_ _ae"></span>. ovale <span class="ff1f ws0">infections </span></span></span></span></div><div class="t m0 xb hb y9ee ff17 fs8 fc3 sc0 lsfe ws372">Relapse and r<span class="_ _a"></span>ecrudescence cannot be distinguished reliably in these infections,</div><div class="t m0 xb hb y9ef ff17 fs8 fc3 sc0 ls1d9 ws18c">as they will usually have the same genotype. Nev<span class="_ _a"></span>er<span class="_ _8"></span>theless the <span class="ff1a">in vivo </span><span class="ws0">assess-</span></div><div class="t m0 xb hb y9f0 ff17 fs8 fc3 sc0 ls12 ws543">ment of chloroquine susceptibility can be performed using the same format</div><div class="t m0 xb hb y9f1 ff17 fs8 fc3 sc0 ls13 ws4ed">as for <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum<span class="ff17 ls12 ws544">, with a follow-up period of 28 or prefer<span class="_ _a"></span>ably 35 days, and</span></span></div><div class="t m0 xb hb y9f2 ff17 fs8 fc3 sc0 ls13 ws44">preferably accompanied by measur<span class="_ _a"></span>ement of whole blood chloroquine and</div><div class="t m0 xb hb y1147 ff17 fs8 fc3 sc0 ls95 wsec">desethychloroquine lev<span class="_ _a"></span>els. Recurrent infections within this period pr<span class="_ _a"></span>esenting</div><div class="t m0 xb hb y1148 ff17 fs8 fc3 sc0 ls5b ws78">with whole blood chloroquine + desethychlor<span class="_ _a"></span>oquine concentrations exceeding</div><div class="t m0 xb hb y1149 ff17 fs8 fc3 sc0 ls88 wsce">100 ng/ml can be considered as resistant whether they ar<span class="_ _a"></span>e a relapse, a</div><div class="t m0 xb hb y114a ff17 fs8 fc3 sc0 lse6 ws177">recrudescence, or even a new infection, as this concentr<span class="_ _a"></span>ation should be</div><div class="t m0 xb hb y114b ff17 fs8 fc3 sc0 ls13 ws0">suppressive <span class="ff1a ws14">(50, 53, 54)</span>. </div><div class="t m0 xb h23 ycac ff24 fs11 fc8 sc0 ls27a ws0">In vitro <span class="ff1e">resistance tests </span></div><div class="t m0 xb hb y9f9 ff17 fs8 fc3 sc0 ls111 ws4a1">T<span class="_ _4b"></span>o suppor<span class="_ _8"></span>t evidence of a failing antimalarial, <span class="ff1a">in vitro </span>tests can be used to pro<span class="_ _a"></span>vide</div><div class="t m0 xb hb y9fa ff17 fs8 fc3 sc0 ls12 ws344">a more accurate measur<span class="_ _a"></span>e of drug sensitivity under controlled experimental</div><div class="t m0 xb hb y114c ff17 fs8 fc3 sc0 lsc8 ws83">conditions. Parasites obtained fr<span class="_ _a"></span>om finger<span class="_ _a"></span>-prick blood are placed in microtitre</div><div class="t m0 xb hb y114d ff17 fs8 fc3 sc0 ls12 ws545">wells, exposed to precisely kno<span class="_ _a"></span>wn concentrations of a particular drug and</div><div class="t m0 xb hb y114e ff17 fs8 fc3 sc0 ls12 ws425">examined for the inhibition of maturation into schizont par<span class="_ _a"></span>asite stages <span class="ff1a ls13 ws0">(55)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb y114f ff17 fs8 fc3 sc0 ls12 ws462">This test ov<span class="_ _a"></span>ercomes some of the many confounding factors influencing the</div><div class="t m0 xb hb y1150 ff17 fs8 fc3 sc0 ls12 ws3e8">results of <span class="ff1a ls13">in vivo </span>tests, such as subther<span class="_ _a"></span>apeutic drug concentrations and the</div><div class="t m0 xb hb y1151 ff17 fs8 fc3 sc0 ls12 ws45">influence of host factors on parasite gro<span class="_ _a"></span>wth (e.g. factors related to acquired</div><div class="t m0 xb hb y1152 ff17 fs8 fc3 sc0 ls12 ws546">immunity), and therefore pr<span class="_ _a"></span>ovide a more accur<span class="_ _a"></span>ate picture of the “true” lev<span class="_ _a"></span>el</div><div class="t m0 xb hb y1153 ff17 fs8 fc3 sc0 ls345 ws12d">of resistance to the drug. Multiple tests can be performed on parasite isolates,</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfba" class="pf w1 h4" data-page-no="ba"><div class="pc pcba w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">176</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls1a4 ws2a5">using several drugs and drug combinations simultaneously<span class="_ _c"></span>. New experimental</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 lsef wsab">drugs can also be tested in this way<span class="_ _4b"></span>. However<span class="_ _4b"></span>, partly because <span class="ff1a wsb1">in vitro <span class="ff17">tests do</span></span></div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls10e ws1c8">not include host factors, the correlation between r<span class="_ _a"></span>esults of <span class="ff1a">in vitro </span><span class="ws0">and </span><span class="ff1a ls7f">in viv<span class="_ _a"></span>o</span></div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 lsc1 ws132">tests is not consistent and is not well understood. Furthermore, different</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls12 ws4df">parasite isolates may adapt differently to cultur<span class="_ _a"></span>e, which may affect the test</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls346 ws547">result. F<span class="_ _a"></span>or example, if a resistant strain adapts less well to cultur<span class="_ _a"></span>e and</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls34 ws14a">therefore dies off earlier<span class="_ _4b"></span>, the outcome is an over<span class="_ _a"></span>estimation of its susceptibility<span class="_ _4b"></span>.</div><div class="t m0 x9 hb y10e ff17 fs8 fc3 sc0 ls166 ws91">Prodrugs such as pr<span class="_ _a"></span>oguanil, which require conversion into activ<span class="_ _a"></span>e metabolites</div><div class="t m0 x9 hb y10f ff17 fs8 fc3 sc0 ls60 ws85">in the human host, cannot be tested, and <span class="ff1a ws286">P<span class="_ _c"></span>. vivax, P<span class="_ _ae"></span>. ovale <span class="ff17 ws0">and<span class="_ _67"> </span><span class="ff1a">P<span class="_ _c"></span>. malariae <span class="ff17">cannot</span></span></span></span></div><div class="t m0 x9 hb y110 ff17 fs8 fc3 sc0 ls1b2 ws1b2">be evaluated <span class="ff1a">in vitr<span class="_ _a"></span>o <span class="ff17">owing to constraints in culturing these species (although</span></span></div><div class="t m0 x9 hb y111 ff17 fs8 fc3 sc0 ls2c2 ws98">this has now lar<span class="_ _a"></span>gely been overcome for <span class="ff1a ws0">P<span class="_ _ae"></span>.<span class="_ _3"> </span>vivax<span class="ff17">). <span class="_ _66"></span></span><span class="ws98">In vitro <span class="ff17">testing is more</span></span></span></div><div class="t m0 x9 hb y2be ff17 fs8 fc3 sc0 ls12 ws245">demanding in terms of technology and resources, and is not ideal for r<span class="_ _a"></span>outine</div><div class="t m0 x9 hb y2bf ff17 fs8 fc3 sc0 ls12 ws548">drug efficacy evaluation under field conditions. It should ther<span class="_ _a"></span>efore primarily</div><div class="t m0 x9 hb y484 ff17 fs8 fc3 sc0 ls12 ws470">be used to pro<span class="_ _a"></span>vide additional information to suppor<span class="_ _8"></span>t clinical efficacy data at</div><div class="t m0 x9 hb y485 ff17 fs8 fc3 sc0 ls12 ws0">selected resistance-monitoring sites. </div><div class="t m0 x9 h23 y1154 ff1e fs11 fc8 sc0 ls27a ws0">Molecular markers</div><div class="t m0 x9 hb ya23 ff17 fs8 fc3 sc0 ls12 ws15b">In recent years, molecular tests hav<span class="_ _a"></span>e been developed for the detection of</div><div class="t m0 x9 hb ya24 ff17 fs8 fc3 sc0 ls77 wsb4">parasite gene mutations or amplifications associated with resistance to</div><div class="t m0 x9 hb ya25 ff17 fs8 fc3 sc0 ls12 ws53d">antimalarials as an additional means of assessing levels of drug resistance.</div><div class="t m0 x9 hb ya26 ff17 fs8 fc3 sc0 ls331 ws389">These methods are based on PCR, using small amounts of parasite DNA</div><div class="t m0 x9 hb ya27 ff17 fs8 fc3 sc0 ls12 ws0">material in finger<span class="_ _b"></span>-prick blood dried on filter paper<span class="_ _b"></span>. </div><div class="t m0 x9 hb y1023 ff17 fs8 fc3 sc0 lse2 ws138">Information on the prev<span class="_ _a"></span>alence of gene mutations may give an indication of the</div><div class="t m0 x9 hb yfee ff17 fs8 fc3 sc0 ls347 ws549">level of drug resistance in an ar<span class="_ _a"></span>ea, and relatively well-defined molecular</div><div class="t m0 x9 hb yfef ff17 fs8 fc3 sc0 ls12 ws54a">markers of resistance have been established for pyrimethamine (<span class="ff1a ws0">Pfdhfr <span class="ff17">and</span></span></div><div class="t m0 x9 hb yff0 ff1a fs8 fc3 sc0 ls1be ws0">Pvdhfr<span class="ff17 ws294">), sulfado<span class="_ _a"></span>xine (<span class="ff1a ws0">Pfdhps</span>) and chloroquine (<span class="ff1a ws0">Pfcr<span class="_ _8"></span>t1<span class="ff17 ls189">) <span class="_ _a"></span><span class="ff1a ls1be ws203">(56, 57)<span class="ff17">. Amplification</span></span></span></span></span></div><div class="t m0 x9 hb y1024 ff17 fs8 fc3 sc0 ls327 ws0">of <span class="_ _9"></span><span class="ff1a">Pfmdr<span class="_ _3"> </span></span><span class="ws519">(for mefloquine resistance) is considerably more technically</span></div><div class="t m0 x9 hb y1025 ff17 fs8 fc3 sc0 ls13 ws42b">demanding, requiring v<span class="_ _a"></span>alidated real-time PCR. No markers are yet av<span class="_ _a"></span>ailable</div><div class="t m0 x9 hb y1026 ff17 fs8 fc3 sc0 ls12 ws0">for other antimalarials. </div><div class="t m0 x9 hb y1155 ff17 fs8 fc3 sc0 ls12 ws54b">These methods have their disadv<span class="_ _a"></span>antages. The r<span class="_ _a"></span>esults are seldom available</div><div class="t m0 x9 hb y1156 ff17 fs8 fc3 sc0 ls12 ws8f">rapidly<span class="_ _c"></span>, and mutations and the measured therapeutic efficacy do not always</div><div class="t m0 x9 hb y1157 ff17 fs8 fc3 sc0 ls239 ws2cd">correlate well, as many factors determine the ther<span class="_ _a"></span>apeutic response in addition</div><div class="t m0 x9 hb y1158 ff17 fs8 fc3 sc0 lse5 ws176">to parasite sensitivity to the antimalarial drug treatment. Ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, serial</div><div class="t m0 x9 hb y1159 ff17 fs8 fc3 sc0 ls12 ws25c">assessment of molecular markers can be a useful guide to the emergence of</div><div class="t m0 x9 hb y115a ff17 fs8 fc3 sc0 ls110 ws424">resistance, especially if used consistently o<span class="_ _a"></span>ver time in comparable study</div><div class="t m0 x9 hb y115b ff17 fs8 fc3 sc0 lsa8 ws10a">populations to detect trends. <span class="_ _a"></span>The methods may also provide useful guidance</div><div class="t m0 x9 hb y115c ff17 fs8 fc3 sc0 ls12 ws286">on choices of treatment during acute malaria epidemics, where time will not</div><div class="t m0 x9 hb y115d ff17 fs8 fc3 sc0 ls12 ws44f">allow for clinical efficacy tests, but where it may be critical to av<span class="_ _a"></span>oid the use</div><div class="t m0 x9 hb y115e ff17 fs8 fc3 sc0 ls53 ws160">of a particular drug <span class="ff1a ls31b ws0">(58)</span>. The requirements for technical skills and labor<span class="_ _a"></span>atory</div><div class="t m0 x9 hb y115f ff17 fs8 fc3 sc0 ls23b ws1c7">facilities prevent the r<span class="_ _a"></span>outine use of these methods in most drug efficacy</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfbb" class="pf w1 h4" data-page-no="bb"><div class="pc pcbb w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">177</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls1d8 ws173">testing sites, although they are becoming increasingly used in labor<span class="_ _a"></span>atories in</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls12 ws54c">endemic areas – particularly those suppor<span class="_ _8"></span>ting clinical trials. Moreov<span class="_ _a"></span>er<span class="_ _b"></span>, the</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls12 ws3ac">results are subject to err<span class="_ _a"></span>or and must be considered carefully<span class="_ _c"></span>. For example, a</div><div class="t m0 xb h59 ya1 ff17 fs8 fc3 sc0 ls233 ws17b">patient may have an infection with two different genotypes on day <span class="fs11 ls0 ws0">0<span class="_ _67"> </span></span>but, only</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls181 ws264">one genotype is detected with PCR. If one genotype is sensitive and the other</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls83 wsc7">is resistant, the resistant genotype may persist until day 14 despite antimalarial</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls348 ws54d">treatment, while the sensitive genotype will be clear<span class="_ _a"></span>ed; if detected, the</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 ls202 ws348">presence of the resistant genotype on day 14 may then incorr<span class="_ _a"></span>ectly be interpreted</div><div class="t m0 xb hb y10f ff17 fs8 fc3 sc0 ls12 ws0">as reinfection and not as recrudescence <span class="ff1a ls53">(59)</span><span class="ls13">. </span></div><div class="t m0 xb hb y190 ff17 fs8 fc3 sc0 ls2a1 ws423">While monitoring of molecular markers may only be possible at central</div><div class="t m0 xb hb y191 ff17 fs8 fc3 sc0 ls25 ws34">laboratories, it can support monitoring programmes that rely on <span class="ff1a">in viv<span class="_ _a"></span>o <span class="ff17 ws0">testing,</span></span></div><div class="t m0 xb hb y192 ff17 fs8 fc3 sc0 ls64 ws54e">and also play an important par<span class="_ _8"></span>t in early-warning systems to guide treatment</div><div class="t m0 xb hb y193 ff17 fs8 fc3 sc0 lsab ws2fe">policies coordinated at national and regional lev<span class="_ _a"></span>els. With newly dev<span class="_ _a"></span>eloped high-</div><div class="t m0 xb hb y2c0 ff17 fs8 fc3 sc0 ls163 ws50">throughput methods <span class="ff1a">(60, 61)</span>, more compr<span class="_ _a"></span>ehensive population-based analyses</div><div class="t m0 xb hb y2c1 ff17 fs8 fc3 sc0 ls2ac wsa3">will also be possible, which may allow for a better understanding and prediction</div><div class="t m0 xb hb y2c2 ff17 fs8 fc3 sc0 ls64 ws0">of the future spread of r<span class="_ _a"></span>esistance <span class="ff1a">(40, 42)</span>. </div><div class="t m0 xb h23 ya23 ff1e fs11 fc8 sc0 ls27a ws0">Efficacy testing in animal models</div><div class="t m0 xb hb y1160 ff17 fs8 fc3 sc0 ls71 wsa7">In addition to <span class="ff1a">in vivo </span>efficacy studies inv<span class="_ _a"></span>olving human par<span class="_ _8"></span>ticipants, drug</div><div class="t m0 xb hb y1161 ff17 fs8 fc3 sc0 lsa6 ws107">sensitivity can be tested in animal models. Although such models do not</div><div class="t m0 xb hb y1162 ff17 fs8 fc3 sc0 ls12 ws212">play an important role in routine efficacy-monitoring programmes, they may</div><div class="t m0 xb hb y1163 ff17 fs8 fc3 sc0 ls12 ws473">be useful in the testing of newly developed drugs, not yet appr<span class="_ _a"></span>oved for use</div><div class="t m0 xb hb y1164 ff17 fs8 fc3 sc0 lsfe ws372">in humans, or to minimize the influence of host immunity on drug efficacy<span class="_ _4b"></span>, while</div><div class="t m0 xb hb y1165 ff17 fs8 fc3 sc0 ls12 ws54f">retaining the influence of some of the extrinsic factors observed in <span class="ff1a ls13">in vivo</span></div><div class="t m0 xb hb y1166 ff17 fs8 fc3 sc0 ls13 ws0">studies. </div><div class="t m0 xb h2e y1167 ff19 fs3 fc3 sc0 ls0 wsc1">A6.5.2<span class="_ _a7"> </span>Repor<span class="_ _8"></span>ting of treat<span class="_ _8"></span>ment failures</div><div class="t m0 xb hb y1168 ff17 fs8 fc3 sc0 ls0 ws2e6">Reports of cases of treatment failure and decreased drug sensitivity hav<span class="_ _a"></span>e</div><div class="t m0 xb hb y1169 ff17 fs8 fc3 sc0 ls31b ws2c2">often pro<span class="_ _a"></span>vided impor<span class="_ _8"></span>tant first evidence for more widespread resistance in an</div><div class="t m0 xb hb y116a ff17 fs8 fc3 sc0 ls1f ws1e">area. Although such evidence is subject to bias, it can be collected without much</div><div class="t m0 xb hb y116b ff17 fs8 fc3 sc0 ls218 ws216">effort at peripheral health centres. If standardized and register<span class="_ _a"></span>ed, such reports</div><div class="t m0 xb hb y116c ff17 fs8 fc3 sc0 ls1b9 ws4ba">can make a valuable contribution to national early-warning systems, facilitating</div><div class="t m0 xb hb y116d ff17 fs8 fc3 sc0 ls13 ws14">cost-effective monitoring by national progr<span class="_ _a"></span>ammes. </div><div class="t m0 xb h2e y116e ff19 fs3 fc3 sc0 ls80 ws0">A6.5.3<span class="_ _a7"> </span>Cr<span class="_ _8"></span>iteria for antimalar<span class="_ _8"></span>ial drug p<span class="_ _8"></span>olic<span class="_ _8"></span>y change</div><div class="t m0 xb hb y116f ff17 fs8 fc3 sc0 ls1db ws0">The <span class="ff1a ws13c">WHO malaria tr<span class="_ _a"></span>eatment guidelines <span class="ff17">recommend that antimalarial treatment</span></span></div><div class="t m0 xb hb y1170 ff17 fs8 fc3 sc0 ls12 ws18e">policy should be changed at treatment failure r<span class="_ _a"></span>ates considerably lower than</div><div class="t m0 xb hb y1171 ff17 fs8 fc3 sc0 ls5e ws7f">those recommended previously<span class="_ _c"></span>. This major change reflects the av<span class="_ _a"></span>ailability of</div><div class="t m0 xb hb y1172 ff17 fs8 fc3 sc0 ls12 ws13b">highly effective drugs, and the recognition both of the consequences of drug</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfbc" class="pf w1 h4" data-page-no="bc"><div class="pc pcbc w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1b ws0">178</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls172 ws18a">resistance, in terms of morbidity and mortality<span class="_ _4b"></span>, and of the impor<span class="_ _8"></span>tance of high</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls12 ws0">cure rates in malaria contr<span class="_ _a"></span>ol.</div><div class="t m0 x9 hb y1f3 ff17 fs8 fc3 sc0 ls1e ws1d">It is now recommended that a change of first-line tr<span class="_ _a"></span>eatment should be initiated</div><div class="t m0 x9 hb y18a ff17 fs8 fc3 sc0 ls13 ws27">if the total failure proportion exceeds 10%. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, it is acknowledged that</div><div class="t m0 x9 hb y18b ff17 fs8 fc3 sc0 lsa2 ws102">a decision to change may be influenced by a number of other factors, including</div><div class="t m0 x9 hb y18c ff17 fs8 fc3 sc0 ls12 ws44a">the prev<span class="_ _a"></span>alence and geographical distribution of reported treatment failures,</div><div class="t m0 x9 hb y18d ff17 fs8 fc3 sc0 lsd0 ws149">health service provider and/or patient dissatisfaction with the treatment,</div><div class="t m0 x9 hb y18e ff17 fs8 fc3 sc0 ls25c ws3ec">political and economical contexts, and the availability of affor<span class="_ _a"></span>dable alternatives</div><div class="t m0 x9 hb y18f ff17 fs8 fc3 sc0 ls12 ws0">to the commonly used treatment.</div><div class="t m0 x9 h12 y1173 ff19 fs6 fc4 sc0 ls1 ws0">A6.6<span class="_ _52"> </span>References</div><div class="t mc x9 h17 y1174 ff17 fsb fc3 sc0 ls105 ws0">1.<span class="_ _46"> </span>Bonhoeffer S, Lipsitch M, Levin BR. Ev<span class="_ _a"></span>aluating treatment protocols to prev<span class="_ _a"></span>ent</div><div class="t mc x7a h17 y1175 ff17 fsb fc3 sc0 ls105 ws0">antibiotic resistance. <span class="ff1a ws1d4">Proceedings of the National Academy of Sciences of the</span></div><div class="t mc x7a h17 y1176 ff1a fsb fc3 sc0 ls1e0 ws0">USA<span class="ff17 ls2e2 ws1d3">, 1997, 94:12106–12111.</span></div><div class="t mc x9 h17 y1177 ff17 fsb fc3 sc0 ls105 ws0">2.<span class="_ _44"> </span>Lipsitch M, Levin BR. The population dynamics of antimicr<span class="_ _a"></span>obial chemotherapy<span class="_ _4b"></span>.</div><div class="t mc x7a h17 y1178 ff1a fsb fc3 sc0 ls105 ws0">Antimicrobial Agents and Chemotherapy<span class="ff17 lsd6 ws218">, 1997, 41:363–373.</span></div><div class="t mc x9 h17 y1179 ff17 fsb fc3 sc0 ls105 ws0">3.<span class="_ _44"> </span>Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient,</div><div class="t mc x7a h17 y117a ff17 fsb fc3 sc0 ls105 ws0">hospitals and the community using simple mathematical models. <span class="ff1a">Philosophical</span></div><div class="t mc x7a h17 y117b ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ransactions of the Royal Society of L<span class="_ _a"></span>ondon, Series B, Biological Sciences<span class="ff17 ws1d4">, 1999,</span></div><div class="t mc x7a h17 y117c ff17 fsb fc3 sc0 ls105 ws0">354:721–738.</div><div class="t mc x9 h17 y117d ff17 fsb fc3 sc0 ls105 ws502">4.<span class="_ _44"> </span>Peters W<span class="_ _b"></span>. <span class="ff1a ws0">Chemotherapy and drug resistance in malaria<span class="ff17">, 2nd ed. London,</span></span></div><div class="t mc x7a h17 y117e ff17 fsb fc3 sc0 ls105 ws0">Academic Press, 1987.</div><div class="t mc x9 h17 y117f ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>White NJ. Antimalarial drug resistance and combination chemotherapy<span class="_ _c"></span>.</div><div class="t mc x7a h4d y1180 ff1a fsb fc3 sc0 ls105 ws0">Philosophical T<span class="_ _4b"></span>ransactions of the Royal Society of L<span class="_ _a"></span>ondon, Series B, Biological</div><div class="t mc x7a h17 y1181 ff1a fsb fc3 sc0 ls105 ws0">Sciences<span class="ff17">, 1999, 354:739–749.</span></div><div class="t mc x9 h17 y1182 ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>Jeffery GM, Eyles DE. Infectivity to mosquitoes of <span class="ff1a">Plasmodium falciparum </span><span class="lsd6">as</span></div><div class="t mc x7a h17 y1183 ff17 fsb fc3 sc0 ls105 ws0">related to gametocyte density and duration of infection. <span class="ff1a">American Journal of</span></div><div class="t mc x7a h17 y1184 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 1955, 4:781–789.</span></div><div class="t mc x9 h17 y1185 ff17 fsb fc3 sc0 ls105 ws0">7.<span class="_ _39"> </span>Mackinnon MJ, Hastings IM. The evolution of multiple drug resistance in malaria</div><div class="t mc x7a h17 y1186 ff17 fsb fc3 sc0 ls105 ws0">parasites. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls0">,</span></span></div><div class="t mc x7a h17 y1187 ff17 fsb fc3 sc0 ls130 ws19a">1998, 92:188–195.</div><div class="t mc x9 h17 y1188 ff17 fsb fc3 sc0 ls130 ws0">8.<span class="_ _44"> </span>Hastings IM, Mackinnon MJ. The emergence of drug-resistant malaria.</div><div class="t mc x7a h17 y1189 ff1a fsb fc3 sc0 ls137 ws0">Parasitology<span class="ff17 ls104 ws35b">, 1998, 117:411–417.</span></div><div class="t mc x9 h17 y118a ff17 fsb fc3 sc0 ls105 ws0">9.<span class="_ _44"> </span>Roper C et al. Intercontinental spread of pyrimethamine-r<span class="_ _a"></span>esistant malaria.</div><div class="t mc x7a h17 y118b ff1a fsb fc3 sc0 ls105 ws0">Science<span class="ff17 ws19a">, 2004, 305:1124.</span></div><div class="t mc x9 h17 y118c ff17 fsb fc3 sc0 ls105 ws19a">10.<span class="_ _68"> </span>Dye C, <span class="_ _a"></span>Williams BG. Multigenic drug resistance among inbred malaria par<span class="_ _a"></span>asites.</div><div class="t mc x7a h17 y118d ff1a fsb fc3 sc0 ls105 ws19a">Proceedings of the R<span class="_ _a"></span>oyal Society of London, Series B, Biological Sciences<span class="ff17 ws0">, 1997,</span></div><div class="t mc x7a h17 y118e ff17 fsb fc3 sc0 ls105 ws218">264: 61–67.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfbd" class="pf w1 h4" data-page-no="bd"><div class="pc pcbd w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">179</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">11.<span class="_ _0"> </span>Gatton ML, Mar<span class="_ _8"></span>tin LB, Cheng Q. Evolution of r<span class="_ _a"></span>esistance to sulfadoxine-</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">pyrimethamine in <span class="ff1a">Plasmodium falciparum</span>. <span class="ff1a">Antimicrobial Agents and</span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Chemotherapy<span class="ff17 ws19a">, 2004, 48:2116–2123. </span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">12.<span class="_ _68"> </span>Rathod PK, McErlean <span class="_ _b"></span>T<span class="_ _a"></span>, Lee PC. <span class="_ _b"></span>V<span class="_ _a"></span>ariations in frequencies of drug resistance in</div><div class="t mc x4d h17 yd65 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum<span class="ff17">. </span><span class="ws1d4">Proceedings of the National Academy of Sciences of the</span></div><div class="t mc x4d h17 yd66 ff1a fsb fc3 sc0 ls1e0 ws0">USA<span class="ff17 ls137 ws1d4">, 1997, 94:9389–9393.</span></div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls130 ws19a">13.<span class="_ _68"> </span>Cowman AF<span class="_ _c"></span>, G<span class="_ _8"></span>alatis D, Thompson JK. Selection for mefloquine resistance in</div><div class="t mc x4d h17 yd68 ff1a fsb fc3 sc0 ls130 ws0">Plasmodium falciparum <span class="ff17">is linked to amplification of the </span>pfmdr1 <span class="ff17">gene and cross-</span></div><div class="t mc x4d h17 yd87 ff17 fsb fc3 sc0 ls130 ws0">resistance to halofantrine and quinine. <span class="ff1a ls137 ws1d4">Proceedings of the National Academy of</span></div><div class="t mc x4d h17 yec8 ff1a fsb fc3 sc0 ls137 ws0">Sciences of the USA<span class="ff17">, 1994, 91:1143–1147.</span></div><div class="t mc xb h17 yd88 ff17 fsb fc3 sc0 ls137 ws0">14.<span class="_ _3"> </span>Looareesuwan S et al. Clinical studies of atov<span class="_ _a"></span>aquone, alone or in combination</div><div class="t mc x4d h17 yd89 ff17 fsb fc3 sc0 ls137 ws0">with other antimalarial drugs, for treatment of acute uncomplicated malaria in</div><div class="t mc x4d h17 yec9 ff17 fsb fc3 sc0 ls137 ws0">Thailand. <span class="ff1a">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 1996, 54:62–66.</span></span></div><div class="t mc xb h17 yd8b ff17 fsb fc3 sc0 ls137 ws0">15.<span class="_ _68"> </span>Reed MB et al. <span class="ff1a">Pgh1 </span>modulates sensitivity and resistance to multiple</div><div class="t mc x4d h17 yeca ff17 fsb fc3 sc0 ls137 ws0">antimalarials in <span class="ff1a">Plasmodium falciparum. Nature</span><span class="ws1d4">, 2000, 403: 906–909.</span></div><div class="t mc xb h17 yd8d ff17 fsb fc3 sc0 ls137 ws0">16.<span class="_ _3"> </span>Korsinczky M. et al. Mutations in <span class="ff1a">Plasmodium falciparum </span>cytochrome b that ar<span class="_ _a"></span>e</div><div class="t mc x4d h17 yd8e ff17 fsb fc3 sc0 ls137 ws0">associated with atov<span class="_ _a"></span>aquone resistance are located at a putativ<span class="_ _a"></span>e drug-binding</div><div class="t mc x4d h17 yecd ff17 fsb fc3 sc0 ls137 ws0">site. <span class="ff1a">Antimicrobial Agents and Chemotherapy</span><span class="ls104 ws35b">, 2000, 44: 2100–2108.</span></div><div class="t mc xb h17 yd90 ff17 fsb fc3 sc0 ls105 ws0">17.<span class="_ _68"> </span>White N<span class="_ _8"></span>J. Antimalarial pharmacokinetics and treatment regimens. <span class="ff1a">British Journal</span></div><div class="t mc x4d h17 yd91 ff1a fsb fc3 sc0 ls105 ws0">of Clinical Pharmacology<span class="ff17 ls2e2">, 1992, 34:1–10.</span></div><div class="t mc xb h17 yd92 ff17 fsb fc3 sc0 ls105 ws0">18.<span class="_ _3"> </span>White N<span class="_ _8"></span>J, van <span class="_ _b"></span>Vugt M, Ezz<span class="_ _a"></span>et F<span class="_ _4b"></span>. Clinical pharmacokinetics and pharmacodynamics</div><div class="t mc x4d h17 yd93 ff17 fsb fc3 sc0 ls105 ws0">of artemether-lumefantrine. <span class="ff1a">Clinical Pharmacokinetics</span><span class="ls104 ws35b">, 1999, 37:105–125. </span></div><div class="t mc xb h17 yd94 ff17 fsb fc3 sc0 ls105 ws0">19.<span class="_ _3"> </span>Watkins <span class="_ _a"></span>WM, Mosobo M. T<span class="_ _b"></span>reatment of <span class="ff1a">Plasmodium falciparum </span>malaria with</div><div class="t mc x4d h17 ydaf ff17 fsb fc3 sc0 ls105 ws0">pyrimethamine-sulphadoxine: selective pr<span class="_ _a"></span>essure for resistance is a function of</div><div class="t mc x4d h17 ydb0 ff17 fsb fc3 sc0 ls105 ws0">long elimination half-life. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine</span></div><div class="t mc x4d h17 y118f ff1a fsb fc3 sc0 ls105 ws1d4">and Hygiene<span class="ff17 ws0">, 1973, 87:75–78.</span></div><div class="t mc xb h17 yd95 ff17 fsb fc3 sc0 ls105 ws1d4">20.<span class="_ _5"> </span>Nzila AM et al. Molecular evidence of greater selective pressure for drug</div><div class="t mc x4d h17 ydb1 ff17 fsb fc3 sc0 ls105 ws0">resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine</div><div class="t mc x4d h17 ydb2 ff17 fsb fc3 sc0 ls105 ws0">compared with the shorter<span class="_ _a"></span>-acting chlorproguanil/dapsone on K<span class="_ _a"></span>enyan</div><div class="t mc x4d h17 y1190 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum. Journal of Infectious Diseases<span class="ff17 ws1d4">, 2000, 181:2023–2028.</span></div><div class="t mc xb h17 ydb4 ff17 fsb fc3 sc0 ls105 ws0">21.<span class="_ _68"> </span>Hastings I, <span class="_ _a"></span>Watkins <span class="_ _b"></span>WM, White NJ. The evolution of drug-resistance in malaria:</div><div class="t mc x4d h17 ydb5 ff17 fsb fc3 sc0 ls105 ws0">the role of the terminal elimination half-life. <span class="ff1a">Philosophical <span class="_ _a"></span>T<span class="_ _b"></span>ransactions of the</span></div><div class="t mc x4d h17 y1191 ff1a fsb fc3 sc0 ls105 ws0">Ro<span class="_ _a"></span>yal Society London B Biological Sciences<span class="ff17">, 2002, 357:505–519.</span></div><div class="t mc xb h17 ydb7 ff17 fsb fc3 sc0 ls105 ws0">22.<span class="_ _5"> </span>White N<span class="_ _8"></span>J. Assessment of the pharmacodynamic properties of antimalarial drugs</div><div class="t mc x4d h17 ydb8 ff1a fsb fc3 sc0 ls105 ws0">in vivo<span class="ff17">. </span>Antimicrobial Agents and Chemother<span class="_ _a"></span>apy<span class="ff17 ws19a">, 1997, 41: 1413–1422.</span></div><div class="t mc xb h17 ydb9 ff17 fsb fc3 sc0 ls105 ws0">23.<span class="_ _95"> </span>Price RN et al. Risk factors for gametocyte carriage in uncomplicated falciparum</div><div class="t mc x4d h17 ydba ff17 fsb fc3 sc0 ls105 ws0">malaria. <span class="ff1a">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17">1999, 60:</span></span></div><div class="t mc x4d h17 ydbb ff17 fsb fc3 sc0 ls138 ws0">1019–1023.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfbe" class="pf w1 h4" data-page-no="be"><div class="pc pcbe w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1b ws0">180</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">24.<span class="_ _5"> </span>Cur<span class="_ _8"></span>tis CF<span class="_ _4b"></span>, Otoo LN. A simple model of the build-up of resistance to mixtures of</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">antimalarial drugs. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17">, 1986, 80: 889–892.</span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">25.<span class="_ _95"> </span>Hastings IM. The origins of antimalarial drug resistance. <span class="ff1a ws1d4">T<span class="_ _b"></span>rends in Par<span class="_ _a"></span>asitology<span class="ff17 ls0 ws0">,</span></span></div><div class="t mc x7a h17 yd65 ff17 fsb fc3 sc0 ls130 ws19a">2004, 20:512–518. </div><div class="t mc x9 h17 yee3 ff17 fsb fc3 sc0 ls130 ws0">26.<span class="_ _5"> </span>Peters W<span class="_ _4b"></span>. Drug resistance – a perspective. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Ro<span class="_ _a"></span>yal Society of</span></div><div class="t mc x7a h17 yd67 ff1a fsb fc3 sc0 ls130 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ws218">, 1969, 63:25–45.</span></div><div class="t mc x9 h17 y1192 ff17 fsb fc3 sc0 ls130 ws0">27.<span class="_ _95"> </span>Peters W<span class="_ _4b"></span>. The prev<span class="_ _a"></span>ention of antimalarial drug resistance. <span class="ff1a">Pharmacology and</span></div><div class="t mc x7a h17 yd69 ff1a fsb fc3 sc0 ls130 ws0">Therapeutics<span class="ff17">, 1990, 47:499–508. </span></div><div class="t mc x9 h17 y1193 ff17 fsb fc3 sc0 ls130 ws0">28. Chawira AN et al. The effect of combinations of qinghaosu (artemisinin) with</div><div class="t mc x7a h17 yd6b ff17 fsb fc3 sc0 ls130 ws0">standard antimalarial drugs in the suppressiv<span class="_ _a"></span>e treatment of malaria in mice.</div><div class="t mc x7a h17 yd6c ff1a fsb fc3 sc0 ls130 ws0">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene<span class="ff17">, 1987,</span></div><div class="t mc x7a h17 yd8a ff17 fsb fc3 sc0 ls130 ws0">81:554–558.</div><div class="t mc x9 h17 yd6e ff17 fsb fc3 sc0 ls130 ws19a">29.<span class="_ _5"> </span>White N<span class="_ _8"></span>J et al. Averting a malaria disaster<span class="_ _b"></span>. <span class="ff1a ws0">Lancet</span>, 1999, 353:1965–1967.</div><div class="t mc x9 h17 yd6f ff17 fsb fc3 sc0 ls130 ws0">30.<span class="_ _95"> </span>Su, X et al. Complex polymorphisms in an appro<span class="_ _a"></span>ximately 330 kDa protein are</div><div class="t mc x7a h17 yd70 ff17 fsb fc3 sc0 ls130 ws0">linked to chloroquine-resistant <span class="ff1a">P<span class="_ _c"></span>. falciparum <span class="ff17">in Southeast Asia and Africa. </span>Cell<span class="ff17 ls0">,</span></span></div><div class="t mc x7a h17 ydbc ff17 fsb fc3 sc0 ls1dc ws1d2">1997, 91: 593–603.</div><div class="t mc x9 h17 yd72 ff17 fsb fc3 sc0 ls105 ws0">31.<span class="_ _68"> </span>Nosten F et al. Effects of artesunate-mefloquine combination on incidence of</div><div class="t mc x7a h17 yd73 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum <span class="ff17">malaria and mefloquine resistance in western <span class="_ _a"></span>Thailand;</span></div><div class="t mc x7a h17 ydbd ff17 fsb fc3 sc0 ls105 ws0">a prospective study<span class="_ _c"></span>. <span class="ff1a">Lancet</span>, 2000, 356: 297–302.</div><div class="t mc x9 h17 yd75 ff17 fsb fc3 sc0 ls105 ws0">32.<span class="_ _95"> </span>Brockman A et al. <span class="ff1a">Plasmodium falciparum </span>antimalarial drug susceptibility on the</div><div class="t mc x7a h17 yd76 ff17 fsb fc3 sc0 ls105 ws0">northwestern border of Thailand during five y<span class="_ _a"></span>ears of extensive artesunate-</div><div class="t mc x7a h17 yd94 ff17 fsb fc3 sc0 ls105 ws0">mefloquine use. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and</span></div><div class="t mc x7a h17 ydaf ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17 ws19a">, 2000, 94, 537–544.</span></div><div class="t mc x9 h17 yd79 ff17 fsb fc3 sc0 ls105 ws0">33.<span class="_ _95"> </span>Wongsrichanalai C et al. Epidemiology of drug-r<span class="_ _a"></span>esistant malaria. <span class="ff1a">Lancet</span></div><div class="t mc x7a h17 yd7a ff1a fsb fc3 sc0 ls105 ws0">Infectious Diseases<span class="ff17">, 2002, 2:209–218.</span></div><div class="t mc x9 h17 yd7b ff17 fsb fc3 sc0 ls105 ws1d4">34.<span class="_ _95"> </span>W<span class="_ _a"></span>ellems TE, Plow<span class="_ _a"></span>e CV<span class="_ _b"></span>. Chloroquine-resistant malaria. <span class="ff1a ws0">Journal of Infectious</span></div><div class="t mc x7a h17 yd7c ff1a fsb fc3 sc0 ls105 ws0">Diseases<span class="ff17 ws19a">, 2001, 184:770–776.</span></div><div class="t mc x9 h17 ydbf ff17 fsb fc3 sc0 ls105 ws0">35.<span class="_ _95"> </span>Vieira PP<span class="_ _6"> </span>et al. pfcrt Polymorphism and the spread of chloroquine resistance in</div><div class="t mc x7a h17 yd7e ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum <span class="ff17">populations across the Amazon Basin. </span>Journal of</div><div class="t mc x7a h17 yd7f ff1a fsb fc3 sc0 ls105 ws0">Infectious Diseases<span class="ff17 lsd6 ws218">, 2004, 190:417–424. </span></div><div class="t mc x9 h17 yd80 ff17 fsb fc3 sc0 lsd6 ws19a">36.<span class="_ _95"> </span>Hurwitz ES, Johnson D, Campbell CC. Resistance of <span class="ff1a ls105 ws0">Plasmodium falciparum</span></div><div class="t mc x7a h17 yd81 ff17 fsb fc3 sc0 ls105 ws0">malaria to sulfadoxine-pyrimethamine (“F<span class="_ _a"></span>ansidar”) in a refugee camp in</div><div class="t mc x7a h17 yd82 ff17 fsb fc3 sc0 ls105 ws0">Thailand. <span class="ff1a">Lancet</span><span class="ls2e2 ws1d3">, 1981, 1:1068–1070.</span></div><div class="t mc x9 h17 yd83 ff17 fsb fc3 sc0 ls130 ws19a">37.<span class="_ _95"> </span>Checchi F et al. High <span class="_ _8"></span><span class="ff1a ws0">Plasmodium falciparum <span class="ff17">resistance to chloroquine and</span></span></div><div class="t mc x7a h17 yd84 ff17 fsb fc3 sc0 ls130 ws0">sulfadoxine-pyrimethamine in Harper<span class="_ _4b"></span>, Liberia: results in vivo and analysis of</div><div class="t mc x7a h17 yd85 ff17 fsb fc3 sc0 ls137 ws1d4">point mutations. <span class="ff1a ws0">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yd86 ff1a fsb fc3 sc0 ls137 ws0">Hygiene<span class="ff17">, 2002, 96:664–669.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfbf" class="pf w1 h4" data-page-no="bf"><div class="pc pcbf w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xbd he y9 ff16 fs5 fc3 sc0 ls3 ws2">Annex 6 - Resistance to antimalarials</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">181</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">38.<span class="_ _5"> </span>Kofoed PE et al. <span class="_ _a"></span>T<span class="_ _b"></span>reatment of uncomplicated malaria in children in Guinea-Bissau</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws19a">with chloroquine, quinine, and sulfadoxine-pyrimethamine. <span class="ff1a ws0">T<span class="_ _4b"></span>ransactions of the</span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 2002, 96:304–309.</span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">39.<span class="_ _95"> </span>Plowe CV et al. Sustained clinical efficacy of sulfado<span class="_ _a"></span>xine-pyrimethamine for</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated falciparum malaria in Malawi after 10 years as first line treatment:</div><div class="t mc x4d h17 yd66 ff17 fsb fc3 sc0 ls105 ws0">five year pr<span class="_ _a"></span>ospective study<span class="_ _4b"></span>. <span class="ff1a">British Medical Journal</span>, 2004, 328:545.</div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">40.<span class="_ _5"> </span>Anderson TJ. Mapping drug resistance genes in <span class="ff1a">Plasmodium falciparum </span><span class="ls349">by</span></div><div class="t mc x4d h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">genome-wide association. <span class="ff1a">Current Drug <span class="_ _a"></span>T<span class="_ _4b"></span>argets. Infectious Disorders<span class="ff17">, 2004,</span></span></div><div class="t mc x4d h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">4:65–78.</div><div class="t mc xb h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">41.<span class="_ _3"> </span>Nair S et al. A selective sweep driven by pyrimethamine treatment in southeast</div><div class="t mc x4d h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">Asian malaria parasites. <span class="ff1a">Molecular Biology and Ev<span class="_ _a"></span>olution<span class="ff17 ls1dc ws1d2">, 2003, 20:1526–1536.</span></span></div><div class="t mc xb h17 yd6c ff17 fsb fc3 sc0 ls105 ws0">42.<span class="_ _5"> </span>Roper C et al. Antifolate antimalarial resistance in southeast Africa: a population-</div><div class="t mc x4d h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">based analysis. <span class="ff1a">Lancet</span>, 2003, 361:1174–1181.</div><div class="t mc xb h17 yd6e ff17 fsb fc3 sc0 ls105 ws0">43.<span class="_ _95"> </span>Nosten F et al. Mefloquine-resistant falciparum malaria on the <span class="_ _a"></span>Thai-Burmese</div><div class="t mc x4d h17 yd8c ff17 fsb fc3 sc0 ls105 ws0">border<span class="_ _b"></span>. <span class="ff1a">Lancet</span><span class="ws19a">, 1991, 337:1140–1143.</span></div><div class="t mc xb h17 yd70 ff17 fsb fc3 sc0 ls105 ws0">44.<span class="_ _5"> </span>Fontanet AL et al. High pr<span class="_ _a"></span>evalence of mefloquine-resistant falciparum malaria in</div><div class="t mc x4d h17 ydbc ff17 fsb fc3 sc0 ls105 ws27d">eastern Thailand. <span class="ff1a ws19a">Bulletin of the W<span class="_ _a"></span>orld Health Organization<span class="ff17">, 1993, 71:377–383.</span></span></div><div class="t mc xb h17 yd72 ff17 fsb fc3 sc0 ls105 ws1d4">45.<span class="_ _95"> </span>W<span class="_ _a"></span>ernsdorfer WH. Epidemiology of drug resistance in malaria. <span class="ff1a ws27d">Acta T<span class="_ _b"></span>ropica<span class="ff17 ws0">, 1994,</span></span></div><div class="t mc x4d h17 yd73 ff17 fsb fc3 sc0 ls105 ws0">56:143–156.</div><div class="t mc xb h17 yd74 ff17 fsb fc3 sc0 ls105 ws0">46.<span class="_ _5"> </span>Price R<span class="_ _8"></span>N et al. Mefloquine resistance in <span class="ff1a">Plasmodium falciparum </span>and increased</div><div class="t mc x4d h17 yd75 ff17 fsb fc3 sc0 ls105 ws0">pfmdr1 gene copy number<span class="_ _b"></span>. <span class="ff1a">Lancet</span>, 2004, 364:438–447.</div><div class="t mc xb h17 y1194 ff17 fsb fc3 sc0 ls105 ws1d4">47.<span class="_ _95"> </span>Zalis MG et al. Characterization of <span class="ff1a ws0">Plasmodium falciparum <span class="ff17">isolated from the</span></span></div><div class="t mc x4d h17 yd77 ff17 fsb fc3 sc0 ls105 ws0">Amazon region of Brazil: evidence for quinine r<span class="_ _a"></span>esistance. <span class="ff1a">American Journal of</span></div><div class="t mc x4d h17 yd78 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls2e2 ws1d3">, 1998, 58:630–637. </span></div><div class="t mc xb h17 y1195 ff17 fsb fc3 sc0 ls105 ws0">48. Duraisingh MT<span class="_ _6"> </span>et al. Linkage disequilibrium between two chromosomally distinct</div><div class="t mc x4d h17 ydbe ff17 fsb fc3 sc0 ls105 ws0">loci associated with increased resistance to chlor<span class="_ _a"></span>oquine in <span class="ff1a">Plasmodium</span></div><div class="t mc x4d h17 yd7b ff1a fsb fc3 sc0 ls105 ws0">falciparum<span class="ff17">. </span>Parasitology<span class="ff17 ws19a">, 2000, 121:1–7.</span></div><div class="t mc xb h4d y1196 ff1a fsb fc3 sc0 ls105 ws0">49.<span class="_ _5"> </span>Assessment and monitoring of antimalarial drug efficacy for the treatment of</div><div class="t mc x4d h17 ydbf ff1a fsb fc3 sc0 ls105 ws0">uncomplicated falciparum malaria<span class="ff17 ws1d4">. Geneva, <span class="_ _a"></span>W<span class="_ _a"></span>orld Health Organization, 2003</span></div><div class="t mc x4d h17 yd7e ff17 fsb fc3 sc0 ls31a ws4fa">(document WHO/HTM/RBM/2003.50).</div><div class="t mc xb h17 y1197 ff17 fsb fc3 sc0 ls105 ws0">50.<span class="_ _95"> </span>White NJ. The assessment of antimalarial drug efficacy<span class="_ _4b"></span>. <span class="ff1a ws1d4">T<span class="_ _b"></span>rends in Parasitology<span class="_ _4b"></span>,</span></div><div class="t mc x4d h17 yd80 ff17 fsb fc3 sc0 ls105 ws0">2002, 18: 458–464. </div><div class="t mc xb h17 y1198 ff17 fsb fc3 sc0 ls105 ws0">51.<span class="_ _68"> </span>Ringwald P<span class="_ _c"></span>. Monitoring antimalarial drug efficacy<span class="_ _4b"></span>. <span class="ff1a">Clinical Infectious Diseases</span><span class="ls0">,</span></div><div class="t mc x4d h17 y1199 ff17 fsb fc3 sc0 ls105 ws0">2004, 38:1192-1193.</div><div class="t mc xb h4d y119a ff1a fsb fc3 sc0 ls105 ws0">52.<span class="_ _95"> </span>Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated</div><div class="t mc x4d h17 y119b ff1a fsb fc3 sc0 ls105 ws0">falciparum malaria in areas with intense transmission<span class="ff17">. Genev<span class="_ _a"></span>a, W<span class="_ _b"></span>orld Health</span></div><div class="t mc x4d h17 y119c ff17 fsb fc3 sc0 ls105 ws0">Organization, 1996 (document <span class="_ _a"></span>WHO/MAL/96.1077).</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc0" class="pf w1 h4" data-page-no="c0"><div class="pc pcc0 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">182</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls130 ws19a">53.<span class="_ _95"> </span>Baird JK et al. Diagnosis of resistance to chloroquine by <span class="ff1a ws0">Plasmodium vivax<span class="ff17 ls0">:</span></span></div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">timing of recurrence and whole blood chlor<span class="_ _a"></span>oquine levels. <span class="ff1a">American Journal of</span></div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 1997, 56:621–626. </span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">54.<span class="_ _95"> </span>Baird JK. Chloroquine resistance in <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax<span class="ff17">. </span>Antimicrobial Agents and</span></div><div class="t mc x7a h17 yd65 ff1a fsb fc3 sc0 ls105 ws0">Chemotherapy<span class="ff17">, 2004, 48:4075–4083.</span></div><div class="t mc x9 h17 yee3 ff17 fsb fc3 sc0 ls105 ws0">55.<span class="_ _95"> </span>Rieckmann K.H. et al. Drug sensitivity of <span class="ff1a">Plasmodium falciparum</span>. An in-vitro</div><div class="t mc x7a h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">microtechnique. <span class="ff1a">Lancet</span>, 1978, 1:22–23. </div><div class="t mc x9 h17 y1192 ff17 fsb fc3 sc0 ls105 ws0">56.<span class="_ _95"> </span>Djimde A et al. A molecular marker for chloroquine-resistant falciparum malaria.</div><div class="t mc x7a h17 yd69 ff1a fsb fc3 sc0 ls105 ws0">New England Journal of Medicine<span class="ff17 ws19a">, 2001, 344:257–263.</span></div><div class="t mc x9 h17 y1193 ff17 fsb fc3 sc0 ls105 ws0">57.<span class="_ _64"> </span>Kublin J.G. et al. Molecular markers for failure of sulfado<span class="_ _a"></span>xine-pyrimethamine and</div><div class="t mc x7a h17 yd6b ff17 fsb fc3 sc0 ls105 ws0">chlorproguanil-dapsone treatment of <span class="ff1a">Plasmodium falciparum </span>malaria. <span class="ff1a">Journal of</span></div><div class="t mc x7a h17 yd6c ff1a fsb fc3 sc0 ls105 ws0">Infectious Diseases<span class="ff17">, 2002, 185:380–388.</span></div><div class="t mc x9 h17 yd6d ff17 fsb fc3 sc0 ls105 ws0">58.<span class="_ _5"> </span>Djimde A et al. Molecular diagnosis of resistance to antimalarial drugs during</div><div class="t mc x7a h17 yd6e ff17 fsb fc3 sc0 ls105 ws0">epidemics and in war zones. <span class="ff1a">Journal of Infectious Diseases, </span>2004, 190:853–855.</div><div class="t mc x9 h17 yd6f ff17 fsb fc3 sc0 ls105 ws19a">59.<span class="_ _95"> </span>Snounou G, Beck HP<span class="_ _c"></span>. The use of PCR genotyping in the assessment of</div><div class="t mc x7a h17 yd70 ff17 fsb fc3 sc0 ls105 ws0">recrudescence or reinfection after antimalarial drug tr<span class="_ _a"></span>eatment. <span class="ff1a">Parasitology</span></div><div class="t mc x7a h17 ydbc ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _4b"></span>oday<span class="ff17 ws19a">, 1998, 14:462–467.</span></div><div class="t mc x9 h17 yd72 ff17 fsb fc3 sc0 ls105 ws0">60.<span class="_ _5"> </span>Pearce RJ et al. Molecular determination of point mutation haplotypes in the</div><div class="t mc x7a h17 yd73 ff17 fsb fc3 sc0 ls105 ws0">dihydrofolate reductase and dihy<span class="_ _a"></span>dropteroate synthase of <span class="ff1a">Plasmodium</span></div><div class="t mc x7a h17 ydbd ff1a fsb fc3 sc0 ls105 ws0">falciparum <span class="ff17">in three districts of northern T<span class="_ _4b"></span>anzania. <span class="ff1a">Antimicrobial Agents and</span></span></div><div class="t mc x7a h17 yd92 ff1a fsb fc3 sc0 ls105 ws0">Chemotherapy<span class="ff17">, 2003, 47:1347–1354.</span></div><div class="t mc x9 h17 yd76 ff17 fsb fc3 sc0 ls105 ws0">61.<span class="_ _3"> </span>Alifrangis A et al. A simple high-throughput method to detect <span class="ff1a">P<span class="_ _c"></span>. falciparum <span class="ff17">single</span></span></div><div class="t mc x7a h17 yd94 ff17 fsb fc3 sc0 ls105 ws0">nucleotide polymorphisms in the dihydrofolate reductase, dihy<span class="_ _a"></span>dropterate</div><div class="t mc x7a h17 ydaf ff17 fsb fc3 sc0 ls105 ws0">synthase, and <span class="ff1a">P<span class="_ _c"></span>. falciparum <span class="ff17">chloroquine resistance transporter genes using</span></span></div><div class="t mc x7a h17 ydb0 ff17 fsb fc3 sc0 ls105 ws0">polymerase chain reaction- and enzyme-linked immunosorbent assay-based</div><div class="t mc x7a h17 y118f ff17 fsb fc3 sc0 ls105 ws0">technology<span class="_ _4b"></span>. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 2005,</span></span></div><div class="t mc x7a h17 yed6 ff17 fsb fc3 sc0 ls105 ws0">72:155–162.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc1" class="pf w1 h4" data-page-no="c1"><div class="pc pcc1 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 y119d ff1b fs10 fc7 sc0 ls270 ws0">Annex 7. <span class="_ _97"> </span><span class="fc0">Uncomplicated <span class="ff1f">P<span class="_ _ae"></span>. falciparum <span class="ff1b">malaria<span class="_ _c4"> </span><span class="fc4">185</span></span></span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc2" class="pf w1 h4" data-page-no="c2"><div class="pc pcc2 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc3" class="pf w1 h4" data-page-no="c3"><div class="pc pcc3 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x81 he y9 ff16 fs5 fc3 sc0 ls51 ws1">Annex 7 - Uncomplicated <span class="ff1d lsad ws0">Plasmodium falciparum<span class="_ _95"> </span><span class="ff16 lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">185</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 7</div><div class="t m0 x95 hf y895 ff18 fs6 fc3 sc0 ls9e ws0">UNCOMPLIC<span class="_ _8"></span>A<span class="_ _a"></span>TED <span class="ff2e ls1">P<span class="_ _c"></span>. FAL<span class="_ _b"></span>CI<span class="_ _8"></span>P<span class="_ _b"></span>ARU<span class="_ _8"></span>M <span class="ff18">MALAR<span class="_ _8"></span>IA </span></span></div><div class="t m0 xb h12 y896 ff19 fs6 fc4 sc0 ls0 ws95">A7.1<span class="_ _33"> </span>How do ar<span class="_ _8"></span>temisinin combination therapies</div><div class="t m0 xa4 h12 y119e ff19 fs6 fc4 sc0 ls0 ws95">compare with non-artemisinin monotherapies?</div><div class="t m0 xb hb y119f ff17 fs8 fc3 sc0 lsa3 ws103">Systematic r<span class="_ _a"></span>eview and meta-analysis of individual patient data from 16</div><div class="t m0 xb hb y11a0 ff17 fs8 fc3 sc0 ls270 ws175">randomized trials (total of 5948 people) that studied the effects of the addition</div><div class="t m0 xb hb y11a1 ff17 fs8 fc3 sc0 ls34a ws4f5">of artesunate to monotherapy for falciparum malaria <span class="ff1a ws0">(1)<span class="_ _3"> </span></span>(search date,</div><div class="t m0 xb hb y11a2 ff17 fs8 fc3 sc0 ls14 ws25d">September 2002). The analysis compar<span class="_ _a"></span>ed odds ratios (OR) of parasitological</div><div class="t m0 xb hb y11a3 ff17 fs8 fc3 sc0 lsc8 ws83">failure at days 14 and 28 (artesunate combination compared to monotherapy)</div><div class="t m0 xb hb y11a4 ff17 fs8 fc3 sc0 ls45 wsbb">and calculated combined summary ORs across trials using standard methods.</div><div class="t m0 xb hb y11a5 ff17 fs8 fc3 sc0 ls262 ws38e">Results comprise par<span class="_ _a"></span>asite failure including re-infections by day 28 in 14 trials</div><div class="t m0 xb hb y11a6 ff17 fs8 fc3 sc0 lsc0 ws17d">(Figure A7.1), and parasite failur<span class="_ _a"></span>e excluding re-infections in 11 trials (Figure A7.2).</div><div class="t m0 xb h5a y11a7 ff1a fs5 fc3 sc0 ls34b ws0">df, degrees of fr<span class="_ _a"></span>eedom; OR: Mantel-Haenszel odds ratio; CI: confidence inter<span class="_ _8"></span>val</div><div class="t m0 xb h58 y11a8 ff22 fs5 fc4 sc0 ls14c ws0">Figure A7.1</div><div class="t m0 x1b h3f y11a9 ff1b fs9 fc3 sc0 ls16 ws0">Artemisinin derivatives administered in combination compar<span class="_ _a"></span>ed with</div><div class="t m0 x1b h3f y11aa ff1b fs9 fc3 sc0 ls16 ws0">monotherapy alone: total failures by day 28 (r<span class="_ _a"></span>e-infections included);</div><div class="t m0 x1b h3f y11ab ff1b fs9 fc3 sc0 ls16 ws0">data from the International Artemisinin Study Group individual</div><div class="t m0 x1b h3f y11ac ff1b fs9 fc3 sc0 ls16 ws0">patient data meta-analysis <span class="ff1f ls2f3">(1)</span></div></div><div class="t m0 x8f h5b y11ad ff2f fs21 fc3 sc0 ls0 ws0">Study</div><div class="t m0 x8f h5b y11ae ff2f fs21 fc3 sc0 ls0 ws0">or sub-category</div><div class="t m12 x89 h5c y11af ff30 fs21 fc3 sc0 ls34c ws0">0.44 [0.21, 0.90]</div><div class="t m12 x89 h5c y11b0 ff30 fs21 fc3 sc0 ls34c ws0">0.32 [0.21, 0.50]</div><div class="t m12 x89 h5c y11b1 ff30 fs21 fc3 sc0 ls34c ws0">0.83 [0.48, 1.45]</div><div class="t m12 x89 h5c y11b2 ff30 fs21 fc3 sc0 ls34c ws0">0.46 [0.34, 0.62]</div><div class="t m12 x7d h5c y11b3 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11b4 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11b5 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x89 h5c y11b6 ff30 fs21 fc3 sc0 ls34c ws0">0.29 [0.11, 0.73]</div><div class="t m12 x89 h5c y11b7 ff30 fs21 fc3 sc0 ls34c ws0">0.49 [0.32, 0.73]</div><div class="t m12 x89 h5c y11b8 ff30 fs21 fc3 sc0 ls34c ws0">0.29 [0.19, 0.45]</div><div class="t m12 x89 h5c y11b9 ff30 fs21 fc3 sc0 ls34c ws0">0.13 [0.08, 0.23]</div><div class="t m12 x89 h5c y11ba ff30 fs21 fc3 sc0 ls34c ws0">0.47 [0.08, 2.62]</div><div class="t m12 x89 h5c y11bb ff30 fs21 fc3 sc0 ls34c ws0">0.44 [0.26, 0.72]</div><div class="t m12 x89 h5c y11bc ff30 fs21 fc3 sc0 ls34c ws0">0.32 [0.26, 0.40]</div><div class="t m12 x7d h5c y11bd ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11be ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11bf ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11c0 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11c1 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11c2 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x89 h5c y11c3 ff30 fs21 fc3 sc0 ls34c ws0">0.01 [0.00, 0.11]</div><div class="t m12 x89 h5c y11c4 ff30 fs21 fc3 sc0 ls34c ws0">0.12 [0.05, 0.24]</div><div class="t m12 x89 h5c y11c5 ff30 fs21 fc3 sc0 ls34c ws0">0.07 [0.03, 0.13]</div><div class="t m12 x89 h5c y11c6 ff30 fs21 fc3 sc0 ls34c ws0">0.30 [0.26, 0.36]</div><div class="t m12 x7d h5c y11c7 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 x7d h5c y11c8 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m0 x3c h5b y11ad ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>reatment</div><div class="t m0 x28 h5b y11ae ff2f fs21 fc3 sc0 ls0 ws0">n/N</div><div class="t m0 x81 h5b y11ad ff2f fs21 fc3 sc0 ls0 ws0">Control</div><div class="t m0 x3d h5b y11ae ff2f fs21 fc3 sc0 ls0 ws0">n/N</div><div class="t m12 xc0 h5b y11ad ff2f fs21 fc3 sc0 ls0 ws0">OR (fixed)</div><div class="t m12 x55 h5b y11ae ff2f fs21 fc3 sc0 ls0 ws0">95% CI<span class="_ _84"> </span>Quality</div><div class="t m0 x5b h5d y11c9 ff30 fs22 fc3 sc0 ls34d ws550">Favours treatment</div><div class="t m13 xd8 h5d y11c9 ff30 fs22 fc3 sc0 ls34d ws551">Favours control</div><div class="t m0 x54 h5b y11ad ff2f fs21 fc3 sc0 ls0 ws0">OR (fixed)</div><div class="t m0 xd9 h5b y11ae ff2f fs21 fc3 sc0 ls0 ws552">95% CI</div><div class="t m0 xb4 h5b y11ca ff2f fs21 fc3 sc0 ls0 ws0">0.01<span class="_ _8c"> </span>1<span class="_ _c5"></span>0.1<span class="_ _c6"> </span>10<span class="_ _3b"> </span>100</div><div class="t m0 x17 h5b y11cb ff2f fs21 fc3 sc0 ls0 ws0">28/98 </div><div class="t m0 x81 h5b y11cc ff2f fs21 fc3 sc0 ls0 ws0">108/183</div><div class="t m0 x17 h5b y11cd ff2f fs21 fc3 sc0 ls0 ws0">33/156</div><div class="t m0 x9c h5b y11ce ff2f fs21 fc3 sc0 ls0 ws0">437</div><div class="t m0 x5a h5e y11cf ff2f fs23 fc3 sc0 ls0 ws0">14/94<span class="_ _8"></span> </div><div class="t m0 x5a h5e y11d0 ff2f fs23 fc3 sc0 ls0 ws0">57/180</div><div class="t m0 x5a h5e y11d1 ff2f fs23 fc3 sc0 ls0 ws0">29/159</div><div class="t m0 x3a h5e y11d2 ff2f fs23 fc3 sc0 ls34e ws0">433</div><div class="t m0 x17 h5b y11d3 ff2f fs21 fc3 sc0 ls0 ws0">20/193</div><div class="t m0 x81 h5b y11d4 ff2f fs21 fc3 sc0 ls0 ws0">121/189</div><div class="t m0 x81 h5b y11d5 ff2f fs21 fc3 sc0 ls0 ws0">107/189</div><div class="t m0 x17 h5b y11d6 ff2f fs21 fc3 sc0 ls0 ws0">99/129</div><div class="t m0 x3d h5b y11d7 ff2f fs21 fc3 sc0 ls0 ws0">4/93 </div><div class="t m0 x17 h5b y11d8 ff2f fs21 fc3 sc0 ls0 ws0">89/144</div><div class="t m0 x9c h5b y11d9 ff2f fs21 fc3 sc0 ls0 ws0">937</div><div class="t m0 x49 h5b y11da ff2f fs21 fc3 sc0 ls0 ws0">6/187</div><div class="t m0 x5a h5b y11db ff2f fs21 fc3 sc0 ls0 ws0">89/192</div><div class="t m0 x5a h5b y11dc ff2f fs21 fc3 sc0 ls0 ws0">52/189</div><div class="t m0 x5a h5b y11dd ff2f fs21 fc3 sc0 ls0 ws0">41/134</div><div class="t m0 x49 h5b y11de ff2f fs21 fc3 sc0 ls0 ws0">2/97 </div><div class="t m0 x5a h5b y11df ff2f fs21 fc3 sc0 ls0 ws0">48/116</div><div class="t m0 xba h5b y11e0 ff2f fs21 fc3 sc0 ls0 ws0"> 915</div><div class="t m0 x17 h5b y11e1 ff2f fs21 fc3 sc0 ls0 ws0">46/169</div><div class="t m0 x17 h5b y11e2 ff2f fs21 fc3 sc0 ls0 ws0">57/181</div><div class="t m0 x9c h5b y11e3 ff2f fs21 fc3 sc0 ls0 ws0">350</div><div class="t m0 x49 h5b y11e4 ff2f fs21 fc3 sc0 ls0 ws0">1/180</div><div class="t m0 x49 h5b y11e5 ff2f fs21 fc3 sc0 ls0 ws0">9/179</div><div class="t m0 x3a h5b y11e6 ff2f fs21 fc3 sc0 ls0 ws0">359</div><div class="t m0 xb5 h5b y11e7 ff2f fs21 fc3 sc0 ls0 ws0">1724<span class="_ _c7"></span>1707</div><div class="t m0 x8f h5b y11e8 ff2f fs21 fc4 sc0 ls0 ws0">Review: <span class="_ _17"> </span>Artesunate combination treatments for malaria</div><div class="t m0 x8f h5b y11e9 ff2f fs21 fc4 sc0 ls0 ws0">Comparison: <span class="_ _5a"> </span>01 Artesunate combinations versus no artesunate</div><div class="t m0 x8f h5b y11ea ff2f fs21 fc4 sc0 ls0 ws0">Outcome: <span class="_ _18"> </span>02 P<span class="_ _a"></span>arasitaemia by day 28 (all)</div><div class="t m0 x8f h5b y11eb ff2f fs21 fc4 sc0 ls0 ws0">02 Amodiaquine</div><div class="t m0 x8f h5b y11ec ff2f fs21 fc3 sc0 ls0 ws553"> Gabon <span class="_ _6f"> </span> </div><div class="t m0 x8f h5b y11ed ff2f fs21 fc3 sc0 ls0 ws553"> Ken_AMRF</div><div class="t m0 x8f h5b y11ee ff2f fs21 fc3 sc0 ls0 ws553"> Senegal</div><div class="t m0 x8f h5b y11ef ff2f fs21 fc4 sc0 ls0 ws0">Subtotal (95% CI)</div><div class="t m0 x8f h5b y11f0 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>otal events: 100 (T<span class="_ _b"></span>reatment), 169 (Control)</div><div class="t m0 x8f h5b y11f1 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for hetetogeneity: Chi</div><div class="t m0 x1b h5f y11f2 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 xda h5b y11f3 ff2f fs21 fc3 sc0 ls0 ws0"> = 7.01, df = 2(P = 0.03),<span class="_ _a"></span> I</div><div class="t m0 xdb h5f y11f2 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x5d h5b y11f3 ff2f fs21 fc3 sc0 ls0 ws0"> = 71.5%</div><div class="t m0 x8f h5b y11f4 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for overall effect: Z = 5.06 (P &lt; 0.00001)</div><div class="t m0 xb h5b y11f5 ff2f fs21 fc4 sc0 ls0 ws0">03 Sulfadoxine-pyrimethamine</div><div class="t m0 xb h5b y11f6 ff2f fs21 fc3 sc0 ls0 ws553"> Gambia</div><div class="t m0 xb h5b y11f7 ff2f fs21 fc3 sc0 ls0 ws553"> Ken_KMRI</div><div class="t m0 xb h5b y11f8 ff2f fs21 fc3 sc0 ls0 ws553"> Ken_W</div><div class="t m0 xb h5b y11f9 ff2f fs21 fc3 sc0 ls0 ws553"> Malawi</div><div class="t m0 xb h5b y11fa ff2f fs21 fc3 sc0 ls0 ws553"> Peru</div><div class="t m0 xb h5b y11fb ff2f fs21 fc3 sc0 ls0 ws553"> Uganda</div><div class="t m0 xb h5b y11fc ff2f fs21 fc4 sc0 ls0 ws0">Subtotal (95% CI)</div><div class="t m0 xb h5b y11fd ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>otal events: 238 (T<span class="_ _b"></span>reatment), 440 (Control)</div><div class="t m0 xb h5b y11fe ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for hetetogeneity: Chi</div><div class="t m0 x46 h5f y11ff ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 xda h5b y1200 ff2f fs21 fc3 sc0 ls0 ws0"> = 15.56, df = 5(P = 0.008),<span class="_ _a"></span> I</div><div class="t m0 x72 h5f y11ff ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 xb3 h5b y1200 ff2f fs21 fc3 sc0 ls0 ws0"> = 67.9%</div><div class="t m0 xb h5b y1201 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for overall effect: Z = 10.05 (P &lt; 0.00001)</div><div class="t m0 x8f h5b y1202 ff2f fs21 fc4 sc0 ls0 ws0">04 Mefloquine</div><div class="t m0 x8f h5b y1203 ff2f fs21 fc3 sc0 ls0 ws553"> Thai-2</div><div class="t m0 x8f h5b y1204 ff2f fs21 fc3 sc0 ls0 ws553"> Thai-3</div><div class="t m0 x8f h5b y1205 ff2f fs21 fc4 sc0 ls0 ws0">Subtotal (95% CI)</div><div class="t m0 x8f h5b y1206 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>otal events: 10 (T<span class="_ _b"></span>reatment), 103 (Control)</div><div class="t m0 x8f h5b y1207 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for hetetogeneity: Chi</div><div class="t m0 x1b h5f y1208 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 xda h5b y1209 ff2f fs21 fc3 sc0 ls0 ws0"> = 4.14, df = 1(P = 0.04),<span class="_ _a"></span> I</div><div class="t m0 xdb h5f y1208 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x5d h5b y1209 ff2f fs21 fc3 sc0 ls0 ws0"> = 75.9%</div><div class="t m0 x8f h5b y120a ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for overall effect: Z = 7.80 (P &lt; 0.00001)</div><div class="t m0 x8f h5b y120b ff2f fs21 fc4 sc0 ls0 ws0">T<span class="_ _a"></span>otal (95% CI)</div><div class="t m0 x8f h5b y120c ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>otal events: 348 (T<span class="_ _b"></span>reatment), 712 (Control)</div><div class="t m0 x8f h5b y120d ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for hetetogeneity: Chi</div><div class="t m0 x1b h5f y120e ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 xda h5b y120f ff2f fs21 fc3 sc0 ls0 ws0"> = 44.83, df = 10(P = 0.04),<span class="_ _a"></span> I</div><div class="t m0 x72 h5f y120e ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x60 h5b y120f ff2f fs21 fc3 sc0 ls0 ws0"> = 77.7%</div><div class="t m0 x8f h5b y1210 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for overall effect: Z = 13.80 (P &lt; 0.00001)</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc4" class="pf w1 h4" data-page-no="c4"><div class="pc pcc4 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">186</div><div class="t m0 x9 h5a y1211 ff1a fs5 fc3 sc0 ls34b ws0">df, degrees of fr<span class="_ _a"></span>eedom; OR: Mantel-Haenszel odds ratio; CI: confidence inter<span class="_ _8"></span>val</div><div class="t m0 x9 h58 y1212 ff22 fs5 fc4 sc0 ls14c ws0">Figure A7.2</div><div class="t m0 x5 h3f y1213 ff1b fs9 fc3 sc0 ls16 ws0">Artemisinin derivatives administered in combination compar<span class="_ _a"></span>ed with</div><div class="t m0 x5 h3f y1214 ff1b fs9 fc3 sc0 ls2f3 ws1a">monotherapy alone: total failures by day 28 (reinfections ex<span class="_ _a"></span>cluded);</div><div class="t m0 x5 h3f y1215 ff1b fs9 fc3 sc0 ls16 ws0">data from the International Artemisinin Study Group individual</div><div class="t m0 x5 h3f y1216 ff1b fs9 fc3 sc0 ls16 ws0">patient data meta-analysis <span class="ff1f ls2f3">(16)</span></div><div class="t m0 x9 h12 y1217 ff19 fs6 fc4 sc0 ls9a ws0">A7.2 <span class="_ _5a"> </span>Are there any non-artemisinin combination</div><div class="t m0 x28 h12 y1218 ff19 fs6 fc4 sc0 ls2 ws34a">therapies that provide an alternative to standard</div><div class="t m0 x28 h12 y1219 ff19 fs6 fc4 sc0 ls1 ws0">monotherapy?</div><div class="t m0 x9 h2e y121a ff19 fs3 fc3 sc0 ls2a5 ws554">A7.2.1<span class="_ _a7"> </span>S<span class="_ _8"></span>ulfadoxine-pyr<span class="_ _8"></span>imethamine + chloroquine compared</div><div class="t m0 xba h2e y121b ff19 fs3 fc3 sc0 ls2a5 ws554">with sulfadoxine-pyrimethamine</div><div class="t m0 x9 h23 y121c ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 x9 hb y121d ff17 fs8 fc3 sc0 ls3b ws26">One systematic review <span class="ff1a ls201 ws0">(2)<span class="_ _6"> </span></span>(search date 2001), which identified no randomiz<span class="_ _a"></span>ed</div><div class="t m0 x9 hb y121e ff17 fs8 fc3 sc0 ls96 ws481">controlled trials (RCT<span class="_ _c"></span>s) meeting the criteria of at least a 28-day follow-up</div><div class="t m0 x9 hb y121f ff17 fs8 fc3 sc0 ls78 ws172">period for a clinical trial. No subsequent RCT<span class="_ _4b"></span>s meeting the inclusion criteria but</div><div class="t m0 x9 hb y1220 ff17 fs8 fc3 sc0 ls2b1 ws470">five with follow-up periods shorter than 28 days <span class="ff1a ls34f ws0">(3–7)</span>, which are described below<span class="_ _4b"></span>.</div><div class="t m0 x9 hb y1221 ff17 fs8 fc3 sc0 ls206 ws1a3">The first subsequent RCT (160 childr<span class="_ _a"></span>en and adults, Colombia, 1999-2002), found</div><div class="t m0 x9 hb y1222 ff17 fs8 fc3 sc0 ls12 ws10e">a lower tr<span class="_ _a"></span>eatment failure rate at day 21 with the combination treatment than</div><div class="t m0 x9 hb y1223 ff17 fs8 fc3 sc0 ls29d ws422">with sulfadoxine-pyrimethamine alone (11/64 (17%) with the combination, 19/79</div><div class="t m0 x9 hb y1224 ff17 fs8 fc3 sc0 ls150 ws168">(26%) with sulfadoxine-pyrimethamine alone, no statistical data reported) <span class="ff1a ls21f ws0">(3)<span class="ff17">. </span></span></div></div><div class="t m0 xbb h5b y1225 ff2f fs21 fc3 sc0 ls0 ws0">Study</div><div class="t m0 xbb h5b y1226 ff2f fs21 fc3 sc0 ls0 ws0">or sub-category</div><div class="t m12 xd3 h5c y1227 ff30 fs21 fc3 sc0 ls34c ws0">0.39 [0.17, 0.90]</div><div class="t m12 xd3 h5c y1228 ff30 fs21 fc3 sc0 ls34c ws0">0.28 [0.18, 0.45]</div><div class="t m12 xd3 h5c y1229 ff30 fs21 fc3 sc0 ls34c ws0">0.94 [0.45, 1.96]</div><div class="t m12 xd3 h5c y122a ff30 fs21 fc3 sc0 ls34c ws0">0.40 [0.28, 0.57]</div><div class="t m12 xbe h5c y1227 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 xbe h5c y1228 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 xbe h5c y1229 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 xd3 h5c y122b ff30 fs21 fc3 sc0 ls34c ws0">0.28 [0.10, 0.78]</div><div class="t m12 xd3 h5c y122c ff30 fs21 fc3 sc0 ls34c ws0">0.35 [0.22, 0.56]</div><div class="t m12 xd3 h5c y122d ff30 fs21 fc3 sc0 ls34c ws0">0.08 [0.04, 0.16]</div><div class="t m12 xd3 h5c y122e ff30 fs21 fc3 sc0 ls34c ws0">0.24 [0.13, 0.42]</div><div class="t m12 xd3 h5c y122f ff30 fs21 fc3 sc0 ls34c ws0">0.22 [0.17, 2.30]</div><div class="t m12 xbe h5c y1230 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 xbe h5c y1231 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 xbe h5c y1232 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 xbe h5c y1233 ff30 fs21 fc3 sc0 ls0 ws0">D</div><div class="t m12 xd3 h5c y1234 ff30 fs21 fc3 sc0 ls34c ws0">0.28 [0.23, 0.35]</div><div class="t m0 x17 h5b y1225 ff2f fs21 fc3 sc0 ls0 ws0">Artesunate</div><div class="t m0 x9c h5b y1226 ff2f fs21 fc3 sc0 ls0 ws0">n/N</div><div class="t m0 x52 h5b y1225 ff2f fs21 fc3 sc0 ls0 ws0">Placebo</div><div class="t m0 xdc h5b y1226 ff2f fs21 fc3 sc0 ls0 ws0">n/N</div><div class="t m12 x7d h5b y1225 ff2f fs21 fc3 sc0 ls0 ws0">OR (fixed)</div><div class="t m12 x59 h5b y1235 ff2f fs21 fc3 sc0 ls0 ws0">95% CI<span class="_ _84"> </span>Quality</div><div class="t m0 x5e h5b y1225 ff2f fs21 fc3 sc0 ls0 ws0">OR (fixed)</div><div class="t m0 x1d h5b y1226 ff2f fs21 fc3 sc0 ls0 ws552">95% CI</div><div class="t m0 x75 h5b y1236 ff2f fs21 fc3 sc0 ls0 ws0">21/98 </div><div class="t m0 x53 h5b y1237 ff2f fs21 fc3 sc0 ls0 ws0">84/182</div><div class="t m0 x53 h5b y1238 ff2f fs21 fc3 sc0 ls0 ws0">16/141</div><div class="t m0 x42 h5b y1239 ff2f fs21 fc3 sc0 ls0 ws0">421</div><div class="t m0 x9c h5e y123a ff2f fs23 fc3 sc0 ls0 ws0">9/94<span class="_ _8"></span> </div><div class="t m0 xb5 h5e y123b ff2f fs23 fc3 sc0 ls0 ws0">35/179</div><div class="t m0 xb5 h5e y123c ff2f fs23 fc3 sc0 ls0 ws0">16/149</div><div class="t m0 xdd h5e y123d ff2f fs23 fc3 sc0 ls0 ws0">422</div><div class="t m0 x53 h5b y123e ff2f fs21 fc3 sc0 ls0 ws0">17/191</div><div class="t m0 x53 h5b y123f ff2f fs21 fc3 sc0 ls0 ws0">77/181</div><div class="t m0 x53 h5b y1240 ff2f fs21 fc3 sc0 ls0 ws0">77/113</div><div class="t m0 x53 h5b y1241 ff2f fs21 fc3 sc0 ls0 ws0">77/131</div><div class="t m0 x42 h5b y1242 ff2f fs21 fc3 sc0 ls0 ws0">616</div><div class="t m0 x9c h5b y1243 ff2f fs21 fc3 sc0 ls0 ws0">5/187</div><div class="t m0 xb5 h5b y1244 ff2f fs21 fc3 sc0 ls0 ws0">37/179</div><div class="t m0 xb5 h5b y1245 ff2f fs21 fc3 sc0 ls0 ws0">18/120</div><div class="t m0 xb5 h5b y1246 ff2f fs21 fc3 sc0 ls0 ws0">24/110</div><div class="t m0 x94 h5b y1247 ff2f fs21 fc3 sc0 ls0 ws0"> 596</div><div class="t m0 x41 h5b y1248 ff2f fs21 fc3 sc0 ls0 ws0">1037<span class="_ _c7"></span>1018</div><div class="t m0 xbb h5b y1249 ff2f fs21 fc4 sc0 ls0 ws0">Review: <span class="_ _17"> </span>Artesunate combination treatments for malaria</div><div class="t m0 xbb h5b y124a ff2f fs21 fc4 sc0 ls0 ws0">Comparison: <span class="_ _5a"> </span>01 Artesunate combinations versus no artesunate</div><div class="t m0 xbb h5b y124b ff2f fs21 fc4 sc0 ls0 ws0">Outcome: <span class="_ _18"> </span>02 P<span class="_ _a"></span>arasitological failure by day 28 (failure excludes re-infection)</div><div class="t m0 xbb h5b y124c ff2f fs21 fc4 sc0 ls0 ws0">02 Background drug: amodiaquine</div><div class="t m0 xbb h5b y124d ff2f fs21 fc3 sc0 ls0 ws553"> Gabon <span class="_ _6f"> </span> </div><div class="t m0 xbb h5b y124e ff2f fs21 fc3 sc0 ls0 ws553"> Ken_AMRF</div><div class="t m0 xbb h5b y124f ff2f fs21 fc3 sc0 ls0 ws553"> Senegal</div><div class="t m0 xbb h5b y1250 ff2f fs21 fc4 sc0 ls0 ws0">Subtotal (95% CI)</div><div class="t m0 xbb h5b y1251 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>otal events: 60 (Artesunate),<span class="_ _a"></span> 121 (Placebo)</div><div class="t m0 xbb h5b y1252 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for hetetogeneity: Chi</div><div class="t m0 x5 h5f y1253 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x5f h5b y1254 ff2f fs21 fc3 sc0 ls0 ws0"> = 7.25, df = 2 (P = 0.03),<span class="_ _a"></span> I</div><div class="t m0 x50 h5f y1253 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x2b h5b y1254 ff2f fs21 fc3 sc0 ls0 ws0"> = 72.4%</div><div class="t m0 xbb h5b y1255 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for overall effect: Z = 5.11 (P &lt; 0.00001)</div><div class="t m0 x9 h5b y1256 ff2f fs21 fc4 sc0 ls0 ws0">03 Background drug: sulfadoxine-pyrimethamine</div><div class="t m0 x9 h5b y1257 ff2f fs21 fc3 sc0 ls0 ws553"> Gambia</div><div class="t m0 x9 h5b y1258 ff2f fs21 fc3 sc0 ls0 ws553"> Ken_KMRI</div><div class="t m0 x9 h5b y1259 ff2f fs21 fc3 sc0 ls0 ws553"> Malawi</div><div class="t m0 x9 h5b y125a ff2f fs21 fc3 sc0 ls0 ws553"> Uganda</div><div class="t m0 x9 h5b y125b ff2f fs21 fc4 sc0 ls0 ws0">Subtotal (95% CI)</div><div class="t m0 x9 h5b y125c ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>otal events: 84 (Artesunate),<span class="_ _a"></span> 242 (Placebo)</div><div class="t m0 x9 h5b y125d ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for hetetogeneity: Chi</div><div class="t m0 x66 h5f y125e ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x5f h5b y125f ff2f fs21 fc3 sc0 ls0 ws0"> = 13.23, df = 3 (P = 0.004),<span class="_ _a"></span> I</div><div class="t m0 x2c h5f y125e ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x2c h5b y125f ff2f fs21 fc3 sc0 ls0 ws0"> = 77.3%</div><div class="t m0 x9 h5b y1260 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for overall effect: Z = 9.95 (P &lt; 0.00001)</div><div class="t m0 xbb h5b y1261 ff2f fs21 fc4 sc0 ls0 ws0">T<span class="_ _a"></span>otal (95% CI)</div><div class="t m0 xbb h5b y1262 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>otal events: 144 (Artesunate),<span class="_ _a"></span> 363 (Placebo)</div><div class="t m0 xbb h5b y1263 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for hetetogeneity: Chi</div><div class="t m0 x5 h5f y1264 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 x5f h5b y1265 ff2f fs21 fc3 sc0 ls0 ws0"> = 26.35, df = 6 (P = 0.0002),<span class="_ _a"></span> I</div><div class="t m0 x86 h5f y1264 ff2f fs24 fc3 sc0 ls0 ws0">2</div><div class="t m0 xb4 h5b y1265 ff2f fs21 fc3 sc0 ls0 ws0"> = 77.2%</div><div class="t m0 xbb h5b y1266 ff2f fs21 fc3 sc0 ls0 ws0">T<span class="_ _a"></span>est for overall effect: Z = 10.99 (P &lt; 0.00001)</div><div class="t m0 xc7 h5d y1267 ff30 fs22 fc3 sc0 ls34d ws0">Favours artesunate<span class="_ _97"> </span>Favours placebo</div><div class="t m0 x34 h5b y1268 ff2f fs21 fc3 sc0 ls0 ws0">0.01<span class="_ _8e"> </span>1<span class="_ _c8"></span>0.1<span class="_ _78"> </span>10<span class="_ _44"> </span>100<span class="_ _c9"></span>0.001<span class="_ _ca"> </span>1000</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc5" class="pf w1 h4" data-page-no="c5"><div class="pc pcc5 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x81 he y9 ff16 fs5 fc3 sc0 ls51 ws1">Annex 7 - Uncomplicated <span class="ff1d lsad ws0">Plasmodium falciparum<span class="_ _95"> </span><span class="ff16 lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">187</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls205 ws1ab">The second subsequent RCT (71 childr<span class="_ _a"></span>en, Uganda, 2001) found a lower tr<span class="_ _a"></span>eatment</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls64 ws61">failure rate at day 14 with the combination tr<span class="_ _a"></span>eatment than with sulfadoxine-</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls207 ws2b9">pyrimethamine alone (4/32 (13%) with the combination, 5/30 (17%) with</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls64 ws0">sulfadoxine-pyrimethamine alone, no statistical data reported) <span class="ff1a ls7f">(4)</span><span class="ls10e">. </span></div><div class="t m0 xb hb y18b ff17 fs8 fc3 sc0 ls12 ws391">The third subsequent RCT<span class="_ _5"> </span>(52 children and adults, Lao People<span class="_ _a"></span>’<span class="_ _b"></span>s Democratic</div><div class="t m0 xb hb y18c ff17 fs8 fc3 sc0 ls350 ws555">Republic, 2001) found no significant differ<span class="_ _a"></span>ence in adequate clinical and</div><div class="t m0 xb hb y18d ff17 fs8 fc3 sc0 ls1d ws1c">parasitological responses at day 14 (20/24 with the combination, 23/28 with</div><div class="t m0 xb hb y18e ff17 fs8 fc3 sc0 ls22 ws5e">sulfadoxine-pyrimethamine alone; relativ<span class="_ _a"></span>e risk (RR): 1.01, 95% CI: 0.8–1.3) <span class="ff1a ws0">(5)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb y1269 ff17 fs8 fc3 sc0 ls12 ws37f">The fourth subsequent RCT (88 children and adults, Uganda, 2001) found no</div><div class="t m0 xb hb y126a ff17 fs8 fc3 sc0 lsdf ws16d">significant difference in adequate clinical response (27/27 with the combination,</div><div class="t m0 xb hb y126b ff17 fs8 fc3 sc0 ls12 ws0">29/29 with sulfadoxine-pyrimethamine alone) <span class="ff1a ls13">(6)</span><span class="ls0">.</span></div><div class="t m0 xb hb y126c ff17 fs8 fc3 sc0 ls331 ws389">The fifth subsequent RCT (305 childr<span class="_ _a"></span>en and adults, Uganda, 2001–2002)</div><div class="t m0 xb hb y126d ff17 fs8 fc3 sc0 ls126 ws1dc">found no significant difference in adequate clinical response (141/152 with the</div><div class="t m0 xb hb y126e ff17 fs8 fc3 sc0 ls12 ws0">combination, 119/140 with sulfadoxine-pyrimethamine alone) <span class="ff1a ls14">(7)</span><span class="ls0">.</span></div><div class="t m0 xb h23 y126f ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 xb hb yba2 ff17 fs8 fc3 sc0 lsa0 ws4f">Only one RCT r<span class="_ _a"></span>epor<span class="_ _8"></span>ted on adverse events <span class="ff1a ws0">(7)</span><span class="ws13b">. It found that o<span class="_ _a"></span>verall, the incidence</span></div><div class="t m0 xb hb yba3 ff17 fs8 fc3 sc0 ls12 wsea">of possible adverse ev<span class="_ _a"></span>ents was higher in those receiving the combination</div><div class="t m0 xb hb yca4 ff17 fs8 fc3 sc0 ls208 ws458">therapy than in those receiving sulfado<span class="_ _a"></span>xine-pyrimethamine monotherapy<span class="_ _4b"></span>.</div><div class="t m0 xb hb ya68 ff17 fs8 fc3 sc0 ls96 wsef">This could be explained by the higher incidences of pruritus, nausea and</div><div class="t m0 xb hb y1270 ff17 fs8 fc3 sc0 ls146 ws207">vomiting in the combination group<span class="_ _a"></span>. When mild adv<span class="_ _a"></span>erse events were ex<span class="_ _a"></span>cluded</div><div class="t m0 xb hb y1271 ff17 fs8 fc3 sc0 lsb8 ws127">from the analysis, there was no significant differ<span class="_ _a"></span>ence between the groups. One</div><div class="t m0 xb hb yd32 ff17 fs8 fc3 sc0 ls1fe ws99">severe adv<span class="_ _a"></span>erse event was reported in the monotherapy group<span class="_ _a"></span>, namely an</div><div class="t m0 xb hb yd33 ff17 fs8 fc3 sc0 ls1b3 ws28">elevated alanine aminotr<span class="_ _a"></span>ansferase measurement on day 14 in a girl of 3 years</div><div class="t m0 xb hb yd34 ff17 fs8 fc3 sc0 ls222 ws343">of age. This ev<span class="_ _a"></span>ent was not accompanied by symptoms and resolved within two</div><div class="t m0 xb hb yd35 ff17 fs8 fc3 sc0 ls12 ws0">weeks without medical intervention.</div><div class="t m0 xb h23 yd07 ff1e fs11 fc8 sc0 ls27a ws0">Comment</div><div class="t m0 xb hb y1272 ff17 fs8 fc3 sc0 ls12 ws556">The systematic review <span class="ff1a ls14 ws0">(2)<span class="_ _7c"> </span></span>identified two RCT<span class="_ _4b"></span>s comparing sulfadoxine-pyri-</div><div class="t m0 xb hb y1273 ff17 fs8 fc3 sc0 lse7 ws178">methamine + chloroquine to sulfadoxine-pyrimethamine alone <span class="ff1a">(8, 9)<span class="_ _a"></span><span class="ff17">. However<span class="_ _4b"></span>,</span></span></div><div class="t m0 xb hb y1274 ff17 fs8 fc3 sc0 ls0 ws81">neither trial met the WHO inclusion criteria. </div><div class="t m0 xb hb y1275 ff17 fs8 fc3 sc0 ls5b ws78">The first RCT (85 childr<span class="_ _a"></span>en aged <span class="ff1c ls0 ws0">&lt;<span class="_ _6"> </span></span>12 years, Papua New Guinea, 1980) compared</div><div class="t m0 xb hb y1276 ff17 fs8 fc3 sc0 ls184 ws267">combination treatment using sulfadoxine-pyrimethamine + an atypical single</div><div class="t m0 xb hb y1277 ff17 fs8 fc3 sc0 ls6d wsa3">dose of chloroquine of 10 mg/kg daily to sulfadoxine-pyrimethamine alone <span class="ff1a ws0">(8)<span class="ff17">. </span></span></div><div class="t m0 xb hb y1278 ff17 fs8 fc3 sc0 ls12a ws1e1">The second RCT (405 childr<span class="_ _a"></span>en aged 1–10 years,<span class="_ _95"> </span>The G<span class="_ _8"></span>ambia, 1995) had a high</div><div class="t m0 xb hb y1279 ff17 fs8 fc3 sc0 ls1fa ws43c">rate of loss to follow-up (30% in the sulfado<span class="_ _a"></span>xine-pyrimethamine + chloroquine</div><div class="t m0 xb hb y127a ff17 fs8 fc3 sc0 ls12 ws0">group<span class="_ _a"></span>, 26% in the monotherapy group) <span class="ff1a ls13">(9)</span><span class="ls0">.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc6" class="pf w1 h4" data-page-no="c6"><div class="pc pcc6 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1b ws0">188</div><div class="t m0 x9 h2e yaa1 ff19 fs3 fc3 sc0 ls69 ws1b0">A7.2.2<span class="_ _a7"> </span>S<span class="_ _8"></span>ulfadoxine-pyr<span class="_ _8"></span>imethamine + amodiaquine compared</div><div class="t m0 xba h2e y127b ff19 fs3 fc3 sc0 ls2a5 ws554">with sulfadoxine-pyrimethamine </div><div class="t m0 x9 h23 y127c ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 x9 hb y127d ff17 fs8 fc3 sc0 ls34 ws7f">One systematic review <span class="ff1a ls33 ws0">(2) <span class="_ _b"></span><span class="ff17 ls34 ws7f">(search date 2001), which identified four RCT<span class="_ _4b"></span>s, three</span></span></div><div class="t m0 x9 hb y127e ff17 fs8 fc3 sc0 ls22 ws1ad">in Africa <span class="ff1a ls34 ws0">(10–12) </span>and one in China <span class="ff1a ls42 ws0">(13)<span class="_ _6"> </span></span>(484 people). One subsequent RCT <span class="ff1a ws0">(14)<span class="ff17">. </span></span></div><div class="t m0 x9 hb y127f ff17 fs8 fc3 sc0 lsf ws12f">Three of the RCT<span class="_ _c"></span>s identified by the systematic review found slightly higher cure</div><div class="t m0 x9 hb y1280 ff17 fs8 fc3 sc0 ls12 ws225">rates at day 28 with sulfadoxine-pyrimethamine + amodiaquine than with</div><div class="t m0 x9 hb y1281 ff17 fs8 fc3 sc0 ls2b2 ws355">sulfadoxine-pyrimethamine alone, although the o<span class="_ _a"></span>verall difference did not</div><div class="t m0 x9 hb y1282 ff17 fs8 fc3 sc0 ls3a ws1b2">reach statistical significance <span class="ff1a lse3 ws0">(2)</span>. Similarly<span class="_ _c"></span>, two RCT<span class="_ _b"></span>s (one in Mozambique, and</div><div class="t m0 x9 hb y1283 ff17 fs8 fc3 sc0 ls277 ws410">one in China, 1985–1986, 116 people) identified by the review found no</div><div class="t m0 x9 hb y1284 ff17 fs8 fc3 sc0 ls16c ws244">significant difference in mean parasite clear<span class="_ _a"></span>ance times between the two</div><div class="t m0 x9 hb y1285 ff17 fs8 fc3 sc0 ls12 ws53b">treatment groups <span class="ff1a ls5e ws557">(10, 13)</span>. Ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, the Chinese trial (69 people) found a</div><div class="t m0 x9 hb y1286 ff17 fs8 fc3 sc0 lsed ws191">significantly shorter mean fever clearance time with the combination treatment</div><div class="t m0 x9 hb y1287 ff17 fs8 fc3 sc0 ls12 ws0">than with the monotherapy <span class="ff1a ls53">(13)</span><span class="ls13">. </span></div><div class="t m0 x9 hb y1288 ff17 fs8 fc3 sc0 ls32c ws293">The subsequent RCT (191 childr<span class="_ _a"></span>en aged under 10 years, Cameroon, 2001)</div><div class="t m0 x9 hb y1289 ff17 fs8 fc3 sc0 ls233 ws17b">found a significantly higher adequate clinical response with a negative smear</div><div class="t m0 x9 hb y128a ff17 fs8 fc3 sc0 ls12 ws558">at day 28 with the combination treatment than with the monotherapy <span class="ff1a ls13 ws0">(14)<span class="ff17 ls0">.</span></span></div><div class="t m0 x9 hb y128b ff17 fs8 fc3 sc0 ls351 ws4b8">Similarly<span class="_ _4b"></span>, mean fever clearance time was significantly lo<span class="_ _a"></span>wer with the</div><div class="t m0 x9 hb y128c ff17 fs8 fc3 sc0 ls12 ws0">combination treatment than with the monotherapy<span class="_ _c"></span>.</div><div class="t m0 x9 h23 y128d ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 x9 hb y128e ff17 fs8 fc3 sc0 ls103 ws1b5">The Chinese trial identified by the systematic review found no significant</div><div class="t m0 x9 hb y128f ff17 fs8 fc3 sc0 ls12 ws474">difference in the rate of adv<span class="_ _a"></span>erse events between the two treatment gr<span class="_ _a"></span>oups</div><div class="t m0 x9 hb y1290 ff17 fs8 fc3 sc0 ls352 ws401">(41.7% with the combination, 42.9% with the monotherapy); <span class="ff1a ls0 ws0">p<span class="_ _3"> </span></span>value and</div><div class="t m0 x9 hb y1291 ff17 fs8 fc3 sc0 lsbf ws12e">absolute numbers not reported) <span class="ff1a ls249 ws0">(13)</span>. Sinus bradycardia and v<span class="_ _a"></span>omiting were the</div><div class="t m0 x9 hb y1292 ff17 fs8 fc3 sc0 ls12 ws23d">most frequent adverse ev<span class="_ _a"></span>ents ov<span class="_ _a"></span>erall, and were also more fr<span class="_ _a"></span>equent with the</div><div class="t m0 x9 hb y1293 ff17 fs8 fc3 sc0 ls82 wsc3">combination treatment than with sulfadoxine-pyrimethamine alone (no</div><div class="t m0 x9 hb y1294 ff17 fs8 fc3 sc0 ls8e wsdd">statistical data reported). However<span class="_ _4b"></span>, abdominal pain, headache and dizziness</div><div class="t m0 x9 hb y1295 ff17 fs8 fc3 sc0 ls12 wsd0">were mor<span class="_ _a"></span>e common with the monotherapy (no statistical data reported). The</div><div class="t m0 x9 hb y1296 ff17 fs8 fc3 sc0 ls12 ws101">Ugandan trial reported no serious adverse effects in either treatment gr<span class="_ _a"></span>oup,</div><div class="t m0 x9 hb y1297 ff17 fs8 fc3 sc0 ls2b5 ws182">whereas that conducted in Mozambique gave no information on adv<span class="_ _a"></span>erse</div><div class="t m0 x9 hb y1298 ff17 fs8 fc3 sc0 ls3d ws0">events <span class="_ _a"></span><span class="ff1a ls31 ws1b3">(10, 11)<span class="ff17 ls17a ws53">. The latter trial (400 people) measur<span class="_ _a"></span>ed haemoglobin and white</span></span></div><div class="t m0 x9 hb y1299 ff17 fs8 fc3 sc0 ls12 ws351">blood cell count throughout the follow-up period and found no significant</div><div class="t m0 x9 hb y129a ff17 fs8 fc3 sc0 ls12 ws0">difference between the tr<span class="_ _a"></span>eatments <span class="ff1a">(11)</span><span class="ls13">. </span></div><div class="t m0 x9 hb y129b ff17 fs8 fc3 sc0 ls12 ws43b">The subsequent RCT found a significantly higher r<span class="_ _a"></span>ate of fatigue, the most</div><div class="t m0 x9 hb y129c ff17 fs8 fc3 sc0 ls13c ws189">common adverse effect o<span class="_ _a"></span>verall, with the combination treatment than with the</div><div class="t m0 x9 hb y129d ff17 fs8 fc3 sc0 ls238 ws1ff">monotherapy (59/62 (95%) with the combination, 47/62 (76%) with the</div><div class="t m0 x9 hb y129e ff17 fs8 fc3 sc0 ls13 ws0">monotherapy<span class="_ _c"></span>, <span class="_ _9"></span><span class="ff1a ls0">p<span class="_ _95"> </span><span class="ff1c">&lt;<span class="_ _64"> </span></span></span><span class="ls12 ws559">0.05). Similarly<span class="_ _4b"></span>, there were higher r<span class="_ _a"></span>ates of headache and</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc7" class="pf w1 h4" data-page-no="c7"><div class="pc pcc7 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x81 he y9 ff16 fs5 fc3 sc0 ls51 ws1">Annex 7 - Uncomplicated <span class="ff1d lsad ws0">Plasmodium falciparum<span class="_ _95"> </span><span class="ff16 lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">189</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls111 ws345">vomiting with the combination treatment than with the monother<span class="_ _a"></span>apy (headache:</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls12 ws1a3">4/62 (6%) with the combination, 0/62 (0%) with the monotherapy<span class="_ _c"></span>, <span class="ff1a ls0 ws0">p <span class="ff1c">&lt;<span class="_ _5"> </span></span></span><span class="ws0">0.05;</span></div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 lsb9 ws128">vomiting: 14/62 (23%) with the combination, 5/62 (8%) with the monotherapy<span class="_ _c"></span>,</div><div class="t m0 xb hb ya1 ff1a fs8 fc3 sc0 ls0 ws0">p <span class="ff1c">&lt;<span class="_ _5"> </span><span class="ff17 ls12 ws349">0.05). There was also an increased r<span class="_ _a"></span>ate of pruritus with the combination</span></span></div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls15c ws26e">treatment than with sulfadoxine-pyrimethamine alone, although the differ<span class="_ _a"></span>ence</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls12 ws189">did not reach statistical significance (9/62 (15%) with the combination, 3/62</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls2b5 ws182">(5%) with the monotherapy<span class="_ _c"></span>, <span class="ff1a ls0 ws0">p<span class="_ _68"> </span></span>value not r<span class="_ _a"></span>epor<span class="_ _8"></span>ted). One person receiving</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 ls244 ws19f">sulfadoxine-pyrimethamine monotherapy pr<span class="_ _a"></span>esented with purulent vesicles in</div><div class="t m0 xb hb y10f ff17 fs8 fc3 sc0 ls12 ws0">the thoracic region (no further information provided) <span class="ff1a ls13">(14)<span class="ff17">. </span></span></div><div class="t m0 xb h2e y129f ff19 fs3 fc3 sc0 ls69 ws1b0">A7.2.3<span class="_ _a7"> </span>S<span class="_ _8"></span>ulfadoxine-pyr<span class="_ _8"></span>imethamine + amodiaquine compared</div><div class="t m0 x9d h2e y12a0 ff19 fs3 fc3 sc0 ls80 ws0">with amodiaquine</div><div class="t m0 xb h23 yfca ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y113 ff17 fs8 fc3 sc0 ls42 ws43c">One systematic review <span class="ff1a ws0">(2) <span class="_ _a"></span><span class="ff17 ws5b">(search date 2001), which identified three RCT<span class="_ _c"></span>s, one</span></span></div><div class="t m0 xb hb ye4a ff17 fs8 fc3 sc0 ls12 ws172">each in China, Mozambique and Uganda) <span class="ff1a ls44 wsb7">(10, 11, 13)</span><span class="ls13 ws215">. <span class="_ _a"></span>Three subsequent RCT<span class="_ _c"></span>s</span></div><div class="t m0 xb hb ye4b ff1a fs8 fc3 sc0 ls12 ws0">(14–16)<span class="ff17 ls13">. </span></div><div class="t m0 xb hb y12a1 ff17 fs8 fc3 sc0 ls64 ws55a">T<span class="_ _b"></span>wo RCT<span class="_ _4b"></span>s (150 people in China, 1985–1986 <span class="ff1a ls244 ws0">(13)<span class="_ _64"> </span></span>and Mozambique, 1986 <span class="ff1a lsc4 ws0">(10)</span></div><div class="t m0 xb hb y12a2 ff17 fs8 fc3 sc0 ls64 ws18c">identified by the review found higher parasitological cur<span class="_ _a"></span>e rates at day 28 with</div><div class="t m0 xb hb y12a3 ff17 fs8 fc3 sc0 ls2c5 ws242">the combination treatment than with amodiaquine alone. Owing to the apparent</div><div class="t m0 xb hb y12a4 ff17 fs8 fc3 sc0 ls64 ws43">heterogeneity between individual study r<span class="_ _a"></span>esults, the combined relative risk as</div><div class="t m0 xb hb ye50 ff17 fs8 fc3 sc0 ls126 wsec">assessed by several methods did not r<span class="_ _a"></span>each significance (see comment below).</div><div class="t m0 xb hb ye51 ff17 fs8 fc3 sc0 ls64 ws13a">These trials found a slightly shorter mean parasite clearance time with the</div><div class="t m0 xb hb ye52 ff17 fs8 fc3 sc0 ls26b wsbb">combination treatment than with the monotherapy<span class="_ _c"></span>, although the difference did</div><div class="t m0 xb hb ye53 ff17 fs8 fc3 sc0 ls64 ws109">not reach significance. Similarly<span class="_ _c"></span>, the Chinese trial (97 people) found a shor<span class="_ _8"></span>ter</div><div class="t m0 xb hb ye54 ff17 fs8 fc3 sc0 ls309 ws4e1">mean fever clearance time with the combination tr<span class="_ _a"></span>eatment than with the</div><div class="t m0 xb hb ye55 ff17 fs8 fc3 sc0 ls1b3 wseb">monotherapy<span class="_ _c"></span>, although the difference did not reach statistical significance</div><div class="t m0 xb hb ye56 ff1a fs8 fc3 sc0 ls244 ws0">(13)<span class="ff17 ls64">. The U<span class="_ _a"></span>gandan trial <span class="ff1a">(11) </span>only reported parasite outcomes at day 7.</span></div><div class="t m0 xb hb y12a5 ff17 fs8 fc3 sc0 lsb4 ws122">The first subsequent RCT (159 childr<span class="_ _a"></span>en aged 0.5–10.0 years, Nigeria, 2000-2001)</div><div class="t m0 xb hb y12a6 ff17 fs8 fc3 sc0 ls2d2 ws3a6">found no significant difference in cure r<span class="_ _a"></span>ates at day 28 or in mean fever</div><div class="t m0 xb hb y12a7 ff17 fs8 fc3 sc0 ls12 ws84">clearance times between the two tr<span class="_ _a"></span>eatment groups. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, mean parasite</div><div class="t m0 xb hb y12a8 ff17 fs8 fc3 sc0 lsef wsab">clearance time was significantly shorter with the combination treatment than</div><div class="t m0 xb hb y12a9 ff17 fs8 fc3 sc0 ls12 ws0">with amodiaquine alone <span class="ff1a ls13">(15)<span class="ff17">. </span></span></div><div class="t m0 xb hb y12aa ff17 fs8 fc3 sc0 ls63 ws8a">The second subsequent RCT (127 childr<span class="_ _a"></span>en aged under 10 years, Cameroon, 2001)</div><div class="t m0 xb hb y12ab ff17 fs8 fc3 sc0 ls12 ws54a">found a significantly higher adequate clinical response with negative smear</div><div class="t m0 xb hb y12ac ff17 fs8 fc3 sc0 ls242 ws3b2">at day 28 with the combination treatment than with amodiaquine alone.</div><div class="t m0 xb hb y12ad ff17 fs8 fc3 sc0 ls12 ws55b">Howev<span class="_ _a"></span>er<span class="_ _b"></span>, there was no significant difference in mean fev<span class="_ _a"></span>er clearance time</div><div class="t m0 xb hb y12ae ff17 fs8 fc3 sc0 ls12 ws0">between the two groups <span class="ff1a ls13">(14)<span class="ff17">. </span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc8" class="pf w1 h4" data-page-no="c8"><div class="pc pcc8 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">190</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls12 ws558">The third subsequent RCT<span class="_ _95"> </span>(235 children aged 6–59 months, Uganda, 2001)</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls18f wsdc">found a lower par<span class="_ _a"></span>asitological failure rate at day 28 with combination treatment</div><div class="t m0 x9 hb ya0 ff1a fs8 fc3 sc0 ls12 ws0">(16)<span class="ff17 ls0">.</span></div><div class="t m0 x9 h23 y12af ff1e fs11 fc8 sc0 ls27a ws0">Harms </div><div class="t m0 x9 hb y12b0 ff17 fs8 fc3 sc0 ls13 ws55c">The Chinese RCT identified by the r<span class="_ _a"></span>eview reported a slightly higher rate of</div><div class="t m0 x9 hb ybef ff17 fs8 fc3 sc0 ls166 ws91">adverse ev<span class="_ _a"></span>ents with the combination treatment than with amodiaquine alone</div><div class="t m0 x9 hb y9e4 ff17 fs8 fc3 sc0 lsf9 ws516">(41.7% with the combination, 36% with the monotherapy<span class="_ _c"></span>, <span class="ff1a ls0 ws0">p<span class="_ _6"> </span></span>value not reported)</div><div class="t m0 x9 hb y9e5 ff1a fs8 fc3 sc0 ls53 ws0">(13)<span class="ff17 ls12 ws40b">. Sinus bradycar<span class="_ _a"></span>dia and vomiting were the most fr<span class="_ _a"></span>equent adverse events</span></div><div class="t m0 x9 hb y9e6 ff17 fs8 fc3 sc0 ls29b ws55">ov<span class="_ _a"></span>erall and were also mor<span class="_ _a"></span>e frequent with the combination treatment than with</div><div class="t m0 x9 hb yb9d ff17 fs8 fc3 sc0 ls1e1 ws312">the monotherapy (no statistical data reported). The U<span class="_ _a"></span>gandan RCT reported no</div><div class="t m0 x9 hb yb9e ff17 fs8 fc3 sc0 ls12 ws93">serious adverse effects in either treatment gr<span class="_ _a"></span>oup, whereas that conducted in</div><div class="t m0 x9 hb yb9f ff17 fs8 fc3 sc0 ls12 ws0">Mozambique gave no information on adv<span class="_ _a"></span>erse events <span class="ff1a ls44 ws64">(10, 11)</span><span class="ls13">. </span></div><div class="t m0 x9 hb y12b1 ff17 fs8 fc3 sc0 ls2a9 ws94">The first subsequent RCT found thr<span class="_ _a"></span>ee children with sleep disturbance secondary</div><div class="t m0 x9 hb y12b2 ff17 fs8 fc3 sc0 ls7b wsb8">to pruritus but there was no significant difference betw<span class="_ _a"></span>een the treatments (2/75</div><div class="t m0 x9 hb y12b3 ff17 fs8 fc3 sc0 lse4 ws174">with the combination, 1/82 with the monotherapy<span class="_ _c"></span>, <span class="_ _8"></span><span class="ff1a ls0 ws0">p<span class="_ _3"> </span></span><span class="ls310 ws225">value not reported).</span></div><div class="t m0 x9 hb y12b4 ff17 fs8 fc3 sc0 ls12 ws0">All other adverse r<span class="_ _a"></span>eactions were reported as mild <span class="ff1a ls13">(15)<span class="ff17">. </span></span></div><div class="t m0 x9 hb y12b5 ff17 fs8 fc3 sc0 lsbf ws12e">The second subsequent RCT found no significant differ<span class="_ _a"></span>ence in fatigue between</div><div class="t m0 x9 hb y12b6 ff17 fs8 fc3 sc0 ls13 ws94">treatments (59/62 (95%) with the combination treatment, 54/61 (89%) with</div><div class="t m0 x9 hb y12b7 ff17 fs8 fc3 sc0 ls64 wsa4">amodiaquine alone, <span class="ff1a ls0 ws0">p<span class="_ _6"> </span></span>value not r<span class="_ _a"></span>epor<span class="_ _8"></span>ted). Cutaneous reactions (dermatitis in</div><div class="t m0 x9 hb y12b8 ff17 fs8 fc3 sc0 ls12 ws548">the hip area in one person and diffuse urticaria at day 5 in one person) were</div><div class="t m0 x9 hb y12b9 ff17 fs8 fc3 sc0 ls1af ws126">recorded in two people r<span class="_ _a"></span>eceiving the monotherapy (0/62 (0%) with the</div><div class="t m0 x9 hb y12ba ff17 fs8 fc3 sc0 ls12 ws447">combination, 2/61 (3%) with the monotherapy<span class="_ _c"></span>, <span class="ff1a ls0 ws0">p<span class="_ _3"> </span></span>value not reported) <span class="ff1a ls13 ws0">(14)<span class="ff17">. </span></span></div><div class="t m0 x9 hb y12bb ff17 fs8 fc3 sc0 ls12 ws1db">The third subsequent RCT<span class="_ _6"> </span>reported both treatments to be well tolerated and</div><div class="t m0 x9 hb y12bc ff17 fs8 fc3 sc0 ls12 ws0">found no serious adverse effects <span class="ff1a">(16)</span><span class="ls0">.</span></div><div class="t m0 x9 h23 yd06 ff1e fs11 fc8 sc0 ls27a ws0">Comment</div><div class="t m0 x9 hb y12bd ff17 fs8 fc3 sc0 ls12 ws4a1">The systematic review show<span class="_ _a"></span>ed significant differences in parasitological cure</div><div class="t m0 x9 hb y1272 ff17 fs8 fc3 sc0 ls12 wsd7">rates at day 28 between the two RCT<span class="_ _c"></span>s <span class="ff1a ls14e ws8b">(10, 13)</span>. However<span class="_ _4b"></span>, the reviewers found</div><div class="t m0 x9 hb y1273 ff17 fs8 fc3 sc0 ls12 ws55d">no significant difference between tr<span class="_ _a"></span>eatments when using a random effects</div><div class="t m0 x9 hb y1274 ff17 fs8 fc3 sc0 ls5e ws7f">model, or worst and best case scenarios assuming that people lost to follow-</div><div class="t m0 x9 hb y12be ff17 fs8 fc3 sc0 ls12 ws0">up were either all tr<span class="_ _a"></span>eatment failures or successes <span class="ff1a ls14">(2)</span><span class="ls0">.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc9" class="pf w1 h4" data-page-no="c9"><div class="pc pcc9 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x81 he y9 ff16 fs5 fc3 sc0 ls51 ws1">Annex 7 - Uncomplicated <span class="ff1d lsad ws0">Plasmodium falciparum<span class="_ _95"> </span><span class="ff16 lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">191</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls0 ws95">A7.3.<span class="_ _39"> </span>How do ar<span class="_ _8"></span>temisinin combination therapies</div><div class="t m0 xa4 h12 y12b ff19 fs6 fc4 sc0 ls0 ws95">compare with non-artemisinin combinations?</div><div class="t m0 xb h2e ycb4 ff19 fs3 fc3 sc0 ls69 ws0">A7.3.1<span class="_ _a7"> </span>Ar<span class="_ _8"></span>tesunate + sulfadoxine-pyr<span class="_ _8"></span>imethamine </div><div class="t m0 xb h23 y12bf ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y12c0 ff17 fs8 fc3 sc0 ls12 ws53b">No systematic review<span class="_ _b"></span>. One RCT<span class="_ _5"> </span>(276 children aged 6–59 months, Uganda,</div><div class="t m0 xb hb y12c1 ff17 fs8 fc3 sc0 ls2cb ws4a3">2001) comparing artesunate (3 days) + sulfadoxine-pyrimethamine with</div><div class="t m0 xb hb y12c2 ff17 fs8 fc3 sc0 ls182 ws130">amodiaquine + sulfadoxine-pyrimethamine <span class="ff1a ws0">(16)</span>. It found that parasitological</div><div class="t m0 xb hb y12c3 ff17 fs8 fc3 sc0 lsaa ws110">failure at day 28 was significantly increased in the gr<span class="_ _a"></span>oup receiving artesunate</div><div class="t m0 xb hb y12c4 ff17 fs8 fc3 sc0 ls5d ws7e">(3 days) + sulfadoxine-pyrimethamine compared to that in the gr<span class="_ _a"></span>oup receiving</div><div class="t m0 xb hb y12c5 ff17 fs8 fc3 sc0 ls42 ws5b">amodiaquine + sulfadoxine-pyrimethamine (PCR-unadjusted treatment failur<span class="_ _a"></span>e</div><div class="t m0 xb hb y12c6 ff17 fs8 fc3 sc0 ls26e wsa1">at day 28: 42/144 (29%) with artesunate (3 days) + sulfadoxine-pyrimethamine,</div><div class="t m0 xb hb y136 ff17 fs8 fc3 sc0 ls94 wsea">22/132 (17%) with amodiaquine + sulfadoxine-pyrimethamine; OR: 0.49;</div><div class="t m0 xb hb y12c7 ff17 fs8 fc3 sc0 ls12 ws4ac">95% CI: 0.27–0.87). Howev<span class="_ _a"></span>er<span class="_ _b"></span>, it found no significant difference in treatment</div><div class="t m0 xb hb y12c8 ff17 fs8 fc3 sc0 ls26 ws2a">failure rates at day 28 betw<span class="_ _a"></span>een the two groups once new infections had been</div><div class="t m0 xb hb y12c9 ff17 fs8 fc3 sc0 ls14 ws523">excluded (PCR-adjusted treatment failur<span class="_ _a"></span>e at day 28: 17/132 (13%) with ar<span class="_ _8"></span>te-</div><div class="t m0 xb hb y12ca ff17 fs8 fc3 sc0 lsbe ws37f">sunate (3 days) + sulfadoxine-pyrimethamine, 29/134 (22%) with amodiaquine</div><div class="t m0 xb hb y12cb ff17 fs8 fc3 sc0 ls13 ws14">+ sulfadoxine-pyrimethamine; OR: 0.59; 95% CI: 0.29–1.18, <span class="ff1a ls0 ws0">p <span class="ff17 ls12">= 0.14).</span></span></div><div class="t m0 xb h23 y12cc ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 xb hb y12cd ff17 fs8 fc3 sc0 ls13 ws14">The same RCT gav<span class="_ _a"></span>e no information on adverse events <span class="ff1a ls12 ws0">(16)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb h12 y12ce ff19 fs6 fc4 sc0 ls86 wsca">A7.4<span class="_ _33"> </span>W<span class="_ _9"></span>hich is the best ar<span class="_ _8"></span>temisinin combination</div><div class="t m0 xa4 h12 y12cf ff19 fs6 fc4 sc0 ls1 ws0">therapy?</div><div class="t m0 xb h2e y12d0 ff19 fs3 fc3 sc0 ls80 ws0">A7.4.1<span class="_ _a7"> </span>Ar<span class="_ _8"></span>temether-lumefantr<span class="_ _8"></span>ine (6 doses) compared with</div><div class="t m0 x9d h2e y12d1 ff19 fs3 fc3 sc0 ls80 ws0">artemether-lumefant<span class="_ _8"></span>rine (4 doses)</div><div class="t m0 xb h23 y12d2 ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y12d3 ff17 fs8 fc3 sc0 ls14 ws4a6">One RCT <span class="ff1a lsa8 ws0">(17)</span><span class="ls12 ws55e">; the RCT<span class="_ _6"> </span>(238 adults and children, Thailand, 1996–1997) found</span></div><div class="t m0 xb hb y12d4 ff17 fs8 fc3 sc0 ls76 wsab">a significantly higher rate of cure at day 28 with the 6-dose r<span class="_ _a"></span>egimen given ov<span class="_ _a"></span>er</div><div class="t m0 xb hb y12d5 ff17 fs8 fc3 sc0 ls10e wsc6">3 days than with the 4-dose regimen also given o<span class="_ _a"></span>ver 3 days (PCR-unadjusted</div><div class="t m0 xb hb y12d6 ff17 fs8 fc3 sc0 ls10e ws4e5">treatment cure r<span class="_ _a"></span>ate for intention to treat population at day 28: 96/118 (81%);</div><div class="t m0 xb hb y12d7 ff17 fs8 fc3 sc0 ls188 ws1bd">95% CI: 73.1–87.9% with the 6-dose regimen, 85/120 (71%); 95% CI: 61.8–78.8%</div><div class="t m0 xb hb y12d8 ff17 fs8 fc3 sc0 lsb3 wsaa">with the 4-dose regimen, <span class="ff1a ls0 ws0">p<span class="_ _7c"> </span><span class="ff1c">&lt;<span class="_ _68"> </span></span></span><span class="lsfb">0.001; PCR-adjusted treatment cur<span class="_ _a"></span>e rate for</span></div><div class="t m0 xb hb y12d9 ff17 fs8 fc3 sc0 ls110 ws6f">evaluable population: 93/96 (97%); 95% CI: 91.1–99.4% with the 6-dose</div><div class="t m0 xb hb y12da ff17 fs8 fc3 sc0 ls2ea wsae">regimen, 85/102 (83%); 95% CI: 74.7–90.0% with the 4-dose r<span class="_ _a"></span>egimen, <span class="ff1a ls0 ws0">p<span class="_ _67"> </span><span class="ff1c">&lt;<span class="_ _6"> </span><span class="ff17 ls353">0.001).</span></span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfca" class="pf w1 h4" data-page-no="ca"><div class="pc pcca w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">192</div><div class="t m0 x9 h23 yd3c ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 x9 hb yd3d ff17 fs8 fc3 sc0 ls12 ws55f">The RCT r<span class="_ _a"></span>epor<span class="_ _8"></span>ted all adverse events to be mild or moder<span class="_ _a"></span>ate in severity and</div><div class="t m0 x9 hb yd3e ff17 fs8 fc3 sc0 ls30b ws46f">possibly attributable to malaria <span class="ff1a ls57 ws0">(17)</span>. It found no adverse cardio<span class="_ _a"></span>vascular</div><div class="t m0 x9 hb yd3f ff17 fs8 fc3 sc0 ls1b3 ws28">effects. It found four serious adverse ev<span class="_ _a"></span>ents that the authors did not consider</div><div class="t m0 x9 hb yd40 ff17 fs8 fc3 sc0 ls166 ws91">to be related to treatment. <span class="_ _b"></span>The trial found no changes in QRS duration and PR</div><div class="t m0 x9 hb yd41 ff17 fs8 fc3 sc0 ls12 ws12f">interval during treatment in 66 people who had regular electr<span class="_ _a"></span>ocardiographic</div><div class="t m0 x9 hb yd42 ff17 fs8 fc3 sc0 ls12 ws31">monitoring. Similarly<span class="_ _4b"></span>, it found no differences in mean and median QT<span class="_ _4b"></span>c values</div><div class="t m0 x9 hb yd43 ff17 fs8 fc3 sc0 ls12 ws0">between treatment gr<span class="_ _a"></span>oups.</div><div class="t m0 x9 h2e y12db ff19 fs3 fc3 sc0 ls80 ws0">A7.4.2<span class="_ _a7"> </span>Ar<span class="_ _8"></span>temether-lumefantr<span class="_ _8"></span>ine (6 doses) compared with</div><div class="t m0 xba h2e y12dc ff19 fs3 fc3 sc0 ls80 ws0">artesunate (3 day<span class="_ _8"></span>s) + mefloquine</div><div class="t m0 x9 h23 y12dd ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 x9 hb y12de ff17 fs8 fc3 sc0 ls12 ws34b">One systematic review (search date 2004, two RCT<span class="_ _c"></span>s, 419 people, Thailand,</div><div class="t m0 x9 hb y12df ff17 fs8 fc3 sc0 ls12 ws0">1997–1998 and 1998–1999) <span class="ff1a ls13">(18)<span class="ff17">. </span></span></div><div class="t m0 x9 hb y12e0 ff17 fs8 fc3 sc0 ls0 ws184">The review found a higher proportion of people with parasitaemia at day 28</div><div class="t m0 x9 hb y12e1 ff17 fs8 fc3 sc0 ls24b ws3c7">with artemether-lumefantrine tr<span class="_ _a"></span>eatment than with ar<span class="_ _8"></span>tesunate-mefloquine</div><div class="t m0 x9 hb y12e2 ff17 fs8 fc3 sc0 ls13 ws73">although the pooled difference did not reach statistical significance (PCR-</div><div class="t m0 x9 hb y12e3 ff17 fs8 fc3 sc0 ls2d1 ws1b6">unadjusted parasitaemia rate 11/289 (4%) with artemether<span class="_ _a"></span>-lumefantrine,</div><div class="t m0 x9 hb y12e4 ff17 fs8 fc3 sc0 ls17b ws258">0/100 (0%) with artesunate-mefloquine, RR: 4.20; 95% CI: 0.55–31.93, <span class="ff1a ls0 ws0">p<span class="_ _6"> </span><span class="ff17 ls354">= 0.2;</span></span></div><div class="t m0 x9 hb y12e5 ff17 fs8 fc3 sc0 ls13 ws560">PCR-adjusted parasitaemia rate 9/289 (3%) with artemether<span class="_ _a"></span>-lumefantrine,</div><div class="t m0 x9 hb y12e6 ff17 fs8 fc3 sc0 lsbe ws37f">0/100 (0%) with artesunate-mefloquine, RR: 3.50; 95% CI: 0.45–27.03, <span class="ff1a ls0 ws0">p<span class="_ _6"> </span></span><span class="ws0">= 0.2;</span></div><div class="t m0 x9 hb y12e7 ff17 fs8 fc3 sc0 ls6c ws99">see comment below). <span class="_ _a"></span>The first RCT (219 adults and children aged o<span class="_ _a"></span>ver 12</div><div class="t m0 x9 hb y12e8 ff17 fs8 fc3 sc0 ls29a ws436">years, <span class="_ _a"></span>Thailand, 1998–1999) identified by the review found no significant</div><div class="t m0 x9 hb y12e9 ff17 fs8 fc3 sc0 ls337 wsd6">difference in median parasite clear<span class="_ _a"></span>ance time between the two treatment</div><div class="t m0 x9 hb y12ea ff17 fs8 fc3 sc0 ls203 ws342">groups (29 h; 95% CI: 29–32 h in 164 people r<span class="_ _a"></span>eceiving ar<span class="_ _8"></span>temether<span class="_ _a"></span>-lumefantrine,</div><div class="t m0 x9 hb y12eb ff17 fs8 fc3 sc0 ls12 ws50f">31 h; 95% CI: 26–31 h in 55 people receiving artesunate-mefloquine, <span class="ff1a ls0 ws0">p </span><span class="ws0">value</span></div><div class="t m0 x9 hb y12ec ff17 fs8 fc3 sc0 lsef wsab">not reported) <span class="ff1a ws0">(19)</span>. Similarly<span class="_ _4b"></span>, it found no significant difference in median fever</div><div class="t m0 x9 hb y12ed ff17 fs8 fc3 sc0 ls13 ws276">clearance time (29 h; 95% CI: 23–37 h in 76 people receiving artemether<span class="_ _a"></span>-</div><div class="t m0 x9 hb y12ee ff17 fs8 fc3 sc0 ls1f9 ws22c">lumefantrine, 23 h; 95% CI: 15–30 h in 29 people receiving artesunate-</div><div class="t m0 x9 hb y12ef ff17 fs8 fc3 sc0 ls12 ws0">mefloquine, <span class="_ _9"></span><span class="ff1a ls0">p<span class="_ _64"> </span></span><span class="ws561">value not reported) or in median gametocyte clearance time</span></div><div class="t m0 x9 hb y12f0 ff17 fs8 fc3 sc0 ls2e7 ws562">between treatments (72 h; 95% CI: 34–163 h in 26 people r<span class="_ _a"></span>eceiving ar<span class="_ _8"></span>temether<span class="_ _a"></span>-</div><div class="t m0 x9 hb y12f1 ff17 fs8 fc3 sc0 ls355 ws563">lumefantrine, 85 h; 95% CI: 46–160 h in 10 people receiving artesunate-</div><div class="t m0 x9 hb y12f2 ff17 fs8 fc3 sc0 ls2c6 ws0">mefloquine, <span class="_ _66"></span><span class="ff1a ls0">p<span class="_ _3"> </span></span><span class="ws4e1">value not reported). The systematic review did not r<span class="_ _a"></span>epor<span class="_ _8"></span>t</span></div><div class="t m0 x9 hb y12f3 ff17 fs8 fc3 sc0 ls12 ws0">results for any other outcomes from the second RCT<span class="_ _4b"></span>.</div><div class="t m0 x9 h23 y12f4 ff1e fs11 fc8 sc0 ls27a ws0">Harms </div><div class="t m0 x9 hb y12f5 ff17 fs8 fc3 sc0 ls152 wseb">The systematic review found fewer mild to moder<span class="_ _a"></span>ate adverse events with</div><div class="t m0 x9 hb y12f6 ff17 fs8 fc3 sc0 ls142 ws202">artemether-lumefantrine than with artesunate-mefloquine, although the</div><div class="t m0 x9 hb y12f7 ff17 fs8 fc3 sc0 ls114 ws2ee">differences did not reach statistical significance (nausea 4/150 (3%) with</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfcb" class="pf w1 h4" data-page-no="cb"><div class="pc pccb w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x81 he y9 ff16 fs5 fc3 sc0 ls51 ws1">Annex 7 - Uncomplicated <span class="ff1d lsad ws0">Plasmodium falciparum<span class="_ _95"> </span><span class="ff16 lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">193</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls12 ws279">artemether-lumefantrine, 6/50 (12%) with artesunate-mefloquine; vomiting</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls13 ws49a">4/150 (3%) compared to 5/50 (10%); sleep disorders: 2/150 (1%) compar<span class="_ _a"></span>ed</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls12 wse2">to 8/50 (16%); dizziness: 8/150 (5%) compared to 18/50 (36%); <span class="ff1a ls0 ws0">p<span class="_ _6"> </span></span>values not</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls13 ws0">reported) <span class="_ _8"></span><span class="ff1a">(18)</span><span class="ls12 ws564">. It found no significant difference in the proportion of people</span></div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls65 ws1ab">with severe adv<span class="_ _a"></span>erse events between the two tr<span class="_ _a"></span>eatment groups (one person with</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls12 ws0">each treatment). </div><div class="t m0 xb h2e y12f8 ff19 fs3 fc3 sc0 ls80 ws0">A7.4.3<span class="_ _a7"> </span>Ar<span class="_ _8"></span>temether-lumefantr<span class="_ _8"></span>ine (6 doses) compared with</div><div class="t m0 x9d h2e y12f9 ff19 fs3 fc3 sc0 ls80 ws0">artesunate (3 day<span class="_ _8"></span>s) + amodiaquine</div><div class="t m0 xb h23 y12fa ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y12fb ff17 fs8 fc3 sc0 ls12 ws546">No RCT<span class="_ _4b"></span>s with a 28-day follow-up period but one (295 children under 5 years</div><div class="t m0 xb hb y12fc ff17 fs8 fc3 sc0 ls1f1 wsa0">of age, Burundi, 2001–2002) with a 14-day follow-up period <span class="ff1a ws0">(20)</span>. <span class="_ _a"></span>The trial found</div><div class="t m0 xb hb y12fd ff17 fs8 fc3 sc0 ls42 ws5b">no significant difference in the proportion of people with adequate clinical and</div><div class="t m0 xb hb y12fe ff17 fs8 fc3 sc0 ls233 ws17b">parasitological response at day 14 betw<span class="_ _a"></span>een the treatments (140/141 (99.3%);</div><div class="t m0 xb hb y12ff ff17 fs8 fc3 sc0 ls5b ws78">95% CI: 97.9–100.0% with artemether-lumefantrine, 142/149 (95.3%); 95% CI:</div><div class="t m0 xb hb y1300 ff17 fs8 fc3 sc0 ls12 ws0">91.9–98.7% with artesunate-amodiaquine, <span class="ff1a ls0">p </span>value not reported).</div><div class="t m0 xb h23 y1301 ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 xb hb y1302 ff17 fs8 fc3 sc0 ls13e ws1fd">The RCT found no significant differ<span class="_ _a"></span>ence in adverse events between the</div><div class="t m0 xb hb y1303 ff17 fs8 fc3 sc0 ls12 ws565">treatment groups other than v<span class="_ _a"></span>omiting, which was significantly less frequent</div><div class="t m0 xb hb y1304 ff17 fs8 fc3 sc0 ls12 ws10d">on days 1 and 2 with artemether-lumefantrine than with artesunate-amodi-</div><div class="t m0 xb hb y1305 ff17 fs8 fc3 sc0 ls17c ws14f">aquine (day 1, 5% with artemether-lumefantrine, 13% with artesunate-</div><div class="t m0 xb hb y1306 ff17 fs8 fc3 sc0 ls12 ws0">amodiaquine; day 2, 1% compared to 5%; <span class="ff1a ls0">p </span>v<span class="_ _a"></span>alues not reported <span class="ff1a ls13">(20)</span><span class="ls0">.</span></div><div class="t m0 xb h12 y1307 ff19 fs6 fc4 sc0 ls1 ws0">A7.5<span class="_ _52"> </span>References</div><div class="t mc xb h17 y1308 ff17 fsb fc3 sc0 ls105 ws0">1.<span class="_ _46"> </span>Adjuik M et al. Ar<span class="_ _8"></span>tesunate combinations for treatment of malaria: meta-analysis.</div><div class="t mc x4d h17 y1309 ff1a fsb fc3 sc0 ls105 ws0">Lancet<span class="ff17">, 2004, 363:9–17 (search date 2003; primary sources, studies sponsored</span></div><div class="t mc x4d h17 y130a ff17 fsb fc3 sc0 ls105 ws19a">by the WHO/UNICE<span class="_ _8"></span>F/U<span class="_ _8"></span>NDP/World Bank Special Progr<span class="_ _a"></span>amme for Research and</div><div class="t mc x4d h17 y130b ff17 fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>raining in T<span class="_ _b"></span>ropical Diseases, Medline, Cochrane Contr<span class="_ _a"></span>olled T<span class="_ _b"></span>rials Register<span class="_ _4b"></span>, and</div><div class="t mc x4d h17 y130c ff17 fsb fc3 sc0 ls105 ws19a">contact with investigators of published trials).</div><div class="t mc xb h17 y130d ff17 fsb fc3 sc0 ls356 ws0">2.<span class="_ _39"> </span>McIntosh HM. Chloroquine or amodiaquine combined with sulfadoxine-</div><div class="t mc x4d h17 y130e ff17 fsb fc3 sc0 ls356 ws0">pyrimethamine for treating uncomplicated malaria. In: <span class="ff1a">The Cochrane Libr<span class="_ _a"></span>ary<span class="_ _b"></span>,</span></div><div class="t mc x4d h17 y130f ff1a fsb fc3 sc0 ls356 ws0">Issue 4<span class="ff17">. Chichester<span class="_ _b"></span>, John W<span class="_ _a"></span>iley &amp; Sons, 2004. (Search date 2001. Primary sources:</span></div><div class="t mc x4d h17 y1310 ff17 fsb fc3 sc0 ls356 ws0">The Cochrane Infectious Diseases Group trials r<span class="_ _a"></span>egister<span class="_ _b"></span>, the Cochrane Controlled</div><div class="t mc x4d h17 y1311 ff17 fsb fc3 sc0 ls356 ws0">T<span class="_ _b"></span>rials Register<span class="_ _b"></span>, Medline, Embase, Science Citation Index, African Index Medicus and</div><div class="t mc x4d h17 y1312 ff17 fsb fc3 sc0 ls356 ws0">Lilacs, plus contact with experts in the field and pharmaceutical manufacturers).</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfcc" class="pf w1 h4" data-page-no="cc"><div class="pc pccc w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">194</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">3.<span class="_ _44"> </span>Blair S et al. Eficacia terapeutica de tres esquemas de traitamiento de malaria no</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws1d4">complicado por <span class="ff1a ws0">Plasmodium falciparum<span class="ff17">, Antioquia, Colombia, 2002.</span></span></div><div class="t mc x7a h17 yd63 ff17 fsb fc3 sc0 ls105 ws0">[Therapeutic efficacy of 3 treatment pr<span class="_ _a"></span>otocols for non-complicated <span class="ff1a">Plasmodium</span></div><div class="t mc x7a h17 yec7 ff1a fsb fc3 sc0 ls105 ws0">falciparum <span class="ff17">malaria, Antioquia, Colombia, 2002.] </span>Biomedica<span class="ff17 ls1dc ws1d2">, 2003, 23:318–327 </span></div><div class="t mc x9 h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">4.<span class="_ _44"> </span>Ogwang S et al. Clinical and parasitological response of <span class="ff1a">Plasmodium falciparum</span></div><div class="t mc x7a h17 yd66 ff17 fsb fc3 sc0 ls105 ws0">to chloroquine and sulfadoxine-pyrimethamine in rur<span class="_ _a"></span>al Uganda. <span class="ff1a">Wienerische</span></div><div class="t mc x7a h17 yf77 ff1a fsb fc3 sc0 ls105 ws502">Klinische W<span class="_ _a"></span>ochenschrift<span class="ff17 ls1dc ws1d2">, 2003, 115(Suppl. 3):45–49.</span></div><div class="t mc x9 h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>Schwobel B et al. <span class="_ _a"></span>Therapeutic efficacy of chloroquine plus sulpha-</div><div class="t mc x7a h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">doxine/pyrimethamine compared with monother<span class="_ _a"></span>apy with either chloroquine or</div><div class="t mc x7a h17 yec8 ff17 fsb fc3 sc0 ls105 ws0">sulphadoxine/pyrimethamine in uncomplicated <span class="ff1a">Plasmodium falciparum </span>malaria</div><div class="t mc x7a h17 y1313 ff17 fsb fc3 sc0 ls105 ws0">in Laos. <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and International Health<span class="ff17 ls31a ws1cc">, 2003, 8:19–24.</span></span></div><div class="t mc x9 h17 yd89 ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>Ndyomugyenyi R, Magnussen P<span class="_ _c"></span>, Clarke S. The efficacy of chlor<span class="_ _a"></span>oquine,</div><div class="t mc x7a h17 yec9 ff17 fsb fc3 sc0 ls105 ws0">sulfadoxine-pyrimethamine and a combination of both for the treatment of</div><div class="t mc x7a h17 y1314 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated <span class="ff1a">Plasmodium falciparum </span>malaria in an area of low tr<span class="_ _a"></span>ansmission in</div><div class="t mc x7a h17 y1315 ff17 fsb fc3 sc0 ls105 ws0">western Uganda. <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and International Health<span class="ff17">, 2004, 9:47–52.</span></span></div><div class="t mc x9 h17 yecb ff17 fsb fc3 sc0 ls105 ws0">7.<span class="_ _39"> </span>Gasasira AF et al. Comparative efficacy of aminoquinoline-antifolate</div><div class="t mc x7a h17 yecc ff17 fsb fc3 sc0 ls105 ws0">combinations for the treatment of uncomplicated falciparum malaria in Kampala,</div><div class="t mc x7a h17 y1316 ff17 fsb fc3 sc0 ls105 ws0">Uganda. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls31a ws1cc">, 2003, 68:127–132.</span></span></div><div class="t mc x9 h17 yece ff17 fsb fc3 sc0 ls105 ws0">8.<span class="_ _44"> </span>Darlow B et al. Sulfadoxine-pyrimethamine for the tr<span class="_ _a"></span>eatment of acute malaria in</div><div class="t mc x7a h17 yecf ff17 fsb fc3 sc0 ls105 ws0">children in Papua New Guinea. I. <span class="ff1a">Plasmodium falciparum</span>. <span class="ff1a">American Journal of</span></div><div class="t mc x7a h17 y1317 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 lsd6 ws218">, 1982, 31:1–9. </span></div><div class="t mc x9 h17 yed1 ff17 fsb fc3 sc0 ls105 ws0">9.<span class="_ _44"> </span>Bojang K<span class="_ _8"></span>A et al. A trial of F<span class="_ _a"></span>ansidar plus chloroquine or Fansidar alone for the</div><div class="t mc x7a h17 yed2 ff17 fsb fc3 sc0 ls105 ws0">treatment of uncomplicated malaria in Gambian children. <span class="ff1a">T<span class="_ _b"></span>ransactions of the</span></div><div class="t mc x7a h17 y1318 ff1a fsb fc3 sc0 ls105 ws0">Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 1998, 92:73–76.</span></div><div class="t mc x9 h17 yed4 ff17 fsb fc3 sc0 ls105 ws0">10.<span class="_ _68"> </span>Schapira A, Schwalbach JF<span class="_ _4b"></span>. Ev<span class="_ _a"></span>aluation of four therapeutic regimens for falciparum</div><div class="t mc x7a h17 yed5 ff17 fsb fc3 sc0 ls105 ws0">malaria in Mozambique, 1986. <span class="ff1a ws19a">Bulletin of the W<span class="_ _b"></span>orld Health Organization<span class="ff17 ws0">, 1988,</span></span></div><div class="t mc x7a h17 y1319 ff17 fsb fc3 sc0 ls105 ws0">66:219–226.</div><div class="t mc x9 h17 yed7 ff17 fsb fc3 sc0 ls105 ws0">11.<span class="_ _0"> </span>Staedke SG et al. Amodiaquine, sulfadoxine-pyrimethamine, and combination</div><div class="t mc x7a h17 yed8 ff17 fsb fc3 sc0 ls105 ws0">therapy for treatment of uncomplicated malaria in K<span class="_ _a"></span>ampala, Uganda: a</div><div class="t mc x7a h17 yed9 ff17 fsb fc3 sc0 ls105 ws0">randomised trial. <span class="ff1a">Lancet</span><span class="ws1d4">, 2001, 358:368–374.</span></div><div class="t mc x9 h17 yeda ff17 fsb fc3 sc0 ls105 ws0">12.<span class="_ _68"> </span>Dinis D<span class="_ _a"></span>V<span class="_ _4b"></span>, Schapira A. Étude comparative de la sulfadoxine-pyrimethamine et de</div><div class="t mc x7a h17 yedb ff17 fsb fc3 sc0 ls105 ws0">l’amodiaquine+sulfadoxine–pyrimethamine dans le traitement du paludisme à</div><div class="t mc x7a h17 yedc ff17 fsb fc3 sc0 ls105 ws0">Plasmodium falciparum chloroquino-résistant à Maputo, Mozambique</div><div class="t mc x7a h17 y131a ff17 fsb fc3 sc0 ls105 ws0">[Comparative study of sulfado<span class="_ _a"></span>xine-pyrimethamine and amodiaquine +</div><div class="t mc x7a h17 y131b ff17 fsb fc3 sc0 ls105 ws0">sulfadoxine-pyrimethamine for the treatment of malaria caused by chlor<span class="_ _a"></span>oquine-</div><div class="t mc x7a h17 y131c ff17 fsb fc3 sc0 ls105 ws0">resistant Plasmodium falciparum in Maputo, Mozambique.] <span class="ff1a">Bulletin de la</span></div><div class="t mc x7a h17 y131d ff1a fsb fc3 sc0 ls105 ws0">Societéé de Pathologie Exotique, <span class="ff17 ws1d4">1990, 83:521–528.</span></div><div class="t mc x9 h17 y131e ff17 fsb fc3 sc0 ls105 ws0">13.<span class="_ _68"> </span>Huang QL<span class="_ _6"> </span>et al. [Efficacy of amodiaquine, F<span class="_ _a"></span>ansidar and their combination in the</div><div class="t mc x7a h17 y131f ff17 fsb fc3 sc0 ls105 ws0">treatment of chloroquine r<span class="_ _a"></span>esistant falciparum malaria.] <span class="ff1a ws1d4">Zhongguo Ji Sheng</span></div><div class="t mc x7a h17 y1320 ff1a fsb fc3 sc0 ls105 ws0">Chong Xue Y<span class="_ _4b"></span>u Ji Sheng Chong Bing Za Zhi<span class="ff17 ws19a">, 1988, 6:292–295 (in Chinese).</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfcd" class="pf w1 h4" data-page-no="cd"><div class="pc pccd w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x81 he y9 ff16 fs5 fc3 sc0 ls51 ws1">Annex 7 - Uncomplicated <span class="ff1d lsad ws0">Plasmodium falciparum<span class="_ _95"> </span><span class="ff16 lsee">malaria</span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">195</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">14.<span class="_ _3"> </span>Basco LK et al. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">and the sulfadoxine-pyrimethamine-amodiaquine combination against</div><div class="t mc x4d h17 yd63 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated <span class="ff1a">Plasmodium falciparum </span>malaria in young children in Cameroon.</div><div class="t mc x4d h17 yec7 ff1a fsb fc3 sc0 ls105 ws19a">Bulletin of the W<span class="_ _b"></span>orld Health Organization<span class="ff17 ws0">, 2002, 80:538–545.</span></div><div class="t mc xb h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">15.<span class="_ _68"> </span>Sowunmi A. A randomiz<span class="_ _a"></span>ed comparison of chloroquine, amodiaquine and their</div><div class="t mc x4d h17 yd66 ff17 fsb fc3 sc0 ls105 ws0">combination with pyrimethamine-sulfadoxine in the treatment of acute,</div><div class="t mc x4d h17 yf77 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated, <span class="ff1a">Plasmodium falciparum </span>malaria in children. <span class="ff1a">Annals of <span class="_ _a"></span>T<span class="_ _b"></span>ropical</span></div><div class="t mc x4d h17 y1321 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Parasitology<span class="ff17">, 2002, 96:227–238.</span></div><div class="t mc xb h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">16.<span class="_ _3"> </span>Rwagacondo CE et al. Efficacy of amodiaquine alone and combined with</div><div class="t mc x4d h17 yec8 ff17 fsb fc3 sc0 ls105 ws0">sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with</div><div class="t mc x4d h17 y1313 ff17 fsb fc3 sc0 ls105 ws0">artesunate. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ls357 ws566">, 2003,</span></span></div><div class="t mc x4d h17 y1322 ff17 fsb fc3 sc0 ls31a ws0">68:743–747.</div><div class="t mc xb h17 yec9 ff17 fsb fc3 sc0 ls105 ws0">17.<span class="_ _68"> </span>van V<span class="_ _b"></span>ugt MV et al. Efficacy of six doses of artemether-lumefantrine (benflumetol)</div><div class="t mc x4d h17 y1314 ff17 fsb fc3 sc0 ls105 ws0">in multidrug-resistant <span class="ff1a">Plasmodium falciparum </span>malaria. <span class="ff1a">American Journal of</span></div><div class="t mc x4d h17 y1315 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 1999, 60:936–942.</span></div><div class="t mc xb h17 yecb ff17 fsb fc3 sc0 ls105 ws0">18.<span class="_ _3"> </span>Omari A<span class="_ _8"></span>A, Gamble C, G<span class="_ _8"></span>arner P<span class="_ _c"></span>. Ar<span class="_ _8"></span>temether<span class="_ _a"></span>-lumefantrine for treating</div><div class="t mc x4d h17 yecc ff17 fsb fc3 sc0 ls105 ws1d4">uncomplicated falciparum malaria. In: <span class="ff1a ws0">The Cochrane Library<span class="_ _4b"></span>, Issue 4, 2004.</span></div><div class="t mc x4d h17 y1316 ff17 fsb fc3 sc0 ls105 ws0">Chichester<span class="_ _b"></span>, John W<span class="_ _a"></span>iley &amp; Sons (search date 2004, primary sources Cochrane</div><div class="t mc x4d h17 y1323 ff17 fsb fc3 sc0 ls105 ws0">Infectious Diseases Group trials register<span class="_ _4b"></span>, the Cochrane Controlled <span class="_ _a"></span>T<span class="_ _b"></span>rials Register<span class="_ _b"></span>,</div><div class="t mc x4d h17 y1324 ff17 fsb fc3 sc0 ls105 ws0">Medline, Embase, Science Citation Index, African Index Medicus and Lilacs, plus</div><div class="t mc x4d h17 y1325 ff17 fsb fc3 sc0 ls105 ws1d4">contact with experts in the field and pharmaceutical manufacturers).</div><div class="t mc xb h17 y1326 ff17 fsb fc3 sc0 ls105 ws0">19.<span class="_ _3"> </span>Lefevre G et al. A clinical and pharmacokinetic trial of six doses of artemether<span class="_ _a"></span>-</div><div class="t mc x4d h17 y1327 ff17 fsb fc3 sc0 ls105 ws0">lumefantrine for multidrug-resistant <span class="ff1a">Plasmodium falciparum </span>malaria in <span class="_ _a"></span>Thailand.</div><div class="t mc x4d h17 y1328 ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 2001, 64:247–256.</span></div><div class="t mc xb h17 y1329 ff17 fsb fc3 sc0 ls105 ws0">20.<span class="_ _5"> </span>Ndayiragije A et al. Efficacité de combinaisons thérapeutiques avec les dérivés de</div><div class="t mc x4d h17 y132a ff17 fsb fc3 sc0 ls105 ws0">l’artémisinine dans le traitement de l’accès palustre non-compliqué au Burundi.</div><div class="t mc x4d h17 y132b ff17 fsb fc3 sc0 ls105 ws0">[Efficacy of therapeutic combinations with artemisinin derivatives in the</div><div class="t mc x4d h17 y132c ff17 fsb fc3 sc0 ls105 ws0">treatment of non complicated malaria in Burundi.] <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x4d h17 y132d ff1a fsb fc3 sc0 ls105 ws0">International Health<span class="ff17 lsd6 ws218">, 2004, 9:673–679. </span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfce" class="pf w1 h4" data-page-no="ce"><div class="pc pcce w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfcf" class="pf w1 h4" data-page-no="cf"><div class="pc pccf w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 y132e ff1b fs10 fc7 sc0 ls270 ws0">Annex 8. <span class="_ _49"> </span><span class="fc0 ws406">Malaria treatment and HIV/AI<span class="_ _8"></span>DS<span class="_ _cb"> </span></span><span class="fc4 ls358">199</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd0" class="pf w1 h4" data-page-no="d0"><div class="pc pcd0 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd1" class="pf w1 h4" data-page-no="d1"><div class="pc pcd1 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4f he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 8 - Malaria treatment and HIV/AIDS</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">199</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 8</div><div class="t m0 x47 hf y895 ff18 fs6 fc3 sc0 ls1 ws567">MALAR<span class="_ _8"></span>IA TRE<span class="_ _8"></span>A<span class="_ _b"></span>TME<span class="_ _8"></span>NT AND <span class="_ _8"></span>H<span class="_ _8"></span>IV/AIDS</div><div class="t m0 xb hb y132f ff17 fs8 fc3 sc0 ls12 ws39">Malaria and H<span class="_ _8"></span>IV/AIDS share determinants of vulnerability<span class="_ _4b"></span>. Given the wide</div><div class="t m0 xb hb y1330 ff17 fs8 fc3 sc0 lsb1 ws11c">geographical o<span class="_ _a"></span>verlap in occurrence and the resulting pr<span class="_ _a"></span>evalence of co-infection,</div><div class="t m0 xb hb y1331 ff17 fs8 fc3 sc0 ls32c ws444">the interaction between the two diseases clearly has major public health</div><div class="t m0 xb hb y1332 ff17 fs8 fc3 sc0 ls12 ws0">implications <span class="_ _8"></span><span class="ff1a ls13">(1)</span><span class="ws26d">. In sub-Saharan Africa, around 300 million cases of malaria</span></div><div class="t m0 xb hb y1333 ff17 fs8 fc3 sc0 ls1fe ws220">occur annually and an estimated 25 million adults and children are living</div><div class="t m0 xb hb y1334 ff17 fs8 fc3 sc0 ls12 ws178">with HIV/AI<span class="_ _8"></span>DS. In 2003 in Africa, H<span class="_ _8"></span>IV/AI<span class="_ _8"></span>DS claimed the lives of an estimated</div><div class="t m0 xb hb y1335 ff17 fs8 fc3 sc0 ls85 wsc9">2.2 million people <span class="ff1a ws0">(2)</span>, and malaria 1 million, especially children <span class="ff1a lsef ws0">(3)</span>. In South-</div><div class="t m0 xb hb y1336 ff17 fs8 fc3 sc0 ls24 ws26">East Asia, Latin America and the Caribbean there is also significant o<span class="_ _a"></span>verlap of</div><div class="t m0 xb hb y1337 ff17 fs8 fc3 sc0 ls13 ws14">these two diseases.</div><div class="t m0 xb h12 y1338 ff19 fs6 fc4 sc0 ls1 ws17a">A8.1<span class="_ _52"> </span>Epidemiological overlaps bet<span class="_ _8"></span>ween malar<span class="_ _8"></span>ia </div><div class="t m0 xa4 h12 y1339 ff19 fs6 fc4 sc0 ls9a ws95">and HIV/AIDS</div><div class="t m0 xb hb y133a ff17 fs8 fc3 sc0 ls21d ws2ad">The impact of the interaction of malaria and HIV/AI<span class="_ _8"></span>DS is most apparent in areas</div><div class="t m0 xb hb y133b ff17 fs8 fc3 sc0 ls95 wsec">with generalized HIV/AI<span class="_ _8"></span>DS epidemics and stable malaria. Sub-Saharan Africa</div><div class="t m0 xb hb y133c ff17 fs8 fc3 sc0 ls12 ws40b">carries a high burden of both diseases, thus co-infection is common in many</div><div class="t m0 xb hb y133d ff17 fs8 fc3 sc0 ls348 ws54d">areas. In the most sever<span class="_ _a"></span>ely affected countries (Central African Republic,</div><div class="t m0 xb hb y133e ff17 fs8 fc3 sc0 ls2b9 ws8c">Malawi, Mozambique, Zambia and Zimbabwe), more than 90% of the population</div><div class="t m0 xb hb y133f ff17 fs8 fc3 sc0 ls12 ws568">are exposed to malaria and the prev<span class="_ _b"></span>alence of H<span class="_ _8"></span>IV infection in adults is <span class="ff1c ls0 ws0">οϖερ</span></div><div class="t m0 xb hb y1340 ff17 fs8 fc3 sc0 lsa8 ws0">10% <span class="_ _9"></span><span class="ff1a ls14">(2)</span><span class="ls12 ws164">. In contrast, southern Africa, which has a relatively low bur<span class="_ _a"></span>den of</span></div><div class="t m0 xb hb y1341 ff17 fs8 fc3 sc0 ls12 ws569">malaria, is the worst affected subregion for HIV infection with prevalence as</div><div class="t m0 xb hb y1342 ff17 fs8 fc3 sc0 ls274 ws40d">high as 30%. The fr<span class="_ _a"></span>equent malaria epidemics in southern Africa may<span class="_ _4b"></span>, however<span class="_ _4b"></span>,</div><div class="t m0 xb hb y1343 ff17 fs8 fc3 sc0 ls12 ws0">increase the risk of dual infection. </div><div class="t m0 xb hb y1344 ff17 fs8 fc3 sc0 ls12 ws55f">In Latin America and the Caribbean, some ov<span class="_ _a"></span>erlap of malaria and H<span class="_ _8"></span>IV/AI<span class="_ _8"></span>DS</div><div class="t m0 xb hb y1345 ff17 fs8 fc3 sc0 ls12 ws182">occurs in the general population in Belize, Br<span class="_ _a"></span>azil, El Salvador<span class="_ _4b"></span>, Guatemala,</div><div class="t m0 xb hb y1346 ff17 fs8 fc3 sc0 ls359 ws19e">Guyana and Honduras. South-East Asian countries, such as Cambodia,</div><div class="t m0 xb hb y1347 ff17 fs8 fc3 sc0 ls12 ws56a">Myanmar and <span class="_ _b"></span>Thailand, have a generalized HIV/AI<span class="_ _8"></span>DS epidemic but malaria</div><div class="t m0 xb hb y1348 ff17 fs8 fc3 sc0 ls61 ws86">distribution is heterogeneous in this region. Significant o<span class="_ _a"></span>verlap is likely to occur</div><div class="t m0 xb hb y1349 ff17 fs8 fc3 sc0 ls232 ws90">in a number of Indian cities with urban malaria and increasing HIV transmission.</div><div class="t m0 xb hb y134a ff17 fs8 fc3 sc0 ls22f ws396">Considering that an estimated one billion people in South-East Asia are</div><div class="t m0 xb hb y134b ff17 fs8 fc3 sc0 ls12 ws254">exposed to unstable malaria, it is clear that even a small o<span class="_ _a"></span>verlap of malaria</div><div class="t m0 xb hb y134c ff17 fs8 fc3 sc0 ls12 ws0">and HIV/AI<span class="_ _8"></span>DS in these settings may have a large public health impact.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd2" class="pf w1 h4" data-page-no="d2"><div class="pc pcd2 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">200</div><div class="t m0 x9 h12 y12a ff19 fs6 fc4 sc0 ls9a ws0">A8.2<span class="_ _33"> </span>Evidence of inter<span class="_ _8"></span>actions bet<span class="_ _8"></span>ween malaria </div><div class="t m0 x28 h12 y12b ff19 fs6 fc4 sc0 ls9a ws95">and HIV/AIDS</div><div class="t m0 x9 h2e ycb4 ff19 fs3 fc3 sc0 ls80 ws0">A8.2.1<span class="_ _a7"> </span>Impact of H<span class="_ _8"></span>IV/AIDS on malaria dur<span class="_ _8"></span>ing pregnanc<span class="_ _8"></span>y</div><div class="t m0 x9 hb ycb5 ff17 fs8 fc3 sc0 ls161 ws31e">There is substantial evidence of the effects of interactions betw<span class="_ _a"></span>een malaria and</div><div class="t m0 x9 hb ycb6 ff17 fs8 fc3 sc0 ls64 ws1cb">HIV/AI<span class="_ _8"></span>DS in pregnant women. H<span class="_ _8"></span>IV infection impairs the ability of pregnant</div><div class="t m0 x9 hb ycb7 ff17 fs8 fc3 sc0 ls1bf ws235">women to control a <span class="ff1a ws19b">P<span class="_ _c"></span>. falciparum <span class="ff17 ws0">infection <span class="_ _9"></span></span>(4, 5)<span class="ff17 ws235">. They are more likely to</span></span></div><div class="t m0 x9 hb ycb8 ff17 fs8 fc3 sc0 ls64 ws389">develop clinical and placental malaria, more often hav<span class="_ _a"></span>e detectable malaria</div><div class="t m0 x9 hb ycb9 ff17 fs8 fc3 sc0 ls15c ws229">parasitaemia and have higher malaria par<span class="_ _a"></span>asite densities in peripheral blood <span class="ff1a ws0">(6,</span></div><div class="t m0 x9 hb ycba ff1a fs8 fc3 sc0 ls21e ws0">7)<span class="ff17 ls341 ws25e">. Compared to women with either malaria or HIV infection, co-infected</span></div><div class="t m0 x9 hb ycbb ff17 fs8 fc3 sc0 ls7e ws72">pregnant women are at incr<span class="_ _a"></span>eased risk of anaemia, preterm birth and intrauterine</div><div class="t m0 x9 hb ycbc ff17 fs8 fc3 sc0 lseb ws40d">growth r<span class="_ _a"></span>etardation <span class="ff1a">(8, 9)</span>. As a result, children born to women with dual malaria</div><div class="t m0 x9 hb ycbd ff17 fs8 fc3 sc0 ls17a ws2c2">and HIV infection are at high risk of low bir<span class="_ _8"></span>th weight and death during infancy<span class="_ _4b"></span>. </div><div class="t m0 x9 hb y134d ff17 fs8 fc3 sc0 ls12 ws41a">The presence of HIV/AI<span class="_ _8"></span>DS may result in a poorer response to tr<span class="_ _a"></span>eatment with</div><div class="t m0 x9 hb y134e ff17 fs8 fc3 sc0 ls347 ws549">antimalarials and to intermittent preventiv<span class="_ _a"></span>e treatment for malaria during</div><div class="t m0 x9 hb y134f ff17 fs8 fc3 sc0 ls23b ws481">pregnancy<span class="_ _c"></span>. Fur<span class="_ _8"></span>thermore, there is a risk of adv<span class="_ _a"></span>erse reactions if SP for the</div><div class="t m0 x9 hb y1350 ff17 fs8 fc3 sc0 ls10e ws1c8">prevention of malaria in pr<span class="_ _a"></span>egnant women and cotrimoxazole (a coformulation</div><div class="t m0 x9 hb y1351 ff17 fs8 fc3 sc0 ls143 ws203">of trimethoprim and sulfamethoxazole) for pr<span class="_ _a"></span>ophylaxis against oppor<span class="_ _8"></span>tunistic</div><div class="t m0 x9 hb y1352 ff17 fs8 fc3 sc0 ls12 ws0">infections are taken together<span class="_ _4b"></span>, as both are sulfa-containing medicines.</div><div class="t m0 x9 h2e y1353 ff19 fs3 fc3 sc0 ls80 ws0">A8.2.2<span class="_ _a7"> </span>Impact of H<span class="_ _8"></span>IV/AIDS on malaria in non-pregnant</div><div class="t m0 xba h2e y1354 ff19 fs3 fc3 sc0 ls69 ws0">adults </div><div class="t m0 x9 hb y1355 ff17 fs8 fc3 sc0 ls1a8 ws3b6">Evidence on inter<span class="_ _a"></span>actions between malaria and H<span class="_ _8"></span>IV/AIDS in non-pregnant</div><div class="t m0 x9 hb y1356 ff17 fs8 fc3 sc0 lsed ws2bc">adults is accumulating. In areas with stable malaria, HIV infection increases the</div><div class="t m0 x9 hb y1357 ff17 fs8 fc3 sc0 ls64 ws19f">risk of malaria infection and clinical malaria in adults, especially in those with</div><div class="t m0 x9 hb y1358 ff17 fs8 fc3 sc0 ls2cc wsc9">advanced immunosuppr<span class="_ _a"></span>ession <span class="ff1a ls245 ws0">(10–12)</span>. In settings with unstable malaria, H<span class="_ _8"></span>IV<span class="_ _b"></span>-</div><div class="t m0 x9 hb y1359 ff17 fs8 fc3 sc0 ls229 ws1c8">infected adults with AIDS are at increased risk of severe malaria and death <span class="ff1a ls42 ws0">(13,</span></div><div class="t m0 x9 hb y135a ff1a fs8 fc3 sc0 lsae ws0">14)<span class="ff17 ws21">. Antimalarial treatment failure may be mor<span class="_ _a"></span>e common in H<span class="_ _8"></span>IV<span class="_ _a"></span>-infected adults</span></div><div class="t m0 x9 hb y135b ff17 fs8 fc3 sc0 ls10e ws14">with low CD4 cell counts than in those not infected with HIV <span class="ff1a ws0">(15, 16)<span class="ff17">. </span></span></div><div class="t m0 x9 h2e y135c ff19 fs3 fc3 sc0 ls35a ws56b">A8.2.3<span class="_ _a7"> </span>Effects of malar<span class="_ _8"></span>ia on HIV infection</div><div class="t m0 x9 hb y135d ff17 fs8 fc3 sc0 ls12 ws113">Acute malaria episodes cause a temporary increase in replication of HIV and</div><div class="t m0 x9 hb y135e ff17 fs8 fc3 sc0 ls2f ws3d">hence in plasma viral load <span class="ff1a ls53 ws0">(17)</span>. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, so far there is no evidence that</div><div class="t m0 x9 hb y135f ff17 fs8 fc3 sc0 ls12 ws2a3">malaria has a substantial effect on the clinical progression of HIV infection,</div><div class="t m0 x9 hb y1360 ff17 fs8 fc3 sc0 ls186 ws268">HIV transmission or response to antiretro<span class="_ _a"></span>viral treatment in areas wher<span class="_ _a"></span>e</div><div class="t m0 x9 hb y1361 ff17 fs8 fc3 sc0 ls12 ws0">malaria and HIV overlap. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd3" class="pf w1 h4" data-page-no="d3"><div class="pc pcd3 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4f he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 8 - Malaria treatment and HIV/AIDS</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">201</div><div class="t m0 xb h2e yaa1 ff19 fs3 fc3 sc0 ls80 ws0">A8.2.4<span class="_ _a7"> </span>H<span class="_ _8"></span>IV/AIDS and malaria in children</div><div class="t m0 xb hb y1033 ff17 fs8 fc3 sc0 lsbf ws130">Few studies hav<span class="_ _a"></span>e examined the interaction of malaria and HIV/AI<span class="_ _8"></span>DS in children</div><div class="t m0 xb hb y1034 ff1a fs8 fc3 sc0 ls2cc ws121">(18, 19)<span class="ff17">. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, H<span class="_ _8"></span>IV<span class="_ _b"></span>-infected children with advanced immunosuppression</span></div><div class="t m0 xb hb y1035 ff17 fs8 fc3 sc0 ls22 ws52c">may have more episodes of clinical malaria and higher par<span class="_ _a"></span>asite densities than</div><div class="t m0 xb hb y1036 ff17 fs8 fc3 sc0 ls21f ws1c">those whose immune status is less compromised. In areas of unstable malaria,</div><div class="t m0 xb hb y1037 ff17 fs8 fc3 sc0 ls22 ws2a">HIV-infected childr<span class="_ _a"></span>en may be more likely to experience sever<span class="_ _a"></span>e disease or coma</div><div class="t m0 xb hb y1038 ff1a fs8 fc3 sc0 ls22 ws0">(20)<span class="ff17">. </span></div><div class="t m0 xb h2e y1362 ff19 fs3 fc3 sc0 ls80 ws0">A8.2.5<span class="_ _a7"> </span>Dr<span class="_ _8"></span>ug interactions</div><div class="t m0 xb hb y1363 ff17 fs8 fc3 sc0 ls64 ws56c">There are curr<span class="_ _a"></span>ently no documented clinical or pharmacological interactions</div><div class="t m0 xb hb y1364 ff17 fs8 fc3 sc0 ls35b wsd8">between antimalarials and antiretr<span class="_ _a"></span>ovirals. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, pharmacokinetic interactions</div><div class="t m0 xb hb y1365 ff17 fs8 fc3 sc0 ls350 ws56d">between certain antimalarials and non-nucleoside reverse transcriptase</div><div class="t m0 xb hb y1366 ff17 fs8 fc3 sc0 ls64 ws40d">inhibitors and protease inhibitors are theor<span class="_ _a"></span>etically possible and could lead to</div><div class="t m0 xb hb y1367 ff17 fs8 fc3 sc0 ls8e ws3c7">toxicity<span class="_ _c"></span>. This suggests that patients receiving protease inhibitors (and the</div><div class="t m0 xb hb y1368 ff17 fs8 fc3 sc0 ls88 ws56e">non-nucleoside reverse tr<span class="_ _a"></span>anscriptase inhibitor delavirdine) should avoid</div><div class="t m0 xb hb y1369 ff17 fs8 fc3 sc0 ls2cd wscd">halofantrine. Other antimalarials such as artemether-lumefantrine may also hav<span class="_ _a"></span>e</div><div class="t m0 xb hb y136a ff17 fs8 fc3 sc0 ls64 ws0">the potential to interact with antiretr<span class="_ _a"></span>ovirals. </div><div class="t m0 xb hb y136b ff17 fs8 fc3 sc0 ls1d3 ws2f2">Medicines used in the management of opportunistic infections in people</div><div class="t m0 xb hb y136c ff17 fs8 fc3 sc0 lse2 ws138">living with H<span class="_ _8"></span>IV/AIDS may also interact with antimalarials <span class="ff1a ws0">(21)</span>. Interactions are</div><div class="t m0 xb hb y136d ff17 fs8 fc3 sc0 ls16b ws242">possible between cotrimoxaz<span class="_ _a"></span>ole, which is used for prophylaxis of oppor<span class="_ _8"></span>tunistic</div><div class="t m0 xb hb y136e ff17 fs8 fc3 sc0 ls112 ws1c4">infections, and SP<span class="_ _c"></span>, which is used for intermittent preventiv<span class="_ _a"></span>e treatment of</div><div class="t m0 xb hb y136f ff17 fs8 fc3 sc0 ls3a ws1b2">malaria in pregnant women in some parts of Africa. It is recommended that SP</div><div class="t m0 xb hb y1370 ff17 fs8 fc3 sc0 ls12 ws37d">should not be given if co-trimo<span class="_ _a"></span>xazole is being taken daily as this probably</div><div class="t m0 xb hb y1371 ff17 fs8 fc3 sc0 ls12 ws111">pro<span class="_ _a"></span>vides an equivalent antimalarial effect. <span class="_ _a"></span>While more research is r<span class="_ _a"></span>equired,</div><div class="t m0 xb hb y1372 ff17 fs8 fc3 sc0 ls21b ws2d9">emphasis should be placed on close monitoring and pharmacovigilance in the</div><div class="t m0 xb hb y1373 ff17 fs8 fc3 sc0 ls12 ws0">treatment of malaria and HIV/AI<span class="_ _8"></span>DS.</div><div class="t m0 xb h12 y1374 ff19 fs6 fc4 sc0 ls0 ws95">A8.3<span class="_ _33"> </span>Implic<span class="_ _8"></span>ations for health sy<span class="_ _8"></span>stems </div><div class="t m0 xa4 h12 y1375 ff19 fs6 fc4 sc0 ls0 ws95">and ser<span class="_ _9"></span>vice deliver<span class="_ _8"></span>y </div><div class="t m0 xb hb y1376 ff17 fs8 fc3 sc0 lsc1 ws132">In HIV-infected individuals, the use of a malaria case definition based on</div><div class="t m0 xb hb y1377 ff17 fs8 fc3 sc0 ls12 ws50c">fever alone can result in a febrile illness that may be due to a wide r<span class="_ _a"></span>ange of</div><div class="t m0 xb hb y1378 ff17 fs8 fc3 sc0 ls26b ws3f1">ordinary<span class="_ _4b"></span>, virulent and oppor<span class="_ _8"></span>tunistic infections being misdiagnosed and treated</div><div class="t m0 xb hb y1379 ff17 fs8 fc3 sc0 ls37 wsc0">as malaria <span class="ff1a">(22, 23)</span>. This may lead to inappr<span class="_ _a"></span>opriate care of HIV-infected adults</div><div class="t m0 xb hb y137a ff17 fs8 fc3 sc0 ls12 ws33d">with severe febrile illnesses due to causes other than malaria. <span class="_ _b"></span>With the use</div><div class="t m0 xb hb y137b ff17 fs8 fc3 sc0 lsf ws12f">of more costly antimalarials, it has become necessary to give greater emphasis</div><div class="t m0 xb hb y137c ff17 fs8 fc3 sc0 ls95 wsec">to parasitological diagnosis <span class="ff1a ws0">(24)</span>, and this is particularly impor<span class="_ _8"></span>tant in areas of</div><div class="t m0 xb hb y137d ff17 fs8 fc3 sc0 ls12 ws0">high prev<span class="_ _a"></span>alence of H<span class="_ _8"></span>IV infection.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd4" class="pf w1 h4" data-page-no="d4"><div class="pc pcd4 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">202</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 lsc9 ws13d">In areas affected by malaria and HIV/AI<span class="_ _8"></span>DS, integrated health services are crucial</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls35c ws56f">for the introduction of new drugs and diagnostic materials, and offer</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls12 ws0">opportunities for joint planning, training and ser<span class="_ _8"></span>vice delivery<span class="_ _4b"></span>. </div><div class="t m0 x9 h12 y137e ff19 fs6 fc4 sc0 ls86 wsca">A8.4<span class="_ _33"> </span>Ke<span class="_ _8"></span>y recommendations </div><div class="t m0 x9 hd y137f ff1e fs8 fc3 sc0 ls12 ws0">WHO makes the following recommendations (25).</div><div class="t m0 x1b h1e y1380 ff1b fs8 fc3 sc0 ls0 ws2e6">•<span class="_ _7a"> </span>HIV<span class="_ _a"></span>-infected pregnant women in areas with stable malaria should –</div><div class="t m0 x37 h1e y1381 ff1b fs8 fc3 sc0 ls12 ws570">depending on the stage of HIV infection – receive either intermittent</div><div class="t m0 x37 h1e y1382 ff1b fs8 fc3 sc0 ls56 ws72">preventiv<span class="_ _a"></span>e treatment for malaria with at least three doses of sulfado<span class="_ _a"></span>xine-</div><div class="t m0 x37 h1e y1383 ff1b fs8 fc3 sc0 ls37 ws48">pyrimethamine or daily cotrimoxazole pr<span class="_ _a"></span>ophylaxis for HIV/AI<span class="_ _8"></span>DS oppor-</div><div class="t m0 x37 h1e y1384 ff1b fs8 fc3 sc0 ls224 ws11e">tunistic infections. Malarial illness in HIV<span class="_ _a"></span>-infected pregnant women</div><div class="t m0 x37 h1e y1385 ff1b fs8 fc3 sc0 ls12 ws28c">who are receiving cotrimo<span class="_ _a"></span>xazole prophylaxis should be managed with</div><div class="t m0 x37 h1e y1386 ff1b fs8 fc3 sc0 ls12 ws0">non-sulfa antimalarials. </div><div class="t m0 x1b h1e y1387 ff1b fs8 fc3 sc0 ls191 ws278">•<span class="_ _7a"> </span>In areas with stable malaria and a high prev<span class="_ _a"></span>alence of HIV infection, use</div><div class="t m0 x37 h1e y1388 ff1b fs8 fc3 sc0 ls12 ws571">of a fever<span class="_ _b"></span>-based malaria case definition may result in febrile illnesses</div><div class="t m0 x37 h1e y1389 ff1b fs8 fc3 sc0 ls28f ws42a">caused by opportunistic infections being misdiagnosed as malaria,</div><div class="t m0 x37 h1e y138a ff1b fs8 fc3 sc0 ls47 ws67">leading to ov<span class="_ _a"></span>er<span class="_ _8"></span>treatment of malaria. Confirmatory parasitological testing</div><div class="t m0 x37 h1e y138b ff1b fs8 fc3 sc0 ls12 ws572">for malaria should be applied with high priority in patients at risk of</div><div class="t m0 x37 h1e y138c ff1b fs8 fc3 sc0 ls2cc ws47e">HIV/AI<span class="_ _8"></span>DS (in particular in older children and adults). In addition, health</div><div class="t m0 x37 h1e y138d ff1b fs8 fc3 sc0 ls12 ws0">pro<span class="_ _a"></span>viders should offer H<span class="_ _8"></span>IV testing and counselling. </div><div class="t m0 x1b h1e y138e ff1b fs8 fc3 sc0 ls12 ws2a5">•<span class="_ _7a"> </span>In countries with generalized HIV/AIDS epidemics, routine monitoring</div><div class="t m0 x37 h1e y138f ff1b fs8 fc3 sc0 ls185 wscc">of antimalarial drug efficacy or effectiveness should include assessment</div><div class="t m0 x37 h1e y1390 ff1b fs8 fc3 sc0 ls12 ws0">of the effect of HIV on antimalarial treatment outcomes.</div><div class="t m0 x1b h1e y1391 ff1b fs8 fc3 sc0 ls218 ws216">•<span class="_ _7a"> </span>Further research should be undertaken to evaluate possible interactions</div><div class="t m0 x37 h1e y1392 ff1b fs8 fc3 sc0 ls21a ws373">between antimalarials and antiretr<span class="_ _a"></span>ovirals, and pharmaco<span class="_ _a"></span>vigilance</div><div class="t m0 x37 h1e y1393 ff1b fs8 fc3 sc0 ls17b ws258">should be introduced to monitor adverse drug r<span class="_ _a"></span>eactions for both the new</div><div class="t m0 x37 h1e y1394 ff1b fs8 fc3 sc0 ls12 ws0">antimalarials and antiretro<span class="_ _a"></span>virals.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd5" class="pf w1 h4" data-page-no="d5"><div class="pc pcd5 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x4f he y9 ff16 fs5 fc3 sc0 lsee ws2">Annex 8 - Malaria treatment and HIV/AIDS</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">203</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls1 ws0">A8.5<span class="_ _52"> </span>References</div><div class="t mc xb h17 yf53 ff17 fsb fc3 sc0 ls105 ws0">1.<span class="_ _46"> </span>Hay S et al. The global distribution and population at risk of malaria: past,</div><div class="t mc x4d h17 yf54 ff17 fsb fc3 sc0 ls105 ws0">present, and future. <span class="ff1a">Lancet Infectious Diseases</span>, 2004, 4:327–336.</div><div class="t mc xb h17 yf55 ff17 fsb fc3 sc0 ls105 ws0">2.<span class="_ _54"> </span><span class="ff1a">UNAI<span class="_ _8"></span>DS 2004 report on the global AI<span class="_ _8"></span>DS epidemic</span>. Geneva, Joint United Nations</div><div class="t mc x4d h17 yf56 ff17 fsb fc3 sc0 ls105 ws0">Progr<span class="_ _a"></span>amme on H<span class="_ _8"></span>IV/AI<span class="_ _8"></span>DS, 2004 (UN<span class="_ _8"></span>AIDS. Repor<span class="_ _8"></span>t on the global H<span class="_ _8"></span>IV/AIDS</div><div class="t mc x4d h17 y1395 ff17 fsb fc3 sc0 ls105 ws0">epidemic. June 2004).</div><div class="t mc xb h17 yf58 ff17 fsb fc3 sc0 ls105 ws0">3.<span class="_ _44"> </span>Korenromp EL<span class="_ _67"> </span>et al. Measurement of trends in childhood malaria mor<span class="_ _8"></span>tality in</div><div class="t mc x4d h17 y1396 ff17 fsb fc3 sc0 ls105 ws0">Africa: an assessment of progress to<span class="_ _a"></span>wards targets based on verbal autopsy<span class="_ _c"></span>.</div><div class="t mc x4d h17 y1397 ff1a fsb fc3 sc0 ls105 ws0">Lancet Infectious Diseases<span class="ff17 ls1dc ws1d2">, 2003, 3:349–358.</span></div><div class="t mc xb h17 yf5b ff17 fsb fc3 sc0 ls105 ws0">4.<span class="_ _44"> </span>Steketee RW et al. Impairment of a pregnant woman<span class="_ _b"></span>’<span class="_ _b"></span>s acquired ability to limit</div><div class="t mc x4d h17 y1398 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum <span class="ff17 ws19a">by infection with human immunodeficiency virus type-1.</span></div><div class="t mc x4d h17 y1399 ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 1996, 55:42–49.</span></div><div class="t mc xb h17 yf5e ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>T<span class="_ _4b"></span>er Kuile F et al. <span class="_ _a"></span>The burden of co-infection with human immunodeficiency virus</div><div class="t mc x4d h17 y139a ff17 fsb fc3 sc0 ls105 ws0">type 1 and malaria in pregnant women in sub-Saharan Africa. <span class="ff1a">American Journal of</span></div><div class="t mc x4d h17 y139b ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 2004, 71:41–54. </span></div><div class="t mc xb h17 yf61 ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>van Eijk et al. Human immunodeficiency virus seropositivity and malaria as risk</div><div class="t mc x4d h17 y139c ff17 fsb fc3 sc0 ls105 ws0">factors for third-trimester anemia in asymptomatic pregnant women in western</div><div class="t mc x4d h17 y139d ff17 fsb fc3 sc0 ls105 ws0">K<span class="_ _a"></span>enya. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 2001, 65:623–630.</span></span></div><div class="t mc xb h17 y139e ff17 fsb fc3 sc0 ls105 ws1d4">7.<span class="_ _39"> </span>van Eijk AM et al. <span class="_ _a"></span>The effect of dual infection with HIV and malaria on pregnancy</div><div class="t mc x4d h17 y139f ff17 fsb fc3 sc0 ls105 ws0">outcome in western K<span class="_ _b"></span>enya. <span class="_ _8"></span><span class="ff1a lsd6">AIDS<span class="ff17 ws19a">, 2003, 17, 585–594.</span></span></div><div class="t mc xb h17 y13a0 ff17 fsb fc3 sc0 ls105 ws0">8.<span class="_ _44"> </span>Bloland PB et al. Maternal HIV infection and infant mor<span class="_ _8"></span>tality in Malawi: evidence</div><div class="t mc x4d h17 y13a1 ff17 fsb fc3 sc0 ls105 ws0">for increased mortality due to placental malaria infection. <span class="ff1a lsd6">AI<span class="_ _8"></span>DS<span class="ff17 ws19a">, 1995, 9:721–726.</span></span></div><div class="t mc xb h17 y13a2 ff17 fsb fc3 sc0 ls105 ws0">9.<span class="_ _44"> </span>Inion I et al. Placental malaria and perinatal transmission of human immuno-</div><div class="t mc x4d h17 y13a3 ff17 fsb fc3 sc0 ls105 ws0">deficiency virus type 1. <span class="ff1a">Journal of Infectious Diseases</span>, 2003, 188:1675–1678. </div><div class="t mc xb h17 y13a4 ff17 fsb fc3 sc0 ls105 ws19a">10.<span class="_ _68"> </span>L<span class="_ _a"></span>eaver RJ, Haile Z, <span class="_ _a"></span>Watters D<span class="_ _a"></span>A. H<span class="_ _8"></span>IV and cerebral malaria. <span class="ff1a ws0">T<span class="_ _b"></span>ransactions of the</span></div><div class="t mc x4d h17 y13a5 ff1a fsb fc3 sc0 ls105 ws0">Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 1990, 84:201. </span></div><div class="t mc xb h17 y13a6 ff17 fsb fc3 sc0 ls105 ws0">11.<span class="_ _0"> </span>Niyongabo <span class="_ _a"></span>T et al. Prognostic indicators in adult cer<span class="_ _a"></span>ebral malaria: a study in</div><div class="t mc x4d h17 y13a7 ff17 fsb fc3 sc0 ls105 ws0">Burundi, an area of high prev<span class="_ _a"></span>alence of HIV infection. <span class="_ _8"></span><span class="ff1a ws27d">Acta T<span class="_ _b"></span>ropica<span class="ff17 ws0">, 1994,</span></span></div><div class="t mc x4d h17 y13a8 ff17 fsb fc3 sc0 ls105 ws0">56:299–305. </div><div class="t mc xb h17 y13a9 ff17 fsb fc3 sc0 ls105 ws0">12.<span class="_ _68"> </span>Whitworth J et al. Effect of H<span class="_ _8"></span>IV<span class="_ _a"></span>-1 and increasing immunosuppression on malaria</div><div class="t mc x4d h17 y13aa ff17 fsb fc3 sc0 ls105 ws0">parasitaemia and clinical episodes in adults in rural U<span class="_ _a"></span>ganda: a cohor<span class="_ _8"></span>t study<span class="_ _4b"></span>.</div><div class="t mc x4d h17 y13ab ff1a fsb fc3 sc0 ls105 ws0">Lancet<span class="ff17 ls2e2 ws1d3">, 2000, 356:1051–1056. </span></div><div class="t mc xb h17 y13ac ff17 fsb fc3 sc0 ls105 ws0">13.<span class="_ _68"> </span>Khasnis AA, Karnad DR. Human immunodeficiency virus type 1 infection in</div><div class="t mc x4d h17 y13ad ff17 fsb fc3 sc0 ls105 ws0">patients with severe falciparum malaria in urban India. <span class="ff1a">Journal of P<span class="_ _a"></span>ostgraduate</span></div><div class="t mc x4d h17 y13ae ff1a fsb fc3 sc0 ls105 ws0">Medicine<span class="ff17">, 2003, 49:114–117.</span></div><div class="t mc xb h17 y13af ff17 fsb fc3 sc0 ls105 ws0">14.<span class="_ _3"> </span>Grimwade K et al. H<span class="_ _8"></span>IV infection as a cofactor for severe falciparum malaria in</div><div class="t mc x4d h17 y13b0 ff17 fsb fc3 sc0 ls105 ws0">adults living in a region of unstable malaria transmission in South Africa. <span class="ff1a lsd6">AIDS</span><span class="ls0">,</span></div><div class="t mc x4d h17 y13b1 ff17 fsb fc3 sc0 ls105 ws0">2004, 18:547–554.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd6" class="pf w1 h4" data-page-no="d6"><div class="pc pcd6 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">204</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">15.<span class="_ _68"> </span>Colebunders R et al. Incidence of malaria and efficacy of oral quinine in patients</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">recently infected with human immunodeficiency virus in Kinshasa, Zaire. <span class="ff1a">Journal</span></div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">of Infection<span class="ff17 ls2e2 ws1d3">, 1990, 21:167–173.</span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">16.<span class="_ _3"> </span>Birku Y et al. Delayed clearance of <span class="ff1a">Plasmodium falciparum </span>in patients with</div><div class="t mc x7a h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">human immunodeficiency virus co-infection treated with artemisinin. <span class="ff1a">Ethiopian</span></div><div class="t mc x7a h17 yd66 ff1a fsb fc3 sc0 ls105 ws0">Medical Journal<span class="ff17 ws19a">, 2002, 40(Suppl. 1):17–26. </span></div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls105 ws19a">17.<span class="_ _68"> </span>James G K et al. Effect of <span class="ff1a ws0">Plasmodium falciparum <span class="ff17">malaria on concentration of H<span class="_ _8"></span>IV<span class="_ _b"></span>-</span></span></div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">1-RNA in the blood of adults in rural Malawi: a prospective cohort study<span class="_ _4b"></span>. <span class="_ _8"></span><span class="ff1a">Lancet</span><span class="ls0">,</span></div><div class="t mc x7a h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">2005, 365:233–240.</div><div class="t mc x9 h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">18.<span class="_ _3"> </span>Nguyen-Dinh et al. Absence of association between <span class="ff1a">Plasmodium falciparum</span></div><div class="t mc x7a h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">malaria and human immunodeficiency virus infection in children in Kinshasa,</div><div class="t mc x7a h17 yd89 ff17 fsb fc3 sc0 ls105 ws0">Zaire. <span class="ff1a ws19a">Bulletin of the <span class="_ _a"></span>World Health Or<span class="_ _a"></span>ganization<span class="ff17">, 1987, 65:607–613. </span></span></div><div class="t mc x9 h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">19.<span class="_ _3"> </span>T<span class="_ _b"></span>aha T<span class="_ _67"> </span>et al. Childhood malaria parasitaemia and human immunodeficiency virus</div><div class="t mc x7a h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">infection in Malawi. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yeca ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17">, 1994, 88:164–165. </span></div><div class="t mc x9 h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">20.<span class="_ _5"> </span>Grimwade K et al. Childhood malaria in a region of unstable transmission and</div><div class="t mc x7a h17 yd8e ff17 fsb fc3 sc0 ls105 ws0">high human immunodeficiency virus prev<span class="_ _a"></span>alence. <span class="ff1a">Pediatric Infectious Disease</span></div><div class="t mc x7a h17 yecd ff1a fsb fc3 sc0 ls105 ws0">Journal<span class="ff17 ls2e2 ws1d3">, 2003, 22:1057–1063. </span></div><div class="t mc x9 h17 yd90 ff17 fsb fc3 sc0 ls105 ws0">21.<span class="_ _68"> </span>L<span class="_ _a"></span>efèvre G et al. Pharmacokinetics and electrocardiogr<span class="_ _a"></span>aphic pharmacodynamics</div><div class="t mc x7a h17 yd91 ff17 fsb fc3 sc0 ls105 ws0">of artemether-lumefantrine (Riamet®®) with concomitant administr<span class="_ _a"></span>ation of</div><div class="t mc x7a h17 yed0 ff17 fsb fc3 sc0 ls105 ws0">ketoconazole in healthy subjects. <span class="ff1a">British Journal of Clinical Pharmacology</span>, 2002,</div><div class="t mc x7a h17 yed1 ff17 fsb fc3 sc0 ls105 ws0">54:485–492</div><div class="t mc x9 h17 yf78 ff17 fsb fc3 sc0 ls105 ws0">22.<span class="_ _5"> </span>Francesconi P et al. HIV<span class="_ _4b"></span>, malaria parasites, and acute febrile episodes in Ugandan</div><div class="t mc x7a h17 yed3 ff17 fsb fc3 sc0 ls105 ws0">adults: a case–control study<span class="_ _4b"></span>. <span class="ff1a lsd6">AIDS</span>, 2001, 15:2445–450.</div><div class="t mc x9 h17 ydb0 ff17 fsb fc3 sc0 ls105 ws0">23.<span class="_ _95"> </span>Fr<span class="_ _a"></span>ench N et al. Increasing rates of malarial fever with deterior<span class="_ _a"></span>ating immune</div><div class="t mc x7a h17 y118f ff17 fsb fc3 sc0 ls105 ws0">status in HIV-1-infected U<span class="_ _a"></span>gandan adults. <span class="ff1a lsd6">AIDS</span><span class="ls137 ws1d4">, 2001, 15:899–906.</span></div><div class="t mc x9 h4d yd95 ff1a fsb fc3 sc0 ls137 ws0">24.<span class="_ _5"> </span>The role of laboratory diagnosis to suppor<span class="_ _8"></span>t malaria disease management: focus</div><div class="t mc x7a h4d ydb1 ff1a fsb fc3 sc0 ls137 ws0">on the use of RDT<span class="_ _4b"></span>s in areas of high transmission deploying A<span class="_ _a"></span>CT treatment.</div><div class="t mc x7a h17 ydb2 ff17 fsb fc3 sc0 ls137 ws0">Geneva, <span class="_ _b"></span>World Health Organization, in press. </div><div class="t mc x9 h4d ydb3 ff1a fsb fc3 sc0 ls137 ws0">25.<span class="_ _95"> </span>Report of a technical consultation: malaria and H<span class="_ _8"></span>IV interactions and their</div><div class="t mc x7a h17 ydb4 ff1a fsb fc3 sc0 ls130 ws19a">implications for public health policy: Geneva, Switz<span class="_ _a"></span>erland, 23–25 June 2004<span class="ff17 ls0 ws0">.</span></div><div class="t mc x7a h17 ydb5 ff17 fsb fc3 sc0 ls105 ws0">Geneva, <span class="_ _b"></span>World Health Organization, 2004.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd7" class="pf w1 h4" data-page-no="d7"><div class="pc pcd7 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 y13b2 ff1b fs10 fc7 sc0 ls270 ws0">Annex 9.<span class="_ _2d"> </span><span class="fc0">T<span class="_ _b"></span>reatment of sever<span class="_ _a"></span>e <span class="ff1f">P<span class="_ _ae"></span>. falciparum <span class="ff1b">malaria<span class="_ _cc"> </span><span class="fc4 ls35d">207</span></span></span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd8" class="pf w1 h4" data-page-no="d8"><div class="pc pcd8 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd9" class="pf w1 h4" data-page-no="d9"><div class="pc pcd9 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">207</div><div class="t m0 x94 hf y7d ff18 fs6 fc3 sc0 ls271 ws408">ANNEX 9</div><div class="t m0 x26 hf y895 ff18 fs6 fc3 sc0 ls1 ws17a">TREAT<span class="_ _b"></span>M<span class="_ _8"></span>ENT OF SEVER<span class="_ _8"></span>E <span class="ff2e ws0">P<span class="_ _c"></span>. F<span class="_ _a"></span>ALCIP<span class="_ _b"></span>ARUM <span class="ff18">MAL<span class="_ _8"></span>AR<span class="_ _8"></span>IA</span></span></div><div class="t m0 xb h12 y896 ff19 fs6 fc4 sc0 ls0 ws95">A9.1<span class="_ _33"> </span>Is a loading dose of quinine (20 mg/kg) super<span class="_ _8"></span>ior</div><div class="t m0 xa4 h12 y119e ff19 fs6 fc4 sc0 ls1 ws0">to no loading dose?</div><div class="t m0 xb h23 y13b3 ff1e fs11 fc8 sc0 ls27a ws0">Summar<span class="_ _8"></span>y</div><div class="t m0 xb hb y13b4 ff17 fs8 fc3 sc0 ls2cc ws47e">One systematic review<span class="_ _b"></span>, and one subsequent randomized controlled trial (RCT)</div><div class="t m0 xb hb y13b5 ff17 fs8 fc3 sc0 ls9d wsfc">in children found no significant difference in mortality between quinine</div><div class="t m0 xb hb y13b6 ff17 fs8 fc3 sc0 ls12 ws545">regimens with a high initial quinine dose and those with no loading dose.</div><div class="t m0 xb hb y13b7 ff17 fs8 fc3 sc0 ls12 ws0">Howev<span class="_ _a"></span>er<span class="_ _b"></span>, parasite and fever clear<span class="_ _a"></span>ance times were reduced in the former<span class="_ _4b"></span>.</div><div class="t m0 xb h23 y13b8 ff1e fs11 fc8 sc0 ls27a ws0">Benefits </div><div class="t m0 xb hb y13b9 ff17 fs8 fc3 sc0 ls12 ws573">One systematic review (search date 2002, thr<span class="_ _a"></span>ee RCT<span class="_ _4b"></span>s, 92 people) <span class="ff1a ls13 ws0">(1)</span><span class="ws574">. One</span></div><div class="t m0 xb hb y13ba ff17 fs8 fc3 sc0 ls13 ws14">subsequent RCT <span class="ff1a ls14 ws0">(2)</span><span class="ws0">. </span></div><div class="t m0 xb hb y13bb ff17 fs8 fc3 sc0 ls64 wse3">The systematic review found no significant difference in mortality between a</div><div class="t m0 xb hb y13bc ff17 fs8 fc3 sc0 ls7f ws25d">group receiving a high initial dose of quinine (20 mg salt/kg or 16 mg base/kg</div><div class="t m0 xb hb y13bd ff17 fs8 fc3 sc0 ls22c ws2f4">given by the intramuscular (i.m.) r<span class="_ _a"></span>oute or by i.v<span class="_ _b"></span>. infusion) followed by a standar<span class="_ _a"></span>d</div><div class="t m0 xb hb y13be ff17 fs8 fc3 sc0 ls1fa ws110">dose of quinine, and one receiving the standard dose but no loading dose (two</div><div class="t m0 xb hb y13bf ff17 fs8 fc3 sc0 lsc4 ws10a">RCT<span class="_ _4b"></span>s; 2/35 (5.7%) died in the group receiving a high initial dose, 5/37 (13.5%)</div><div class="t m0 xb hb y13c0 ff17 fs8 fc3 sc0 ls64 ws3a9">with no loading dose; RR: 0.43; 95% CI: 0.09–2.15) <span class="ff1a ws0">(1)</span>. One of the RCT<span class="_ _4b"></span>s (39</div><div class="t m0 xb hb y13c1 ff17 fs8 fc3 sc0 lsa8 ws225">children) found no significant difference betw<span class="_ _a"></span>een the two groups in mean</div><div class="t m0 xb hb y13c2 ff17 fs8 fc3 sc0 ls2f wsa7">time to reco<span class="_ _a"></span>ver consciousness (14 h with a high initial dose, 13 h with no</div><div class="t m0 xb hb y13c3 ff17 fs8 fc3 sc0 ls25c ws2a">loading dose, weighted mean difference (WMD) 1.0 h; 95% CI: –8.8 h to +10.8 h)</div><div class="t m0 xb hb y13c4 ff1a fs8 fc3 sc0 lsfe ws0">(3)<span class="ff17 ls61 ws175">. Parasite clear<span class="_ _a"></span>ance and fever clearance times wer<span class="_ _a"></span>e shor<span class="_ _8"></span>ter for the high initial</span></div><div class="t m0 xb hb y13c5 ff17 fs8 fc3 sc0 ls64 ws101">dose group than for the group with no loading dose (par<span class="_ _a"></span>asite clearance time:</div><div class="t m0 xb hb y13c6 ff17 fs8 fc3 sc0 lsa0 ws78">two RCT<span class="_ _4b"></span>s, 67 people, WMD 7.4 h; 95% CI: –13.2 h to –1.6 h; fever clearance time,</div><div class="t m0 xb hb y13c7 ff17 fs8 fc3 sc0 ls3b ws26">two RCT<span class="_ _4b"></span>s, 68 people, WMD –11.1 h; 95% CI: –20.0 h to –2.2 h). The subsequent</div><div class="t m0 xb hb y13c8 ff17 fs8 fc3 sc0 ls2ab ws282">RCT (72 childr<span class="_ _a"></span>en aged 8 months to15 years in T<span class="_ _c"></span>ogo, 1999–2000) found no</div><div class="t m0 xb hb y13c9 ff17 fs8 fc3 sc0 ls64 ws575">significant difference between the gr<span class="_ _a"></span>oup receiving a high initial dose of i.v<span class="_ _b"></span>.</div><div class="t m0 xb hb y13ca ff17 fs8 fc3 sc0 ls96 ws481">quinine (20 mg salt/kg ov<span class="_ _a"></span>er 4 h, then 10 mg salt/kg every 12 h) and that</div><div class="t m0 xb hb y13cb ff17 fs8 fc3 sc0 ls64 ws22f">receiving no loading dose (15 mg salt/kg every 12 h) in mortality (2/35 (6%)</div><div class="t m0 xb hb y13cc ff17 fs8 fc3 sc0 ls64 ws576">with a high initial dose, 2/37 (5%) with no loading dose, RR: 1.06; 95% CI:</div><div class="t m0 xb hb y13cd ff17 fs8 fc3 sc0 ls21f ws0">0.16–7.1) <span class="_ _a"></span><span class="ff1a">(2). <span class="ff17 ws4b4">It also found no significant difference betw<span class="_ _a"></span>een the two groups for</span></span></div><div class="t m0 xb hb y13ce ff17 fs8 fc3 sc0 ls25a ws174">reco<span class="_ _a"></span>very of consciousness (35.5 h with a high initial dose, 28.6 h with no</div><div class="t m0 xb hb y13cf ff17 fs8 fc3 sc0 ls21f ws4b4">loading dose, WMD: +6.9 h; 95% CI: –0.6 h to +14.4 h) or time to 100% parasite</div><div class="t m0 xb hb y13d0 ff17 fs8 fc3 sc0 ls64 ws0">clearance (48 h compared to 60 h).</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfda" class="pf w1 h4" data-page-no="da"><div class="pc pcda w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1b ws0">208</div><div class="t m0 x9 h23 yd3c ff1e fs11 fc8 sc0 ls27a ws0">Harms </div><div class="t m0 x9 hb y13d1 ff17 fs8 fc3 sc0 ls12 ws49f">The systematic review found no significant difference betw<span class="_ _a"></span>een the groups</div><div class="t m0 x9 hb y13d2 ff17 fs8 fc3 sc0 ls35e ws2d8">receiving a high initial dose of quinine and no loading dose in rate of</div><div class="t m0 x9 hb y13d3 ff17 fs8 fc3 sc0 ls27 ws30">hypoglycaemia (two RCT<span class="_ _c"></span>s; 4/35 (11%) hypoglycaemia with a high initial dose,</div><div class="t m0 x9 hb y13d4 ff17 fs8 fc3 sc0 ls13 ws127">3/37 (8%) with no loading dose, RR: 1.39; 95% CI: 0.32–6.00) <span class="ff1a ws0">(1)</span>. In one RCT</div><div class="t m0 x9 hb y13d5 ff17 fs8 fc3 sc0 ls35f ws577">(33 people) included in the review<span class="_ _b"></span>, transient par<span class="_ _8"></span>tial hearing loss was</div><div class="t m0 x9 hb y13d6 ff17 fs8 fc3 sc0 ls44 ws93">significantly increased in the group r<span class="_ _a"></span>eceiving a high initial dose (10/17 (59%)</div><div class="t m0 x9 hb y13d7 ff17 fs8 fc3 sc0 ls4e ws232">compared to 3/16 (19%), RR: 3.14; 95% CI: 1.05–9.38) <span class="ff1a ls297 ws0">(4)</span>. In another (39</div><div class="t m0 x9 hb y13d8 ff17 fs8 fc3 sc0 ls29c ws43b">children), there was no significant differ<span class="_ _a"></span>ence between the two groups in</div><div class="t m0 x9 hb y13d9 ff17 fs8 fc3 sc0 ls13 ws31">neurological sequelae (1/18 (6%) with a high initial dose, 2/21 (10%) with no</div><div class="t m0 x9 hb y13da ff17 fs8 fc3 sc0 ls12 ws0">loading dose, RR: 0.58; 95% CI: 0.06–5.91) <span class="ff1a ls14">(3)</span><span class="ls0">.</span></div><div class="t m0 x9 h12 y13db ff19 fs6 fc4 sc0 ls1c ws144">A9.2<span class="_ _33"> </span>Is intramuscular quinine as effective as</div><div class="t m0 x28 h12 y13dc ff19 fs6 fc4 sc0 ls52 ws578">intravenous quinine?</div><div class="t m0 x9 h23 y13dd ff1e fs11 fc8 sc0 ls279 ws0">Summar<span class="_ _8"></span>y </div><div class="t m0 x9 hb y13de ff17 fs8 fc3 sc0 ls24d ws1a2">One RCT in childr<span class="_ _a"></span>en found no significant difference between i.m. and i.v<span class="_ _4b"></span>.</div><div class="t m0 x9 hb y13df ff17 fs8 fc3 sc0 ls12 ws579">quinine in reco<span class="_ _a"></span>very times or death. However<span class="_ _4b"></span>, the study may have lacked the</div><div class="t m0 x9 hb y13e0 ff17 fs8 fc3 sc0 ls12 ws0">power to detect clinically important differences between treatments.</div><div class="t m0 x9 h23 y13e1 ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 x9 hb y13e2 ff17 fs8 fc3 sc0 ls5f ws84">No systematic review<span class="_ _b"></span>. One RCT (59 childr<span class="_ _a"></span>en aged <span class="ff1c ls0 ws0">&lt;</span><span class="ls16b ws242">12 years, K<span class="_ _b"></span>enya, 1989-1990),</span></div><div class="t m0 x9 hb y13e3 ff17 fs8 fc3 sc0 ls244 ws19f">which compared i.m. quinine (20 mg salt/kg loading immediately follow<span class="_ _a"></span>ed by</div><div class="t m0 x9 hb y13e4 ff17 fs8 fc3 sc0 ls14 ws57a">10 mg salt/kg every 12 h) with standard-dose quinine giv<span class="_ _a"></span>en by i.v<span class="_ _b"></span>. infusion</div><div class="t m0 x9 hb y13e5 ff17 fs8 fc3 sc0 ls1a9 ws262">(10 mg salt/kg every 12 h) in sever<span class="_ _a"></span>e falciparum malaria <span class="ff1a ws0">(3)</span><span class="ls31b ws2c2">. The trial found no</span></div><div class="t m0 x9 hb y13e6 ff17 fs8 fc3 sc0 ls12 ws57b">significant difference in mortality<span class="_ _4b"></span>, mean parasite clearance time or reco<span class="_ _a"></span>very</div><div class="t m0 x9 hb y13e7 ff17 fs8 fc3 sc0 ls142 ws202">time to drinking or walking, but may have lacked the pow<span class="_ _a"></span>er to detect a</div><div class="t m0 x9 hb y13e8 ff17 fs8 fc3 sc0 ls222 ws343">clinically important difference (mor<span class="_ _8"></span>tality: 3/20 (15%) deaths with i.m. quinine,</div><div class="t m0 x9 hb y13e9 ff17 fs8 fc3 sc0 ls2ad ws464">1/18 (5.6%) with i.v<span class="_ _4b"></span>. quinine, RR: 2.7; 95% CI: 0.3–23.7; mean parasite</div><div class="t m0 x9 hb y13ea ff17 fs8 fc3 sc0 ls32c ws444">clearance time: 57 h compared to 58 h, <span class="_ _b"></span>WM<span class="_ _8"></span>D: –1.0 h; 95% CI: –12.2 h to</div><div class="t m0 x9 hb y13eb ff17 fs8 fc3 sc0 ls1d8 ws173">+10.2 h; mean reco<span class="_ _a"></span>very times to drinking 47 h compared to 32 h, <span class="_ _a"></span>WM<span class="_ _8"></span>D: +15 h;</div><div class="t m0 x9 hb y13ec ff17 fs8 fc3 sc0 ls12 ws42b">95% CI: –5.6 h to + 35.6 h; mean reco<span class="_ _a"></span>very times to walking: 98 h compared</div><div class="t m0 x9 hb y13ed ff17 fs8 fc3 sc0 ls12 ws0">to 96 h, WMD: +2.0 h; 95% CI: –24.5 h to +28.5 h).</div><div class="t m0 x9 h23 y13ee ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 x9 hb y13ef ff17 fs8 fc3 sc0 lsae ws118">Neurological sequelae wer<span class="_ _a"></span>e repor<span class="_ _8"></span>ted in two children in the i.m. group<span class="_ _a"></span>, and one</div><div class="t m0 x9 hb y13f0 ff17 fs8 fc3 sc0 ls2da ws345">child in the i.v<span class="_ _4b"></span>. group had transient neurological sequelae that were not speci-</div><div class="t m0 x9 hb y13f1 ff17 fs8 fc3 sc0 ls13 ws14">fied (2/20 (10%) compared to 1/18 (5.6%), RR: 1.8; 95% CI: 0.2–18.2) <span class="ff1a ls14 ws0">(3)<span class="ff17 ls0">.</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfdb" class="pf w1 h4" data-page-no="db"><div class="pc pcdb w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">209</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 lsc3 ws139">A9.3<span class="_ _33"> </span>Is int<span class="_ _8"></span>rarectal quinine as effective as intravenous</div><div class="t m0 xa4 h12 y12b ff19 fs6 fc4 sc0 lsc3 ws139">or intramuscular quinine?</div><div class="t m0 xb h23 y13f2 ff1e fs11 fc8 sc0 ls279 ws0">Summar<span class="_ _8"></span>y </div><div class="t m0 xb hb y63b ff17 fs8 fc3 sc0 ls1e1 ws312">One systematic review of 8 trials detected no difference in effect on par<span class="_ _a"></span>asites,</div><div class="t m0 xb hb y63c ff17 fs8 fc3 sc0 ls12 ws57c">clinical illness between the rectal gr<span class="_ _a"></span>oup and either i.m or i.v<span class="_ _b"></span>. groups. Some</div><div class="t m0 xb hb y63d ff17 fs8 fc3 sc0 ls12 ws0">studies howev<span class="_ _a"></span>er excluded patients with severe malaria.</div><div class="t m0 xb h23 y13f3 ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y13f4 ff17 fs8 fc3 sc0 ls13 ws3bd">One systematic review (search date 2005, eight RCT<span class="_ _c"></span>s, 1247 people) <span class="ff1a ws0">(5)</span><span class="ws33">. Five</span></div><div class="t m0 xb hb y13f5 ff17 fs8 fc3 sc0 ls73 ws50">trials compared intrar<span class="_ _a"></span>ectal quinine with i.v quinine infusion, while 6 compared</div><div class="t m0 xb hb y13f6 ff17 fs8 fc3 sc0 ls360 ws574">with intramuscular quinine. <span class="_ _a"></span>The systematic review found no significant</div><div class="t m0 xb hb y13f7 ff17 fs8 fc3 sc0 ls1ad ws2b8">difference between intr<span class="_ _a"></span>arectal with i.v<span class="_ _b"></span>. or i.m. routes for death, parasite</div><div class="t m0 xb hb y21c ff17 fs8 fc3 sc0 ls1f1 wsa0">clearance by 48 hours and 7 days, parasite clear<span class="_ _a"></span>ance time, fever clearance time,</div><div class="t m0 xb hb y13f8 ff17 fs8 fc3 sc0 lsfc ws37e">coma reco<span class="_ _a"></span>very time, duration of hospitalization, and time to drinking. Howev<span class="_ _a"></span>er</div><div class="t m0 xb hb y13f9 ff17 fs8 fc3 sc0 ls1fa ws43c">trials reporting these outcomes were small, which resulted in lar<span class="_ _a"></span>ge confidence</div><div class="t m0 xb hb y13fa ff17 fs8 fc3 sc0 ls12 ws0">intervals for all the outcomes.</div><div class="t m0 xb h23 y13fb ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 xb hb y13fc ff17 fs8 fc3 sc0 ls2b ws182">No reported rectal irritation. Muciod stools, howev<span class="_ _a"></span>er<span class="_ _b"></span>, were reported in 4</div><div class="t m0 xb hb y13fd ff17 fs8 fc3 sc0 ls70 wsa2">patients receiving rectal quinine. No statistically significant differ<span class="_ _a"></span>ence between</div><div class="t m0 xb hb y13fe ff17 fs8 fc3 sc0 lse2 ws138">painful swelling at the site of application or pain at the site of application after</div><div class="t m0 xb hb y13ff ff17 fs8 fc3 sc0 ls12 ws0">administration <span class="ff1a ls13">(5).</span></div><div class="t m0 xb h12 y1400 ff19 fs6 fc4 sc0 ls9e wsfd">A9.4<span class="_ _33"> </span>Is int<span class="_ _8"></span>ravenous ar<span class="_ _8"></span>tesunate superior to</div><div class="t m0 xa4 h12 y1401 ff19 fs6 fc4 sc0 ls52 ws578">intravenous quinine?</div><div class="t m0 xb h23 y1402 ff1e fs11 fc8 sc0 ls27a ws0">Summar<span class="_ _8"></span>y</div><div class="t m0 xb hb y1403 ff17 fs8 fc3 sc0 ls3f ws7c">One large multi-centre trial fr<span class="_ _a"></span>om South-East Asia enrolling 1461 patients</div><div class="t m0 xb hb y1404 ff17 fs8 fc3 sc0 ls12 ws17c">(including 202 children less than 15 years old) found a significant adv<span class="_ _a"></span>antage</div><div class="t m0 xb hb y1405 ff17 fs8 fc3 sc0 ls12 wsb6">of artesunate over quinine in mortality (15% vs 22%<span class="ff31 fs11 ls0 ws0">).<span class="_ _5"> </span></span>There was an absolute</div><div class="t m0 xb hb y1406 ff17 fs8 fc3 sc0 ls361 ws86">reduction in mortality of 34.7% (95% CI: 18.5–47.6%; <span class="ff1a ls0 ws0">P<span class="_ _67"> </span></span>= 0.002) in the ar<span class="_ _8"></span>tesunate</div><div class="t m0 xb hb y1407 ff17 fs8 fc3 sc0 ls22 ws0">group<span class="_ _a"></span>. Quinine was associated with hypoglycaemia (RR: 3.2, <span class="ff1a ls0">P </span>= 0.009). </div><div class="t m0 xb h23 y1408 ff1e fs11 fc8 sc0 ls27a ws0">Benefits </div><div class="t m0 xb hb y1409 ff17 fs8 fc3 sc0 ls13 ws57d">No systematic reviews: two RCT<span class="_ _c"></span>s. The first (113 adults with severe malaria,</div><div class="t m0 xb hb y140a ff17 fs8 fc3 sc0 ls13 wsa4">Thailand) comparing i.v<span class="_ _4b"></span>. ar<span class="_ _8"></span>tesunate (2.4 mg/kg initially<span class="_ _b"></span>, 1.2 mg/kg 12 h later<span class="_ _4b"></span>,</div><div class="t m0 xb hb y140b ff17 fs8 fc3 sc0 ls13 ws8b">then 1.2 mg/kg daily) to i.v<span class="_ _4b"></span>. quinine (20 mg/kg initially<span class="_ _b"></span>, then 10 mg/kg every</div><div class="t m0 xb hb y140c ff17 fs8 fc3 sc0 ls3d ws0">8<span class="_ _6"> </span>h) <span class="ff1a">(6)</span><span class="wsbd">. It found no significant differ<span class="_ _a"></span>ence between the treatments in mortality</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfdc" class="pf w1 h4" data-page-no="dc"><div class="pc pcdc w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">210</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls13 wse8">after 300 h (7/59 (12%) artesunate, 12/54 (22%) quinine, RR: 0.53; 95% CI:</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls233 ws17b">0.23–1.26). It found that artesunate significantly improved par<span class="_ _a"></span>asite clearance</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls26e wsa1">time, but that there was no significant difference in fev<span class="_ _a"></span>er clearance time or coma</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls29e ws79">reco<span class="_ _a"></span>very time (parasite clearance time: 63 h with artesunate, 76 h with</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls1e1 ws0">quinine, <span class="_ _a"></span><span class="ff1a ls0">p<span class="_ _6"> </span><span class="ff17 ls1e1 ws312">= 0.019; fever clearance time: 41 h compared to 65 h, </span>p<span class="_ _67"> </span><span class="ff17 ls1e1 ws312">= 0.2; coma</span></span></div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 ls8e ws370">reco<span class="_ _a"></span>very time: 17 h compared to 18 h, <span class="ff1a ls0 ws0">p <span class="ff17 ls12">= 0.6).</span></span></div><div class="t m0 x9 hb y18d ff17 fs8 fc3 sc0 ls362 ws556">The second<span class="_ _5"> </span>RCT is a large multi-centre trial (SEAQU<span class="_ _a"></span>AMA<span class="_ _b"></span>T study group:</div><div class="t m0 x9 hb y18e ff17 fs8 fc3 sc0 ls12 ws53f">Bangladesh, India, Indonesia and Myanmar) with 1431 patients enr<span class="_ _a"></span>olled <span class="ff1a ls14 ws0">(7)<span class="ff17 ls0">.</span></span></div><div class="t m0 x9 hb y18f ff17 fs8 fc3 sc0 ls237 ws2d">It found that mortality of 15% (107/7<span class="_ _8"></span>30 in the ar<span class="_ _8"></span>tesunate group was significantly</div><div class="t m0 x9 hb y190 ff17 fs8 fc3 sc0 ls12 ws26e">lower than the 22% (164/731) in the quinine group<span class="_ _a"></span>. An absolute reduction of</div><div class="t m0 x9 hb y191 ff17 fs8 fc3 sc0 ls13 wsa1">34.7% (95% CI: 18.5–47.6%; <span class="ff1a ls0 ws0">P<span class="_ _6"> </span></span><span class="ls12">= 0.0002) in the ar<span class="_ _8"></span>tesunate group. <span class="_ _a"></span>There are,</span></div><div class="t m0 x9 hb y192 ff17 fs8 fc3 sc0 ls345 ws12d">howev<span class="_ _a"></span>er<span class="_ _b"></span>, still insufficient data for children, particularly from high transmission</div><div class="t m0 x9 hb y193 ff17 fs8 fc3 sc0 ls12 ws0">settings. </div><div class="t m0 x9 h23 ya20 ff1e fs11 fc8 sc0 ls27a ws0">Harms </div><div class="t m0 x9 hb y1146 ff17 fs8 fc3 sc0 ls2aa ws460">The first RCT found that artesunate significantly reduced hypoglycaemia</div><div class="t m0 x9 hb y140d ff17 fs8 fc3 sc0 ls30 ws3e">compared with quinine (6/59 (10%) compared to 15/54 (28%), RR: 0.37; 95%</div><div class="t m0 x9 hb y140e ff17 fs8 fc3 sc0 ls3a ws347">CI: 0.15–0.88) <span class="ff1a ws0">(6)</span><span class="ws1b2">. One person treated with artesunate developed an urticarial</span></div><div class="t m0 x9 hb y1160 ff17 fs8 fc3 sc0 ls12 ws28d">rash. A similar finding was obtained in the second RCT<span class="_ _6"> </span>where treatment with</div><div class="t m0 x9 hb y1161 ff17 fs8 fc3 sc0 ls12 ws57e">artesunate was well tolerated, whereas quinine was associated with hypo-</div><div class="t m0 x9 hb y1162 ff17 fs8 fc3 sc0 ls13 ws14">glycaemia (RR: 3.2; 95% CI: 1.3–7.8; <span class="ff1a ls0 ws0">P<span class="_ _6"> </span></span>= 0.009) <span class="ff1a ls14 ws0">(7)<span class="ff17 ls0">.</span></span></div><div class="t m0 x9 h12 y140f ff19 fs6 fc4 sc0 ls1c ws144">A9.5<span class="_ _33"> </span>Is intramuscular ar<span class="_ _8"></span>temether as effective as</div><div class="t m0 x28 h12 y1410 ff19 fs6 fc4 sc0 ls52 ws578">intravenous quinine?</div><div class="t m0 x9 h23 y1411 ff1e fs11 fc8 sc0 ls27a ws0">Summar<span class="_ _8"></span>y</div><div class="t m0 x9 hb y1412 ff17 fs8 fc3 sc0 lsa1 ws100">T<span class="_ _b"></span>wo systematic reviews and three subsequent RCT<span class="_ _c"></span>s found no significant</div><div class="t m0 x9 hb y1413 ff17 fs8 fc3 sc0 lsf ws12f">difference in death rates betw<span class="_ _a"></span>een the groups receiving artemether and quinine</div><div class="t m0 x9 hb y1414 ff17 fs8 fc3 sc0 ls13 ws14">for severe malaria.</div><div class="t m0 x9 h23 y1415 ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 x9 hb y1416 ff17 fs8 fc3 sc0 ls12 ws56a">T<span class="_ _b"></span>wo systematic reviews <span class="ff1a ls13">(8, 9) </span>and three subsequent RCT<span class="_ _c"></span>s <span class="ff1a ls1a9 ws0">(10–12)</span><span class="ws163">. The <span class="_ _8"></span>first</span></div><div class="t m0 x9 hb y1417 ff17 fs8 fc3 sc0 ls54 ws6f">review (search date not r<span class="_ _a"></span>epor<span class="_ _8"></span>ted, seven RCT<span class="_ _4b"></span>s, 1919 adults and children)</div><div class="t m0 x9 hb y1418 ff17 fs8 fc3 sc0 ls12 ws49a">analysed individual participant data <span class="ff1a ls14 ws0">(8)</span>. It found no significant difference in</div><div class="t m0 x9 hb y1419 ff17 fs8 fc3 sc0 ls13 ws57f">mortality between i.m. ar<span class="_ _8"></span>temether and quinine given by i.v<span class="_ _4b"></span>. infusion or i.m</div><div class="t m0 x9 hb y141a ff17 fs8 fc3 sc0 ls12 ws4b3">injection (the latter in one RCT only) in sev<span class="_ _a"></span>ere falciparum malaria (mortality</div><div class="t m0 x9 hb y141b ff17 fs8 fc3 sc0 ls13 ws24">136/961 (14%) with artemether<span class="_ _b"></span>, 164/958 (17%) with quinine; O<span class="_ _8"></span>R: 0.80; 95%</div><div class="t m0 x9 hb y141c ff17 fs8 fc3 sc0 ls16d ws120">CI: 0.62–1.02). Parasite clear<span class="_ _a"></span>ance was faster with ar<span class="_ _8"></span>temether than with quinine</div><div class="t m0 x9 hb y141d ff17 fs8 fc3 sc0 ls12 ws580">(OR: 0.62; 95% CI: 0.56–0.69). The review found no significant differ<span class="_ _a"></span>ence in</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfdd" class="pf w1 h4" data-page-no="dd"><div class="pc pcdd w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">211</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls12 ws581">the speed of coma reco<span class="_ _a"></span>very<span class="_ _4b"></span>, fever clearance time or neurological sequelae</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls281 ws222">between artemether and quinine (coma recovery time, OR: 1.09; 95% CI:</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls1c3 ws439">0.97–1.22; fever clearance time, OR: 1.01; 95% CI: 0.90–1.15; neurological</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls14 ws15">sequelae, OR: 0.82; 95% CI: 0.59–1.15). </div><div class="t m0 xb hb y18b ff17 fs8 fc3 sc0 ls12 ws379">The second review (search date 1999, 11 RCT<span class="_ _c"></span>s, 2142 people) found a small</div><div class="t m0 xb hb y18c ff17 fs8 fc3 sc0 ls270 ws175">significant reduction in mortality for i.m. ar<span class="_ _8"></span>temether compared with i.v<span class="_ _4b"></span>. quinine</div><div class="t m0 xb hb y18d ff17 fs8 fc3 sc0 ls143 ws203">(OR: 0.72; 95% CI: 0.57–0.91) <span class="ff1a ws0">(9)</span><span class="wsd0">. However<span class="_ _4b"></span>, more rigorous analysis excluding</span></div><div class="t m0 xb hb y18e ff17 fs8 fc3 sc0 lsbe ws37f">three poorer quality trials found no significant differ<span class="_ _a"></span>ence in mor<span class="_ _8"></span>tality (OR: 0.79;</div><div class="t m0 xb hb y18f ff17 fs8 fc3 sc0 ls192 ws27a">95% CI: 0.59–1.05). The r<span class="_ _a"></span>eview found no significant difference in neurological</div><div class="t m0 xb hb y190 ff17 fs8 fc3 sc0 ls12 ws582">sequelae at reco<span class="_ _a"></span>very between the ar<span class="_ _8"></span>temether and quinine groups (OR: 0.8;</div><div class="t m0 xb hb y191 ff17 fs8 fc3 sc0 ls13 ws14">95% CI: 0.52–1.25). </div><div class="t m0 xb hb y141e ff17 fs8 fc3 sc0 ls1d ws1c">The first subsequent RCT (105 people aged 15–40 years with cer<span class="_ _a"></span>ebral malaria</div><div class="t m0 xb hb y141f ff17 fs8 fc3 sc0 ls83 wsc7">in Bangladesh) compared i.m. artemether (160 mg initially<span class="_ _4b"></span>, then 80 mg/kg once</div><div class="t m0 xb hb y194 ff17 fs8 fc3 sc0 ls3d wsbd">daily) with i.v<span class="_ _4b"></span>. quinine (loading dose 20 mg/kg, then 10 mg/kg every 8 h) <span class="ff1a lsc8 ws0">(10)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb y195 ff17 fs8 fc3 sc0 ls12 ws10e">It found no significant difference in death rates betw<span class="_ _a"></span>een the ar<span class="_ _8"></span>temether and</div><div class="t m0 xb hb y196 ff17 fs8 fc3 sc0 ls220 ws353">quinine groups (9/51 (18%) compared to 10/54 (19%), OR: 0.94; 95% CI:</div><div class="t m0 xb hb y1420 ff17 fs8 fc3 sc0 ls2b9 ws8c">0.35–2.55). Mean fever clearance time and coma r<span class="_ _a"></span>ecovery time wer<span class="_ _a"></span>e significantly</div><div class="t m0 xb hb y1421 ff17 fs8 fc3 sc0 ls12 ws583">longer for artemether than for quinine (fever clearance time: 58 h compared</div><div class="t m0 xb hb y1422 ff17 fs8 fc3 sc0 ls146 ws207">to 47 h, WMD: 11.0 h; 95% CI: 1.6–20.4 h; coma reco<span class="_ _a"></span>very time: 74 h compared</div><div class="t m0 xb hb y1423 ff17 fs8 fc3 sc0 ls204 ws350">to 53 h, WMD: 20.8 h; 95% CI: 3.6–38.0 h). Ther<span class="_ _a"></span>e was no significant difference</div><div class="t m0 xb hb y1424 ff17 fs8 fc3 sc0 ls29e ws79">in mean parasite clearance time betw<span class="_ _a"></span>een ar<span class="_ _8"></span>temether and quinine (52 h</div><div class="t m0 xb hb y1425 ff17 fs8 fc3 sc0 ls12 ws0">compared to 61 h, <span class="_ _a"></span>WM<span class="_ _8"></span>D: 8.6 h; 95% CI: 22.5 h to +5.3 h).</div><div class="t m0 xb hb y1426 ff17 fs8 fc3 sc0 ls12 ws584">The second subsequent RCT (41 childr<span class="_ _a"></span>en with severe malaria in Sudan, 40</div><div class="t m0 xb hb y1427 ff17 fs8 fc3 sc0 ls5d ws7e">analysed) compared i.m. artemether (3.2 mg/kg loading dose, then 1.6 mg/kg</div><div class="t m0 xb hb y1428 ff17 fs8 fc3 sc0 ls1fa ws43c">once a day) with i.v<span class="_ _4b"></span>. quinine (loading dose 20 mg/kg, then 10 mg/kg every 8 h)</div><div class="t m0 xb hb y1429 ff17 fs8 fc3 sc0 ls12 ws262">(11). It found that artemether significantly increased fever clearance time but</div><div class="t m0 xb hb y142a ff17 fs8 fc3 sc0 ls12 ws585">found no significant difference between artemether and quinine in time to</div><div class="t m0 xb hb y142b ff17 fs8 fc3 sc0 ls12 ws33e">parasite clearance (mean fev<span class="_ _a"></span>er clearance time: 30.5 h with artemether<span class="_ _b"></span>, 18 h</div><div class="t m0 xb hb y142c ff17 fs8 fc3 sc0 ls2de ws47f">with quinine, <span class="ff1a ls0 ws0">p<span class="_ _3"> </span></span>= 0.02; mean parasite clearance time: 16 h compared to</div><div class="t m0 xb hb y142d ff17 fs8 fc3 sc0 ls21f ws0">22.4 h, <span class="_ _b"></span><span class="ff1a ls0">p <span class="ff1c">&gt;<span class="_ _67"> </span><span class="ff17 ls21f ws15f">0.05). There w<span class="_ _a"></span>ere no deaths in the ar<span class="_ _8"></span>temether group<span class="_ _a"></span>, one child died</span></span></span></div><div class="t m0 xb hb y142e ff17 fs8 fc3 sc0 ls12 ws0">with quinine (0/20 (0%) compared to 1/21 (5%), <span class="ff1a ls0">p </span>v<span class="_ _a"></span>alue not reported). </div><div class="t m0 xb hb y142f ff17 fs8 fc3 sc0 ls290 ws2ff">The third subsequent RCT<span class="_ _67"> </span>(77 comatose children aged 3 months–15 years with</div><div class="t m0 xb hb y1430 ff17 fs8 fc3 sc0 ls13 ws515">cerebral malaria) compar<span class="_ _a"></span>ed i.m. ar<span class="_ _8"></span>temether (1.6 mg/kg every 12 h) with i.v<span class="_ _b"></span>.</div><div class="t m0 xb hb y1431 ff17 fs8 fc3 sc0 ls14 ws586">quinine (10 mg/kg every 8 h) (<span class="ff1a ls3c ws0">12</span><span class="ls12 ws531">). It found no significant difference in death</span></div><div class="t m0 xb hb y1432 ff17 fs8 fc3 sc0 ls219 ws371">rates between the artemether and quinine groups (3/38 (8%) compared to 2/39</div><div class="t m0 xb hb y1433 ff17 fs8 fc3 sc0 ls13 ws0">(5%), <span class="ff1a ls0">p<span class="_ _6"> </span></span><span class="ls12 wsa0">value not reported). There was no significant differ<span class="_ _a"></span>ence between the</span></div><div class="t m0 xb hb y1434 ff17 fs8 fc3 sc0 ls12 ws489">two groups in mean fever clear<span class="_ _a"></span>ance time, coma recov<span class="_ _a"></span>ery time and parasite</div><div class="t m0 xb hb y1435 ff17 fs8 fc3 sc0 ls206 ws1a3">clearance time (fever clear<span class="_ _a"></span>ance time 31 h compared to 36 h; coma reco<span class="_ _a"></span>very time:</div><div class="t m0 xb hb y1436 ff17 fs8 fc3 sc0 ls1d4 ws2f4">21 h compared to 26 h; parasite clear<span class="_ _a"></span>ance time 36 h compared to 41 h; <span class="ff1a ls22a ws0">p </span><span class="ws0">v<span class="_ _b"></span>alues</span></div><div class="t m0 xb hb y1437 ff17 fs8 fc3 sc0 ls12 ws0">not reported for any comparison). </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfde" class="pf w1 h4" data-page-no="de"><div class="pc pcde w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">212</div><div class="t m0 x9 h23 yd3c ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 x9 hb yd3d ff17 fs8 fc3 sc0 ls12 ws587">The two systematic reviews <span class="ff1a ls13">(8, 9) </span>and one of the subsequent RCT<span class="_ _c"></span>s <span class="ff1a ls14 ws0">(3) </span><span class="ws0">found</span></div><div class="t m0 x9 hb yd3e ff17 fs8 fc3 sc0 ls1a4 ws2a5">no significant difference in neurological sequelae betw<span class="_ _a"></span>een the ar<span class="_ _8"></span>temether and</div><div class="t m0 x9 hb yd3f ff17 fs8 fc3 sc0 ls42 ws5b">quinine groups (systematic reviews, see the Benefits section; subsequent trial</div><div class="t m0 x9 hb yd40 ff17 fs8 fc3 sc0 ls326 ws517">3/51 (6%) with artemether<span class="_ _b"></span>, 1/54 (2%) with quinine, RR: 3.18; 95% CI:</div><div class="t m0 x9 hb yd41 ff17 fs8 fc3 sc0 ls12 ws2d6">0.34–29.56). Howev<span class="_ _a"></span>er<span class="_ _b"></span>, in the first review<span class="_ _b"></span>, rates for the combined outcome of</div><div class="t m0 x9 hb yd42 ff17 fs8 fc3 sc0 ls16b ws242">death or neurological sequelae wer<span class="_ _a"></span>e lower for artemether than for quinine (O<span class="_ _8"></span>R:</div><div class="t m0 x9 hb yd43 ff17 fs8 fc3 sc0 ls13 ws14">0.77; 95% CI: 0.62–0.96, <span class="ff1a ls0 ws0">p </span><span class="ws0">= 0.02) <span class="ff1a ls14">(8)</span>. </span></div><div class="t m0 x9 hb y1438 ff17 fs8 fc3 sc0 ls363 ws588">The second subsequent RCT found that one child tr<span class="_ _a"></span>eated with quinine</div><div class="t m0 x9 hb y1439 ff17 fs8 fc3 sc0 ls163 ws36e">developed hypoglycaemia (0/20 (0%) with artemether<span class="_ _4b"></span>, 1/21 (5%) with quinine,</div><div class="t m0 x9 hb y143a ff1a fs8 fc3 sc0 lsc2 ws0">(11)<span class="ff17 ws137">. It reported no neurological problems in either treatment gr<span class="_ _a"></span>oup after</span></div><div class="t m0 x9 hb y143b ff17 fs8 fc3 sc0 ls50 ws40">28 days of follow-up<span class="_ _a"></span>. </div><div class="t m0 x9 hb y143c ff17 fs8 fc3 sc0 ls364 ws589">The third subsequent RCT<span class="_ _7c"> </span>found no significant difference in transient</div><div class="t m0 x9 hb y143d ff17 fs8 fc3 sc0 ls224 ws11e">neurological sequelae between the artemether and quinine groups (2/38</div><div class="t m0 x9 hb y143e ff17 fs8 fc3 sc0 ls12 ws0">(5%) compared to 1/39 (3%), <span class="ff1a ls53">(12)</span><span class="ls13">. </span></div><div class="t m0 x9 h23 y143f ff1e fs11 fc8 sc0 ls27a ws0">Comment</div><div class="t m0 x9 hb y1440 ff17 fs8 fc3 sc0 ls12 ws579">The third subsequent randomized contr<span class="_ _a"></span>olled trial did not use loading doses</div><div class="t m0 x9 hb y1441 ff17 fs8 fc3 sc0 ls12 wsa4">of either artemether or quinine at the beginning of treatment <span class="ff1a ls53 ws0">(12)</span><span class="ls13 ws58a">. There was</span></div><div class="t m0 x9 hb y1442 ff17 fs8 fc3 sc0 ls12 ws122">a fourth subsequent RCT (52 people) <span class="ff1a ls53 ws0">(13)</span>. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, it was not clear whether</div><div class="t m0 x9 hb y1443 ff17 fs8 fc3 sc0 ls12 ws0">participants had severe malaria, and outcomes were poorly r<span class="_ _a"></span>epor<span class="_ _8"></span>ted. </div><div class="t m0 x9 h12 y1444 ff19 fs6 fc4 sc0 ls86 wsca">A9.6<span class="_ _33"> </span>Is int<span class="_ _8"></span>ramuscular artemotil as eff<span class="_ _8"></span>ective</div><div class="t m0 x28 h12 y1445 ff19 fs6 fc4 sc0 ls268 ws58b">as intravenous quinine?</div><div class="t m0 x9 hb y1446 ff17 fs8 fc3 sc0 ls12 ws58c">Cochrane R<span class="_ _a"></span>eview (search date August 2004). T<span class="_ _4b"></span>wo small trials (<span class="ff1a ls0 ws0">n<span class="_ _95"> </span></span>= 194) met</div><div class="t m0 x9 hb y1447 ff17 fs8 fc3 sc0 ls102 wsb2">the inclusion criteria <span class="ff1a ws0">(14)</span>. Both trials compared i.m. artemotil with quinine given</div><div class="t m0 x9 hb y1448 ff17 fs8 fc3 sc0 ls144 ws204">by i.v<span class="_ _4b"></span>. infusion in children with cerebral malaria and reported on similar</div><div class="t m0 x9 hb y1449 ff17 fs8 fc3 sc0 ls12 ws58d">outcomes. Ther<span class="_ _a"></span>e was no statistically significant difference in the number of</div><div class="t m0 x9 hb y144a ff17 fs8 fc3 sc0 ls13 ws3ea">deaths (RR: 0.75; 95% CI: 0.43–1.30, <span class="ff1a ls0 ws0">n </span><span class="ls12 ws393">= 194, 2 trials), neur<span class="_ _a"></span>ological complic-</span></div><div class="t m0 x9 hb y144b ff17 fs8 fc3 sc0 ls365 ws58e">ations (RR: 1.18;, 95% CI: 0.31–4.46, <span class="ff1a ls0 ws0">n<span class="_ _3"> </span></span>= 58, 1 trial), or other outcomes</div><div class="t m0 x9 hb y144c ff17 fs8 fc3 sc0 ls12 ws220">including time to regain consciousness, parasite clear<span class="_ _a"></span>ance time and fever</div><div class="t m0 x9 hb y144d ff17 fs8 fc3 sc0 ls26e wsa1">clearance time. <span class="_ _a"></span>The meta-analyses lack the statistical power to detect important</div><div class="t m0 x9 hb y144e ff17 fs8 fc3 sc0 ls13 ws0">differences.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfdf" class="pf w1 h4" data-page-no="df"><div class="pc pcdf w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">213</div><div class="t m0 xb h12 y12a ff19 fs6 fc4 sc0 ls9e wsfd">A9.7<span class="_ _33"> </span>Is rectal ar<span class="_ _8"></span>temisinin as eff<span class="_ _8"></span>ective as intravenous</div><div class="t m0 xa4 h12 y12b ff19 fs6 fc4 sc0 ls9a ws0">quinine?</div><div class="t m0 xb h23 y13f2 ff1e fs11 fc8 sc0 ls27a ws0">Summar<span class="_ _8"></span>y</div><div class="t m0 xb hb y63b ff17 fs8 fc3 sc0 ls25c ws3ec">One systematic review of small RCT<span class="_ _c"></span>s found no significant difference in mor<span class="_ _8"></span>tality</div><div class="t m0 xb hb y63c ff17 fs8 fc3 sc0 ls13 ws14">between rectal artemisinin and quinine given by i.v<span class="_ _4b"></span>. infusion.</div><div class="t m0 xb h23 y144f ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y1450 ff17 fs8 fc3 sc0 ls2a1 ws165">One systematic review (search date 1999, thr<span class="_ _a"></span>ee RCT<span class="_ _4b"></span>s) comparing rectal</div><div class="t m0 xb hb y13f4 ff17 fs8 fc3 sc0 ls12 ws16c">artemisinin with i.v<span class="_ _b"></span>. quinine in severe malaria (<span class="ff1a ls0 ws0">9</span><span class="ls13">). <span class="_ _a"></span>T<span class="_ _b"></span>wo RCT<span class="_ _4b"></span>s were conducted</span></div><div class="t m0 xb hb y13f5 ff17 fs8 fc3 sc0 ls12 ws38">in 1996–1997. Meta-analysis showed lo<span class="_ _a"></span>wer mor<span class="_ _8"></span>tality with artemisinin and</div><div class="t m0 xb hb y13f6 ff17 fs8 fc3 sc0 ls1a9 ws262">quicker coma reco<span class="_ _a"></span>very time, but the difference was not significant (mortality<span class="_ _b"></span>,</div><div class="t m0 xb hb y13f7 ff17 fs8 fc3 sc0 ls8e wsdd">three RCT<span class="_ _c"></span>s, 9/87 (10%) with ar<span class="_ _8"></span>temisinin, 16/98 (16%) with quinine, RR: 0.73;</div><div class="t m0 xb hb y21c ff17 fs8 fc3 sc0 ls13 ws58f">95% CI: 0.35–1.50; coma reco<span class="_ _a"></span>very<span class="_ _4b"></span>, two RCT<span class="_ _4b"></span>s, 59 people, WMD: –9.0 h; 95%</div><div class="t m0 xb hb y13f8 ff17 fs8 fc3 sc0 ls247 ws21">CI: –19.7 h to +1.7 h). Fev<span class="_ _a"></span>er clearance times were not significantly differ<span class="_ _a"></span>ent (no</div><div class="t m0 xb hb y13f9 ff17 fs8 fc3 sc0 ls13 ws0">figures pro<span class="_ _a"></span>vided).</div><div class="t m0 xb h23 y1451 ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 xb hb y1452 ff17 fs8 fc3 sc0 ls12 ws529">One RCT in childr<span class="_ _a"></span>en found that ar<span class="_ _8"></span>temisinin significantly reduced the risk of</div><div class="t m0 xb hb y13fc ff17 fs8 fc3 sc0 ls13 ws582">hypoglycaemia compared with quinine (3/30 (10%) with artemisinin, 19/30</div><div class="t m0 xb hb y13fd ff17 fs8 fc3 sc0 ls13 ws14">(63%) with quinine, RR: 0.16; 95% CI: 0.05–0.48) <span class="ff1a ws0">(15)<span class="ff17">. </span></span></div><div class="t m0 xb h12 y1453 ff19 fs6 fc4 sc0 ls9a ws0">A9.8<span class="_ _33"> </span>P<span class="_ _a"></span><span class="ls366 ws590">re-referral treat<span class="ls367 wsd8">ment with rectal ar<span class="_ _8"></span>tesunate:<span class="_ _5"> </span>should</span></span></div><div class="t m0 xa4 h12 y1454 ff19 fs6 fc4 sc0 ls368 ws591">rectal artesunate be used in preference to quinine?</div><div class="t m0 xb h23 y1455 ff1e fs11 fc8 sc0 ls27a ws0">Summar<span class="_ _8"></span>y</div><div class="t m0 xb hb y1456 ff17 fs8 fc3 sc0 lsa3 ws103">There are no data fr<span class="_ _a"></span>om trials with sufficient statistical power to assess</div><div class="t m0 xb hb y1457 ff17 fs8 fc3 sc0 lsfc ws37e">differences in mortality following treatment with rectal artesunate and quinine</div><div class="t m0 xb hb y1403 ff17 fs8 fc3 sc0 ls1fa ws43c">in people with moderate or sever<span class="_ _a"></span>e malaria. The objectiv<span class="_ _a"></span>e of the trials that have</div><div class="t m0 xb hb y1404 ff17 fs8 fc3 sc0 ls12 ws342">been conducted was to establish the safety and efficacy of rectal artesunate</div><div class="t m0 xb hb y1405 ff17 fs8 fc3 sc0 ls12 ws592">as pre-referr<span class="_ _a"></span>al treatment where there is no access to par<span class="_ _a"></span>enteral treatment.</div><div class="t m0 xb hb y1406 ff17 fs8 fc3 sc0 ls2cc ws47e">Comparisons between rectal artesunate and i.v<span class="_ _b"></span>. artesunate or i.v<span class="_ _b"></span>., i.m. quinine</div><div class="t m0 xb hb y1407 ff17 fs8 fc3 sc0 ls12 ws593">have been carried out to assess parasitological and clinical r<span class="_ _a"></span>esponse in the</div><div class="t m0 xb hb y1458 ff17 fs8 fc3 sc0 ls13 ws14">12 or 24 hours immediately after treatment <span class="ff1a ls53 ws55e">(16, 17)</span><span class="ls0 ws0">.</span></div><div class="t m0 xb h23 y1459 ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y145a ff17 fs8 fc3 sc0 ls2ae ws1c">T<span class="_ _b"></span>wo randomized, open-label Phase II and three randomised open label Phase III</div><div class="t m0 xb hb y145b ff17 fs8 fc3 sc0 ls12 ws185">studies have been conducted in people with moderately sev<span class="_ _a"></span>ere malaria, i.e.</div><div class="t m0 xb hb y145c ff17 fs8 fc3 sc0 ls43 ws60">patients who could not take drugs by mouth but did not have features of sev<span class="_ _a"></span>ere</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe0" class="pf w1 h4" data-page-no="e0"><div class="pc pce0 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">214</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls182 ws130">malaria and its complications <span class="ff1a ls146 ws207">(16, 17)</span>. Patients in the artesunate group in the</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls13 ws42">Phase II<span class="_ _8"></span>I studies were rescued if their par<span class="_ _a"></span>asitaemia did not decline to below</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls146 ws207">60% of baseline parasitaemia or if they deteriorated clinically and dev<span class="_ _a"></span>eloped</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls16e ws245">features of sever<span class="_ _a"></span>e malaria, convulsions or coma within 24 hours of treatment. </div><div class="t m0 x9 hb y18b ff17 fs8 fc3 sc0 ls12 ws594">Artesunate had a superior effect in all efficacy measures immediately after</div><div class="t m0 x9 hb y18c ff17 fs8 fc3 sc0 ls12 ws33c">treatment. In children tr<span class="_ _a"></span>eated with ar<span class="_ _8"></span>tesunate, 80/87 (92%) had a parasite</div><div class="t m0 x9 hb y18d ff17 fs8 fc3 sc0 ls12 ws518">density lower than 60% of baseline, compar<span class="_ _a"></span>ed to 3/22 (14%) of those who</div><div class="t m0 x9 hb y18e ff17 fs8 fc3 sc0 ls66 ws3f">received quinine (RR: 0.09; 95% CI: 0.04–0.19, <span class="ff1a ls0 ws0">p<span class="_ _67"> </span><span class="ff1c">&lt;<span class="_ _9"></span></span></span>0.0001). In adult, parasitaemia</div><div class="t m0 x9 hb y18f ff17 fs8 fc3 sc0 ls8e wsdd">at 12 hours was lower than 60% of baseline in 26/27 (96%) in the artesunate</div><div class="t m0 x9 hb y190 ff17 fs8 fc3 sc0 ls55 ws70">group<span class="_ _a"></span>, compared to 3/8 (38%) in the quinine group. (RR: 0.06; 95% CI:</div><div class="t m0 x9 hb y191 ff17 fs8 fc3 sc0 ls236 ws0">0.01–0.44, <span class="ff1a ls0">p<span class="_ _67"> </span><span class="ff1c">&lt;</span></span><span class="ws2ea">0.001). The differ<span class="_ _a"></span>ences were more significant at 24 h. Artesunate</span></div><div class="t m0 x9 hb y192 ff17 fs8 fc3 sc0 ls13 wse3">and/or dihydroartemisinin were detected in plasma within 12 h in all adults</div><div class="t m0 x9 hb y193 ff17 fs8 fc3 sc0 ls12 ws0">and in 84/87 of the children. </div><div class="t m0 x9 h23 ya20 ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 x9 hb y1146 ff17 fs8 fc3 sc0 ls67 ws1f9">A single administration of artesunate suppositories at a dose of 10 mg/kg was</div><div class="t m0 x9 hb y140d ff17 fs8 fc3 sc0 ls1b3 ws28">well tolerated in both childr<span class="_ _a"></span>en and adults. There was no significant differ<span class="_ _a"></span>ence</div><div class="t m0 x9 hb y140e ff17 fs8 fc3 sc0 ls12 ws564">in frequency of adverse ev<span class="_ _a"></span>ents (defined as any new symptom, worsening of</div><div class="t m0 x9 hb y1160 ff17 fs8 fc3 sc0 ls7f wsc0">any existing symptom, sign or abnormal laboratory value) betw<span class="_ _a"></span>een treatment</div><div class="t m0 x9 hb y1161 ff17 fs8 fc3 sc0 ls12 ws57b">groups. Other than local reactions at the site of the i.m. quinine injection in</div><div class="t m0 x9 hb y1162 ff17 fs8 fc3 sc0 ls12 ws58f">three adult patients, the few adverse ev<span class="_ _a"></span>ents that occurred could have been</div><div class="t m0 x9 hb y1163 ff17 fs8 fc3 sc0 ls12 ws0">attributable to falciparum malaria or to pre-existing disease.</div><div class="t m0 x9 h12 y8c5 ff19 fs6 fc4 sc0 ls1 ws17a">A9.9<span class="_ _52"> </span>Should dexamethasone be given routinel<span class="_ _8"></span>y?</div><div class="t m0 x9 h23 y145d ff1e fs11 fc8 sc0 ls27a ws0">Summar<span class="_ _8"></span>y</div><div class="t m0 x9 hb yf04 ff17 fs8 fc3 sc0 ls12 ws52f">One systematic review found no significant difference in mortality between</div><div class="t m0 x9 hb y145e ff17 fs8 fc3 sc0 ls204 ws350">dexamethasone and placebo, but gastrointestinal bleeding and seizures w<span class="_ _a"></span>ere</div><div class="t m0 x9 hb y145f ff17 fs8 fc3 sc0 ls12 ws0">more common with dexamethasone.</div><div class="t m0 x9 h23 y1460 ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 x9 hb y1461 ff17 fs8 fc3 sc0 ls12 ws595">One systematic review (search date 1999, two RCT<span class="_ _c"></span>s, 143 people with severe</div><div class="t m0 x9 hb y1462 ff17 fs8 fc3 sc0 ls181 ws264">cerebral malaria tr<span class="_ _a"></span>eated with quinine), which compared dexamethasone with</div><div class="t m0 x9 hb y1463 ff17 fs8 fc3 sc0 ls12 ws42e">placebo ov<span class="_ _a"></span>er 48 h (18). One RCT was conducted in Indonesia, the other in</div><div class="t m0 x9 hb y1464 ff17 fs8 fc3 sc0 ls27 ws30">Thailand. The r<span class="_ _a"></span>eview found no significant difference in mortality (14/71 (20%)</div><div class="t m0 x9 hb y1465 ff17 fs8 fc3 sc0 lsae ws118">with dexamethasone, 16/72 (25%) with placebo, RR: 0.89; 95% CI: 0.47–1.68).</div><div class="t m0 x9 hb y1466 ff17 fs8 fc3 sc0 ls2b0 ws46e">One RCT found a longer mean time between start of treatment and coma</div><div class="t m0 x9 hb y1467 ff17 fs8 fc3 sc0 ls1b2 ws1a4">resolution with dexamethasone (76.0 h compared to 57.0 h, <span class="ff1a ls0 ws0">p<span class="_ _67"> </span><span class="ff1c">&lt;<span class="_ _66"></span></span></span>0.02) (18), but</div><div class="t m0 x9 hb y1468 ff17 fs8 fc3 sc0 ls13 ws45e">the other found no significant difference (83.4 h compared to 80.0 h, <span class="_ _b"></span>WM<span class="_ _8"></span>D:</div><div class="t m0 x9 hb y1469 ff17 fs8 fc3 sc0 ls13 ws14">+3.4 h; 95% CI: –31.3 h to +38.1 h) (20). </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe1" class="pf w1 h4" data-page-no="e1"><div class="pc pce1 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">215</div><div class="t m0 xb h23 yd3c ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 xb hb yd3d ff17 fs8 fc3 sc0 ls45 wsbb">The review found that dexamethasone significantly increased gastr<span class="_ _a"></span>ointestinal</div><div class="t m0 xb hb yd3e ff17 fs8 fc3 sc0 ls75 wsb0">bleeding and seizures compared with placebo (gastr<span class="_ _a"></span>ointestinal bleeding 7/71</div><div class="t m0 xb hb yd3f ff17 fs8 fc3 sc0 ls369 ws596">(10%) with dexamethasone, 0/72 (0%) with placebo, RR: 8.17; 95% CI:</div><div class="t m0 xb hb yd40 ff17 fs8 fc3 sc0 ls13 ws14b">1.05–63.6; seizures 1/71 (15.5%) compared to 3/72 (4%), RR: 3.3<span class="_ _a"></span>2; 95% CI:</div><div class="t m0 xb hb yd41 ff17 fs8 fc3 sc0 ls160 ws0">1.05–10.47) <span class="ff1a ls13">(18)</span><span class="ls0">.</span></div><div class="t m0 xb h23 y146a ff1e fs11 fc8 sc0 ls27a ws0">Comment</div><div class="t m0 xb hb y146b ff17 fs8 fc3 sc0 ls12 wsdc">No effect of the steroid on mortality was shown, but the trials were small. Its</div><div class="t m0 xb hb y146c ff17 fs8 fc3 sc0 ls12 ws0">effect on disability was not reported.</div><div class="t m0 xb h12 y146d ff19 fs6 fc4 sc0 ls0 ws95">A9.10<span class="_ _1"> </span>Is an initial blood t<span class="_ _8"></span>ransfusion effective </div><div class="t m0 xa4 h12 y146e ff19 fs6 fc4 sc0 ls1b ws1">for treating malar<span class="_ _8"></span>ial anaemia?</div><div class="t m0 xb h23 y146f ff1e fs11 fc8 sc0 ls279 ws0">Summar<span class="_ _8"></span>y </div><div class="t m0 xb hb y1470 ff17 fs8 fc3 sc0 ls2b0 ws46e">One systematic review found insufficient data to be sure whether r<span class="_ _a"></span>outine</div><div class="t m0 xb hb y1471 ff17 fs8 fc3 sc0 ls95 wsec">administration of blood to clinically stable children (no r<span class="_ _a"></span>espiratory distress or</div><div class="t m0 xb hb y1472 ff17 fs8 fc3 sc0 ls112 ws136">cardiac failure) with sev<span class="_ _a"></span>ere anaemia in endemic malarious areas reduces</div><div class="t m0 xb hb y1473 ff17 fs8 fc3 sc0 ls12 ws2b6">death, or results in higher haematocrit measured at one month. <span class="_ _b"></span>The review</div><div class="t m0 xb hb y1474 ff17 fs8 fc3 sc0 ls2a8 ws229">found no significant difference between tr<span class="_ _a"></span>ansfusion and no transfusion for the</div><div class="t m0 xb hb y13e1 ff17 fs8 fc3 sc0 lsfe ws372">combined outcome of death or severe adv<span class="_ _a"></span>erse events. <span class="_ _a"></span>T<span class="_ _b"></span>ransmission of hepatitis</div><div class="t m0 xb hb y1475 ff17 fs8 fc3 sc0 ls36a ws10e">B or H<span class="_ _8"></span>IV was not reported. No RCT<span class="_ _4b"></span>s examining the effects of transfusion in adults</div><div class="t m0 xb hb y1476 ff17 fs8 fc3 sc0 ls12 ws0">with malaria.</div><div class="t m0 xb h23 y1477 ff1e fs11 fc8 sc0 ls27a ws0">Benefits</div><div class="t m0 xb hb y1478 ff17 fs8 fc3 sc0 ls7f ws2f7">One systematic review (search date 1999, RCT<span class="_ _c"></span>s, 230 children with malarial</div><div class="t m0 xb hb y1479 ff17 fs8 fc3 sc0 ls91 ws597">anaemia; packed cell volume range 12–17%) <span class="ff1a ls22 ws0">(21)<span class="ff17 ws1a1">. <span class="_ _b"></span>The first RCT (116 children,</span></span></div><div class="t m0 xb hb y147a ff17 fs8 fc3 sc0 ls36b wsc7">United Republic of <span class="_ _a"></span>T<span class="_ _4b"></span>anzania) compared initial blood transfusion with conservative</div><div class="t m0 xb hb y147b ff17 fs8 fc3 sc0 ls33e ws1f">treatment, and the second (114 children, <span class="_ _b"></span>The G<span class="_ _8"></span>ambia) compared blood transfusion</div><div class="t m0 xb hb y147c ff17 fs8 fc3 sc0 ls1fb ws27">with iron supplements. Both trials excluded childr<span class="_ _a"></span>en who were clinically unstable</div><div class="t m0 xb hb y147d ff17 fs8 fc3 sc0 ls22 ws3cb">with respiratory distress or signs of car<span class="_ _a"></span>diac failure. Meta-analysis found fewer</div><div class="t m0 xb hb y147e ff17 fs8 fc3 sc0 ls22 wscd">deaths in the transfused children, but the differ<span class="_ _a"></span>ence was not significant (1/118</div><div class="t m0 xb hb y147f ff17 fs8 fc3 sc0 lsec ws110">(1%) with transfusion, 3/112 (3%) with control, RR: 0.41; 95% CI: 0.06–2.70). No</div><div class="t m0 xb hb y1480 ff17 fs8 fc3 sc0 ls22 ws0">RCT<span class="_ _4b"></span>s examining the effects of transfusion in adults with malaria.</div><div class="t m0 xb h23 y1481 ff1e fs11 fc8 sc0 ls27a ws0">Harms</div><div class="t m0 xb hb y1482 ff17 fs8 fc3 sc0 ls64 ws544">The systematic review found that coma and convulsions occurred mor<span class="_ _a"></span>e often</div><div class="t m0 xb hb y1483 ff17 fs8 fc3 sc0 ls64 wsb3">after transfusion (8/118 (6.8%) with transfusion, 0/112 (0%) without, RR: 8.6;</div><div class="t m0 xb hb y1484 ff17 fs8 fc3 sc0 ls64 ws516">95% CI: 1.1 to 66.0) with seven of the eight adv<span class="_ _a"></span>erse events occurring in one of</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe2" class="pf w1 h4" data-page-no="e2"><div class="pc pce2 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls9a ws0">216</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls249 ws207">the RCT<span class="_ _4b"></span>s. Meta-analysis combining deaths and severe adv<span class="_ _a"></span>erse events found no</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls60 ws128">significant difference between childr<span class="_ _a"></span>en who received transfusions and those who</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls22 ws16c">did not (8/118 (7%) with transfusion, 3/112 (3%) without transfusion, RR: 2.5;</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls22 ws0">95% CI: 0.7–9.3). T<span class="_ _4b"></span>ransmission of hepatitis B or H<span class="_ _8"></span>IV was not reported <span class="ff1a">(21)</span><span class="ls0">.</span></div><div class="t m0 x9 h23 ycfb ff1e fs11 fc8 sc0 ls27a ws0">Comment</div><div class="t m0 x9 hb ybef ff17 fs8 fc3 sc0 ls85 wsc9">Studies wer<span class="_ _a"></span>e small and loss to follow-up was greater than 10%; both of these</div><div class="t m0 x9 hb y9e4 ff17 fs8 fc3 sc0 ls22c ws38c">factors are potential sources of bias. In the first RCT<span class="_ _4b"></span>, one child in the transfusion</div><div class="t m0 x9 hb y9e5 ff17 fs8 fc3 sc0 lsb9 ws128">group and one child in the conservative tr<span class="_ _a"></span>eatment group required an additional</div><div class="t m0 x9 hb y9e6 ff17 fs8 fc3 sc0 ls3d wsbd">transfusion after clinical assessment. In the second RCT<span class="_ _4b"></span>, 10 children allocated</div><div class="t m0 x9 hb yb9d ff17 fs8 fc3 sc0 lsca ws13e">to receive ir<span class="_ _a"></span>on supplements later required transfusion when packed cell</div><div class="t m0 x9 hb yb9e ff17 fs8 fc3 sc0 ls13 ws14">volume fell below 12% or they sho<span class="_ _a"></span>wed signs of respiratory distress.</div><div class="t m0 x9 h12 y1485 ff19 fs6 fc4 sc0 ls9a ws0">A9.11<span class="_ _1"> </span>S<span class="_ _8"></span>hould phenobarbital be given to pat<span class="_ _8"></span>ients?</div><div class="t m0 x9 hb y1486 ff17 fs8 fc3 sc0 ls36c ws272">Cochrane R<span class="_ _a"></span>eview, sear<span class="_ _a"></span>ch date 2004 <span class="ff1a ws0">(22)</span>. Three RCT<span class="_ _c"></span>s with a total of 573</div><div class="t m0 x9 hb y1487 ff17 fs8 fc3 sc0 ls22d ws394">participants met the inclusion criteria. All three compared phenobarbital with</div><div class="t m0 x9 hb y1488 ff17 fs8 fc3 sc0 ls219 ws371">placebo or no treatment. In the two trials with adequate allocation concealment,</div><div class="t m0 x9 hb y1489 ff17 fs8 fc3 sc0 ls9d wsfc">death was more common in the anticonvulsant group (RR: 2.0; 95% CI:</div><div class="t m0 x9 hb y148a ff17 fs8 fc3 sc0 ls236 ws2ea">1.20–3.33, fixed-effect model). In all three trials, phenobarbital was associated</div><div class="t m0 x9 hb y148b ff17 fs8 fc3 sc0 ls40 ws56">with fewer convulsions than placebo or no treatment (RR: 0.30; 95% CI:</div><div class="t m0 x9 hb y148c ff17 fs8 fc3 sc0 ls12 ws0">0.19–0.45, fixed-effect model).</div><div class="t m0 x9 h12 y148d ff19 fs6 fc4 sc0 ls9a ws0">A9.12<span class="_ _1"> </span>Hy<span class="_ _8"></span>perpar<span class="_ _8"></span>asitaemia in non-immune </div><div class="t m0 x28 h12 y148e ff19 fs6 fc4 sc0 ls9a ws0">or semi-immune populations</div><div class="t m0 x9 h23 y148f ff1e fs11 fc8 sc0 ls279 ws0">Background</div><div class="t m0 x9 hb y1490 ff17 fs8 fc3 sc0 ls36d ws286">Since the classic paper by Field and Niven in 1937 <span class="ff1a ws0">(23)</span><span class="ls36e ws3ab">, patients with high parasite</span></div><div class="t m0 x9 hb y1491 ff17 fs8 fc3 sc0 ls26b wsbb">counts have been known to be at incr<span class="_ _a"></span>eased risk of dying. W<span class="_ _b"></span>orking in Peninsular</div><div class="t m0 x9 hb y1492 ff17 fs8 fc3 sc0 ls36a ws6c">Malaysia they showed that <span class="ff1a">P<span class="_ _ae"></span>. falciparum <span class="ff17">parasite counts of <span class="ff1c ls0 ws0">&gt;<span class="_ _67"> </span></span><span class="ls2ef ws48e">100 000/μl of blood</span></span></span></div><div class="t m0 x9 hb y1493 ff17 fs8 fc3 sc0 ls64 ws2a6">(2%) were associated with an incr<span class="_ _a"></span>eased risk of mor<span class="_ _8"></span>tality<span class="_ _4b"></span>, while patients with</div><div class="t m0 x9 hb y1494 ff17 fs8 fc3 sc0 ls64 ws116">counts of <span class="ff1c ls0 ws0">&gt;<span class="_ _9"></span></span>500 000/μl had a more than 50% chance of dying. Following this</div><div class="t m0 x9 hb y1495 ff17 fs8 fc3 sc0 ls64 ws598">observation, hyperparasitaemic patients have been consider<span class="_ _a"></span>ed to be at high</div><div class="t m0 x9 hb y1496 ff17 fs8 fc3 sc0 ls1a4 ws41">risk. They ar<span class="_ _a"></span>e often classified as having severe malaria and accordingly tr<span class="_ _a"></span>eated</div><div class="t m0 x9 hb y1497 ff17 fs8 fc3 sc0 ls64 ws0">with parenteral antimalarial drugs wher<span class="_ _a"></span>ever possible.</div><div class="t m0 x9 hb y1498 ff17 fs8 fc3 sc0 ls1fa ws43c">Many hyperparasitaemic patients have evidence of vital or<span class="_ _a"></span>gan dysfunction but</div><div class="t m0 x9 hb y1499 ff17 fs8 fc3 sc0 ls12 ws262">there is a subgroup of individuals in whom no other manifestations of sev<span class="_ _a"></span>ere</div><div class="t m0 x9 hb y149a ff17 fs8 fc3 sc0 ls12 ws30f">disease occur<span class="_ _b"></span>. These patients hav<span class="_ _a"></span>e symptoms and signs compatible with a</div><div class="t m0 x9 hb y149b ff17 fs8 fc3 sc0 ls192 ws27a">diagnosis of uncomplicated malaria in association with a high parasite count.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe3" class="pf w1 h4" data-page-no="e3"><div class="pc pce3 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">217</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls24d ws1a2">They usually have a predominance of y<span class="_ _a"></span>oung ring forms in the peripheral</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 lsaa ws110">blood smear<span class="_ _4b"></span>, which suggests that the sequestered biomass is relatively small</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 lsd5 ws74">compared with the circulating par<span class="_ _a"></span>asite numbers. On the Thai-Burmese border<span class="_ _4b"></span>,</div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 ls12 ws28d">the mortality of falciparum malaria in patients with counts of parasitized red</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls164 ws19b">blood cells <span class="ff1c ls0 ws0">&lt;</span>4% was approximately 0.1%, whereas with counts <span class="ff1c ls0 ws0">&gt;</span>4% but</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls12 ws390">without vital organ dysfunction, the mortality was 3% <span class="ff1a ls13 ws0">(24)</span>. In another study</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls83 wsc7">in eastern Thailand, 48 hyperpar<span class="_ _a"></span>asitaemic patients were inadvertently included</div><div class="t m0 xb hb y10e ff17 fs8 fc3 sc0 lse7 ws178">in a cohort of 224 patients (mainly adult men) being followed up after receiving</div><div class="t m0 xb hb y10f ff17 fs8 fc3 sc0 ls1e ws1d">mefloquine treatment for uncomplicated disease in order to identify pr<span class="_ _a"></span>edictors</div><div class="t m0 xb hb y110 ff17 fs8 fc3 sc0 ls18c ws26f">of treatment failure. <span class="_ _a"></span>Y<span class="_ _b"></span>oung age, low admission haemoglobin, a history of</div><div class="t m0 xb hb y111 ff17 fs8 fc3 sc0 ls12 ws599">diarrhoea at the start of treatment or soon after<span class="_ _b"></span>, three or more mefloquine</div><div class="t m0 xb hb y2be ff17 fs8 fc3 sc0 lsc5 ws13b">treatments within the preceding y<span class="_ _a"></span>ear and hyperparasitaemia on an admission</div><div class="t m0 xb hb y2bf ff17 fs8 fc3 sc0 ls13c ws189">blood film were all pr<span class="_ _a"></span>edictors of subsequent treatment failure <span class="ff1a ws0">(25)</span><span class="ws59a">. The study</span></div><div class="t m0 xb hb y484 ff17 fs8 fc3 sc0 ls36f ws59b">took place at a time when mefloquine resistance was becoming well</div><div class="t m0 xb hb y485 ff17 fs8 fc3 sc0 ls1e1 ws312">established. The authors concluded that, in ar<span class="_ _a"></span>eas of multidrug resistance, the</div><div class="t m0 xb hb y9cc ff17 fs8 fc3 sc0 ls370 ws59c">initial parasite load becomes a critical determinant of treatment failur<span class="_ _a"></span>e</div><div class="t m0 xb hb y9cd ff17 fs8 fc3 sc0 ls9c wsfa">because strains have intermediate susceptibility to drugs. P<span class="_ _a"></span>atients with little</div><div class="t m0 xb hb y9ce ff17 fs8 fc3 sc0 lsdf ws16d">or no immunity to malaria (i.e. children) are at incr<span class="_ _a"></span>eased risk of treatment failure.</div><div class="t m0 xb hb y9cf ff17 fs8 fc3 sc0 ls12 ws4b9">In a review of the predictors of tr<span class="_ _a"></span>eatment failure in a large series of patients</div><div class="t m0 xb hb y9d0 ff17 fs8 fc3 sc0 ls23a ws2e9">studied on the western border of <span class="_ _a"></span>Thailand, the relative risk of tr<span class="_ _a"></span>eatment</div><div class="t m0 xb hb y149c ff17 fs8 fc3 sc0 ls12 ws4ef">failure was increased in patients with par<span class="_ _a"></span>asite counts <span class="ff1c ls0 ws0">&gt;</span><span class="ls44 ws254">10 000/μl (RR: 1.36;</span></div><div class="t m0 xb hb y149d ff17 fs8 fc3 sc0 ls1f1 ws86">95% CI: 1.12–1.66) <span class="ff1a ws0">(25)</span><span class="lsf7 ws1ad">. In Uganda, it was found that pretr<span class="_ _a"></span>eatment parasitaemia</span></div><div class="t m0 xb hb y149e ff1c fs8 fc3 sc0 ls0 ws0">&gt;<span class="ff17 ls13 ws111">100 000/μl was associated with treatment failure in adults (OR for failure:</span></div><div class="t m0 xb hb y149f ff17 fs8 fc3 sc0 ls24 ws26">2.26; 95% CI: 1.30–3.92), but the authors stated that this was due to a strong</div><div class="t m0 xb hb y14a0 ff17 fs8 fc3 sc0 ls12 ws0">association with body temperature in a multiv<span class="_ _b"></span>ariate analysis <span class="ff1a ls13">(26)</span><span class="ls0">.</span></div><div class="t m0 xb h23 y14a1 ff1e fs11 fc8 sc0 ls27a ws0">Definition</div><div class="t m0 xb hb ya2d ff17 fs8 fc3 sc0 lsdf ws16d">There is no uniformly agreed definition of hyperpar<span class="_ _a"></span>asitaemia. Some publications</div><div class="t m0 xb hb ya2e ff17 fs8 fc3 sc0 ls12 ws486">use a parasite count <span class="ff1c ls0 ws0">&gt;</span><span class="ls13 ws48b">100 000/μl of blood. Others use a pr<span class="_ _a"></span>opor<span class="_ _8"></span>tion of para-</span></div><div class="t m0 xb hb ya2f ff17 fs8 fc3 sc0 lsc9 ws13d">sitized red blood cells <span class="ff1c ls0 ws0">&gt;<span class="_ _a"></span><span class="ff17 ls237">4%, <span class="ff1c ls0">&gt;<span class="_ _a"></span><span class="ff17 ls237 ws13d">5% or<span class="_ _5"> </span><span class="ff1c ls0 ws0">&gt;</span><span class="ws2d">10%. In areas of high malaria tr<span class="_ _a"></span>ansmission,</span></span></span></span></span></div><div class="t m0 xb hb y14a2 ff17 fs8 fc3 sc0 ls1b2 ws1a4">mortality rates in patients with 4% or 5% parasitaemia are considerably lo<span class="_ _a"></span>wer</div><div class="t m0 xb hb y14a3 ff17 fs8 fc3 sc0 ls12 wsd8">than in areas of low tr<span class="_ _a"></span>ansmission because of the influence of host immunity<span class="_ _4b"></span>.</div><div class="t m0 xb h23 y14a4 ff1e fs11 fc8 sc0 ls27a ws0">T<span class="_ _b"></span>reatment studies</div><div class="t m0 xb h25 y14a5 ff1f fs12 fc4 sc0 ls4f ws542">Is parenteral tr<span class="_ _a"></span>eatment better?</div><div class="t m0 xb hb y14a6 ff17 fs8 fc3 sc0 ls2d wsce">There are v<span class="_ _a"></span>ery few studies specifically looking at treatment failure as an</div><div class="t m0 xb hb y14a7 ff17 fs8 fc3 sc0 lsdf ws86">outcome in hyperparasitaemic patients. A study working with hyperparasitaemic</div><div class="t m0 xb hb y14a8 ff17 fs8 fc3 sc0 ls0 ws0">(<span class="ff1c">&gt;</span><span class="ls64 ws83">4%) patients in a low-tr<span class="_ _a"></span>ansmission setting, compared oral (artesunate for 3</span></div><div class="t m0 xb hb y14a9 ff17 fs8 fc3 sc0 ls64 ws12b">days + mefloquine on day 2) with i.v<span class="_ _4b"></span>. therapy (loading-dose quinine regimen</div><div class="t m0 xb hb y14aa ff17 fs8 fc3 sc0 ls2a ws2b8">for 24 h followed by mefloquine). P<span class="_ _a"></span>atients in the oral therapy group had</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe4" class="pf w1 h4" data-page-no="e4"><div class="pc pce4 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 x9e h9 ya ff17 fs6 fc4 sc0 ls1 ws0">218</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 lsef ws22d">significantly faster parasite and fever clear<span class="_ _a"></span>ance and shor<span class="_ _8"></span>ter hospital stays</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls5d ws267">than those in the intravenous ther<span class="_ _a"></span>apy group. No patients pr<span class="_ _a"></span>ogressed to severe</div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls2bf ws304">disease. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, 28-day cure rates for the or<span class="_ _a"></span>al therapy group wer<span class="_ _a"></span>e poorer than</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 lsdf ws86">in non-hyperparasitaemic controls r<span class="_ _a"></span>eceiving the same treatment (70% compared</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls64 ws59d">to 96%). It was concluded that patients with hyperparasitaemia in areas of</div><div class="t m0 x9 hb yc1 ff17 fs8 fc3 sc0 lsaa ws93">multidrug resistance need a longer course of treatment to deal with the lar<span class="_ _a"></span>ger</div><div class="t m0 x9 hb y10d ff17 fs8 fc3 sc0 ls64 ws0">parasite biomass <span class="ff1a">(27)</span><span class="ls0">.</span></div><div class="t m0 x9 hb y18e ff17 fs8 fc3 sc0 ls12 ws59e">In one study from a high-transmission setting, 84 hyperpar<span class="_ _a"></span>asitaemic (<span class="ff1c ls0 ws0">&gt;<span class="_ _66"></span><span class="ff17 ls13">5%)</span></span></div><div class="t m0 x9 hb y18f ff17 fs8 fc3 sc0 ls13 ws53">children aged 1–10 years wer<span class="_ _a"></span>e assigned at random to receive either 5 days of</div><div class="t m0 x9 hb y190 ff17 fs8 fc3 sc0 lsa7 ws109">i.m. artemether or a single oral dose of mefloquine. Cure rates assessed at day</div><div class="t m0 x9 hb y191 ff17 fs8 fc3 sc0 ls13 ws28">14 were similar in the two gr<span class="_ _a"></span>oups (98% at day 14 for ar<span class="_ _8"></span>temether<span class="_ _b"></span>, 100% at day</div><div class="t m0 x9 hb y192 ff17 fs8 fc3 sc0 ls14 ws25d">28 for mefloquine), although parasite clearance was faster in the artemether</div><div class="t m0 x9 hb y193 ff17 fs8 fc3 sc0 lsa5 ws429">group<span class="_ _a"></span>. Four patients in the mefloquine group wer<span class="_ _a"></span>e excluded because of</div><div class="t m0 x9 hb y2c0 ff17 fs8 fc3 sc0 ls25 ws27">vomiting, but no patients progr<span class="_ _a"></span>essed to severe disease. <span class="_ _a"></span>The authors concluded</div><div class="t m0 x9 hb y2c1 ff17 fs8 fc3 sc0 ls12 ws3f1">that oral therapy may be giv<span class="_ _a"></span>en safely to hyperparasitaemic patients in Africa</div><div class="t m0 x9 hb y2c2 ff17 fs8 fc3 sc0 ls12 ws59f">pro<span class="_ _a"></span>vided that they can tolerate it orally and the parasites ar<span class="_ _a"></span>e fully sensitive</div><div class="t m0 x9 hb y2c3 ff17 fs8 fc3 sc0 ls12 ws0">to the drug <span class="ff1a ls1c3">(28)</span><span class="ls0">.</span></div><div class="t m0 x9 hb y1421 ff17 fs8 fc3 sc0 ls114 ws39">Another study from an area of stable tr<span class="_ _a"></span>ansmission showed rapid par<span class="_ _a"></span>asite</div><div class="t m0 x9 hb y1422 ff17 fs8 fc3 sc0 ls2d3 ws11c">clearance in all 32 patients with par<span class="_ _a"></span>asitaemias of 5–35% (mean 10.8%) following</div><div class="t m0 x9 hb y1423 ff17 fs8 fc3 sc0 ls1d8 wseb">oral amodiaquine therapy<span class="_ _c"></span>. Follow-up was to day 14 only and ther<span class="_ _a"></span>e was no</div><div class="t m0 x9 hb y1424 ff17 fs8 fc3 sc0 ls64 ws547">comparative tr<span class="_ _a"></span>eatment arm. The authors concluded that hyperparasitaemic</div><div class="t m0 x9 hb y1425 ff17 fs8 fc3 sc0 ls1f ws180">patients can safely be treated with oral ther<span class="_ _a"></span>apy if they have no features of sev<span class="_ _a"></span>ere</div><div class="t m0 x9 hb y14ab ff17 fs8 fc3 sc0 lsca ws22c">disease and can be closely monitored in the first 3 days <span class="ff1a ls9b ws0">(29)</span><span class="ws5a0">. The same</span></div><div class="t m0 x9 hb y14ac ff17 fs8 fc3 sc0 ls256 ws357">conclusion was reached from another cohort study from an area of stable</div><div class="t m0 x9 hb y14ad ff17 fs8 fc3 sc0 ls64 ws0">malaria transmission <span class="ff1a">(30)</span><span class="ls0">.</span></div><div class="t m0 x9 h25 y14ae ff1f fs12 fc4 sc0 ls4f ws542">Is duration of treatment important?</div><div class="t m0 x9 hb y14af ff17 fs8 fc3 sc0 ls1bf ws235">A study of 100 hyperparasitaemic (<span class="ff1c ls0 ws0">&gt;</span><span class="lse5 ws2f9">4%) adults and children on the <span class="_ _a"></span>Thai-</span></div><div class="t m0 x9 hb y14b0 ff17 fs8 fc3 sc0 ls6c ws1b6">Burmese border compared tr<span class="_ _a"></span>eatment with oral artesunate given alone for</div><div class="t m0 x9 hb y14b1 ff17 fs8 fc3 sc0 ls76 wsab">5 days with artesunate given for 5 days + mefloquine on day 2. Recrudescence</div><div class="t m0 x9 hb y14b2 ff17 fs8 fc3 sc0 ls2af ws541">(i.e. treatment failure) r<span class="_ _a"></span>ates were 36% and 6% respectiv<span class="_ _a"></span>ely<span class="_ _4b"></span>. T<span class="_ _b"></span>wo further</div><div class="t m0 x9 hb y14b3 ff17 fs8 fc3 sc0 lsc4 ws10a">hyperparasitaemic treatment gr<span class="_ _a"></span>oups were then investigated: 34 patients with</div><div class="t m0 x9 hb y14a4 ff17 fs8 fc3 sc0 ls64 ws5a1">recrudescent malaria following tr<span class="_ _a"></span>eatment with ar<span class="_ _8"></span>tesunate + mefloquine who</div><div class="t m0 x9 hb y14b4 ff17 fs8 fc3 sc0 ls64 ws4b0">then received artesunate for 7 days; and 132 patients from a malaria v<span class="_ _a"></span>accine</div><div class="t m0 x9 hb y14b5 ff17 fs8 fc3 sc0 ls239 ws200">study with primary infections who received artesunate for 7 days + mefloquine</div><div class="t m0 x9 hb y14b6 ff17 fs8 fc3 sc0 ls64 ws5a2">on day 2. In these two groups, which wer<span class="_ _a"></span>e non-randomized and not strictly</div><div class="t m0 x9 hb y14b7 ff17 fs8 fc3 sc0 ls151 ws381">comparable, recrudescence r<span class="_ _a"></span>ates were 26% and 7%, respectiv<span class="_ _a"></span>ely<span class="_ _4b"></span>. The authors</div><div class="t m0 x9 hb y14b8 ff17 fs8 fc3 sc0 ls64 ws2e9">concluded that duration of treatment is important, par<span class="_ _8"></span>ticularly when using</div><div class="t m0 x9 hb y14b9 ff17 fs8 fc3 sc0 ls64 ws5a3">artemisinin derivatives with short half-lives; that the addition of mefloquine</div><div class="t m0 x9 hb y14ba ff17 fs8 fc3 sc0 ls103 wsea">impro<span class="_ _a"></span>ved cure rates; and that it is important that the parasite counts are</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe5" class="pf w1 h4" data-page-no="e5"><div class="pc pce5 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">219</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls10e ws5a4">reduced massively by artesunate before using mefloquine so that selection</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls10e ws0">pressure for r<span class="_ _a"></span>esistance to mefloquine can be minimized <span class="ff1a">(31)</span><span class="ls0">.</span></div><div class="t m0 xb h23 y14bb ff1e fs11 fc8 sc0 ls27a ws0">Patients with extreme hyperpar<span class="_ _a"></span>asitaemia (<span class="ff1c ls0">&gt;</span>20%)</div><div class="t m0 xb hb ya59 ff17 fs8 fc3 sc0 ls12 ws4ee">There have been no tr<span class="_ _a"></span>eatment studies looking at these patients specifically<span class="_ _4b"></span>.</div><div class="t m0 xb hb ya5a ff17 fs8 fc3 sc0 ls12 ws5a5">They are often treated as having sev<span class="_ _a"></span>ere malaria even if they can take or<span class="_ _a"></span>al</div><div class="t m0 xb hb ya5b ff17 fs8 fc3 sc0 ls12 ws526">treatment. In low-tr<span class="_ _a"></span>ansmission settings this group of patients was excluded</div><div class="t m0 xb hb ya5c ff17 fs8 fc3 sc0 ls143 ws203">from hyperparasitaemia studies because of the risks of clinical deterior<span class="_ _a"></span>ation.</div><div class="t m0 xb hb ya5d ff17 fs8 fc3 sc0 ls12 ws5a6">Current practice for patients with par<span class="_ _a"></span>asitaemia <span class="ff1c ls0 ws0">&gt;</span><span class="ws58d">20% in these settings is to</span></div><div class="t m0 xb hb ya5e ff17 fs8 fc3 sc0 lsf9 ws516">give parenter<span class="_ _a"></span>al ar<span class="_ _8"></span>tesunate (or parenteral quinine if artesunate is not available),</div><div class="t m0 xb hb ya5f ff17 fs8 fc3 sc0 ls166 ws91">but this approach is not based on evidence </div><div class="t m0 x29 hb yb9d ff1b fs9 fc4 sc0 lsba ws5a7">(E. Ashley<span class="_ _4b"></span>, personal communication)<span class="ff17 fs8 fc3 ls0 ws0">.</span></div><div class="t m0 xb hb yb9e ff17 fs8 fc3 sc0 ls346 ws547">In Nigeria, where there ar<span class="_ _a"></span>e higher transmission rates, an upper limit to</div><div class="t m0 xb hb yb9f ff17 fs8 fc3 sc0 ls12 ws5a8">hyperparasitaemia was not used but the patients with extreme hyperpar<span class="_ _a"></span>a-</div><div class="t m0 xb hb yba0 ff17 fs8 fc3 sc0 ls58 ws212">sitaemia were not analysed as a separ<span class="_ _a"></span>ate group, so no data specific to this group</div><div class="t m0 xb hb ya20 ff17 fs8 fc3 sc0 ls12 ws81">are av<span class="_ _a"></span>ailable. </div><div class="t m0 xb h23 y126f ff1e fs11 fc8 sc0 ls27a ws0">Conclusions and recommendations</div><div class="t m0 xb hb yba2 ff17 fs8 fc3 sc0 ls62 ws89">Hyperparasitaemia carries an incr<span class="_ _a"></span>eased risk of mor<span class="_ _8"></span>tality in falciparum malaria.</div><div class="t m0 xb hb yba3 ff17 fs8 fc3 sc0 ls115 ws3b8">The activity of artemisinin derivatives against circulating par<span class="_ _a"></span>asites makes</div><div class="t m0 xb hb yca4 ff17 fs8 fc3 sc0 ls12 ws144">them particularly effective in hyperparasitaemic patients who have no other</div><div class="t m0 xb hb ya68 ff17 fs8 fc3 sc0 ls309 wsb9">signs of severity<span class="_ _c"></span>. T<span class="_ _b"></span>reatment failure rates ar<span class="_ _a"></span>e higher in hyperparasitaemic</div><div class="t m0 xb hb y1270 ff17 fs8 fc3 sc0 ls12 ws0">patients. This is also a potential sour<span class="_ _a"></span>ce of anew drug resistance.</div><div class="t m0 xb hb y14bc ff17 fs8 fc3 sc0 ls12 ws3a2">Hyperparasitaemic patients with no signs of sev<span class="_ _a"></span>ere disease may be treated</div><div class="t m0 xb hb y14bd ff17 fs8 fc3 sc0 ls12 ws0">with oral artemisinin derivatives pr<span class="_ _a"></span>ovided that the following apply:</div><div class="t m0 xb hb y14be ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls220 ws353">Patients must be monitored closely for the first 48 h after initiation of</span></div><div class="t m0 x26 hb y14bf ff17 fs8 fc3 sc0 ls12 ws0">treatment.</div><div class="t m0 xb hb y14c0 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws444">They must tolerate the drug(s) well, i.e. without diarrhoea or v<span class="_ _a"></span>omiting.</span></div><div class="t m0 xb hb y14c1 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls25 ws27">For r<span class="_ _a"></span>egimens containing mefloquine, the mefloquine should be given on day</span></div><div class="t m0 x26 hb y14c2 ff17 fs8 fc3 sc0 ls29a ws436">2 when it is better tolerated, with a low<span class="_ _a"></span>er incidence of early vomiting,</div><div class="t m0 x26 hb y14c3 ff17 fs8 fc3 sc0 ls12 ws0">rather than on day 0.</div><div class="t m0 xb hb y14c4 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 wsd2">If possible, additional oral artemisinin derivative should be giv<span class="_ _a"></span>en so that</span></div><div class="t m0 x26 hb y14c5 ff17 fs8 fc3 sc0 ls22 wsc4">the total treatment course is 5–7 days. <span class="_ _a"></span>This has been studied only for ar<span class="_ _8"></span>te-</div><div class="t m0 x26 hb y14c6 ff17 fs8 fc3 sc0 ls22 ws0">sunate + <span class="ls12 ws5e">mefloquine (artesunate 4 mg/kg immediately then 2 mg/kg/day</span></div><div class="t m0 x26 hb y14c7 ff17 fs8 fc3 sc0 ls76 wsb3">for a further 4–6 days + mefloquine 25 mg/kg given as a split dose after the</div><div class="t m0 x26 hb y14c8 ff17 fs8 fc3 sc0 lsbd ws2ed">second day). Alternatively<span class="_ _c"></span>, the first dose of ar<span class="_ _8"></span>temisinin derivative can be giv<span class="_ _a"></span>en</div><div class="t m0 x26 hb y14c9 ff17 fs8 fc3 sc0 ls12 ws0">parenterally or r<span class="_ _a"></span>ectally to ensure adequate absorption.</div><div class="t m0 xb hb y14ca ff17 fs8 fc3 sc0 ls12 ws37b">Non-immune patients with parasitaemia <span class="ff1c ls0 ws0">&gt;</span>20% should continue to receiv<span class="_ _a"></span>e</div><div class="t m0 xb hb y14cb ff17 fs8 fc3 sc0 ls12 ws5a9">parenteral ther<span class="_ _a"></span>apy wherever possible, as there is no evidence for or against</div><div class="t m0 xb hb y14cc ff17 fs8 fc3 sc0 ls12 ws0">using oral treatment in this gr<span class="_ _a"></span>oup and the risks are high.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe6" class="pf w1 h4" data-page-no="e6"><div class="pc pce6 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">220</div><div class="t m0 x9 h12 y12a ff19 fs6 fc4 sc0 ls9e ws0">A9.12<span class="_ _1"> </span>References </div><div class="t mc x9 h17 yf53 ff17 fsb fc3 sc0 ls105 ws0">1.<span class="_ _46"> </span>Lesi A, Meremikwu M. High first dose quinine for treating sev<span class="_ _a"></span>ere malaria. In: <span class="ff1a">The</span></div><div class="t mc x7a h17 yf54 ff1a fsb fc3 sc0 ls105 ws1d4">Cochrane Library<span class="_ _4b"></span>, Issue 2, 2003<span class="ff17 ws0">. (Oxford: Update Software. Sear<span class="_ _a"></span>ch date 2002;</span></div><div class="t mc x7a h17 y14cd ff17 fsb fc3 sc0 ls105 ws0">primary sources Cochrane Infectious Diseases Group specialised trials r<span class="_ _a"></span>egister<span class="_ _b"></span>,</div><div class="t mc x7a h17 y14ce ff17 fsb fc3 sc0 ls105 ws0">Cochrane Controlled <span class="_ _a"></span>T<span class="_ _b"></span>rials Register<span class="_ _b"></span>, Medline, Embase, Lilacs, conference</div><div class="t mc x7a h17 y14cf ff17 fsb fc3 sc0 ls105 ws0">proceedings, resear<span class="_ _a"></span>chers working in the field, and hand searches of references). </div><div class="t mc x9 h17 y14d0 ff17 fsb fc3 sc0 ls105 ws0">2.<span class="_ _44"> </span>Assimadi J<span class="_ _8"></span>K et al. [Intravenous quinine treatment of cer<span class="_ _a"></span>ebral malaria in African</div><div class="t mc x7a h17 y14d1 ff17 fsb fc3 sc0 ls105 ws0">children: comparison of a loading dose regimen to a r<span class="_ _a"></span>egimen without loading</div><div class="t mc x7a h17 y14d2 ff17 fsb fc3 sc0 ls105 ws0">dose]. <span class="ff1a">Archives de P<span class="_ _a"></span>ediatrie<span class="ff17 ws19a">, 2002, 9:587–594 (in French).</span></span></div><div class="t mc x9 h17 y14d3 ff17 fsb fc3 sc0 ls105 ws0">3.<span class="_ _44"> </span>Pasvol G et al. Quinine treatment of sever<span class="_ _a"></span>e falciparum malaria in African children:</div><div class="t mc x7a h17 y14d4 ff17 fsb fc3 sc0 ls105 ws0">a randomized comparison of three r<span class="_ _a"></span>egimens. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical</span></div><div class="t mc x7a h17 y14d5 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene<span class="ff17 lsd6 ws218">, 1991, 45:702–713.</span></div><div class="t mc x9 h17 y14d6 ff17 fsb fc3 sc0 ls105 ws0">4.<span class="_ _44"> </span>T<span class="_ _4b"></span>ombe M, Bhatt KM, Obel AOK. Quinine loading dose in severe falciparum</div><div class="t mc x7a h17 y14d7 ff17 fsb fc3 sc0 ls105 ws0">malaria at K<span class="_ _a"></span>enyatta National Hospital, K<span class="_ _a"></span>enya. <span class="ff1a">East African Medical Journal</span>, 1992,</div><div class="t mc x7a h17 y14d8 ff17 fsb fc3 sc0 ls2e1 ws0">69:670–674.</div><div class="t mc x9 h17 y14d9 ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>Eisenhut M, Omari AA. Intrarectal quinine for treating <span class="ff1a">Plasmodium falciparum</span></div><div class="t mc x7a h17 y14da ff17 fsb fc3 sc0 ls105 ws0">malaria. <span class="ff1a">Cochrane Database Syst R<span class="_ _a"></span>ev<span class="_ _b"></span>, <span class="ff17 lsd6 ws218">2005, 25(1): CD004009</span></span></div><div class="t mc x9 h17 y139d ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>Newton PN et al. Randomized comparison of artesunate and quinine in the</div><div class="t mc x7a h17 y14db ff17 fsb fc3 sc0 ls105 ws0">treatment of sever<span class="_ _a"></span>e falciparum malaria. <span class="ff1a">Clinical Infectious Diseases</span><span class="ls357 ws566">, 2003,</span></div><div class="t mc x7a h17 y14dc ff17 fsb fc3 sc0 ls2e2 ws0">37:7–16.</div><div class="t mc x9 h17 y14dd ff17 fsb fc3 sc0 ls1dc ws1d2">7.<span class="_ _39"> </span>South-East Asian Quinine Artesunate Malaria T<span class="_ _b"></span>rial (S<span class="_ _8"></span>EAQUAMA<span class="_ _b"></span>T) group.</div><div class="t mc x7a h17 y14de ff17 fsb fc3 sc0 ls105 ws0">Artesunate versus quinine for treatment of severe falciparum malaria: a</div><div class="t mc x7a h17 y14df ff17 fsb fc3 sc0 ls105 ws20a">randomized T<span class="_ _b"></span>rial. <span class="ff1a ws0">Lancet, </span><span class="lsd6 ws218">2005, 366:717-725. </span></div><div class="t mc x9 h17 y14e0 ff17 fsb fc3 sc0 ls105 ws0">8.<span class="_ _44"> </span>Artemether Quinine Meta-analysis Study Group. A meta-analysis using individual</div><div class="t mc x7a h17 y14e1 ff17 fsb fc3 sc0 ls105 ws0">patient data of trials comparing artemether with quinine in the treatment of</div><div class="t mc x7a h17 y14e2 ff17 fsb fc3 sc0 ls105 ws0">severe falciparum malaria. <span class="ff1a">T<span class="_ _4b"></span>ransactions of the Royal Society <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine</span></div><div class="t mc x7a h17 y14e3 ff1a fsb fc3 sc0 ls105 ws1d4">and Hygiene<span class="ff17 ws19a">, 2001, 95:637–650. (Search date not reported; primary sources</span></div><div class="t mc x7a h17 y14e4 ff17 fsb fc3 sc0 ls105 ws0">Medline, Cochrane, and discussions with an international panel of malaria</div><div class="t mc x7a h17 y14e5 ff17 fsb fc3 sc0 ls105 ws0">clinical investigators). </div><div class="t mc x9 h17 y14e6 ff17 fsb fc3 sc0 ls105 ws0">9.<span class="_ _44"> </span>McIntosh H<span class="_ _8"></span>M, Olliaro P<span class="_ _c"></span>. Artemisinin derivatives for tr<span class="_ _a"></span>eating severe malaria</div><div class="t mc x7a h17 y14e7 ff17 fsb fc3 sc0 ls105 ws0">(Cochrane Review). In: <span class="ff1a">The Cochr<span class="_ _a"></span>ane Library<span class="_ _4b"></span>, Issue 2, 2001<span class="ff17">. (Oxford: Update</span></span></div><div class="t mc x7a h17 y14e8 ff17 fsb fc3 sc0 ls105 ws0">Software. Search date 1999; primary sources Cochrane Infectious Diseases</div><div class="t mc x7a h17 y14e9 ff17 fsb fc3 sc0 ls105 ws0">Group <span class="_ _a"></span>T<span class="_ _b"></span>rials Register<span class="_ _b"></span>, Medline, Bids, Science Citation Index, Embase, African</div><div class="t mc x7a h17 y14ea ff17 fsb fc3 sc0 ls105 ws0">Index Medicus, Lilacs, hand searches of refer<span class="_ _a"></span>ence lists and conference abstracts,</div><div class="t mc x7a h17 y14eb ff17 fsb fc3 sc0 ls105 ws19a">and contact with organizations and resear<span class="_ _a"></span>chers in the field and pharmaceutical</div><div class="t mc x7a h17 y14ec ff17 fsb fc3 sc0 ls105 ws0">companies).</div><div class="t mc x9 h17 y14ed ff17 fsb fc3 sc0 ls105 ws0">10.<span class="_ _68"> </span>F<span class="_ _a"></span>aiz A et al. A randomized controlled trial comparing artemether and quinine in</div><div class="t mc x7a h17 y14ee ff17 fsb fc3 sc0 ls105 ws0">the treatment of cerebr<span class="_ _a"></span>al malaria in Bangladesh. <span class="ff1a">Indian Journal of Malariology</span><span class="ls0">,</span></div><div class="t mc x7a h17 y14ef ff17 fsb fc3 sc0 ls105 ws0">2001, 38:9–18.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe7" class="pf w1 h4" data-page-no="e7"><div class="pc pce7 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xdb he y9 ff16 fs5 fc3 sc0 ls3 ws0">Annex 9 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of severe <span class="ff1d lsad">Plasmodium falciparum<span class="_ _95"> </span></span><span class="lsee">malaria</span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">221</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">11.<span class="_ _0"> </span>Adam I et al. Comparison of intramuscular artemether and intravenous quinine in</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">the treatment of Sudanese children with sev<span class="_ _a"></span>ere falciparum malaria. <span class="ff1a">East African</span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Medical Journal<span class="ff17">, 2002, 79:621–625. </span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">12.<span class="_ _68"> </span>Satti GM, Elhassan SH, Ibrahim SA. <span class="_ _a"></span>The efficacy of ar<span class="_ _8"></span>temether versus quinine in</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">the treatment of cerebr<span class="_ _a"></span>al malaria. <span class="ff1a">Journal of the Egyptian Society of Parasitology</span><span class="ls0">,</span></div><div class="t mc x4d h17 yd66 ff17 fsb fc3 sc0 ls105 ws0">2002, 32:611–623. </div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">13.<span class="_ _68"> </span>Singh NB et al. Ar<span class="_ _8"></span>temether vs quinine therapy in <span class="ff1a">Plasmodium falciparum </span>malaria</div><div class="t mc x4d h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">in Manipur – a preliminary report. <span class="ff1a">Journal of Communicable Diseases</span>, 2001,</div><div class="t mc x4d h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">33:83–87.</div><div class="t mc xb h17 yd6a ff17 fsb fc3 sc0 ls105 ws1d4">14.<span class="_ _3"> </span>Afolabi BB, Okoromah CN. Intramuscular ar<span class="_ _8"></span>teether for treating sever<span class="_ _a"></span>e malaria. In:</div><div class="t mc x4d h17 yd88 ff1a fsb fc3 sc0 ls105 ws0">The Cochrane Database of Systematic R<span class="_ _a"></span>eviews 2004, Issue 4<span class="ff17">. </span></div><div class="t mc xb h17 yd6c ff17 fsb fc3 sc0 ls105 ws0">15.<span class="_ _68"> </span>Birku Y<span class="_ _4b"></span>, Makonnen E, Bjorkman A. Comparison of rectal artemisinin with</div><div class="t mc x4d h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">intravenous quinine in the tr<span class="_ _a"></span>eatment of severe malaria in Ethiopia. <span class="ff1a">East African</span></div><div class="t mc x4d h17 yd8b ff1a fsb fc3 sc0 ls105 ws0">Medical Journal<span class="ff17">, 1999, 76:154–159. </span></div><div class="t mc xb h17 yd8c ff17 fsb fc3 sc0 ls105 ws0">16.<span class="_ _3"> </span>Krishna S et al. Bioavailability and preliminary clinical efficacy of intrarectal</div><div class="t mc x4d h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">artesunate in Ghanaian children with moderate malaria. <span class="ff1a">Antimicrobial Agents</span></div><div class="t mc x4d h17 yd8e ff1a fsb fc3 sc0 ls105 ws0">and Chemotherapy<span class="ff17">, 2001, 45:509–516.</span></div><div class="t mc xb h17 yd8f ff17 fsb fc3 sc0 ls105 ws0">17.<span class="_ _68"> </span>Barnes K<span class="_ _8"></span>I et al. Efficacy of rectal artesunate compared with parenteral quinine in</div><div class="t mc x4d h17 yd90 ff17 fsb fc3 sc0 ls105 ws0">initial treatment of moderately sev<span class="_ _a"></span>ere malaria in African children and adults: a</div><div class="t mc x4d h17 yd91 ff17 fsb fc3 sc0 ls105 ws0">randomised study<span class="_ _4b"></span>. <span class="ff1a">Lancet</span><span class="lsd6 ws218">, 2004, 363:1598–1605.</span></div><div class="t mc xb h17 yd92 ff17 fsb fc3 sc0 ls105 ws0">18.<span class="_ _3"> </span>Prasad K, Garner P<span class="_ _c"></span>. Steroids for treating cerebr<span class="_ _a"></span>al malaria. In: <span class="ff1a">The Cochrane</span></div><div class="t mc x4d h17 yd93 ff1a fsb fc3 sc0 ls1dc ws1d2">Library<span class="_ _4b"></span>, Issue 2, 2003<span class="ff17 ls105 ws0">. (Oxford: Update Software. Search date 1999; primary</span></div><div class="t mc x4d h17 yf78 ff17 fsb fc3 sc0 ls105 ws0">sources <span class="_ _a"></span>T<span class="_ _a"></span>rials Register of the Cochr<span class="_ _a"></span>ane Infectious Diseases Group and Cochrane</div><div class="t mc x4d h17 yed3 ff17 fsb fc3 sc0 ls105 ws27d">Controlled T<span class="_ _b"></span>rials Register<span class="_ _b"></span>.) </div><div class="t mc xb h17 ydb0 ff17 fsb fc3 sc0 ls105 ws0">19.<span class="_ _3"> </span>Warrell D<span class="_ _a"></span>A et al. Dexamethasone prov<span class="_ _a"></span>es deleterious in cerebral malaria. A</div><div class="t mc x4d h17 y118f ff17 fsb fc3 sc0 ls105 ws19a">double-blind trial in 100 comatose patients. <span class="ff1a ws0">New England Journal of Medicine<span class="ff17 ls0">,</span></span></div><div class="t mc x4d h17 yed6 ff17 fsb fc3 sc0 ls2e2 ws1d3">1982, 306:313–319. </div><div class="t mc xb h17 ydb1 ff17 fsb fc3 sc0 ls105 ws0">20.<span class="_ _5"> </span>Hoffman SL et al. High-dose dexamethasone in quinine-treated patients with</div><div class="t mc x4d h17 ydb2 ff17 fsb fc3 sc0 ls105 ws0">cerebral malaria: a double-blind, placebo-contr<span class="_ _a"></span>olled trial. <span class="ff1a">Journal of Infectious</span></div><div class="t mc x4d h17 y1190 ff1a fsb fc3 sc0 ls105 ws0">Diseases<span class="ff17">, 1988, 158:325–331. </span></div><div class="t mc xb h17 ydb4 ff17 fsb fc3 sc0 ls105 ws0">21.<span class="_ _68"> </span>Meremikwu M, Smith HJ. Blood transfusion for treating malarial anaemia</div><div class="t mc x4d h17 ydb5 ff17 fsb fc3 sc0 ls105 ws0">(Cochrane Review). In: <span class="ff1a">The Cochr<span class="_ _a"></span>ane Library<span class="ff17 lsd6">, </span>Issue 3, 2001<span class="ff17">. (Oxford: Update</span></span></div><div class="t mc x4d h17 y1191 ff17 fsb fc3 sc0 ls105 ws0">Software. Search date 1999; primary sources <span class="_ _a"></span>T<span class="_ _b"></span>rials Register of the Cochrane</div><div class="t mc x4d h17 yedd ff17 fsb fc3 sc0 ls105 ws0">Infectious Diseases Group, Embase, African Index Medicus, Lilacs, hand sear<span class="_ _a"></span>ches</div><div class="t mc x4d h17 yede ff17 fsb fc3 sc0 ls105 ws0">of reference lists, and contact with experts.)</div><div class="t mc xb h17 y14f0 ff17 fsb fc3 sc0 ls105 ws0">22.<span class="_ _5"> </span>Meremikwu M, Marson AG. Routine anticonvulsants for treating cer<span class="_ _a"></span>ebral malaria.</div><div class="t mc x4d h17 yee0 ff1a fsb fc3 sc0 ls105 ws0">The Cochrane Database of Systematic R<span class="_ _a"></span>eviews <span class="ff17">2002, Issue 2. (Article No.</span></div><div class="t mc x4d h17 yee1 ff17 fsb fc3 sc0 ls104 ws35b">CD002152. DOI: 10.1002/14651858.CD002152). </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe8" class="pf w1 h4" data-page-no="e8"><div class="pc pce8 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">222</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">23.<span class="_ _95"> </span>Field JW<span class="_ _b"></span>, Niven JC. A note on pr<span class="_ _a"></span>ognosis in relation to parasite counts in acute</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">subtertian malaria. <span class="ff1a">T<span class="_ _a"></span>ransactions of the Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17 ws19a">, 1937, 30:569–574.</span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws1d4">24.<span class="_ _5"> </span>Fontanet AL, W<span class="_ _b"></span>alker AM. Predictors of treatment failure in multiple drug-resistant</div><div class="t mc x7a h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">falciparum malaria: results from a 42-day follo<span class="_ _a"></span>w-up of 224 patients in eastern</div><div class="t mc x7a h17 yd66 ff17 fsb fc3 sc0 ls105 ws0">Thailand. <span class="ff1a">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene<span class="ff17">, 1993, 49:465–472. </span></span></div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">25.<span class="_ _95"> </span>ter Kuile FO et al. Pr<span class="_ _a"></span>edictors of mefloquine treatment failure: a prospectiv<span class="_ _a"></span>e study</div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">of 1590 patients with uncomplicated falciparum malaria. <span class="ff1a">T<span class="_ _b"></span>ransactions of the</span></div><div class="t mc x7a h17 yd87 ff1a fsb fc3 sc0 ls105 ws0">Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17 ws19a">, 1995, 89:660–664.</span></div><div class="t mc x9 h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">26.<span class="_ _5"> </span>Dorsey G et al. Predictors of chloroquine treatment failur<span class="_ _a"></span>e in children and adults</div><div class="t mc x7a h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">with falciparum malaria in Kampala, Uganda. <span class="ff1a">American Journal of <span class="_ _b"></span>T<span class="_ _a"></span>ropical</span></div><div class="t mc x7a h17 yd89 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene<span class="ff17 ls1dc ws1d2">, 2000, 62:686–692.</span></div><div class="t mc x9 h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">27.<span class="_ _95"> </span>Luxembur<span class="_ _a"></span>ger C et al. Oral ar<span class="_ _8"></span>tesunate in the treatment of uncomplicated</div><div class="t mc x7a h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">hyperparasitemic falciparum malaria. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yeca ff1a fsb fc3 sc0 ls105 ws0">Hygiene<span class="ff17 ws19a">, 1995, 53:522–525. </span></div><div class="t mc x9 h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">28. Sowunmi A, W<span class="_ _b"></span>alker O, Akindele JA. Severe falciparum malaria: survival with oral</div><div class="t mc x7a h17 yd8e ff17 fsb fc3 sc0 ls105 ws0">therapy<span class="_ _4b"></span>. <span class="ff1a">T<span class="_ _b"></span>ropical and Geographical Medicine<span class="ff17">, 1992, 44:352–354.</span></span></div><div class="t mc x9 h17 yd8f ff17 fsb fc3 sc0 ls105 ws0">29.<span class="_ _5"> </span>Ndounga M, Basco LK. Rapid clearance of <span class="ff1a">Plasmodium falciparum </span>hyper-</div><div class="t mc x7a h17 yd90 ff17 fsb fc3 sc0 ls105 ws0">parasitaemia after oral amodiaquine tr<span class="_ _a"></span>eatment in patients with uncomplicated</div><div class="t mc x7a h17 yd91 ff17 fsb fc3 sc0 ls105 ws0">malaria. <span class="ff1a ws27d">Acta T<span class="_ _b"></span>ropica<span class="ff17 ls1dc ws1d2">, 2003, 88:27–32. </span></span></div><div class="t mc x9 h17 yd92 ff17 fsb fc3 sc0 ls105 ws0">30.<span class="_ _95"> </span>Sowunmi A et al. Open comparison of artemether and mefloquine in</div><div class="t mc x7a h17 yd93 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated <span class="ff1a">Plasmodium falciparum </span>hyperparasitaemia in children. <span class="ff1a">Annals of</span></div><div class="t mc x7a h17 yf78 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Paediatrics<span class="ff17">, 1996, 16:5–9.</span></div><div class="t mc x9 h17 ydaf ff17 fsb fc3 sc0 ls105 ws0">31.<span class="_ _68"> </span>Price R et al. Artesunate and mefloquine in the treatment of uncomplicated</div><div class="t mc x7a h17 ydb0 ff17 fsb fc3 sc0 ls105 ws0">multidrug-resistant hyperparasitaemic falciparum malaria. <span class="ff1a">T<span class="_ _b"></span>ransactions of the</span></div><div class="t mc x7a h17 y118f ff1a fsb fc3 sc0 ls105 ws0">Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene<span class="ff17">, 1998, 92:207–211.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe9" class="pf w1 h4" data-page-no="e9"><div class="pc pce9 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xb h22 y14f1 ff1b fs10 fc7 sc0 ls270 ws0">Annex 10.<span class="_ _50"> </span><span class="fc0">T<span class="_ _b"></span>reatment of <span class="ff1f">P<span class="_ _ae"></span>. viv<span class="_ _a"></span>ax, P<span class="_ _ae"></span>. ov<span class="_ _a"></span>ale</span></span></div><div class="t m0 x37 h22 y14f2 ff1b fs10 fc0 sc0 ls270 ws0">and <span class="ff1f">P<span class="_ _ae"></span>. malariae <span class="ff1b">infections </span></span></div><div class="t m0 xde h22 y14f3 ff1b fs10 fc4 sc0 ls371 ws0">225</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfea" class="pf w1 h4" data-page-no="ea"><div class="pc pcea w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfeb" class="pf w1 h4" data-page-no="eb"><div class="pc pceb w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">225</div><div class="t m0 x76 hf y7d ff18 fs6 fc3 sc0 ls1 ws0">ANN<span class="_ _8"></span>E<span class="_ _8"></span>X 10</div><div class="t m0 x8f hf y895 ff18 fs6 fc3 sc0 ls1b ws0">TREAT<span class="_ _b"></span>M<span class="_ _8"></span>ENT OF <span class="ff2e ws5aa">P<span class="_ _c"></span>. VIV<span class="_ _a"></span>A<span class="_ _8"></span>X<span class="ff18 ws0">, <span class="ff2e ls1">P<span class="_ _4b"></span>. OV<span class="_ _a"></span>ALE <span class="ff18 ls1b">AND </span>P<span class="_ _4b"></span>. MALAR<span class="_ _8"></span>IAE</span></span></span></div><div class="t m0 x17 hf y905 ff18 fs6 fc3 sc0 ls1c ws0">IN<span class="_ _8"></span>FECTIONS</div><div class="t m0 xb h12 y906 ff19 fs6 fc4 sc0 ls53 ws0">A10.1<span class="_ _1"> </span>Introduct<span class="_ _8"></span>ion</div><div class="t m0 xb hb y907 ff1a fs8 fc3 sc0 ls1e2 ws5ab">P<span class="_ _c"></span>. vivax<span class="ff17 ls12 ws4db">, the second major human malaria species, constitutes about 41% of</span></div><div class="t m0 xb hb y908 ff17 fs8 fc3 sc0 ls208 ws458">malaria cases worldwide <span class="ff1a">(1, 2) </span>and is the dominant species of malaria in</div><div class="t m0 xb hb y14f4 ff17 fs8 fc3 sc0 ls122 ws4b4">many areas outside Africa. It is prev<span class="_ _b"></span>alent in the Middle East, Asia, the Western</div><div class="t m0 xb hb y14f5 ff17 fs8 fc3 sc0 ls12 ws147">Pacific and Central and South America. It is r<span class="_ _a"></span>arer in Africa and almost absent</div><div class="t m0 xb hb y14f6 ff17 fs8 fc3 sc0 ls6e ws59b">from W<span class="_ _a"></span>est Africa <span class="_ _8"></span><span class="ff1a ws0">(2). <span class="_ _66"></span></span><span class="ws2cb">In most areas where <span class="ff1a ls2dc ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax<span class="_ _7c"> </span><span class="ff17 ls6e ws2cb">is prevalent, malaria</span></span></span></div><div class="t m0 xb hb y14f7 ff17 fs8 fc3 sc0 ls12 ws14c">transmission rates ar<span class="_ _a"></span>e low and, therefore, the affected populations achiev<span class="_ _a"></span>e</div><div class="t m0 xb hb y14f8 ff17 fs8 fc3 sc0 ls12 ws4db">little immunity to this parasite. Consequently<span class="_ _c"></span>, people of all ages, adults and</div><div class="t m0 xb hb y14f9 ff17 fs8 fc3 sc0 ls238 ws1ff">children alike are at risk of acquiring <span class="ff1a ls2aa ws0">P<span class="_ _ae"></span>.<span class="_ _3"> </span>vivax<span class="_ _3"> </span><span class="ff17 ls238">infections <span class="_ _66"></span></span>(2)<span class="ff17 ls238 ws5ac">. Where <span class="_ _8"></span>both</span></span></div><div class="t m0 xb hb y14fa ff1a fs8 fc3 sc0 ls13 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _6"> </span><span class="ff17 ls12">and </span><span class="ls14">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff17 ls13 ws25f">prev<span class="_ _a"></span>ail, the incidence rates of <span class="ff1a ls14 ws0">P<span class="_ _c"></span>. viv<span class="_ _b"></span>ax <span class="ff17 ls12 ws38c">tend to peak</span></span></span></span></div><div class="t m0 xb hb y14fb ff17 fs8 fc3 sc0 ls83 wsc7">in people of a younger age than those of <span class="ff1a">P<span class="_ _c"></span>. falciparum (3)<span class="ff17">. <span class="_ _a"></span>The other two human</span></span></div><div class="t m0 xb hb y14fc ff17 fs8 fc3 sc0 ls13 ws44d">malaria parasite species, <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _64"> </span>malariae<span class="_ _7c"> </span><span class="ff17 ls12">and <span class="_ _9"></span></span><span class="ls38">P.<span class="_ _2"> </span>o v<span class="_ _67"> </span>a l<span class="_ _67"> </span>e <span class="ff17 ls12 ws5ad">, are generally much less</span></span></span></div><div class="t m0 xb hb y14fd ff17 fs8 fc3 sc0 ls12 ws0">prev<span class="_ _a"></span>alent worldwide.</div><div class="t m0 xb hb y14fe ff17 fs8 fc3 sc0 ls64 ws42f">Among the four species of <span class="ff1a ws0">Plasmodium </span>that affect humans, only <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _95"> </span>vivax <span class="ff17">and</span></span></div><div class="t m0 xb hb y14ff ff1a fs8 fc3 sc0 ls64 ws0">P<span class="_ _c"></span>. ovale <span class="ff17 wsa6">have the ability to form hypnoz<span class="_ _a"></span>oites, parasite stages in the liver that</span></div><div class="t m0 xb hb y1500 ff17 fs8 fc3 sc0 ls64 ws4da">can result in relapse infections w<span class="_ _a"></span>eeks to months after the primary infection.</div><div class="t m0 xb hb y1501 ff1a fs8 fc3 sc0 ls85 ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax<span class="_ _7c"> </span><span class="ff17 ls90 ws260">preferentially inv<span class="_ _a"></span>ades reticulocytes and this may lead to anaemia.</span></div><div class="t m0 xb hb y1502 ff17 fs8 fc3 sc0 ls36d ws286">Repeated infections lead to a chr<span class="_ _a"></span>onic anaemia that can affect personal well-being,</div><div class="t m0 xb hb y1503 ff17 fs8 fc3 sc0 ls151 ws381">thereby impairing human and economic development in affected populations.</div><div class="t m0 xb hb y1504 ff17 fs8 fc3 sc0 ls64 ws28f">The residual malaria burden of <span class="ff1a ws0">P<span class="_ _ae"></span>.<span class="_ _95"> </span>vivax <span class="ff17 ws28f">is likely to be underestimated, and is</span></span></div><div class="t m0 xb hb y1505 ff17 fs8 fc3 sc0 ls64 ws5b">increasing in some regions of the world <span class="ff1a ls14 ws0">(2)</span>. Appr<span class="_ _a"></span>opriate case management of</div><div class="t m0 xb hb y1506 ff1a fs8 fc3 sc0 ls64 ws0">P<span class="_ _c"></span>. vivax <span class="ff17">malaria will help to minimiz<span class="_ _a"></span>e the global malaria burden. </span></div><div class="t m0 xb hb y1507 ff17 fs8 fc3 sc0 ls348 ws0">Although <span class="_ _9"></span><span class="ff1a ls241">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax<span class="_ _7c"> </span><span class="ff17 ws3b7">is known to be benign malaria, it causes a severe and</span></span></div><div class="t m0 xb hb y1508 ff17 fs8 fc3 sc0 ls22 ws427">debilitating febrile illness. V<span class="_ _a"></span>ivax malaria can also occasionally r<span class="_ _a"></span>esult in severe</div><div class="t m0 xb hb y1509 ff17 fs8 fc3 sc0 ls22 ws294">disease with life-threatening end-organ inv<span class="_ _a"></span>olvement, similar to sever<span class="_ _a"></span>e disease</div><div class="t m0 xb hb y150a ff17 fs8 fc3 sc0 ls22 ws272">in falciparum malaria. Severe viv<span class="_ _b"></span>ax malaria manifestations can present with</div><div class="t m0 xb hb y150b ff17 fs8 fc3 sc0 ls1b9 ws1b2">cerebral malaria <span class="ff1a ls78 ws0">(4)</span><span class="lsb1 ws1a4">, sev<span class="_ _a"></span>ere anaemia <span class="ff1a ls78 ws0">(5)</span><span class="ls1b9 ws1b2">, jaundice <span class="ff1a ls78 ws0">(5)</span>, acute respiratory distress</span></span></div><div class="t m0 xb hb y150c ff17 fs8 fc3 sc0 ls22 ws0">syndrome <span class="ff1a ls10e">(6)</span><span class="ws5ae">, splenic rupture </span><span class="ff1a ls10e">(7)</span><span class="ws5ae">, acute renal failure </span><span class="ff1a ls17a">(8–10)</span><span class="ws1a5">, sev<span class="_ _a"></span>ere thrombo-</span></div><div class="t m0 xb hb y150d ff17 fs8 fc3 sc0 ls22 ws0">cytopenia <span class="ff1a ls64 ws48b">(7, 11) </span><span class="ws48b">and pancytopenia </span><span class="ff1a ls10e">(5)</span><span class="wsf8">. The underlying mechanisms of sever<span class="_ _a"></span>e</span></div><div class="t m0 xb hb y150e ff17 fs8 fc3 sc0 ls375 ws13d">manifestations are not well understood, and may be of an inflammatory pathology</div><div class="t m0 xb hb y150f ff17 fs8 fc3 sc0 ls151 ws2ee">similar to that seen in falciparum malaria. During pregnancy<span class="_ _c"></span>, infection with</div><div class="t m0 xb hb y1510 ff1a fs8 fc3 sc0 lsef ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax<span class="ff17 lsba wsaa">, as with </span><span class="lsba">P<span class="_ _ae"></span>.<span class="_ _3"> </span>falciparum<span class="ff17 wsaa">, reduces birth weight. In primegravidae, the</span></span></div><div class="t m0 xb hb y1511 ff17 fs8 fc3 sc0 ls22 ws131">reduction is appro<span class="_ _a"></span>ximately two-thirds that associated with <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum<span class="_ _6"> </span><span class="ff17 lsfc">(110 g</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfec" class="pf w1 h4" data-page-no="ec"><div class="pc pcec w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls9a ws0">226</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls26e ws31e">compared to 170 g), but the effect does not decline with successive pr<span class="_ _a"></span>egnancies,</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls1d9 ws2fd">indeed in the one large series in which this was studied, it increased <span class="ff1a ls44 ws0">(12)<span class="ff17 ls0">.</span></span></div><div class="t m0 x9 hb ya0 ff17 fs8 fc3 sc0 ls2a0 ws96">Chronic anaemia, sequestration and pr<span class="_ _a"></span>o-inflammatory cytokines in the placenta</div><div class="t m0 x9 hb ya1 ff17 fs8 fc3 sc0 ls75 ws458">lead to lower birth weights <span class="ff1a lsc8 ws353">(12, 14)</span>, increasing the risk of low birth weight</div><div class="t m0 x9 hb yc0 ff17 fs8 fc3 sc0 ls0 ws0">(<span class="ff1c">&lt;</span><span class="ls22">2500 g) and thus the risk of neonatal death.</span></div><div class="t m0 x9 h12 y43b ff19 fs6 fc4 sc0 ls9a ws0">A10.2<span class="_ _1"> </span>Diagnosis</div><div class="t m0 x9 hb y598 ff17 fs8 fc3 sc0 ls12 ws50c">Diagnosis of vivax malaria is based on micr<span class="_ _a"></span>oscopy<span class="_ _4b"></span>. R<span class="_ _8"></span>DT<span class="_ _c"></span>s based on immuno-</div><div class="t m0 x9 hb y599 ff17 fs8 fc3 sc0 ls12 ws254">chromatographic methods ar<span class="_ _a"></span>e available for the detection of non-falciparum</div><div class="t m0 x9 hb y59a ff17 fs8 fc3 sc0 lsa7 ws109">malaria. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, their sensitivities for detecting parasitaemias of ≤500/<span class="ff1c ls0 ws0">μ</span><span class="wsde">l ar<span class="_ _a"></span>e</span></div><div class="t m0 x9 hb y59b ff17 fs8 fc3 sc0 ls13 ws0">low <span class="_ _a"></span><span class="ff1a ls12">(15–21)<span class="ff17 ws2cd">. The r<span class="_ _a"></span>elatively high cost of these tests is a further impediment to</span></span></div><div class="t m0 x9 hb y59c ff17 fs8 fc3 sc0 ls12 ws11b">their widespread use in endemic areas. Molecular markers for genotyping</div><div class="t m0 x9 hb y59d ff1a fs8 fc3 sc0 ls14 ws0">P<span class="_ _c"></span>.<span class="_ _95"> </span>vivax <span class="ff17 ls13 ws53a">parasites are available for the </span><span class="ls12">dhfr <span class="ff17 ws53a">gene, and those for chloroquine</span></span></div><div class="t m0 x9 hb y59e ff17 fs8 fc3 sc0 ls12 ws0">resistance are under dev<span class="_ _a"></span>elopment.</div><div class="t m0 x9 h12 y1512 ff19 fs6 fc4 sc0 ls1 ws0">A10.3<span class="_ _1"> </span>T<span class="_ _c"></span>reatment</div><div class="t m0 x9 hb y1513 ff17 fs8 fc3 sc0 ls274 ws40d">The objectives of treatment of viv<span class="_ _b"></span>ax malaria are to cure the acute infection and</div><div class="t m0 x9 hb y1514 ff17 fs8 fc3 sc0 ls2f0 ws256">also to clear hypnozoites from the liv<span class="_ _a"></span>er to prevent future r<span class="_ _a"></span>elapses. This is kno<span class="_ _a"></span>wn</div><div class="t m0 x9 hb y1515 ff17 fs8 fc3 sc0 ls12 ws0">as radical cure. </div><div class="t m0 x9 hb y1516 ff17 fs8 fc3 sc0 ls12 ws5af">There are r<span class="_ _a"></span>elatively few studies on the treatment of <span class="ff1a ls13 ws0">P<span class="_ _ae"></span>.<span class="_ _95"> </span>vivax. <span class="ff17 ls12 ws63">Only 11% of the</span></span></div><div class="t m0 x9 hb y1517 ff17 fs8 fc3 sc0 ls12 wsf9">435 published antimalarial drug trials have been on <span class="ff1a ls14 ws0">P<span class="_ _ae"></span>.<span class="_ _3"> </span>vivax<span class="_ _3"> </span><span class="ff17 ls12">malaria <span class="_ _66"></span></span><span class="ls13">(22)<span class="ff17 ls0">.</span></span></span></div><div class="t m0 x9 h2e y1518 ff19 fs3 fc3 sc0 ls2a5 ws554">A10.3.1<span class="_ _7c"> </span>S<span class="_ _8"></span>tandard oral regimen</div><div class="t m0 x9 hb y1519 ff17 fs8 fc3 sc0 ls12 wsac">Chloroquine monotherapy (25 mg base/kg b<span class="_ _a"></span>w over 3 days) is r<span class="_ _a"></span>ecommended</div><div class="t m0 x9 hb y151a ff17 fs8 fc3 sc0 ls50 ws1fa">as the standard treatment for viv<span class="_ _a"></span>ax malaria because the parasite remains</div><div class="t m0 x9 hb y151b ff17 fs8 fc3 sc0 ls12 ws5b0">sensitive to chloroquine in much of the world. P<span class="_ _a"></span>rimaquine (0.25 or 0.5 mg</div><div class="t m0 x9 hb y151c ff17 fs8 fc3 sc0 ls12 ws76">base/kg bw in a single daily dose for 14 days) is used as a supplement to the</div><div class="t m0 x9 hb y151d ff17 fs8 fc3 sc0 lsa0 wsff">standard treatment for the purpose of er<span class="_ _a"></span>adicating dormant parasites in the liver</div><div class="t m0 x9 hb y151e ff17 fs8 fc3 sc0 ls206 ws1a3">and preventing r<span class="_ _a"></span>elapses. The optimal dose of primaquine differs in geographical</div><div class="t m0 x9 hb y151f ff17 fs8 fc3 sc0 ls6a ws96">areas depending on the relapsing natur<span class="_ _a"></span>e of the infecting strain, and it remains</div><div class="t m0 x9 hb y1520 ff17 fs8 fc3 sc0 ls249 ws28e">unclear in patients of heavy body weight <span class="ff1a ws0">(23)</span>. <span class="_ _a"></span>This combination of chloroquine</div><div class="t m0 x9 hb y1521 ff17 fs8 fc3 sc0 ls2c0 ws206">and primaquine constitutes treatment to achieve r<span class="_ _a"></span>adical cure of vivax malaria. </div><div class="t m0 x9 hb y1522 ff17 fs8 fc3 sc0 ls12 ws127">Primaquine also has weak activity against blood stage parasites. <span class="_ _b"></span>The radical</div><div class="t m0 x9 hb y1523 ff17 fs8 fc3 sc0 ls1c9 ws137">cure regimen of viv<span class="_ _b"></span>ax malaria with chloroquine and primaquine therefore</div><div class="t m0 x9 hb y1524 ff17 fs8 fc3 sc0 ls12 ws47a">conforms to the definition of a combination therapy<span class="_ _c"></span>. The combination of any</div><div class="t m0 x9 hb y1525 ff17 fs8 fc3 sc0 lsf7 ws1ad">antimalarial against <span class="ff1a ls1f1 ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff17 lsf7 ws1ad">infections with primaquine has impro<span class="_ _a"></span>ved cure r<span class="_ _a"></span>ates</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfed" class="pf w1 h4" data-page-no="ed"><div class="pc pced w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">227</div><div class="t m0 xb hb y9e ff1a fs8 fc3 sc0 lse5 ws176">(24, 28) <span class="ff17 ls1bf ws403">and is therefore useful in the tr<span class="_ _a"></span>eatment of chloroquine-resistant</span></div><div class="t m0 xb hb y9f ff1a fs8 fc3 sc0 ls14 ws0">P<span class="_ _c"></span>. vivax <span class="ff17 ls12">infections.</span></div><div class="t m0 xb h2e y1526 ff19 fs3 fc3 sc0 ls80 wsc1">A10.3.2<span class="_ _7c"> </span>T<span class="_ _4b"></span>reatment of dr<span class="_ _8"></span>ug-resistant <span class="ff29 ls376 ws0">P.<span class="_ _2"> </span>v<span class="_ _6"> </span>i<span class="_ _6"> </span>v<span class="_ _6"> </span>a<span class="_ _6"> </span>x</span></div><div class="t m0 xb hb y24c ff17 fs8 fc3 sc0 ls2a ws38">Therapeutic efficacy data av<span class="_ _a"></span>ailable to date indicate that <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax<span class="_ _3"> </span><span class="ff17">remains</span></span></div><div class="t m0 xb hb y43a ff17 fs8 fc3 sc0 ls200 ws25">sensitive to chloroquine thr<span class="_ _a"></span>oughout most of the world <span class="ff1a">(26, 29–43)</span>. Indonesia</div><div class="t m0 xb hb y43b ff17 fs8 fc3 sc0 ls12 ws53d">is exceptional in that high therapeutic failur<span class="_ _a"></span>e rates ranging from 5% to 84%</div><div class="t m0 xb hb y39c ff17 fs8 fc3 sc0 ls8e wsdd">have been reported on day 28 of follow-up <span class="ff1a ws25d">(25, 26, 44–49)</span><span class="ls160">. <span class="_ _a"></span>There are reports</span></div><div class="t m0 xb hb y39d ff17 fs8 fc3 sc0 ls278 ws411">of chloroquine failure as both tr<span class="_ _a"></span>eatment and prophylaxis against <span class="ff1a ls310 ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax</span></div><div class="t m0 xb hb y154 ff17 fs8 fc3 sc0 ls2bc wsc2">malaria from sever<span class="_ _a"></span>al countries and regions where the species is endemic</div><div class="t m0 xb hb y155 ff1a fs8 fc3 sc0 ls13 ws0">(50–53)<span class="ff17 ls12 ws5b1">. Some of these studies did not measure chloroquine drug concen-</span></div><div class="t m0 xb hb y156 ff17 fs8 fc3 sc0 ls37 ws48">trations, so that it is questionable whether these findings repr<span class="_ _a"></span>esented strictly</div><div class="t m0 xb hb y112 ff17 fs8 fc3 sc0 ls12 ws0">defined chloroquine resistance <span class="ff1a ls13 ws14">(34, 38, 39, 41, 43, 54–57)</span><span class="ls0">.</span></div><div class="t m0 xb hb y1527 ff17 fs8 fc3 sc0 ls12 ws493">Antimalarials that are effective against <span class="ff1a ls13 ws0">P<span class="_ _ae"></span>.<span class="_ _64"> </span>falciparum<span class="_ _64"> </span><span class="ff17 ls12 ws493">are generally effective</span></span></div><div class="t m0 xb hb y1528 ff17 fs8 fc3 sc0 ls2d0 ws3df">against the other human malarias. The ex<span class="_ _a"></span>ception to this is sulfadoxine-</div><div class="t m0 xb hb y1529 ff17 fs8 fc3 sc0 ls12 ws3ed">pyrimethamine to which <span class="ff1a ls14 ws0">P<span class="_ _c"></span>.<span class="_ _7c"> </span>vivax<span class="_ _64"> </span><span class="ff17 ls12 ws3ed">is commonly resistant. Owing to the high</span></span></div><div class="t m0 xb hb y152a ff17 fs8 fc3 sc0 ls13 ws5b2">prev<span class="_ _a"></span>alence of <span class="ff1a ls12 ws0">dhfr<span class="_ _64"> </span><span class="ff17 ws5b3">mutations (</span><span class="ls13">pvdhfr</span><span class="ff17 ws5b3">) in </span><span class="ls14">P<span class="_ _c"></span>.<span class="_ _95"> </span>vivax<span class="ff17 ls12 ws359">, resistance to sulfado<span class="_ _a"></span>xine-</span></span></span></div><div class="t m0 xb hb y152b ff17 fs8 fc3 sc0 ls2b2 ws355">pyrimethamine develops faster in this parasite than in <span class="ff1a ws0">P<span class="_ _ae"></span>.<span class="_ _3"> </span>falciparum<span class="ff17">,<span class="_ _68"> </span>and</span></span></div><div class="t m0 xb hb y152c ff17 fs8 fc3 sc0 ls12 ws0">resistant <span class="ff1a ls14">P<span class="_ _c"></span>.<span class="_ _64"> </span>vivax <span class="ff17 ls12 ws5b4">become prevalent in areas wher<span class="_ _a"></span>e this drug is used for the</span></span></div><div class="t m0 xb hb y152d ff17 fs8 fc3 sc0 ls12 ws0">treatment of falciparum malaria <span class="ff1a ls14 ws15">(37, 58–66)</span><span class="ls0">.</span></div><div class="t m0 xb hb y152e ff17 fs8 fc3 sc0 ls1d3 ws2f2">The recommended treatment for chlor<span class="_ _a"></span>oquine-resistant <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax<span class="_ _7c"> </span><span class="ff17 ws2f2">is quinine</span></span></div><div class="t m0 xb hb y152f ff17 fs8 fc3 sc0 lsd5 ws74">(10 mg salt/kg bw three times a day for 7 days) <span class="ff1a ls5d ws0">(67)</span><span class="ls67 ws1f9">. Ho<span class="_ _a"></span>wever<span class="_ _4b"></span>, it is not an ideal</span></div><div class="t m0 xb hb y1530 ff17 fs8 fc3 sc0 ls12 ws5b5">treatment because of the toxicity of quinine and the poor adher<span class="_ _a"></span>ence to this</div><div class="t m0 xb hb y1531 ff17 fs8 fc3 sc0 ls12 ws297">regimen. A study in <span class="_ _a"></span>Thailand has found that treatment of vivax malaria with</div><div class="t m0 xb hb y1532 ff17 fs8 fc3 sc0 ls140 ws200">quinine leads to early relapses. <span class="_ _a"></span>This may be because quinine has a shor<span class="_ _8"></span>t half-</div><div class="t m0 xb hb y1533 ff17 fs8 fc3 sc0 ls12 ws0">life, and no antihypnozoite activity <span class="ff1a ls31b">(37)</span><span class="ls13">. </span></div><div class="t m0 xb hb y1534 ff17 fs8 fc3 sc0 ls12 ws10b">Other treatments that have been tested for the tr<span class="_ _a"></span>eatment of <span class="ff1a ls38 ws0">P.<span class="_ _68"> </span>v i<span class="_ _67"> </span>v a x<span class="_ _68"> </span></span><span class="ws0">malaria</span></div><div class="t m0 xb hb y1535 ff17 fs8 fc3 sc0 ls12 ws0">with varying degrees of efficacy include the follo<span class="_ _a"></span>wing drugs.</div><div class="t m0 xb hb y1536 ff17 fs8 fc3 sc0 ls377 ws5b6">Amodiaquine (25–30 mg base/kg bw given o<span class="_ _a"></span>ver 3 days) has been used</div><div class="t m0 xb hb y1537 ff17 fs8 fc3 sc0 ls12 ws5b7">effectively for the treatment of chlor<span class="_ _a"></span>oquine-resistant vivax malaria <span class="_ _a"></span><span class="ff1a ls44 ws0">(67) <span class="_ _8"></span><span class="ff17 ls12">and</span></span></div><div class="t m0 xb hb y1538 ff17 fs8 fc3 sc0 ls12 ws131">has been well tolerated <span class="ff1a ls50 ws0">(68–70)</span>. Primaquine must be added for r<span class="_ _a"></span>adical cure.</div><div class="t m0 xb hb y1539 ff17 fs8 fc3 sc0 ls15c ws26e">Mild nausea, vomiting and abdominal pain are the commonly r<span class="_ _a"></span>epor<span class="_ _8"></span>ted adverse</div><div class="t m0 xb hb y153a ff17 fs8 fc3 sc0 ls12 ws0">reactions <span class="ff1a ls53">(70)</span><span class="ls0">.</span></div><div class="t m0 xb hb y153b ff17 fs8 fc3 sc0 ls14 ws25d">Mefloquine (15 mg base/kg bw as a single dose) has been found to be highly</div><div class="t m0 xb hb y153c ff17 fs8 fc3 sc0 ls13 ws14">effective with a treatment success of 100% <span class="ff1a ls31b ws0">(37)<span class="ff17 ls0">.</span></span></div><div class="t m0 xb hb y153d ff17 fs8 fc3 sc0 ls13 ws592">Halofantrine (24 mg base/kg bw ov<span class="_ _a"></span>er 12 hours in three divided doses) has</div><div class="t m0 xb hb y153e ff17 fs8 fc3 sc0 ls28 ws34">shown v<span class="_ _a"></span>aried efficacy in vivax malaria <span class="ff1a ls3e">(24, 25, 36, 37) </span>but is not r<span class="_ _a"></span>ecommended</div><div class="t m0 xb hb y153f ff17 fs8 fc3 sc0 ls12 ws0">because of its known cardioto<span class="_ _a"></span>xicity<span class="_ _4b"></span>. </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfee" class="pf w1 h4" data-page-no="ee"><div class="pc pcee w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1b ws0">228</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls1d9 ws18c">Doxycy<span class="_ _a"></span>cline alone (100 mg twice a day for 7 days) is not recommended for the</div><div class="t m0 x9 hb y9f ff17 fs8 fc3 sc0 ls12 ws0">treatment of viv<span class="_ _a"></span>ax malaria because of its poor efficacy <span class="ff1a ls13">(46)<span class="ff17">. </span></span></div><div class="t m0 x9 hb y1f3 ff17 fs8 fc3 sc0 ls22 ws3e">Artemisinin derivatives as monotherapy for 3–7 days hav<span class="_ _a"></span>e shown poor efficacy</div><div class="t m0 x9 hb y18a ff17 fs8 fc3 sc0 ls22 ws113">in vivax malaria, with day 28 cur<span class="_ _a"></span>e rates of 47–77% <span class="ff1a ls91 ws1a0">(27, 37, 55)</span>. The addition of</div><div class="t m0 x9 hb y18b ff17 fs8 fc3 sc0 ls22 ws4e5">primaquine to these regimes impro<span class="_ _a"></span>ved the day 28 cure r<span class="_ _a"></span>ates to 100% <span class="ff1a">(27, 71)</span><span class="ls0 ws0">.</span></div><div class="t m0 x9 hb y1540 ff17 fs8 fc3 sc0 ls12 ws264">Combinations of chloroquine (25 mg base/kg bw giv<span class="_ _a"></span>en in divided doses over</div><div class="t m0 x9 hb y1541 ff17 fs8 fc3 sc0 ls12 ws3ef">3 days) and sulfadoxine-pyrimethamine (based on a pyrimethamine dosage</div><div class="t m0 x9 hb y1542 ff17 fs8 fc3 sc0 ls197 ws28c">of 1.25 mg/kg bw as a single dose) or chloroquine (25 mg base/kg bw in divided</div><div class="t m0 x9 hb y1269 ff17 fs8 fc3 sc0 ls0 ws2e6">doses ov<span class="_ _a"></span>er 3 days) and doxycycline (100 mg twice a day for 7 days) hav<span class="_ _a"></span>e</div><div class="t m0 x9 hb y126a ff17 fs8 fc3 sc0 ls1b9 ws4ba">shown modest efficacy (71–82%) and have not sho<span class="_ _a"></span>wn significant improv<span class="_ _a"></span>ements</div><div class="t m0 x9 hb y126b ff17 fs8 fc3 sc0 ls12 ws0">in cure rate compar<span class="_ _a"></span>ed with chloroquine alone <span class="ff1a ls160 ws4e5">(46, 70)</span><span class="ls0">.</span></div><div class="t m0 x9 hb y126c ff17 fs8 fc3 sc0 ls12 ws304">Other combinations of artesunate (4 mg/kg bw, single daily dose for 3 days)</div><div class="t m0 x9 hb y126d ff17 fs8 fc3 sc0 ls378 ws5b8">and sulfadoxine-pyrimethamine (based on a pyrimethamine dosage of</div><div class="t m0 x9 hb y126e ff17 fs8 fc3 sc0 ls345 ws12d">1.25 mg/kg bw<span class="_ _a"></span>, single dose), when used in areas of high chloroquine-r<span class="_ _a"></span>esistant</div><div class="t m0 x9 hb y1543 ff1a fs8 fc3 sc0 ls14 ws0">P<span class="_ _c"></span>. vivax <span class="ff17 ls12">(w<span class="_ _a"></span>est Papua), produced 28-day cure r<span class="_ _a"></span>ates of less than 90% <span class="ff1a ls13">(64)</span><span class="ls0">.</span></span></div><div class="t m0 x9 hb y1544 ff17 fs8 fc3 sc0 ls1fc ws343">Artemether-lumefantrine (the latter formerly kno<span class="_ _a"></span>wn as benflumetol) (16 tablets</div><div class="t m0 x9 hb y1545 ff17 fs8 fc3 sc0 ls21d wscc">for 3 days or 20 tablets for 5 days given twice a day in divided doses) has sho<span class="_ _a"></span>wn</div><div class="t m0 x9 hb y1546 ff17 fs8 fc3 sc0 ls64 ws3ea">significantly shorter parasite clearance times than in the standard regimen of</div><div class="t m0 x9 hb y1547 ff17 fs8 fc3 sc0 ls31b ws176">chloroquine + primaquine. How<span class="_ _a"></span>ever<span class="_ _4b"></span>, these regimens were associated with</div><div class="t m0 x9 hb y1548 ff17 fs8 fc3 sc0 ls7a wse2">higher relapse rates than with chlor<span class="_ _a"></span>oquine + primaquine in the nine months of</div><div class="t m0 x9 hb y1549 ff17 fs8 fc3 sc0 ls1e ws1b2">follow up <span class="ff1a ws0">(72)</span>. In another ev<span class="_ _a"></span>aluation of the efficacy of ar<span class="_ _8"></span>temether<span class="_ _a"></span>-lumefantrine</div><div class="t m0 x9 hb y154a ff17 fs8 fc3 sc0 ls64 ws0">against <span class="ff1a">P<span class="_ _ae"></span>. falciparum <span class="ff17 ws175">the population studied included patients who w<span class="_ _a"></span>ere also</span></span></div><div class="t m0 x9 hb y154b ff17 fs8 fc3 sc0 ls64 ws45">infected with <span class="ff1a ws0">P<span class="_ _c"></span>. vivax<span class="ff17 ws45">. Although high r<span class="_ _a"></span>ates of <span class="ff1a ws0">P<span class="_ _c"></span>. vivax <span class="ff17 ws45">parasite clear<span class="_ _a"></span>ance were</span></span></span></span></div><div class="t m0 x9 hb y154c ff17 fs8 fc3 sc0 ls64 ws13c">noted within 42 h, in 6/16 patients parasites reappear<span class="_ _a"></span>ed before 28 days <span class="ff1a ls14 ws0">(73)<span class="ff17 ls10e">. </span></span></div><div class="t m0 x9 hb y154d ff17 fs8 fc3 sc0 ls110 ws424">The best combinations for the treatment of <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _3"> </span>vivax<span class="_ _7c"> </span><span class="ff17 ws424">are those containing</span></span></div><div class="t m0 x9 hb y154e ff17 fs8 fc3 sc0 ls1fc ws214">primaquine when given at antihypnozoite doses <span class="ff1a ls1db ws438">(24, 29, 37, 39, 56, 70, 7<span class="_ _a"></span>4, 75)<span class="ff17 ls0 ws0">.</span></span></div><div class="t m0 x9 hb y154f ff17 fs8 fc3 sc0 ls50 ws1fa">The addition of primaquine at the standard dose of 0.25 mg/kg bw<span class="_ _b"></span>, once</div><div class="t m0 x9 hb y1550 ff17 fs8 fc3 sc0 ls12 ws16e">daily for 14 days to chloroquine has impro<span class="_ _a"></span>ved the cure r<span class="_ _a"></span>ates in chloroquine-</div><div class="t m0 x9 hb y1551 ff17 fs8 fc3 sc0 ls4b ws6c">resistant viv<span class="_ _a"></span>ax malaria <span class="ff1a">(25, 39, 54, 56)</span>. Further<span class="_ _b"></span>, at higher doses (0.5–0.6 mg/kg,</div><div class="t m0 x9 hb y1552 ff17 fs8 fc3 sc0 lsfa ws3ea">once daily for 14 days), primaquine appears to be effective in areas wher<span class="_ _a"></span>e there</div><div class="t m0 x9 hb y1553 ff17 fs8 fc3 sc0 ls12 ws0">are presumed primaquine-r<span class="_ _a"></span>esistant hypnozoite infections <span class="ff1a ls13 ws14">(27, 76)</span><span class="ls0">.</span></div><div class="t m0 x9 hb y1554 ff17 fs8 fc3 sc0 ls26 ws0">Unlike <span class="_ _a"></span><span class="ff1a">P<span class="_ _c"></span>.<span class="_ _6"> </span>falciparum<span class="ff17 ls182">, <span class="ff1a">P<span class="_ _ae"></span>. viv<span class="_ _a"></span>ax <span class="ff17 ls26 ws2a">cannot be cultur<span class="_ _a"></span>ed continuously <span class="ff1a ls2ab">in vitro</span>, so that</span></span></span></span></div><div class="t m0 x9 hb y1555 ff17 fs8 fc3 sc0 ls165 ws238">it is more difficult to determine the <span class="ff1a">in vitro </span>sensitivity of <span class="ff1a ws0">P<span class="_ _ae"></span>. vivax<span class="_ _6"> </span><span class="ff17 ws3">to antimalarials.</span></span></div><div class="t m0 x9 hb y1556 ff1a fs8 fc3 sc0 ls239 ws12d">In vivo <span class="ff17 ls345">assessment of the therapeutic efficacy of drugs against </span><span class="ls1fa ws0">P<span class="_ _ae"></span>. viv<span class="_ _a"></span>ax <span class="ff17 ls345">malaria</span></span></div><div class="t m0 x9 hb y1557 ff17 fs8 fc3 sc0 ls24e ws3cd">is also compounded by difficulties in distinguishing recrudescences due to drug-</div><div class="t m0 x9 hb y1558 ff17 fs8 fc3 sc0 ls8c ws5b9">resistant infections from r<span class="_ _a"></span>elapses. The interval between the primary and</div><div class="t m0 x9 hb y1559 ff17 fs8 fc3 sc0 lsc4 ws1b3">repeat infection can serve as a general guide. If the recurr<span class="_ _a"></span>ence appears within</div><div class="t m0 x9 hb y155a ff17 fs8 fc3 sc0 ls12 ws3d7">16 days of starting treatment of the primary infection it is almost cer<span class="_ _8"></span>tainly a</div><div class="t m0 x9 hb y155b ff17 fs8 fc3 sc0 ls13 ws0">recrudescence due to therapeutic failur<span class="_ _a"></span>e. A recurrence between days 17 and</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfef" class="pf w1 h4" data-page-no="ef"><div class="pc pcef w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls9a ws0">229</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls6c ws99">28 may be either a recrudescence by chloroquine-r<span class="_ _a"></span>esistant parasites or a</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls12 ws494">relapse. Beyond day 28 any r<span class="_ _a"></span>ecurrence probably repr<span class="_ _a"></span>esents a relapse in an</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls2b3 ws52c">infection of chloroquine-sensitive <span class="ff1a">P<span class="_ _ae"></span>. vivax (77, 78)<span class="ff17">. A recurr<span class="_ _a"></span>ent vivax parasitaemia</span></span></div><div class="t m0 xb hb ya1 ff17 fs8 fc3 sc0 lsca ws44">in the presence of chloroquine blood lev<span class="_ _a"></span>els exceeding 100 ng/ml, and a</div><div class="t m0 xb hb yc0 ff17 fs8 fc3 sc0 ls90 wse2">parasite genotype identical with the primary infection as detected by PCR are</div><div class="t m0 xb hb yc1 ff17 fs8 fc3 sc0 ls12 ws481">more suggestive of chlor<span class="_ _a"></span>oquine resistance of the primary infection than a</div><div class="t m0 xb hb y10d ff17 fs8 fc3 sc0 ls12 ws0">relapse infection.</div><div class="t m0 xb h2e y153 ff19 fs3 fc3 sc0 ls35a ws56b">A10.3.3<span class="_ _7c"> </span>Preventive therapy for relapses</div><div class="t m0 xb hb y154 ff17 fs8 fc3 sc0 ls15a ws223">Primaquine is the only av<span class="_ _a"></span>ailable and marketed drug that can eliminate the latent</div><div class="t m0 xb hb y155 ff17 fs8 fc3 sc0 ls8e ws25d">hypnozoite reservoirs of <span class="ff1a ls160 ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>vivax<span class="_ _6"> </span><span class="ff17 ls8e">and<span class="_ _6"> </span><span class="ff1a">P<span class="_ _c"></span>.<span class="_ _6"> </span>ov<span class="_ _a"></span>ale <span class="ff17 wsdd">that cause r<span class="_ _a"></span>elapses. There is no</span></span></span></span></div><div class="t m0 xb hb y156 ff17 fs8 fc3 sc0 ls2f0 ws256">evidence that treatment courses shorter than 14 days are effective in prev<span class="_ _a"></span>enting</div><div class="t m0 xb hb y112 ff17 fs8 fc3 sc0 ls1a3 ws0">relapses <span class="_ _9"></span><span class="ff1a ws35f">(39, 56, 79, 80)</span><span class="ws202">. Relapse rates and primaquine sensitivity v<span class="_ _a"></span>ary</span></div><div class="t m0 xb hb y157 ff17 fs8 fc3 sc0 ls12 ws5ba">geographically<span class="_ _c"></span>. The reported incidences of relapses range from 11–26.7% in</div><div class="t m0 xb hb y43c ff17 fs8 fc3 sc0 ls12 ws0">India <span class="ff1a ws47e">(56, 81) <span class="_ _a"></span><span class="ff17">to 49–51% in Afghanistan <span class="ff1a ls13 ws0">(79)</span><span class="ws66">. Relapses may occur one to four</span></span></span></div><div class="t m0 xb hb y43d ff17 fs8 fc3 sc0 ls12 ws124">times after initiation of radical treatment <span class="ff1a ls53 ws5bb">(80, 82)</span>. In patients tr<span class="_ _a"></span>eated with</div><div class="t m0 xb hb y735 ff17 fs8 fc3 sc0 ls1e1 ws312">chloroquine, the first relapse is often suppr<span class="_ _a"></span>essed by pharmacologically active</div><div class="t m0 xb hb y736 ff17 fs8 fc3 sc0 ls12 ws5bc">concentrations of chloroquine and ther<span class="_ _a"></span>efore does not manifest clinically or</div><div class="t m0 xb hb y737 ff17 fs8 fc3 sc0 ls45 wsbb">parasitologically<span class="_ _c"></span>. The first clinically manifested relapse has been reported any</div><div class="t m0 xb hb y738 ff17 fs8 fc3 sc0 ls7f wsc0">time after day 16 and up to four years following the primary infection <span class="ff1a">(83, 85)</span><span class="ls0 ws0">.</span></div><div class="t m0 xb hb y739 ff17 fs8 fc3 sc0 ls90 wse2">Host immunity is also considered to be a major contributor to the therapeutic</div><div class="t m0 xb hb y2c7 ff17 fs8 fc3 sc0 ls114 ws2ee">response against relapses <span class="ff1a lsa6 ws0">(86)</span>. Risk factors associated with r<span class="_ _a"></span>elapses are</div><div class="t m0 xb hb y73a ff17 fs8 fc3 sc0 ls12 ws1b5">female sex, higher parasitaemia at baseline, shorter number of days with</div><div class="t m0 xb hb y73b ff17 fs8 fc3 sc0 ls12 ws0">symptoms prior to baseline, and a lower dose of primaquine <span class="ff1a ls14">(83)</span><span class="ls13">. </span></div><div class="t m0 xb hb y155c ff17 fs8 fc3 sc0 ls4e ws232">Hypnozoites of many strains of <span class="ff1a ws0">P<span class="_ _ae"></span>.<span class="_ _3"> </span>vivax<span class="_ _3"> </span><span class="ff17 ws232">are susceptible to a total dose of</span></span></div><div class="t m0 xb hb y155d ff17 fs8 fc3 sc0 ls22d ws394">210 mg of primaquine <span class="ff1a ws27a">(24, 37, 54, 75, 79, 83, 87)<span class="ff17 ls192">. Infections with the Chesson</span></span></div><div class="t m0 xb hb y155e ff17 fs8 fc3 sc0 ls166 ws91">strain or primaquine-resistant str<span class="_ _a"></span>ains prevalent in southern r<span class="_ _a"></span>egions of South-</div><div class="t m0 xb hb y155f ff17 fs8 fc3 sc0 ls2bf ws48e">East Asia and Oceania require a higher dosage of primaquine (22.5 mg or 30 mg</div><div class="t m0 xb hb y1560 ff17 fs8 fc3 sc0 ls165 ws238">per day for 14 days for a total dose of 315 mg or 420 mg, respectively) to pr<span class="_ _a"></span>event</div><div class="t m0 xb hb y1561 ff17 fs8 fc3 sc0 ls13 ws0">relapses <span class="_ _8"></span><span class="ff1a ws9a">(56, 74, 76)<span class="ff17 ls12">. Primaquine is contr<span class="_ _a"></span>aindicated in patients with severe</span></span></div><div class="t m0 xb hb y1562 ff17 fs8 fc3 sc0 ls200 ws25">variants of the inherited enzyme deficiency<span class="_ _c"></span>, G6PD <span class="ff1a">(88, 89) </span>(see section below</div><div class="t m0 xb hb y1563 ff17 fs8 fc3 sc0 ls13 ws14">on adverse effects).</div><div class="t m0 xb hb y1564 ff17 fs8 fc3 sc0 lsc4 ws1b3">Although, the long 14-day course of primaquine is a clear disadv<span class="_ _a"></span>antage, it has</div><div class="t m0 xb hb y1565 ff17 fs8 fc3 sc0 ls22d ws394">been shown that poor adherence to unsupervised 14-day primaquine therapy</div><div class="t m0 xb hb y1566 ff17 fs8 fc3 sc0 ls29c ws43b">can be ov<span class="_ _a"></span>ercome effectively through patient education <span class="ff1a ls1fd ws0">(90)</span><span class="ws35">. The lengthy</span></div><div class="t m0 xb hb y1567 ff17 fs8 fc3 sc0 ls122 ws4b4">treatment courses and follow-up periods make the assessment of primaquine</div><div class="t m0 xb hb y1568 ff17 fs8 fc3 sc0 ls12 ws5bd">efficacy difficult. Thus, the identification of <span class="ff1a ls14 ws0">P<span class="_ _ae"></span>. vivax <span class="ff17 ls12 ws5be">strains that are r<span class="_ _a"></span>esistant</span></span></div><div class="t m0 xb hb y1569 ff17 fs8 fc3 sc0 ls12 ws0">to chloroquine and/or to primaquine presents major challenges. </div><div class="t m0 xb hb y156a ff17 fs8 fc3 sc0 ls22 ws66">Alternative drugs ar<span class="_ _a"></span>e much needed for the radical treatment of <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>vivax<span class="_ _67"> </span><span class="ff17">malaria</span></span></div><div class="t m0 xb hb y156b ff17 fs8 fc3 sc0 ls330 ws3ec">resistant to chloroquine and/or primaquine. A new drug, tafenoquine, is curr<span class="_ _a"></span>ently</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff0" class="pf w1 h4" data-page-no="f0"><div class="pc pcf0 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">230</div><div class="t m0 x9 hb y9e ff17 fs8 fc3 sc0 ls22 ws431">being evaluated as an alternativ<span class="_ _a"></span>e to primaquine in the prevention of r<span class="_ _a"></span>elapses</div><div class="t m0 x9 hb y9f ff1a fs8 fc3 sc0 ls22 ws0">(91)<span class="ff17 ws1f">. Howev<span class="_ _a"></span>er<span class="_ _b"></span>, this too has haemolytic potential in G6PD-deficient individuals. </span></div><div class="t m0 x9 h2e y1526 ff19 fs3 fc3 sc0 ls0 wsc1">A10.3.4<span class="_ _7c"> </span>T<span class="_ _4b"></span>reatment of severe and complic<span class="_ _8"></span>ated vivax malaria</div><div class="t m0 x9 hb y24c ff17 fs8 fc3 sc0 lse4 ws174">Prompt and effectiv<span class="_ _a"></span>e management should be the same as for severe and</div><div class="t m0 x9 hb y43a ff17 fs8 fc3 sc0 ls12 ws296">complicated falciparum malaria (set out in section 8 of the main document). </div><div class="t m0 x9 h2e y156c ff19 fs3 fc3 sc0 ls80 ws0">A10.3.5<span class="_ _7c"> </span>T<span class="_ _4b"></span>reatment of malaria c<span class="_ _8"></span>aused by <span class="ff29 ls379">P<span class="_ _ae"></span>.<span class="_ _6"> </span>ovale <span class="ff19 ls69">and <span class="ff29">P<span class="_ _ae"></span>.<span class="_ _6"> </span>malariae</span></span></span></div><div class="t m0 x9 hb y156d ff17 fs8 fc3 sc0 ls229 ws5e">Resistance of <span class="ff1a ws0">P<span class="_ _ae"></span>. ov<span class="_ _a"></span>ale <span class="ff17">and <span class="_ _b"></span><span class="ff1a">P<span class="_ _c"></span>. malariae <span class="ff17 ws5e">to antimalarials is not w<span class="_ _a"></span>ell characterized</span></span></span></span></div><div class="t m0 x9 hb y156e ff17 fs8 fc3 sc0 ls12 ws30">and these infections are considered to be gener<span class="_ _a"></span>ally sensitive to chloroquine.</div><div class="t m0 x9 hb y156f ff17 fs8 fc3 sc0 ls12 ws55">Only a single study in Indonesia has reported <span class="ff1a ls13 ws0">P<span class="_ _c"></span>. malariae <span class="_ _a"></span><span class="ff17 ls12 ws55">resistant to chloro-</span></span></div><div class="t m0 x9 hb y1570 ff17 fs8 fc3 sc0 ls12 ws0">quine <span class="ff1a ls53">(63)</span><span class="ws471">. The r<span class="_ _a"></span>ecommended treatment for radical cure of <span class="ff1a ls38 ws0">P.<span class="_ _7c"> </span>o<span class="_ _67"> </span>v a l<span class="_ _67"> </span>e </span>, another</span></div><div class="t m0 x9 hb y1571 ff17 fs8 fc3 sc0 ls12 ws2b4">relapsing malaria, is the same as that for <span class="ff1a ls14 ws0">P<span class="_ _c"></span>. vivax,<span class="_ _95"> </span><span class="ff17 ls12 ws2b4">i.e. with chloroquine and</span></span></div><div class="t m0 x9 hb y1572 ff17 fs8 fc3 sc0 lsa8 ws10a">primaquine. The high pr<span class="_ _a"></span>evalence of G6PD-deficiency status in areas endemic</div><div class="t m0 x9 hb y1573 ff17 fs8 fc3 sc0 ls13 ws0">for <span class="_ _8"></span><span class="ff1a ls38">P.<span class="_ _2"> </span>o v a l<span class="_ _67"> </span>e<span class="_ _2"> </span></span><span class="ls12 ws5bf">calls for the same caution in the use of primaquine as stated in</span></div><div class="t m0 x9 hb y1574 ff17 fs8 fc3 sc0 ls8e ws5c0">section A10.3.3. <span class="ff1a ls13 ws0">P<span class="_ _c"></span>.<span class="_ _7c"> </span>malariae<span class="_ _64"> </span><span class="ff17 ls12 ws44c">forms no hypnozoites and so does not require</span></span></div><div class="t m0 x9 hb y7ff ff17 fs8 fc3 sc0 ls12 ws0">radical cure with primaquine.</div><div class="t m0 x9 h2e y1575 ff19 fs3 fc3 sc0 ls308 ws4e0">A10.3.6<span class="_ _7c"> </span>Adverse effects and contraindic<span class="_ _8"></span>ations</div><div class="t m0 x9 hb y1576 ff1a fs8 fc3 sc0 ls7f ws0">Chloroquine<span class="_ _6"> </span><span class="ff17 wsc0">is generally well toler<span class="_ _a"></span>ated. Common adverse effects include mild</span></div><div class="t m0 x9 hb y1577 ff17 fs8 fc3 sc0 ls12 ws0">dizziness, nausea, vomiting, abdominal pain and itching <span class="ff1a ls8e ws15">(3, 67 86)</span><span class="ls13">. </span></div><div class="t m0 x9 hb y1578 ff1a fs8 fc3 sc0 ls1fc ws0">Primaquine<span class="_ _6"> </span><span class="ff17 ws214">can induce a life-threatening haemolysis in those who are deficient</span></div><div class="t m0 x9 hb y1579 ff17 fs8 fc3 sc0 ls13 ws242">in the enzyme G6PD (see section A10.3.3). A full course of primaquine, given</div><div class="t m0 x9 hb y157a ff17 fs8 fc3 sc0 ls12 ws57b">as a daily dose of 0.25 mg base/kg bw for 14 days, is reported to be safe in</div><div class="t m0 x9 hb y157b ff17 fs8 fc3 sc0 lsbf ws12e">populations where G6PD deficiency is either absent or readily diagnosable but</div><div class="t m0 x9 hb y157c ff17 fs8 fc3 sc0 ls1d1 ws131">could induce a self-limiting haemolysis in those with mild G6PD deficiency <span class="ff1a ls26b ws0">(34,</span></div><div class="t m0 x9 hb y157d ff1a fs8 fc3 sc0 ls12 ws523">54, 56)<span class="ff17">. T<span class="_ _c"></span>o reduce the risk of haemolysis in such individuals, an intermittent</span></div><div class="t m0 x9 hb y157e ff17 fs8 fc3 sc0 lsbc ws6b">primaquine regimen of 0.75 mg base/kg weekly for 8 weeks can be giv<span class="_ _a"></span>en under</div><div class="t m0 x9 hb y157f ff17 fs8 fc3 sc0 ls12 ws98">medical supervision. This regimen is safe and effective <span class="ff1a ls13 ws0">(89)</span><span class="ws136">. In non-G6PD</span></div><div class="t m0 x9 hb y1580 ff17 fs8 fc3 sc0 ls37 ws48">deficient individuals, a high dose of primaquine (30 mg/day) has been shown</div><div class="t m0 x9 hb y1581 ff17 fs8 fc3 sc0 ls12 ws1a8">to be safe and effective for Chesson strain <span class="ff1a ls14 ws0">P<span class="_ _ae"></span>. viv<span class="_ _a"></span>ax<span class="_ _6"> </span><span class="ff17 ls12 ws1a8">malaria in South-East Asia</span></span></div><div class="t m0 x9 hb y1582 ff17 fs8 fc3 sc0 ls0 ws32d">during a 28-day follow-up <span class="ff1a ls13 ws3b4">(27, 74, 76)</span><span class="ls14 ws47a">. In r<span class="_ _a"></span>egions where prev<span class="_ _a"></span>alence of G6PD</span></div><div class="t m0 x9 hb y1583 ff17 fs8 fc3 sc0 lsaa ws110">deficiency is relatively high, G6PD testing is r<span class="_ _a"></span>equired before administration of</div><div class="t m0 x9 hb y1584 ff17 fs8 fc3 sc0 ls2cc ws47e">primaquine. Primaquine is not recommended during pr<span class="_ _a"></span>egnancy and in infancy</div><div class="t m0 x9 hb y1585 ff17 fs8 fc3 sc0 ls12 ws5c1">since limited safety data are av<span class="_ _a"></span>ailable in these groups <span class="ff1a ls53 ws0">(67)</span><span class="ws5c2">. Abdominal pain</span></div><div class="t m0 x9 hb y1586 ff17 fs8 fc3 sc0 ls222 ws343">and/or cramps are commonly r<span class="_ _a"></span>epor<span class="_ _8"></span>ted when primaquine is taken on an empty</div><div class="t m0 x9 hb y1587 ff17 fs8 fc3 sc0 ls13 ws19d">stomach. Gastrointestinal toxicity is dose-related and is impr<span class="_ _a"></span>oved by taking</div><div class="t m0 x9 hb y1588 ff17 fs8 fc3 sc0 ls12 ws5c3">primaquine with food. Primaquine may cause weakness, uneasiness in the</div><div class="t m0 x9 hb y1589 ff17 fs8 fc3 sc0 ls28f ws42a">chest, haemolytic anaemia, methaemoglobinaemia (which occurs in non-</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff1" class="pf w1 h4" data-page-no="f1"><div class="pc pcf1 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">231</div><div class="t m0 xb hb y9e ff17 fs8 fc3 sc0 ls37a ws49c">haemolysed red cells), leukopenia, and suppression of my<span class="_ _a"></span>eloid series.</div><div class="t m0 xb hb y9f ff17 fs8 fc3 sc0 ls2a ws38">Therefore, primaquine should not be giv<span class="_ _a"></span>en in conditions predisposing to</div><div class="t m0 xb hb ya0 ff17 fs8 fc3 sc0 ls12 ws3e7">granulocytopenia, including rheumatoid arthritis and lupus erythematosus. </div><div class="t m0 xb h12 y24c ff19 fs6 fc4 sc0 ls9a ws0">A10.4<span class="_ _1"> </span>Monitor<span class="_ _8"></span>ing therapeutic effic<span class="_ _8"></span>ac<span class="_ _8"></span>y</div><div class="t m0 xb hb y24d ff17 fs8 fc3 sc0 ls12 ws4df">There is a need to monitor the antimalarial sensitivity of <span class="ff1a ls14 ws0">P<span class="_ _c"></span>. vivax<span class="_ _95"> </span><span class="ff17 ls12 ws5c4">in order to</span></span></div><div class="t m0 xb hb y597 ff17 fs8 fc3 sc0 ls12 ws5a6">impro<span class="_ _a"></span>ve the treatment of viv<span class="_ _a"></span>ax malaria, in par<span class="_ _8"></span>ticular in view of its emerging</div><div class="t m0 xb hb y598 ff17 fs8 fc3 sc0 ls12 ws2f7">resistance to chloroquine. An <span class="ff1a ls13">in vitr<span class="_ _a"></span>o <span class="ff17 ws3c7">test system has been developed for</span></span></div><div class="t m0 xb hb y599 ff17 fs8 fc3 sc0 ls37b ws5c5">assessing the parasite<span class="_ _a"></span>’<span class="_ _b"></span>s sensitivity to antimalarials <span class="ff1a">(92, 93)</span>. A modified</div><div class="t m0 xb hb y59a ff17 fs8 fc3 sc0 ls2cb ws4a3">version of the standard <span class="_ _b"></span>WHO <span class="ff1a ls77 wsb4">in vitro <span class="ff17 ws268">microtest for determination of the</span></span></div><div class="t m0 xb hb y59b ff17 fs8 fc3 sc0 lsd5 ws74">antimalarial sensitivity of <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum<span class="_ _67"> </span><span class="ff17 ws1f9">has been used successfully for assess-</span></span></div><div class="t m0 xb hb y59c ff17 fs8 fc3 sc0 ls12 ws2ce">ing the antimalarial sensitivity of <span class="ff1a ls14 ws0">P<span class="_ _c"></span>. vivax<span class="_ _95"> </span><span class="ff17 ls12 ws2ce">populations and for screening the</span></span></div><div class="t m0 xb hb y59d ff17 fs8 fc3 sc0 ls13 ws3ab">efficacy of new antimalarials by measuring minimal inhibitory concentration</div><div class="t m0 xb hb y59e ff17 fs8 fc3 sc0 ls12 ws5c6">(MIC), and the concentrations providing 50% and 90% inhibition (IC</div><div class="t m0 x33 h11 y158a ff17 fs5 fc3 sc0 ls4f ws0">50</div><div class="t m0 xdf hb y59e ff17 fs8 fc3 sc0 ls12 ws5c6">), and</div><div class="t m0 xb hb y59f ff17 fs8 fc3 sc0 ls247 ws0">(IC</div><div class="t m0 x26 h11 y7fe ff17 fs5 fc3 sc0 ls37c ws0">90</div><div class="t m0 x8d hb y59f ff17 fs8 fc3 sc0 ls247 ws0">) <span class="_ _a"></span><span class="ff1a ws312">(87, 89)<span class="ff17 ls1e1">. WHO has also recently intr<span class="_ _a"></span>oduced a revised protocol for <span class="ff1a ls247">in vivo</span></span></span></div><div class="t m0 xb hb y5a0 ff17 fs8 fc3 sc0 ls12 ws58">monitoring of the therapeutic efficacy of chloroquine in <span class="ff1a ls14 ws0">P<span class="_ _ae"></span>. viv<span class="_ _a"></span>ax <span class="ff17 ls12">malaria <span class="_ _b"></span><span class="ff1a ls53">(95)<span class="ff17 ls0">.</span></span></span></span></div><div class="t m0 xb hb y5a1 ff17 fs8 fc3 sc0 ls182 ws130">The revised protocol includes measur<span class="_ _a"></span>ement of blood chloroquine levels, PCR</div><div class="t m0 xb hb y158b ff17 fs8 fc3 sc0 ls2bc ws48d">genotyping and the use of molecular markers (only available for the <span class="ff1a ls81 ws0">dhfr</span></div><div class="t m0 xb hb y158c ff17 fs8 fc3 sc0 ls219 ws371">gene) to help clarify and complete the ov<span class="_ _a"></span>erall picture of drug resistance. A better</div><div class="t m0 xb hb y158d ff17 fs8 fc3 sc0 ls12 wse4">understanding of the molecular mechanisms underlying drug resistance in</div><div class="t m0 xb hb y158e ff1a fs8 fc3 sc0 ls14 ws0">P<span class="_ _c"></span>. vivax <span class="ff17 ls12">is needed to impr<span class="_ _a"></span>ove the monitoring of chlor<span class="_ _a"></span>oquine resistance.</span></div><div class="t m0 xb h12 y158f ff19 fs6 fc4 sc0 ls9a ws0">A10.5<span class="_ _1"> </span>Conc<span class="_ _8"></span>lusions and recommendations</div><div class="t m0 xb hb y1590 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws267">The standard oral r<span class="_ _a"></span>egimen of chloroquine of 25 mg base/kg bw given o<span class="_ _a"></span>ver</span></div><div class="t m0 x26 hb yeba ff17 fs8 fc3 sc0 lsc7 ws3">3 days + primaquine at either a low (0.25 mg base/kg bw per day for 14 days)</div><div class="t m0 x26 hb y1591 ff17 fs8 fc3 sc0 ls3c ws31">or high (0.5–0.75 mg base/kg bw per day for 14 days) dose is effective and</div><div class="t m0 x26 hb y1592 ff17 fs8 fc3 sc0 ls5d ws7e">safe for the radical cure of chlor<span class="_ _a"></span>oquine-sensitive <span class="ff1a ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>vivax<span class="_ _6"> </span><span class="ff17 ws229">malaria in patients</span></span></div><div class="t m0 x26 hb y1593 ff17 fs8 fc3 sc0 ls12 ws0">with no G6PD deficiency<span class="_ _4b"></span>. </div><div class="t m0 xb hb y1594 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls21d ws2ad">Of the limited alternative treatments that hav<span class="_ _a"></span>e been evaluated, amodiaquine</span></div><div class="t m0 x26 hb y1595 ff17 fs8 fc3 sc0 ls12 ws5c7">is a promising monotherapy and has been sho<span class="_ _a"></span>wn to be effective for the</div><div class="t m0 x26 hb y1596 ff17 fs8 fc3 sc0 ls12 ws0">treatment of chloroquine-r<span class="_ _a"></span>esistant <span class="ff1a ls14">P<span class="_ _c"></span>. vivax <span class="ff17 ls12">malaria (cure r<span class="_ _a"></span>ate <span class="ff16 ls0">&gt;</span><span class="ls13">90%). </span></span></span></div><div class="t m0 xb hb y1597 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls7a wsb7">In areas where infections of drug-r<span class="_ _a"></span>esistant <span class="ff1a ws0">P<span class="_ _c"></span>. falciparum<span class="_ _6"> </span><span class="ff17">and/or <span class="_ _a"></span><span class="ff1a ls0">P<span class="ff17">.<span class="_ _6"> </span></span><span class="ls2cc">vivax<span class="_ _6"> </span><span class="ff17">are</span></span></span></span></span></span></div><div class="t m0 x26 hb y1598 ff17 fs8 fc3 sc0 ls9c wsfa">common, drug regimens to treat both species effectiv<span class="_ _a"></span>ely must be used. An</div><div class="t m0 x26 hb y1599 ff17 fs8 fc3 sc0 ls12 ws243">ACT<span class="_ _64"> </span>that does not include sulfadoxine-pyrimethamine would be a good</div><div class="t m0 x26 hb y159a ff17 fs8 fc3 sc0 ls12 ws0">choice.</div><div class="t m0 xb hb y159b ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls12 ws286">The use of high-dose primaquine (0.5–0.75 mg base/kg bw per day for 14</span></div><div class="t m0 x26 hb y159c ff17 fs8 fc3 sc0 ls7a wsb7">days), with either chloroquine or another effective antimalarial, is essential</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff2" class="pf w1 h4" data-page-no="f2"><div class="pc pcf2 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">232</div><div class="t m0 x16 hb y9e ff17 fs8 fc3 sc0 ls37d ws3a6">for trying to prevent relapses of primaquine-r<span class="_ _a"></span>esistant or primaquine-</div><div class="t m0 x16 hb y9f ff17 fs8 fc3 sc0 ls12 ws0">tolerant <span class="ff1a ls0">P<span class="ff17">. </span><span class="ls14">viv<span class="_ _a"></span>ax.</span></span></div><div class="t m0 x9 hb y8d2 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 ls13 ws26a">A primaquine regimen of 0.75 mg base/kg bw once per week for 8 w<span class="_ _a"></span>eeks</span></div><div class="t m0 x16 hb y335 ff17 fs8 fc3 sc0 ls12 ws350">is recommended as antirelapse ther<span class="_ _a"></span>apy for <span class="ff1a ls14 ws0">P<span class="_ _c"></span>. viv<span class="_ _a"></span>ax <span class="ff17 ls12">and <span class="_ _b"></span><span class="ff1a ls38">P.<span class="_ _3"> </span>o v a<span class="_ _67"> </span>l e<span class="_ _3"> </span><span class="ff17 ls12 ws350">malaria in</span></span></span></span></div><div class="t m0 x16 hb y336 ff17 fs8 fc3 sc0 ls12 ws0">patients with mild G6PD deficiency<span class="_ _4b"></span>. </div><div class="t m0 x9 hb y337 ff17 fs8 fc4 sc0 ls0 ws0">•<span class="_ _7a"> </span><span class="fc3 lsa4 ws104">Increased efforts are needed to evaluate alternativ<span class="_ _a"></span>e treatments for <span class="ff1a ls184 ws0">P<span class="_ _c"></span>.<span class="_ _6"> </span>vivax</span></span></div><div class="t m0 x16 hb y338 ff17 fs8 fc3 sc0 ls1b2 ws1a4">strains that are r<span class="_ _a"></span>esistant to chloroquine. Urgent needs include establishing</div><div class="t m0 x16 hb y339 ff1a fs8 fc3 sc0 ls13 ws41b">in vitro <span class="ff17 ls12 ws587">culture of </span><span class="ls14 ws0">P<span class="_ _ae"></span>. vivax <span class="ff17 ls12 ws587">to permit the assessment of drug susceptibility<span class="_ _c"></span>,</span></span></div><div class="t m0 x16 hb y33a ff17 fs8 fc3 sc0 ls12 ws185">research to impr<span class="_ _a"></span>ove understanding of the molecular mechanisms of drug</div><div class="t m0 x16 hb y33b ff17 fs8 fc3 sc0 ls12 ws37d">resistance, and the development of better tools for genotyping <span class="ff1a ls14 ws0">P<span class="_ _ae"></span>.<span class="_ _7c"> </span>vivax<span class="ff17 ls13">. </span></span></div><div class="t m0 x9 h12 y159d ff19 fs6 fc4 sc0 ls1 ws0">A10.6<span class="_ _1"> </span>References</div><div class="t mc x9 h17 y159e ff17 fsb fc3 sc0 lsd2 ws0">1.<span class="_ _46"> </span>Hay SI et al. The global distribution and population at risk of malaria: past,</div><div class="t mc x7a h17 y159f ff17 fsb fc3 sc0 lsd8 ws0">present, <span class="ls137 ws1d4">and future. <span class="ff1a ws0">Lancet Infectious Diseases, <span class="ff17">2004, 4: 3<span class="_ _a"></span>27–336.</span></span></span></div><div class="t mc x9 h17 y15a0 ff17 fsb fc3 sc0 ls137 ws0">2.<span class="_ _44"> </span>Mendis K et al. The neglected burden of <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria. </span>American</span></div><div class="t mc x7a h17 y15a1 ff1a fsb fc3 sc0 ls137 ws0">Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 lsd6 ws218">2001, 64:97–106.</span></div><div class="t mc x9 h17 y15a2 ff17 fsb fc3 sc0 ls105 ws0">3.<span class="_ _44"> </span>Tjitra E. <span class="ff1a">Improving the diagnosis and treatment of malaria in Eastern Indonesia</span></div><div class="t mc x7a h17 y15a3 ff17 fsb fc3 sc0 ls105 ws0">[dissertation]. Menzies School of Health Research, Northern T<span class="_ _4b"></span>erritor<span class="_ _8"></span>y University<span class="_ _4b"></span>,</div><div class="t mc x7a h17 y15a4 ff17 fsb fc3 sc0 ls105 ws0">Darwin, Australia, 2001.</div><div class="t mc x9 h17 y15a5 ff17 fsb fc3 sc0 ls105 ws0">4.<span class="_ _44"> </span>Beg MA et al. Cerebral involvement in benign tertian malaria. <span class="ff1a">American Journal </span></div><div class="t mc x7a h17 y15a6 ff1a fsb fc3 sc0 ls105 ws0">of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 ws19a">2002, 67:230–232.</span></div><div class="t mc x9 h17 y15a7 ff17 fsb fc3 sc0 ls105 ws0">5.<span class="_ _39"> </span>Mohapatra MK et al. Atypical manifestations of <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria.</span></span></div><div class="t mc x7a h17 y15a8 ff1a fsb fc3 sc0 ls105 ws0">Indian Journal of Malariology<span class="_ _4b"></span>, <span class="ff17">2002, 39:18–25.</span></div><div class="t mc x9 h17 y15a9 ff17 fsb fc3 sc0 ls105 ws0">6.<span class="_ _44"> </span>T<span class="_ _4b"></span>anios M<span class="_ _8"></span>A et al. Acute respiratory distress syndr<span class="_ _a"></span>ome complicating <span class="ff1a">Plasmodium</span></div><div class="t mc x7a h17 y15aa ff1a fsb fc3 sc0 ls105 ws0">vivax <span class="ff17">malaria. </span>Critical Car<span class="_ _a"></span>e Medicine, <span class="ff17 ws218">2001, 29:665–667.</span></div><div class="t mc x9 h17 y15ab ff17 fsb fc3 sc0 ls105 ws0">7.<span class="_ _39"> </span>Oh MD et al. Clinical features of vivax malaria. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _a"></span>ropical</span></div><div class="t mc x7a h17 y15ac ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene, <span class="ff17">2001, 65:143–146.</span></div><div class="t mc x9 h17 y15ad ff17 fsb fc3 sc0 ls105 ws0">8.<span class="_ _44"> </span>Mehta KS et al. Sever<span class="_ _a"></span>e acute renal failure in malaria. <span class="ff1a">Journal of Postgraduate</span></div><div class="t mc x7a h17 y15ae ff1a fsb fc3 sc0 ls105 ws0">Medicine, <span class="ff17">2001, 47:24–26.</span></div><div class="t mc x9 h17 y15af ff17 fsb fc3 sc0 ls105 ws0">9.<span class="_ _44"> </span>Naqvi R et al. Outcome in severe acute renal failur<span class="_ _a"></span>e associated with malaria.</div><div class="t mc x7a h17 y15b0 ff1a fsb fc3 sc0 ls105 ws0">Nephrology<span class="_ _4b"></span>, Dialysis, T<span class="_ _b"></span>ransplantation, <span class="ff17 lsd6 ws218">2003, 18:1820–1823.</span></div><div class="t mc x9 h17 y15b1 ff17 fsb fc3 sc0 lsd6 ws19a">10.<span class="_ _68"> </span>Prakash J et al. Acute r<span class="_ _a"></span>enal failure in <span class="ff1a ls105 ws0">Plasmodium vivax <span class="ff17">malaria. </span>Journal of the</span></div><div class="t mc x7a h17 y15b2 ff1a fsb fc3 sc0 ls105 ws0">Association of Physicians of India, <span class="ff17 ws1d4">2003, 51:265–267.</span></div><div class="t mc x9 h17 y15b3 ff17 fsb fc3 sc0 ls105 ws0">11.<span class="_ _0"> </span>Makkar RP et al. <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria presenting with severe thr<span class="_ _a"></span>ombo-</span></span></div><div class="t mc x7a h17 y15b4 ff17 fsb fc3 sc0 ls105 ws0">cytopenia. <span class="ff1a">Brazilian Journal of Infectious Diseases, </span><span class="ws19a">2002, 6:263–265.</span></div><div class="t mc x9 h17 y15b5 ff17 fsb fc3 sc0 ls105 ws19a">12.<span class="_ _68"> </span>Nosten F et al. Effects of <span class="ff1a ws0">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria in pregnancy<span class="_ _4b"></span>. <span class="ff1a">Lancet</span><span class="ws1d4">, 1999,</span></span></span></div><div class="t mc x7a h17 y15b6 ff17 fsb fc3 sc0 ls105 ws0">354:546–549.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff3" class="pf w1 h4" data-page-no="f3"><div class="pc pcf3 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">233</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 lsd6 ws218">13.<span class="_ _68"> </span>Udomsangpetch R et al. Rosette formation by <span class="ff1a ls105 ws0">Plasmodium viv<span class="_ _a"></span>ax. T<span class="_ _b"></span>ransactions </span></div><div class="t mc x4d h17 yd62 ff1a fsb fc3 sc0 ls105 ws0">of the Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene, <span class="ff17 ls2df ws219">1995, 89:635–637.</span></div><div class="t mc xb h17 y15b7 ff17 fsb fc3 sc0 ls105 ws0">14.<span class="_ _3"> </span>Fried M et al. Malaria elicits type 1 cytokines in the human placenta: IF<span class="_ _8"></span>N-gamma</div><div class="t mc x4d h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">and TNF-alpha associated with pregnancy outcomes. <span class="ff1a">Journal of Immunology<span class="_ _4b"></span>,</span></div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">1998, 160:2523–2530.</div><div class="t mc xb h17 yee3 ff17 fsb fc3 sc0 ls105 ws0">15.<span class="_ _68"> </span>Tjitra E et al. Field ev<span class="_ _a"></span>aluation of the ICT malaria P<span class="_ _c"></span>.f/P<span class="_ _c"></span>.v immunochromatographic</div><div class="t mc x4d h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">test for detection of <span class="ff1a">Plasmodium falciparum </span>and <span class="ff1a">Plasmodium vivax </span>in patients</div><div class="t mc x4d h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">with a presumptive clinical diagnosis of malaria in eastern Indonesia. <span class="ff1a">Journal of</span></div><div class="t mc x4d h17 yd87 ff1a fsb fc3 sc0 ls105 ws0">Clinical Microbiology<span class="_ _4b"></span>, <span class="ff17 ls104 ws35b">1999, 37:2412–2417.</span></div><div class="t mc xb h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">16.<span class="_ _3"> </span>Coleman R<span class="_ _8"></span>E et al. Field evaluation of the ICT<span class="_ _6"> </span>Pf/Pv immunochromatographic test</div><div class="t mc x4d h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">for the detection of asymptomatic malaria in a <span class="ff1a">Plasmodium falciparum/vivax</span></div><div class="t mc x4d h17 yd89 ff17 fsb fc3 sc0 ls105 ws0">endemic area in <span class="_ _a"></span>Thailand. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical Medicine and Hygiene,</span></div><div class="t mc x4d h17 yec9 ff17 fsb fc3 sc0 ls105 ws19a">2002, 66:379–383.</div><div class="t mc xb h17 yd8b ff17 fsb fc3 sc0 ls105 ws19a">17.<span class="_ _68"> </span>Iqbal J, Khalid N, Hira PR. Comparison of two commercial assays with exper<span class="_ _8"></span>t</div><div class="t mc x4d h17 yeca ff17 fsb fc3 sc0 ls105 ws0">microscopy for confirmation of symptomatically diagnosed malaria. <span class="ff1a">Journal of</span></div><div class="t mc x4d h17 yecb ff1a fsb fc3 sc0 ls105 ws0">Clinical Microbiology<span class="_ _4b"></span>, <span class="ff17 lsd6 ws218">2002, 40:4675–4678.</span></div><div class="t mc xb h17 yd8e ff17 fsb fc3 sc0 ls105 ws0">18.<span class="_ _3"> </span>Farcas GA et al. E<span class="_ _a"></span>valuation of the Binax NOW ICT<span class="_ _67"> </span>test versus polymerase chain</div><div class="t mc x4d h17 yecd ff17 fsb fc3 sc0 ls105 ws0">reaction and microscopy for the detection of malaria in r<span class="_ _a"></span>eturned travelers.</div><div class="t mc x4d h17 yece ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 ls1dc ws1d2">2003, 69:589–592.</span></div><div class="t mc xb h17 yd91 ff17 fsb fc3 sc0 ls105 ws0">19.<span class="_ _3"> </span>Figueiredo FAF et al. P<span class="_ _a"></span>erformance of an immunochromatography test for viv<span class="_ _a"></span>ax</div><div class="t mc x4d h17 yed0 ff17 fsb fc3 sc0 ls356 ws1d4">malaria in the Amazon region, Brazil.<span class="_ _67"> </span><span class="ff1a ls37e ws218">Revista de Saude Publica, </span><span class="ls37f ws1d2">2003, 37:390–392.</span></div><div class="t mc xb h17 yd93 ff17 fsb fc3 sc0 ls105 ws0">20.<span class="_ _5"> </span>Forney JR et al. Devices for rapid diagnosis of malaria: evaluation of prototype</div><div class="t mc x4d h17 yf78 ff17 fsb fc3 sc0 ls105 ws0">assays that detect <span class="ff1a">Plasmodium falciparum </span>histidine-rich protein 2 and a</div><div class="t mc x4d h17 yed3 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium vivax<span class="ff17">-specific antigen. </span>Journal of Clinical Micr<span class="_ _a"></span>obiology<span class="_ _4b"></span>, <span class="ff17 ls380">2003,</span></div><div class="t mc x4d h17 yed4 ff17 fsb fc3 sc0 ls105 ws0">41:2358–2366.</div><div class="t mc xb h17 y118f ff17 fsb fc3 sc0 ls105 ws0">21.<span class="_ _68"> </span>K<span class="_ _a"></span>olaczinski J et al. Comparison of the OptiMAL rapid antigen test with field</div><div class="t mc x4d h17 yed6 ff17 fsb fc3 sc0 ls105 ws0">microscopy for the detection of <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">and </span>P<span class="_ _c"></span>.<span class="_ _4"> </span>falciparum:</span></div><div class="t mc x4d h17 yed7 ff17 fsb fc3 sc0 ls105 ws0">considerations for the application of the rapid test in Afghanistan. <span class="ff1a">Annals of</span></div><div class="t mc x4d h17 yed8 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Parasitology<span class="_ _c"></span>, <span class="ff17">2004, 98:15–20.</span></div><div class="t mc xb h17 y1190 ff17 fsb fc3 sc0 ls105 ws0">22.<span class="_ _5"> </span>Myint HY et al. A systematic overview of published antimalarial drug trials.</div><div class="t mc x4d h17 yeda ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene, <span class="ff17">2004,</span></div><div class="t mc x4d h17 yedb ff17 fsb fc3 sc0 ls105 ws0">98:73–81.</div><div class="t mc xb h17 y1191 ff17 fsb fc3 sc0 ls105 ws0">23.<span class="_ _95"> </span>Schwartz E, Regev-Y<span class="_ _b"></span>ochay G, Kurnik D. Short repor<span class="_ _8"></span>t: a consideration of</div><div class="t mc x4d h17 yedd ff17 fsb fc3 sc0 ls105 ws0">primaquine dose adjustment for radical cure of <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria.</span></span></div><div class="t mc x4d h17 yede ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 ws19a">2000, 62:393–395.</span></div><div class="t mc xb h17 y14f0 ff17 fsb fc3 sc0 ls105 ws0">24.<span class="_ _5"> </span>Tjitra E et al. Randomized comparativ<span class="_ _a"></span>e study of chloroquine and halofantrine in</div><div class="t mc x4d h17 yee0 ff17 fsb fc3 sc0 ls105 ws0">vivax malaria patients. <span class="ff1a">Medical Journal of Indonesia, </span><span class="ws19a">1995, 4:30–36.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff4" class="pf w1 h4" data-page-no="f4"><div class="pc pcf4 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">234</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">25.<span class="_ _95"> </span>Baird JK et al. T<span class="_ _b"></span>reatment of chloroquine-resistant <span class="ff1a">Plasmodium viv<span class="_ _b"></span>ax <span class="ff17">with</span></span></div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws1d4">chloroquine and primaquine or halofantrine. <span class="ff1a ws0">Journal of Infectious Diseases, <span class="ff17 ls104">1995,</span></span></div><div class="t mc x7a h17 yd63 ff17 fsb fc3 sc0 ls104 ws0">171:1678–1682.</div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls130 ws19a">26.<span class="_ _5"> </span>Fryauff DJ et al. Sur<span class="_ _8"></span>vey of in vivo sensitivity to chlor<span class="_ _a"></span>oquine by <span class="ff1a ws0">Plasmodium</span></div><div class="t mc x7a h17 yd65 ff1a fsb fc3 sc0 ls130 ws0">falciparum <span class="ff17">and </span>P<span class="_ _c"></span>.<span class="_ _4"> </span>vivax <span class="ff17">in L<span class="_ _a"></span>ombok, Indonesia. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical</span></span></div><div class="t mc x7a h17 yd66 ff1a fsb fc3 sc0 ls130 ws0">Medicine and Hygiene, <span class="ff17">1997, 56: 241–244.</span></div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls130 ws0">27.<span class="_ _95"> </span>Silachamroon U et al. Clinical trial of oral artesunate with or without high-dose</div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls130 ws0">primaquine for the treatment of viv<span class="_ _a"></span>ax malaria in Thailand. <span class="ff1a">American Journal of</span></div><div class="t mc x7a h17 yd87 ff1a fsb fc3 sc0 ls130 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene, <span class="ff17 ls31a ws1cc">2003, 69:14–18.</span></div><div class="t mc x9 h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">28. Baird J<span class="_ _8"></span>K, Rieckmann KH. Can primaquine therapy for viv<span class="_ _a"></span>ax malaria be improv<span class="_ _a"></span>ed?</div><div class="t mc x7a h17 yd88 ff1a fsb fc3 sc0 ls105 ws1d4">T<span class="_ _b"></span>rends in Parasitology<span class="_ _c"></span>, <span class="ff17">2003, 19:115–120.</span></div><div class="t mc x9 h17 yd6c ff17 fsb fc3 sc0 ls105 ws0">29.<span class="_ _5"> </span>T<span class="_ _b"></span>an-ariya P et al. Clinical r<span class="_ _a"></span>esponse and susceptibility in vitro of <span class="ff1a">Plasmodium vivax</span></div><div class="t mc x7a h17 yd8a ff17 fsb fc3 sc0 ls105 ws0">to the standard regimen of chlor<span class="_ _a"></span>oquine in Thailand. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Ro<span class="_ _a"></span>yal</span></div><div class="t mc x7a h17 yd8b ff1a fsb fc3 sc0 ls105 ws0">Society of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17">1995, 89:426–429.</span></div><div class="t mc x9 h17 yd8c ff17 fsb fc3 sc0 ls105 ws19a">30.<span class="_ _95"> </span>Baird JK et al. Sur<span class="_ _8"></span>vey of resistance to chlor<span class="_ _a"></span>oquine by <span class="ff1a ws0">Plasmodium vivax <span class="ff17">in</span></span></div><div class="t mc x7a h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">Indonesia. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene,</span></div><div class="t mc x7a h17 yd8e ff17 fsb fc3 sc0 ls105 ws0">1996, 90:409–411.</div><div class="t mc x9 h17 yd8f ff17 fsb fc3 sc0 ls105 ws0">31.<span class="_ _68"> </span>Baird JK et al. Chloroquine sensitive <span class="ff1a">Plasmodium falciparum </span>and <span class="ff1a">P<span class="_ _c"></span>.<span class="_ _0"> </span>vivax <span class="ff17">in</span></span></div><div class="t mc x7a h17 yd90 ff17 fsb fc3 sc0 ls105 ws0">central Jav<span class="_ _a"></span>a, Indonesia. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine</span></div><div class="t mc x7a h17 yd91 ff1a fsb fc3 sc0 ls105 ws1d4">and Hygiene, <span class="ff17 lsd6 ws1d3">1996, 90:412–413.</span></div><div class="t mc x9 h17 yd92 ff17 fsb fc3 sc0 ls105 ws0">32.<span class="_ _95"> </span>Baird JK et al. Sur<span class="_ _8"></span>vey of resistance to chlor<span class="_ _a"></span>oquine of falciparum and vivax malaria</div><div class="t mc x7a h17 yd93 ff17 fsb fc3 sc0 ls356 ws0">in Palawan, <span class="_ _a"></span>The Philippines. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine</span></div><div class="t mc x7a h17 yf78 ff1a fsb fc3 sc0 ls105 ws1d4">and Hygiene, <span class="ff17 ws19a">1996, 90:413–4144.</span></div><div class="t mc x9 h17 ydaf ff17 fsb fc3 sc0 ls105 ws0">33.<span class="_ _95"> </span>Fryauff DJ et al. Survey of resistance <span class="ff1a">in vivo </span>to chlor<span class="_ _a"></span>oquine of <span class="ff1a">Plasmodium</span></div><div class="t mc x7a h17 ydb0 ff1a fsb fc3 sc0 ls105 ws0">falciparum <span class="ff17">and </span>P<span class="_ _c"></span>. vivax <span class="ff17">in North Sulawesi, Indonesia. </span>T<span class="_ _b"></span>ransactions of the Royal</div><div class="t mc x7a h17 y118f ff1a fsb fc3 sc0 ls105 ws0">Society of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 ls2e2 ws1d3">1998, 92:82–83.</span></div><div class="t mc x9 h17 yd95 ff17 fsb fc3 sc0 ls105 ws0">34.<span class="_ _95"> </span>Looar<span class="_ _a"></span>eesuwan S et al. Chloroquine sensitivity of <span class="ff1a">Plasmodium vivax </span><span class="ws27d">in Thailand.</span></div><div class="t mc x7a h17 ydb1 ff1a fsb fc3 sc0 ls105 ws0">Annals of T<span class="_ _4b"></span>ropical Medicine and Parasitology<span class="_ _4b"></span>, <span class="ff17 ws1d4">1999, 93:225–230.</span></div><div class="t mc x9 h17 yd7d ff17 fsb fc3 sc0 ls105 ws0">35.<span class="_ _95"> </span>Fryauff DJ et al. <span class="ff1a">In vivo </span><span class="ws19a">responses to antimalarials by <span class="_ _a"></span><span class="ff1a ws0">Plasmodium falciparum <span class="ff17">and</span></span></span></div><div class="t mc x7a h17 ydb3 ff1a fsb fc3 sc0 ls105 ws0">P<span class="_ _c"></span>.<span class="_ _4"> </span>vivax <span class="ff17">fr<span class="_ _a"></span>om isolated Gag island of nor<span class="_ _8"></span>thwest Irian Jaya, Indonesia. <span class="ff1a">American</span></span></div><div class="t mc x7a h17 ydb4 ff1a fsb fc3 sc0 ls105 ws0">Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17">1999, 60:542–546.</span></div><div class="t mc x9 h17 ydc0 ff17 fsb fc3 sc0 ls105 ws0">36.<span class="_ _95"> </span>T<span class="_ _4b"></span>aylor WRJ et al. Assessing drug sensitivity of <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17 ws1d4">to halofantrine</span></span></div><div class="t mc x7a h17 ydb6 ff17 fsb fc3 sc0 ls105 ws1d4">or chloroquine in southern, central <span class="_ _a"></span>Vietnam using an extended 28-day <span class="ff1a ws0">in vivo</span></div><div class="t mc x7a h17 ydb7 ff17 fsb fc3 sc0 ls105 ws0">test and polymerase chain reaction genotyping. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical</span></div><div class="t mc x7a h17 ydb8 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene<span class="ff17 ws1d4">, 2000, 62:693–697.</span></div><div class="t mc x9 h17 ydb9 ff17 fsb fc3 sc0 ls105 ws0">37.<span class="_ _95"> </span>Pukrittayakamee S et al. Therapeutic responses to differ<span class="_ _a"></span>ent antimalarial drugs in</div><div class="t mc x7a h17 ydba ff17 fsb fc3 sc0 ls105 ws0">vivax malaria. <span class="ff1a">Antimicr<span class="_ _a"></span>obial Agents and Chemotherapy<span class="ff17 lscc ws4bf">, 2000, 44:1680–1685.</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff5" class="pf w1 h4" data-page-no="f5"><div class="pc pcf5 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">235</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">38.<span class="_ _5"> </span>McGready R et al. The effects of quinine and chloroquine antimalarial tr<span class="_ _a"></span>eatments</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">in the first trimester of pregnancy<span class="_ _4b"></span>. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _a"></span>T<span class="_ _b"></span>ropical</span></div><div class="t mc x4d h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene<span class="ff17">, 2002, 96:180–184.</span></div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">39.<span class="_ _95"> </span>Y<span class="_ _b"></span>adav RS, Ghosh SK. Radical curativ<span class="_ _a"></span>e efficacy of five-day regimen of primaquine</div><div class="t mc x4d h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">for treatment of <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria in India. </span>Journal of Parasitology<span class="_ _4b"></span>, <span class="ff17">2002,</span></span></div><div class="t mc x4d h17 yd66 ff17 fsb fc3 sc0 ls2e3 ws0">88:1042–1044.</div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">40.<span class="_ _5"> </span>Nandy A et al. Monitoring the chloroquine sensitivity of <span class="ff1a">Plasmodium vivax </span>from</div><div class="t mc x4d h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">Calcutta and Orissa, India. <span class="ff1a">Annals of T<span class="_ _b"></span>ropical Medicine and P<span class="_ _a"></span>arasitology<span class="_ _4b"></span>, <span class="ff17 ls380">2003,</span></span></div><div class="t mc x4d h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">97:215–220.</div><div class="t mc xb h17 yd6a ff17 fsb fc3 sc0 ls105 ws0">41.<span class="_ _3"> </span>Baird J<span class="_ _8"></span>K et al. Chloroquine for the treatment of uncomplicated malaria in Guyana.</div><div class="t mc x4d h17 yd88 ff1a fsb fc3 sc0 ls105 ws0">Annals of T<span class="_ _4b"></span>ropical Medicine and Parasitology<span class="_ _4b"></span>, <span class="ff17">2002, 96:339–348.</span></div><div class="t mc xb h17 yd6c ff17 fsb fc3 sc0 ls105 ws0">42.<span class="_ _5"> </span>Castillo CM, Osorio LE, Palma GI. Assessment of therapeutic response of</div><div class="t mc x4d h17 yd8a ff1a fsb fc3 sc0 ls105 ws0">Plasmodium vivax <span class="ff17">and </span>Plasmodium falciparum <span class="ff17">to chlor<span class="_ _a"></span>oquine in a malaria</span></div><div class="t mc x4d h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">transmission free ar<span class="_ _a"></span>ea in Colombia. <span class="ff1a">Memorias do Instituto Oswaldo Cruz, </span>2002,</div><div class="t mc x4d h17 yeca ff17 fsb fc3 sc0 ls105 ws0">97:559–562.</div><div class="t mc xb h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">43.<span class="_ _95"> </span>Ruebush <span class="_ _a"></span>TK et al. Chloroquine-resistant <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria in Peru.</span></span></div><div class="t mc x4d h17 yd8e ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 ls31a ws1cc">2003, 69:548–552.</span></div><div class="t mc xb h17 yd8f ff17 fsb fc3 sc0 ls105 ws0">44.<span class="_ _5"> </span>Baird J<span class="_ _8"></span>K et al. <span class="ff1a">In vivo </span><span class="ws19a">resistance to chlor<span class="_ _a"></span>oquine by <span class="ff1a ws0">Plasmodium vivax <span class="ff17">and</span></span></span></div><div class="t mc x4d h17 yd90 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium falciparum <span class="ff17">at Nabire, Irian Jaya, Indonesia. </span>American Journal of</div><div class="t mc x4d h17 yd91 ff1a fsb fc3 sc0 ls105 ws0">T<span class="_ _b"></span>ropical Medicine and Hygiene, <span class="ff17">1997, 56:627–631.</span></div><div class="t mc xb h17 yd92 ff17 fsb fc3 sc0 ls105 ws0">45.<span class="_ _95"> </span>Fryauff DJ et al. Chloroquine-r<span class="_ _a"></span>esistant <span class="ff1a">Plasmodium vivax </span>in transmigr<span class="_ _a"></span>ation</div><div class="t mc x4d h17 yd93 ff17 fsb fc3 sc0 ls105 ws0">settlements of W<span class="_ _b"></span>est Kalimantan, Indonesia. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical</span></div><div class="t mc x4d h17 yf78 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene, <span class="ff17 lsd6 ws218">1998, 59:513–518.</span></div><div class="t mc xb h17 ydaf ff17 fsb fc3 sc0 ls105 ws0">46.<span class="_ _5"> </span>T<span class="_ _b"></span>aylor <span class="_ _a"></span>WRJ et al. Chloroquine/doxycy<span class="_ _a"></span>cline combination versus chloroquine alone</div><div class="t mc x4d h17 ydb0 ff17 fsb fc3 sc0 ls105 ws0">and doxycy<span class="_ _a"></span>cline alone for the treatment of <span class="ff1a">Plasmodium falciparum </span>and</div><div class="t mc x4d h17 y118f ff1a fsb fc3 sc0 ls105 ws0">Plasmodium vivax <span class="ff17">malaria in northeastern Irian Jaya, Indonesia. </span>American</div><div class="t mc x4d h17 yed6 ff1a fsb fc3 sc0 ls105 ws0">Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 ws1d4">2001, 64:223–228.</span></div><div class="t mc xb h17 ydb1 ff17 fsb fc3 sc0 ls105 ws0">47.<span class="_ _95"> </span>Fryauff DJ et al. The drug sensitivity and tr<span class="_ _a"></span>ansmission dynamics of human malaria</div><div class="t mc x4d h17 ydb2 ff17 fsb fc3 sc0 ls105 ws0">on Nias Island, North Sumatra, Indonesia. <span class="ff1a">Annals of T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x4d h17 y1190 ff1a fsb fc3 sc0 ls105 ws0">Parasitology<span class="_ _c"></span>, <span class="ff17">2002, 96:447–462.</span></div><div class="t mc xb h17 ydb4 ff17 fsb fc3 sc0 ls105 ws0">48. Maguire JD et al. Chloroquine-resistant <span class="ff1a">Plasmodium malariae </span><span class="ws1d4">in south Sumatra,</span></div><div class="t mc x4d h17 ydb5 ff17 fsb fc3 sc0 ls105 ws0">Indonesia. <span class="ff1a">Lancet</span>, 2002, 360:58–60.</div><div class="t mc xb h17 ydb6 ff17 fsb fc3 sc0 ls105 ws0">49.<span class="_ _5"> </span>Sumawinata IW et al. V<span class="_ _b"></span>ery high risk of therapeutic failure with chloroquine for</div><div class="t mc x4d h17 ydb7 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated <span class="ff1a">Plasmodium falciparum </span>and <span class="ff1a">P<span class="_ _c"></span>.<span class="_ _4"> </span>vivax <span class="ff17">malaria in Indonesian</span></span></div><div class="t mc x4d h17 ydb8 ff17 fsb fc3 sc0 ls105 ws0">Papua. <span class="ff1a">American Journal of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and Hygiene, <span class="ff17 ls357 ws566">2003, 68:416–420.</span></span></div><div class="t mc xb h17 ydb9 ff17 fsb fc3 sc0 ls105 ws0">50.<span class="_ _95"> </span>Schuurkamp GJ et al, Chloroquine-resistant <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">in Papua New</span></span></div><div class="t mc x4d h17 ydba ff17 fsb fc3 sc0 ls105 ws0">Guinea. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical Medicine and Hygiene,</span></div><div class="t mc x4d h17 ydbb ff17 fsb fc3 sc0 lsd6 ws218">1992, 86:121–122.</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff6" class="pf w1 h4" data-page-no="f6"><div class="pc pcf6 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">236</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">51.<span class="_ _68"> </span>Myat-Phone-K<span class="_ _b"></span>yaw et al. Emergence of chloroquine-resistant Plasmodium viv<span class="_ _a"></span>ax in</div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">Myanmar (Burma). <span class="ff1a">T<span class="_ _b"></span>ransactions of the R<span class="_ _a"></span>oyal Society of T<span class="_ _4b"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Hygiene, <span class="ff17 ls31a ws1cc">1993, 87:687.</span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls130 ws19a">52.<span class="_ _95"> </span>Marlar<span class="_ _a"></span>-Than et al. Development of resistance to chlor<span class="_ _a"></span>oquine by <span class="ff1a ws0">Plasmodium</span></div><div class="t mc x7a h17 yd65 ff1a fsb fc3 sc0 ls130 ws0">vivax <span class="ff17">in M<span class="_ _a"></span>yanmar<span class="_ _b"></span>. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and</span></span></div><div class="t mc x7a h17 yd66 ff1a fsb fc3 sc0 ls130 ws0">Hygiene, <span class="ff17 ws19a">1995, 89:307–308.</span></div><div class="t mc x9 h17 yd67 ff17 fsb fc3 sc0 ls130 ws0">53.<span class="_ _95"> </span>Dua VK, Kar PK, Sharma <span class="_ _b"></span>VP<span class="_ _4b"></span>. Chloroquine resistant <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">malaria in</span></span></div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls130 ws0">India. <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and International Health, <span class="ff17 ls137">1996, 1:816–819.</span></span></div><div class="t mc x9 h17 yd69 ff17 fsb fc3 sc0 ls137 ws0">54.<span class="_ _95"> </span>Buchachart K et al. Effect of primaquine standard dose (15 mg/day for 14 days) </div><div class="t mc x7a h17 yd6a ff17 fsb fc3 sc0 ls137 ws0">in the treatment of viv<span class="_ _a"></span>ax malaria patients in Thailand. <span class="ff1a">Southeast Asian Journal </span></div><div class="t mc x7a h17 yd88 ff1a fsb fc3 sc0 ls130 ws19a">of T<span class="_ _4b"></span>ropical Medicine and Public Health, <span class="ff17 ws0">2001, 32:720–726.</span></div><div class="t mc x9 h17 yd6c ff17 fsb fc3 sc0 ls130 ws0">55.<span class="_ _95"> </span>Phan GT et al. Artemisinin or chloroquine for blood stage <span class="ff1a">Plasmodium vivax</span></div><div class="t mc x7a h17 yd8a ff17 fsb fc3 sc0 ls356 ws1d4">malaria in V<span class="_ _a"></span>ietnam. <span class="ff1a">T<span class="_ _b"></span>ropical Medicine and International Health, <span class="ff17 ws0">2002, 7:858–864.</span></span></div><div class="t mc x9 h17 yd6e ff17 fsb fc3 sc0 ls105 ws0">56.<span class="_ _95"> </span>Gogtay NJ et al. Efficacies of 5- and 14-day primaquine regimens in the prevention</div><div class="t mc x7a h17 yd8c ff17 fsb fc3 sc0 ls105 ws0">of relapse in <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">infections. </span>Annals of T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yd8d ff1a fsb fc3 sc0 ls105 ws0">Parasitology<span class="_ _c"></span>, <span class="ff17 ws19a">1999, 93:809–812.</span></div><div class="t mc x9 h17 ydbc ff17 fsb fc3 sc0 ls105 ws0">57.<span class="_ _64"> </span>Alecrim MC, Alecrim <span class="_ _a"></span>W<span class="_ _b"></span>, Macedo V<span class="_ _c"></span>. <span class="ff1a">Plasmodium vivax </span>resistance to chloroquine</div><div class="t mc x7a h17 yd8f ff17 fsb fc3 sc0 ls105 ws0">(R2) and mefloquine (R3) in Brazilian Amazon region. <span class="ff1a">R<span class="_ _a"></span>evista da Sociedade</span></div><div class="t mc x7a h17 yd90 ff1a fsb fc3 sc0 ls105 ws0">Brasiliera de Medicina <span class="_ _a"></span>T<span class="_ _b"></span>ropical, <span class="ff17 ls1dc ws1d2">1999, 32:67–68.</span></div><div class="t mc x9 h17 ydbd ff17 fsb fc3 sc0 ls1dc ws1d4">58.<span class="_ _5"> </span>Y<span class="_ _b"></span>oung M<span class="_ _8"></span>D, Burgens RW<span class="_ _4b"></span>. Pyrimethamine resistance in <span class="ff1a ls105 ws0">Plasmodium vivax <span class="ff17">malaria.</span></span></div><div class="t mc x7a h17 yd92 ff1a fsb fc3 sc0 ls105 ws19a">Bulletin of the W<span class="_ _b"></span>orld Health Organization, <span class="ff17 lsd6 ws218">1959, 20:27–36.</span></div><div class="t mc x9 h17 yd76 ff17 fsb fc3 sc0 ls105 ws0">59.<span class="_ _95"> </span>Laing AB. Hospital and field trials of sulformethoxine with pyrimethamine against</div><div class="t mc x7a h17 yd94 ff17 fsb fc3 sc0 ls105 ws0">Malaysian strains of <span class="ff1a">Plasmodium falciparum </span>and <span class="ff1a">P<span class="_ _c"></span>.<span class="_ _0"> </span>vivax. Medical Journal of</span></div><div class="t mc x7a h17 ydaf ff1a fsb fc3 sc0 ls105 ws0">Malaysia, <span class="ff17 ls31a ws1cc">1968, 23:5–19.</span></div><div class="t mc x9 h17 yd79 ff17 fsb fc3 sc0 ls105 ws0">60.<span class="_ _5"> </span>Doberstyn E<span class="_ _8"></span>B et al. T<span class="_ _b"></span>reatment of viv<span class="_ _a"></span>ax malaria with sulfadoxine-pyrimethamine</div><div class="t mc x7a h17 yd7a ff17 fsb fc3 sc0 ls105 ws0">and with pyrimethamine alone. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _b"></span>T<span class="_ _a"></span>ropical</span></div><div class="t mc x7a h17 yd95 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene, <span class="ff17 ls2e2 ws1d3">1979, 73:15–17.</span></div><div class="t mc x9 h17 yd7c ff17 fsb fc3 sc0 ls105 ws0">61.<span class="_ _3"> </span>De Pecoulas PE et al. Sequence variations in the <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">dihydrofolate</span></span></div><div class="t mc x7a h17 yd7d ff17 fsb fc3 sc0 ls105 ws0">reductase-thymidylate synthase gene and their relationship with pyrimethamine</div><div class="t mc x7a h17 ydb3 ff17 fsb fc3 sc0 ls105 ws0">resistance. <span class="ff1a">Molecular Biochemistry and Parasitology<span class="_ _c"></span>, <span class="ff17 ws1d4">1998, 92:265–27<span class="_ _8"></span>3.</span></span></div><div class="t mc x9 h17 yd7f ff17 fsb fc3 sc0 ls105 ws0">62.<span class="_ _5"> </span>Imwong M et al. Association of genetic mutations in <span class="ff1a">Plasmodium vivax dhfr </span>with</div><div class="t mc x7a h17 ydc0 ff17 fsb fc3 sc0 ls105 ws19a">resistance to sulfadoxine-pyrimethamine geogr<span class="_ _a"></span>aphical and clinical correlates.</div><div class="t mc x7a h17 ydb6 ff1a fsb fc3 sc0 ls105 ws0">Antimicrobial Agents and Chemotherapy<span class="_ _c"></span>, <span class="ff17 lsd6 ws218">2001, 45:3122–3127.</span></div><div class="t mc x9 h17 yd82 ff17 fsb fc3 sc0 ls105 ws0">63.<span class="_ _95"> </span>Maguire JD et al. Chloroquine or sulfadoxine-pyrimethamine for the tr<span class="_ _a"></span>eatment of</div><div class="t mc x7a h17 ydc1 ff17 fsb fc3 sc0 ls105 ws0">uncomplicated <span class="ff1a">Plasmodium falciparum </span>malaria during an epidemic in Central</div><div class="t mc x7a h17 ydb9 ff17 fsb fc3 sc0 ls10b ws0">Java, Indonesia. <span class="ff1a">Annals of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and Parasitology<span class="_ _c"></span>, <span class="ff17 ls70 ws1d2">2002, 96:655–668.</span></span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff7" class="pf w1 h4" data-page-no="f7"><div class="pc pcf7 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">237</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">64.<span class="_ _5"> </span>Tjitra E et al. Efficacies of ar<span class="_ _8"></span>tesunate-sulfadoxine-pyrimethamine and</div><div class="t mc x4d h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">chloroquine-sulfadoxine-pyrimethamine in viv<span class="_ _b"></span>ax malaria pilot studies:</div><div class="t mc x4d h17 yd63 ff17 fsb fc3 sc0 ls105 ws0">relationship to <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax dhfr <span class="ff17">mutations. </span>Antimicrobial Agents and</span></div><div class="t mc x4d h17 yec7 ff1a fsb fc3 sc0 ls105 ws0">Chemotherapy<span class="_ _4b"></span>, <span class="ff17">2002, 46:3947–3053.</span></div><div class="t mc xb h17 yd65 ff17 fsb fc3 sc0 ls105 ws0">65.<span class="_ _95"> </span>Imwong M et al. Nov<span class="_ _a"></span>el point mutations in the dihydrofolate reductase gene of</div><div class="t mc x4d h17 yd66 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium vivax: <span class="ff17 ws19a">evidence for sequential selection by drug pr<span class="_ _a"></span>essure.</span></div><div class="t mc x4d h17 yf77 ff1a fsb fc3 sc0 ls105 ws0">Antimicrobial Agents and Chemotherapy<span class="_ _c"></span>, <span class="ff17 ls1dc ws1d2">2003, 47:1514–1521.</span></div><div class="t mc xb h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">66. Hastings M<span class="_ _8"></span>D et al. Dihydrofolate reductase mutations in <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax <span class="ff17">from</span></span></div><div class="t mc x4d h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">Indonesia and therapeutic response to sulfado<span class="_ _a"></span>xine plus pyrimethamine. <span class="ff1a">Journal</span></div><div class="t mc x4d h17 yec8 ff1a fsb fc3 sc0 ls105 ws0">of Infectious Diseases, <span class="ff17">2004, 189:744–750.</span></div><div class="t mc xb h17 yd88 ff17 fsb fc3 sc0 ls381 ws0">67.<span class="_ _95"> </span><span class="ff1a ls105">The use of antimalarial drugs. Report of an informal consultation. <span class="ff17 ws4bd">Geneva, World</span></span></div><div class="t mc x4d h17 yd89 ff17 fsb fc3 sc0 ls105 ws0">Health Organization, 2001.</div><div class="t mc xb h17 yd8a ff17 fsb fc3 sc0 ls105 ws1d4">68. Cooper RD, Rieckmann KH. Efficacy of amodiaquine against a chloroquine-</div><div class="t mc x4d h17 yd8b ff17 fsb fc3 sc0 ls10b ws0">resistant strain of <span class="ff1a">Plasmodium viv<span class="_ _a"></span>ax. T<span class="_ _b"></span>ransactions of the R<span class="_ _a"></span>oyal Society of T<span class="_ _4b"></span>ropical</span></div><div class="t mc x4d h17 yeca ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene, <span class="ff17">1990, 84: 473.</span></div><div class="t mc xb h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">69. Rieckmann KH. Monitoring the response of malaria infections to treatment.</div><div class="t mc x4d h17 yd8e ff1a fsb fc3 sc0 ls105 ws19a">Bulletin of the W<span class="_ _b"></span>orld Health Organization, <span class="ff17 ws1d4">1990, 68:759–760.</span></div><div class="t mc xb h17 yd8f ff17 fsb fc3 sc0 lsd6 ws218">70.<span class="_ _95"> </span>Tjitra E. <span class="ff1a ls105 ws19a">Randomised comparativ<span class="_ _a"></span>e study of the therapeutic efficacy of chloroquine</span></div><div class="t mc x4d h4d yd90 ff1a fsb fc3 sc0 ls105 ws0">alone versus combined chloroquine plus sulphado<span class="_ _a"></span>xine-pyrimethamine and</div><div class="t mc x4d h4d yd91 ff1a fsb fc3 sc0 ls10b ws0">amodiaquine alone for the treatment of viv<span class="_ _a"></span>ax malaria in Bangka island, Indonesia</div><div class="t mc x4d h17 yed0 ff17 fsb fc3 sc0 ls137 ws1d4">(Report of the WHO funded study). 2003, Jakarta, National Institute of Health</div><div class="t mc x4d h17 yed1 ff17 fsb fc3 sc0 ls137 ws0">Research and Dev<span class="_ _a"></span>elopment, Ministry of Health, Republic Indonesia.</div><div class="t mc xb h17 yf78 ff17 fsb fc3 sc0 ls137 ws0">71.<span class="_ _68"> </span>da Silva RS et al. Short course schemes for vivax malaria treatment. <span class="ff1a">R<span class="_ _a"></span>evista da</span></div><div class="t mc x4d h17 yed3 ff1a fsb fc3 sc0 ls137 ws0">Sociedade Brasiliera de Medicina <span class="_ _a"></span>T<span class="_ _b"></span>ropical, <span class="ff17 ws1d2">2003, 36:235–239.</span></div><div class="t mc xb h17 ydb0 ff17 fsb fc3 sc0 ls10b ws0">72.<span class="_ _64"> </span>Li X et al. [Observation on efficacy of ar<span class="_ _8"></span>temether compound against vivax malaria.]</div><div class="t mc x4d h17 y118f ff1a fsb fc3 sc0 ls105 ws0">Zhongguo Ji Sheng Chong Xue Y<span class="_ _4b"></span>u Ji Sheng Chong Bing Za Zhi <span class="ff17">[Chinese journal of</span></div><div class="t mc x4d h17 yed6 ff17 fsb fc3 sc0 lsd6 ws218">parasitology and parasitic disease], 1999, 17:175–177 [in Chinese].</div><div class="t mc xb h17 ydb1 ff17 fsb fc3 sc0 ls105 ws0">73.<span class="_ _95"> </span>Lefèvre G et al. A clinical and pharmacokinetic trial of six doses of artemether<span class="_ _a"></span>-</div><div class="t mc x4d h17 ydb2 ff17 fsb fc3 sc0 ls105 ws0">lumefantrine for multidrug resistant <span class="ff1a">Plasmodium falciparum </span>malaria in <span class="_ _a"></span>Thailand.</div><div class="t mc x4d h17 y1190 ff1a fsb fc3 sc0 ls105 ws0">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17">2001, 64:247–256.</span></div><div class="t mc xb h17 ydb4 ff17 fsb fc3 sc0 ls105 ws0">74.<span class="_ _95"> </span>Fryauff DJ et al. Halofantrine and primaquine for radical cure of malaria in Irian</div><div class="t mc x4d h17 ydb5 ff17 fsb fc3 sc0 ls105 ws0">Jaya, Indonesia. <span class="ff1a">Annals of T<span class="_ _4b"></span>ropical Medicine and Parasitology<span class="_ _4b"></span>, <span class="ff17 ws1d4">1997, 91:7–16.</span></span></div><div class="t mc xb h17 ydb6 ff17 fsb fc3 sc0 ls105 ws0">75.<span class="_ _64"> </span>V<span class="_ _b"></span>alibayov A et al. Clinical efficacy of chloroquine follo<span class="_ _a"></span>wed by primaquine for</div><div class="t mc x4d h17 ydb7 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium vivax <span class="ff17">tr<span class="_ _a"></span>eatment in Azerbaijan. <span class="ff1a ws27d">Acta T<span class="_ _b"></span>ropica, <span class="_ _8"></span><span class="ff17 ws0">2003, 88:99–102.</span></span></span></div><div class="t mc xb h17 ydc1 ff17 fsb fc3 sc0 ls105 ws0">76.<span class="_ _95"> </span>Wilairatana P<span class="_ _6"> </span>et al. Efficacy of primaquine regimens for primaquine-resistant</div><div class="t mc x4d h17 ydb9 ff1a fsb fc3 sc0 ls105 ws0">Plasmodium vivax <span class="ff17">malaria in <span class="_ _a"></span>Thailand. <span class="ff1a">American Journal of T<span class="_ _b"></span>ropical Medicine </span></span></div><div class="t mc x4d h17 ydba ff1a fsb fc3 sc0 ls105 ws1d4">and Hygiene, <span class="ff17 ws0">1999, 61:973–977.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff8" class="pf w1 h4" data-page-no="f8"><div class="pc pcf8 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1b ws0">238</div><div class="t mc x9 h17 yd61 ff17 fsb fc3 sc0 ls382 ws19a">77.<span class="_ _7c"> </span>Baird JK et al. Diagnosis of resistance to chloroquine by <span class="ff1a ws0">Plasmodium vivax: <span class="ff17">timing</span></span></div><div class="t mc x7a h17 yd62 ff17 fsb fc3 sc0 ls105 ws0">of recurrence and whole blood chlor<span class="_ _a"></span>oquine levels. <span class="ff1a">American Journal of T<span class="_ _4b"></span>ropical</span></div><div class="t mc x7a h17 yd63 ff1a fsb fc3 sc0 ls105 ws0">Medicine and Hygiene, <span class="ff17">1997, 56: 621–626.</span></div><div class="t mc x9 h17 yd64 ff17 fsb fc3 sc0 ls105 ws0">78.<span class="_ _95"> </span>Most H et al. Chloroquine for treatment of acute attacks of viv<span class="_ _a"></span>ax malaria. <span class="ff1a">Journal</span></div><div class="t mc x7a h17 yd65 ff1a fsb fc3 sc0 ls105 ws0">of the American Medical Association, <span class="ff17 ls2e2 ws1d3">1946, 131:963–967.</span></div><div class="t mc x9 h17 yee3 ff17 fsb fc3 sc0 ls105 ws0">79.<span class="_ _95"> </span>Rowland M, Dur<span class="_ _a"></span>ani N. Randomized controlled trials of 5- and 14 days primaquine</div><div class="t mc x7a h17 yd67 ff17 fsb fc3 sc0 ls105 ws0">therapy against relapses of viv<span class="_ _a"></span>ax malaria in an Afghan refugee settlement in</div><div class="t mc x7a h17 yd68 ff17 fsb fc3 sc0 ls105 ws0">Pakistan. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Ro<span class="_ _a"></span>yal Society of T<span class="_ _b"></span>ropical Medicine and Hygiene,</span></div><div class="t mc x7a h17 yd87 ff17 fsb fc3 sc0 ls105 ws0">1999, 93:641–643.</div><div class="t mc x9 h17 yd6a ff17 fsb fc3 sc0 ls105 ws4bd">80.<span class="_ _5"> </span>Dua VK, <span class="_ _8"></span>Sharma VP<span class="_ _c"></span>. <span class="_ _8"></span><span class="ff1a ws0">Plasmodium vivax <span class="ff17">r<span class="_ _a"></span>elapses after 5 days of primaquine</span></span></div><div class="t mc x7a h17 yd88 ff17 fsb fc3 sc0 ls105 ws0">treatment, in some industrial complexes of India. <span class="ff1a">Annals of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine</span></div><div class="t mc x7a h17 yd89 ff1a fsb fc3 sc0 ls105 ws1d4">and Parasitology<span class="_ _c"></span>, <span class="ff17 lsd6 ws218">2001, 95:655–659.</span></div><div class="t mc x9 h17 yd8a ff17 fsb fc3 sc0 lsd6 ws19a">81.<span class="_ _3"> </span>Adak T<span class="_ _b"></span>, Sharma <span class="_ _a"></span>VP<span class="_ _c"></span>, Orlov VS. S<span class="_ _a"></span>tudies on the <span class="ff1a ls105 ws0">Plasmodium vivax <span class="ff17">relapse pattern </span></span></div><div class="t mc x7a h17 yd8b ff17 fsb fc3 sc0 ls105 ws0">in Delhi, India. <span class="ff1a">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17">1998,</span></span></div><div class="t mc x7a h17 yeca ff17 fsb fc3 sc0 ls138 ws0">59:175–179.</div><div class="t mc x9 h17 yd8d ff17 fsb fc3 sc0 ls105 ws0">82. Kitchener SJ, Auliff AM, Rieckmann KH. Malaria in the Australian Defense Force</div><div class="t mc x7a h17 yd8e ff17 fsb fc3 sc0 ls105 ws1d4">during and after participation in the International Force in East T<span class="_ _a"></span>imor (I<span class="_ _8"></span>NTE<span class="_ _8"></span>RFET<span class="_ _8"></span>).</div><div class="t mc x7a h17 yecd ff1a fsb fc3 sc0 ls105 ws0">Medical Journal of Australia, <span class="ff17 ls104 ws35b">2000, 173:583–585.</span></div><div class="t mc x9 h17 yd90 ff17 fsb fc3 sc0 ls105 ws0">83.<span class="_ _5"> </span>Duar<span class="_ _8"></span>te EC et al. Association of subtherapeutic dosages of a standard drug</div><div class="t mc x7a h17 yd91 ff17 fsb fc3 sc0 ls105 ws0">regimen with failures in pr<span class="_ _a"></span>eventing relapses of viv<span class="_ _a"></span>ax malaria. <span class="ff1a">American Journal </span></div><div class="t mc x7a h17 yed0 ff1a fsb fc3 sc0 ls105 ws0">of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17">2001, 65:471–476.</span></div><div class="t mc x9 h17 yd93 ff17 fsb fc3 sc0 ls105 ws0">84. Durante ME et al. Case repor<span class="_ _8"></span>t: An unusual late relapse of <span class="ff1a">Plasmodium vivax</span></div><div class="t mc x7a h17 yf78 ff17 fsb fc3 sc0 ls105 ws0">malaria. <span class="ff1a">American Journal of T<span class="_ _4b"></span>ropical Medicine and Hygiene, <span class="ff17 lscc ws4bf">2003, 68:159–160.</span></span></div><div class="t mc x9 h17 ydaf ff17 fsb fc3 sc0 ls130 ws19a">85.<span class="_ _5"> </span>Pukrittayakamee S et al. Therapeutic responses to antimalarial and antibacterial</div><div class="t mc x7a h17 ydb0 ff17 fsb fc3 sc0 ls130 ws0">drugs in vivax malaria. <span class="ff1a ws27d">Acta T<span class="_ _b"></span>ropica, <span class="ff17 ws0">2004, 89:351–356.</span></span></div><div class="t mc x9 h17 yd7a ff17 fsb fc3 sc0 ls130 ws0">86. White N<span class="_ _8"></span>J. The assessment of antimalarial drug efficacy<span class="_ _c"></span>. <span class="_ _8"></span><span class="ff1a ls137 ws1d4">T<span class="_ _b"></span>rends in Parasitology<span class="_ _c"></span>,</span></div><div class="t mc x7a h17 yd95 ff17 fsb fc3 sc0 ls137 ws0">2002, 18:458–464.</div><div class="t mc x9 h17 yd7c ff17 fsb fc3 sc0 ls130 ws19a">87.<span class="_ _95"> </span>Congpuong K et al. Sensitivity of <span class="ff1a ws0">Plasmodium vivax </span>to chloroquine in Sa K<span class="_ _a"></span>aeo</div><div class="t mc x7a h17 yd7d ff17 fsb fc3 sc0 ls130 ws27d">Pro<span class="_ _a"></span>vince, Thailand. <span class="_ _8"></span><span class="ff1a">Acta T<span class="_ _b"></span>ropica,<span class="_ _5"> </span><span class="ff17 ls2e2 ws1d3">2002, 83:117–121.</span></span></div><div class="t mc x9 h17 yd7e ff17 fsb fc3 sc0 ls10b ws0">88. Baird J<span class="_ _8"></span>K, Hoffman SL. Primaquine therapy for malaria. <span class="ff1a">Clinical Infectious Diseases,</span></div><div class="t mc x7a h17 yd7f ff17 fsb fc3 sc0 lsd6 ws218">2004, 39:1336–1345.</div><div class="t mc x9 h17 yd80 ff17 fsb fc3 sc0 ls105 ws0">89. T<span class="_ _4b"></span>aylor WR. Antimalarial drug toxicity: a review<span class="_ _4b"></span>. <span class="ff1a">Drug Safety<span class="_ _b"></span>, <span class="ff17">2004, 27:25–61.</span></span></div><div class="t mc x9 h17 y1198 ff17 fsb fc3 sc0 ls105 ws0">90.<span class="_ _5"> </span>Leslie <span class="_ _a"></span>T et al. Compliance with 14-day primaquine therapy for radical cur<span class="_ _a"></span>e of vivax</div><div class="t mc x7a h17 y1199 ff17 fsb fc3 sc0 ls105 ws0">malaria – a randomized placebo-controlled trial comparing unsupervised with</div><div class="t mc x7a h17 yd83 ff17 fsb fc3 sc0 ls105 ws0">supervised treatment. <span class="ff1a">T<span class="_ _b"></span>ransactions of the Royal Society of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and</span></div><div class="t mc x7a h17 yd84 ff1a fsb fc3 sc0 ls105 ws0">Hygiene, <span class="ff17">2004, 98:168–173.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff9" class="pf w1 h4" data-page-no="f9"><div class="pc pcf9 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7b he y9 ff16 fs5 fc3 sc0 ls372 ws17a">Annex 10 - <span class="_ _a"></span>T<span class="_ _b"></span>reatment of <span class="ff1d ls373 ws34a">Plasmodium vivax, P<span class="_ _c"></span>. ovale <span class="_ _a"></span><span class="ff16 ls374 ws0">and <span class="ff1d">P<span class="_ _c"></span>. malariae infections</span></span></span></div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">239</div><div class="t mc xb h17 yd61 ff17 fsb fc3 sc0 ls105 ws0">91.<span class="_ _3"> </span>Walsh DS et al. Efficacy of monthly tafenoquine for prophylaxis of <span class="ff1a">Plasmodium</span></div><div class="t mc x4d h17 yd62 ff1a fsb fc3 sc0 ls382 ws0">vivax <span class="ff17">and multidrug-r<span class="_ _a"></span>esistant <span class="ff1a">P<span class="_ _c"></span>. falciparum <span class="ff17">malaria. </span>Journal of Infectious Diseases,</span></span></div><div class="t mc x4d h17 yd63 ff17 fsb fc3 sc0 ls130 ws19a">2004, 190:1456–1463.</div><div class="t mc xb h17 yd64 ff17 fsb fc3 sc0 ls130 ws0">92.<span class="_ _5"> </span>Chotivanich K et al. Ex-vivo short-term culture and developmental assessment of</div><div class="t mc x4d h4d yd65 ff1a fsb fc3 sc0 ls130 ws0">Plasmodium vivax. T<span class="_ _4b"></span>ransactions of the Royal Society of <span class="_ _a"></span>T<span class="_ _b"></span>ropical Medicine and</div><div class="t mc x4d h17 yd66 ff1a fsb fc3 sc0 ls130 ws0">Hygiene, <span class="ff17">2001, 95:677–680.</span></div><div class="t mc xb h17 yd67 ff17 fsb fc3 sc0 ls130 ws0">93.<span class="_ _95"> </span>T<span class="_ _4b"></span>asanor O et al. An <span class="ff1a">in vitro </span>system for assessing the sensitivity of <span class="ff1a">Plasmodium</span></div><div class="t mc x4d h17 yd68 ff1a fsb fc3 sc0 ls130 ws0">vivax <span class="ff17">to chlor<span class="_ _a"></span>oquine. <span class="ff1a ws27d">Acta T<span class="_ _b"></span>ropica,<span class="_ _5"> </span><span class="ff17 ws0">2002, 83:49–61.</span></span></span></div><div class="t mc xb h17 yd69 ff17 fsb fc3 sc0 ls383 ws0">94<span class="_ _8"></span>.<span class="_ _95"> </span>Russell BM et al. Simple <span class="ff1a">in vitro </span>assay for determining the sensitivity of <span class="ff1a">Plasmodium</span></div><div class="t mc x4d h17 yd6a ff1a fsb fc3 sc0 ls130 ws0">vivax <span class="ff17">isolates fr<span class="_ _a"></span>om fresh human blood to antimalarials in areas where <span class="ff1a">P<span class="_ _c"></span>. vivax <span class="ff17">is</span></span></span></div><div class="t mc x4d h17 yd88 ff17 fsb fc3 sc0 ls130 ws0">endemic. <span class="ff1a">Antimicrobial Agents and Chemotherapy<span class="_ _c"></span>, <span class="_ _8"></span><span class="ff17 ls104 ws35b">2003, 47:170–173.</span></span></div><div class="t mc xb h17 yd6c ff17 fsb fc3 sc0 ls381 ws0">95.<span class="_ _95"> </span><span class="ff1a ls105">Assessment and monitoring of antimalarial drug efficacy for the treatment of</span></div><div class="t mc x4d h17 yd8a ff1a fsb fc3 sc0 ls105 ws0">uncomplicated falciparum malaria. <span class="ff17 ws1d4">Geneva, <span class="_ _a"></span>W<span class="_ _a"></span>orld Health Organization, 2003.</span></div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pffa" class="pf w1 h4" data-page-no="fa"><div class="pc pcfa w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m4 xb h60 y15b8 ff32 fs8 fc3 sc0 ls0 ws0">A<span class="_ _cd"></span><span class="fc1 sc2">A</span></div><div class="t m4 xb h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">Abdominal pain   92, 94, 103, 109, 115, 188, 227, 230</div><div class="t m4 xb h60 y15ba ff32 fs8 fc3 sc0 ls13 ws0">Acetaminophen   28</div><div class="t m4 xb h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">Acidosis   5, 38, 41-42, 52-53, 55-56, 112</div><div class="t m4 xb h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">Acquired infections   15, 163</div><div class="t m4 xb h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">ACT<span class="_ _7a"> </span>1, 9, 17-24, 26, 27, 29-36, 39, 48-50, 61, 64, 65, 68, 70, 71, 83, 99, 101, 137</div><div class="t m4 xb h60 y15be ff32 fs8 fc3 sc0 ls13 ws0">Acute   </div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">failure, renal   5, 38, 48, 52, 53, 55, 66, 128, 225, 232</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">infection   68, 163, 165, 200, 225, 226</div><div class="t m4 x4d h60 y15c0 ff32 fs8 fc3 sc0 ls13 ws0">malaria   </div><div class="t m4 x98 h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">falciparum   1, 5, 16, 29, 32, 39, 65, 66, 68, 123-128, 179, 194, 195, 204, 205, 207, 222, </div><div class="t m4 x98 h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">225, 226</div><div class="t m4 x98 h60 y15c3 ff32 fs8 fc3 sc0 ls13 ws0">subtertian   222</div><div class="t m4 x98 h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">uncomplicated   7, 16, 29, 32, 39, 124-128, 179, 194, 195, 222</div><div class="t m4 x98 h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">vivax   5, 65-69, 225, 226, 232, 233, 237, 238</div><div class="t m4 xb h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">Adherence   12, 30-32, 70, 71, 155, 157, 163, 165, 227, 229</div><div class="t m4 xb h60 y15c6 ff32 fs8 fc3 sc0 ls13 ws14">Adjunctive treatment   42, 51</div><div class="t m4 xb h60 y15c7 ff32 fs8 fc3 sc0 ls13 ws14">Adverse   </div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls1ae ws0">effects   7, 14, 17, 30, 33, 38, 39, 48, 88, 89, 94, 106-108, 115, 116, 124, 125, 190, 215, 229, 230</div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">events   19, 124, 187, 188, 190-193, 214-216</div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">reactions   18, 31, 39, 90, 91, 96, 108, 109, 123-125, 190, 200, 202, 214, 227</div><div class="t m4 xb h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">Agranulocytosis   89, 91, 103, 108, 115</div><div class="t m4 xb h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">Allergic reactions   90, 91, 125</div><div class="t m4 xb h60 y15cd ff32 fs8 fc3 sc0 ls13 ws14">4-aminoquinoline(s)   87, 89, 171</div><div class="t m4 xb h60 y15ce ff32 fs8 fc3 sc0 ls13 ws14">8-aminoquinolines   63, 64, 102, 135</div><div class="t m4 xb h60 y15cf ff32 fs8 fc3 sc0 ls13 ws0">Amodiaquine<span class="_ _7a"> </span><span class="ls87">12, 18, 20-25, 31, 33, 40, 48, 63-65, 89, 122, 123, 160, 172, 173, 188-191, 193-195, 237</span></div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">artesunate   21-25, 48, 64, 65, 123, 191, 193, 195, 222</div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">base   20, 24, 25, 30, 65, 89, 227, 231</div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">combination   18, 20, 21, 23, 25, 33, 49, 65, 172, 187-191, 194, 195</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">monotherapy   22, 25, 187-190, 231</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">oral   20, 48, 123, 218, 222, 231</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls13 ws14">prophylaxis   89, 123</div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">resistance   12, 18, 21-23, 25, 33, 63, 64, 89, 159, 160, 173, 231</div><div class="t m4 xb h60 y15d6 ff32 fs8 fc3 sc0 ls13 ws0">Anaemic heart failure   55</div><div class="t m4 xb h60 y15d7 ff32 fs8 fc3 sc0 ls13 ws14">Antibacterial drugs   238</div><div class="t m4 xb h60 y15d8 ff32 fs8 fc3 sc0 ls13 ws0">Antiemetics   29</div><div class="t m4 xb h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">Antifolate   63, 67, 105, 160, 161, 164-166, 179, 181, 194</div><div class="t m4 x4d h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">antimalarials   63, 160, 165-167</div><div class="t m4 x4d h60 y15db ff32 fs8 fc3 sc0 ls12 ws0">resistance   63, 67, 160, 161, 164-167, 179, 181</div><div class="t m4 xb h60 y15dc ff32 fs8 fc3 sc0 ls13 ws0">Antimalarial   </div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">efficacy   1, 2, 7, 13-16, 21, 33, 40, 66, 70, 84, 87, 172-176, 181, 227, 228, 231, 237-239</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">failure   14, 15, 31, 35, 38, 52, 53, 60, 66, 109, 110, 155, 164, 168, 171, 173, 174, 177, 227, 228</div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">medicines   1, 12, 13, 27, 30, 34, 35, 37, 39, 46, 84, 122, 141, 160, 200, 201</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">policy   2, 4, 14, 15, 36, 83, 141, 177</div><div class="t m4 x4d h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">regimens   12, 27, 30, 39, 163, 165, 179, 231</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pffb" class="pf w1 h4" data-page-no="fb"><div class="pc pcfb w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc3 he y9 ff16 fs5 fc3 sc0 lsad ws0">Index</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">241</div><div class="t m4 x4d h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">resistance   1, 2, 7, 12-18, 23, 26, 30, 31, 37, 41, 42, 63, 66, 67, 137-143, 155-173, 175-182, </div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">226, 227, 230, 231</div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">toxicity   89, 98, 100, 103, 109, 116, 118, 123, 126, 201, 238</div><div class="t m4 x4d h60 y15bb ff32 fs8 fc3 sc0 lsae ws5c8">treatment 1-4, <span class="_ _c3"></span><span class="lsed ws0">7-12, 14-17, 29-42, 45-47, 49, 50, 58-63, 66, 67, 69-73, 83, 84, 134-142, 170-182,</span></div><div class="t m4 x4d h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">200-203, 226-228, 230-232</div><div class="t m4 xb h60 y15bd ff32 fs8 fc3 sc0 ls13 ws0">Antipyretic   </div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">drugs   27, 28, 52</div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls13 ws14">medicines   1</div><div class="t m4 xb h60 y15bf ff32 fs8 fc3 sc0 ls13 ws14">Anti-relapse therapy   71</div><div class="t m4 xb h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">Antiretro<span class="_ _a"></span>virals   201, 202</div><div class="t m4 xb h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">Artemether   17, 21-24, 26, 37, 38, 44-49, 58-60, 95-97, 100-102, 125, 126, 191-193, 195, 210-212,</div><div class="t m4 xb h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">218, 220-222, 228</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">benflumetol   96, 101, 125, 142, 195, 228</div><div class="t m4 x4d h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">intramuscular   42, 44, 47, 49, 59, 60, 96, 97, 100, 125, 126, 210, 212, 221</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls87 ws0">lumefantrine   21-24, 26, 37, 38, 40, 48, 64, 96, 97, 101, 102, 122, 126, 173, 179, 191-193, 195, 228</div><div class="t m4 x98 h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">combination   23, 24, 49, 96, 191, 195</div><div class="t m4 x98 h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">regimen   21, 23, 24, 37, 191, 228</div><div class="t m4 x98 h60 y15c7 ff32 fs8 fc3 sc0 ls13 ws0">treatment <span class="_ _2"> </span><span class="ls87">23, 24, 26, 27, 37, 38, 40, 41, 48, 49, 64, 102, 126, 173, 179, 191-193, 195, 201, 228</span></div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">quinine   37, 38, 40, 42-49, 58, 59, 64, 101, 122, 210-212, 220, 221</div><div class="t m4 xb h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">Artemisinin   17, 18, 30, 31, 33-35, 44-50, 58, 59, 61, 63, 64, 95-100, 124, 125, 134, 135, 139, 161-</div><div class="t m4 xb h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">165, 185, 186, 213, 218-221</div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">combination   1, 17, 18, 20, 23, 33, 63, 83, 95, 96, 99, 139, 161, 164, 170, 172, 185-187, 191</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls13 ws14">component   18</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls12 ws0">compounds   17, 18, 30, 97, 124, 125, 171</div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">derivativ<span class="_ _a"></span>es   1, 12, 17, 30, 31, 33-35, 44-48, 58, 59, 61, 63, 64, 95, 96, 124, 125, 135, 163-165, </div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">185, 186, 218-220</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">dihydro-   17, 44, 47, 95-99, 122, 182</div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">non-   18, 185, 186, 191</div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">oral   17, 20, 34, 47, 50, 61, 95, 97-99, 101, 124, 125, 204, 219</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">rectal   44, 46, 47, 49, 50, 95, 98, 99, 124, 213, 221</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls1ae ws0">resistance   1, 12, 13, 17, 18, 20, 23, 30, 33, 42, 63, 64, 95, 139-141, 161-167, 170, 171, 180, 219</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls12 ws0">suppositories   49, 50, 95, 99</div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">susceptibility   63, 161, 162, 165, 170</div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">treatment   1, 17, 18, 30, 31, 33-35, 42-50, 57-59, 61-64, 83, 135, 139-141, 149, 186, 187, 190, </div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">191, 213, 218-221</div><div class="t m4 xb h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">Artemotil   17, 42, 44, 45, 47, 95-97, 100, 212</div><div class="t m4 xb h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">Artesunate   20-26, 32, 34, 36, 37, 44-51, 58-61, 64, 65, 94-99, 125, 126, 142, 165, 166, 191-193,</div><div class="t m4 xb h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">209, 210, 213, 214, 217-222</div><div class="t m4 x4d h60 y15db ff32 fs8 fc3 sc0 ls12 ws0">amodiaquine   21-25, 48, 64, 65, 123, 191, 193, 195, 222</div><div class="t m4 x4d h60 y15dc ff32 fs8 fc3 sc0 ls12 ws0">combinations   17, 19, 20, 23, 25, 32, 49, 61, 95, 96, 140, 165, 166, 171, 180, 185, 191, 228</div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">dose   21-26, 34, 47, 49-51, 61, 93, 97-99, 171, 214, 217, 219, 220, 228, 234</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">formulation   22, 32, 49, 50, 59, 99</div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">intramuscular   42, 44, 47, 49, 59, 60, 96-98, 123, 125, 126, 210, 221</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">intrarectal   51, 126, 220, 221</div><div class="t m4 x4d h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">intravenous   44, 47, 49, 59, 60, 98, 125, 209, 210, 218, 221</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pffc" class="pf w1 h4" data-page-no="fc"><div class="pc pcfc w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">242</div><div class="t m4 x4d h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">mefloquine   21-23, 25, 26, 49, 61, 93, 94, 123, 137, 140, 142, 165, 166, 171, 180, 192, 193, </div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">217-219, 222</div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">oral   20, 36, 47, 48, 50, 59-61, 95, 98, 99, 123, 125, 126, 217-219, 222, 234</div><div class="t m4 x4d h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">parenteral   36, 37, 42, 44, 46-49, 58, 59, 95, 213, 217, 219, 221</div><div class="t m4 x4d h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">rectal   36, 44, 46, 47, 49, 50, 60, 95, 98, 99, 126, 209, 213, 221</div><div class="t m4 x4d h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">resistance   17, 21-23, 25, 42, 64, 70, 95, 137, 140, 142, 165, 166, 171, 180, 219, 236</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">sulfadoxine-pyrimethamine   21-23, 25, 64, 65, 70, 166, 171, 191, 195, 228, 236, 237</div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">suppositories   49-51, 59, 95, 99, 214</div><div class="t m4 xb h60 y15bf ff32 fs8 fc3 sc0 ls13 ws0">Asymptomatic   </div><div class="t m4 x4d h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">malaria   1, 33, 39, 138, 152, 158, 203, 233</div><div class="t m4 x4d h60 y15c1 ff32 fs8 fc3 sc0 ls13 ws0">parasitaemia   39</div><div class="t m4 xb h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">Atov<span class="_ _a"></span>aquone   16, 20, 22, 37, 38, 40, 103-105, 113, 126, 127, 161, 162, 164, 179</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">combination   16, 20-22, 105, 161, 179</div><div class="t m4 x4d h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">proguanil   16, 20, 22, 37, 38, 40, 103-105, 126, 127, 161, 165</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">resistance   16, 105, 161, 162, 164, 165, 179</div><div class="t m4 xb h60 y15e2 ff32 fs8 fc3 sc0 ls0 ws0">B<span class="_ _ce"></span><span class="fc1 sc2">B</span></div><div class="t m4 xb h60 y15c7 ff32 fs8 fc3 sc0 ls13 ws14">Benign malaria   66, 225</div><div class="t m4 xb h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">Biguanides   105, 106, 160, 161</div><div class="t m4 xb h60 y15c9 ff32 fs8 fc3 sc0 ls13 ws0">Blood   </div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls13 ws0">chloroquine   1<span class="_ _a"></span>, <span class="ls1ae">16, 42, 63, 67, 94, 118, 119, 134, 171, 175, 176, 182, 226, 227, 229, 231, 236-239</span></div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">infection   5, 31, 54, 57, 58, 62, 63, 66, 67, 94, 134, 135, 137, 149, 158, 159, 163, 200, 204, </div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">228, 229</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls13 ws0">parasites   </div><div class="t m4 x98 h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">P<span class="_ _c"></span>. vivax   5, 148, 226-229</div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls13 ws0">schizontocidal   16</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">transfusion   42, 55, 56, 58, 215, 221</div><div class="t m4 xb h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">Breast milk   34, 88, 90, 92, 94, 106-109, 111, 115</div><div class="t m4 xb h60 y15e3 ff32 fs8 fc3 sc0 ls0 ws0">C<span class="_ _cd"></span><span class="fc1 sc2">C</span></div><div class="t m4 xb h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">Candidate replacement drugs   155</div><div class="t m4 xb h60 y15d4 ff32 fs8 fc3 sc0 ls13 ws0">Cardiac   </div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">arrest   110</div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">failure   110, 215</div><div class="t m4 xb h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">Cardiotoxicity   37, 38, 89, 110, 126, 227</div><div class="t m4 xb h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">Cerebral malaria   5, 7, 29, 49, 52, 54, 57, 66, 120, 121, 125, 129, 203, 211, 212, 214, 220, 221</div><div class="t m4 xb h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">Chloroquine   12, 13, 63-67, 70, 87-89, 118, 119, 122, 123, 128, 129, 139-142, 158-160, 162-173,</div><div class="t m4 xb h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">175, 176, 180-182, 186, 187, 193-195, 226-239</div><div class="t m4 x4d h60 y15db ff32 fs8 fc3 sc0 ls12 ws0">base   20, 30, 63, 65, 70, 87, 89, 226-228, 230-232</div><div class="t m4 x4d h60 y15dc ff32 fs8 fc3 sc0 ls12 ws0">blood   16, 42, 63, 67, 95, 119, 134, 158, 163, 171, 175, 176, 182, 226, 229, 238, 239</div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">combined   65, 70, 123, 170, 193, 195, 237</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">doxycy<span class="_ _a"></span>cline   20, 40, 170, 228, 235</div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls13 ws0">failure   </div><div class="t m4 x98 h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">treatment   1, 35, 168, 171-173, 182, 186, 222, 227-229, 236</div><div class="t m4 x4d h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">oral   20, 63, 119, 122, 123, 222, 226, 231, 234</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pffd" class="pf w1 h4" data-page-no="fd"><div class="pc pcfd w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc3 he y9 ff16 fs5 fc3 sc0 lsad ws0">Index</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">243</div><div class="t m4 x4d h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">parenteral   42, 43, 88</div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls13 ws0">resistance   </div><div class="t m4 x98 h60 y15ba ff33 fs8 fc3 sc0 ls13 ws0">P<span class="_ _c"></span>. falciparum<span class="_ _b1"> </span><span class="ff32 ls12">12, 19, 25, 63, 64, 66, 68, 87, 139, 140, 155, 159, 160, 166-169, 172, 175, </span></div><div class="t m4 x98 h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">180, 182, 183</div><div class="t m4 x98 h60 y15bc ff33 fs8 fc3 sc0 ls13 ws0">P<span class="_ _c"></span>. vivax <span class="_ _2"> </span><span class="ff32 ls12">12, 13, 62-64, 66-68, 70, 176, 226, 227, 229-232, 234-236</span></div><div class="t m4 x4d h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">sensitive   13, 63, 65, 66, 70, 138-140, 158, 163, 226, 227, 229-231, 234</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">sulfadoxine-pyrimethanine   1, 12, 16, 18, 25, 63-65, 90, 141, 142, 166-169, 171-173, 180-182, </div><div class="t m4 xb h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">186-188, 194, 195, 228, 236, 237</div><div class="t m4 xb h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">Chlorproguanil   16, 21, 33, 63, 106, 107, 127, 160, 179, 182</div><div class="t m4 xb h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">Clindamycin   17, 20, 32-34, 37, 38, 40, 48, 49, 53, 114, 115, 122, 170</div><div class="t m4 xb h60 y15c1 ff32 fs8 fc3 sc0 ls13 ws0">Clinical   </div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">diagnosis   8, 9, 11, 27, 46, 54, 62, 69, 84, 145, 147, 150-152, 173, 182, 204, 233</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">disease   5, 8, 69, 84, 133, 147, 201, 204, 237</div><div class="t m4 x4d h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">failure   5, 14, 35, 48, 52, 128, 155, 168, 171, 173, 174, 186, 187, 190, 200, 232</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">malaria   5, 6, 8, 11, 12, 44-46, 48-54, 84, 122-129, 133, 147, 148, 150-152, 172-176, 199-201, </div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">219-221, 232-234, 236-238</div><div class="t m4 xb h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">Co-formulation   30, 32, 104, 105</div><div class="t m4 xb h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">Co-infection   11, 203, 204</div><div class="t m4 xb h60 y15c8 ff32 fs8 fc3 sc0 ls13 ws0">Combinations   </div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls13 ws0">aminoquinoline-antifolate   194</div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">amodiaquine   18, 20, 21, 23-25, 33, 48, 65, 172, 188-191, 193-195</div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">artemether-lumefantrine   23, 24, 48, 191, 193, 195, 228</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 lsed ws0">artemisinin-based, non ar<span class="_ _8"></span>temisinin-based   1, 17, 18, 20, 23, 33, 61, 63, 83, 95, 96, 99, 139, 164,</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls12 ws0">165, 170, 185, 186, 191</div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">artesunate-mefloquine   142, 165, 180</div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">atov<span class="_ _a"></span>aquone-proguanil   16, 20, 22, 161</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">chemotherapy   1, 128, 142, 178, 179</div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">chloroquine-doxy<span class="_ _a"></span>cycline   20, 32, 128, 170, 228, 235</div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">drug   16-18, 21, 49, 63, 96, 99, 106, 128, 139, 140, 142, 159, 164-166, 170-172, 175, 176, </div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">178-180</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">fixed-dose   61, 90, 92, 99</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls12 ws0">mefloquine   20, 23, 25, 33, 49, 61, 63, 110, 137, 140, 142, 165, 166, 171, 179, 180</div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls291 ws0">RDT<span class="_ _7a"> </span>11</div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls13 ws14">sulfadoxine-pyrimethamine, amodiaquine   172, 195</div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls13 ws14">sulfone-biguanide   161</div><div class="t m4 x4d h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">treatment   1, 16, 17, 19, 20, 22-25, 33, 34, 48, 49, 61, 63, 65, 66, 83, 92, 137, 138, 186-191, </div><div class="t m4 x4d h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">193-195, 226-228</div><div class="t m4 xb h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">Complex emergencies   11, 69-71</div><div class="t m4 xb h60 y15db ff32 fs8 fc3 sc0 ls13 ws0">Complicated   </div><div class="t m4 x4d h60 y15dc ff32 fs8 fc3 sc0 ls13 ws0">malaria   </div><div class="t m4 x98 h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">falciparum   1, 66, 194, 195, 230</div><div class="t m4 x98 h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">vivax   65, 66, 229, 230</div><div class="t m4 xb h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">Confirmatory diagnosis   8, 9, 149, 150</div><div class="t m4 xb h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">Convulsions   29, 41, 52, 53, 57, 88, 89, 91, 92, 94, 124, 214-216</div><div class="t m4 xb h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">Corticosteroids   52, 54, 55</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pffe" class="pf w1 h4" data-page-no="fe"><div class="pc pcfe w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">244</div><div class="t m4 xb h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">Cotrimoxazole   25, 39, 93, 104, 200-202</div><div class="t m4 xb h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">C<span class="_ _a"></span>ycloguanil   105, 106, 127, 160, 161</div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">resistance   105, 160, 161</div><div class="t m4 xb h60 y15e4 ff32 fs8 fc3 sc0 ls0 ws0">D<span class="_ _cf"></span><span class="fc1 sc2">D</span></div><div class="t m4 xb h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">Dapsone   16, 20, 21, 33-35, 91, 92, 106-108, 179, 182</div><div class="t m4 xb h61 y15be ff33 fs8 fc3 sc0 ls12 ws0">De nov<span class="_ _a"></span>o  </div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">mutation   162, 163, 166</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">resistance   1, 17, 157-159, 162-166</div><div class="t m4 xb h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">Dexamethasone   55, 214, 215, 221</div><div class="t m4 xb h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">Diagnosis   8-11, 26, 27, 36, 46, 50, 54, 60, 62, 69, 84, 147, 149-152, 182, 226, 232, 233</div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">clinical   8, 9, 11, 27, 46, 54, 62, 69, 84, 147, 150-152, 172, 181, 204, 233, 237</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">parasitological   8-11, 84, 150, 152, 172, 201</div><div class="t m4 x4d h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">rapid   9, 46, 62, 149-152, 233</div><div class="t m4 xb h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">Dihydroartemisinin   17, 22, 47, 95-99, 122, 125, 126, 214</div><div class="t m4 xb h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">Doxycy<span class="_ _a"></span>cline   20, 32, 37, 38, 40, 48, 49, 111-114, 122, 128, 129, 170, 228, 235</div><div class="t m4 xb h60 y15c6 ff32 fs8 fc3 sc0 ls13 ws14">Drug   </div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">combinations   16, 18, 165, 172, 176, 180</div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">efficacy   7, 13, 14, 16, 18, 21, 40, 58, 84, 87, 117, 123, 172-177, 181, 227-229, 237-239</div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">hepatotoxic   113</div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">interactions   9, 88, 89, 93, 94, 96-100, 102-104, 106-108, 110, 112, 114, 115, 122, 129, 156, </div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">201, 202</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">intramuscular   40, 42, 52, 59, 60, 90, 96-98, 100, 114, 116, 118, 123</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls12 ws0">intrarectal   40, 118</div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">oral   17, 19, 27, 28, 48, 59-61, 63, 95, 97-99, 101, 104-106, 113-115, 118, 119, 122-125, 127, </div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">128, 218, 219</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">patterns   2, 14, 155, 157, 172</div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">resistance   1, 2, 7, 12-18, 26, 31, 42, 63, 70, 73, 138-143, 155-173, 175-182, 217, 226, 227, </div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">231, 232</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">resistant   17, 89, 101, 125, 126, 138-140, 142, 156-160, 162-166, 175-178, 180-182, 222, 227-</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">229, 231, 232, 235, 237</div><div class="t m4 xb h60 y15e5 ff32 fs8 fc3 sc0 ls0 ws0">E<span class="_ _d0"></span><span class="fc1 sc2">E</span></div><div class="t m4 xb h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">Epidemic   2, 6, 11, 59, 60, 69-72, 84, 155, 176, 182, 199, 202, 203, 236</div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">falciparum   11, 59, 60, 69, 70, 84, 155, 182, 203, 236</div><div class="t m4 x4d h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">mixed   69, 70</div><div class="t m4 x4d h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">vivax   11, 68-71, 155, 236, 237</div><div class="t m4 xb h60 y15e6 ff32 fs8 fc3 sc0 ls0 ws0">F<span class="_ _b4"></span><span class="fc1 sc2">F</span></div><div class="t m4 xb h60 y15dc ff32 fs8 fc3 sc0 ls13 ws0">Failur<span class="_ _a"></span>e   </div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">acute renal   5, 38, 48, 52, 53, 55, 66, 128, 225, 232</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls13 ws0">anaemic heart   55</div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">antimalarial treatment   14, 15, 31, 35, 38, 52, 53, 177, 200</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">blood   14, 24, 27, 31, 52, 53, 55, 110, 139, 171, 173, 215, 217, 229</div><div class="t m4 x4d h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">cardiac   110, 215</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfff" class="pf w1 h4" data-page-no="ff"><div class="pc pcff w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc3 he y9 ff16 fs5 fc3 sc0 lsad ws0">Index</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">245</div><div class="t m4 x4d h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">chloroquine   1, 35, 166-168, 171, 173, 182, 186, 222, 227, 229, 235, 236</div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">clinical   5, 14, 35, 48, 53, 127, 128, 155, 164, 168, 171, 173-175, 186, 187, 189, 200, 232</div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">impairment   56, 112, 114</div><div class="t m4 x4d h60 y15bb ff32 fs8 fc3 sc0 ls14 ws0">late</div><div class="t m4 x98 h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">clinical   173, 174</div><div class="t m4 x98 h60 y15bd ff32 fs8 fc3 sc0 ls13 ws14">parasitological   173-175</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">parasite   5, 9, 14, 18, 38, 60, 121, 163, 173, 185, 217, 218, 222, 229</div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">parasitological   9, 14, 17, 21, 31, 173-175, 185, 187, 190, 191</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">renal   5, 38, 48, 52, 53, 55, 56, 66, 109, 110, 112, 114, 128, 225, 232</div><div class="t m4 x4d h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">total   15, 20, 24, 174, 178, 185, 186</div><div class="t m4 x4d h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">treatment   5-7, 14, 15, 17-20, 31, 32, 34, 35, 38, 39, 48, 155, 156, 167, 168, 171-175, 177, 178, </div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">186, 187, 189-191, 217-219, 226-229</div><div class="t m4 xb h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">Falciparum   31-41, 55-66, 68-70, 123-128, 135-137, 139-142, 157-162, 166-170, 178-183, 193-195,</div><div class="t m4 xb h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">203-205, 207-211, 219-222, 225-228, 233-237</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls13 ws0">chloroquine   <span class="ls1ae">12, 42, 63-67, 70, 87-89, 128, 139-142, 158-160, 166-169, 171, 172, 175, 180-182, </span></div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">194, 195, 226-231, 233-237</div><div class="t m4 x4d h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">infections   5, 11, 12, 38, 39, 62-66, 68-70, 87, 134, 135, 137, 138, 141, 142, 157, 158, 175, </div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">200, 203, 204, 225, 226, 228</div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">malaria   16, 17, 27-29, 31-43, 55-66, 68-70, 123-128, 139-142, 151, 152, 178-183, 193-195, </div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">199, 200, 203-205, 207-217, 219-222, 225-239</div><div class="t m4 x98 h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">complicated   66, 194, 195, 230</div><div class="t m4 x98 h60 y15cb ff32 fs8 fc3 sc0 ls13 ws0">non-, un-   62, 226</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">parasites   5, 11, 15-17, 56, 60, 62, 87, 108, 109, 135-142, 148, 149, 157-160, 172, 207-210, </div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls12 ws0">216-219, 225-228</div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">Plasmodium   5, 95, 123-128, 136, 141, 142, 148, 151, 152, 167-170, 178-182, 193-195, 203, </div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">204, 219-222, 225, 233-237, 239</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">resistance   1, 2, 12, 16-19, 22, 23, 25, 26, 63, 64, 66, 67, 139-142, 155, 157-162, 166-173, </div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">175, 178-182, 226, 227, 234-236</div><div class="t m4 x98 h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">mefloquine   12, 22, 23, 63, 64, 124, 137, 140, 142, 160, 161, 166, 167, 169-171, 179-181, </div><div class="t m4 x98 h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">218, 219, 236</div><div class="t m4 xb h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">First-line treatment   15, 20, 31, 33, 36, 38, 65, 172, 178</div><div class="t m4 xb h60 y15e5 ff32 fs8 fc3 sc0 ls0 ws0">G<span class="_ _cf"></span><span class="fc1 sc2">G</span></div><div class="t m4 xb h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">G6PD deficiency   65, 71, 103, 230-232</div><div class="t m4 xb h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">Gametocytocidal   70, 71, 102, 134, 135, 137, 139, 141</div><div class="t m4 xb h60 y15d8 ff32 fs8 fc3 sc0 ls13 ws14">Glasgow coma scale   42</div><div class="t m4 xb h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">Guidelines   1-4, 6, 8, 10, 12, 14-16, 20-22, 28-30, 32, 38-40, 72, 73, 75, 77-81, 83, 84, 176-178</div><div class="t m4 xb h60 y15e6 ff32 fs8 fc3 sc0 ls0 ws0">H<span class="_ _cf"></span><span class="fc1 sc2">H</span></div><div class="t m4 xb h60 y15dc ff32 fs8 fc3 sc0 ls12 ws0">Halofantrine   22, 33, 37, 38, 88, 94, 101, 110, 162, 169, 179, 201, 227, 233, 234, 237</div><div class="t m4 xb h60 y15dd ff32 fs8 fc3 sc0 ls13 ws0">Hepatic   </div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls13 ws14">dysfunction   40, 48</div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">impairments   97, 98, 114</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">schizonts   16, 71, 91, 95, 102, 105, 175</div><div class="t m4 xb h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">Hepatitis   89, 91, 108, 215, 216</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf100" class="pf w1 h4" data-page-no="100"><div class="pc pc100 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">246</div><div class="t m4 xb h60 y9e ff32 fs8 fc3 sc0 ls13 ws14">Hepatotoxic   113</div><div class="t m4 xb h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">H<span class="_ _8"></span>IV   2, 10, 38, 39, 73, 75, 147, 164, 197, 199-204, 215, 216</div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">AIDS   10, 38, 39, 73, 75, 147, 197, 199-204</div><div class="t m4 x4d h60 y15bb ff32 fs8 fc3 sc0 ls13 ws14">co-infection   203, 204</div><div class="t m4 x4d h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">infected   10, 39, 200-202, 204</div><div class="t m4 x4d h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">infection   38, 39, 164, 199-204</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">patients   10, 38, 39, 201-204</div><div class="t m4 xb h60 y15e7 ff32 fs8 fc3 sc0 ls0 ws0">I<span class="_ _65"></span><span class="fc1 sc2">I</span></div><div class="t m4 xb h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">Infants   33-36, 69, 112, 116-118, 128, 203</div><div class="t m4 xb h60 y15c1 ff32 fs8 fc3 sc0 ls13 ws0">Infection(s)   </div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">acquired   12, 14, 15, 64, 158, 163, 165, 203</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">acute   5, 38, 66, 68, 163, 165, 173, 200, 225, 226, 232</div><div class="t m4 x4d h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">bacterial   54, 57, 58, 111, 115</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">blood   5, 31, 53, 57, 58, 62, 63, 67, 94, 134, 135, 137, 149, 158, 159, 162, 173, 175, 200</div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">chloroquine   1, 12, 63-67, 70, 87, 134, 139, 142, 158, 173, 175, 186, 226-231, 234-237</div><div class="t m4 x4d h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">co-   11, 203, 204</div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">H<span class="_ _8"></span>IV<span class="_ _4b"></span>, H<span class="_ _8"></span>IV/AI<span class="_ _8"></span>DS   38, 39, 73, 75, 164, 199-204</div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">liver   62, 64, 94, 163, 225, 226</div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">malaria   5-7, 10-12, 14-18, 36-40, 57, 58, 62-70, 75, 134-143, 147, 149-151, 157-159, 163-166, </div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">199-204, 225-228, 230-237</div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">mixed   68-70, 142, 150</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">opportunistic   39, 200-202</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls13 ws14">placental   200, 203</div><div class="t m4 x4d h61 y15ce ff33 fs8 fc3 sc0 ls13 ws0">Plasmodium   </div><div class="t m4 x98 h60 y15cf ff33 fs8 fc3 sc0 ls13 ws0">falciparum<span class="_ _b1"> </span><span class="ff32 ls12">5, 127, 136, 137, 142, 151, 178, 203, 204, 219, 222, 225, 233-236</span></div><div class="t m4 x98 h60 y14a0 ff33 fs8 fc3 sc0 ls13 ws0">ov<span class="_ _a"></span>ale<span class="_ _b1"> </span><span class="ff32 ls12">5, 62, 223, 225, 227, 229, 231, 233, 235</span></div><div class="t m4 x98 h60 y15d0 ff33 fs8 fc3 sc0 ls14 ws0">vivax<span class="_ _7a"> </span><span class="ff32 ls12">5, 62, 223, 225-229, 231-237</span></div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">primaquine   11, 63-66, 68, 70, 135, 137, 226, 228-232, 235, 236</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">primary   7, 12, 62, 138, 157, 158, 163, 164, 218, 225, 228, 229</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">recrudescent   15, 142, 158, 163, 173, 218</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls12 ws0">recurrent   20, 58, 173, 175, 229</div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">relapse   11, 62, 64, 66, 175, 225, 229, 236</div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">repeated   62, 64, 225</div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls13 ws0">resistant   <span class="ls1ae">17, 39, 64, 65, 67, 138, 139, 142, 158-160, 163-165, 175, 177, 178, 222, 227-232, 237</span></div><div class="t m4 x4d h60 y15d8 ff33 fs8 fc3 sc0 ls13 ws0">Salmonella<span class="_ _b1"> </span><span class="ff32 ls12">54, 57</span></div><div class="t m4 x4d h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">single   62, 65, 164, 230</div><div class="t m4 x4d h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">transmissible   157, 158</div><div class="t m4 xb h60 y15db ff32 fs8 fc3 sc0 ls12 ws0">Insecticide-treated nets   69, 134, 140</div><div class="t m4 xb h60 y15dc ff32 fs8 fc3 sc0 ls13 ws0">Intermittent   </div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls13 ws0">regimen   230</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">treatment   1, 2, 22, 23, 39, 40, 200-202</div><div class="t m4 xb h60 y15e8 ff32 fs8 fc3 sc0 ls0 ws0">K<span class="_ _cd"></span><span class="fc1 sc2">K</span></div><div class="t m4 xb h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">K<span class="_ _a"></span>washiorkor   117-120, 128, 129</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf101" class="pf w1 h4" data-page-no="101"><div class="pc pc101 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc3 he y9 ff16 fs5 fc3 sc0 lsad ws0">Index</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1b ws0">247</div><div class="t m4 xb h60 y15b8 ff32 fs8 fc3 sc0 ls0 ws0">L<span class="_ _b4"></span><span class="fc1 sc2">L</span></div><div class="t m4 xb h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">Lactating women   34, 35, 112, 114, 127</div><div class="t m4 xb h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">Lumefantrine   20-24, 26, 33, 37, 38, 40, 48, 64, 96, 97, 101, 102, 110, 122, 126, 191-193, 195, 228</div><div class="t m4 xb h60 y15e4 ff32 fs8 fc3 sc0 ls0 ws0">M<span class="_ _d1"></span><span class="fc1 sc2">M</span></div><div class="t m4 xb h60 y15bd ff32 fs8 fc3 sc0 ls13 ws0">Malaria   </div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">acute   5, 6, 16, 26, 29, 38, 52, 55, 56, 66, 68, 101, 123-128, 163, 194, 195, 225, 226, 232</div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">anaemia   5, 8, 12, 14, 32, 41, 55, 56, 58, 66, 103, 107, 108, 110, 121, 215, 225, 226</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">asymptomatic   33, 39, 137, 152, 158, 203, 233</div><div class="t m4 x4d h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">benign   66, 225, 232</div><div class="t m4 x4d h60 y15c1 ff32 fs8 fc3 sc0 lsed ws0">blood   5, 6, 14, 16, 42, 52-59, 62, 63, 67, 71, 94, 95, 102, 133-135, 148, 149, 158, 159, 172-173,</div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">215-217</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">cerebral, adult   203, 214</div><div class="t m4 x4d h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">chemotherapy   1, 123, 125-128, 141, 142, 178, 179, 182, 221, 234, 236, 237, 239</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">clinical   1, 2, 5, 6, 8, 11, 12, 35-37, 41, 42, 44-46, 50-54, 122-129, 147, 150-152, 172-177, 179, </div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">200, 201, 232-234</div><div class="t m4 x4d h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">complicated  /  non-complicated   194, <span class="ff33 ls13">see also: <span class="ff32">malaria, uncomplicated</span></span></div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">diagnosis   8-11, 26, 27, 36, 46, 50, 54, 60, 62, 69, 84, 147, 149-152, 182, 226, 232, 233</div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">epidemics   2, 6, 11, 69-71, 155, 176, 182, 199, 202</div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">frequent   39, 46, 56, 59, 64, 89, 97, 170, 190, 193, 199</div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">human   5, 62, 91, 127, 133, 134, 148, 151, 203, 204, 225, 227, 233, 235, 239</div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">ICT<span class="_ _7a"> </span>151, 152, 233</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">imported   151</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls12 ws0">incidence   6, 10, 12, 26, 49, 61, 133, 134, 137, 138, 140, 142, 147, 165, 180, 204, 225</div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">microscopy   9-11, 62, 68, 147-152, 226, 233</div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">moderate   10, 11, 60, 65, 126, 137, 159, 173, 174, 192, 213, 221</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">ov<span class="_ _a"></span>ale   5, 11, 37, 62, 63, 65-69, 73, 75, 87, 102, 108, 135, 148, 223, 225, 229-233</div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">parasites   5, 6, 8, 9, 11-18, 60, 62, 133-142, 147, 148, 150, 151, 155-159, 163-166, 172, 173, </div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">175, 176, 207-212, 216-219, 225-228</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls13 ws14">placental   200, 203</div><div class="t m4 x4d h61 y15d3 ff33 fs8 fc3 sc0 ls13 ws0">plasmodium   </div><div class="t m4 x98 h60 y15d4 ff33 fs8 fc3 sc0 ls13 ws0">falciparum<span class="_ _b1"> </span><span class="ff32 ls12">123-128, 136, 137, 141, 142, 151, 152, 167, 178-183, 185, 193-195, 203-205, </span></div><div class="t m4 x98 h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">207, 209-211, 217, 219-222, 225, 233-237</div><div class="t m4 x98 h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">non-falciparum   62, 226</div><div class="t m4 x98 h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">uncomplicated   2, 5, 7, 8, 16-17, 27, 29, 34, 37-37, 50, 60-62, 70, 84, 96, 109, 124, 125, </div><div class="t m4 x98 h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">142, 179, 181, 183, 185, 187, 189, 191, 193-195, 216, 222, 235, 236, 239</div><div class="t m4 x98 h60 y15d9 ff33 fs8 fc3 sc0 ls14 ws0">vivax<span class="_ _7a"> </span><span class="ff32 ls12">5, 62, 148, 152, 182, 223, 225-229, 231-239</span></div><div class="t m4 x4d h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">rapid diagnostic tests   9, 62, 69, 148, 151</div><div class="t m4 x4d h60 y15db ff32 fs8 fc3 sc0 ls13 ws0">severe   </div><div class="t m4 x98 h60 y15dc ff32 fs8 fc3 sc0 ls12 ws0">anaemia   5, 8, 41, 55, 56, 58, 66, 110, 215, 225</div><div class="t m4 x98 h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">malaria   1, 2, 5-8, 11, 12, 16, 29, 35-63, 65, 66, 69, 70, 109, 110, 121-128, 147, 200-205, </div><div class="t m4 x98 h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">207-222, 225, 226, 232, 233</div><div class="t m4 x98 h60 y15df ff32 fs8 fc3 sc0 ls13 ws14">non-severe   123</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">species   5, 11, 18, 62, 63, 66, 68-70, 84, 95, 103, 141, 147, 148, 155, 225, 227, 231</div><div class="t m4 x4d h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">stable / unstable   5, 6, 10, 11, 56, 66, 133, 199-204, 215, 218</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf102" class="pf w1 h4" data-page-no="102"><div class="pc pc102 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1b ws0">248</div><div class="t m4 x4d h60 y9e ff32 fs8 fc3 sc0 ls13 ws0">subtertian   222</div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls13 ws0">tertian   232</div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls13 ws0">transmission   </div><div class="t m4 x98 h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">high   5-8, 10, 11, 14, 27, 32, 33, 55, 56, 60, 66, 68-71, 133, 134, 137-140, 149, 158, 163-</div><div class="t m4 x98 h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">165, 203, 204</div><div class="t m4 x98 h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">low   6, 10-12, 14, 32, 45, 46, 56, 58-60, 62, 64, 68, 133, 137-141, 158, 172-174, 217</div><div class="t m4 x98 h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">moderate   10, 11, 14, 60, 137, 173, 174</div><div class="t m4 x98 h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">stable   5, 10, 11, 56, 66, 133, 215, 218</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls13 ws0">treatment   </div><div class="t m4 x98 h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">guidelines   1-4, 6, 8, 10, 14-16, 20-22, 28-30, 32, 38-40, 72, 73, 75, 77, 78, 80, 81, 83, 84,</div><div class="t m4 x98 h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">176-178</div><div class="t m4 x98 h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">policy   2, 4, 14, 15, 83, 141, 174, 177, 204</div><div class="t m4 x98 h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">uncomplicated   1, 2, 7, 8, 16, 17, 23, 27-29, 31-41, 60-63, 70, 124-128, 142, 179, 181, 193-</div><div class="t m4 x98 h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">195, 222, 235, 236</div><div class="t m4 xb h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">Malnutrition   40, 117-121, 128, 129</div><div class="t m4 xb h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">Mass treatment   71, 72, 168</div><div class="t m4 xb h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">Mefloquine   20-23, 25, 26, 32, 33, 61, 63, 64, 93, 94, 122-124, 140, 160-163, 165-167, 169-171,</div><div class="t m4 xb h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">179-181, 192, 193, 217-219, 222</div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls13 ws0">artesunate   <span class="ls1ae">21-23, 25, 26, 48, 61, 64, 94, 123, 137, 140, 142, 165, 166, 171, 192, 193, 217-219,</span></div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">222</div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">combination   20, 23, 25, 33, 49, 63, 110, 137, 140, 142, 165, 166, 171, 179, 180</div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">concentrations   88, 93, 94, 110, 162, 163, 165</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">monotherapy   22, 169-171</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls13 ws21">resistance  <span class="_ _95"> </span>1<span class="_ _a"></span>2,<span class="_ _b"></span> 21<span class="_ _a"></span>-2<span class="_ _b"></span>3,<span class="_ _a"></span> 25<span class="_ _b"></span>, 3<span class="_ _a"></span>3<span class="_ _a"></span>, 6<span class="_ _a"></span>3<span class="_ _a"></span>, 6<span class="_ _b"></span>4,<span class="_ _a"></span> <span class="ls2cd ws14">124, 137, 140, 142, 158, 160-171, 176, 179-181, 217-219, 236</span></div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">treatment   25, 26, 31, 32, 40, 41, 48, 49, 61, 63, 64, 94, 95, 124, 137, 138, 140, 166-168, 192, </div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">193, 217-220, 222, 223, 227, 228</div><div class="t m4 xb h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">Microscopy   9-11, 31, 62, 68, 147-152, 226, 233</div><div class="t m4 xb h60 y15d0 ff32 fs8 fc3 sc0 ls13 ws0">Mixed   </div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">epidemics   69, 70</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">falciparum   68-70</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">infections   68-70, 142, 143, 150</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls13 ws0">vivax   67-70</div><div class="t m4 xb h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">Monitoring   15, 27, 29, 36, 37, 46, 59, 66, 78, 152, 155, 172, 176, 177, 181, 201, 202, 231</div><div class="t m4 xb h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">Monotherapies   16, 17, 19, 21, 22, 24-27, 34, 37, 139, 169-171, 185-190, 194, 226, 228, 231</div><div class="t m4 xb h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">Multidrug resistance   23, 171, 217, 218, 237</div><div class="t m4 xb h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">Mutation   126, 157, 159-164, 166, 169, 170, 172, 176, 179, 180, 182, 227, 236, 237</div><div class="t m4 x4d h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">de nov<span class="_ _a"></span>o   162, 163, 165, 166</div><div class="t m4 x4d h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">parasite   156, 159, 160, 162, 166, 172, 176, 227</div><div class="t m4 xb h60 y15e9 ff32 fs8 fc3 sc0 ls0 ws0">N<span class="_ _cf"></span><span class="fc1 sc2">N</span></div><div class="t m4 xb h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">Nephrotoxic   113</div><div class="t m4 xb h60 y15de ff32 fs8 fc3 sc0 ls13 ws0">Neurological   </div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">sequelae   208, 211, 212</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">syndrome   124</div><div class="t m4 xb h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">Neurotoxicity   31, 96, 97, 125</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf103" class="pf w1 h4" data-page-no="103"><div class="pc pc103 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc3 he y9 ff16 fs5 fc3 sc0 lsad ws0">Index</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">249</div><div class="t m4 xb h60 y15b8 ff32 fs8 fc3 sc0 ls0 ws0">O<span class="_ _d2"></span><span class="fc1 sc2">O</span></div><div class="t m4 xb h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws81">Oral   </div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">amodiaquine   20, 48, 123, 218, 222, 231</div><div class="t m4 x4d h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">artemisinin   17, 18, 20, 34, 47, 49, 50, 61, 95-100, 124, 125, 204, 219</div><div class="t m4 x4d h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">artesunate   20, 36, 47-50, 59-61, 95, 98, 99, 123, 125, 126, 217-219, 222, 234</div><div class="t m4 x4d h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">chloroquine   1, 20, 63, 119, 122, 123, 222, 226, 231, 234</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12a ws5c9">drugs   17, 18, <span class="ls64 ws14">27, 28, 49, 60, 61, 63, 70, 71, 97-101, 104-106, 113-115, 118, 119, 122, 123, 127,</span></div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">128, 157, 218, 219, 231</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">quinine   34, 47-49, 59, 101, 109, 119, 123, 124, 127, 128, 204, 217, 219, 220</div><div class="t m4 x4d h60 y15c0 ff32 fs8 fc3 sc0 ls13 ws0">sulfadoxine-pyrimethamine   20, 39</div><div class="t m4 x4d h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">therapy   20, 48, 49, 59, 95, 99, 124, 127, 217-219, 222, 234</div><div class="t m4 xb h60 y15ea ff32 fs8 fc3 sc0 ls0 ws0">P<span class="_ _d3"></span><span class="fc1 sc2">P</span></div><div class="t m4 xb h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">Paracetamol   28, 104</div><div class="t m4 xb h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">Parasitaemia   9, 10, 14, 21, 27, 31, 41, 42, 60, 61, 138, 139, 149, 173-175, 192, 203, 204, 214, 217-</div><div class="t m4 xb h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">219, 229</div><div class="t m4 x4d h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">asexual   17, 41, 138, 139</div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls13 ws14">asymptomatic   39</div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">baseline   214, 229</div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls13 ws0">hyper<span class="_ _b"></span>-   222</div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">malarial   11, 155</div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls13 ws14">persistent   175</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">recurrent   173, 229</div><div class="t m4 xb h60 y15cd ff32 fs8 fc3 sc0 ls13 ws0">Parasitological   </div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">cure rates   12, 14, 21, 189, 190</div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">diagnosis   8-11, 84, 150-152, 173, 201</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">failure   14, 17, 21, 31, 173, 174, 185, 187, 190, 191</div><div class="t m4 xb h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">PfCR<span class="_ _a"></span>T<span class="_ _7a"> </span>87, 139, 159, 160, 176</div><div class="t m4 xb h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">PfH<span class="_ _8"></span>RP<span class="_ _b1"> </span>149, 151</div><div class="t m4 xb h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">PfM<span class="_ _8"></span>DR   87, 139, 160, 161, 169, 170, 176, 179</div><div class="t m4 xb h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">Pharmacovigilance   25, 30, 128, 201, 202</div><div class="t m4 xb h60 y15d4 ff32 fs8 fc3 sc0 ls12 ws0">Phenobarbital   57, 114, 216</div><div class="t m4 xb h60 y15d5 ff32 fs8 fc3 sc0 ls13 ws14">Placental   200, 203</div><div class="t m4 xb h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">Plasmodium   5, 62, 95, 103, 123-128, 136, 141, 142, 151, 152, 167-171, 178-182, 193-195, 203,</div><div class="t m4 xb h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">204, 219-222, 225, 231-239</div><div class="t m4 x4d h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">blood stage   62, 226, 236</div><div class="t m4 x4d h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">falciparum   123-128, 136, 137, 141, 142, 151, 152, 167-170, 178-183, 185, 193-195, 203-205, </div><div class="t m4 x4d h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">207, 209-211, 217, 219-222, 225, 233-237</div><div class="t m4 x4d h60 y15db ff32 fs8 fc3 sc0 ls12 ws0">malariae   5, 62, 148, 167, 171, 223, 225, 227, 229, 231, 233, 235</div><div class="t m4 x4d h60 y15dc ff32 fs8 fc3 sc0 ls12 ws0">ov<span class="_ _a"></span>ale   5, 62, 148, 223, 225, 227, 229, 231, 233, 235</div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">resistance   141-143, 167-172, 178-182, 219, 229, 231, 232, 234-236, 238</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">severe   125, 193, 203, 205, 207, 209-211, 213, 215-217, 219-222, 232</div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">vivax   5, 62, 148, 152, 171, 182, 223, 225-229, 231-239</div><div class="t m4 xb h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">Pregnancy   2, 6, 7, 10, 11, 31-34, 48, 58-60, 62, 96, 104-106, 110, 112, 125-127, 200-203, 225,</div><div class="t m4 xb h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">226, 232, 233</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf104" class="pf w1 h4" data-page-no="104"><div class="pc pc104 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">250</div><div class="t m4 xb h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">Pre-r<span class="_ _a"></span>eferral   46, 49-51, 84, 213</div><div class="t m4 xb h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">Primaquine   11, 33, 40, 63-66, 68, 70, 71, 95, 102, 103, 122, 126, 135, 137, 141, 142, 226-238</div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">base   63-65, 70, 71, 102, 226-228, 230-232</div><div class="t m4 x4d h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">infection   11, 63, 64, 66, 68, 137, 226, 228, 229</div><div class="t m4 x4d h60 y15bc ff32 fs8 fc3 sc0 ls13 ws0">intermittent   230</div><div class="t m4 x4d h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">regimens   64, 66, 226, 228, 230-232, 234-237</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">resistant   64, 65, 227-232, 234, 236, 237, 239</div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls13 ws0">tolerant   232</div><div class="t m4 xb h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">Proguanil   16, 20, 22, 33, 37, 38, 40, 63, 103-107, 126, 127, 160, 161, 165, 176</div><div class="t m4 xb h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">Protein-ener<span class="_ _a"></span>gy   118, 119, 121, 128</div><div class="t m4 xb h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">Pulmonary   5, 41, 52, 53, 55, 58, 66, 91</div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">oedema   5, 41, 53, 55, 58, 66</div><div class="t m4 xb h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">Pyrimethamine   20-23, 25, 33, 39, 40, 63-65, 90-93, 160-162, 166-169, 171-173, 178-182, 186-</div><div class="t m4 xb h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">189, 191, 194, 195, 228, 236, 237</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">dose   21-23, 25, 26, 63, 90, 92, 129, 171, 187, 191, 228, 231</div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls13 ws14">resistance   1,<span class="_ _a"></span> <span class="ls1ae ws0">12, 13, 16, 18, 21-23, 25, 33, 63, 64, 70, 160-162, 166-171, 173, 176, 178-182, 236</span></div><div class="t m4 x4d h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">sulfadoxine   12, 20-23, 25, 30, 31, 39, 40, 63-65, 90-92, 141, 142, 166-169, 171-173, 179-182, </div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">186-189, 191, 194, 195, 236, 237</div><div class="t m4 xb h60 y15eb ff32 fs8 fc3 sc0 ls0 ws0">Q<span class="_ _d2"></span><span class="fc1 sc2">Q</span></div><div class="t m4 xb h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">Quinidine   37, 42, 46, 48, 102, 108, 110, 128</div><div class="t m4 xb h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">Quinine   12, 32-34, 37, 38, 42-49, 51, 58, 59, 93, 94, 108-110, 119-124, 127-129, 169, 170, 181,</div><div class="t m4 xb h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">207-214, 219-221, 227</div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls12 ws0">base   47, 51, 93, 109, 120, 207, 227</div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">combined   123, 124, 170, 212</div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">injection   43, 44, 46, 47, 109, 110, 120, 210, 214</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">intrarectal   51, 209, 220, 221</div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">intravenous   43, 44, 47, 49, 59, 110, 111, 120, 127, 208-210, 212, 213, 218, 220, 221</div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">monotherapy   34, 170</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">oral   34, 47, 48, 50, 59, 60, 101, 109, 119, 123, 124, 127, 128, 204, 217-219</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">parenteral   37, 42-44, 46-49, 58, 59, 127, 213, 217, 219, 221</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls13 ws0">poisoning   128</div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">rectal   44, 46-50, 60, 124, 209, 213, 221</div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">resistance   12, 33, 42, 64, 122, 163, 169, 170, 179-181, 227</div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">urine   109, 127</div><div class="t m4 xb h60 y15ec ff32 fs8 fc3 sc0 ls0 ws0">R<span class="_ _cd"></span><span class="fc1 sc2">R</span></div><div class="t m4 xb h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">Radical cure   62, 64-66, 87, 102, 226, 227, 230, 231, 233, 237, 238</div><div class="t m4 xb h60 y15db ff32 fs8 fc3 sc0 ls12 ws0">Rapid diagnostic tests   9, 62, 69, 148, 151</div><div class="t m4 xb h60 y15dc ff32 fs8 fc3 sc0 ls13 ws0">Recommendation   </div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">base   1, 2, 20, 47, 65, 70, 231</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">dosage   123</div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">dose   21, 22, 26, 34, 37, 38, 43, 49, 50, 61, 65, 70, 119, 122, 171, 231</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls13 ws14">evidence-based   2, 56</div><div class="t m4 x4d h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">key   77, 202</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf105" class="pf w1 h4" data-page-no="105"><div class="pc pc105 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc3 he y9 ff16 fs5 fc3 sc0 lsad ws0">Index</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">251</div><div class="t m4 x4d h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">policy   2, 4, 15, 83</div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">treatment   1-4, 8, 10, 11, 14, 15, 17-23, 26-29, 32-41, 43, 44, 46, 48-50, 57, 59-61, 70, 77, 78, </div><div class="t m4 x4d h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">83, 84</div><div class="t m4 xb h60 y15bb ff32 fs8 fc3 sc0 ls13 ws0">Rectal   </div><div class="t m4 x4d h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">artemisinin   44, 46, 47, 49, 50, 95, 96, 98, 99, 124, 125, 213, 221</div><div class="t m4 x4d h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">artesunate   36, 44, 46, 47, 49-51, 59, 60, 95, 98, 99, 126, 209, 213, 221</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">diazepam   52, 53</div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">dihydroartemisinin   47, 95, 98, 99, 126</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">quinine   43-49, 59, 124, 209, 213, 221</div><div class="t m4 xb h60 y15c0 ff32 fs8 fc3 sc0 ls13 ws0">Renal   </div><div class="t m4 x4d h60 y15c1 ff32 fs8 fc3 sc0 ls13 ws14">blood flow   119</div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">failure   5, 38, 48, 52, 53, 55, 66, 109, 110, 112, 114, 128, 225, 232</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">impairment   41, 53, 56, 97, 98, 106, 112, 114, 115</div><div class="t m4 xb h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">Resistance   1-3, 12-23, 25, 26, 30, 31, 41, 42, 63-67, 69, 70, 124-126, 137-143, 155-173, 175-182,</div><div class="t m4 xb h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">194, 195, 217-219, 226-232, 234-239</div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls13 ws14">aminoquinoline   87, 89, 160</div><div class="t m4 x4d h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">antibiotic   157, 170, 178</div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">antifolate   63, 67, 160, 161, 164-166, 179, 181</div><div class="t m4 x4d h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">antimalarial   1, 2, 12-18, 30, 31, 41, 42, 66, 67, 84, 85, 87, 89, 91, 92, 137-140, 155-167, 171, </div><div class="t m4 x4d h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">172, 175-182, 226, 231</div><div class="t m4 x4d h60 y15ca ff32 fs8 fc3 sc0 ls13 ws14">artemisinin   1, <span class="ls1ae ws0">12, 17, 18, 20, 23, 30, 33, 63, 64, 95, 124, 125, 139, 161-165, 170, 185, 218, 219</span></div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">atov<span class="_ _a"></span>aquone   16, 105, 126, 161, 162, 164, 179</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">chloroquine   12, 13, 42, 63-67, 70, 87, 89, 122, 134, 139, 140, 158-160, 162-173, 175, 176, </div><div class="t m4 x4d h60 y15cd ff32 fs8 fc3 sc0 ls12 ws0">180-182, 194, 226-239</div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">cycloguanil   105, 160, 161</div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">de nov<span class="_ _a"></span>o   17, 157-159, 162-166</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">falciparum   1, 12, 16, 17, 23, 63-66, 124-126, 139-142, 157-162, 166-170, 178-183, 194, 195, </div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">222, 226-228, 230, 231, 234-237</div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">in vivo   13, 14, 63, 66, 67, 95, 123, 139, 161, 162, 172, 175-177, 179, 180, 228, 231, 234, 235</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls13 ws0">mefloquine   <span class="ls1ae">12, 21-23, 25, 33, 63, 64, 124, 137, 140, 142, 160-163, 165-167, 169-171, 179-181,</span></div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">217-219, 222</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls12 ws0">multidrug   23, 101, 125, 126, 169, 171, 195, 217, 218, 222, 237, 239</div><div class="t m4 xa6 h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">primaquine   33, 63-66, 70, 71, 95, 141, 142, 226-234, 236-238</div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">significant   14, 18, 19, 63, 137, 140-142, 164, 165, 167, 170, 173, 228</div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">stable   66, 164</div><div class="t m4 x4d h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">sulfadoxine-pyrimethamine   1, 12, 16, 18, 21-23, 25, 39, 63-65, 70, 134, 166-169, 171-173, </div><div class="t m4 x4d h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">180-182, 194, 195, 236, 237</div><div class="t m4 x4d h60 y15da ff32 fs8 fc3 sc0 ls12 ws0">sulfone   161</div><div class="t m4 x4d h60 y15db ff32 fs8 fc3 sc0 ls12 ws0">suspected   11, 26, 70, 150</div><div class="t m4 xb h60 y15dc ff32 fs8 fc3 sc0 ls12 ws0">Respiratory distr<span class="_ _a"></span>ess   38, 41, 42, 55, 66, 215, 216, 225, 232</div><div class="t m4 xb h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">Rifampicin   108, 110, 114, 128</div><div class="t m4 xb h60 y15ed ff32 fs8 fc3 sc0 ls0 ws0">S<span class="_ _cd"></span><span class="fc1 sc2">S</span></div><div class="t m4 xb h60 y15e0 ff32 fs8 fc3 sc0 ls13 ws14">Second-line treatment   31, 32</div><div class="t m4 xb h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">Semi-immune   26, 27, 216</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf106" class="pf w1 h4" data-page-no="106"><div class="pc pc106 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 x7 h8 y9 ff1d fs5 fc3 sc0 ls3 ws2">Guidelines for the treatment of malaria</div><div class="t m0 xcc h9 ya ff17 fs6 fc4 sc0 ls1 ws0">252</div><div class="t m4 xb h60 y9e ff32 fs8 fc3 sc0 ls12 ws0">Sequelae   32, 208, 211, 212</div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">neurological   208, 211, 212</div><div class="t m4 xb h60 y15ba ff32 fs8 fc3 sc0 ls12 ws0">Sulfadoxine   12, 20-23, 25, 30, 31, 39, 40, 63-65, 90-92, 141, 142, 166-169, 171-173, 179-182, 186-</div><div class="t m4 xb h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">189, 191, 194, 195, 236, 237</div><div class="t m4 x4d h60 y15bc ff32 fs8 fc3 sc0 ls12 ws0">artemisinin   1, 12, 18, 20, 23, 30, 31, 33, 35, 40, 42, 63, 64, 167, 172, 185, 186, 191</div><div class="t m4 x4d h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">artesunate   21-23, 25, 26, 42, 64, 65, 70, 142, 166, 171, 191, 195, 228, 237</div><div class="t m4 x4d h60 y15be ff32 fs8 fc3 sc0 ls12 ws0">intramuscular   42, 43, 90, 92, 123</div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">pyrimethamine   20-23, 25, 33, 39, 40, 63-65, 90-92, 141, 142, 166-169, 171-173, 179-182, </div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">186-189, 191, 194, 195, 228, 236, 237</div><div class="t m4 x98 h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">artesunate   21-23, 25, 26, 42, 64, 65, 70, 123, 142, 166, 171, 191, 195, 228, 237</div><div class="t m4 x98 h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">chloroquine   12, 13, 42, 63-65, 70, 123, 128, 129, 141, 142, 166, 167, 171-173, 180-182, </div><div class="t m4 x98 h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">186, 187, 194, 195, 228, 231, 236, 237</div><div class="t m4 x98 h60 y15c3 ff32 fs8 fc3 sc0 ls13 ws0">combination   1,<span class="_ _a"></span> <span class="ls1ae">16, 18, 20, 21, 23, 25, 33, 65, 90-92, 166, 171, 172, 185-189, 191, 194, 195</span></div><div class="t m4 x98 h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">oral   20, 21, 39, 90, 92, 123</div><div class="t m4 x98 h60 y15c4 ff32 fs8 fc3 sc0 ls13 ws0">resistance   1<span class="_ _a"></span>, <span class="ls1ae">12, 13, 16, 18, 21-23, 25, 33, 42, 63, 64, 70, 166-171, 173, 176, 179-182, 236</span></div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">resistance   1, 12, 13, 16, 18, 21-23, 25, 33, 42, 63, 64, 70, 166-171, 173, 176, 179-182, 236</div><div class="t m4 xb h60 y15ee ff32 fs8 fc3 sc0 ls0 ws0">T<span class="_ _d0"></span><span class="fc1 sc2">T</span></div><div class="t m4 xb h60 y15c8 ff32 fs8 fc3 sc0 ls12 ws0">T<span class="_ _4b"></span>etracyclines   17, 20, 32-35, 40, 48, 94, 104, 111-114, 121, 129, 170</div><div class="t m4 xb h60 y15c9 ff32 fs8 fc3 sc0 ls12 ws0">Thrombocytopenia   66, 91, 92, 94, 110, 112, 115, 225, 232</div><div class="t m4 xb h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">T<span class="_ _4b"></span>oxicity   88-90, 92, 94, 96-101, 103, 104, 106-110, 112, 114-116, 118, 123, 126, 127, 201, 227, 230,</div><div class="t m4 xb h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">238</div><div class="t m4 xb h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">T<span class="_ _b"></span>ravellers   2, 36-38, 94</div><div class="t m4 xb h60 y15cd ff32 fs8 fc3 sc0 ls13 ws0">T<span class="_ _b"></span>reatment   </div><div class="t m4 x4d h60 y15ce ff32 fs8 fc3 sc0 ls12 ws0">adjunctive   42, 51</div><div class="t m4 x4d h60 y15cf ff32 fs8 fc3 sc0 ls13 ws0">amodiaquine   <span class="lsed">12, 18, 20, 22-25, 31, 33, 40, 63-65, 89, 123, 160, 172, 173, 188-191, 193-195, 237</span></div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">artemether-lumefantrine   23, 24, 26, 37, 38, 40, 48, 64, 102, 126, 173, 179, 191-193, 195, 201,</div><div class="t m4 x98 h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">228</div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">artemisinin(-based)   17, 18, 30, 31, 33-35, 44-50, 58, 59, 61, 63, 64, 95-100, 124, 125, 161, </div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">170, 185, 186, 191, 213, 218-221</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">chloroquine   1, 12, 13, 42, 63-67, 70, 87-89, 122, 123, 140-142, 158-160, 166-169, 171-173, </div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls12 ws0">180-182, 186, 187, 193-195, 226-239</div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">combination   1, 11, 16-25, 33, 49, 63, 92, 105-107, 140, 142, 164-166, 179, 180, 185-191, 194, </div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">195, 226</div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls13 ws0">failure   <span class="lsed ws14">14, 15, 19, 20, 31, 38, 48, 52, 110, 155, 173, 174, 177, 178, 185-187, 190, 191, 217-219, </span></div><div class="t m4 x4d h60 y15d8 ff32 fs8 fc3 sc0 ls12 ws0">222, 227, 228</div><div class="t m4 x4d h60 y15d9 ff32 fs8 fc3 sc0 ls12 ws0">first-line   15, 20, 31, 33, 36, 38, 65, 172, 178</div><div class="t m4 x4d h60 y15da ff32 fs8 fc3 sc0 ls13 ws14">generic   83</div><div class="t m4 x4d h60 y15db ff32 fs8 fc3 sc0 ls13 ws0">guidelines   <span class="ls87">1-4, 6, 8, 10, 14-16, 20-22, 28-30, 32, 38-40, 72, 73, 75, 77, 78, 80, 81, 83, 84, 176-178</span></div><div class="t m4 x4d h60 y15dc ff32 fs8 fc3 sc0 ls12 ws0">hyperparasitaemic   60, 61, 157, 216-219, 222</div><div class="t m4 x4d h60 y15dd ff32 fs8 fc3 sc0 ls12 ws0">mass   71, 72, 168</div><div class="t m4 x4d h60 y15de ff32 fs8 fc3 sc0 ls12 ws0">mefloquine   25, 26, 49, 61, 63, 64, 93, 94, 123, 124, 137, 140, 160, 161, 165-167, 169, 170, </div><div class="t m4 x4d h60 y15df ff32 fs8 fc3 sc0 ls12 ws0">179-181, 192, 193, 217-219, 222</div><div class="t m4 x4d h60 y15e0 ff32 fs8 fc3 sc0 ls12 ws0">oral   17, 19-21, 27, 28, 34, 36, 39, 48, 50, 59-61, 104-107, 114, 115, 121, 122, 124-126, 217-</div><div class="t m4 x4d h60 y15e1 ff32 fs8 fc3 sc0 ls12 ws0">219, 222</div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf107" class="pf w1 h4" data-page-no="107"><div class="pc pc107 w1 h4"><div class="c x4 y6 w1 h6"><div class="t m0 xc3 he y9 ff16 fs5 fc3 sc0 lsad ws0">Index</div><div class="t m0 xe h9 ya ff17 fs6 fc4 sc0 ls1 ws0">253</div><div class="t m4 x4d h60 y9e ff32 fs8 fc3 sc0 ls13 ws0">parasitological (late)   173-175</div><div class="t m4 x4d h60 y15b9 ff32 fs8 fc3 sc0 ls12 ws0">parenteral   16, 27, 29, 36, 37, 42-44, 46, 48, 49, 52, 58, 59, 61, 88, 92, 115, 216, 217, 219</div><div class="t m4 x4d h60 y15ba ff33 fs8 fc3 sc0 ls13 ws0">Plasmodium<span class="_ _b1"> </span><span class="ff32 lsed ws14">5, 95, 103, 123-125, 136, 141, 142, 151, 152, 167-171, 179-182, 187, 189, 193-195,</span></div><div class="t m4 x4d h60 y15bb ff32 fs8 fc3 sc0 ls12 ws0">204, 219-222, 231-239</div><div class="t m4 x98 h60 y15bc ff33 fs8 fc3 sc0 ls13 ws0">falciparum<span class="_ _b1"> </span><span class="ff32 ls12">5, 123-126, 136, 137, 141, 142, 151, 152, 167-170, 179-182, 193-195, 203-205, </span></div><div class="t m4 x98 h60 y15bd ff32 fs8 fc3 sc0 ls12 ws0">207, 209-211, 217, 219-222, 233-237, 239</div><div class="t m4 x98 h60 y15be ff33 fs8 fc3 sc0 ls14 ws0">vivax<span class="_ _7a"> </span><span class="ff32 ls12">5, 152, 171, 182, 223, 225-229, 231-239</span></div><div class="t m4 x4d h60 y80e ff32 fs8 fc3 sc0 ls12 ws0">policy   2, 4, 14, 15, 83, 141, 174, 177, 204</div><div class="t m4 x4d h60 y15bf ff32 fs8 fc3 sc0 ls12 ws0">preventiv<span class="_ _a"></span>e   2, 22, 39, 200-202, 229</div><div class="t m4 x4d h60 y15c0 ff32 fs8 fc3 sc0 ls12 ws0">primaquine   11, 33, 40, 63-66, 68, 70, 71, 95, 126, 135, 137, 141, 142, 226-238</div><div class="t m4 x4d h60 y15c1 ff32 fs8 fc3 sc0 ls12 ws0">quinine   12, 32-34, 37, 38, 42-49, 51, 58, 59, 93, 94, 108-110, 119-121, 127, 128, 169, 170, </div><div class="t m4 x4d h60 y15c2 ff32 fs8 fc3 sc0 ls12 ws0">181, 207-214, 219-221, 227</div><div class="t m4 x4d h60 y15c3 ff32 fs8 fc3 sc0 ls12 ws0">recommendations   1-4, 10, 11, 14, 15, 19, 20, 22, 23, 26-28, 32-40, 43-46, 49, 50, 57, 59-61, </div><div class="t m4 x4d h60 y2bf ff32 fs8 fc3 sc0 ls12 ws0">65, 70, 77, 78, 83, 84</div><div class="t m4 x4d h60 y15c4 ff32 fs8 fc3 sc0 ls12 ws0">regimens   18, 26, 27, 30, 39, 43, 49, 55, 61, 157, 179, 194, 207, 219, 220, 228, 236, 237</div><div class="t m4 x4d h60 y15c5 ff32 fs8 fc3 sc0 ls12 ws0">second-line   31, 32, 139</div><div class="t m4 x4d h60 y15c6 ff32 fs8 fc3 sc0 ls12 ws0">sulfadoxine-pyrimethamine   1, 16, 22, 23, 25, 30, 31, 39, 40, 64, 65, 121, 167-169, 171-173, </div><div class="t m4 x4d h60 y15c7 ff32 fs8 fc3 sc0 ls12 ws0">180-182, 186-189, 191, 194, 195, 236, 237</div><div class="t m4 xb h60 y15eb ff32 fs8 fc3 sc0 ls0 ws0">U<span class="_ _cf"></span><span class="fc1 sc2">U</span></div><div class="t m4 xb h60 y15ca ff32 fs8 fc3 sc0 ls12 ws0">Urine   53, 56, 89-91, 106, 107, 109, 112, 114, 115, 127</div><div class="t m4 x4d h60 y15cb ff32 fs8 fc3 sc0 ls12 ws0">quinine   109, 127, 128</div><div class="t m4 x4d h60 y15cc ff32 fs8 fc3 sc0 ls12 ws0">urinary tract   89, 90, 113</div><div class="t m4 xb h60 y15ef ff32 fs8 fc3 sc0 ls0 ws0">V<span class="_ _cd"></span><span class="fc1 sc2">V</span></div><div class="t m4 xb h60 y15cf ff32 fs8 fc3 sc0 ls12 ws0">Viv<span class="_ _a"></span>ax   5, 11-13, 37, 62-71, 73, 75, 87, 102, 108, 135, 160, 161, 171, 175, 176, 182, 225-239</div><div class="t m4 x4d h60 y14a0 ff32 fs8 fc3 sc0 ls12 ws0">complicated   66, 230</div><div class="t m4 x4d h60 y15d0 ff32 fs8 fc3 sc0 ls12 ws0">DHPS   161</div><div class="t m4 x4d h60 y15d1 ff32 fs8 fc3 sc0 ls12 ws0">epidemics   11, 69-71, 155</div><div class="t m4 x4d h60 y15d2 ff32 fs8 fc3 sc0 ls12 ws0">infection   5, 11, 12, 62-64, 66-68, 135, 225, 226, 228, 229</div><div class="t m4 x4d h60 y15d3 ff32 fs8 fc3 sc0 ls12 ws0">malaria   5, 10-12, 14, 37, 62-71, 73, 75, 77, 102, 148, 152, 167, 181, 182, 222, 225-239</div><div class="t m4 x4d h60 y15d4 ff32 fs8 fc3 sc0 ls12 ws0">mixed   68-70</div><div class="t m4 x4d h60 y15d5 ff32 fs8 fc3 sc0 ls12 ws0">relapses   62, 64, 226-230, 232, 238</div><div class="t m4 x4d h60 y15d6 ff32 fs8 fc3 sc0 ls12 ws0">resistant   64, 65, 67, 160, 161, 176, 182, 222, 227-232, 234-237, 239</div><div class="t m4 x4d h60 y15d7 ff32 fs8 fc3 sc0 ls12 ws0">sensitive   13, 63, 65, 66, 70, 226, 227, 229-231, 234 </div></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf108" class="pf w1 h4" data-page-no="108"><div class="pc pc108 w1 h4"></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf109" class="pf w1 h4" data-page-no="109"><div class="pc pc109 w1 h4"><div class="t m0 x3 h5 y5 ff34 fs3 fc2 sc0 ls0 ws0"> </div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,-158.457000,-111.685000]}'></div></div>
<div id="pf10a" class="pf w15 h62" data-page-no="10a"><div class="pc pc10a w15 h62"><div class="t m0 xe0 h1 y0 ff35 fs0 fc0 sc0 ls0 ws0">G U<span class="_ _0"> </span>I<span class="_ _1"> </span>D E L<span class="_ _2"> </span>I<span class="_ _1"> </span>N<span class="_ _1"> </span>E<span class="_ _2"> </span>S<span class="_ _2"> </span> </div><div class="t m0 xe0 h1 y1 ff35 fs0 fc0 sc0 ls0 ws0">F<span class="_ _2"> </span>O R  <span class="_ _2"> </span>T<span class="_ _1"> </span>H<span class="_ _2"> </span>E<span class="_ _2"> </span> <span class="_ _2"> </span>T<span class="_ _2"> </span>R<span class="_ _0"> </span>E<span class="_ _0"> </span>A<span class="_ _3"> </span>T<span class="_ _1"> </span>M<span class="_ _2"> </span>E<span class="_ _2"> </span>N<span class="_ _0"> </span>T</div><div class="t m0 xe0 h1 y2 ff35 fs0 fc0 sc0 ls0 ws0">O F  <span class="_ _2"> </span>M<span class="_ _0"> </span>A<span class="_ _0"> </span>L<span class="_ _1"> </span>A<span class="_ _1"> </span>R<span class="_ _4"> </span>I<span class="_ _0"> </span>A</div><div class="t m1 xe1 h2 y3 ff35 fs1 fc0 sc0 ls0 ws0">G U<span class="_ _5"> </span>I<span class="_ _6"> </span>D E<span class="_ _6"> </span>L<span class="_ _6"> </span>I<span class="_ _6"> </span>N<span class="_ _6"> </span>E<span class="_ _6"> </span>S   F<span class="_ _6"> </span>O R  <span class="_ _6"> </span>T<span class="_ _6"> </span>H E<span class="_ _6"> </span>  T<span class="_ _6"> </span>R<span class="_ _6"> </span>E<span class="_ _6"> </span>A T<span class="_ _6"> </span>M<span class="_ _6"> </span>E<span class="_ _6"> </span>N<span class="_ _6"> </span>T   O<span class="_ _6"> </span>F   M<span class="_ _5"> </span>A<span class="_ _6"> </span>L<span class="_ _6"> </span>A<span class="_ _6"> </span>R<span class="_ _5"> </span>I<span class="_ _6"> </span>A</div><div class="t m0 xab h3 y4 ff36 fs2 fc1 sc1 ls0 ws0">GTMcover-production.pdf   11.1.2006   7:10:05<span class="_ _7"></span><span class="fc2 sc0">GTMcover-production.pdf   11.1.2006   7:10:05</span></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,-175.454000,-1073.830000]}'></div></div>
</div>
<div class="loading-indicator">
<img alt="" src="data:image/png;base64,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"/>
</div>
</body>
</html>
